Date,Open,High,Low,Close,Adj close,Volume,Sentiment_gpt,News_flag,Scaled_sentiment,New_text,Potency
2010-02-09 00:00:00+00:00,53.880001068115234,54.880001068115234,53.33000183105469,54.09000015258789,54.09000015258789,2965000.0,5.0,1.0,1.000025,"Biogen Idec Inc. (NASDAQ: BIIB ) announced earnings of $1.20 per share this morning, which beat estimates by 15 cents a share. The January 2011 30-35 strangle crossed 5,000 times out of the gate thanks to an investor who sold these spreads for $5.08 . The company also issued upside guidance for the year, which sent the stock up 86 cents, or 1.6%, to $53.70 during the first 30 minutes of trading.",
2010-07-20 00:00:00+00:00,52.650001525878906,54.130001068115234,51.7400016784668,54.02000045776367,54.02000045776367,4645500.0,2.0,1.0,0.250025,"Earnings Preview On the earnings front, Biogen Idec Inc. ( BIIB ), Goldman Sachs Group Inc. ( GS ), Johnson & Johnson ( JNJ ), PepsiCo Inc. ( PEP ), Boston Scientific Corp. ( BSX ), Juniper Networks Inc. ( JNPR ), Seagate Technology ( STX ), VMware Inc. ( VMW ), and Yahoo! While Wall Street cheered early earnings reports on Monday, last night's disappointing results from technology bellwethers IBM Corp. and Texas Instruments Inc. have swept away any lingering bullish investor sentiment. Economic Calendar June's building permits and housing starts will hit the Street today, while the market will be graced with the weekly report on U.S. petroleum supplies tomorrow.",
2010-09-21 00:00:00+00:00,57.63999938964844,58.27999877929688,57.209999084472656,58.22999954223633,58.22999954223633,2373200.0,4.0,1.0,0.7500249999999999,"The shares rallied on the news, but they have been struggling to break above $58--a level that also held BIIB in check during the summer. BIIB is down 0.5 percent to $57.51 in midday trading but is up 16 percent in the last three months. Biogen Idec is struggling at resistance, and one trader is positioning for a push lower.",
2010-11-03 00:00:00+00:00,63.09000015258789,63.33000183105469,62.66999816894531,63.0,63.0,2670400.0,3.0,1.0,0.5000249999999999,Shares of Biogen Idec ( BIIB ) are down following news the company plans to cut 13% of its workforce and consolidate research sites to cut costs. In the latest earnings news: --OpenTable Inc ( OPEN ) is surging by double digits after the online restaurant reservation provider reported third quarter results that beat Wall Street's expectations. --Hartford Financial Services Group ( HIG ) shares are sharply higher after the company reported Q3 core earnings of $1.43 compared to $1.56 a year earlier and topped the Thomson Reuters mean analyst estimate for $0.97. New Article Shares of Biogen Idec ( BIIB ) are down following news the company plans to cut 13% of its workforce and consolidate research sites to cut costs. In the latest earnings news: --OpenTable Inc ( OPEN ) is surging by double digits after the online restaurant reservation provider reported third quarter results that beat Wall Street's expectations. --Hartford Financial Services Group ( HIG ) shares are sharply higher after the company reported Q3 core earnings of $1.43 compared to $1.56 a year earlier and topped the Thomson Reuters mean analyst estimate for $0.97.,
2011-02-16 00:00:00+00:00,67.16999816894531,67.4800033569336,66.83000183105469,67.36000061035156,67.36000061035156,1587400.0,2.0,1.0,0.250025,"in response to the news that Roche Holding AG (RHHBY.PK) would acquire the outstanding publicly held interest in Genentech for a total payment of approximately $47 billion in cash. Recall that the NBI is calculated under a modified capitalization-weighted methodology, taking into account the total market value of the companies it tracks and not just their share prices. In conclusion, the reallocation of funds following a significant merger and acquisition transaction for cash doesn't appear to benefit larger biotechnology companies with similar risk/reward profiles in terms of relative stock performance(Tier 1).",
2011-04-21 00:00:00+00:00,100.0,106.98999786376952,99.3000030517578,99.6999969482422,99.6999969482422,16442600.0,3.0,1.0,0.5000249999999999,"Earnings Preview Today's earnings docket will also feature reports from Morgan Stanley (MS), Capital One Financial ( COF ), Philip Morris (PM), Fifth Third Bancorp ( FITB ), and Biogen Idec Inc. ( BIIB ), just to name a few. After skyrocketing to a multi-year high on Wednesday, the Dow Jones Industrial Average (DJIA ) is set to end the holiday-shortened week on an even higher note. Meanwhile, a bevy of blue chips are also poised for earnings-induced gains, with Honeywell (HON), Travelers (TRV), and General Electric ( GE ) all emerging from the big-cap earnings confessional.",
2011-04-28 00:00:00+00:00,99.66999816894533,99.77999877929688,98.08000183105467,98.97000122070312,98.97000122070312,3400000.0,2.0,1.0,0.250025,"Biogen Idec (Nasdaq: BIIB ) , a competitor in the biotech space, announced that a newly-developed MS drug known as BG-12 has shown to be even more effective in clinical studies than Copaxone. For starters, it has signed a far-reaching deal with Procter & Gamble (NYSE: PG ) to join forces to make and sell all of P&G's over-the counter drugs outside of North America. Analysts at UBS concur: ""Eventually, we think investors will look at the underlying fundamentals and realize that the free cash flow ( FCF ) build up at this company is significant, that it's mergers and acquisitions track record is pretty good and that Copaxone is probably worth more than nothing.""",
2011-06-22 00:00:00+00:00,99.79000091552734,100.66999816894533,98.9000015258789,99.47000122070312,99.47000122070312,5334200.0,1.0,1.0,2.4999999999997247e-05,"Already, we have seen Roche ( RHHBY ) acquire Genentech and Sanofi ( SNY ) gobble up Genzyme; and Morningstar equity analysts see several other biotechs as likely takeout targets, including Biogen Idec ( BIIB ), Seattle Genetics ( SGEN ), Actelion, Exelixis, and BioMarin ( BMRN ). By Morningstar : By Robert Goldsborough For exchange-traded fund investors, there is virtually no other place in the equity markets where the benefits of diversification are more apparent than in the notoriously volatile biotechnology sector of health care. First Trust NYSE Arca Biotech Index (FBT) Like XBI, this is an equal-weight ETF, meaning that upstarts sit shoulder-to-shoulder with established players like Biogen Idec, Amgen (AMGN), and Celgene (CELG).",
2011-06-23 00:00:00+00:00,98.63999938964844,100.77999877929688,97.8000030517578,100.66999816894533,100.66999816894533,3107500.0,2.0,1.0,0.250025,"Shares of Biogen ( BIIB ) are lower following word that that Icahn Capital, the company's fourth largest shareholder, cut its stake to 3.4% from 5.6%. Stocks are off session lows but still down sharply in mid-day trading, as bearish sentiment, sparked by investor concern over rising unemployment claims, threatens to erase the Street's four-session winning streak. Bed Bath & Beyond ( BBBY ) is higher following its report that Q1 EPS of $0.72, ahead of the analyst consensus of $0.63 per share on Thomson Reuters. New Article Shares of Biogen ( BIIB ) are lower following word that that Icahn Capital, the company's fourth largest shareholder, cut its stake to 3.4% from 5.6%. Stocks are off session lows but still down sharply in mid-day trading, as bearish sentiment, sparked by investor concern over rising unemployment claims, threatens to erase the Street's four-session winning streak. Bed Bath & Beyond ( BBBY ) is higher following its report that Q1 EPS of $0.72, ahead of the analyst consensus of $0.63 per share on Thomson Reuters.",
2011-07-21 00:00:00+00:00,104.4800033569336,106.05999755859376,104.44000244140624,105.62000274658205,105.62000274658205,1267200.0,3.0,1.0,0.5000249999999999,"His three favorite names in the ETF are Teva Pharmaceutical (TEVA), Vertex Pharmaceuticals (VRTX) and Biogen Idec (BIIB). Biogen Idec Inc. (BIIB): Biotechnology Industry. (List compiled by Alexander Crawford) Biotech stocks as a whole tend to underperform after the annual American Society of Clinical Oncology (ASCO) conference in June.",
2011-07-22 00:00:00+00:00,105.54000091552734,106.0500030517578,104.88999938964844,105.55999755859376,105.55999755859376,1145700.0,3.0,1.0,0.5000249999999999,"Biogen Idec Inc. (BIIB): Biotechnology Industry. (List compiled by Becca Lipman) The two largest US pharmacy benefit managers are combining forces: Express Scripts (ESRX) will buy Medco Health Solution (MHS) for about $29 billion . Furthermore, ""analysts say these companies are expected to benefit from the health-care overhaul law, which will bring millions of Americans under insurance coverage,"" according to Nathalie Tadena and Lauren Pollock of Marketwatch.",
2011-08-09 00:00:00+00:00,86.91000366210938,90.55999755859376,83.83000183105469,89.43000030517578,89.43000030517578,3684600.0,3.0,1.0,0.5000249999999999,"In company news: Shares of Biogen Idec ( BIIB ) and Abbott Laboratories ( ABT ) are mixed after the companies announced positive top-line results from the first trial for their drug Daclizumab HYP in relapsing-remitting multiple sclerosis. But a new policy statement from the Federal Reserve's Open Market Committee, due this afternoon, could strongly influence late trading, depending on its message. That changed in the wake of a recent round of weak economic data, the U.S. credit downgrade and continuing concern over European sovereign debt. New Article In company news: Shares of Biogen Idec ( BIIB ) and Abbott Laboratories ( ABT ) are mixed after the companies announced positive top-line results from the first trial for their drug Daclizumab HYP in relapsing-remitting multiple sclerosis. But a new policy statement from the Federal Reserve's Open Market Committee, due this afternoon, could strongly influence late trading, depending on its message. That changed in the wake of a recent round of weak economic data, the U.S. credit downgrade and continuing concern over European sovereign debt.",
2011-10-26 00:00:00+00:00,115.93000030517578,119.75,114.27999877929688,116.91999816894533,116.91999816894533,5169800.0,3.0,1.0,0.5000249999999999,"In mid-day company news: Biogen Idec ( BIIB ) shares are higher after the company said that its BG-12 pill to treat multiple sclerosis met its treatment goals in a study. Stocks are mostly higher - though the Nasdaq is off - at the session's half on concern that European debt talks are stalling, capping gains from data showing new home sale last month rose more than expected, although they were down year-over-year. The German parliament is expected to back Merkel in the vote and give her a mandate to negotiate a package of measures to tackle the debt crisis at a summit of euro-zone leaders in Brussels this evening, the Wall Street Journal reported. New Article In mid-day company news: Biogen Idec ( BIIB ) shares are higher after the company said that its BG-12 pill to treat multiple sclerosis met its treatment goals in a study. Stocks are mostly higher - though the Nasdaq is off - at the session's half on concern that European debt talks are stalling, capping gains from data showing new home sale last month rose more than expected, although they were down year-over-year. The German parliament is expected to back Merkel in the vote and give her a mandate to negotiate a package of measures to tackle the debt crisis at a summit of euro-zone leaders in Brussels this evening, the Wall Street Journal reported.",
2011-10-28 00:00:00+00:00,117.73999786376952,120.66000366210938,116.5500030517578,118.72000122070312,118.72000122070312,2143300.0,3.0,1.0,0.5000249999999999,"Earnings Preview Today's earnings docket will also feature reports from Chevron ( CVX ), Arch Coal ( ACI ), Biogen Idec ( BIIB ), BorgWarner ( BWA ), Lear Corp. (LEA), Newmont Mining (NEM), Newell Rubbermaid (NWL), Pilgrim's Pride (PPC), Provident Financial Services (PFS), and Weyerhaeuser (WY). Furthermore, with the initial relief rally out of the way, it seems Wall Street is now focused on the implementation and execution of the aforementioned plan, which includes bolstering the scope of the European Financial Stability Facility (EFSF). Meanwhile, Samsung sparked a halo lift for its fellow Korean tech stocks after unseating Apple as the world's leading maker of smartphones, with the firm offering an upbeat fourth-quarter forecast to boot.",
2011-11-21 00:00:00+00:00,107.18000030517578,108.77999877929688,106.30999755859376,107.88999938964844,107.88999938964844,1653700.0,3.0,1.0,0.5000249999999999,"The study evaluated patients who suffered from a demyelinating event such as optic neuritis, myelopathy or brainstem syndrome and had magnetic resonance imaging brain scans consistent with early signs of MS. We note that Rebif is already marketed worldwide as a treatment for relapsing forms of MS. Apart from Rebif, other MS treatments available in the market include Biogen Idec 's ( BIIB ) Tysabri and Avonex and Teva Pharmaceuticals' ( TEVA ) Copaxone. BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. On approval, the drug can be used in patients who have experienced a single demyelinating event, and are at high risk of converting to MS. Merck KGaA had submitted the European application for the extended indication of Rebif in June 2011.",
2011-11-25 00:00:00+00:00,108.9000015258789,110.23999786376952,108.9000015258789,109.1999969482422,109.1999969482422,864800.0,4.0,1.0,0.7500249999999999,"Moreover, the company has collaborations with some of the big pharmaceutical players like Merck ( MRK ), Medtronic ( MDT ), Novartis ( NVS ), Biogen Idec ( BIIB ), Roche ( RHHBY ), Takeda, Kyowa Hakko Kirin, and Cubist Pharmaceuticals ( CBST ) to further develop and utilize its core technology. ALNYLAM PHARMA ( ALNY ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report CUBIST PHARM ( CBST ): Free Stock Analysis Report MEDTRONIC ( MDT ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Alnylam Pharmaceuticals Inc. ( ALNY ) recently presented data from an early stage study of its pipeline candidate ALN-TTR01 at a scientific conference in Japan.",
2011-12-01 00:00:00+00:00,114.9499969482422,116.5,114.19000244140624,116.4800033569336,116.4800033569336,1326500.0,3.0,1.0,0.5000249999999999,"Moreover, the company has collaborations with some of the big pharmaceutical players like Merck ( MRK ), Medtronic ( MDT ), Novartis ( NVS ), Biogen Idec ( BIIB ), Roche ( RHHBY ), Takeda, Kyowa Hakko Kirin, and Cubist Pharmaceuticals to further develop and utilize its core technology. ALNYLAM PHARMA ( ALNY ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report CUBIST PHARM ( CBST ): Free Stock Analysis Report MEDTRONIC ( MDT ): Free Stock Analysis Report MERCK & CO INC ( MRK ): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Alnylam is developing ALN-RSV01 on its own while Cubist Pharmaceuticals ( CBST ) has the opt-in right to collaborate with the company in future for the lung transplant indication.",
2011-12-07 00:00:00+00:00,111.72000122070312,112.43000030517578,110.01000213623048,111.76000213623048,111.76000213623048,1004200.0,2.0,1.0,0.250025,"The company has collaborations or deals with some big pharmaceutical players such as Roche ( RHHBY ), Biogen ( BIIB ), Medtronic ( MDT ), Takeda, Kyowa Hakko Kirin, Cubist Pharmaceuticals ( CBST ) and Isis Pharmaceuticals ( ISIS ) to further develop and utilize its core technology. ALNYLAM PHARMA ( ALNY ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report CUBIST PHARM ( CBST ): Free Stock Analysis Report GLAXOSMITHKLINE ( GSK ): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi).",
2011-12-23 00:00:00+00:00,111.4499969482422,111.4499969482422,110.16999816894533,110.79000091552734,110.79000091552734,736200.0,4.0,1.0,0.7500249999999999,"Another major competitor could be Biogen Idec's ( BIIB"">BIIB ) BG-12, which has shown encouraging data so far. BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report SANOFI-AVENTIS ( SNY ): Free Stock Analysis Report To read this article on Zacks.com click here. However, both doses ofAubagio were found to be safe and well tolerated.Sanofi plans to present detailed data from the phase IIITENERE trial at an upcoming medical meeting.",
2011-12-29 00:00:00+00:00,110.19000244140624,110.76000213623048,109.22000122070312,110.63999938964844,110.63999938964844,1100500.0,3.0,1.0,0.5000249999999999,"For Immediate Release Chicago, IL - December 29, 2011 - Today, Zacks Equity Research discusses the Pharma & Biotech, including Vertex Pharma ( VRTX ), Human Genome Sciences Inc. ( HGSI ), Biogen Idec ( BIIB ) and Perrigo Company ( PRGO ). In the biotech space, we are positive on Biogen Idec ( BIIB ). 9339 support@zacks.com http://www.zacks.com BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report HUMAN GENOME ( HGSI ): Free Stock Analysis Report PERRIGO COMPANY ( PRGO ): Free Stock Analysis Report VERTEX PHARM ( VRTX ): Free Stock Analysis Report To read this article on Zacks.com click here.",
2011-12-30 00:00:00+00:00,110.41000366210938,111.08999633789062,110.0500030517578,110.0500030517578,110.0500030517578,938200.0,4.0,1.0,0.7500249999999999,"Moreover, the company has collaborated with some big pharmaceutical players, such as Roche ( RHHBY ), Biogen ( BIIB ), Medtronic, Takeda, Kyowa Hakko Kirin, Cubist Pharmaceuticals ( CBST ) and Isis Pharmaceuticals ( ISIS ), to further develop and utilize its core technology. ALNYLAM PHARMA ( ALNY ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report CUBIST PHARM (CBST): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. Alnylam Pharmaceuticals Inc ( ALNY ) recently announced pre-clinical data from a trial evaluating its pipeline candidate ALN-HTT for the treatment of Huntington's disease ( HD ).",
2012-01-12 00:00:00+00:00,115.72000122070312,116.41000366210938,114.87000274658205,116.3000030517578,116.3000030517578,1817100.0,3.0,1.0,0.5000249999999999,"Biogen Idec ( BIIB ) recently joined hands with Isis Pharmaceuticals, Inc. ( ISIS ) for the development and commercialization of an antisense drug for the treatment of spinal muscular atrophy ( SMA ). BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report ISIS PHARMACEUT ( ISIS ): Free Stock Analysis Report To read this article on Zacks.com click here. The Candidate The exclusive, global option and collaboration agreement relates to the development of ISIS-SMNRx, which is currently in a phase I study.",
2012-01-13 00:00:00+00:00,116.0,117.9800033569336,115.36000061035156,116.02999877929688,116.02999877929688,1404800.0,3.5,1.0,0.6250249999999999,"Stocks recently featured in the blog include General Motors Co. ( GM ), Toyota Motor Corp. ( TM ), Ford Motor Co. ( F ), Biogen Idec ( BIIB ) and Isis Pharmaceuticals, Inc. ( ISIS ). Isis-Biogen Team Up Biogen Idec ( BIIB ) recently joined hands with Isis Pharmaceuticals, Inc. ( ISIS ) for the development and commercialization of an antisense drug for the treatment of spinal muscular atrophy ( SMA ). 9339 support@zacks.com http://www.zacks.com BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report FORD MOTOR CO ( F ): Free Stock Analysis Report GENERAL MOTORS ( GM ): Free Stock Analysis Report ISIS PHARMACEUT ( ISIS ): Free Stock Analysis Report TOYOTA MOTOR CP (TM): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Already marketing biosimilars outside the US, Sandoz has begun phase III trials for its biosimilar version of Biogen ( BIIB )/ Roche 's ( RHHBY ) cancer drug Rituxan in first line follicular lymphoma. AMGEN INC ( AMGN ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report HOSPIRA INC ( HSP ): Free Stock Analysis Report JOHNSON & JOHNS ( JNJ ): Free Stock Analysis Report MERCK & CO INC ( MRK ): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. With more than $60 billion of biologic sales slated to lose patent protection through 2017, the biosimilars market -- which is currently in a nascent stage -- represents a huge, untapped commercial opportunity.",
2012-01-20 00:00:00+00:00,117.0,119.55999755859376,116.86000061035156,118.13999938964844,118.13999938964844,3396400.0,4.0,1.0,0.7500249999999999,"We recently reiterated our Neutral recommendation on Biogen Idec ( BIIB ). ABBOTT LABS ( ABT ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, Tysabri, the company's second MS product, continues to see an increase in patients despite carrying a ""black box"" warning for the risk of progressive multifocal leukoencephalopathy ( PML ) and other cautionary language.",
2012-01-24 00:00:00+00:00,115.97000122070312,117.2699966430664,115.97000122070312,117.02999877929688,117.02999877929688,1900200.0,3.5,1.0,0.6250249999999999,"Angiomax (bivalirudin), which was acquired from Biogen Idec, Inc. ( BIIB ) in 1996, is used as an anticoagulant in patients undergoing coronary angioplasty. BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report HOSPIRA INC ( HSP ): Free Stock Analysis Report MEDICINES CO ( MDCO ): Free Stock Analysis Report MYLAN INC ( MYL ): Free Stock Analysis Report DOCTOR REDDYS ( RDY ): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. APP also agreed to dismiss its appeal of a court decision to treat the patent extension application for Angiomax as having been filed on a timely basis. New Article Biogen Idec ( BIIB ) and Elan Corporation, plc ( ELN ) recently announced that the US Food and Drug Administration (FDA) has approved a label change for Tysabri. BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report ELAN CP PLC ADR ( ELN ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report To read this article on Zacks.com click here. As per the updated label, anti-JC virus antibody status is a risk factor for developing progressive multifocal leukoencephalopathy ( PML ), a rare and life threatening brain infection.",
2012-01-25 00:00:00+00:00,116.58999633789062,118.61000061035156,116.43000030517578,118.3499984741211,118.3499984741211,1847200.0,4.0,1.0,0.7500249999999999,"Abbott Labs, along with partner Biogen ( BIIB ), moved daclizumab into a phase III study for the treatment of relapsing-remitting multiple sclerosis ( RRMS ). ABBOTT LABS ( ABT ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report BRISTOL-MYERS ( BMY ): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs ( ABT ) reported fourth quarter earnings of $1.45 per share, a penny above the Zacks Consensus Estimate and at the higher end of the guidance range provided by the company.",
2012-01-26 00:00:00+00:00,118.91000366210938,118.9800033569336,117.2300033569336,117.8499984741211,117.8499984741211,1651700.0,4.0,1.0,0.7500249999999999,"Stocks recently featured in the blog include The Boeing Company ( BA ), Lockheed Martin Corporation ( LMT ), Abbott Labs ( ABT ), Bristol-Myers Squibb ( BMY ) and Biogen ( BIIB ). Abbott Labs, along with partner Biogen ( BIIB ), moved daclizumab into a phase III study for the treatment of relapsing-remitting multiple sclerosis ( RRMS ). 9339 support@zacks.com http://www.zacks.com ABBOTT LABS ( ABT ): Free Stock Analysis Report BOEING CO ( BA ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report LOCKHEED MARTIN (LMT): Free Stock Analysis Report To read this article on Zacks.com click here.",
2012-01-27 00:00:00+00:00,118.3499984741211,119.5,118.18000030517578,118.55999755859376,118.55999755859376,1551600.0,3.0,1.0,0.5000249999999999,"The study evaluated patients who suffered from a demyelinating event such as optic neuritis, myelopathy or brainstem syndrome and had magnetic resonance imaging brain scans consistent with early signs of MS. We note that Rebif is already marketed worldwide as a treatment for relapsing forms of MS. Apart from Rebif, other MS treatments available in the market include Biogen Idec 's ( BIIB ) Tysabri and Avonex and Teva Pharmaceuticals ' ( TEVA ) Copaxone. BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report TEVA PHARM ADR ( TEVA ): Free Stock Analysis Report To read this article on Zacks.com click here. Merck KGaA ( MKGAF ) was recently buoyed by the news of European Commission ( EC ) approving its lead drug Rebif for the treatment of patients who have experienced a single demyelinating event, and are at high risk of getting multiple sclerosis ( MS ).",
2012-01-30 00:00:00+00:00,116.94000244140624,117.26000213623048,115.0199966430664,116.58000183105467,116.58000183105467,2297300.0,3.0,1.0,0.5000249999999999,"Biogen Idec Inc. ( BIIB ) is slated to announce its fourth quarter and fiscal 2011 results on January 31. BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report ELAN CP PLC ADR ( ELN ): Free Stock Analysis Report To read this article on Zacks.com click here. Third Quarter Highlights Biogen Idec Inc. reported third-quarter earnings per share of $1.59, well above the Zacks Consensus Estimate of $1.51 and the year-earlier figure of $1.33. New Article Biogen Idec ( BIIB ) and Elan Corporation, plc ( ELN ) recently announced that they are conducting a phase III study of Tysabri for secondary-progressive multiple sclerosis (""SPMS""). BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report ELAN CP PLC ADR ( ELN ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report To read this article on Zacks.com click here. Tysabri is approved in the US for relapsing forms of multiple sclerosis (""MS"") in patients who show inadequate response to or are unable to tolerate other treatments.",
2012-02-01 00:00:00+00:00,118.45999908447266,122.83000183105467,118.3499984741211,121.26000213623048,121.26000213623048,3018200.0,3.0,1.0,0.5000249999999999,"Stocks recently featured in the blog include Pfizer Inc. ( PFE ), Biogen Idec ( BIIB ), Elan Corp. ( ELN ), Novartis ( NVS ) and Roche ( RHHBY ). Biogen Beats, but Outlook Weak Biogen Idec ( BIIB ) reported fourth-quarter earnings per share of $1.51, well above the Zacks Consensus Estimate of $1.46 and the year-ago earnings of $1.41. 9339 support@zacks.com http://www.zacks.com BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report ELAN CP PLC ADR ( ELN ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here.",
2012-02-03 00:00:00+00:00,122.23999786376952,122.77999877929688,121.05999755859376,121.87999725341795,121.87999725341795,1198500.0,4.0,1.0,0.7500249999999999,"BIIB - Biogen Idec Inc. Biogen discovers, develops, manufactures and markets therapeutics in areas of neurology, immunology, hemophilia and oncology around the world. AMGEN INC ( AMGN ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report HUMANA INC NEW ( HUM ): Free Stock Analysis Report KROGER CO ( KR ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report To read this article on Zacks.com click here. This company has an average broker rating and a Zacks #2 Rank (Buy), and its stock price remains attractive based on a 0.2 Price/Sales ratio compared to a P/S of 0.8 for industry peers.",
2012-02-09 00:00:00+00:00,120.04000091552734,120.04000091552734,116.62999725341795,117.77999877929688,117.77999877929688,2101200.0,2.0,1.0,0.250025,"Looking deeper, we can see key biotechnology stocks like Amgen ( AMGN ), Celgene (NASDAQ: CLG) and Biogen Idec ( BIIB ) all retreating from recent annual highs. But with the neutral ratings all three of these stocks have earned so far - and positive edges of less than half a percent - it is also true that AMGN, BIIB, CELG and other biotechnology stocks may have further to fall. And having recently looked at distribution in the transportation sector, today's report reviews growing short-term weakness among biotechnology stocks.",
2012-02-14 00:00:00+00:00,118.61000061035156,120.08000183105467,118.12000274658205,119.6999969482422,119.6999969482422,1029400.0,3.0,1.0,0.5000249999999999,"We note that Elan has a co-development agreement with Biogen Idec Inc. ( BIIB ) for Tysabri, under which Elan markets the drug in the US and books the entire sales as its revenues. ALKERMES INC ( ALKS ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report ELAN CP PLC ADR ( ELN ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report To read this article on Zacks.com click here. During the reported quarter, selling, general and administrative (""SG&A"") expenses increased 9% to $58.2 million.",
2012-02-17 00:00:00+00:00,118.86000061035156,118.9000015258789,116.22000122070312,116.4499969482422,116.4499969482422,1889900.0,4.0,1.0,0.7500249999999999,"Biogen Idec ( BIIB ) recently signed a deal to acquire privately-held biotech company, Stromedix, Inc. With this acquisition, Biogen will gain access to treatments being developed for fibrosis and organ failure. BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report ISIS PHARMACEUT ( ISIS ): Free Stock Analysis Report To read this article on Zacks.com click here. The candidate is scheduled to enter into a phase II study that will be conducted in patients with idiopathic pulmonary fibrosis ( IPF ).",
2012-02-21 00:00:00+00:00,116.4499969482422,116.62000274658205,115.25,115.66999816894533,115.66999816894533,1556800.0,3.0,1.0,0.5000249999999999,"Acorda has a licensing agreement with Biogen Idec ( BIIB ) for the development and commercialization of Ampyra outside the US. ACORDA THERAPT ( ACOR ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report ELAN CP PLC ADR ( ELN ): Free Stock Analysis Report WATSON PHARMA ( WPI ): Free Stock Analysis Report To read this article on Zacks.com click here. In July 2011, Biogen received conditional approval for Fampyra (ex-US trade name of Ampyra) in the EU, as a treatment for improving walking in adult patients with multiple sclerosis.",
2012-02-23 00:00:00+00:00,116.2300033569336,117.9000015258789,115.9000015258789,116.6999969482422,116.6999969482422,836900.0,4.0,1.0,0.7500249999999999,"Angiomax, acquired from Biogen Idec Inc. ( BIIB ), is the lead product at The Medicines Company. BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report MEDICINES CO ( MDCO ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report To read this article on Zacks.com click here. The Medicines Company ( MDCO ) reported fourth-quarter earnings of 47 cents per share, including the impact of stock-based compensation expense.",
2012-02-28 00:00:00+00:00,115.02999877929688,116.98999786376952,115.02999877929688,116.68000030517578,116.68000030517578,1326300.0,4.0,1.0,0.7500249999999999,Biogen Idec ( BIIB ) and Samsung Biologics recently announced the setting up of their biosimilars joint venture (JV). BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report To read this article on Zacks.com click here. The joint venture brings together Biogen's expertise in biologics and Samsung's acumen and experience in new business development.,
2012-02-29 00:00:00+00:00,115.51000213623048,117.95999908447266,115.48999786376952,116.47000122070312,116.47000122070312,1572000.0,2.0,1.0,0.250025,"Stocks recently featured in the blog include Encana Corporation ( ECA ), Enbridge Inc. ( ENB ), BankAtlantic Bancorp Inc. ( BBX ), BB&T Corporation ( BBT ) and Biogen Idec ( BIIB ). Biogen-Samsung Set Up JV Biogen Idec ( BIIB ) and Samsung Biologics recently announced the setting up of their biosimilars joint venture (JV). 9339 support@zacks.com http://www.zacks.com BB&T CORP ( BBT ): Free Stock Analysis Report BANKATLANTIC -A ( BBX ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report ENCANA CORP ( ECA ): Free Stock Analysis Report ENBRIDGE INC ( ENB ): Free Stock Analysis Report To read this article on Zacks.com click here.",
2012-03-05 00:00:00+00:00,118.16000366210938,119.94000244140624,116.97000122070312,118.41999816894533,118.41999816894533,1198300.0,4.0,1.0,0.7500249999999999,"Biogen Idec ( BIIB ) recently announced the submission of a new drug application (NDA) for its oral multiple sclerosis candidate, BG-12. BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report SANOFI-AVENTIS ( SNY ): Free Stock Analysis Report To read this article on Zacks.com click here. The NDA was based on data from the phase III DEFINE and CONFIRM studies which showed that treatment with BG-12 led to a significant reduction in disease activity in multiple sclerosis patients.",
2012-03-16 00:00:00+00:00,120.41999816894533,121.69000244140624,119.58000183105467,120.04000091552734,120.04000091552734,2196700.0,3.0,1.0,0.5000249999999999,"( BIIB ). ALKERMES INC ( ALKS ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report ELAN CP PLC ADR ( ELN ): Free Stock Analysis Report To read this article on Zacks.com click here. Elan ( ELN ) recently announced that it has sold 24.15 million shares, or 76% of its stake in Alkermes plc ( ALKS ).",
2012-03-19 00:00:00+00:00,120.0,120.4800033569336,119.56999969482422,119.97000122070312,119.97000122070312,732800.0,5.0,1.0,1.000025,"Biogen Idec ( BIIB ) recently signed an exclusive, worldwide option and collaboration agreement with privately held MAKScientific, LLC. ABBOTT LABS ( ABT ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report ISIS PHARMACEUT ( ISIS ): Free Stock Analysis Report To read this article on Zacks.com click here. The deal relates to the development and commercialization of drug candidates for the treatment of multiple sclerosis ( MS ) and other neurodegenerative diseases.",
2012-04-11 00:00:00+00:00,125.72000122070312,127.5500030517578,125.02999877929688,125.02999877929688,125.02999877929688,1793000.0,3.0,1.0,0.5000249999999999,"Biogen Idec Inc. ( BIIB ) is unchanged at $125.03, with 443,144 shares traded. As reported by Zacks, the current mean recommendation for BIIB is in the ""buy range"". Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter ending Mar 2012.",
2012-04-13 00:00:00+00:00,125.08000183105467,126.1999969482422,124.79000091552734,125.33999633789062,125.33999633789062,825800.0,3.0,1.0,0.5000249999999999,Biogen Idec ( BIIB ) recently announced the launch of Fampyra in Canada. ABBOTT LABS ( ABT ): Free Stock Analysis Report ACORDA THERAPT ( ACOR ): Free Stock Analysis Report BAYER A G -ADR ( BAYRY ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Fampyra gained approval in Canada in February 2012 for the symptomatic improvement of walking ability in adult multiple sclerosis ( MS ) patients.,
2012-04-25 00:00:00+00:00,128.08999633789062,130.80999755859375,127.4000015258789,129.2899932861328,129.2899932861328,1151200.0,2.0,1.0,0.250025,"We note that Gilenya could face competition from Biogen Idec's ( BIIB ) oral MS candidate BG-12 on approval. BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report To read this article on Zacks.com click here. Swiss pharmaceutical giant Novartis ( NVS ) reported earnings per share of $1.27 for the first quarter of 2012, missing the Zacks Consensus Estimate by $0.05.",
2012-04-26 00:00:00+00:00,129.44000244140625,130.9199981689453,128.99000549316406,130.8000030517578,130.8000030517578,1019000.0,3.0,1.0,0.5000249999999999,"Angiomax, acquired from Biogen Idec Inc. ( BIIB ), is the lead product at The Medicines Company. ASTRAZENECA PLC ( AZN ): Free Stock Analysis Report BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report MEDICINES CO ( MDCO ): Free Stock Analysis Report PFIZER INC ( PFE ): Free Stock Analysis Report To read this article on Zacks.com click here. The Medicines Company ( MDCO ) reported first quarter earnings of 21 cents per share, including the impact of stock-based compensation expense.",
2012-05-01 00:00:00+00:00,131.61000061035156,134.6699981689453,129.9199981689453,131.8300018310547,131.8300018310547,2154300.0,4.0,1.0,0.7500249999999999,"BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report ELAN CP PLC ADR ( ELN ): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Elan has a co-development agreement with Biogen Idec Inc. ( BIIB ) for Tysabri, under which Elan markets the drug in the US and books the entire sales as its revenues. Outside the US, Biogen is responsible for distribution, and Elan records as revenue its share of the profit/loss on these sales of Tysabri. New Article Biogen Idec ( BIIB ) reported first quarter earnings per share of $1.39, below the Zacks Consensus Estimate of $1.44 and the year-ago earnings of $1.42. BIOGEN IDEC INC ( BIIB ): Free Stock Analysis Report ELAN CP PLC ADR ( ELN ): Free Stock Analysis Report NOVARTIS AG-ADR ( NVS ): Free Stock Analysis Report To read this article on Zacks.com click here. We note that both Avonex and Tysabri are facing additional competition in the form of Novartis' ( NVS ) Gilenya which was launched in early Oct 2010.",
2012-05-02 00:00:00+00:00,131.19000244140625,135.38999938964844,131.19000244140625,135.16000366210938,135.16000366210938,1515300.0,3.0,1.0,0.5000249999999999,"New Purchases: A , HSY , IP , EWH , Added Positions: PG , LLY , JNJ , KMB , GIS , CLX , K , DELL , MDT , CBST , Reduced Positions: ABX , NEM , PNRA , GG , MAT , GOLD , EBAY , UA , TJX , BVN , CSCO , AU , ADTN , XLNX , CHL , HUM , SYNA , BRCM , GFI , BBBY , BMC , TXN , VRTX , LH , AMZN , GILD , PDCO , MSFT , SYK , BDX , ESI , ACE , HMY , SYY , AEM , NVS , SYNT , GPS , ORCL , QLGC , FRX , FSLR , RMD , SBS , Sold Out: ROST , AZO , MA , INTU , QCOM , BCR , NKE , PETM , COV , AFL , COH , BAX , SOHU , OTEX , WDC , ACN , WU , CTSH , ADBE , TER , HPQ , WHR , CAH , VPRT , PRX , IPXL , IDXX , TECH , NYT , EWC , SNP , CIG , EOC , SSRX , ELP , PHI , For the details of John Hussman 's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=John+Hussman This is the sector weightings of his portfolio: These are the top 5 holdings of John Hussman Biogen Idec Inc ( BIIB ) - 1,000,000 shares, 2.4% of the total portfolio. Hussman has repeated saying that the market is overvalued, overbought, and ""within the most negative 1% of historical return/risk profiles."" GuruFocus also provides promising stock ideas in 3 monthly newsletters sent to Premium Members .",
2012-05-04 00:00:00+00:00,132.99000549316406,133.32000732421875,130.52000427246094,130.97000122070312,130.97000122070312,1070200.0,4.0,1.0,0.7500249999999999,"Acorda has a licensing agreement with Biogen Idec ( BIIB ) for the development and commercialization of Ampyra outside the U.S. ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report To read this article on Zacks.com click here. In July 2011, Biogen received conditional approval for Fampyra (ex-U.S. trade name of Ampyra) in the E.U., as a treatment for improved walking in adult patients with multiple sclerosis.",
2012-05-08 00:00:00+00:00,131.60000610351562,133.05999755859375,130.85000610351562,132.92999267578125,132.92999267578125,1273900.0,3.0,1.0,0.5000249999999999,PDL BioPharma receives royalties on worldwide net sales of Roche Holdings Ltd.'s ( RHHBY ) Avastin and Herceptin; Roche and Novartis' ( NVS ) Lucentis and Xolair; and Elan Corporation ( ELN ) and Biogen Idec's ( BIIB ) Tysabri. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PDL BIOPHARMA (PDLI): Free Stock Analysis Report To read this article on Zacks.com click here. First quarter 2011 revenues were boosted by a $10 million sum received from UCB Pharma S.A. as final settlement of a legal dispute.,
2012-05-11 00:00:00+00:00,134.27000427246094,137.5,134.22999572753906,136.7100067138672,136.7100067138672,1189000.0,2.5,1.0,0.375025,"Biotech firm Biogen-Idec (Nasdaq: BIIB ) and dental supplies distributor Henry Schein (Nasdaq: HSIC ) aren't trying to bring attention to a lagging stock -- each trades near its 52-week high . The companies I discuss below have recently announced major stock buyback plans, and in a market slump, they'd be active buyers at a time when few friends can be found. The long slog back to relevance In a similar vein, health care information provider Allscripts (Nasdaq: MDRX ) is currently suffering from a botched merger , which I previously discussed in this article . New Article Biogen Idec ( BIIB ) recently announced the acceptance of its regulatory filings in the U.S. and E.U. ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. The regulatory filings were based on data from the phase III DEFINE and CONFIRM studies which showed that treatment with BG-12 led to a significant reduction in disease activity in multiple sclerosis patients.",
2012-05-14 00:00:00+00:00,135.8699951171875,137.67999267578125,135.5399932861328,136.8699951171875,136.8699951171875,934300.0,4.0,1.0,0.7500249999999999,"In addition, Zacks Equity Research provides analysis on Biogen Idec ( BIIB ), Abbott ( ABT ) and Novartis ( NVS ) Full analysis of all these stocks is available at http://at.zacks.com/?id=2678 . Latest Posts on the Zacks Analyst Blog : Standard Review for Biogen's BG-12 Biogen Idec ( BIIB ) recently announced the acceptance of its regulatory filings in the U.S. and E.U. 9339 support@zacks.com http://www.zacks.com ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report EASTMAN CHEM CO (EMN): Free Stock Analysis Report KIRKLANDS INC (KIRK): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here.",173.3560028076172
2012-05-18 00:00:00+00:00,133.05999755859375,133.3300018310547,130.4600067138672,131.5800018310547,131.5800018310547,1838700.0,3.0,1.0,0.5000249999999999,"Biogen Idec ( BIIB ) and Elan Corporation, plc ( ELN ) recently announced the publishing of research from the Tysabri risk management program in the New England Journal of Medicine . BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report To read this article on Zacks.com click here. As per the updated label, anti-JC virus antibody status is a risk factor for developing PML, a rare and life-threatening brain infection.",178.22630310058594
2012-05-21 00:00:00+00:00,132.1999969482422,132.74000549316406,131.30999755859375,132.25999450683594,132.25999450683594,1479600.0,3.0,1.0,0.5000249999999999,"Stocks recently featured in the blog include Dr. Reddy's Laboratories ( RDY ), Bristol-Myers Squibb & Co. ( BMY ), Teva Pharmaceutical Industries Ltd. ( TEVA ), Biogen Idec ( BIIB ) and Elan Corporation, plc ( ELN ). Data on Elan and Biogen's Tysabri Biogen Idec ( BIIB ) and Elan Corporation, plc ( ELN ) recently announced the publishing of research from the Tysabri risk management program in the New England Journal of Medicine . 9339 support@zacks.com http://www.zacks.com BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report DOCTOR REDDYS (RDY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here.",185.283203125
2012-05-24 00:00:00+00:00,131.0800018310547,132.6199951171875,130.8300018310547,131.64999389648438,131.64999389648438,1069600.0,3.0,1.0,0.5000249999999999,"( BIIB ), have a strategic alliance to develop and commercialize ERBB3 antibodies for the treatment of cancer. AVEO PHARMACEUT (AVEO): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The multi-center, dose escalation study will evaluate the candidate's safety and preliminary tolerability among other endpoints.",173.8811492919922
2012-05-25 00:00:00+00:00,132.25,132.89999389648438,131.07000732421875,131.55999755859375,131.55999755859375,757200.0,3.0,1.0,0.5000249999999999,"Biogen Idec ( BIIB ) recently announced that Health Canada has approved a change in the label of its multiple sclerosis (MS) drug, Tysabri. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. The new label of the drug indicates anti-JC virus (JCV) antibody status as a risk factor for developing a rare, serious brain infection known as progressive multifocal leukoencephalopathy (PML).",180.91714477539062
2012-05-30 00:00:00+00:00,130.9199981689453,131.8300018310547,130.25,130.83999633789062,130.83999633789062,1272200.0,4.0,1.0,0.7500249999999999,"We are positive on Isis' agreements with GlaxoSmithKline ( GSK ) and Biogen ( BIIB ) which not only validate its antisense technology but also provide Isis Pharma with funds in the form of upfront, milestone and other payments. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Genzyme, a Sanofi ( SNY ) company, and partner Isis Pharmaceuticals Inc. ( ISIS ) recently announced that their new drug application (NDA) for pipeline candidate Kynamro has been accepted by the US Food and Drug Administration (FDA) for standard review.",196.07362365722656
2012-06-04 00:00:00+00:00,126.4499969482422,130.91000366210938,126.38999938964844,130.7899932861328,130.7899932861328,1510000.0,4.0,1.0,0.7500249999999999,"Another major competitor could be Biogen Idec's ( BIIB ) BG-12, which is currently under regulatory review in both the US and the EU. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report (MKGAF): ETF Research Reports NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Sanofi's ( SNY ) subsidiary, Genzyme, recently announced encouraging top-line results on its phase III candidate, Aubagio (teriflunomide).",210.3990478515625
2012-06-08 00:00:00+00:00,132.7100067138672,134.44000244140625,132.22999572753906,133.52000427246094,133.52000427246094,919900.0,3.0,1.0,0.5000249999999999,"( BIIB ) have also entered the biosimilar space through various agreements. AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report HOSPIRA INC (HSP): Free Stock Analysis Report (MKGAF): ETF Research Reports DOCTOR REDDYS (RDY): Free Stock Analysis Report To read this article on Zacks.com click here. The companies will co-develop and commercialize a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies (MAbs). New Article The company has around 100 client tenants in the area including the likes of GlaxoSmithKline plc ( GSK ), Abbott Laboratories ( ABT ), Biogen Idec Inc. ( BIIB ), Novartis AG ( NVS ), Quest Diagnostics Inc. ( DGX ), Thermo Fisher Scientific Inc. ( TMO ) and others. ABBOTT LABS (ABT): Free Stock Analysis Report ALEXANDRIA REAL (ARE): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report QUEST DIAGNOSTC (DGX): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report SYNTA PHARMACT (SNTA): Free Stock Analysis Report THERMO FISHER (TMO): Free Stock Analysis Report To read this article on Zacks.com click here. It owns and operates approximately 3.5 million square feet of office and high-quality laboratory space in close proximity to the renowned academic and medical institutions of world.",213.98236083984375
2012-06-14 00:00:00+00:00,134.6699981689453,139.2100067138672,134.3800048828125,138.66000366210938,138.66000366210938,1597300.0,3.5,1.0,0.6250249999999999,"PDL BioPharma receives royalties on worldwide net sales of Roche Holdings Ltd.'s ( RHHBY ) Avastin and Herceptin; Roche and Novartis' ( NVS ) Lucentis and Xolair; and Elan Corporation ( ELN ) and Biogen Idec's ( BIIB ) Tysabri. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PDL BIOPHARMA (PDLI): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. Effective from the second quarter of 2011, PDL BioPharma started paying back a portion of the royalties it receives on Lucentis sales outside the US to Novartis. New Article ( BIIB ) is the company's exclusive partner to develop and commercialize Ampyra (ex-US trade name: Fampyra) outside the US. ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report To read this article on Zacks.com click here. No pharmaceutical treatment is currently available for these impairments - this provides Acorda with significant commercial opportunity if Ampyra is developed successfully for this patient population.",208.59262084960938
2012-06-15 00:00:00+00:00,139.13999938964844,140.67999267578125,138.27000427246094,140.00999450683594,140.00999450683594,1904300.0,2.0,1.0,0.250025,"Gilenya is the only oral therapy approved treating patients suffering from relapsing forms of MS. Data from the TRANSFORMS study revealed reductions in relapses and MRI measures in patients who shifted from Biogen Idec Inc. 's ( BIIB ) MS drug Avonex to Gilenya in the extended phase. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis AG ( NVS ) recently announced new long-term data from an extended phase III head-to-head TRANSFORMS study, which evaluated its multiple sclerosis (MS) candidate Gilenya (fingolimod).",211.02127075195312
2012-07-06 00:00:00+00:00,144.02999877929688,144.9199981689453,141.85000610351562,142.4600067138672,142.4600067138672,831400.0,3.0,1.0,0.5000249999999999,"Biogen Idec ( BIIB ) and partner Swedish Orphan Biovitrum recently announced that they are evaluating their hemophilia candidates, long-acting factor VIII and long-acting factor IX (rFVIIIFc and rFIXFc), in children below 12 years of age. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. A convenient dosing schedule (supported by a longer duration of action and a suitable safety profile) could help these candidates capture share from existing products in the hemophilia market.",205.2433319091797
2012-07-10 00:00:00+00:00,144.36000061035156,145.72999572753906,142.89999389648438,143.75,143.75,1151000.0,5.0,1.0,1.000025,BIIB rose 0.49 percent to $143.16 yesterday and is up 30 percent so far this year. The trader collected a credit of $2.90 and stands to earn infinite profits if the drug maker continues to push higher. He or she will be forced to buy shares if they fall below $130 but may be comfortable with the risk because that level was resistance in April and became support the next month.,200.26829528808594
2012-07-11 00:00:00+00:00,143.3000030517578,143.44000244140625,140.1699981689453,142.0,142.0,1060100.0,4.0,1.0,0.7500249999999999,"We are also positive on Isis Pharma's agreements with GlaxoSmithKline ( GSK ) and Biogen Idec ( BIIB ), which not only validate its antisense technology but also provide Isis Pharma with funds in the form of upfront, milestone and other payments. AEGERION PHARMA (AEGR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Isis Pharma's lead pipeline candidate, Kynamro (mipomersen), is being developed for the treatment of familial hypercholesterolemia (FH).",180.86351013183594
2012-07-13 00:00:00+00:00,143.16000366210938,144.89999389648438,142.35000610351562,144.61000061035156,144.61000061035156,733400.0,3.0,1.0,0.5000249999999999,"Stocks discussed include: Ocwen Financial ( OCN ), Nationstar Mortgage ( NSM ), Amgen ( AMGN ), Biogen IDEC ( BIIB ), Dean Foods ( DF ), Catamaran (CTRX) and BioReference Labs (BRLI) . And in the long run, avoiding things like herd-driven buying at the top and desperation selling at the bottom (which is apparently a male specialty) enables women to edge ahead in the long-term results column. But the temptation to predict the upturn might be too strong for whichever sex is more competitive, and I don't think it's hugely controversial to say that men, as a group, fit that description pretty well.",176.5974578857422
2012-07-18 00:00:00+00:00,145.94000244140625,146.6699981689453,144.80999755859375,144.9600067138672,144.9600067138672,747900.0,3.0,1.0,0.5000249999999999,"Abbott Labs, along with partner Biogen ( BIIB ), is evaluating daclizumab in a phase III study for the treatment of relapsing-remitting multiple sclerosis (RRMS). ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs is currently evaluating Humira's safety and efficacy in adult patients with moderate to severe hidradenitis suppurativa (HS).",184.71954345703125
2012-07-20 00:00:00+00:00,143.77000427246094,144.38999938964844,142.11000061035156,142.2100067138672,142.2100067138672,1168500.0,2.0,1.0,0.250025,"Gilenya could, however, face competition from Biogen Idec's ( BIIB ) oral MS candidate BG-12, which is currently under regulatory review in the EU and US. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, the Committee for Medicinal Products for Human Use (CHMP) recently voted in favor of using Afinitor in advanced breast cancer patients.",190.339599609375
2012-07-23 00:00:00+00:00,142.1199951171875,142.1199951171875,137.8800048828125,139.22999572753906,139.22999572753906,1128500.0,3.0,1.0,0.5000249999999999,"Biogen Idec Inc. ( BIIB ) is slated to announce its second quarter results on Tuesday, July 24, before the opening bell. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report To read this article on Zacks.com click here. Global in-market net revenues of Tysabri, which is partnered with Elan Corp. ( ELN ), came in at $399 million (up 14%) in the first quarter of 2012.",194.78526306152344
2012-07-24 00:00:00+00:00,142.52000427246094,142.67999267578125,137.9600067138672,139.47999572753906,139.47999572753906,1313300.0,4.0,1.0,0.7500249999999999,"Biogen Idec ( BIIB ) reported second quarter earnings per share of $1.82, well above the Zacks Consensus Estimate of $1.56 and 34.8% above the year-ago earnings of $1.35. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. We note that both Avonex and Tysabri are facing additional competition in the form of Novartis' ( NVS ) Gilenya which was launched in early Oct 2010.",200.0088653564453
2012-07-26 00:00:00+00:00,144.44000244140625,148.30999755859375,144.1699981689453,147.75,147.75,1430000.0,4.0,1.0,0.7500249999999999,"Angiomax, acquired from Biogen Idec Inc. ( BIIB ), is the lead product at The Medicines Company. ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report To read this article on Zacks.com click here. The company has a worldwide development and collaboration agreement with AstraZeneca for acute ischemic heart disease compounds including Brilinta, Angiomax and Cangrelor.",206.3182373046875
2012-07-27 00:00:00+00:00,149.0,150.22999572753906,148.1999969482422,149.47000122070312,149.47000122070312,1422300.0,5.0,1.0,1.000025,"Amgen ( AMGN ),Celgene ( CELG ),Biogen Idec ( BIIB ),Gilead Sciences ( GILD ) andRegeneron Pharmaceutical ( REGN ) all topped analyst consensus views, plus raised their Q3 and full-year guidance. The recent Glaxo-Human Genome and Bristol-Amylin deals are classic examples of big pharmas buying biotechs to fill out their pipelines as their blockbuster patents expire. In a July 20 report, RBC Capital Markets analyst Michael Yee citedBioMarin (BMRN),Pharmacyclics (PCYC) andIncyte (INCY) as stocks that have rallied on buyout speculation.",199.0205078125
2012-07-30 00:00:00+00:00,149.72000122070312,150.2899932861328,146.92999267578125,147.27999877929688,147.27999877929688,864600.0,4.0,1.0,0.7500249999999999,"We note that Elan has a co-development agreement with Biogen Idec Inc. ( BIIB ) for Tysabri, under which Elan markets the drug in the US and books the entire sales as its revenues. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Total revenues included Tysabri sales recorded by Elan, adjustments related to Azactam (which the company no longer markets) and royalties.",188.8328857421875
2012-08-01 00:00:00+00:00,146.3000030517578,147.88999938964844,144.02999877929688,144.27999877929688,144.27999877929688,962200.0,4.0,1.0,0.7500249999999999,"Acorda has a licensing agreement with Biogen Idec ( BIIB ) for the development and commercialization of Ampyra outside the US. ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report WATSON PHARMA (WPI): Free Stock Analysis Report To read this article on Zacks.com click here. In July 2011, Biogen received conditional approval for Fampyra (ex-US trade name of Ampyra) in the EU, as a treatment for improved walking in adult patients with multiple sclerosis.",186.17111206054688
2012-08-02 00:00:00+00:00,142.8800048828125,144.61000061035156,141.8800048828125,143.8000030517578,143.8000030517578,1115600.0,4.0,1.0,0.7500249999999999,"The country's best-performing funds of the past three months have been stoking their portfolios with big-cap biotech stocks, such asAlexion Pharmaceuticals ( ALXN ),Amgen ( AMGN ), Biogen Idec ( BIIB ) andRegeneron Pharmaceuticals ( REGN ). Amgen,Gilead Sciences ( GILD ), Alexion andOnyx Pharmaceuticals (ONXX) each has notched new 52-week highs in recent weeks. Fast-food chainsPapa John's International (PZZA) andAFC Enterprises (AFCE), which runs Popeyes Chicken, have been stellar performers.",194.7989044189453
2012-08-06 00:00:00+00:00,145.2899932861328,146.25999450683594,144.57000732421875,145.4600067138672,145.4600067138672,704900.0,3.5,1.0,0.6250249999999999,"We remind investors that the company has alliances with players such as Medtronic, Inc. ( MDT ), Novartis AG ( NVS ), Biogen Idec Inc. ( BIIB ), Roche Holdings Ltd. ( RHHBY ), Cubist Pharmaceuticals Inc. ( CBST ) for its expertise in RNAi therapeutics. ALNYLAM PHARMA (ALNY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CUBIST PHARM (CBST): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. Alnylam Pharmaceuticals Inc. ( ALNY ) recently earned development milestone payment of $3.2 million from GlaxoSmithKline ( GSK ). New Article Biogen Idec Inc. ( BIIB ): Executive Vice President and General Counsel Susan H. Alexander sold 59,235 Shares Executive Vice President and General Counsel of Biogen Idec Inc. ( BIIB ) Susan H. Alexander sold 59,235 shares during the past week at an average price of $145.1. Executive Vice President and General Counsel Susan H. Alexander sold 49,800 shares of BIIB stock on 06/15/2012 at the average price of $140. Senior Vice President, General Counsel and Secretary Dorian Daley sold 20,000 shares of ORCL stock on 07/17/2012 at the average price of $30.",182.99169921875
2012-08-09 00:00:00+00:00,144.86000061035156,145.3300018310547,142.72000122070312,143.08999633789062,143.08999633789062,1209800.0,3.5,1.0,0.6250249999999999,"Key players in the multiple sclerosis market include Biogen ( BIIB ) and Novartis ( NVS ) among others. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. The study will be conducted under the US Food and Drug Administration's (FDA) Special Protocol Assessment (SPA) program. New Article In addition to the $25 million milestone payment from Genzyme, second quarter 2012 revenues included the amortization of the $29 million upfront fee received from Biogen Idec ( BIIB ) earlier this year. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Results were driven by a $25 million milestone payment received from Sanofi's ( SNY ) subsidiary, Genzyme, related to the acceptance of the new drug application (NDA) for Kynamro (mipomersen).",169.2264404296875
2012-08-13 00:00:00+00:00,145.05999755859375,145.14999389648438,143.17999267578125,144.5399932861328,144.5399932861328,593900.0,3.0,1.0,0.5000249999999999,"Between here and there, we might suggest taking advantage of dips by adding market leaders like Google Inc. (GOOG), Amazon Inc. (AMZN), Apple Inc. (AAPL), Biogen Idec Inc. (BIIB), Fossil, Inc. (FOSL) and some of your favorites. However, the pause was accompanied by a fall in volume, which can be interpreted in one of two ways: Investors expect stocks to rise and are unwilling to sell, or; Buyers are hoping for a mild correction to buy the dip. Weve read that $1 trillion in easing has been priced into stocks, and many brokers, such as Goldman Sachs, believe QE3 is a done deal in month number 9.",174.39663696289062
2012-08-14 00:00:00+00:00,145.02999877929688,145.89999389648438,144.2899932861328,145.5,145.5,512700.0,2.5,1.0,0.375025,"The drug is marketed outside the US under the trade name of Fampyra by Biogen Idec Inc. ( BIIB ) under a license agreement with Acorda. ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics Inc. ( ACOR ) recently announced results from a post-marketing commitment study evaluating a 5 mg dose of Ampyra (dalfampridine-ER) for improvement in walking in patients suffering from multiple sclerosis (MS). New Article While one company will focus on drug discovery, the other, which will retain the company name, will have Tysabri (co-marketed with Biogen Idec Inc. ( BIIB )), ELND005 (phase II) and Elan's interest in Johnson & Johnson 's ( JNJ ) Janssen Alzheimer Immunotherapy. ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Elan Corporation ( ELN ) recently announced its decision to split into two separate publicly traded companies.",180.6363067626953
2012-08-16 00:00:00+00:00,147.39999389648438,147.75,145.85000610351562,146.83999633789062,146.83999633789062,465300.0,3.0,1.0,0.5000249999999999,"Regulus Therapeutics Inc. and Biogen Idec ( BIIB ) recently entered into a deal to identify microRNAs (micro-RiboNucleic Acids) as biomarkers for multiple sclerosis (MS). ALNYLAM PHARMA (ALNY): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, MicroRNA biomarkers have the potential to assist in the selection of optimal patient segments for clinical trials, developing companion diagnostics and monitoring disease progression or relapse.",194.38572692871094
2012-08-22 00:00:00+00:00,143.8300018310547,145.8000030517578,143.50999450683594,144.9199981689453,144.9199981689453,799200.0,4.0,1.0,0.7500249999999999,"The company has collaborated with several companies including Glaxo, Sanofi, AstraZeneca and Biogen Idec ( BIIB ) for microRNA therapeutics. ALNYLAM PHARMA (ALNY): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. In a separate private placement, AstraZeneca ( AZN ) has agreed to buy $25.0 million worth of Regulus's common stock at the initial public offering price.",187.31826782226562
2012-08-28 00:00:00+00:00,146.94000244140625,147.3699951171875,146.0,146.42999267578125,146.42999267578125,614700.0,2.0,1.0,0.250025,"Key players in the multiple sclerosis market include Biogen ( BIIB ) and Novartis ( NVS ) among others. BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report (MKGAF): ETF Research Reports NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Sanofi's ( SNY ) subsidiary, Genzyme, recently announced that the US Food and Drug Administration (FDA) has issued a refuse-to-file letter in relation to its marketing application for Lemtrada (alemtuzumab).",205.5106964111328
2012-08-29 00:00:00+00:00,147.16000366210938,147.2100067138672,145.60000610351562,145.88999938964844,145.88999938964844,689500.0,4.0,1.0,0.7500249999999999,"Alnylam had earlier entered into key partnerships with companies like Medtronic, Inc. ( MDT ), Novartis AG ( NVS ), Biogen Idec Inc. ( BIIB ), Roche Holding AG ( RHHBY ), Takeda Pharmaceutical Company Limited ( TKPYY) and Cubist Pharmaceuticals Inc. ( CBST ) to share its RNAi know-how. ALNYLAM PHARMA (ALNY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CUBIST PHARM (CBST): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report MONSANTO CO-NEW (MON): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report (RHHBY): ETF Research Reports (TKPYY): ETF Research Reports To read this article on Zacks.com click here. Alnylam Pharmaceuticals, Inc. ( ALNY ) and Monsanto Company ( MON ) recently formed a strategic alliance to implement biological technologies in the field of agriculture.",202.4864044189453
2012-09-05 00:00:00+00:00,147.27999877929688,147.74000549316406,145.63999938964844,146.6699981689453,146.6699981689453,626200.0,2.0,1.0,0.250025,"IBD: Biogen Idec's ( BIIB ) quarterly earnings per share rebounded, growing 34% after falling by 2% the prior quarter. When we think about a market operating in uncertain times, to the extent you can find high-quality names with a nice income component, that bolsters your overall return case. Deininger: Avago is a semiconductor company that is part of the supply chain that is enabling the radio frequency technology within the handset market.",206.1822967529297
2012-09-06 00:00:00+00:00,147.77000427246094,152.75,147.77000427246094,152.19000244140625,152.19000244140625,1187500.0,3.5,1.0,0.6250249999999999,"Alnylam also has collaborations or deals with players, such as Novartis AG ( NVS ), Biogen Idec Inc. ( BIIB ) and Roche Holding AG ( RHHBY ) to further develop and utilize its core technology. ALNYLAM PHARMA (ALNY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CUBIST PHARM (CBST): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. Alnylam Pharmaceuticals, Inc. ( ALNY ) recently presented complete results from a phase IIb trial on ALN-RSV01 at the European Respiratory Society's (ERS) Annual Meeting. New Article While one company will focus on drug discovery, the other, which will retain the company name, will have Tysabri (co-marketed with Biogen Idec Inc. ( BIIB )), ELND005 (phase II) and Elan's interest in Johnson & Johnson 's ( JNJ ) Janssen Alzheimer Immunotherapy. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. ELND005 is being developed as an adjunctive maintenance treatment in patients suffering from bipolar I disorder (BPD 1) to lengthen the time period between mood episodes.",207.56304931640625
2012-09-07 00:00:00+00:00,153.07000732421875,153.1999969482422,150.6199951171875,152.5,152.5,666200.0,3.0,1.0,0.5000249999999999,"PDL BioPharma receives royalties on worldwide net sales of Roche Holdings Ltd. 's ( RHHBY ) Avastin and Herceptin; Roche/ Novartis ' ( NVS ) Lucentis and Xolair; and Elan Corporation/Biogen Idec 's ( ELN / BIIB ) Tysabri. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PDL BIOPHARMA (PDLI): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. Effective from the second quarter of 2011, PDL BioPharma started paying back a portion of the royalties it receives on Lucentis sales outside the US to Novartis.",211.80978393554688
2012-09-14 00:00:00+00:00,152.44000244140625,154.24000549316406,150.64999389648438,154.24000549316406,154.24000549316406,1269400.0,3.5,1.0,0.6250249999999999,"Another major competitor could be Biogen Idec 's (BIIB) BG-12, which is currently under regulatory review in the US and the EU. Per the terms of the deal, Oncodesign's Nanocyclix technology will be applied exclusively in several of Sanofi's kinase target programs for a period of four years. Sanofi is liable to pay up to 130 million as technology access fee and on the achievement of discovery, development, regulatory and commercial milestones along with low single-digit royalties on net sales. New Article Biogen Idec ( BIIB ) recently announced that it has sold its royalty and other rights related to GlaxoSmithKline's ( GSK ) Benlysta to a fund managed by DRI Capital. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report To read this article on Zacks.com click here. Once this period expires, DRI will be entitled to full royalty payments on Benlysta sales barring certain cases.",210.20114135742188
2012-09-18 00:00:00+00:00,154.75999450683594,156.52000427246094,154.4499969482422,155.8000030517578,155.8000030517578,1075700.0,2.0,1.0,0.250025,"For example, Risperdal Consta is marketed by Johnson & Johnson ( JNJ ), Ampyra/ Fampyra is marketed by Acorda Therapeutics, Inc. ( ACOR ) in the US and by Biogen Idec ( BIIB ) in ex-US markets. ACORDA THERAPT (ACOR): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. We are moving back to a Neutral recommendation on Alkermes plc ( ALKS ) as we believe the stock is fairly valued at current levels.",199.00369262695312
2012-09-24 00:00:00+00:00,155.0800018310547,155.13999938964844,153.0,154.39999389648438,154.39999389648438,832600.0,4.5,1.0,0.8750249999999999,"Positive earnings estimate revisions, a strong second quarter and an upbeat guidance for 2012 helped Biogen Idec, Inc. ( BIIB ) hit its 52-week high on September 20, 2012. Learn More>> BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, this Zacks #1 Rank (Strong Buy) biotechnology company has delivered positive earnings surprises in six of the last eight quarters with an average beat of 5.6%. New Article Biogen Idec Inc. ( BIIB ) Reached the 52-Week High of $154.58 The prices of Biogen Idec Inc. ( BIIB ) shares have reached $154.58, which is 1.0% off the 52-week high of $156.06. CEO George A. Scangos , Director Robert W. Pangia and Director Stephen A. Sherwin sold shares of BIIB stock. IDEC Pharmaceuticals Corporation is a biopharmaceutical company engaged primarily in the research, development and commercialization of targeted therapies for the treatment of cancer and autoimmune and inflammatory diseases.",190.8890380859375
2012-09-27 00:00:00+00:00,152.1300048828125,153.08999633789062,150.25999450683594,150.7100067138672,150.7100067138672,1743800.0,4.0,1.0,0.7500249999999999,"Biogen Idec ( BIIB ) and partner, Swedish Orphan Biovitrum, recently presented positive phase III top-line results on their long-acting factor IX (rFIXFc) candidate for hemophilia B. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Results from the global, open-label, multi-center B-LONG study showed that rFIXFc was effective in controlling and preventing bleeding, routine prophylaxis, and perioperative management.",183.15570068359375
2012-10-05 00:00:00+00:00,152.0,154.0399932861328,151.8699951171875,152.52999877929688,152.52999877929688,965700.0,3.0,1.0,0.5000249999999999,"The company has collaborated with several companies including Glaxo, Sanofi, AstraZeneca and Biogen Idec ( BIIB ) for microRNA therapeutics. ALNYLAM PHARMA (ALNY): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. In order to cover over allotments, the underwriters have been granted a 30-day option by Regulus to buy another 1.7 million shares at initial public offering price.",187.23623657226562
2012-10-10 00:00:00+00:00,149.63999938964844,151.0399932861328,147.00999450683594,147.2899932861328,147.2899932861328,870800.0,3.0,1.0,0.5000249999999999,"PDL BioPharma receives royalties on worldwide net sales of Roche Holdings Ltd. 's ( RHHBY ) Avastin and Herceptin; Roche/ Novartis ' ( NVS ) Lucentis and Xolair; and Elan Corporation / Biogen Idec 's ( ELN / BIIB ) Tysabri. (AXGN): ETF Research Reports BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PDL BIOPHARMA (PDLI): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. PDL BioPharma, Inc. ( PDLI ) and AxoGen, Inc. ( AXGN ) recently completed a structured financing transaction.",179.61801147460938
2012-10-12 00:00:00+00:00,147.50999450683594,149.77999877929688,146.97000122070312,147.1999969482422,147.1999969482422,1084400.0,3.0,1.0,0.5000249999999999,"The company has collaborated with several companies including Glaxo, Sanofi, AstraZeneca and Biogen Idec ( BIIB ) for microRNA therapeutics. ALNYLAM PHARMA (ALNY): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report (RGLS): ETF Research Reports SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Regulus, founded by Alnylam Pharmaceuticals ( ALNY ) and Isis Pharma, announced the pricing of its initial public offering earlier this month. New Article Elan Corporation ( ELN ) and partner Biogen Idec ( BIIB ) recently presented data from 11 company-sponsored Tysabri (natalizumab) studies at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report To read this article on Zacks.com click here. The results showed that 37% of the patients treated with Tysabri were free of clinical and radiological disease activity over the study period. New Article Data from the TRANSFORMS study revealed reductions in relapses and MRI measures in patients who shifted from Biogen Idec Inc. 's ( BIIB ) MS drug Avonex to Gilenya in the extended phase. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis AG ( NVS ) recently announced results from two large phase III studies of its multiple sclerosis (MS) drug Gilenya.",182.49667358398438
2012-10-17 00:00:00+00:00,153.05999755859375,154.91000366210938,152.41000366210938,153.77999877929688,153.77999877929688,813400.0,3.0,1.0,0.5000249999999999,"Abbott Labs, along with partner Biogen ( BIIB ), is evaluating daclizumab in a phase III study for the treatment of relapsing-remitting multiple sclerosis (RRMS). ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Labs also gained US approval for Humira for the treatment of moderately to severely active ulcerative colitis (UC) in patients who have not responded adequately to conventional therapy.",188.08517456054688
2012-10-18 00:00:00+00:00,152.0,152.49000549316406,148.35000610351562,149.55999755859375,149.55999755859375,2018400.0,2.0,1.0,0.250025,"We are positive on Acorda's June 2009 agreement with Biogen Idec ( BIIB ) for the development and commercialization of Fampyra (ex-US trade name of Ampyra) in ex-US markets. ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. We recently initiated coverage on commercial-stage biopharmaceutical company Acorda Therapeutics, Inc. ( ACOR ) with a Neutral recommendation and a target price of $25.00.",193.26736450195312
2012-10-19 00:00:00+00:00,150.02000427246094,151.4600067138672,144.83999633789062,145.64999389648438,145.64999389648438,2151700.0,2.0,1.0,0.250025,Abbott Labs has partnered with Biogen Idec ( BIIB ) for daclizumab. ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The study was being conducted to evaluate the safety and efficacy of bardoxolone methyl in patients with stage 4 chronic kidney disease (CKD) and type II diabetes.,178.93218994140625
2012-10-23 00:00:00+00:00,143.75999450683594,144.0,141.13999938964844,142.05999755859375,142.05999755859375,1055200.0,3.0,1.0,0.5000249999999999,"Acorda has a license and collaboration agreement with Biogen Idec ( BIIB ) for the development and commercialization of Fampyra outside the US. ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The patent is related to Acorda's lead product Ampyra (dalfampridine, 10 mg).",182.89501953125
2012-10-24 00:00:00+00:00,142.58999633789062,144.02999877929688,141.5800018310547,142.05999755859375,142.05999755859375,1655200.0,3.6666666666666665,1.0,0.6666916666666666,"Biogen Idec Inc. ( BIIB ) is reporting for the quarter ending September 30, 2012. BIIB missed the consensus earnings per share in the 1st calendar quarter by -3.47%. Zacks Investment Research reports that the 2012 Price to Earnings ratio for BIIB is 21.99 vs. an industry ratio of -5.20, implying that they will have a higher earnings growth than their competitors in the same industry. New Article Another major competitor could be Biogen Idec's ( BIIB ) BG-12, which is currently under regulatory review in the US and EU. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Sanofi ( SNY ) and its subsidiary Genzyme recently presented positive data on its oral treatment for relapsing forms of multiple sclerosis (RMS), Aubagio (teriflunomide). New Article BIIB is up 0.91 percent to $143.35 in afternoon trading. Biogen Idec has dropped before tomorrow's earnings report, but one trader is taking a bullish position. optionMONSTER's Heat Seeker monitoring program detected the purchase of 2,500 November 145 calls for $4.80.",187.51300048828125
2012-10-25 00:00:00+00:00,145.0,146.4499969482422,144.14999389648438,144.42999267578125,144.42999267578125,1381400.0,3.333333333333333,1.0,0.5833583333333334,"Angiomax, acquired from Biogen Idec Inc. ( BIIB ), is the lead product at The Medicines Company. ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report To read this article on Zacks.com click here. The company has a worldwide development and collaboration agreement with AstraZeneca for acute ischemic heart disease compounds including Brilinta, Angiomax and Cangrelor. New Article Biogen Idec ( BIIB ) reported third quarter earnings per share of $1.90, well above the Zacks Consensus Estimate of $1.61 and 19.5% above the year-ago earnings of $1.59. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report (RHHBY): ETF Research Reports SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. On its second quarter call, Biogen had noted that it expects Tysabri sales to continue being impacted by a deferred revenue issue in Italy despite its efforts to resolve the situation. New Article We note that Elan has a co-development agreement with Biogen Idec Inc. ( BIIB ) for Tysabri, under which Elan markets the drug in the US and books the entire sales as its revenues. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. The sales in ROW were impacted by negative currency translations and $47.0 million of deferred revenue in Italy.",195.6311798095703
2012-11-01 00:00:00+00:00,139.3000030517578,140.5399932861328,138.2100067138672,139.02999877929688,139.02999877929688,1165300.0,3.0,1.0,0.5000249999999999,"The companies that experienced the reductions are: Gilead Sciences Inc. ( GILD ), Biogen Idec Inc. ( BIIB ), Pall Corp. ( PLL ), Onyx Pharmaceuticals ( ONXX ) and Regeneron Pharmaceuticals ( REGN ). Pennsylvania-based Vanguard Health Care Fund has reduced its stake of five companies out of the seven total transactions it reported recently for its third quarter portfolio update. As the largest fund in the global health and biotech category, according to its website, Vanguard reduced the most in fluid management solutions provider, Pall Corp., by 61.56 percent of its shares with the company.",211.3033905029297
2012-11-02 00:00:00+00:00,138.97000122070312,139.3800048828125,137.57000732421875,138.41000366210938,138.41000366210938,1325200.0,2.0,1.0,0.250025,"Acorda has a licensing agreement with Biogen Idec ( BIIB ) for the development and commercialization of Ampyra outside the US. ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report To read this article on Zacks.com click here. In July 2011, Biogen received conditional approval for Fampyra (ex-US trade name of Ampyra) in the EU, as a treatment for improved walking in adult patients with multiple sclerosis.",216.24252319335938
2012-11-07 00:00:00+00:00,139.6199951171875,139.86000061035156,138.25999450683594,138.35000610351562,138.35000610351562,1037600.0,3.0,1.0,0.5000249999999999,"The gross proceedings include $50.9 million from the sale of common stock in the IPO, $25.0 million from the sale of common stock in a private placement to AstraZeneca ( AZN ) and $5.0 million from the sale of a convertible note to Biogen Idec ( BIIB ) in August this year. ALNYLAM PHARMA (ALNY): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CUBIST PHARM (CBST): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report (RHHBY): ETF Research Reports SANOFI-AVENTIS (SNY): Free Stock Analysis Report (TKPYY): ETF Research Reports To read this article on Zacks.com click here. The increase in G&A expenses was primarily attributable to the hike in consulting and professional services related to the company's business and legal activities. New Article PDL BioPharma receives royalties on worldwide net sales of Roche Holdings Ltd. 's ( RHHBY ) Avastin and Herceptin; Roche/ Novartis ' ( NVS ) Lucentis and Xolair; and Elan Corporation/Biogen Idec 's ( ELN / BIIB ) Tysabri. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PDL BIOPHARMA (PDLI): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. Effective from the second quarter of 2011, PDL BioPharma started paying back a portion of the royalties it receives on Lucentis sales outside the US to Novartis.",216.9738311767578
2012-11-16 00:00:00+00:00,137.60000610351562,142.0,137.60000610351562,141.24000549316406,141.24000549316406,2349100.0,2.0,1.0,0.250025,"For example, Risperdal Consta is marketed by Johnson & Johnson ( JNJ ), Ampyra/ Fampyra is marketed by Acorda Therapeutics, Inc. ( ACOR ) in the US and by Biogen Idec ( BIIB ) in the ex-US markets. ACORDA THERAPT (ACOR): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. We are reverting to a Neutral recommendation on Alkermes plc ( ALKS ) from Outperform as we believe that the stock is fairly valued at current levels.",223.8845977783203
2012-11-19 00:00:00+00:00,141.85000610351562,143.5800018310547,139.83999633789062,143.52999877929688,143.52999877929688,1433500.0,2.5,1.0,0.375025,"Alnylam has formed major alliances with leading companies, such as Medtronic, Inc. ( MDT ), Novartis ( NVS ), Biogen Idec ( BIIB ) and Roche Holdings ( RHHBY ). ALNYLAM PHARMA (ALNY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. As per the new licensing agreement, some intellectual property (IP) elements regarding lipid nanoparticle (LNP) technology for ribo nucleic acid interference (RNAi) therapeutics have been merged and clarified. New Article Align Technologies ( ALGN ) sold October 18th, Alexion ( ALXN ) was sold October 24th, Biogen Idec ( BIIB ) was sold October 31st, Express Scripts (ESRX) was sold October 19th, HMS Holdings (HMSY) was sold October 4th, and Healthstream (HSTM) was sold October 23rd. Times like these force us to examine our priorities and sometimes our investment performance isn't as significant as the welfare of our own families and friends. I spent much of the month selling off many of my holdings on what appeared to be growing weakness in the market, the sector, and in the individual stocks held.",226.0116729736328
2012-12-07 00:00:00+00:00,151.4600067138672,152.0,150.4499969482422,151.2899932861328,151.2899932861328,765000.0,3.0,1.0,0.5000249999999999,PDL BioPharma receives royalties on worldwide net sales of Roche Holdings Ltd. 's ( RHHBY ) Avastin and Herceptin; Roche/ Novartis ' ( NVS ) Lucentis and Xolair; and Elan Corporation / Biogen Idec 's ( ELN / BIIB ) Tysabri. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PDL BIOPHARMA (PDLI): Free Stock Analysis Report (RHHBY): ETF Research Reports To read this article on Zacks.com click here. We note that the US Food and Drug administration cleared Perjeta in June 2012 for treating patients suffering from HER2-positive late-stage (metastatic) breast cancer.,209.05105590820312
2012-12-12 00:00:00+00:00,154.33999633789062,154.5,151.97000122070312,152.35000610351562,152.35000610351562,873100.0,3.0,1.0,0.5000249999999999,"IBB allocates about 28 percent to biotech's big four - Amgen, Celgene (NASDAQ: CELG ), Biogen (NASDAQ: BIIB ) and Gilead Sciences (NASDAQ: GILD ). One of the advantages of sector ETFs is that these funds allow investors to participate in some of the upside of mergers and acquisitions news without the burden of having to pick the shares of the exact that is being acquired. ETFs help temper that risk for investors and offer another advantage: It is far easier to identify sectors with multiple takeover targets than it is to buy the single stock from that group that will be the next to draw a suitor's affection.",221.0748748779297
2012-12-14 00:00:00+00:00,151.08999633789062,152.5399932861328,150.19000244140625,151.25,151.25,730700.0,4.0,1.0,0.7500249999999999,"The company has partnership agreements with leading pharmaceuticals companies like Biogen ( BIIB ), Sanofi ( SNY ), Eli Lilly ( LLY ) and GlaxoSmithKline ( GSK ) among others. ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. AstraZeneca is also obligated to pay Isis Pharma milestone payments and royalties on the sale of commercialized products.",216.43397521972656
2012-12-17 00:00:00+00:00,151.86000061035156,153.0399932861328,150.74000549316406,152.64999389648438,152.64999389648438,815200.0,4.0,1.0,0.7500249999999999,"The company has partnership agreements with leading pharmaceuticals companies like Biogen ( BIIB ), Eli Lilly ( LLY ) and GlaxoSmithKline ( GSK ), among others. AEGERION PHARMA (AEGR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. The companies are seeking US Food and Drug Adminstration (FDA) approval for the use of Kynamro for the treatment of patients with homozygous familial hypercholesterolemia (HoFH).",195.23898315429688
2012-12-27 00:00:00+00:00,148.38999938964844,149.5,146.3300018310547,147.75999450683594,147.75999450683594,1072700.0,3.0,1.0,0.5000249999999999,"Here are 5 stocks added to the Zacks #1 Rank (""strong buy"") List today: American Eagle Outfitters ( AEO ) ANADIGICS, Inc. ( ANAD ) Arbitron Inc. ( ARB ) ATMI Inc. ( ATMI ) Biogen Idec Inc. ( BIIB ) View the entire Zacks #1 Rank List . AMER EAGLE OUTF (AEO): Free Stock Analysis Report ANADIGICS CORP (ANAD): Free Stock Analysis Report ARBITRON INC (ARB): Free Stock Analysis Report ATMI INC (ATMI): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",194.20925903320312
2013-01-03 00:00:00+00:00,142.25,149.0,141.72999572753906,147.86000061035156,147.86000061035156,5816600.0,1.0,1.0,2.4999999999997247e-05,"Here are 5 stocks added to the Zacks #5 Rank (""strong sell"") List today: Aeropostale, Inc ( ARO ) Anglo American plc (ADR) ( AAUKY ) Asia Entertainment & Resources Ltd. ( AERL ) BG Group plc (ADR) ( BRGYY ) Biogen Idec Inc. ( BIIB ) View the entire Zacks #5 Rank List . ANGLO AMER -PLC (AAUKY): Free Stock Analysis Report ASIA ENTMNT&RES (AERL): Free Stock Analysis Report AEROPOSTALE INC (ARO): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BG GRP PLC-ADR (BRGYY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen Idec Inc. ( BIIB ) is -9.17 at $140.83, with 459,449 shares traded. As reported by Zacks, the current mean recommendation for BIIB is in the ""buy range"". Sirius XM Radio Inc. ( SIRI ) is +0.01 at $3.03, with 250,203 shares traded., following a 52-week high recorded in prior regular session.",197.91574096679688
2013-01-08 00:00:00+00:00,145.52999877929688,146.52000427246094,144.08999633789062,144.38999938964844,144.38999938964844,1760100.0,4.0,1.0,0.7500249999999999,"Biogen Idec ( BIIB ) recently submitted a Biologics License Application (BLA) seeking US Food and Drug Administration (FDA) approval for its long-acting factor IX (rFIXFc) candidate for hemophilia B. Biogen and its partner, Swedish Orphan Biovitrum, had presented positive phase III top-line results on rFIXFc last year. AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Results from the global, open-label, multi-center B-LONG study showed that rFIXFc was effective in controlling and preventing bleeding, routine prophylaxis, and perioperative management.",178.1118621826172
2013-01-09 00:00:00+00:00,144.1999969482422,146.8800048828125,143.6999969482422,144.0800018310547,144.0800018310547,2098900.0,3.0,1.0,0.5000249999999999,"In ex-US territories Biogen Idec ( BIIB ) markets the product as Fampyra. ACORDA THERAPT (ACOR): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report IRONWOOD PHARMA (IRWD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, the key marketed products at Alkermes include Risperdal Consta (schizophrenia and bipolar disorder), Invega Sustenna (schizophrenia), Vivitrol (opioid and alcohol dependence), Ampyra/Fampyra (improving walking ability in multiple sclerosis patients) and Bydureon (type II diabetes).",188.8072509765625
2013-01-17 00:00:00+00:00,143.0,144.17999267578125,142.52999877929688,143.72000122070312,143.72000122070312,1499700.0,2.0,1.0,0.250025,Biogen Idec Inc. ( BIIB ) and partner Elan Corporation ( ELN ) recently submitted applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking to update the label of their multiple sclerosis (MS) drugTysabri (natalizumab). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report To read this article on Zacks.com click here. The companies are looking to get Tysabri approved as a first line treatment for patients suffering from certain relapsing forms of multiple sclerosis (MS) who have tested negative for antibodies to the JC virus (JCV).,188.81834411621094
2013-01-25 00:00:00+00:00,146.94000244140625,147.49000549316406,144.5500030517578,146.1999969482422,146.1999969482422,1183000.0,5.0,1.0,1.000025,"Biogen Idec Inc. ( BIIB ) is reporting for the quarter ending December 31, 2012. BIIB missed the consensus earnings per share in the 1st calendar quarter of 2012 by -3.47%. Zacks Investment Research reports that the 2012 Price to Earnings ratio for BIIB is 22.39 vs. an industry ratio of -9.20, implying that they will have a higher earnings growth than their competitors in the same industry.",173.30560302734375
2013-01-28 00:00:00+00:00,149.63999938964844,156.94000244140625,147.77000427246094,149.99000549316406,149.99000549316406,2993000.0,2.6666666666666665,1.0,0.4166916666666666,"Biogen Idec ( BIIB ) reported fourth quarter earnings per share of $1.40, missing the Zacks Consensus Estimate of $1.46 and 6.7% below the year-ago earnings. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Global in-market net revenues of Tysabri, which is partnered with Elan Corp. ( ELN ), came in at $433 million (up 14%) in the fourth quarter of 2012. New Article Earnings Notable companies expected to report earnings Monday include: Biogen Idec (NASDAQ: BIIB ) is expected to report fourth quarter EPS of $1.46 vs. $1.51 a year ago. However, the moves come in spite of a rally in financials in Italy as Banco Monte Dei Paschi di Sienna had its capital plan approved, paving the way for it receive bailout funds. The Bank of Korean may be the latest nation looking to weaken its currency following similar moves by Japan, as capital inflows are strengthening the Won and hurting exports. New Article This morning's major earnings reports are a bit on the weak side, with Caterpillar and Biogen Idec ( BIIB ) missing expectations, while Roper Industries ( ROP ) beating on earnings but missing on revenues. Sheraz Mian Director of Research BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CATERPILLAR INC (CAT): Free Stock Analysis Report ROPER INDS INC (ROP): Free Stock Analysis Report YAHOO! Rampant optimism, stemming from positive economic data and a decent Q4 earnings season, has pushed the S&P 500 to above 1500 and the Dow Jones Industrial Average within a few hundred points of all-time high.",170.7554168701172
2013-01-29 00:00:00+00:00,149.66000366210938,154.9600067138672,149.6300048828125,153.9199981689453,153.9199981689453,2203500.0,2.5,1.0,0.375025,"NASDAQ Market Wrap As of 1/29/2013 4:44:01 PM BILLIONS OF 2.01 NASDAQ SHARES TRADED TODAY 100 STOCKS REACHED A 52 WEEK HIGH 4 THOSE REACHING LOWS TOTALEDBiogen Idec Inc.[BIIB]TOPS ADVANCERS LISTOF NASDAQ 100 % 2.62 INDEXBIIB ROSE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ( STX ) had the largest percent change down (-9.36%) while Biogen Idec Inc. ( BIIB ) had the largest percent change gain rising 2.62%. Tuesday's session closes with the NASDAQ Composite Index at 3,153.66. New Article  Banco Bradesco SA (NYSE: BBD ) posted fourth quarter earnings per share of $0.37, missing the Zacks Consensus Estimate of $0.38  Biogen Idec Inc. (NASDAQ: BIIB ) reported fourth quarter earnings per share of $1.40, lower than the Zacks Consensus Estimate of $1.46  Roper Industries, Inc. (NYSE: ROP ) reported fourth quarter earnings per share of $1.48, beating the Zacks Consensus Estimate of $1.46  Old National Bancorp (NYSE: ONB ) posted fourth quarter earnings per share of $0.23, in line with the Zacks Consensus Estimate BANCO BRADESCO (BBD): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report OLD NATL BCP (ONB): Free Stock Analysis Report ROPER INDS INC (ROP): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",183.50682067871094
2013-02-04 00:00:00+00:00,156.14999389648438,157.27000427246094,155.10000610351562,155.72999572753906,155.72999572753906,1205600.0,2.0,1.0,0.250025,( BIIB ). ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report To read this article on Zacks.com click here. Tysabri is approved for the treatment of multiple sclerosis (MS) and Crohn's disease and is developed in collaboration with Biogen Idec.,186.6726531982422
2013-02-06 00:00:00+00:00,165.5500030517578,167.35000610351562,160.61000061035156,160.97999572753906,160.97999572753906,2857700.0,2.0,1.0,0.250025,"Biotechnology firm Elan (NYSE: ELN ) plunged 10 percent after the company announced that it was selling its 50 percent stake in multiple-sclerosis drug Tysabri to Biogen Idec (NASDAQ: BIIB ) for $3.25 billion. The greenback was generally higher on the day, with the PowerShares DB US Dollar Bullish ETF (NYSE: UUP ) trading up around 0.30 percent heading into the close of equities. Stock Movers Take Two Interactive Software (NASDAQ: TTWO ), a video game publisher, jumped 14 percent after strong third-quarter earnings. New Article (-) ELN, Sells its stake in Tysabri back to joint venture partner Biogen Idec ( BIIB ) for $3.25 billion and 12% of global net sales during the first year after the deal close. BIIB is up 2.7% today. Energy stocks finished slightly lower while crude oil erased early declines after a government report show inventories rose less than expected.",184.24436950683594
2013-02-07 00:00:00+00:00,161.5399932861328,162.02999877929688,158.75,160.3000030517578,160.3000030517578,1193200.0,2.5,1.0,0.375025,"Biogen Buys Tysabri Rights Elan also announced that it agreed to restructure the Tysabri collaboration with Biogen Idec Inc. ( BIIB ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report To read this article on Zacks.com click here. The upside in ROW sales reflect an increase in units sold, which was eventually offset partially by unfavorable pricing and foreign currency movements. New Article AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Idec Inc. ( BIIB ). Shareholders who purchased AMGN stock prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports AMGN's forecasted earnings growth in 2013 as 5.77%, compared to an industry average of 11.2%.",173.02801513671875
2013-02-14 00:00:00+00:00,165.6699981689453,165.77000427246094,163.4499969482422,164.58999633789062,164.58999633789062,1203600.0,2.0,1.0,0.250025,"Acorda has a licensing agreement with Biogen Idec ( BIIB ) for the development and commercialization of Ampyra outside the US. ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, Acorda is preparing to submit a 505(b)(2) type new drug application (NDA) for diazepam nasal spray for the management of seizure in certain epilepsy patients.",176.88888549804688
2013-02-21 00:00:00+00:00,164.8000030517578,165.47000122070312,161.97000122070312,162.60000610351562,162.60000610351562,1162500.0,3.0,1.0,0.5000249999999999,"In fact, Samsung Bioepis is a joint venture between Biogen Idec ( BIIB ) and Samsung Biologics. AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, Samsung Bioepis will be entitled to receive product supply income as well as additional payments on the achievement of pre-specified clinical and regulatory milestones.",183.21762084960938
2013-02-25 00:00:00+00:00,164.08999633789062,166.9499969482422,161.25,161.36000061035156,161.36000061035156,1215800.0,3.0,1.0,0.5000249999999999,"Zevalin is also being evaluated against Biogen Idec Inc. 's ( BIIB ) Rituxan in previously untreated patients with follicular non-Hodgkin's lymphoma. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report SPECTRUM PHARMA (SPPI): Free Stock Analysis Report UTD THERAPEUTIC (UTHR): Free Stock Analysis Report To read this article on Zacks.com click here. Sales from Folotyn, which was added to Spectrum Pharma's portfolio following its acquisition of Allos Therapeutics, Inc. in Sep 2012, came in at $14.4 million in the fourth quarter of 2012. New Article Elan Corporation, plc ( ELN ) recently provided an update after it announced the restructuring of the Tysabri collaboration with Biogen Idec ( BIIB ). ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report UTD THERAPEUTIC (UTHR): Free Stock Analysis Report To read this article on Zacks.com click here. Elan mentioned in its press release that it expects to invest a portion of the $3.25 billion into multiple business assets.",171.68353271484375
2013-02-26 00:00:00+00:00,160.64999389648438,163.52000427246094,160.4199981689453,161.99000549316406,161.99000549316406,1381100.0,3.0,1.0,0.5000249999999999,"Notably, Biogen Idec ( BIIB ) gained full strategic, commercial and operational control over Tysabri earlier this month. ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report UTD THERAPEUTIC (UTHR): Free Stock Analysis Report To read this article on Zacks.com click here. Royalty Pharma's offer comes close on the heels of the update provided by Elan on its future plans after it announced the restructuring of multiple sclerosis drug Tysabri.",190.0234832763672
2013-03-05 00:00:00+00:00,170.0800018310547,173.72000122070312,170.0500030517578,171.30999755859375,171.30999755859375,1371200.0,4.0,1.0,0.7500249999999999,"Biogen Idec ( BIIB ) recently announced that its Biologics License Application (BLA) for its long-acting factor IX (rFIXFc) candidate for hemophilia B has been accepted by the US Food and Drug Administration (FDA) for standard review. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report QLT INC (QLTI): Free Stock Analysis Report To read this article on Zacks.com click here. Results from the global, open-label, multi-center B-LONG study showed that rFIXFc was effective in controlling and preventing bleeding, routine prophylaxis, and perioperative management.",184.2152862548828
2013-03-07 00:00:00+00:00,172.44000244140625,173.0,171.0,171.47000122070312,171.47000122070312,968900.0,3.0,1.0,0.5000249999999999,"Last month, Biogen Idec ( BIIB ) had gained full strategic, commercial and operational control over Tysabri for an upfront payment of $3.25 billion to Elan. AGENUS INC (AGEN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report To read this article on Zacks.com click here. The dividend policy will enable the company's shareholders to enjoy long-term cash flow generated by multiple sclerosis drug Tysabri.",187.4800567626953
2013-03-11 00:00:00+00:00,171.85000610351562,174.2100067138672,171.4199981689453,174.13999938964844,174.13999938964844,1092200.0,3.0,1.0,0.5000249999999999,"In Feb 2013, Biogen Idec ( BIIB ) will gain full strategic, commercial and operational control over Tysabri for an upfront payment of $3.25 billion to Elan. AGENUS INC (AGEN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report To read this article on Zacks.com click here. Elan Corporation plc ( ELN ) recently provided an update on its proposed $1billion share repurchase program which is expected to be implemented after the close of the Tysabri (multiple sclerosis) restructuring transaction.",195.8353271484375
2013-03-13 00:00:00+00:00,175.6199951171875,176.33999633789062,174.22999572753906,176.14999389648438,176.14999389648438,1191500.0,4.0,1.0,0.7500249999999999,"Biogen Idec ( BIIB ) recently announced the submission of a Biologics License Application (BLA) for its recombinant factor VIII Fc fusion protein (rFVIIIFc). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report OSIRIS THERAPTC (OSIR): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. With the FDA granting standard review, a response from the agency regarding the approval status of rFIXFc should be out in the fourth quarter of this year.",192.482666015625
2013-03-19 00:00:00+00:00,175.77999877929688,177.5500030517578,174.72000122070312,175.61000061035156,175.61000061035156,1236400.0,4.0,1.0,0.7500249999999999,"Biogen Idec ( BIIB ) and Elan Corporation plc ( ELN ) recently announced results from several studies of multiple sclerosis drug, Tysabri (natalizumab). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. We note that, Biogen will gain full strategic, commercial and operational control over Tysabri for an upfront payment of $3.25 billion to Elan.",188.75294494628906
2013-03-22 00:00:00+00:00,176.8800048828125,178.89999389648438,176.8800048828125,178.0,178.0,929300.0,5.0,1.0,1.000025,"Biogen Idec ( BIIB ) recently announced additional patent protection for its oral multiple sclerosis candidate, Tecfidera (dimethyl fumarate). ATHERSYS INC (ATHX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report XOMA CORP (XOMA): Free Stock Analysis Report To read this article on Zacks.com click here. The recently issued patent, covering the daily dosing regimen of Tecfidera 480 mg, is set to expire in 2028.",205.705322265625
2013-03-25 00:00:00+00:00,178.47999572753906,178.47999572753906,175.6300048828125,176.22000122070312,176.22000122070312,1136600.0,3.333333333333333,1.0,0.5833583333333334,"Another major competitor could be Biogen Idec 's ( BIIB ) Tecfidera (dimethyl fumarate, formerly BG-12) which is currently under regulatory review in the US and EU. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. The company is looking to get Aubagio approved for the treatment of relapsing forms of multiple sclerosis (RMS) in adult patients. New Article Biogen Ide c ( BIIB ) recently received good news with the Committee for Medicinal Products for Human Use (CHMP) issuing a positive opinion regarding the approval of the company's oral multiple sclerosis candidate, Tecfidera. ATHERSYS INC (ATHX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Results from studies showed that treatment with Tecfidera led to a significant reduction in disease activity in multiple sclerosis patients. New Article Biotech's ""big four"" of Amgen (NASDAQ: AMGN ), Biogen Idec (NASDAQ: BIIB ), Celgene (NASDAQ: CELG ) and Gilead Sciences (NASDAQ: GILD ) combine for over 28 percent of IBB's weight. This time around, the ETFs under the spotlight will be sector funds populated by a fair amount of stocks that are currently trading well above their 200-day moving averages. With that, here are a few ETFs with a significant amount of their total weight currently allocated to stocks trading at least 10 percent above their simple 200-day moving averages.",203.4973907470703
2013-03-28 00:00:00+00:00,186.6000061035156,192.9199981689453,186.3600006103516,192.6199951171875,192.6199951171875,3995000.0,3.333333333333333,1.0,0.5833583333333334,"The four horsemen of the biotechnology - Amgen (NASDAQ: AMGN ), Biogen Idec (NASDAQ: BIIB ), Celgene (NASDAQ: CELG ) and Gilead Sciences (NASDAQ: GILD ) - all hit new 52-week highs earlier Thursday. Gilead, Amgen, Celgene and Biogen, in that order, represent four of IBB's top-six holdings and combine for over 29 percent of the ETF's weight. FBT, which has $283.4 million in AUM, allocates approximately 22 percent of its weight to the aforementioned quartet of biotech giants. New Article Tecfidera, Biogen Idec's ( BIIB ) oral multiple sclerosis treatment, gained FDA approval recently for the first-line treatment of people with relapsing forms of multiple sclerosis. ATHERSYS INC (ATHX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Given the product's efficacy and safety profile, we expect strong sales ramp up once it is launched. New Article NASDAQ Market Wrap As of 3/28/2013 4:44:01 PM BILLIONS OF 1.54 NASDAQ SHARES TRADED TODAY 138 STOCKS REACHED A 52 WEEK HIGH 7 THOSE REACHING LOWS TOTALEDBiogen Idec Inc.[BIIB]TOPS ADVANCERS LISTOF NASDAQ 100 % 5.44 INDEXBIIB ROSE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Apple Inc. ( AAPL ) had the largest percent change down (-2.08%) while Biogen Idec Inc. ( BIIB ) had the largest percent change gain rising 5.44%. The Dow Jones index closed up .36% for the day; a total of 52.38 points.",198.97042846679688
2013-04-02 00:00:00+00:00,194.94000244140625,199.5399932861328,194.22999572753903,198.19000244140625,198.19000244140625,2039300.0,4.0,1.0,0.7500249999999999,"Here are 5 stocks added to the Zacks Rank #1 (""strong buy"") List today: Advent Software, Inc. ( ADVS ) Banco Macro SA (ADR) ( BMA ) Biogen Idec Inc. ( BIIB ) Blackbaud, Inc. ( BLKB ) Cepheid ( CPHD ) View the entire Zacks Rank #1 List . ADVENT SOFTWARE (ADVS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BLACKBAUD INC (BLKB): Free Stock Analysis Report BANCO MACRO-ADR (BMA): Free Stock Analysis Report CEPHEID INC (CPHD): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",209.63580322265625
2013-04-03 00:00:00+00:00,198.3800048828125,199.0500030517578,194.1600036621093,195.7400054931641,195.7400054931641,1824400.0,4.0,1.0,0.7500249999999999,Elan Corporation plc ( ELN ) recently closed its Tysabri (natalizumab) collaboration transaction with Biogen Idec ( BIIB ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report QLT INC (QLTI): Free Stock Analysis Report To read this article on Zacks.com click here. The company intends to refinance its outstanding debt through a share repurchase program by utilizing $1 billion of the upfront proceeds.,213.36163330078125
2013-04-04 00:00:00+00:00,197.759994506836,198.8699951171875,194.47999572753903,195.67999267578125,195.67999267578125,1199200.0,3.5,1.0,0.6250249999999999,"Meanwhile, Elan recently closed its Tysabri (natalizumab) collaboration transaction with Biogen Idec ( BIIB ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report QLT INC (QLTI): Free Stock Analysis Report To read this article on Zacks.com click here. In its latest press release Elan stated that it will take into consideration any credible proposal from Royalty Pharma or any other company alongside the strategic transactions. New Article Currently, companies like Transcept Pharmaceuticals, Inc. ( TSPT ), Cleveland BioLabs, Inc. ( CBLI ) and Biogen Idec Inc. ( BIIB ) look more attractive with a Zacks Rank #1 (Strong Buy). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CLEVELAND BIOLB (CBLI): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report TRANSCEPT PHARM (TSPT): Get Free Report To read this article on Zacks.com click here. Repros Therapeutics Inc. ( RPRX ) recently provided top-line results from the ZA-301 study on its late-stage candidate, Androxal, which is being evaluated for the treatment of secondary hypogonadism.",219.7822265625
2013-04-05 00:00:00+00:00,193.0500030517578,193.9900054931641,191.8000030517578,193.3099975585937,193.3099975585937,1317900.0,1.0,1.0,2.4999999999997247e-05,"Other Zacks #1 Ranked stocks include Cytokinetics, Incorporated ( CYTK ), Biogen Idec Inc. ( BIIB ) and Athersys, Inc. ( ATHX ). ATHERSYS INC (ATHX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report QLT INC (QLTI): Free Stock Analysis Report To read this article on Zacks.com click here. As per the terms of the deal, Mati was granted a 90-day option by QLT to buy the assets related to its PPDS technology for $0.5 million.",217.51443481445312
2013-04-08 00:00:00+00:00,193.6000061035156,194.8800048828125,192.3300018310547,194.1300048828125,194.1300048828125,709200.0,3.5,1.0,0.6250249999999999,"Other medical products companies worth considering are Biogen Idec Inc. ( BIIB ), XOMA Corporation ( XOMA ) and Cleveland BioLabs, Inc. ( CBLI ), all which carry a Zacks Rank #1 (Strong Buy). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CLEVELAND BIOLB (CBLI): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report XOMA CORP (XOMA): Free Stock Analysis Report To read this article on Zacks.com click here. Inherited disease, exome, cardiomyopathy, cancer and autism form an important part of TruSight's content set. New Article Biogen ( BIIB ) looks more attractive at present with a Zacks Rank #1 (Strong Buy). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report To read this article on Zacks.com click here. Vertex Pharmaceuticals Incorporated ( VRTX ) and Bristol-Myers Squibb Company ( BMY ) recently entered into a non-exclusive agreement for the phase II development of once-daily all-oral treatment regimens combining Vertex Pharma's VX-135 and Bristol-Myers' daclatasvir for the treatment of hepatitis C virus (HCV) infections.",212.5178985595703
2013-04-10 00:00:00+00:00,193.69000244140625,198.44000244140625,193.22000122070312,198.33999633789065,198.33999633789065,887300.0,2.0,1.0,0.250025,"We note that apart from Aubagio, FDA approved oral multiple sclerosis therapies include Novartis ' ( NVS ) Gilenya and Biogen Idec 's ( BIIB ) Tecfidera (dimethyl fumarate, formerly BG-12). ALLERGAN INC (AGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Sanofi 's ( SNY ) subsidiary Genzyme recently announced that its oral candidate for relapsing forms of multiple sclerosis (RMS), Aubagio (teriflunomide) 14 mg, has gained approval from Argentina's National Administration of Drugs, Food and Medical Technology (ANMAT).",217.0259552001953
2013-04-11 00:00:00+00:00,198.94000244140625,201.0,197.17999267578125,200.259994506836,200.259994506836,884900.0,3.0,1.0,0.5000249999999999,"The ETF's other biotech holdings include Biogen (NASDAQ: BIIB ), Celgene (NASDAQ: CELG ) and Vivus (NASDAQ: VVUS ). With biotech stocks and ETFs surging higher this year , it is likely PJP's exposure to that sector that has helped it slightly outpace PPH year-to-date. Due to the duplication among U.S.-based blue-chip pharmaceuticals names, it does not make sense for investors to own PJP and PPH simultaneously.",229.3044891357422
2013-04-16 00:00:00+00:00,201.509994506836,202.47999572753903,197.7400054931641,202.1300048828125,202.1300048828125,1308100.0,4.0,1.0,0.7500249999999999,"Meanwhile, Elan closed its Tysabri (natalizumab) collaboration transaction with Biogen Idec ( BIIB ) earlier this month. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report QLT INC (QLTI): Free Stock Analysis Report WUXI PHARMATECH (WX): Free Stock Analysis Report To read this article on Zacks.com click here. As a result, Biogen gained full strategic, commercial and operational control over the multiple sclerosis drug. New Article And for its MS drug Ampyra (marketed as Fampyra in Europe and sold there byBiogen Idec ( BIIB ), it receives royalties fromAcorda Therapeutics ( ACOR ). Chief Executive Richard Pops likes to make it very clear about the company he leads:Alkermes ( ALKS ) is not your run-of-the mill biotech firm. Padmanabhan estimates Alkermes' injectable version for treating schizophrenia, aripiprazole lauroxil or ALKS 9070 for short, could generate more than $500 million in peak sales worldwide.",226.07797241210938
2013-04-19 00:00:00+00:00,197.6499938964844,203.72000122070312,197.5,203.2700042724609,203.2700042724609,942600.0,3.0,1.0,0.5000249999999999,"Meanwhile, Elan closed its Tysabri (natalizumab) collaboration transaction with Biogen Idec ( BIIB ) earlier this month. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report QLT INC (QLTI): Free Stock Analysis Report WUXI PHARMATECH (WX): Free Stock Analysis Report To read this article on Zacks.com click here. Elan Corporation ( ELN ) recently announced the final results of its modified Dutch auction tender offer of a maximum aggregate value of $1 billion. New Article Stocks discussed include: Biogen Idec ( BIIB ), Cabot Oil & Gas ( COG ), Activision Blizzard ( ATVI ), FleetCor ( FLT ) , and many others. Then there are the bigger risks that we try to get a handle on, like sneaking through an intersection that's (technically) a red light, climbing up almost any ladder for any reason and defending the value of our investment portfolios from the vagaries of the market. He gives the examples of JP Morgan Chase (JPM) , which beat on earnings, and Infosys (INFY) , which disappointed, and how options could have helped lower risk.",221.47079467773438
2013-04-22 00:00:00+00:00,204.8600006103516,216.6699981689453,204.3600006103516,215.1999969482422,215.1999969482422,2678300.0,2.75,1.0,0.437525,"Meanwhile, Elan closed its Tysabri (natalizumab) collaboration transaction with Biogen Idec ( BIIB ) earlier this month. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report QLT INC (QLTI): Free Stock Analysis Report WUXI PHARMATECH (WX): Free Stock Analysis Report To read this article on Zacks.com click here. Elan' Board of Directors believed that Royalty Pharma's offer significantly undervalued the company's current business platform and its future prospects. New Article Vertex Pharmaceuticals Incorporated ( VRTX ) had the largest percent change down (-3.82%) while Biogen Idec Inc. ( BIIB ) had the largest percent change gain rising 5.87%. NASDAQ Market Wrap As of 4/22/2013 4:44:01 PM BILLIONS OF 1.6 NASDAQ SHARES TRADED TODAY 41 STOCKS REACHED A 52 WEEK HIGH 15 THOSE REACHING LOWS TOTALEDBiogen Idec Inc.[BIIB]TOPS ADVANCERS LISTOF NASDAQ 100 % 5.87 INDEXBIIB ROSE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The Dow Jones index closed up .14% for the day; a total of 19.66 points. New Article We expect Biogen Idec, Inc. ( BIIB ) to report lower-than-expected earnings when it releases its first-quarter 2013 results before the opening bell on Apr 25. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report VIVUS INC (VVUS): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, results were adversely affected by a correction in the accounting for taxes on capitalized interest at Biogen's Denmark facility. New Article Stock Movers Shares of Biogen Idec (NASDAQ: BIIB ) rose better than 6 percent after the company's multiple sclerosis drug Tecfidera recorded a strong second week of sales. The PowerShares DB US Dollar Index Bullish ETF (NYSE: UUP ), which tracks the performance of the greenback versus a basket of foreign currencies, had lost 0.07 percent to $22.49. Meredith Corporation (NYSE: MDP ) was trading up around 4 percent on the day after Deutsche Bank raised its price target and expectations for the company's third-quarter earnings results.",226.03382873535156
2013-04-23 00:00:00+00:00,216.8800048828125,217.8000030517578,211.22999572753903,212.759994506836,212.759994506836,1971700.0,1.0,1.0,2.4999999999997247e-05,"The bio and pharma stocks seem to be leading the way with many big moves in stocks like Celgene ( CELG ), Biogen ( BIIB ), Regeneron ( REGN ), and Amgen ( AMGN ) to name a few. Netflix ( NFLX ), which has been a very strong stock since its last earnings release, delivered another blockbuster report and had some nice after hours trading once it cleared $197ish. Intel (INTC) and Microsoft (MSFT) started to come on the radar over the last week, and despite some manic action both look like they could be destined for higher prices.",236.99380493164062
2013-04-24 00:00:00+00:00,211.92999267578125,212.3099975585937,205.9100036621093,206.17999267578125,206.17999267578125,1584900.0,2.5,1.0,0.375025,"Biogen Idec Inc. ( BIIB ) is reporting for the quarter ending March 31, 2013. Zacks Investment Research reports that the 2013 Price to Earnings ratio for BIIB is 27.74 vs. an industry ratio of -8.10, implying that they will have a higher earnings growth than their competitors in the same industry. The diversified operations company's consensus earnings per share forecast from the 10 analysts that follow the stock is $1.65. New Article With the enrollment of the first patient which is expected in May 2013, Isis Pharma will become eligible to receive a $3.5 million milestone payment from partner, Biogen Idec Inc. ( BIIB ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CLEVELAND BIOLB (CBLI): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report REPLIGEN (RGEN): Free Stock Analysis Report To read this article on Zacks.com click here. The open-label, multiple-dose, dose-escalation pilot phase II study will be performed in eight infants for the treatment of SMA.",238.1545867919922
2013-04-25 00:00:00+00:00,212.22999572753903,217.6699981689453,212.1000061035156,216.0,216.0,1984800.0,3.25,1.0,0.5625249999999999,"Biogen (NASDAQ: BIIB ) is expected to report first quarter EPS of $1.59 vs. $1.40 a year ago. Newmont Mining (NYSE: NEM ) shares rose 1.22 percent pre-market on higher metals prices this morning. Google (NASDAQ: GOOG ) shares traded near flat on reports that the company has reached a settlement with the EU on its anti-trust probe. New Article Acorda has an agreement with Biogen Idec Inc. ( BIIB ) for marketing Ampyra outside the US under the trade name Fampyra. ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) and Mayo Clinic announced the enrollment of the first patient in a phase I safety study of rHIgM22. New Article Biogen Idec ( BIIB ) reported first quarter earnings per share of $1.96, well above the Zacks Consensus Estimate of $1.57 and 41% above the year-ago earnings. ATHERSYS INC (ATHX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CLEVELAND BIOLB (CBLI): Free Stock Analysis Report OSIRIS THERAPTC (OSIR): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, Avonex, Biogen's lead multiple sclerosis (MS) product, posted first quarter revenues of $746 million (up 13%). New Article Tysabri Transaction Meanwhile, Elan closed its Tysabri (natalizumab) collaboration transaction with Biogen Idec ( BIIB ) earlier this month. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report WUXI PHARMATECH (WX): Free Stock Analysis Report To read this article on Zacks.com click here. Elan is eligible to receive a royalty payment of 12% on worldwide net sales of Tysabri (for all indications) for the first year.",242.6118621826172
2013-04-26 00:00:00+00:00,215.88999938964844,218.4600067138672,212.52999877929688,213.58999633789065,213.58999633789065,1083400.0,2.0,1.0,0.250025,"Biogen Idec (NASDAQ: BIIB ) reported first quarter EPS of $1.97 vs. $1.59 on revenue of $1.4 billion vs. $1.41 billion expected. Archer Daniels Midland (NYSE: ADM ) increased its bid for Australian company Graincorp to $4.3 billion, making the deal a near certainty to go through according to analysts. Expedia (NASDAQ: EXPE ) reported first quarter EPS of $0.25 vs. $0.23 on revenue of $1.01 billion vs. $967.4 million estimate.",247.72918701171875
2013-04-30 00:00:00+00:00,223.94000244140625,226.17999267578125,218.2100067138672,218.92999267578125,218.92999267578125,1622000.0,3.0,1.0,0.5000249999999999,"On the other hand, RSP's top-10 holdings, a group that includes First Solar (NASDAQ: FSLR ), GameStop (NYSE: GME ) and Biogen (NASDAQ: BIIB ), combine for less than three percent of that ETF's weight. Just over two decades ago, the SPDR S&P 500 (NYSE: SPY ) was born, forever altering the U.S. investment landscape in the process. In a new research note, S&P Capital IQ credits RSP with helping set the stage for the launch of scores of ETFs that eschew cap-weighting in favor of other methodologies.",239.8477325439453
2013-05-02 00:00:00+00:00,214.67999267578125,219.0800018310547,213.259994506836,217.3000030517578,217.3000030517578,1124500.0,4.0,1.0,0.7500249999999999,"The nation's top-performing funds the past three months have been adding medical stocks to their portfolios, such as big biotech firmsCelgene ( CELG ),Biogen Idec ( BIIB ) andAmgen ( AMGN ) andRegeneron Pharmaceuticals ( REGN ), in their latest reporting periods. As the housing market starts to recover, building supply retailer Home Depot (HD) and self-storage facility REITExtra Space Storage (EXR), have garnered buying interest by leading funds. The Sell Side The country's leading funds have been unloading a handful of drug giants, such asPfizer (PFE) andBristol-Myers Squibb (BMY), in their latest reporting periods.",231.5395050048828
2013-05-06 00:00:00+00:00,221.72000122070312,222.0,215.38999938964844,215.72999572753903,215.72999572753903,942200.0,2.5,1.0,0.375025,"Acorda has a licensing agreement with Biogen Idec ( BIIB ) for the development and commercialization of Ampyra outside the US. ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTAVIS INC (ACT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report To read this article on Zacks.com click here. Quarter in Detail Bulk of net product revenues at Acorda came from Ampyra sales, which was approved by the US Food and Drug Administration (FDA) in Jan 2010 for the improvement of walking in multiple sclerosis patients. New Article We note that companies like Biogen Idec Inc. ( BIIB ) are also developing therapies targeting the hemophilia market. ABBVIE INC (ABBV): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CONCEPTUS INC (CPTS): Free Stock Analysis Report To read this article on Zacks.com click here. Since patient safety was the primary objective of the study, the company discontinued the BAY 86-6150 trial as a precautionary measure.",229.7921142578125
2013-05-07 00:00:00+00:00,214.8099975585937,216.6199951171875,211.6300048828125,212.5500030517578,212.5500030517578,1119600.0,4.0,1.0,0.7500249999999999,"The most recent disappointment was the high profile failure of Biogen's ( BIIB ) dexpramipexole. The initial trial of these stem cells was in amyotrophic lateral sclerosis or ALS, a progressive and always fatal neurological disease that affects motor neurons in the spinal column. As was previously mentioned, breathing is controlled by neurons in the cervical (upper) region of the spine and most ALS patients die of respiratory failure or pneumonia caused by impaired respiration.",250.3950653076172
2013-05-08 00:00:00+00:00,212.02999877929688,215.6199951171875,209.57000732421875,210.7100067138672,210.7100067138672,1141500.0,3.0,1.0,0.5000249999999999,"In the second half of 2013, Seattle Genetics will initiate a phase II frontline study of Adcetris in combination with Roche Holding / Biogen Idec 's ( RHHBY / BIIB ) Rituxan and standard chemotherapy (R-CHOP) for patients with diffuse large B-cell lymphoma. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report SEATTLE GENETIC (SGEN): Free Stock Analysis Report TRANSCEPT PHARM (TSPT): Get Free Report To read this article on Zacks.com click here. Seattle Genetics intends to submit a supplemental biologics license application (sBLA) in the first half of 2013 for the use of Adcetris in the retreatment of patients and for extended duration of use beyond 16 cycles of therapy.",235.89634704589844
2013-05-10 00:00:00+00:00,210.759994506836,213.3800048828125,209.0500030517578,213.22000122070312,213.22000122070312,1108500.0,3.0,1.0,0.5000249999999999,"The research firm as a three-star rating on Biogen Idec (NASDAQ: BIIB ) and a four-star rating on Amgen (NASDAQ: AMGN ), two of the other members of the Big Four biotech stocks. Recently, it was an announcement by Vertex (NASDAQ: VRTX ) that its cystic fibrosis drug Kalydeco and an experimental treatment, VX-661, showed promising results in a mid-stage clinical trial that sent biotech ETFs soaring . We see widening adoption of biomarker research and genetic-targeted clinical studies helping to shorten development times and bolster pipeline productivity.""",231.99993896484375
2013-05-13 00:00:00+00:00,216.5,222.92999267578125,215.94000244140625,222.7400054931641,222.7400054931641,1593200.0,3.0,1.0,0.5000249999999999,"AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Idec Inc. ( BIIB ). Shareholders who purchased AMGN stock prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports AMGN's forecasted earnings growth in 2013 as 11.51%, compared to an industry average of 7.6%.",225.27943420410156
2013-05-14 00:00:00+00:00,223.3999938964844,231.9900054931641,222.75,229.83999633789065,229.83999633789065,1972300.0,4.0,1.0,0.7500249999999999,"Isis Pharmaceuticals Inc. ( ISIS ) recently announced that it has received a milestone payment of $3.5 million from its partner, Biogen Idec Inc. ( BIIB ). ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report LANNETT INC (LCI): Free Stock Analysis Report To read this article on Zacks.com click here. The milestone payment was triggered by dosing of the first patient in a phase II study evaluating ISIS-SMNin infants suffering from spinal muscular atrophy (SMA).",219.7224578857422
2013-05-17 00:00:00+00:00,228.3600006103516,228.8600006103516,224.6000061035156,226.8500061035156,226.8500061035156,1243900.0,2.0,1.0,0.250025,"Running through screens I spotted Biogen Idec ( BIIB ). I've already bought and sold this one once today (trading around my core position) but am now contemplating and will likely be employing a buy stop strategy (rinse and repeat) as I think it will see numerous breaks into fresh highs in the coming days/weeks. Long-Term Vs. Short-Term Michael Gayed The honey badger stock market continues to disregard any weak economic data, pushing higher today with leadership in defensive sectors like utilities, consumer staples, and health care.",219.43325805664062
2013-05-20 00:00:00+00:00,226.0500030517578,234.4600067138672,224.3300018310547,225.17999267578125,225.17999267578125,1281700.0,4.0,1.0,0.7500249999999999,"The US Food and Drug Administration (FDA) recently accepted Biogen Idec's ( BIIB ) Biologics License Application (BLA) for its hemophilia A candidate, Eloctate (recombinant factor VIII Fc fusion protein). ALKERMES INC (ALKS): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. A convenient dosing schedule (supported by a longer duration of action and a suitable safety profile) could help Eloctate and Alprolix capture share from existing products in the hemophilia market.",234.4364471435547
2013-05-21 00:00:00+00:00,226.1699981689453,234.1999969482422,226.0,231.3300018310547,231.3300018310547,1364500.0,3.0,1.0,0.5000249999999999,"We note that Biogen Idec 's ( BIIB ) hemophilia B candidate, Alprolix, is currently under FDA review. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report SALIX PHARM-LTD (SLXP): Free Stock Analysis Report SANTARUS INC (SNTS): Free Stock Analysis Report To read this article on Zacks.com click here. Novo Nordisk ( NVO ) recently announced positive phase III data on its hemophilia B candidate, N9-GP, from the paradigm 2 study.",237.48960876464844
2013-05-22 00:00:00+00:00,232.2700042724609,238.8300018310547,230.0599975585937,233.07000732421875,233.07000732421875,1404900.0,2.0,1.0,0.250025,"Acorda has a license and collaboration agreement with Biogen Idec ( BIIB ) for the development and commercialization of Fampyra outside the US. ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report SANTARUS INC (SNTS): Free Stock Analysis Report To read this article on Zacks.com click here. 8,440,703) related to Ampyra twice-daily dosing of less than 15 mg has been issued by the US Patent and Trademark Office (USPTO).",237.07740783691406
2013-05-23 00:00:00+00:00,230.25,235.1000061035156,226.009994506836,232.6199951171875,232.6199951171875,1231200.0,4.0,1.0,0.7500249999999999,"Biogen Idec ( BIIB ) recently submitted a Biologics License Application (BLA) in the US for its multiple sclerosis candidate, Plegridy (peginterferon beta-1a). ABBVIE INC (ABBV): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The company is looking to gain US Food and Drug Administration approval for Plegridy for relapsing forms of multiple sclerosis (RMS).",253.3839569091797
2013-05-31 00:00:00+00:00,237.17999267578125,240.4900054931641,237.009994506836,237.4900054931641,237.4900054931641,1337300.0,3.0,1.0,0.5000249999999999,"Apart from Teva, the multiple sclerosis market has several players like Biogen ( BIIB ), Novartis ( NVS ) and Pfizer ( PFE ) among others. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Teva Pharmaceutical Industries Ltd. ( TEVA ) recently announced that its supplemental new drug application (sNDA) for its thrice-weekly dosing regimen of Copaxone has been accepted for review by the US Food and Drug Administration (FDA).",249.87196350097656
2013-06-03 00:00:00+00:00,234.1499938964844,234.6999969482422,220.0800018310547,227.38999938964844,227.38999938964844,2464200.0,4.0,1.0,0.7500249999999999,"However, companies that currently look well-positioned include Biogen Idec ( BIIB ) and Anika TherapeuticsInc. AMGEN INC (AMGN): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. While Synribo is approved for the treatment of adults with chronic myelogenous leukemia (CML), tbo-filgrastim is approved for the reduction of the duration of severe neutropenia in certain types of cancer (non-myeloid malignancies) patients who are receiving chemotherapy that affects the bone marrow.",242.7118377685547
2013-06-04 00:00:00+00:00,224.22000122070312,225.0,218.3800048828125,219.7400054931641,219.7400054931641,2515100.0,3.5,1.0,0.6250249999999999,"Stocks that currently look well-positioned include companies like Biogen Idec ( BIIB ) and Anika Therapeutics ( ANIK ). ASTELLAS PHARMA (ALPMY): Get Free Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report To read this article on Zacks.com click here. Medivation, Inc. ( MDVN ) and Astellas Pharma Inc. ( ALPMY ) recently announced that their prostate cancer treatment Xtandi, gained approval in Canada following a priority review. New Article Biogen Idec Inc. ( BIIB ) had the largest percent change down (-3.36%) while Monster Beverage Corporation ( MNST ) had the largest percent change gain rising 10.45%. The Dow Jones index closed down -.5% for the day; a total of -76.49 points. NASDAQ Market Wrap As of 6/4/2013 4:44:00 PM BILLIONS OF 1.81 NASDAQ SHARES TRADED TODAY 42 STOCKS REACHED A 52 WEEK HIGH 8 THOSE REACHING LOWS TOTALEDMonster Beverage Corporation[MNST]TOPS ADVANCERS LISTOF NASDAQ 100 % 10.45 INDEXMNST ROSE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",254.40196228027344
2013-06-05 00:00:00+00:00,219.0,223.6000061035156,209.8699951171875,214.1000061035156,214.1000061035156,2335600.0,5.0,1.0,1.000025,"At present, companies like Biogen Idec ( BIIB ) and Anika Therapeutics ( ANIK ) look well-positioned with both being Zacks Rank #1 (Strong Buy) stocks. ANIKA THERAPEUT (ANIK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report To read this article on Zacks.com click here. The option may be exercised by The Medicines Co. once it reviews results from an ongoing phase III study being conducted with ProFibrix' lead biologic, Fibrocaps.",257.6935729980469
2013-06-06 00:00:00+00:00,214.3500061035156,221.3500061035156,212.8699951171875,221.19000244140625,221.19000244140625,1612200.0,5.0,1.0,1.000025,"Other companies that currently look well-positioned include Biogen Idec ( BIIB ) and Anika Therapeutics Inc. ( ANIK ) with both being Zacks Rank #1 (Strong Buy) stocks. ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report To read this article on Zacks.com click here. We note that ISIS-STAT3Rx is the first of Isis Pharma's generation 2.5 chemistry candidates which are supposed to be significantly more potent than drugs currently in development and which could, therefore, be more effective in addressing difficult-to-treat cancers like DLBCL.",258.45135498046875
2013-06-10 00:00:00+00:00,225.8099975585937,226.6000061035156,220.47000122070312,222.19000244140625,222.19000244140625,1020900.0,3.0,1.0,0.5000249999999999,"Royalty Pharma believed that the amount represented a 52% to 92% premium to $3.25 billion, at which Elan sold approximately half of its interest in Tysabri to Biogen Idec Inc. ( BIIB ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report SANTARUS INC (SNTS): Free Stock Analysis Report To read this article on Zacks.com click here. Royalty Pharma also reduced the Acceptance Threshold to 50% plus one Elan share in accordance with the terms of the revised offer document.",256.5362243652344
2013-06-11 00:00:00+00:00,219.6199951171875,225.0,218.3099975585937,223.02999877929688,223.02999877929688,1331800.0,3.5,1.0,0.6250249999999999,"We are positive on Isis Pharma's collaborations with companies like Xenon, Biogen ( BIIB ) and AstraZeneca ( AZN ) among others, which not only validate its antisense technology but also provide Isis Pharma with funds in the form of upfront, milestone and other payments. ANIKA THERAPEUT (ANIK): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report To read this article on Zacks.com click here. Isis Pharma's association with Xenon goes back to 2010 when the companies signed an agreement for the discovery and development of antisense drugs for the treatment of anemia of chronic disorders (ACD). New Article In terms of holdings, Gilead Sciences ( GILD ) , Amgen ( AMGN ) , and Biogen ( BIIB ) take the top three spots and account for about 36% of assets, suggesting a relatively heavy level of concentration. This fund's holdings profile is similar to BBH, as GILD, AMGN, and BIIB all find their way into the top five. Click to get this free report >> AMGEN INC (AMGN): Free Stock Analysis Report MKT VEC-BIOTECH (BBH): ETF Research Reports BIOGEN IDEC INC (BIIB): Free Stock Analysis Report FT-AMEX BIOTEC (FBT): ETF Research Reports GILEAD SCIENCES (GILD): Free Stock Analysis Report ISHARES NDQ BIO (IBB): ETF Research Reports SPDR-HLTH CR (XLV): ETF Research Reports To read this article on Zacks.com click here.",255.78985595703125
2013-06-12 00:00:00+00:00,217.6999969482422,218.8999938964844,204.1199951171875,206.5500030517578,206.5500030517578,2778600.0,2.0,1.0,0.250025,"Biogen Idec Inc. ( BIIB ) had the largest percent change down (-7.39%) while Expedia, Inc. ( EXPE ) had the largest percent change gain rising .95%. Wednesday's session closes with the NASDAQ Composite Index at 3,400.43. The Dow Jones index closed down -.84% for the day; a total of -126.79 points. New Article Biogen Idec (NASDAQ: BIIB ) fell more than 7 percent after the stock was downgraded at Citigroup from Buy to Neutral. The multi-year rally in risk assets has been driven in large part by huge liquidity injections from the Fed and other central banks, and investors worry about economic growth in the absence of these programs. Nearing the close of equities, the PowerShares DB US Dollar Index Bullish ETF (NYSE: UUP ), which tracks the performance of the greenback versus a basket of foreign currencies, was down 0.09 percent to $21.96.",258.28887939453125
2013-06-13 00:00:00+00:00,205.8600006103516,210.8699951171875,204.5599975585937,209.5800018310547,209.5800018310547,2011600.0,3.0,1.0,0.5000249999999999,"Companies such as Biogen Idec Inc. ( BIIB ) and Jazz Pharmaceuticals Public Limited Company ( JAZZ ) appear to be favorably placed with a Zacks Rank #1 (Strong Buy). ABBVIE INC (ABBV): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers Squibb Company ( BMY ) recently presented encouraging long-term data from a phase IIIb study (AMPLE: n=646) on its rheumatoid arthritis (RA) candidate Orencia. New Article Companies such as Biogen Idec Inc. ( BIIB ), Anika Therapeutics Inc. ( ANIK ) and Jazz Pharmaceuticals Public Limited Company ( JAZZ ) appear to be favorably placed with a Zacks Rank #1 (Strong Buy). ANIKA THERAPEUT (ANIK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report To read this article on Zacks.com click here. Celgene Corporation ( CELG ) recently announced encouraging results from a phase III study (PALACE 1) on its pipeline candidate apremilast.",261.22314453125
2013-06-14 00:00:00+00:00,212.0,217.6499938964844,208.4199981689453,211.9900054931641,211.9900054931641,1569400.0,2.6666666666666665,1.0,0.4166916666666666,"Brandon Perry My old ugly/expensive friend Biogen Idec Inc. ( BIIB ) is getting rejected by the old uptrend. The OMT is a program designed to give the European Central Bank (ECB) the ability to purchase government bonds as a ""backstop"" against higher interest rates. This trade was put on and added to in massive amounts over the previous weeks and will take some time to fully unwind should strengthening continue (which is likely due to near-record level speculative short positioning). New Article Companies such as Biogen Idec Inc. ( BIIB ), appear to be favorably placed with a Zacks Rank #1 (Strong Buy). AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Results from the multi-center, double-blind, placebo-controlled, parallel-group phase III study showed that treatment with apremilast caused significant improvements in the symptoms of the disease compared to placebo in psoriatic arthritis patients across both dosage strengths. New Article However, competition is intensifying in the MS market for Gilenya given the presence of various treatments from Biogen Idec ( BIIB ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CUBIST PHARM (CBST): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. It was also observed that the rate of brain volume loss lessened in patients, who switched to Gilenya from standard interferon treatment.",249.7781524658203
2013-06-17 00:00:00+00:00,214.009994506836,216.0,206.6199951171875,207.75,207.75,1650000.0,3.5,1.0,0.6250249999999999,"Stocks such as Biogen Idec Inc. ( BIIB ), Jazz Pharmaceuticals Public Limited Company ( JAZZ ) and Anika Therapeutics Inc. ( ANIK ) appear to be more favorably placed. ANIKA THERAPEUT (ANIK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report To read this article on Zacks.com click here. Encouraging news flowed in at Celgene Corporation ( CELG ) from Europe with the European Commission (EC) amending the company's marketing authorisation for Revlimid and approving the drug for an additional indication. New Article We remind investors that in Apr 2013 Elan sold its Tysabri stake to Biogen Idec Inc. ( BIIB ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report THERAVANCE INC (THRX): Free Stock Analysis Report To read this article on Zacks.com click here. In light of the offers and interests received so far, Elan Corporation, plc ( ELN ) recently announced that it is gearing up for a formal sale process. New Article Other Zacks Rank #1 stocks that warrant a look are Anika Therapeutics Inc. ( ANIK ) and Biogen Idec Inc. ( BIIB ). ALEXION PHARMA (ALXN): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report To read this article on Zacks.com click here. The much hyped Supreme Court ruling regarding legal claims that challenge its patent landscape is out for Myriad Genetics Inc. ( MYGN ) and it seems like a halfway triumph for this molecular diagnostic company. New Article Companies that currently look well-positioned include Biogen Idec ( BIIB ), Anika Therapeutics ( ANIK ), and Alexion Pharmaceuticals ( ALXN ). ALEXION PHARMA (ALXN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Last year, Amgen had received a complete response letter (CRL) from the FDA for its supplemental biologics license application s(BLA) for Xgeva for the delay of bone metastases in prostate cancer.",250.43319702148438
2013-06-18 00:00:00+00:00,210.47000122070312,211.6199951171875,206.42999267578125,210.8000030517578,210.8000030517578,1440700.0,3.25,1.0,0.5625249999999999,"Stocks such as Biogen Idec Inc. ( BIIB ), Jazz Pharmaceuticals Public Limited Company ( JAZZ ) and Santarus, Inc. ( SNTS ) appear to be more favorably placed. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report PERRIGO COMPANY (PRGO): Free Stock Analysis Report SANTARUS INC (SNTS): Free Stock Analysis Report To read this article on Zacks.com click here. The spate of acquisitions at Perrigo Company ( PRGO ) continued with its purchase of an ophthalmic sterile ointment and the solution product portfolio from the privately-held Fera Pharmaceuticals, for approximately $93 million in cash. New Article Among others in the industry, Anika Therapeutics Inc. ( ANIK ) and Biogen Idec Inc. ( BIIB ) carry a favorable Zacks Rank #1 (Strong Buy) and appear impressive. ANIKA THERAPEUT (ANIK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report DAVITA INC (DVA): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report To read this article on Zacks.com click here. On the other hand, DaVita is responsible for providing dialysis services to patients suffering from chronic kidney failure and end stage renal disease. New Article Stocks such as Biogen Idec Inc. ( BIIB ), Jazz Pharmaceuticals Public Limited Company ( JAZZ ) and Santarus, Inc. ( SNTS ) appear to be more favorably placed. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report SANTARUS INC (SNTS): Free Stock Analysis Report To read this article on Zacks.com click here. Celgene Corporation ( CELG ) announced recently that its pipeline candidate apremilast (30 mg, twice daily) has fared well in a phase II study (BCT-001). New Article Companies that currently look well-positioned include Biogen Idec ( BIIB ) and Novo Nordisk ( NVO ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. Before the deal closes in the third quarter of 2013, Aragon will transfer all assets apart from the androgen receptor antagonist program to a new company that will be spun-off.",256.44744873046875
2013-06-19 00:00:00+00:00,210.47000122070312,211.259994506836,203.58999633789065,203.8000030517578,203.8000030517578,1213600.0,3.0,1.0,0.5000249999999999,"Companies that currently look well-positioned include Biogen Idec ( BIIB ), Santarus, Inc. ( SNTS ) and Novo Nordisk ( NVO ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report SANTARUS INC (SNTS): Free Stock Analysis Report To read this article on Zacks.com click here. Aspen Pharma has also offered to purchase the related manufacturing site in France, Notre-Dame de Bondeville.",269.3829345703125
2013-06-20 00:00:00+00:00,201.6000061035156,202.97000122070312,197.6999969482422,199.5800018310547,199.5800018310547,1937200.0,3.0,1.0,0.5000249999999999,"Companies that currently look well-positioned include Biogen Idec ( BIIB ) and Novo Nordisk ( NVO ). ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. AstraZeneca ( AZN ) and its partner Bristol-Myers Squibb Company ( BMY ) recently announced disappointing top-line data from a phase IV study (SAVOR-TIMI-53; n = 16,500) on their diabetes drug, Onglyza, a dipeptidyl peptidase-4 (DPP-4) inhibitor. New Article ( BIIB ) and Aeterna Zentaris, Inc . AETERNA ZENTARS (AEZS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report PLURISTEM THERA (PSTI): Free Stock Analysis Report To read this article on Zacks.com click here. Pluristem Therapeutics Inc. ( PSTI ) recently announced that it has provided the US Food and Drug Administration (FDA) with additional information regarding the clinical trials for intermittent claudication (IC) pursuant to a clinical hold on the phase II IC study earlier this month.",265.6031188964844
2013-06-21 00:00:00+00:00,201.009994506836,202.97999572753903,194.6600036621093,199.07000732421875,199.07000732421875,3518200.0,4.0,1.0,0.7500249999999999,"Right now, Biogen Idec Inc. ( BIIB ) and Jazz Pharmaceuticals ( JAZZ ) look more attractive with a Zacks Rank #1 (Strong Buy). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report SEATTLE GENETIC (SGEN): Free Stock Analysis Report TAKEDA PHARMACT (TKPYY): Get Free Report To read this article on Zacks.com click here. Seattle Genetics, Inc. ( SGEN ) and partner Takeda Pharmaceuticals ( TKPYY ) recently reported results from a post-hoc analysis evaluating progression-free survival (PFS) in patients treated with Adcetris. New Article Right now, Jazz Pharmaceuticals Public Limited Company ( JAZZ ) and Biogen Idec Inc. ( BIIB ) look more attractive with a Zacks Rank #1 (Strong Buy). ALIMERA SCIENCE (ALIM): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report PSIVIDA CORP (PSDV): Free Stock Analysis Report To read this article on Zacks.com click here. pSivida Corp. ( PSDV ) recently announced that the UK's National Institute for Health and Care Excellence (NICE) has issued draft guidance where it recommends Iluvien for the treatment of pseudophakic patients with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.",256.38848876953125
2013-06-24 00:00:00+00:00,197.8000030517578,203.6499938964844,195.1000061035156,200.4600067138672,200.4600067138672,1820100.0,2.0,1.0,0.250025,"Companies that currently look well-positioned include Biogen Idec ( BIIB ) and Novo Nordisk ( NVO ). ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. AstraZeneca ( AZN ) and partner Bristol-Myers Squibb Company ( BMY ) recently announced results from a two-week phase IIa pilot study (n= 70) on their diabetes drug, Forxiga (dapagliflozin).",263.27569580078125
2013-06-25 00:00:00+00:00,201.75,202.3099975585937,196.69000244140625,199.1499938964844,199.1499938964844,1199500.0,4.5,1.0,0.8750249999999999,"Other companies that currently look well-positioned include Biogen Idec ( BIIB ), Aeterna Zentaris Inc. ( AEZS ) and Protalix BioTherapeutics, Inc. ( PLX ). AETERNA ZENTARS (AEZS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report PROTALIX BIOTHR (PLX): Free Stock Analysis Report To read this article on Zacks.com click here. The candidate's safety profile was also good with no discontinuations, clinically meaningful elevations in liver enzymes, flu-like symptoms, or major adverse events being reported. New Article In these patients the disease must be refractory to both Roche / Biogen Idec Inc. 's ( RHHBY / BIIB ) Rituxan (rituximab) and chemotherapy or radioimmunotherapy. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report INFINITY PHARMA (INFI): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report To read this article on Zacks.com click here. Infinity Pharmaceuticals, Inc. ( INFI ) recently announced positive results from a phase I study on its pipeline candidate IPI-145.",261.9964294433594
2013-06-26 00:00:00+00:00,201.57000732421875,209.8699951171875,200.259994506836,208.42999267578125,208.42999267578125,1477600.0,2.0,1.0,0.250025,"Other Stocks to Consider Other stocks in the Medical-Biomed/Gene industry that are currently performing well include Biogen Idec ( BIIB ), Targacept ( TRGT ) and Protalix BioTherapeutics ( PLX ). AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PROTALIX BIOTHR (PLX): Free Stock Analysis Report TARGACEPT INC (TRGT): Free Stock Analysis Report To read this article on Zacks.com click here. On Jun 26, we upgraded genetic devices maker Affymetrix Inc. ( AFFX ) to Neutral from Underperform, as we believe that the company has reasonable upside potential going forward, despite disappointing first-quarter results. New Article We note that the RCHOP regimen includes Roche / Biogen Idec Inc. 's ( RHHBY / BIIB ) Rituxan (rituximab). ALNYLAM PHARMA (ALNY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report To read this article on Zacks.com click here. Celgene Corporation ( CELG ) recently presented data on its cancer drug, Revlimid (as a combination therapy) in patients suffering from various forms of non-Hodgkin's lymphoma.",264.11480712890625
2013-06-27 00:00:00+00:00,209.8000030517578,212.97999572753903,207.82000732421875,208.8099975585937,208.8099975585937,1400700.0,3.5,1.0,0.6250249999999999,"Companies such as Biogen Idec Inc. ( BIIB ), Jazz Pharmaceuticals Public Limited Company ( JAZZ ) and Alnylam Pharmaceuticals, Inc. ( ALNY ) appear to be more attractive. ALNYLAM PHARMA (ALNY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report To read this article on Zacks.com click here. Celgene Corporation ( CELG ) recently inked a deal with German company MorphoSys to co-develop oncology candidate MOR202 on a global basis for treating patients with multiple myeloma and certain cancer forms. New Article While we remain on the sidelines for Integra, other stocks such as Biogen Idec Inc. ( BIIB ) and Protalix BioTherapeutics Inc. ( PLX ) are worth considering. AFFYMAX INC (AFFY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report INTEGRA LIFESCI (IART): Free Stock Analysis Report PROTALIX BIOTHR (PLX): Free Stock Analysis Report To read this article on Zacks.com click here. After a series of product recalls in April and a disappointing first quarter, Integra LifeSciences Holdings Corporation ( IART ) witnessed a favorable event.",259.56707763671875
2013-06-28 00:00:00+00:00,221.67999267578125,224.6300048828125,215.1300048828125,215.1999969482422,215.1999969482422,3110400.0,2.0,1.0,0.250025,"Companies that currently look well-positioned include Biogen Idec ( BIIB ), Santarus, Inc. ( SNTS ) and Novo Nordisk ( NVO ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report SANTARUS INC (SNTS): Free Stock Analysis Report To read this article on Zacks.com click here. GlaxoSmithKline ( GSK ) recently announced that the US Food and Drug Administration (FDA) granted breakthrough therapy designation to its late-stage candidate, drisapersen.",261.4173583984375
2013-07-01 00:00:00+00:00,220.25,223.8000030517578,217.72999572753903,217.8800048828125,217.8800048828125,1523000.0,3.0,1.0,0.5000249999999999,"With Onyx open to offers from other bidders, it is also possible that other big players in the biopharma space like Celgene Corporation ( CELG ) and Biogen Idec Inc. ( BIIB ) express interest in Onyx resulting in a bidding war. AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report ONYX PHARMA INC (ONXX): Free Stock Analysis Report To read this article on Zacks.com click here. Onyx Pharmaceuticals, Inc. ( ONXX ) rejected a $120 per share takeover bid from Amgen Inc. ( AMGN ).",254.0630340576172
2013-07-03 00:00:00+00:00,214.9900054931641,218.6699981689453,214.52999877929688,217.5,217.5,362300.0,3.6666666666666665,1.0,0.6666916666666666,"Biogen Idec ( BIIB ) and Swedish Orphan Biovitrum AB recently presented new data on their hemophilia B candidate, Alprolix, at the XXIV International Society on Thrombosis and Haemostasis (ISTH) Congress. AETERNA ZENTARS (AEZS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report PROTALIX BIOTHR (PLX): Free Stock Analysis Report To read this article on Zacks.com click here. Results from the global, open-label, multi-center B-LONG study had shown that Alprolix was effective in controlling and preventing bleeding, routine prophylaxis, and perioperative management. New Article Companies such as Biogen Idec Inc. ( BIIB ) and Jazz Pharmaceuticals Public Limited Company ( JAZZ ) appear to be more attractive. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here. Zoetis Inc. ( ZTS ), the former Animal Health business of Pfizer Inc. ( PFE ), announced recently that it intends to expand its manufacturing facility in Lincoln, Neb. New Article At present, companies like Biogen Idec ( BIIB ) and Protalix BioTherapeutics, Inc. ( PLX ) look attractive. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report PROTALIX BIOTHR (PLX): Free Stock Analysis Report VIROPHARMA (VPHM): Free Stock Analysis Report To read this article on Zacks.com click here. The Medicines Company ( MDCO ) recently presented positive results on its phase III antibiotic candidate, oritavancin.",259.65277099609375
2013-07-05 00:00:00+00:00,220.2700042724609,223.94000244140625,220.1199951171875,221.6499938964844,221.6499938964844,806100.0,4.0,1.0,0.7500249999999999,"At present, companies like Biogen Idec ( BIIB ), Aeterna Zentaris ( AEZS ) and Protalix BioTherapeutics, Inc. ( PLX ) look well positioned. AETERNA ZENTARS (AEZS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report PROTALIX BIOTHR (PLX): Free Stock Analysis Report To read this article on Zacks.com click here. Earlier, in Dec 2012, the company had presented positive data on oritavancin from another phase III study, SOLO- I.",249.4899444580078
2013-07-08 00:00:00+00:00,223.3800048828125,225.22000122070312,217.5,218.07000732421875,218.07000732421875,943600.0,3.6,1.0,0.6500250000000001,"Biogen Idec ( BIIB ) and Swedish Orphan Biovitrum AB recently presented new data on their hemophilia A candidate, Eloctate, at the XXIV International Society on Thrombosis and Haemostasis (ISTH) Congress. AETERNA ZENTARS (AEZS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTORI THERAPEU (CYTX): Free Stock Analysis Report PROTALIX BIOTHR (PLX): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Biogen and Swedish Orphan Biovitrum had initially presented positive top-line results on Eloctate from the global, multi-center, phase III A-LONG study last year. New Article Other Stocks to Consider Other companies that currently look well-positioned include Biogen Idec Inc. ( BIIB ) and Protalix BioTherapeutics, Inc. ( PLX ) with both carrying a Zacks Rank #1 (Strong Buy). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report PROTALIX BIOTHR (PLX): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Growth Drivers Isis Pharma, a Zacks Rank #2 (Buy) stock, received a major boost earlier this year when the US Food and Drug Administration (FDA) approved Kynamro, developed in collaboration with Genzyme, a Sanofi ( SNY ) company. New Article Right now, Biogen Idec Inc. (BIIB) looks more attractive with a ZacksRank #1 (Strong Buy). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK KGAA (MKGAF): Get Free Report THRESHOLD PHARM (THLD): Free Stock Analysis Report To read this article on Zacks.com click here. The two changes made to the protocol include trial expansion to 620 patients (from 450) and the elimination of an interim futility analysis of progression-free survival (PFS). New Article Meanwhile, stocks such as Biogen Idec Inc. (BIIB) and Jazz Pharmaceuticals Public Limited Company (JAZZ) appear to be more favorably placed. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PERRIGO COMPANY (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Perrigo Company ( PRGO ) soared to a 52-week high of $123.95 during the second half of the trading session on Jul 5, 2013 buoyed by a series of positive developments. New Article Stocks That Warrant a Look While we expect BioMarin to perform in line with its peers and industry levels in the coming months and advice investors to wait for a better entry point before accumulating shares, one can consider stocks such as Biogen Idec Inc. ( BIIB ) and Jazz Pharmaceuticals ( JAZZ ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. The Marketing Authorization Application for Vimizim had been granted accelerated assessment status by the European Medicines Agency.",228.06732177734375
2013-07-09 00:00:00+00:00,219.1999969482422,220.9199981689453,215.8099975585937,219.259994506836,219.259994506836,829100.0,2.0,1.0,0.250025,"We note that companies like Biogen Idec Inc. ( BIIB ) are also developing therapies targeting the hemophilia market. BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. Bayer ( BAYRY ) recently initiated a phase III study on BAY 94-9027 in children (up to 12 years of age) for the treatment of hemophilia A. New Article At present, companies that look well-positioned include Biogen Idec ( BIIB ), Peregrine Pharmaceuticals, Inc. ( PPHM ) and Cytori Therapeutics, Inc. ( CYTX ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report CYTORI THERAPEU (CYTX): Free Stock Analysis Report PEREGRINE PHARM (PPHM): Free Stock Analysis Report To read this article on Zacks.com click here. The company reported a programming error in the multinational, double-blind, randomized, placebo-controlled study which is evaluating the safety, tolerability and efficacy of tirasemtiv.",238.54293823242188
2013-07-11 00:00:00+00:00,222.6100006103516,226.0,220.8300018310547,223.3000030517578,223.3000030517578,1260900.0,4.666666666666667,1.0,0.9166916666666668,"Biotechnology has been a leader this year, as evidenced in charts like Gilead Sciences (GILD), Celgene Corp (CELG), Regeneron Pharmaceuticals (REGN), Biogen Idec (BIIB), and even the sub-industry ETF itself (XBI). Stop Loss Biogen Idec, Inc BIIB Biotechnology 9.6 +47.77% 4.79 Why We Like The Stock: Biogen Idec Inc (BIIB) is our most compelling buy today due to the fact that it is a top rated stock (in terms of earnings strength and company/industry performance) with a positive technical set-up. BIIB has a stellar long-term uptrend dating all the way back to June of 2010, when it was priced just below . New Article At present, Biogen Idec ( BIIB ) looks well-positioned with a Zacks Rank #1 (Strong Buy). ACORDA THERAPT (ACOR): Free Stock Analysis Report ASTELLAS PHARMA (ALPMY): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NEUROGESX INC (NGSX): Get Free Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) recently added two neuropathic pain management assets to its portfolio. New Article Companies such as Biogen Idec Inc. ( BIIB ) and Jazz Pharmaceuticals Public Limited Company ( JAZZ ) appear to be more attractive. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PHARMACYCLICS (PCYC): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Pharmacyclics, Inc. ( PCYC ) soared to a 52-week high of $102.05 on Jul 10, 2013 buoyed by its submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval for oncology candidate, ibrutinib.",235.08778381347656
2013-07-22 00:00:00+00:00,234.69000244140625,234.7400054931641,222.08999633789065,231.6699981689453,231.6699981689453,2486000.0,3.75,1.0,0.6875249999999999,"( BIIB ) has Earnings ESP of +2.19% and holds a Zacks Rank #3. AMERISOURCEBRGN (ABC): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report FOREST LABS A (FRX): Free Stock Analysis Report WALGREEN CO (WAG): Free Stock Analysis Report To read this article on Zacks.com click here. AmerisourceBergen Corporation ( ABC ) is scheduled to report third quarter fiscal 2013 results (ended Mar 31, 2013) before the opening bell on Jul 24, 2013. New Article ( BIIB ) has Earnings ESP of +2.19% and holds a Zacks Rank #3. ACTAVIS INC (ACT): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report FOREST LABS A (FRX): Free Stock Analysis Report To read this article on Zacks.com click here. Alexion Pharmaceuticals, Inc. ( ALXN ) is scheduled to release its second quarter 2013 results before the opening bell on Wednesday, Jul 25. New Article ( BIIB ) has Earnings ESP of +2.19% and holds a Zacks Rank #3. ACTAVIS INC (ACT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report FOREST LABS A (FRX): Free Stock Analysis Report IRONWOOD PHARMA (IRWD): Free Stock Analysis Report To read this article on Zacks.com click here. Forest Laboratories, Inc. ( FRX ) is scheduled to report its first quarter fiscal 2014 (ended Jun 30, 2013) earnings before the opening bell on Jul 23, 2013. New Article ( BIIB ) has Earnings ESP of +2.19% and holds a Zacks Rank #3. ACTAVIS INC (ACT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report FOREST LABS A (FRX): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. Eli Lilly and Company ( LLY ) is set to report second quarter 2013 results on Jul 24, before the opening bell.",225.1605224609375
2013-07-24 00:00:00+00:00,222.72999572753903,226.97000122070312,221.17999267578125,226.6100006103516,226.6100006103516,1455800.0,3.333333333333333,1.0,0.5833583333333334,"(BIIB) has Earnings ESP of +2.19% and holds a Zacks Rank #3 (Hold). ACTAVIS INC (ACT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MOMENTA PHARMA (MNTA): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Actavis, Inc. (ACT) is scheduled to report second quarter 2013 earnings before the opening bell on Jul 25, 2013. New Article (BIIB ) is scheduled to report second quarter 2013 earnings before the opening bell on Jul 25, 2013. ACTAVIS INC (ACT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MOMENTA PHARMA (MNTA): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. The combination of Biogen's Zacks Rank #3 and an ESP of +2.19% makes us confident of an earnings beat on Jul 25. New Article Biogen Idec Inc. ( BIIB ) is reporting for the quarter ending June 30, 2013. BIIB missed the consensus earnings per share in the 4th calendar quarter of 2012 by -4.11%. Zacks Investment Research reports that the 2013 Price to Earnings ratio for BIIB is 27.83 vs. an industry ratio of -9.40, implying that they will have a higher earnings growth than their competitors in the same industry.",222.30087280273438
2013-07-25 00:00:00+00:00,233.52999877929688,233.97000122070312,222.1999969482422,227.47999572753903,227.47999572753903,2392700.0,4.0,1.0,0.7500249999999999,"Biogen Idec ( BIIB ) reported second quarter earnings per share of $2.29 (including the impact of stock-based compensation expense), well above the Zacks Consensus Estimate of $1.83 and 25.8% above the year-ago earnings. ACTELION LTD (ALIOF): Get Free Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report To read this article on Zacks.com click here. Newly launched multiple sclerosis (MS) drug, Tecfidera, drove second quarter results. New Article We note that Tysabri is currently marketed by Biogen Idec ( BIIB ) and Elan receives royalties on the drug. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report WUXI PHARMATECH (WX): Free Stock Analysis Report To read this article on Zacks.com click here. Elan Corporation ( ELN ) reported breakeven earnings in the second quarter of 2013 from its continuing operations, compared to the year-ago loss of 16 cents per share. New Article Biogen Idec (NASDAQ: BIIB ) is expected to report second quarter EPS of $1.93 vs. $1.82 a year ago on revenue of $1.62 billion vs. $1.42 billion a year ago. S&P 500 futures fell below the key 1685 level which was acting as support over the last few days and potentially signal a bearish outside reversal, which could imply a correction is due. McDonald's (NYSE: MCD ) shares fell 1.6 percent pre-market following a series of negative analyst actions after its weak earnings report earlier this week.",222.08815002441406
2013-07-26 00:00:00+00:00,226.3999938964844,227.759994506836,218.1600036621093,223.22999572753903,223.22999572753903,1403400.0,3.0,1.0,0.5000249999999999,Biogen Idec (NASDAQ: BIIB ) reported second quarter EPS of $2.30 vs. $1.93 a year ago on revenue of $1.7 billion vs. $1.62 billion expected. PBOC Governor Zhou said that there were downward pressures on the Chinese economy overnight and hinted that large-scale stimulus from either the government or the central bank will not come. Vertex Pharmaceuticals (NASDAQ: VRTX ) shares declined 9.27 percent pre-market as the company announced that the FDA has put a hold on one of its clinical studies for its Hepatitis-C drug VX-135.,224.51344299316406
2013-07-31 00:00:00+00:00,217.4900054931641,221.6999969482422,216.0599975585937,218.1300048828125,218.1300048828125,1202900.0,4.0,1.0,0.7500249999999999,"At present, companies like Biogen Idec ( BIIB ) and Gilead Sciences, Inc. ( GILD ) look attractive with both carrying a Zacks Rank #1 (Strong Buy). AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. While products like Enbrel, Neulasta, Xgeva and Prolia performed well, revenues benefited from a $185 million positive adjustment to previous estimates related to managed Medicaid rebates based on recent claims experience.",204.8623809814453
2013-08-01 00:00:00+00:00,218.82000732421875,221.5800018310547,218.02999877929688,220.1999969482422,220.1999969482422,1119600.0,4.0,1.0,0.7500249999999999,"Other companies in the pharma space that are worth considering include Biogen Idec Inc. ( BIIB ) and Gilead Sciences Inc. ( GILD ). BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Sales of new products like Xarelto (anticoagulant), Eylea (eye medicine) and Stivarga (oncology) boosted the Pharmaceuticals segment.",208.90548706054688
2013-08-02 00:00:00+00:00,220.3800048828125,227.8000030517578,220.3000030517578,227.759994506836,227.759994506836,1529600.0,2.5,1.0,0.375025,"Meanwhile, other stocks such as Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ) currently look more attractive in the pharma space with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report TAKEDA PHARMACT (TKPYY): Get Free Report To read this article on Zacks.com click here. AMAG is looking to get Feraheme's label expanded for the treatment of CKD adults suffering from IDA with a history of unsuccessful oral iron therapy. New Article Meanwhile, other companies like Biogen Idec Inc. ( BIIB ) look better positioned with a Zacks Rank #1 (Strong Buy). ASTELLAS PHARMA (ALPMY): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CUBIST PHARM (CBST): Free Stock Analysis Report OPTIMER PHARMAC (OPTR): Free Stock Analysis Report To read this article on Zacks.com click here. Quarter in Details Revenues in the reported quarter included Dificid sales in the U.S. and Canada along with contract revenue of $1.1 million (down 94.8%) under the company's collaboration agreement with Astellas Pharma Europe, a subsidiary of Astellas Pharma, Inc. ( ALPMY ). New Article Other companies in the pharma space that are worth considering include Biogen Idec Inc. ( BIIB ) and Gilead Sciences Inc. ( GILD ). ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. AstraZeneca 's ( AZN ) second-quarter 2013 core earnings of $1.20 per American Depositary Share (ADS) beat the Zacks Consensus Estimate of $1.17. New Article Moreover, new competition has entered the multiple sclerosis market in the form of Biogen's ( BIIB ) Tecfidera. ACTAVIS INC (ACT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SIMCERE PHARMAC (SCR): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Lower generic sales in the U.S. and Europe along with negative currency movement in ROW markets, especially Japan, led to the decline in revenues despite the strong performance of Copaxone and the OTC segment.",206.4366912841797
2013-08-05 00:00:00+00:00,228.0,229.0,225.1000061035156,227.57000732421875,227.57000732421875,969800.0,3.0,1.0,0.5000249999999999,"Other companies like Biogen Idec ( BIIB ), Gilead Sciences ( GILD ) and Actelion ( ALIOF ), all carrying a Zacks Rank #1 (Strong Buy), are also expected to do well in the Medical-Biomed/Gene industry. AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Selling, general and administrative (SG&A) expenses decreased 17.3% to $33.5 million, mainly due to the company's restructuring plans, headcount reduction and lower IT spending. New Article Acorda has a licensing agreement with Biogen Idec ( BIIB ) for the development and commercialization of Ampyra outside the U.S. Ampyra is available outside the U.S. under the trade name Fampyra. ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTAVIS INC (ACT): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Quarter in Detail The bulk of net product revenues at Acorda came from Ampyra, which is marketed for the improvement of walking in multiple sclerosis patients.",217.52867126464844
2013-08-06 00:00:00+00:00,227.2100067138672,227.3600006103516,221.6999969482422,221.82000732421875,221.82000732421875,771200.0,3.0,1.0,0.5000249999999999,"Companies that currently look attractive include Biogen Idec Inc. ( BIIB ), carrying a Zacks Rank #1 (Strong Buy). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Weaker revenues were primarily due to generic competition (481 million), European pricing pressure and an adjustment related to inventory mismanagement in Brazil. New Article Companies that currently look attractive include Biogen Idec Inc. ( BIIB ), carrying a Zacks Rank #1 (Buy). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. GlaxoSmithKline ( GSK ) recently announced that the decision on the approval of its diabetes candidate, albiglutide, from the U.S. Food and Drug Administration (FDA) has been delayed by three months. New Article Meanwhile, stocks such as Biogen Idec Inc. ( BIIB ) look more attractive with a Zacks Rank #1 (Strong Buy). BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report COMPUGEN LTD (CGEN): Get Free Report SEATTLE GENETIC (SGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Bayer 's ( BAYRY ) HealthCare segment recently entered into an oncology collaboration and licence agreement with Compugen Ltd. ( CGEN ) for an upfront payment of $10 million.",217.76251220703125
2013-08-07 00:00:00+00:00,220.63999938964844,223.0,217.1300048828125,217.759994506836,217.759994506836,1114500.0,3.75,1.0,0.6875249999999999,"Companies that currently look attractive include Actelion Ltd. ( ALIOF ), Biogen Idec Inc. ( BIIB ) and Gilead Sciences Inc. ( GILD ), carrying a Zacks Rank #1 (Buy). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. A randomized, observer-blind, placebo-controlled, multi-center, multi-national, phase III trial has stared enrolling patients under the Cdiffense program. New Article Other companies in the pharma space that are worth considering include Biogen Idec Inc. ( BIIB ), which carries a Zacks Rank #1 (Strong Buy). BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report To read this article on Zacks.com click here. Bayer ( BAYRY ) along with partner, Regeneron Pharmaceuticals Inc. ( REGN ) recently announced positive 52-week data from the phase III VIVID-DME and VISTA-DME studies on VEGF Trap-Eye for the treatment of diabetic macular edema (DME). New Article Currently, companies like Biogen Idec ( BIIB ) and Gilead Sciences, Inc. ( GILD ) look attractive, each with a Zacks Rank #1 (Strong Buy). ACTAVIS INC (ACT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ENDO PHARMACEUT (ENDP): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Endo Health Solutions ' ( ENDP ) second quarter 2013 earnings (excluding special items) of $1.42 per share handsomely beat the Zacks Consensus Estimate of $1.15 and increased 12% from the year-ago period. New Article Other companies like Biogen Idec ( BIIB ), Gilead Sciences ( GILD ) and Actelion ( ALIOF ), all carrying a Zacks Rank #1 (Strong Buy), are also expected to do well in the Medical-Biomed/Gene industry. AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Thanks to AFFX's strategic restructuring plans and its acquisition of eBioscience in Jun 2012 that has opened new avenues for the company and turned its focus away from the beleaguered Gene Expression business.",212.58319091796875
2013-08-08 00:00:00+00:00,219.6999969482422,220.0,215.8699951171875,216.88999938964844,216.88999938964844,807800.0,3.75,1.0,0.6875249999999999,"Companies that currently look attractive include Actelion Ltd. ( ALIOF ), Biogen Idec Inc. ( BIIB ) and Gilead Sciences Inc. ( GILD ), carrying a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report To read this article on Zacks.com click here. GlaxoSmithKline ( GSK ) recently announced that it has submitted a variation to the Marketing Authorisation for its oncology drug, Votrient to the European Medicines Agency. New Article Other stocks like Biogen Idec Inc. ( BIIB ), Gilead Sciences Inc. ( GILD ) and Actelion Ltd. ( ALIOF ) presently look more attractive with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report SPECTRUM PHARMA (SPPI): Free Stock Analysis Report To read this article on Zacks.com click here. Marqibo is currently approved in the U.S. for the treatment of adults suffering from Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed after two or more anti-leukemia therapies. New Article The studies include, a thirteen-week toxicology study, a phase I radiolabled XP23829 metabolism and disposition study, and a study evaluating the pharmacokinetics of XP23829 plus Biogen Idec Inc.'s (BIIB) Tecfidera at its approved dose. The drug is approved in the U.S. for the treatment of moderate-to-severe primary restless legs syndrome (RLS) as well as for the management of postherpetic neuralgia (PHN) in adults. Results from the phase III trial showed that AP failed to achieve statistically significant improvement compared to placebo in patients suffering from spasticity due to multiple sclerosis (MS). New Article Other companies like Biogen Idec ( BIIB ), Gilead Sciences ( GILD ) and Actelion ( ALIOF ), all carrying a Zacks Rank #1 (Strong Buy), are also expected to do well in the Medical-Biomed/Gene industry. AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. It uses Affymetrix's one-of-a-kind Molecular Inversion Probe (MIP) technology to deliver prompt and accurate results in just 48 hours.",222.06744384765625
2013-08-09 00:00:00+00:00,214.75,217.1000061035156,212.009994506836,212.3500061035156,212.3500061035156,1028900.0,2.5,1.0,0.375025,"Meanwhile, other stocks such as Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ) currently look more attractive in the pharma space with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report TAKEDA PHARMACT (TKPYY): Get Free Report To read this article on Zacks.com click here. Feraheme is currently approved as an injectable drug for intravenous use as iron replacement therapy for the treatment of IDA in adults suffering from chronic kidney disease (CKD). New Article Biogen Idec Inc. ( BIIB ) had the largest percent change down (-2.09%) while Randgold Resources Limited ( GOLD ) had the largest percent change gain rising 3.89%. The Dow Jones index closed down -.47% for the day; a total of -72.81 points. NASDAQ Market Wrap As of 8/9/2013 4:44:02 PM BILLIONS OF 1.52 NASDAQ SHARES TRADED TODAY 45 STOCKS REACHED A 52 WEEK HIGH 18 THOSE REACHING LOWS TOTALEDRandgold Resources Limited[GOLD]TOPS ADVANCERS LISTOF NASDAQ 100 % 3.89 INDEXGOLD ROSE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",225.99981689453125
2013-08-15 00:00:00+00:00,209.4100036621093,209.8600006103516,205.72999572753903,206.52999877929688,206.52999877929688,814900.0,4.0,1.0,0.7500249999999999,"Currently, companies like Actelion Ltd. ( ALIOF ) and Biogen Idec ( BIIB ) look well-positioned. ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. Eli Lilly and Company ( LLY ) received a boost recently with its phase III oncology candidate, necitumumab, achieving the primary endpoint in a study (SQUIRE) conducted in patients with stage IV metastatic squamous non-small cell lung cancer (NSCLC).",223.90167236328125
2013-08-16 00:00:00+00:00,205.6100006103516,208.9199981689453,205.27999877929688,206.88999938964844,206.88999938964844,1252200.0,4.25,1.0,0.8125249999999999,"Right now, Biogen Idec Inc. ( BIIB ) looks attractive with a Zacks Rank #1 (Strong Buy). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. We believe the label expansion of Menveo and approval of Bexsero in early 2013 will strengthen Novartis' meningococcal franchise and boost results going forward. New Article And in March, the FDA approved Biogen's ( BIIB ) multiple sclerosis drug Tecfidera. The benchmark S&P 500 biotech sector ETF ( XBI ) is up an incredible 36% year to date, handily outperforming the 19% rise for the S&P 500. There is still money to be made in biotech, but my advice is that investors look past mutual funds and ETFs and instead invest in individual companies. New Article Companies which look attractive include Gilead Sciences Inc. ( GILD ), Biogen Idec Inc. ( BIIB ) and Actelion Ltd. ( ALIOF ) with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report APPRICUS BIOSCI (APRI): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Apricus' marketing approval application for Vitaros designated Netherlands as the Reference Member State (RMS) on behalf of nine other European Concerned Member States (France, Germany, Italy, UK, Ireland, Spain, Sweden, Belgium and Luxembourg) that participated in the procedure. New Article However, companies such as Biogen Idec Inc. ( BIIB ) look more attractive with a Zacks Rank #1 (Strong Buy). AMGEN INC (AMGN): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ONYX PHARMA INC (ONXX): Free Stock Analysis Report To read this article on Zacks.com click here. According to a report published by Bloomberg, Onyx Pharma is now faced with delays over a dispute with its potential buyer Amgen Inc. ( AMGN ).",217.8996124267578
2013-08-19 00:00:00+00:00,207.1499938964844,209.9499969482422,206.83999633789065,206.8699951171875,206.8699951171875,639800.0,3.333333333333333,1.0,0.5833583333333334,"Currently, companies like Questcor Pharmaceuticals Inc. (QCOR), Biogen Idec Inc. (BIIB) and Actelion Ltd. (ALIOF) look well positioned in the pharma space with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report QUESTCOR PHARMA (QCOR): Free Stock Analysis Report TAKEDA PHARMACT (TKPYY): Get Free Report To read this article on Zacks.com click here. It was approved in the U.S. for the treatment of schizophrenia in Oct 2010 and for major depressive episodes associated with bipolar I disorder in Jun 2013. New Article Companies which look attractive include Biogen Idec Inc. ( BIIB ) and Actelion Ltd. ( ALIOF ) with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report SPECTRUM PHARMA (SPPI): Free Stock Analysis Report To read this article on Zacks.com click here. The candidate will be developed for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epileptics who cannot take the oral form of topiramate. New Article ( BIIB ) and Gilead Sciences Inc . ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CHELSEA THERAP (CHTP): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Chelsea Therapeutics International, Ltd. ( CHTP ) recently made some progress with its late-stage pipeline candidate, Northera.",224.186279296875
2013-08-20 00:00:00+00:00,206.8099975585937,209.25,206.2400054931641,206.5500030517578,206.5500030517578,736400.0,3.0,1.0,0.5000249999999999,"Other players like Actelion ( ALIOF ), Biogen Idec Inc. ( BIIB ) and Gilead Sciences, Inc. ( GILD ) currently look more attractive in the pharma space with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report LANNETT INC (LCI): Free Stock Analysis Report To read this article on Zacks.com click here. On the other hand, Jerome Stevens has the option to terminate the agreement if Lannett fails to meet the minimum purchase requirement of the contract.",231.7518310546875
2013-08-21 00:00:00+00:00,205.6100006103516,210.97999572753903,203.5500030517578,208.0800018310547,208.0800018310547,999500.0,2.5,1.0,0.375025,"At present, companies like Actelion Ltd. ( ALIOF ), Biogen Idec ( BIIB ) and Gilead Sciences, Inc. ( GILD ) look well-positioned with all three being Zacks Rank #1 (Strong Buy) stocks. ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report XOMA CORP (XOMA): Free Stock Analysis Report To read this article on Zacks.com click here. The company expects research and development spend to increase this year mainly due to the ongoing global phase III development of lead candidate, gevokizumab, for the non-infectious uveitis (NIU) indications and XOMA's ongoing phase II proof-of-concept program. New Article Currently, companies like Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ) look more attractive with a Zacks Rank #1 (Strong Buy). ABBVIE INC (ABBV): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here. Repros Therapeutics Inc. ( RPRX ) recently announced six months interim results from the ongoing ZA-303 study on its lead pipeline candidate, Androxal. New Article Currently, companies like Questcor Pharmaceuticals Inc. ( QCOR ), Biogen Idec Inc. ( BIIB ) and Actelion Ltd. ( ALIOF ) look well positioned with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report QUESTCOR PHARMA (QCOR): Free Stock Analysis Report SAVIENT PHARM (SVNT): Free Stock Analysis Report To read this article on Zacks.com click here. Krystexxa is approved for the treatment of chronic gout in adult patients who do not respond to conventional therapy. New Article At present, companies like Actelion Ltd. ( ALIOF ), Biogen Idec ( BIIB ) and Gilead Sciences, Inc. ( GILD ) look well-positioned with all three being Zacks Rank #1 (Strong Buy) stocks. ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GTX INC (GTXI): Free Stock Analysis Report To read this article on Zacks.com click here. GTx, Inc. ( GTXI ) suffered a setback recently with its phase III candidate, enobosarm, failing to meet overall requirements for the co-primary responder endpoints of lean body mass and physical function as agreed upon with the U.S. Food and Drug Administration (FDA).",227.20089721679688
2013-08-22 00:00:00+00:00,208.3500061035156,212.7700042724609,208.009994506836,211.47999572753903,211.47999572753903,612400.0,3.0,1.0,0.5000249999999999,"Other Stocks to Consider At present, Biogen Idec ( BIIB ) looks well-positioned with a Zacks Rank #1 (Strong Buy). AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report ONYX PHARMA INC (ONXX): Free Stock Analysis Report To read this article on Zacks.com click here. Onyx Pharma is engaged in the development of novel cancer therapies that target the molecular basis of the disease.",226.4707489013672
2013-08-26 00:00:00+00:00,212.0200042724609,214.9199981689453,210.9900054931641,212.33999633789065,212.33999633789065,803100.0,3.75,1.0,0.6875249999999999,"At present, Biogen Idec ( BIIB ) looks well-positioned with a Zacks Rank #1 (Strong Buy). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report IMMUNOMEDICS (IMMU): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Epratuzumab, the most advanced pipeline candidate at Immunomedics, is being evaluated for the treatment of moderate-to-severe systemic lupus erythematosus (SLE). New Article Other stocks that look attractive include Biogen Idec Inc. ( BIIB ), Gilead Sciences Inc. ( GILD ) and Affymetrix Inc. ( AFFX ). AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. We note that in Jul 2013, Actelion had entered into an agreement with Ceptaris to acquire the latter, contingent upon the FDA's approval of Valchlor. New Article At present, companies like Biogen Idec ( BIIB ) and Gilead Sciences, Inc. ( GILD ) look well-positioned with both being Zacks Rank #1 (Strong Buy) stocks. AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ONYX PHARMA INC (ONXX): Free Stock Analysis Report To read this article on Zacks.com click here. The deal is slated to close in early fourth quarter 2013 and will be financed by committed bank loans of $8.1 billion and cash available in the U.S. Onyx Pharma had rejected a $120 per share takeover bid by Amgen In Jun 2013. New Article At present, companies like Actelion Ltd. ( ALIOF ), Biogen Idec ( BIIB ) and Gilead Sciences, Inc. ( GILD ) look well-positioned with all three being Zacks Rank #1 (Strong Buy) stocks. ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report XOMA CORP (XOMA): Free Stock Analysis Report To read this article on Zacks.com click here. The company expects research and development spend to increase this year mainly due to the ongoing global phase III development of lead candidate, gevokizumab, for non-infectious uveitis (NIU) and XOMA's ongoing phase II proof-of-concept program.",230.9507598876953
2013-08-27 00:00:00+00:00,210.08999633789065,211.7100067138672,207.38999938964844,207.6499938964844,207.6499938964844,725900.0,3.333333333333333,1.0,0.5833583333333334,"At present, companies like Actelion Ltd. ( ALIOF ), Biogen Idec ( BIIB ) and Gilead Sciences, Inc. ( GILD ) look well-positioned with all three being Zacks Rank #1 (Strong Buy) stocks. ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. In Canada, Sanofi has started enrolling volunteers for the randomized, observer-blind, placebo-controlled, multi-center, multi-national (across 17 countries), phase III trial. New Article At present, companies like Biogen Idec ( BIIB ) look well-positioned with a Zacks Rank #1 (Strong Buy). AMGEN INC (AMGN): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ONYX PHARMA INC (ONXX): Free Stock Analysis Report To read this article on Zacks.com click here. AstraZeneca ( AZN ) recently announced that its global biologics research and development arm, MedImmune, has entered into an agreement to acquire privately-held U.S. based company, Amplimmune. New Article At present, companies like Biogen Idec ( BIIB ) and Gilead Sciences, Inc. ( GILD ) look attractive with both carrying a Zacks Rank #1 (Strong Buy). ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report RIGEL PHARMCTCL (RIGL): Free Stock Analysis Report To read this article on Zacks.com click here. AstraZeneca arrived at the decision based on mixed data from the OSKIRA phase III program and decided against pursuing regulatory filings for the candidate.",235.2550506591797
2013-08-28 00:00:00+00:00,208.2700042724609,211.2899932861328,206.6000061035156,209.7100067138672,209.7100067138672,809600.0,3.6666666666666665,1.0,0.6666916666666666,"Investors looking for strong growth at a reasonable price in the biotech sector may want to buy into the Biogen Idec ( BIIB ) story. AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ONYX PHARMA INC (ONXX): Free Stock Analysis Report To read this article on Zacks.com click here. The biotech space is likely to find greater focus in the wake Amgen's ( AMGN ) purchase of ONXY Pharmaceuticals ( ONXX ). New Article At present, companies like Biogen Idec ( BIIB ) look well-positioned - Biogen carries a Zacks Rank #1 (Strong Buy). AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report ONYX PHARMA INC (ONXX): Free Stock Analysis Report To read this article on Zacks.com click here. Amgen ( AMGN ) recently announced that it will be presenting new data on two promising pipeline candidates, omecamtiv mecarbil and AMG-145, at the upcoming ESC Congress, organized by the European Society of Cardiology, in early September. New Article At present, companies like Biogen Idec ( BIIB ) and Gilead Sciences, Inc. ( GILD ) look well-positioned with both being Zacks #1 Ranked (Strong Buy) stocks. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report OREXIGEN THERAP (OREX): Free Stock Analysis Report TAKEDA PHARMACT (TKPYY): Get Free Report To read this article on Zacks.com click here. The company stated that the Independent Data Monitoring Committee for the Light Study expects sufficient major adverse cardiovascular events to occur by Oct 2013, which would facilitate an interim analysis by early December.",231.81005859375
2013-08-29 00:00:00+00:00,209.19000244140625,217.07000732421875,209.02999877929688,214.1300048828125,214.1300048828125,859700.0,4.0,1.0,0.7500249999999999,"At present, companies like Actelion Ltd. ( ALIOF ), Biogen Idec ( BIIB ) and Gilead Sciences, Inc. ( GILD ) look well-positioned with all three being Zacks Rank #1 (Strong Buy) stocks. ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Sanofi ( SNY ) recently announced encouraging top-line data from a trial evaluating Fluzone high-dose vaccine for the prevention of influenza in people aged 65 years and older. New Article However, others stocks which look attractive include Biogen Idec Inc. ( BIIB ), Actavis, Inc. ( ACT ) and Actelion Ltd. ( ALIOF ), each with a Zacks Rank #1 (Strong Buy). ACTAVIS INC (ACT): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SIMCERE PHARMAC (SCR): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Simcere's decision to go private comes in the wake of tough business conditions that it has been facing in the last few months.",224.0381622314453
2013-08-30 00:00:00+00:00,213.9900054931641,214.5599975585937,210.8699951171875,213.0200042724609,213.0200042724609,1002300.0,4.666666666666667,1.0,0.9166916666666668,"Other Stocks to Consider Besides Affymetrix, other companies like Biogen Idec ( BIIB ), Gilead Sciences ( GILD ) and Actelion ( ALIOF ), all carrying a Zacks Rank #1 (Strong Buy), are also expected to do well in the Medical-Biomed/Gene industry. AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. On Aug 29, Zacks Investment Research upgraded genetic devices maker Affymetrix ( AFFX ) to Outperform, based on its improved prospects. New Article Currently, companies like Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ) look well positioned in the pharma space with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ONYX PHARMA INC (ONXX): Free Stock Analysis Report To read this article on Zacks.com click here. The European approval of Stivarga was based on positive results from Bayer's phase III CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) study. New Article In the second quarter, PRIMECAP was actively trading and trimming some of its top holdings, including Amgen Inc. ( AMGN ) and Biogen Idec Inc. ( BIIB ), two biotechnology medicine and pharmaceutical companies. Track historical pricing, revenue and net income: The five-year trading history shows a remarkable green streak of gains: Biogen Idec Inc. ( BIIB ): Reduced Impacts Portfolio: -0.28% Current Shares: 18,246,809 Up 45% over 12 months, Biogen Idec Inc., a biotechnology company, has a market cap of $50.47 billion; its shares were traded at around $212.57 with a P/E ratio of 31.70. PRIMECAP currently holds 7.72% of AMGN shares outstanding and 4.99% of BIIB.",206.3892364501953
2013-09-03 00:00:00+00:00,216.0,222.4499969482422,213.0500030517578,221.7899932861328,221.7899932861328,1223400.0,3.25,1.0,0.5625249999999999,"We note that apart from Aubagio, FDA-approved oral multiple sclerosis therapies include Novartis ' ( NVS ) Gilenya and Biogen Idec 's ( BIIB ) Tecfidera. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Sanofi ( SNY ) announced that its oral drug Aubagio 14 mg, has gained approval from the European Commission (EC). New Article Companies that currently look well-positioned include Biogen Idec ( BIIB ), carrying a Zacks Rank #1 (Strong Buy). ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. AstraZeneca ( AZN ) recently announced full data from the SAVOR study (n = 16,492) on its diabetes drug, Onglyza, a dipeptidyl peptidase-4 (DPP-4) inhibitor. New Article (BIIB),GileadSciences Inc.(GILD) and Affymetrix Inc.(AFFX) . AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Results from the SERAPHIN study (n=742) showed that the risk of a morbidity/mortality event was cut by 45% in patients who were administered Opsumit compared to those on placebo. New Article At present, companies like Biogen Idec ( BIIB ), Actelion Ltd. ( ALIOF ) and Gilead Sciences, Inc. ( GILD ) look well-positioned with all three being Zacks Rank #1 (Strong Buy) stocks. ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report To read this article on Zacks.com click here. Earlier this year in June, Isis Pharma had reported impressive results from a phase II study on ISIS-APOCIIIRx at the American Diabetes Association (ADA).",204.0690460205078
2013-09-04 00:00:00+00:00,223.63999938964844,231.6499938964844,223.0,230.58999633789065,230.58999633789065,1905400.0,3.0,1.0,0.5000249999999999,"We note that Elan currently receives royalty payments at 12% on worldwide net sales of the multiple sclerosis drug, Tysabri, after it sold the drug's stake to Biogen Idec Inc. ( BIIB ) in April this year. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report PERRIGO COMPANY (PRGO): Free Stock Analysis Report WUXI PHARMATECH (WX): Free Stock Analysis Report To read this article on Zacks.com click here. The phase IIa study will be evaluating the safety and pharmacokinetics of ELND005 compared to placebo in young adults suffering from Down syndrome without dementia, and will also include select cognitive and behavioural measures. New Article Other stocks like Biogen Idec Inc. ( BIIB ), Gilead Sciences Inc. ( GILD ) and Actelion Ltd. ( ALIOF ) presently look more attractive with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report SPECTRUM PHARMA (SPPI): Free Stock Analysis Report To read this article on Zacks.com click here. Spectrum Pharmaceuticals, Inc. ( SPPI ) recently launched its newly acquired drug, Marqibo, in the U.S. Marqibo is approved in the U.S. for the treatment of adults suffering from Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed after being treated with two or more anti-leukemia therapies.",217.8828582763672
2013-09-05 00:00:00+00:00,229.8099975585937,231.72000122070312,226.0200042724609,227.6999969482422,227.6999969482422,1074700.0,3.3333333333333326,1.0,0.5833583333333334,"Right now, Actelion Ltd. ( ALIOF ), Biogen Idec Inc. ( BIIB ) and Gilead Sciences Inc. ( GILD ) look more attractive with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CHELSEA THERAP (CHTP): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. However, the FDA later informed the company of deficiencies in the NDA regarding the formatting of certain submitted electronic datasets and statistical programs describing the methods used to generate tables and listings. New Article Other attractive picks are Affymetrix Inc. ( AFFX ) and Biogen Idec Inc. ( BIIB ), carrying a Zacks Rank #1 (Strong Buy). AFFYMETRIX INC (AFFX): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report To read this article on Zacks.com click here. Recently, Myriad Genetics Inc. ( MYGN ) inked an expanded, nonexclusive worldwide collaboration agreement with AstraZeneca ( AZN ) to offer companion diagnostics for the latter's pivotal Phase 3 clinical development program for the oncology candidate olaparib. New Article At present, companies like Biogen Idec ( BIIB ) and Gilead Sciences Inc. ( GILD ) look attractive with both being Zacks Rank #1 (Strong Buy) stocks. AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. The study (n=613), conducted in patients hospitalized with acute heart failure (AHF), evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of an intravenous formulation of omecamtiv mecarbil. New Article At present, companies like Actelion Ltd. ( ALIOF ), Biogen Idec ( BIIB ) and Gilead Sciences Inc. ( GILD ) look attractive with all three being Zacks Rank #1 (Strong Buy) stocks. ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report To read this article on Zacks.com click here. The Medicines Company ( MDCO ) recently announced the presentation and publication of a pooled analysis of three phase III studies conducted on its antiplatelet candidate, Cangrelor. New Article (BIIB) and Affymetrix Inc.(AFFX) . AFFYMETRIX INC (AFFX): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. ARIAD Pharmaceuticals, Inc. (ARIA) recently completed 50% enrollment in the randomized phase III EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) study being conducted on Iclusig (ponatinib) in newly diagnosed chronic myeloid leukemia (CML) patients. New Article (BIIB),GileadSciences Inc.(GILD) and Affymetrix Inc.(AFFX) . AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report TAKEDA PHARMACT (TKPYY): Get Free Report To read this article on Zacks.com click here. The U.S. Food and Drug Administration (FDA) recently granted priority review to Takeda Pharmaceutical Company Limited 's (TKPYY) Biologics License Application (BLA) for vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC).",216.286865234375
2013-09-06 00:00:00+00:00,229.5,230.0,224.42999267578125,225.17999267578125,225.17999267578125,1256400.0,2.25,1.0,0.312525,"Companies that currently look well-positioned include Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ) with a Zacks Rank #1 (Strong Buy) and Jazz Pharmaceuticals ( JAZZ ) with a Zacks Rank #2 (Buy). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report To read this article on Zacks.com click here. GlaxoSmithKline ( GSK ) recently announced disappointing data from the phase III DERMA study on its MAGE-A3 cancer immunotherapeutic. New Article Other stocks that warrant a look are Actelion Ltd. ( ALIOF ), Affymetrix Inc. ( AFFX ) and Biogen Idec Inc. ( BIIB ). AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report To read this article on Zacks.com click here. Recently, Myriad Genetics Inc. ( MYGN ) launched its major pipeline product myRisk Hereditary Cancer. New Article Currently, companies like Biogen Idec Inc. ( BIIB ) look better positioned in the pharma space with a Zacks Rank #1 (Strong Buy). BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ONYX PHARMA INC (ONXX): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report To read this article on Zacks.com click here. The HealthCare segment of Bayer ( BAYRY ) recently submitted a marketing authorization application in the EU for Stivarga for the treatment of patients suffering from gastrointestinal stromal tumors (GlST) who were previously treated with two tyrosine kinase inhibitors. New Article Currently, companies like Biogen Idec ( BIIB ), Gilead Sciences Inc. ( GILD ) and Actelion Ltd. ( ALIOF ) look well-positioned with all three being Zacks Rank #1 (Strong Buy) stocks. ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report To read this article on Zacks.com click here. Demand should increase further with the UK recommending Zostavax for the routine vaccination of individuals aged 70 (and 79 years catch-up cohort) for the prevention of shingles and shingles-related post-herpetic neuralgia from Sep 1, 2013.",204.2628936767578
2013-09-09 00:00:00+00:00,226.08999633789065,229.0,224.94000244140625,228.8600006103516,228.8600006103516,891600.0,3.799999999999999,1.0,0.700025,"ISIS will receive an upfront payment of $100 million, most of which will be reflected as R&D expense in BIIB's Q3 financial results. ISIS is eligible to receive milestone payments, license fees and royalty payments for all treatments developed through this collaboration, with the specific amount dependent upon the modality of the molecule advanced by BIIB. Isis Pharmaceuticals ( ISIS ) and Biogen ( BIIB ) said they entered into a broad, multi-year collaboration to leverage antisense technology to advance the treatment of neurological diseases. New Article In company news, Isis Pharmaceuticals ( ISIS ) is up more than 10% after announcing a multi-year research and development accord with Biogen Idec ( BIIB ) on antisense technology to treat neurological diseases. Under the deal, ISIS will receive a $100-million upfront payment from BIIB. BIIB shares are up 0.9% at $227 each. New Article (+) ISIS, Receives $100-mln upfront payment from Biogen Idec ( BIIB ) as part of multi-year pact to research, develop antisense technology to treat neurological diseases. Stocks rallied today, extending their rebound from the August sell-off following bullish data out of Asia this weekend and afternoon reports the Syrian government may turn over its chemical weapons to international authorities in a bid to avoid a U.S. military strike. ""We, for the sake of protecting our people and children and country and due to our trust in the Russian efforts, will cooperate fully with Russia in this regard so as to take away the excuses of this aggression,"" Syrian Foreign Minister Walid Moallem said in a statement. New Article Shares of Isis Pharmaceuticals (NASDAQ: ISIS ) got a boost, shooting up 11.64 percent to $31.17 after the company and Biogen Idec (NASDAQ: BIIB ) announced a strategic collaboration to develop new treatments for neurological disorders. Koch Industries will pay $38.50 per share to Molex's shareholders, representing a 31% premium to the company's common stock price of $29.34 on Friday. Equities Trading UP Molex (NASDAQ: MOLX ) shot up 31.36 percent to $38.54 after the company agreed to be acquired by Koch Industries for $7.2 billion in cash. New Article In other sector news, (+) ISIS, Receives $100-mln upfront payment from Biogen Idec ( BIIB ) as part of multi-year pact to research, develop antisense technology to treat neurological diseases. In company news, Oncolytics Biotech Inc. ( ONCY ) is up over 21% at $3.22 a share after the development-stage company reported positive final tumor response data from Phase II testing of its Reolysin drug candidate in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma. Out of 25 evaluable patients who had more than one cycle of therapy, 23 - or 92% - of the test subject exhibited overall tumor shrinkage. New Article ISIS will receive an upfront payment of $100 million, most of which will be reflected as R&D expense in BIIB's Q3 financial results. ISIS is eligible to receive milestone payments, license fees and royalty payments for all treatments developed through this collaboration, with the specific amount dependent upon the modality of the molecule advanced by BIIB. Isis Pharmaceuticals ( ISIS ) and Biogen ( BIIB ) said they entered into a broad, multi-year collaboration to leverage antisense technology to advance the treatment of neurological diseases. New Article In company news, Isis Pharmaceuticals ( ISIS ) is up more than 10% after announcing a multi-year research and development accord with Biogen Idec ( BIIB ) on antisense technology to treat neurological diseases. Under the deal, ISIS will receive a $100-million upfront payment from BIIB. BIIB shares are up 0.9% at $227 each. New Article Currently, companies like Biogen Idec ( BIIB ), Gilead Sciences Inc. ( GILD ) and Actelion Ltd. ( ALIOF ) look well-positioned with all three being Zacks Rank #1 (Strong Buy) stocks. ACTELION LTD (ALIOF): Get Free Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. The phase II study compared the efficacy and safety of olaparib versus placebo in patients suffering from platinum-sensitive, relapsed, high grade serous ovarian cancer. New Article Isis Pharmaceuticals (NASDAQ: ISIS ) shot up 13.93 percent to $31.81 after the company and Biogen Idec (NASDAQ: BIIB ) announced a strategic collaboration to develop new treatments for neurological disorders. Carl Icahn spoke on Bloomberg television this afternoon, announcing he will not pursue additional efforts to defeat Michael Dell's proposal for the company. Stock Movers Molex (NASDAQ: MOLX ) rose 31.66 percent to $38.63 after the company agreed to be acquired by Koch Industries for $7.2 billion in cash. New Article Currently, companies like Actelion Ltd. ( ALIOF ), Gilead Sciences Inc. ( GILD ) and Biogen Idec Inc. ( BIIB ) look well positioned in the pharma space with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Bayer's CropScience unit, which is engaged in developing and marketing chemical crop protection products (insecticides, herbicides, and fungicides), seeds and integrated plant biotechnology solutions for agricultural and non-agricultural uses, contributed around 93 million from Russia in 2012. New Article Shares of Isis Pharmaceuticals (NASDAQ: ISIS ) got a boost, shooting up 13.07 percent to $31.58 after the company and Biogen Idec (NASDAQ: BIIB ) announced a strategic collaboration to develop new treatments for neurological disorders. Koch Industries will pay $38.50 per share to Molex's shareholders, representing a 31% premium to the company's common stock price of $29.34 on Friday. Equities Trading UP Molex (NASDAQ: MOLX ) shot up 31.62 percent to $38.62 after the company agreed to be acquired by Koch Industries for $7.2 billion in cash.",203.528076171875
2013-09-10 00:00:00+00:00,230.0,230.3500061035156,224.7899932861328,228.69000244140625,228.69000244140625,932200.0,3.428571428571428,1.0,0.6071678571428573,"Companies that currently look well-positioned include Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ) with a Zacks Rank #1 (Strong Buy) and Jazz Pharmaceuticals ( JAZZ ) with a Zacks Rank #2 (Buy). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report To read this article on Zacks.com click here. GlaxoSmithKline ( GSK ) recently announced that it has entered into an agreement with a Japanese consumer goods company, Suntory Beverage & Food Ltd., to divest its nutritional drinks brands, Lucozade and Ribena, for 1.35 billion in cash. New Article Biogen Idec ( BIIB ) and Isis Pharmaceuticals, Inc. ( ISIS ) are teaming up yet again - this time for the use of Isis Pharma's antisense technology for the development of treatments for neurological diseases. ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report To read this article on Zacks.com click here. The companies first collaborated in early 2012 for the development of antisense drugs to treat spinal muscular atrophy. New Article At present, companies like Biogen Idec ( BIIB ) and Gilead Sciences, Inc. ( GILD ) look attractive with both sporting a Zacks Rank #1 (Strong Buy). ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report RIGEL PHARMCTCL (RIGL): Free Stock Analysis Report To read this article on Zacks.com click here. Rigel Pharmaceuticals, Inc. ( RIGL ) recently announced that it has reduced its work force by approximately 18% (30 positions) in order to utilize its resources more efficiently. New Article Companies that currently look well-positioned include Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ) with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PEREGRINE PHARM (PPHM): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Peregrine Pharmaceuticals, Inc. ( PPHM ) reported a net loss of 5 cents per share in the first quarter of fiscal 2014 (ended Jul 31, 2013), in line with the Zacks Consensus Estimate. New Article Amicus Therapeutics ( FOLD ), a biopharmaceutical company engaged in therapies for rare and orphan diseases, has entered a collaboration with Biogen Idec ( BIIB ) to discover, develop and commercialize novel small molecules for the treatment of Parkinson's disease. FOLD is up 19% at $3.03 in pre-market trade; BIIB is up 0.7% at $230.50. The collaboration will build upon preclinical studies at Amicus and independent published research that suggest increasing activity of the lysosomal enzyme glucocerobrosidase in the brain may correct alpha-synuclein pathology and other deficits associated with Parkinson's disease. New Article Amicus Therapeutics ( FOLD ), a biopharmaceutical company engaged in therapies for rare and orphan diseases, has entered a collaboration with Biogen Idec ( BIIB ) to discover, develop and commercialize novel small molecules for the treatment of Parkinson's disease. FOLD is up 19% at $3.03 in pre-market trade; BIIB is up 0.7% at $230.50. The collaboration will build upon preclinical studies at Amicus and independent published research that suggest increasing activity of the lysosomal enzyme glucocerobrosidase in the brain may correct alpha-synuclein pathology and other deficits associated with Parkinson's disease. New Article  Shares of Molex Incorporated (NASDAQ: MOLX ) gained 31.7% after Koch Industries agreed to buy the company for $7.2 billion  ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS ) and Biogen Idec Inc (NASDAQ: BIIB ) gained 13.9% and 1.6%, respectively after the companies agreed to collaborate on drugs for neurological disorders  Piedmont Natural Gas Company, Inc. (NYSE: PNY ) reported a third quarter loss per share of $0.03, above the Zacks Consensus Estimate loss of $0.08  Hi-Tech Pharmacal Co. (NASDAQ: HITK ) reported first quarter earnings per share of $0.44, below the Zacks Consensus Estimate of $0.53 BIOGEN IDEC INC (BIIB): Free Stock Analysis Report HI TECH PHARMA (HITK): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report MOLEX INC (MOLX): Free Stock Analysis Report PIEDMONT NAT GA (PNY): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",209.4730987548828
2013-09-11 00:00:00+00:00,228.5,236.5399932861328,227.7899932861328,236.27000427246088,236.27000427246088,1220800.0,3.6,1.0,0.6500250000000001,"( BIIB ) and Affymetrix Inc. ( AFFX ). AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report VIROPHARMA (VPHM): Free Stock Analysis Report To read this article on Zacks.com click here. Actelion Ltd. ( ALIOF ) recently announced that it will initiate a phase III development program with its clostridium difficile-associated diarrhea (CDAD) candidate, cadazolid. New Article Meanwhile, other companies like Actelion Ltd. ( ALIOF ), Biogen Idec Inc. ( BIIB ) and Gilead Sciences Inc. ( GILD ) look better positioned with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report LANNETT INC (LCI): Free Stock Analysis Report To read this article on Zacks.com click here. Net revenues during fiscal 2013 were up primarily due to increased sales in the company's thyroid deficiency category. New Article Shortly after announcing its fourth collaboration with Isis Pharmaceuticals ( ISIS ), biotech company Biogen Idec ( BIIB ) announced another deal - this time with biopharma company, Amicus Therapeutics ( FOLD ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AMICUS THERAPT (FOLD): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report To read this article on Zacks.com click here. The collaboration is based on preclinical studies performed by Amicus as well as independent published research which indicate that increasing activity of the lysosomal enzyme glucocerobrosidase (GCase) in the brain may correct alpha-synuclein pathology and other deficits associated with Parkinson's disease. New Article The first, randomized, double-blind, placebo-controlled, multiple ascending dose-escalation study evaluated the pharmacokinetics, safety and tolerability of two formulations of XP23829 versus Biogen Idec Inc. 's ( BIIB ) Tecfidera (dimethyl fumarate) in healthy adult subjects. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report XENOPORT INC (XNPT): Free Stock Analysis Report To read this article on Zacks.com click here. Xenoport, Inc. ( XNPT ) recently announced initial results from two phase I studies on XP23829, a fumaric acid ester candidate. New Article Companies that currently look well-positioned include Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ) with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report THERAVANCE INC (THRX): Free Stock Analysis Report To read this article on Zacks.com click here. The companies are looking to get the candidate approved in the U.S. as a maintenance bronchodilator therapy (once daily) to relieve symptoms in adults suffering from chronic obstructive pulmonary disease (COPD).",199.2518310546875
2013-09-12 00:00:00+00:00,236.7700042724609,238.5,233.0800018310547,234.1100006103516,234.1100006103516,1112200.0,4.0,1.0,0.7500249999999999,"( BIIB ) also appear to be attractive. ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report To read this article on Zacks.com click here. ORR for the study refers to the proportion of patients achieving a confirmed complete or partial response following treatment with idelalisib. New Article Right now, Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ) looks well placed with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PLURISTEM THERA (PSTI): Free Stock Analysis Report UTD THERAPEUTIC (UTHR): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Pluristem develops placenta-based cell therapies in collaboration with companies like United Therapeutics or through research and clinical institutions. New Article ( BIIB ) and Affymetrix Inc. ( AFFX ), which carry a Zacks Rank #1. AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Actelion Ltd. ( ALIOF ) recently presented morbidity and mortality data on pipeline candidate, Opsumit, from a pivotal phase III study, SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome), at the European Respiratory Society Annual Congress.",203.39569091796875
2013-09-13 00:00:00+00:00,234.9499969482422,236.07000732421875,231.5399932861328,234.7100067138672,234.7100067138672,650400.0,3.5,1.0,0.6250249999999999,"(BIIB),GileadSciences Inc.(GILD) and Affymetrix Inc.(AFFX) . AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report OMEROS CORP (OMER): Free Stock Analysis Report To read this article on Zacks.com click here. Omeros plans to initiate phase II studies on OMS824 for treating patients suffering from Huntington's disease and schizophrenia by the end of 2013. New Article Meanwhile, stocks such as Actelion Ltd. ( ALIOF ), Biogen Idec Inc. ( BIIB ) and Gilead Sciences Inc. ( GILD ), carrying a Zacks Rank #1 (Strong Buy), currently look more attractive. ACTELION LTD (ALIOF): Get Free Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Alexion Pharmaceuticals, Inc. ( ALXN ) recently announced preliminary results from a single-arm phase II study (n=47) on Soliris, being developed to prevent acute antibody-mediated rejection (AMR) in sensitized deceased-donor kidney transplant recipients.",196.55459594726562
2013-09-16 00:00:00+00:00,238.02999877929688,240.3800048828125,236.3099975585937,239.57000732421875,239.57000732421875,1042600.0,4.333333333333333,1.0,0.8333583333333333,"Currently, companies that look well-positioned include Actelion Ltd. ( ALIOF ) and Biogen Idec ( BIIB ). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report VIROPHARMA (VPHM): Free Stock Analysis Report To read this article on Zacks.com click here. The Medicines Company ( MDCO ) recently announced the presentation of data on its antibiotic candidate, oritavancin, at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). New Article Companies like Roche ( RHHBY ), Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ) too are Zacks #1 Ranked stocks. ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report To read this article on Zacks.com click here. We remind investors that Gilead gained approval from the U.S. Food and Drug Administration (FDA) for Stribild in Aug 2012 as a first-line therapy for treating adults with HIV-1 infection. New Article Stocks which appear to be more attractive, include Gilead Sciences Inc. ( GILD ), Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ), each with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Good news flowed in at Alexion Pharmaceuticals, Inc. ( ALXN ) from Japan when the country's Ministry of Health, Labour and Welfare approved the company's sole marketed product, Soliris (eculizumab), for treating patients suffering from atypical hemolytic uremic syndrome (aHUS).",202.80812072753906
2013-09-18 00:00:00+00:00,245.9900054931641,246.4900054931641,240.0500030517578,246.3500061035156,246.3500061035156,1606300.0,4.0,1.0,0.7500249999999999,"Some better performing biotechnology stocks include Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and Gilead Sciences Inc. ( GILD ). Click to get this free report >> AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CLOVIS ONCOLOGY (CLVS): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Clovis Oncology, Inc. ( CLVS ) was a big mover last session, as the company saw its shares rise by over 7% on the day. New Article Currently, companies like Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ) look more attractive with a Zacks Rank #1 (Strong Buy). ABBVIE INC (ABBV): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Repros Therapeutics Inc. ( RPRX ) reached a 52-week high of $28.30 in the first half of the trading session on Sep 17. New Article In company news, Biogen Idec ( BIIB ) is up 2.4% at $245.74 a share shortly before the closing bell, even climbing to a new 52-week high of $246.46 today despite analysts at Bank of America Merrill Lynch reducing their price target for the biotech firm by $68.50 - or about 22% from its prior target- to $240.50 a share. In other sector news, (+) ATOS, Inks pact with McKesson's ( MCK ) medical-surgical unit to distribute and sell its MASCT device and patient collection kits nationwide. (-) PBMD, Said its CVac drug candidate failed to show statistically significant improvement in patient survival in Phase II testing in patients with epithelial ovarian cancer patients in first or second remission compared to a placebo. New Article Meanwhile companies such as Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ) look better positioned with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report DENDREON CORP (DNDN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. The drug is approved in the EU for the treatment of asymptomatic or minimally symptomatic metastatic (non-visceral) castrate resistant prostate cancer in adults.",209.3024139404297
2013-09-19 00:00:00+00:00,247.02999877929688,248.9499969482422,244.6199951171875,247.97999572753903,247.97999572753903,1395600.0,3.75,1.0,0.6875249999999999,"On completion of the deal, Perrigo's revenue stream would be boosted as it will receive significant royalties on multiple sclerosis drug Tysabri from Biogen Idec Inc. ( BIIB ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report PERRIGO COMPANY (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. The cash and stock deal ($8.6 billion), cleared by the boards of directors of both the companies, is expected to close by the end of calendar year 2013. New Article Meanwhile, companies such as Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ) look better positioned with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CHEMOCENTRYX (CCXI): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report To read this article on Zacks.com click here. ChemoCentryx, Inc. ( CCXI ) recently announced that partner GlaxoSmithKline ( GSK ) has returned all rights to the former's pipeline candidate vercirnon. New Article On Sep 18, we upgraded biotech company, Biogen Idec ( BIIB ) to Outperform based on its strong performance in the first half of 2013, raised outlook and improving prospects. ANTHERA PHARMA (ANTH): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen, which focuses on the development, manufacture and marketing of therapies for the treatment of multiple sclerosis and other autoimmune disorders, neurodegenerative diseases and hemophilia, became a Zacks #1 Rank (Strong Buy) stock shortly after reporting impressive second quarter results. New Article Meanwhile, companies such as Actelion Ltd. ( ALIOF ), Gilead Sciences Inc. ( GILD ) and Biogen Idec Inc. ( BIIB ) look better positioned with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report BIOCRYST PHARMA (BCRX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. The candidate is the lead compound in BioCryst's broad-spectrum antiviral research program, and is being developed for the treatment for Marburg virus disease.",208.5640411376953
2013-09-20 00:00:00+00:00,248.27999877929688,248.75,246.0500030517578,248.1300048828125,248.1300048828125,1673300.0,3.4,1.0,0.600025,"Other stocks that look attractive include Biogen Idec Inc. ( BIIB ), Gilead Sciences Inc. ( GILD ) and Affymetrix Inc. ( AFFX ). AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report PACIRA PHARMACT (PCRX): Free Stock Analysis Report To read this article on Zacks.com click here. The study was conducted to evaluate Exparel as the foundation of a multimodal postsurgical pain management regimen for patients undergoing total knee arthroplasty (TKA). New Article Companies like Gilead Sciences Inc. ( GILD ) and Biogen Idec Inc. ( BIIB ) look well placed. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report THERAVANCE INC (THRX): Free Stock Analysis Report To read this article on Zacks.com click here. Theravance, Inc. ( THRX ) and partner GlaxoSmithKline ( GSK ) announced recently that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of their candidate fluticasone furoate/vilanterol (FF/VI) (proposed brand name: Relvar Ellipta) in the EU. New Article Stocks that currently look attractive include Biogen Idec Inc. ( BIIB ), Gilead Sciences Inc . AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report OMEROS CORP (OMER): Free Stock Analysis Report To read this article on Zacks.com click here. The phase II trial will evaluate OMS824's tolerability, safety, pharmacokinetics and potential interactions with other related medications in patients suffering from stable schizophrenia. New Article Some better performing biotechnology stocks include Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and Gilead Sciences Inc. ( GILD ). Click to get this free report >> AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report To read this article on Zacks.com click here. The move came on the back of solid volume too, as far more shares changed hands than in a normal session. New Article Other stocks that look attractive include Biogen Idec Inc. ( BIIB ), Gilead Sciences Inc. ( GILD ) and Affymetrix Inc. ( AFFX ). AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. We note that in Jul 2013, Actelion had entered into an agreement with Ceptaris to acquire the latter, contingent upon the FDA's approval of Valchlor and some additional closing conditions.",216.98960876464844
2013-09-23 00:00:00+00:00,248.3999938964844,248.3999938964844,241.5200042724609,242.6699981689453,242.6699981689453,1059900.0,4.0,1.0,0.7500249999999999,"Currently, companies like Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ) look more attractive with a Zacks Rank #1 (Strong Buy). ABBVIE INC (ABBV): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here. The subsequent announcement of additional positive top-line data from the ZA-302 study helped in the maintenance of the upward trend. New Article Stocks which appear to be more attractive, include Gilead Sciences Inc. ( GILD ), Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ), each with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Alexion Pharmaceuticals, Inc. ( ALXN ) announced that encouraging interim data from an ongoing phase II study on its pipeline candidate asfotase alfa was presented by researchers. New Article Biogen Idec Inc. ( BIIB ) is currently looking to get its hemophilia A candidate, Eloctate, approved in the U.S. Novo Nordisk currently carries a Zacks Rank #2 (Buy). BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report To read this article on Zacks.com click here. Novo Nordisk A/S ( NVO ) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its hemophilia A candidate, NovoEight. New Article Companies like Gilead Sciences Inc. ( GILD ) and Biogen Idec Inc. ( BIIB ) look well placed. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report THERAVANCE INC (THRX): Free Stock Analysis Report To read this article on Zacks.com click here. Japan's Ministry of Health, Labour and Welfare cleared Theravance, Inc. ( THRX ) and partner GlaxoSmithKline 's ( GSK ) Relvar Ellipta (fluticasone furoate/vilanterol) in two dosages-100/25 mcg and 200/25 mcg-for treating patients suffering from bronchial asthma.",225.73199462890625
2013-09-24 00:00:00+00:00,242.4600067138672,243.97000122070312,240.88999938964844,243.5399932861328,243.5399932861328,849100.0,4.333333333333333,1.0,0.8333583333333333,"Stocks such as Biogen Idec Inc. ( BIIB ) and Actelion Ltd. ( ALIOF ) currently look better positioned with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. ALN-TTRsc is a sub cutaneous ribo nucleic acid interference (RNAi) therapeutic targeting the transthyretin (TTR) gene that is being developed for the treatment of TTR-mediated amyloidosis (ATTR). New Article On completion of the deal, Perrigo's revenue stream would be boosted as it will receive significant royalties on multiple sclerosis drug Tysabri from Biogen Idec Inc. ( BIIB ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report PERRIGO COMPANY (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. Perrigo Company ( PRGO ) announced the launch of its generic version of the privately held Arbor Pharma's Nitrolingual pumpspray (nitroglycerin lingual spray: 400 mcg). New Article Companies like Gilead Sciences Inc. ( GILD ), Biogen Idec Inc. ( BIIB ) and Actelion Ltd. ( ALIOF ) are well placed with a Zacks Rank #1 (Strong Buy). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. The study is designed to evaluate patients suffering from neuronal ceroid lipofuscinosis type II (NCL-II), a form of Batten disease.",239.29676818847656
2013-10-04 00:00:00+00:00,236.38999938964844,241.4499969482422,235.3999938964844,240.3000030517578,240.3000030517578,1326000.0,3.0,1.0,0.5000249999999999,"Click to get this free report >> BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report PWRSH-DYN BIO (PBE): ETF Research Reports REGENERON PHARM (REGN): Free Stock Analysis Report To read this article on Zacks.com click here. With ever-increasing healthcare spending and an insatiable demand for new drugs, the biotechnology sector looks poised for good growth going forward. For investors seeking to apply this methodology to their portfolio in the Biotechnology sector, we have taken a closer look at the top ranked PowerShares Dynamic Biotech/Genome ETF ( PBE ) .",238.15814208984375
2013-10-08 00:00:00+00:00,235.3699951171875,237.75,225.1100006103516,225.5,225.5,1556400.0,3.0,1.0,0.5000249999999999,"The top ten holdings account for 58 percent of the allocation with Biogen Idec (NASDAQ: BIIB )and Celgene (NASDAQ: CELG ) accounting for 17 percent. A sector that does not appear to be linked to the government shutdown and the recent selling is taking a big hit the last few days. The biotech stocks are coming under heavy selling pressure as investors lock in big profits from earlier this year. New Article However, competition is intensifying in the MS market for Gilenya given the presence of various treatments from Biogen Idec ( BIIB ). ALLERGAN INC (AGN): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis ' ( NVS ) multiple sclerosis (MS) drug Gilenya continues to show its efficacy in treating patients in the long run.",227.39141845703125
2013-10-09 00:00:00+00:00,226.9600067138672,228.1499938964844,221.07000732421875,223.8500061035156,223.8500061035156,1429600.0,3.0,1.0,0.5000249999999999,"We note that apart from Aubagio, currently available oral multiple sclerosis therapies include Novartis ' ( NVS ) Gilenya and Biogen Idec 's ( BIIB ) Tecfidera. ALLERGAN INC (AGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Sanofi 's ( SNY ) Aubagio is currently marketed in the U.S. as a once-daily treatment for patients with relapsing forms of multiple sclerosis.",228.94110107421875
2013-10-14 00:00:00+00:00,232.6499938964844,238.97000122070312,231.0200042724609,238.83999633789065,238.83999633789065,701800.0,2.0,1.0,0.250025,( BIIB ) has Earnings ESP of +0.91% and holds a Zacks Rank #2 (Buy). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report To read this article on Zacks.com click here. We believe the diversity and strength of the company's underlying businesses will continue to provide solid growth in future.,238.71975708007812
2013-10-15 00:00:00+00:00,237.69000244140625,239.07000732421875,236.19000244140625,236.47000122070312,236.47000122070312,765700.0,2.0,1.0,0.250025,"( BIIB ) has Earnings ESP of +0.91% and holds a Zacks Rank #2 (Buy). ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. However, the business environment continues to be challenging in 2013 due to austerity measures in developed markets and weak economic conditions elsewhere in the world.",241.55487060546875
2013-10-16 00:00:00+00:00,236.57000732421875,241.8800048828125,236.3500061035156,241.17999267578125,241.17999267578125,1149400.0,2.0,1.0,0.250025,"Acorda has a license and collaboration agreement with Biogen Idec ( BIIB ) for the development and commercialization of Fampyra outside the U.S. Ampyra is being studied for other indications as well including cerebral palsy (encouraging efficacy data presented from a phase II proof-of-concept study) and post-stroke deficits. ACORDA THERAPT (ACOR): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc. ( ACOR ) continues to work on expanding the label of its lead product, Ampyra (dalfampridine-ER).",234.12374877929688
2013-10-17 00:00:00+00:00,241.0200042724609,247.4600067138672,240.0500030517578,247.1000061035156,247.1000061035156,932700.0,3.0,1.0,0.5000249999999999,"Isis Pharmaceuticals, Inc. ( ISIS ) will receive a $10 million milestone payment from Biogen Idec ( BIIB ) under their Jun 2012 agreement. ACTELION LTD (ALIOF): Get Free Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report To read this article on Zacks.com click here. As per the terms of the exclusive, worldwide option and collaboration agreement, Biogen had made an upfront payment of $12 million to Isis Pharma.",229.36997985839844
2013-10-18 00:00:00+00:00,246.6999969482422,246.8600006103516,241.6600036621093,244.8999938964844,244.8999938964844,1122400.0,3.0,1.0,0.5000249999999999,"Biogen Idec Inc. ( BIIB ) is currently looking to get its hemophilia A candidate, Eloctate, approved in the U.S. Biogen expects approval for Eloctate in the second quarter of 2014. AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report To read this article on Zacks.com click here. The share price of Novo Nordisk ( NVO ) continued to increase following approval from the U.S. Food and Drug Administration (FDA) for its hemophilia A candidate, NovoEight.",229.16635131835938
2013-10-25 00:00:00+00:00,250.52999877929688,252.8300018310547,247.759994506836,252.259994506836,252.259994506836,1350800.0,3.2,1.0,0.550025,"We note that Tysabri is currently marketed by Biogen Idec ( BIIB ) while Elan receives royalties on the drug. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report PERRIGO COMPANY (PRGO): Free Stock Analysis Report WUXI PHARMATECH (WX): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline Update In Sep 2013, Elan initiated a phase IIa study on ELND005 to evaluate the safety and pharmacokinetics of the candidate in comparison to placebo in young adults suffering from Down syndrome without dementia. New Article (See also: Weekend Apple Inc. Roundup: The Real Star of Apple's Big Event Was... ) Monday, October 28 US Economics (Time Zone: EDT) 09:15 Industrial Production - consensus 0.4%, prior 0.4% 09:15 Capacity Utilization - consensus 78%, prior 77.8% 09:15 Manufacturing Production - consensus 0.3%, prior 0.7% 10:00 Pending Home Sales YoY - consensus 1.8%, prior 2.9% 10:30 Dallas Fed Manufacturing - prior 12.8 11:00 Fed to purchase $4.25b-$5.25b notes in 4 to 5-year range 11:30 Treasury selling $34b 3-month bills, $30b 6-month bills 1:00 Treasury selling $32b in 2 -year notes Global Economics (Time Zone: GMT) CNY Leading Index Earnings Before: Merck ( MRK ) Biogen ( BIIB ) After: Masco ( MAS ) Apple ( AAPL ) Riverbed (RVBD) Linn Energy (LINE) Tuesday, October 29 US Economics (Time Zone: EDT) 08:30 Sep Producer Price Index YoY - consensus 0.6%, prior 1.4% 08:30 PPI Ex Food & Energy YoY - consensus 1.2%, prior 1.1% 08:30 Sep Retail Sales - consensus 0.0%, prior 0.2% 08:30 Retail Sales Ex Auto - consensus 0.4%, prior 0.1% 08:30 Retail Sales Ex Auto & Gas - consensus 0.5%, prior 0.1% 09:00 Aug S&P/Case Shiller Home Price Index MoM - consensus 0.5%, prior 0.62% 09:00 S&P/CS HPI YoY - consensus 12.4%, prior 12.39% 10:00 Business Inventories - consensus 0.3%, prior 0.4% 10:00 Conference Board Consumer Confidence - consensus 75.0, prior 79.7 11:00 Fed to purchase $1.25b-$1.75b bonds in 23 to 30-year range 11:30 Treasury selling 4-week bills 1:00 Treasury selling $35b 5-year notes Global Economics (Time Zone: GMT) JPY Retail Sales JPY Employment 07:00 EUR German GfK Consumer Confidence 09:30 GBP Net Consumer Credit 06:30 INR Reserve Bank of India Rate Decision Earnings Before: Archer-Daniels-Midland (ADM) Cummins (CMI) Pfizer (PFE) US Steel (X) Arch Coal (ACI) Valero Energy (VLO) Aetna (AET) After: Cirrus Logic (CRUS) Gilead Sciences (GILD) Aflac (AFL) Buffalo Wild Wings (BWLD) LinkedIn (LNKD) Yelp (YELP) 3D Systems (DDD) Jetblue (JBLU) Caesar's (CZR) Wednesday, October 30 US Economics (Time Zone: EDT) 07:00 MBA Mortgage Applications 08:15 ADP Private Payrolls - consensus 150K, prior 166K 08:30 Consumer Price Index YoY - consensus 1.2%, prior 1.5% 08:30 CPI Ex Food & Energy YoY - consensus 1.8%, prior 1.8% 2:00 FOMC Rate Decision 1:00pm Treasury selling $29b 7-year notes Global Economics (Time Zone: GMT) JPY Industrial Production 07:00 CHF UBS Consumption Indicator 08:00 EUR Spanish GDP 08:55 EUR German Employment 10:00 EUR Eurozone Economic Confidence 13:00 EUR German CPI 10:30 Germany selling EU4b 10-year notes Earnings Before: Hess (HES) Corning (GLW) Comcast (CMCSA) Walter Energy (WLT) Sprint (S) Phillips 66 (PSX) After: Kraft Foods (KRFT) Marriott (MAR) Skyworks (SWKS) Atmel (ATML) Starbucks (SBUX) JDS Uniphase (JDSU) MetLife (MET) Expedia (EXPE) Facebook ( FB ) Visa (V) General Motors (GM) Thursday, October 31 US Economics (Time Zone: EDT) 07:30 RBC Consumer Outlook Index 08:30 Initial Jobless Claims - consensus 310k, prior 308k 08:30 Continuing Claims - consensus 2863K, prior 2925K 09:00 ISM Milwaukee - prior 55.00 09:45 Chicago PMI - consensus 55.0, prior 55.7 11:00 Fed to purchase $750m-$1b bonds in 11 to 19-year range Global Economics (Time Zone: GMT) JPY Japanese Investors Buying of Foreign Stocks/Bonds JPY Bank of Japan Rate Decision 00:00 NZD NBNZ Business Confidence 00:30 AUD Private Sector Credit 05:00 JPY Housing Starts 07:00 EUR German Retail Sales 10:00 EUR Eurozone Unemployment Rate 10:00 EUR Eurozone CPI It is very unlikely that the Fed will make any changes in policy because the advance estimate of third quarter GDP was delayed and won't be out until next week, along with a number of economic data releases. The Fed will still not be able to fully quantify the effect of the government shutdown on the economy, but it seems likely it will announce new goals related to GDP growth rather than unemployment in the coming meetings. New Article Biogen Idec Inc. ( BIIB ) is reporting for the quarter ending September 30, 2013. BIIB missed the consensus earnings per share in the 4th calendar quarter of 2012 by -4.11%. Zacks Investment Research reports that the 2013 Price to Earnings ratio for BIIB is 28.45 vs. an industry ratio of 16.90, implying that they will have a higher earnings growth than their competitors in the same industry. New Article Daily Schedule Monday Earnings Releases Expected: Herbalife LTD. (NYSE: HLF ), Apple Inc. (NASDAQ: AAPL ), Biogen Idec Inc. (NASDAQ: BIIB ), Merck & Company, Inc. (NYSE: MRK ) Economic Releases Expected: South Koran current account, US pending home sales, US industrial production, Italian business confidence. After viewing the company's new product line and previewing its new free software Goldman Sachs decided to maintain its Buy rating and keep the 12-month price target fixed. Facebook recently announced objective based ad buying and reporting, improved Custom Audiences through retargeting, and availability to all advertisers regardless of size. New Article Biogen Idec ( BIIB ) is scheduled to report third quarter 2013 earnings before the opening bell on Oct 28, 2013. ACTAVIS PLC (ACT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report To read this article on Zacks.com click here. The combination of Biogen's Zacks Rank #3 and an ESP of +1.40% makes us confident of an earnings beat on Oct 28.",234.53968811035156
2013-10-28 00:00:00+00:00,250.47000122070312,262.0,245.02999877929688,254.42999267578125,254.42999267578125,2578800.0,2.5,1.0,0.375025,"Biogen Idec Inc. (NASDAQ: BIIB ) is expected to report third quarter EPS of $2.10 on revenue of $1.78 billion, compared to last year's EPS of $1.91 on revenue of $1.39 billion. After the second quarter showed a negative trend in iPad sales, many will be watching for a reversal; though it is possible that the decline will continue as customers wait for November to upgrade to Apple's latest model. Bank of America was found liable for making bad home loans and passing them on to Freddie Mac and Fannie Mae under a long unused civil fraud statute, Financial Institutions Reform, Recovery and Enforcement Act. New Article Biogen Idec ( BIIB ) reported third quarter earnings per share of $2.35 (including the impact of stock-based compensation expense), well above the Zacks Consensus Estimate of $2.14 and 23.7% above the year-ago earnings. ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report To read this article on Zacks.com click here. Newly launched multiple sclerosis (MS) drug, Tecfidera, drove third quarter results.",230.497314453125
2013-10-29 00:00:00+00:00,255.8500061035156,256.0,249.1300048828125,254.38999938964844,254.38999938964844,875300.0,3.0,1.0,0.5000249999999999," Biogen Idec Inc (NASDAQ: BIIB ) posted third quarter earnings per share of $2.34, higher than the Zacks Consensus Estimate of $2.14  Bank of Hawaii Corporation (NYSE: BOH ) reported third quarter earnings per share of $0.85, a cent higher than the Zacks Consensus Estimate  Cna Financial Corp (NYSE: CNA ) posted third quarter earnings per share of $1.0, easily surpassing the Zacks Consensus Estimate of $0.76  Loews Corporation (NYSE: L ) reported third quarter earnings per share of $0.84, beating the Zacks Consensus Estimate of $0.77 BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BANK OF HAWAII (BOH): Free Stock Analysis Report CNA FINL CORP (CNA): Free Stock Analysis Report LOEWS CORP (L): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",226.32492065429688
2013-10-31 00:00:00+00:00,249.22999572753903,251.0,244.1699981689453,244.19000244140625,244.19000244140625,1176100.0,3.333333333333333,1.0,0.5833583333333334,"Additional competition has entered the multiple sclerosis market in the form of Biogen's ( BIIB ) Tecfidera which is off to a strong start. ACTAVIS PLC (ACT): Free Stock Analysis Report AKORN INC (AKRX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Focus areas remain high-value complex generics, expansion in emerging markets and broadening of the specialty medicines and OTC business portfolio. New Article Current treatments for blood cancers include Genentech's Rituxan, which is now owned by Biogen Idec (BIIB), and Celgene 's (CELG) Revlimid. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PHARMACYCLICS (PCYC): Free Stock Analysis Report To read this article on Zacks.com click here. PCYC's primary drug candidate is ibrutinib, the first in class of a new wave of oral agents ready to transform the treatment of white blood cell, or B-cell, malignancies. New Article On completion of the deal, Perrigo's revenue stream would be boosted as it will receive significant royalties on multiple sclerosis drug Tysabri from Biogen Idec Inc. ( BIIB ). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ELAN CP PLC ADR (ELN): Free Stock Analysis Report PERRIGO COMPANY (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. Perrigo Company 's ( PRGO ) first-quarter fiscal 2014 (ended Sep 28, 2013) earnings of $1.52 per share breezed past the Zacks Consensus Estimate by 12 cents.",230.10067749023438
2013-11-01 00:00:00+00:00,245.57000732421875,248.32000732421875,239.6100006103516,243.1000061035156,243.1000061035156,1593300.0,3.0,1.0,0.5000249999999999,"Additional competition has entered the U.S. market in the form of Biogen's ( BIIB ) Tecfidera. AKORN INC (AKRX): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. With the U.S. Federal Court of Appeals delivering unfavorable rulings regarding the validity of certain Copaxone patents (which means generic competition could materialize sooner than expected), Teva intends to launch the 3TW formulation aggressively in the first half of 2014, provided it gains approval.",232.81613159179688
2013-11-04 00:00:00+00:00,243.7899932861328,245.9499969482422,239.8500061035156,240.07000732421875,240.07000732421875,942200.0,2.0,1.0,0.250025,"Acorda has a licensing agreement with Biogen Idec ( BIIB ) for the development and commercialization of Ampyra outside the U.S. Ampyra is available outside the U.S. under the trade name Fampyra. ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics Inc.'s ( ACOR ) shares, which were down 4.3% immediately after the release of third quarter 2013 results, were up marginally (0.9%) in Friday's trading session.",235.70062255859375
2013-11-06 00:00:00+00:00,245.2700042724609,245.97999572753903,237.6300048828125,238.47999572753903,238.47999572753903,1046700.0,3.0,1.0,0.5000249999999999,"Isis Pharma will be recording new revenues in the fourth quarter under its fourth deal with Biogen Idec ( BIIB ). AEGERION PHARMA (AEGR): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report To read this article on Zacks.com click here. Earlier this year, Isis Pharma had said that it would provide an update on its fourth quarter call on the product's performance.",233.641357421875
2013-11-20 00:00:00+00:00,245.6699981689453,249.9600067138672,243.0,246.1199951171875,246.1199951171875,1014400.0,4.0,1.0,0.7500249999999999,"The only news of significance was an update on Biogen's ( BIIB ) hemophilia A candidate, Eloctate. Click to get this free report >> ALNYLAM PHARMA (ALNY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CADENCE PHARMA (CADX): Free Stock Analysis Report PHARMACYCLICS (PCYC): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report VIROPHARMA (VPHM): Free Stock Analysis Report To read this article on Zacks.com click here. The guidelines, which will benefit statins and lead to an increase in their use, have left a question mark on the regulatory process for PSCK9 inhibitors, a new class of cholesterol management drugs currently in development.",240.67311096191406
2013-11-22 00:00:00+00:00,278.0,289.9700012207031,274.9800109863281,285.6199951171875,285.6199951171875,4698000.0,3.0,1.0,0.5000249999999999,"Healthcare stocks are again leading the pack, with shares of Biogen ( BIIB ) outperforming the sector. Stocks are flatlining near their record highs as the Dow Industrial and S&P 500 struggle to close higher for the seventh consecutive week. A dearth of major economic data and a slowing trickle of company earnings is resulting in more consolidation as investors begin positioning before a holiday-shortened trading week next week. New Article Healthcare stocks are again leading the pack, with shares of Biogen ( BIIB ) outperforming the sector. (+) BIIB (+10.9%) European Medicines Agency agreed the active substance in Biogen's Tecfidera multiple-sclerosis treatment, dymethil fumarate, is qualified as a new active substance. Stocks are little changed today, with the Dow Industrial and S&P 500 flatlining near their record highs in a struggle to close higher for a seventh week in a row.",247.91925048828125
2013-11-25 00:00:00+00:00,286.5400085449219,297.9800109863281,284.510009765625,295.8800048828125,295.8800048828125,2727900.0,4.0,1.0,0.7500249999999999,"One of the year's highest-flying sectors, biotechs already had soared to new highs just one session prior on news thatBiogen Idec ( BIIB ) won regulatory approval in Europe. Breakthrough drug-study results fromCubist Pharmaceutials ( CBST ) that practically guarantee regulatory approval boosted biotechnology ETFs to nose-bleed levels Monday. ""If approved globally, CXA-201 would give Cubist the opportunity to (1) launch a second potential blockbuster antibiotic, (2) build an ex-U.S. sales and marketing infrastructure that could be leveraged with future products, and (3) provide an additional revenue stream ahead of generic competition for Cubicin,"" wrote Credit Suisse analysts, who rated shares outperform. New Article Biogen Idec Inc. ( BIIB ) was a big mover last session with shares rising over 13% on the day. Click to get this free report >> AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report To read this article on Zacks.com click here. Its Zacks Consensus Estimate also moved higher over the same period, implying more solid trading potential for Biogen Idec. New Article Biogen Idec ( BIIB ) shares shot up 13.15% immediately after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted new active substance (NAS) designation to dimethyl fumarate in the company's new oral multiple sclerosis treatment, Tecfidera. ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Tecfidera, which is currently available in the U.S. for the treatment of people with relapsing forms of multiple sclerosis, is yet to gain approval in the EU.",256.9928894042969
2013-11-26 00:00:00+00:00,295.95001220703125,297.79998779296875,288.5799865722656,289.20001220703125,289.20001220703125,1584800.0,4.0,1.0,0.7500249999999999,"Related: ETFs for Turkey Day (PBJ, IYT, XRT, TUR) A big move in Biogen Idec (NASDAQ: BIIB ) in the last two trading sessions, the ETFs biggest holding, has been the catalyst for the biotech breakout. Brent crude is more closely tied to the Middle East and Iran and would likely fall if Iranian oil sanctions are lifted. The selling was odd because a removal of the Iranian oil sanctions, which did not occur, should not have such a big affect on the niche energy sector.",276.4175109863281
2013-12-02 00:00:00+00:00,291.7099914550781,298.82000732421875,290.5199890136719,294.8399963378906,294.8399963378906,1128500.0,3.0,1.0,0.5000249999999999,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",274.4643249511719
2013-12-03 00:00:00+00:00,294.1700134277344,294.25,286.5599975585937,287.760009765625,287.760009765625,1419500.0,3.0,1.0,0.5000249999999999,"The FDA action date for Biogen Idec's ( BIIB ) hemophilia B candidate, Alprolix, has been pushed back by three months, which means the company will most likely be able to launch Alprolix later in the first half of 2014 provided it gains FDA approval for its Biologics License Application (BLA). ACORDA THERAPT (ACOR): Free Stock Analysis Report AETERNA ZENTARS (AEZS): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The FDA had asked Biogen to submit additional information related to the validation of a manufacturing step for Alprolix.",281.1211242675781
2013-12-04 00:00:00+00:00,285.8999938964844,289.239990234375,282.3800048828125,285.82000732421875,285.82000732421875,900200.0,2.0,1.0,0.250025,"Last week, three biotech majors, Celgene ( CELG ), Biogen ( BIIB ) and Gilead ( GILD ) touched new 52-week highs as they continued to benefit from positive updates in the EU, announced in the previous week. Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CUBIST PHARM (CBST): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report LEXICON PHARMA (LXRX): Free Stock Analysis Report ONCOMED PHARMA (OMED): Free Stock Analysis Report OREXIGEN THERAP (OREX): Free Stock Analysis Report To read this article on Zacks.com click here. So Orexigen has a lot going for it - possible regulatory approvals, extensive data, a strong marketing partner, additional partnership deals - this is definitely a stock to watch out for.",278.29022216796875
2013-12-05 00:00:00+00:00,284.95001220703125,288.7300109863281,282.1199951171875,284.9200134277344,284.9200134277344,1159000.0,5.0,1.0,1.000025,"2013 Product Revenue Break-Up Biogen Idec Inc. (BIIB): Read the Full Research Report Want the latest recommendations from Zacks Investment Research? Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen has collaborations with companies like Roche (Rituxan), Acorda (Fampyra), Biovitrum (Eloctate and Alprolix) and AbbVie (daclizumab) among others.",281.6717529296875
2013-12-10 00:00:00+00:00,286.8299865722656,288.8999938964844,281.2799987792969,285.2300109863281,285.2300109863281,937500.0,4.0,1.0,0.7500249999999999,"The study will evaluate the safety and efficacy of IPI-145 in iNHL patients whose disease is refractory to radioimmunotherapy or to both Roche / Biogen Idec Inc. 's ( RHHBY / BIIB ) Rituxan (rituximab) and chemotherapy and who have progressed within six months of receiving their last therapy. ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report INFINITY PHARMA (INFI): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Get Free Report To read this article on Zacks.com click here. Infinity Pharmaceuticals, Inc. ( INFI ) announced positive results from two phase I studies on IPI-145, being developed for the treatment of patients suffering from relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) and chronic lymphocytic leukemia (CLL).",270.3958435058594
2013-12-31 00:00:00+00:00,279.92999267578125,281.489990234375,278.6000061035156,279.57000732421875,279.57000732421875,640600.0,4.0,1.0,0.7500249999999999,"Drum roll please: Biogen Idec (BIIB) Oceanrg Intl (OII) EcoLab (ECL) These probably werent the companies you were expecting. With no option to fast-forward and no visible light at the end of the tunnel, I gave up the fight and clicked the video window closed. If youre wondering how I found them, I used a VectorVest Scan named Ruler Stocks which automatically identifies companies with highly predictable earnings, but if you want to find your own, you absolutely can, all you need to do is follow the money!",276.5719299316406
2014-01-03 00:00:00+00:00,279.79998779296875,280.8399963378906,275.4800109863281,277.3999938964844,277.3999938964844,656000.0,5.0,1.0,1.000025,"The acquisition of Elan, completed in Dec 2013 for approximately $8.6 billion, has boosted Perrigo's revenue stream further as it is now eligible to receive significant royalties on multiple sclerosis drug Tysabri from BiogenIdec ( BIIB ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report FOREST LABS A (FRX): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. Through the deal, Perrigo expects to generate post-tax annual operating expense and tax savings in excess of $150 million.",277.1222229003906
2014-01-09 00:00:00+00:00,292.04998779296875,297.0,288.0,289.75,289.75,1318700.0,2.0,1.0,0.250025,"Sangamo Biosciences (NASDAQ: SGMO ) shot up 29.01 percent to $17.61 after the company and Biogen Idec (NASDAQ: BIIB ) announced the global collaboration to develop treatments for hemoglobinopathies. Equities Trading UP Shares of Intercept Pharmaceuticals (NASDAQ: ICPT ) got a boost, shooting up 289.85 percent to $282.21 after the company reported that the FLINT trial of obeticholic acid has been stopped early and the NASH primary endpoint has been met. Equities Trading DOWN Shares of Pier 1 Imports (NYSE: PIR ) were down 12.33 percent to $20.45 after the company reported weak December sales and lowered its outlook.",278.5404052734375
2014-01-10 00:00:00+00:00,291.57000732421875,299.8500061035156,286.29998779296875,299.3099975585937,299.3099975585937,1866900.0,2.5,1.0,0.375025,"Additional competition has entered the multiple sclerosis market in the form of Biogen 's ( BIIB ) Tecfidera which is off to a strong start. ACTAVIS PLC (ACT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Vigodman is credited with returning MAI to profitability by bringing about improvements in day-to-day operations and investing in areas that would boost organic growth. New Article The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",277.5220947265625
2014-01-13 00:00:00+00:00,299.3500061035156,302.95001220703125,281.54998779296875,283.6700134277344,283.6700134277344,2305500.0,4.0,1.0,0.7500249999999999,"Sangamo BioSciences, Inc. ( SGMO ) recently entered into a worldwide collaboration and license agreement with Biogen Idec ( BIIB ). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SANGAMO BIOSCI (SGMO): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. A lot of pharmaceutical companies enter into collaboration and license agreements to obtain funding for research and development programs, to leverage technological knowhow as well as gain access to marketing expertise.",282.6119384765625
2014-01-14 00:00:00+00:00,284.70001220703125,300.6700134277344,280.3099975585937,297.4700012207031,297.4700012207031,1651400.0,3.5,1.0,0.6250249999999999,"I suggest Celgene ( CELG ), Biogen ( BIIB ) and Gilead ( GILD ) as three large-cap examples. In order to meet the expectations that premium implies, the biotech sector will have to fulfill its promise and deliver both margin and earnings growth. The FDA said GILD's sofosbuvir cured 90% of patients with the most common form of the virus in just 12 weeks; that's a high percentage in a much shorter period of time. New Article This includes amortized revenues of $9.1 million resulting from the $110 million payment received from Biogen Idec ( BIIB ) for Fampyra. ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report To read this article on Zacks.com click here. The company met with the FDA in December to discuss the phase III protocol and is currently incorporating recommendations made by the agency.",275.6669921875
2014-01-17 00:00:00+00:00,293.6000061035156,298.9800109863281,293.19000244140625,297.4800109863281,297.4800109863281,1413600.0,5.0,1.0,1.000025,"Following the completion of the $8.6 billion deal, Perrigo's revenue stream has been boosted as it is now eligible to receive significant royalties on multiple sclerosis drug Tysabri from Biogen Idec Inc. ( BIIB ). ADVAXIS INC (ADXS): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report To read this article on Zacks.com click here. For fiscal 2014, revenues from the segment are expected to grow in the range of 25%-29% over fiscal 2013 levels The generic unit at Perrigo was further strengthened earlier in the week with the U.S. Food and Drug Administration (FDA) granting final approval to Perrigo's abbreviated new drug application (ANDA) to sell its generic version of Valeant Pharmaceuticals International, Inc. 's ( VRX ) Vanos cream (0.1%).",286.7664794921875
2014-01-23 00:00:00+00:00,307.2300109863281,315.3800048828125,305.4800109863281,314.9599914550781,314.9599914550781,1578700.0,4.0,1.0,0.7500249999999999,"( BIIB ) has an Earnings ESP of +9.01% and holds a Zacks Rank #3. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers Squibb Company ( BMY ) is scheduled to release its fourth quarter 2013 results before the opening bell on Friday, Jan 24.",294.748291015625
2014-01-27 00:00:00+00:00,303.6099853515625,303.8599853515625,292.5299987792969,297.8800048828125,297.8800048828125,1515300.0,1.6666666666666667,1.0,0.1666916666666666,Biogen Idec Inc. ( BIIB ) has an Earnings ESP of +9.01% and holds a Zacks Rank #2. ACTAVIS PLC (ACT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Amgen Inc. ( AMGN ) is set to report fourth quarter 2013 results on Jan 28 after market close. New Article We note that several oral multiple sclerosis therapies are currently available including Novartis ' ( NVS ) Gilenya and Biogen Idec 's ( BIIB ) Tecfidera among others. ACTAVIS PLC (ACT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. The CHMP rendered a negative opinion as it believes that the potential risks associated with Nerventra outweigh the benefits based on currently available data. New Article Biogen Idec Inc. ( BIIB ) has an Earnings ESP of +9.01% and holds a Zacks Rank #2. ACTAVIS PLC (ACT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Pfizer Inc. ( PFE ) is scheduled to report fourth quarter 2013 results before the opening bell on Jan 28.,286.66510009765625
2014-01-28 00:00:00+00:00,302.3800048828125,306.0,297.0199890136719,305.6499938964844,305.6499938964844,1723700.0,3.5,1.0,0.6250249999999999,"Biogen Idec Inc. ( BIIB ) is reporting for the quarter ending December 31, 2013. BIIB missed the consensus earnings per share in the 4th calendar quarter of 2012 by -4.11%. Zacks Investment Research reports that the 2013 Price to Earnings ratio for BIIB is 33.81 vs. an industry ratio of 3.40, implying that they will have a higher earnings growth than their competitors in the same industry. New Article Biogen Idec Inc. ( BIIB ) is scheduled to report fourth quarter 2013 results before the opening bell on Jan 29. ABBVIE INC (ABBV): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen's new multiple sclerosis product, Tecfidera, which is off to a strong start should continue performing well and drive revenues. New Article Biogen Idec Inc. ( BIIB ) has an Earnings ESP of +9.01% and holds a Zacks Rank #2 (Buy). ACTAVIS PLC (ACT): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Alexion Pharmaceuticals, Inc. ( ALXN ) is set to report fourth quarter 2013 results before the opening bell on Jan 30. New Article Other healthcare companies like Eli Lilly ( LLY ) and Biogen ( BIIB ) will be reporting later this week. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues were impacted by the loss of exclusivity of certain products including Lipitor, the expiry of the Spiriva collaboration in some countries, the expiration of the Enbrel agreement and purchasing patterns for Prevnar in some emerging markets.",280.8193359375
2014-01-29 00:00:00+00:00,299.0299987792969,318.4200134277344,292.82000732421875,305.4599914550781,305.4599914550781,2773800.0,3.8,1.0,0.7000249999999999,"And, Biogen Idec ( BIIB ) reports Q4 revenue of $1.96 bln, better than the analyst consensus of $1.92 bln on Capital IQ. Health benefit company WellPoint, Inc. ( WLP ) said adjusted EPS for Q4 2013 was down 15.5% year over year to $0.87, in line with the Capital IQ consensus. For the full year 2014, the company expects revenue growth of about 22% to 25% and EPS of $11.00 to $11.20. New Article Apart from injectables, several oral therapies including Novartis ' ( NVS ) Gilenya and Biogen Idec 's ( BIIB ) Tecfidera are also available. ACTAVIS PLC (ACT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Teva has undertaken several initiatives (including developing new candidates targeting MS and the new formulation of Copaxone) to mitigate this loss. New Article Biogen Idec Inc. ( BIIB ): Earnings ESP of +9.01% and Zacks Rank #2 (Buy). AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report XOMA CORP (XOMA): Free Stock Analysis Report To read this article on Zacks.com click here. Our proven model shows that Affymetrix is likely to beat earnings because it has the right combination of two key ingredients. New Article And, Biogen Idec ( BIIB ) reports Q4 revenue of $1.96 bln, better than the analyst consensus of $1.92 bln on Capital IQ. Health benefit company WellPoint, Inc. ( WLP ) said adjusted EPS for Q4 2013 was down 15.5% year over year to $0.87, in line with the Capital IQ consensus. For the full year 2014, the company expects revenue growth of about 22% to 25% and EPS of $11.00 to $11.20. New Article Biogen Idec ( BIIB ) reported fourth quarter earnings per share of $2.34 (including the impact of stock-based compensation expense), well above the Zacks Consensus Estimate of $2.22 and 67.1% above the year-ago earnings. AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report To read this article on Zacks.com click here. Newly launched multiple sclerosis (MS) drug, Tecfidera, drove fourth quarter results.",279.5889587402344
2014-01-31 00:00:00+00:00,313.0799865722656,317.45001220703125,311.010009765625,312.6400146484375,312.6400146484375,1312900.0,3.0,1.0,0.5000249999999999,"Here are 5 stocks added to the Zacks #1 Rank (""strong buy"") List today: ACE Limited ( ACE ) Archer Daniels Midland Company ( ADM ) Arrow Financial Corporation ( AROW ) Ball Corporation ( BLL ) Biogen Idec Inc ( BIIB ) View the entire Zacks #1 Rank List . ACE LIMITED (ACE): Free Stock Analysis Report ARCHER DANIELS (ADM): Free Stock Analysis Report ARROW FINL CORP (AROW): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BALL CORP (BLL): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",290.3691711425781
2014-02-03 00:00:00+00:00,314.8399963378906,316.989990234375,298.1499938964844,300.3900146484375,300.3900146484375,2205400.0,3.25,1.0,0.5625249999999999,"Some better-ranked stocks in the same space include Actelion Ltd. ( ALIOF ), Affymetrix Inc. ( AFFX ) and Biogen Idec Inc. ( BIIB ). Click to get this free report >> AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report INTERMUNE INC (ITMN): Free Stock Analysis Report To read this article on Zacks.com click here. InterMune Inc. ( ITMN ) saw a big move last session, as the company's shares fell by near 18% on the day. New Article The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Other stocks which look attractive at current levels include Actelion ( ALIOF ) and Biogen Idec Inc. ( BIIB ). ACTAVIS PLC (ACT): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that Actavis acquired Warner Chilcott in 2013 resulting in the creation of a leading global specialty pharmaceutical company with focus on women's health, urology, gastroenterology and dermatology.",286.2430114746094
2014-02-04 00:00:00+00:00,299.010009765625,310.0599975585937,298.1499938964844,308.17999267578125,308.17999267578125,2141100.0,4.5,1.0,0.8750249999999999,"Following the acquisition of Elan, Perrigo's revenue stream has been boosted as it is now eligible to receive significant royalties on multiple sclerosis drug Tysabri from Biogen Idec ( BIIB ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report HOSPIRA INC (HSP): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. Perrigo Company plc ( PRGO ) is set to report second quarter fiscal year 2014 results on Feb 6 before the market opens. New Article Some better-ranked stocks in the same sector include Actelion ( ALIOF ) and Biogen Idec Inc. ( BIIB ). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PLURISTEM THERA (PSTI): Free Stock Analysis Report UTD THERAPEUTIC (UTHR): Free Stock Analysis Report To read this article on Zacks.com click here. NIAID expects to expand the scope of its PLX-RAD research if the data from this study on irradiated animals' hematological systems turns out to be positive.",278.6137390136719
2014-02-05 00:00:00+00:00,307.3900146484375,307.3900146484375,294.0199890136719,299.92999267578125,299.92999267578125,1887900.0,4.0,1.0,0.7500249999999999,"However, some of the well-placed stocks that are worth a look in the MedBio Gene industry include Biogen Idec Inc. ( BIIB ), Affymetrix Inc. ( AFFX ), and Actelion Ltd. ( ALIOF ). AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GENOMIC HEALTH (GHDX): Free Stock Analysis Report To read this article on Zacks.com click here. Besides, on Nov 25, 2013 Genomic Health entered into an exclusive in-licensing agreement with Almac Group for technology and intellectual property in order to develop a multi-gene test used for predicting benefits from DNA damage-based chemotherapy drugs.",279.0267028808594
2014-02-06 00:00:00+00:00,301.8800048828125,307.3500061035156,300.6700134277344,301.010009765625,301.010009765625,1384600.0,3.2,1.0,0.550025,"Better-placed stocks that are worth a look include Actelion Ltd. ( ALIOF ), Affymetrix Inc. ( AFFX ) and Biogen Idec Inc. ( BIIB ), each sporting a Zacks Rank #1 (Strong Buy). AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Myriad Genetics Inc. ( MYGN ) climbed 15.12% to $31.29 ever since the company announced its decision to enter the huge potential autoimmune diagnostic market through the acquisition of Crescendo Bioscience. New Article Other players in the biomed/gene industry include Alexion Pharmaceuticals, Inc. ( ALXN ), Biogen Idec Inc. ( BIIB ), and Cambrex Corporation ( CBM ). AFFYMETRIX INC (AFFX): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report To read this article on Zacks.com click here. For the full year, R&D expenses dropped 17.6% to $47.7 million, driven by low spending of supplies, consulting, IT facilities, and lower headcount related costs. New Article Specialty Sciences: Segmental revenues came in at $7 million as royalties received by Perrigo on multiple sclerosis drug Tysabri from Biogen Idec ( BIIB ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report NUVASIVE INC (NUVA): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. Perrigo Company plc 's ( PRGO ) second-quarter fiscal 2014 (ended Dec 28, 2013) earnings of $1.87 per share easily beat the Zacks Consensus Estimate of $1.60. New Article ( ACT ), Actelion Ltd. ( ALIOF ) and Biogen Idec Inc ( BIIB ). ACTAVIS PLC (ACT): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Pernix Therapeutics Holdings, Inc. ( PTX ) jumped 68.9% on the back of an institutional investment by Athyrium Capital Management and the appointment of a new Chief Executive Officer (CEO). New Article Some better ranked stocks in the pharmaceutical sector include Actelion Ltd. ( ALIOF ), Alexion Pharmaceuticals, Inc. ( ALXN ) and Biogen Idec Inc. ( BIIB ). ACTELION LTD (ALIOF): Get Free Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report To read this article on Zacks.com click here. The Medicines Company's Carbavance, combines a carbapenem antibiotic with a novel beta-lactamase inhibitor, which is being developed for the treatment of patients with multi-drug resistant (MDR) gram-negative infections.",284.1321716308594
2014-02-07 00:00:00+00:00,303.1300048828125,316.0199890136719,301.3800048828125,315.5400085449219,315.5400085449219,1504600.0,3.5,1.0,0.6250249999999999,"Some other stocks worth considering include Actelion Ltd. ( ALIOF ), Biogen Idec Inc. ( BIIB ) and WuXi PharmaTech (Cayman) Inc. ( WX ). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SPECTRUM PHARMA (SPPI): Free Stock Analysis Report WUXI PHARMATECH (WX): Free Stock Analysis Report To read this article on Zacks.com click here. Spectrum Pharma is looking to get Beleodaq approved in the U.S. for the treatment of patients suffering from relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). New Article Additional competition has entered the U.S. market in the form of Biogen's ( BIIB ) Tecfidera. ACTAVIS PLC (ACT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report DOCTOR REDDYS (RDY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Earnings were affected by the loss/decline of several highly profitable products that were sold in the previous year as well as an increase in selling and marketing and R&D spend.",295.3525695800781
2014-02-10 00:00:00+00:00,315.5400085449219,318.2300109863281,311.6700134277344,317.9599914550781,317.9599914550781,1249800.0,3.5,1.0,0.6250249999999999,"Some better-ranked stocks in the biotech sector include Biogen ( BIIB ) and Alexion Pharmaceuticals ( ALXN ). ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PUMA BIOTECHNLG (PBYI): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Background Puma Biotech had gained certain intellectual property portfolio from Pfizer ( PFE ) in 2011 when it had licensed neratinib. New Article AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Idec Inc. ( BIIB ). Shareholders who purchased AMGN stock prior to the ex-dividend date are eligible for the cash dividend payment. The following ETF(s) have AMGN as a top-10 holding: iShares NASDAQ Biotechnology Index Fund ( IBB ) PowerShares Dynamic Pharmaceuticals ( PJP ) PowerShares Dynamic Biotech &Genome ( PBE ) Select Sector SPDR Fund - Health Care ( XLV ) Merrill Lynch Biotech HOLDRS ( BBH ). New Article ( ALXN ) and Biogen Idec Inc. ( BIIB ). Click to get this free report >> ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report To read this article on Zacks.com click here. ( CBM ).The stock of this company in the Bio-Medical and Generic drugs space has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Strong Buy. New Article The top three holdings are Merck (NYSE: MRK ), Biogen Idec (NASDAQ: BIIB ) and Gilead Sciences (NASDAQ: GILD ). The stock market pulled back like clockwork over the last few weeks as the S&P 500 fell six percent from an all-time high to the low on Wednesday. Add in the CBOE Volatility Index (VIX) hitting a yearly closing high this week and it was a great setup for stocks to bounce.",299.2047424316406
2014-02-11 00:00:00+00:00,314.3099975585937,319.8999938964844,313.0,319.82000732421875,319.82000732421875,1564600.0,3.333333333333333,1.0,0.5833583333333334,"Some better-ranked stocks in the same industry include Actelion Ltd. ( ALIOF ), Alexion Pharmaceuticals, Inc. ( ALXN ) and Biogen Idec Inc. ( BIIB ). Click to get this free report >> ACTELION LTD (ALIOF): Get Free Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NEWLINK GENETIC (NLNK): Free Stock Analysis Report To read this article on Zacks.com click here. NewLink Genetics Corporation ( NLNK ) was a big mover last session, as the company saw its shares rise by over 8% on the day. New Article Some better-ranked players in the pharma industry include Actelion Ltd. ( ALIOF ), Endocyte Inc. ( ECYT ) and Biogen Idec Inc. ( BIIB ). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ENDOCYTE INC (ECYT): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that Repros had announced encouraging top-line results in Sep 2013, from its second phase III study, ZA-302, on Androxal. New Article Some better-ranked stocks in the same space include Actyelion Ltd. ( ALIOF ), Alexion Pharmaceuticals, Inc. ( ALXN ) and Biogen Idec Inc. ( BIIB ). Click to get this free report >> ACTELION LTD (ALIOF): Get Free Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SUNESIS PHARMA (SNSS): Free Stock Analysis Report To read this article on Zacks.com click here. Sunesis Pharmaceuticals, Inc. ( SNSS ) saw a big move last session, as the company's shares fell by over 5% on the day.",297.4179992675781
2014-02-13 00:00:00+00:00,316.8099975585937,329.45001220703125,315.0,328.6199951171875,328.6199951171875,1311400.0,3.0,1.0,0.5000249999999999,"If you are still interested in the Medical industry, you may instead consider some better-ranked stocks including Alexion Pharmaceuticals, Inc. ( ALXN ), Biogen Idec Inc. ( BIIB ), and Cambrex Corporation ( CBM ). Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report GENOMIC HEALTH (GHDX): Free Stock Analysis Report To read this article on Zacks.com click here. Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. New Article Some better-ranked stocks in the biotechnology sector include Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ). ACTELION LTD (ALIOF): Get Free Report ASTELLAS PHARMA (ALPMY): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report VICAL INC (VICL): Free Stock Analysis Report To read this article on Zacks.com click here. The year-ago figure included a $10 million milestone payment from partner Astellas Pharma, Inc. ( ALPMY ) related to the development of ASP0113.",297.52587890625
2014-02-14 00:00:00+00:00,329.4800109863281,331.739990234375,327.1000061035156,328.2900085449219,328.2900085449219,1054300.0,3.333333333333333,1.0,0.5833583333333334,"( BIIB ). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ENDOCYTE INC (ECYT): Free Stock Analysis Report REGADO BIOSCI (RGDO): Free Stock Analysis Report To read this article on Zacks.com click here. Regado is developing REG2, an extended release formulation of pegnivacogin, which is the prime component in company's lead candidate REG1. New Article Some better-ranked stocks in the same sector include Actelion Ltd. ( ALIOF ), Alexion Pharmaceuticals, Inc. ( ALXN ) and Biogen Idec Inc. ( BIIB ). Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> ACTELION LTD (ALIOF): Get Free Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CHELSEA THERAP (CHTP): Free Stock Analysis Report To read this article on Zacks.com click here. Chelsea Therapeutics International Ltd. ( CHTP ) saw a big move last session, as the company's shares fell by over 7% on the day. New Article ( ECYT ), Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ENDOCYTE INC (ECYT): Free Stock Analysis Report OMEROS CORP (OMER): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company.",305.29888916015625
2014-02-18 00:00:00+00:00,327.8999938964844,335.989990234375,326.9599914550781,334.9800109863281,334.9800109863281,966900.0,2.0,1.0,0.250025,The year 2014 will be eventful for Vanda as it launches Hetlioz in the U.S. Investors looking for better-ranked stocks in the biopharma sector may consider companies like Endocyte Inc ( ECYT ) and Biogen Idec Inc. ( BIIB ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ENDOCYTE INC (ECYT): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report To read this article on Zacks.com click here. Vanda expects to file a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for Hetlioz (Non-24) in 2014. New Article Acorda's Ampyra is marketed in the ex-U.S. markets under the trade name Fampyra by Biogen Idec ( BIIB ). ACORDA THERAPT (ACOR): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The guidance includes commercialization expenses associated with the potential launch of Plumiaz (proposed trade name for diazepam nasal spray) which is yet to gain FDA approval.,304.8185119628906
2014-02-19 00:00:00+00:00,334.1199951171875,335.3900146484375,326.6499938964844,328.45001220703125,328.45001220703125,825700.0,3.333333333333333,1.0,0.5833583333333334,"Better-placed stocks that are worth a look include Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and Actelion Ltd. ( ALIOF ). AFFYMETRIX INC (AFFX): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report To read this article on Zacks.com click here. Myriad is currently targeting expansion of its pipeline with products for diverse indications including oncology, women's health, urology, dermatology, autoimmune and inflammatory disease and neuroscience. New Article Investors looking for better-ranked stocks in the biopharma sector may consider companies like Endocyte Inc ( ECYT ), Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CHELSEA THERAP (CHTP): Free Stock Analysis Report ENDOCYTE INC (ECYT): Free Stock Analysis Report To read this article on Zacks.com click here. Chelsea Therapeutics International Ltd. ( CHTP ) gained accelerated approval from the U.S. Food and Drug Administration (FDA) for Northera for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). New Article ( CBM ), Emergent BioSolutions, Inc. ( EBS ) and Biogen Idec Inc. ( BIIB ). Click to get this free report >> BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report DISCOVERY LABS (DSCO): Free Stock Analysis Report EMERGENT BIOSOL (EBS): Free Stock Analysis Report To read this article on Zacks.com click here. Discovery Laboratories Inc. ( DSCO ) was a big mover last session, as its shares rose nearly 9% on the day.",299.3869934082031
2014-02-20 00:00:00+00:00,330.3299865722656,335.8800048828125,323.3099975585937,335.1099853515625,335.1099853515625,1317200.0,2.5,1.0,0.375025,"Investors looking for better-ranked stocks in the biopharma sector may consider companies like Endocyte Inc. ( ECYT ) and Biogen Idec Inc. ( BIIB ). BAXTER INTL (BAX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ENDOCYTE INC (ECYT): Free Stock Analysis Report ONCONOVA THERAP (ONTX): Free Stock Analysis Report To read this article on Zacks.com click here. Rigosertib failed to meet its primary endpoint of significant improvement in median overall survival compared to best supportive care (BSC) in the ONTIME study. New Article ( ALXN ) and Biogen Idec Inc. ( BIIB ). ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report DYNAVAX TECH CP (DVAX): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report To read this article on Zacks.com click here. Consequently, Dynavax decided to withdraw its MAA as the required timeframe for response under the regulatory process is not sufficient to collect the clinical data. New Article Investors may also consider other biopharmaceutical companies like Biogen Idec Inc. ( BIIB ) and Alexion Pharmaceuticals, Inc. ( ALXN ) which sport a Zacks Rank #1 (Strong Buy). ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report INSMED INC (INSM): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that in Jul 2013, Insmed reported encouraging results from a phase III study on Arikace for the treatment of Pa in CF patients, when compared to twice-daily Novartis ' ( NVS ) TOBI (tobramycin inhalation solution). New Article ( ECYT ), Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ENDOCYTE INC (ECYT): Free Stock Analysis Report OMEROS CORP (OMER): Free Stock Analysis Report To read this article on Zacks.com click here. Last month, Omeros provided positive results from a phase IIa study on OMS824, which is being evaluated for the treatment of schizophrenia.",305.31561279296875
2014-02-21 00:00:00+00:00,336.3699951171875,349.7699890136719,334.4700012207031,347.1099853515625,347.1099853515625,1814700.0,2.5,1.0,0.375025,"Investors looking for better-ranked stocks in the biopharma sector may consider companies like Endocyte Inc. ( ECYT ) and Biogen Idec Inc. ( BIIB ). BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ENDOCYTE INC (ECYT): Free Stock Analysis Report ONCOMED PHARMA (OMED): Free Stock Analysis Report To read this article on Zacks.com click here. OncoMed Pharmaceuticals, Inc. ( OMED ) announced that it has commenced the third phase Ib study on pipeline candidate OMP-54F28 with Paraplatin and Taxol in patients with platinum-sensitive ovarian cancer. New Article Some other better-ranked stocks in the biopharmaceutical sector include Alexion Pharmaceuticals, Inc. ( ALXN ) and Biogen Idec Inc. ( BIIB ). ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report XENOPORT INC (XNPT): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Horizant is approved in the US for the treatment of moderate-to-severe primary restless legs syndrome (RLS) as well as the management of postherpetic neuralgia (PHN) in adults.",311.86419677734375
2014-02-24 00:00:00+00:00,348.1499938964844,353.4700012207031,345.6199951171875,345.6300048828125,345.6300048828125,1668100.0,3.1666666666666665,1.0,0.5416916666666668,"The candidate is being developed in collaboration with Biogen Idec ( BIIB ). ALKERMES INC (ALKS): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report To read this article on Zacks.com click here. Interim results from the open-label, multiple dose study conducted on ISIS-SMN Rx showed that children on the 9mg dosage experienced an average increase of 3.7 points in muscle function score. New Article ( ECYT ), Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ). ACTELION LTD (ALIOF): Get Free Report AMARIN CORP PLC (AMRN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ENDOCYTE INC (ECYT): Free Stock Analysis Report To read this article on Zacks.com click here. Amarin Corporation plc ( AMRN ) announced that Vascepa was given three years of marketing exclusivity by the U.S. Food and Drug Administration (FDA) in connection with the MARINE indication. New Article Some better ranked stocks in the health care sector include Alexion Pharmaceuticals, Inc. ( ALXN ), Biogen Idec Inc. ( BIIB ) and Acceleron Pharma, Inc. ( XLRN ). ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PROGENICS PHARM (PGNX): Free Stock Analysis Report ACCELERON PHARM (XLRN): Free Stock Analysis Report To read this article on Zacks.com click here. Progenics said that it will use the funds raised from the offering for its research and development (R&D) activities and general corporate purposes. New Article Some stocks in the basic materials sector looking equally good include Alexion Pharmaceuticals, Inc. ( ALXN ), Biogen Idec Inc. ( BIIB ) and Emergent BioSolutions, Inc. ( EBS ). Click to get this free report >> ACADIA PHARMA (ACAD): Get Free Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report EMERGENT BIOSOL (EBS): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc. ( ACAD ) was a big mover last session, as the company saw its shares rise by over 17% on the day. New Article Some better-ranked stocks in the same industry include Alexion Pharmaceuticals, Inc. ( ALXN ), Biogen Idec Inc. ( BIIB ) and Actelion Ltd. ( ALIOF ). Click to get this free report >> ACTELION LTD (ALIOF): Get Free Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report STEMLINE THERAP (STML): Free Stock Analysis Report To read this article on Zacks.com click here. Stemline Therapeutics, Inc. ( STML ) was a big mover last session with its shares rising over 8% on the day. New Article Some better-ranked stocks in the same sector include Alexion Pharmaceuticals ( ALXN ) and Biogen Idec Inc. ( BIIB ). ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PLURISTEM THERA (PSTI): Free Stock Analysis Report UTD THERAPEUTIC (UTHR): Free Stock Analysis Report To read this article on Zacks.com click here. ( PSTI ) develops placenta-based cell therapies in collaboration with companies like United Therapeutics ( UTHR ) or through research and clinical institutions.",307.1576232910156
2014-02-25 00:00:00+00:00,346.510009765625,349.5400085449219,343.1099853515625,346.29998779296875,346.29998779296875,1350500.0,2.75,1.0,0.437525,"Better-ranked biomedical stocks include Alexion Pharmaceuticals, Inc. ( ALXN ), Biogen Idec Inc. ( BIIB ) and Actelion Ltd. ( ALIOF ). Click to get this free report >> ACTELION LTD (ALIOF): Get Free Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SYNTA PHARMACT (SNTA): Free Stock Analysis Report To read this article on Zacks.com click here. Synta Pharmaceuticals Corp. ( SNTA ) was a big mover last session with its shares rising nearly 9% on the day. New Article Some better ranked stocks in the biopharmaceutical sector include Alexion Pharmaceuticals, Inc. ( ALXN ), Biogen Idec Inc. ( BIIB ) and Acceleron Pharma, Inc. ( XLRN ). ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ACCELERON PHARM (XLRN): Free Stock Analysis Report XOMA CORP (XOMA): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that XOMA has a license and collaboration agreement with Servier to jointly develop and commercialize gevokizumab for multiple indications. New Article Some better ranked stocks in the biopharmaceutical sector include Alexion Pharmaceuticals, Inc. ( ALXN ), Biogen Idec Inc. ( BIIB ) and Acceleron Pharma, Inc. ( XLRN ). ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report ACCELERON PHARM (XLRN): Free Stock Analysis Report To read this article on Zacks.com click here. Updates on the regulatory front are eagerly awaited by investors in the pharma/biotech sector as they impact the share price of the concerned company. New Article Investors may also consider companies like Lannett Co., Inc. ( LCI ) and Biogen Idec Inc. ( BIIB ), which carry a comparable Zacks Rank #1. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ENDOCYTE INC (ECYT): Free Stock Analysis Report LANNETT INC (LCI): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline Update Endocyte is seeking EU approval for vintafolide (platinum-resistant ovarian cancer) and for a folate-targeted molecular imaging agent, etarfolatide.",307.967041015625
2014-02-26 00:00:00+00:00,342.1700134277344,353.0,337.3099975585937,343.2099914550781,343.2099914550781,1192400.0,3.5,1.0,0.6250249999999999,"Some better-ranked stocks in the same sector include Biogen Idec Inc. ( BIIB ) carrying a Zacks Rank #1 (Strong Buy). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report INTERMUNE INC (ITMN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. InterMune, Inc. 's ( ITMN ) shares escalated a massive 170.8% and also touched a 52-week high after the company announced encouraging top-line results from the phase III ASCEND study on Esbriet (pirfenidone). New Article Biogen Idec Inc. Our third choice is Biogen Idec Inc. ( BIIB ). ACTAVIS PLC (ACT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report DOCTOR REDDYS (RDY): Free Stock Analysis Report To read this article on Zacks.com click here. Three decades later, the first batch of biosmilars is nearing approval in the U.S. And like generics before them, they are opening up new avenues of growth and generating new challenges at the same time.",307.2832946777344
2014-02-27 00:00:00+00:00,342.5,348.3900146484375,340.7699890136719,343.8599853515625,343.8599853515625,1149800.0,3.5,1.0,0.6250249999999999,"Investors looking for better-ranked stocks in the biopharma sector may consider companies like Actelion Ltd. ( ALIOF ), Lannett Co., Inc. ( LCI ) and Biogen Idec Inc. ( BIIB ). AEGERION PHARMA (AEGR): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report LANNETT INC (LCI): Free Stock Analysis Report To read this article on Zacks.com click here. Aegerion also gained marketing approval in Canada and Mexico for Juxtapid as an adjunctive treatment for adult HoFH patients. New Article Investors looking for better-ranked stocks in the biopharma sector may consider companies like Actelion Ltd. ( ALIOF ), Lannett Co., Inc. ( LCI ) and Biogen Idec Inc. ( BIIB ). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report LANNETT INC (LCI): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report To read this article on Zacks.com click here. Neupro, which is marketed as a treatment for Parkinson's disease (PD) and restless legs syndrome (RLS), recorded sales of 182 million, up 39%.",300.10302734375
2014-02-28 00:00:00+00:00,346.1600036621094,349.95001220703125,335.0199890136719,340.67999267578125,340.67999267578125,1861900.0,3.6,1.0,0.6500250000000001,"A better-ranked stock in the biopharmaceutical sector is Biogen Idec Inc. ( BIIB ) carrying a Zacks Rank #1 (Strong Buy). BAXTER INTL (BAX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report HALOZYME THERA (HALO): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report To read this article on Zacks.com click here. Halozyme's partner Baxter International Inc. ( BAX ) submitted an amended biologics license application (BLA) for HyQvia and pre-clinical data (for the treatment of primary immunodeficiency (PI)) in response to the Complete Response Letter (CRL) issued by the U.S. Food and Drug Administration (FDA) in 2012. New Article Other better-ranked stock in the biopharmaceutical sector include Biogen Idec Inc. ( BIIB ) and Alexion Pharmaceuticals, Inc. ( ALXN ), which carry a Zacks Rank #1 (Strong Buy). ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report IDENIX PHARMA (IDIX): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline Update Idenix, which focuses primarily on the development of treatments for hepatitis C virus (HCV), will be reporting data from the seven-day proof-of-concept portion of a phase I/II study on IDX21437, its lead uridine-based nucleotide prodrug candidate, in the first half of 2014. New Article Some better-positioned stocks in the biotech sector include Biogen Idec ( BIIB ) and Alkermes plc ( ALKS ). ALKERMES INC (ALKS): Free Stock Analysis Report ASTELLAS PHARMA (ALPMY): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report To read this article on Zacks.com click here. Xtandi is approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received docetaxel. New Article Here are 5 stocks added to the Zacks Rank #1 (strong buy) List today: Alkermes Plc ( ALKS ) Alleghany Corporation ( Y ) Atlantic Tele-Network, Inc. ( ATNI ) Biogen Idec Inc ( BIIB ) Cadence Design Systems Inc ( CDNS ) View the entire Zacks Rank #1 List . ALKERMES INC (ALKS): Free Stock Analysis Report ATLANTIC TELE-N (ATNI): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CADENCE DESIGN (CDNS): Free Stock Analysis Report ALLEGHANY CORP (Y): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Among the largest underlying components of IBB, in trading today Biogen Idec Inc (Symbol: BIIB) is up about 1.1%, Gilead Sciences, Inc. (Symbol: GILD) is up about 0.6%, and Amgen Inc (Symbol: AMGN) is up by about 2%. The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $144.45 per share, with $275.40 as the 52 week high point - that compares with a last trade of $271.96. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",293.04949951171875
2014-03-03 00:00:00+00:00,340.67999267578125,342.3599853515625,331.2200012207031,338.3800048828125,338.3800048828125,1340400.0,4.0,1.0,0.7500249999999999,"Some better ranked stocks in the biotechnology sector include Alexion Pharmaceuticals, Inc. ( ALXN ) and Biogen Idec Inc. ( BIIB ). ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. The drug is also approved for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C virus (HCV) infection. New Article Better-ranked stocks in the biomedical industry include Alexion Pharmaceuticals, Inc. ( ALXN ), Biogen Idec Inc. ( BIIB ) and Actelion Ltd. ( ALIOF ). Click to get this free report >> ACTELION LTD (ALIOF): Get Free Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report TRANSITN THERAP (TTHI): Get Free Report To read this article on Zacks.com click here. This breaks the recent trend for the company, as the stock is now trading above the past one month's volatile price range of $6.02 to $6.77.",290.6109924316406
2014-03-04 00:00:00+00:00,343.5299987792969,346.739990234375,341.1000061035156,343.1499938964844,343.1499938964844,1107500.0,3.0,1.0,0.5000249999999999,"Better-placed stocks that are worth a look include Amgen Inc. ( AMGN ), Biogen Idec Inc. ( BIIB ) and Actelion Ltd. ( ALIOF ). ACTELION LTD (ALIOF): Get Free Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report To read this article on Zacks.com click here. Per the findings of this data, 65% of physicians changed their original treatment plan on prostate cancer patients based on Myriad Genetic's 46-gene molecular diagnostic testProlaris. New Article ( CBM ), Emergent BioSolutions, Inc. ( EBS ) and Biogen Idec Inc. ( BIIB ). Click to get this free report >> BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report DENDREON CORP (DNDN): Free Stock Analysis Report EMERGENT BIOSOL (EBS): Free Stock Analysis Report To read this article on Zacks.com click here. Dendreon Corp. ( DNDN ) was a big mover last session, as its shares rose nearly 15% on the day. New Article The top-performing funds the past three months have been adding medical stocks in their latest reporting periods, includingActavis ( ACT ),Alexion Pharmaceuticals ( ALXN ),Biogen Idec ( BIIB ) andSalix Pharmaceuticals ( SLXP ). Best-performing funds have been nibbling on gaming/equipment stocks, such as casino operatorsWynn (WYNN),Las Vegas Sands (LVS) andMelco Crown Entertainment (MPEL). Hong Kong-based Melco is currently developing the City of Dreams Manila casino resort in the Philippines, slated to open later this year.",279.7687683105469
2014-03-05 00:00:00+00:00,345.2300109863281,346.29998779296875,338.8599853515625,339.0,339.0,1003300.0,3.25,1.0,0.5625249999999999,"Biogen Idec Inc. Our third choice is Biogen Idec Inc. ( BIIB ) . AEGERION PHARMA (AEGR): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. For example, Sanofi ( SNY ) produces Kynamro, used to treat a life-threatening inherited cholesterol disorder, which costs patients between $235,000 to $295,000 a year. New Article Here are 5 stocks added to the Zacks Rank #1 (strong buy) List today: AudioCodes Ltd. ( AUDC ) Biogen Idec Inc ( BIIB ) China Mobile Games & Entnmnt Grp Ltd ( CMGE ) Crown Castle International Corp. ( CCI ) E TRADE Financial Corporation ( ETFC ) View the entire Zacks Rank #1 List . AUDIOCODES LTD (AUDC): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CROWN CASTLE (CCI): Free Stock Analysis Report CHINA MOBIL-ADR (CMGE): Get Free Report E TRADE FINL CP (ETFC): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Stocks such as Gilead Sciences ( GILD ), Alkermes ( ALKS ) and Biogen Idec ( BIIB ) carry the same rank as Alexion. ALKERMES INC (ALKS): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. The drug has been recording strong sales in both its approved indications - paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). New Article Right now, Gilead Sciences ( GILD ) and Biogen Idec ( BIIB ) also look well placed. ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report DYNAVAX TECH CP (DVAX): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. New Article Some better-ranked biomedical stocks worth considering are Alexion Pharmaceuticals, Inc. ( ALXN ), Biogen Idec Inc. ( BIIB ) and Gilead Sciences Inc. ( GILD ). Click to get this free report >> ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report SUNESIS PHARMA (SNSS): Free Stock Analysis Report To read this article on Zacks.com click here. Sunesis Pharmaceuticals, Inc. ( SNSS ) was a big mover last session, as the company saw its shares rise nearly 7% on the day. New Article Some better-ranked stocks in the same sector include Alexion Pharmaceuticals, Inc. ( ALXN ), Alkermes plc ( ALKS ) and Biogen Idec Inc. ( BIIB ). Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >> ALKERMES INC (ALKS): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report OVASCIENCE (OVAS): Free Stock Analysis Report To read this article on Zacks.com click here. The move came on pretty good volume too with far more shares changing hands than in a normal session. New Article Some better ranked stocks in the health care sector include Alexion Pharmaceuticals, Inc. ( ALXN ), Biogen Idec Inc. ( BIIB ) and Novo Nordisk ( NVO ). ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report To read this article on Zacks.com click here. At week 24 of treatment, in the last four hours of the chamber challenge, MK-8237 demonstrated significant dose- and time-dependent reduction in average total nasal symptom score (TNSS). New Article Some better-ranked stocks in the biotech sector include Alexion Pharmaceuticals, Inc. ( ALXN ), Biogen Idec Inc. ( BIIB ) and Gilead Sciences Inc. ( GILD ). ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report XOMA CORP (XOMA): Free Stock Analysis Report To read this article on Zacks.com click here. XOMA will focus on the phase III study on gevokizumab for inflammatory pyoderma gangrenosum (PG), which is expected to commence in 2014.",279.97772216796875
2014-03-06 00:00:00+00:00,346.8599853515625,353.0,334.010009765625,340.69000244140625,340.69000244140625,2233200.0,3.5,1.0,0.6250249999999999,"Biogen Idec Inc. ( BIIB ) and Eisai Co., Ltd. ( ESALY ) announced a development and commercialization agreement for a couple of Alzheimer's disease (AD) candidates in Eisai's pipeline. According to the terms of the deal, Eisai enjoys an option to collaborate with Biogen for the latter's AD candidates - BIIB037 (an anti-A antibody, phase Ib) and an anti-tau monoclonal antibody. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report EISAI CO LTD (ESALY): Get Free Report GILEAD SCIENCES (GILD): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Two other components making moves today are Costco Wholesale ( COST ), trading down 3.0%, and Biogen Idec ( BIIB ), trading up 3.4% on the day. In early trading on Thursday, shares of Baidu ( BIDU ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.0%. And the worst performing Nasdaq 100 component thus far on the day is Staples ( SPLS ), trading down 12.8%.",289.2154846191406
2014-03-07 00:00:00+00:00,341.7900085449219,342.8500061035156,323.7200012207031,328.75,328.75,2785600.0,3.8,1.0,0.7000249999999999,"Stocks worth considering include Alexion Pharmaceuticals, Inc. ( ALXN ), Biogen Idec Inc. ( BIIB ) and WuXi PharmaTech (Cayman) Inc. ( WX ). ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SPECTRUM PHARMA (SPPI): Free Stock Analysis Report WUXI PHARMATECH (WX): Free Stock Analysis Report To read this article on Zacks.com click here. Spectrum Pharma reported fourth quarter 2013 loss (including stock-based compensation and depreciation but excluding other special items) of a penny per share. New Article We remind investors that Sangamo was also in the news earlier this year when it inked a deal with Biogen Idec ( BIIB ) on the development of therapeutics for hemoglobinopathies resulting from the abnormal structure or underproduction of hemoglobin. ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report SANGAMO BIOSCI (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. SB-728-T is an autologous CD4+ T-cell candidate where the gene for CCR5, a co-receptor for the dreaded virus to enter, is modified using ZFN-mediated genome editing to disrupt the CCR5 protein. New Article Biogen Idec Inc. Our third choice is Biogen Idec Inc. ( BIIB ). AEGERION PHARMA (AEGR): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. For example, Aegerion Pharmaceuticals, Inc. ( AEGR ) produces Juxtapid, used to treat a life threatening inherited cholesterol disorder, which costs patients between $235,000 to $295,000 a year. New Article Some better-ranked biomedical stocks worth considering are Alexion Pharmaceuticals, Inc. ( ALXN ), Gilead Sciences Inc. ( GILD ) and Biogen Idec Inc. ( BIIB ). While ALXN sports a Zacks Rank #1 (Strong Buy), GILD and BIIB bear a Zacks Rank #2 (Buy). Click to get this free report >> ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report SANGAMO BIOSCI (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. New Article And the worst performing Nasdaq 100 component thus far on the day is Biogen Idec ( BIIB ), trading down 4.2%. VIDEO: Nasdaq 100 Movers: BIIB, INTU The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Biogen Idec is showing a gain of 16.8% looking at the year to date performance.",278.36920166015625
2014-03-10 00:00:00+00:00,327.6499938964844,338.6000061035156,327.010009765625,338.0,338.0,1471000.0,4.0,1.0,0.7500249999999999,"Among the largest underlying components of IBB, in trading today Biogen Idec Inc (Symbol: BIIB) is up about 1%, Amgen Inc (Symbol: AMGN) is up about 0.8%, and Regeneron Pharmaceuticals, Inc. (Symbol: REGN) is lower by about 0.2%. The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $153.07 per share, with $275.40 as the 52 week high point - that compares with a last trade of $257.07. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article On Mar 8, Zacks Investment Research upgraded Biogen Idec Inc. ( BIIB ) to a Zacks Rank #1 (Strong Buy). ALKERMES INC (ALKS): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. While Tecfidera should continue performing well, Tysabri and Avonex should remain strong contributors to the top line. New Article Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Biogen Idec Inc ( BIIB ) Compressco Partners LP ( GSJK ) Crown Castle International Corp. ( CCI ) Delhaize Group ( DEG ) Delta Natural Gas Company, Inc. ( DGAS ) View the entire Zacks Rank #1 List . BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CROWN CASTLE (CCI): Free Stock Analysis Report DELHAIZE-LE (DEG): Free Stock Analysis Report DELTA NAT GAS (DGAS): Free Stock Analysis Report COMPRESSCO PTNR (GSJK): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Other better-ranked stocks in the medical sector include Cambrex Corporation ( CBM ), Alkermes plc ( ALKS ) and Biogen Idec Inc. ( BIIB ). Click to get this free report >> AEGERION PHARMA (AEGR): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report To read this article on Zacks.com click here. Aegerion Pharmaceuticals, Inc. ( AEGR ) was a big mover last session, as its shares rose nearly 11% on the day. New Article Some better-ranked stocks in the same sector include Biogen Idec Inc. ( BIIB ) carrying a Zacks Rank #1 (Strong Buy). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report INTERMUNE INC (ITMN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of InterMune, Inc. ( ITMN ) were up around 10.8% on Mar 7 to end the day's trading at $33.87, after reports from news agencies like Reuters and CNBC claimed that the company was attracting takeover interest from several pharmaceutical giants.",268.3638610839844
2014-03-11 00:00:00+00:00,338.25,341.260009765625,334.19000244140625,335.989990234375,335.989990234375,1025600.0,4.0,1.0,0.7500249999999999,"( BIIB ) carry the same rank as Alexion. ALKERMES INC (ALKS): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. This time, the biopharmaceutical company has lifted its outlook (both for the top and bottom lines) for 2014 following a reimbursement deal with France on Soliris.",274.5310974121094
2014-03-12 00:00:00+00:00,333.04998779296875,340.3800048828125,332.2799987792969,339.54998779296875,339.54998779296875,879300.0,2.0,1.0,0.250025,"Biogen ( BIIB ) - Eisai Tie Up: Biogen is expanding its efforts to develop a treatment for Alzheimer's disease. Click to get this free report >> ALEXION PHARMA (ALXN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CHIMERIX INC (CMRX): Free Stock Analysis Report INTERMUNE INC (ITMN): Free Stock Analysis Report KYTHERA BIOPHRM (KYTH): Free Stock Analysis Report NEWLINK GENETIC (NLNK): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report XOMA CORP (XOMA): Free Stock Analysis Report To read this article on Zacks.com click here. These companies have been told to evaluate potential neurocognitive adverse events across the global development program for the experimental drug, especially in long-term studies. New Article Some other well-placed stocks that are worth a look include Biogen Idec Inc. ( BIIB ) and Actelion Ltd. ( ALIOF ). ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report LABORATORY CP (LH): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Myriad Genetics Inc. ( MYGN ) slashed 8.34% at yesterday's close, soon after an unfavorable court bid, according to a Bloomberg report.",274.1646423339844
2014-03-13 00:00:00+00:00,341.0400085449219,342.5899963378906,329.0299987792969,332.04998779296875,332.04998779296875,1064900.0,3.0,1.0,0.5000249999999999,"Some better-ranked stocks in the biopharma sector include Alexion Pharmaceuticals, Inc. ( ALXN ), Gilead Sciences Inc. ( GILD ) and Biogen Idec Inc. ( BIIB ). ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report FATE THERAPEUTC (FATE): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. This year, the company expects to file an Investigational New Drug application (IND) for a proprietary Wnt7a protein analog to evaluate its safety and efficacy in promoting muscle regeneration.",262.34808349609375
2014-03-14 00:00:00+00:00,333.3999938964844,340.0,329.2300109863281,332.489990234375,332.489990234375,1330400.0,2.5,1.0,0.375025,"Biogen Idec ( BIIB ) is a better-ranked stock in the sector with a Zacks Rank #2 (Buy). ATHERSYS INC (ATHX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. During the fourth quarter of 2013, Athersys completed enrolling patients in a phase II study on its MultiStem cell therapy. New Article However, Biogen Idec Inc. ( BIIB ) currently has an option to develop AV-203 in ex-North America territories. ASTELLAS PHARMA (ALPMY): Get Free Report ALEXION PHARMA (ALXN): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. A decrease in expenses pertaining to the development of ficlatuzumab and tivozanib also led to the reduction in R&D costs.",263.1112365722656
2014-03-17 00:00:00+00:00,334.8299865722656,349.0,334.32000732421875,345.6000061035156,345.6000061035156,1561000.0,4.0,1.0,0.7500249999999999,"Components of that ETF showing particular strength include shares of Biogen Idec ( BIIB ), up about 4.2% and shares of Intermune ( ITMN ), up about 3.8% on the day. In trading on Monday, the First Trust NYSE Arca Biotechnology Index Fund ETF ( FBT ) is outperforming other ETFs, up about 1.6% on the day. Among components of that ETF with the weakest showing on Monday were shares of McEwen Mining ( MUX ), lower by about 11.2%, and shares of New Gold (NGD), lower by about 6.7% on the day. New Article Two other components making moves today are Express Scripts Holding ( ESRX ), trading down 0.7%, and Biogen Idec ( BIIB ), trading up 4.0% on the day. ( YHOO ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.0%. And the worst performing Nasdaq 100 component thus far on the day is Illumina ( ILMN ), trading down 2.1%. New Article In early trading on Monday, shares of Biogen Idec ( BIIB ) topped the list of the day's best performing components of the S&P 500 index, trading up 3.9%. VIDEO: S&P 500 Movers: VRSN, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Year to date, Biogen Idec registers a 23.5% gain.",258.8345947265625
2014-03-18 00:00:00+00:00,346.79998779296875,354.07000732421875,345.70001220703125,351.94000244140625,351.94000244140625,1511100.0,4.0,1.0,0.7500249999999999,"And, Biogen Idec ( BIIB ) said the U.S. Food and Drug Administration has extended the date for reviewing the Biologics License Application of its Plegridy drug to treat relapsing forms of multiple sclerosis. In healthcare stocks news, Novogen ( NVGN ) American depository shares jumped in Tuesday's pre-market session, after the pharmaceutical company and its joint venture with Yale University, CanTx Inc., said lead candidate drug Trx-1 demonstrated ""a potent anti-cancer effect"" in mice xenografted with human ovarian-cancer stem cells. The so-called Prescription Drug User Fee Act (PDUFA) date was extended by three months, the standard extension period, to allow additional time for the review, according to the pharmaceutical company. New Article Much-awaited data include proof-of-concept or proof of biology read-outs on candidates like anti-CD40 ligand (lupus - phase II); anti-LINGO (MS/ acute optic neuritis), BIIB037 (Alzheimer's disease), neublastin (neuropathic pain) and STX-100 (idiopathic pulmonary fibrosis). Biotech company, Biogen Idec ( BIIB ), will be added to the S&P100 index after market close on Friday, Mar 21. ALKERMES INC (ALKS): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here.",258.08673095703125
2014-03-19 00:00:00+00:00,352.489990234375,358.8900146484375,347.0,350.010009765625,350.010009765625,1341500.0,3.0,1.0,0.5000249999999999,"Major stocks from the sector such as Pfizer Inc. (NYSE: PFE ), Merck & Co. Inc. (NYSE: MRK ), Gilead Sciences Inc. (NASDAQ: GILD ), Amgen Inc. (NASDAQ: AMGN ) and Biogen Idec Inc. (NASDAQ: BIIB ) gained 1.6%, 0.2%, 3.1%, 2.9% and 1.8%, respectively. APPLE INC (AAPL): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report GOOGLE INC-CL A (GOOG): Free Stock Analysis Report INTL BUS MACH (IBM): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report MICROSOFT CORP (MSFT): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report VERIZON COMM (VZ): Free Stock Analysis Report To read this article on Zacks.com click here. Receding fears of further military action related to Russia's annexation of Crimea helped benchmarks end in the green for the second straight day. New Article Biotech company, Biogen Idec ( BIIB ), well known for its strong presence in the multiple sclerosis (MS) market, is facing a delay in the approval process for its MS pipeline candidate, Plegridy. ABBVIE INC (ABBV): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen and partner AbbVie ( ABBV ) are conducting a two-year phase III study (DECIDE) on daclizumab with results due later this year. New Article Biogen ( BIIB ) to Be Added to S&P 100: Biogen's shares were up 3.9% on news that it will be added to the S&P 100 index after market close on Friday, Mar 21. Click to get this free report >> AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report FIVEPRIME THERA (FPRX): Free Stock Analysis Report GERON CORP (GERN): Free Stock Analysis Report INTERCEPT PHARM (ICPT): Free Stock Analysis Report IDENIX PHARMA (IDIX): Free Stock Analysis Report To read this article on Zacks.com click here. Even if imetelstat studies continue, concerns about LFT abnormalities could limit the commercial potential of the candidate and restrict its long-term usage.",274.3312683105469
2014-03-20 00:00:00+00:00,348.2699890136719,353.20001220703125,344.7200012207031,347.0400085449219,347.0400085449219,1369100.0,3.0,1.0,0.5000249999999999,"Drug maker - Biogen Idec ( BIIB ) - has seen a huge rally in its share price after it announced that the stock would be added to the mega cap index after market close on Friday, March 21. The changes would be modest for the ETF world, as the inclusion of BIIB in the S&P 100 index will not increase much choices in the space for investors seeking a broad exposure and a concentrated play on the stock. Following the inclusion of BIIB as an S&P 100 member, the largest ETF in the space - iShares S&P 100 ETF ( OEF ) - tracking the S&P 100 index would also add Biogen to its roster.",275.25360107421875
2014-03-21 00:00:00+00:00,355.0,355.0,313.0799865722656,318.5299987792969,318.5299987792969,5748300.0,3.5,1.0,0.6250249999999999,"In other sector news, (+) AVEO, (+5.2%) Regains worldwide rights to AV-203, a clinical-stage ErbB3 inhibitory antibody candidate, from Biogen Idec ( BIIB ). In company news, Endocyte ( ECYT ) soared Friday, more than doubling in value to set a new all-time high after saying its vintafolide drug candidate slowed the progression of lung cancer during Phase IIb testing. Separately, ECYT and partner Merck ( MRK ) today said European regulators issued positive opinions for the companies' Vynfinit chemotherapy and Folcepri and Neocepr imaging components, granting conditional marketing authorizations for the treatment of adult patients with certain forms of ovarian cancer. New Article In other sector news, (+) AVEO, (+5.2%) Regains worldwide rights to AV-203, a clinical-stage ErbB3 inhibitory antibody candidate, from Biogen Idec ( BIIB ). In company news, Endocyte ( ECYT ) soared Friday, more than doubling in value to set a new all-time high after saying its vintafolide drug candidate slowed the progression of lung cancer during Phase IIb testing. Separately, ECYT and partner Merck ( MRK ) today said European regulators issued positive opinions for the companies' Vynfinit chemotherapy and Folcepri and Neocepr imaging components, granting conditional marketing authorizations for the treatment of adult patients with certain forms of ovarian cancer.",256.13311767578125
2014-03-24 00:00:00+00:00,320.20001220703125,322.0,300.32000732421875,312.6000061035156,312.6000061035156,3748000.0,2.6666666666666665,1.0,0.4166916666666666,"Gilead Sciences Inc. (NASDAQ: GILD ) and Biogen Idec Inc. (NASDAQ: BIIB ) were the biggest drags on the S&P 500. AMGEN INC (AMGN): Free Stock Analysis Report AMAZON.COM INC (AMZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report COMCAST CORP A (CMCSA): Free Stock Analysis Report DISNEY WALT (DIS): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report MCDONALDS CORP (MCD): Free Stock Analysis Report PRICELINE.COM (PCLN): Free Stock Analysis Report UNITEDHEALTH GP (UNH): Free Stock Analysis Report To read this article on Zacks.com click here. For a look at the issues currently facing the markets, make sure to read today's Ahead of Wall Street article The Dow Jones Industrial Average (DJI) dropped 0.2% to close Friday's trading session at 16,302.77. New Article Biogen Idec ( BIIB ) announced that its hemophilia B drug, Alprolix, gained approval in Canada. Apart from receiving a response from regulatory authorities regarding Eloctate, Alprolix and Plegridy, Biogen expects several proof-of-concept or proof of biology read-outs this year, including data on anti-LINGO (acute optic neuritis), BIIB037 (Alzheimer's disease), neublastin (neuropathic pain), STX-100 (idiopathic pulmonary fibrosis) and anti-CD40 (lupus). ALKERMES INC (ALKS): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. New Article The large-cap biotech stocks suffered the most in the broad sector sell-off with Biogen Idec ( BIIB ) plunging 8%, Gilead down 6%, Celgene ( CELG ) down 3.7% and Amgen ( AMGN ) down 3%. The crushed stocks - GILD, AMGN, BIIB and CELG - occupy the top four positions in the basket with a combined 41% of assets. Click to get this free report >> AMGEN INC (AMGN): Free Stock Analysis Report MKT VEC-BIOTECH (BBH): ETF Research Reports BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ISHARES NDQ BIO (IBB): ETF Research Reports SPDR-SP BIOTECH (XBI): ETF Research Reports To read this article on Zacks.com click here.",263.7212829589844
2014-03-26 00:00:00+00:00,313.0799865722656,317.2799987792969,305.92999267578125,305.92999267578125,305.92999267578125,1975900.0,2.0,1.0,0.250025,"Biogen ( BIIB ) Backs out of AVEO Collaboration: Biogen returned rights to experimental cancer drug, AV-203, to AVEO Oncology. Click to get this free report >> AGENUS INC (AGEN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CUBIST PHARM (CBST): Free Stock Analysis Report ENDOCYTE INC (ECYT): Free Stock Analysis Report FIVEPRIME THERA (FPRX): Free Stock Analysis Report GERON CORP (GERN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report INTERCEPT PHARM (ICPT): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report MANNKIND CORP (MNKD): Free Stock Analysis Report To read this article on Zacks.com click here. The biotech sector, which has had an incredibly good run over the last two years, tumbled on Friday with the trigger being a letter issued to Gilead ( GILD ) by lawmakers. New Article Among the largest underlying components of IBB, in trading today Biogen Idec Inc (Symbol: BIIB) is up about 0.9%, Amgen Inc (Symbol: AMGN) is up about 1.6%, and Regeneron Pharmaceuticals, Inc. (Symbol: REGN) is up by about 2.1%. The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $154.39 per share, with $275.40 as the 52 week high point - that compares with a last trade of $242.62. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",256.0547790527344
2014-03-31 00:00:00+00:00,296.1099853515625,306.94000244140625,296.1099853515625,305.8699951171875,305.8699951171875,1952500.0,2.5,1.0,0.375025,"Apart from receiving a response from regulatory authorities regarding Eloctate and Plegridy, Biogen expects several proof-of-concept or proof of biology read-outs this year including data on anti-LINGO (acute optic neuritis), BIIB037 (Alzheimer's disease), neublastin (neuropathic pain), STX-100 (idiopathic pulmonary fibrosis) and anti-CD40 (lupus). Biogen ( BIIB ) gained U.S. approval for its hemophilia B treatment, Alprolix. ALKERMES INC (ALKS): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Shares of bio-tech companies such as Gilead Sciences Inc. (NASDAQ: GILD ), Biogen Idec Inc. (NASDAQ: BIIB ) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) plunged 4%, 5.1% and 4.2%, respectively. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CISCO SYSTEMS (CSCO): Free Stock Analysis Report CHEVRON CORP (CVX): Free Stock Analysis Report D R HORTON INC (DHI): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report INTEL CORP (INTC): Free Stock Analysis Report LENNAR CORP -A (LEN): Free Stock Analysis Report LUMBER LIQUIDAT (LL): Free Stock Analysis Report MICROSOFT CORP (MSFT): Free Stock Analysis Report ORACLE CORP (ORCL): Free Stock Analysis Report RYLAND GRP INC (RYL): Free Stock Analysis Report USG CORP (USG): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report EXXON MOBIL CRP (XOM): Free Stock Analysis Report To read this article on Zacks.com click here. For a look at the issues currently facing the markets, make sure to read today's Ahead of Wall Street article The Dow Jones Industrial Average (DJI) gained 0.4% to close Friday's trading session at 16,323.06.",258.138916015625
2014-04-07 00:00:00+00:00,286.3599853515625,297.760009765625,281.5899963378906,294.19000244140625,294.19000244140625,2427600.0,2.0,1.0,0.250025,"Biogen Idec Inc. ( BIIB ), Gilead Sciences Inc. ( GILD ), Vertex Pharmaceuticals Incorporated ( VRTX ) and Amgen Inc. ( AMGN ) decreased 4.5%, 2.4%, 4.8% and 4.0%, respectively. ALCOA INC (AA): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report AMAZON.COM INC (AMZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report FACEBOOK INC-A (FB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report NETFLIX INC (NFLX): Free Stock Analysis Report PANDORA MEDIA (P): Free Stock Analysis Report TRIPADVISOR INC (TRIP): Free Stock Analysis Report TESLA MOTORS (TSLA): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report To read this article on Zacks.com click here. Facebook, Inc. ( FB ), electric car maker Tesla Motors, Inc. ( TSLA ) and Internet radio service provider Pandora Media, Inc. ( P ) plunged 4.6%, 5.9% and 4.9%, respectively.",258.6069030761719
2014-04-10 00:00:00+00:00,300.1000061035156,300.9100036621094,284.57000732421875,287.3500061035156,287.3500061035156,2635700.0,4.0,1.0,0.7500249999999999,"The much larger Biogen Idec ($73bn market cap) will have proof of concept results later this year for BIIB033, and despite differing mechanisms of action, the first evidence of utility in humans will bring investors around on what is now an early-stage asset at Acorda. Biogen Idec's ( BIIB ) BIIB033, an anti-LINGO monoclonal antibody, works in a similar remyelinating fashion. BIIB033 is being studied in an acute optic neuritis ( ( AON )) trial that could inform future developments of BIIB033 in MS patients, in addition to a trial in relapsing remitting MS ( (RRMS)) as an adjunctive therapy alongside Avonex. New Article So companies like Biogen ( BIIB ) and Alexion Pharmaceuticals, Inc. ( ALXN ) were also badly hit as investors got jittery that their newly approved drugs would also be subjected to the same pricing scrutiny. ALKERMES INC (ALKS): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. The sector, which has had an incredibly good run over the last two years, tumbled in the latter part of March with the trigger being a letter issued to Gilead ( GILD ) by lawmakers.",258.189208984375
2014-04-11 00:00:00+00:00,284.8900146484375,292.79998779296875,273.7300109863281,274.0,274.0,2742500.0,5.0,1.0,1.000025,"Biogen Idec ( BIIB ) and partner Swedish Orphan Biovitrum AB (Sobi) reported positive top-line data on their hemophilia A candidate, Eloctate from a phase III pediatric study (Kids A-LONG). ALEXION PHARMA (ALXN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ZIOPHARM ONCLGY (ZIOP): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, Biogen is conducting the phase III Kids B-LONG study with Alprolix for the treatment of hemophilia B in children below 12 years of age.",260.8950500488281
2014-04-14 00:00:00+00:00,277.9100036621094,285.989990234375,274.0,279.5199890136719,279.5199890136719,1880100.0,3.5,1.0,0.6250249999999999,"Big names in the biotech sector like Alexion Pharmaceuticals ( ALXN ) and Biogen Idec ( BIIB ) dragged the biotech index down. ALEXION PHARMA (ALXN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Other major indices, including the Dow Jones Industrial Average (^DJI), too registered steep declines on that day, driven by the biotech selloff. New Article Biogen Idec Inc. ( BIIB ) has an Earnings ESP of +8.14% and holds a Zacks Rank #3 (Hold). ABBVIE INC (ABBV): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CUBIST PHARM (CBST): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report To read this article on Zacks.com click here. Although revenues will continue to be impacted by genericization, the strong performance of the pharmaceuticals segment especially products like Remicade, Zytiga, Prezista, Invokana, Stelara, Intelence, Xarelto, Simponi, Velcade and Invega Sustenna should partially offset the negative impact of genericization.",262.9930114746094
2014-04-15 00:00:00+00:00,280.54998779296875,288.8399963378906,272.0199890136719,285.489990234375,285.489990234375,1871100.0,2.0,1.0,0.250025,"Stocks to Consider Here are some other stocks in the broader healthcare sector that you may want to consider as our model shows that these have the right combination of elements to post an earnings beat this season: Biogen Idec Inc. ( BIIB ) has an Earnings ESP of +8.14% and holds a Zacks Rank #3 (Hold). ABBVIE INC (ABBV): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is scheduled to report first quarter 2014 results before the opening bell on Apr 16, 2014.",265.36944580078125
2014-04-17 00:00:00+00:00,291.0,296.0,289.760009765625,290.5400085449219,290.5400085449219,1283400.0,2.0,1.0,0.250025,"We note that AbbVie has partnered programs with several companies, including Biogen ( BIIB ). ABBVIE INC (ABBV): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company.",269.05712890625
2014-04-21 00:00:00+00:00,290.6000061035156,298.57000732421875,290.20001220703125,297.9800109863281,297.9800109863281,984400.0,3.0,1.0,0.5000249999999999,"Biogen Idec Inc. ( BIIB ) has an Earnings ESP of +8.14% and holds a Zacks Rank #3 (Hold). ACTAVIS PLC (ACT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. Amgen Inc. ( AMGN ) is set to report first quarter 2014 results on Apr 22 after the market closes. New Article Biogen Idec Inc. ( BIIB ) has an Earnings ESP of +8.14% and holds a Zacks Rank #3. ACTAVIS PLC (ACT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. Factors to Consider We expect a meaningful contribution from potential blockbuster hepatitis C virus (HCV) treatment, Sovaldi, this quarter.",261.1439514160156
2014-04-22 00:00:00+00:00,300.5,309.1700134277344,300.0,306.20001220703125,306.20001220703125,1776700.0,3.857142857142857,1.0,0.7143107142857144,"Biogen Idec Inc. ( BIIB ) is reporting for the quarter ending March 31, 2014. In the past year BIIB has beat the expectations every quarter. Zacks Investment Research reports that the 2014 Price to Earnings ratio for BIIB is 26.39 vs. an industry ratio of -10.20, implying that they will have a higher earnings growth than their competitors in the same industry. New Article Other better-ranked stocks in the medical sector include TrovaGene, Inc. ( TROV ), ZIOPHARM Oncology, Inc. (ZIOP) and Biogen Idec Inc. ( BIIB ). Click to get this free report >> BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report TROVAGENE INC (TROV): Get Free Report ZIOPHARM ONCLGY (ZIOP): Free Stock Analysis Report To read this article on Zacks.com click here. Cytokinetics, Incorporated ( CYTK ) was a big mover last session, as its shares rose nearly 14% on the day. New Article KB Financial Group's historical revenue and net income: The analysis on KB Financial Group reports that the company has enough cash to cover all of its debt, it has shown predictable revenue and earnings growth, and its dividend yield is near a 10-year high. The Peter Lynch Chart suggests that the company is currently undervalued : KB Financial has a market cap of $13.56 billion. Ken Fisher (Trades, Portfolio)'s historical holding history: Celgene is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. New Article Biogen Idec Inc. ( BIIB ) is a Zacks Rank #1 stock with an Earnings ESP of +8.14%. ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. The sell-off was triggered by lawmakers issuing a letter to Gilead Sciences Inc. ( GILD ) questioning the pricing of its recently approved hepatitis C virus (HCV) treatment, Sovaldi. New Article Some better-ranked stocks include Amgen Inc. ( AMGN ), Biogen Idec Inc. ( BIIB ) and Regeneron Pharmaceuticals, Inc. ( REGN ). AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that Sarepta's shares tumbled in November last year after the FDA had stated that the NDA filing of eteplirsen would be premature at that time. New Article Biogen Idec Inc. ( BIIB ) is scheduled to report first quarter 2014 results before the opening bell on Apr 23. ACTAVIS PLC (ACT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen has an impressive track record and delivered positive earnings surprises in the last four quarters with an average beat of 15.62%. New Article Other Stocks to Consider Here are some other companies you may want to consider as our model shows that they have the right combination of elements -- a positive Zacks Earnings ESP and a Zacks Rank #1, #2 or #3 Biogen Idec Inc. ( BIIB ) has an Earnings ESP of +8.14% and holds a Zacks Rank #1 (Strong Buy). ACTAVIS PLC (ACT): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report To read this article on Zacks.com click here. Our proven model conclusively shows that Alexion is likely to beat earnings this quarter because it has the right combination of two key ingredients.",265.655517578125
2014-04-23 00:00:00+00:00,309.0,311.1000061035156,295.489990234375,306.75,306.75,2594700.0,3.5,1.0,0.6250249999999999,"In company news, Biogen Idec ( BIIB ) was narrowly lower in late trading Wednesday, giving back earlier gains that followed the biotech conglomerate posting strong revenue growth in its latest quarter, beating Wall Street expectations, although its Q1 earnings came up short of analyst projections for the period. The company earned $2.47 per share, lagging the Capital IQ consensus by $0.09 per share, although BIIB said its GAAP and non-GAAP earnings included a $0.35 charge linked to a $118 million research and development expense from its collaboration agreement with Eisai on Alzheimer's disease. BIIB also issued upside FY14 guidance, increasing its EPS outlook by $0.35 per share to a new range of $11.35 to $11.45, excluding non-recurring items, beating the Street view by at least $0.02 per share. New Article And, Biogen Idec ( BIIB ) shares were higher in recent pre-market trade after issuing a FY14 EPS guidance range that exceeded analysts' expectations, while Q1 earnings was shy of the street view. In healthcare stocks news, Amgen ( AMGN ) shares were down about 2.8% after it reported disappointing Q1 earnings and revenue late Tuesday and guided below the Street view for full-year 2014 results. The consensus estimate in the Capital IQ survey looked for $4.8 billion in revenue. New Article A better-ranked stock in the biotech sector is Biogen Idec ( BIIB ), a Zacks Rank #1 (Strong Buy) stock. AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report To read this article on Zacks.com click here. The company has been taking steps to improve Enbrel's performance which includes optimization of the sales force, higher direct-to-consumer (DTC) advertising and increased focus on appropriate access. New Article Other better-ranked stocks in the medical sector include TrovaGene, Inc. ( TROV ), ZIOPHARM Oncology, Inc. ( ZIOP ) and Biogen Idec Inc. ( BIIB ). Click to get this free report >> BIOGEN IDEC INC (BIIB): Free Stock Analysis Report REVANCE THERAP (RVNC): Free Stock Analysis Report TROVAGENE INC (TROV): Get Free Report ZIOPHARM ONCLGY (ZIOP): Free Stock Analysis Report To read this article on Zacks.com click here. Revance Therapeutics, Inc. ( RVNC ) was a big mover last session, as its shares rose nearly 26% on the day. New Article In company news, Biogen Idec ( BIIB ) was narrowly lower in late trading Wednesday, giving back earlier gains that followed the biotech conglomerate posting strong revenue growth in its latest quarter, beating Wall Street expectations, although its Q1 earnings came up short of analyst projections for the period. The company earned $2.47 per share, lagging the Capital IQ consensus by $0.09 per share, although BIIB said its GAAP and non-GAAP earnings included a $0.35 charge linked to a $118 million research and development expense from its collaboration agreement with Eisai on Alzheimer's disease. BIIB also issued upside FY14 guidance, increasing its EPS outlook by $0.35 per share to a new range of $11.35 to $11.45, excluding non-recurring items, beating the Street view by at least $0.02 per share. New Article Biogen Idec ( BIIB ) reported first quarter 2014 earnings per share of $2.45 (including the impact of stock-based compensation expense), missing the Zacks Consensus Estimate of $2.58 but surpassing the year-ago earnings by 25%. BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report To read this article on Zacks.com click here. The company said that first quarter 2014 earnings were impacted by about 35 cents due to its new Alzheimer's disease collaboration agreement with Eisai.",271.14483642578125
2014-04-24 00:00:00+00:00,307.0,308.7200012207031,286.4800109863281,294.8399963378906,294.8399963378906,2385300.0,3.0,1.0,0.5000249999999999,"Two other components making moves today are Biogen Idec ( BIIB ), trading down 4.8%, and Lam Research Corp ( LRCX ), trading up 7.9% on the day. Year to date, Zimmer Holdings registers a 13.4% gain. And the worst performing S&P 500 component thus far on the day is Xilinx ( XLNX ), trading down 9.4%. New Article Biogen Idec Inc. (NASDAQ: BIIB ) reported first quarter 2014 earnings per share of $2.45 (including the impact of stock-based compensation expense), missing the Zacks Consensus Estimate of $2.58 per share. APPLE INC (AAPL): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BOEING CO (BA): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BEAZER HOMES (BZH): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report D R HORTON INC (DHI): Free Stock Analysis Report FACEBOOK INC-A (FB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report LENNAR CORP -A (LEN): Free Stock Analysis Report PULTE GROUP ONC (PHM): Free Stock Analysis Report AT&T INC (T): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report To read this article on Zacks.com click here. For a look at the issues currently facing the markets, make sure to read today's Ahead of Wall Street article The Dow Jones Industrial Average (DJI) dropped 0.1% to close Wednesday's trading session at 16,501.65. New Article Some better-ranked stocks include ImmunoGen, Inc. ( IMGN ) and Biogen Idec Inc. ( BIIB ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report IMMUNOGEN INC (IMGN): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report SPECTRUM PHARMA (SPPI): Free Stock Analysis Report To read this article on Zacks.com click here. Spectrum Pharmaceuticals ( SPPI ) announced encouraging results from a phase II pivotal study on captisol-enabled melphalan.",276.7920837402344
2014-04-25 00:00:00+00:00,293.0400085449219,296.739990234375,285.5799865722656,285.8099975585937,285.8099975585937,1727700.0,1.0,1.0,2.4999999999997247e-05,"Below is a chart of eBay Inc. versus Biogen Idec Inc plotting their respective size rank within the S&P 500 over time (EBAY plotted in blue; BIIB plotted in green): Below is a three month price history chart comparing the stock performance of EBAY vs. BIIB: Another reason market capitalization is important is where it places a company in terms of its size tier in relation to peers - much like the way a mid-size sedan is typically compared to other mid-size sedans (and not SUV's). In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, eBay Inc. (Symbol: EBAY) has taken over the #57 spot from Biogen Idec Inc (Symbol: BIIB), according to The Online Investor . In the case of eBay Inc. (Symbol: EBAY), the market cap is now $68.18 billion, versus Biogen Idec Inc (Symbol: BIIB) at $67.56 billion.",278.41766357421875
2014-05-01 00:00:00+00:00,287.1099853515625,291.989990234375,283.29998779296875,286.75,286.75,1312700.0,2.0,1.0,0.250025,"The news not only brought down Gilead's stock price, it also impacted other companies like Celgene (CELG), Biogen (BIIB), Alexion (ALXN), Amgen (AMGN) and Regeneron (REGN) on concerns that these companies too would find their new treatments coming under the same pricing scrutiny. Apart from strong earnings, acquisition deals and regulatory updates on pipeline candidates have also boosted the share prices of some biotech stocks in the last few days. Given the huge number of industry participants, pinpointing stocks that have the potential to beat estimates could appear to be a daunting task, but our proprietary methodology makes it fairly simple.",282.6675109863281
2014-05-05 00:00:00+00:00,280.6099853515625,291.3099975585937,279.0,290.0599975585937,290.0599975585937,1177900.0,3.0,1.0,0.5000249999999999,"Two other components making moves today are Whole Foods Market ( WFM ), trading down 2.5%, and Biogen Idec ( BIIB ), trading up 1.0% on the day. In early trading on Monday, shares of Gilead Sciences ( GILD ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 1.0%. Wynn Resorts is showing a gain of 11.1% looking at the year to date performance.",278.5260009765625
2014-05-06 00:00:00+00:00,287.7699890136719,291.0899963378906,285.5199890136719,285.94000244140625,285.94000244140625,1236900.0,4.0,1.0,0.7500249999999999,The acquisition of Elan has boosted Perrigo's revenue stream as it is now eligible to receive significant royalties on multiple sclerosis drug Tysabri from Biogen Idec ( BIIB ). ALLERGAN INC (AGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report XENOPORT INC (XNPT): Free Stock Analysis Report To read this article on Zacks.com click here. Perrigo Company ( PRGO ) is set to report third quarter fiscal 2014 results on May 7 before the market opens.,268.63470458984375
2014-05-07 00:00:00+00:00,286.260009765625,288.25,278.1000061035156,284.0,284.0,1379600.0,2.5,1.0,0.375025,"Specialty Sciences: Segmental revenues came in at $53.4 million due to royalties received by Perrigo on multiple sclerosis drug Tysabri from Biogen Idec ( BIIB ). BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report DOCTOR REDDYS (RDY): Free Stock Analysis Report To read this article on Zacks.com click here. Perrigo Company plc 's ( PRGO ) third-quarter fiscal 2014 (ended Mar 29, 2014) earnings of $1.31 per share were well short of the Zacks Consensus Estimate of $1.53. New Article Isis Pharma has partnered programs with Biogen Idec Inc. ( BIIB ) and Roche ( RHHBY ), among others. ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report To read this article on Zacks.com click here. The company intends to initiate a phase III study on ISIS-APOCIIIRx in patients suffering from familial chylomicronemia syndrome (FCS) in mid-2014 and a second phase III study later this year in patients with triglycerides higher than 880 milligrams per deciliter.",273.6952819824219
2014-05-08 00:00:00+00:00,286.0,291.2799987792969,281.82000732421875,282.9599914550781,282.9599914550781,1230200.0,2.0,1.0,0.250025,Revenue in the first quarter 2014 included a one-time revenue of $14.1 million (previously deferred revenue) as a result of the amended agreement with Biogen Idec Inc. ( BIIB ). Click to get this free report ASTELLAS PHARMA (ALPMY): Get Free Report ALEXION PHARMA (ALXN): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The narrower year-over-year loss was primarily due to lower operating expenses and higher collaboration revenues. New Article The company expects to initiate a phase III study (DYNAMO+R) on IPI-145 in combination with Roche Holding / Biogen Idec Inc. 's ( RHHBY / BIIB ) Rituxan (rituximab) in patients suffering from relapsed indolent non-Hodgkin lymphoma (iNHL) later in the year. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report INFINITY PHARMA (INFI): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report SPECTRUM PHARMA (SPPI): Free Stock Analysis Report To read this article on Zacks.com click here. Infinity Pharma also has plans to start a phase II study on IPI-145 for the treatment of treatment-nave patients suffering from iNHL.,267.6636047363281
2014-05-14 00:00:00+00:00,294.8699951171875,301.2099914550781,293.3299865722656,296.5,296.5,1030700.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of IWB, in trading today United Parcel Service Inc (Symbol: UPS) is down about 0.8%, Biogen Idec Inc (Symbol: BIIB) is up about 1.1%, and eBay Inc. (Symbol: EBAY) is higher by about 0.6%. The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $86.84 per share, with $106.51 as the 52 week high point - that compares with a last trade of $106.01. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",271.7287902832031
2014-05-27 00:00:00+00:00,303.239990234375,310.04998779296875,299.5,309.7699890136719,309.7699890136719,1308500.0,2.0,1.0,0.250025,"Here are the top holdings of the NDX (QQQ is the tracking ETF)... Top Ten Holdings with Weightings Apple Inc AAPL: 13.13% Microsoft Corp MSFT: 8.37% Google Inc Class A GOOGL: 3.74% Google Inc GOOG: 3.68% Amazon.com Inc AMZN: 3.49% Qualcomm Inc QCOM: 3.32% Intel Corp INTC: 3.31% Gilead Sciences Inc GILD: 3.01% Cisco Systems Inc CSCO: 2.97% Facebook Inc Class A FB: 2.95% %Assets in Top 10: 47.96% (as of March 31 from PowerShares data) Other popular Tech, Biotech, and Consumer Discretionary names in the index include Netflix (NFLX) and Priceline (PCLN), Biogen-Idec (BIIB) and Celgene, and Starbucks and Costco. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NETFLIX INC (NFLX): Free Stock Analysis Report PRICELINE.COM (PCLN): Free Stock Analysis Report To read this article on Zacks.com click here. My topic today revolves around institutional appetite for these big ""growth"" stocks, if INTC and CSCO can still be called that. New Article We note that several oral multiple sclerosis therapies are currently available including Novartis ' ( NVS ) Gilenya and Biogen Idec 's ( BIIB ) Tecfidera among others. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. The CHMP, while issuing the negative opinion in January, stated that the potential risks associated with Nerventra outweighed the benefits based on the data available.",272.32666015625
2014-05-28 00:00:00+00:00,311.0199890136719,315.4200134277344,308.0400085449219,308.8099975585937,308.8099975585937,1160400.0,3.0,1.0,0.5000249999999999,"( YHOO ), trading down 1.8%, and Biogen Idec ( BIIB ), trading up 1.6% on the day. And the worst performing Nasdaq 100 component thus far on the day is Tesla Motors ( TSLA ), trading down 2.3%. Tesla Motors is showing a gain of 37.4% looking at the year to date performance.",262.48162841796875
2014-05-29 00:00:00+00:00,314.8599853515625,319.94000244140625,314.5400085449219,319.8500061035156,319.8500061035156,1769500.0,3.6666666666666665,1.0,0.6666916666666666,"VIDEO: Nasdaq 100 Movers: GMCR, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Thursday, shares of Biogen Idec ( BIIB ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.7%. And the worst performing Nasdaq 100 component thus far on the day is Keurig Green Mountain ( GMCR ), trading down 1.2%. New Article Array BioPharma ( ARRY ) announced that it has entered into a drug discovery collaboration agreement with Biogen Idec ( BIIB ). Click to get this free report ARRAY BIOPHARMA (ARRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. As per the terms of the agreement, Biogen will be responsible for all aspects of clinical development and commercialization, which includes research funding for three years, various milestone payments and royalties to Array BioPharma. New Article Two other components making moves today are Xylem ( XYL ), trading down 2.4%, and Biogen Idec ( BIIB ), trading up 2.8% on the day. In early trading on Thursday, shares of Tyson Foods ( TSN ) topped the list of the day's best performing components of the S&P 500 index, trading up 5.3%. Year to date, Tyson Foods registers a 28.3% gain.",264.6957092285156
2014-06-05 00:00:00+00:00,320.1700134277344,321.20001220703125,315.82000732421875,320.1300048828125,320.1300048828125,1116900.0,3.0,1.0,0.5000249999999999,"Shares of Gilead Sciences Inc. (NASDAQ: GILD ), Amgen Inc. (NASDAQ: AMGN ), Biogen Idec Inc. (NASDAQ: BIIB ) and Celgene Corporation (NASDAQ: CELG ) increased 0.6%, 1.7%, 0.7% and 2.1%, respectively. Click to get this free report AUTOMATIC DATA (ADP): Free Stock Analysis Report APPLE INC (AAPL): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report DISNEY WALT (DIS): Free Stock Analysis Report MCDONALDS CORP (MCD): Free Stock Analysis Report FORD MOTOR CO (F): Free Stock Analysis Report TWENTY-FST CF-A (FOXA): Free Stock Analysis Report To read this article on Zacks.com click here. Benchmarks erased day's initial losses and ended in the green after investors shrugged off dismal labor market data to focus on an encouraging services sector report.",271.7685241699219
2014-06-09 00:00:00+00:00,320.0,321.4800109863281,316.0799865722656,318.1600036621094,318.1600036621094,775200.0,4.0,1.0,0.7500249999999999,"Biogen ( BIIB ) gained FDA approval for its hemophilia A treatment, Eloctate. Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report OSIRIS THERAPTC (OSIR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Eloctate can be used for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults as well as children with hemophilia A. Hemophilia A, a rare, chronic, genetic disorder under which blood clotting ability is impaired, can lead to recurrent and extended bleeding episodes.",276.4460144042969
2014-06-10 00:00:00+00:00,316.20001220703125,319.8399963378906,312.6099853515625,315.44000244140625,315.44000244140625,1015900.0,3.0,1.0,0.5000249999999999,"With the initiation of this study, Isis Pharma earned a milestone payment of $14 million from Biogen Idec ( BIIB ). Click to get this free report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. The companies intend to initiate phase III studies on ISIS-SMNRx for the treatment of spinal muscular atrophy (SMA) in infants shortly and in children later this year.",274.2540588378906
2014-06-11 00:00:00+00:00,314.0400085449219,314.989990234375,308.0,310.7200012207031,310.7200012207031,909700.0,3.0,1.0,0.5000249999999999,"Another Hemophilia Win for Biogen ( BIIB ): Biogen now has another hemophilia treatment in its portfolio with the FDA approving Eloctate (hemophilia A). Click to get this free report OREXIGEN THERAP (OREX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report HALOZYME THERA (HALO): Free Stock Analysis Report IDENIX PHARMA (IDIX): Free Stock Analysis Report CLOVIS ONCOLOGY (CLVS): Free Stock Analysis Report RECEPTOS INC (RCPT): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from the usual study results, last week's top stories include the lifting of clinical holds for two experimental treatments as well as the granting of fast track and orphan drug status to a couple of candidates.",259.45928955078125
2014-06-17 00:00:00+00:00,306.989990234375,307.4599914550781,302.010009765625,304.7900085449219,304.7900085449219,860400.0,4.0,1.0,0.7500249999999999,"Finally, Isis Pharmaceuticals ( ISIS ) says it has earned a $10 million milestone payment from Biogen Idec ( BIIB ) associated with the validation of an undisclosed target to treat a neurological disorder. In healthcare stocks news, GW Pharmaceuticals ( GWPH ) shares were up 6% pre-market after the company said preliminary data from a trial into its Epidiolex treatment for drug-resistant epilepsy showed positive results. The company released physician reports of efficacy and safety data on 27 children and young adults with treatment-resistant epilepsy who have been treated with GW's investigational cannabidiol ( CBD ) product candidate for a period of 12 weeks. New Article Finally, Isis Pharmaceuticals ( ISIS ) says it has earned a $10 million milestone payment from Biogen Idec ( BIIB ) associated with the validation of an undisclosed target to treat a neurological disorder. In healthcare stocks news, GW Pharmaceuticals ( GWPH ) shares were up 6% pre-market after the company said preliminary data from a trial into its Epidiolex treatment for drug-resistant epilepsy showed positive results. The company released physician reports of efficacy and safety data on 27 children and young adults with treatment-resistant epilepsy who have been treated with GW's investigational cannabidiol ( CBD ) product candidate for a period of 12 weeks.",265.61376953125
2014-06-18 00:00:00+00:00,305.510009765625,310.3599853515625,304.6199951171875,309.8099975585937,309.8099975585937,1068300.0,4.0,1.0,0.7500249999999999,"With oral treatments like Biogen's (BIIB) Tecfidera doing exceptionally well and gaining significant market share, Merck KGaA and Ono Pharma would have needed to conduct large and extensive phase III studies which would have led to a delay in the filing of a new drug application. We remind investors that in Oct 2011, Merck KGaA had licensed exclusive development and commercialization rights to Ono Pharma's ceralifimod outside of Japan, Korea and Taiwan. Last week, the company entered into an agreement with MorphoSys AG for the discovery and development of therapeutic antibodies against undisclosed immune checkpoints. New Article Biogen Idec ( BIIB ) and partner AbbVie ( ABBV ) announced positive top-line results from a phase III trial, DECIDE, on pipeline candidate, daclizumab. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. The global, randomized, double-blind, multicenter study was conducted to evaluate the superiority of daclizumab vis--vis Avonex, as a potential treatment for relapsing-remitting multiple sclerosis.",274.99810791015625
2014-06-24 00:00:00+00:00,313.5899963378906,319.260009765625,312.6600036621094,314.2300109863281,314.2300109863281,1105200.0,3.0,1.0,0.5000249999999999,"Some better-ranked stocks in the biotech sector include Biogen Idec Inc. ( BIIB ), Regeneron Pharmaceuticals, Inc. ( REGN ) and Vical Inc. ( VICL ). Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report XENOPORT INC (XNPT): Free Stock Analysis Report VICAL INC (VICL): Free Stock Analysis Report To read this article on Zacks.com click here. XenoPort, Inc. ( XNPT ) announced that it has commenced a multi-center, randomized, double-blind, placebo-controlled phase II study on its next-generation fumaric acid candidate, XP23829. New Article Below are 5 stocks that have all been upgraded within the last 4 weeks: BIIB Biogen LUV Southwest Airlines NFG National Fuel Gas TOWR Tower International XRS TAL Education Group Get the rest of the stocks on this list and sign up for your free trial of the Research Wizard. Click to get this free report TAL EDUCATN-ADR (XRS): Free Stock Analysis Report TOWER INTL INC (TOWR): Free Stock Analysis Report NATL FUEL GAS (NFG): Free Stock Analysis Report SOUTHWEST AIR (LUV): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Results The tests pretty much confirmed what I had already suspected - but the magnitude was a lot larger than I thought.",284.1946105957031
2014-06-25 00:00:00+00:00,313.0899963378906,318.0,312.5799865722656,314.760009765625,314.760009765625,1051700.0,4.0,1.0,0.7500249999999999,"A better-ranked stock in the biotech sector is Biogen Idec Inc. ( BIIB ), carrying a Zacks Rank #1 (Strong Buy). Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report TG THERAPEUTICS (TGTX): Free Stock Analysis Report To read this article on Zacks.com click here. Additionally, the company will receive $207 million on the achievement of specific milestones and tiered royalties of 6%9.5% on net sales of licensed products. New Article We note that Isis Pharma has partnership agreements with leading pharmaceuticals companies like Biogen Idec ( BIIB ) and Roche ( RHHBY ), among others. Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that Isis Pharma had inked a deal with Glaxo in Mar 2010 for the development of up to six programs.",294.9673156738281
2014-06-26 00:00:00+00:00,315.67999267578125,319.8800048828125,312.8699951171875,318.6300048828125,318.6300048828125,1027500.0,2.333333333333333,1.0,0.3333583333333332,"Better-ranked stocks in the healthcare sector include Regeneron Pharmaceuticals ( REGN ), Allergan ( AGN ) and Biogen Idec ( BIIB ). Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Results from the analysis revealed that treatment nave advanced melanoma patients in the nivolumab arm demonstrated superior overall survival (the primary endpoint) compared to those receiving chemotherapy (dacarbazine). New Article Some better-ranked stocks in the Medical and Biomedical industry include ANI Pharmaceuticals, Inc. ( ANIP ), Biogen Idec Inc. ( BIIB ) and Oncolytics Biotech Inc. ( ONCY ). Click to get this free report PROTHENA CP PLC (PRTA): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ONCOLYTICS BIO (ONCY): Free Stock Analysis Report To read this article on Zacks.com click here. Prothena Corporation plc ( PRTA ) saw a big move last session, as the company's shares fell over 5% on the day. New Article Some better-ranked stocks worth considering include Regeneron Pharmaceuticals, Inc. ( REGN ), Biogen Idec Inc. ( BIIB ) and The Medicines Company ( MDCO ). Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Auxilium Pharmaceuticals, Inc. ( AUXL ) announced that partner, Swedish Orphan Biovitrum AB (Sobi), has filed for an extension of the label for Xiapex in the EU to include the indication of Peyronie's disease.",289.1189880371094
2014-06-27 00:00:00+00:00,318.57000732421875,320.989990234375,315.6700134277344,318.1300048828125,318.1300048828125,969400.0,2.0,1.0,0.250025,"Some better-ranked stocks worth considering include Regeneron Pharmaceuticals, Inc. ( REGN ), Biogen Idec Inc. ( BIIB ) and The Medicines Company ( MDCO ). Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CORONADO BIOSCI (CNDO): Free Stock Analysis Report To read this article on Zacks.com click here. Coronado Biosciences, Inc. ( CNDO ) announced disappointing top-line results from a pilot study on TSO (Trichuris suis ova or CNDO-201).",290.4778137207031
2014-06-30 00:00:00+00:00,317.1600036621094,319.6199951171875,315.010009765625,315.3099975585937,315.3099975585937,938200.0,3.5,1.0,0.6250249999999999,"Other attractive players in the same industry include ANI Pharmaceuticals, Inc. ( ANIP ), Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ), all carrying a Zacks Rank #1 (Strong Buy). Click to get this free report ANI PHARMACEUT (ANIP): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report DISCOVERY LABS (DSCO): Free Stock Analysis Report To read this article on Zacks.com click here. This stock, trading in a volatile price range of $1.66 to $1.87 in the past one-month time frame, showed a pick-up yesterday at $1.79. New Article Some better-ranked stocks in the health care sector include Biogen ( BIIB ) and Regeneron Pharmaceuticals ( REGN ). Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. LY2963016, which has been filed under the European Medicines Agency's (EMA) biosimilar pathway, has the same amino acid sequence as Sanofi's ( SNY ) Lantus (insulin glargine). New Article Investors looking for well-positioned stocks in the health care sector may consider Biogen Idec Inc. ( BIIB ), ANI Pharmaceuticals, Inc. ( ANIP ) and ARIAD Pharmaceuticals, Inc. ( ARIA ). Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. UCB SA ( UCBJF ) announced positive data from two studies on Vimpat as an early adjunctive therapy in adults suffering from partial-onset seizures. New Article Other Stocks to Consider While Integra Lifesciences' Zacks Rank does not call for investor attention, some better-ranked stocks in the similar industry include Actelion Ltd. ( ALIOF ), ANI Pharmaceuticals, Inc. ( ANIP ) and Biogen Idec Inc. ( BIIB ). Click to get this free report INTEGRA LIFESCI (IART): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Over the past several quarters, Integra Lifesciences has been witnessing weak revenues across its U.S. Spine and Others segments owing to continued pricing pressure and challenging market conditions.",284.52838134765625
2014-07-01 00:00:00+00:00,317.0299987792969,326.2300109863281,315.239990234375,324.739990234375,324.739990234375,1179500.0,3.6666666666666665,1.0,0.6666916666666666,"Better-ranked stocks in the healthcare sector include Regeneron Pharmaceuticals ( REGN ), Biogen Idec ( BIIB ) and The Medicines Company ( MDCO ). Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NPS PHARMA INC (NPSP): Free Stock Analysis Report To read this article on Zacks.com click here. Data from the study revealed additional and clinically meaningful reductions in the volume and days/week of parenteral support requirements in patients who continued treatment with the drug beyond two years. New Article Other Stocks to Consider Investors interested in the biomedical sector can consider stocks like Actelion Ltd. ( ALIOF ), ANI Pharmaceuticals, Inc. ( ANIP ) and Biogen Idec Inc. ( BIIB ). Click to get this free report ILLUMINA INC (ILMN): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Consistent with its strategy to expand in the growing non-invasive prenatal testing (NIPT) market in Europe, leading life sciences company Illumina Inc. ( ILMN ) has entered into three separate partnership agreements. New Article Some better-ranked stocks in the biotech sector include Biogen Idec Inc. ( BIIB ), The Medicines Company ( MDCO ) and Regeneron Pharmaceuticals, Inc. ( REGN ). Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SYNAGEVA BIOPHM (GEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Synageva BioPharma Corp. ( GEVA ) announced that sebelipase alfa met the primary endpoint in a randomized, double-blind, placebo-controlled phase III study (Acid Lipase Replacement Investigating Safety and Efficacy  ARISE).",281.87890625
2014-07-02 00:00:00+00:00,325.25,332.7799987792969,324.010009765625,331.0,331.0,1183800.0,3.75,1.0,0.6875249999999999,"Some better-ranked stocks in the health care sector include Actelion Ltd. ( ALIOF ), Biogen Idec Inc. ( BIIB ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. We note that although Kalydeco had not met the primary endpoint of mean absolute change from baseline compared to placebo in a phase III study in CF patients aged 6 years, a pre-specified 24-week long subset analysis in 50 patients aged 18 years showed statistically significant improvements in lung function apart from other key secondary endpoints. New Article Other attractive players in the healthcare industry include ANI Pharmaceuticals, Inc. ( ANIP ), Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ), all carrying a Zacks Rank #1 (Strong Buy). Click to get this free report AMICUS THERAPT (FOLD): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Amicus Therapeutics, Inc. ( FOLD ) was a big mover last session, as the company saw its shares surge nearly 20% on the day. New Article A healthcare stock carrying the same rank as Regeneron is Biogen Idec ( BIIB ). Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Sanofi is looking to buy the additional interest in the market or privately, or by way of derivatives subject to regulatory framework at an agreed-upon price. New Article Amgen presently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the biotech sector include Biogen Idec Inc. ( BIIB ) and Horizon Pharma, Inc. ( HZNP ). Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report To read this article on Zacks.com click here. Amgen 's ( AMGN ) shares were up 1.64% after the company announced that the FDA has granted Breakthrough Therapy Designation to its experimental oncology drug, blinatumomab for the treatment of adults suffering from Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).",275.3390808105469
2014-07-03 00:00:00+00:00,330.79998779296875,332.92999267578125,328.2300109863281,331.1499938964844,331.1499938964844,700600.0,3.0,1.0,0.5000249999999999,"Some better-ranked stocks in the health care sector include Actelion Ltd. ( ALIOF ), Biogen Idec Inc. ( BIIB ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. CureVac is also eligible to receive additional milestone payments up to 150.5 million based on the achievement of certain clinical, regulatory and commercial targets. New Article Some better-ranked stocks in the health care sector include Actelion Ltd. ( ALIOF ), Biogen Idec Inc. ( BIIB ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Jazz Pharma markets defibrotide in Europe under the brand name Defitelio for the treatment of severe hepatic veno-occlusive disease (VOD) in patients over one month of age undergoing hematopoietic stem cell transplantation therapy.",285.86895751953125
2014-07-07 00:00:00+00:00,329.3999938964844,332.9700012207031,324.0,325.67999267578125,325.67999267578125,802300.0,2.6666666666666665,1.0,0.4166916666666666,"Some better-ranked stocks in the same sector include Biogen Idec Inc. ( BIIB ), The Medicines Company ( MDCO ) and Osiris Therapeutics, Inc. ( OSIR ). Click to get this free report BIND THERAPEUTC (BIND): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report OSIRIS THERAPTC (OSIR): Free Stock Analysis Report To read this article on Zacks.com click here. Although this slump was obviously disappointing, the current year earnings consensus has moved higher over the past few weeks for this clinical-stage nanomedicine platform company. New Article Investors looking for well-positioned stocks in the health care sector may consider Biogen Idec Inc. ( BIIB ), ANI Pharmaceuticals, Inc. ( ANIP ) and ARIAD Pharmaceuticals, Inc. ( ARIA ). Click to get this free report ANI PHARMACEUT (ANIP): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report To read this article on Zacks.com click here. UCB SA ( UCBJF ) and Dermira, Inc. announced that they have entered into a licensing agreement for the development and commercialization of Cimzia in dermatology. New Article Other Stocks to Consider However, investors interested in the sector can consider stocks like Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ). Click to get this free report INTEGRA LIFESCI (IART): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Over the past several quarters, Integra has been witnessing weak revenues across its U.S. Spine and Others segment owing to continued pricing pressure and challenging market conditions.",288.1819152832031
2014-07-08 00:00:00+00:00,324.0,324.6000061035156,316.9100036621094,317.5899963378906,317.5899963378906,1235700.0,3.4,1.0,0.600025,"Better-ranked stocks in the healthcare sector include Actelion ( ALIOF ) and Biogen Idec ( BIIB ). Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers Squibb Company ( BMY ) received encouraging news when the Japanese Ministry of Health, Labour and Welfare (MHLW) cleared its combination therapy of Daklinza (daclatasvir) and Sunvepra (asunaprevir) for treating patients suffering from the genotype 1 strain of chronic hepatitis C virus (HCV), including those affected by compensated cirrhosis. New Article Other attractive players in the healthcare industry include Agenus Inc. ( AGEN ), Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ), all carrying a Zacks Rank #1 (Strong Buy). Click to get this free report ONCOLYTICS BIO (ONCY): Free Stock Analysis Report AGENUS INC (AGEN): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Oncolytics Biotech Inc. ( ONCY ) was a big mover last session, as the company saw its shares rise nearly 10% on the day. New Article A better-ranked stock in the health care sector, Biogen Idec Inc. ( BIIB ), holds a Zacks Rank #1 (Strong Buy). Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Sanofi 's ( SNY ) new drug application (NDA) for its basal insulin candidate, Toujeo, has been accepted for review by the FDA. New Article Some better-ranked stocks worth considering include Biogen Idec Inc. ( BIIB ) and The Medicines Company ( MDCO ). Click to get this free report ENDO INTL PLC (ENDP): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BIODELIVERY SCI (BDSI): Free Stock Analysis Report To read this article on Zacks.com click here. The double-blind, randomized, withdrawal phase III study evaluated the efficacy and safety of BEMA buprenorphine in opioid-experienced patients suffering from chronic lower back pain. New Article 102 of 197 tracked.Gilead Sciences ( GILD ) is the biggest in the group, followed byAmgen ( AMGN ),Biogen Idec ( BIIB ),Celgene (CELG) and then Alexion. Earlier this year, Alexion started a rolling submission process with the Food and Drug Administration for approval to treat hypophosphatasia ( HPP ), a rare genetic disease that affects bone formation. In its severe form, which appears in about one out of 100,000 births, it can kill children very quickly, and even the survivors can suffer problems such as deformed limbs, rickets and difficulty breathing due to malformed chests.",284.12921142578125
2014-07-09 00:00:00+00:00,322.6199951171875,322.8699951171875,313.6099853515625,320.1400146484375,320.1400146484375,1027100.0,3.0,1.0,0.5000249999999999,"Some better-ranked stocks in the biomedical industry include Actelion Ltd. ( ALIOF ), Biogen Idec Inc. ( BIIB ) and Curis, Inc. ( CRIS ). Click to get this free report CHINA BIOLOGIC (CBPO): Get Free Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CURIS INC (CRIS): Free Stock Analysis Report To read this article on Zacks.com click here. China Biologic Products, Inc. ( CBPO ) was a big mover last session, as the company saw its shares rise nearly 11% on the day.",283.6668701171875
2014-07-10 00:00:00+00:00,317.1000061035156,321.4100036621094,315.0,319.1199951171875,319.1199951171875,825300.0,2.75,1.0,0.437525,"However, some better-ranked stocks that are outperforming in the Biomedical sector are Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ), both with a Zacks Rank #1 (Strong Buy). Click to get this free report MYRIAD GENETICS (MYGN): Free Stock Analysis Report TESARO INC (TSRO): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. While we are impressed with the company's strong fundamentals, as once again reflected in the last reported quarter's financial performance, we believe emerging competitors and pricing pressure amid a challenging macroeconomic scenario might plague the stock in the future. New Article Some better-ranked stocks worth considering include Actelion Ltd. ( ALIOF ), Synergy Pharmaceuticals, Inc. ( SGYP ) and Biogen Idec Inc. ( BIIB ). Click to get this free report REGADO BIOSCI (RGDO): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SYNERGY PHARMAC (SGYP): Free Stock Analysis Report To read this article on Zacks.com click here. Regado Biosciences, Inc. ( RGDO ) announced that the FDA has placed a clinical hold on patient enrollment and dosing in the ongoing phase III REGULATE-PCI study. New Article Investors interested in the biomedical industry may also consider stocks like Actelion Ltd. ( ALIOF ), Biogen Idec Inc. ( BIIB ) and Osiris Therapeutics, Inc. ( OSIR ). Click to get this free report LEXICON PHARMA (LXRX): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report OSIRIS THERAPTC (OSIR): Free Stock Analysis Report To read this article on Zacks.com click here. Lexicon Pharmaceuticals, Inc. ( LXRX ) was a big mover last session with its shares rising nearly 8% on the day. New Article Better-ranked stocks in the health care sector include Actelion ( ALIOF ), Biogen Idec ( BIIB ) and The MedicinesCompany ( MDCO ). Click to get this free report MEDICINES CO (MDCO): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Celgene Corporation 's ( CELG ) marketed drug, Otezla, performed disappointingly in a phase III study (POSTURE) in the ankylosing spondylitis indication.",281.8514709472656
2014-07-11 00:00:00+00:00,320.0,323.44000244140625,316.0400085449219,322.2200012207031,322.2200012207031,946900.0,2.333333333333333,1.0,0.3333583333333332,"A better-ranked stock in the biotech sector is Biogen Idec Inc. ( BIIB ), carrying a Zacks Rank #1 (Strong Buy). Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ONCOLYTICS BIO (ONCY): Free Stock Analysis Report To read this article on Zacks.com click here. Oncolytics Biotech Inc. 's ( ONCY ) shares gained 2.7% following the company's announcement that it has finished enrolling patients in an open-label, multi-institution, two-arm randomized phase II study (OSU-10045) on its oncology candidate, Reolysin. New Article ( BIIB ) and Curis, Inc . Click to get this free report KAMADA LTD (KMDA): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CURIS INC (CRIS): Free Stock Analysis Report To read this article on Zacks.com click here. Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. New Article Some better-ranked stocks in the Med-Biomed/Gene industry include Actelion Ltd. ( ALIOF ), Biogen Idec Inc. ( BIIB ) and Curis, Inc. ( CRIS ). Click to get this free report SAREPTA THERAP (SRPT): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CURIS INC (CRIS): Free Stock Analysis Report To read this article on Zacks.com click here. This slump shouldn't be too much of a surprise to investors, as though the biopharmaceutical company has seen no negative revision in the past few weeks, its current year loss consensus has widened over the last 30 days.",284.16943359375
2014-07-14 00:00:00+00:00,325.1199951171875,325.1199951171875,319.0599975585937,319.75,319.75,876500.0,3.0,1.0,0.5000249999999999,"Better-ranked stocks in the healthcare sector include The Medicines Company ( MDCO ), Biogen Idec ( BIIB ) and Celgene Corporation ( CELG ). Click to get this free report MEDICINES CO (MDCO): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Controversy surrounding the pricing of Gilead Sciences ' ( GILD ) blockbuster hepatitis C virus (HCV) treatment, Sovaldi, does not seem to end. New Article Some better-ranked stocks in the biotech sector include Biogen Idec Inc. ( BIIB ) and The Medicines Company ( MDCO ). Click to get this free report SUNESIS PHARMA (SNSS): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SEATTLE GENETIC (SGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Updates on the regulatory front are eagerly awaited by investors in the pharma/biotech sector as they impact the share price of the concerned company. New Article Other Stocks to Consider Here are some other companies you may want to consider as our model shows these also have the right combination of elements to post an earnings beat this quarter: Biogen Idec Inc. ( BIIB ) has an earnings ESP of +2.19% and carries a Zacks Rank #1. Click to get this free report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Note that stocks with Zacks Rank #1, 2 and 3 have a significantly higher chance of beating earnings. New Article Some other notable medical stocks that warrant a look are Amsurg Corp. ( AMSG ), BioGen Idec Inc. ( BIIB ) and Curis, Inc. ( CRIS ). Click to get this free report AMSURG CORP (AMSG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CURIS INC (CRIS): Free Stock Analysis Report BRUKER CORP (BRKR): Free Stock Analysis Report To read this article on Zacks.com click here. Massachusetts-based scientific instruments manufacturer Bruker Corporation ( BRKR ) recently launched its first integrated scanning probe microscopy (SPM) infrared system titled Inspire.",282.47039794921875
2014-07-15 00:00:00+00:00,320.760009765625,321.8099975585937,311.9200134277344,312.0,312.0,1391100.0,2.75,1.0,0.437525,"Some better-ranked stocks in the health sector include BioMarin Pharmaceutical Inc. ( BMRN ) and Biogen Idec Inc. ( BIIB ), each carrying a Zacks Rank #1 (Strong Buy). Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PEREGRINE PHARM (PPHM): Free Stock Analysis Report To read this article on Zacks.com click here. The company is conducting a pivotal phase III study, SUNRISE (Stimulating ImmUne RespoNse thRough BavItuximab in a PhaSE III Lung Cancer Study), on bavituximab for second-line NSCLC. New Article Some better-ranked medical stocks that are worth considering are Actelion Ltd. ( ALIOF ), Anthera Pharmaceuticals, Inc. ( ANTH ) and Biogen Idec Inc. ( BIIB ). Click to get this free report EXELIXIS INC (EXEL): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report ANTHERA PHARMA (ANTH): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $3.25 to $3.71 in the past one-month time frame. New Article Some other notable medical stocks that warrant a look are Amsurg Corp. ( AMSG ), BioGen Idec Inc. ( BIIB ) and Curis, Inc. ( CRIS ). Click to get this free report AMSURG CORP (AMSG): Free Stock Analysis Report CVS CAREMARK CP (CVS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CURIS INC (CRIS): Free Stock Analysis Report To read this article on Zacks.com click here. It is thus naturally expected that this deal will boost the prospects of CVS Caremark as a pharmacy innovation company within the fast-growing Hispanic market. New Article Biogen Idec Inc. ( BIIB ) has an Earnings ESP of +2.19% and holds a Zacks Rank #1 (Strong Buy). Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. Abbott Laboratories ( ABT ) is set to report second quarter 2014 results on Jul 16 before market opens.",282.29351806640625
2014-07-16 00:00:00+00:00,313.8299865722656,313.8299865722656,302.54998779296875,303.739990234375,303.739990234375,1803800.0,3.0,1.0,0.5000249999999999,"Some better-ranked stocks in the health care sector include BioMarin Pharmaceutical Inc. ( BMRN ), Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ), each carrying a Zacks Rank #1 (Strong Buy). Click to get this free report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report ARENA PHARMA (ARNA): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Arena Pharma's pipeline includes several other candidates including APD811 (pulmonary arterial hypertension, phase II expected to start shortly), APD334 (autoimmune diseases, ongoing), and temanogreal (thrombotic diseases, phase I completed).",288.7664489746094
2014-07-17 00:00:00+00:00,301.8500061035156,307.989990234375,298.3099975585937,299.2900085449219,299.2900085449219,1651300.0,3.333333333333333,1.0,0.5833583333333334,"( ALIOF ) and BiogenIdec Inc. ( BIIB ), each carrying a Zacks Rank #1 (Strong Buy). Click to get this free report MEDICINES CO (MDCO): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report LANNETT INC (LCI): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of LannettCompany ( LCI ) plummeted 17.09% on the news that the Connecticut Attorney General has issued a subpoena related to the pricing of its generic version of the cardiovascular drug Lanoxin (digoxin). New Article Some better-ranked stocks in the health care sector include BioMarin Pharmaceutical Inc. ( BMRN ) and Biogen Idec Inc. ( BIIB ), each carrying a Zacks Rank #1 (Strong Buy). Click to get this free report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Repros Therapeutics Inc. ( RPRX ) announced that it has received additional guidance from the FDA related to its secondary hypogonadism candidate, Androxal. New Article Some other notable medical stocks that warrant a look include Amsurg Corp. ( AMSG ), BioGen Idec Inc. ( BIIB ) and Curis, Inc. ( CRIS ). Click to get this free report AMSURG CORP (AMSG): Free Stock Analysis Report CVS CAREMARK CP (CVS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CURIS INC (CRIS): Free Stock Analysis Report To read this article on Zacks.com click here. Per the terms of the collaborations, CVS Caremark will offer critical prescription and visit information to these healthcare providers through the secured electronic medical record (EMR) systems, by which they will remain interconnected.",287.7818908691406
2014-07-21 00:00:00+00:00,303.0400085449219,304.239990234375,300.3999938964844,302.5,302.5,1027800.0,3.6,1.0,0.6500250000000001,"Alkermes believes that ALKS 8700 offers differentiated dosing and tolerability compared to Biogen Idec 's ( BIIB ) MS drug Tecfidera. Click to get this free report ALKERMES INC (ALKS): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. In line with efforts to develop its pipeline, last week Alkermes announced the commencement of a phase I study (n~125) on ALKS 8700, a monomethyl fumarate molecule, for treating MS patients. New Article Some better-ranked stocks in the same industry include Alexion Pharmaceuticals, Inc. ( ALXN ), Biogen Idec Inc. ( BIIB ) and BioMarin Pharmaceutical Inc. ( BMRN ), all with a Zacks Rank #1 (Strong Buy). Click to get this free report BLUEBIRD BIO (BLUE): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report To read this article on Zacks.com click here. bluebird bio, Inc. ( BLUE ) was a big mover last session, as the company saw its shares surge over 10% on the day. New Article Some better-ranked stocks in the biotech sector include Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ). Click to get this free report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. New Article Much of the credit goes toBiogen 's ( BIIB ) blockbuster oral MS drug Tecfidera, which was approved last year. Biogen Idec heads into its second-quarter earnings report on one of its best rolls in years, as the biotech continues to benefit from heavy demand for its drugs to treat multiple sclerosis, cancer and autoimmune diseases. In June, Biogen said the Food and Drug Administration approved Eloctate for the control and prevention of bleeding episodes, surgical management and routine prophylaxis in adults and children with hemophilia A. New Article Investors interested in the biomedical industry may consider better-ranked stocks like Curis, Inc. ( CRIS ), Biogen Idec Inc. ( BIIB ) and Actelion Ltd. ( ALIOF ). Click to get this free report ULTRAGENYX PHAR (RARE): Free Stock Analysis Report CURIS INC (CRIS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report To read this article on Zacks.com click here. Ultragenyx Pharmaceutical Inc. ( RARE ) was a big mover last session with its shares rising nearly 8% on the day.",291.0812683105469
2014-07-22 00:00:00+00:00,305.17999267578125,308.67999267578125,302.94000244140625,303.6700134277344,303.6700134277344,1200100.0,2.5,1.0,0.375025,"Biogen Idec Inc. ( BIIB ) is reporting for the quarter ending June 30, 2014. BIIB missed the consensus earnings per share in the 1st calendar quarter of 2014 by -5.04%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for BIIB is 25.88 vs. an industry ratio of 3.60, implying that they will have a higher earnings growth than their competitors in the same industry. New Article Biogen Idec Inc. ( BIIB ) is scheduled to report its second-quarter 2014 results before the opening bell on Jul 23. Click to get this free report HOSPIRA INC (HSP): Free Stock Analysis Report ENDO INTL PLC (ENDP): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Factors at Play Biogen holds a strong position in the multiple sclerosis (MS) market.",291.732666015625
2014-07-23 00:00:00+00:00,335.0,343.5899963378906,331.0,337.6000061035156,337.6000061035156,4143000.0,3.7777777777777777,1.0,0.6944694444444444,"Biogen Idec Inc. ( BIIB ) is among the leading biotechnology companies. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report AMSURG CORP (AMSG): Free Stock Analysis Report ACADIA HEALTHCR (ACHC): Free Stock Analysis Report To read this article on Zacks.com click here. To expand coverage, President Obama introduced drastic health care reforms, which aimed at bringing down the country's uninsured rate. New Article Although futures were higher into the open with better-than-expected earnings from AAPL, Biogen Idec ( BIIB ) and Pepsi ( PEP ), equities began to unwind early gains on reports of two Ukrainian fighter jets shot down by Russian separatists, less than a week after the downing of a Malaysia Airlines jet. (+) BIIB (+10.96%) Receives European approval for Plegridy Multiple Sclerosis drug, Stocks are mixed at midday with strength in Apple ( AAPL ) and biotechs lifting the tech-heavy Nasdaq Composite index, while the Dow Jones Industrial Average continues to be plagued by geo-political developments as well as losses for component companies Boeing ( BA ) and McDonalds ( MCD ). New Article Two other components making moves today are Juniper Networks ( JNPR ), trading down 10.9%, and Biogen Idec ( BIIB ), trading up 11.7% on the day. In early trading on Wednesday, shares of Intuitive Surgical ( ISRG ) topped the list of the day's best performing components of the S&P 500 index, trading up 13.0%. Year to date, Intuitive Surgical registers a 15.3% gain. New Article Some better-ranked stocks in the health care sector are Salix Pharmaceuticals Ltd. ( SLXP ), The Medicines Company ( MDCO ) and Biogen Idec Inc. ( BIIB ). Click to get this free report AVANIR PHARM (AVNR): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SALIX PHARM-LTD (SLXP): Free Stock Analysis Report To read this article on Zacks.com click here. Earlier this week, Avanir Pharmaceuticals, Inc. ( AVNR ) announced that its investigational new drug (IND) application for AVP-786 for a phase II study for the adjunctive treatment of major depressive disorder (MDD) has been accepted by the FDA. New Article Biogen Idec (NASDAQ: BIIB ) shares were also up, gaining 12.08 percent to $340.34 after the company reported upbeat Q2 results and lifted its FY14 forecast. Top Headline PepsiCo (NYSE: PEP ) reported better-than-expected second-quarter results and raised its full-year earnings outlook. Equities Trading UP Puma Biotechnology (NYSE: PBYI ) shares shot up 284.96 percent to $227.24 after the company released positive top line results from its Phase 3 PB272 trial in initial treatment for breast cancer. New Article But the S&P 500 and the Nasdaq Composite indices extended their advance after better-than-expected financial performance by Apple ( AAPL ) and Biogen Idec ( BIIB ) among other firms reporting results last night and today. Stocks ended mixed Wednesday with blue-chips struggling throughout much of today's session following weak quarterly results for a pair of component companies on the Dow Jones Industrial Average. It was a light day for economic data, with the Mortgage Banker's Association today reporting a surprise 0.3% rise in single-family homes under contract, returning to positive ground following an 8.0% decline last week. New Article Biogen Idec ( BIIB ) reported second quarter 2014 earnings per share of $3.48 (including the impact of stock-based compensation expense), way above the Zacks Consensus Estimate of $2.80 and the year-ago earnings of $2.29 per share. Click to get this free report MEDICINES CO (MDCO): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. While oral multiple sclerosis (MS) drug, Tecfidera, contributed significantly to revenues, the company also benefited from the approval of an agreement with the Italian National Medicines Agency (AIFA) relating to Tysabri sales in Italy from Feb 2013 through Mar 2014. New Article Biogen Idec (NASDAQ: BIIB ) shares were also up, gaining 11.53 percent to $338.68 after the company reported upbeat Q2 results and lifted its FY14 forecast. Equities Trading UP Puma Biotechnology (NYSE: PBYI ) shares shot up 287.57 percent to $228.78 after the company released positive top line results from its Phase 3 PB272 trial in initial treatment for breast cancer. CONMED (NASDAQ: CNMD ) shares tumbled 12.27 percent to $37.48 after the company reported that its board has ended the review of strategic alternatives. New Article Biogen Idec (NASDAQ: BIIB ) shares were also up, gaining 11.15 percent to $337.57 after the company reported upbeat Q2 results and lifted its FY14 forecast. Top Headline PepsiCo (NYSE: PEP ) reported better-than-expected second-quarter results and raised its full-year earnings outlook. Equities Trading UP Puma Biotechnology (NYSE: PBYI ) shares shot up 288.73 percent to $229.48 after the company released positive top line results from its Phase 3 PB272 trial in initial treatment for breast cancer.",286.803955078125
2014-07-24 00:00:00+00:00,337.6000061035156,339.8299865722656,335.2200012207031,336.7900085449219,336.7900085449219,1599900.0,3.4,1.0,0.6000250000000001,"Some better-ranked stocks in the healthcare space include Biogen Idec ( BIIB ) and TheMedicines Company ( MDCO ). Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The biopharmaceutical company's second quarter adjusted earnings (including stock based compensation expenses) of $2.32 per share trumped the Zacks Consensus Estimate of $1.61. New Article Some better-ranked stocks in the health care sector are The Medicines Company ( MDCO ), Salix Pharmaceuticals Ltd. ( SLXP ) and Biogen Idec Inc. ( BIIB ). Click to get this free report MEDICINES CO (MDCO): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SALIX PHARM-LTD (SLXP): Free Stock Analysis Report To read this article on Zacks.com click here. Additionally, Actelion is enrolling patients in a phase III study (IMPACT), on cadazolid, for the treatment of clostridium difficile-associated diarrhea. New Article Some better-ranked stocks in the Biomedical industry that warrant a look include Biogen Idec Inc. ( BIIB ), Curis, Inc. ( CRIS ) and EnzoBiochem Inc. ( ENZ ). Click to get this free report ILLUMINA INC (ILMN): Free Stock Analysis Report ENZO BIOCHEM (ENZ): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CURIS INC (CRIS): Free Stock Analysis Report To read this article on Zacks.com click here. Top-line growth was mainly driven by healthy worldwide demand for consumables, new instruments and NIPT (Non-Invasive PreNatal) testing from the company's sequencing business. New Article Investors looking for well-positioned stocks in the biotech sector may consider Biogen Idec Inc. ( BIIB ), which carries a Zacks Rank #1 (Strong Buy). Click to get this free report VALEANT PHARMA (VRX): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. UCB SA ( UCBJF ) announced positive top-line results from a phase III study (n=768) on epilepsy candidate, brivaracetam. New Article Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Accuray Incorporated ( ARAY ) American River Bankshares ( AMRB ) AU Optronics Corp. ( AUO ) Biogen Idec Inc ( BIIB ) Blue Capital Reinsurance Holdings Ltd ( BCRH ) View the entire Zacks Rank #1 List . Click to get this free report ACCURAY INC (ARAY): Free Stock Analysis Report AMER RIVER BSH (AMRB): Free Stock Analysis Report AU OPTRONCS-ADR (AUO): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BLUE CAP REINSR (BCRH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen Idec Inc. ( BIIB ) reported better-than-expected quarterly earnings and sales results. Click to get this free report APPLE INC (AAPL): Free Stock Analysis Report MICROSOFT CORP (MSFT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report INTUITIVE SURG (ISRG): Free Stock Analysis Report PEPSICO INC (PEP): Free Stock Analysis Report BOEING CO (BA): Free Stock Analysis Report CATERPILLAR INC (CAT): Free Stock Analysis Report EXXON MOBIL CRP (XOM): Free Stock Analysis Report CHEVRON CORP (CVX): Free Stock Analysis Report To read this article on Zacks.com click here. However, analysts took a dim view of Boeing's results and Caterpillar reported weak monthly sales, leading to losses for the blue-chip index. New Article Better-ranked stocks in the healthcare sector include The Medicines Company ( MDCO ) and Biogen Idec ( BIIB ). Click to get this free report ALEXION PHARMA (ALXN): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Alexion Pharmaceuticals ' ( ALXN ) second-quarter 2014 earnings (including stock-based compensation expense) of 99 cents per share were in line with the Zacks Consensus Estimate. New Article Among the largest underlying components of IYH, in trading today Pfizer Inc (Symbol: PFE) is up about 0.1%, AbbVie Inc. (Symbol: ABBV) is off about 0.4%, and Biogen Idec Inc (Symbol: BIIB) is lower by about 0.1%. The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $103.22 per share, with $131.43 as the 52 week high point - that compares with a last trade of $130.26. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Some better-ranked stocks in the biotechnology industry include Biogen Idec Inc. ( BIIB ), Curis, Inc. ( CRIS ) and Enzo Biochem Inc. ( ENZ ). Click to get this free report ARRAY BIOPHARMA (ARRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CURIS INC (CRIS): Free Stock Analysis Report ENZO BIOCHEM (ENZ): Get Free Report To read this article on Zacks.com click here. Array BioPharma, Inc. ( ARRY ) was a big mover last session, as the company saw its shares rise by nearly 11% on the day. New Article Biogen Idec Inc. ( BIIB ) was a big mover last session, as its shares rose over 11% on the day. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CURIS INC (CRIS): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report ENZO BIOCHEM (ENZ): Get Free Report To read this article on Zacks.com click here. This breaks the recent trend for the company, as the stock is now trading above the volatile price range of $299.29 to $331.15 in the past one-month timeframe.",283.5708923339844
2014-07-25 00:00:00+00:00,334.7799987792969,337.5,332.7699890136719,335.45001220703125,335.45001220703125,1068600.0,3.75,1.0,0.6875249999999999,"Better-ranked stocks in the healthcare sector include Salix Pharmaceuticals Ltd. ( SLXP ), Biogen Idec ( BIIB ) and Allergan ( AGN ). Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SALIX PHARM-LTD (SLXP): Free Stock Analysis Report To read this article on Zacks.com click here. Market share gains, geographic expansion and increased duration of therapy drove sales in the reported quarter. New Article Other attractive players in the healthcare industry include Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ) carrying a Zacks Rank #1 (Strong Buy) and Amicus Therapeutics, Inc. ( FOLD ) with a Zacks Rank #2 (Buy). Click to get this free report AGENUS INC (AGEN): Free Stock Analysis Report AMICUS THERAPT (FOLD): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report To read this article on Zacks.com click here. Agenus Inc. ( AGEN ) was a big mover last session, as the company saw its shares shoot up over 11% on the day. New Article Other better-ranked stocks in the broader medical sector include Actelion Ltd. ( ALIOF ), Biogen Idec Inc. ( BIIB ) and Curis, Inc. ( CRIS ). Click to get this free report EXELIXIS INC (EXEL): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CURIS INC (CRIS): Free Stock Analysis Report To read this article on Zacks.com click here. Exelixis, Inc. ( EXEL ) was a big mover last session, as its shares rose over 11% on the day. New Article Some better-ranked stocks in the health care sector include Allergan ( AGN ) and Biogen ( BIIB ). Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie said that adjusted SG&A was 27.1% of sales in the second quarter -- this reflects the company's investment in its growth brands as well as preparations for the potential launch of its hepatitis C virus (HCV) combination therapy.",286.36669921875
2014-07-28 00:00:00+00:00,334.67999267578125,338.3399963378906,332.1000061035156,336.3900146484375,336.3900146484375,995600.0,2.0,1.0,0.250025,"Biotech ETFs seesawed in recent weeks, sliding after grim Fed comments, perking up after blockbuster earnings from big-cap leadersGilead ( GILD ) andBiogen ( BIIB ), and slumping again upon more modest news fromCelgene ( CELG ) andAlexion ( ALXN ). But the boost proved short-lived, with the funds swooning amid Celgene and Alexion's muted earnings news the next day. Industry Comparisons The subsector carries ripe valuations vs. the broader health care sector and U.S. stock market .",287.81634521484375
2014-07-31 00:00:00+00:00,342.7200012207031,342.8599853515625,333.3500061035156,334.3900146484375,334.3900146484375,1168500.0,4.0,1.0,0.7500249999999999,"Biogen Idec Inc. ( BIIB ) is a Biotechnology firm that could be an interesting play for investors. These positive earnings estimate revisions suggest that analysts are becoming more optimistic on BIIB's earnings for the coming quarter and year. Current Quarter Estimates for BIIB Though there have been no estimates revisions in the past 30 days, consensus estimates have increased from $2.84 a share 30 days ago, to $3.53 today, a move of 24.3%.",275.9842224121094
2014-08-11 00:00:00+00:00,327.29998779296875,327.44000244140625,319.07000732421875,320.3399963378906,320.3399963378906,983000.0,3.0,1.0,0.5000249999999999,"AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Idec Inc. ( BIIB ). Zacks Investment Research reports AMGN's forecasted earnings growth in 2014 as 6.96%, compared to an industry average of 13%. The following ETF(s) have AMGN as a top-10 holding: iShares NASDAQ Biotechnology Index Fund ( IBB ) Market Vectors Wide Moat ETF ( MOAT ) PowerShares Dynamic Pharmaceuticals ( PJP ) PowerShares Dynamic Biotech &Genome ( PBE ) Merrill Lynch Biotech HOLDRS ( BBH ). New Article The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Biogen Idec ( BIIB ) is now the #114 analyst pick, moving up by 1 spot. Looking at the stock price movement year to date, Biogen Idec ( BIIB ) is showing a gain of 15.8%. VIDEO: S&P 500 Analyst Moves: BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",269.77301025390625
2014-08-14 00:00:00+00:00,335.04998779296875,338.510009765625,333.6600036621094,337.010009765625,337.010009765625,1319200.0,4.0,1.0,0.7500249999999999,"Specialty Sciences: Segmental revenues came in at $86 million due to royalties received by Perrigo on multiple sclerosis drug Tysabri from Biogen Idec ( BIIB ). Click to get this free report PERRIGO CO PLC (PRGO): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AKORN INC (AKRX): Free Stock Analysis Report To read this article on Zacks.com click here. Perrigo Company 's ( PRGO ) fourth-quarter fiscal 2014 (ended Jun 28, 2014) earnings of $1.74 per share beat the Zacks Consensus Estimate of $1.55.",266.1876220703125
2014-08-19 00:00:00+00:00,344.82000732421875,348.489990234375,343.2900085449219,345.8399963378906,345.8399963378906,815700.0,2.0,1.0,0.250025,"Among the largest underlying components of IYH, in trading today Amgen Inc (Symbol: AMGN) is off about 0.6%, Biogen Idec Inc (Symbol: BIIB) is up about 0.6%, and Celgene Corp. (Symbol: CELG) is up by about 0.5%. The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $103.22 per share, with $131.75 as the 52 week high point - that compares with a last trade of $131.37. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",265.6763916015625
2014-08-20 00:00:00+00:00,343.67999267578125,345.4599914550781,340.6700134277344,342.5799865722656,342.5799865722656,700100.0,3.0,1.0,0.5000249999999999,"Top holdings of the fund include Biogen Idec Inc (BIIB), UnitedHealth Group Inc (UNH) and Forest Laboratories Inc. Mid-Cap Growth Fund Rydex Series Trust Mid-Cap Advantage A (RYAHX) seeks to provide 150% of the return of the daily performance of the S&P MidCap 400 Index. Click to get this free report Get Your Free (SHRAX): Fund Analysis Report Get Your Free (RYAHX): Fund Analysis Report Get Your Free (MDGCX): Fund Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report UNITEDHEALTH GP (UNH): Free Stock Analysis Report EQUINIX INC (EQIX): Free Stock Analysis Report UTD RENTALS INC (URI): Free Stock Analysis Report SL GREEN REALTY (SLG): Free Stock Analysis Report PITNEY BOWES IN (PBI): Free Stock Analysis Report To read this article on Zacks.com click here. These funds focus on realizing an appreciable amount of capital growth by investing in stocks of firms whose value is projected to rise over the long term.",276.1750793457031
2014-08-22 00:00:00+00:00,339.8399963378906,341.8999938964844,337.0,339.9700012207031,339.9700012207031,677300.0,4.0,1.0,0.7500249999999999,"The open-label, single-arm study evaluated Revlimid in combination with Roche/Biogen Idec's ( RHHBY / BIIB ) Rituxan (rituximab) in addition to cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (conventional R-CHOP) as a first-line therapy in patients suffering from diffuse large b-cell lymphoma (DLBCL). Click to get this free report CELGENE CORP (CELG): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Earlier this week Celgene announced that data from a phase II study (n=64) on Revlimid (as a combination therapy) was published in the Journal of Clinical Oncology.",280.6384582519531
2014-09-02 00:00:00+00:00,345.4700012207031,347.7900085449219,340.6000061035156,342.67999267578125,342.67999267578125,715600.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of IBB, in trading today Celgene Corp. (Symbol: CELG) is up about 0.6%, Biogen Idec Inc (Symbol: BIIB) is off about 0.7%, and Alexion Pharmaceuticals Inc. (Symbol: ALXN) is lower by about 0.1%. The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $191.29 per share, with $278.78 as the 52 week high point - that compares with a last trade of $275.83. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",265.6734313964844
2014-09-03 00:00:00+00:00,343.3699951171875,345.8099975585937,342.1700134277344,344.1199951171875,344.1199951171875,735700.0,3.0,1.0,0.5000249999999999,"In June, Biogen Idec and partner AbbVie said their multiple sclerosis drug daclizumab beat Rebif, which is sold by EMD Serono and Pfizer . That's a healthy pile of cash that Biogen Idec could use to repurchase shares, especially if they go on sale, or acquire drugs through licensing or purchasing entire companies. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster.",262.27862548828125
2014-09-10 00:00:00+00:00,325.989990234375,333.0,325.989990234375,332.0799865722656,332.0799865722656,811100.0,3.0,1.0,0.5000249999999999,"Biogen ( BIIB ) was the biggest loser among the big biotechs last week with its shares declining 4.63%. Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report INFINITY PHARMA (INFI): Free Stock Analysis Report NPS PHARMA INC (NPSP): Free Stock Analysis Report KERYX BIOPHARMA (KERX): Free Stock Analysis Report To read this article on Zacks.com click here. Keryx Biopharmaceuticals ( KERX ) was also in the headlines - the company's shares declined despite receiving FDA approval for its oral, ferric iron-based compound. New Article So what: According to the additional abstract released today, RPC1063 was shown to cause a 53% annualized relapse reduction in the highest dosing group, which, as Investors Business Dailypointed out , is right in line with some recently approved multiple sclerosis therapies such as Biogen Idec 's Tecfidera. Now what: We've certainly witnessed steady improvement in MS-based lesion reduction and lower relapses of MS incidence in recent years (in clinical trials) through the development of new oral meds, but the need for more options and better medications is still clearly there. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster.",270.7298278808594
2014-09-12 00:00:00+00:00,327.3099975585937,328.1600036621094,321.1099853515625,323.3900146484375,323.3900146484375,802500.0,4.0,1.0,0.7500249999999999,"Biogen Idec Inc. ( BIIB ) announced encouraging two-year data from the phase III ADVANCE study which evaluated the efficacy, safety and tolerability of Plegridy in patients suffering from relapsing-remitting multiple sclerosis (RRMS). Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. We believe that the positive two-year data from the ADVANCE study will boost both physicians' and patients' confidence in Plegridy. New Article While we are pleased with Sanofi's efforts to develop its MS pipeline, we note that once approved, Lemtrada will be entering a market largely dominated by players like Biogen ( BIIB ). Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Earlier this week, Sanofi 's ( SNY ) subsidiary, Genzyme, announced positive interim data on its multiple sclerosis (MS) candidate, Lemtrada (alemtuzumab), from the second year of an extension study. New Article BIIB data by YCharts Dominating an indication Some of this decade's best biotechnology companies have succeeded by dominating the treatment of one specific indication. Despite a rocky road early on because of an investigation into cases of a rare form of brain disease known as PML, Tysabri has become another big seller, generating sales of $1.5 billion last year. That revenue strength has carried over into 2014 with Biogen reporting sales of Tecfidera reached $700 million in the second quarter, giving it an annualized run rate that suggests it could soon displace Avonex as the company's best seller once it's rolled out in more countries abroad.",274.5697326660156
2014-09-15 00:00:00+00:00,323.3999938964844,323.9700012207031,315.7099914550781,320.1199951171875,320.1199951171875,1062800.0,3.5,1.0,0.6250249999999999,"Biogen Idec Inc. ( BIIB ) and partner AbbVie Inc. ( ABBV ) announced detailed positive results from the phase III study, DECIDE, on their multiple sclerosis (MS) candidate, Zinbryta (daclizumab). Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The global, randomized, double-blind, two- to three-year phase III study assessed whether Zinbryta is superior to Avonex for the treatment of patients suffering from relapsing-remitting multiple sclerosis (RRMS). New Article Some better-ranked stocks in the biotech sector include Gilead Sciences Inc. ( GILD ), Biogen Idec Inc. ( BIIB ) and Amgen Inc. ( AMGN ). Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AMARIN CORP PLC (AMRN): Free Stock Analysis Report To read this article on Zacks.com click here. In Jan 2014, the Division of Metabolism and Endocrinology Products (DEMP) declined to re-instate the ANCHOR SPA agreement, which the Office of Drug Evaluation II upheld in Apr 2014.",292.2623596191406
2014-09-16 00:00:00+00:00,319.4200134277344,328.75,318.69000244140625,326.8800048828125,326.8800048828125,991200.0,4.0,1.0,0.7500249999999999,"Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Ameresco Inc ( AMRC ) Amira Nature Foods Ltd ( ANFI ) AXT Inc ( AXTI ) Biogen Idec Inc ( BIIB ) China Petroleum & Chemical Corp ( SNP ) View the entire Zacks Rank #1 List . Click to get this free report AMERESCO INC-A (AMRC): Free Stock Analysis Report AMIRA NATURE FD (ANFI): Free Stock Analysis Report AXT INC (AXTI): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CHINA PETRO&CHM (SNP): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",289.50347900390625
2014-09-17 00:00:00+00:00,328.4200134277344,330.9800109863281,322.69000244140625,327.5799865722656,327.5799865722656,1088600.0,2.5,1.0,0.375025,"Some better-ranked stocks in the health care sector include Gilead Sciences Inc. ( GILD ), Biogen Idec Inc. ( BIIB ) and Amgen Inc. ( AMGN ). Click to get this free report MERCK & CO INC (MRK): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. New Article Among the largest underlying components of VUG, in trading today Biogen Idec Inc (Symbol: BIIB) is down about 0.2%, United Parcel Service Inc (Symbol: UPS) is up about 1.8%, and eBay Inc. (Symbol: EBAY) is up by about 0.1%. The chart below shows the one year price performance of VUG, versus its 200 day moving average: Looking at the chart above, VUG's low point in its 52 week range is $82.23 per share, with $102.41 as the 52 week high point - that compares with a last trade of $101.26. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",280.6474914550781
2014-09-18 00:00:00+00:00,328.8599853515625,330.29998779296875,325.3599853515625,329.989990234375,329.989990234375,637100.0,3.8,1.0,0.7000249999999999,"Some better-ranked stocks in the health care sector include Gilead Sciences Inc. ( GILD ), Biogen Idec Inc. ( BIIB ) and Amgen Inc. ( AMGN ). Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Sanofi ( SNY ) announced that it has entered into an agreement with privately-held company, MyoKardia, Inc. to discover and develop targeted therapeutics for heritable heart diseases called cardiomyopathies. New Article Other Stocks to Consider However, investors interested in the sector can consider stocks like Illumina Inc. ( ILMN ) and Biogen Idec Inc. ( BIIB ). Click to get this free report INTEGRA LIFESCI (IART): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report COVIDIEN PLC (COV): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. On Jul 3, 2014, we issued an updated research report on Integra LifeSciences Holdings Corporation ( IART ) - a forerunner in regenerative medicine. New Article Some better-ranked stocks in the healthcare sector are Gilead Sciences Inc. ( GILD ), Medivation, Inc. ( MDVN ) and Biogen Idec Inc. ( BIIB ). Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Alnylam Pharmaceuticals, Inc. ( ALNY ) intends to file a clinical trial application (CTA) for ALN-CC5 by year end. New Article Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: Biogen Idec Inc ( BIIB ) CBIZ, Inc. ( CBZ ) Home Loan Servicing Solutions Ltd ( HLSS ) John Bean Technologies Corp ( JBT ) Team Health Holdings LLC ( TMH ) View the entire Zacks Rank #1 List . Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CBIZ INC (CBZ): Free Stock Analysis Report HOME LOAN SERVC (HLSS): Free Stock Analysis Report JOHN BEAN TECH (JBT): Free Stock Analysis Report TEAM HEALTH HLD (TMH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Some better-ranked stocks in the healthcare sector include Biogen Idec Inc. ( BIIB ), Cambrex Corporation. Click to get this free report REPROS THERAPEU (RPRX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Repros Therapeutics Inc. ( RPRX ) saw a big move last session, as the company's shares fell more than 10% on the day.",271.7851257324219
2014-09-19 00:00:00+00:00,329.510009765625,334.82000732421875,327.489990234375,329.239990234375,329.239990234375,1742600.0,3.5,1.0,0.6250249999999999,"In the heathcare version of ""Where the Money Is"", guest Brian Orelli joins regulars Michael Douglass and David Williamson to discuss the state of the healthcare sector. Eli Lilly and AstraZeneca hooked up to develop early stage BACE inhibitor AZD3293, while the New York state attorney general sued Actavis over its plans to pull a version of an already approved Alzheimer's drug, Namenda, off the market. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. New Article Some better-ranked stocks in the biotechnology industry include Biogen Idec Inc. ( BIIB ), Cambrex Corporation. Click to get this free report ARENA PHARMA (ARNA): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report CHINA BIOLOGIC (CBPO): Get Free Report To read this article on Zacks.com click here. Arena Pharmaceuticals, Inc. ( ARNA ) was a big mover last session, as the company saw its shares rise by nearly 10% on the day.",274.17034912109375
2014-09-22 00:00:00+00:00,327.3599853515625,330.3399963378906,325.010009765625,329.760009765625,329.760009765625,1027400.0,4.0,1.0,0.7500249999999999,"Zydelig, for the CLL indication, is approved in combination with Roche/Biogen Idec's ( RHHBY )/( BIIB ) Rituxan for treating patients who have received at least one prior therapy or as a first-line treatment in patients who are unsuitable for chemotherapy due to a genetic mutation. Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The European Commission has approved Gilead Sciences, Inc. 's ( GILD ) Zydelig for the treatment of chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL) - two incurable forms of blood cancer. New Article We note that Isis Pharma has partnership agreements with leading health care companies like Biogen Idec Inc. ( BIIB ) and Genzyme, among others. Click to get this free report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ACHOGEN INC (AKAO): Free Stock Analysis Report To read this article on Zacks.com click here. The milestone payment was earned on the initiation of a phase III study on plazomicin, an aminoglycoside being developed for the treatment of patients suffering from serious multi-drug resistant (MDR), gram-negative bacterial infections.",280.5146484375
2014-09-25 00:00:00+00:00,344.04998779296875,345.6499938964844,333.0599975585937,333.3999938964844,333.3999938964844,1554900.0,3.0,1.0,0.5000249999999999,"Stocks like Gilead Sciences (GILD), Biogen Idec (BIIB) and Amgen (AMGN) have bullish Power Gauge ratings and are strong technically. As recently as yesterday the S&P Select SPDR Health Care ETF (XLV) equaled its 12 month high of 65.31. These are the stocks to buy, with the added bonus that the strength of the Health Care Sector as a whole puts the wind at your back.",290.0592346191406
2014-10-03 00:00:00+00:00,323.3299865722656,331.010009765625,321.6300048828125,327.0899963378906,327.0899963378906,1306500.0,4.0,1.0,0.7500249999999999,Perrigo also receives significant royalties on multiple sclerosis drug Tysabri from Biogen Idec ( BIIB ) following the Elan acquisition. Click to get this free report ABAXIS INC (ABAX): Free Stock Analysis Report HAEMONETICS CP (HAE): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. Perrigo acquired Elan Corporation late last year in a bid to boost its revenue stream and save taxes.,280.793701171875
2014-10-07 00:00:00+00:00,325.0,325.0,315.82000732421875,315.9200134277344,315.9200134277344,1053300.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of XLV, in trading today Amgen Inc (Symbol: AMGN) is off about 0.2%, Bristol-Myers Squibb Co. (Symbol: BMY) is down about 1.8%, and Biogen Idec Inc (Symbol: BIIB) is lower by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $169.9 million dollar inflow -- that's a 1.5% increase week over week in outstanding units (from 174,615,324 to 177,265,324). The chart below shows the one year price performance of XLV, versus its 200 day moving average: Looking at the chart above, XLV's low point in its 52 week range is $49.58 per share, with $65.31 as the 52 week high point - that compares with a last trade of $63.65.",285.4529113769531
2014-10-08 00:00:00+00:00,315.6600036621094,325.7799987792969,312.0,324.5899963378906,324.5899963378906,1271500.0,2.0,1.0,0.250025,"In trading on Wednesday, shares of Biogen Idec Inc (Symbol: BIIB) crossed below their 200 day moving average of $315.01, changing hands as low as $312.00 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $221.07 per share, with $358.89 as the 52 week high point - that compares with a last trade of $313.25. According to the ETF Finder at ETF Channel, BIIB makes up 8.21% of the Biotech ETF (Symbol: BBH) which is trading lower by about 0.2% on the day Wednesday.",280.8694152832031
2014-10-13 00:00:00+00:00,314.7900085449219,315.75,300.989990234375,301.739990234375,301.739990234375,2302500.0,4.0,1.0,0.7500249999999999,"The candidate is being developed in collaboration with Biogen Idec ( BIIB ). Click to get this free report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, increase in the six-minute walk and the upper limb mobility test were superior to previously reported data.",280.7855224609375
2014-10-15 00:00:00+00:00,297.2900085449219,311.20001220703125,295.2699890136719,305.69000244140625,305.69000244140625,2210900.0,3.0,1.0,0.5000249999999999,"If the company wins its interference proceeding against Biogen ( BIIB ) and completes Phase 3 trials, the stock price should skyrocket (or if Biogen attempts an acquisition), but investors were unwilling to place that bet on Wednesday. Great Western Bancorp, a spinoff of National Australia Bank with 162 branches in the Midwest and $9 billion of assets, priced its IPO below the range and ended Wednesday flat. Renaissance Capital's IPO ETF tracks the index, and its top holdings include Alibaba (BABA), Twitter ( TWTR ), Zoetis (ZTS), Workday (WDAY) and Hilton (HLT).",281.16998291015625
2014-10-16 00:00:00+00:00,299.9100036621094,309.0,296.54998779296875,302.739990234375,302.739990234375,1384400.0,3.0,1.0,0.5000249999999999,"In its own words, ""Cardinal Health sustainability initiatives focus on pollution prevention, energy efficiency, waste reduction, and designing products, packaging and services to be environmentally friendly."" Its surgical gloves, for example, are sold in half-fold packaging: The dispenser boxes require at least 15% less cardboard and take up at least 30% less room, and the individual pouches are at least 48% smaller than alternatives. As my colleague George Budwell has pointed out , buyout speculation has sent the shares skyrocketing, but Allergan itself isn't in favor of a combination, as it expects to grow plenty fast on its own.",267.13067626953125
2014-10-17 00:00:00+00:00,305.3599853515625,313.7200012207031,304.75,306.7099914550781,306.7099914550781,1782200.0,2.0,1.0,0.250025,"The company later recovered somewhat as investors appeared to put some weight in the company winning an interference proceeding against Biogen Idec ( BIIB ) over patents and completing Phase 3 trials for its potentially lucrative MS drug. Thanks to a market rally on Friday, the five deals averaged 11% and the week's largest IPO, fiber optic network owner Zayo Group, had a strong 16% debut. The company operates one of the largest fiber optic networks in the US, and the telecom giant has done so by making over 30 acquisitions in its 7-year history, including the $2.2 billion purchase of AboveNet in 2012.",274.0225830078125
2014-10-20 00:00:00+00:00,305.239990234375,321.4800109863281,305.239990234375,311.4100036621094,311.4100036621094,1513800.0,2.0,1.0,0.250025,Biogen Idec Inc. ( BIIB ) is scheduled to report third-quarter 2014 results before the opening bell on Oct 22. Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Factors at Play Biogen holds a strong position in the multiple sclerosis (MS) market. New Article Revenues are expected to benefit from increased collaboration revenues from companies like Biogen Idec ( BIIB ). Click to get this free report TEVA PHARM ADR (TEVA): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report SANGAMO BIOSCI (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. Sangamo Biosciences Inc. ( SGMO ) is set to report its third quarter 2014 results on Oct 22 after the market closes.,275.88714599609375
2014-10-21 00:00:00+00:00,320.9700012207031,326.8999938964844,316.0299987792969,326.7699890136719,326.7699890136719,1851500.0,3.5,1.0,0.6250249999999999,"That makes this time of year particularly perilous, so we asked three of our top analysts to crunch the numbers and tell us which companies they believe will deliver this earning's season's biggest surprises. Todd Campbell: Picking companies that may surprise is a bit of a guessing game, but I think that Biogen has a very good shot at outpacing analysts revenue and profit outlook. Remember, these are just my humble estimates and I could be wrong, but the PREVAIL data and subsequent Food and Drug Administration label expansion would indicate to me the strong potential for future outperformance . New Article Biogen Idec Inc. ( BIIB ) is reporting for the quarter ending September 30, 2014. BIIB missed the consensus earnings per share in the 1st calendar quarter of 2014 by -5.04%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for BIIB is 24.60 vs. an industry ratio of -3.40, implying that they will have a higher earnings growth than their competitors in the same industry.",279.04541015625
2014-10-22 00:00:00+00:00,300.0,314.95001220703125,290.8500061035156,309.07000732421875,309.07000732421875,7067000.0,3.2,1.0,0.550025,"And the worst performing S&P 500 component thus far on the day is Biogen Idec ( BIIB ), trading down 6.6%. VIDEO: S&P 500 Movers: BIIB, BRCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Biogen Idec is showing a gain of 9.2% looking at the year to date performance. New Article And the worst performing Nasdaq 100 component thus far on the day is Biogen Idec ( BIIB ), trading down 7.4%. VIDEO: Nasdaq 100 Movers: BIIB, BRCM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Biogen Idec is showing a gain of 8.2% looking at the year to date performance. New Article Biogen Idec ( BIIB ) reported third quarter 2014 earnings per share of $3.79 (including the impact of stock-based compensation expense), way above the Zacks Consensus Estimate of $3.22 and the year-ago earnings of $2.34 per share. Click to get this free report MEDIVATION INC (MDVN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report HALOZYME THERA (HALO): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. The significantly higher guidance reflects the continued strong performance of Tecfidera and updated expectations. New Article Despite meeting analyst expectations on revenue, and beating on the earnings-per-share side, Biogen Idec traded down more than 10% at one point today after announcing that a patient taking its oral multiple sclerosis drug Tecfidera contracted progressive multifocal leukoencephalopathy, or PML. Six percent of patients taking Tecfidera had lymphocyte counts less than about half of the normal level, so discontinuations because of lymphopenia could cut into revenue, but wouldn't be disastrous. In order to outsmart Wall Street and realize multi-bagger returns, you'll need The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. New Article Source: Biogen and Author's Calculations Now what: Similar concerns were raised for Novartis' last fall when a Gilenya patient was diagnosed with a case of PML. Regardless, Biogen investors will want to watch this situation carefully over the coming quarters to see whether script volume slides, or more PML cases are diagnosed. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster.",273.9816589355469
2014-10-23 00:00:00+00:00,314.0,319.3500061035156,311.0,316.0599975585937,316.0599975585937,2126200.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of IWF, in trading today Visa Inc (Symbol: V) is up about 1.8%, Union Pacific Corp (Symbol: UNP) is up about 3.9%, and Biogen Idec Inc (Symbol: BIIB) is higher by about 1.6%. The chart below shows the one year price performance of IWF, versus its 200 day moving average: Looking at the chart above, IWF's low point in its 52 week range is $80.60 per share, with $93.98 as the 52 week high point - that compares with a last trade of $90.89. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",286.0429992675781
2014-10-24 00:00:00+00:00,315.7200012207031,322.0,315.29998779296875,321.6700134277344,321.6700134277344,1262900.0,2.0,1.0,0.250025,"Despite posting better-than-expected earnings, Biogen Idec's ( BIIB ) shares fell 5.4% immediately after the release of third quarter results. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report PDL BIOPHARMA (PDLI): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report To read this article on Zacks.com click here. The decline in share price reflects concerns regarding the growth prospects of Biogen's oral multiple sclerosis (MS) treatment, Tecfidera.",283.67510986328125
2014-10-27 00:00:00+00:00,321.8900146484375,323.1199951171875,317.0,319.9800109863281,319.9800109863281,1114800.0,3.0,1.0,0.5000249999999999,"Some better-ranked stocks in the health care sector include Biogen ( BIIB ) and Allergan ( AGN ). Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report To read this article on Zacks.com click here. However, the strong performance of these products was offset by lower revenues of Isentress, Gardasil, Singulair, Nasonex, Victrelis, PegIntron, Cozaar/Hyzaar, and Temodar. New Article Gilead Sciences has captured investors' attention this year thanks to wildly impressive sales of its hepatitis C drug Sovaldi, but the company is by no means the only fast-growing big biotech out there. Gilead's bottom line might jump in the coming year thanks to billions of dollars in expected sales for Harvoni, its next-generation hepatitis C drug, but three big-cap biotechs could grow profit even more quickly. The results were impressive, but speculators took shares lower after Biogen reported that an MS patient taking its fast-growing oral drug Tecfidera died after being diagnosed with PML, a rare brain disease. New Article During Biogen's third-quarterearnings conference call the company reported that one patient who took Tecfidera for four years died after being diagnosed with progressive multifocal leukoencephalopathy, or PML, a rare viral disease that damages the material that protects white matter of the brain. Since PML isn't new to doctors treating patients with MS, existing treatment protocols will likely mean the risk to Tecfidera's market share is smaller than some may fear. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. New Article Some other stocks worth considering in the health care sector include AMAG Pharmaceuticals, Inc. ( AMAG ) and Biogen Idec Inc. ( BIIB ). Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Allergan, Inc. ( AGN ) reported third-quarter 2014 earnings of $1.78 per share, above the Zacks Consensus Estimate of $1.76.",266.2151794433594
2014-10-28 00:00:00+00:00,321.2099914550781,321.2200012207031,314.8999938964844,318.0299987792969,318.0299987792969,1642000.0,2.8,1.0,0.4500249999999999,"Some better-ranked stocks in the Med-Biomed/Generic industry include AMAG Pharmaceuticals, Inc. ( AMAG ), Array BioPharma, Inc. ( ARRY ) and Biogen Idec Inc. ( BIIB ). Click to get this free report SAREPTA THERAP (SRPT): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report ARRAY BIOPHARMA (ARRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Sarepta Therapeutics, Inc. ( SRPT ) saw a big move last session, as the company's shares fell by nearly 33% on the day. New Article Biogen ( BIIB ) is a better-ranked stock in the biotech sector with a Zacks Rank #1 (Strong Buy). Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The company has been taking steps to improve Enbrel's performance which includes optimization of the sales force, higher direct-to-consumer (DTC) advertising and increased focus on appropriate access. New Article Other biomedical stocks to consider would be Illumina Inc. ( ILMN ), or Biogen Idec ( BIIB ). Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Research-based biopharmaceutical juggernaut, Gilead Sciences ( GILD ) announced its financial results for fiscal Q3 2014 after the market closed on Tuesday. New Article Some better-ranked stocks in the health care sector include AMAG Pharmaceuticals, Inc. ( AMAG ) and Biogen Idec Inc. ( BIIB ). Click to get this free report SAREPTA THERAP (SRPT): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PROSENA HLDG BV (RNA): Free Stock Analysis Report To read this article on Zacks.com click here. Sarepta Therapeutics, Inc. 's ( SRPT ) shares plunged 32.5% on news that the company will not be submitting its New Drug Application (NDA) for Duchenne muscular dystrophy (DMD) candidate, eteplirsen, by year end. New Article Some better-ranked stocks in the health care sector include Biogen ( BIIB ), Allergan ( AGN ), and AbbVie ( ABBV ). Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Pfizer Inc - Earnings Surprise | FindTheBest Revenues were impacted by the loss of exclusivity of certain products including Detrol LA (in the U.S.), the expiry of the Spiriva collaboration in some countries and the Enbrel agreement.",272.4289855957031
2014-10-29 00:00:00+00:00,317.94000244140625,320.989990234375,312.5599975585937,315.0599975585937,315.0599975585937,1509000.0,3.0,1.0,0.5000249999999999,"Investors looking for well-ranked stocks in the health care sector can consider Biogen Idec Inc. ( BIIB ), Illumina Inc. ( ILMN ) and Medivation, Inc. ( MDVN ). Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Amgen ( AMGN ) shares gained 6.1% immediately after the company held a business review meeting and provided a comprehensive overview of its initiatives geared towards growth objectives, and strategic and capital allocation plans. New Article Some better-ranked stocks in the health care sector include Biogen Idec Inc. ( BIIB ) and Medivation, Inc. ( MDVN ). Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Vertex Pharma is currently seeking approval for Kalydeco in cystic fibrosis patients with at least one copy of the R117H mutation in both the U.S. and EU. New Article Some better-ranked biomedical stocks worth considering are Medivation, Inc. ( MDVN ), Illumina Inc. ( ILMN ) and Biogen Idec Inc. ( BIIB ). Click to get this free report MEDICINES CO (MDCO): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. This breaks the recent trend of the company as the stock is now trading above the past one month's volatile price range of $20.36 to $23.34.",279.6658630371094
2014-10-30 00:00:00+00:00,315.0899963378906,323.7200012207031,313.9100036621094,321.0,321.0,1084400.0,3.0,1.0,0.5000249999999999,"Investors interested in the biomedical industry may also consider stocks like Medivation, Inc. ( MDVN ), Illumina Inc. ( ILMN ) and Biogen Idec Inc. ( BIIB ). Click to get this free report ONCOLYTICS BIO (ONCY): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Oncolytics Biotech Inc. ( ONCY ) was a big mover last session with its shares surging almost 26% on the day. New Article Other top players in the space including Celgene ( CELG ), Biogen Idec ( BIIB ) and Alexion Pharmaceuticals ( ALXN ) have also easily managed to beat our estimates on both earnings and revenues. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MKT VEC-BIOTECH (BBH): ETF Research Reports SPDR-SP BIOTECH (XBI): ETF Research Reports To read this article on Zacks.com click here. GILD Earnings in Focus The company reported solid third-quarter numbers with net income more than tripling to $2.73 billion from $789 million in the year-ago quarter.",279.5818786621094
2014-10-31 00:00:00+00:00,330.0,330.5,318.6600036621094,321.0799865722656,321.0799865722656,1699600.0,3.1666666666666665,1.0,0.5416916666666668,"Investors interested in the biomedical industry may also consider stocks like Medivation, Inc. ( MDVN ), Illumina Inc. ( ILMN ) and Biogen Idec Inc. ( BIIB ). Click to get this free report INCYTE CORP (INCY): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Incyte Corporation ( INCY ) was a big mover last session with its shares rising nearly 11% on the day. New Article A better-ranked stock in the health care sector is Biogen Idec Inc. ( BIIB ) carrying a Zacks Rank #1 (Strong Buy). Click to get this free report INCYTE CORP (INCY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline Update Incyte informed that in August this year, the FDA granted Priority Review designation to its supplemental New Drug Application (sNDA) for Jakafi for the treatment of patients with polycythemia vera who are resistant to or are intolerant of hydroxyurea. New Article Some better-ranked biotechnology stocks include AMAG Pharmaceuticals, Inc. ( AMAG ), Biogen Idec Inc. ( BIIB ) and Dyax Corp. ( DYAX ). Click to get this free report BIND THERAPEUTC (BIND): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report DYAX CORP (DYAX): Free Stock Analysis Report To read this article on Zacks.com click here. This reverses the recent trend of the company, as the stock is now trading above volatile price range of $7.71 to $8.76 in the past one month. New Article Other well-performing stocks in the biomedical/gene industry include AMAG Pharmaceuticals, Inc. ( AMAG ), Biogen Idec Inc. ( BIIB ) and Illumina Inc. ( ILMN ). Click to get this free report ILLUMINA INC (ILMN): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Earnings also grew 60% on a year-over-year basis, driven by strong top-line growth, cost control and margin improvement. New Article Some equally well-ranked stocks in the health care sector include Biogen Idec Inc. ( BIIB ) and Medivation, Inc. ( MDVN ). Click to get this free report AMAG PHARMA INC (AMAG): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The company had met the FDA in Jun 2014 regarding its supplemental New Drug Application (sNDA) for Feraheme, for which it had received a complete response letter in Jan 2014. New Article Ampyra is marketed in ex-U.S. markets under the trade name Fampyra by Biogen Idec ( BIIB ). Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NEWLINK GENETIC (NLNK): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline Update Acorda is working on refiling the new drug application for Plumiaz nasal spray for the treatment of patients with epilepsy who experience cluster seizures.",276.0907897949219
2014-11-03 00:00:00+00:00,320.7799987792969,323.20001220703125,319.6600036621094,321.25,321.25,1196100.0,4.0,1.0,0.7500249999999999,"Some better-ranked stocks in the biotech sector are Biogen Idec Inc. ( BIIB ), Medivation Inc. ( MDVN ) and Gilead Sciences Inc. ( GILD ). Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SEATTLE GENETIC (SGEN): Free Stock Analysis Report To read this article on Zacks.com click here. The company is evaluating Adcetris in the phase III AETHERA study in Hodgkin lymphoma patients who are at risk of relapse of the disease.",282.8882141113281
2014-11-04 00:00:00+00:00,319.8999938964844,323.8800048828125,319.0299987792969,322.0599975585937,322.0599975585937,1130700.0,4.0,1.0,0.7500249999999999,"Some better-ranked stocks in the health care sector include AMAG Pharmaceuticals, Inc. ( AMAG ) and Biogen Idec Inc. ( BIIB ). Click to get this free report MANNKIND CORP (MNKD): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Consensus Estimate for the quarter was earnings of 9 cents per share.",286.9672546386719
2014-11-05 00:00:00+00:00,324.57000732421875,324.8599853515625,318.5,319.54998779296875,319.54998779296875,1016100.0,2.0,1.0,0.250025,"Some other stocks that are worth considering in the health care sector include AMAG Pharmaceuticals, Inc. ( AMAG ) and Biogen Idec Inc. ( BIIB ). Click to get this free report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report EISAI CO LTD (ESALY): Get Free Report To read this article on Zacks.com click here. It plans to initiate a phase III study on JZP-110 for the treatment of excessive daytime sleepiness (EDS) in patients suffering from narcolepsy in the first half of 2015. New Article AVEO is in collaboration with several companies like Biodesix and Biogen ( BIIB ). Click to get this free report HOSPIRA INC (HSP): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report INFINITY PHARMA (INFI): Free Stock Analysis Report To read this article on Zacks.com click here. The company has recorded positive earnings surprises in three of the four trailing quarters with an average beat of 19.23%.",299.5840759277344
2014-11-06 00:00:00+00:00,320.8599853515625,324.29998779296875,320.2699890136719,323.4700012207031,323.4700012207031,1377000.0,3.333333333333333,1.0,0.5833583333333334,"Specialty Sciences: Segmental revenues came in at $91.9 million due to royalties received by Perrigo on multiple sclerosis drug Tysabri from Biogen Idec ( BIIB ). Click to get this free report PERRIGO CO PLC (PRGO): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Perrigo Company 's ( PRGO ) first-quarter fiscal 2015 (ended Sep 27, 2014) earnings of $1.40 per share missed the Zacks Consensus Estimate of $1.45. New Article Some better-ranked biotech stocks include Biogen Idec ( BIIB ), Affymetrix Inc. ( AFFX ) and Cytokinetics ( CYTK ) - all three carry a Zacks Rank #1 (Strong Buy). Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. Vertex Pharma had presented highly-awaited pivotal phase III data from a couple of studies (TRAFFIC and TRANSPORT) evaluating the above combination earlier this year. New Article Some better-ranked stocks in the health care sector include AMAG Pharmaceuticals, Inc. ( AMAG ) and Biogen Idec Inc. ( BIIB ). Click to get this free report AMAG PHARMA INC (AMAG): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Despite the increase in revenues, higher operating expenses led to the wider year-over-year loss.",307.9848327636719
2014-11-07 00:00:00+00:00,324.6600036621094,325.0,319.6199951171875,320.75,320.75,1102800.0,3.8,1.0,0.7000249999999999,"AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Idec Inc. ( BIIB ). Zacks Investment Research reports AMGN's forecasted earnings growth in 2014 as 12.47%, compared to an industry average of 15.3%. The following ETF(s) have AMGN as a top-10 holding: iShares NASDAQ Biotechnology Index Fund ( IBB ) Market Vectors Morningstar Wide Moat ETF ( MOAT ) PowerShares Dynamic Pharmaceuticals ( PJP ) PowerShares Dynamic Biotech &Genome ( PBE ) Merrill Lynch Biotech HOLDRS ( BBH ). New Article Some better-ranked biotech stocks include Biogen ( BIIB ) and Cytokinetics ( CYTK ). Click to get this free report MEDIVATION INC (MDVN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. Medivation expects Xtandi's label expansion in the EU for the pre-chemo population to occur in Jan 2015, which means a $45 million milestone payment will be triggered at that point of time. New Article But in August, the biotech launched its first independent phase 3 trial; it is testing ISIS-APOCIII for patients with familial chylomicronemia syndrome, or FCS, a rare genetic disorder resulting in extremely high triglyceride levels. And there should be at least another $27 million from Biogen Idec when Isis later this year starts the phase 3 CHERISH study on ISIS-SMN in children with spinal muscular atrophy. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. New Article Some better-ranked stocks worth considering in the biomedical industry are Agenus Inc. ( AGEN ), AMAG Pharmaceuticals, Inc. ( AMAG ) and Biogen Idec Inc. ( BIIB ). Click to get this free report KERYX BIOPHARMA (KERX): Free Stock Analysis Report AGENUS INC (AGEN): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Keryx Biopharmaceuticals Inc. ( KERX ) was a big mover last session with its shares rising nearly 12% on the day. New Article PML, or progressive multifocal leukoencephalopathy, is a potentially deadly brain infection caused by a relatively benign virus that can become active in patients with weakened immune systems. Tecfidera causes lymphopenia, or low lymphocytes, the white blood cells responsible for fighting infections, so it's not all that surprising that a patient eventually developed PML. As Kingsley said, most of those initial sales have come from patients who were taking other medications as prophylactic (prophy) therapies because Biogen Idec's drugs offer fewer infusions.",311.82293701171875
2014-11-10 00:00:00+00:00,320.19000244140625,327.8999938964844,319.0,327.8699951171875,327.8699951171875,1220500.0,3.25,1.0,0.5625249999999999,"Some better-ranked biotech stocks include Biogen Idec ( BIIB ), Cytokinetics ( CYTK ) and Alexion Pharmaceuticals, Inc. ( ALXN ). Click to get this free report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report To read this article on Zacks.com click here. Given the FDA's additional requirements, Sarepta now expects to submit a new drug application (NDA) for eteplirsen by mid-2015 instead of year end 2014. New Article Among the largest underlying components of VHT, in trading today Biogen Idec Inc (Symbol: BIIB) is up about 0.6%, Celgene Corp. (Symbol: CELG) is up about 0.7%, and Eli Lilly & Co. (Symbol: LLY) is higher by about 0.6%. The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $95.69 per share, with $124.88 as the 52 week high point - that compares with a last trade of $123.23. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Some better-ranked stocks in the health care space include AMAG Pharmaceuticals, Inc. ( AMAG ) and Biogen Idec Inc. ( BIIB ). Click to get this free report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Repros Therapeutics Inc. ( RPRX ) shot up 56.9% on Nov 7, following a successful meeting with the FDA regarding the expected new drug application (NDA) submission for Androxal. New Article Some better-ranked stocks in the health care sector are Auxilium Pharmaceuticals ( AUXL ), Biogen ( BIIB ) and Cytokinetics ( CYTK ). Click to get this free report INTERCEPT PHARM (ICPT): Free Stock Analysis Report AUXILIUM PHARMA (AUXL): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. ( ICPT ) plunged 30.1% following the publication of additional results from the FLINT trial on its lead candidate, obeticholic acid (OCA) in The Lancet .",318.9422607421875
2014-11-11 00:00:00+00:00,327.7099914550781,330.3699951171875,322.6499938964844,324.5899963378906,324.5899963378906,847500.0,3.6666666666666665,1.0,0.6666916666666666,"Some better-ranked stocks in the health care sector include Biogen ( BIIB ) and Cytokinetics ( CYTK ). Click to get this free report DYNAVAX TECH CP (DVAX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. Positive news flowed in for Dynavax Technologies Corporation ( DVAX ) when the company announced that the independent Data and Safety Monitoring Board (DSMB) completed its first prespecified review of the ongoing phase III trial on experimental hepatitis B vaccine, Heplisav-B, and recommended the continuation of the study without any changes. New Article Some better-ranked stocks worth considering in the biomedical industry are Affymetrix Inc. ( AFFX ), AMAG Pharmaceuticals, Inc. ( AMAG ) and Biogen Idec Inc. ( BIIB ). Click to get this free report OREXIGEN THERAP (OREX): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Orexigen Therapeutics, Inc. ( OREX ) was a big mover last session with its shares surging over 33% on the day. New Article A better-ranked stock in the biotech sector is Biogen Idec Inc. ( BIIB ), carrying a Zacks Rank #1 (Strong Buy). Click to get this free report AEGERION PHARMA (AEGR): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Aegerion Pharmaceuticals, Inc.'s ( AEGR ) shares gained 8.2% immediately on news that the company has signed an agreement with AstraZeneca ( AZN ) to acquire the latter's Myalept (metreleptin for injection).",333.25775146484375
2014-11-13 00:00:00+00:00,322.25,322.25,314.3299865722656,317.9800109863281,317.9800109863281,1126200.0,2.0,1.0,0.250025,"In trading on Thursday, shares of Biogen Idec Inc (Symbol: BIIB) crossed below their 200 day moving average of $318.37, changing hands as low as $314.33 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $231.00 per share, with $358.89 as the 52 week high point - that compares with a last trade of $317.98. According to the ETF Finder at ETF Channel, BIIB makes up 7.49% of the Biotech ETF (Symbol: BBH) which is trading lower by about 0.8% on the day Thursday.",335.4124450683594
2014-11-14 00:00:00+00:00,317.9599914550781,318.0199890136719,300.3500061035156,305.42999267578125,305.42999267578125,2557300.0,4.25,1.0,0.8125249999999999,"These include AMAG Pharmaceuticals ( AMAG ), ANI Pharmaceuticals ( ANIP ) and Biogen Idec ( BIIB ). Click to get this free report AFFYMETRIX INC (AFFX): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Positive estimate revisions owing to impressive third quarter results and a raised guidance primarily drove the upside. New Article Besides AstraZeneca, Isis Pharma has partnership agreements with other leading health care companies like Biogen Idec Inc. ( BIIB ) and Sanofi ( SNY ). Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The companies aim to develop new delivery methods, which will not only enhance the access of antisense oligonucleotides into specific organs and cells but will also target the tissue more effectively. New Article The largest fund, the iShares Nasdaq Biotechnology Fund (IBB) holds a total of 126 companies led by Amgen (AMGN), Celgene (CELG), Regeneron (REGN), Gilead (GILD) and Biogen Idec (BIIB) while the more focused First Trust NYSE ARCA Biotech Index Fund (FBT) has 30 holdings led by Incyte (INCY), Isis (ISIS), Biomarin (BMRN), Alkermes (ALKS) and Pharmacyclics (PCYC). Truly innovative and transformative advances in any industry or sector are rare, but when they come along, investors must ensure that they stay on the right side of history. Buying Eastman Kodak rather than the upstart Apple (AAPL) with its camera phone thingies probably looked to some like the smart, conservative play back in 2007, but ignoring change can be costly. New Article Some better-ranked biotech stocks include Biogen Idec ( BIIB ) and Affymetrix Inc ( AFFX ). Click to get this free report GERON CORP (GERN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Imetelstat is being evaluated for a variety of hematologic myeloid malignancies such as myelofibrosis (MF), myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML).",316.4649658203125
2014-11-17 00:00:00+00:00,305.0,308.6499938964844,301.8599853515625,302.4200134277344,302.4200134277344,1390200.0,3.0,1.0,0.5000249999999999,"Moreover, Lemtrada, an intravenously administered drug, will be entering the highly crowded MS market which currently has several oral treatments available like Biogen Idec Inc.'s ( BIIB ) Tecfidera and Novartis' ( NVS ) Gilenya. Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Sanofi 's ( SNY ) Lemtrada has finally gained FDA approval for the treatment of patients suffering from relapsing forms of multiple sclerosis (MS). New Article Other well-placed stocks in the health care sector include Biogen Idec ( BIIB ), Impax Laboratories Inc. ( IPXL ) and Mylan, Inc. ( MYL ). Click to get this free report MALLINCKRODT PL (MNK): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. In Mar 2014, the FDA had approved Mallinckrodt's new drug application for Xartemis XR for the management of acute pain severe enough to require opioid treatment. New Article Some better-ranked stocks in the health care sector include AMAG Pharmaceuticals, Inc. ( AMAG ) and Biogen Idec Inc. ( BIIB ). Click to get this free report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Alnylam Pharmaceuticals, Inc. ( ALNY ) presented positive initial results from a phase II study on revusiran at the American Heart Association meeting. New Article Some better-ranked stocks in the health care sector are Biogen Idec Inc. ( BIIB ), AMAG Pharmaceuticals, Inc. ( AMAG ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report KITE PHARMA INC (KITE): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. In Oct 2014, the company intends to submit an investigational new drug application to the FDA by year-end to initiate a phase I/II single-arm multi-center study on its lead candidate, KTE-C19, in patients suffering from diffuse large B cell lymphoma who have failed two or more lines of therapy.",325.03912353515625
2014-11-18 00:00:00+00:00,305.67999267578125,306.9800109863281,303.0199890136719,305.5599975585937,305.5599975585937,1643200.0,3.6666666666666665,1.0,0.6666916666666666,"Another Zacks Rank #1 stock is Biogen Idec ( BIIB ). Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. With the Allergan acquisition, Actavis will be able to strengthen its global presence especially in Canada, Europe and Southeast Asia and other high-value growth markets like China, India, the Middle East and Latin America. New Article Some better-ranked stocks in the health care sector are Biogen Idec Inc. ( BIIB ), AMAG Pharmaceuticals, Inc. ( AMAG ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report KITE PHARMA INC (KITE): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. This designation will also make Kite Pharma eligible for certain financial benefits along with protocol assistance from the EMA during the development phase and direct access to the centralized authorization procedure. New Article Investors interested in the biomedical industry may consider stocks like Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and AMAG Pharmaceuticals, Inc. ( AMAG ). Click to get this free report SUNESIS PHARMA (SNSS): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report To read this article on Zacks.com click here. Sunesis Pharmaceuticals, Inc. ( SNSS ) was a big mover last session with its shares surging over 38% on the day.",317.90814208984375
2014-11-19 00:00:00+00:00,304.6000061035156,305.5,302.1000061035156,303.6099853515625,303.6099853515625,1956800.0,3.0,1.0,0.5000249999999999,"Other well-placed stocks in the health care sector include Biogen Idec ( BIIB ), Impax Laboratories Inc. ( IPXL ) and Mylan, Inc. ( MYL ). Click to get this free report MALLINCKRODT PL (MNK): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MYLAN INC (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Mallinckrodt ( MNK ) reported adjusted earnings of $1.68 per share in the fourth quarter of fiscal 2014, beating the Zacks Consensus Estimate of $1.34.",301.4470520019531
2014-11-20 00:00:00+00:00,300.1000061035156,303.9800109863281,297.8299865722656,299.1000061035156,299.1000061035156,1772400.0,5.0,1.0,1.000025,"Other well-placed stocks in the health care sector include Biogen Idec ( BIIB ) and Impax Laboratories Inc. ( IPXL ). Click to get this free report AGIOS PHARMACT (AGIO): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. AG-120 is being evaluated for treating patients with IDH1-mutant positive advanced hematologic malignancies, including acute myeloid leukemia (AML).",291.04669189453125
2014-11-21 00:00:00+00:00,305.2799987792969,305.2799987792969,301.32000732421875,303.54998779296875,303.54998779296875,1828000.0,3.142857142857143,1.0,0.5357392857142856,"Other better-ranked biomedical stocks include AMAG Pharmaceuticals, Inc. ( AMAG ), ANI Pharmaceuticals, Inc. ( ANIP ) and Biogen Idec Inc. ( BIIB ). Click to get this free report AMAG PHARMA INC (AMAG): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report EPIRUS BIOPHARM (EPRS): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. EPIRUS Biopharmaceuticals, Inc. ( EPRS ) was a big mover last session, as its shares rose nearly 16% on the day. New Article Some better-ranked stocks in the health care sector are AMAG Pharmaceuticals, Inc. ( AMAG ), Biogen Idec Inc. ( BIIB ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report NOVAVAX INC (NVAX): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that in September this year, Novavax initiated the enrollment of 50 pregnant women in a phase II study to evaluate the safety and immunogenicity of the RSV F vaccine. New Article Some better-ranked stocks in the biotech sector are Cytokinetics, Inc. ( CYTK ) and Biogen Idec Inc. ( BIIB ). Click to get this free report EPIZYME INC (EPZM): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report EISAI CO LTD (ESALY): Get Free Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. The open label, multi-center, phase I dose escalation study is evaluating EPZ-6438 (administered twice-daily orally) as a single agent for the treatment of advanced solid tumors and B-cell non-Hodgkin lymphomas (NHL). New Article Investors interested in the biomedical industry may consider stocks like Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and AMAG Pharmaceuticals, Inc. ( AMAG ). Click to get this free report XOMA CORP (XOMA): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report To read this article on Zacks.com click here. This breaks the recent trend of the company as the stock is now trading above the volatile price range of $3.81 to $4.29 since Oct 31. New Article Stocks that currently look attractive in the broad health care sector include Allegan ( AGN ) and Biogen Idec ( BIIB ). Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. The new Tuas facility is equipped with multiple technologies which should facilitate speed, productivity and flexibility in commercial-scale manufacturing of biologics. New Article However, other important drugs that PDL currently receives royalty revenue will be nearing their patent expiration period sooner than later, such as Biogen Idec 's Tysabri. This unpredictability of its business model and the fact that it has no control over the sales success or production of the therapies it's receiving royalty rights from makes PDL BioPharma a very risky high-yield dividend stock, and one that you'd probably be best off avoiding altogether. The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. New Article Other Stocks to Consider Investors interested in this sector can also consider stocks like Biogen Idec Inc. ( BIIB ), Heska Corporation ( HSKA ) and Affymetrix Inc. ( AFFX ). Click to get this free report ILLUMINA INC (ILMN): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report To read this article on Zacks.com click here. Illumina delivered an impressive quarter with both the top and the bottom line surpassing the respective Zacks Consensus Estimate.",282.4866943359375
2014-11-24 00:00:00+00:00,305.6099853515625,308.8399963378906,304.7799987792969,306.739990234375,306.739990234375,1388200.0,3.4,1.0,0.600025,"Immunomedics mentioned that in a compassion-use case study report, it was found that a pemphigus vulgaris patient refractory to multiple agents including Biogen ( BIIB )/Roche's ( RHHBY ) Rituxan was successfully treated with veltuzumab. Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report UCB SA (UCBJF): Get Free Report IMMUNOMEDICS (IMMU): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Immunomedics Inc. ( IMMU ) announced that the FDA has granted orphan drug status to its anti-CD20 antibody, veltuzumab, for the treatment of pemphigus. New Article Among the largest underlying components of SPY, in trading today Boeing Co. (Symbol: BA) is up about 1.4%, ConocoPhillips (Symbol: COP) is off about 0.4%, and Biogen Idec Inc (Symbol: BIIB) is up by about 1%. For a complete list of holdings, visit the SPY Holdings page  The chart below shows the one year price performance of SPY, versus its 200 day moving average: Looking at the chart above, SPY's low point in its 52 week range is $173.71 per share, with $207.8445 as the 52 week high point - that compares with a last trade of $207.26. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Investors interested in the biomedical industry may consider stocks like Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and AMAG Pharmaceuticals, Inc. ( AMAG ). Click to get this free report ENZO BIOCHEM (ENZ): Get Free Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report To read this article on Zacks.com click here. Enzo Biochem Inc. ( ENZ ) was a big mover last session with its shares rising nearly 7% on the day. New Article Investors interested in the biomedical industry may also consider stocks like Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and AMAG Pharmaceuticals, Inc. ( AMAG ). Click to get this free report OCERA THERAPEUT (OCRX): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report To read this article on Zacks.com click here. Ocera Therapeutics, Inc. ( OCRX ) was a big mover last session with its shares rising over 9% on the day. New Article Some better-ranked stocks in the health care space include Allergan ( AGN ) and Biogen Idec Inc. ( BIIB ). Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie's treatment, once approved, will enter the highly lucrative HCV market that is currently dominated by Gilead's ( GILD ) Sovaldi which has raked in multi-billion dollar sales for the company.",288.7896728515625
2014-11-25 00:00:00+00:00,307.0,307.6400146484375,302.45001220703125,305.3999938964844,305.3999938964844,1947200.0,5.0,1.0,1.000025,"Other better-ranked biomedical stocks include AMAG Pharmaceuticals, Inc. ( AMAG ), ANI Pharmaceuticals, Inc. ( ANIP ) and Biogen Idec Inc. ( BIIB ). Click to get this free report AMAG PHARMA INC (AMAG): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CORONADO BIOSCI (CNDO): Free Stock Analysis Report To read this article on Zacks.com click here. Coronado Biosciences, Inc. ( CNDO ) was a big mover last session, as its shares rose nearly 9% on the day. New Article A better-ranked stock in the health care sector is Biogen Idec Inc. ( BIIB ) carrying a Zacks Rank #1 (Strong Buy). Click to get this free report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report PROSENA HLDG BV (RNA): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report To read this article on Zacks.com click here. The deal, which is slated to close in the first quarter of 2015, is expected to be accretive to BioMarin's earnings beginning 2017 assuming drisapersen gains early approvals.",286.14892578125
2014-11-26 00:00:00+00:00,305.0,305.8299865722656,301.3900146484375,304.9200134277344,304.9200134277344,1085800.0,3.5,1.0,0.6250249999999999,"A better-ranked stock in the biotech sector is Biogen Idec Inc. ( BIIB ), carrying a Zacks Rank #1 (Strong Buy). Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report INTRA-CELLULAR (ITCI): Free Stock Analysis Report To read this article on Zacks.com click here. Intra-Cellular Therapies, Inc. ( ITCI ) announced that it has enrolled the first patient in a randomized, double-blind, placebo-controlled phase III study (ITI-007-301) on its lead candidate, ITI-007, for the treatment of schizophrenia. New Article With the initiation of this study, Isis Pharma earned a milestone payment of $27 million from its partner Biogen ( BIIB ). Click to get this free report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. The randomized, double-blind, sham-procedure controlled 15-month second phase III study (CHERISH) will be conducted on approximately 120 non-ambulatory SMA children aged between 2 to 12 years. New Article Some better-ranked stocks in the health care sector include Biogen Idec Inc. ( BIIB ), AMAG Pharmaceuticals, Inc. ( AMAG ) and Amgen Inc. ( AMGN ). Click to get this free report ALEXION PHARMA (ALXN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Alexion Pharmaceuticals, Inc. ( ALXN ) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted Soliris orphan drug designation for the treatment of patients suffering from neuromyelitis optica (NMO), an ultra-rare neurologic disorder. New Article Investors looking for well-positioned stocks in the biomedical sector may consider Affymetrix Inc. ( AFFX ), AMAG Pharmaceuticals, Inc. ( AMAG ) and Biogen Idec Inc. ( BIIB ). Click to get this free report KYTHERA BIOPHRM (KYTH): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Kythera Biopharmaceuticals, Inc. ( KYTH ) was a big mover last session, as the company saw its shares rise roughly 6% on the day.",278.7453918457031
2014-11-28 00:00:00+00:00,307.5799865722656,310.2099914550781,305.9700012207031,307.69000244140625,307.69000244140625,849100.0,3.0,1.0,0.5000249999999999,"Some other players in the healthcare industry include AMAG Pharmaceuticals, Inc. ( AMAG ), Biogen Idec Inc. (BIIB) and Illumina Inc. ( ILMN ), all carrying a Zacks Rank #1 (Strong Buy). Click to get this free report ONCOTHYREON INC (ONTY): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Oncothyreon Inc. ( ONTY ) was a big mover last session, as the company saw its shares rise slightly over 10% on the day.",273.2371520996094
2014-12-01 00:00:00+00:00,306.42999267578125,310.4800109863281,306.1099853515625,308.44000244140625,308.44000244140625,1146100.0,3.0,1.0,0.5000249999999999,"Some better-ranked stocks in the health care sector include Amgen Inc. ( AMGN ) and Biogen Idec Inc. ( BIIB ). Click to get this free report DYNAVAX TECH CP (DVAX): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Dynavax Technologies Corporation ( DVAX ) regained full rights to its pipeline candidate, DV1179, following the expiration of its collaboration agreement with GlaxoSmithKline ( GSK ). New Article Other Stocks to Consider Some better-ranked biotech stocks include Biogen Idec ( BIIB ), Affymetrix Inc. ( AFFX ) and Cytokinetics ( CYTK ) - all three carry a Zacks Rank #1 (Strong Buy). Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Vertex Pharmaceuticals Incorporated ( VRTX ) hit a 52-week high of $120.91 during the trading session on Nov 28 as the FDA action date for the label expansion of its lead product, Kalydeco, draws nearer.",284.0117492675781
2014-12-02 00:00:00+00:00,335.6499938964844,336.6499938964844,323.4100036621094,328.2699890136719,328.2699890136719,6209500.0,3.636363636363635,1.0,0.6591159090909091,"Among the largest underlying components of MTUM, in trading today Micron Technology Inc. (Symbol: MU) is up about 1%, Actavis plc (Symbol: ACT) is down about 0.1%, and Biogen Idec Inc (Symbol: BIIB) is up by about 6.9%. For a complete list of holdings, visit the MTUM Holdings page  The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $56.73 per share, with $69.22 as the 52 week high point - that compares with a last trade of $68.67. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article VIDEO: S&P 500 Movers: NEM, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Tuesday, shares of Biogen ( BIIB ) topped the list of the day's best performing components of the S&P 500 index, trading up 6.9%. And the worst performing S&P 500 component thus far on the day is Newmont Mining ( NEM ), trading down 3.1%. New Article Investors interested in the biomedical industry may consider better-ranked stocks like Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and Illumina Inc. ( ILMN ). Click to get this free report MEDICINOVA INC (MNOV): Get Free Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. This breaks the recent trend of the company as the stock is now trading above the past one month's volatile price range of $2.88 to $3.32. New Article In company news, Biogen Idec ( BIIB ) advanced Tuesday after the biotech conglomerate reported promising early-stage trial results for its prospective Alzheimer's treatment along with plans to move ""very aggressively"" with Phase III testing of the drug. In other sector news, (+) IMNP, (+12.9%) A panel of industry experts, including senior executives from Pfizer ( PFE ), GlaxoSmithKline ( GSK ) and Biogen Idec ( BIIB ), name the company's bertilimumab allergy treatment as one of the top autoimmune/anti-inflammatory projects to watch. In a presentation at an industry conference in Boston, the company said its BIIB037 drug candidate had a significant effect on cognition among patients in the study after 54 weeks of use during Phase I studies, along with reduced amyloid deposits on the brain. New Article Investors interested in the biomedical industry may consider better-ranked stocks like Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and Illumina Inc. ( ILMN ). Click to get this free report INTRA-CELLULAR (ITCI): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. This breaks the recent trend of the company as the stock is now trading above the past one month's volatile price range of $13.96 to $15.24. New Article Component companies Chevron ( CVX ) and Exxon Mobile ( XOM ) were the biggest gainers on the Dow Jones Industrial Average while Biogen Idec ( BIIB ) was atop the S&P 500 after reporting positive early-stage trial results for a prospective Alzheimer's treatment and plans to proceed to Phase III testing. Led by gains in the biotech and energy sectors and by a much greater-than-expected rise in October construction spending, all three of the major market indices were posting constructive gains on Tuesday. Unauthorized reproduction is strictly prohibited. New Article VIDEO: Nasdaq 100 Movers: NXPI, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Tuesday, shares of Biogen ( BIIB ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 6.6%. And the worst performing Nasdaq 100 component thus far on the day is NXP Semiconductors ( NXPI ), trading down 1.6%. New Article A better-ranked stock in the biotech sector is Biogen Idec, Inc. ( BIIB ), carrying a Zacks Rank #1 (Strong Buy). Click to get this free report BAXTER INTL (BAX): Free Stock Analysis Report MOMENTA PHARMA (MNTA): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Momenta Pharmaceuticals, Inc. 's ( MNTA ) oncology candidate, necuparanib, has received fast track designation from the FDA for the first-line treatment of metastatic pancreatic cancer in combination with Abraxane and Gemzar. New Article Some better-ranked stocks in the health care sector include Biogen Idec Inc. ( BIIB ) and Amgen Inc. ( AMGN ). Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PHARMACYCLICS (PCYC): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Pharmacyclics, Inc. ( PCYC ) and partner Janssen Biotech, a Johnson & Johnson ( JNJ ) company, announced that the European Medicines Agency (EMA) has accepted a type II variation application for Imbruvica for the treatment of adult patients with Waldenstrom's macroglobulinemia (WM). New Article Biogen Idec ( BIIB ) lead the healthcare advance after the company announced positive results from its Alzheimer's treatment. (+) AVNR To be acquired by Otsuka Pharmaceutical for $17/per share (+) CODE Cypress Semiconductor ( CY ) to buy Spansion for $1.59 billion in stock (+) TASR and DGLY Extends Monday's gains after White House allocates $75 million for body cameras (-) VNCE Beats earnings estimates, but leaves guidance unchanged (-) MFRM Misses Q3 earnings estimates after Monday's close (-) WMS Announces 10 million share follow-on offering The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Earlier in the year, we have seen Biogen Idec Inc. ( BIIB ) entering into a development and commercialization agreement with Eisai Co., Ltd. ( ESALY ) for a couple of Alzheimer's disease candidates in Eisai's pipeline (read more: Biogen-Eisai Ink Alzheimer's Deal ). Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report EISAI CO LTD (ESALY): Get Free Report To read this article on Zacks.com click here. AstraZeneca ( AZN ) and Eli Lilly and Company ( LLY ) announced the initiation of the phase II/III AMARANTH study on AZD3293 (LY3314814) being developed for the treatment of Alzheimer's disease.",291.9479064941406
2014-12-03 00:00:00+00:00,328.5199890136719,347.739990234375,328.5199890136719,347.3399963378906,347.3399963378906,4668700.0,4.0,1.0,0.7500249999999999,"A better-ranked stock in the health care sector is Biogen Idec Inc ( BIIB ), carrying a Zacks Rank #1 (Strong Buy). Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PUMA BIOTECHNLG (PBYI): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Puma Biotechnology, Inc. ( PBYI ) were down in after-market hours trading following the company's announcement that the New Drug Application (NDA) for its pipeline candidate neratinib (PB272) will be delayed till the first quarter of 2016. New Article Biogen Idec Inc. 's ( BIIB ) shares were up 6.4% immediately after the company reported encouraging interim results from an early-stage study on its anti-amyloid beta antibody, BIIB037. Biogen is evaluating BIIB037 for the treatment of Alzheimer's disease. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. New Article A better-ranked stock in the biotech sector is Biogen Idec, Inc. ( BIIB ) carrying a Zacks Rank #1 (Strong Buy). Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report UTD THERAPEUTIC (UTHR): Free Stock Analysis Report ACTELION LTD (ALIOF): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Actelion Ltd. ( ALIOF ) announced that it has submitted a centralized marketing authorization application to the European Medicines Agency (EMA) for its pulmonary arterial hypertension (PAH) candidate, Uptravi (selexipag). New Article Some other well-placed stocks worth reckoning in the med-biomed/generic industry are Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report AFFYMETRIX INC (AFFX): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Molecular diagnostics provider Myriad Genetics, Inc. ( MYGN ) has unveiled new clinical data revealing that the company's Prolaris test, used to predict prostate cancer aggressiveness, can save $6 billion for the healthcare system over a period of 10 years. New Article Biogen Idec Inc. (BIIB) was a big mover last session, as its shares rose over 6% on the day. Click to get this free report ILLUMINA INC (ILMN): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. This breaks the recent trend for the company, as the stock is now trading above the volatile price range of $299.1 to $328.27 in the past one-month time frame. New Article On Tuesday, shares of Biogen Idec Inc. ( BIIB ) jumped 6.4% after revealing its plan to start phase III trial of its drug, BIIB 037, which has been developed to treat Alzheimer patients. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report CHEVRON CORP (CVX): Free Stock Analysis Report EXXON MOBIL CRP (XOM): Free Stock Analysis Report EOG RES INC (EOG): Free Stock Analysis Report MARATHON OIL CP (MRO): Free Stock Analysis Report AVANIR PHARM (AVNR): Free Stock Analysis Report CYPRESS SEMICON (CY): Free Stock Analysis Report SPANSION INC (CODE): Free Stock Analysis Report GENERAL MOTORS (GM): Free Stock Analysis Report TOYOTA MOTOR CP (TM): Free Stock Analysis Report HONDA MOTOR (HMC): Free Stock Analysis Report FORD MOTOR CO (F): Free Stock Analysis Report To read this article on Zacks.com click here. For a look at the issues currently facing the markets, make sure to read today's Ahead of Wall Street article The Dow Jones Industrial Average (DJI) rose 0.6% to close at 17,879.55. New Article Some other stocks that are worth considering in the health care sector include Valeant Pharmaceuticals International, Inc. ( VRX ), Affymetrix Inc. ( AFFX ) and Biogen Idec Inc. ( BIIB ). Click to get this free report AFFYMETRIX INC (AFFX): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report To read this article on Zacks.com click here. The request was based on the company's work with the regulatory body due to Jazz Pharma's limited knowledge about the use of Xyrem in children or adolescents.",296.60113525390625
2014-12-04 00:00:00+00:00,345.8800048828125,350.8900146484375,337.5400085449219,341.17999267578125,341.17999267578125,2533600.0,3.1666666666666665,1.0,0.5416916666666668,"Without getting too technical, Isis relies heavily on its roughly one dozen collaborative partners to supply milestone revenue and development/marketing expertise, so having AstraZeneca in its corner is a good thing. Lastly, in late November Isis announced the initiation and dosing of the first patient with ISIS-SMNrx in its phase 3 CHERISH trial for 120 non-ambulatory children with spinal muscular atrophy. Because the company is beginning to see more of its trials move into the late-stages of their development, it's quite possible its costs will rise in the coming years, which may negatively affect its bottom line and expand its losses. New Article Other well-placed stocks in the same industry include Affymetrix Inc. ( AFFX ), ANI Pharmaceuticals, Inc. ( ANIP ) and Biogen Idec Inc. ( BIIB ). Click to get this free report SEQUENOM INC (SQNM): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. This reverses the recent trend of the company, as the stock is now trading above the volatile price range of $2.78 to $3.31 in the past one-month time frame. New Article Some equally well-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. ( ANIP ), Biogen Idec Inc. ( BIIB ) and Illumina Inc. ( ILMN ). Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Amgen Inc. 's ( AMGN ) Blincyto (blinatumomab) gained FDA approval for the treatment of patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). New Article Some better-ranked stocks in the health care sector include Amgen Inc. ( AMGN ), ANI Pharmaceuticals, Inc. ( ANIP ) and Biogen Idec Inc. ( BIIB ). Click to get this free report ADMA BIOLOGICS (ADMA): Get Free Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. RI-002, which is a specialty plasma-derived, polyclonal, intravenous immune globulin (IGIV), met the primary endpoint of the phase III study - prevention of serious bacterial infections (SBI) in immune-compromised PIDD patients. New Article Some better-ranked stocks in the biotech sector are Biogen Idec Inc. ( BIIB ), Amgen Inc. ( AMGN ) and Cytokinetics, Inc. ( CYTK ). Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report SYNAGEVA BIOPHM (GEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Synageva BioPharma Corp. 's ( GEVA ) shares gained 3.6% immediately after the company announced the completion of the rolling submission of a biologics license application (BLA) to the FDA for its lead candidate, sebelipase alfa. New Article Right now, Biogen Idec Inc. ( BIIB ) also looks attractive with a Zacks Rank #1 (Strong Buy). Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ARRAY BIOPHARMA (ARRY): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Array BioPharma Inc. ( ARRY ) shot up in after-market hours trading after the company announced reaching a definitive agreement with Novartis ( NVS ) to regain full worldwide rights to oncology candidate binimetinib, an MEK inhibitor.",294.363037109375
2014-12-05 00:00:00+00:00,341.989990234375,345.92999267578125,339.7099914550781,340.8699951171875,340.8699951171875,1460300.0,3.25,1.0,0.5625249999999999,"A better-ranked stock in the health care sector is Biogen Idec Inc. ( BIIB ) carrying a Zacks Rank #1 (Strong Buy). Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Incyte Corporation 's ( INCY ) Jakafi gained FDA approval for the treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea. New Article Some other well-placed stocks worth reckoning in the medical sector are Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report AFFYMETRIX INC (AFFX): Free Stock Analysis Report WALGREEN CO (WAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. As of Nov 30, 2014, Walgreens operated 8,330 store locations in 50 U.S. states, the District of Columbia, Puerto Rico and the U.S. Virgin Islands, including 8,229 drugstores (up 30 from the year ago level). New Article Other well-placed stocks in the same industry include Affymetrix Inc. ( AFFX ), ANI Pharmaceuticals, Inc. ( ANIP ) and Biogen Idec Inc. ( BIIB ). Click to get this free report ARRAY BIOPHARMA (ARRY): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. This reverses the recent trend of the company, as the stock is now trading above the volatile price range of $3.53 to $4.03 in the past one-month time frame. New Article In June this year, the FDA cleared Biogen Idec's ( BIIB ) hemophilia A treatment, Eloctate (EU trade name: Elocta) for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults as well as children with hemophilia A. Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The HealthCare segment at Bayer ( BAYRY ) announced that the company has submitted Marketing Authorization Application in Europe for BAY 81-8973, a recombinant Factor VIII compound.",295.7475891113281
2014-12-08 00:00:00+00:00,341.95001220703125,347.2799987792969,340.8999938964844,344.04998779296875,344.04998779296875,1395400.0,2.857142857142857,1.0,0.4643107142857143,"Some better-ranked biotech stocks include Cytokinetics, Inc. ( CYTK ) and Biogen Idec Inc. ( BIIB ). Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. The study evaluated Kyprolis plus Celgene's ( CELG ) Revlimid and low-dose dexamethasone in multiple myeloma patients whose disease relapsed after being treated with one to three prior regimens. New Article Other well-placed stocks in the same industry include Affymetrix Inc. ( AFFX ), ANI Pharmaceuticals, Inc. ( ANIP ) and Biogen Idec Inc. ( BIIB ). Click to get this free report KINDRED BIOSCI (KIN): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Kindred Biosciences, Inc. ( KIN ) was a big mover last session, as the company saw its shares rise by nearly 11% on the day. New Article Investors interested in the biomedical industry may also consider stocks like Biogen Idec Inc. ( BIIB ), Affymetrix Inc. ( AFFX ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report COMPUGEN LTD (CGEN): Get Free Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. This breaks the recent trend of the company as the stock is now trading above the past one month's volatile price range of $6.44 to $7.40. New Article Some better-ranked stocks in the biotech sector are Biogen Idec Inc. ( BIIB ) and Amgen Inc. ( AMGN ). Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Based on the data, AbbVie stated its intention to conduct additional studies for evaluating venetoclax in combination with other drugs for the treatment of AML. New Article Some better-ranked stocks in the biotech sector are Biogen Idec Inc. ( BIIB ) and Amgen Inc. ( AMGN ). Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report TAKEDA PHARMACT (TKPYY): Get Free Report SEATTLE GENETIC (SGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Seattle Genetics, Inc. ( SGEN ) and Takeda Pharmaceutical Company Limited ( TKPYY ) announced four-year overall survival data from a pivotal phase II study evaluating the efficacy and safety of Adcetris for the treatment of relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). New Article Some better-ranked stocks in the health care sector include Biogen Idec Inc. ( BIIB ) and Amgen Inc. ( AMGN ). Click to get this free report PHARMACYCLICS (PCYC): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Pharmacyclics, Inc. ( PCYC ) announced that it has launched a large, observational, prospective registry, informCLL, which aims to explore the natural history of chronic lymphocytic leukemia (CLL), examine how currently approved targeted therapies including Imbruvica are being used to treat patients with CLL and provide a comparison to treatments using conventional chemoimmunotherapy. New Article Investors interested in the biomedical industry may also consider stocks like Biogen Idec Inc. ( BIIB ), Affymetrix Inc. ( AFFX ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report CARA THERAPEUTC (CARA): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. The move came on solid volume too with far more shares changing hands than in a normal session.",300.6247253417969
2014-12-09 00:00:00+00:00,340.3999938964844,348.0599975585937,337.57000732421875,347.6099853515625,347.6099853515625,1295500.0,3.0,1.0,0.5000249999999999,"A better-ranked stock in the biotech sector is Biogen Idec Inc. ( BIIB ) carrying a Zacks Rank #1 (Strong Buy). Click to get this free report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Results from the study were published in The New England Journal of Medicine and are expected to be presented at the 56th American Society of Hematology meeting. New Article However, some better-ranked stocks in the med-biomed/gene industry include Biogen Idec Inc. ( BIIB ), Affymetrix Inc. ( AFFX ) and NI Pharmaceuticals, Inc. ( ANIP ), all sporting a Zacks Rank #1 (Strong Buy). Click to get this free report ANI PHARMACEUT (ANIP): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $0.66 to $0.71 over the past one-month time frame. New Article Some other players in the healthcare industry include Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and Illumina Inc. ( ILMN ), all carrying a Zacks Rank #1 (Strong Buy) Want the latest recommendations from Zacks Investment Research? Click to get this free report BLUEBIRD BIO (BLUE): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. bluebird bio, Inc. ( BLUE ) was a big mover last session, as the company saw its shares surge over 9% on the day. New Article Some other stocks worth considering include Cytokinetics, Inc. ( CYTK ) and Biogen Idec Inc. ( BIIB ). Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Xgeva is already approved for the prevention of skeletal-related events (SREs) in patients having bone metastases from solid tumors. New Article Meanwhile, the company also announced new data from a phase II study evaluating Imbruvica in combination with Roche/Biogen Idec's ( RHHBY )/( BIIB ) Rituxan (rituximab) in patients with relapsed or refractory MCL. Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PHARMACYCLICS (PCYC): Free Stock Analysis Report To read this article on Zacks.com click here. Pharmacyclics, Inc. ( PCYC ) announced new 27-month median follow-up data on Imbruvica in patients with relapsed/refractory mantle cell lymphoma (MCL). New Article Other well-placed stocks in the same industry include Affymetrix Inc. ( AFFX ), ANI Pharmaceuticals, Inc. ( ANIP ) and Biogen Idec Inc. ( BIIB ). Click to get this free report ACCELERON PHARM (XLRN): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Acceleron Pharma, Inc. ( XLRN ) was a big mover last session, as the company saw its shares rise by around 14% on the day. New Article Some better-ranked stocks in the health care sector include Amgen Inc. ( AMGN ) and Biogen Idec Inc. ( BIIB ). Click to get this free report DYNAVAX TECH CP (DVAX): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Dynavax Technologies Corp. ( DVAX ) announced that the company has amended its existing research and license agreement with AstraZeneca plc ( AZN ).",312.51605224609375
2014-12-10 00:00:00+00:00,346.8500061035156,349.8800048828125,342.6199951171875,343.5899963378906,343.5899963378906,1449200.0,3.2,1.0,0.550025,"( BIIB ) and Amgen Inc . Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Based on the data, AbbVie stated its intention to conduct additional studies for evaluating venetoclax in combination with other drugs for the treatment of AML. New Article Some other stocks that are worth considering in the healthcare sector include Valeant Pharmaceuticals International, Inc. ( VRX ) and Biogen Idec Inc. ( BIIB ). Click to get this free report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CONCERT PHARMA (CNCE): Free Stock Analysis Report To read this article on Zacks.com click here. Xyrem is approved for the treatment of cataplexy and excessive daytime sleepiness in patients suffering from narcolepsy, a serious neurological disorder. New Article That changed Tuesday, when news on its Alzheimer's drug candidate (BIIB037) spiked the stock up over 6% in one day. Source: Biogen Idec As the year begins to come to a close, biotechnology investors are right to wonder what stocks may be worth owning as we head into 2015. With its highly profitable MS portfolio, an exciting pipeline, and Eloctate as an anchor tenant in a possible hemophilia franchise, this stock should do a heck of a lot more than mark time in 2015. New Article Better-ranked biotechnology stocks include Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report AVALANCHE BIOT (AAVL): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Avalanche Biotechnologies, Inc. ( AAVL ) was a big mover last session, as the company saw its shares rise over 6% on the day. New Article Some well-placed stocks worth reckoning in the med-biomed/generic industry are Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report AFFYMETRIX INC (AFFX): Free Stock Analysis Report MYRIAD GENETICS (MYGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. The first one demonstrated the ability of Myriad's myChoice Homologous Recombination Deficiency (HRD) test in predicting more accurately the response to platinum-based therapy in patients who are in the early stage of triple negative breast cancer (TNBC).",306.36480712890625
2014-12-11 00:00:00+00:00,344.8699951171875,351.3800048828125,341.8599853515625,342.3299865722656,342.3299865722656,1471700.0,4.0,1.0,0.7500249999999999,"However, some better-ranked stocks in the med-biomed/gene industry include Biogen Idec Inc. ( BIIB ), Affymetrix Inc. ( AFFX ) and NI Pharmaceuticals, Inc. ( ANIP ), all sporting a Zacks Rank #1 (Strong Buy). Click to get this free report ANI PHARMACEUT (ANIP): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Ophthotech Corporation ( OPHT ) was a big mover last session, as the company saw its shares rise more than 5% on the day. New Article The company receives royalties from companies like Roche ( RHHBY ), Biogen ( BIIB ) and Novartis ( NVS ) among others. Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. PDL BioPharma expects royalties from the Queen et al. licenses to increase 34% from the year-ago period to approximately $132 million. New Article Biogen Idec Inc ( BIIB ) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front. More bullishness may especially be the case when investors consider what has been happening for BIIB on the earnings estimate revision front lately. Recently, the 50 Day Moving Average for BIIB broke out above the 200 Day Simple Moving Average, suggesting a short-term bullish trend. New Article Some other stocks worth reckoning in the med-biomed/generic industry are Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report AFFYMETRIX INC (AFFX): Free Stock Analysis Report GENOMIC HEALTH (GHDX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Genomic Health presented the initial results from these two studies at the 2014 Society of Urologic Oncology (SUO) Annual Meeting and the ongoing 2014 San Antonio Breast Cancer Symposium (SABCS).",309.5325927734375
2014-12-12 00:00:00+00:00,339.2300109863281,349.9800109863281,338.5,344.489990234375,344.489990234375,1559100.0,3.5,1.0,0.6250249999999999,"1: An Alzheimer's breakthrough Perhaps the biggest catalyst in the near term for Biogen Idec is its experimental Alzheimer's disease drug BIIB037. In October, when Biogen Idec reported its third-quarter results, the company confirmed that a patient taking Tecfidera had died from a rare brain infection known as progressive multifocal leukoencephalopathy, or PML. As you might imagine, investors panicked and considered that tougher warnings could be applied to Tecfidera's packaging, or that physicians might hold off on prescribing the drug altogether. New Article Investors interested in the biomedical industry may also consider stocks like Biogen Idec Inc. ( BIIB ), Affymetrix Inc. ( AFFX ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report SANGAMO BIOSCI (SGMO): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Sangamo Biosciences Inc. ( SGMO ) was a big mover last session with shares rising over 7% on the day. New Article Some better-ranked stocks in the same industry include Affymetrix Inc. ( AFFX ), ANI Pharmaceuticals, Inc. ( ANIP ) and Biogen Idec Inc. ( BIIB ). Click to get this free report ALDER BIOPHARMA (ALDR): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Alder Biopharmaceuticals Inc. ( ALDR ) was a big mover last session, as the company saw its shares rise by nearly 32% on the day. New Article Some better-ranked stocks in the same sector include Affymetrix Inc. ( AFFX ), ANI Pharmaceuticals, Inc. ( ANIP ) and Biogen Idec Inc. ( BIIB ). Click to get this free report CELLADON CORP (CLDN): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Celladon Corporation ( CLDN ) saw a big move last session, as the company's shares fell nearly 9% on the day.",310.3255615234375
2014-12-15 00:00:00+00:00,346.5,346.6499938964844,333.1199951171875,335.79998779296875,335.79998779296875,1402800.0,3.6666666666666665,1.0,0.6666916666666666,"Some other stocks that are worth considering in the health care sector include Amgen Inc. ( AMGN ), Affymetrix Inc. ( AFFX ) and Biogen Idec Inc. ( BIIB ). Click to get this free report JAZZ PHARMACEUT (JAZZ): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Investors in the pharma/biotech sector eagerly wait for pipeline updates as they play an important role in deciding whether or not to invest in a particular company. New Article Some better-ranked stocks in the health care sector include Biogen Idec Inc. ( BIIB ), ANI Pharmaceuticals, Inc. ( ANIP ) and Amgen Inc. ( AMGN ). Click to get this free report ALEXION PHARMA (ALXN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Alexion Pharmaceuticals, Inc. ( ALXN ) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted Soliris orphan drug designation for the treatment of patients suffering from myasthenia gravis (MG). New Article Some better-ranked stocks in the Med-Biomed/Generic industry include Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report ALDER BIOPHARMA (ALDR): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Alder Biopharmaceuticals Inc. ( ALDR ) saw a big move last session, as the company's shares fell by about 6% on the day.",302.02874755859375
2014-12-16 00:00:00+00:00,333.3800048828125,339.8299865722656,324.69000244140625,325.1300048828125,325.1300048828125,1834400.0,3.5,1.0,0.6250249999999999,"Some better-ranked stocks in the health care sector include Amgen Inc. ( AMGN ), ANI Pharmaceuticals, Inc. ( ANIP ) and Biogen Idec Inc. ( BIIB ). Click to get this free report ALKERMES INC (ALKS): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. The randomized, open-label study will assess the pharmacokinetics, safety and tolerability of aripiprazole lauroxil when administered over new extended durations - at one month, six-week and two-month intervals. New Article Some better-ranked stocks in the Med-Biomed/Generic industry include Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report BIODELIVERY SCI (BDSI): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. BioDelivery Sciences International, Inc. ( BDSI ) saw a big move last session, as the company's shares fell by about 11% on the day. New Article Some better-ranked stocks in the same sector include Affymetrix Inc. ( AFFX ), ANI Pharmaceuticals, Inc. ( ANIP ) and Biogen Idec Inc. ( BIIB ). Click to get this free report OVASCIENCE (OVAS): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The life sciences company has seen a flat track record when it comes to current year estimate revisions over the past few weeks, and the consensus for earnings hasn't been in a trend either. New Article Other Stocks to Consider Investors interested in the same sector may also consider stocks like Biogen Idec Inc. ( BIIB ), Amgen Inc. ( AMGN ) and Affymetrix Inc. ( AFFX ). Click to get this free report ILLUMINA INC (ILMN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Another major highlight of the quarter was the company's optimistic full-year outlook for both top- and bottom-line growth. New Article Some other companies worth reckoning in the med-biomed/generic industry are Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report AFFYMETRIX INC (AFFX): Free Stock Analysis Report GENOMIC HEALTH (GHDX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Conducted by the research institute Women's Healthcare Study Group (WSG), this clinical trial aimed at assessing the efficiency of an anthracycline-free adjuvant chemotherapy regime. New Article Some other players in the healthcare industry include Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and Illumina Inc. ( ILMN ), all carrying a Zacks Rank #1 (Strong Buy) Want the latest recommendations from Zacks Investment Research? Click to get this free report TREVENA INC (TRVN): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ILLUMINA INC (ILMN): Free Stock Analysis Report To read this article on Zacks.com click here. Trevena, Inc. ( TRVN ) was a big mover last session, as the company saw its shares rise over 7% on the day. New Article Better-ranked stocks in the health care sector include Amgen Inc. ( AMGN ) and Biogen Idec Inc. ( BIIB ). Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report OPKO HEALTH INC (OPK): Free Stock Analysis Report To read this article on Zacks.com click here. OPKO will also receive initial royalty payments related to the commercialization of hGH-CTP for GHD in adults, which depends on regulatory approval. New Article Acorda has a licensing agreement with Biogen ( BIIB ) for Fampyra in markets outside the U.S. Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. The multi-center, double-blind, randomized phase III study will evaluate the safety and tolerability of Ampyra in approximately 540 patients who have experienced an ischemic stroke at least six months before enrollment.",300.1357727050781
2014-12-18 00:00:00+00:00,339.3599853515625,353.70001220703125,337.7099914550781,353.70001220703125,353.70001220703125,2401800.0,3.0,1.0,0.5000249999999999,"Some better-ranked companies worth reckoning in the medical sector instead are Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report BRUKER CORP (BRKR): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Scientific instruments manufacturer, Bruker Corporation ( BRKR ), launched its new biological microscopic technology - BioScope Resolve - at the Sixth AFM BioMed Conference that was held in San Diego, CA from Dec 13-17, 2014.",296.81634521484375
2014-12-19 00:00:00+00:00,343.2799987792969,361.9299926757813,343.0599975585937,360.6700134277344,360.6700134277344,3691300.0,3.75,1.0,0.6875249999999999,"Some better-ranked stocks in the biotech sector are Biogen Idec Inc. ( BIIB ), Cytokinetics, Inc. ( CYTK ) and Amgen Inc. ( AMGN ). Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report SEATTLE GENETIC (SGEN): Free Stock Analysis Report To read this article on Zacks.com click here. Seattle Genetics, Inc. ( SGEN ) announced that it has initiated an open-label, multi-center, dose-escalation phase Ib study on SGN-CD33A for the treatment of patients with newly diagnosed acute myeloid leukemia (AML). New Article Some better-ranked companies worth reckoning in the med-biomed/generic industry instead are Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report INTEGRA LIFESCI (IART): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. The pre-meshed bilayer matrix of this product can be used in the post-excisional treatment of life-threatening full-thickness or deep partial-thickness thermal injuries, as well as in the repair of scar contractures. New Article Some better-ranked stocks in the health care sector include Biogen Idec Inc. ( BIIB ) and Amgen Inc. ( AMGN ). Click to get this free report AGENUS INC (AGEN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Agenus Inc. ( AGEN ) jumped more than 17% after its partner GlaxoSmithKline ( GSK ) announced encouraging results from the pivotal phase III ZOE-50 study on HZ/su. New Article Biogen Idec Biogen Idec's growth throughout the remainder of the decade will be fueled by its lineup of multiple sclerosis drugs, as well as the potential behind experimental Alzheimer's disease drug BIIB037. Experimental Alzheimer's drug BIIB037 could be critical as well. The largest pharmaceutical company in the world, Pfizer , is a fixture in a number of retirement portfolios, and it's a staple holding of income investors looking for exposure to the healthcare sector.",288.1876525878906
2014-12-22 00:00:00+00:00,352.0,356.6499938964844,345.2300109863281,352.2900085449219,352.2900085449219,2170400.0,3.625,1.0,0.6562749999999999,"Among the largest underlying components of XLV, in trading today Biogen Idec Inc (Symbol: BIIB) is down about 3%, Actavis plc (Symbol: ACT) is down about 1%, and Allergan, Inc (Symbol: AGN) is higher by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $211.6 million dollar inflow -- that's a 1.7% increase week over week in outstanding units (from 181,765,324 to 184,765,324). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article A better-ranked biomedical stock is Biogen Idec Inc. ( BIIB ) with a Zacks Rank #1 (Strong Buy). Click to get this free report PROTHENA CP PLC (PRTA): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Prothena Corporation plc ( PRTA ) was a big mover last session, as its shares rose almost 6% on the day. New Article Some better-ranked stocks in the healthcare sector include Amgen Inc. ( AMGN ) and Biogen Idec Inc. ( BIIB ). Click to get this free report OREXIGEN THERAP (OREX): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report TAKEDA PHARMACT (TKPYY): Get Free Report To read this article on Zacks.com click here. The drug was recommended as an adjunct to a reduced-calorie diet and physical activity for chronic weight management in obese (Body Mass Index, or BMI,  30 kg/m2) or overweight (BMI  27 kg/m2) adults suffering from at least one weight-related co-morbid condition including type II diabetes, dyslipidaemia or controlled hypertension. New Article Key Picks from the Sector Some better-ranked companies worth reckoning in the med-biomed/generic industry are Affymetrix Inc. ( AFFX ), Biogen Idec Inc. ( BIIB ) and ANI Pharmaceuticals, Inc. ( ANIP ). Click to get this free report GENOMIC HEALTH (GHDX): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. However, management expects this loss to reduce in 2015 with Genomic Health's improved leverage in international, ductal carcinoma in situ (DCIS) and prostate cancer businesses. New Article A better-ranked stock in the biopharma space is Amgen and Biogen Idec Inc. ( BIIB ), both sporting a Zacks Rank #1 (Strong Buy). Click to get this free report CELGENE CORP (CELG): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Celgene Corporation ( CELG ) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion for continuous oral treatment with Revlimid in treatment nave adults suffering from multiple myeloma who are not eligible for stem cell transplantation. New Article Another biomedical stock worth considering is Biogen Idec Inc. ( BIIB ) with a Zacks Rank #1 (Strong Buy). Click to get this free report PUMA BIOTECHNLG (PBYI): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Puma Biotechnology, Inc. ( PBYI ) was a big mover last session, as its shares rose over 6% on the day. New Article Some better-ranked stocks in the health care sector are Biogen Idec Inc. ( BIIB ), Allergan Inc. ( AGN ) and AbbVie Inc. ( ABBV ). Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report NOVO-NORDISK AS (NVO): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. With NovoMix slated to lose patent protection in the EU (2014-2015) and the U.S. (2017) as well as a number of other products including NovoRapid and Norditropin in 2017, label expansion for Tresiba is expected to boost the top line. New Article Some better-ranked stocks in the health care sector are Biogen Idec Inc. ( BIIB ), Allergan Inc. ( AGN ) and AbbVie Inc. ( ABBV ). Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Roche ( RHHBY ) recently announced it has agreed to acquire a privately-held Austrian biotechnology company named Dutalys GmbH.",289.0575256347656
2014-12-24 00:00:00+00:00,335.5299987792969,343.6199951171875,334.9800109863281,340.8900146484375,340.8900146484375,965800.0,3.0,1.0,0.5000249999999999,Investors looking for well-positioned stocks in the health care sector may consider stocks like Biogen Idec ( BIIB ) and Shire ( SHPG ). Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. ( VNDA ) recently announced that it has reached a settlement agreement with Novartis AG ( NVS ) related to Fanapt.,290.05426025390625
2014-12-26 00:00:00+00:00,342.9200134277344,345.54998779296875,338.0199890136719,342.3999938964844,342.3999938964844,1138700.0,3.0,1.0,0.5000249999999999,"Shares of several biotech companies including Biogen Idec Inc. ( BIIB ) and Amgen Inc. ( AMGN ) have declined 5.5% and 5.6% respectively, since the Express Scripts deal. Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Although Gilead Sciences Inc. ( GILD ), one of the leading biotech companies in the U.S., recovered 2.1% on Wednesday, overall the stock has plunged approximately 15.8% after pharmacy benefit manager Express Scripts ( ESRX ) entered into an agreement with AbbVie Inc. ( ABBV ). New Article In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Devon Energy Corp. (Symbol: DVN) has taken over the #107 spot from Biogen Idec Inc (Symbol: BIIB), according to ETF Channel . Below is a chart of Devon Energy Corp. versus Biogen Idec Inc plotting their respective rank within the S&P 500 over time (DVN plotted in blue; BIIB plotted in green): Below is a three month price history chart comparing the stock performance of DVN vs. BIIB: DVN,BIIB makes up 2.31% of the First Trust Value Line Equity Allocation Index Fund ETF ( FVI ) DVN is currently trading up about 1.8%, while BIIB is up about 0.3% midday Friday. Favorites  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Among others Gilead Sciences Inc. ( GILD ), Amgen Inc. ( AMGN ), Biogen Idec Inc. ( BIIB ) and Regeneron Pharmaceuticals, Inc. ( REGN ) gained 2.1%, 2%, 1.5% and 1.5%, respectively. Click to get this free report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report EXXON MOBIL CRP (XOM): Free Stock Analysis Report CHEVRON CORP (CVX): Free Stock Analysis Report CHESAPEAKE ENGY (CHK): Free Stock Analysis Report EOG RES INC (EOG): Free Stock Analysis Report MARATHON OIL CP (MRO): Free Stock Analysis Report To read this article on Zacks.com click here. Markets ended modestly higher on Wednesday's abbreviated trading session banking on initial claims dropping to a seven-week low and gains in biotechs.",283.0538635253906
2014-12-30 00:00:00+00:00,341.510009765625,345.010009765625,339.42999267578125,342.19000244140625,342.19000244140625,933500.0,3.5,1.0,0.6250249999999999,"Some better-ranked stocks in the health care sector include Biogen Idec ( BIIB ), The Medicines Company ( MDCO ) and Regado Biosciences, Inc. ( RGDO ). Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report REGADO BIOSCI (RGDO): Free Stock Analysis Report To read this article on Zacks.com click here. Kalydeco has now been approved for use in patients suffering from CF aged six years and above with an R117H mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. New Article Some better-ranked stocks in the biotech sector are The Medicines Company ( MDCO ), Regado Biosciences, Inc. ( RGDO ) and Biogen Idec Inc. ( BIIB ). Click to get this free report MEDICINES CO (MDCO): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report REGADO BIOSCI (RGDO): Free Stock Analysis Report IGNYTA INC (RXDX): Free Stock Analysis Report To read this article on Zacks.com click here. Ignyta, Inc. 's ( RXDX ) lead candidate, entrectinib (RXDX-101), has received orphan drug status as well as rare pediatric disease designation from the FDA for the treatment of neuroblastoma.",285.1352233886719
2015-01-06 00:00:00+00:00,339.9800109863281,346.6400146484375,334.3999938964844,334.6499938964844,334.6499938964844,1898200.0,3.6666666666666665,1.0,0.6666916666666666,"In early trading on Tuesday, shares of Biogen Idec ( BIIB ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.3%. VIDEO: Nasdaq 100 Movers: NXPI, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing Nasdaq 100 component thus far on the day is NXP Semiconductors ( NXPI ), trading down 3.1%. New Article In phase 1 studies, BIIB037 helped to improve cognition in patients exhibiting early stages of the disease when measured after 54 weeks, and it also led to dose- and time-dependent reductions in beta-amyloid levels in the brain. So what: The big impetus for Biogen's move higher was early stage data on BIIB037 , a drug designed to treat Alzheimer's disease. Because of its impressive results, BIIB037 is moving directly into phase 3 studies and is expected to deliver results sometime in 2016. New Article Besides Janssen, Isis Pharma has partnership agreements with other leading health care companies like Biogen Idec ( BIIB ) and AstraZeneca ( AZN ). The agreement focuses on Isis Pharma's RNA-targeted technology platform and Janssen's expertise in autoimmune disorders and therapeutic formulation. Isis Pharma's agreements with these companies not only validate its antisense technology but also provide it with funds in the form of upfront, milestone and other payments.",287.54132080078125
2015-01-07 00:00:00+00:00,338.0899963378906,354.0,338.04998779296875,353.239990234375,353.239990234375,2484300.0,4.5,1.0,0.8750249999999999,"While mCRPC was a more lucrative label, having renal cell carcinoma in its pocket, along with its existing metastatic medullary thyroid cancer indication, could get Exelixis near profitability. Also, the coBRIM study involving Roche 's Zelboraf and Exelixis-developed cobimetinib delivered excellent late-stage data as treatment for BRAF V600 mutation-positive advanced melanoma and has the potential to be approved in the U.S. by late 2015. Biogen's antibody drug seeks to block the protein, potentially allowing the body to counteract the disease and regrow the myelin sheath. New Article Ultimately the results showed a seven-fold lower incidence in venous thrombosis in ISIS-FXIrx-treated patients than those who took enoxaparin, a commonly prescribed anticoagulant. In early December, Isis published the results from its midstage study involving ISIS-APOCIIIrx in patients with Familial Chylomicronemia in TheNew England Journal of Medicine . That's why The Motley Fool's chief investment officer just published a brand-new research report that reveals his top stock for the year ahead.",281.58868408203125
2015-01-08 00:00:00+00:00,359.4200134277344,360.0,341.7099914550781,350.25,350.25,4277700.0,3.0,1.0,0.5000249999999999,"And the worst performing Nasdaq 100 component thus far on the day is Biogen Idec ( BIIB ), trading down 2.9%. VIDEO: Nasdaq 100 Movers: BIIB, TSCO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Biogen Idec is showing a gain of 1.0% looking at the year to date performance.",284.5943603515625
2015-01-09 00:00:00+00:00,349.7799987792969,352.0799865722656,338.239990234375,342.3399963378906,342.3399963378906,2562100.0,4.0,1.0,0.7500249999999999,"Among the largest underlying components of IYH, in trading today Biogen Idec Inc (Symbol: BIIB) is down about 2.4%, Medtronic, Inc. (Symbol: MDT) is off about 0.5%, and Actavis plc (Symbol: ACT) is lower by about 0.2%. For a complete list of holdings, visit the IYH Holdings page  The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $115.40 per share, with $150.27 as the 52 week high point - that compares with a last trade of $148.37. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Biogen Idec ( BIIB ) announced positive top-line results from a randomized, double-blind, placebo-controlled phase II study (RENEW) on anti-LINGO-1 for the treatment of patients suffering from acute optic neuritis. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report REGADO BIOSCI (RGDO): Free Stock Analysis Report NEWLINK GENETIC (NLNK): Free Stock Analysis Report To read this article on Zacks.com click here. Patients treated with anti-LINGO-1 showed biological repair of their visual system as anti-LINGO-1 led to the recovery of optic nerve latency, compared to placebo. New Article Isis Pharma has partnership agreements with leading health care companies like Biogen Idec ( BIIB ) and AstraZeneca ( AZN ). Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. On its third quarter conference call, the company had mentioned that it expects to improve upon its initial guidance of net operating loss in the low $50 million range.",280.5753173828125
2015-01-12 00:00:00+00:00,345.5,350.0,343.7099914550781,347.8399963378906,347.8399963378906,1899200.0,4.0,1.0,0.7500249999999999,"Even if that drug (BIIB037) gets shot down, which is certainly very possible with a 99% failure rate among Alzheimer's treatments, Biogen has three more Alzheimer's drugs under development -- two with collaborator Eisai Co. Ltd . Bottom line: While Gilead looks like the better buy right now, Biogen leads the $18 billion global MS market, and its launch of two hemophilia drugs will bring it some needed diversity in revenue. With the recent label expansion for moderate to severe plaque psoriasis in the U.S. and a looming European approval, Otezla could begin a rapid ascension into blockbuster territory, making it a key drug to watch going forward.",282.4819641113281
2015-01-13 00:00:00+00:00,352.8099975585937,361.9100036621094,348.3500061035156,352.739990234375,352.739990234375,2489400.0,3.5,1.0,0.6250249999999999,"Some better-ranked stocks in the biotech sector are Alexion Pharmaceuticals, Inc. ( ALXN ) and Biogen Idec Inc. ( BIIB ). Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report SEATTLE GENETIC (SGEN): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Seattle Genetics, Inc. ( SGEN ) and partner Bristol-Myers Squibb Company ( BMY ) have inked a deal to develop an investigational combination of the former's antibody-drug conjugate, Adcetris and the latter's immunotherapy, Opdivo. New Article Earlier this week, Biogen Idec ( BIIB ) announced its intention to acquire U.K.-based Convergence Pharmaceuticals, a clinical stage biopharmaceutical company with a focus on developing treatments for neuropathic pain. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report SANGAMO BIOSCI (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. CNV1014802 has shown clinical activity in proof of concept studies for trigeminal neuralgia and lumbosacral radiculopathy (sciatica).",281.4173583984375
2015-01-14 00:00:00+00:00,348.0,355.6099853515625,347.5199890136719,348.75,348.75,1429900.0,3.0,1.0,0.5000249999999999,"Meanwhile Isis Pharmaceuticals ( ISIS ) said it earned a $7 million milestone payment from Biogen Idec ( BIIB ) related to the advancement of the open-label extension study of its ISIS-SMNRx in children with spinal muscular atrophy (SMA). AMGN: flat Health-care shares were generally higher in pre-market trade Wednesday. In health-care stocks news, AstraZeneca ( AZN ) shares were higher in recent pre-market trade as it said a large scale trial to study a drug to prevent atherothrombotic events in patients who had experience a heart attack one to three years before the study started met its primary efficacy endpoint.",285.66259765625
2015-01-15 00:00:00+00:00,350.0400085449219,354.54998779296875,339.6600036621094,339.8800048828125,339.8800048828125,1665700.0,4.0,1.0,0.7500249999999999,"During the JP Morgan presentation, AbbVie didn't offer specific sales guidance for Viekira Pak, but did say that it will provide more insight into revenue projections during the fourth-quarterearnings conference call which is scheduled for later this month. Whether or not the company can maintain its shareholder-friendly commitments once Humira loses patent protection remains to be seen, but it would appear, at least based on its comments at the JP Morgan conference, that it has multiple therapies that it believes may eventually blunt that risk. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster.",274.1626281738281
2015-01-21 00:00:00+00:00,361.4100036621094,366.1700134277344,358.2200012207031,361.8299865722656,361.8299865722656,1337000.0,2.5,1.0,0.375025,"Early next week, companies like Amgen ( AMGN ) and Biogen ( BIIB ) will be reporting fourth quarter results. Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report NPS PHARMA INC (NPSP): Free Stock Analysis Report To read this article on Zacks.com click here. With the FDA lifting the hold, the company will be allowed to enroll and dose new patients once the Institutional Review Boards (IRBs) approve the revised trial protocols. New Article From education to foreign policy to immigration, President Barack Obama covered a lot in his State of the Union speech on Tuesday evening. While started by the U.S. Department of Energy and the National Institutes of Health, the sequencing of the human genome was completed by an international consortium that included scientists in the United Kingdom, France, Japan, Germany, China, and other countries. If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster.",266.8995666503906
2015-01-26 00:00:00+00:00,357.6300048828125,362.8399963378906,355.45001220703125,362.4400024414063,362.4400024414063,1330600.0,3.0,1.0,0.5000249999999999,"Investors eyeing a purchase of Biogen Idec Inc (Symbol: BIIB) stock, but cautious about paying the going market price of $361.14/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to BIIB's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. For other put options contract ideas at the various different available expirations, visit the BIIB Stock Options page of StockOptionsChannel.com. New Article Roche ,Johnson & Johnson ( JNJ ) andBiogen Idec ( BIIB ) have also announced deals.Zillow ( Z )is likely to merge withTrulia (TRLA). That ripple could lift M&A exchange traded funds .Index IQ Merger Arbitrage (MNA), the segment leader, has seen assets balloon roughly 227% over the past year to $83.2 million. He notes that fat corporate balance sheets, historically low interest rates and private equity buyers fueled 2014's merger mania.",270.22637939453125
2015-01-27 00:00:00+00:00,358.2799987792969,364.760009765625,357.1300048828125,357.8900146484375,357.8900146484375,1446300.0,3.5,1.0,0.6250249999999999,"Biogen Idec ( BIIB ), a strong player in the multiple sclerosis (MS) market, will be reporting fourth quarter and full year 2014 results on Jan 29, after the market closes. Zacks Rank: BIIB's Zacks Rank #3 increases the predictive power of ESP. Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Biogen Idec Inc. ( BIIB ) is reporting for the quarter ending December 31, 2014. BIIB missed the consensus earnings per share in the 1st calendar quarter of 2014 by -5.04%. Zacks Investment Research reports that the 2014 Price to Earnings ratio for BIIB is 26.91 vs. an industry ratio of -7.60, implying that they will have a higher earnings growth than their competitors in the same industry.",272.2066955566406
2015-01-29 00:00:00+00:00,351.5299987792969,354.6099853515625,345.760009765625,353.25,353.25,1707800.0,3.0,1.0,0.5000249999999999,"I wouldn't pencil in revenue from BIIB037 just yet -- a lot more Alzheimer's disease drugs have failed than have succeeded -- but if the phase 3 program is successful, it's not hard to see BIIB037 being as large as the big three combined. The most likely candidate for the job is BIIB037, an Alzheimer's disease drug that Biogen is fast tracking straight from phase 1b to phase 3 because the interim data was so good. As you'd expect, switching from other therapies to Tecfidera has slowed down as Biogen runs out of patients looking for other treatment options -- first in the U.S., and then in Europe where it launched later -- which explains the slower growth in the latter half of the year. New Article Some better-ranked biotech stocks include Alexion Pharmaceuticals, Inc. ( ALXN ), Celgene Corp. ( CELG ) and Biogen Idec ( BIIB ). Click to get this free report ALEXION PHARMA (ALXN): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Operating expenses will go up as the company gears up for the potential launch of its Kalydeco-lumacaftor combination (FDA action date: Jul 5; EU approval could come in the fourth quarter) and a phase III program evaluating VX-661+Kalydeco.",280.07818603515625
2015-01-30 00:00:00+00:00,372.75,397.0,372.75,389.1600036621094,389.1600036621094,4029800.0,3.0,1.0,0.5000249999999999,"Biotech company, Biogen Idec ( BIIB ), reported fourth quarter 2014 earnings per share of $4.08 (including the impact of stock-based compensation expense), way above the Zacks Consensus Estimate of $3.74 and the year-ago earnings of $2.33 per share. Click to get this free report CELGENE CORP (CELG): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report To read this article on Zacks.com click here. The U.S. label update in December following the reporting of a progressive multifocal leukoencephalopathy (PML)-related death of a patient on Tecfidera as well as the recent launch of Plegridy also affected growth. New Article Among the largest underlying components of IUSG, in trading today Verizon Communications Inc (Symbol: VZ) is down about 0.5%, Biogen Idec Inc (Symbol: BIIB) is up about 10.7%, and Honeywell International, Inc. (Symbol: HON) is lower by about 1.2%. For a complete list of holdings, visit the IUSG Holdings page  The chart below shows the one year price performance of IUSG, versus its 200 day moving average: Looking at the chart above, IUSG's low point in its 52 week range is $66.61 per share, with $80.09 as the 52 week high point - that compares with a last trade of $77.48. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article What: Shares in Biogen Idec surged higher by 10% after the company announced fourth quarter and full year results, including earnings that exceeded Wall Street analysts' expectations. The ongoing success of its MS therapies and the potential growth from these newly launched drugs has Biogen guiding investors to expect sales to climb between 14% and 16% this year and for adjusted EPS to reach between $16.60 and $17. If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. New Article In early trading on Friday, shares of Biogen Idec ( BIIB ) topped the list of the day's best performing components of the S&P 500 index, trading up 11.2%. Year to date, Biogen Idec registers a 15.8% gain. And the worst performing S&P 500 component thus far on the day is PACCAR ( PCAR ), trading down 4.4%. New Article Two other components making moves today are Citrix Systems ( CTXS ), trading down 2.6%, and Biogen Idec ( BIIB ), trading up 10.6% on the day. In early trading on Friday, shares of Amazon.com ( AMZN ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 11.0%. And the worst performing Nasdaq 100 component thus far on the day is PACCAR ( PCAR ), trading down 4.7%.",286.1929016113281
2015-02-02 00:00:00+00:00,389.0299987792969,394.9800109863281,382.0,390.0,390.0,1832700.0,3.0,1.0,0.5000249999999999,"Biogen Idec Inc. ( BIIB ) was a big mover last session, as the company saw its shares rise over 10% on the day. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report To read this article on Zacks.com click here. Yesterday's rally breaks the trend for the company, as the stock is now trading above the volatile price range of $334.65 to $363.28 in the past one-month time frame.",295.4529724121094
2015-02-03 00:00:00+00:00,390.7300109863281,395.5,386.3399963378906,393.8900146484375,393.8900146484375,1781500.0,4.0,1.0,0.7500249999999999,"Top mutual funds have been adding to heavy-hitting medical issues such asCelgene ( CELG ) andBiogen Idec ( BIIB ) in their latest reporting periods. Property REITs such asPebblebrook Hotel (PEB),Extra Space Storage (EXR),Regency Centers (REG), were stellar performers. Its portfolio of fitness brands includes Bowflex, Nautilus, Schwinn and Universal, sold through retail and direct sales to consumers. New Article BIIB data by YCharts What: Shares of Biogen Idec , a global biopharmaceutical company with a primary focus on developing therapies to treat multiple sclerosis, rallied 15% in January, based on data from S&P Capital IQ , after announcing better-than-expected fourth-quarter earnings results. Additionally, ongoing research into new drug candidates, such as BIIB037 for Alzheimer's disease and its optic neuritis drug hopeful anti-Lingo-1, could provide the extra kick to send Biogen's shares even higher with a steady foundation being laid down by its MS product portfolio. The primary growth driver for Q4 remained twice-daily MS pill Tecfidera whose sales grew to $916 million and is on pace to top $4 billion in revenue next year. New Article In fact, shares have now fallen by over 13% from their 52-week high following the high-volume sell-off that accompanied the company's fourth-quarter earnings release, as shown by this chart: Weaker than expected projections for Viekira Pak going forward appear to have accelerated the stock's decline. Putting all this doom and gloom aside for the moment, it's important to remember AbbVie has richly rewarded its shareholders, through the market-trouncing performance of its stock, billions in share buybacks, and multiple increases to the dividend, since the company was spun off from Abbott Laboratories in January 2013. AbbVie and partner Biogen Idec , for instance, last year successfully completed late-stage trials for the monoclonal antibody daclizumab as a potential treatment for the relapsing remitting form of multiple sclerosis, meaning a regulatory filing should be close at hand.",288.6828918457031
2015-02-04 00:00:00+00:00,388.6000061035156,394.4800109863281,381.3599853515625,391.1199951171875,391.1199951171875,2165000.0,4.5,1.0,0.8750249999999999,"Biogen Idec Inc ( BIIB ) has been on the move lately as the stock has risen by 15.8% in the past four weeks, and it is currently trading well above its 20-Day SMA. While there can be no telling for sure, it is certainly encouraging that earnings estimates have risen in the past few weeks on the company, suggesting that sentiment on BIIB is moving in the right direction. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Under-promised and over-delivered Chairman and CEO Rick Gonzalez spoke only a few seconds before noting that sales and earnings topped the company's projections for the year. Management thinks the market for this indication could approach $1 billion annually.However, it's worth keeping in mind that the drug is set to lose patent protection in the U.S. by December 2016. If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster.",287.745361328125
2015-02-05 00:00:00+00:00,393.7000122070313,402.3999938964844,390.1099853515625,401.7900085449219,401.7900085449219,1576200.0,4.0,1.0,0.7500249999999999,"AMAG Pharmaceuticals, Inc. ( AMAG ) and Biogen Idec Inc. ( BIIB ) are also equally well-ranked stocks in the health care sector. Click to get this free report ALLERGAN INC (AGN): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. The enlarged entity will be among the top 10 pharmaceutical companies across the world based on sales (expected to be over $23 billion in 2015). New Article Other equally well-ranked stocks in the health care sector are AMAG Pharmaceuticals, Inc. ( AMAG ), Amgen Inc. ( AMGN ) and Biogen Idec Inc. ( BIIB ). Click to get this free report BLUEBIRD BIO (BLUE): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Updates on the regulatory front are eagerly awaited by investors in the pharma/biotech sector as they impact the share price of the concerned company. New Article Specialty Sciences : Segmental revenues came in at $86.6 million due to royalties received by Perrigo on multiple sclerosis drug Tysabri from Biogen Idec ( BIIB ). Click to get this free report AMAG PHARMA INC (AMAG): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. Perrigo Company 's ( PRGO ) second-quarter fiscal 2015 (ended Dec 27, 2014) earnings of $1.82 per share beat the Zacks Consensus Estimate of $1.78.",288.97979736328125
2015-02-06 00:00:00+00:00,400.2999877929688,407.9400024414063,399.0,402.0,402.0,1640500.0,2.5,1.0,0.375025,"BIIB Earnings in Focus Biogen ( BIIB ) reported mixed fourth quarter results, beating the bottom-line estimates, but marginally missing on the top line. Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report ISHARES NDQ BIO (IBB): ETF Research Reports PWRSH-DYN BIO (PBE): ETF Research Reports MKT VEC-BIOTECH (BBH): ETF Research Reports To read this article on Zacks.com click here. Pricing war in the hepatitis C virus (HCV) market has led the company to guide revenues for 2015 lower than Street estimates (read: Gilead Falls on AbbVie and Express Scripts Deal: 3 Biotech ETFs to Watch ). New Article Some better-ranked stocks in the health care space include AMAG Pharmaceuticals, Inc. ( AMAG ) and Biogen Idec Inc. ( BIIB ). Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues from the Generics sub-group at Sanofi were down 0.6% to 467 million in the fourth quarter of 2014, reflecting lower sales in Western Europe.",302.4481506347656
2015-02-09 00:00:00+00:00,398.0499877929688,402.8399963378906,396.4599914550781,396.8800048828125,396.8800048828125,1440400.0,2.5,1.0,0.375025,"AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Idec Inc. ( BIIB ). Shareholders who purchased AMGN stock prior to the ex-dividend date are eligible for the cash dividend payment. The following ETF(s) have AMGN as a top-10 holding: iShares Nasdaq Biotechnology Index Fund ( IBB ) PowerShares Dynamic Biotechnology & Genome Portfolio ( PBE ) PowerShares Dynamic Pharmaceuticals Portfolio ( PJP ) SPDR Health Care Select Sector Fund ( XLV ) Market Vectors Biotech ETF ( BBH ). New Article The company also signed a deal with Biogen Idec ( BIIB ) in Jan 2014 for the research, development and commercialization of the ZFP Therapeutics development program in hemoglobinopathies targeting sickle cell disease and beta-thalassemia. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report SANGAMO BIOSCI (SGMO): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Factors Influencing Fourth-Quarter and 2014 Results Since Sangamo is a clinical-stage biopharmaceutical company, currently focused on the development of its ZFP Therapeutics pipeline, investors are expected to keep an eye on its progress.",306.1877746582031
2015-02-10 00:00:00+00:00,398.0499877929688,400.8599853515625,394.05999755859375,395.1300048828125,395.1300048828125,1811600.0,3.75,1.0,0.6875249999999999,"Part 1 (n=56), a single-ascending-dose, placebo-controlled study evaluated the safety, tolerability and PK of a range of single doses (49 mg to 980 mg) of ALKS 8700 and a dose that would provide MMF exposure comparable to Biogen's ( BIIB ) Tecfidera (240 mg). Click to get this free report ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PROTHENA CP PLC (PRTA): Free Stock Analysis Report OPHTHOTECH CORP (OPHT): Free Stock Analysis Report To read this article on Zacks.com click here. The three-part, randomized, double-blind phase I study was conducted to evaluate the safety, tolerability and pharmacokinetics (PK) of several oral formulations of ALKS 8700 as compared to both placebo and active control groups in 104 healthy volunteers. New Article Some better-ranked stocks in the health care sector include Alnylam Pharmaceuticals, Inc. ( ALNY ) and Biogen Idec Inc. ( BIIB ). Click to get this free report OREXIGEN THERAP (OREX): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report TAKEDA PHARMACT (TKPYY): Get Free Report To read this article on Zacks.com click here. Orexigen Therapeutics, Inc. ( OREX ) announced encouraging updates on its weight loss drug, Mysimba. New Article Some better-ranked stocks in the health care sector include Biogen Idec ( BIIB ), Allergan ( AGN ) and Array Biopharmaceuticals, Inc. ( ARRY ). Click to get this free report ONCOLYTICS BIO (ONCY): Free Stock Analysis Report ALLERGAN INC (AGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ARRAY BIOPHARMA (ARRY): Free Stock Analysis Report To read this article on Zacks.com click here. Oncolytics Biotech Inc. ( ONCY ) announced that it has submitted an application to FDA for obtaining orphan drug designation for Reolysin for the treatment of high-grade gliomas (HGG) in pediatric patients. New Article Google X confirmed on Jan. 27 that it has joined forces with Biogen Idec Inc. (Nasdaq: BIIB ), a large-cap biotech firm known for its multiple sclerosis ( MS ) drugs. Elon Musk , of Tesla Motors Inc. (Nasdaq: TSLA ) electric vehicles and SpaceX rockets fame, thinks he has the solution: a network of hundreds of low-orbiting satellites that will deliver high-speed, low-cost Internet to the most remote places on Earth. And it advances the Mountain View, Calif.-based company's bid to use satellites to provide wireless web access to the two-thirds of the world's 7 billion people who lack good Internet service.",294.9261169433594
2015-02-11 00:00:00+00:00,394.8599853515625,396.8599853515625,388.5299987792969,390.0,390.0,1766300.0,4.5,1.0,0.8750249999999999,"Some better-ranked stocks in the broader health care sector include McKesson Corporation ( MCK ), Biogen Idec ( BIIB ), and AmerisourceBergen Corporation ( ABC ). Click to get this free report AMERISOURCEBRGN (ABC): Free Stock Analysis Report MCKESSON CORP (MCK): Free Stock Analysis Report CHARLES RVR LAB (CRL): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Fourth Quarter in Detail We remind investors that in Mar 2014, Charles River had entered into a definitive agreement to acquire the contract research organization (CRO) services division of Galapagos NV. New Article What:Sangamo Biosciences shares surged more than 14% higher at mid-day after it reported mostly better-than-expected fourth quarter earnings results and issued 2015 guidance that was above Wall Street forecasts. Since there aren't any phase 3 programs under way, Sangamo is highly speculative investment that will trade based on trial data, including results from the mid stage Alzheimer's study that are expected this year. If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster.",311.60125732421875
2015-02-12 00:00:00+00:00,394.6900024414063,395.0,386.1400146484375,392.1099853515625,392.1099853515625,1755100.0,3.333333333333333,1.0,0.5833583333333334,"Some better-ranked stocks in the health care sector include BioMarin Pharmaceutical Inc. ( BMRN ), Biogen Idec ( BIIB ) and Alnylam Pharmaceuticals, Inc. ( ALNY ). Click to get this free report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ONCOLYTICS BIO (ONCY): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, Oncolytics is now eligible to receive benefits like tax credits for research and development costs, annual grant funding as well as request for the waiving of certain administrative fees. New Article However, with Gilead Sciences' sales growth set to slow this year, investors may find that these three top biotech stocks prove to be a better bet in 2015. Regeneron is also co-developing fully human monoclonal antibodies with Sanofi , three of which are in mid- to late-stage trials : alirocumab (a PCSK9 drug for cholesterol), sarilumab (rheumatoid arthritis), and dupilumab (allergic diseases). If you hope to outsmart Wall Street and realize multi-bagger returns you will need to get in early -- check out The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. New Article Other favorably-placed stocks in the healthcare sector include Biodel Inc. ( BIIB ), Lannett Company, Inc ( LCI ) and Impax Laboratories ( IPXL ). Click to get this free report SUCAMPO PHARMAC (SCMP): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report LANNETT INC (LCI): Free Stock Analysis Report To read this article on Zacks.com click here. Per the agreement, Sucampo or R-Tech Ueno will grant Par Pharma the license for a generic version of Rescula (unoprostone isopropyl ophthalmic solution) 0.15% before the latest patent expiration in Jul 2021.",299.78839111328125
2015-02-13 00:00:00+00:00,391.6799926757813,394.3900146484375,387.239990234375,391.6600036621094,391.6600036621094,1180000.0,2.0,1.0,0.250025,"Better-ranked stocks in the health care sector include Biogen Idec Inc. ( BIIB ) and Achillion Pharmaceuticals, Inc. ( ACHN ). Click to get this free report IRONWOOD PHARMA (IRWD): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Ironwood said that during the fourth quarter Almirall lowered its inventory demand forecast in Europe due to higher commercial challenges. New Article Ampyra is marketed in ex-U.S. markets under the trade name Fampyra by Biogen Idec ( BIIB ). Click to get this free report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline Update Acorda is working on refiling the new drug application for Plumiaz nasal spray for the treatment of patients with epilepsy who experience cluster seizures.",315.5096435546875
2015-02-18 00:00:00+00:00,396.8299865722656,401.8699951171875,396.5199890136719,401.1199951171875,401.1199951171875,782800.0,3.0,1.0,0.5000249999999999,"Shares of bio-tech companies such as Amgen Inc. ( AMGN ), Biogen Idec Inc. ( BIIB ), Celgene Corporation ( CELG ) and Regeneron Pharmaceuticals, Inc. ( REGN ) increased 0.5%, 1.6%, 0.4% and 0.4%, respectively. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report LENNAR CORP -A (LEN): Free Stock Analysis Report D R HORTON INC (DHI): Free Stock Analysis Report TOLL BROTHERS (TOL): Free Stock Analysis Report BEAZER HOMES (BZH): Free Stock Analysis Report GOODYEAR TIRE (GT): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report To read this article on Zacks.com click here. For a look at the issues currently facing the markets, make sure to read today's Ahead of Wall Street article The Dow Jones Industrial Average (DJI) gained 0.2%, to close at 18,047.58.",322.36163330078125
2015-02-25 00:00:00+00:00,405.3200073242188,412.0199890136719,400.5700073242188,408.9400024414063,408.9400024414063,1114100.0,2.0,1.0,0.250025,"Biogen disclosed some phase 1 data for its early-stage Alzheimer's drug, BIIB037, at an investor conference last December, but the information released was sparse on details. The Alzheimer's Disease and Parkinson's Disease, or ADPD, meeting March 18-22 will be the first time investors get more details about BIIB037's activity. While the results have drawn a lot of attention so far, just keep in mind there are plenty of examples of Alzheimer's disease drugs that looked good in early-stage trials only to flop when tested in a larger population.",314.3882751464844
2015-02-27 00:00:00+00:00,410.2300109863281,411.30999755859375,405.7999877929688,409.5899963378906,409.5899963378906,1371000.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of IVW, in trading today Medtronic plc (Symbol: MDT) is down about 0.3%, Celgene Corp. (Symbol: CELG) is down about 0.8%, and Biogen Idec Inc (Symbol: BIIB) is lower by about 0.6%. For a complete list of holdings, visit the IVW Holdings page  The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $95.88 per share, with $117.02 as the 52 week high point - that compares with a last trade of $116.73. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",303.9417724609375
2015-03-02 00:00:00+00:00,410.6700134277344,416.8200073242188,406.3999938964844,415.7900085449219,415.7900085449219,1347300.0,5.0,1.0,1.000025,"Biogen IdecBIIB and Swedish Orphan Biovitrum AB (Sobi) announced positive top-line results from a global, open-label, multicenter phase III study (Kids B-Long) on Alprolix for the treatment of children under age 12 suffering from severe hemophilia B. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report THERAVANCE INC (THRX): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report To read this article on Zacks.com click here. According to the company press release, hemophilia B affects nearly 4,000 people in the U.S. Alprolix, which is developed and commercialized by Biogen together with Swedish Orphan Biovitrum, delivered sales of $76 million in 2014. New Article Isis Pharma has partnership programs with Biogen BIIB and GlaxoSmithKline GSK among others. Click to get this free report THERAVANCE INC (THRX): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Isis Pharma is conducting a phase III study on ISIS-APOCIIIRx in patients suffering from familial chylomicronemia syndrome (FCS).",301.6484069824219
2015-03-03 00:00:00+00:00,415.0,415.1700134277344,407.1199951171875,412.7900085449219,412.7900085449219,1235300.0,4.0,1.0,0.7500249999999999,"Others doing well in the group wereBiogen Idec ( BIIB ),Pharmacyclics ( PCYC ) andSalix Pharmaceuticals ( SLXP ). The smart money also showed some love for a handful of household brands, such as iPhone makerApple ( AAPL ), building supply retailerLowe's (LOW), energy drink makerMonster Beverage (MNST) and apparel makerHanesbrands (HBI). IBD spotted 13 best-performing funds the past three months buyingRackspace Holdings (RAX), investing an estimated $64 million in their latest reporting periods.",307.15069580078125
2015-03-06 00:00:00+00:00,424.2300109863281,424.2300109863281,416.239990234375,417.6300048828125,417.6300048828125,1643700.0,4.0,1.0,0.7500249999999999,"Isis Pharmaceuticals ( ISIS ) said Friday it has earned a $9 million milestone payment from Biogen Idec ( BIIB ) related to advancing the ongoing phase 3 study evaluating its ISIS-SMNRx in infants with spinal muscular atrophy. Calithera Biosciences ( CALA ) shares jumped in pre-bell trading Friday after the clinical-stage pharmaceutical company said late Thursday it gained exclusive worldwide rights to research, develop and commercialize a portfolio of enzymes used in cancer tumor treatment. Horizon Pharma ( HZNP ), a specialty biopharmaceutical company, on Friday priced an upsized $350 million 144a offering of exchangeable senior notes due 2022, with the size of the offering increased from the previously announced $300 million.",297.2516784667969
2015-03-09 00:00:00+00:00,417.2300109863281,417.6499938964844,411.6000061035156,415.510009765625,415.510009765625,1516100.0,4.0,1.0,0.7500249999999999,"Isis Pharmaceuticals, Inc.ISIS announced that it has earned a milestone payment of $9 million from its partner Biogen BIIB . Apart from ISIS-SMNRx, other candidates under their collaboration include ISIS-DMPKRx (myotonic dystrophy type 1) and two neurodegenerative disease candidates - ISIS-BIIB3Rx and ISIS-BIIB4Rx. Click to get this free report THERAVANCE INC (THRX): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here.",297.8661804199219
2015-03-10 00:00:00+00:00,409.6700134277344,420.4400024414063,409.6099853515625,414.2000122070313,414.2000122070313,1400700.0,2.0,1.0,0.250025,"Among the largest underlying components of XLV, in trading today Medtronic plc (Symbol: MDT) is off about 1%, Biogen Idec Inc (Symbol: BIIB) is down about 0.4%, and Celgene Corp. (Symbol: CELG) is up by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $46.7 million dollar outflow -- that's a 0.4% decrease week over week (from 183,615,324 to 182,965,324). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",297.1788330078125
2015-03-13 00:00:00+00:00,407.0899963378906,416.7000122070313,407.0899963378906,413.3500061035156,413.3500061035156,1744700.0,3.5,1.0,0.6250249999999999,"And even among the large caps, you often see divergent performances that you might not see in other corners of the market (such as consumers or financials for example), and we can see this with a quick comparison between Biogen ( BIIB ) and Amgen ( AMGN ) over just the last three months. In this time frame BIIB has outperformed by over 2,000 bps showing that security selection can be vital in this space, and even among the giants. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ISHARES NDQ BIO (IBB): ETF Research Reports SPDR-SP BIOTECH (XBI): ETF Research Reports PRO-ULT NDQ BIO (BIB): ETF Research Reports BIOSH-BIO CLNCL (BBC): ETF Research Reports To read this article on Zacks.com click here. New Article The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Biogen Idec ( BIIB ) is now the #69 analyst pick, moving up by 1 spot. Looking at the stock price movement year to date, Biogen Idec ( BIIB ) is showing a gain of 20.9%. VIDEO: S&P 500 Analyst Moves: BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",287.1396789550781
2015-03-16 00:00:00+00:00,415.4599914550781,422.3699951171875,414.2200012207031,421.3200073242188,421.3200073242188,1564500.0,4.0,1.0,0.7500249999999999,"For Immediate Release Chicago, IL- March 16, 2015 - Today, Zacks Investment Ideas feature highlights Features: Biogen ( BIIB -Free Report), Amgen ( AMGN -Free Report), SPDR S&P Biotech ETF ( XBI -Free Report), BioShares Biotechnology Clinical Trials Fund ( BBC -Free Report) and ProShares Ultra Nasdaq Biotechnology ETF ( BIB -Free Report). And even among the large caps, you often see divergent performances that you might not see in other corners of the market (such as consumers or financials for example), and we can see this with a quick comparison between Biogen ( BIIB -Free Report) and Amgen ( AMGN -Free Report) over just the last three months. In this time frame BIIB has outperformed by over 2,000 bps showing that security selection can be vital in this space, and even among the giants.",284.51202392578125
2015-03-17 00:00:00+00:00,420.1000061035156,426.4800109863281,417.5,426.1199951171875,426.1199951171875,1968900.0,3.0,1.0,0.5000249999999999,IBB has over $8.2 billion dedicated to 150 biotech stocks in a market cap weighted structure that is dominated by top names such as Biogen Idec Inc (BIIB) and Celgene Corp (CELG). A more reasonable strategy is to access this theme though a diversified exchange-traded fund in order to spread your risk over multiple companies and potentially enhance your returns over time. This ETF seeks to replicate the makeup of the Poliwogg Medical Breakthroughs Index by selecting small and mid-cap companies in both the biotech and pharmaceutical fields.,286.7230529785156
2015-03-19 00:00:00+00:00,434.7999877929688,439.8999938964844,431.3299865722656,433.6499938964844,433.6499938964844,2471900.0,5.0,1.0,1.000025,"His previous experience includes 25 years in the biopharmaceutical industry, with time at two biotechs that some would categorize as great already -- Amgen (NASDAQ: AMGN) and Biogen Idec (NASDAQ: BIIB). The drug treats two very rare diseases -- paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) -- that don't have any other approved treatments. The biotech has clinical trials under way targeting the drug as a potential treatment for neurological diseases refractory myasthenia gravis and relapsing neuromyelitis optica as well as delayed graft function and antibody mediated rejection, both of which are transplant-related conditions .",280.1005554199219
2015-03-20 00:00:00+00:00,475.9200134277344,480.1799926757813,456.05999755859375,475.9800109863281,475.9800109863281,10643200.0,3.5,1.0,0.6250249999999999,"Biotech stocks also provided a boost, with Biogen Idec ( BIIB ) climbing to an all-time high after reporting positive early test results for a prospective Alzheimer's drug. (+) PRTA, Releases Phase I test results indicating its experimental PRX002 immunotherapy treatment reduces protein thought to be linked to the start and spread of Parkinson's disease. (-) THRX, FDA advisory panel limits recommended use of once-a-day ""rescue"" inhaler to adult asthma patients, voting 18-2 against allowing adolescents ages 12 to 17 to use the device. New Article Meanwhile, Biogen Idec ( BIIB ) shares surged 8.9% after the biotechnology company said an interim study showed reduction in amyloid plaque in Alzheimer's patients. The Friday climb follows an up-then-down run in the wake of the Federal Reserve's Wednesday signal that it won't be so quick to raise interest rates. In equities, jeweler Tiffany & Co.'s ( TIF ) shares fell 3.2% in recent pre-market trading after warning of minimal growth in 2015 as the strong dollar weighs on translating overseas sales. New Article In early trading on Friday, shares of Biogen Idec ( BIIB ) topped the list of the day's best performing components of the S&P 500 index, trading up 6.6%. VIDEO: S&P 500 Movers: MAC, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Year to date, Biogen Idec registers a 36.2% gain. New Article Biotech companies also received a shot-in-the-arm following positive study results for a prospective Alzheimer's treatment developed by Biogen Idec's ( BIIB ), also sending its stock to a record high. Despite pressure from a stronger dollar, NKE reported higher revenue and earnings during its fiscal Q3 compared with year-ago levels, lifting shares of the athletic apparel maker to a new all-time high. During last night's meeting in Brussels, Greek Prime Minister Alexis Tsipras reassured EU members his government will soon present a full set of economic reforms. New Article Among the largest underlying components of XLV, in trading today Amgen Inc (Symbol: AMGN) is up about 0.2%, Biogen Idec Inc (Symbol: BIIB) is up about 5.6%, and Celgene Corp. (Symbol: CELG) is lower by about 0.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $260.9 million dollar inflow -- that's a 1.9% increase week over week in outstanding units (from 182,865,324 to 186,365,324). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article In early trading on Friday, shares of Biogen Idec ( BIIB ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 7.0%. VIDEO: Nasdaq 100 Movers: DISH, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Dish Network is showing a gain of 1.1% looking at the year to date performance. New Article Biogen Idec Inc. ( BIIB ) is +33.35 at $467.00, with 377,378 shares traded., following a 52-week high recorded in prior regular session. The following are the most active stocks for the pre-market session : Macerich Company (The) ( MAC ) is -6.65 at $86.85, with 1,383,718 shares traded. As reported in the last short interest update the days to cover for PRTA is 7.306459; this calculation is based on the average trading volume of the stock. New Article Meanwhile, Biogen Idec ( BIIB ) shares surged 7.2% after the biotechnology company said an interim study showed reduction in amyloid plaque in Alzheimer's patients. U.S. stock futures pointed higher Friday after a weak session Thursday, taking a cue from European markets as Germany expressed optimism that a deal could be reached with Greece, even as no date was set for the beleaguered southern-European country to receive much-needed funds. In equities, jeweler Tiffany & Co.'s ( TIF ) shares fell 3.6% in recent pre-market trading after warning of minimal growth in 2015 as the strong dollar weighs on translating overseas sales.",274.8730163574219
2015-03-23 00:00:00+00:00,466.0700073242188,474.0,460.5,463.7300109863281,463.7300109863281,3712600.0,4.0,1.0,0.7500249999999999,"Biogen Idec Inc. 's BIIB shares hit a new 52-week high of $475.98 on Mar 20 after the company reported positive pre-specified interim results from a phase Ib study (PRIME) on its anti-amyloid beta antibody, aducanumab (BIIB037). Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here. The randomized, double-blind, placebo-controlled, multiple-dose phase Ib study is being conducted to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of aducanumab in patients suffering from prodromal or mild AD. New Article The upside was owing to the company's announcement of positive data from the pre-specified interim analysis of PRIME - the Phase 1b study of aducanumab (BIIB037) in patients with prodromal or mild Alzheimer's disease. Biogen Idec Inc. ( BIIB ) was a big mover last session with shares rising nearly 10% on the day. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report To read this article on Zacks.com click here. New Article The company raised $567 million through a secondary offering and concurrent selling of shares to its partner Sanofi in January, putting it with a little under $1.4 billion in its war chest. Source: Martin Abegglen via Flickr Dan Caplinger : I'd appreciate the chance to buy up shares of Biogen at a discount if the entire biotech sector got routed. If you hope to outsmart Wall Street and realize multi-bagger returns, you will need to get in early -- check out The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. New Article In a new research note, Raymond James analyst Steven Schwartz wrote GNW investors ""were receiving a free option on"" Biogen Idec's ( BIIB ) BIIB037 prospective Alzheizer's treatment, explaining that ""about 50% of Genworth's long-term care insurance claims payments are for Alzheimer's or other forms of dementia."" ""If - and it's a big if - BIIB037 is successful, then the results for Genworth's long-term care business could be significant,"" Schwartz said. BIIB was down about 2.5% at $463.94 a share in afternoon trade, earlier sinking to a session low of $462.80 a share.",282.6376647949219
2015-03-24 00:00:00+00:00,462.989990234375,467.6400146484375,452.010009765625,452.7099914550781,452.7099914550781,2481400.0,3.0,1.0,0.5000249999999999,"While Ampyra is sold in the US, it is marketed in abroad under the trade name Fampyra by Biogen Idec BIIB . Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report ROSS STORES (ROST): Free Stock Analysis Report GOLDMAN SACHS (GS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report HSBC HOLDINGS (HSBC): Free Stock Analysis Report To read this article on Zacks.com click here. Data from the U.S. Commodity Futures Trading Commission showed bets by hedge fund managers that the dollar will gain against the euro jumped 27% since the beginning of the year and currently remains at a two-year high.",276.9310607910156
2015-03-25 00:00:00+00:00,449.05999755859375,450.25,431.3900146484375,431.6300048828125,431.6300048828125,3743700.0,3.333333333333333,1.0,0.5833583333333334,"Innovating treatment Research indicates that Parkinson's, as well as other neurodegenerative diseases, could be caused by a build-up of alpha-synuclein, a protein that is found in neurons in the brain and helps neurotransmitters send messages to one another. Although PRX-002 remains in the very earliest of human clinical trials, an initial look at results from a phase 1 study show that PRX-002 leads to an average reduction in free serum alpha-synuclein levels of up to 96%. If you hope to outsmart Wall Street and realize multi-bagger returns, you will need to get in early -- check out The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. New Article It's been an eventful week on the pipeline front with companies like Biogen BIIB , Prothena PRTA and Vertex VRTX coming out with data. Hopes for a new Alzheimer's treatment are up with Biogen reporting positive data from a pre-specified interim analysis of a phase Ib study on aducanumab (BIIB037). Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report PROTHENA CP PLC (PRTA): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Stocks recently featured in the blog include the HSBC Holdings plc ( HSBC - Free Report ), Goldman Sachs ( GS - Free Report ), Acorda Therapeutics, Inc. ( ACOR - Free Report ), Biogen Idec ( BIIB - Free Report ) and Ross Stores Inc. ( ROST - Free Report ). While Ampyra is sold in the US, it is marketed in abroad under the trade name Fampyra by Biogen Idec ( BIIB - Free Report ). Get the full Report on HSBC - FREE Get the full Report on GS - FREE Get the full Report on ACOR - FREE Get the full Report on BIIB - FREE Get the full Report on ROST - FREE Follow us on Twitter: http://twitter.com/zacksresearch Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.",277.6869201660156
2015-03-26 00:00:00+00:00,427.7999877929688,432.8800048828125,420.4100036621094,428.9299926757813,428.9299926757813,3353800.0,2.0,1.0,0.250025,"Stocks recently featured in the blog include the Biogen ( BIIB - Free Report ), Prothena ( PRTA - Free Report ), Vertex ( VRTX - Free Report ), Gilead ( GILD - Free Report ) and Amgen ( AMGN - Free Report ). Here are highlights from Wednesday's Analyst Blog: Biotech Stock Roundup: Biogen Soars It's been an eventful week on the pipeline front with companies like Biogen ( BIIB - Free Report ), Prothena ( PRTA - Free Report ) and Vertex ( VRTX - Free Report ) coming out with data. Hopes for a new Alzheimer's treatment are up with Biogen reporting positive data from a pre-specified interim analysis of a phase Ib study on aducanumab (BIIB037).",277.8429870605469
2015-03-30 00:00:00+00:00,433.6799926757813,437.0,428.6000061035156,431.6199951171875,431.6199951171875,1600100.0,4.0,1.0,0.7500249999999999,"BiogenBIIB and partner AbbVie Inc. ABBV announced that the European Medicines Agency has accepted for review their marketing application for multiple sclerosis (MS) candidate, Zinbryta (daclizumab). Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report To read this article on Zacks.com click here. According to the Multiple Sclerosis Association of America, nearly 400,000 individuals in the U.S. and 2.5 million people across the world suffer from MS. We note that Biogen holds a strong position in the MS market with drugs like Avonex, Tysabri and Tecfidera in its portfolio.",275.2067565917969
2015-03-31 00:00:00+00:00,430.1600036621094,433.9800109863281,422.1000061035156,422.239990234375,422.239990234375,1808700.0,4.0,1.0,0.7500249999999999,"BiogenBIIB announced that the European Medicines Agency (EMA) has accepted its biosimilar candidate, SB2 for review. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report HOSPIRA INC (HSP): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report To read this article on Zacks.com click here. The company is looking to get SB2 approved for all the indications of Remicade which include rheumatoid arthritis, adult Crohn's disease, pediatric Crohn's disease, ulcerative colitis, pediatric ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and psoriasis.",272.5450744628906
2015-04-01 00:00:00+00:00,423.2000122070313,423.4700012207031,407.5499877929688,413.80999755859375,413.80999755859375,2709200.0,3.6666666666666665,1.0,0.6666916666666666,"Biogen Idec Inc. ( BIIB ), Celgene Corporation ( CELG ), Vertex Pharmaceuticals Incorporated ( VRTX ) and Regeneron Pharmaceuticals, Inc. ( REGN ) decreased 2.2%, 3.9%, 2.7% and 1.8%, respectively. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report BOEING CO (BA): Free Stock Analysis Report GENL ELECTRIC (GE): Free Stock Analysis Report EXXON MOBIL CRP (XOM): Free Stock Analysis Report CHEVRON CORP (CVX): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report HOSPIRA INC (HSP): Free Stock Analysis Report STAPLES INC (SPLS): Free Stock Analysis Report OFFICE DEPOT (ODP): Free Stock Analysis Report CISCO SYSTEMS (CSCO): Free Stock Analysis Report PEPSICO INC (PEP): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report To read this article on Zacks.com click here. For a look at the issues currently facing the markets, make sure to read today's Ahead of Wall Street article The Dow Jones Industrial Average (DJI) declined 1.1%, or 200.19 points, to close at 17,776.12. New Article What: Shares in Receptos surged by as much as 10% today after announcing that it had completed enrollment in its phase 3 trial for the treatment of multiple sclerosis and amid chatter of a potential buyer. So What : Receptos has been one of biotech's top performing stocks on optimism that its MS drug ozanimod could outperform Biogen 's top-selling Avonex in late stage trials. During phase 2 trials, ozanimod successfully achieved its primary endpoint of reducing the number of brain lesions in MS patients. New Article Meanwhile, it's been an eventful week on the pipeline and regulatory front as well with companies like Conatus CNAT , Amgen AMGN and Biogen BIIB coming out with updates. Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report OREXIGEN THERAP (OREX): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report CONATUS PHARMA (CNAT): Free Stock Analysis Report To read this article on Zacks.com click here. Once again, acquisition news made it to the headlines with Horizon Pharma HZNP announcing that it will be acquiring Hyperion Therapeutics HPTX .",281.0466003417969
2015-04-02 00:00:00+00:00,415.3999938964844,416.4800109863281,410.6400146484375,412.4400024414063,412.4400024414063,1700700.0,4.0,1.0,0.7500249999999999,"Stocks recently featured in the blog include the Horizon Pharma ( HZNP - Free Report ), Hyperion Therapeutics ( HPTX - Free Report ), Conatus ( CNAT - Free Report ), Amgen ( AMGN - Free Report ) and Biogen ( BIIB - Free Report ). Meanwhile, it's been an eventful week on the pipeline and regulatory front as well with companies like Conatus ( CNAT - Free Report ), Amgen ( AMGN - Free Report ) and Biogen ( BIIB - Free Report ) coming out with updates. Click to get this free report HORIZON PHARMA (HZNP): Free Stock Analysis Report HYPERION THERAP (HPTX): Free Stock Analysis Report CONATUS PHARMA (CNAT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Among the largest underlying components of IWF, in trading today Actavis plc (Symbol: ACT) is up about 0.7%, Biogen Inc (Symbol: BIIB) is off about 0.4%, and Celgene Corp. (Symbol: CELG) is lower by about 0.4%. For a complete list of holdings, visit the IWF Holdings page  The chart below shows the one year price performance of IWF, versus its 200 day moving average: Looking at the chart above, IWF's low point in its 52 week range is $83.25 per share, with $101.51 as the 52 week high point - that compares with a last trade of $98.87. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",288.2632141113281
2015-04-07 00:00:00+00:00,415.5,425.3699951171875,415.1300048828125,418.0899963378906,418.0899963378906,1571900.0,3.0,1.0,0.5000249999999999,"IBD: What do you like aboutBiogen ( BIIB ), which was your No. The idea is that we build a portfolio that can generate good performance, but with risk-adjusted returns that can outperform both our benchmark, the Russell 1000 Growth, and our peer group in various market conditions for the long term. IBD: Is the scientific community's ability to gather more data that shows genetic correlations to successful trial treatments a key?",287.4645080566406
2015-04-09 00:00:00+00:00,424.6000061035156,431.7799987792969,419.4800109863281,426.6300048828125,426.6300048828125,1340900.0,3.0,1.0,0.5000249999999999,"Bio-tech stocks including Amgen Inc. ( AMGN ), Biogen Idec Inc. ( BIIB ), Celgene Corporation ( CELG ), Vertex Pharmaceuticals Incorporated ( VRTX ) and Regeneron Pharmaceuticals, Inc. ( REGN ) increased 1.9%, 1.7%, 2.2%, 2.8% and 2.6%, respectively. Click to get this free report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report KB HOME (KBH): Free Stock Analysis Report BEAZER HOMES (BZH): Get Free Report RYLAND GRP INC (RYL): Get Free Report TOLL BROTHERS (TOL): Free Stock Analysis Report HOME DEPOT (HD): Free Stock Analysis Report EXXON MOBIL CRP (XOM): Free Stock Analysis Report CHEVRON CORP (CVX): Free Stock Analysis Report EOG RES INC (EOG): Free Stock Analysis Report To read this article on Zacks.com click here. For a look at the issues currently facing the markets, make sure to read today's Ahead of Wall Street article The Dow Jones Industrial Average (DJI) gained almost 0.2%, to close at 17,902.51.",292.0572509765625
2015-04-13 00:00:00+00:00,426.7000122070313,432.4700012207031,422.5199890136719,423.3599853515625,423.3599853515625,1263300.0,4.5,1.0,0.8750249999999999,"The Earnings ESP for Biogen BIIB is +0.26% and it carries a Zacks Rank #1 (Strong Buy). Click to get this free report HOSPIRA INC (HSP): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report IMMUNOGEN INC (IMGN): Free Stock Analysis Report To read this article on Zacks.com click here. J&J's track record has been pretty good over the past few quarters with the company beating earnings estimates all throughout 2014. New Article That stock is of course Biogen ( BIIB ) a biotech company which may be the perfect mix between growth and stability for investors seeking a top choice in the ever-popular biotechnology sector. However, the company has several therapies that help people with Multiple Sclerosis while drugs here (including AVONEX, TECFIDERA, and TYSABRI) account for the bulk of BIIB's revenue. Beyond the company's solid lineup of drugs right now, investors should note that BIIB also has a great drug pipeline as well.",285.9120788574219
2015-04-14 00:00:00+00:00,423.989990234375,426.4800109863281,417.7099914550781,423.5700073242188,423.5700073242188,1365100.0,3.0,1.0,0.5000249999999999,"Other well-ranked stocks in the health care sector are ANI Pharmaceuticals, Inc. ANIP , Horizon Pharma plc HZNP and Biogen Inc. BIIB . Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report AETERNA ZENTARS (AEZS): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. The confirmatory study will be conducted as a two-way crossover with the insulin tolerance test as the benchmark comparator on patients with a medical history of risks related to AGHD. New Article Among the better-ranked stocks in the health care sector are Amgen Inc. AMGN , Biogen Idec Inc. BIIB and Affymetrix Inc. AFFX . Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Alnylam Pharmaceuticals, Inc.ALNY announced that pre-clinical results on ALN-AT3, the company's investigational RNAi therapeutic targeting antithrombin (AT) for the treatment of hemophilia and rare bleeding disorders (RBD), were published in Nature Medicine . New Article Companies that currently look attractive in the health care space include Amgen AMGN and Biogen BIIB . Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report CARDINAL HEALTH (CAH): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. However, hepatitis C virus (HCV) treatment Olysio continued to feel the impact of additional competition with sales declining 27% sequentially and 33.9% from the year-ago quarter.",276.1951599121094
2015-04-15 00:00:00+00:00,430.760009765625,432.739990234375,424.5700073242188,430.9599914550781,430.9599914550781,2038100.0,3.6666666666666665,1.0,0.6666916666666666,"BiogenBIIB announced positive new data from the phase II RENEW study on anti-LINGO-1 for acute optic neuritis (AON). Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report FORWARD PHARMA (FWP): Free Stock Analysis Report To read this article on Zacks.com click here. Results revealed statistically significant improvement in recovery of optic nerve conduction latency, as measured by full-field visual evoked potential (FF-VEP), in patients treated with anti-LINGO-1 at the last study visit (week 32) as compared to placebo. New Article Biogen BIIB provided detailed phase II results on anti-LINGO-1 for acute optic neuritis. Click to get this free report ALEXION PHARMA (ALXN): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GW PHARMA-ADR (GWPH): Free Stock Analysis Report TEKMIRA PHARMAC (TKMR): Free Stock Analysis Report To read this article on Zacks.com click here. The company, which had provided top-line results earlier this year, reported a statistically significant improvement in recovery of optic nerve conduction latency as compared to placebo. New Article Affymetrix Inc. AFFX , Biogen Inc. BIIB and Amgen Inc. AMGN are better-ranked stocks in the health care sector, carrying a Zacks Rank #1 (Strong Buy). Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The HealthCare segment at BayerBAYRY announced that it will be expanding the global clinical development program for its oncology candidate, copanlisib (BAY 80-6946).",289.58087158203125
2015-04-16 00:00:00+00:00,428.1400146484375,432.8800048828125,428.0,428.6499938964844,428.6499938964844,1109000.0,3.0,1.0,0.5000249999999999,"Some better-ranked stocks in the health care sector include Biogen Inc. BIIB and Affymetrix Inc. AFFX . Click to get this free report VIVUS INC (VVUS): Free Stock Analysis Report AFFYMETRIX INC (AFFX): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. VIVUS, Inc.VVUS has filed a lawsuit in the U.S. District Court for the District of New Jersey against Teva Pharmaceutical Industries Ltd. TEVA in response to an Abbreviated New Drug Application (ANDA) filed by the latter for the generic version of VIVUS' obesity product Qsymia capsules CIV. New Article Other favorably-placed stocks in the health care sector include Horizon Pharma plc HZNP , Biogen Inc. BIIB and Valeant Pharmaceuticals VRX . Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report To read this article on Zacks.com click here. We note that the FDA granted priority review and fast track designation to Corlanor for the treatment of chronic heart failure in Aug 2014 and Apr 2014, respectively.",301.9350280761719
2015-04-17 00:00:00+00:00,424.0,426.989990234375,416.8399963378906,419.4400024414063,419.4400024414063,1837600.0,3.333333333333333,1.0,0.5833583333333334,"Biogen ( BIIB ) is a Zacks Rank #1 stock with an Earnings ESP of +0.26%. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report To read this article on Zacks.com click here. Last month, AbbVie ( ABBV ) entered into an agreement to acquire Pharmacyclics ( PCYC ) for approximately $21 billion to gain partial rights to Imbruvica. New Article Other Stocks to Consider Here are some other companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter: Biogen Inc. BIIB , earnings ESP of +0.26% and a Zacks Rank #1. Click to get this free report ILLUMINA INC (ILMN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEI PHARMA INC (MEIP): Free Stock Analysis Report MIRATI THERAPTC (MRTX): Free Stock Analysis Report To read this article on Zacks.com click here. In fact, over the past four quarters, Illumina's earnings have outpaced the Zacks Consensus Estimate with an average beat of 20.3%. New Article Stocks to Consider Here are some companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter: Biogen Inc. BIIB , earnings ESP of +0.51% and a Zacks Rank #1 (Strong Buy). Click to get this free report INTUITIVE SURG (ISRG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEI PHARMA INC (MEIP): Free Stock Analysis Report MIRATI THERAPTC (MRTX): Free Stock Analysis Report To read this article on Zacks.com click here. In the last reported quarter, Intuitive Surgical's adjusted EPS of $4.18 steered past the Zacks Consensus Estimate by 21.8% or 75 cents, but declined 4.1% on a year-over-year basis.",292.8418273925781
2015-04-20 00:00:00+00:00,424.6600036621094,424.7699890136719,419.0,422.9200134277344,422.9200134277344,1183300.0,3.0,1.0,0.5000249999999999,"The Earnings ESP for Biogen BIIB is +0.51% and it carries a Zacks Rank #1. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report IMMUNOGEN INC (IMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Biotech major, AmgenAMGN , will be reporting first quarter earnings results on Apr 21 after the market closes. New Article A better-ranked stock in the same sector is Biogen Inc. ( BIIB ), holding a Zacks Rank #1 (Strong Buy). Click to get this free report CLOVIS ONCOLOGY (CLVS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Clovis Oncology, Inc. ( CLVS ) saw a big move last session, as the company's shares fell by over 5% on the day. New Article Some better-ranked stocks in the health care sector are AVEO Pharmaceuticals, Inc. AVEO and Biogen Inc. BIIB . Click to get this free report ATHERSYS INC (ATHX): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report To read this article on Zacks.com click here. Athersys, Inc.ATHX announced interim results from a phase II study on MultiStem cell therapy, which failed to show any significant difference as compared to placebo as measured by the Global Stroke Recovery Assessment scale. New Article Biogen Inc. BIIB has an Earnings ESP of +0.51% and carries a Zacks Rank #1. Click to get this free report ABBOTT LABS (ABT): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. However, strengthening of the dollar against almost every currency and declining oil prices have significantly clouded the global economic outlook for 2015. New Article Some better-ranked stocks in the health care sector are AVEO Pharmaceuticals, Inc. AVEO and Biogen Inc. BIIB . Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers Squibb CompanyBMY received encouraging news when its phase III study (CheckMate - 057) on intravenous human programmed death receptor-1 (PD-1) blocking antibody, Opdivo, was stopped early as an assessment conducted by the independent Data Monitoring Committee (DMC) concluded that the study has met its endpoint.",283.0632019042969
2015-04-21 00:00:00+00:00,425.1900024414063,426.1700134277344,420.1700134277344,422.1099853515625,422.1099853515625,1224600.0,3.416666666666666,1.0,0.6041916666666668,"The Earnings ESP for Biogen BIIB is +0.51% and it carries a Zacks Rank #1 (Strong Buy). Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report PHARMACYCLICS (PCYC): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report IMMUNOGEN INC (IMGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVieABBV , which has been in the news thanks to the approval of its hepatitis C virus (HCV) treatment Viekira Pak as well as its intention to acquire Pharmacyclics PCYC , will be reporting first quarter 2015 earnings results on Apr 23, before the market opens. New Article Other favorably-placed stocks in the health care sector include CorMedix, Inc. CRMD , AVEO Pharmaceuticals, Inc. AVEO and Biogen Inc. BIIB . Click to get this free report ACTAVIS PLC (ACT): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report CORMEDIX INC (CRMD): Free Stock Analysis Report To read this article on Zacks.com click here. Actavis plcACT received positive news on the regulatory front with the FDA expanded Botox's label for the treatment of adults with upper limb spasticity to include two thumb muscles (flexor pollicis longus and adductor pollicis) as well as an increase in the maximum dose of the drug from 360 to 400 units. New Article Other Stocks to Consider Here are some other companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter: Biogen Inc. BIIB , earnings ESP of +0.51% and a Zacks Rank #1. Click to get this free report RESMED INC (RMD): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEI PHARMA INC (MEIP): Free Stock Analysis Report MIRATI THERAPTC (MRTX): Free Stock Analysis Report To read this article on Zacks.com click here. The company has been focusing on product development and innovation for quite a few months now to maintain its leadership position in the sleep disordered breathing (SDB) market and expand its sales base. New Article Biogen BIIB with an Earnings ESP of +0.51% and a Zacks Rank #1. Click to get this free report BAXTER INTL (BAX): Free Stock Analysis Report ATHENAHEALTH IN (ATHN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NEKTAR THERAP (NKTR): Free Stock Analysis Report To read this article on Zacks.com click here. We expect the BioScience segment to report strong results owing to growing demand for Hemophilia drugs. New Article The Earnings ESP for Biogen BIIB is +0.51% and it carries a Zacks Rank #1 (Strong Buy). Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report IMMUNOGEN INC (IMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Eli Lilly and CompanyLLY is set to report first quarter 2015 earnings results on Apr 23 before the market opens. New Article Biogen BIIB with an Earnings ESP of +0.51% and a Zacks Rank #1. Click to get this free report BOSTON SCIENTIF (BSX): Free Stock Analysis Report BARD C R INC (BCR): Free Stock Analysis Report ATHENAHEALTH IN (ATHN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Factors at Play We believe that Lutonix drug coated-balloon (DCB) will be the key growth catalyst for Bard in the first quarter. New Article The Earnings ESP for Biogen BIIB is +0.51% and it sports a Zacks Rank #1. Click to get this free report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report IMMUNOGEN INC (IMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Alexion Pharmaceuticals, Inc.ALXN is scheduled to report first-quarter 2015 earnings results on Apr 23, before the opening bell. New Article Some better-ranked stocks in the health care sector are AVEO Pharmaceuticals, Inc. AVEO and Biogen Inc. BIIB . Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report To read this article on Zacks.com click here. Results revealed that patients treated with the combination regimen showed a much higher objective response rate (ORR) of 61% as compared to 11% in those under Yervoy monotherapy. New Article A stock worth considering in the Med-Products space is Biogen Inc. ( BIIB ) with a Zacks Rank #1 (Strong Buy). Click to get this free report FATE THERAPEUTC (FATE): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The move continues the recent uptrend of the company as the stock has gained roughly 36% in the past one-month time frame. New Article Biogen BIIB with an Earnings ESP of +0.51% and a Zacks Rank #1. Click to get this free report MEDASSETS INC (MDAS): Free Stock Analysis Report HEALTHWAYS INC (HWAY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AIR METHODS CRP (AIRM): Free Stock Analysis Report To read this article on Zacks.com click here. Factors at Play Healthways has a substantial and active pipeline of potential contracts with new and existing customers in both domestic and international markets. New Article Stocks to Consider Here are some companies you may want to consider instead as our model shows they have the right combination of elements to post an earnings beat this quarter: Biogen Inc. BIIB , earnings ESP of +0.51% and a Zacks Rank #1. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEI PHARMA INC (MEIP): Free Stock Analysis Report MEAD JOHNSON NU (MJN): Free Stock Analysis Report MIRATI THERAPTC (MRTX): Free Stock Analysis Report To read this article on Zacks.com click here. Factors at Play As the company enters 2015, management expects to face significant headwinds from a strengthening dollar and thus anticipates earnings to remain partially exposed to currency fluctuations. New Article A better-ranked stock in the health care space is Biogen Inc. BIIB carrying a Zacks Rank #1 (Strong Buy). Click to get this free report PHARMACYCLICS (PCYC): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. In a separate press release, the company announced that Imbruvica was effective in the treatment of pancreatic ductal adenocarcinoma as far as results from a transgenic mouse model and an in-vivo model of patient-derived xenograft mice (grafts of tissue taken from a pancreatic cancer patient and grafted into a mouse) are concerned.",288.033935546875
2015-04-22 00:00:00+00:00,423.8800048828125,425.9599914550781,418.54998779296886,423.57000732421886,423.57000732421886,1298200.0,3.5,1.0,0.6250249999999999,"Better-ranked stocks in the med-biomed/generic industry include Biogen Inc. BIIB , CorMedix, Inc. CRMD and Cytori Therapeutics, Inc. CYTX . Click to get this free report ILLUMINA INC (ILMN): Free Stock Analysis Report CYTORI THERAPEU (CYTX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CORMEDIX INC (CRMD): Free Stock Analysis Report To read this article on Zacks.com click here. An increased demand from clinical customers, solid operational execution and a greater-than-anticipated tax benefit contributed to the impressive year-over-year improvement in Illumina's first quarter adjusted EPS. New Article Some better-ranked stocks in the health care sector are Biogen Inc. BIIB , Horizon Pharma plc HZNP and Amgen Inc. AMGN . Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report To read this article on Zacks.com click here. In the rest of the world, sales increased 10%, primarily due to strong performance at emerging markets like China and several countries in Asia and Latin America. New Article Other equally well-ranked biotech stocks include Biogen BIIB and Osiris Therapeutics OSIR . Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report OSIRIS THERAPTC (OSIR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues of Amgen's other ESA, Epogen, grew 16% to $534 million, mainly driven by price increase and to a lesser extent by higher demand. New Article Stocks recently featured in the blog include the Gilead Sciences Inc. ( GILD - Free Report ), Biogen Inc. ( BIIB - Free Report ), Geron Corp. ( GERN - Free Report ), Johnson & Johnson ( JNJ - Free Report ) and Anthera Pharmaceuticals, Inc. ( ANTH - Free Report ). Among the large-cap biotech companies, Biogen Inc. ( BIIB - Free Report ) with a focus on neurology, immunology and hemophilia looks attractive. Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report GERON CORP (GERN): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ANTHERA PHARMA (ANTH): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Other Stocks to Consider Here are some other companies you may want to consider as our model shows they have the right combination of elements to post an earnings beat this quarter: Biogen Inc. BIIB , earnings ESP of +0.51% and a Zacks Rank #1. Click to get this free report EDWARDS LIFESCI (EW): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MEI PHARMA INC (MEIP): Free Stock Analysis Report MIRATI THERAPTC (MRTX): Free Stock Analysis Report To read this article on Zacks.com click here. Over the past few quarters, Edwards has successfully retained its place in the MedTech headlines on the back of a strong product portfolio, which is expected to further strengthen its foothold across all of its operating businesses. New Article Some better-ranked stocks in the health care sector include CorMedix, Inc. CRMD and Biogen BIIB . Click to get this free report IMMUNOMEDICS (IMMU): Free Stock Analysis Report UCB SA (UCBJF): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CORMEDIX INC (CRMD): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline and regulatory updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. New Article The Earnings ESP for Biogen BIIB is +0.51% and it sports a Zacks Rank #1 (Strong Buy). Click to get this free report INCYTE CORP (INCY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AGENUS INC (AGEN): Free Stock Analysis Report IMMUNOGEN INC (IMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Although the company's revenues were rising in the last few quarters, its bottom line was affected by higher operating expenses. New Article Among the better-ranked stocks in the health care sector are Amgen Inc. AMGN and Biogen Idec Inc. BIIB . Click to get this free report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Alnylam Pharmaceuticals, Inc.ALNY announced encouraging results from its phase II open-label extension (OLE) study on patisiran. New Article Later this week, companies like AbbVie ABBV and Biogen BIIB will be reporting first quarter results. Click to get this free report MEDICINES CO (MDCO): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report To read this article on Zacks.com click here. Earnings season in the biotech sector started on a positive note with Amgen AMGN reporting better-than-expected first quarter 2015 results. New Article Specialty Sciences: Segmental revenues came in at $81.9 million due to royalties received by Perrigo on multiple sclerosis drug Tysabri from Biogen Inc. BIIB . Click to get this free report TEVA PHARM ADR (TEVA): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. Perrigo Company 's PRGO third-quarter fiscal 2015 (ended Mar 28, 2015) earnings of $1.85 per share beat the Zacks Consensus Estimate of $1.80.",299.504638671875
2015-04-23 00:00:00+00:00,423.0,431.8399963378906,421.0,430.2799987792969,430.2799987792969,1938200.0,3.181818181818181,1.0,0.5454795454545455,"Some better-ranked stocks in the health care sector include Biogen BIIB , AVEO Pharmaceuticals, Inc. AVEO and Agenus, Inc. AGEN . Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report AGENUS INC (AGEN): Free Stock Analysis Report To read this article on Zacks.com click here. First-quarter revenues slipped 1% to $4.645 billion, reflecting generic competition for Cymbalta and Evista in the U.S. as well as negative currency movement. New Article Biogen IDEC ( BIIB ) also dropped on an earnings miss, while Microsoft ( MSFT ) surged after its Q1 report late Thursday that beat the Street. Biogen Idec ( BIIB ) shares gave up earlier pre-market gains after reporting Q1 earnings and revenue that fell short of analysts' estimates. Steven Madden (SHOO), a footwear and accessories designer and marketer, reported Q1 results that topped the Street view on EPS and total revenues as the company reaffirmed full year guidance. New Article Baxter's Bioscience business, which is scheduled to be spun out as Baxalta later this year, was the star of the show with sales growing 8% at constant currencies. In the middle of next month, the separate management teams plan to hold investor meetings to break out their individual outlooks for the companies, including financial guidance. In March, the drug passed a phase 3 trial, although it needs to expand manufacturing before it can submit marketing applications to regulators. New Article A better-ranked stock in the biotech sector is Biogen BIIB with a Zacks Rank #1 (Strong Buy). Click to get this free report ABBVIE INC (ABBV): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report PHARMACYCLICS (PCYC): Free Stock Analysis Report To read this article on Zacks.com click here. Growing awareness, favorable clinical data, additional indications and expansion into new markets should help the product to continue contributing significantly to the top-line. New Article Other well-ranked stocks in the biotech sector include Biogen Inc. BIIB and AVEO Pharmaceuticals, Inc. AVEO . Click to get this free report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report To read this article on Zacks.com click here. Isis Pharmaceuticals, Inc.ISIS announced encouraging data from an ongoing open-label extension (OLE) study on ISIS-TTR for the treatment of patients suffering from familial amyloid polyneuropathy (FAP). New Article Acorda has a licensing agreement with Biogen BIIB for Fampyra in markets outside the U.S. Acorda is currently working on expanding Ampyra's label into additional indications. Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc.ACOR presented data from a phase I study on rHIgM22, a remyelinating antibody being evaluated for the treatment of multiple sclerosis (MS). New Article Some better-ranked stocks in the health care sector include CorMedix, Inc. CRMD , AVEO Pharmaceuticals, Inc. AVEO and Biogen BIIB . Click to get this free report CAPRICOR THERAP (CAPR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report CORMEDIX INC (CRMD): Free Stock Analysis Report To read this article on Zacks.com click here. Capricor Therapeutics, Inc.CAPR announced that CAP-1002 has been granted orphan drug status by the FDA for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). New Article Biogen BIIB , a strong player in the multiple sclerosis (MS) market, will be reporting first quarter 2015 earnings results on Apr 24, before the market opens. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report UTD THERAPEUTIC (UTHR): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. However, on a brighter note, the top-line should benefit from the continuing sales ramp up of Plegridy and the hemophilia products - Alprolix and Eloctate. New Article Biogen Inc. ( BIIB ) is reporting for the quarter ending March 31, 2015. BIIB missed the consensus earnings per share in the 1st calendar quarter of 2014 by -5.04%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for BIIB is 24.97 vs. an industry ratio of -10.70, implying that they will have a higher earnings growth than their competitors in the same industry. New Article Biogen BIIB is a better-ranked stock in the health care space carrying a Zacks Rank #1 (Strong Buy). Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Gilead Sciences, Inc.GILD announced encouraging data from several phase II studies evaluating hepatitis C virus (HCV) drug Harvoni and other Sovaldi-based regimens in HCV infected patients with advanced liver disease, including patients with decompensated cirrhosis, fibrosing cholestatic hepatitis C and portal hypertension. New Article Some better-ranked stocks in the health care space include Biogen Inc. BIIB , AVEO Pharmaceuticals, Inc. AVEO and Horizon Pharma HZNP . Click to get this free report EMERGENT BIOSOL (EBS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report To read this article on Zacks.com click here. The company was investigating its operations along with that of its suppliers and contract manufacturers after it discovered foreign particles in a limited number of vials in two manufactured lots of BioThrax earlier in the year.",304.0128479003906
2015-04-24 00:00:00+00:00,410.0,410.8699951171875,395.0,401.7099914550781,401.7099914550781,6084400.0,3.3333333333333326,1.0,0.5833583333333334,"Biogen blamed everything except perhaps the weather for the slowdown: One fewer shipping week in the U.S. versus the prior quarter Increased discounts and allowances specific to the first quarter of 2015 Slight drawdown of inventory at specialty pharmacies Updated pricing assumptions in Germany Currency changes Launch of Biogen's Plegridy Overall slowing of the multiple sclerosis market Last year's case of progressive multifocal leukoencephalopathy Let's run through the excuses: The number of shipping weeks is certainly the best excuse up there, since it isn't going to affect the growth trajectory. The bigger issue is whether patients and their doctors are worried about progressive multifocal leukoencephalopathy, a potentially deadly brain infection. If the issue keeps patients from switching and the growth of the overall multiple sclerosis market is slowing, it'll make it hard for Biogen to keep Tecfidera growing. New Article While there were a few sectors in the Nasdaq that were noticeably softer -- semiconductors and biotechs were both lower on missed earnings from Biogen ( BIIB ) and Altera ( ALTR ) -- the record high for shares of Amazon and Starbucks elevated the tech-heavy index at the open and kept it buoyant at 5100 despite today's disappointing data on durable goods orders. (-) BIIB (-6.60%) Q1 results miss estimates, Evercore says MS drug sales were weak (-) IMGN (-2.54%) Reported weaker-than-expected fiscal Q3 earnings and sales and cut its FY sales guidance. Investors were spooked by the lack of business investment, sending the Dow and S&P 500 lower at the open, while the Nasdaq continued to gain altitude. New Article Biogen BIIB is a better-ranked stock in the health care space carrying a Zacks Rank #1 (Strong Buy). Click to get this free report MERCK & CO INC (MRK): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Merck & Co. Inc.MRK reported encouraging data from an ongoing pivotal (C-EDGE) phase III program evaluating its once-daily combination regimen - grazoprevir (NS3/4A proteaseinhibitor)/elbasvir (NS5A replication complex inhibitor) - in patients with or without cirrhosis who are infected with chronic hepatitis C virus (HCV) genotypes 1, 4 or 6. New Article Biotech company, BiogenBIIB , reported first quarter 2015 earnings per share of $3.82 (including the impact of stock-based compensation expense), well below the Zacks Consensus Estimate of $3.91 but 55.9% above the year-ago earnings. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CYTORI THERAPEU (CYTX): Free Stock Analysis Report OSIRIS THERAPTC (OSIR): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report To read this article on Zacks.com click here. Oral multiple sclerosis (MS) drug Tecfidera grew 63.1% from the year-ago period to $824.9 million. New Article Cambridge, MA-based Biogen ( BIIB ), one of the world's leading biotechnology companies, focuses on therapeutic areas including neurology, immunology and hemophilia. BIIB has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last three quarters with an average surprise of 11.6% in the last four quarters. Currently, BIIB has a Zacks Rank #1 (Strong Buy), but that could definitely change following the company's earnings report which was just released. New Article Some better-ranked stocks in the health care sector are Actelion ALIOF , Biogen Idec BIIB and Horizon Pharma HZNP , each carrying a Zacks Rank #1 (Strong Buy). Click to get this free report INTERCEPT PHARM (ICPT): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report To read this article on Zacks.com click here. Intercept PharmaceuticalsICPT released post-hoc analyses from the phase IIb trial, FLINT, on lead candidate obeticholic acid (OCA) in patients suffering from nonalcoholic steatohepatitis (NASH).",303.0892028808594
2015-04-27 00:00:00+00:00,401.75,403.4500122070313,388.0799865722656,389.2699890136719,389.2699890136719,3432000.0,3.0,1.0,0.5000249999999999,"Stocks recently featured in the blog include the Biogen Inc. ( BIIB ), NV5 Holdings, Inc. ( NVEE ), Tractor Supply Company ( TSCO ), ULTA Salon, Cosmetics & Fragrance, Inc. ( ULTA ) and Intuit Inc. ( INTU ). For instance, Biogen Inc. ( BIIB ) has gained 27% year-to-date and is up 48% over the last 12 months. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report NV5 HOLDING INC (NVEE): Free Stock Analysis Report TRACTOR SUPPLY (TSCO): Free Stock Analysis Report ULTA SALON COSM (ULTA): Free Stock Analysis Report INTUIT INC (INTU): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Biogen BIIB and Actelion Ltd. ALIOF are two better-ranked stocks in the health care sector carrying a Zacks Rank #1 (Strong Buy). Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Gilead Sciences, Inc.GILD and Bristol-Myers Squibb Company BMY announced encouraging results from their respective studies on hepatitis C virus (HCV). New Article  Shares of American Airlines Group Inc. ( AAL ) gained 2.4% after the company reported earnings per share of $1.73, beating the Zacks Consensus Estimate by 3 cents  Biogen Inc.'s ( BIIB ) shares declined 6.6% after the company posted first quarter earnings per share of $3.82, below the Zacks Consensus Estimate of $3.91  Shares of Xerox Corporation ( XRX ) dropped 8.8% after the company reported first quarter revenues of $4.469 billion that missed the Zacks Consensus Estimate of $4.511 billion  Shares of Juniper Networks, Inc. ( JNPR ) climbed 8.9% after the company posted first quarter revenues of $1.067 billion that beat the Zacks Consensus Estimate of $1.044 billion Want the latest recommendations from Zacks Investment Research? Click to get this free report AMER AIRLINES (AAL): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report XEROX CORP (XRX): Free Stock Analysis Report JUNIPER NETWRKS (JNPR): Free Stock Analysis Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days.",304.16864013671875
2015-04-28 00:00:00+00:00,388.7999877929688,391.8699951171875,374.3599853515625,374.6799926757813,374.6799926757813,4923900.0,2.4444444444444446,1.0,0.3611361111111111,"Another attractive stock, Biogen BIIB , declined more than 3% on Apr 27 to end the day's trading at $389.27. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELLADON CORP (CLDN): Free Stock Analysis Report To read this article on Zacks.com click here. Celladon Corp.'s CLDN shares took a nosedive of 80.7% on Monday to end the day's trading at $2.64 after announcing that its lead candidate, Mydicar, has failed to meet both the primary and secondary endpoints in the phase IIb CUPID2 study. New Article In a phase 1b trial targeted at Alzheimer's disease patients, aducanumab (previously known as BIIB037) led to a pronounced degree of beta amyloid removal -- beta amyloid is the plaque that sticks to our brains and progressively disrupts cognitive function -- and a substantial improvement in two cognitive function tests. In the case of Gilead Sciences, it has two relatively new hepatitis C therapies (Sovaldi and Harvoni) which have dramatically boosted HCV cure rates into the 90-percentile while also reducing the severity of side effects when compared to previous standards of care. On top of its HCV dynamic duo, Gilead Sciences also has several blockbuster HIV/AIDS drugs, including Stribild, which eliminated all detectable traces of the HIV-1 virus in a late-stage clinical trial at the 48-week mark. New Article Meanwhile, in the branded segment, Copaxone should continue to grow modestly in the U.S. Copaxone could well benefit from the concerns surrounding the use of Biogen's BIIB oral multiple sclerosis (MS) treatment, Tecfidera. Click to get this free report TEVA PHARM ADR (TEVA): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. Teva Pharmaceutical Industries LimitedTEVA is scheduled to report its first-quarter 2015 earnings results on Apr 30, before the opening bell. New Article Investors looking for well-ranked stocks in the health care sector may consider Biogen Inc. BIIB , Horizon Pharma plc HZNP and AVEO Pharmaceuticals, Inc. AVEO . Click to get this free report CELLADON CORP (CLDN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report To read this article on Zacks.com click here. Celladon Corporation 's CLDN shares plummeted 80.7% following the company's announcement that randomized, double-blind, placebo-controlled, multinational phase IIb study (CUPID2) on advanced heart failure patients was unsuccessful in meeting both primary and secondary endpoints. New Article Some better-ranked stocks in the health care sector include Biogen BIIB and Amgen AMGN . Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report HOSPIRA INC (HSP): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. GIP segment revenues remained flat at $3.1 billion reflecting the performance of Lyrica in the U.S. and Japan, Xeljanz in the U.S. and Eliquis across the world. New Article Shares of Biogen Inc. ( BIIB ) dropped 3.1% after safety concerns compelled patients to reconsider using its multiple-sclerosis drug. Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report CELLADON CORP (CLDN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report RESTAURANT BRND (QSR): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report UNITEDHEALTH GP (UNH): Free Stock Analysis Report KB HOME (KBH): Free Stock Analysis Report BEAZER HOMES (BZH): Free Stock Analysis Report To read this article on Zacks.com click here. For a look at the issues currently facing the markets, make sure to read today's Ahead of Wall Street article The Dow Jones Industrial Average (DJI) declined 0.2% to close at 18,037.97. New Article A better-ranked stock in the health care space is Biogen BIIB . Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. In March this year, Opdivo received its second FDA approval for the treatment of patients suffering from metastatic squamous non-small cell lung cancer with progression on or after platinum-based chemotherapy. New Article Some better-ranked stocks in the health care space include Biogen BIIB and AVEO Pharmaceuticals, Inc. AVEO . Click to get this free report HOSPIRA INC (HSP): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report To read this article on Zacks.com click here. Strong sales of drugs in the company's Specialty Injectable Pharmaceuticals (SIP) and Other Pharma segments benefited the top line. New Article Some better-ranked stocks in the health care sector include CorMedix, Inc. CRMD , AVEO Pharmaceuticals, Inc. AVEO and Biogen BIIB . Click to get this free report REDHILL BIO-ADR (RDHL): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report CORMEDIX INC (CRMD): Free Stock Analysis Report To read this article on Zacks.com click here. The ERADICATE Hp study will evaluate the safety and efficacy of RHB-105 as a first-line treatment for confirmed H. pylori bacterial infection.",296.938720703125
2015-04-29 00:00:00+00:00,377.9700012207031,388.4500122070313,376.0,383.7799987792969,383.7799987792969,3255600.0,3.75,1.0,0.6875249999999999,"Stocks recently featured in the blog include the Celladon Corp. ( CLDN ), Amgen ( AMGN ), Biogen ( BIIB ) and Alnylam Pharmaceuticals, Inc. ( ALNY ). Another attractive stock, Biogen ( BIIB ), declined more than 3% on Apr 27 to end the day's trading at $389.27. Click to get this free report CELLADON CORP (CLDN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Some better-ranked biotech stocks include Biogen BIIB and Amgen AMGN . Click to get this free report CELLDEX THERAPT (CLDX): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Celldex recognizes revenues from product development and licensing agreements and contracts and grants. New Article Other Stocks to Consider Apart from BioMarin, CorMedix, Inc. CRMD , AVEO Pharmaceuticals, Inc. AVEO and Biogen BIIB also carry a Zacks Rank #1 (Strong Buy). Click to get this free report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report CORMEDIX INC (CRMD): Free Stock Analysis Report To read this article on Zacks.com click here. Continued strong performance of key products like Naglazyme, Aldurazyme, Kuvan, Vimizim and Firdapse should help the company achieve its guidance. New Article Other equally well-ranked stocks in the health care sector include CorMedix, Inc. CRMD , AVEO Pharmaceuticals, Inc. AVEO and Biogen BIIB . Click to get this free report AETERNA ZENTARS (AEZS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report CORMEDIX INC (CRMD): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company.",291.32977294921875
2015-04-30 00:00:00+00:00,380.8900146484375,383.8299865722656,368.8800048828125,373.9299926757813,373.9299926757813,2685900.0,3.0,1.0,0.5000249999999999,"Stocks recently featured in the blog include the Amgen ( AMGN ), Celladon ( CLDN ), Biogen ( BIIB ), Celgene ( CELG ) and Gilead ( GILD ). Meanwhile, Biogen's ( BIIB ) results were also a disappointment. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report CELLADON CORP (CLDN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Some better-ranked stocks in the health care sector include Biogen BIIB , CorMedix, Inc. CRMD and Cytori Therapeutics, Inc. CYTX . Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report CYTORI THERAPEU (CYTX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CORMEDIX INC (CRMD): Free Stock Analysis Report To read this article on Zacks.com click here. Operating expenses will go up as the company gears up for the potential launch of Orkambi (the Kalydeco-lumacaftor combination - FDA action date: Jul 5; EU approval could come in the fourth quarter) and a phase III program evaluating VX-661+Kalydeco. New Article Some better-ranked stocks in the broader healthcare sector include Biogen Inc. BIIB , and Horizon Pharma plc HZNP . Click to get this free report AMERISOURCEBRGN (ABC): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report WALGREENS BAI (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. AmerisourceBergen Corp.ABC posted earnings (excluding employee severance, LIFO expense, warrants, litigation, restructuring and acquisition costs) of $1.45 per share in the second quarter of fiscal 2015, beating the Zacks Consensus Estimate of $1.18 and above the year-ago figure of $1.06. New Article Some better-ranked stocks in the health care sector include Biogen BIIB , CorMedix, Inc. CRMD and Cytori Therapeutics, Inc. CYTX . Click to get this free report CELGENE CORP (CELG): Free Stock Analysis Report CYTORI THERAPEU (CYTX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CORMEDIX INC (CRMD): Free Stock Analysis Report To read this article on Zacks.com click here. Quarter in Details Net sales of Revlimid, the key growth driver at Celgene, came in at $1.3 billion, reflecting an increase of 17.4% over the year-ago period.",287.55572509765625
2015-05-01 00:00:00+00:00,377.5199890136719,388.1400146484375,377.5199890136719,386.2200012207031,386.2200012207031,2737400.0,3.6666666666666665,1.0,0.6666916666666668,"Some better-ranked stocks in the health care sector include Biogen BIIB and Cytori Therapeutics, Inc. CYTX . Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report CYTORI THERAPEU (CYTX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Gilead Sciences, Inc. 's GILD first-quarter earnings (including stock-based compensation expenses) of $2.89 per share surpassed the Zacks Consensus Estimate of $2.78. New Article Some better-ranked stocks in the health care sector are Biogen Inc. BIIB , Actelion Ltd. ALIOF and Horizon Pharma plc HZNP . Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report To read this article on Zacks.com click here. Earlier this week, Bristol-Myers Squibb CompanyBMY announced that the FDA has accepted its supplemental Biologics License Application (sBLA) for Opdivo for treatment-naive patients suffering from unresectable or metastatic melanoma. New Article Some better-ranked stocks in the health care sector include CorMedix, Inc. CRMD , Aeterna Zentaris Inc. AEZS and Biogen BIIB . Click to get this free report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AETERNA ZENTARS (AEZS): Free Stock Analysis Report ONCOLYTICS BIO (ONCY): Free Stock Analysis Report CORMEDIX INC (CRMD): Free Stock Analysis Report To read this article on Zacks.com click here. Oncolytics Biotech Inc. 's ONCY lead pipeline candidate, Reolysin has been granted orphan drug status by the EMA for the treatment of pancreatic cancer. New Article Some better-ranked stocks in the broader health care sector include Biogen Inc. BIIB , Arqule Inc. ARQL and Horizon Pharma plc HZNP . Click to get this free report VALEANT PHARMA (VRX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report ARQULE INC (ARQL): Free Stock Analysis Report To read this article on Zacks.com click here. Valeant Pharmaceuticals International, IncVRX reported first-quarter 2015 cash earnings per share of $2.36 (excluding special items and non-cash expenses), up from the year-ago figure of $1.76. New Article Some other well-ranked stocks in the health care sector include Actelion Ltd. ALIOF and Biogen Inc. BIIB , both carrying a Zacks Rank #1 (Strong Buy). Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Consensus Estimate for total revenues of $873 million is within the company's updated guidance. New Article Other well-ranked stocks in the health care sector include Biogen BIIB , CorMedix, Inc. CRMD and Cytori Therapeutics, Inc. CYTX . Click to get this free report CYTORI THERAPEU (CYTX): Free Stock Analysis Report SURMODICS (SRDX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report CORMEDIX INC (CRMD): Free Stock Analysis Report To read this article on Zacks.com click here. The company expects research and development expenses to increase by approximately 5% to 7% in fiscal 2015 primarily driven by the drug coated balloon program.",284.61077880859375
2015-05-04 00:00:00+00:00,389.4500122070313,393.8900146484375,384.75,386.2200012207031,386.2200012207031,1456400.0,3.4,1.0,0.6000250000000001,"Stocks recently featured in the blog include the Bristol-Myers Squibb Company ( BMY ), Biogen Inc. ( BIIB ), Actelion Ltd. ( ALIOF ) and Horizon Pharma plc ( HZNP ). Some better-ranked stocks in the health care sector are Biogen Inc. ( BIIB ), Actelion Ltd. ( ALIOF ) and Horizon Pharma plc ( HZNP ). Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Some better-ranked med-biomed/generic stocks are Biogen Inc. BIIB , BioMarin Pharmaceutical Inc. BMRN and Illumina Inc. ILMN . Click to get this free report ILLUMINA INC (ILMN): Free Stock Analysis Report INTEGRA LIFESCI (IART): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. However, including certain one-time items, the company reported net income of $8.4 million or 25 cents per share, reflecting a massive year-over-year improvement of 280.1% or 257.1%, respectively. New Article Other well-ranked stock in the health care space includes Biogen BIIB carrying a Zacks Rank #1 (Strong Buy). Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report PHARMACYCLICS (PCYC): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that Imbruvica gained FDA approval for all lines of therapy for the treatment of patients suffering from Waldenstrom's macroglobulinemia (WM) in Jan 2015. New Article Ampyra is marketed in ex-U.S. markets under the trade name Fampyra by Biogen BIIB . Click to get this free report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline Update Acorda is currently evaluating a twice-daily formulation of Ampyra in a phase III study for post-stroke deficits. New Article Some better-ranked stocks in the health care sector include Aeterna Zentaris Inc. AEZS and Biogen BIIB . Click to get this free report KYTHERA BIOPHRM (KYTH): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AETERNA ZENTARS (AEZS): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline and regulatory updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. New Article Based on Celgene's 2020 projections of at least $20 billion in sales and $12.50 in EPS, the company still appears to have room to run. This $19 trillion industry could destroy the Internet One bleeding-edge technology is about to put the World Wide Web to bed. You can follow him on CAPS under the screen name TMFUltraLong , track every pick he makes under the screen name TrackUltraLong , and check him out on Twitter, where he goes by the handle @TMFUltraLong .The Motley Fool recommends Celgene, Coca-Cola, and Gilead Sciences. New Article Factors at Play This Quarter Isis Pharma's antisense drug delivery platform has resulted in partnerships with leading health care companies including Biogen BIIB and GlaxoSmithKline GSK among others and provides the company with a steady stream of funds in the form of upfront, milestone and other payments. Click to get this free report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report ACTAVIS PLC (ACT): Free Stock Analysis Report To read this article on Zacks.com click here. During the first quarter, Isis Pharma received several milestone payments from partners Glaxo and Biogen which should boost revenues. New Article A better-ranked stock in the health care sector is Biogen Inc. BIIB carrying a Zacks Rank #1 (Strong Buy). Click to get this free report NEKTAR THERAP (NKTR): Free Stock Analysis Report BAXTER INTL (BAX): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Nektar reported disappointing top-line data from the phase III study (BEACON) on NKTR-102 (metastatic breast cancer) in March this year. New Article Some better-ranked stocks in the health care sector include BioMarin Pharmaceutical Inc. BMRN and Biogen Inc. BIIB . Click to get this free report ALKERMES INC (ALKS): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Manufacturing and royalty revenues included $46.9 million (down 5.4%) from the company's long-acting atypical antipsychotic franchise, Risperdal Consta and Invega Sustenna. New Article Another better-ranked stock in the health care sector is Biogen Inc. BIIB carrying a Zacks Rank #1 (Strong Buy). Click to get this free report INCYTE CORP (INCY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Last December, the FDA approved Jakafi for the treatment of patients with polycythemia vera (PV) who have had an inadequate response or are intolerant to hydroxyurea.",293.73968505859375
2015-05-05 00:00:00+00:00,385.0,388.4500122070313,381.0,385.7999877929688,385.7999877929688,1594800.0,2.6666666666666665,1.0,0.4166916666666666,"Some better-ranked stocks in the health care sector are Biogen Inc. BIIB , Actelion Ltd. ALIOF and Horizon Pharma HZNP . Click to get this free report ZOETIS INC (ZTS): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report To read this article on Zacks.com click here. Zoetis markets its offerings primarily across the following species: cattle, swine, poultry, others (livestock) and dogs, cats and horses (companion animals). New Article But health/biotech funds tumbled 3.1%, hit in part by soft earnings fromBiogen ( BIIB ) and a sales miss forCelgene ( CELG ). Emerging markets were also among bond-fund winners last month, ticking along nicely as investors sought out riskier assets in the face of lackluster economic data. That fear -- despite the Fed's move to keep rates lower for longer -- also weighed on companies involved in producing and delivering gas, water and power. New Article Because of better screening procedures during blood transfusions since the 1990s and the recent advent of powerful new treatments like Sovaldi/Harvoni, these vital markets could disappear within the next decade, casting doubt on the duo's long-term sustainability in terms of value creation. And then you have all of the clinical-stage oncology specialists such as Kite Pharma and Juno Therapeutics , among many others, that trade at mind-blowing valuations based on their real-world prospects of ever bringing an actual drug to market. Gilead could thus pay cash for both of these companies and still have plenty left over for additional acquisitions, making them fairly low-risk assets that would significantly augment the biotech's fledgling cancer pipeline.",313.845458984375
2015-05-06 00:00:00+00:00,387.25,389.989990234375,380.4100036621094,383.55999755859375,383.55999755859375,1279700.0,3.5,1.0,0.6250249999999999,"CVS runs the pharmacies that dispense drugs made by Biogen and others, including a massive chain of pharmacy-equipped convenience stores. In other words, Enanta and Biogen may depend on Aspen's products to optimize their own manufacturing and supply chain processes, hooking right in to CVS at the end of the line. To learn more about what The Motley Fool thinks about current investment trends, and receive a special free report about what might be the next big industry to come out of Silicon Valley, just click here now . New Article Isis Pharma has partnership programs with companies like Biogen BIIB among others. Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Isis Pharma expanded its partnership portfolio by announcing an agreement with Bayer's BAYRY HealthCare division under which the latter will develop and commercialize the former's ISIS-FXIRx for the prevention of thrombosis.",309.9115295410156
2015-05-07 00:00:00+00:00,384.0,388.0700073242188,380.6099853515625,383.2900085449219,383.2900085449219,1298100.0,2.0,1.0,0.250025,"BIIB data by YCharts What: Shares of biotech blue chip stock Biogen were creamed in April, with its shares dipping 11% according to data from S&P Capital IQ , after the company reported disappointing first-quarter earnings results on April 24. Sales of the drug were about $110 million below what Wall Street had been expecting, and ultimately this translated into an adjusted profit of $3.82 per share, also $0.09 light of consensus estimates. For investors it means Biogen's top-line growth is going to slow unless its hemophilia drugs and Plegridy really ramp up quickly.",303.183837890625
2015-05-11 00:00:00+00:00,403.2000122070313,404.0,395.0,396.9100036621094,396.9100036621094,1574400.0,4.0,1.0,0.7500249999999999,"AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports AMGN's forecasted earnings growth in 2015 as 10.18%, compared to an industry average of 6.8%. The following ETF(s) have AMGN as a top-10 holding: iShares Nasdaq Biotechnology Index Fund ( IBB ) PowerShares Dynamic Pharmaceuticals ( PJP ) PowerShares Dynamic Biotech &Genome ( PBE ) SPDR Select Sector Fund - Health Care ( XLV ) Market Vectors Biotech ETF ( BBH ).",303.0902099609375
2015-05-13 00:00:00+00:00,396.0,398.3800048828125,388.7200012207031,390.0400085449219,390.0400085449219,1169500.0,3.0,1.0,0.5000249999999999,Biogen BIIB was the highest gainer (23.14%) over the last six months. Click to get this free report ALEXION PHARMA (ALXN): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report OREXIGEN THERAP (OREX): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SYNAGEVA BIOPHM (GEVA): Free Stock Analysis Report NEWLINK GENETIC (NLNK): Free Stock Analysis Report To read this article on Zacks.com click here. Orexigen and partner Takeda announced that they will be terminating their cardiovascular (CV) outcomes trial - the Light Study - based on the recommendation of the Executive Steering Committee (ESC).,300.8337097167969
2015-05-14 00:00:00+00:00,392.9800109863281,395.1099853515625,387.3699951171875,394.3500061035156,394.3500061035156,1612600.0,2.0,1.0,0.250025,"What: Shares of Sangamo Biosciences fell as much as 12% today after providing a clinical update at the annual meeting of the American Society of Gene and Cell Therapy. This press release follows yesterday's update in which Sangamo and its partner Biogen Idec announced a decision to consolidate development paths for its zinc finger nuclease (ZFN)-mediated genome editing programs targeting beta-thalassemia and sickle cell disease. This consolidation, which Sangamo claims will lead to greater efficiency, will result in a delay of its Phase 1 clinical trial start date, which is now slated to begin in 2016.",299.22991943359375
2015-05-21 00:00:00+00:00,400.239990234375,401.6499938964844,397.9700012207031,401.1499938964844,401.1499938964844,859000.0,2.0,1.0,0.250025,"Biotech stocks such as Amgen Inc. ( AMGN ), Regeneron Pharmaceuticals, Inc. ( REGN ) and Biogen Inc. ( BIIB ) increased 0.3% 1.7% and 1.5%, respectively. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report EXXON MOBIL CRP (XOM): Free Stock Analysis Report CHEVRON CORP (CVX): Free Stock Analysis Report SCHLUMBERGER LT (SLB): Free Stock Analysis Report CONOCOPHILLIPS (COP): Free Stock Analysis Report KB HOME (KBH): Free Stock Analysis Report HOME DEPOT (HD): Free Stock Analysis Report LOWES COS (LOW): Free Stock Analysis Report TARGET CORP (TGT): Free Stock Analysis Report To read this article on Zacks.com click here. Benchmarks ended mixed yesterday after Fed minutes showed officials looked past a June rate hike amid slow economic growth.",300.35107421875
2015-05-26 00:00:00+00:00,397.1700134277344,399.9299926757813,391.6199951171875,392.8800048828125,392.8800048828125,899800.0,2.0,1.0,0.250025,"That means that if biotech stocks roll-over, then shares of industry Goliaths Biogen , Gilead Sciences , and Celgene Corporation could take it on the chin. Portola is developing the first antidote to the billion-dollar blockbuster Factor Xa anticoagulants and it's already released phase 3 data showing that its drug andexanet alfa successfully reverses the effect of both Xarelto and Eliquis. However, for investors willing to accept the risk of owning stocks in this industry, a market sell-off could create opportunities, even in small-cap companies with compelling late-stage research programs like Ophthotech and Portola.",306.33538818359375
2015-05-28 00:00:00+00:00,402.2999877929688,403.8500061035156,399.1000061035156,400.1000061035156,400.1000061035156,789100.0,2.0,1.0,0.250025,"Among the largest underlying components of OEF, in trading today AbbVie Inc. (Symbol: ABBV) is off about 1%, Boeing Co. (Symbol: BA) is off about 0.5%, and Biogen Inc (Symbol: BIIB) is lower by about 0.8%. For a complete list of holdings, visit the OEF Holdings page  The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $81.54 per share, with $94.22 as the 52 week high point - that compares with a last trade of $93.47. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",305.1991271972656
2015-06-02 00:00:00+00:00,391.3599853515625,391.760009765625,384.0,387.6199951171875,387.6199951171875,1947100.0,2.0,1.0,0.250025,"Two other components making moves today are Biogen ( BIIB ), trading down 1.9%, and Citrix Systems ( CTXS ), trading up 1.6% on the day. In early trading on Tuesday, shares of Wynn Resorts ( WYNN ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 1.7%. And the worst performing Nasdaq 100 component thus far on the day is Vertex Pharmaceuticals ( VRTX ), trading down 2.1%.",312.5829772949219
2015-06-04 00:00:00+00:00,385.5,387.5400085449219,382.5400085449219,384.3399963378906,384.3399963378906,1527600.0,3.0,1.0,0.5000249999999999,"Now what: In short, this was just business as usual for Isis, which is approaching 40 drugs in its clinical and preclinical pipeline and is sporting about a dozen high-profile licensing partners. Between its therapeutic diversity and licensing deals, Isis has billions of dollars in potential milestones and royalty payments waiting for the taking. This is a situation where Isis only needs a few successes to potentially validate its drug development platform and turn those losses into substantial gains.",307.2475280761719
2015-06-08 00:00:00+00:00,387.6600036621094,389.3900146484375,384.6700134277344,386.3699951171875,386.3699951171875,777000.0,2.0,1.0,0.250025,"Biotech stocks such as Regeneron Pharmaceuticals, Inc. ( REGN ) and Biogen Inc. ( BIIB ) increased 4% and 0.9%, respectively. Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report PROCTER & GAMBL (PG): Free Stock Analysis Report COCA COLA CO (KO): Free Stock Analysis Report WAL-MART STORES (WMT): Free Stock Analysis Report CVS HEALTH CORP (CVS): Free Stock Analysis Report PHILIP MORRIS (PM): Free Stock Analysis Report To read this article on Zacks.com click here. For a look at the issues currently facing the markets, make sure to read today's Ahead of Wall Street article The Dow Jones Industrial Average (DJI) declined 0.3% to close at 17,849.46.",292.224853515625
2015-06-11 00:00:00+00:00,390.6000061035156,395.1499938964844,390.1600036621094,393.5400085449219,393.5400085449219,1323300.0,4.0,1.0,0.7500249999999999,"GILD is a part of the Health Care sector, which includes companies such as Amgen Inc. ( AMGN ) and Biogen Inc. ( BIIB ). Shareholders who purchased GILD prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports GILD's forecasted earnings growth in 2015 as 39.57%, compared to an industry average of 8.2%.",290.4164123535156
2015-06-12 00:00:00+00:00,391.260009765625,395.7999877929688,386.25,388.7699890136719,388.7699890136719,1078400.0,4.0,1.0,0.7500249999999999,"We remind investors that Isis Pharma is developing ISIS-SMNRx under a collaboration agreement with Biogen BIIB . Click to get this free report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Isis Pharmaceuticals, Inc.ISIS reported encouraging results from the ongoing phase II study on ISIS-SMNRx in infants suffering from type I spinal muscular atrophy (SMA).",298.3359069824219
2015-06-19 00:00:00+00:00,406.6099853515625,414.0,406.6099853515625,411.0499877929688,411.0499877929688,2951900.0,4.0,1.0,0.7500249999999999,"Biotech stocks such as Gilead Sciences Inc. ( GILD ), Regeneron Pharmaceuticals, Inc. ( REGN ), Biogen Inc. ( BIIB ), Amgen Inc. ( AMGN ) and Celgene Corporation ( CELG ) increased 1.9%, 2.9%, 2.7%, 2.9% and 4.2%, respectively. Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report NEXTERA ENERGY (NEE): Free Stock Analysis Report EXELON CORP (EXC): Free Stock Analysis Report SOUTHERN CO (SO): Free Stock Analysis Report PG&E CORP (PCG): Free Stock Analysis Report DUKE ENERGY CP (DUK): Free Stock Analysis Report To read this article on Zacks.com click here. For a look at the issues currently facing the markets, make sure to read today's Ahead of Wall Street article The Dow Jones Industrial Average (DJI) gained 1% to close at 18,115.84.",293.15618896484375
2015-06-23 00:00:00+00:00,419.6499938964844,420.989990234375,414.0400085449219,416.260009765625,416.260009765625,1081300.0,3.0,1.0,0.5000249999999999,"Biotech stocks such as Gilead Sciences Inc. ( GILD ), Biogen Inc. ( BIIB ), Amgen Inc. ( AMGN ) and Celgene Corporation ( CELG ) increased 1.4%, 1.6%, 0.9% and 1.9%, respectively. Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report WELLS FARGO-NEW (WFC): Free Stock Analysis Report JPMORGAN CHASE (JPM): Free Stock Analysis Report BANK OF AMER CP (BAC): Free Stock Analysis Report CITIGROUP INC (C): Free Stock Analysis Report GOLDMAN SACHS (GS): Free Stock Analysis Report NEXTERA ENERGY (NEE): Free Stock Analysis Report EXELON CORP (EXC): Free Stock Analysis Report SOUTHERN CO (SO): Free Stock Analysis Report DUKE ENERGY CP (DUK): Free Stock Analysis Report To read this article on Zacks.com click here. Jeroen Dijsselbloem, who chairs the Eurogroup of finance ministers, was optimistic about reaching a deal later this week after Greece submitted a new set of reform proposals to avoid the country from defaulting. New Article We note that Isis Pharma has an agreement with Biogen BIIB for the development and commercialization of ISIS-SMNRx for the treatment of SMA. Click to get this free report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Currently, Isis Pharma is evaluating ISIS-SMNRx in two phase III studies - ENDEAR and CHERISH - for the treatment of infants and children suffering from SMA, respectively.",284.1834411621094
2015-06-25 00:00:00+00:00,412.9200134277344,417.6799926757813,410.05999755859375,411.2900085449219,411.2900085449219,902000.0,2.0,1.0,0.250025,"However, companies like Biogen BIIB are looking to bring AD treatments to the market. Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report TRANSITN THERAP (TTHI): Free Stock Analysis Report To read this article on Zacks.com click here. Transition Therapeutics Inc. 's TTHI shares plunged 74.1% immediately after the company reported that one of its lead pipeline candidates, ELND005, failed to achieve the primary endpoint in a phase II/III study.",281.5133056640625
2015-06-29 00:00:00+00:00,404.5,407.8599853515625,395.8999938964844,396.2099914550781,396.2099914550781,1474100.0,3.0,1.0,0.5000249999999999,"Even further out, Biogen's pipeline includes at least one potential blockbuster: BIIB-037 is a promising therapy that could offer new hope to Alzheimer's patients. During early-stage trials, results for BIIB-037 were so strong that Biogen decided to skip straight to phase 3 trials, which should begin by year end. For example, each of these three companies offers investors strong revenue growth, rock-solid balance sheets, and pipelines that are packed with potential blockbusters. New Article Among the largest underlying components of VUG, in trading today Oracle Corp. (Symbol: ORCL) is down about 0.8%, Visa Inc (Symbol: V) is off about 1.8%, and Biogen Inc (Symbol: BIIB) is lower by about 0.8%. For a complete list of holdings, visit the VUG Holdings page  The chart below shows the one year price performance of VUG, versus its 200 day moving average: Looking at the chart above, VUG's low point in its 52 week range is $91.80 per share, with $110.78 as the 52 week high point - that compares with a last trade of $108.00. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",288.17633056640625
2015-07-01 00:00:00+00:00,408.3200073242188,409.9800109863281,404.3800048828125,405.4100036621094,405.4100036621094,992500.0,2.333333333333333,1.0,0.3333583333333332,"Biogen BIIB and partner Swedish Orphan Biovitrum said that their regulatory application for hemophilia B treatment, Alprolix, has been accepted for review in the EU. Click to get this free report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report INTERCEPT PHARM (ICPT): Free Stock Analysis Report JUNO THERAPEUTC (JUNO): Free Stock Analysis Report To read this article on Zacks.com click here. Just a few days after the EMA accepted BioMarin's BMRN regulatory application for its experimental Duchenne muscular dystrophy (DMD) treatment, drisapersen, the company announced that the FDA has granted priority review status to the drug in the U.S. New Article Biotech stocks such as Gilead Sciences Inc. ( GILD ), Biogen Inc. ( BIIB ), Amgen Inc. ( AMGN ) and Celgene Corporation ( CELG ) increased 1.4%, 1.9%, 1.3% and 0.7%, respectively. Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report EXXON MOBIL CRP (XOM): Free Stock Analysis Report SCHLUMBERGER LT (SLB): Free Stock Analysis Report CONOCOPHILLIPS (COP): Free Stock Analysis Report TRANSOCEAN LTD (RIG): Free Stock Analysis Report BERKSHIRE HTH-B (BRK.B): Free Stock Analysis Report COMCAST CORP A (CMCSA): Free Stock Analysis Report DISNEY WALT (DIS): Free Stock Analysis Report INTL BUS MACH (IBM): Free Stock Analysis Report JPMORGAN CHASE (JPM): Free Stock Analysis Report CITIGROUP INC (C): Free Stock Analysis Report To read this article on Zacks.com click here. For a look at the issues currently facing the markets, make sure to read today's Ahead of Wall Street article The Dow Jones Industrial Average (DJI) gained 0.1% to close at 17,619.51. New Article Currently approved drugs in the hemophilia A market include Biogen Idec's BIIB Eloctate for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults as well as children with hemophilia A. Bayer carries a Zacks Rank #2 (Buy). Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN IDEC INC (BIIB): Free Stock Analysis Report EMERGENT BIOSOL (EBS): Free Stock Analysis Report To read this article on Zacks.com click here. The HealthCare segment at BayerBAYRY announced that the company has submitted a Marketing Authorization Application in Japan for BAY 81-8973, a recombinant factor VIII compound.",288.6054992675781
2015-07-02 00:00:00+00:00,407.2900085449219,407.9800109863281,403.1499938964844,404.2799987792969,404.2799987792969,928600.0,3.875,1.0,0.7187749999999999,"What : Shares of the clinical-stage biopharma Applied Genetic Technologies Corporation rose by 23% today on a huge surge in volume after the company inked a broad research collaboration with biotech giant Biogen to develop multiple gene therapy treatments for rare diseases of the eye. If any products make it to the commercial stage, Applied Genetic would also be eligible to receive royalty payments in the range ofsingle-digits to the mid-teens percentage-wise on annual net sales. All told, Applied Genetic is definitely worth a deeper look following this licensing agreement with a top dog in biotech, but you may not want to buy shares until its therapeutic platform matures a bit further. New Article Biogen Inc (NASDAQ: BIIB ) and AGTC announced entering into a collaboration related to the development of gene therapies in ophthalmology. Top Headline Centene Corp (NYSE: CNC ) announced its plans to acquire Health Net, Inc. (NYSE: HNT ) Health Net, Inc. in a cash and stock deal valued at around $6.8 billion, including the assumption of $500 million in debt. Shares of Applied Genetic Technologies Corp (NASDAQ: AGTC ) got a boost, shooting up 21 percent to $19.72. New Article (+) XOOM (+21.01%) Agreed to be acquired by PayPal for $890 mln (+) AGTC (+17.04%) Inks deal with Biogen ( BIIB ) to get $124 mln upfront plus milestone payments and royalties (+) HNT (+10.01%) Merge with Centene (CNE) in $6.8 billion stock and cash deal Wall Street closed lower for a second week as fresh worries about the fate of Greece coupled with technical resistance in the S&P 500 and Nasdaq Composite put a lid on Thursday's modest gains following the June non-farm payroll report. The Dow Jones Industrial Average underperformed as losses in component stocks DuPont ( DD ) and United Healthcare ( UNH ) weighed on the blue-chip index. New Article (+) XOOM (+20.97%) Agreed to be acquired by PayPal for $890 mln (+) AGTC (+16.85%) Inks deal with Biogen ( BIIB ) to get $124 mln upfront plus milestone payments and royalties (+) PRGS (+8.06%) Reported better-than-expected Q2 earnings and raised FY15 outlook Stock futures were building on the cautious gains from earlier this morning as June's employment report saw payrolls rise a slightly less than expected 223,000 but the jobless rate dipped to 5.3%, a scenario that underscored strength in the economy without giving making a rate hike by the Federal Reserve seem urgent. This morning's other job-related release was eclipsed by the more pivotal non-farm payroll report, but the 281,000 increase in initial jobless claims beat expectations for a 270,000 gain. New Article (+) XOOM (+22.22%) Agreed to be acquired by PayPal for $890 mln (+) AGTC (+18.27%) Inks deal with Biogen ( BIIB ) to get $124 mln upfront plus milestone payments and royalties (+) HNT (+10.87%) Merge with Centene (CNE) in $6.8 billion stock and cash deal (+) NVEE (+4.08%) Buys infrastructure engineering firm RBA Group Stocks were struggling to stay on the plus side Thursday, surrendering very modest gains from earlier today after the S&P 500 and Nasdaq Composite indices found solid technical resistance at 2,080 and 5,040, respectively, putting equities at risk to close in the red for a second straight week. EU-zone markets, however, slipped back into the red as overseas investors remain on edge ahead of Greece's Sunday referendum. New Article Biogen Inc (NASDAQ: BIIB ) and AGTC announced entering into a collaboration related to the development of gene therapies in ophthalmology. Shares of International Speedway Corp (NASDAQ: ISCA ) were down 6 percent to $34.74 after the company reported downbeat Q2 results. Supplies of natural gas increased 69 billion cubic feet for the week ended June 26, the U.S. Energy Information Administration said. New Article Biogen Inc (NASDAQ: BIIB ) and AGTC announced entering into a collaboration related to the development of gene therapies in ophthalmology. Shares of International Speedway Corp (NASDAQ: ISCA ) were down 5 percent to $34.96 after the company reported downbeat Q2 results. Supplies of natural gas increased 69 billion cubic feet for the week ended June 26, the U.S. Energy Information Administration said. New Article In other sector news, (+) AGTC, (+15.6%) Receives $124 million upfront payment as part of its collaboration and licensing agreement with Biogen ( BIIB ), which is investing $30 million in AGTC, buying 1.45 million shares at $20.63 each. After the deal was announced, Cognizant Tech ( CTSH ) said continued implementation of its seven-year master services agreement with HealthNet could be delayed or terminated because of likely overlaps resulting from the upcoming merger with Centene. HealthNet and Cognizant began their partnership two years ago with a total contract value of $520 million.",296.8054504394531
2015-07-07 00:00:00+00:00,405.25,409.9100036621094,400.3299865722656,408.05999755859375,408.05999755859375,1488900.0,3.0,1.0,0.5000249999999999,"There are also milestone payments of up to $472.5 million collectively for the two lead programs, and AGTC will get royalties in the high-single digit to mid-teen percentages of annual net sales if the drugs make it to market. The trial was arguably designed as a quick readout as to whether anti-LINGO-1 would work in multiple sclerosis -- both diseases have a lack of myelin on nerves, which anti-LINGO-1 seeks to reverse -- but if Biogen decided to pursue AON further, the experience with Applied Genetic Technologies could be helpful. Avalanche Biotechnologies tumbled last month after investors were disappointed with phase 2a data testing its gene therapy AVA-101 in wet age-related macular degeneration. New Article General consensus is that holding IBB instead of individual stocks will shield you from overall risk with biotechs because the bigger ones like Gilead ( GILD ), Biogen ( BIIB ), Celgene ( CELG ), and Amgen ( AMGN ) are cheaper and bring down the valuation of the entire ETF. Returns for the Nasdaq during that time period are listed below (I included the subsequent 3 years after the peak of that bubble as well): According to iShares, the trailing P/E of IBB is 31.10, which is high but not necessarily unheard of. When I look at the forward analyst estimates from Yahoo, I calculate a P/E close to 70 using non-GAAP numbers, which is extremely high by historical standards and given a history of drug failures and choppy earnings growth within the biotech space over longer periods of time.",302.0359191894531
2015-07-08 00:00:00+00:00,405.0,406.2300109863281,396.7300109863281,397.6799926757813,397.6799926757813,1312900.0,3.5,1.0,0.6250249999999999,"Among the largest underlying components of VUG, in trading today Oracle Corp. (Symbol: ORCL) is off about 0.1%, Visa Inc (Symbol: V) is down about 1.3%, and Biogen Inc (Symbol: BIIB) is lower by about 1.8%. For a complete list of holdings, visit the VUG Holdings page  The chart below shows the one year price performance of VUG, versus its 200 day moving average: Looking at the chart above, VUG's low point in its 52 week range is $91.80 per share, with $110.78 as the 52 week high point - that compares with a last trade of $106.91. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Biogen BIIB signed up with Applied Genetic AGTC for the development of gene-based therapies for multiple ophthalmic diseases. Click to get this free report ALEXION PHARMA (ALXN): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report APPLIED GEN TEC (AGTC): Free Stock Analysis Report VERSARTIS INC (VSAR): Free Stock Analysis Report To read this article on Zacks.com click here. The key update over the last few days in the biotech sector came from Vertex VRTX which gained FDA approval for its new cystic fibrosis drug, Orkambi.",301.61669921875
2015-07-09 00:00:00+00:00,403.55999755859375,404.3599853515625,399.2900085449219,399.2900085449219,399.2900085449219,1325300.0,3.0,1.0,0.5000249999999999,"Stocks recently featured in the blog include the Vertex ( VRTX ), Biogen ( BIIB ), Applied Genetic ( AGTC ), Gilead ( GILD ) and Alexion ( ALXN ). Biogen ( BIIB ) signed up with Applied Genetic ( AGTC ) for the development of gene-based therapies for multiple ophthalmic diseases. Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report APPLIED GEN TEC (AGTC): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report To read this article on Zacks.com click here.",304.1199645996094
2015-07-10 00:00:00+00:00,401.0,401.4400024414063,381.8599853515625,388.2300109863281,388.2300109863281,3887500.0,3.333333333333333,1.0,0.5833583333333334,"Following mid-phase trial disappointments, GlaxoSmithKline punted RVT-101 in December to Roivant in exchange for $5 million up front, milestones, and double-digit royalties on any eventual sales. In December, Biogen reported early-stage trial results for its most promising Alzheimer's disease drug, aducanumab, which impressed industry watchers. Today, Americans are already spending more than $200 billion annually caring for Alzheimer's disease patients, so the market demand for therapies that can ease that burden could be massive. New Article And the worst performing S&P 500 component thus far on the day is Biogen ( BIIB ), trading down 3.7%. VIDEO: S&P 500 Movers: BIIB, GCI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Friday, shares of Gannett Company ( GCI ) topped the list of the day's best performing components of the S&P 500 index, trading up 7.1%. New Article Especially high volume was seen for the $387.50 strike put option expiring July 10, 2015 , with 1,260 contracts trading so far today, representing approximately 126,000 underlying shares of BIIB. Below is a chart showing GOOGL's trailing twelve month trading history, with the $560 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 13,079 contracts, representing approximately 1.3 million underlying shares or approximately 103.2% of BIIB's average daily trading volume over the past month, of 1.3 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $387.50 strike highlighted in orange: And Coca-Cola Co (Symbol: KO) saw options trading volume of 104,204 contracts, representing approximately 10.4 million underlying shares or approximately 77.8% of KO's average daily trading volume over the past month, of 13.4 million shares.",302.4019775390625
2015-07-13 00:00:00+00:00,391.2099914550781,395.7900085449219,388.6400146484375,391.2300109863281,391.2300109863281,1517900.0,3.0,1.0,0.5000249999999999,"BiogenBIIB announced that its lead research and development (R&D) executive, Douglas Williams, Ph.D., is about to leave the company at the end of July. Click to get this free report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report AVALANCHE BIOT (AAVL): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that after George A. Scangos, Ph.D., joined Biogen as the chief executive officer (CEO) in 2010, a number of strategic, operational and organizational changes were announced to increase focus and efficiency.",305.7778015136719
2015-07-14 00:00:00+00:00,396.9500122070313,403.2099914550781,393.7200012207031,400.2000122070313,400.2000122070313,1507200.0,3.6666666666666665,1.0,0.6666916666666666,"In health-care stocks news, biopharmaceutical company Biogen Idec ( BIIB ) has been upgraded by analysts at Bank of America to a buy rating from neutral. Cardinal Health ( CAH ) shares were downgraded by Evercore ISI to hold from buy. And Celator Pharmaceuticals ( CPXX ) rose in Tuesday's pre-market trading after the clinical-stage biopharmaceutical company said it has commenced the enrollment of patients in its investigator-initiated Phase 2 clinical study evaluating CPX-351 (cyatarabine:daunorubicin) Liposome Injection as a treatment for patients with newly diagnosed Acute Myeloid Leukemia (AML) at high risk for induction treatment mortality. New Article Biogen ( BIIB ) has inked a collaboration and license agreement with Applied Genetic for the development of gene-based therapies for multiple ophthalmic diseases. Biogen ( BIIB ), based in Cambridge, MA, is a global biopharmaceutical company focused on developing and commercializing therapies for neurological, autoimmune and hematologic disorders. Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Biotech stocks such as Gilead Sciences Inc. ( GILD ), Biogen Inc. ( BIIB ), Amgen Inc. ( AMGN ) and Celgene Corporation ( CELG ) increased 0.7%, 0.8%, 1.1% and 1.7%, respectively. Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report AMER AIRLINES (AAL): Free Stock Analysis Report UNITED CONT HLD (UAL): Free Stock Analysis Report JETBLUE AIRWAYS (JBLU): Free Stock Analysis Report ALASKA AIR GRP (ALK): Free Stock Analysis Report INTEL CORP (INTC): Free Stock Analysis Report APPLE INC (AAPL): Free Stock Analysis Report MICROSOFT CORP (MSFT): Free Stock Analysis Report AT&T INC (T): Free Stock Analysis Report GOOGLE INC-CL A (GOOGL): Free Stock Analysis Report INTL BUS MACH (IBM): Free Stock Analysis Report To read this article on Zacks.com click here. For a look at the issues currently facing the markets, make sure to read today's Ahead of Wall Street article The Dow Jones Industrial Average (DJI) gained 1.2% or 217.27 points to close at 17,977.68.",314.2559814453125
2015-07-15 00:00:00+00:00,404.5899963378906,407.8299865722656,399.5299987792969,400.5499877929688,400.5499877929688,1471800.0,5.0,1.0,1.000025,"Isis Pharmaceuticals, Inc.ISIS announced that it has earned a milestone payment of $2.15 million from its partner Biogen BIIB . Click to get this free report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ELEVEN BIOTHERP (EBIO): Free Stock Analysis Report To read this article on Zacks.com click here. The milestone payment is related to the advancement of an ongoing pivotal phase III study (CHERISH) on ISIS-SMNRx in children suffering from spinal muscular atrophy (SMA).",321.2696228027344
2015-07-16 00:00:00+00:00,402.7200012207031,407.30999755859375,402.0499877929688,403.7300109863281,403.7300109863281,1335500.0,4.0,1.0,0.7500249999999999,"The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Biogen ( BIIB ) is now the #127 analyst pick, moving up by 46 spots. Looking at the stock price movement year to date, Biogen ( BIIB ) is showing a gain of 19.5%. VIDEO: S&P 500 Analyst Moves: BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",303.7862243652344
2015-07-17 00:00:00+00:00,406.3699951171875,407.1300048828125,401.75,404.6600036621094,404.6600036621094,1890300.0,1.0,1.0,2.4999999999997247e-05,"Especially high volume was seen for the $440 strike call option expiring July 24, 2015 , with 809 contracts trading so far today, representing approximately 80,900 underlying shares of BIIB. Below is a chart showing SNDK's trailing twelve month trading history, with the $65 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 11,616 contracts thus far today. That number of contracts represents approximately 1.2 million underlying shares, working out to a sizeable 78.1% of BIIB's average daily trading volume over the past month, of 1.5 million shares.",294.08526611328125
2015-07-21 00:00:00+00:00,410.3500061035156,412.239990234375,405.510009765625,409.5,409.5,1768700.0,3.0,1.0,0.5000249999999999,"Biogen Inc. BIIB has an Earnings ESP of +0.49% and carries a Zacks Rank #3. Click to get this free report MEDICINES CO (MDCO): Free Stock Analysis Report AMERISOURCEBRGN (ABC): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report WALGREENS BAI (WBA): Free Stock Analysis Report To read this article on Zacks.com click here. However, overall prescription volume growth from an improving U.S. economy along with positive contributions from health care reforms should support the top line. New Article On Wednesday, the biotech is scheduled to present data for its Alzheimer's disease drug, aducanumab, and then on Friday we'll get second-quarter earnings from Biogen. Anxiety We've already seen pretty good looking data from aducanumab in Alzheimer's patients, and Biogen has quickly moved into a phase 3 program. The 10 mg dose also showed a statistically significant slowing of clinical decline on the CDR-SB scale, a measurement of a patient's cognitive and functional performance. New Article While the drug clearly helps multiple sclerosis patients, Gilenya has warnings on its label about the potential for heart problems, infections, and liver damage. Patients taking Gilenya have to be watched for six hours after receiving their first dose and are supposed to get an electrocardiogram at the end of the observation to confirm that there aren't any heart problems. Receptos has already completed enrollment in one of its phase 3 trials, testing Ozanimod against Biogen Idec 's Avonex in patients with relapsing multiple sclerosis.",294.3487243652344
2015-07-22 00:00:00+00:00,393.6499938964844,401.1099853515625,389.6099853515625,391.739990234375,391.739990234375,4053500.0,3.0,1.0,0.5000249999999999,"Companies like Celgene, Biogen BIIB and AbbVie will be reporting second quarter results later this week. Click to get this free report ALEXION PHARMA (ALXN): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report EXELIXIS INC (EXEL): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report FIVEPRIME THERA (FPRX): Free Stock Analysis Report To read this article on Zacks.com click here. Amgen also announced positive top-line data on its immuno-oncology treatment, Blincyto, from a phase II study in adults with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia (ALL). New Article IBB holds 145 stocks, with roughly 16% of assets in top holdingsCelgene ( CELG ) andBiogen ( BIIB ) together. Given Illumina's glum revenue picture, ETF investors may want to watch for a spillover effect on other life science companies. The likes ofSynergy Pharmaceuticals (SGYP),Radius Health (RDUS) andProthena (PRTA) -- in which IBB has small stakes -- may have early-stage drugs yet to come to market. New Article Last week, the company earned a milestone payment of $2.15 million from Biogen BIIB for the advancement of one of its pipeline candidates, ISIS-SMNRx, in children with spinal muscular atrophy into late-stage development. Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Isis Pharmaceuticals, Inc.ISIS announced the commencement of a phase I/IIa study on ISIS-HTTRx in patients suffering from Huntington's disease (HD).",289.4391784667969
2015-07-23 00:00:00+00:00,394.1700134277344,396.2300109863281,384.510009765625,385.0499877929688,385.0499877929688,2602500.0,3.75,1.0,0.6875249999999999,"Eli Lilly and CompanyLLY and Biogen BIIB presented data on their experimental Alzheimer's disease (AD) candidates at the Alzheimer's Association International Conference. While Eli Lilly presented data from a pre-specified secondary analysis of phase III studies (EXPEDITION, EXPEDITION2 and EXPEDITION-EXT) on solanezumab, Biogen showcased new data from a pre-specified interim analysis from a phase Ib study (PRIME) on its anti-amyloid beta antibody, aducanumab (BIIB037). Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report AGIOS PHARMACT (AGIO): Free Stock Analysis Report To read this article on Zacks.com click here. New Article BiogenBIIB , a strong player in the multiple sclerosis (MS) market, will be reporting second quarter 2015 earnings results on Jul 24, before the market opens. Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. However, on a brighter note, the top-line should benefit from the continuing sales ramp up of Plegridy and the hemophilia products - Alprolix and Eloctate. New Article Biogen Inc. ( BIIB ) is reporting for the quarter ending June 30, 2015. BIIB missed the consensus earnings per share in the 1st calendar quarter of 2015 by -2.3%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for BIIB is 23.57 vs. an industry ratio of -30.10, implying that they will have a higher earnings growth than their competitors in the same industry. New Article Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $397.50 strike highlighted in red: Considering the fact that the $397.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the September 4th expiration.",285.30743408203125
2015-07-24 00:00:00+00:00,327.0,327.0,299.760009765625,300.0299987792969,300.0299987792969,16634100.0,2.181818181818181,1.0,0.2954795454545454,"In trading on Friday, shares of Biogen Inc (Symbol: BIIB) crossed below their 200 day moving average of $375.07, changing hands as low as $315.01 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $290.85 per share, with $480.18 as the 52 week high point - that compares with a last trade of $317.15. According to the ETF Finder at ETF Channel, BIIB makes up 8.07% of the iShares Nasdaq Biotechnology ETF (Symbol: IBB) which is trading lower by about 1.9% on the day Friday. New Article Cambridge, MA-based Biogen ( BIIB ), one of the world's leading biotechnology companies, focuses on therapeutic areas including neurology, immunology and hemophilia. Currently, BIIB has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. BIIB has a pretty good earnings track record with the company delivering positive earnings surprises in three of the last fourth quarters with an average surprise of 12.28%. New Article Particularly high volume was seen for the $300 strike put option expiring July 24, 2015 , with 1,845 contracts trading so far today, representing approximately 184,500 underlying shares of BIIB. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 59,869 contracts have traded so far, representing approximately 6.0 million underlying shares. That amounts to about 352.3% of BIIB's average daily trading volume over the past month of 1.7 million shares. New Article Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 44.4% Average next regular session additional gain: 1.6% Over the prior three fiscal years (12 quarters), when shares of BIIB rose in the extended-hours session in reaction to its earnings announcement, history shows that 44.4% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.6%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 0% Over that same historical period, when shares of BIIB dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 0.0% by the following regular session close. Extended-Hours Dollar Volume: $30,824,624 Biogen Idec ( BIIB ) is due to issue its quarterly earnings report in the upcoming extended-hours session. New Article That's Biogen's BIIB037, also known as Aducanumab. Essentially the Phase I trials showed that this drug does a great job of reducing the plaque buildups that are thought to interrupt communication between cells in the brain. The mission is to look at the data, see where it works best, and then be able to structure a Phase III trial for this drug that can play to its strengths and allow it to win eventual approval. New Article And the worst performing S&P 500 component thus far on the day is Biogen ( BIIB ), trading down 16.9%. VIDEO: S&P 500 Movers: BIIB, AMZN The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Two other components making moves today are Capital One Financial ( COF ), trading down 10.8%, and Juniper Networks ( JNPR ), trading up 6.8% on the day. New Article And the worst performing Nasdaq 100 component thus far on the day is Biogen ( BIIB ), trading down 16.6%. VIDEO: Nasdaq 100 Movers: BIIB, AMZN The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Friday, shares of Amazon.com ( AMZN ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 16.1%. New Article And Biogen Idec ( BIIB ), a biotechnology company, reported Q2 results that topped the Street view on earnings per share but missed on total revenues and guided full year results to fall short of expectations. In health-care stocks news, Cancer Genetics ( CGIX ) says it has suspended activity on the sale of shares through an ""at-the-market"" offering. Meanwhile, Recro Pharma ( REPH ), which is developing multiple non-opioid therapeutics for the treatment of acute post operative pain, released more information from its Phase II trial for Dex IN, an intranasal formulation of dexmedetomidine, for the treatment of acute pain in adult patients undergoing bunionectomy surgery. New Article In trading on Friday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 21.2, after changing hands as low as $315.01 per share. A bullish investor could look at BIIB's 21.2 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of BIIB shares: Looking at the chart above, BIIB's low point in its 52 week range is $290.85 per share, with $480.18 as the 52 week high point - that compares with a last trade of $315.36. New Article Shares of Biogen ( BIIB ) have fallen over 20% today, following the release of the company's latest earnings report after the closing bell yesterday. While BIIB was able to beat on earnings, posting an EPS of $4.22 against the Zacks Consensus Estimate of $4.07, a revenue miss and lowered guidance has the market in a selling frenzy (also read Biogen Beats on 2Q Earnings, Misses on Revenues ). Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Biogen Inc. ( BIIB ) is -47.05 at $338.00, with 503,231 shares traded. The following are the most active stocks for the pre-market session : Exelixis, Inc. ( EXEL ) is -0.05 at $5.83, with 899,740 shares traded.EXEL is scheduled to provide an earnings report on 7/30/2015, for the fiscal quarter ending Jun2015. As reported in the last short interest update the days to cover for T is 8.705175; this calculation is based on the average trading volume of the stock.",284.81109619140625
2015-07-27 00:00:00+00:00,305.3999938964844,325.0,303.760009765625,309.42999267578125,309.42999267578125,9975000.0,2.5714285714285725,1.0,0.3928821428571428,"Biotech major, Biogen BIIB , well known for its strong presence in the multiple sclerosis (MS) market, saw its shares plunging 22.08% on weak second quarter revenues and a lowered outlook for the year. Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report EXELIXIS INC (EXEL): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report BLUEBIRD BIO (BLUE): Free Stock Analysis Report To read this article on Zacks.com click here. The first sign of trouble for Biogen emerged when the company confirmed a case of progressive multifocal leukoencephalopathy (PML) in a patient on oral MS treatment, Tecfidera, in Oct 2014. New Article While there's little doubt that the market has been willing to pay a decently sized premium for this double-digit earnings bonanza among drugmakers in general, the long and short of it is that this incredible rise has had a healthy fundamental basis. Digging into the details, Biogen reported a 7% increase in revenue for the quarter at $2.59 billion, but the Street was expecting a figure closer to 7.5%, in terms of year-over-year sales growth. Although Illumina isn't a drugmaker per se, it does play an important supporting role in the development of next-generation drugs and cellular therapies, making it a key stock to keep tabs on regarding the overall health of the pharma industry as a whole. New Article VIDEO: Nasdaq 100 Movers: MYL, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Monday, shares of Biogen ( BIIB ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 6.6%. And the worst performing Nasdaq 100 component thus far on the day is Mylan ( MYL ), trading down 13.8%. New Article Biotech stocks took a beating following Biogen Inc.'s ( BIIB ) second quarter revenue miss and lower guidance for the rest of the year. Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report AMAZON.COM INC (AMZN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report DU PONT (EI) DE (DD): Free Stock Analysis Report DOW CHEMICAL (DOW): Free Stock Analysis Report MONSANTO CO-NEW (MON): Free Stock Analysis Report PRAXAIR INC (PX): Free Stock Analysis Report EXXON MOBIL CRP (XOM): Free Stock Analysis Report CHEVRON CORP (CVX): Free Stock Analysis Report SCHLUMBERGER LT (SLB): Free Stock Analysis Report CONOCOPHILLIPS (COP): Free Stock Analysis Report TRANSOCEAN LTD (RIG): Free Stock Analysis Report To read this article on Zacks.com click here. For a look at the issues currently facing the markets, make sure to read today's Ahead of Wall Street article The Dow Jones Industrial Average (DJI) lost 0.9% to close at 17,568.53 The Standard & Poor's 500 (S&P 500) declined 1.1% to 2,079.65. New Article Biotechnology ETFs, among this year's top-performing sector funds, suffered a blow last Friday, when Biogen Inc (NASDAQ: BIIB ) pared 2015 after it reported disappointing results for an experimental drug to treat Alzheimer's disease. Over the course of the week, investors will be treated to earnings reports from Anadarko Petroleum, ConocoPhillips, Occidental Petroleum and Williams Cos. XLE's earnings parade gets more significant on Friday when Dow components Exxon Mobil and Chevron, the two largest U.S. oil companies, report. The iShares MSCI Brazil Capped ETF (NYSE: EWZ ) is off 14 percent over the past month and currently resides at its lowest levels since early 2009. New Article Biotech ETFs languished late last week after Biogen Inc (NASDAQ: BIIB ) pared 2015 after it reported disappointing results for an experimental drug to treat Alzheimer's disease. For those looking for signs of risk appetite being restored, there is potentially ominous news from a marquee leadership group: Biotechnology stocks and the relevant exchange traded funds. One day does not make a trend, but Monday's bullish performances for bearish biotech ETFs could be a warning sign for an industry group that comprises 10.5 percent of the S&P 500's weight. New Article Second-quarter sales of Tecfidera were only 7% higher than the first quarter, which isn't a horrible growth rate, but it's much slower than investors expected. That ""safety event"" Kingsley mentions was a case of progressive multifocal leukoencephalopathy, or PML, which Biogen reported last October. To learn more about what The Motley Fool thinks about current investment trends, and receive a special free report about what might be the next big industry to come out of Silicon Valley, just click here now .",283.75653076171875
2015-07-28 00:00:00+00:00,312.5199890136719,320.510009765625,308.67999267578125,319.92999267578125,319.92999267578125,3547000.0,3.0,1.0,0.5000249999999999,"At Biogen ( BIIB ), a filing with the SEC revealed that on Monday, Director Stelios Papadopoulos bought 10,000 shares of BIIB, for a cost of $304.88 each, for a total investment of $3.05M. VIDEO: Tuesday 7/28 Insider Buying Report: BIIB, MJN The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Papadopoulos was up about 3.2% on the purchase at the high point of today's trading session, with BIIB trading as high as $314.60 at last check today. New Article When combined with its previous buyback authorization, Celgene now has the green light to repurchase about $5.2 billion worth of its common stock on the open market. Thanks to the ridiculously successful launches of hepatitis C drugs Sovaldi and Harvoni, revenue and profit growth rates have simply been jaw-dropping. Gilead went big recently with its decision to return cash to shareholders, as the company announced a massive $15 billion share buyback program. New Article Stocks recently featured in the blog include the Biogen ( BIIB ), Ligand Pharmaceuticals Inc. ( LGND ), bluebird bio, Inc. ( BLUE ), Regeneron Pharmaceuticals, Inc. ( REGN ) and Exelixis, Inc. ( EXEL ). Here are highlights from Monday's Analyst Blog: Forget Biogen, Buy These Promising Biotechs Instead Biotech major, Biogen ( BIIB ), well known for its strong presence in the multiple sclerosis (MS) market, saw its shares plunging 22.08% on weak second quarter revenues and a lowered outlook for the year. Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report BLUEBIRD BIO (BLUE): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report EXELIXIS INC (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here.",285.16802978515625
2015-07-30 00:00:00+00:00,312.5400085449219,319.4200134277344,310.5199890136719,317.0,317.0,2303900.0,3.5,1.0,0.6250249999999999,"Stocks recently featured in the blog include the Biogen ( BIIB ), AbbVie ( ABBV ), Regeneron ( REGN ), Amgen ( AMGN ) and XOMA ( XOMA ). Here are highlights from Wednesday's Analyst Blog: Biotech Stock Roundup Several major biotech companies like Biogen ( BIIB ), AbbVie ( ABBV ), Celgene and Gilead reported second quarter results over the last five trading days. Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report XOMA CORP (XOMA): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Yet, biotech remains a terrific place to find multi-baggers , as companies that can successfully bring a new drug to market can see their share price soar, providing investors with huge returns in a short period of time. Myelin is critical to helping nerve impulses properly send signals in the body, and the scar tissue created from MS disrupts this process, causing a huge range of symptoms like fatigue, difficulty walking, and numbness. International pricing pressure for the drug appears to be dragging down recent sales growth, sending investors running and bringing Biogen's price-to-earnings ratio to a level it hasn't seen in several years.",289.6989440917969
2015-08-03 00:00:00+00:00,320.3299865722656,325.8099975585937,319.1099853515625,324.3800048828125,324.3800048828125,3024800.0,3.0,1.0,0.5000249999999999,"Higher Revenues Could Drive Q2 Results Isis Pharma's antisense technology has allowed it to enter into several agreements with leading health care companies like Biogen BIIB among others that provide the company with a steady stream of funds in the form of upfront, milestone and other payments. Click to get this free report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AGIOS PHARMACT (AGIO): Free Stock Analysis Report To read this article on Zacks.com click here. Isis Pharma's track record has been pretty good with the company having comfortably beaten estimates in the last three of the four quarters.",292.84698486328125
2015-08-04 00:00:00+00:00,325.8800048828125,334.79998779296875,324.5199890136719,330.3800048828125,330.3800048828125,3586200.0,3.5,1.0,0.6250249999999999,"On the other hand, Biogen ( BIIB ) beats on earnings but its revenues fell short of the Zacks Consensus Estimate. GILD (15.73%), AMGN (10.96%), CELG (9.98%), BIIB (7.87%) and ALXN (5.93%) take the top five spots in the fund and together make up roughly half of the fund's assets (see: all the Healthcare ETFs here ). CELG, AMGN, GILD, BIIB and ALXN occupy the first three, fifth and sixth spots in the fund, respectively, with a combined exposure of 36.4%. New Article Among the largest underlying components of VUG, in trading today Oracle Corp. (Symbol: ORCL) is up about 0.6%, Visa Inc (Symbol: V) is up about 0.4%, and Biogen Inc (Symbol: BIIB) is higher by about 1.8%. For a complete list of holdings, visit the VUG Holdings page  The chart below shows the one year price performance of VUG, versus its 200 day moving average: Looking at the chart above, VUG's low point in its 52 week range is $91.80 per share, with $111.92 as the 52 week high point - that compares with a last trade of $110.40. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",293.8460693359375
2015-08-05 00:00:00+00:00,333.0,338.510009765625,332.8099975585937,335.4100036621094,335.4100036621094,2308000.0,3.0,1.0,0.5000249999999999,"Other big-cap biotechs, such asAmgen ( AMGN ) andBiogen ( BIIB ), will also fall far short of Celgene's expected growth rate, analysts say. Meanwhile,Gilead Sciences ( GILD ) -- the biotech firm behind hepatitis C drug Harvoni and its predecessor Sovaldi -- is expected to see earnings slow to low single digits over that time starting in 2016 as patients cure out of the liver virus. The biggest deal, announced mid-July and valued at $7.2 billion, is Celgene's pending acquisition of Receptos, a biotech firm whose lead drug, Ozanimod, has shown good results in treating ulcerative colitis and relapsing multiple sclerosis. New Article The primary culprits were weaker-than-expected second-quarter earnings results and early stage data involving Alzheimer's drug aducanumab that didn't exactly thrill investors. On the other hand, Biogen has levers it can pull to boost its shareholder value, including cost cuts, share buybacks, and perhaps even instituting a dividend. This $19 trillion industry could destroy the Internet One bleeding-edge technology is about to put the World Wide Web to bed. New Article Specialty Sciences: Segmental revenues comprising royalties received by Perrigo on multiple sclerosis drug Tysabri from Biogen Inc. BIIB came in at $83.6 million, down 3% year over year. Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. The increase in revenues was partially offset by unfavorable foreign currency movements and lower sales volume in the VMS and animal health categories.",303.1554260253906
2015-08-06 00:00:00+00:00,336.6700134277344,337.5,315.29998779296875,316.6000061035156,316.6000061035156,3830000.0,3.0,1.0,0.5000249999999999,"Although it's unclear how efficacious aducanumab will prove to be, there's a significant opportunity ahead for any drug that improves disease progression or cognition because Alzheimer's is notoriously tough to treat and affects millions of patients. Yet, despite the robust top- and bottom-line growth, investors jettisoned shares in the company last month on concerns that its merger with competitor Health Net would take its eye off the ball, weigh down its bottom line as integration costs kick in, and reduce the likelihood of being acquired itself. In the case of Mylan, Biogen, and Centene, however, each is a market leader with catalysts that could support ongoing future growth, and for that reason, picking up shares on sale may prove to be a savvy long-term move.",307.9939880371094
2015-08-07 00:00:00+00:00,316.0,316.19000244140625,305.6600036621094,309.0,309.0,4259000.0,3.5,1.0,0.6250249999999999,"Two other components making moves today are Biogen ( BIIB ), trading down 2.0%, and VimpelCom ( VIP ), trading up 5.0% on the day. And the worst performing Nasdaq 100 component thus far on the day is Tesla Motors ( TSLA ), trading down 2.5%. Tesla Motors is showing a gain of 7.9% looking at the year to date performance. New Article Some better-ranked stocks in the health care sector include Actelion Ltd. ALIOF , AMAG Pharmaceuticals, Inc. AMAG and Biogen Inc. BIIB each sporting a Zacks Rank #1 (Strong Buy). Click to get this free report EMERGENT BIOSOL (EBS): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Quarter in Detail Emergent generates product sales from two segments - Biodefense and Biosciences.",323.47021484375
2015-08-12 00:00:00+00:00,312.29998779296875,317.8599853515625,307.5,316.7300109863281,316.7300109863281,1962800.0,2.6666666666666665,1.0,0.4166916666666666,"In early trading on Wednesday, shares of Biogen ( BIIB ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 0.4%. VIDEO: Nasdaq 100 Movers: YHOO, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing Nasdaq 100 component thus far on the day is Yahoo! New Article Among the largest underlying components of VUG, in trading today Oracle Corp. (Symbol: ORCL) is off about 1.6%, Visa Inc (Symbol: V) is off about 0.8%, and Biogen Inc (Symbol: BIIB) is lower by about 1%. For a complete list of holdings, visit the VUG Holdings page  The chart below shows the one year price performance of VUG, versus its 200 day moving average: Looking at the chart above, VUG's low point in its 52 week range is $91.80 per share, with $111.92 as the 52 week high point - that compares with a last trade of $107.47. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports AMGN's forecasted earnings growth in 2015 as 11.95%, compared to an industry average of 7.7%. The following ETF(s) have AMGN as a top-10 holding: iShares Nasdaq Biotechnology Index Fund ( IBB ) PowerShares Dynamic Pharmaceuticals ( PJP ) PowerShares Dynamic Biotech &Genome ( PBE ) SPDR Select Sector Fund - Health Care ( XLV ) Market Vectors Biotech ETF ( BBH ).",331.76776123046875
2015-08-19 00:00:00+00:00,311.989990234375,319.3500061035156,310.5,315.82000732421875,315.82000732421875,1832400.0,2.0,1.0,0.250025,"Biogen BIIB lost 22.19% over the last six months with Regeneron being the highest gainer (47.04%) during this period as well. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report OMEROS CORP (OMER): Free Stock Analysis Report KITE PHARMA INC (KITE): Free Stock Analysis Report AVALANCHE BIOT (AAVL): Free Stock Analysis Report To read this article on Zacks.com click here. AVEO Oncology's shares received a boost with the company signing an exclusive, worldwide license agreement with Novartis for the development and commercialization of AV-380 (cachexia) and related antibodies.",333.6598205566406
2015-08-20 00:00:00+00:00,314.7799987792969,316.8999938964844,309.2099914550781,309.8999938964844,309.8999938964844,1913200.0,2.0,1.0,0.250025,"ALFA is home to some Carl Icahn favorites, including Apple Inc. (NASDAQ: AAPL ) and Biogen (NASDAQ: BIIB ). ""The ETF is comprise of the top US listed equity positions reported on Form 13F by a select group of hedge funds that the index provider Solactive deems as having moderate turnover rates and concentrated holdings,"" said S&P Capital IQ in a recent note. No stock accounts for more than 2.8 percent of GURU's weight and the ETF's top 10 holdings are currently littered with Ackman favorites including Mondelez International Inc. (NASDAQ: MDLZ ) and Valeant Pharmaceuticals Inc. (NYSE: VRX ).",335.42779541015625
2015-08-25 00:00:00+00:00,292.6400146484375,298.0,281.5,281.75,281.75,3744200.0,3.0,1.0,0.5000249999999999,"Acorda has a licensing agreement with Biogen BIIB for Fampyra in markets outside the U.S. Click to get this free report ALLERGAN PLC (AGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Ampyra is Acorda's flagship product and is currently approved in the U.S. for the improvement of walking in multiple sclerosis patients. New Article Biogen Inc. ( BIIB ) saw a big move last session, as the company's shares fell by nearly 6% on the day. This continues the recent downtrend for BIIB, as the stock is now down 17% since Aug 5, 2015. BIIB currently has a Zacks Rank #3 (Hold) while its Earnings ESP is +0.51%.",331.1064758300781
2015-08-26 00:00:00+00:00,290.1000061035156,298.6099853515625,283.44000244140625,298.25,298.25,3133900.0,2.0,1.0,0.250025,Biogen BIIB lost 31.1% over the last six months with Regeneron being the highest gainer (17.96%) during this period. Click to get this free report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report VITAL THERAPIES (VTL): Free Stock Analysis Report MACROCURE LTD (MCUR): Free Stock Analysis Report To read this article on Zacks.com click here. The company announced that its lead pipeline candidate CureXcell is not likely to meet the primary endpoint in a late-stage study being conducted for venous leg ulcers.,326.63555908203125
2015-08-27 00:00:00+00:00,301.3699951171875,308.5,299.3599853515625,304.489990234375,304.489990234375,2498600.0,2.0,1.0,0.250025,"Among the largest underlying components of IVW, in trading today Nike (Symbol: NKE) is up about 1.9%, Biogen Inc (Symbol: BIIB) is up about 3%, and Kinder Morgan Inc. (Symbol: KMI) is higher by about 2.8%. For a complete list of holdings, visit the IVW Holdings page  The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $85.21 per share, with $119.39 as the 52 week high point - that compares with a last trade of $111.11. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",315.8276672363281
2015-08-31 00:00:00+00:00,302.1600036621094,304.510009765625,296.4700012207031,297.29998779296875,297.29998779296875,1642400.0,3.0,1.0,0.5000249999999999,Applied Genetic Technologies Corporation 's AGTC share price has been increasing since the company announced that it has earned a milestone payment from collaboration partner with Biogen Inc. BIIB . Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report APPLIED GEN TEC (AGTC): Free Stock Analysis Report To read this article on Zacks.com click here. Applied Genetic said that it has achieved a patient enrollment milestone in the X-linked retinoschisis (XLRS) study and will receive a payment of $5 million from Biogen.,313.78662109375
2015-09-02 00:00:00+00:00,298.4800109863281,304.42999267578125,293.6099853515625,304.2099914550781,304.2099914550781,2271600.0,4.0,1.0,0.7500249999999999,"Performance Over the last five trading days, Gilead GILD recorded a decline of 1.04% while Biogen BIIB was the highest gainer (3.82%) among major biotechs. Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report INTERCEPT PHARM (ICPT): Free Stock Analysis Report AMICUS THERAPT (FOLD): Free Stock Analysis Report To read this article on Zacks.com click here. Investor focus will remain on the ramp up of these two treatments as well as their formulary status and pricing action by pharmacy benefit managers (Read more: Amgen's PCSK9 Inhibitor, Repatha, Approved in the U.S. ).",310.829833984375
2015-09-03 00:00:00+00:00,306.4700012207031,309.7200012207031,300.8399963378906,301.6300048828125,301.6300048828125,1787800.0,4.0,1.0,0.7500249999999999,"Those earnings estimates shouldn't be in any jeopardy as a result of international financial worries -- Gilead's only real Chinese connection is that suppliers of raw materials used to manufacture several of its anti-viral drugs are located in China. Patients with conditions like blood cancer, psoriasis, or psoriatic arthritis aren't likely to turn their backs on the biotech's stable of drugs regardless of what happens on the macroeconomic scene. The company didn't make any heads spin with its second-quarter earnings announced around the time the stock began its decline, but those results were solid .",304.2431335449219
2015-09-04 00:00:00+00:00,297.7200012207031,304.1400146484375,295.0299987792969,302.260009765625,302.260009765625,1696600.0,3.5,1.0,0.6250249999999999,"Among the largest underlying components of IYH, in trading today AbbVie Inc. (Symbol: ABBV) is down about 2%, Medtronic PLC (Symbol: MDT) is down about 1.7%, and Biogen Inc (Symbol: BIIB) is lower by about 0.2%. For a complete list of holdings, visit the IYH Holdings page  The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $108.00 per share, with $164.98 as the 52 week high point - that compares with a last trade of $147.32. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article We note that Biogen's BIIB Eloctate is already approved for the treatment of hemophilia A. Interestingly, this is the fourth time in 2015 that Roche has received the Breakthrough Therapy designation for its candidates. Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Roche HoldingRHHBY announced that ACE910 has received Breakthrough Therapy status from the FDA for the prophylactic treatment of patients aged 12 years or above, who are suffering from hemophilia A with factor VIII inhibitors.",292.8751220703125
2015-09-09 00:00:00+00:00,313.54998779296875,317.8299865722656,302.4700012207031,303.4800109863281,303.4800109863281,1623500.0,2.0,1.0,0.250025,"Meanwhile, Biogen BIIB lost 26.1% over the last six months with Regeneron being the highest gainer (28.6%) during this period as well. Click to get this free report GERON CORP (GERN): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report TETRAPHASE PHAR (TTPH): Free Stock Analysis Report ACADIA PHARMA (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Tetraphase suffered a huge setback with its experimental antibiotic, eravacycline, failing to achieve the primary endpoint in a late stage study.",294.65911865234375
2015-09-10 00:00:00+00:00,302.9100036621094,315.7699890136719,302.1099853515625,312.6199951171875,312.6199951171875,2189600.0,2.6666666666666665,1.0,0.4166916666666666,"Biogen BIIB has signed up with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of the latter's MT-1303, an oral compound that targets the S1P receptor. Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen said that the candidate has successfully completed a phase II study for MS and the company intends to move ahead rapidly with this indication. New Article Two other components making moves today are Seagate Technology ( STX ), trading down 3.8%, and Biogen ( BIIB ), trading up 1.3% on the day. In early trading on Thursday, shares of Liberty LiLAC Group ( LILA ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 1.3%. Wynn Resorts is lower by about 53.7% looking at the year to date performance. New Article If the drug is approved, Biogen will owe Mitsubishi Tanabe Pharma royalties on sales, although the exact percentage wasn't disclosed. While the license looks like a good move for Biogen, it does raise a few questions for the other companies developing drugs targeting the S1P1 receptor. The trial was in healthy volunteers, but presumably since the mechanism of action is working, it should help patients with autoimmune diseases as the S1P1 drugs ahead of it have.",294.2406921386719
2015-09-11 00:00:00+00:00,310.6700134277344,315.5,307.2099914550781,315.3699951171875,315.3699951171875,1928100.0,3.333333333333333,1.0,0.5833583333333334,"In company news, Akebia Therapeutics ( AKBA ) was surging in late Friday trading after late yesterday hiring an executive from biotech conglomerate Biogen Idec ( BIIB ) as its new senior vice president and chief scientific officer. Separately, the company yesterday named Ramin Farzaneh-Far to be its vice president of medical research. In other sector news, (+) ARWR, Nominates ARC-HIF2 as its first therapeutic candidate to treat clear-cell renal cell carcinoma. New Article GILD is a part of the Health Care sector, which includes companies such as Amgen Inc. ( AMGN ) and Biogen Inc. ( BIIB ). Shareholders who purchased GILD prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports GILD's forecasted earnings growth in 2015 as 51.58%, compared to an industry average of 7.9%. New Article Unfortunately, dominance in this field by Baxter -- or its recently spun-off biopharmaceutical segment, Baxalta -- has made realizing this opportunity far more challenging than expected. This tried-and-true method of drug-delivery seems to be working, as results from its pivotal trial suggest twice weekly infusions should effectively control bleeding episodes. A little further out Around the time Baxter submitted its application for BAX-855, Roche presented compelling data from a mid-stage study with an even longer-lasting hemophilia A therapy.",289.84027099609375
2015-09-14 00:00:00+00:00,316.8900146484375,318.20001220703125,311.94000244140625,316.2300109863281,316.2300109863281,1811700.0,4.5,1.0,0.8750249999999999,"While Tecfidera, Biogen's big growth engine, missed its mark last quarter -- creating the kind of nasty surprise Wall Street analysts hate -- it's still the top-selling oral MS drug. George Budwell : Amgen is one of my personal favorite blue-chip biotechs right now because the stock offers both solid growth prospects, as well as a rock-solid dividend payment. All told, Amgen is a dividend-paying biotech that should see double-digit growth on its top and bottom lines in the years to come, making it worth a deeper look by investors looking for a safe haven in this turbulent market. New Article Despite all of this focus on shareholders, Gilead currently trades at less than 9 times its 2016 earnings estimates, making it a great stock for investors who are looking for income, share repurchases, and value. Yes, Biogen faces a lot of competition, but with a proven track record, solid balance sheet, and some intriguing drugs in the works, I think owning it makes sense. For instance, Gilead is currently developing a potential functional cure for HIV in the TLR-7 agonist GS-9620, a monoclonal antibody, simtuzumab, and an ASK-1 inhibitor, GS-4997, for the massive untapped nonalcoholic steatohepatitis market, and a wide diversity of products for both solid tumors and hematological malignancies.",291.7214050292969
2015-09-17 00:00:00+00:00,321.19000244140625,330.5400085449219,318.3800048828125,325.29998779296875,325.29998779296875,2589200.0,2.5,1.0,0.375025,"Snow increased his stake in Biogen Inc. ( BIIB ) by 320%, and the company looks undervalued at the current price of $319.56. He relies on extensive research to determine the probability of a solution, gain confidence in the company's ability to survive difficult times and estimate the value of the stock once the difficulty has passed. Adjusted income from continuing operations was 40 cents per diluted share (non-GAAP), a 29% increase compared to the same quarter of a year before. New Article Multiple sclerosis patients suffer from poor signal conduction along nerve cells because their immune systems have damaged the myelin sheathing vital to their function. Mega-blockbuster opportunities Just two years following its launch, Tecfidera achieved an annual sales rate of $3.5 billion despite PML concerns and the fact that the drug, though effective at reducing disease progression, does nothing to repair damaged myelin. Promising Alzheimer's candidate aducanumab excited Wall Street when the highest dosage -- 10 mg per kilogram of body weight -- in a phase 1 trial significantly slowed the rate of cognitive decline as measured by two tests compared with placebo.",295.59527587890625
2015-09-22 00:00:00+00:00,292.5199890136719,300.0,289.0,299.0599975585937,299.0599975585937,4391700.0,1.0,1.0,2.4999999999997247e-05,"Biogen Inc.BIIB - Cambridge, MA-based Biogen, well known for its multiple sclerosis (MS) treatments, saw its shares slide 5.56% yesterday. Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Turing Pharmaceuticals, headed by ex-hedge fund manager, Martin Shkreli, had acquired rights to Daraprim from Impax Laboratories just last month and reportedly hiked its price from $13.50 to $750 per tablet.",288.00823974609375
2015-09-23 00:00:00+00:00,299.2699890136719,303.7900085449219,296.29998779296875,298.3399963378906,298.3399963378906,1642900.0,3.0,1.0,0.5000249999999999,"Meanwhile, Biogen BIIB lost 27.7% over the last six months with Regeneron REGN being the highest gainer (23.5%) during this period (See the last biotech stock roundup here: Biosimilar Competition for Amgen, Tetraphase Hit By Disappointing Data ). Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report INTRA-CELLULAR (ITCI): Free Stock Analysis Report TRACON PHARMACT (TCON): Free Stock Analysis Report JUNO THERAPEUTC (JUNO): Free Stock Analysis Report To read this article on Zacks.com click here. Hillary Clinton's tweet on Monday regarding high drug prices spooked biotech investors and resulted in the NASDAQ Biotechnology index shedding 4.41% in just one trading session.",280.4845886230469
2015-09-25 00:00:00+00:00,298.7799987792969,298.7799987792969,280.32000732421875,284.7900085449219,284.7900085449219,3366100.0,3.0,1.0,0.5000249999999999,"Stocks such as Regeneron Pharmaceuticals, Inc. ( REGN ), Gilead Sciences Inc. ( GILD ), Biogen Inc. ( BIIB ), Amgen Inc. ( AMGN ) and Celgene Corporation ( CELG ) decreased 2.7%, 2.8%, 1.8%, 1.5% and 2.7%, respectively. Click to get this free report CATERPILLAR INC (CAT): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report WELLS FARGO-NEW (WFC): Free Stock Analysis Report MORGAN STANLEY (MS): Free Stock Analysis Report BANK OF AMER CP (BAC): Free Stock Analysis Report CITIGROUP INC (C): Free Stock Analysis Report JPMORGAN CHASE (JPM): Free Stock Analysis Report To read this article on Zacks.com click here. For a look at the issues currently facing the markets, make sure to read today's Ahead of Wall Street article The Dow Jones Industrial Average (DJI) declined 0.5% to close at 16,201.32. New Article Biopharmaceutical company Biogen Idec ( BIIB ) said it has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for the marketing authorization of ELOCTA in the treatment of hemophilia A. In health-care stocks news, Navidea Biopharmaceuticals ( NAVB ) reported Friday morning its Macrophage Therapeutics unit developed the first two therapeutic Manocept immunoconstructs, MT-1001 and MT-2001, designed to target and kill activated CD206+ macrophages. And Amgen ( AMGN ) shares were 0.9% higher at $144.77 pre-market after the company said it received a positive opinion from the Committee for Medicinal Products for Human Use ( CHMP ) recommending marketing authorization for two of its drugs.",286.88458251953125
2015-10-01 00:00:00+00:00,291.989990234375,292.8900146484375,282.45001220703125,287.29998779296875,287.29998779296875,2871900.0,3.0,1.0,0.5000249999999999,"The big biotech announced on Sept. 9 its agreement to exclusively license MT-1303, a drug from Mitsubishi Tanabe Pharma Corporation, that also intends to treat ulcerative colitis, multiple sclerosis, and other autoimmune diseases. The drugs work by interfering with the signaling of the lipid mediator S1P, which ultimately reduces white blood cell migration to areas of inflammation. Biogen hasn't thrown out potential revenue numbers for MT-1303, but chief medical officer Dr. Alfred Sandrock said that it ""could be a best-in-class S1P modulator"". New Article Stocks recently featured in the blog include the Regeneron ( REGN ), Vertex ( VRTX ), Gilead ( GILD ), Biogen ( BIIB ) and Celgene ( CELG ). Other products that got a positive opinion from the CHMP include Biogen's ( BIIB ) hemophilia A treatment, Elocta and Celgene's ( CELG ) blood cancer treatment, Vidaza (label expansion) among others. Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report To read this article on Zacks.com click here.",285.84356689453125
2015-10-02 00:00:00+00:00,283.3800048828125,290.75,280.7200012207031,290.3500061035156,290.3500061035156,2982000.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of VUG, in trading today MasterCard Inc (Symbol: MA) is down about 1.7%, Union Pacific Corp (Symbol: UNP) is down about 1.1%, and Biogen Inc (Symbol: BIIB) is lower by about 0.7%. For a complete list of holdings, visit the VUG Holdings page  The chart below shows the one year price performance of VUG, versus its 200 day moving average: Looking at the chart above, VUG's low point in its 52 week range is $91.80 per share, with $111.92 as the 52 week high point - that compares with a last trade of $99.42. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",292.1480712890625
2015-10-05 00:00:00+00:00,291.42999267578125,292.4800109863281,282.760009765625,286.54998779296875,286.54998779296875,2703000.0,5.0,1.0,1.000025,"There's no telling where shares in Celgene Corporation , Gilead Sciences , or BIogen are heading in the next days or weeks, but all three are biotechnology powerhouses with the kind of staying power that makes them worthy of considering for long-term portfolios. In the following slideshow, I tell you which one of these companies' long-term forecast has me giddy, which one has a dirt cheap valuation that makes me think it's a bargain, and which has the financial chops to weather any storm. The next billion-dollar iSecret The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology.",281.43377685546875
2015-10-06 00:00:00+00:00,282.4100036621094,282.9800109863281,269.0,275.989990234375,275.989990234375,4291600.0,3.0,1.0,0.5000249999999999,"Acorda has a licensing agreement with Biogen Inc. BIIB for Fampyra in markets outside the U.S. Click to get this free report ALLERGAN PLC (AGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc.ACOR revealed through an 8K filing that it has entered into a settlement agreement with Allergan plc AGN to resolve the patent litigation related to its flagship product, Ampyra.",271.84454345703125
2015-10-07 00:00:00+00:00,279.8599853515625,284.6199951171875,274.010009765625,279.239990234375,279.239990234375,3469900.0,4.0,1.0,0.7500249999999999,"Incyte's therapy is the only one currently approved by the Food and Drug Administration to treat myelofibrosis, and it led to a greater number of patients experiencing at least a 35% decrease in spleen size relative to the placebo in clinical trials. With a number of biotech buyouts occurring at roughly three times the peak sales estimates of a company's portfolio, Vertex appears aggressively valued on a fundamental basis. With the exception of a handful of relatively early stage oncology products, Vertex is reliant on Orkambi and Kalydeco, which could leave it exposed to significant downside if a competing therapy eventually does emerge. New Article Performance Over the last five trading days, Biogen BIIB recorded a decline of 0.81% while Vertex was the highest gainer (9.65%) among the major biotechs. Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AMICUS THERAPT (FOLD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report SPARK THERAPEUT (ONCE): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, in the backdrop of concerns regarding high pricing, the PBM said that it will provide additional long-term protection for its payers and patients by capping the entire plan cost in 2016 for PCSK9 inhibitors for clients enrolled in the Cholesterol Care Value (CCV) program.",278.5747375488281
2015-10-08 00:00:00+00:00,278.3299865722656,281.5,272.2799987792969,279.8800048828125,279.8800048828125,2558900.0,4.0,1.0,0.7500249999999999,"Key biotech stocks including Celgene Corporation ( CELG ), Amgen Inc. ( AMGN ), Gilead Sciences Inc. ( GILD ), Regeneron Pharmaceuticals, Inc. ( REGN ) and Biogen Inc. ( BIIB ) increased 4.3%, 4.8%, 2.8%, 5.6% and 1.2%, respectively. Click to get this free report CELGENE CORP (CELG): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report DU PONT (EI) DE (DD): Free Stock Analysis Report DOW CHEMICAL (DOW): Free Stock Analysis Report MONSANTO CO-NEW (MON): Free Stock Analysis Report LYONDELLBASEL-A (LYB): Free Stock Analysis Report ECOLAB INC (ECL): Free Stock Analysis Report CHEVRON CORP (CVX): Free Stock Analysis Report YUM! For a look at the issues currently facing the markets, make sure to read today's Ahead of Wall Street article The Dow Jones Industrial Average (DJI) gained 0.7% or 122.10 points to close at 16,912.29. New Article While we are pleased with the encouraging data on MS drugs, we note that the market is highly competitive given the presence of companies like Biogen Inc. BIIB and Novartis AG NVS among others. Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. New five-year data from the extension study on Lemtrada showed that in the majority of relapsing remitting multiple sclerosis patients when treated with Lemtrada, consistent treatment effects were maintained across relapse, disability, brain atrophy and magnetic resonance imaging (MRI) lesion activities for three additional years in the extension study (three, four and five).",284.06671142578125
2015-10-09 00:00:00+00:00,279.6300048828125,280.0,267.2699890136719,269.1600036621094,269.1600036621094,4047200.0,5.0,1.0,1.000025,"Market leader Biogen Inc. BIIB , with key drugs like Tecfidera, Avonex and Tysabri, is collaborating with AbbVie ABBV for another MS candidate, Zinbryta. Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Data from the studies showed that ocrelizumab was superior to interferon beta-1a (Rebif) in lowering the three major markers of disease activity over the two-year controlled treatment period in patients suffering from relapsing MS. Additionally, a separate study, ORATORIO, showed that ocrelizumab significantly reduced the progression of clinical disability sustained for at least 12 weeks (the primary endpoint) and 24 weeks (a secondary endpoint) compared to placebo in patients suffering from PPMS.",286.11376953125
2015-10-12 00:00:00+00:00,270.9200134277344,270.9200134277344,263.510009765625,264.6700134277344,264.6700134277344,3686800.0,3.0,1.0,0.5000249999999999,"Its diverse lines of low, mid and high-power lasers and amplifiers are used in materials processing, advanced, communications and medical applications. Biogen Inc.' s (BIIB) EPS grew by 28.30% over the last five years. As a result of expansion in existing and new OEM customers, the company delivered a 21% increase in materials processing sales during the second quarter.",276.9172058105469
2015-10-15 00:00:00+00:00,256.3099975585937,268.5299987792969,254.0,268.4100036621094,268.4100036621094,2750300.0,2.0,1.0,0.250025,"Tangled web ahead For investors in either Roche or Novartis, bringing one of these antibodies to market would be a nice bump, but it isn't about to break them if they eventually fail. We've seen the effects safety data has on drug sales for less threatening forms of MS. During Arzerra's pivotal leukemia trial, 19 patients suffered fatal infections. The patients' disease probably bears the brunt of responsibility for those infections, but I don't see any new RRMS therapies reshaping this market unless they can boast a perfect safety record.",273.7171325683594
2015-10-19 00:00:00+00:00,270.8699951171875,276.5,268.0400085449219,273.0199890136719,273.0199890136719,2940000.0,3.0,1.0,0.5000249999999999,"BiogenBIIB , a well-known name in the multiple sclerosis (MS) market, will be reporting third quarter 2015 earnings results on Oct 21, before the market opens. Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. On the second quarter 2015 call, the company admitted that the reacceleration in Tecfidera's growth that it was expecting did not happen.",270.7859802246094
2015-10-20 00:00:00+00:00,273.0599975585937,277.2900085449219,264.5799865722656,265.8099975585937,265.8099975585937,3539800.0,3.0,1.0,0.5000249999999999,"Key biotech stocks including Celgene Corporation ( CELG ), Amgen Inc. ( AMGN ), Gilead Sciences Inc. ( GILD ), Regeneron Pharmaceuticals, Inc. ( REGN ) and Biogen Inc. ( BIIB ) increased 1.3%, 1.2%, 0.8%, 1.7% and 0.2%, respectively. Click to get this free report CELGENE CORP (CELG): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report INTEL CORP (INTC): Free Stock Analysis Report APPLE INC (AAPL): Free Stock Analysis Report MICROSOFT CORP (MSFT): Free Stock Analysis Report ALPHABET INC-A (GOOGL): Free Stock Analysis Report FACEBOOK INC-A (FB): Free Stock Analysis Report HALLIBURTON CO (HAL): Free Stock Analysis Report MORGAN STANLEY (MS): Free Stock Analysis Report EXXON MOBIL CRP (XOM): Free Stock Analysis Report CHEVRON CORP (CVX): Free Stock Analysis Report To read this article on Zacks.com click here. For a look at the issues currently facing the markets, make sure to read today's Ahead of Wall Street article The Dow Jones Industrial Average (DJI) rose 0.1% to close at 17,230.54. New Article With the initiation of this study, Isis earned a milestone payment of $11 million from its partner Biogen Inc. BIIB . Click to get this free report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Isis Pharmaceuticals, Inc.ISIS announced the commencement of an open-label extension study (SHINE) on ISIS-SMNRx in infants and children suffering from spinal muscular atrophy (SMA). New Article During the latest meeting of the European Committee for Treatment and Research in Multiple Sclerosis, investigators laid out some very compelling data that suggest Biogen's entire MS franchise is at risk. Biogen's Avonex, and its more recently approved longer-lasting version, Plegridy, pulled in a combined $1.4 billion in the first half of the year, comprising 28% of total sales for the period. It's hard to make apples-to-apples efficacy comparisons of ocrelizumab to Tecfidera and Tysabri, but its stellar performance versus Rebif certainly suggests it has what it takes to compete fiercely.",266.06707763671875
2015-10-21 00:00:00+00:00,285.0,291.010009765625,262.45001220703125,276.3399963378906,276.3399963378906,8374300.0,2.1666666666666665,1.0,0.2916916666666666,"On Wednesday, biotechnology company Biogen Inc ( BIIB ) said in their Q3 earningsrelease that it will be cutting 11% of its workforce as well as canceling some development programs in a restructuring plan that the company hopes will bring them $250 million per year. In pre-market trading , BIIB soared over 7%, and is currently up $0.97, or 0.37%, to $266.78. Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report WHOLE FOODS MKT (WFM): Free Stock Analysis Report WAL-MART STORES (WMT): Free Stock Analysis Report HEWLETT PACKARD (HPQ): Free Stock Analysis Report TWITTER INC (TWTR): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Among the largest underlying components of BBH, in trading today Celgene Corp. (Symbol: CELG) is down about 1.8%, Biogen Inc (Symbol: BIIB) is up about 3%, and Baxalta Inc (Symbol: BXLT) is up by about 0.3%. For a complete list of holdings, visit the BBH Holdings page  The chart below shows the one year price performance of BBH, versus its 200 day moving average: Looking at the chart above, BBH's low point in its 52 week range is $95.76 per share, with $145.52 as the 52 week high point - that compares with a last trade of $114.67. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Biotech company, BiogenBIIB , reported third quarter 2015 earnings per share of $4.48, well above the Zacks Consensus Estimate of $3.83 and 18.2% above the year-ago earnings. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AEGERION PHARMA (AEGR): Free Stock Analysis Report To read this article on Zacks.com click here. The company attributed the 18% sequential improvement in U.S. revenues to the rebalancing of an inventory reduction in the wholesale channel in the second quarter of 2015. New Article Biotech stocks including Celgene Corporation ( CELG ), Amgen Inc. ( AMGN ), Gilead Sciences Inc. ( GILD ), Regeneron Pharmaceuticals, Inc. ( REGN ) and Biogen Inc. ( BIIB ) decreased 2.7%, 2.6%, 1.9%, 1.7% and 2.6%, respectively. Click to get this free report CELGENE CORP (CELG): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report INTL BUS MACH (IBM): Free Stock Analysis Report HARLEY-DAVIDSON (HOG): Free Stock Analysis Report UTD TECHS CORP (UTX): Free Stock Analysis Report VERIZON COMM (VZ): Free Stock Analysis Report TRAVELERS COS (TRV): Free Stock Analysis Report To read this article on Zacks.com click here. For a look at the issues currently facing the markets, make sure to read today's Ahead of Wall Street article The Dow Jones Industrial Average (DJI) declined 0.1% to close at 17,217.11. New Article Cambridge, MA-based BiogenBIIB , one of the world's leading biotechnology companies, focuses on therapeutic areas including neurology, immunology and hemophilia. BIIB has a pretty good earnings track record with the company delivering positive earnings surprises in three of the last fourth quarters with an average surprise of 7.05%. Currently, BIIB has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. New Article Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 44.4% Average next regular session additional gain: 1.6% Over the prior three fiscal years (12 quarters), when shares of BIIB rose in the extended-hours session in reaction to its earnings announcement, history shows that 44.4% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.6%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 3.4% Over that same historical period, when shares of BIIB dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 3.4% by the following regular session close. Extended-Hours Dollar Volume: $60,776,642 Biogen Idec ( BIIB ) is due to issue its quarterly earnings report in the upcoming extended-hours session.",254.325439453125
2015-10-22 00:00:00+00:00,276.3299865722656,283.4800109863281,270.07000732421875,276.8299865722656,276.8299865722656,4522700.0,2.5,1.0,0.375025,"Specialty Sciences: Segmental revenues comprising royalties received by Perrigo on multiple sclerosis drug Tysabri from Biogen Inc. BIIB came in at $84.5 million, down 8% year over year. Click to get this free report TEVA PHARM ADR (TEVA): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report To read this article on Zacks.com click here. Perrigo Company 's PRGO third-quarter 2015 earnings of $1.76 per share beat the Zacks Consensus Estimate of $1.74. New Article Separate from the earnings release, Biogen said that its clinical trial testing Tysabri in secondary progressive multiple sclerosis failed. That's obviously good news for Teva Pharmaceuticals, Pfizer, and Novartis, but we'll have to wait until the companies report third-quarter earnings to confirm that it's actually helped them. The savings won't flow to the earnings line, though, as the company said it plans to increase spending on Tecfidera marketing, as well as research and development.",250.04698181152344
2015-10-23 00:00:00+00:00,279.0,280.8800048828125,270.70001220703125,276.989990234375,276.989990234375,3866400.0,2.6666666666666665,1.0,0.4166916666666666,"Long-term shareholders will have to hope that the headwinds the unit faced were a result of one-time effects from recent acquisitions, and that once those new purchases are fully integrated into the overall business, Alcoa will be able to take maximum advantage and start generating increased profits from them. While Biogen's management has a terrific track record of triumphing against the odds, this biotech has been traveling a rough road lately , and the new strategy introduces even more uncertainty. Additionally, Morgan Stanley's investment management division actually lost money for the quarter (Goldman's earned a $670 million profit). New Article Kyprolis won FDA approval in July as a treatment in combination with Revlimid and dexamethasone for relapsed multiple myeloma. Sales for multiple sclerosis (MS) drug Tecfidera, the biotech's top seller, are growing quickly -- but more slowly than most expected. Anti-LINGO 1, which is in phase 2 clinical trials, takes a new approach to slowing progression of MS by protecting nerves from the disease. New Article Ampyra is marketed in ex-U.S. markets under the trade name Fampyra by Biogen Inc. BIIB . Click to get this free report ALLERGAN PLC (AGN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Earlier this month, Acorda entered into a settlement agreements with Allergan plc AGN and Sun Pharmaceutical Industries Ltd. to resolve the patent litigations related to Ampyra.",253.04579162597656
2015-10-27 00:00:00+00:00,276.0,291.7699890136719,275.1099853515625,290.6300048828125,290.6300048828125,3722600.0,2.0,1.0,0.250025,"VIDEO: Tuesday 10/27 Insider Buying Report: BIIB, DKL The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. At Biogen ( BIIB ), a filing with the SEC revealed that on Friday, Director Alexander J. Denner purchased 310,000 shares of BIIB, at a cost of $277.47 each, for a total investment of $86.02M. And at Delek Logistics Partners ( DKL ), there was insider buying on Thursday, by Chairman / CEO Ezra Uzi Yemin who bought 15,000 shares at a cost of $34.11 each, for a trade totaling $511,696.",262.80096435546875
2015-10-28 00:00:00+00:00,291.95001220703125,294.0599975585937,285.5,293.69000244140625,293.69000244140625,3306700.0,2.5,1.0,0.375025,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Third quarter earnings season has kicked off with companies like Biogen BIIB and Gilead GILD reporting results. Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report SPECTRUM PHARMA (SPPI): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. With liver injury warnings being added to the labels, investor focus will remain on the performance of these HCV treatments as well as the company's equation with pharmacy benefit manager, Express Scripts.",264.9359130859375
2015-10-30 00:00:00+00:00,294.0,295.0400085449219,290.0,290.510009765625,290.510009765625,5209100.0,2.0,1.0,0.250025,"Biogen Inc. ( BIIB ) is +5.49 at $296.00, with 1,042,375 shares traded. As reported by Zacks, the current mean recommendation for BIIB is in the ""buy range"". As reported in the last short interest update the days to cover for MKTX is 7.298983; this calculation is based on the average trading volume of the stock. New Article Biogen (BIIB) Photo: leshistory.com At the end of September, upscale specialty grocer Whole Foods Market said that it will cut roughly 1,500 jobs over the next 8 weeks. Click to get this free report DEUTSCHE BK AG (DB): Free Stock Analysis Report TWITTER INC (TWTR): Free Stock Analysis Report WAL-MART STORES (WMT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report WHOLE FOODS MKT (WFM): Free Stock Analysis Report PROCTER & GAMBL (PG): Free Stock Analysis Report MICROSOFT CORP (MSFT): Free Stock Analysis Report CATERPILLAR INC (CAT): Free Stock Analysis Report SCHLUMBERGER LT (SLB): Free Stock Analysis Report HALLIBURTON CO (HAL): Free Stock Analysis Report BAKER-HUGHES (BHI): Free Stock Analysis Report JPMORGAN CHASE (JPM): Free Stock Analysis Report HEWLETT PACKARD (HPQ): Free Stock Analysis Report To read this article on Zacks.com click here. According to a report published by consulting firm Challenger, Gray & Christmas, the month of September saw 58,877 job cuts, an increase of nearly 43% from August.",266.5398254394531
2015-11-02 00:00:00+00:00,294.5199890136719,303.3099975585937,293.3299865722656,303.0799865722656,303.0799865722656,2785800.0,3.0,1.0,0.5000249999999999,"When Biogen (NASDAQ: BIIB) reported third-quarter results recently, it announced some serious operational changes to come. While advertising might help restore growth of Tecfidera sales in the U.S., it's the investment into mid- and late-stage clinical studies that will provide returns over the long term. Phase 2 results suggest it isn't associated with unwanted decreases in heart rate when patients receive their first doses, which could help it break into markets already served by other drugs of the same class.",264.615478515625
2015-11-04 00:00:00+00:00,299.8399963378906,302.3900146484375,293.04998779296875,296.57000732421875,296.57000732421875,2437700.0,2.0,1.0,0.250025,"Tecfidera and Gilenya's third-quarter performance shows that they're reshaping how doctors treat patients, but Biogen and Novartis may soon begin losing market share to Sanofi's Aubagio, another oral-MS drug that's growing even more quickly. In October 2014, Sanofi reported that Aubagio patients participating in its Tower study had a statistically significant reduction in annual relapse rate and relative risk of sustained disability progression versus placebo. That finding could give doctors yet another reason to prescribe Aubagio over Biogen's Tecfidera and Novartis' Gilenya, but we'll have to wait a couple of quarters to see if that proves to be the case.",265.14385986328125
2015-11-05 00:00:00+00:00,294.1499938964844,295.010009765625,288.5,293.0299987792969,293.0299987792969,2259900.0,3.0,1.0,0.5000249999999999,"Factors at Play This Quarter Isis' antisense technology has resulted in partnerships with several leading health care companies like Biogen Inc. BIIB among others that not only validate its technology platform but also provide the company with a steady stream of funds in the form of upfront, milestone and other payments. Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report To read this article on Zacks.com click here. Both companies entered into a multi-year collaboration for the discovery and development of antisense drugs mainly focused on treating cardiovascular, metabolic and kidney diseases.",261.6058654785156
2015-11-06 00:00:00+00:00,293.0899963378906,296.1000061035156,287.7300109863281,295.3500061035156,295.3500061035156,2449600.0,2.5,1.0,0.375025,"Several companies like Gilead Sciences Inc. GILD , Amgen Inc. AMGN , Biogen Inc. BIIB , Celgene Corporation, Vertex Pharmaceuticals Inc. and Baxalta Inc. among others delivered better-than-expected earnings with companies like Amgen and Biogen even raising their guidance for 2015. Click to get this free report UTD THERAPEUTIC (UTHR): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report EXPRESS SCRIPTS (ESRX): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report To read this article on Zacks.com click here. It got more exciting when pharmacy benefit manager, Express Scripts Holding Company ESRX , announced that it will list both Amgen and Sanofi/Regeneron's PCSK9 inhibitors, Repatha and Praluent, respectively, on its National Preferred Formulary that covers about 25 million Americans. New Article Biotech Earnings in Detail Biogen Inc. ( BIIB ) reported third-quarter 2015 earnings per share of $4.48 that were higher than the Zacks Consensus Estimate of $3.83 and 18.2% above the year-ago level. Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report ISHARES NDQ BIO (IBB): ETF Research Reports MKT VEC-BIOTECH (BBH): ETF Research Reports To read this article on Zacks.com click here. However, the recent quarterly results depicted that the biotech sector held up well as all of them delivered better-than-expected earnings while most of them beat the top-line expectations and raised their outlook.",258.8292541503906
2015-11-09 00:00:00+00:00,294.0,298.0,291.760009765625,293.3999938964844,293.3999938964844,1786200.0,2.0,1.0,0.250025,"As an added bonus, this ETF is designed to limit the risk of major downward price movements by holding shares in over 140 companies, removing most, if not all, of the possibility of getting entirely wiped out by a single negative regulatory or clinical event. We'll start by assessing these companies' potential for growth in the near term, as well as the health of their balance sheets, in case a so-called ""black swan"" decides to pay a visit to biotech next year. After all, it's quite telling that Regeneron, the only company expected to generate double-digit growth next year -- and that lacks a serious debt problem to boot -- is projected to do so based in large part on the launch of its new cholesterol-lowering drug Praluent.",269.33642578125
2015-11-11 00:00:00+00:00,297.94000244140625,303.29998779296875,293.7900085449219,293.8900146484375,293.8900146484375,2084700.0,3.333333333333333,1.0,0.5833583333333334,"Biogen Inc. ( BIIB ) 's EPS has grown by 28.3% over the last five years. Its segments include Asset management, Property, Renewable energy, Infrastructure, Private equity, Residential development, Service and Corporate. Brookfield's businesses are performing well and are expanding their global real asset management franchise with the major developments and significant transactions across all its platforms. New Article AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports AMGN's forecasted earnings growth in 2015 as 16.18%, compared to an industry average of 7.9%. The following ETF(s) have AMGN as a top-10 holding: iShares Nasdaq Biotechnology Index Fund ( IBB ) PowerShares Dynamic Pharmaceuticals ( PJP ) PowerShares Dynamic Biotech &Genome ( PBE ) SPDR Select Sector Fund - Health Care ( XLV ) Market Vectors Biotech ETF ( BBH ). New Article Among the largest underlying components of VUG, in trading today MasterCard Inc (Symbol: MA) is up about 0.3%, United Parcel Service Inc (Symbol: UPS) is off about 0.3%, and Biogen Inc (Symbol: BIIB) is higher by about 1.9%. For a complete list of holdings, visit the VUG Holdings page  The chart below shows the one year price performance of VUG, versus its 200 day moving average: Looking at the chart above, VUG's low point in its 52 week range is $93.61 per share, with $111.92 as the 52 week high point - that compares with a last trade of $109.17. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",273.2320251464844
2015-11-16 00:00:00+00:00,285.92999267578125,286.75,278.2799987792969,283.5299987792969,283.5299987792969,1960100.0,2.0,1.0,0.250025,"Aducanumab is the company's exciting Alzheimer's compound that, in phase 1 studies, led to statistically significant improvements in cognition for early stage patients. Anti-LINGO-1 is the company's experimental next-generation MS therapy, and has demonstrated its ability to repair aspects of the central nervous system in studies. In theory, both have $5 billion-plus in peak sales potential if they breeze through phase 3 trials, but Biogen may be unwilling to show its cards (i.e. pay a dividend) before it has these results in hand. New Article ( BIIB ), a Cambridge, Mass.-based biotechnology company, for an average price of $330.23 per share. PRIMECAP makes its decisions with a three- to five-year window in mind and will hold shares longer if the numbers justify doing so. PRIMECAP's most noteworthy third-quarter transaction was the sale of its 5,110,640-share stake in Polypore International Inc. ( NYSE:PPO ), a Charlotte, N.C.-based technology company, for an average price of $60.08 per share.",279.906005859375
2015-11-17 00:00:00+00:00,284.20001220703125,285.7699890136719,278.54998779296875,279.489990234375,279.489990234375,2348500.0,1.0,1.0,2.4999999999997247e-05,"Investors began to send shares lower in May that it and partner Biogen announced that they would be consolidating plans for their development programs that are targeting beta-thalassemia and sickle cell disease. Given that both Biogen and Shire have changed the terms of their initial collaboration deals since the start of the year, investors have probably been losing confidence in the company's technology, which could be the reason that shares have been sent tumbling. While Sangamo's technology is certainly exciting, given that its most advanced compound is currently only in phase 2 development, it will still be several years before the company could start to generate meaningful revenue from product sales.",283.0201721191406
2015-11-18 00:00:00+00:00,280.6499938964844,292.67999267578125,279.3099975585937,291.9800109863281,291.9800109863281,2253200.0,2.0,1.0,0.250025,Performance Vertex VRTX was the highest gainer (7.87%) among major biotech stocks over the last five trading days with Biogen BIIB declining 4.61% during this period. Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report CLOVIS ONCOLOGY (CLVS): Free Stock Analysis Report To read this article on Zacks.com click here. Clovis Oncology's CLVS shares plunged 70% as the company is possibly facing a delay in gaining FDA approval for its lead pipeline candidate.,273.72991943359375
2015-11-19 00:00:00+00:00,292.0,292.5,286.5299987792969,289.44000244140625,289.44000244140625,1625100.0,2.0,1.0,0.250025,"Commercializing Amgen 's recently approved cholesterol fighter Repatha across the EU hit a road block this week when cost crunchers in the U.K. determined that the drug didn't deliver the right balance of efficacy and price. That is a dramatic decrease in cholesterol, a naturally occurring fatty substance critical to making hormones and aiding in digestion. Historically, the medical community has accepted cholesterol-lowering as a proxy for improving cardiovascular outcomes, suggesting that if Amgen returns, then NICE will OK Repatha.",273.6079406738281
2015-11-24 00:00:00+00:00,290.9599914550781,292.6099853515625,288.010009765625,289.1499938964844,289.1499938964844,1325400.0,4.0,1.0,0.7500249999999999,"And Biogen ( BIIB ) Tuesday reported that the European Commission ( EC ) has approved ELOCTA for the treatment of hemophilia A in all 28 European Union (EU) member states, as well as Iceland, Liechtenstein and Norway. In health-care stocks news, Synthetic Biologics ( SYN ), a biopharmaceutical company, said the U.S. Patent and Trademark Office has issued a patent that covers the use of a range of compounds, including the active agent of SYN-010, for the treatment of irritable bowel syndrome with constipation. Novartis AG ( NVS ), a pharmaceutical company, said the European Commission has approved its Entresto for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction. New Article A couple of other well-ranked stocks in the health care sector are GW Pharmaceuticals plc GWPH and Biogen BIIB . Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report GW PHARMA-ADR (GWPH): Free Stock Analysis Report To read this article on Zacks.com click here. Gilead Sciences, Inc.GILD announced that its tenofoviralafenamide (TAF)-based HIV drug, Genvoya, has been approved by the European Commission (EC). New Article A couple of other well-ranked stocks in the health care sector are GW Pharmaceuticals plc GWPH and Biogen BIIB . Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report GW PHARMA-ADR (GWPH): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers Squibb CompanyBMY announced that the FDA has cleared its intravenous human programmed death receptor-1 (PD-1) blocking antibody, Opdivo, for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.",266.7161865234375
2015-11-25 00:00:00+00:00,290.0,292.8599853515625,289.2900085449219,292.29998779296875,292.29998779296875,1140100.0,2.6666666666666665,1.0,0.4166916666666666,"Moreover, Biogen BIIB got EU approval for its hemophilia A treatment, Elocta. Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here. It was a pretty eventful week in the biotech sector - KaloBios KBIO grabbed headlines with the company getting funds from a Martin Shkreli led group. New Article A couple of favorably ranked stocks in the health care sector are GW Pharmaceuticals plc GWPH and Biogen BIIB . Click to get this free report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report GW PHARMA-ADR (GWPH): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report To read this article on Zacks.com click here. BioMarin Pharmaceutical Inc.BMRN announced that the FDA's Peripheral and Central Nervous System Drugs Advisory Committee's vote on Kyndrisa was not favorable. New Article A couple of better-ranked stocks in the health care sector are GW Pharmaceuticals plc GWPH and Biogen BIIB . Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report GW PHARMA-ADR (GWPH): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers Squibb CompanyBMY announced that the FDA has cleared its intravenous human programmed death receptor-1 (PD-1) blocking antibody, Opdivo, for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.",270.6850280761719
2015-11-27 00:00:00+00:00,292.9700012207031,294.1000061035156,290.7799987792969,293.2099914550781,293.2099914550781,465800.0,3.0,1.0,0.5000249999999999,"Stocks recently featured in the blog include BioMarin ( BMRN ), Amgen ( AMGN ), Vertex ( VRTX ), Gilead ( GILD ), Biogen ( BIIB ) and Repros ( RPRX ). Moreover, Biogen ( BIIB ) got EU approval for its hemophilia A treatment, Elocta. Click to get this free report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report To read this article on Zacks.com click here.",271.022705078125
2015-11-30 00:00:00+00:00,293.1600036621094,294.260009765625,285.1000061035156,286.8599853515625,286.8599853515625,1679300.0,3.0,1.0,0.5000249999999999,"After a failed bid for Mylan earlier this year, Teva successfully inked a deal in July to purchase Allergan PLC 's generics business for a whopping $40.5 billion. Copaxone 40 mg isn't just a defensive play either -- its uptake in Germany is outperforming Biogen 's leading competitor drug, Tecfidera. So far, competitors like Biogen -- which is struggling after Tecfidera was recently linked with a rare, deadly brain infection in a patient -- have failed to unseat it. New Article Data in a late-breaking abstract for a presentation at the American Society of Hematology meeting next week shows by just how much the tipple combination helps patients compared to the two drugs. But if you do the statistics on the data patients who have died, there's a 45% reduction in the risk of death by taking the triple drug combination, compared with the Rituxan and Treanda alone. Gilead is testing Zydelig as a first-line treatment before Treanda and Rituxan would be used, potentially making the triple combination obsolete fairly soon after it's approved.",267.704345703125
2015-12-01 00:00:00+00:00,289.29998779296875,290.5899963378906,285.79998779296875,290.0400085449219,290.0400085449219,1684300.0,3.0,1.0,0.5000249999999999,"Biogen's slump may not be over quite yet According to S&P Captial IQ , Biogen's stock isnearly 40% off its 52-week high: BIIB data by YCharts The biotech's lengthy downward spiral started after safety concerns dampened sales of its flagship multiple sclerosis drug, Tecfidera, in the first quarter. Given the firm's ability to drive trends within the market, investors big and small would be wise to keep a close eye on BlackRock's quarterly activity. CELG data by YCharts The concern seems to be that Revlimid's revenues could start to fall if payers are able to install a value-based reimbursement scheme for cancer drugs with multiple indications.",252.73341369628906
2015-12-02 00:00:00+00:00,289.1400146484375,290.3900146484375,284.5799865722656,284.9599914550781,284.9599914550781,1369000.0,2.5,1.0,0.375025,"Meanwhile, Biogen BIIB lost 26.94% over the last six months with Alexion being the highest gainer (10.03%) during this period. Click to get this free report ALEXION PHARMA (ALXN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report XOMA CORP (XOMA): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report REPROS THERAPEU (RPRX): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Repros Therapeutics RPRX suffered a setback with the FDA issuing a complete response letter (CRL) for the company's lead pipeline candidate. New Article Earlier this year, Biogen reported promising phase 1 study results for its Alzheimer's drug, aducanumab/ BIIB-037, that were so good the company decided to skip mid-stage studies and advance the drug into a large late-stage study involving more than 1,300 patients. Anavex Life Sciences Corp. 's media department has been busy lately touting the potential benefits of Alzheimer's disease drugs in its pipeline, but the company's research is in the uber-early stages. Research into the development of sigma-1 agonists stems from studies conducted as early as 2005 showing that they may offer neuroprotective activity against amyloid toxicity, alleviating cognitive deficits and reducing neuronal damage in Alzheimer's patients.",239.83984375
2015-12-03 00:00:00+00:00,284.2200012207031,285.5799865722656,274.2300109863281,275.44000244140625,275.44000244140625,1902700.0,2.5,1.0,0.375025,"These include royalties of $14 million and $104.9 million from Biogen Inc. BIIB and Roche Holding AG's RHHBY Genentech, Inc., respectively, due from the Queen et al. patent license as well as a royalty payment of $5.3 million for Glumetza for the month of October from Valeant Pharmaceuticals International, Inc. VRX . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report PDL BIOPHARMA (PDLI): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. PDL BioPharma, Inc.PDLI announced that it received cash payments worth $133.7 million from Nov 1, 2015 through Dec 1, 2015. New Article Among the largest underlying components of IBB, in trading today Regeneron Pharmaceuticals, Inc. (Symbol: REGN) is down about 0.7%, Biogen Inc (Symbol: BIIB) is down about 1.4%, and Alexion Pharmaceuticals Inc. (Symbol: ALXN) is lower by about 2.2%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $284.16 per share, with $400.79 as the 52 week high point - that compares with a last trade of $329.06. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",240.5542449951172
2015-12-07 00:00:00+00:00,283.3099975585937,284.9800109863281,279.70001220703125,281.6300048828125,281.6300048828125,1739700.0,2.0,1.0,0.250025,"Although the latest price swing for Anavex occurred in response to a preclinical stage program, the company's lead Alzheimer's candidate, 2-73, has produced some compelling results in clinical trials. This outcome pinned hopes to a smaller dosage that, a couple of months later, produced surprisingly weak results with regard to cognitive decline, and only a slight safety improvement. According to clinicaltrials.gov, full results of the phase 2a trial, including 52-week data with cognitive measurements used by Lilly and Biogen, should be ready this month, although the company hasn't announced a date to present them. New Article Approvals in either indication probably wouldn't generate blockbuster results for volanesorsen on their own, but they could open the door for the drug to work its way into a role of treating high-triglyceride patients not caused by genetic factors. In its previously reported phase 2 trial from December 2014, Isis' data showed a sevenfold lower incidence rate of venous thrombosis in patients undergoing total knee replacements compared to the cohort taking Lovenox. Plenty of chances to hit home runs Isis Pharmaceuticals' shareholders understand the risk that a majority of the company's developing drugs could wind up failing.",235.51991271972656
2015-12-09 00:00:00+00:00,286.2099914550781,290.0899963378906,283.0199890136719,284.6099853515625,284.6099853515625,1525400.0,3.0,1.0,0.5000249999999999,"Last month, Biogen Inc.'s BIIB joint venture with Samsung Biologics, Samsung Bioepis, received a positive opinion from the EMA's Committee for Medicinal Products for Human Use for its MAA for its proposed biosimilar version (Benepali) of Enbrel. Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. NovartisNVS announced that the European Medicines Agency (EMA) has accepted its generic arm Sandoz's Marketing Authorisation Application (MAA) for a biosimilar version of Pfizer Inc.'s (PFE) blockbuster drug, Enbrel.",237.22003173828125
2015-12-10 00:00:00+00:00,285.3599853515625,291.2200012207031,284.67999267578125,289.8800048828125,289.8800048828125,1422800.0,1.0,1.0,2.4999999999997247e-05,"Shares of Isis Pharmaceuticals , a predominantly clinical-stage antisense drug developer, soared 27% in November, based on data from S&P Capital IQ , after reporting an abundance of positive trial outcomes. The biggest boost for Isis Pharmaceuticals came from its data release at the American Heart Association's Scientific Sessions at the University of California, San Diego, my alma mater. The two are currently partnered on the development of ISIS-SMN rx , an experimental drug designed to treat spinal muscular atrophy in infants and children.",223.25579833984375
2015-12-11 00:00:00+00:00,285.5400085449219,288.5899963378906,282.2300109863281,283.4599914550781,283.4599914550781,2029900.0,2.5,1.0,0.375025,"GILD is a part of the Health Care sector, which includes companies such as Amgen Inc. ( AMGN ) and Biogen Inc. ( BIIB ). Shareholders who purchased GILD prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports GILD's forecasted earnings growth in 2015 as 51.35%, compared to an industry average of 10.2%. New Article Among the largest underlying components of IBB, in trading today Amgen Inc (Symbol: AMGN) is off about 0.8%, Regeneron Pharmaceuticals, Inc. (Symbol: REGN) is off about 1.8%, and Biogen Inc (Symbol: BIIB) is lower by about 1.2%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $284.16 per share, with $400.79 as the 52 week high point - that compares with a last trade of $323.77. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",222.57469177246094
2015-12-14 00:00:00+00:00,283.7699890136719,285.0,276.42999267578125,282.3900146484375,282.3900146484375,1649800.0,4.0,1.0,0.7500249999999999,"Isis Pharmaceuticals, Inc.ISIS announced that its partner Biogen Inc. BIIB has started a phase I/II study on ISIS-SOD1Rx (previously known as ISIS-BIIB3Rx) in patients suffering from amyotrophic lateral sclerosis (ALS). Apart from ISIS-SOD1Rx, candidates that are being developed under this collaboration include nusinersen (spinal muscular atrophy), ISIS-DMPK-2.5Rx (myotonic dystrophy type 1), and an undisclosed neurodegenerative disease candidate, ISIS-BIIB4Rx. Click to get this free report ISIS PHARMACEUT (ISIS): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ACHILLION PHARM (ACHN): Free Stock Analysis Report To read this article on Zacks.com click here.",236.60693359375
2015-12-16 00:00:00+00:00,292.2300109863281,299.67999267578125,290.0,299.2900085449219,299.2900085449219,2104200.0,3.0,1.0,0.5000249999999999,"Meanwhile, Biogen BIIB lost 25.54% over the last six months with Regeneron being the highest gainer (10.90%) during this period. Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report CLOVIS ONCOLOGY (CLVS): Free Stock Analysis Report AKEBIA THERAP (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. Some of the markets include key expansion regions like Brazil, China, Colombia, Hong Kong, Israel, Singapore, South Korea, Taiwan and Thailand. New Article Biogen ( BIIB ), a global biopharmaceutical company, is collaborating with Arsia Therapeutics in the development of subcutaneous injection versions of the intravenous treatment for hemophilia. In health-care stocks news, Marinus Pharmaceuticals ( MRNS ), which focuses on the development of treatments for epilepsy and neuropsychiatric disorders, said it has completed patient recruitment for the Phase 3 clinical trial of ganaxolone, a CNS-selective GABAA modulator, in adults with drug-resistant focal onset seizures. And biopharmaceutical company Alkermes ( ALKS ) reported Wednesday new developments and milestones related to its proprietary product and late-stage pipeline portfolio of medicines for the treatment of central nervous system ( CNS ) diseases.",232.35459899902344
2015-12-17 00:00:00+00:00,299.0400085449219,300.8699951171875,296.3800048828125,297.1700134277344,297.1700134277344,1705300.0,4.0,1.0,0.7500249999999999,The company is currently enrolling patients in the EVOLVE-1 study on ALKS 8700 for MS. A head-to-head study (EVOLVE-2) on ALKS 8700 in comparison with Biogen Inc.'s BIIB Tecfidera is expected to be initiated in mid-2016. Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report To read this article on Zacks.com click here. Alkermes plc 's ALKS shares hit a 52-week high after the company announced new developments and milestones related to three of its candidates and an approved product for the treatment of central nervous system (CNS) diseases.,239.76112365722656
2015-12-21 00:00:00+00:00,294.8399963378906,297.8599853515625,293.5,297.5599975585937,297.5599975585937,1137600.0,3.0,1.0,0.5000249999999999,"Brian Feroldi : While 2015 was a decent year to have money in biotech stocks in general, investors in Medivation , a profitable biotechnology company focused on treating cancer, were left behind. First, Lexicon met its primary endpoint in both the TELESTAR and TELECAST phase 3 trials involving telotristat etiprate, a treatment for carcinoid syndrome in cancer patients with metastatic neuroendocrine tumors. The third study, expected in Q1 2017, is examining what proportion of trial patients have A1C levels below 7% at the 24-week mark, and it has secondary efficacy endpoints that include body weight and systolic blood pressure changes from baseline.",250.6807098388672
2015-12-24 00:00:00+00:00,300.2900085449219,303.8699951171875,299.5,302.2900085449219,302.2900085449219,537100.0,2.0,1.0,0.250025,"The larger firms in the space, such as Amgen (AMGN)*, Biogen (BIIB), Regeneron (REGN) and Gilead (GILD), still have some product risk, but it is the execution on existing, proven therapies and the introduction of new revenue streams that will provide the catalyst for increases in stock prices next year. As these companies mature, and actual sales and execution come to the fore, that trend will continue and maybe even intensify, which is why it is important for investors to diversify when considering biotech. Mindful of the effects of generics on big pharmaceutical companies over the years the large biotech firms have been acting to undercut the imitators that will undoubtedly come as patent protection expires on some of the early therapies.",252.6904296875
2016-01-07 00:00:00+00:00,286.5199890136719,289.989990234375,283.0299987792969,284.010009765625,284.010009765625,1844900.0,3.0,1.0,0.5000249999999999,"The Vanguard Health Care Fund doubled its stake in Biogen Inc. ( BIIB ), one of the world's leading biotechnology companies, in the third quarter. BIIB 15-Year Financial Data The intrinsic value of BIIB Peter Lynch Chart of BIIB Biogen's main focus is developing therapies for serious neurological, autoimmune and rare diseases. This company has many great signs, and Hynes had the opportunity to work and gain experience from Owens for two decades.",256.9659423828125
2016-01-08 00:00:00+00:00,284.6499938964844,288.1099853515625,280.0,280.5899963378906,280.5899963378906,1808900.0,2.0,1.0,0.250025,"Celgene made a significant move in July when it announced a $7 billion acquisition of Receptos in order to get its hands on promising multiple sclerosis drug Ozanimod. Celgene agreed to pay, or paid $7.2 billion to buy Receptos -- to get its hands on a multiple sclerosis drug named Ozanimod. And then in thinking about it, there was some news that was released that Biogen licensed a pretty similar drug to Ozanimod that's also being studied for multiple sclerosis and some other autoimmune diseases. New Article Investors eyeing a purchase of Biogen Inc (Symbol: BIIB) stock, but cautious about paying the going market price of $284.91/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to BIIB's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. For other put options contract ideas at the various different available expirations, visit the BIIB Stock Options page of StockOptionsChannel.com.",262.4522399902344
2016-01-14 00:00:00+00:00,268.57000732421875,283.29998779296875,265.3699951171875,280.57000732421875,280.57000732421875,2414300.0,3.5,1.0,0.6250249999999999,"The big question is whether strong data will hold up, as BIIB will still need to conduct many trials for the drug to earn an FDA approval to treat the 5 million worldwide that suffer from this disease. Biotech Stocks: Biogen ( BIIB ) Biogen Inc ( BIIB ) stock has fallen 10% this year, but that's minor compared to the 40% that BIIB has fallen from its peak last year. Much like CELG creates the majority of its revenue from a single product, BIIB relies on its MS franchise, mainly Tysabri and Tecfidera. New Article This chart helps us maintain a proper perspective on Celgene's ""disappointing"" 2016 earnings outlook. There's one other thing to consider: Celgene anticipates that annual revenues will exceed $21 billion with adjusted earnings per share topping $13 by 2020. The next billion-dollar iSecret The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology.",268.0916442871094
2016-01-15 00:00:00+00:00,271.010009765625,279.8900146484375,269.25,273.3299865722656,273.3299865722656,2579900.0,4.0,1.0,0.7500249999999999,"Lastly, pay close attention to an exciting late-stage therapy for spinal muscular atrophy known as nusinersen. A phase 2 open-label study reported by Ionis demonstrated encouraging efficacy, with 10 ambulatory children improving in the six-minute walk test by a mean of 24.4 meters 12 to 16 months after the baseline. Even if all three of its key therapies above fail in clinical trials, which I believe is unlikely, it could always fall back on its leading MS therapeutics, growing hemophilia program, and partnered oncology products. New Article Biogen Inc. ( BIIB ), based in Cambridge, MA, is a global biopharmaceutical company focused on developing and commercializing therapies for neurological, autoimmune and hematologic disorders. Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report To read this article on Zacks.com click here. Although the sector has witnessed its share of ups and downs over the past few quarters, right now the market sentiment seems to be improving driven by upgraded guidance, product approvals, and encouraging pipeline updates.",266.33984375
2016-01-20 00:00:00+00:00,263.25,272.7799987792969,257.6600036621094,269.3500061035156,269.3500061035156,2368300.0,2.0,1.0,0.250025,"Samsung Bioepis, the joint venture between Biogen BIIB and Samsung BioLogics, gained EU approval for its biosimilar version of Amgen's AMGN Enbrel (etanercept). Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ELEVEN BIOTHERP (EBIO): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report To read this article on Zacks.com click here. With this acquisition, Acorda, which focuses on developing treatments that restore function and improve the lives of people with neurological disorders, will be adding a late-stage Parkinson's disease (PD) candidate (tozadenant) to its pipeline. New Article Four huge biotech companies are critical to the index: Gilead Sciences ( GILD ), Celgene ( CELG ), Biogen ( BIIB ) and Amgen ( AMGN ). The 10 Best Stocks to Buy for 2016 You have to believe that, in the long run, this is something to own if the market turns against you but if it doesn't, well, you're looking at annualized profits near 100%. How Would You Like An Extra Paycheck?Watch My 7:18 Minute Training Video Free The post The Weekly Play: Sell Calls on This Sector ( IBB ) appeared first on InvestorPlace .",273.966064453125
2016-01-25 00:00:00+00:00,269.4599914550781,271.2099914550781,261.29998779296875,262.1000061035156,262.1000061035156,1792400.0,3.0,1.0,0.5000249999999999,"BiogenBIIB , a well-known name in the multiple sclerosis (MS) market, will be reporting fourth quarter 2015 earnings results on Jan 27, before the market opens. Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Tecfidera Performance Remains Key Focus Area Biogen expects modest patient growth in the U.S. for its MS products. New Article Biogen BIIB has an Earnings ESP of +2.21% and a Zacks Rank #2. Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report To read this article on Zacks.com click here. Bristol-Myers Squibb CompanyBMY is scheduled to report fourth-quarter 2015 results on Jan 28, before the opening bell.",262.55859375
2016-01-26 00:00:00+00:00,262.760009765625,264.4800109863281,257.7799987792969,259.8699951171875,259.8699951171875,2108200.0,4.0,1.0,0.7500249999999999,"Biogen Inc. ( BIIB ) is reporting for the quarter ending December 31, 2015. BIIB missed the consensus earnings per share in the 1st calendar quarter of 2015 by -2.3%. Zacks Investment Research reports that the 2015 Price to Earnings ratio for BIIB is 15.79 vs. an industry ratio of -20.20, implying that they will have a higher earnings growth than their competitors in the same industry.",263.8299560546875
2016-01-27 00:00:00+00:00,275.04998779296875,285.2799987792969,270.3399963378906,273.260009765625,273.260009765625,5159600.0,3.142857142857143,1.0,0.5357392857142856,"In early trading on Wednesday, shares of Biogen ( BIIB ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.7%. VIDEO: Nasdaq 100 Movers: AAPL, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing Nasdaq 100 component thus far on the day is Apple ( AAPL ), trading down 4.8%. New Article Gainers were few and far between among the most actively traded stocks but Biogen Idec ( BIIB ) was a bright spot after Q4 results topped views. BIIB was up over 5%. U.S. stock futures were in the red Wednesday as crude oil prices edged lower again and Apple's ( AAPL ) quarterly earnings and outlook disappointed markets. New Article Two other components making moves today are Boeing ( BA ), trading down 9.2%, and Biogen ( BIIB ), trading up 5.3% on the day. In early trading on Wednesday, shares of Capital One Financial ( COF ) topped the list of the day's best performing components of the S&P 500 index, trading up 5.6%. And the worst performing S&P 500 component thus far on the day is Total System Services ( TSS ), trading down 11.7%. New Article Freeport benefited today from rising prices for copper and crude oil, and shareholders hope that the commodities market can finally end its long losing streak and start a longer-term rebound in the near future. Investors are also responding to Freeport's new efforts to reduce its debt, and it continues to look at the potential for asset sales, joint ventures, or other strategic options to raise cash and get itself into a better condition financially. Massive writedowns from falling commodity prices caused Freeport to post a sizable loss for the fourth quarter, but the company remains confident that it can emerge from its slump, and bring patient investors long-term rewards. New Article To help answer that question, we asked our team of Motley Fool contributors to share a healthcare stock that they think doesn't require constant monitoring. That dominant market position gives its business a lot of predictability, and its products can be counted on to deliver results in good and bad economic times. Selena Maranjian : It's obvious why you might want to invest in the healthcare sector: With our population growing and aging, and many diseases and conditions requiring treatment, it's assured of plenty of demand. New Article Gainers were few and far between among the most actively traded stocks but Biogen Idec ( BIIB ) was a bright spot after Q4 results topped views. BIIB was up over 5%. U.S. equities were poised for a lower open Wednesday as Tuesday's rally proved short lived and as oil prices fell once again. New Article Cambridge, MA-based BiogenBIIB , one of the world's leading biotechnology companies, focuses on therapeutic areas including neurology, immunology and hemophilia. BIIB has a pretty good earnings track record with the company delivering positive earnings surprises in three of the last four quarters with an average surprise of 6.86%. Currently, BIIB has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released.",260.9915771484375
2016-01-28 00:00:00+00:00,275.7699890136719,276.9700012207031,261.70001220703125,265.9599914550781,265.9599914550781,3056500.0,3.0,1.0,0.5000249999999999,Biogen Inc.BIIB was a big mover last session with its shares rising over 5% on the day. Is BIIB going up? Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report BAXALTA INC (BXLT): Free Stock Analysis Report To read this article on Zacks.com click here.,261.5563659667969
2016-01-29 00:00:00+00:00,268.4200134277344,273.8999938964844,265.70001220703125,273.0599975585937,273.0599975585937,3080400.0,2.0,1.0,0.250025,"The fund has a definite tilt toward large cap stocks at 63% with the largest allocation to the top three firms - Biogen ( BIIB ), Celgene ( CELG ) and Amgen ( AMGN ) - with over 9% share each. Click to get this free report ISHARES NDQ BIO (IBB): ETF Research Reports BIOGEN INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. In particular, the twin attacks of political uncertainty surrounding healthcare reform, and soft enrollment in public health insurance exchanges is weighing heavily on the sector's performance and will continue to do so throughout the year.",263.9491882324219
2016-02-02 00:00:00+00:00,267.739990234375,271.20001220703125,265.1600036621094,266.0599975585937,266.0599975585937,1929800.0,2.75,1.0,0.437525,"That patent portfolio generated a $104.9 million royalty payment from Biogen ( BIIB ) during November, the company recently disclosed, saying last night its absence will begin to be felt during the April-to-June period. According to CEO John McLaughlin in prepared remarks, PDL already is seeing an increase in deal flow as more companies are negatively affected by falling equity prices and more debt transactions are being offered at less favorable terms. Net proceeds will be used to repay existing debt, including the entire balance 100% on its revolving credit facility as well as funding its development pipeline and potential acquisitions. New Article A small decline isn't all that unexpected since the oral medications, including Tecfidera, are taking market share from the injected drugs. What management had to say Reaccelerating sales of Tecfidera is key to short-term growth, but Paul Clancy, Biogen's CFO, wasn't making any promises for increases in the U.S. ""While we're hopeful our recently launched marketing campaign can reaccelerate growth, we remain cautious, as we believe we will not ascertain the impact until the second quarter of this year,"" Clancy said. Two phase 3 trials testing nusinersen, which Biogen licensed from Ionis Pharmaceuticals , are expected to read out in the first half of next year. New Article The New Year's hangover the S&P 500 is still suffering hit the iShares Nasdaq Biotechnology index twice as hard, but long-term minded investors should be ready to party. Leapfrogging its way into the CAR-T arena, Celgene made a $1 billion investment that includes rights to candidates directed at two promising targets, about 9% (and the potential for up to 30%) of Juno's shares, and a seat on its board of directors. I don't expect this to be the case as a recent Senate Finance Committee report indicated less than 2.4% of roughly 700,000 Medicaid enrollees with Hepatitis C were treated with Sovaldi in 2014 due to access restrictions. New Article Big bang drug launches, such as Tecfidera's release by Biogen Inc. BIIB in 2013, have been missing in recent years particularly over the last 12 months. Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report BLUEBIRD BIO (BLUE): Free Stock Analysis Report JUNO THERAPEUTC (JUNO): Free Stock Analysis Report UTD THERAPEUTIC (UTHR): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report INSYS THERAP (INSY): Free Stock Analysis Report To read this article on Zacks.com click here. Given the fact that sector fundamentals remain strong and the long-term outlook of such companies is bright, this may be a good time to pick up such stocks on the cheap.",250.98907470703125
2016-02-03 00:00:00+00:00,267.5799865722656,270.739990234375,261.0,270.42999267578125,270.42999267578125,2085800.0,4.0,1.0,0.7500249999999999,"Biogen's BIIB share price was up with the company topping estimates and seeing a sequential improvement in sales of its oral multiple sclerosis (MS) treatment, Tecfidera. Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report INTREXON CORP (XON): Free Stock Analysis Report AXOVANT SCIENC (AXON): Free Stock Analysis Report NEWLINK GENETIC (NLNK): Free Stock Analysis Report To read this article on Zacks.com click here. Incyte INCY suffered a setback last week with a mid-stage study (colorectal cancer) evaluating Jakafi (ruxolitinib) plus Stivarga (regorafenib) being stopped early due to lack of sufficient efficacy in an interim analysis.",249.66224670410156
2016-02-04 00:00:00+00:00,270.1600036621094,279.3800048828125,269.1099853515625,273.2699890136719,273.2699890136719,2073400.0,2.0,1.0,0.250025,"Among the largest underlying components of FBT, in trading today Bio-Techne Corp (Symbol: TECH) is up about 0.8%, Qiagen N.V. (Symbol: QGEN) is down about 1.1%, and Biogen Inc (Symbol: BIIB) is higher by about 2.5%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the First Trust NYSE Arca Biotechnology Index Fund (Symbol: FBT) where we have detected an approximate $106.9 million dollar outflow -- that's a 4.7% decrease week over week (from 27,800,002 to 26,500,002). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",255.73721313476562
2016-02-05 00:00:00+00:00,271.1000061035156,272.6700134277344,258.4599914550781,263.8599853515625,263.8599853515625,2856900.0,1.0,1.0,2.4999999999997247e-05,"Particularly high volume was seen for the $245 strike put option expiring February 12, 2016 , with 2,240 contracts trading so far today, representing approximately 224,000 underlying shares of BIIB. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Biogen Inc (Symbol: BIIB), where a total volume of 13,984 contracts has been traded thus far today, a contract volume which is representative of approximately 1.4 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 59.4% of BIIB's average daily trading volume over the past month, of 2.4 million shares.",253.76170349121094
2016-02-09 00:00:00+00:00,246.5399932861328,255.0,243.8500061035156,249.9900054931641,249.9900054931641,2386900.0,3.0,1.0,0.5000249999999999,"Although several well-known biotech industry players like Amgen Inc. ( AMGN ), Biogen ( BIIB ) and Gilead ( GILD ) easily managed to beat estimates on both earnings and revenues, other companies including Alexion Pharmaceuticals ( ALXN ) and Celgene Corporation ( CELG ) reported disappointing or mixed results. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ISHARES NDQ BIO (IBB): ETF Research Reports FT-AMEX BIOTEC (FBT): ETF Research Reports PWRSH-DYN BIO (PBE): ETF Research Reports MKT VEC-BIOTECH (BBH): ETF Research Reports To read this article on Zacks.com click here. Quite expectedly, investors will keep an eye on biotech earnings for the rest of this season to assess whether the sector can pull off another turnaround supported by strong pipelines, innovative treatments, growing demand for drugs, especially for rare-to-treat diseases, an aging population and increased health care spending (read: What Lies Ahead for Biotech ETFs in 2016? New Article Take Biogen (NASDAQ: BIIB). Again, this was during a period when shares increased more than a thousand-fold: It's hard to grasp how the best-performing stock of the last 20 years could spend the majority of that time with returns that would make you want to vomit. In 2009, Charlie Munger was asked how concerned he was that Berkshire Hathaway (NYSE: BRK-B) shares - which made up most of his net worth - dropped more than 50%.",244.18020629882812
2016-02-10 00:00:00+00:00,253.3500061035156,257.3699951171875,249.27999877929688,252.1999969482422,252.1999969482422,1763500.0,3.0,1.0,0.5000249999999999,"AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports AMGN's forecasted earnings growth in 2016 as 3.55%, compared to an industry average of 11.1%. The following ETF(s) have AMGN as a top-10 holding: iShares Nasdaq Biotechnology Index Fund ( IBB ) PowerShares Dynamic Biotech &Genome ( PBE ) PowerShares Dynamic Pharmaceuticals ( PJP ) SPDR Select Sector Fund - Health Care ( XLV ) Market Vectors Biotech ETF ( BBH ).",239.01966857910156
2016-02-11 00:00:00+00:00,246.3099975585937,250.0200042724609,243.02999877929688,245.1100006103516,245.1100006103516,2171200.0,3.0,1.0,0.5000249999999999,"At Holdings Channel , we have reviewed the latest batch of the 32 most recent 13F filings for the 12/31/2015 reporting period, and noticed that Biogen Inc (Symbol: BIIB) was held by 11 of these funds. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the sum total across groups of funds from one reporting period to another can be a lot more revealing and relevant, providing interesting stock ideas that merit further research, like Biogen Inc (Symbol: BIIB). Below, let's take a look at the change in BIIB positions, for this latest batch of 13F filers: In terms of shares owned, we count 1 of the above funds having increased existing BIIB positions from 09/30/2015 to 12/31/2015, with 8 having decreased their positions.",239.17506408691406
2016-02-12 00:00:00+00:00,248.77999877929688,249.1999969482422,242.07000732421875,247.22000122070312,247.22000122070312,2119500.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of IYH, in trading today Johnson & Johnson (Symbol: JNJ) is off about 0.7%, Biogen Inc (Symbol: BIIB) is down about 0.6%, and Thermo Fisher Scientific Inc (Symbol: TMO) is higher by about 1.1%. For a complete list of holdings, visit the IYH Holdings page  The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $108.00 per share, with $164.98 as the 52 week high point - that compares with a last trade of $130.66. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Ampyra is marketed in ex-U.S. markets under the trade name Fampyra by Biogen Inc. BIIB . Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report BIOTIE THERAPS (BITI): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda is currently evaluating a twice-daily formulation of Ampyra in a phase III study for post-stroke deficits with an interim analysis expected this year.",251.10354614257812
2016-02-18 00:00:00+00:00,266.6000061035156,266.9599914550781,258.510009765625,259.04998779296875,259.04998779296875,1536200.0,3.0,1.0,0.5000249999999999,"Specialty Sciences: Segmental revenues comprising royalties of $83.9 million received by Perrigo on multiple sclerosis drug Tysabri from Biogen Inc. BIIB , down 3% year over year. Click to get this free report PERRIGO CO PLC (PRGO): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report To read this article on Zacks.com click here. Quarter in Detail Perrigo reports revenues primarily from the following segments: Consumer Healthcare, Branded Consumer Healthcare (the newly acquired Omega business), Prescription Pharmaceuticals, Specialty Sciences, and Other (which includes the active pharmaceutical ingredients (API) business).",258.9350280761719
2016-02-22 00:00:00+00:00,265.260009765625,266.0,261.3399963378906,265.8299865722656,265.8299865722656,1218100.0,2.0,1.0,0.250025,"Among the largest underlying components of UPRO, in trading today Biogen Inc (Symbol: BIIB) is up about 0.8%, Abbott Laboratories (Symbol: ABT) is up about 1.4%, and Danaher Corp. (Symbol: DHR) is higher by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro S&P500 (Symbol: UPRO) where we have detected an approximate $69.1 million dollar outflow -- that's a 7.5% decrease week over week (from 18,100,000 to 16,750,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",253.95974731445312
2016-02-23 00:00:00+00:00,264.8099975585937,265.8599853515625,257.8999938964844,258.989990234375,258.989990234375,1539200.0,4.0,1.0,0.7500249999999999,"Ionis' antisense technology has resulted in partnerships with several leading health care companies like Biogen Inc. BIIB and GlaxoSmithKline plc GSK among others that not only validate its technology platform but also provide the company with a steady stream of funds in the form of upfront, milestone and other payments. Click to get this free report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report SERES THERAPEUT (MCRB): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Ionis has a pretty good track record with the company having beaten estimates in three of the last four quarters with an average positive earnings surprise of 32.26%.",263.1570129394531
2016-02-26 00:00:00+00:00,264.0599975585937,266.4700012207031,260.8800048828125,264.489990234375,264.489990234375,1603200.0,3.0,1.0,0.5000249999999999,"In addition, the company plans to initiate a head-to-head study on ALKS 8700, to evaluate the gastrointestinal tolerability of the candidate in comparison with Biogen Inc.'s BIIB Tecfidera, for the treatment of patients with multiple sclerosis in mid-20Array6. Click to get this free report AMAG PHARMA INC (AMAG): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline Update Along with its financial results, Alkermes reported positive top-line data from a randomized, open-label, pharmacokinetic study of a two-month dosing interval of Aristada for the treatment of schizophrenia. New Article We note that Ionis has partnership programs with companies like Biogen Inc. BIIB and GlaxoSmithKline plc GSK among others. Click to get this free report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Enrollment in a phase III study (NEURO-TTR) on IONIS-TTRRx in patients with familial amyloid polyneuropathy (FAP) is completed.",263.4457092285156
2016-03-04 00:00:00+00:00,269.6400146484375,269.67999267578125,263.1300048828125,263.94000244140625,263.94000244140625,1640800.0,2.0,1.0,0.250025,"Share prices of major biotech companies like Gilead Sciences Inc. GILD , Biogen Inc. BIIB , Amgen Inc. AMGN , Vertex Pharmaceuticals Inc. VRTX and Regeneron Pharmaceuticals, Inc. REGN were hit by Hillary Clinton's ""price gouging"" tweet last year and her vow to fight drug pricing. Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report VALEANT PHARMA (VRX): Free Stock Analysis Report To read this article on Zacks.com click here. Republican presidential candidate Donald Trump's plans for healthcare reform and Obamacare have been posted on his website.",268.0358581542969
2016-03-07 00:00:00+00:00,262.1400146484375,272.44000244140625,261.20001220703125,269.5199890136719,269.5199890136719,1678700.0,2.0,1.0,0.250025,"Among the largest underlying components of VUG, in trading today AbbVie Inc. (Symbol: ABBV) is down about 1.6%, United Parcel Service Inc (Symbol: UPS) is trading flat, and Biogen Inc (Symbol: BIIB) is up by about 0.4%. For a complete list of holdings, visit the VUG Holdings page  The chart below shows the one year price performance of VUG, versus its 200 day moving average: Looking at the chart above, VUG's low point in its 52 week range is $92.47 per share, with $111.92 as the 52 week high point - that compares with a last trade of $102.28. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Stocks recently featured in the blog include Valeant Pharmaceuticals International, Inc. ( VRX ), Gilead Sciences Inc. ( GILD ), Biogen Inc. ( BIIB ), Amgen Inc. ( AMGN ) and Regeneron Pharmaceuticals, Inc. ( REGN ). Share prices of major biotech companies like Gilead Sciences Inc. ( GILD ), Biogen Inc. ( BIIB ), Amgen Inc. ( AMGN ) and Regeneron Pharmaceuticals, Inc. ( REGN ) were hit by Hillary Clinton's ""price gouging"" tweet last year and her vow to fight drug pricing. Click to get this free report VALEANT PHARMA (VRX): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report To read this article on Zacks.com click here.",266.60113525390625
2016-03-08 00:00:00+00:00,267.239990234375,269.0199890136719,260.7799987792969,261.2799987792969,261.2799987792969,1552100.0,3.0,1.0,0.5000249999999999,"Talk about impressive opportunities Biogen has had strong success in treating multiple sclerosis and hemophilia, and management is directing research into a rapidly expanding group of difficult-to-treat diseases. All of these drugs are in phase 2 or 3, and each has an intriguing data set that, if it bears out in late-stage trials, could spell a fundamental shift in patient treatment for these terrible diseases. Biogen's blockbuster oral MS therapy Tecfidera has seen its growth trajectory flatten after its label was updated to reflect its association with cases of primary multifocal leukoencephalopathy (PML).",270.37945556640625
2016-03-11 00:00:00+00:00,255.97999572753903,260.0400085449219,255.1000061035156,259.739990234375,259.739990234375,1759900.0,2.5,1.0,0.375025,"GILD is a part of the Health Care sector, which includes companies such as Amgen Inc. ( AMGN ) and Biogen Inc. ( BIIB ). Shareholders who purchased GILD prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports GILD's forecasted earnings growth in 2016 as -2.76%, compared to an industry average of 5.6%. New Article SolarCity Corp: SCTY Stock Is Burning Too Hot Case in point, even with an earnings blowout in late January , shares of BIIB haven't even been able to reclaim the highs of a very temporary relief bid immediately on the heels of the report. The weekly chart of BIIB stock shows a name that's been under sufficient technical pressure, in terms of time and price, as to put it on the radar for a bullish trend change. If it's biopharma giant Biogen Inc ( BIIB ), it's looking more and more like lower prices are in store.",273.885986328125
2016-03-15 00:00:00+00:00,257.4700012207031,257.9200134277344,248.5399932861328,250.3300018310547,250.3300018310547,1954800.0,5.0,1.0,1.000025,"The major holdings of IBB include Celgene ( CELG ), Biogen ( BIIB ) and Gilead Sciences ( GILD ). The $6.04 billion exchange traded fund's downward-sloping relative strength line reflects the weakness found in the charts of most major biotechs. That means its recent price performance is in the top two percentile of all stocks and ETFs tracked by IBD.",262.5658874511719
2016-03-16 00:00:00+00:00,250.4199981689453,256.19000244140625,247.6100006103516,250.83999633789065,250.83999633789065,1744800.0,2.6666666666666665,1.0,0.4166916666666666,"Buckingham acquired a 17,389-share stake in Biogen Inc. ( BIIB ), a Cambridge, Massachusetts-based biotechnology company, paying an average price of $287.66 per share. Buckingham invested in Vanguard Short-Term Corporate Bond ETF ( VCSH ), acquiring a 69,074-share stake for an average price of $79.06 per share. Buckingham invested in a 70,636-share stake in Duke Energy Corporation ( DUK ), a Charlotte, North Carolina-based electric power holding company. New Article Meanwhile, Biogen Inc. BIIB is evaluating its Alzheimer's disease candidate, aducanumab, in phase III studies. Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report AMAG PHARMA INC (AMAG): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report To read this article on Zacks.com click here. However, the functional outcome will be measured in the same manner as designed previously, and will be considered as a key secondary endpoint of the study. New Article ( AGN ), Gilead Sciences Inc. ( GILD ), Celgene Corporation ( CELG ) and Biogen Inc. ( BIIB ) fell 3.4%, 1.1%, 2% and 2.9%, respectively. Click to get this free report VALEANT PHARMA (VRX): Free Stock Analysis Report ALLERGAN PLC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report APPLE INC (AAPL): Free Stock Analysis Report MORGAN STANLEY (MS): Free Stock Analysis Report To read this article on Zacks.com click here. For a look at the issues currently facing the markets, make sure to read today's Ahead of Wall Street article The Dow Jones Industrial Average (DJI) increased only 0.1%, to close at 17,251.53.",256.3240051269531
2016-03-17 00:00:00+00:00,250.0,250.02999877929688,242.25,246.3099975585937,246.3099975585937,1895000.0,3.0,1.0,0.5000249999999999,"For Immediate Release Chicago, IL - March 16, 2016 - Today, Zacks Equity Research discusses the Pharma/Bio, including Valeant ( VRX ), Pfizer ( PFE ), Amgen ( AMGN ) and Biogen ( BIIB ). Apart from Novartis, companies like Merck, Amgen, Pfizer, Biogen ( BIIB ) and Allergan are targeting the highly lucrative biosimilars market. Click to get this free report VALEANT PHARMA (VRX): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here.",253.2395782470703
2016-03-18 00:00:00+00:00,247.8300018310547,251.1600036621093,243.2100067138672,250.77999877929688,250.77999877929688,3347900.0,3.0,1.0,0.5000249999999999,"Top holdings include large-cap stocks: Celgene Corp ( CELG ), Amgen Inc ( AMGN ), and Biogen Inc ( BIIB ). It's difficult to forecast where the next burst of strength will come from at the sector or industry level unless you are betting on short-term moves with tight stop losses. My current mix of stocks is directed towards broad, low volatility or quality-focused indexes that I believe offer a more stable platform to participate in further upside momentum.",266.27276611328125
2016-03-21 00:00:00+00:00,249.5200042724609,257.4100036621094,247.009994506836,256.04998779296875,256.04998779296875,1451300.0,4.0,1.0,0.7500249999999999,"Two drugs in particular -- Enbrel, which treats rheumatoid arthritis, and Neulasta, which boosts a patients white blood cell count -- each ring up more than a billion dollars in sales each quarter . Valuation checkup Biotech stocks have taken a beating recently, and both Amgen and Biogen have been sold off hard over the past year. I must admit I'm a fan of both companies, and I think each has a good chance of producing market-beating returns from here, but when forced to pick a winner, I'd give the nod to Amgen.",260.76885986328125
2016-03-23 00:00:00+00:00,257.0,258.3500061035156,253.58999633789065,255.2400054931641,255.2400054931641,1545600.0,4.0,1.0,0.7500249999999999,"We remind investors that AVEO had regained worldwide rights to AV-203 from Biogen Inc. BIIB in Mar 2014. Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report OPHTHOTECH CORP (OPHT): Free Stock Analysis Report To read this article on Zacks.com click here. AVEO Pharmaceuticals, Inc.AVEO announced that it has entered into an exclusive collaboration and license agreement granting CANbridge Life Sciences global rights (excluding the U.S, Canada and Mexico) to AV-203.",258.15911865234375
2016-03-24 00:00:00+00:00,253.7899932861328,257.5400085449219,251.1300048828125,254.69000244140625,254.69000244140625,1077100.0,2.0,1.0,0.250025,"The U.S. Patent and Trademark Office said that it will conduct an inter partes review of a patent covering Biogen's BIIB oral multiple sclerosis drug, Tecfidera. Click to get this free report REGENERON PHARM (REGN): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report KITE PHARMA INC (KITE): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Patent infringement lawsuits were in focus in the biotech sector this week with some important jury rulings affecting companies like Gilead GILD , Amgen AMGN and Regeneron REGN .",255.25140380859375
2016-03-28 00:00:00+00:00,255.0500030517578,256.7099914550781,251.4499969482422,251.759994506836,251.759994506836,1019000.0,3.0,1.0,0.5000249999999999,"The requirement of a specific prescription means biosimilar manufacturers will likely need to do at least some marketing to get doctors to prescribe their version -- something makers of small-molecule generics don't have to do. And while biosimilars might come with lower gross margins, if they're being produced with unused manufacturing capacity, the extra revenue could be a substantial addition to their earnings. The Foolish way to invest in this trend Biosimilars offer a new, potentially lucrative market for both branded and generic drugmakers, but picking a winner will likely take some time as we wait to see how the dynamics of the new industry play out. New Article Stocks recently featured in the blog include Gilead ( GILD ), Amgen ( AMGN ), Regeneron ( REGN ), Ionis ( IONS ) and Biogen ( BIIB ) . The U.S. Patent and Trademark Office said that it will conduct an inter partes review of a patent covering Biogen's ( BIIB ) oral multiple sclerosis drug, Tecfidera. Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here.",250.23941040039062
2016-04-04 00:00:00+00:00,260.5599975585937,266.0,260.0400085449219,264.010009765625,264.010009765625,2414500.0,2.0,1.0,0.250025,"Among the largest underlying components of IYH, in trading today Eli Lilly & Co. (Symbol: LLY) is down about 0.2%, Abbott Laboratories (Symbol: ABT) is up about 0.4%, and Biogen Inc (Symbol: BIIB) is higher by about 0.9%. For a complete list of holdings, visit the IYH Holdings page  The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $108.00 per share, with $164.98 as the 52 week high point - that compares with a last trade of $143.63. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",251.24008178710938
2016-04-06 00:00:00+00:00,266.3299865722656,280.5799865722656,266.1700134277344,279.57000732421875,279.57000732421875,3018800.0,4.0,1.0,0.7500249999999999,"A couple of major biotech companies, AbbVie ABBV and Biogen BIIB , got positive CHMP opinions for their marketing applications in the EU. Click to get this free report ALEXION PHARMA (ALXN): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report INTERCEPT PHARM (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Key highlights in the biotech sector this week include the FDA approval of Gilead's GILD third TAF-based HIV treatment as well as an acquisition announcement by the company.",246.6809844970703
2016-04-07 00:00:00+00:00,278.0299987792969,280.70001220703125,271.1499938964844,273.0400085449219,273.0400085449219,2006100.0,3.0,1.0,0.5000249999999999,"Below is a twelve month price history chart comparing the stock performance of ALXN, BIIB, and SIG: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of SPXT's underlying holdings with notable upside to their analyst target prices are Alexion Pharmaceuticals Inc. (Symbol: ALXN), Biogen Inc (Symbol: BIIB), and Signet Jewelers Ltd (Symbol: SIG). Similarly, BIIB has 31.88% upside from the recent share price of $279.57 if the average analyst target price of $368.69/share is reached, and analysts on average are expecting SIG to reach a target price of $158.12/share, which is 31.73% above the recent price of $120.04.",241.69822692871094
2016-04-08 00:00:00+00:00,275.0,275.1600036621094,267.3299865722656,270.8299865722656,270.8299865722656,2136000.0,3.0,1.0,0.5000249999999999,"Investors considering a purchase of Biogen Inc (Symbol: BIIB) stock, but tentative about paying the going market price of $269.60/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to BIIB's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. For other put options contract ideas at the various different available expirations, visit the BIIB Stock Options page of StockOptionsChannel.com. New Article Ionis has a collaboration with Biogen Inc. BIIB for nusinersen. Click to get this free report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Ionis Pharmaceuticals, Inc. 's IONS shares plunged 11% after the company announced that the FDA has placed a clinical hold on the phase III CARDIO-TTR study on IONIS-TTRRx.",244.2305145263672
2016-04-11 00:00:00+00:00,271.57000732421875,272.9800109863281,264.2099914550781,265.19000244140625,265.19000244140625,1888500.0,3.0,1.0,0.5000249999999999,"We note that several companies are looking to enter this space including Biogen Inc. BIIB . Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report To read this article on Zacks.com click here. Per the deal, Eli Lilly will lead the development path and will work alongside researchers from AstraZeneca, who will undertake manufacturing responsibilities.",244.56784057617188
2016-04-12 00:00:00+00:00,265.0,268.67999267578125,262.2699890136719,267.6099853515625,267.6099853515625,1459100.0,2.0,1.0,0.250025,"See also Biogen ( BIIB ) Q1 2016 Results - Earnings Call Webcast on seekingalpha.com The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. More broadly, our view of capex is a synthesis of observations from many different sources, including interviews with club general managers, industry benchmark data, ClubCorp's own financial results, and the company's depreciation accounting. The Failure of ClubCorp's Acquisition Strategy Pre-Tax Returns on Average Tangible Invested Capital (ROTIC) Source: Company filings, Kerrisdale analysis * Operating profit represents EBITA (EBITDA less depreciation).",242.4711151123047
2016-04-18 00:00:00+00:00,267.8500061035156,273.3699951171875,267.0400085449219,272.9200134277344,272.9200134277344,1541300.0,4.0,1.0,0.7500249999999999,"InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen Inc ( BIIB ) stock has seen better days. BIIB's industry has been vilified as a bunch of price-gouging companies deserving of punishment. This is the same area that had acted as resistance in late 2013 before BIIB broke out to $350 per share. New Article In health care stocks news, Biogen ( BIIB ) unveiled new research that it claimed reinforces a ""strong and sustained efficacy"" in newly diagnosed multiple sclerosis patients and further supports its long-term safety profile. BIIB shares were down 1.3% at $265 in pre-market trading , with a 52-week range of $242.07 - $431.84. ""Data from a post-hoc analysis show that more than half of newly diagnosed patients treated with TECFIDERA were free from relapses and disability progression for six years, reinforcing that early, effective treatment with TECFIDERA improves long-term clinical outcomes,"" the statement added. New Article Among the largest underlying components of XLV, in trading today Eli Lilly & Co. (Symbol: LLY) is up about 0.6%, Biogen Inc (Symbol: BIIB) is up about 0.9%, and Abbott Laboratories (Symbol: ABT) is higher by about 0.6%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $136.6 million dollar outflow -- that's a 1.1% decrease week over week (from 177,765,324 to 175,815,324). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Biogen Inc.BIIB , a well-known name in the multiple sclerosis (MS) market, will be reporting first quarter 2016 earnings results on Apr 21, before the market opens. Click to get this free report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen is working on growing Tecfidera sales and is pursuing commercial initiatives including new direct to consumer marketing programs.",245.2656707763672
2016-04-19 00:00:00+00:00,273.1000061035156,275.9800109863281,270.2300109863281,271.0,271.0,1397400.0,2.0,1.0,0.250025,"Earnings releases and guidance of the likes of Abbott LaboratoriesABT , Biogen Inc.BIIB , and Novartis AGNVS have always held investors' attention. Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks Consensus Estimate is 39 cents per share (read more: Will Currency Woes Hurt Abbott Labs' Q1 Earnings?",256.8644714355469
2016-04-20 00:00:00+00:00,271.9200134277344,271.9200134277344,263.3099975585937,265.8900146484375,265.8900146484375,2522500.0,3.0,1.0,0.5000249999999999,"Biogen Inc. ( BIIB ) is reporting for the quarter ending March 31, 2016. BIIB missed the consensus earnings per share in the 1st calendar quarter of 2015 by -2.3%. Zacks Investment Research reports that the 2016 Price to Earnings ratio for BIIB is 14.49 vs. an industry ratio of -18.70, implying that they will have a higher earnings growth than their competitors in the same industry.",258.3764953613281
2016-04-21 00:00:00+00:00,268.8399963378906,280.1300048828125,268.8399963378906,279.6000061035156,279.6000061035156,3153600.0,3.0,1.0,0.5000249999999999,"Biotech company, Biogen Inc.BIIB , reported first-quarter 2016 earnings per share of $4.79, well above the Zacks Consensus Estimate of $4.48 and 25% above the year-ago earnings. Biogen Idec Inc. (BIIB) Street EPS & Surprise Percent - Last 5 Quarters | FindTheCompany Sales came in at $2.727 billion, increasing 7% from the year-ago period but just shy of the Zacks Consensus Estimate of $2.758 billion. Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report EMERGENT BIOSOL (EBS): Free Stock Analysis Report To read this article on Zacks.com click here. New Article More From InvestorPlace Alibaba Group Holding Ltd: BABA Goes BOOM and Bulls Take Note 3 'Golden Cross' Standouts Ready to Break Out Biogen Inc (BIIB): Embrace the ""Drug Trade"" The post Energy Select Sector SPDR (ETF): Get Paid to Gas Up on XLE appeared first on InvestorPlace . Technically, the recent price action could be signaling more potential in crude, so setting up an XLE pair trade could capture this upside. 3 Blue-Chip Stocks to Trade Ahead of Earnings The sharp drop in oil prices stripped XLE components to their bare bones. New Article Cambridge, MA-based BiogenBIIB , one of the world's leading biotechnology companies, focuses on therapeutic areas including neurology, immunology and hemophilia. BIIB has a pretty good earnings track record with the company delivering positive earnings surprises in three of the last four quarters with an average surprise of 7.23%. Currently, BIIB has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. New Article The max gain is the distance between strikes minus the net debit, or $22, and will be captured if BIIB can rise above $310. InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen Inc ( BIIB ) stock is trading higher this morning on the shoulders of its latest earnings announcement, and though the movement isn't anything exciting, Biogen's setup is convincing enough to suggest that traders side with the bulls right now. Analysts expected earnings of $4.47 per share, and BIIB delivered $4.79 - a solid beat, but nothing extraordinary. New Article And Biogen ( BIIB ) reported earnings that topped expectations even as its revenue fell short. In health-care stocks news, ADRs of Novartis ( NVS ) were slightly lower pre-market Thursday after the Swiss drugmaker reported mixed Q1 results, with better-than-expected core earnings on lower revenues that missed forecasts, and reaffirmed its full-year revenue outlook just above forecasts. The stock has traded between $69.90 and $106.84 over the past 52 weeks. New Article Biogen, Inc. BIIB Leading biopharmaceutical company Biogen reported Q1 earnings of $4.79 per share, surpassing the Zacks Consensus Estimate of $4.48 per share; cost control and a lower share count were leading factors in the company's earnings beat. Click to get this free report QUALCOMM INC (QCOM): Free Stock Analysis Report VERIZON COMM (VZ): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report UNDER ARMOUR-A (UA): Free Stock Analysis Report GENERAL MOTORS (GM): Free Stock Analysis Report To read this article on Zacks.com click here. Both the top and bottom lines beat the Zacks Consensus Estimate, with adjusted earnings of $0.89 per share (excluding non-recurring items) and revenues of $5.54 billion. New Article More From InvestorPlace 5 Stocks to Buy for an April Money Shower Biogen Inc (BIIB): Embrace the ""Drug Trade"" 5 Beaten Down Tech Stocks To Consider - Now The post Alibaba Group Holding Ltd: BABA Goes BOOM and Bulls Take Note appeared first on InvestorPlace . Fortunately for Chinese stock lovers, Alibaba Group Holding Ltd ( BABA ) wasn't having any of that neutrality business. Chart watchers love to see heavy volume backing a breakout, as it increases the likelihood the resistance breach sticks - and helps deliver follow-through in the days ahead. New Article In company news, Biogen Inc. ( BIIB ) rose Thursday after the biotech conglomerate beat analyst estimates with its Q1 earnings as revenue rose compared with year-ago levels, supported by a 15% year-over-year increase in sales of its drug treatment for relapsing multiple sclerosis. BIIB shares were up almost 5% at $278.74 each, earlier topping out at $279.36 a share. In other sector news, (+) CBAY, (+7.1%) Abingworth Funds discloses 6.8% passive stake, buying 1.6 mln shares, according to SEC 13G filing last night.",251.22828674316406
2016-04-22 00:00:00+00:00,280.3999938964844,283.5400085449219,278.2099914550781,282.70001220703125,282.70001220703125,2355100.0,3.0,1.0,0.5000249999999999,"Biogen Inc: Market Takes the Bull by the Horns Despite Sales Miss (BIIB) The company won't report results until April 27 after the close, with analysts looking for earnings of 62 cents per share on revenues of $5.26 billion. 7 Stocks to Buy Before Summer Arrives Shares have taken out the 50-day moving average for the first time since the December/January selloff, putting a possible test of the February low in play and continuing the underperformance seen from the early December high. Slowing consumer PC sales and a longer upgrade cycle continue to be a drag on results amid efforts to refocus into areas like cloud storage. New Article More From InvestorPlace General Electric Company (GE): Short-Term Bore, Long-Term Deal PayPal Stock: Too Expensive to Buy, Too Soon to Sell (PYPL) Biogen Inc: Market Takes the Bull by the Horns Despite Sales Miss (BIIB) The post Dow Jones Holds 18,000 Despite Weak Tech Earnings appeared first on InvestorPlace . Troubled chipmaker Advanced Micro Devices, Inc. (NASDAQ: AMD ) gained 52.3% after a big first-quarter earnings beat, with upside from CPU and graphics chips sales. Microsoft Corporation (NASDAQ: MSFT ) lost 7.2% after an earnings miss on Thursday night, as efforts in the cloud and other areas aren't yet large enough to compensate for the weakness in the consumer PC market. New Article It appears that, while Tecfidera is still growing, Biogen is losing overall multiple sclerosis market share to Novartis, which reported a 12% increase in sales of Gilenya. Nusinersen, which Biogen is developing with Ionis Pharmaceuticals for treatment of spinal muscular atrophy, is scheduled to read out two phase 3 trials early next year. Updated phase 2 data presented this week by Biogen and Ionis Pharmaceuticals showed that the babies getting the drug continue to develop. New Article PayPal Stock: Too Expensive to Buy, Too Soon to Sell (PYPL) The post Biogen Inc: Market Takes the Bull by the Horns Despite Sales Miss (BIIB) appeared first on InvestorPlace . InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen Inc ( BIIB ), one of the biggest biotech companies on the planet, enjoyed a nice bounce Thursday after reporting first-quarter earnings . BIIB currently enjoys a net margin around 35% compared to the roughly 20% to 30% that more conventional Big Pharma manufacturers command.",260.70111083984375
2016-04-27 00:00:00+00:00,281.57000732421875,282.0,278.5199890136719,280.0599975585937,280.0599975585937,1099100.0,3.0,1.0,0.5000249999999999,"Biogen BIIB kick-started the earnings season for the biotech sector with an earnings beat. Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report CATALYST PHARMA (CPRX): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report To read this article on Zacks.com click here. Catalyst Pharma's shares crashed on news that the FDA has asked the company to conduct an additional adequate and well-controlled study on Firdapse for the resubmission of the NDA for the candidate. New Article Johnson & Johnson JNJ kick-started the season on a positive note, wherein its earnings surpassed expectations and the company raised its outlook for the year, followed by the announcement of better-than-expected earnings by biotech player, Biogen Inc. BIIB . Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AGENUS INC (AGEN): Free Stock Analysis Report KERYX BIOPHARMA (KERX): Free Stock Analysis Report IMMUNOGEN INC (IMGN): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report BAXALTA INC (BXLT): Free Stock Analysis Report To read this article on Zacks.com click here. With the first-quarter earnings season in full swing, investors are possibly seeing a ray of hope, as results reported so far have not been as dismal as expected.",262.4849853515625
2016-04-28 00:00:00+00:00,278.0,284.04998779296875,277.510009765625,281.0799865722656,281.0799865722656,1403300.0,2.0,1.0,0.250025,"Stocks recently featured in the blog include Johnson & Johnson ( JNJ ), Biogen Inc. ( BIIB ), Novartis ( NVS ), Baxalta Incorporated ( BXLT ) and Shire plc ( SHPG ). Johnson & Johnson ( JNJ ) kick-started the season on a positive note, wherein its earnings surpassed expectations and the company raised its outlook for the year, followed by the announcement of better-than-expected earnings by biotech player, Biogen Inc. ( BIIB ). Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report BAXALTA INC (BXLT): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here.",267.2521667480469
2016-04-29 00:00:00+00:00,278.239990234375,280.5299987792969,271.3999938964844,274.989990234375,274.989990234375,1941000.0,3.6,1.0,0.6500250000000001,"Moreover, a head-to-head study on ALKS 8700, to evaluate the gastrointestinal tolerability of the candidate, in comparison with Biogen Inc.'s BIIB Tecfidera, for multiple sclerosis is expected to be initiated in mid 2016. Click to get this free report ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AEGERION PHARMA (AEGR): Free Stock Analysis Report EMERGENT BIOSOL (EBS): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline Update Along with financial results, Alkermes revealed positive preliminary data from a single-ascending dose phase I study on ALKS 7119 for the treatment of agitation in patients with Alzheimer's disease and other central nervous system indications. New Article Ampyra is marketed in ex-U.S. markets under the trade name Fampyra by Biogen Inc. BIIB . Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report EMERGENT BIOSOL (EBS): Free Stock Analysis Report BIOTIE THERAPS (BITI): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda is currently evaluating a twice-daily formulation of Ampyra in a phase III study for post-stroke deficits with data from an interim analysis expected by the fourth quarter. New Article Beats and Misses So Far Several biotech stocks including Biogen Inc. BIIB , Amgen Inc. AMGN , Celgene Corporation, AbbVie Inc., and Baxalta Incorporated and pharma stocks like Johnson & Johnson JNJ , Abbott Laboratories, and Bristol-Myers Squibb Company have not only managed to beat earnings estimates, but some among these have also raised their outlook for the year. Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report MALLINCKRODT PL (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. While in the biotech sector Gilead Sciences Inc. GILD and Alexion Pharmaceuticals, Inc. failed to beat expectations, pharma stocks like GlaxoSmithKline plc and Novartis AG lagged earnings estimates. New Article Abbott Laboratories ABT followed suit, while biotech major, Biogen Inc. BIIB reported better-than-expected quarterly earnings. Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AEGERION PHARMA (AEGR): Free Stock Analysis Report AERIE PHARMACT (AERI): Free Stock Analysis Report PROTHENA CP PLC (PRTA): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report To read this article on Zacks.com click here. Although Aegerion sports a Zacks Rank #1 (Strong Buy), the company's Earnings ESP of 0.00% makes surprise prediction difficult. New Article Among the largest underlying components of IBB, in trading today Biogen Inc (Symbol: BIIB) is off about 1.8%, Celgene Corp. (Symbol: CELG) is off about 2.3%, and Regeneron Pharmaceuticals, Inc. (Symbol: REGN) is lower by about 2.9%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $240.03 per share, with $400.79 as the 52 week high point - that compares with a last trade of $270.06. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",261.3155517578125
2016-05-02 00:00:00+00:00,274.739990234375,274.989990234375,268.8800048828125,273.69000244140625,273.69000244140625,1359300.0,2.5,1.0,0.375025,"Although well-known biotech industry player Amgen Inc. ( AMGN ) easily managed to beat estimates on both earnings and revenues, several other companies including Biogen ( BIIB ), Celgene Corporation ( CELG ), Gilead ( GILD ) and Alexion Pharmaceuticals ( ALXN ) reported disappointing or mixed results. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ISHARES NDQ BIO (IBB): ETF Research Reports FT-AMEX BIOTEC (FBT): ETF Research Reports PWRSH-DYN BIO (PBE): ETF Research Reports VANECK-BIOTECH (BBH): ETF Research Reports To read this article on Zacks.com click here. Additionally, strained balance sheets and macro-economic factors are adding to investors' anxiety (read: Biotech ETFs Hit 52-Week Lows: Time to Buy? New Article Factors to Consider Ionis has partnerships with several leading health care companies like Biogen Inc. BIIB and GlaxoSmithKline plc GSK among others that not only validate its technology platform but also provide the company with a steady stream of funds in the form of upfront, milestone and other payments. At the time of announcing fourth-quarter 2015 results, Ionis revealed that it had already earned $7 million in milestone payments from Biogen for progressing on the phase III program on nusinersen and on IONIS-BIIB4RX; and from Glaxo for initiating a phase I study on IONIS-HBV-LRX. Click to get this free report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report ZOETIS INC (ZTS): Free Stock Analysis Report To read this article on Zacks.com click here.",267.9628601074219
2016-05-04 00:00:00+00:00,271.70001220703125,271.75,262.44000244140625,263.1199951171875,263.1199951171875,1788200.0,3.0,1.0,0.5000249999999999,"Summing up, Gilead's revenue is flattening right now due mostly to a drop off in its hepatitis C franchise, meaning the biotech's long-term outlook is going to depend heavily on its clinical efforts in oncology and other liver diseases such as NASH. Specifically, the company is reportedly making excellent progress in terms of enrolling patients in two late-stage trials assessing aducanumab as a potential treatment for Alzheimer's disease. Biogen's partner Ionis Pharmaceuticals also updated investors at a recent meeting on the ongoing open-label midstage trial of nusinersen in infants with spinal muscular atrophy.",267.7629699707031
2016-05-05 00:00:00+00:00,263.5799865722656,265.3999938964844,262.6300048828125,264.6199951171875,264.6199951171875,1105900.0,4.0,1.0,0.7500249999999999,"We note that Ionis has partnership programs with companies like Biogen Inc. BIIB and GlaxoSmithKline plc GSK among others. Click to get this free report SANOFI-AVENTIS (SNY): Free Stock Analysis Report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Data from a phase III study (NEURO-TTR) on IONIS-TTRRx in patients with familial amyloid polyneuropathy (FAP) is also expected in the first half of 2017. New Article Stocks recently featured in the blog include the Amgen ( AMGN ), Gilead ( GILD ), Celgene ( CELG ), Medivation ( MDVN ) and Biogen ( BIIB ). But in the midst of all this, acquisitions and deals continued to garner interest with Medivation ( MDVN ) confirming it got an unsolicited offer from Sanofi and Biogen ( BIIB ) deciding to spin-off its hemophilia business. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report MEDIVATION INC (MDVN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here.",276.671630859375
2016-05-10 00:00:00+00:00,271.6400146484375,273.6099853515625,269.6000061035156,273.2699890136719,273.2699890136719,1031800.0,2.5,1.0,0.375025,"Key stocks from the sector including Biogen Inc. ( BIIB ), Celgene Corporation ( CELG ), AbbVie Inc. ( ABBV ), Amgen Inc. ( AMGN ) and Gilead Sciences Inc. ( GILD ) increased 2.5%, 2.2%, 1.9%, 1.5% and 1.2%, respectively. Click to get this free report TEVA PHARM ADR (TEVA): Free Stock Analysis Report ALLERGAN PLC (AGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report SPECTRA ENERGY (SE): Free Stock Analysis Report OCCIDENTAL PET (OXY): Free Stock Analysis Report HALLIBURTON CO (HAL): Free Stock Analysis Report SOUTHWESTRN ENE (SWN): Free Stock Analysis Report TESORO CORP (TSO): Free Stock Analysis Report To read this article on Zacks.com click here. For a look at the issues currently facing the markets, make sure to read today's Ahead of Wall Street article The Dow Jones Industrial Average (DJI) decreased 0.2%, to close at 17,705.91. New Article Among the largest underlying components of IWB, in trading today Eli Lilly & Co. (Symbol: LLY) is up about 2%, Time Warner Inc (Symbol: TWX) is up about 0.5%, and Biogen Inc (Symbol: BIIB) is up by about 0.3%. For a complete list of holdings, visit the IWB Holdings page  The chart below shows the one year price performance of IWB, versus its 200 day moving average: Looking at the chart above, IWB's low point in its 52 week range is $93.25 per share, with $119.74 as the 52 week high point - that compares with a last trade of $115.00. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",269.36248779296875
2016-05-12 00:00:00+00:00,268.25,270.54998779296875,259.5899963378906,262.7099914550781,262.7099914550781,1299300.0,4.0,1.0,0.7500249999999999,"Specialty Sciences: Segmental revenues comprised royalties of $88 million received by Perrigo on net sales of Biogen Inc.'s BIIB multiple sclerosis drug Tysabri, up 7% year over year. Click to get this free report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report PERRIGO CO PLC (PRGO): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Quarter in Detail Perrigo reports revenues primarily from the following segments: Consumer Healthcare, Branded Consumer Healthcare (created as a result of the Mar 2015 Omega Pharma acquisition), Prescription (Rx) Pharmaceuticals, Specialty Sciences, and Other (which include the active pharmaceutical ingredients business). New Article AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports AMGN's forecasted earnings growth in 2016 as 7.8%, compared to an industry average of 3.1%. The following ETF(s) have AMGN as a top-10 holding: iShares Nasdaq Biotechnology Index Fund ( IBB ) PowerShares Dynamic Biotech &Genome ( PBE ) PowerShares Dynamic Pharmaceuticals ( PJP ) SPDR Select Sector Fund - Health Care ( XLV ) VanEck Vectors Biotech ETF ( BBH ).",261.1361999511719
2016-05-16 00:00:00+00:00,263.0299987792969,266.95001220703125,262.6000061035156,266.260009765625,266.260009765625,1306100.0,4.0,1.0,0.7500249999999999,"However, BIIB has done a decent job of peeling away its competitors' hold on patients because of the way its therapies replace the clotting factor over the long term, allowing for less frequent and less taxing treatments. InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips News hit the Street last week that Biogen Inc ( BIIB ) plans to spin off its hemophilia drug business as its own publicly traded company. A Growing Business for BIIB BIIB's hemophilia business is growing 89% a year right now, and the two drugs being talked up as part of the spinout generated $182 million last quarter alone.",269.6119384765625
2016-05-19 00:00:00+00:00,262.79998779296875,264.70001220703125,256.4200134277344,258.7200012207031,258.7200012207031,1281200.0,2.0,1.0,0.250025,"Among the largest underlying components of IVW, in trading today Altria Group Inc (Symbol: MO) is up about 0.2%, Priceline Group Inc. (Symbol: PCLN) is off about 1.5%, and Biogen Inc (Symbol: BIIB) is lower by about 2.1%. For a complete list of holdings, visit the IVW Holdings page  The chart below shows the one year price performance of IVW, versus its 200 day moving average: Looking at the chart above, IVW's low point in its 52 week range is $85.21 per share, with $119.85 as the 52 week high point - that compares with a last trade of $113.62. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Particularly high volume was seen for the $240 strike put option expiring May 20, 2016 , with 1,040 contracts trading so far today, representing approximately 104,000 underlying shares of BIIB. Below is a chart showing WDAY's trailing twelve month trading history, with the $72 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 6,958 contracts, representing approximately 695,800 underlying shares or approximately 47.4% of BIIB's average daily trading volume over the past month, of 1.5 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $240 strike highlighted in orange: For the various different available expirations for AHP options , WDAY options , or BIIB options , visit StockOptionsChannel.com.",278.1633605957031
2016-05-24 00:00:00+00:00,266.3299865722656,273.4200134277344,263.94000244140625,272.94000244140625,272.94000244140625,1560900.0,3.0,1.0,0.5000249999999999,"From big pharma players GlaxoSmithKline (NYSE: GSK) and Pfizer (NYSE: PFE) to biotechs Biogen (NASDAQ: BIIB) and Celgene (NASDAQ: CELG) , listen in to hear how the companies stack up for value, dividend, and growth investors. Campbell: Those two drugs, Breo and Anoro, when those were approved, a lot of people thought they would absolutely be the ones, they would take the share away Advair Diskus, they would insulate Glaxo. Harjes: Before we completely pivot to Pfizer, I just want to throw up one more thing about GlaxoSmithKline, which is that they have a shingles vaccine cause Shingrix that could potentially be approved in 2017 to the tune of several billion dollars in annual sales, if expectations are met. New Article Admittedly, there's some evidence that RNAi may be more potent than the technology Ionis has used for with its phase 3 drugs, and that's probably why their pipelines are valued the same despite the size differential. But, it isn't clear that the extra boost will produce a clinical benefit, and Ionis has a next-generation technology that's substantially more potent than what's in its phase 3 drugs. *""Look Who's on Top Now"" appeared in The Wall Street Journal in Aug. 2013, which references Hulbert's rankings of the best-performing stock-picking newsletters over a 5-year period from 2008-2013.",272.22576904296875
2016-05-26 00:00:00+00:00,279.5299987792969,284.2799987792969,279.0899963378906,282.0,282.0,1829400.0,4.0,1.0,0.7500249999999999,"In trading on Thursday, shares of Biogen Inc (Symbol: BIIB) crossed above their 200 day moving average of $280.19, changing hands as high as $284.28 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $242.07 per share, with $420.99 as the 52 week high point - that compares with a last trade of $283.75. According to the ETF Finder at ETF Channel, BIIB makes up 7.72% of the iShares Nasdaq Biotechnology ETF (Symbol: IBB) which is trading lower by about 0.5% on the day Thursday.",262.2854309082031
2016-05-31 00:00:00+00:00,285.0,291.6300048828125,284.6600036621094,289.7300109863281,289.7300109863281,2146500.0,3.0,1.0,0.5000249999999999,"In the U.S., Roche markets MabThera as Rituxan, in collaboration with Biogen BIIB . Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Roche Holding AGRHHBY announced that the European Commission (EC) has approved the subcutaneous (SC) formulation of MabThera (rituximab) for the treatment of patients suffering from previously untreated and relapsed/refractory chronic lymphocytic leukemia (CLL). New Article Biotech Stocks to Buy: Biogen Inc (BIIB) A little over a year ago, Biogen ( BIIB ) was a biotech hero. Its multiple sclerosis drug Tecfidera was a smash hit, and BIIB was a must-have. Unable to shake their worries, BIIB shares lost nearly 50% from their March-2015 peak to this March's low. New Article VIDEO: Nasdaq 100 Movers: CHTR, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Tuesday, shares of Biogen ( BIIB ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.7%. And the worst performing Nasdaq 100 component thus far on the day is Charter Communications ( CHTR ), trading down 1.2%.",263.1307678222656
2016-06-01 00:00:00+00:00,287.9700012207031,289.95001220703125,286.1400146484375,286.82000732421875,286.82000732421875,1418400.0,4.0,1.0,0.7500249999999999,"While companies like Sarepta SRPT , Biogen BIIB , AbbVie ABBV and Intercept ICPT came out with encouraging news, Ionis IONS suffered a setback. Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report INTERCEPT PHARM (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, only prescribers, pharmacies and patients enrolled in the Zinbryta Risk Evaluation and Mitigation Strategy (REMS) Program, which includes required monthly liver function tests, will have access to the treatment. New Article Biogen Inc: Run With the Bulls for Triple-Digit Profits (BIIB) With expiration still several weeks out, there's time for this limited risk strategy to capture the required upside in LVS stock. But while many investors seemingly walked away from the proverbial table in disgust over LVS stock's results, Las Vegas Sands did actually hold its own relative to its peers in a difficult operating market. What's more, as the undisputed leader in the trifecta gaming markets of Singapore, Las Vegas and Macau (complete with supportive cash flow to weather the industry's volatile cycles), the future certainly looks good for LVS stock. New Article Coupled with an increasingly bullish price chart since releasing better-than-expected earnings and a positive outlook - investor support should continue to grow in BIIB and produce additional gains. Tesla Motors Inc: Elon Musk's Confessions Are Just What TSLA Needs Bottom-line though and as, if not more importantly, the vertical can also be adjusted along the way to build an even stronger risk-to-reward spread profile should BIIB continue to improve its standing with bulls. InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips A formidable downtrend has been broken in Biogen Inc ( BIIB ), as the European Medicines Agency's Committee of Medicinal Products for Human Use, or ""CHMP,"" issued a positive opinion on Biogen's Tysabri drug and recommended approval for its expanded use as a disease modifying therapy.",262.9847717285156
2016-06-02 00:00:00+00:00,286.8800048828125,289.9100036621094,286.5599975585937,289.7300109863281,289.7300109863281,1128200.0,3.0,1.0,0.5000249999999999,"In addition, Biogen Inc. BIIB announced that its pipeline candidate, aducanumab, was accepted for the PRIME program for early Alzheimer's disease (AD) primarily based on positive results from the phase Ib placebo-controlled study on aducanumab in patients with prodromal or mild AD. Click to get this free report KITE PHARMA INC (KITE): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. We note that PRIME is a new initiative undertaken by the EMA to provide better scientific guidance and support accelerated review of investigational therapies that address a high unmet medical need.",254.2131805419922
2016-06-03 00:00:00+00:00,289.510009765625,292.69000244140625,283.7900085449219,290.2300109863281,290.2300109863281,1473000.0,3.0,1.0,0.5000249999999999,"Great Stocks to Buy for Summer: Biogen (BIIB) Source: Biogen via YouTube Biotech drug companies aren't always small-time firms whose futures hinge on a single drug in FDA trials. Biogen Inc. ( BIIB ) fits into the latter camp. BIIB's major catalysts come down pipeline and drug approvals. New Article During the fourth quarter worldwide sales totaled $a.6 billion, an increase of a% on a constant currency basis as compared to the prior-year period and also exceeded the companyas previously issued guidance. GuruFocus gives the stock a profitability and growth rating of 7 out of aa with ROE of 47.86% and ROA of 7a7.a8% that are outperforming 94% of the companies in the Global Medical Instruments & Supplies industry. During the first quarter gross merchandise volume (GMV) increased About GuruFocus: GuruFocus.com tracks the stocks picks and portfolio holdings of the world's best investors. New Article However, a collaboration with Biogen (NASDAQ: BIIB) to commercialize multiple sclerosis drug Zinbryta probably won't be one of them. A small niche Zinbryta's black box also includes a number of immune-related disorders, but one important warning missing from the label is the risk of an opportunistic brain infection, progressive multifocal leukoencephalopathy, or PML. A new standard AbbVie's and Sanofi's sales of Zinbryta and Lemtrada could find themselves up against a drug from Roche (NASDAQOTH: RHHBY) that threatens to redefine treatment of relapsing multiple sclerosis.",251.51107788085938
2016-06-07 00:00:00+00:00,264.45001220703125,264.7300109863281,250.8699951171875,252.8600006103516,252.8600006103516,8876400.0,2.142857142857143,1.0,0.2857392857142856,"Especially high volume was seen for the $230 strike put option expiring July 15, 2016 , with 1,262 contracts trading so far today, representing approximately 126,200 underlying shares of BIIB. Below is a chart showing CYTR's trailing twelve month trading history, with the $3 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 16,724 contracts thus far today. That number of contracts represents approximately 1.7 million underlying shares, working out to a sizeable 124.2% of BIIB's average daily trading volume over the past month, of 1.3 million shares. New Article What: Biogen (NASDAQ: BIIB) is down 12% at 1:15 p.m. EDT Tuesday after the biotech reported that opicinumab, one of its most lucrative pipeline drugs, failed a phase 2 clinical trial. No details were reported, but Biogen did note that there was ""evidence of a clinical effect with a complex, unexpected dose-response,"" which means the drug looked like it was working at one -- or potentially more -- of the four doses tested, but not the ones above or below it. A previous trial, called RENEW, in acute optic neuritis, which affects myelin in the eye nerves, showed that the time it takes for the signal to travel between the retina and the visual cortex in the back of the brain was faster in patients receiving opicinumab compared to placebo, but there wasn't an increase in the thickness of the optic nerve neurons and axons nor an increase in visual function. New Article 5 Can't-Miss Dividend Stocks to Buy MS has been a tough disease for the pharmaceutical industry to tackle with direct appraises, though, so patients as well as BIIB investors were optimistic. Just ask Biogen Inc ( BIIB ) investors, who saw the value of BIIB stock slump 12% after the company reported its opicinumab - a phase-2 treatment for neuron damage in multiple sclerosis patients - failed to meet the trial's endpoint . As is so often the case in these setbacks, BIIB investors are asking what happened, and now what? New Article Combined, BIIB and ALXN make up approximately 3.2% of the underlying holdings of XLV. Within that group, Biogen Inc (Symbol: BIIB) and Alexion Pharmaceuticals Inc. (Symbol: ALXN) are two large stocks that are lagging, showing a loss of 12.5% and 10.8%, respectively. Combined, PEG and ED make up approximately 7.1% of the underlying holdings of XLU. New Article On Tuesday, shares of biopharmaceutical company Biogen (BIIB) are plunging, down over 15% in afternoon trading after the company's Phase 2 study of its treatment for relapsing multiple sclerosis failed to meet its primary and secondary endpoints. So far this year, BIIB has underperformed the broader markets, dropping over 5% as of Monday's close. Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. New Article The post Why Biogen Inc (BIIB), LendingClub Corp (LC) and Valeant Pharmaceuticals Intl Inc (VRX) Are Three of Today's Worst Stocks appeared first on InvestorPlace . It could have been worse though, and for Biogen Inc (NASDAQ: BIIB ), LendingClub Corp (NYSE: LC ) and Valeant Pharmaceuticals Intl Inc (NYSE: VRX ) shareholders, it was. Biogen Inc (BIIB) Hopes were high for Biogen MS drug opicinumab, but the company dashed those hopes today by reporting sub-par trial results, sending BIIB down a hefty 12.7% in the process. New Article 3: Biogen Inc.(NASDAQ: BIIB) Biogen racks up billions of dollars in sales every year from medicine that delays the progression of multiple sclerosis, but a moon-shot new drug that could have changed patient treatment forever has flamed out and shares have fallen sharply this week. Because ASCO's annual get-together can put small-cap biotech stocks on the map, investors were excited to learn earlier this year that Immunomedics' therapy for triple-negative breast cancer, sacituzumab govitecan, was selected for an oral presentation. This one-two punch significantly dented the company's share price, but investors may find a silver lining in the fact that ASCO's decision wasn't based on sacituzumab's efficacy in breast cancer. New Article Even though the indexes stayed relatively close to unchanged, several stocks posted big declines, and some of the worst performers included Biogen (NASDAQ: BIIB) , LendingClub (NYSE: LC) , and Valeant Pharmaceuticals (NYSE: VRX) . Biogen had hoped that opicinumab would produce confirmed improvement of neurophysical or cognitive function or disability over the time frame of the study, which covered 72 weeks. However, it revealed that its second-largest shareholder had sold off its stock in LendingClub, and it also warned that loan volume for its standard lending program would likely fall about 5% as a result of its attempts to limit exposure to riskier borrowers. New Article Meanwhile, top losers in the sector included Valeant Pharmaceuticals Intl Inc (NYSE: VRX ), down 21 percent, and Biogen Inc (NASDAQ: BIIB ), down 11 percent. Equities Trading UP China Auto Logistics Inc (NASDAQ: CALI ) shares shot up 172 percent to $2.86 after the company reported that it has sold Zhonghe to Wuxi Huitong Automobile Sales and Service Co., Ltd. (Huitong) for around $62.3 million. Equities Trading DOWN DryShips Inc. (NASDAQ: DRYS ) shares dropped 42 percent to $1.37 after the company announced that it has breached some financial covenants. New Article And the worst performing S&P 500 component thus far on the day is Biogen ( BIIB ), trading down 11.6%. VIDEO: S&P 500 Movers: BIIB, WDC The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Tuesday, shares of Western Digital ( WDC ) topped the list of the day's best performing components of the S&P 500 index, trading up 3.4%. New Article Now, there are questions among investors about whether this rally is sustainable - exacerbated by today's huge drop-off in IBB amid a double-digit hammering of Biogen Inc ( BIIB ) and Alexion Pharmaceuticals, Inc. ( ALXN ), which make up a combined 12% of the Nasdaq biotech ETF. You probably already know that the depressed nature of biotech stocks has a lot to do with politics; for instance, presidential aspirant Hillary Clinton threatening to rein in drug prices if elected into office. Inc. Should Refuse Verizon Communications Inc.'s Insulting Offer (YHOO VZ) On the IBB prospectus page, it's clearly stated that ""holdings are subject to change."" New Article BIIB Revenue (Quarterly) data by YCharts Since Biogen's sales and profit are growing and it remains a giant in multiple sclerosis treatment, I think long-minded investors might be better off thinking of today's disappointing news as an opportunity to buy a top-tier biotech on sale. After all, today's drop means that investors can pay less than 13 times next year's EPS estimates to buy shares, and that could be a bargain. A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. New Article Meanwhile, top losers in the sector included Valeant Pharmaceuticals Intl Inc (NYSE: VRX ), down 13 percent, and Biogen Inc (NASDAQ: BIIB ), down 13 percent. Shares of Navistar International Corp (NYSE: NAV ) got a boost, shooting up 27 percent to $15.41 as the company reported a surprise profit for the second quarter. Equities Trading DOWN DryShips Inc. (NASDAQ: DRYS ) shares dropped 45 percent to $1.31 after the company announced that it has breached some financial covenants. New Article Among components of that ETF with the weakest showing on Tuesday were shares of Biogen ( BIIB ), lower by about 12.2%, and shares of Alexion Pharmaceuticals (ALXN), lower by about 10.8% on the day. Components of that ETF showing particular strength include shares of New Field Exploration ( NFX ), up about 5.3% and shares of EOG Resources ( EOG ), up about 4.8% on the day. VIDEO: Tuesday's ETF Movers: XOP, IBB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",249.48374938964844
2016-06-08 00:00:00+00:00,255.02999877929688,256.7900085449219,251.4100036621093,254.1699981689453,254.1699981689453,3610400.0,1.0,1.0,2.4999999999997247e-05,"While focus was mainly on ASCO data, companies like Biogen BIIB and Sarepta SRPT remained in the limelight on pipeline updates. Click to get this free report ALEXION PHARMA (ALXN): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report To read this article on Zacks.com click here. The company said that despite the missed primary endpoint, it found evidence of a clinical effect with a complex, unexpected dose-response (Read more: Why is Biogen Stock Plunging Today? New Article Biogen Inc.'sBIIB shares declined 12.8% yesterday with the company announcing disappointing top-line results on one of its most-watched experimental multiple sclerosis (MS) treatments, opicinumab (anti-LINGO-1). Click to get this free report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report LIGAND PHARMA-B (LGND): Free Stock Analysis Report IDERA PHARMACT (IDRA): Free Stock Analysis Report RETROPHIN INC (RTRX): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report To read this article on Zacks.com click here. Onivyde is off to an encouraging start and its addition to the National Comprehensive Cancer Network (NCCN) 2016 Clinical Practice Guidelines in Oncology as a category I Treatment Option should also boost sales.",261.7142333984375
2016-06-09 00:00:00+00:00,253.13999938964844,256.19000244140625,249.57000732421875,250.4600067138672,250.4600067138672,2860200.0,4.0,1.0,0.7500249999999999,"It's enormous industry peer, Biogen (NASDAQ: BIIB) is down more than 30% over the same period, slightly underperforming the iShares Nasdaq Biotechnology index (NASDAQ: IBB) , of which Anavex is not a member. Tiny clinical-stage Anavex Life Sciences Corp (NASDAQ: AVXL) recently uplisted from the wild-west of the pink sheets, and its stock price swings since then have been more violent than most western films. The company doesn't even conduct post-earnings release conference calls with investment bank analysts, so the odds of raising enough equity through sales to institutions are pretty slim. New Article Stocks recently featured in the blog include Biogen Inc. ( BIIB ), Merrimack Pharmaceuticals, Inc. ( MACK ), Retrophin, Inc. ( RTRX ), Idera Pharmaceuticals, Inc. ( IDRA ) and Acorda Therapeutics, Inc. ( ACOR ). Here are highlights from Wednesday's Analyst Blog: Forget Biogen: Buy These Biotech Stocks Instead Biogen Inc.'s ( BIIB ) shares declined 12.8% yesterday with the company announcing disappointing top-line results on one of its most-watched experimental multiple sclerosis (MS) treatments, opicinumab (anti-LINGO-1). Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report MERRIMACK PHAR (MACK): Free Stock Analysis Report RETROPHIN INC (RTRX): Free Stock Analysis Report IDERA PHARMACT (IDRA): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report To read this article on Zacks.com click here.",258.8787536621094
2016-06-10 00:00:00+00:00,248.1499938964844,249.0399932861328,244.0200042724609,246.1300048828125,246.1300048828125,2455300.0,2.5,1.0,0.375025,"Let's take a quick look at a few of the biggest contributors to IBB's underperformance as of late below: Biogen ( BIIB ) Biogen shares have been in trouble lately thanks to a weak report on its MS drug results. The Phase 2 trial failed to meet both its primary and secondary endpoints and shares of BIIB plunged as a result (see Why is Biogen Stock Plunging Today? Click to get this free report ISHARES NDQ BIO (IBB): ETF Research Reports BIOGEN INC (BIIB): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report To read this article on Zacks.com click here. New Article And if that isn't reason enough to tune into this week's show, Harjes and Campbell also offer up their thoughts on Biogen Inc. 's(NASDAQ: BIIB) recent clinical trial failure and they debate whether investors should be buyers. The annual American Society of Clinical Oncology (ASCO) conference has come to a close and that's got us wondering which companies deserve a gold star and which don't. Apparently, Immunomedics management outlined or detailed the information that it was scheduled to present at an industry conference in April that violated those embargo rules and, thus, they got yanked.",257.26995849609375
2016-06-13 00:00:00+00:00,245.759994506836,248.3999938964844,244.0399932861328,244.3500061035156,244.3500061035156,1622700.0,2.0,1.0,0.250025,"Stocks recently featured in the blog include iShares Nasdaq Biotechnology( IBB ),Biogen ( BIIB ) , Alexion Pharma ( ALXN ), BioMarin Pharma ( BMRN ) and Regeneron ( REGN ). Let's take a quick look at a few of the biggest contributors to IBB's underperformance as of late below: Biogen ( BIIB ) Biogen shares have been in trouble lately thanks to a weak report on its MS drug results. The Phase 2 trial failed to meet both its primary and secondary endpoints and shares of BIIB plunged as a result (see Why is Biogen Stock Plunging Today? New Article GILD is a part of the Health Care sector, which includes companies such as Amgen Inc. ( AMGN ) and Biogen Inc. ( BIIB ). Shareholders who purchased GILD prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports GILD's forecasted earnings growth in 2016 as -4.26%, compared to an industry average of 2.8%.",249.1224365234375
2016-06-16 00:00:00+00:00,236.9100036621093,243.33999633789065,236.5399932861328,242.19000244140625,242.19000244140625,1995500.0,2.0,1.0,0.250025,"Key stocks from the sector including, Allergan plc ( AGN ), Medtronic plc ( MDT ), Alexion Pharmaceuticals, Inc. ( ALXN ), Biogen Inc. ( BIIB ) and Bristol-Myers Squibb Company ( BMY ) fell 2%, 1.5%, 1.3%, 1.2% and 0.7%, respectively. Click to get this free report ALLERGAN PLC (AGN): Free Stock Analysis Report MEDTRONIC (MDT): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report EXXON MOBIL CRP (XOM): Free Stock Analysis Report CHEVRON CORP (CVX): Free Stock Analysis Report To read this article on Zacks.com click here. Benchmarks ended in the red for the fifth consecutive session on Wednesday after the Fed opted to keep interest rate unchanged and raised concerns about number of hikes this year.",249.28211975097656
2016-06-21 00:00:00+00:00,238.0,238.9900054931641,232.9900054931641,233.0,233.0,1955900.0,2.5,1.0,0.375025,"Less than encouraging news from Gilead Sciences (NASDAQ: GILD) , Ionis Pharmaceuticals (NASDAQ: IONS) , Biogen (NASDAQ: BIIB) , Celgene (NASDAQ: CELG) , and Portola Pharmaceuticals (NASDAQ: PTLA) has led to what I feel are overreactions. There are six main strains of Hepatitis C virus, and by the end of the month the FDA is expected to announce a decision regarding Gilead's combination pill intended to treat them all. The latest beating took place after GlaxoSmithKline decided to postpone a planned phase 3 trial with IONIS-TTRrx for treatment of heart-debilitating symptoms associated with a rare inherited metabolic disease, transthyretin-related amyloidosis. New Article But unlike a broader market near all-time-highs, brakes applied to nice-size, opening gains have kept biotech stocks CELG, REGN and BIIB near 52-week and multiyear lows and looking quite bearish. And nowhere is this more evident than in large-capitalization biotech stocks Celgene Corporation ( CELG ), Regeneron Pharmaceuticals Inc ( REGN ) and Biogen Inc ( BIIB ). Our advice however is not to let those classically bearish charts dissuade you from buying CELG, REGN and BIIB - and companies where growth prospects still look strong.",247.77667236328125
2016-06-23 00:00:00+00:00,237.17999267578125,238.7899932861328,235.759994506836,238.6199951171875,238.6199951171875,1403000.0,2.0,1.0,0.250025,"BIIB data by YCharts . The move in July came after Biogen announced sales growth for its oral multiple sclerosis drug, Tecfidera, was slowing. Celegene's growth prospects In contrast to Biogen, Celgene has had a relatively solid year, with its only downfall being that it's a biotech company.",245.6511993408203
2016-06-24 00:00:00+00:00,232.0,235.3000030517578,229.0,229.0200042724609,229.0200042724609,2685000.0,2.0,1.0,0.250025,"Troubles for Biotech Stocks I think the main reason we've seen the industry struggle recently is because of underperformance in the Big Four - Amgen, Inc. ( AMGN ), Gilead Sciences, Inc. ( GILD ), Celgene Corporation ( CELG ) and Biogen Inc ( BIIB ). However, with the valuations of these big names so low (AMGN's price-to-earnings ratio is 12.2, well below that of the sector and the S&P 500 ), I believe the weakness is actually an opportunity - one that current and probably short-term Brexit-based losses are exacerbating. This has led to plenty of takeovers in recent years, and I expect the trend of Big Pharma paying hefty premiums for the smaller companies to continue. New Article This biotech stock should seriously consider paying a dividend On the other hand, Biogen (NASDAQ: BIIB) should give serious consideration to joining Amgen and Gilead by paying its shareholders a quarterly dividend. Gilead Sciences (NASDAQ: GILD) also joined the dividend party after hepatitis C duo Harvoni and Sovaldi basically made it more money than it knew what to do with. In Alexion's case, that would be Soliris, an enzyme replacement therapy designed to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, both very rare diseases. New Article Should-Be Dividend Stocks: Biogen Inc (BIIB) Biotech companies tend to be pretty stingy when it comes to paying dividends. Still, Biogen Inc ( BIIB ) makes plenty of net income ($3.55 billion in FY15), had operational cash flow of $3.72 billion (up from $2.94 billion and $2.35 billion in FY14 and FY13, respectively), and free cash flow of $3.07 billion in FY15. The 10 Best Dividend Stocks Across All 10 Sectors BIIB has a mere 219-million-share float.",246.107421875
2016-06-27 00:00:00+00:00,227.0,229.5399932861328,223.0200042724609,224.6000061035156,224.6000061035156,2913900.0,2.0,1.0,0.250025,"If Anavex were to test 2-73 in a phase 1 clinical trial (with human subjects) and succeed in one or more of the growing list of neurological disorders it has positive preclinical data for, then it might give the stock some lift. When the company last presented data from the trial, after five weeks of treatment with 2-73, patients showed significant improvements in a couple of tests relating to attention and working memory. Even if the results are amazing, there's no way the FDA will accept a new drug application for treatment of Alzheimer's without trial data in which randomized groups received either 2-73 or a placebo without the knowledge of patients or healthcare staff.",243.84454345703125
2016-06-29 00:00:00+00:00,232.8699951171875,239.8500061035156,232.0,238.9100036621093,238.9100036621093,2881200.0,5.0,1.0,1.000025,"Childhood cerebral adrenoleukodystrophy (CCALD) is deadly inherited disorder caused by a faulty gene that affects roughly 40 boys born in the U.S. each year. It became a major issue for Ionis' stock when Glaxo announced it wasn't going to begin a planned phase 3 trial with the same drug in patients suffering heart damage. I think Wall Street is missing the bigger picture here: The drug in question is one of the company's older, more advanced clinical-stage candidates, but Ionis has a very deep bench.",244.44203186035156
2016-06-30 00:00:00+00:00,239.3099975585937,241.8999938964844,236.6699981689453,241.82000732421875,241.82000732421875,2093200.0,3.0,1.0,0.5000249999999999,"(NASDAQ: BIIB) . Image source: Biogen, Inc. Big Moonshots remain Last year, the company kicked-off a large, multi-year study of aducanumab, a therapy targeting Alzheimer's disease. Tying it together Biogen's sales growth is slowing and investors shouldn't ignore the competitive threats in MS, but it may be wise to give management the benefit of the doubt that they can maintain their leadership in the indication.",239.578125
2016-07-07 00:00:00+00:00,247.2400054931641,249.6600036621093,245.22000122070312,247.2700042724609,247.2700042724609,1140400.0,3.0,1.0,0.5000249999999999,"Key biotech stocks including, Biogen Inc. ( BIIB ), Gilead Sciences Inc. ( GILD ), Regeneron Pharmaceuticals, Inc. ( REGN ), Vertex Pharmaceuticals Incorporated ( VRTX ) and Alexion Pharmaceuticals, Inc. ( ALXN ) rose 2.3%, 2.2%, 3.3%, 3.6% and 3%, respectively. Click to get this free report MEDIVATION INC (MDVN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report ALEXION PHARMA (ALXN): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report UNITEDHEALTH GP (UNH): Free Stock Analysis Report EXXON MOBIL CRP (XOM): Free Stock Analysis Report CHEVRON CORP (CVX): Free Stock Analysis Report To read this article on Zacks.com click here. Benchmarks ended in the green on Wednesday after the FOMC minutes from June meeting showed that most of the Fed policymakers were in favor of keeping rates unchanged.",246.77694702148438
2016-07-08 00:00:00+00:00,248.6300048828125,251.77999877929688,246.1100006103516,251.3000030517578,251.3000030517578,1295600.0,2.0,1.0,0.250025,"Another well-ranked stock in the biotech sector is Biogen Inc. BIIB , which also carries a Zacks Rank #2. Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report KITE PHARMA INC (KITE): Free Stock Analysis Report BLUEBIRD BIO (BLUE): Free Stock Analysis Report JUNO THERAPEUTC (JUNO): Free Stock Analysis Report To read this article on Zacks.com click here. Immuno-oncology focused company, Juno Therapeutics, Inc.JUNO , suffered a huge setback with the FDA placing a clinical hold on the company's phase II study (ROCKET) on JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia (r/r ALL). New Article What: Shares of Biogen Inc. (NASDAQ: BIIB) , a large neurology-focused biotechnology company, tumbled 15.7% last month, according to data from S&P Global Market Intelligence . BIIB data by YCharts So what: Biogen was developing opicinumab, formerly anti-lingo-1, as a first-in-class therapy aimed at repairing multiple sclerosis patients' damaged nerves. When Biogen announced opicinumab failed to significantly improve patient outcomes, Wall Street cleaved about $8 billion from the biotech's market cap in a day.",246.1383514404297
2016-07-12 00:00:00+00:00,253.77999877929688,254.8500061035156,251.2899932861328,253.3600006103516,253.3600006103516,1175100.0,2.0,1.0,0.250025,"Celgene Corp. (NASDAQ: CELG) and Biogen Inc. (NASDAQ: BIIB) are both biotech industry titans, but for investors who can only add one of these two stocks to their portfolio, which is the better buy? Although Biogen has an intriguing Alzheimer's disease moonshot advancing through R&D, various potential blockbusters lurking in Celgene's pipeline are closer to commercialization. Kristine Harjes: With Biogen, as we've mentioned on the show a few times now, they're relying on some of these moonshots at this point, and they do have very successful drugs on the market, and so some of their value proposition is quite clear, but there are also quite a few pretty large question marks surrounding this company.",245.06033325195312
2016-07-20 00:00:00+00:00,259.8699951171875,263.1600036621094,257.57000732421875,262.4100036621094,262.4100036621094,1830200.0,2.5,1.0,0.375025,"Biogen Inc. ( BIIB ) is reporting for the quarter ending June 30, 2016. In the past year BIIB has beat the expectations every quarter. Zacks Investment Research reports that the 2016 Price to Earnings ratio for BIIB is 13.65 vs. an industry ratio of -10.30, implying that they will have a higher earnings growth than their competitors in the same industry. New Article InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen Inc (NASDAQ: BIIB ) shares have been struggling for nearly a year now. The second-quarter 2015 numbers - posted on July 24 of last year - prompted a 22% setback for BIIB stock that same day, which has given up a total of 33% since the fateful day the implosion started. 5 Tech Stocks That Will Be Obsolete by 2020 The BIIB stock investors know and love today, though, isn't the same one that's been punishing them for the past year.",252.07632446289062
2016-07-21 00:00:00+00:00,279.760009765625,282.5400085449219,274.2300109863281,282.45001220703125,282.45001220703125,5548000.0,3.111111111111111,1.0,0.5278027777777778,"Biogen (BIIB) Earnings End a YEAR of Misery Options traders had a call field-day on Wednesday, with these typically bullish bets accounting for 69% of the 582,000 contracts traded on FB. Meanwhile, the 10-day moving average has pulled back to worrisome levels, dipping to 0.58, its lowest point since June 11, 2015 and reflecting an overabundance of optimism in the options pits. In equity option news, Microsoft Corporation (NASDAQ: MSFT ) drew heavy call volume and topped Dow gainers in the wake of better-than-expected fourth-quarter earnings. New Article Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 30% Average next regular session additional gain: 2.6% Over the prior three fiscal years (12 quarters), when shares of BIIB rose in the extended-hours session in reaction to its earnings announcement, history shows that 30.0% of the time (3 events) the stock posted additional gains in the following regular session by an average of 2.6%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 3.4% Over that same historical period, when shares of BIIB dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 3.4% by the following regular session close. Extended-Hours Dollar Volume: $71,013,233 Biogen Idec ( BIIB ) is due to issue its quarterly earnings report in the upcoming extended-hours session. New Article Given the muted growth and minor contribution the division makes to the company's top and bottom lines, BIIB feels it would be better served by committing its hemophilia time and resources to MS opportunities. BIIB Stock: Looking Ahead Analysts' revenue outlooks for the remainder of 2016 and all of 2017 had been lackluster, largely reflecting a slowdown in the sales of its flagship drug Tecfidera. InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biopharma company Biogen Inc (NASDAQ: BIIB ) is on the rise today, with BIIB stock up some 6% as the company finally injected some optimism into what has been a shoddy 2016. New Article More From InvestorPlace Intel Beats on Q2 Earnings, But INTC Stock Slides Biogen Inc (BIIB) Stock: Q2 Earnings End a Year of Misery 10 Stocks to Buy If Donald Trump Becomes President The post E*Trade Financial Corp: ETFC Stock Stepping Into the Spotlight appeared first on InvestorPlace . Analysts are expecting the company to earn 38 cents a share on revenue north of $471 million. InvestorPlace advisor Rick Rouse is offering a special free report, ""The 5 Golden Rules of Options Investing,"" that reveals his rules for options trading success that will help you make double- and triple-digit profits in the months ahead no matter what the market has in store. New Article Biotech company, Biogen Inc.'s BIIB shares were up more than 5% in pre-market trading with the company surpassing earnings expectations by a wide margin. Biogen Inc. (BIIB) Street Actual & Estimate EPS - Last 5 Quarters | FindTheCompany Sales came in at $2.9 billion, increasing 12% from the year-ago period and surpassing the Zacks Consensus Estimate of $2.8 billion. Click to get this free report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report INNOVIVA INC (INVA): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Among the largest underlying components of BIB, in trading today Biogen Inc (Symbol: BIIB) is up about 4.9%, Regeneron Pharmaceuticals, Inc. (Symbol: REGN) is up about 1.6%, and Mylan NV (Symbol: MYL) is lower by about 1.4%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra Nasdaq Biotechnology (Symbol: BIB) where we have detected an approximate $31.3 million dollar outflow -- that's a 6.4% decrease week over week (from 10,950,000 to 10,250,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article In trading on Thursday, shares of Biogen Inc (Symbol: BIIB) crossed above their 200 day moving average of $270.68, changing hands as high as $281.33 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $223.02 per share, with $412.24 as the 52 week high point - that compares with a last trade of $278.87. According to the ETF Finder at ETF Channel, BIIB makes up 7.57% of the iShares Nasdaq Biotechnology ETF (Symbol: IBB) which is trading higher by about 1.6% on the day Thursday. New Article Cambridge, MA-based Biogen BIIB , one of the world's leading biotechnology companies, focuses on therapeutic areas including neurology, immunology and hemophilia. BIIB has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 9.54%. Currently, BIIB has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. New Article On the earnings front, upbeat results from Qualcomm ( QCOM ) and Biogen ( BIIB ) are supporting the Nasdaq Composite. Also, the July Philadelphia Fed business outlook index fell to negative 2.9 from positive 4.7 in June, missing projections for a slight gain to 5.0. European equities have headed south after their impressive winning streak amid disappointment that the ECB did not expand their asset purchase program, as was expected.",257.14208984375
2016-07-22 00:00:00+00:00,282.0899963378906,290.9200134277344,281.3800048828125,287.7799987792969,287.7799987792969,3394600.0,3.5,1.0,0.6250249999999999,"Biogen (NASDAQ: BIIB) posted solid revenue and earnings growth when it released second-quarter earnings on Thursday. But the good earnings news was trumped by the announcement that its CEO, George Scangos, will step down as soon as a replacement can be found. Biogen gained FDA approval for Zinbryta, its newest multiple sclerosis drug that was developed in conjunction with AbbVie (NYSE: ABBV) . New Article Biotechnology and semiconductor majors such as Biogen ( BIIB ) and Qualcomm (QCOM) surged after their quarterly results. In other ETF market action, SPDR Gold Shares (GLD) crept lower Friday despite the appetite for defensive plays. Gold continues to see weakness because the recent rally in world stock markets has hurt the safe-haven asset, according to Kitco News.",262.556640625
2016-07-25 00:00:00+00:00,287.8399963378906,290.5799865722656,285.0199890136719,287.3500061035156,287.3500061035156,1977700.0,4.0,1.0,0.7500249999999999,"For Immediate Release Chicago, IL - July 25, 2016 - Today, Zacks Equity Research discusses Pharma, including Bristol-Myers ( BMY ), Pfizer ( PFE ), Sanofi ( SNY ), Amgen ( AMGN ) and Biogen ( BIIB ). Apart from Novartis, companies like Merck, Amgen, Pfizer, Biogen ( BIIB ) and Allergan are targeting the highly lucrative biosimilars market. Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report SANOFI-AVENTIS (SNY): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. New Article SPDR S&P Biotech ( XBI ) on Thursday broke out of a first-stage base, climbing to its highest level since early June as industry giant Biogen ( BIIB ) trounced analyst estimates for profit and sales growth. Loo also has a positive outlook on an issue of key interest to investors: ""The industry pipeline is also solid as several drugs have blockbuster sales potential,"" he wrote. Now Hillary Clinton, whose tweet on ""price gouging"" triggered that scrutiny, is poised to become the official Democratic candidate for next president of the United States.",269.53076171875
2016-07-27 00:00:00+00:00,286.8299865722656,288.7699890136719,286.0799865722656,288.3500061035156,288.3500061035156,1458200.0,3.0,1.0,0.5000249999999999,"Compounded, they've pushed the internet-only bank's stock down over half from its high and driven its price to book value multiple to levels of banks 70 times bigger: BOFI Price to Book Value data by YCharts Bottom line: BofI is a cost-efficient growth machine, and I don't buy the allegations, which, by the way, are all being pushed by anonymous bloggers with short positions (and potentially very large short-selling financial backers). If you're willing to take on the risk, BofI shares are trading at an incredible discount for a company that's grown earnings like this over the past five years: BOFI EPS Diluted (TTM) data by YCharts A cyclical growth stock Tim Green : On the surface, NXP Semiconductors (NASDAQ: NXPI) doesn't look like much of a growth stock at the moment. Analysts expect NXP's earnings to be roughly flat this year, with substantial growth returning in fiscal 2017.",266.9546203613281
2016-07-28 00:00:00+00:00,288.6099853515625,289.9800109863281,285.07000732421875,289.0299987792969,289.0299987792969,1454500.0,3.25,1.0,0.5625249999999999,"Some better-ranked stocks in the health care sector include Innoviva, Inc. INVA , ANI Pharmaceuticals, Inc. ANIP and Biogen Inc. BIIB . Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report INNOVIVA INC (INVA): Free Stock Analysis Report To read this article on Zacks.com click here. Vertex is currently looking to get Orkambi approved for use in children (6 - 11 years old) -- with the FDA granting priority review, a response should be out by Sep 30, 2016. New Article While it was a ""beat and raise"" quarter for companies like Johnson & Johnson JNJ , Amgen Inc. AMGN and Biogen, Inc. BIIB , Gilead Sciences, Inc. GILD , a big name in the biotech sector, lowered its product sales outlook. Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Q2 earnings season has picked up pace with 208 S&P 500 members, accounting for 50.5% of the index's total market capitalization, having reported results. New Article Stocks recently featured in the blog include Biogen ( BIIB ), Gilead ( GILD ), AbbVie ( ABBV ), Amgen ( AMGN ) and Celgene ( CELG ). Here are highlights from Wednesday's Analyst Blog: Biotech Stock Roundup: Q2 Earnings Beats Earnings season for the biotech sector has kicked off with two big biotech names, Biogen ( BIIB ) and Gilead ( GILD ) reporting second quarter results. Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Some better-ranked stocks in the health care sector include Innoviva, Inc. INVA and Biogen Inc. BIIB . Click to get this free report FRESENIUS MED (FMS): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report INNOVIVA INC (INVA): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues of Amgen's erythropoiesis-stimulating agent (ESA) Aranesp grew 5% from the year-ago quarter to $504 million reflecting higher unit demand in the U.S. given the shift in dialysis customer purchases from Epogen.",255.92124938964844
2016-07-29 00:00:00+00:00,288.8500061035156,290.4599914550781,286.79998779296875,289.92999267578125,289.92999267578125,1338500.0,4.0,1.0,0.7500249999999999,"Moreover, the company, in collaboration with Biogen Inc. BIIB , initiated a phase IIb program on dapirolizumab pegol for the treatment of systemic lupus erythematosus. Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report UCB SA (UCBJF): Free Stock Analysis Report NEKTAR THERAP (NKTR): Free Stock Analysis Report To read this article on Zacks.com click here. Quarterly Highlights Cimzia sales soared 24% to 602 million driven by expanded patient access for inflammatory tumor necrosis factor-mediated diseases.",260.36993408203125
2016-08-01 00:00:00+00:00,300.0,307.5,299.0599975585937,301.8299865722656,301.8299865722656,3565600.0,3.307692307692307,1.0,0.5769480769230767,"(+) TOPS (+129.73%) Reported strong H1 results late Friday, swinging to a profit of $11.6 million in revenue (+) FLTX (+38.72%) To be acquired by Verizon ( VZ ) for $2.4 billion (+) IONS (+35.18%) Disclosed positive results from phase 3 trial of spinal muscular atrophy treatment being developed with Biogen ( BIIB ) (+) ETSY (+13.82%) Initiated at Citigroup with buy rating, $14 price target (+) MEET (+11.51%) Beat Q2 EPS and revenue estimates (+) KOOL (+10.31%) Receives FDA approval on changes for IDE supplement for SurgWerks CLI pivotal trial Losses were mitigated by the Institute for Supply Management ( ISM ) manufacturing index for July which fell to 52.6 from 53.2 in June, dimming the likelihood for the Federal Reserve to hike interest rates next month. (-) VHC (-42.96%) Court orders Apple (AAPL) patent cases to be heard separately (-) KERX (-29.89%) Withdrew 2016 guidance and disclosed an imminent interruption in Auryxia supply (-) ADMA (-20.64%) Received Complete Response Letter from FDA regarding deficiencies from third-party manufacturers of intravenous immune globulin treatment (-) TKAI (-10.32%) Announced late Friday it is cutting workforce by 60% after discontinuation of ARMOR3-SV trial of galeterone (-) SCTY (-6.18%) To be merged with Tesla (TSLA) for $2.6 billion The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article In other sector news, (+) IONS, (+%) Receives $75 mln milestone payment from Biogen ( BIIB ) after its nusinersen drug candidate meets primary endpoint of a statistically significant improvement in motor activity in infants with spinal muscular atrophy compared with untreated infants during Phase III testing. In company news, Inotek Pharmaceuticals Corp ( ITEK ) shares declined Monday after the specialty drugmaker today launched a $50 million public offering of its convertible senior notes maturing 2021. The company expects to use net proceeds to fund ongoing testing of its trabodenoson drug candidate as a potential treatment to reduce intraocular pressure within the eyes, either as a monotherapy or in combination with latanoprost, an FDA-approved glaucoma liquid treatment sold under the Xalatan brand name. New Article The company had been working in tandem with partner Biogen BIIB to develop nusinersen, a drug meant to treat spinal muscular atrophy (SMA) in infants. As per the deal that the companies had with each other, BIIB will pay IONS $75 million for the success and will take over, filing for approval and handling the marketing of the drug. Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. New Article After he did that, he stuck around for a little while at that new entity, and then he went off to be the president and CEO of a company called Abraxis BioScience, which shortly thereafter got sold to Celgene (NASDAQ: CELG) for about $2.9 billion. He's leveraging that experience and that network of people to form a collaboration of industry leaders that hope to make a really, really major impact on treatment in cancer over the next few years. Even just no more than a month ago they announced that they bought a company called Transition Therapeutics for $60 million, which is also a pretty small acquisition, but it's bringing some really interesting candidates to Opko. New Article In other sector news, (+) IONS, Receives $75 mln milestone payment from Biogen ( BIIB ) after its nusinersen drug candidate meets primary endpoint of a statistically significant improvement in motor activity in infants with spinal muscular atrophy compared with untreated infants during Phase III testing. In company news, Eyegate Pharmaceuticals ( EYEG ) advanced Monday after the drugmaker today announced positive data from Phase Ib/IIa testing of using an low-power electrical current to treat patients with post-operative ocular inflammation and pain following cataract surgeries with its its EGP-43 drug candidate. The company said it expects to begin a randomized, placebo-controlled trial of EGP-437 in cataract surgery patients by the end of the year. New Article (+) IONS (+28.13%) Disclosed positive results in a Phase 3 trial of a spinal muscular atrophy treatment it is developing with Biogen ( BIIB ). (-) ADMA (-40.38%) Received a complete response letter from the FDA on its intravenous immune globulin identifying inspection issues and deficiencies at third-party contract manufacturers. (-) KERX (-26.09%) Withdrew 2016 financial guidance and disclosed an imminent interruption in the supply of Auryxia tablets due to a production-related issue. New Article 10 Market Predictions for the Rest of 2016 IONS is developing the treatment, called nusinersen, with biotechnology giant Biogen Inc (NASDAQ: BIIB ). BIIB is planning to treat patients using nusinersen in an upcoming trial. Even some deal-making headlines failed to lift stocks on the first day of August, historically one of the worst months of the year for U.S. equities. New Article VIDEO: Nasdaq 100 Movers: CTXS, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Monday, shares of Biogen ( BIIB ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 5.5%. And the worst performing Nasdaq 100 component thus far on the day is Citrix Systems ( CTXS ), trading down 2.2%. New Article The results convinced partner Biogen (NASDAQ: BIIB) to exercise its option to license nusinersen, triggering a $75 million payment to Ionis Pharmaceuticals. So what: No actual details were presented in the press release or accompanying conference call because this was an interim analysis, and the companies are holding the data for an upcoming medical meeting. Given the life-threatening nature of the disease and lack of treatment options, it seems likely regulators will give nusinersen an accelerated review, potentially putting the drug on the market this time next year, if not sooner. New Article Among its top 25 stock holdings, biotech giants Biogen ( BIIB ), Amgen ( AMGN ) and Celgene ( CELG ) are on the rise after their recent quarterly reports. Energy stock ETFs crumbled Monday, the first trading day of August, as an uptick in production and rig counts rattled investors. The rebound in oil prices from first-quarter lows didn't benefit second-quarter results by much,"" Lindsey Bell, a senior analyst at S&P Global Market Intelligence, wrote Monday. New Article InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen Inc (NASDAQ: BIIB ) stock was up on Monday following positive results from its Phase 3 trial of nusinersen. BIIB stock was up 5% and IONS stock was up 35% as of Monday morning. More From InvestorPlace: 10 Losers That Will Be 2017's Best Stocks to Buy 8 Stocks to Buy If Hillary Clinton Becomes President 7 Things Every Retirement Investor Should Own The post Why Biogen Inc (BIIB) Stock Is Soaring Today appeared first on InvestorPlace . New Article Biogen Inc (NASDAQ: BIIB ) and Ionis Pharmaceuticals evealed that nusinersen, their investigational treatment for spinal muscular atrophy (SMA), met the primary endpoint at interim analysis of the final stage of ENDEAR trial. Insperity posted better-than-expected quarterly earnings, but the company missed analysts' sales estimates. Shares of Keryx Biopharmaceuticals (NASDAQ: KERX ) were down 33 percent to $4.93 after the company revealed that there is an imminent supply interruption of Auryxia (ferric citrate) tablets due to a production-related issue converting active pharmaceutical ingredient (API) to finished drug product. New Article In early trading on Monday, shares of Biogen ( BIIB ) topped the list of the day's best performing components of the S&P 500 index, trading up 5.4%. VIDEO: S&P 500 Movers: RIG, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing S&P 500 component thus far on the day is Transocean ( RIG ), trading down 6.0%.",266.6378173828125
2016-08-02 00:00:00+00:00,302.8800048828125,333.6499938964844,297.6600036621094,330.1099853515625,330.1099853515625,7800000.0,3.8333333333333335,1.0,0.7083583333333334,"IBB has nearly a quarter of its assets in biotech heavyweights Amgen ( AMGN ), Celgene ( CELG ) and Biogen ( BIIB ), which have moved higher after their respective quarterly reports last week. This flagship health care exchange traded fund has jumped 11.9% in the month ended Aug. 1 -- a sharp turnaround in performance that has helped it trim year-to-date losses to 13%. Biogen shares spiked further Monday after the company and its partner Ionis Pharmaceuticals ( IONS ) surprised investors with success in a phase-three clinical trial for their spinal disease treatment. New Article The company's solid second-quarter results come in the wake of a disappointing failure of a next-generation MS drug under development. Scangos detailed plans earlier this year to spin off two fast-growing hemophilia drugs as a separate business to unlock shareholder value. Sizing up suitors With a market cap of nearly $70 billion, Biogen is an industry Goliath, and that means only the deepest-pocketed of its competitors might be in a position to buy the company outright. New Article BIIB data by YCharts Buyers were rewarded with second quarter sales growth of 11.7% year-over-year to $2.9 billion. In addition to nusinersen, the company's partnering with Samsung Bioepis to create biosimilars, or drugs that work similarly to but aren't exact copies of biologics. Last month, European regulators accepted for review the partner's biosimilar to Humira, an autoimmune disease drug with $14 billion in global sales. New Article Biogen Inc (BIIB) Shares of biotechnology giant Biogen Inc surged 9.4% on more than triple the average daily turnover on reports the company is a potential takeover target and that multiple companies could be interested in BIIB. On a sour day for stocks, Avon Products, Inc. (NYSE: AVP ), Biogen Inc (NASDAQ: BIIB ) and Sodastream International Ltd (NASDAQ: SODA ) delivered sweet performances. A report in the Wall Street Journal suggests that Merck & Co., Inc. (NYSE: MRK ), a member of the Dow Jones Industrial Average, and Allergan plc (NYSE: AGN ) could be among the potential suitors for BIIB. New Article After his announcement, the market began speculating that BIIB could be an acquisition target, and it seems any bit of whispers on the matter are enough to send the stock into the stratosphere. InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen Inc (NASDAQ: BIIB ) just made a huge move out of thin air Tuesday evening, spiking 9.5% to $330 as of this writing. Until the surge, BIIB stock was trading in the red in the sub-$300 range. New Article DISH Network Corporation ( DISH ) had the largest percent change down (-8.02%) while Biogen Inc. ( BIIB ) had the largest percent change gain rising 9.37%. NASDAQ Market Wrap As of 8/2/2016 4:45:00 PM BILLIONS OF 2.1 NASDAQ SHARES TRADED TODAY 32 STOCKS REACHED A 52 WEEK HIGH 30 THOSE REACHING LOWS TOTALEDBiogen Inc. [BIIB]TOPS ADVANCERS LISTOF NASDAQ 100 INDEX % 9.37 ROSE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The Dow Jones index closed down -.49% for the day; a total of -90.74 points.",267.9819641113281
2016-08-03 00:00:00+00:00,321.7699890136719,324.29998779296875,310.0599975585937,321.3399963378906,321.3399963378906,6040500.0,2.5,1.0,0.375025,"Regeneron Pharmaceuticals Inc (NASDAQ: REGN ), Biogen Inc (NASDAQ: BIIB ) and Dun & Bradstreet Corp (NYSE: DNB ) are among the parabolic stocks that look ready to cool their engines after some large bullish moves. Biogen Inc (BIIB) Biogen Inc shares jumped more than 9% in trading yesterday on M&A rumors. More From InvestorPlace 10 Market Predictions for the Rest of 2016 10 Losers That Will Be 2017's Best Stocks to Buy The post 3 Big Stock Charts for Wednesday: Regeneron Pharmaceuticals Inc (REGN), Biogen Inc (BIIB) and Dun & Bradstreet Corp (DNB) appeared first on InvestorPlace . New Article Two other components making moves today are Biogen ( BIIB ), trading down 3.9%, and Discovery Communications ( DISCA ), trading up 3.8% on the day. And the worst performing Nasdaq 100 component thus far on the day is Verisk Analytics ( VRSK ), trading down 4.5%. Verisk Analytics is showing a gain of 4.0% looking at the year to date performance.",261.2972412109375
2016-08-04 00:00:00+00:00,320.1499938964844,320.45001220703125,314.010009765625,314.5599975585937,314.5599975585937,2002300.0,2.8,1.0,0.4500249999999999,"Biogen Inc.BIIB : This popular name in the biopharma market works on innovative therapies in the field of serious neurological, autoimmune, and rare diseases. Click to get this free report QUALCOMM INC (QCOM): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ANGLOGOLD LTD (AU): Free Stock Analysis Report STEEL DYNAMICS (STLD): Free Stock Analysis Report TALLGRASS ENRGY (TEGP): Free Stock Analysis Report To read this article on Zacks.com click here. But, in a year full of volatility, it is pointless to ponder on methods which don't consider a stock's future growth rate while calculating its intrinsic merit. New Article AGN Stock Options Pricing Trading activity on Wednesday was fairly unassuming and the options trading which did transpire, may be related to Tuesday's rumors of Allergan's interest in acquiring biotech giantBiogen Inc (NASDAQ: BIIB ). On the other hand and for the still-in-control bears, a decent price run off AGN's May low and into fairly significant layers of technical resistance from roughly $250 - $275, presents an opportunity to short Allergan shares and fade the current counter-trend rally. The math behind the AGN price range calculation is based on the at-the-money weeklys August 12 $252.50 straddle market which trades on implied volatility of 36% with nine calendar days left. New Article While pipeline diversity and growth prospects were touted by both sides of this purported deal, it was the $2 billion in annual cost savings from their combination that really stood out. However, earlier this year the Treasury Department passed new regulations surrounding these so-called tax inversion deals, which ultimately killed the Pfizer-Allergan merger. Purchasing Biogen, which ended Wednesday with a market cap of $70 billion, really wouldn't fit with Merck's inorganic growth strategy as laid out by its management team. New Article Factors to Consider Through partnerships with several leading health care companies like Biogen Inc. BIIB and GlaxoSmithKline plc GSK among others, Ionis earns revenues in the form of upfront, milestone and other payments. Click to get this free report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. However, in the second quarter, the company received a major blow when Glaxo decided against starting a phase III outcome study - CARDIO-TTR - that was planned to evaluate IONIS-TTRRx in patients with transthyretin (TTR) amyloid cardiomyopathy. New Article Sangamo Biosciences also pushed back the start of clinical trials into 2017 for beta-thalassemia and sickle cell disease programs licensed by Biogen (NASDAQ: BIIB) . While certainly larger than the $12.1 million, or $0.17 per share, that Sangamo Biosciences lost in the year-ago quarter, investors are rightfully more focused on the pipeline of the development-stage biotech than its GAAP losses. Delays in starting programs are a double whammy because they result in additional cash burned, which may need to be made up for with dilutive secondary offerings.",249.0640411376953
2016-08-05 00:00:00+00:00,316.1600036621094,318.9100036621094,313.69000244140625,315.9599914550781,315.9599914550781,1358300.0,3.0,1.0,0.5000249999999999,"For Immediate Release Chicago, IL - August 05, 2016 - Stocks in this week's article include: AngloGold Ashanti Ltd. ( AU ), Biogen Inc. ( BIIB ), QUALCOMM Inc. ( QCOM ), Tallgrass Energy GP, LP ( TEGP ) and Steel Dynamics Inc. ( STLD ). Biogen Inc. ( BIIB ) : This popular name in the biopharma market works on innovative therapies in the field of serious neurological, autoimmune, and rare diseases. Click to get this free report ANGLOGOLD LTD (AU): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report QUALCOMM INC (QCOM): Free Stock Analysis Report TALLGRASS ENRGY (TEGP): Free Stock Analysis Report STEEL DYNAMICS (STLD): Free Stock Analysis Report To read this article on Zacks.com click here.",258.6221618652344
2016-08-08 00:00:00+00:00,316.0199890136719,316.3500061035156,309.1600036621094,313.6499938964844,313.6499938964844,2136800.0,4.0,1.0,0.7500249999999999,"Some better-ranked stocks in the healthcare sector include Actelion Limited ALIOF , Agenus Inc. AGEN and Biogen Inc. BIIB . Click to get this free report ACTELION LTD (ALIOF): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AGENUS INC (AGEN): Free Stock Analysis Report INTERCEPT PHARM (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. A marketing authorisation application for the product for the treatment of PBC was accepted by the European Medicines Authority (EMA) in Jun 2015 and is currently under review.",263.0082702636719
2016-08-09 00:00:00+00:00,313.7200012207031,316.239990234375,311.79998779296875,314.4200134277344,314.4200134277344,1132200.0,4.0,1.0,0.7500249999999999,"Stocks recently featured in the blog include Intel Corporation ( INTC ), Align Technology, Inc. ( ALGN ), Qorvo Inc ( QRVO ) and Biogen Inc. ( BIIB ). Biogen Inc. ( BIIB ) develops, manufactures and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. BIIB has a Zacks Rank #2 and a VGM score of 'B'. New Article Among the largest underlying components of QUAL, in trading today Public Service Enterprise Group Inc (Symbol: PEG) is up about 0.2%, Biogen Inc (Symbol: BIIB) is up about 0.4%, and Nike (Symbol: NKE) is up by about 0.1%. For a complete list of holdings, visit the QUAL Holdings page  The chart below shows the one year price performance of QUAL, versus its 200 day moving average: Looking at the chart above, QUAL's low point in its 52 week range is $41.10 per share, with $68.44 as the 52 week high point - that compares with a last trade of $68.38. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",261.98944091796875
2016-08-10 00:00:00+00:00,315.0,315.0,307.1400146484375,308.8699951171875,308.8699951171875,1236300.0,3.333333333333333,1.0,0.5833583333333334,"There's no hiding the fact that BIIB has had management issues in the past - CEO George Scangos announced in July that he would be leaving the company once a replacement was found - but that simply makes it that much more vulnerable in the near-term. It has bounced an unbelievable 41% off its post-Brexit lows, but I think BIIB stock still has plenty of room to run higher. The winners will set themselves apart from the laggards over time, but the one name I like a lot right now is Biogen Inc (NASDAQ: BIIB ). New Article Specialty Sciences: Segmental revenues comprised royalties of $90 million received by Perrigo on net sales of Biogen Inc.'s BIIB multiple sclerosis drug Tysabri, up 7% year over year. Click to get this free report PERRIGO CO PLC (PRGO): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report CORCEPT THERAPT (CORT): Free Stock Analysis Report ANI PHARMACEUT (ANIP): Free Stock Analysis Report To read this article on Zacks.com click here. Perrigo Company plc 's PRGO second-quarter 2016 earnings of $1.93 per share fell short of the Zacks Consensus Estimate of $2.00. New Article We note that Ionis has partnership programs with companies like Biogen Inc. BIIB and GlaxoSmithKline plc GSK among others. Click to get this free report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report GERON CORP (GERN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Under its collaboration with Biogen, the company reported positive results from an interim analysis of a phase III study (ENDEAR) on nusinersen in infantile-onset (consistent with type 1) spinal muscular atrophy (SMA).",263.894287109375
2016-08-12 00:00:00+00:00,311.989990234375,315.2300109863281,311.6499938964844,313.94000244140625,313.94000244140625,993800.0,4.0,1.0,0.7500249999999999,"AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports AMGN's forecasted earnings growth in 2016 as 9.22%, compared to an industry average of 2.8%. The following ETF(s) have AMGN as a top-10 holding: iShares Nasdaq Biotechnology Index Fund ( IBB ) PowerShares Dynamic Pharmaceuticals ( PJP ) PowerShares Dynamic Biotech &Genome ( PBE ) SPDR Select Sector Fund - Health Care ( XLV ) VanEck Vectors Biotech ETF ( BBH ).",272.2927551269531
2016-08-15 00:00:00+00:00,313.3999938964844,315.0799865722656,310.010009765625,313.3900146484375,313.3900146484375,929800.0,3.0,1.0,0.5000249999999999,"MS Franchise & Cost-Cutting to Drive Growth at Biogen (BIIB) According to the covering analyst, MS franchise sales & cost-cutting efforts will continue driving Biogen's performance. Click to get this free report EXELON CORP (EXC): Free Stock Analysis Report CATERPILLAR INC (CAT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report APACHE CORP (APA): Free Stock Analysis Report To read this article on Zacks.com click here. These immediate catalysts aside, the analyst likes AstraZeneca's strong diversified portfolio, expanding presence in emerging markets, ongoing cost-cutting initiatives and robust pipeline. New Article Meanwhile, Allergan was recently in the news as being interested in acquiring biotech major Biogen, Inc. BIIB . Click to get this free report ALLERGAN PLC (AGN): Free Stock Analysis Report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report TEVA PHARM ADR (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Late last week, Allergan plcAGN announced that it will be acquiring a privately held, clinical-stage biotechnology company focused on eye care.",271.2198791503906
2016-08-16 00:00:00+00:00,313.2699890136719,316.6700134277344,312.6400146484375,313.4200134277344,313.4200134277344,946100.0,4.0,1.0,0.7500249999999999,"That said, fundamental catalysts for new drugs are also beginning to favor biotech again with PCSK9 outcomes studies, new drug launches from Regeneron ( REGN ), Amgen ( AMGN ) and Biogen ( BIIB ) possible in 2017 and key PhIII readouts for Celgene ( CELG ) and Incyte ( INCY ) in 2017,"" adds Morgan Stanely in the note posted by Barron's. In fact, the sector historically trades at multiples that are elevated relative to broader benchmarks, but in a year of struggles for biotechnology names, some analysts see value with some big-name biotech stocks. ""US biotechnology stocks have markedly pulled back and now trade in line with US and European pharmaceutical companies on price-to-forward earnings and at a slight discount on price-to-operating cash flow. New Article The Causeway Management CEO also purchased 489,263 shares of Biogen Inc. ( BIIB ) and 1,694,137 shares of PDC Energy Inc. ( PDCE ). As discussed in the fundAAAs prospectus , Ketterer prefers stocks that have low valuations and good financial strength. Additionally, Baidu has a lower price-to-book ratio than 65% of global Internet content and information companies. New Article There's already $85 million more in the bank that the company received after the close of the second quarter from partners Biogen (NASDAQ: BIIB) and Johnson & Johnson . Ionis Pharmaceuticals '(NASDAQ: IONS) earnings conference calls are usually focused on what investors can expect from upcoming releases of clinical trial data, but with top-line results in hand showing that nusinersen helps infants with spinal muscular atrophy, management shifted gears, focusing on getting nusinersen approved and onto the market. Looking forward In addition to infants with spinal muscular atrophy, Ionis and Biogen are also testing nusinersen in patients with the childhood-onset version of the disease in a trial, dubbed CHERISH.",270.8437805175781
2016-08-17 00:00:00+00:00,314.1700134277344,314.7099914550781,311.2900085449219,313.82000732421875,313.82000732421875,852600.0,3.0,1.0,0.5000249999999999,"Over the last six months, Biogen BIIB was up 22.2% while Gilead GILD lost 13.1% (See the last biotech stock roundup here: Earnings in Focus, AbbVie Takes Steps to Block Humira Copycat ). Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report AURINIA PHARMA (AUPH): Free Stock Analysis Report To read this article on Zacks.com click here. The next step is for the company to meet the FDA in the fourth quarter to discuss the next stage of clinical development (Read more: Aurinia Stock Falls on Poor Phase II Lupus Study Data ).",280.733154296875
2016-08-22 00:00:00+00:00,316.1499938964844,320.82000732421875,315.1300048828125,316.8099975585937,316.8099975585937,1317300.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of QLD, in trading today Texas Instruments Inc. (Symbol: TXN) is up about 0.4%, Charter Communications Inc (Symbol: CHTR) is down about 0.3%, and Biogen Inc (Symbol: BIIB) is up by about 0.8%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra QQQ (Symbol: QLD) where we have detected an approximate $33.8 million dollar outflow -- that's a 3.8% decrease week over week (from 10,650,000 to 10,250,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",280.533447265625
2016-08-25 00:00:00+00:00,309.0299987792969,311.9700012207031,301.0199890136719,306.8500061035156,306.8500061035156,1669800.0,3.0,1.0,0.5000249999999999,"Below is a twelve month price history chart comparing the stock performance of HCA, BIIB, and ABT: Combined, HCA, BIIB, and ABT represent 5.59% of the Guggenheim S&P 500 Equal Weight Health Care ETF. Three of RYH's underlying holdings with notable upside to their analyst target prices are HCA Holdings Inc (Symbol: HCA), Biogen Inc (Symbol: BIIB), and Abbott Laboratories (Symbol: ABT). Similarly, BIIB has 13.52% upside from the recent share price of $309.33 if the average analyst target price of $351.14/share is reached, and analysts on average are expecting ABT to reach a target price of $48.82/share, which is 13.08% above the recent price of $43.17.",280.9229431152344
2016-08-31 00:00:00+00:00,307.67999267578125,308.67999267578125,304.2200012207031,305.6300048828125,305.6300048828125,1045000.0,4.5,1.0,0.8750249999999999,"In company news, biotech company Biogen ( BIIB ) was fractionally lower in late Wednesday trading after today reporting positive early-stage trial data for its prospective Alzheimer's treatment. BIIB shares were down about 0.6% at $306.18 each in recent trade, earlier climbing to a session high of $308.88 a share. The pre-clinical animal models and Phase Ib study placebo-controlled study sought to evaluate the company's aducanumab drug candidate in patients with mild Alzheimer's symptoms, demonstrating reduced amyloid-beta levels in the brain. New Article More From InvestorPlace Biogen Inc (BIIB) Stock Is Too Much of a Coin Toss 3 Utility Stocks That Are Running Out of Juice 7 Companies That Could Go Bankrupt Soon The post Tesla Motors Inc (TSLA) Needs More Cash for Gigafactory, Model 3 appeared first on InvestorPlace . InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Tesla Motors Inc (NASDAQ: TSLA ) just announced a second round of financing to fund Model 3 production and equipment for its gigafactory, which it's hoping to complete before the Model 3 release. Source: Via Flickr The news broke via an SEC filing for the proposed merger with another Elon Musk property, SolarCity Corp (NASDAQ: SCTY ).",283.61236572265625
2016-09-02 00:00:00+00:00,311.8299865722656,318.8800048828125,308.6600036621094,313.5899963378906,313.5899963378906,2233900.0,3.333333333333333,1.0,0.5833583333333334,"VIDEO: Nasdaq 100 Movers: AVGO, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Friday, shares of Biogen ( BIIB ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.5%. And the worst performing Nasdaq 100 component thus far on the day is Broadcom ( AVGO ), trading down 2.4%. New Article In company news, Biogen ( BIIB ) rose Friday after federal regulators yesterday selected the biotech's prospective treatment for Alzheimer's disease for fast track designation. BIIB shares were up more than 2% at $312.50 apiece, earlier topping out today at $318.88 a share. The drug, Aducanumab, is currently is in phase 3 testing, with a pair of studies evaluating its safety and efficacy in slowing cognitive impairment and the progression of disability in people with early Alzheimer's disease. New Article Biogen Inc.BIIB announced that the FDA has granted Fast Track designation for its investigational therapy, aducanumab, for the treatment of early-stage Alzheimer's disease (AD). Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report To read this article on Zacks.com click here. Aducanumab is in two global phase III studies - ENGAGE and EMERGE - to evaluate its safety and efficacy in slowing cognitive impairment and progression of disability in patients suffering from early-stage AD.",280.5219421386719
2016-09-06 00:00:00+00:00,310.42999267578125,316.4700012207031,309.1199951171875,310.6700134277344,310.6700134277344,1705400.0,3.0,1.0,0.5000249999999999,"Stocks to Buy: Biogen (BIIB) Click to Enlarge Biogen Inc (NASDAQ: BIIB ) is another company entering a sustained period of strong seasonality. Shares of BIIB average 2% gains in September, 1.6% in October and 4% in November over the past decade. At the same time, chartists have to be pleased with the technicals as BIIB stock experienced a golden cross late last month. New Article More From InvestorPlace 3 Stocks to Watch Today: Monsanto (MON), Biogen (BIIB) and Navistar (NAV) 5 Stocks to Sell for September iPhone 7 Event: What You'll See, And What You Won't The post SPDR Gold Trust (ETF) (GLD) Is Ready to Rally appeared first on InvestorPlace . Click to Enlarge On the daily chart, note that the uptrend in the GLD ETF remained intact last week as the lower end of the trading channel (red dotted lines) held. Click to Enlarge So, last week's bullish reversal in the gold ETF took place at a key confluence support area in multiple time frames.",283.485107421875
2016-09-07 00:00:00+00:00,309.9599914550781,313.7200012207031,309.9599914550781,312.29998779296875,312.29998779296875,1155600.0,2.5,1.0,0.375025,"This list includes Allergan plc Ordinary Shares (NYSE: AGN ) and Biogen Inc (NASDAQ: BIIB ). According to Reuters , the investment bank in question is Morgan Stanley (NYSE: MS ), which GWPH hired to oversee a possible acquisition after the firm was contacted by M&A-hungry drugmakers. The company is hoping to treat a wider range of conditions - including oncology, type 2 diabetes, psychiatric disorders and inflammation - as it researches the therapeutic applications of more than 60 cannabinoid compounds. New Article Fast Track Status for Biogen Alzheimer's Drug Biogen's BIIB experimental treatment for early Alzheimer's disease (AD) got Fast Track status in the U.S. - the designation supports the development of new treatments for serious conditions with an unmet medical need such as Alzheimer's disease. Click to get this free report ALEXION PHARMA (ALXN): Free Stock Analysis Report DYNAVAX TECH CP (DVAX): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report SPECTRUM PHARMA (SPPI): Free Stock Analysis Report COLUCID PHARMA (CLCD): Free Stock Analysis Report To read this article on Zacks.com click here. However, shares rebounded when it became clear that the FDA action date remains unchanged - a response from the agency regarding the approval status of the candidate is expected by Dec 15, 2016.",290.7840270996094
2016-09-08 00:00:00+00:00,311.3500061035156,312.45001220703125,307.4200134277344,307.7300109863281,307.7300109863281,1482300.0,3.0,1.0,0.5000249999999999,"A closer look at Biogen 's(NASDAQ: BIIB) most exciting asset recently caught the attention of the wider public, while Gilead Sciences '(NASDAQ: GILD) hepatitis C virus (HCV) treatment sales have been sliding. The cause of Alzheimer's disease is still a matter of debate, although most investigators agree that buildup of amyloid beta plays a key role, and aducanumab appears to do a great job of removing it. Incoming competition from Merck & Co. and AbbVie has pressured Gilead's pricing power for its HCV antivirals, but healthcare providers in the U.S. are finding it increasingly difficult to restrict the pricey treatments to the sickest patients. New Article Among the largest underlying components of IXJ, in trading today Medtronic PLC (Symbol: MDT) is up about 0.3%, Eli Lilly & Co. (Symbol: LLY) is up about 1.6%, and Biogen Inc (Symbol: BIIB) is lower by about 0.3%. For a complete list of holdings, visit the IXJ Holdings page  The chart below shows the one year price performance of IXJ, versus its 200 day moving average: Looking at the chart above, IXJ's low point in its 52 week range is $89.70 per share, with $107.69 as the 52 week high point - that compares with a last trade of $101.80. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",290.7962341308594
2016-09-09 00:00:00+00:00,304.6199951171875,305.4800109863281,296.07000732421875,296.1000061035156,296.1000061035156,1976200.0,3.0,1.0,0.5000249999999999,"And the worst performing Nasdaq 100 component thus far on the day is Skyworks Solutions, trading down 3.5%. Skyworks Solutions is lower by about 10.3% looking at the year to date performance. VIDEO: Nasdaq 100 Movers: SWKS, STX The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",277.78509521484375
2016-09-12 00:00:00+00:00,294.1400146484375,303.8500061035156,293.8299865722656,302.6600036621094,302.6600036621094,1811000.0,3.0,1.0,0.5000249999999999,"In a recent teleconference, Biogen 's(NASDAQ: BIIB) chief medical officer, Alfred Sandrock, reported that the company's plague-busting antibody, called aducanumab, had been given to 165 patients, and in those who took the highest dose, it ""practically eradicated"" the amyloid plaques in their brains. Building on old failures to create new breakthroughs Dean Hartley, the director of science initiatives at the Alzheimer's Association, explained how the tides are shifting this way: ""We've started to realize that some of these treatments that have been used in clinical trials may actually be more effective if we use them earlier in the disease."" Exciting data, but a slippery problem The risks and barriers for companies working in dementia are huge -- including the fact that our ignorance about this disease is still discouragingly high.",283.6720275878906
2016-09-13 00:00:00+00:00,300.25,300.760009765625,294.739990234375,297.4100036621094,297.4100036621094,1829300.0,2.0,1.0,0.250025,"Moreover, Perrigo, which receives royalties on global sales of Biogen Inc.'s BIIB multiple sclerosis drug Tysabri, should consider divestment or explore other broader strategic alternatives including its Rx Pharmaceuticals business. Click to get this free report PERRIGO CO PLC (PRGO): Free Stock Analysis Report GERON CORP (GERN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. In a letter dated Sep 12, 2016, Starboard Managing Member, Jeffrey C. Smith, urged the Chief Executive Officer of Perrigo, John Hendrickson, and its board of directors to consider improving the company's poor operating and financial performance. New Article GILD is a part of the Health Care sector, which includes companies such as Amgen Inc. ( AMGN ) and Biogen Inc. ( BIIB ). Shareholders who purchased GILD prior to the ex-dividend date are eligible for the cash dividend payment. Zacks Investment Research reports GILD's forecasted earnings growth in 2016 as -7.67%, compared to an industry average of 4.5%.",280.5692443847656
2016-09-14 00:00:00+00:00,298.3399963378906,304.1099853515625,298.2099914550781,299.7900085449219,299.7900085449219,1534200.0,4.0,1.0,0.7500249999999999,"Among major biotech stocks, Alexion was up slightly while Biogen BIIB declined 4.3%. Click to get this free report GERON CORP (GERN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report LEXICON PHARMA (LXRX): Free Stock Analysis Report RAPTOR PHARMACT (RPTP): Free Stock Analysis Report SPECTRUM PHARMA (SPPI): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report To read this article on Zacks.com click here. The reviews were conducted by partner Janssen and the companies have decided to drop the lower dose (4.7 mg/kg) of imetelstat being evaluated in the IMbark study in myelofibrosis patients.",274.03314208984375
2016-09-15 00:00:00+00:00,300.0,304.4599914550781,298.010009765625,302.82000732421875,302.82000732421875,1271400.0,3.333333333333333,1.0,0.5833583333333334,"Shares of major biotech stocks such as Amgen, Inc. ( AMGN ) and Biogen Inc ( BIIB ) advanced 0.5% and 0.8%, respectively. Click to get this free report CHEVRON CORP (CVX): Free Stock Analysis Report EXXON MOBIL CRP (XOM): Free Stock Analysis Report APPLE INC (AAPL): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report CRACKER BARREL (CBRL): Free Stock Analysis Report FORD MOTOR CO (F): Free Stock Analysis Report MONSANTO CO-NEW (MON): Free Stock Analysis Report BAYER A G -ADR (BAYRY): Free Stock Analysis Report ALLERGAN PLC (AGN): Free Stock Analysis Report SALESFORCE.COM (CRM): Free Stock Analysis Report EQUIFAX INC (EFX): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Apple touching its highest level this year coupled with gains in biotech stocks boosted the tech-laden index. New Article Stocks to Trade for 2017: Biogen (BIIB) Click to Enlarge Biogen Inc (NASDAQ: BIIB ) is a well-run pharmaceutical company whose stock has seen tremendous volatility of late. Technically, BIIB stock is at about midpoint of its three-year range. The trade: Sell the January BIIB short strangle for a total of $5 in premium per contract. New Article (NASDAQ: AMGN ), Biogen Inc (NASDAQ: BIIB ) and Celgene Corporation (NASDAQ: CELG ) are among its top holdings. Since IBB is laced with heavy hitters in the drug space, consider it your go-to ETF for playing large caps. In contrast, the lion's share of XBI sits in biotech stocks of the mid- to micro-cap variety.",272.8247985839844
2016-09-19 00:00:00+00:00,304.8299865722656,308.0,303.1700134277344,303.5,303.5,1108300.0,3.0,1.0,0.5000249999999999,"Biogen 's(NASDAQ: BIIB) plaque-busting Alzheimer's disease (AD) drug candidate, aducanumab, could represent a jaw-dropping $20 billion peak commercial opportunity for the company and its shareholders. As an example, Eli Lilly 's(NYSE: LLY) solanezumab -- a drug not unlike aducanumab -- failed to show an improvement in cognitive ability in patients with mild to moderate Alzheimer's disease across two large late-stage studies. Given the disappointing clinical history of anti-amyloid therapies and the fact that researchers still don't fully understand the underlying causes of AD, investors should probably view this $20 billion peak sales estimate purely as a blue sky scenario. New Article Shots on goal Ionis Pharmaceuticals' clinical stage pipeline has a whopping 27 candidates in clinical-stage trials, including three rare disease drugs in phase 3 studies. Alnylam Pharmaceuticals and Ionis were in a tight race to develop treatments for nerve and heart damage associated with hereditary transthyretin amyloidosis. The above chart doesn't include the recent $75 million payment from Biogen, but Ionis is clearly in the lead when it comes to generating revenue by advancing a plethora of candidates through clinical stages.",269.145263671875
2016-09-21 00:00:00+00:00,309.0,312.3900146484375,304.1099853515625,312.0,312.0,1527600.0,3.333333333333333,1.0,0.5833583333333334,"Both its two key holdings, Biogen Inc. ( BIIB ) and Amgen Inc. ( AMGN ) advanced 1.2%. Click to get this free report TOBIRA THERAPTC (TBRA): Free Stock Analysis Report ALLERGAN PLC (AGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report EXXON MOBIL CRP (XOM): Free Stock Analysis Report FEDEX CORP (FDX): Free Stock Analysis Report PETROBRAS-ADR C (PBR): Free Stock Analysis Report KB HOME (KBH): Free Stock Analysis Report FACEBOOK INC-A (FB): Free Stock Analysis Report SONOCO PRODUCTS (SON): Free Stock Analysis Report To read this article on Zacks.com click here. Benchmarks finished slightly higher on Tuesday ahead of the two-day policy meetings of the Fed and Bank of Japan (BOJ) ending today. New Article Over the last six months, Biogen BIIB was up 22.4% while Gilead lost 9.4% (See the last biotech stock roundup here: Horizon-Raptor Acquisition Deal, Geron Down on Pipeline News ). Click to get this free report GERON CORP (GERN): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report TOBIRA THERAPTC (TBRA): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report To read this article on Zacks.com click here. The major announcement that proved to be a shot in the arm for biotech stocks was Allergan's acquisition deal with clinical-stage biopharma company, Tobira Therapeutics TBRA . New Article The top 10 holdings currently include: Amgen, Inc. (NASDAQ: AMGN ), Biogen Inc (NASDAQ: BIIB ), Celgene Corporation (NASDAQ: CELG ), Gilead Sciences, Inc. (NASDAQ: GILD ), Regeneron Pharmaceuticals Inc (NASDAQ: REGN ), Illumina, Inc. (NASDAQ: ILMN ), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ), Mylan NV (NASDAQ: MYL ), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) and Shire PLC (ADR) (NASDAQ: SHPG ). However, due to a recent investigation of the industry's alleged ""overpricing,"" its one-year market return, through August 31, fell 17.76% (Morningstar). 9 Dividend Stocks for a Full Calendar of Safe Income Yesterday, IBB broke from a one-year bear market after establishing a triple bottom that marked a nine-month consolidation.",260.2603759765625
2016-09-26 00:00:00+00:00,311.70001220703125,312.0199890136719,308.67999267578125,309.82000732421875,309.82000732421875,924200.0,2.5,1.0,0.375025,"Although BIIB has traded at a recent price of $312.58/share, the average analyst target is 12.43% higher at $351.43/share. Below is a twelve month price history chart comparing the stock performance of BIIB, INTU, and DISH: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IWL's underlying holdings with notable upside to their analyst target prices are Biogen Inc (Symbol: BIIB), Intuit Inc (Symbol: INTU), and Dish Network Corp (Symbol: DISH). New Article Among the largest underlying components of MOAT, in trading today Biogen Inc (Symbol: BIIB) is down about 0.7%, Tiffany & Co. (Symbol: TIF) is off about 1.4%, and State Street Corp. (Symbol: STT) is lower by about 1%. For a complete list of holdings, visit the MOAT Holdings page  The chart below shows the one year price performance of MOAT, versus its 200 day moving average: Looking at the chart above, MOAT's low point in its 52 week range is $25.96 per share, with $35.00 as the 52 week high point - that compares with a last trade of $33.91. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",257.48956298828125
2016-09-28 00:00:00+00:00,315.989990234375,315.989990234375,308.739990234375,310.54998779296875,310.54998779296875,1020100.0,3.5,1.0,0.6250249999999999,"What happened Tiny biotech Anavex Life Sciences (NASDAQ: AVXL) got a little bigger today after announcing that Biogen (NASDAQ: BIIB) will test the company's lead drug candidate, ANAVEX 2-73, in a preclinical assay. Biogen is likely interested in ANAVEX 2-73 as a potential treatment for multiple sclerosis, where the myelin sheath is broken down. A potential deal is further complicated by the fact that Biogen has a late-stage Alzheimer's disease drug, aducanumab, so even if Biogen wants ANAVEX 2-73 for multiple sclerosis, the larger biotech might be uninterested in paying for development of ANAVEX 2-73 in Alzheimer's disease. New Article InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Anavex Life Sciences Corp. (NASDAQ: AVXL ) is up 44% on news that Biogen Inc (NASDAQ: BIIB ) would test one of its compounds in a neurological protection model. AVXL signed onboard with Biogen to BIIB)+to+Test+Anavex+Life+Sciences+(AVXL)+Lead+Drug+Candidate+ANAVEX+2-73/12077951.html"" rel=""nofollow"">test Anavex's leading drug candidate , Anavex 2-73. According to Anavex CEO Christopher Missling: ""Battling demyelinating diseases such as multiple sclerosis requires an understanding of the processes that cause remyelination to fail. New Article This morning, Anavex Life Sciences (NASDAQ: AVXL) announced an agreement with Biogen (NASDAQ: BIIB) concerning the latter's only clinical-stage candidate, Anavex 2-73. Biogen will conduct a laboratory study with 2-73 in cultures of cells that might play a role in multiple sclerosis, and if the results are positive it will test it in animal models. The odds of it leading to a big new drug development partnership between Anavex and Biogen are extremely long. New Article However, current autoimmune juggernaut Biogen (NASDAQ: BIIB) may have a trick up its sleeve that could blow ozanimod out of the water. Among these, the biggest seller is Biogen's Tecfidera -- with worldwide sales last year coming in just shy of $4 billion -- followed by Novartis ' Gilenya and Sanofi 's rapidly growing Aubagio. In 2014, Receptos made headlines with the announcement that ozanimod (formerly called RPC1063) had met its primary endpoint in a phase 2 trial as treatment for relapsing multiple sclerosis (RMS). New Article In other sector news, (+) AVXL, Signs material transfer agreement with Biogen ( BIIB ), which will test the company's ANAVEX 2-73 drug candidate to treat demyelinating diseases such as multiple sclerosis in an oligodendrocyte precursor cell differentiation assay. The study also will seek to measure other indications of functional recovery, including hospitalization, mortality and life-threatening adverse events in addition to other post-stroke complications such as infection. (-) GALT, GR-MD-02 drug candidate fails to meet primary or secondary endpoints during Phase IIa testing in patients with nonalcoholic steatohepatitis and advanced fibrosis. New Article In other sector news, (+) AVXL, (+45.9%) Signs material transfer agreement with Biogen ( BIIB ), which will test the company's ANAVEX 2-73 drug candidate to treat demyelinating diseases such as multiple sclerosis in an oligodendrocyte precursor cell differentiation assay. Net proceeds, after first paying underwriter discounts and other offering expenses, will fund the company's ongoing and future clinical trials of its somavaratan long-acting form of recombinant human growth hormone. (-) GALT, (-45.0%) GR-MD-02 drug candidate fails to meet primary or secondary endpoints during Phase IIa testing in patients with nonalcoholic steatohepatitis and advanced fibrosis.",255.98728942871094
2016-10-05 00:00:00+00:00,313.2699890136719,313.32000732421875,308.6000061035156,309.70001220703125,309.70001220703125,977300.0,2.0,1.0,0.250025,"Recently, Anavex Life Sciences Corp. (NASDAQ: AVXL) inked an an agreement with Biogen (NASDAQ: BIIB) , joining the ranks of several high-profile drug developers with Biogen partnerships, including Ionis Pharmaceuticals Inc. (NASDAQ: IONS) . Following positive phase 3 results that suggest nusinersen could become the first approved treatment for spinal muscular atrophy, Biogen agreed to pick up the tab for developing and commercializing the drug going forward, triggering a $75 million payment to Ionis in the process. Not a big deal Anavex Life Sciences has sponsored one mid-stage trial with its only clinical-stage candidate, 2-73 for treatment of Alzheimer's disease, and its market cap of just $138 million at recent prices reflects its limited pipeline.",262.85626220703125
2016-10-07 00:00:00+00:00,307.3099975585937,308.0,302.2099914550781,305.5899963378906,305.5899963378906,1526000.0,3.333333333333333,1.0,0.5833583333333334,"On that date, Ionis and its licensing partner Biogen (NASDAQ: BIIB) announced that nusinersen met the primary endpoint in a pre-specified interim analysis of ENDEAR for infantile-onset SMA. What happened Shares of Ionis Pharmaceuticals (NASDAQ: IONS) , a biopharmaceutical company that utilizes its proprietary antisense drug development platform to tackle a variety of disorders, rocketed higher by 24% during the month of September, according to S&P Global Market Intelligence . On top of its NDA filing with the FDA, Biogen is preparing to submit a marketing authorization application with the European Medicines Agency (EMA) in a few weeks. New Article A well-known name in the multiple sclerosis market, Biogen Inc. ( BIIB ) made it to our list of the likely Q3 outperformers, thanks to its Zacks Rank #3 and 2.20% Earnings ESP. Click to get this free report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report BRISTOL-MYERS (BMY): Free Stock Analysis Report UTD THERAPEUTIC (UTHR): Free Stock Analysis Report EXACT SCIENCES (EXAS): Free Stock Analysis Report To read this article on Zacks.com click here. Generic drug maker Mylan N.V. drew flak from lawmakers for over-pricing its epinephrine auto-injector, EpiPen (severe allergic reactions) around the end of Aug 2016. New Article Especially high volume was seen for the $295 strike put option expiring April 21, 2017 , with 750 contracts trading so far today, representing approximately 75,000 underlying shares of BIIB. Below is a chart showing SRPT's trailing twelve month trading history, with the $40 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 6,060 contracts, representing approximately 606,000 underlying shares or approximately 46% of BIIB's average daily trading volume over the past month, of 1.3 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $295 strike highlighted in orange: For the various different available expirations for NLNK options , SRPT options , or BIIB options , visit StockOptionsChannel.com.",255.7075958251953
2016-10-10 00:00:00+00:00,308.0,308.70001220703125,304.2699890136719,304.5899963378906,304.5899963378906,987200.0,2.0,1.0,0.250025,"While these two companies have not competed in the past, Celgene has announced its intention to move into the highly lucrative MS space with its 2014 purchase of small biotech Receptos and its anti-inflammatory drug ozanimod. Receptos made headlines in 2014 with its announcement that ozanimod had met its primary endpoint in a phase 2 trial as a treatment for relapsing multiple sclerosis (RMS) with potentially best in class safety and a once-daily oral dosing. Ozanimod's two Phase III multiple sclerosis trials are expected to read out in the first half of 2017, with the potential to support an approval the following year.",250.36973571777344
2016-10-11 00:00:00+00:00,304.1300048828125,304.5199890136719,296.32000732421875,298.29998779296875,298.29998779296875,1494600.0,4.0,1.0,0.7500249999999999,"Megadeal expectations Biogen (NASDAQ: BIIB) ranked second on the Evercore ISI survey of biotechs most likely to be acquired, with 12% of respondents voting for the company. Rare-disease pick The Evercore ISI survey identified BioMarin Pharmaceutical (NASDAQ: BMRN) as the third most likely biotech buyout over the next year. BioMarin anticipates filing for regulatory approval of pegvaliase, which targets treatment of rare genetic blood disease phenylketonuria (PKU), in fourth-quarter 2016 or first-quarter 2017. New Article I think Amgen (NASDAQ: AMGN) , Biogen (NASDAQ: BIIB) , and Celgene (NASDAQ: CELG) stand at the top of the list. Those drugs are now past their glory days, but the big biotech's product lineup includes enough horsepower to continue fueling steady revenue and earnings growth. Although Repatha got off to a slower start than anticipated due partly to payer pushback on pricing, the drug should still become a big winner for Amgen.",248.94357299804688
2016-10-12 00:00:00+00:00,298.2900085449219,299.1199951171875,291.489990234375,291.8800048828125,291.8800048828125,1823700.0,2.0,1.0,0.250025,"Over the last six months, Biogen BIIB was up 12.5% while Gilead lost 22.9% (See the last biotech stock roundup here: Summit Soars on Sarepta Deal, Regeneron Presents Data ). Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report ALNYLAM PHARMA (ALNY): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report TESARO INC (TSRO): Free Stock Analysis Report CLOVIS ONCOLOGY (CLVS): Free Stock Analysis Report SAREPTA THERAP (SRPT): Free Stock Analysis Report To read this article on Zacks.com click here. Alnylam said that the discontinuation of revusiran will not affect its other RNAi programs including patisiran, currently in late-stage development for the treatment of hATTR amyloidosis with polyneuropathy (hATTR-PN).",240.28802490234375
2016-10-13 00:00:00+00:00,289.19000244140625,296.6199951171875,288.9100036621094,294.4100036621094,294.4100036621094,1571600.0,3.0,1.0,0.5000249999999999,"The fund added to health care names Biogen ( BIIB ) and Edwards Lifesciences ( EW ) as well as consumer cyclical Alibaba Group ( BABA ) in recent portfolio reports. That's the challenge facing John Wilson, Peter Deininger and Tchintcia Barros, managers of $3.3 billion Columbia Large Cap Growth Fund ( GEGTX ). That could make it harder to execute their investment game plan: Find stocks whose earnings growth, they forecast with conviction, will be a lot stronger than most investors expect.",244.4955596923828
2016-10-14 00:00:00+00:00,295.6300048828125,297.3399963378906,290.1300048828125,290.5,290.5,1149800.0,2.5,1.0,0.375025,"Current prescribed treatments for hemophilia A include Biogen Inc.'s BIIB Eloctate and Shire plc's SHPG Adynovate among others. Click to get this free report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report INCYTE CORP (INCY): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report SHIRE PLC-ADR (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. BioMarin Pharmaceutical Inc.BMRN announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the resumption of enrollment in the open-label phase I/II study on its pipeline candidate, BMN 270, which is an experimental gene therapy being evaluated for the treatment of severe hemophilia A. New Article If nusinersen is already available when AveXis is ready to submit an AVXS-101 application, there's little chance the FDA would stretch its limited resources to speed along a second SMA treatment. In 111-patient phase 3 trial, infants receiving nusinersen showed a highly significant improvement over the placebo group in activities such as kicking their feet, crawling, and standing. Ionis Pharmaceuticals has little to worry about with nusinersen's position on the development timeline, a risk-reducing partnership with Biogen, and plenty of other shots on goal .",247.97682189941406
2016-10-17 00:00:00+00:00,289.8900146484375,293.4200134277344,288.25,291.6700134277344,291.6700134277344,1209700.0,4.0,1.0,0.7500249999999999,"Wall Street, after all, thinks that a core AD medication could haul in a monstrous $20 billion in sales by 2030 , given that over 5 million Americans already suffer from this debilitating disease, combined with the fact that there are no disease-modifying treatments available right now. A major drugmaker is quietly rebuilding its Alzheimer's pipeline After experiencing its own failure with the once-promising anti-amyloid therapy bapineuzumab that was being co-developed with J&J, Pfizer (NYSE: PFE) took a step back from this hotly pursued indication, presumably to rethink its strategy moving forward. The heart of the matter is that an effective disease modifying treatment may require something along the lines of an anti-amyloid agent, another compound that slows the reformation of plaques, and still another to treat downstream events such as neurofibrillary tangles.",253.74844360351562
2016-10-18 00:00:00+00:00,292.8699951171875,298.57000732421875,292.6300048828125,295.04998779296875,295.04998779296875,1153100.0,3.5,1.0,0.6250249999999999,"If you had bought shares of Biogen (NASDAQ: BIIB) five years ago and held on to the stock, your initial amount would have nearly tripled. The biotech doesn't appear to be throwing in the towel on the drug yet, however, and is reportedly continuing to analyze the data in an effort to move forward with development. Gilead's blockbuster hepatitis C drug Harvoni has lost much of its luster, with sales experiencing big declines compared to 2015. New Article Investors eyeing a purchase of Biogen Inc (Symbol: BIIB) shares, but tentative about paying the going market price of $294.96/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to BIIB's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. For other put options contract ideas at the various different available expirations, visit the BIIB Stock Options page of StockOptionsChannel.com.",258.68731689453125
2016-10-19 00:00:00+00:00,296.260009765625,296.5400085449219,292.489990234375,295.1400146484375,295.1400146484375,988200.0,3.5,1.0,0.6250249999999999,"Among the largest underlying components of QUAL, in trading today Public Service Enterprise Group Inc (Symbol: PEG) is down about 0.7%, Costco Wholesale Corp (Symbol: COST) is up about 0.8%, and Biogen Inc (Symbol: BIIB) is lower by about 0.2%. For a complete list of holdings, visit the QUAL Holdings page  The chart below shows the one year price performance of QUAL, versus its 200 day moving average: Looking at the chart above, QUAL's low point in its 52 week range is $57.86 per share, with $68.72 as the 52 week high point - that compares with a last trade of $66.64. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Stocks That Should Be Bought Out: Biogen (BIIB) Source: Biogen via YouTube Potential Buyers: Allergan, Merck The healthcare sector is certainly ripe for consolidation as the industry has been struggling under the weight of a changing landscape, public scrutiny and tougher regulations. Worries about the growth prospects of Biogen Inc (NASDAQ: BIIB ), as competition from rival firms increases, have brought the firm's share price down in 2016, making now a good time for Big Pharma companies to consider a takeover. BIIB is by no means small, but big names like Allergan plc Ordinary Shares (NYSE: AGN ) and Merck & Co., Inc. (NYSE: MRK ) might have the financial strength to make such a large purchase.",261.55902099609375
2016-10-20 00:00:00+00:00,293.8500061035156,300.32000732421875,293.7699890136719,299.6600036621094,299.6600036621094,1323700.0,4.0,1.0,0.7500249999999999,"Biogen Inc.BIIB , a well-known name in the multiple sclerosis (MS) market, will be reporting third-quarter 2016 earnings on Oct 26, before market open.Last quarter, the company delivered a positive earnings surprise of 11.09%. Click to get this free report NOVARTIS AG-ADR (NVS): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Factors to Consider Since the emergence of the first progressive multifocal leukoencephalopathy (PML)-related death in a patient on oral MS drug, Tecfidera, investor focus has been on its performance.",252.8330535888672
2016-10-21 00:00:00+00:00,299.07000732421875,299.07000732421875,289.7799987792969,290.6499938964844,290.6499938964844,1567500.0,4.0,1.0,0.7500249999999999,"The 35 stock holdings in this exchange traded fund include Biogen ( BIIB ), Amgen ( AMGN ), Celgene ( CELG ), Gilead Sciences ( GILD ) and Regeneron (REGN). Its portfolio includes Sarepta Therapeutics (SRPT), whose shares rocketed in September after the FDA approved its drug to treat Duchenne muscular dystrophy. Biotechnology ETFs crumbled over the past year, coming under pressure from lackluster earnings as well as negative scrutiny for health care peers Valeant Pharmaceuticals (VRX) and Mylan (MYL) in a politically charged season.",247.42544555664062
2016-10-25 00:00:00+00:00,290.8399963378906,291.0799865722656,285.2699890136719,286.0,286.0,1838300.0,3.5,1.0,0.6250249999999999,"Biogen Inc. ( BIIB ) is reporting for the quarter ending September 30, 2016. In the past year BIIB has beat the expectations every quarter. Zacks Investment Research reports that the 2016 Price to Earnings ratio for BIIB is 14.49 vs. an industry ratio of -1.20, implying that they will have a higher earnings growth than their competitors in the same industry. New Article Multiple sclerosis (MS) market leader Biogen Inc.BIIB is scheduled to report results before the opening bell. Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report MEDICINES CO (MDCO): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ANIKA THERAPEUT (ANIK): Free Stock Analysis Report EXACT SCIENCES (EXAS): Free Stock Analysis Report To read this article on Zacks.com click here. With Q3 earnings picking up pace, approximately 116 S&P 500 members (representing 23.2% of the index's total market capitalization) have already reported quarterly results as of Oct 21.",250.30531311035156
2016-10-26 00:00:00+00:00,294.9800109863281,301.3399963378906,291.29998779296875,296.4599914550781,296.4599914550781,2660100.0,3.0,1.0,0.5000249999999999,"Stocks were defensive at Wednesday's open with disappointing Q3 Apple iPhone sales weighing on the benchmark averages and overshadowing upbeat results from Dow component stock Boeing ( BA ), along with Coca-Cola ( KO ), Biogen ( BIIB ) and Comcast ( CMCSA ). Fueled by a rebound in oil futures, the Dow Jones Industrial Average has erased its early losses and was now trading in the plus column. Shares got a small boost after the open from upbeat economic data that included a 5.2% decline in the U.S.'s trade deficit in goods, a 3.1% increase in new home sales, and a better-than-expected improvement in the preliminary October PMI services sector index to 54.8 from 52.3 in September. New Article Over the last six months, Biogen BIIB was up 0.4% while Gilead lost 27.3% (See the last biotech stock roundup here: ARIAD Down on Drug Pricing Tweet, Regeneron Study on Clinical Hold ). Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report ALKERMES INC (ALKS): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report INOVIO PHARMAC (INO): Free Stock Analysis Report ADURO BIOTECH (ADRO): Free Stock Analysis Report To read this article on Zacks.com click here. The FDA has asked the company to provide additional data supporting the shelf-life of the newly designed and manufactured disposable parts of the Cellectra 5PSP immunotherapy delivery device. New Article Cambridge, MA-based Biogen Inc.BIIB one of the world's leading biotechnology companies, focuses on therapeutic areas including neurology, immunology and hemophilia. BIIB has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 11.39%. BIOGEN INC Price and EPS Surprise BIOGEN INC Price and EPS Surprise | BIOGEN INC Quote Currently, BIIB has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. New Article Two other components making moves today are American Airlines Group ( AAL ), trading down 2.3%, and Biogen ( BIIB ), trading up 4.9% on the day. In early trading on Wednesday, shares of Akamai Technologies ( AKAM ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 14.3%. And the worst performing Nasdaq 100 component thus far on the day is Apple ( AAPL ), trading down 3.9%. New Article Wall Street was expecting BIIB to report revenue of $2.90 billion for the third quarter of the year. InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen Inc (NASDAQ: BIIB ) saw its stock increase on Wednesday following the release of its earnings report for the third quarter of 2016. BIIB reported net income of $1.14 billion during the third quarter of 2016.",246.90367126464844
2016-10-27 00:00:00+00:00,298.0,300.7799987792969,290.510009765625,290.8900146484375,290.8900146484375,1554300.0,3.5,1.0,0.6250249999999999,"Among other pharma companies that reported this week, Biogen Inc BIIB and Merck & Co., Inc MRK beat the estimates for both earnings and sales. Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report VERTEX PHARM (VRTX): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report IMMUNOGEN INC (IMGN): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Vertex Pharmaceuticals Incorporated VRTX also reported results earlier this week - though the company missed estimates, its pipeline update on its next generation correctors brought some relief. New Article Given the dampening U.S. market for multiple sclerosis drugs -- Biogen 's(NASDAQ: BIIB) bread and butter -- the biotech's third-quarter earnings release on Wednesday was about as good as investors could have hoped for. Biogen's newest multiple sclerosis drug Tecfidera continues to be the growth driver, with a 10% year-over-year increase in sales. In August, Biogen and partner Ionis Pharmaceuticals (NASDAQ: IONS) announced that a clinical trial testing nusinersen in spinal muscular atrophy was stopped early because it was clear the drug was working. New Article Biotech company, Biogen Inc.BIIB , known for its strong position in the multiple sclerosis (MS) market, reported third quarter 2016 results before the market opened yesterday with both earnings and revenues surpassing expectations (Read more: Biogen Beats on Q3 Earnings; Tecfidera Propels Sales ). Click to get this free report LILLY ELI & CO (LLY): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Nusinersen represents significant commercial opportunity given the lack of available treatments for patients with spinal muscular atrophy, a leading genetic cause of death in infants. New Article Biogen (NASDAQ: BIIB) is planning to spin off its hemophilia drug business to investors early in 2017, and given that third-quarter earnings show demand for Eloctate and Alprolix are at record highs, the potential to get shares in this new company, Bioverativ, may be a good reason to add Biogen stock to portfolios. Swedish Orphan Biovitrum AB, or Sobi, commercializes the two drugs globally outside the United States, Japan, Canada, and Australia, and it will pay Bioverativ royalties on sales in those markets amounting to the mid-teens of millions. Since Bioverativ is launching with two fast-growing drugs, cash, and little or no debt, it should have plenty of financial flexibility to fund research and development that could help it compete against larger peers in the future, including Baxalta, which was recently acquired by Shire .",257.23895263671875
2016-10-28 00:00:00+00:00,290.2900085449219,290.4700012207031,280.3399963378906,283.6400146484375,283.6400146484375,1884500.0,2.6,1.0,0.400025,"The iShares Nasdaq Biotechnology Index (ETF) (NASDAQ: IBB ) is dropping, led by biotechs such as Biogen Inc (NASDAQ: BIIB ) and Gilead Sciences, Inc. (NASDAQ: GILD ), both off more than 3%. Now, I want to sell mid-term risk on this massive drop in VRX stock to generate income. Click to Enlarge This drop in Valeant stock today is an industry-wide move, in large part sparked by bad news from supplier McKesson Corporation (NYSE: MCK ), which predicted a bad year amid increasing scrutiny of drug prices . New Article The FDA is currently reviewing an application for nusinersen, a drug discovered by Ionis Pharmaceuticals and developed with help from Biogen (NASDAQ: BIIB) , which showed a significant benefit in infants with the most severe form of the disease. GlaxoSmithKline has since decided to wait for results from a late-stage trial in patients at risk of nerve damage, which represents a small percentage of the total population with transthyretin amyloidosis. With $587 million in working capital at the end of June, and nusinersen-related payments from Biogen probably around the corner, Ionis has a solid chance of reaching profitability without diluting shareholders or taking on more debt. New Article Among the largest underlying components of QUAL, in trading today Public Service Enterprise Group Inc (Symbol: PEG) is down about 0.1%, Costco Wholesale Corp (Symbol: COST) is off about 0.5%, and Biogen Inc (Symbol: BIIB) is lower by about 1.7%. For a complete list of holdings, visit the QUAL Holdings page  The chart below shows the one year price performance of QUAL, versus its 200 day moving average: Looking at the chart above, QUAL's low point in its 52 week range is $57.86 per share, with $68.72 as the 52 week high point - that compares with a last trade of $66.27. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Stocks recently featured in the blog include Biogen Inc (NASDAQ: BIIB - Free Report ), Merck & Co., Inc (NYSE: MRK - Free Report ), Eli Lilly and Company (NYSE: LLY - Free Report ), AbbVie Inc.(NYSE: ABBV - Free Report) and ImmunoGen, Inc.(NASDAQ: IMGN - Free Report) . Among other pharma companies that reported this week, Biogen Inc (NASDAQ: BIIB - Free Report ) and Merck & Co., Inc (NYSE: MRK - Free Report ) beat the estimates for both earnings and sales. Get the full Report on BIIB - FREE Get the full Report on MRK - FREE Get the full Report on LLY - FREE Get the full Report on ABBV - FREE Get the full Report on IMGN - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. New Article Ampyra is marketed in ex-U.S. markets under the trade name Fampyra by Biogen Inc. BIIB . Click to get this free report GERON CORP (GERN): Free Stock Analysis Report BIOMARIN PHARMA (BMRN): Free Stock Analysis Report ACORDA THERAPT (ACOR): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. R&D expenses are still expected in the range of $195-$205 million due to the addition of tozadenant to the company's pipeline.",257.0091857910156
2016-11-02 00:00:00+00:00,282.3099975585937,282.3099975585937,277.0899963378906,277.260009765625,277.260009765625,1081900.0,3.0,1.0,0.5000249999999999,"Read on to see why they choose Biogen (NASDAQ: BIIB) , Xencor (NASDAQ: XNCR) , and bluebird bio (NASDAQ: BLUE) . Although the company has repeatedly been the target of buyout rumors in the past, the forthcoming retirement of long-standing CEO George Scangos -- combined with big pharma's seemingly insatiable appetite for mergers and acquisitions of late -- may finally pave the way for a deal. According to Lilly's third-quarter results, the data-collection phase of solanezumab's late-stage trial for patients with mild Alzheimer's disease has officially wrapped up, setting the stage for pivotal data release by December at the latest.",263.0517578125
2016-11-03 00:00:00+00:00,277.6499938964844,278.57000732421875,272.9800109863281,273.489990234375,273.489990234375,1407900.0,2.0,1.0,0.250025,"In trading on Thursday, shares of Biogen Inc (Symbol: BIIB) crossed below their 200 day moving average of $276.66, changing hands as low as $275.56 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $223.02 per share, with $333.65 as the 52 week high point - that compares with a last trade of $277.00. According to the ETF Finder at ETF Channel, BIIB makes up 7.33% of the iShares Nasdaq Biotechnology ETF (Symbol: IBB) which is trading lower by about 0.9% on the day Thursday.",252.72564697265625
2016-11-07 00:00:00+00:00,290.6400146484375,297.2699890136719,289.2300109863281,295.6199951171875,295.6199951171875,2190000.0,3.0,1.0,0.5000249999999999,"What happened Ionis Pharmaceuticals (NASDAQ: IONS) is up 20.8% at noon EST, after announcing with its partner Biogen (NASDAQ: BIIB) that their spinal muscular atrophy (SMA) drug nusinersen, which now goes by the branded name Spinraza, passed another phase 3 trial. The results come from an interim look at the data, which caused the study to be stopped early because it was clear the drug was working. Specifically, over the 15 months patients took Spinraza, they had a mean improvement of 4.0 points on a test that measures different functional motor skills. New Article Biogen Inc (NASDAQ: BIIB ) and Ionis Pharmaceuticals disclosed that SPINRAZA has met the primary endpoint at interim analysis of Phase 3 CHERISH study. Top Headline LendingClub Corp (NYSE: LC ) reported a smaller loss than analysts estimated for the third quarter. Equities Trading DOWN Concordia International Corp (NASDAQ: CXRX ) shares dropped 36 percent to $2.03 after the company reported downbeat results for its third quarter. New Article VIDEO: Nasdaq 100 Movers: LVNTA, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Monday, shares of Biogen ( BIIB ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 5.9%. And the worst performing Nasdaq 100 component thus far on the day is Liberty Ventures ( LVNTA ), trading down 5.2%. New Article Biogen Inc (NASDAQ: BIIB ) and Ionis Pharmaceuticals disclosed that SPINRAZA has met the primary endpoint at interim analysis of Phase 3 CHERISH study. Shares of Cempra Inc (NASDAQ: CEMP ) got a boost, shooting up 19 percent to $8.95 after the company disclosed that the U.S. Food and Drug Administration Advisory Committee voted that efficacy results of its solithromycin outweigh the risks for community-acquired bacterial pneumonia. Equities Trading DOWN Concordia International Corp (NASDAQ: CXRX ) shares dropped 34 percent to $2.10 after the company reported downbeat results for its third quarter. New Article Currently, Molina serves 550,000 marketplace members, making it one of the 10 largest ACA insurers, and management is lobbying for ""modification and adjustment, not wholesale change"" to Obamacare, suggesting it sees the program as a long-term opportunity for upside. Overall, Molina's potential to benefit from rising enrollment in government-facilitated health insurance programs means it's stock is worth considering this month, depending on the election's outcome. However, for those of you with a long time horizon and a vision for Ionis' potentially game-changing drug-development platform, this could be an attractive entry point, with its stock down 29% over the trailing month. New Article For Immediate Release Chicago, IL - November 07, 2016 - Today, Zacks Equity Research discusses the Pharmaceuticals, Part 2, including Bristol-Myers(NYSE: BMY - Free Report ) , Biogen(NASDAQ: BIIB - Free Report ),Merck & Co., Inc.(NYSE: MRK - Free Report ), Celgene Corporation(NASDAQ: CELG - Free Report ) and ARIAD Pharmaceuticals Inc.(NASDAQ: ARIA - Free Report ) . Companies like J&J, Merck, Biogen(NASDAQ: BIIB - Free Report ), Celgene and Bristol-Myers have in fact topped earnings estimates in all three quarters of 2016. Get the full Report on BMY - FREE Get the full Report on BIIB - FREE Get the full Report on MRK - FREE Get the full Report on CELG - FREE Get the full Report on ARIA - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. New Article (+) NILE (+33.90%) To be acquired by Bain Capital and Bow Street for $40.75 per share (+) N (+20.67%) Oracle ( ORCL ) moving ahead with $9.3 billion acquisition with receipt of 21.8 million unaffiliated NetSuite shares (+) IONS (+18.39%) Investigational treatment for spinal muscular atrophy with Biogen ( BIIB ) showed highly statistically significant improvement in motor function (+) DTLK (+18.13%) To be acquired by Insight Enterprises ( NSIT ) for $11.25 per share Risk-averse investors breathed a sigh of relief and poured back into equity assets when the FBI said late Sunday that there was no evidence of wrongdoing in an another batch of emails unearthed from Democratic presidential candidate Hillary Clinton. With Clinton viewed as the presidential candidate least likely to roil financial markets, the Dow rallied nearly 400 points, and the S&P 500 snapped a nine-day losing streak that last occurred 36 years ago with an outsized gain of more than 2%.",241.5640106201172
2016-11-08 00:00:00+00:00,295.20001220703125,299.07000732421875,292.54998779296875,295.6000061035156,295.6000061035156,1031000.0,3.4,1.0,0.600025,"At Holdings Channel , we have reviewed the latest batch of the 20 most recent 13F filings for the 09/30/2016 reporting period, and noticed that Biogen Inc (Symbol: BIIB) was held by 8 of these funds. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the sum total across groups of funds from one reporting period to another can be a lot more revealing and relevant, providing interesting stock ideas that merit further research, like Biogen Inc (Symbol: BIIB). Below, let's take a look at the change in BIIB positions, for this latest batch of 13F filers: In terms of shares owned, we count 3 of the above funds having decreased their positions from 06/30/2016 to 09/30/2016, with 3 new positions. New Article Ionis' agreements with leading health care companies like GlaxoSmithKline plc GSK and Biogen Inc. BIIB continue to validate its antisense technology and provide the company with funds in the form of upfront, milestone and other payments. Click to get this free report GLAXOSMITHKLINE (GSK): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report COHERUS BIOSC (CHRS): Free Stock Analysis Report JUNO THERAPEUTC (JUNO): Free Stock Analysis Report IMPAX LABORATRS (IPXL): Free Stock Analysis Report MYLAN NV (MYL): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. It's nearing the closing bell of the third-quarter 2016 earnings season with approximately 423 S&P 500 members (representing 84.6% of the index's total market capitalization) having reported quarterly results as of Nov 4. New Article While the cause of this underlying relationship isn't altogether clear, the fact remains that size is important when it comes to revenue growth rates. Turning to the specifics, Biogen and its partner Ionis Pharmaceuticals (NASDAQ: IONS) recently announced that the FDA and the European Medicines Agency both agreed to review the regulatory applications for Spinraza (nusinersen) -- a candidate to treat infantile onset spinal muscular atrophy, or SMA -- on an accelerated time line. And, longer term, Spinraza could drive Biogen's annual revenues upward by high single digits -- even after accounting for the milestone and royalty payments owed to Ionis. New Article  Shares of LendingClub Corp ( LC ) surged 15.2% after the company reported third quarter loss per share of $0.04, lower than the Zacks Consensus Estimate was a loss of $0.10  Shares of Sothebys ( BID ) soared 11.2% after the company's revenues in the latest quarter came in at $91.5 million, above analysts' forecasts of $82 million  Biogen Inc.'s ( BIIB ) shares gained 6.7% after the biotech company and Ionis Pharmaceuticals Inc ( IONS ) said that their Phase 3 trial of spinal muscular atrophy drug met its primary endpoint Want the latest recommendations from Zacks Investment Research? Click to get this free report BERKSHIRE HTH-B (BRK.B): Free Stock Analysis Report LENDINGCLUB CP (LC): Free Stock Analysis Report SOTHEBYS (BID): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report To read this article on Zacks.com click here.  Shares of Berkshire Hathaway Inc. ( BRK.B ) gained 2.8% after the company posted third quarter earnings per share of $1.97 that beat the Zacks Consensus Estimate of $1.88. New Article Yesterday, Biogen Inc. BIIB and partner Ionis Pharmaceuticals, Inc. IONS saw their shares soar on positive interim data from a late-stage study on Spinraza, their investigational treatment for spinal muscular atrophy (SMA). Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report CYTOKINETCS INC (CYTK): Free Stock Analysis Report PTC THERAPEUTIC (PTCT): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report AVEXIS INC (AVXS): Free Stock Analysis Report To read this article on Zacks.com click here. Spinraza has blockbuster potential given the lack of FDA approved treatments in the market and enjoys oprhan drug status in both the U.S. and the EU.",243.26235961914062
2016-11-09 00:00:00+00:00,312.0,328.9800109863281,309.67999267578125,319.8599853515625,319.8599853515625,4271700.0,3.0,1.0,0.5000249999999999,"The company's top-line growth was mostly thanks to $96.9 million in licensing fees paid by Biogen (NASDAQ: BIIB) that's related to nusinersen's development. What happened After updating investors on its third-quarter performance this morning, and in the wake of the U.S. presidential election, shares in Ionis Pharmaceuticals (NASDAQ: IONS) are soaring 25% higher at 1:30 p.m. EST. So what Ionis Pharma boasts one of the largest clinical-stage pipelines in biotechnology, and recently, the company's shares have benefited from positive trial results for nusinersen, a therapy that could win FDA approval next year for use in patients diagnosed with spinal muscular atrophy, or SMA. New Article Biotech stocks to buy There are likely to be a lot of ups and downs in biotech as Trump formalizes his healthcare plan, but I think his election is ultimately bullish for biotech stock investors -- especially investors focusing on big market cap biotech stocks, including Gilead Sciences (NASDAQ: GILD) , Celgene Corp. (NASDAQ: CELG) , and Biogen Inc. (NASDAQ: BIIB) . Pros and cons Repealing Obamacare is one of Trump's biggest policy positions, and if he follows through with his plans to dismantle the Affordable Care Act, it will have both good and bad implications for biotech stocks. The enrollment of millions of Americans in private and public insurance plans since Obamacare's inception has undeniably increased prescription volume and boosted revenue at drug companies.",235.89187622070312
2016-11-10 00:00:00+00:00,321.95001220703125,329.8299865722656,319.489990234375,324.3999938964844,324.3999938964844,2665700.0,3.25,1.0,0.5625249999999999,"Among the largest underlying components of XLV, in trading today Johnson & Johnson (Symbol: JNJ) is off about 0.6%, Gilead Sciences, Inc. (Symbol: GILD) is up about 0.3%, and Biogen Inc (Symbol: BIIB) is higher by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $427.7 million dollar inflow -- that's a 3.6% increase week over week in outstanding units (from 167,465,324 to 173,515,324). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Specialty Sciences: Segmental revenues comprised royalties of $93 million received by Perrigo on net sales of Biogen Inc.'s BIIB multiple sclerosis drug Tysabri, up 10% (11% on a constant-currency basis) year over year. Click to get this free report MORGAN STANLEY (MS): Get Free Report PERRIGO CO PLC (PRGO): Get Free Report BIOGEN INC (BIIB): Get Free Report ANIKA THERAPEUT (ANIK): Get Free Report To read this article on Zacks.com click here. FindTheCompany | Graphiq Including amortization and restructuring charges and other one-time items, Perrigo incurred a loss of $8.76 per share in the third quarter of 2016. New Article Biotech Stocks to Buy: Biogen (BIIB) Click to Enlarge Biogen Inc (NASDAQ: BIIB ) is our last biotech stock to buy under the new Trump presidency. Outside political coups, Biogen's recent earnings surprise confirmed BIIB is a name to own based on its solid mix of value and growth. Further, and not hurting investors chances, recent merger overtures from the likes of Merck & Co., Inc. (NYSE: MRK ) and Allergan plc Ordinary Shares (NYSE: AGN ) should provide an additional backstop for BIIB stock investors. New Article Biogen Inc BIIB , Merck & Co., Inc MRK and Amgen Inc. AMGN beat estimates for both earnings and sales. Click to get this free report PFIZER INC (PFE): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report AMGEN INC (AMGN): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report RECRO PHARMA (REPH): Free Stock Analysis Report XBIOTECH INC (XBIT): Free Stock Analysis Report To read this article on Zacks.com click here. The proportion of companies beating both earnings and revenue estimates are modestly tracking above historical periods, though not remarkably.",236.65933227539062
2016-11-11 00:00:00+00:00,320.2900085449219,322.6400146484375,314.4700012207031,319.17999267578125,319.17999267578125,1619500.0,4.0,1.0,0.7500249999999999,"Revenue increased mostly due to Biogen (NASDAQ: BIIB) licensing Spinraza, which earned Ionis $85 million. Ionis Pharmaceuticals (NASDAQ: IONS) reported third-quarter earnings on Wednesday, but investors are rightfully focused on the pending approval of Spinraza for spinal muscular atrophy (SMA) and its progressing pipeline. Last week, Ionis disclosed data from a phase 2 trial testing IONIS-FXIRx in patients with end-stage renal disease, which showed that the drug lowered Factor XI activity, which can predict a reduction in blood clots. New Article AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports AMGN's forecasted earnings growth in 2016 as 11%, compared to an industry average of 2.4%. For more information on the declaration, record and payment dates, visit the AMGN Dividend History page.",234.51014709472656
2016-11-15 00:00:00+00:00,321.54998779296875,323.1499938964844,314.6099853515625,322.5799865722656,322.5799865722656,1685100.0,5.0,1.0,1.000025,"Two of the biggest biotechs around, Biogen (NASDAQ: BIIB) and Celgene (NASDAQ: CELG) , are now enjoying nice runs. Biogen and partner Ionis announced great results from late-stage studies of the experimental drug in treating spinal muscular atrophy. Cancer drug Abraxane isn't generating significant sales growth but should still pull in close to $1 billion this year.",227.69931030273438
2016-11-17 00:00:00+00:00,318.2300109863281,320.239990234375,315.3500061035156,319.29998779296875,319.29998779296875,1459500.0,3.0,1.0,0.5000249999999999,"Stocks recently featured in the blog include Biogen (NASDAQ: BIIB - Free Report ), Honda (NYSE: HMC - Free Report ), Intel (NASDAQ: INTC - Free Report ), CSX Corp. (NASDAQ: CSX - Free Report ) and General Growth Properties (NYSE: GGP - Free Report ). Here are highlights from Wednesday's Analyst Blog: Top Research Reports for Today: INTC, HMC, BIIB Today's Research Daily features new research reports on 16 major stocks, including Biogen (NASDAQ: BIIB - Free Report ), Honda (NYSE: HMC - Free Report ) and Intel (NASDAQ: INTC - Free Report ). Get the full Report on BIIB - FREE Get the full Report on HMC - FREE Get the full Report on INTC - FREE Get the full Report on CSX - FREE Get the full Report on GGP - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. New Article BIIB dominates the drug treatment space for multiple sclerosis, a very challenging condition by which an individual loses muscle control because central nervous tissue hardens in the brain and spinal cord. Next Page Beaten-Down Biotech Stocks to Buy: Biogen Inc (BIIB) Source: Biogen via YouTube Shares of Biogen Inc (NASDAQ: BIIB ) have rallied back toward their 52-week highs since the election, but still represent one of the more compelling investment opportunities in biotech. At a forward price-to-earnings of only 15, BIIB looks to offer a great combination of growth at a reasonable investing entry point.",222.1452178955078
2016-11-21 00:00:00+00:00,318.3599853515625,320.3099975585937,316.5199890136719,318.32000732421875,318.32000732421875,1331100.0,3.0,1.0,0.5000249999999999,"Five companies appear to be poised to potentially dominate this market: AstraZeneca (NYSE: AZN) , Biogen (NASDAQ: BIIB) , Lilly (NYSE: LLY) , Merck (NYSE: MRK) , and Roche (NASDAQOTH: RHHBY) . There's such an intense demand for effective treatments that research and consulting firm GlobalData projects the market for Alzheimer's disease drugs could top $13 billion by 2023. The company recently announced positive findings from an early-stage study of the drug, with patients at the highest dosage of verubecestat experiencing an 84% reduction in amyloid beta. New Article Biogen (NASDAQ: BIIB) appears less expensive than Johnson & Johnson on every front. Wall Street analysts think Biogen will grow earnings at nearly 9% annually over the next few years -- again, well above expectations for J&J. But here's why you should ignore the election: Investing geniuses Tom and David Gardner have spent a long time beating the market no matter who's in the White House.",211.1456756591797
2016-11-22 00:00:00+00:00,320.7900085449219,321.0,314.0199890136719,318.1099853515625,318.1099853515625,1522200.0,2.6666666666666665,1.0,0.4166916666666666,"Biogen (NASDAQ: BIIB) and Gilead Sciences (NASDAQ: GILD) have both entered the phase of their life cycle where it becomes popular to essentially buy revenue by cutting deals for so-called bolt-on acquisitions. In a nutshell, Biogen's top line is anemic relative to both the entire field of revenue generating biopharmas, as well as within its immediate peer group in terms of market cap. During its third-quarter conference call, for instance, Biogen's management didn't lay out any specific plans to broaden its product portfolio via a large acquisition -- beyond saying that the company remains interested in doing deals while its ongoing search for CEO George Scangos' successor progresses. New Article Put Celgene (NASDAQ: CELG) , Biogen (NASDAQ: BIIB) , and Regeneron (NASDAQ: REGN) at the top of the list. Regeneron and partner Sanofi (NYSE: SNY) expect results from a major cardiovascular outcomes study to be announced by early 2018. As a Celgene shareholder, though, I'd be perfectly happy if the company chose instead to buy some smaller biotechs that increase earnings growth even more than projected. New Article BIIB data by YCharts . The fly in Biogen's ointment, though, is that numerous companies are attempting to cut into the biotech's overwhelming share of the MS drug market at the moment, and its clinical efforts to defend its territory have run into multiple setbacks over the past year. Moreover, BioMarin is easily one of the top orphan drug companies in the world with five products on the market and a rich clinical pipeline that sports potential blockbusters like vosoritide for achondroplasia (a form of short-limbed dwarfism).",211.0749969482422
2016-11-23 00:00:00+00:00,293.82000732421875,308.8800048828125,293.79998779296875,305.92999267578125,305.92999267578125,5377500.0,2.5,1.0,0.375025,"In a highly disappointing yet not all-too-surprising news release earlier today, Eli Lilly & Company (NYSE: LLY) says that its late-stage drug solanezumab failed to improve cognition in patients diagnosed with mild to moderate Alzheimer's disease. Biogen is developing aducanumab, a human recombinant monoclonal antibody that it hopes can reduce beta amyloid in the brain, while Axovant is researching intepirdine, a 5-HT6 receptor antagonist, to be used in combination with the blockbuster Alzheimer's disease therapy Aricept. Eli Lilly's failure adds doubt to the validity of targeting beta amyloid plaques, and a phase 3 trial of another 5-HT6 receptor antagonist, idalopirdine, that was conducted by Lundbeck A/S failed to pan out earlier this year. New Article Aducanumab from Biogen (NASDAQ: BIIB) works along the same lines and is in the middle of a big, expensive late-stage study with data expected in 2020. Long-awaited results from a late-stage study showed patients with mild Alzheimer's Disease-related dementia didn't experience a significant benefit when treated with solanezumab versus a placebo. The drug candidate was supposed to slow the rate of cognitive decline by reducing amyloid beta, which are protein fragments that clump together into plaques considered by many to be the root cause of the disease. New Article Biogen Inc. ( BIIB ) had the largest percent change down (-3.83%) while BioMarin Pharmaceutical Inc. ( BMRN ) had the largest percent change gain rising 3.13%. The NASDAQ 100 index closed down -.41% for the day; a total of -19.98 points. The Dow Jones index closed up .31% for the day; a total of 59.31 points. New Article Biogen Inc. ( BIIB ) is -28.11 at $290.00, with 304,772 shares traded. As reported by Zacks, the current mean recommendation for BIIB is in the ""buy range"". The following are the most active stocks for the pre-market session : Eli Lilly and Company ( LLY ) is -10.22 at $65.77, with 3,698,726 shares traded. New Article Image source: Getty Images What happened Shares of Biogen (NASDAQ: BIIB) were down more than 4% in early afternoon trading on Wednesday in response to Eli Lilly (NYSE: LLY) reporting disappointing news about a late-stage clinical trial involving an experimental Alzheimer's disease drug. So what Eli Lilly's EXPEDITION3 trial was testing its experimental compound solanezumab as a treatment for mild dementia due to Alzheimer's disease. A substance called amyloid plaque that accumulates in the brains of patients with Alzheimer's has been hypothesized to lead to the disease's progression. New Article Biogen Inc (NASDAQ: BIIB ) was down to the tune of 5% when the presumed benefit of attacking amyloid plaque was called into question. What was not made clear by the company is the degree to which solanezumab removed amyloid plaque in the so-called Expedition III trial. Had the Eli Lilly study showed an improvement in cognitive function without the reduction of amyloid plaque, a question would have been answered. New Article Biogen Inc. ( BIIB ) is -24.26 at $293.85, with 786,038 shares traded. As reported by Zacks, the current mean recommendation for BIIB is in the ""buy range"". The following are the most active stocks for the pre-market session : Eli Lilly and Company ( LLY ) is -11.69 at $64.30, with 6,253,901 shares traded. New Article Successful launch of Spinraza Ionis and partner Biogen (NASDAQ: BIIB) recently announced great results for Spinraza in treating spinal muscular atrophy. The company should announce additional results in the first half of next year from a late-stage study of volanesorsen in treating familial chylomicronemia syndrome (FCS), a rare disease that causes extremely high triglyceride levels. A third phase 3 study of the experimental drug targeting treatment of another rare genetic disorder, familial partial lipodystrophy (FPS), is expected to wrap up in the third quarter of 2017.",201.5556640625
2016-11-25 00:00:00+00:00,306.4599914550781,307.1499938964844,302.3900146484375,305.20001220703125,305.20001220703125,740900.0,1.0,1.0,2.4999999999997247e-05,"Biogen Inc. BIIB was one the companies that felt the immediate impact of the solanezumab data. Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report JOHNSON & JOHNS (JNJ): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AXOVANT SCIENC (AXON): Free Stock Analysis Report To read this article on Zacks.com click here. Eli Lilly and Company'sLLY shares tumbled 10.5% following the release of highly-awaited data on its experimental Alzheimer's disease (AD) treatment, solanezumab, from a late-stage study.",203.58859252929688
2016-11-29 00:00:00+00:00,304.7300109863281,307.4200134277344,302.5299987792969,302.7699890136719,302.7699890136719,1389500.0,2.0,1.0,0.250025,"This Could Send Facebook Inc (FB) Stock to the Guillotine The post Charles Payne on Biotech: Biogen Inc (BIIB), Intercept Pharmaceuticals Inc (ICPT) appeared first on InvestorPlace . Today, I want to talk about the potential within the biotechnology space - specifically as it concerns Gilead Sciences, Inc. (NASDAQ: GILD ), Biogen Inc (NASDAQ: BIIB ) and Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) Source: Pixelbay (Modified) Not surprisingly, there are both winners and losers from a Trump presidency. BIIB: Biogen is one of the pioneers in biotechnology.",212.6018829345703
2016-11-30 00:00:00+00:00,303.3399963378906,304.29998779296875,293.95001220703125,294.07000732421875,294.07000732421875,2164900.0,2.5,1.0,0.375025,"If you're looking for top stocks to gain exposure to the high-growth biotech space, Biogen Inc. (NASDAQ: BIIB) and Amgen (NASDAQ: AMGN) are both solid picks. Now, the good news is that Biogen and its partner Ionis Pharmaceuticals seem to have a strong case to push the FDA to grant a broad label for their experimental spinal muscular atrophy drug, Spinraza, next year. In contrast, Amgen recently launched Repatha for high cholesterol, and Kyprolis for relapsed or refractory multiple myeloma, and both are expected to generate over $2 billion each in peak sales for the company within a few short years. New Article Among major biotech stocks, Alexion was up 7.3% while Biogen BIIB declined 4.8% on concerns regarding its Alzheimer's disease treatment following the failure of Lilly's investigational Alzheimer's disease treatment (Read more: Will Lilly's Solanezumab Setback Weigh on Other Alzheimer's Stocks? Click to get this free report AMGEN INC (AMGN): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report MOMENTA PHARMA (MNTA): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report AMICUS THERAPT (FOLD): Free Stock Analysis Report JUNO THERAPEUTC (JUNO): Free Stock Analysis Report ARIAD PHARMA (ARIA): Free Stock Analysis Report To read this article on Zacks.com click here. Based on discussions with the FDA, the company said that it needs to collect additional data on gastrointestinal (GI) symptoms in Fabry patients who have an amenable mutation.",207.15760803222656
2016-12-01 00:00:00+00:00,296.32000732421875,296.6499938964844,293.1099853515625,295.7799987792969,295.7799987792969,1684800.0,2.0,1.0,0.250025,"Biogen Inc. BIIB has an Earnings ESP of +1.20%. Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report AVEO PHARMACEUT (AVEO): Free Stock Analysis Report GW PHARMA-ADR (GWPH): Free Stock Analysis Report CLOVIS ONCOLOGY (CLVS): Free Stock Analysis Report To read this article on Zacks.com click here. Factors at Play GW Pharma's key growth driver is Sativex, which is approved outside the U.S. for the treatment of spasticity due to multiple sclerosis.",212.2987060546875
2016-12-02 00:00:00+00:00,296.5299987792969,299.95001220703125,293.0400085449219,297.19000244140625,297.19000244140625,1429400.0,3.0,1.0,0.5000249999999999,"For example, the two largest holdings (Celgene ( CELG ) and Biogen ( BIIB )) have only underperformed the broader market (as measured by the S&P 500) slightly over the last year. If you are a long-term contrarian investor, it may make sense to consider some of the individual stocks within the ETF because you don't have to pay the 0.47% annual expense ratio. From a valuation standpoint, Boeing is not unreasonable considering its price-to-earnings ratio (both trailing twelve months and forward) is within the historical range. New Article Baidu Inc. ( BIDU ) and several biotech companies, including Biogen Inc. ( BIIB ) and Novo Nordisk A/S (NVO), also trade below their median P/S valuation and near their minimum P/S valuation. As of Dec. -, Open Text Corp. (OTEX), AmTrust Financial Services Inc. (AFSI) and Allegiant Travel Co. ( ALGT ) trade at least 6% below their DCF earnings fair value. Based on this chart, more companies trading in Asia and Canada made Buffett and Munger's list of stocks, suggesting that these global markets offer good defensive investment opportunities.",221.98507690429688
2016-12-06 00:00:00+00:00,291.75,294.45001220703125,290.0,291.1600036621094,291.1600036621094,1572600.0,3.5,1.0,0.6250249999999999,"Large-cap biotech Biogen (NASDAQ: BIIB) is somewhat of an oddball in that it's currently experiencing a rapid deceleration in revenue growth, yet Wall Street analysts are suggesting that its shares could still rise by a healthy 13.7% over the next year. That's a critical issue because Biogen's top-selling MS drug Tecfidera has been experiencing a hefty drop-off in sales in the U.S., and the company arguably can't continue to rely on price increases to drive growth indefinitely. While the Street seems extremely confident that Spinraza is destined to grab a broad label for SMA early next year, the U.S. Food and Drug Administration (FDA) has been known to surprise everyone on a fairly regular basis. New Article Since earning FDA approval in 2005, Celgene built its blood cancer drug, Revlimid, into a multibillion-dollar foundation upon which it's laying bricks for blazing long-term growth. Ionis' partner, Biogen , recently submitted applications for the first-ever treatment for the leading genetic cause of infant mortality in the U.S., spinal muscular atrophy. It has reported annual adjusted earnings growth for 32 consecutive years, and it's one of just two publicly traded companies with a pristine triple-A debt rating.",221.2285919189453
2016-12-07 00:00:00+00:00,285.5,288.9700012207031,280.5,285.29998779296875,285.29998779296875,1967400.0,2.0,1.0,0.250025,"In trading on Wednesday, shares of Biogen Inc (Symbol: BIIB) crossed below their 200 day moving average of $281.48, changing hands as low as $281.09 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $223.02 per share, with $333.65 as the 52 week high point - that compares with a last trade of $282.41. According to the ETF Finder at ETF Channel, BIIB makes up 7.32% of the iShares Nasdaq Biotechnology ETF (Symbol: IBB) which is trading lower by about 4.2% on the day Wednesday.",216.38601684570312
2016-12-08 00:00:00+00:00,285.79998779296875,292.9700012207031,278.5799865722656,289.5400085449219,289.5400085449219,4771300.0,2.5,1.0,0.375025,"With its marketing partner Biogen (NASDAQ: BIIB) , Ionis has shown that their joint drug, nusinersen, which will go by the brand name Spinraza, helps children with both early- and late-onset spinal muscular atrophy. The marketing application is already under review by the U.S. Food and Drug Administration and by European regulators, and given the unmet need, Biogen should receive an approval in both places shortly. Kite Pharma has multiple CAR and TCR products in development, using the same basic technology with different target proteins expressed in different types of tumors. New Article Technically speaking, BIIB is testing zone support from the 200-day simple moving average, a bullish gap tied to positive spinal drug trial results and the 50% retracement level. InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips It has been nearly a month and for Biogen Inc (NASDAQ: BIIB ) and the biotech sector, it has been a period of ""Trump & Dump."" Now it's ""time"" to take advantage of value both off and on the price chart with ""the art of the steal"" using a limited-risk, bullish trade in BIIB.",214.10069274902344
2016-12-09 00:00:00+00:00,305.239990234375,306.9800109863281,281.7900085449219,287.7699890136719,287.7699890136719,6257700.0,3.8333333333333335,1.0,0.7083583333333334,"VIDEO: S&P 500 Movers: GRMN, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Friday, shares of Biogen ( BIIB ) topped the list of the day's best performing components of the S&P 500 index, trading up 5.1%. And the worst performing S&P 500 component thus far on the day is Garmin ( GRMN ), trading down 2.5%. New Article Biogen Inc. ( BIIB ) is +11.61 at $301.15, with 127,766 shares traded. As reported by Zacks, the current mean recommendation for BIIB is in the ""buy range"". The following are the most active stocks for the pre-market session : Stillwater Mining Company ( SWC ) is +2.92 at $17.60, with 965,523 shares traded. New Article VIDEO: Nasdaq 100 Movers: LRCX, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Friday, shares of Biogen ( BIIB ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 5.5%. And the worst performing Nasdaq 100 component thus far on the day is Lam Research ( LRCX ), trading down 2.2%. New Article In health-care stocks news, Biogen ( BIIB ) and AbbVie ( ABBV ) said that Canadian health authorities had approved Zinbryta for adult patients with active relapsing remitting multiple sclerosis who inadequately responded to or are unable to tolerate therapies indicated for treating multiple sclerosis. Top Health-care stocks: JNJ: flat Health-care shares were mainly unchanged in pre-market trade on Friday. New Article Whether you buy the Biotech ETF IBB or stock in a couple of market leaders such as Biogen (BIIB), Celgene (CELG) and Pfizer (PFE), the discounts available in pharma and biotech look too good to miss. Once the election was over his talk of a wall shifted from the physical to the metaphorical, locking up Hillary Clinton became less of a priority, and even parts of Obamacare started to look like keepers. The very pro-business look of his cabinet nominations so far, with CEOs rather than politicians filling many key posts, make it unlikely that those around him will be counseling federally mandated price controls for any companies, pharma or not. New Article Key stocks from this sector including Celgene Corporation ( CELG ), Biogen Inc. ( BIIB ) and Regeneron Pharmaceuticals, Inc. ( REGN ) gained 0.4%, 1.5% and 2%, respectively. Click to get this free report GOLDMAN SACHS (GS): Free Stock Analysis Report MORGAN STANLEY (MS): Free Stock Analysis Report BANK OF AMER CP (BAC): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report HUMANA INC NEW (HUM): Free Stock Analysis Report NCI BLDG SYSTEM (NCS): Free Stock Analysis Report To read this article on Zacks.com click here. This along with continued broad based rally following Trump's victory in the Presidential election led financial stocks to emerge as the top gainer among broader sectors.",223.83811950683594
2016-12-12 00:00:00+00:00,289.20001220703125,290.95001220703125,284.07000732421875,286.489990234375,286.489990234375,1776200.0,3.0,1.0,0.5000249999999999,"Biogen Inc. BIIB is also developing an antibody treatment targeting beta amyloid, aducanumab, which is being evaluated in two phase III studies in early AD. Click to get this free report ASTRAZENECA PLC (AZN): Free Stock Analysis Report PFIZER INC (PFE): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Alzheimer's disease has attracted a lot of attention of late given that the market represents huge commercial potential and a successfully developed product could generate billions of dollars in sales once launched. New Article Yet, the reward can be even bigger when drugmakers get it right, and that's particularly evident at United Therapeutics (NASDAQ: UTHR) , Gilead Sciences (NASDAQ: GILD) , and Biogen Inc. (NASDAQ: BIIB) , each of which boasts the best operating margins in the business. During United Therapeutics' third-quarter conference call, management warned that drugs advancing into larger, more costly phase 3 trials will cause its research and development spending to tick higher. The company's sales from drugs targeting these two indications total in the billions of dollars per quarter, and despite tough competition in HIV from ViiV Healthcare and in hepatitis C from AbbVie , Gilead Sciences continues to pass through big money to the bottom line. New Article Last week, Biogen Inc.BIIB presented positive data from a phase I study (PRIME) on its anti-amyloid treatments in development, aducanumab, at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in San Diego. Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ASTRAZENECA PLC (AZN): Free Stock Analysis Report LILLY ELI & CO (LLY): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Last month, Eli Lilly and Company LLY announced that its high-profile investigational Alzheimer's disease drug, solanezumab, has failed to meet the primary endpoint in a late-stage study.",234.7755584716797
2016-12-13 00:00:00+00:00,286.75,289.5,284.8099975585937,287.3800048828125,287.3800048828125,1596200.0,3.0,1.0,0.5000249999999999,"The biotech blue bloods Amgen (NASDAQ: AMGN) , Biogen (NASDAQ: BIIB) , and Gilead Sciences (NASDAQ: GILD) , for instance, are all trading well below their 52-week highs, perhaps creating a golden opportunity to buy these top stocks at a discount. The first headwind is that the biotech's traditional growth drivers, such as the anemia medication Epogen and the white blood cell boosters Neupogen and Neulasta, have been getting hammered in recent quarters because of greater competition. The bright side, however, is that Biogen and its partner Ionis Pharmaceuticals have a fairly good shot at grabbing broad regulatory approval for their experimental spinal muscular atrophy (SMA) drug Spinraza (nusinersen) in early 2017. New Article The iShares Nasdaq Biotechnology Index (ETF) (NASDAQ: IBB ) is down about 10% since Nov. 11; other quality companies like Biogen Inc (NASDAQ: BIIB ) are also down significantly in the past few weeks. Luckily, the options markets offer me hundreds of ways I can trade shares with limited risk exposure. The 7 WORST Stocks to Buy for 2017 The trade: Sell the VRX Apr $7.50/$5 credit put spread for 33 cents per contract.",237.7162628173828
2016-12-14 00:00:00+00:00,288.2099914550781,289.9599914550781,285.239990234375,286.25,286.25,1299300.0,2.5,1.0,0.375025,"Stocks recently featured in the blog include Barclays (NYSE: BCS - Free Report ), Netflix (NASDAQ: NFLX - Free Report ), NIKE (NYSE: NKE - Free Report ), Biogen (NASDAQ: BIIB - Free Report ) and China Petroleum & Chemical (NYSE: SNP - Free Report ). Other noteworthy reports we are featuring today include Biogen (NASDAQ: BIIB - Free Report ) and China Petroleum & Chemical (NYSE: SNP - Free Report ). Get the full Report on BCS - FREE Get the full Report on NFLX - FREE Get the full Report on NKE - FREE Get the full Report on BIIB - FREE Get the full Report on SNP - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. New Article Over the last six months, Biogen BIIB was up 13.9% while Alexion lost 17.5% (See the last biotech stock roundup here: Actelion Remains in M&A Spotlight, ASH Data in Focus ). Click to get this free report ALEXION PHARMA (ALXN): Free Stock Analysis Report REGENERON PHARM (REGN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ACHOGEN INC (AKAO): Free Stock Analysis Report HORIZON PHARMA (HZNP): Free Stock Analysis Report OPHTHOTECH CORP (OPHT): Free Stock Analysis Report To read this article on Zacks.com click here. The candidate achieved the primary endpoint of non-inferiority (for the FDA) and superiority (for the European Medicines Agency - EMA) compared to meropenem in patients with complicated urinary tract infections (cUTI) and acute pyelonephritis (AP).",240.1624298095703
2016-12-16 00:00:00+00:00,287.6199951171875,289.0899963378906,286.0,286.3999938964844,286.3999938964844,2273200.0,2.0,1.0,0.250025,"Among the largest underlying components of OEF, in trading today Walgreens Boots Alliance Inc (Symbol: WBA) is up about 1.2%, Time Warner Inc (Symbol: TWX) is up about 0.1%, and Biogen Inc (Symbol: BIIB) is up by about 0.6%. For a complete list of holdings, visit the OEF Holdings page  The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $81.14 per share, with $101.26 as the 52 week high point - that compares with a last trade of $100.79. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",229.72140502929688
2016-12-20 00:00:00+00:00,280.9800109863281,286.6700134277344,279.1300048828125,285.5899963378906,285.5899963378906,2219600.0,3.333333333333333,1.0,0.5833583333333334,"It's looking like 2016 will turn out to be disappointing for Biogen (NASDAQ: BIIB) shareholders. An early-stage study evaluating BIIB074 in treating chronic facial pain disorder trigeminal neuralgia wraps up in February 2017. Bioverativ spin-off In May, Biogen announced plans to spin off its hemophilia business as an independent, publicly traded company by early 2017. New Article Several companies made headlines to kickoff the second half of December, including Biogen Inc (NASDAQ: BIIB ), Conatus Pharmaceuticals Inc (NASDAQ: CNAT ) and General Motors Company (NYSE: GM ). Here's how they did: Biogen Inc (BIIB) Biogen has made a major management change . BIIB shares fell 0.1% after the bell Monday. New Article Biogen Inc.BIIB has appointed its present chief commercial officer (CCO), Michel Vounatsos, as the new chief executive officer (CEO), effective Jan 6, 2017. Click to get this free report ALLERGAN PLC (AGN): Free Stock Analysis Report MERCK & CO INC (MRK): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. However, investors speculate that the appointment of Vounatsos lowers chances of a buyout This in turn, has led to the decline in the company's share price.",233.63848876953125
2016-12-21 00:00:00+00:00,285.0599975585937,285.6499938964844,281.0,283.1099853515625,283.1099853515625,1377800.0,2.0,1.0,0.250025,"Biogen Announces New CEO, Approves Hemophilia Spin-Off: Biogen BIIB announced the appointment of its Executive Vice President and Chief Commercial Officer, Michel Vounatsos, as the new Chief Executive Officer (CEO) and member of the Board of Directors, effective Jan 6, 2017. Click to get this free report ALEXION PHARMA (ALXN): Free Stock Analysis Report GILEAD SCIENCES (GILD): Free Stock Analysis Report ACTELION LTD (ALIOF): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report TESARO INC (TSRO): Free Stock Analysis Report CLOVIS ONCOLOGY (CLVS): Free Stock Analysis Report CONATUS PHARMA (CNAT): Free Stock Analysis Report To read this article on Zacks.com click here. Conatus CNAT is ending the year on a high note with the company signing a lucrative deal with Swiss pharma giant, Novartis. New Article Neurology has always been a difficult field, but this one was unusually nerve-wracking for Eli LIlly & Co. (NYSE: LLY) , and Biogen (NASDAQ: BIIB) . Compared with biotech start-ups with nothing to sell but their own shares, bigger players with profitable operations tend to emerge from clinical trial failures relatively unscathed. Bristol-Myers Squibb's tale of hubris took a dark turn because it measured Opdivo against standard chemotherapy in newly diagnosed lung cancer patients expressing PD-L1 on just 5% or more of their tumor cells. New Article Biogen Inc.BIIB announced that its board of directors has approved the spin-off of its hemophilia business into a new company Bioverativ Inc. A look at Biogen' year-to-date share price movement shows that the company has underperformed the Zacks classified Large Cap Pharmaceutical industry. Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report To read this article on Zacks.com click here. Note that Biogen has declared a special dividend distribution of all of the outstanding shares of Bioverativ common stock.",238.10122680664062
2016-12-27 00:00:00+00:00,295.1700134277344,296.3800048828125,290.75,291.1199951171875,291.1199951171875,1453100.0,3.0,1.0,0.5000249999999999,"Ionis Pharmaceuticals, Inc.IONS and Biogen Inc. BIIB announced that the FDA has approved Spinraza (nusinersen), an antisense drug, for the treatment of spinal muscular atrophy (SMA). Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report HESKA CORP (HSKA): Free Stock Analysis Report VANDA PHARMACT (VNDA): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Note that Ionis' year-to-date share price movement shows that the company has outperformed the Zacks classified Medical-Drugs industry. New Article AbbVie already faces indirect competition in Europe from Biogen 's(NASDAQ: BIIB) biosimilars, as well as Enbrel and Remicade. Sales for hepatitis C virus (HCV) drug Viekira are already falling in the U.S. AbbVie attributed this decline primarily to the entrance of a new competitor. The company is fully aware of the potential threat from acalabrutinib and is moving to quickly advance Imbruvica into other indications to stay ahead of AstraZeneca. New Article Spinraza was developed through a collaboration with Biogen ( BIIB ), who also holds the license for future development, manufacturing and commercialization of the drug. BIIB shares also were higher, rising about 1.4% at $291.61 each after advancing as high as $296.38 a share this morning. In company news, Ionis Pharmaceuticals ( IONS ) advanced Tuesday after the U.S. Food and Drug Administration late Friday approved the company's Spinraza drug candidate for the treatment of spinal muscular atrophy in children and adults. New Article Biogen (NASDAQ: BIIB) won European regulatory approval in January for Benepali, a biosimilar to Enbrel. Pfizer is already seeing big sales declines for its array of products that have recently lost or are about to lose patent exclusivity, particularly Lyrica and Celebrex. Exelixis (NASDAQ: EXEL) announced clinical results in October for its kidney cancer drug Cabometyx in a head-to-head comparison with Sutent.",228.1620330810547
2016-12-28 00:00:00+00:00,291.989990234375,292.1099853515625,288.5,289.25,289.25,1036200.0,2.75,1.0,0.437525,"Biogen BIIB and Ionis IONS got an early Christmas gift with the FDA approving their spinal muscular atrophy (SMA) treatment Spinraza three months within the filing of the regulatory application. Click to get this free report VERTEX PHARM (VRTX): Free Stock Analysis Report CELGENE CORP (CELG): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report SEATTLE GENETIC (SGEN): Free Stock Analysis Report ANTHERA PHARMA (ANTH): Free Stock Analysis Report SYNERGY PHARMAC (SGYP): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. With the drug being the first treatment to be approved for SMA, a leading genetic cause of death in infants and toddlers that is marked by progressive, debilitating muscle weakness, the market potential is huge. New Article Among the largest underlying components of QUAL, in trading today Kimberly-Clark Corp. (Symbol: KMB) is trading flat, Public Service Enterprise Group Inc (Symbol: PEG) is up about 0.1%, and Biogen Inc (Symbol: BIIB) is lower by about 0.3%. For a complete list of holdings, visit the QUAL Holdings page  The chart below shows the one year price performance of QUAL, versus its 200 day moving average: Looking at the chart above, QUAL's low point in its 52 week range is $57.86 per share, with $70.50 as the 52 week high point - that compares with a last trade of $69.60. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article The approval made Ionis eligible to receive a $60 million milestone payment from marketing partner Biogen (NASDAQ: BIIB) and could open the door to further gains in the future, but investors apparently decided that the company had climbed far enough in a short period of time. Many stocks gave back some of their recent gains from the post-election rally, and Twilio (NYSE: TWLO) , Northern Dynasty Minerals (NYSEMKT: NAK) , and Ionis Pharmaceuticals (NASDAQ: IONS) were among the worst performers on the day. Many investors heralded the fact that the company had expanded its relationship with Amazon and its web services unit, pointing to the success of its partner as potentially carrying over to support Twilio's own growth. New Article Last Friday, Christmas came early for Biogen (NASDAQ: BIIB) and Ionis Pharmaceuticals (NASDAQ: IONS) with the FDA approval of their spinal muscular atrophy (SMA) drug Spinraza (nusinersen). Although this disease is rare, with a U.S. incidence rate of 1 in 10,000 live births, it is the leading genetic cause of death in infants, and prior to Spinraza's approval it lacked any form of effective pharmaceutical intervention. So based on the prevailing trends for other orphan drugs on the market -- and admittedly, there is a lot of play in these figures -- we can expect something along the lines of 40% of all SMA patients in the U.S. to be correctly diagnosed, and around 90% of this sub-group to eventually receive pharmaceutical intervention in the form of Spinraza.",231.4048309326172
2016-12-30 00:00:00+00:00,287.7900085449219,288.5599975585937,282.6400146484375,283.5799865722656,283.5799865722656,1327200.0,3.0,1.0,0.5000249999999999,"Some partners include Roche (Venclexta - oncology), Biogen Inc. BIIB (Zinbryta - multiple sclerosis), Bristol-Myers Squibb Company BMY (Empliciti - multiple myeloma), Ablynx (vobarilizumab - inflammatory diseases including rheumatoid arthritis and systemic lupus erythematosus) and Boehringer Ingelheim (risankizumab - immunology) among others. Click to get this free report BRISTOL-MYERS (BMY): Free Stock Analysis Report ABBOTT LABS (ABT): Free Stock Analysis Report BIOGEN INC (BIIB): Free Stock Analysis Report ABBVIE INC (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. North Chicago, IL-based AbbVie Inc.ABBV came into existence on Jan 1, 2013, after Abbott Laboratories ABT divested its pharmaceutical division.",232.98910522460938
2017-01-03 00:00:00+00:00,285.82000732421875,293.20001220703125,284.8599853515625,291.7099914550781,291.7099914550781,1763400.0,2.0,1.0,0.250025,"In December, Biogen (NASDAQ: BIIB) reported updated phase 1b results for aducanumab showing that, at the 54-week mark, there was a statistically significant reduction of amyloid plaque compared to placebo, and a slowing in disease progression versus placebo. Big mistake number two I also predicted that investors would realize they were under-valuing clinical stage drug developer Portola Pharmaceuticals (NASDAQ: PTLA) , and send its shares higher. As a refresher, Portola Pharmaceuticals entered 2016 expecting an FDA decision on AndexXa, which, if approved, would be the first reversal agent available for factor Xa anticoagulants that are rapidly displacing warfarin.",232.42327880859375
2017-01-04 00:00:00+00:00,291.5899963378906,296.8299865722656,290.0400085449219,294.04998779296875,294.04998779296875,1273500.0,2.0,1.0,0.250025,"However, with the news that Biogen (NASDAQ: BIIB) quietly discontinued future development of their experimental anti-inflammatory and autoimmune product MT-1303, did Biogen just wave the white flag to Celgene (NASDAQ: CELG) ? During Biogen's Q3earnings call Michael D. Ehlers, Executive Vice-President of Research and Development, cited the regulatory competitive landscape and strategic priorities as primary drivers of this decision. While Biogen has discontinued future development of MT-1303, this does not mean that the current king of multiple sclerosis has decided to altogether halt its pursuit of new MS treatments. New Article Yesterday, Biogen (NASDAQ: BIIB) and its partner Ionis Pharmaceuticals (NASDAQ: IONS) announced that their newly approved spinal muscular atrophy (SMA) drug Spinraza will sport an initial WAC price of $125,000 per vial. However, most countries lack a formal legal definition for this particular subcategory of rare diseases, giving drug companies ample leeway to price novel orphan therapies at their own discretion. While the biotech is counting on Spinraza's strong efficacy profile to push payers into covering this life-saving drug, recent history shows that this strategy doesn't always work.",233.65187072753906
2017-01-05 00:00:00+00:00,294.8099975585937,296.32000732421875,292.2200012207031,293.57000732421875,293.57000732421875,1318600.0,3.0,1.0,0.5000249999999999,"The company has a collaboration agreement with Biogen Inc. BIIB for Spinraza. Click to get this free report BIOGEN INC (BIIB): Free Stock Analysis Report CAMBREX CORP (CBM): Free Stock Analysis Report IONIS PHARMACT (IONS): Free Stock Analysis Report ARBUTUS BIOPH (ABUS): Free Stock Analysis Report To read this article on Zacks.com click here. Results from the study revealed that IONIS-GCGRrx demonstrated statistically significant improvements in hemoglobin A1c (HbA1c) and other measures of glucose control at 26 weeks. New Article Among the largest underlying components of IYH, in trading today Celgene Corp. (Symbol: CELG) is down about 0.7%, Biogen Inc (Symbol: BIIB) is off about 0.1%, and Aetna Inc. (Symbol: AET) is up by about 1.6%. For a complete list of holdings, visit the IYH Holdings page  The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $129.10 per share, with $157.77 as the 52 week high point - that compares with a last trade of $147.05. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Of course, for Spinraza, which Biogen (NASDAQ: BIIB) and Ionis recently got approved for spinal muscular atrophy, side effects aren't an issue because there aren't any other treatment options at the moment. Ionis Pharmaceuticals (NASDAQ: IONS) gave investors an update on its pipeline today with a slide deck that contained a whopping 65 entries. As noted on the slide, Ionis and Biogen are exploring a Ligand Conjugated Antisense (LICA) strategy to target a drug directly to the muscle, which should increase the potency.",239.83758544921875
2017-01-06 00:00:00+00:00,294.5899963378906,296.4100036621094,292.3900146484375,295.0,295.0,1082500.0,3.0,1.0,0.5000249999999999,"Biogen Inc. BIIB exercised its option to enter into an exclusive, global license agreement with California-based private biotechnology company, Amunix Operating Inc., to incorporate the latter's proprietary XTEN half-life extension technology in developing a recombinant Factor IX candidate. Click to get this free report Arena Pharmaceuticals, Inc. (ARNA): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report Cambrex Corporation (CBM): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen's share price has gained 3.4% in the past one year compared with the Zacks classified Medical-Biomedical and Genetics industry's fall of 17.3%. New Article Biogen (NASDAQ: BIIB) named Michel Vounatsos as CEO on Dec. 19, 2016. Important stuff Even though the Goldman Sachs analyst moderating the discussion probably felt like he was trying to nail Jello to the wall, I wasn't too concerned about Vounatsos' vague and meandering responses to those questions. When asked about Biogen's plan to accelerate enrollment in the phase 3 study of Alzheimer's disease candidate aducanumab, Vounatsos mentioned two specific items. New Article A handful of biotechs showed up in my crystal ball: Incyte (NASDAQ: INCY) , Biogen (NASDAQ: BIIB) , Biomarin (NASDAQ: BMRN) , Gilead Sciences (NASDAQ: GILD) , and Illumina (NASDAQ: ILMN) . Top acquisition favorites don't get bought A few months ago, the good folks at investment bank Evercore ISI surveyed industry observers to find out which biotechs they thought were most likely to be acquired. If President-elect Donald Trump gets his tax proposals enacted, big biotechs should have more cash on their hands beginning in 2018, which could change the dynamics then.",256.0494079589844
2017-01-09 00:00:00+00:00,295.3900146484375,300.0,294.4100036621094,299.0199890136719,299.0199890136719,1430500.0,5.0,1.0,1.000025,"On their list are top medical device stocks, such as Medtronic (NYSE: MDT) , and drugmakers, such as Biogen Inc. (NASDAQ: BIIB) , Johnson & Johnson (NYSE: JNJ) , and BioMarin (NASDAQ: BMRN) . Now that Washington has signed off on the 21st Century Cures Act, deregulation, streamlining, and billions of additional research dollars could cause healthcare stocks to pop. In this clip from The Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes and contributor Todd Campbell share the stocks they think are poised to benefit most from the Cures Act.",242.6607208251953
2017-01-10 00:00:00+00:00,300.4200134277344,301.4200134277344,296.42999267578125,297.7900085449219,297.7900085449219,1408400.0,3.0,1.0,0.5000249999999999,"Ionis' partner, Biogen (NASDAQ: BIIB) , won U.S. regulatory approval for Spinraza in treating spinal muscular atrophy just a few weeks ago. If you were looking for a reason to buy Ionis Pharmaceuticals (NASDAQ: IONS) stock, the biotech's CEO gave several in his presentation at the J.P. Morgan Healthcare Conference on Monday. Late-stage results from a clinical study of volanesorsen in treating rare genetic lipid disorder familial chylomicronemia syndrome (FCS) were solid. New Article Both its two key holdings, Biogen Inc. ( BIIB ) and Amgen Inc. ( AMGN ) advanced 1.4% and 1.3%, respectively. Click to get this free report Baker Hughes Incorporated (BHI): Free Stock Analysis Report Chevron Corporation (CVX): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report lululemon athletica inc. (LULU): Free Stock Analysis Report Urban Outfitters, Inc. (URBN): Free Stock Analysis Report Citrix Systems, Inc. (CTXS): Free Stock Analysis Report Hawaiian Holdings, Inc. (HA): Free Stock Analysis Report Genesco Inc. (GCO): Free Stock Analysis Report To read this article on Zacks.com click here. Equities have been on a tear in recent times, mostly on optimism that President-elect Donald Trump's business-friendly policies will drive growth.",237.03195190429688
2017-01-11 00:00:00+00:00,296.95001220703125,297.8999938964844,285.0,287.1099853515625,287.1099853515625,2450500.0,3.5,1.0,0.6250249999999999,"Especially high volume was seen for the $282.50 strike put option expiring January 13, 2017 , with 529 contracts trading so far today, representing approximately 52,900 underlying shares of BIIB. Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Biogen Inc (Symbol: BIIB), where a total volume of 8,770 contracts has been traded thus far today, a contract volume which is representative of approximately 877,000 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 58.1% of BIIB's average daily trading volume over the past month, of 1.5 million shares. New Article Over the last six months, Biogen BIIB was up 17.9% while Gilead lost 13%. Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report ARIAD Pharmaceuticals, Inc. (ARIA): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. The big news in the biotech sector this week is the acquisition agreement under which Japanese firm Takeda will be acquiring cancer-focused ARIAD ARIA for a whopping $5.2 billion. New Article Combined with the company's pending orphan genetic disease fighting drug Nusinersen - which analysts also believe could become a blockbuster - Vounatsos takes the helm with a full arsenal, making Biogen and BIIB stock look very attractive. InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips The rising cost of prescription drugs, or ""price gouging"" as some would say, was the prevailing theme within the biotech sector in 2016, sending Biogen Inc (NASDAQ: BIIB ) and BIIB stock lower by about 10%. Biogen Has a Full Arsenal for Growth But to what extent can Spinraza elevate BIIB stock? New Article For most biotechs about to turn the profitability corner, launching the first ever treatment for the most common genetic cause of infant mortality might be their biggest headline of the year. But, the launch of Spinraza is just the beginning of a year packed with catalysts for Ionis Pharmaceuticals (NASDAQ: IONS) -- and that's what it's the one biotech stock I want to own in 2017. If skipping ahead to limit the number of receptors glucagon can act on becomes equally popular, it could lead to huge long-term gains for Ionis.",233.3623809814453
2017-01-12 00:00:00+00:00,286.6099853515625,288.989990234375,285.0400085449219,287.7699890136719,287.7699890136719,1354700.0,3.0,1.0,0.5000249999999999,"The strategy also worked with Apple Inc. ( AAPL ), Celgene Corporation ( CELG ), Biogen Inc ( BIIB ), and dozens of other stocks. The article explained that the unfunded liabilities of Social Security have grown so large that our children face impossible headwinds to their retirement. This includes cell phones, tablets, wearables, cameras, wireless headsets, sensors, LED lights, and remote controls.",232.51393127441406
2017-01-13 00:00:00+00:00,288.07000732421875,289.8599853515625,284.25,284.75,284.75,1711500.0,2.6666666666666665,1.0,0.4166916666666666,"(You can read the full research report on Walgreens Boots here>>> ) Other noteworthy reports we are featuring today include Microsoft (MSFT), Biogen (BIIB) and PayPal (PYPL). Biogen (BIIB) Spinraza Approval Provides Top Line Support The Zacks analyst believes that the FDA approval of Spinraza for spinal muscular atrophy, the first approved treatment for the disease, was a huge boost for Biogen. Click to get this free report Walgreens Boots Alliance, Inc. (WBA): Free Stock Analysis Report PayPal Holdings, Inc. (PYPL): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Costco Wholesale Corporation (COST): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Alibaba Group Holding Limited (BABA): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Biogen Inc. ( BIIB ) had the largest percent change down (-1.05%) while Tesla Motors, Inc. ( TSLA ) had the largest percent change gain rising 3.55%. Friday's session closes with the NASDAQ Composite Index reaching a historical high. The index first reached the 5000 mark on 01/11/2017 The total shares traded for the NASDAQ was over 1.8 billion. New Article What happened According to data from S&P Global Market Intelligence , Biogen 's(NASDAQ: BIIB) shares lost 7% in 2016. So what Despite the recent FDA approval of Biogen and Ionis Pharmaceuticals '(NASDAQ: IONS) spinal muscular atrophy drug Spinraza that holds blockbuster sales potential, the biotech remains heavily dependent on Tecfidera for growth. This single-specialty medicine, after all, makes up over 40% of the biotech's annual revenue, meaning that Biogen's top line could be at serious risk if the political ruminations on drug prices turn into legislative action.",239.9899139404297
2017-01-17 00:00:00+00:00,284.2799987792969,286.3500061035156,281.0799865722656,283.010009765625,283.010009765625,1971100.0,2.555555555555556,1.0,0.3889138888888888,"Merrimack Pharmaceuticals, Inc. Price and Consensus Merrimack Pharmaceuticals, Inc. Price and Consensus | Merrimack Pharmaceuticals, Inc. Quote Key Picks A couple of better-ranked stocks in the health care sector include Biogen Inc. BIIB and Intercept Pharmaceuticals ICPT . Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report Merrimack Pharmaceuticals, Inc. (MACK): Free Stock Analysis Report Intercept Pharmaceuticals, Inc. (ICPT): Free Stock Analysis Report To read this article on Zacks.com click here. Onivyde is approved in the U.S., for use in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients diagonised with metastatic adenocarcinoma of the pancreas following Gemzar (gemcitabine)-based therapy. New Article Forward Pharma gets a nice settlement Forward Pharma saw its share price jump by nearly half in the wake of its decision to enter into a settlement and licensing agreement with Biogen (NASDAQ: BIIB) . Investors appear to view Friday's inauguration of Donald Trump as president as a potential endpoint to the stock market rally of the past couple of months, and uncertainty about the priorities of the new administration have left some business leaders wondering if they'll be the federal government's next targets. Noble Energy investors hope that the acquisition will scale up the combined company's production efforts in the Delaware Basin region of West Texas, and bring synergies and other benefits in the future. New Article InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips New Biogen Inc (NASDAQ: BIIB ) CEO Michel Vounatsos must not have been paying much attention to American media or politics over the past year and a half. That's why any owners of BIIB stock may not want to get too excited about the drug's revenue prospects just yet. With 25,000 spinal muscular atrophy patients in the U.S. alone, owners of BIIB stock may be understandably stoked. New Article Biogen Inc (BIIB) Will Win a Battle, But Could Lose the War Noble says it plans to up the output on its new assets by about 50,000 barrels of oil equivalent per day by 2020. Per Ivankoe: ""We value CMG at 26x our F20 EPS of $16.54, discount back 2 years at a 10% cost of equity, and add F19 ending cash per share for our Dec-17 price target of $375. However, today's news and subsequent 1%-plus dip threatens to pull CMG shares off their current perch of around $410, where they've been battling to break above the 200-day moving average. New Article (+) BCEI (+50.75%) Bill Barrett ( BBG ) disclosed interest in reorganized company (+) FWP (+48.23%) Entered into settlement and license agreement with Biogen ( BIIB ) (+) CWEI (+39.69%) To be acquired by Noble Energy ( NBL ) for $2.7 billion The upcoming presidential inauguration was blamed for Tuesday's losses as the expectation dims for President-elect Trump to enact all his policy incentives -- including tax cuts, easing banking regulations, and raising fiscal spending. Wall Street is bracing for a ""sell the fact"" reaction after Friday's swearing-in as President Trump faces a daunting list of policy objectives. New Article Shares of Forward Pharma A/S (NASDAQ: FWP ) got a boost, shooting up 54 percent to $28.25 after Biogen Inc. (NASDAQ: BIIB ) disclosed that it has entered into a settlement and license agreement with Forward Pharma. Top Headline Morgan Stanley (NYSE: MS ) reported better-than-expected fourth quarter earnings and revenue, driven by strong performance at its sales, trading and M&A businesses. Equities Trading UP Benitec Biopharma Ltd (ADR) (NASDAQ: BNTC ) shares shot up 117 percent to $4.02 after the company disclosed that it has received Orphan Drug Designation in the European Union for BB-301 for the treatment of oculopharyngeal muscular dystrophy. New Article (+) FWP (+50.87%) Entered into settlement and license agreement with Biogen ( BIIB ) (+) CWEI (+38.29%) To be acquired by Noble Energy ( NBL ) for $2.7 billion (+) BCEI (+36.68%) Bill Barrett ( BBG ) disclosed interest in re-organized company (+) GEVO (+11.02%) EPA approved pathway for biofuel from feed corn, sees potential for higher value fuel (+) XBIT (+7.58%) Phase 3 data for colorectral cancer therapy published in The Lancet Oncology Since Election Day, the Dow has appreciated by 12% amid expectations for a Trump administration to enact sweeping tax cuts, deregulation of the banking sector, and fiscal stimulus, a daunting list of objectives for a new president. Today's economic data and Fed-speak was eclipsed by Trump's remark about the dollar and British Prime Minister Theresa May's Brexit speech in London this morning despite a larger-than-expected decline in the Empire State December manufacturing index to 6.5 in January from 7.6 in December, and hawkish comments about Federal Reserve monetary policy from Fed Governor Lael Brainard and New York Fed President William Dudley. New Article Investors eyeing a purchase of Biogen Inc (Symbol: BIIB) shares, but tentative about paying the going market price of $285.79/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to BIIB's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. For other put options contract ideas at the various different available expirations, visit the BIIB Stock Options page of StockOptionsChannel.com. New Article More From InvestorPlace Biogen Inc (BIIB) Will Win a Battle, But Could Lose the War The 12 Best Fidelity 401k Funds to Own The 10 Best Stocks to Buy for 2017: The Experts' Picks The post Why Netflix, Inc. (NFLX) Stock Could Pop After Q4 Earnings appeared first on InvestorPlace . For the full year, earnings are projected to rise 46% YOY to 41 cents per share, while full-year revenue of $8.82 billion would mark an increase of 30%. With U.S. streaming subscribers now approaching a level of saturation, global expansion becomes more critical to Netflix and NFLX stock, especially at a time when over-the-top services from Time Warner Inc's (NYSE: TWX ) HBOGo and Viacom, Inc.'s (NASDAQ: VIA , NASDAQ: VIAB ) Showtime Anytime are picking up steam.",237.14797973632812
2017-01-18 00:00:00+00:00,284.7900085449219,286.1600036621094,282.8699951171875,283.6099853515625,283.6099853515625,1079700.0,3.5,1.0,0.6250249999999999,"Stocks recently featured in the blog include Microsoft (NASDAQ: MSFT - Free Report ), Biogen (NASDAQ: BIIB - Free Report ), Home Depot (NYSE: HD - Free Report ), Bristol-Myers (NYSE: BMY - Free Report ) and Berkshire Hathaway (NYSE: BRK.B - Free Report ). Here are highlights from Tuesday's Analyst Blog: Top Research Reports For Wednesday: MSFT, BIIB, HD Today's Research Daily features new research reports on 16 major stocks, including Microsoft (NASDAQ: MSFT - Free Report ), Biogen (NASDAQ: BIIB - Free Report ) and Home Depot (NYSE: HD - Free Report ). Get the full Report on MSFT - FREE Get the full Report on BIIB - FREE Get the full Report on HD - FREE Get the full Report on BMY - FREE Get the full Report on BRK.B - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. New Article Alcobra Ltd. Price and Consensus Alcobra Ltd. Price and Consensus | Alcobra Ltd. Quote Key Picks: A couple of better-ranked stocks in the health care sector include Biogen Inc. BIIB and Intercept Pharmaceuticals ICPT . Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Shire PLC (SHPG): Free Stock Analysis Report Intercept Pharmaceuticals Inc. (ICPT): Free Stock Analysis Report Alcobra Ltd. (ADHD): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Alcobra Ltd.ADHD declined 50.7% after the company reported disappointing top-line results from a phase III study, MEASURE, on experimental candidate metadoxine, extended release (MDX) for the treatment of ADHD in adult patients. New Article Biogen Inc.BIIB recently entered into a settlement and license agreement with Danish biotech, Forward Pharma A/S FWP with respect to an ongoing patent dispute for Biogen's best-selling multiple sclerosis (MS) drug, Tecfidera. Click to get this free report Enzo Biochem Inc. (ENZ): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Anika Therapeutics Inc. (ANIK): Free Stock Analysis Report FORWARD PHARMA (FWP): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen's outperformance was backed by consistently strong earnings results as well as regular positive news flow and regulatory updates. New Article What happened Shares of the Danish drugmaker Forward Pharma A/S (NASDAQ: FWP) gained 48.2% yesterday as the result of a settlement and licensing deal with Biogen (NASDAQ: BIIB) involving an ongoing patent dispute over the multiple sclerosis drug Tecfidera. Per the terms of the deal, Biogen will fork over a non-refundable $1.25 billion licensing fee, and possibly pay 10% to 20% royalties on Tecfidera's net sales to Forward starting in 2021. While that's great news for the drugmaker's shareholders, the ultimate fate of this patent dispute is far from resolved, and hence, the future royalty payments on Tecfidera's sales are not guaranteed.",225.96678161621094
2017-01-19 00:00:00+00:00,282.739990234375,284.8399963378906,279.2300109863281,280.3500061035156,280.3500061035156,1421500.0,3.0,1.0,0.5000249999999999,"Below is a chart showing SWKS's trailing twelve month trading history, with the $74 strike highlighted in orange: For the various different available expirations for NANO options , BIIB options , or SWKS options , visit StockOptionsChannel.com. That amounts to about 47.7% of NANO's average daily trading volume over the past month of 189,070 shares. Particularly high volume was seen for the $25 strike call option expiring January 20, 2017 , with 610 contracts trading so far today, representing approximately 61,000 underlying shares of NANO. New Article Biogen Inc.BIIB , a well-known name in the multiple sclerosis (MS) market, will be reporting fourth-quarter 2016 and full-year earnings on Jan 26, before the market opens.Last quarter, the company delivered a positive earnings surprise of 4.01%. Click to get this free report Eli Lilly and Co. (LLY): Free Stock Analysis Report Allergan PLC (AGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Factors to Consider Since the first progressive multifocal leukoencephalopathy (PML)-related death of a patient on oral MS drug, Tecfidera, investors have been focused on the product's performance.",239.9807891845703
2017-01-24 00:00:00+00:00,275.739990234375,278.3999938964844,271.4700012207031,273.82000732421875,273.82000732421875,1975200.0,3.0,1.0,0.5000249999999999,"Investors who bought Biogen (NASDAQ: BIIB) shares five years ago and held on to them would have received a return of more than 130%. Although Biogen stands to receive royalties on any sales of Ocrevus if it is approved, the drug will probably take market share from Tysabri, in particular. I expect the company to make some smart acquisitions this year -- plus continue to reward shareholders with more buybacks and higher dividends. New Article Gushes, Global Markets and BIIB Stock New CEO Michel Vounatsos wants to get Biogen active in East Asia, in places like China and Korea where it does not yet do business. InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen Inc (NASDAQ: BIIB ) reminds me of a company making big computers in 1977. BIIB is like the early oil business.",252.12118530273438
2017-01-25 00:00:00+00:00,274.5400085449219,277.7799987792969,271.42999267578125,273.239990234375,273.239990234375,2506100.0,2.6666666666666665,1.0,0.4166916666666666,"Multiple sclerosis (MS) market leader Biogen Inc.BIIB is scheduled to release results before market open. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. With Q4 earnings underway, approximately 63 S&P 500 members (representing 19.2% of the index's total market capitalization) have already reported quarterly results as of Jan 20. New Article Biogen Inc. ( BIIB ) is reporting for the quarter ending December 31, 2016. In the past year BIIB has beat the expectations every quarter. Zacks Investment Research reports that the 2016 Price to Earnings ratio for BIIB is 13.58 vs. an industry ratio of 27.60. New Article We would like to remind investors that the company is also a leading provider of generic extended topical prescription products and receives royalties from Biogen Inc's BIIB Multiple Sclerosis drug - Tysabri. Click to get this free report Perrigo Company (PRGO): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Perrigo's share price movement shows that the stock has significantly underperformed the Zacks classified Medical-Products industry in the past one year.",249.4388885498047
2017-01-26 00:00:00+00:00,278.0,285.7799987792969,277.0,278.8900146484375,278.8900146484375,2419000.0,2.6666666666666665,1.0,0.4166916666666666,"Particularly high volume was seen for the $290 strike call option expiring January 27, 2017 , with 462 contracts trading so far today, representing approximately 46,200 underlying shares of BIIB. Below is a chart showing PYPL's trailing twelve month trading history, with the $41 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 9,909 contracts, representing approximately 990,900 underlying shares or approximately 62.9% of BIIB's average daily trading volume over the past month, of 1.6 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $290 strike highlighted in orange: And Mead Johnson Nutrition Co (Symbol: MJN) options are showing a volume of 8,411 contracts thus far today. New Article No one knows where the stock market will go in the short term, but long-term investors might want to buy Celgene Corp. (NASDAQ: CELG) , Regeneron Pharmaceuticals (NASDAQ: REGN) , and Biogen, Inc. (NASDAQ: BIIB) . The company markets four separate drugs that are selling at a billion-dollar blockbuster pace, including Revlimid, the most widely used first- and second-line multiple myeloma therapy, with expected sales of more than $8 billion this year. Given that Celgene's highly profitable, with preliminary EPS of $5.94 in 2016, and it's got a top-tier balance sheet, fast-growing products, and the potential to enter a new multibillion-dollar indication soon, it's one of my favorite top stocks to buy in healthcare right now. New Article Cambridge, MA-based Biogen Inc.BIIB one of the world's leading biotechnology companies, focuses on therapeutic areas including neurology, immunology and hemophilia. BIIB has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 8.15%. Biogen Inc. Price and EPS Surprise Biogen Inc. Price and EPS Surprise | Biogen Inc. Quote Currently, BIIB has a Zacks Rank #2 (Buy), but that could definitely change following the company's earnings report which was just released. New Article Stocks recently featured in the blog include Johnson & Johnson (NYSE: JNJ - Free Report ), Biogen Inc. (NASDAQ: BIIB - Free Report ), Celgene Corporation (NASDAQ: CELG - Free Report ) and Bristol-Myers Squibb Company (NYSE: BMY - Free Report ). Multiple sclerosis (MS) market leader Biogen Inc. (NASDAQ: BIIB - Free Report ) is scheduled to release results before market open. Get the full Report on JNJ - FREE Get the full Report on BIIB - FREE Get the full Report on CELG - FREE Get the full Report on BMY - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. New Article Biogen Inc.BIIB , a well-known name in the multiple sclerosis (MS) market, reported mixed fourth-quarter 2016 results with the company surpassing earnings expectations while missing the same for sales. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Revenues from Anti-CD20 therapeutic programs, which include Biogen's share of Rituxan and Gazyva operating profits, declined 5% from the year-ago period to $318 million in the fourth quarter. New Article However, given the lack of any major bullish news in this morning's quarterly report, analysts may be reluctant to upgrade BIIB stock or boost their price targets. With BIIB trading near oversold levels, and nothing horrible in today's quarterly report, the shares should be able to ride the broad-market rally higher off this near-term bottom. InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen Inc (NASDAQ: BIIB ) stepped into the earnings confessional this morning, and the 22% year-over-year decline in earnings were less inspiring than analysts were hoping for.",249.0113525390625
2017-01-27 00:00:00+00:00,280.4599914550781,281.9800109863281,277.2900085449219,278.2099914550781,278.2099914550781,1353400.0,4.0,1.0,0.7500249999999999,"Biogen 's(NASDAQ: BIIB) fourth-quarter revenue left something to be desired, but the biotech made up for the lackluster growth with a curtailing of expenses, resulting in a solid 12% increase in adjusted earnings per share. Biogen's newest approved drug, Spinraza, which was developed with Ionis Pharmaceuticals (NASDAQ: IONS) , managed just $5 million in sales in the fourth quarter. What management had to say CEO Michel Vounatsos said Spinraza, which treats spinal muscular atrophy, is Biogen's ""most exciting commercial opportunity for 2017,"" but he noted that reimbursement is choppy in the early part of the launch.",254.4424285888672
2017-01-30 00:00:00+00:00,278.2699890136719,278.8999938964844,274.2200012207031,276.0599975585937,276.0599975585937,1300300.0,2.0,1.0,0.250025,"Stocks recently featured in the blog include AT&T (NYSE: T - Free Report ), Biogen (NASDAQ: BIIB - Free Report ), Qualcomm (NASDAQ: QCOM - Free Report ), Facebook (NASDAQ: FB - Free Report ) and Royal Caribbean (NYSE: RCL - Free Report ). In today's write-up, we are featuring analyst reports on 16 major stocks, including reports on AT&T (NYSE: T - Free Report ), Biogen (NASDAQ: BIIB - Free Report ) and Qualcomm (NASDAQ: QCOM - Free Report ). Get the full Report on T - FREE Get the full Report on BIIB - FREE Get the full Report on QCOM - FREE Get the full Report on FB - FREE Get the full Report on RCL - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.",256.956298828125
2017-02-02 00:00:00+00:00,263.760009765625,264.5199890136719,260.5,264.2300109863281,264.2300109863281,2733900.0,2.8,1.0,0.4500249999999999,"Their success has come largely at the expense of prior-generation therapies, including those sold by Shire, Bayer, CSLBehring, and Novo Nordisk. In order to blunt the risk of Eloctate to its top-selling hemophilia A drug, Advate, Baxalta won FDA approval of Adyvonate, a twice-weekly therapy, in November 2015. Undeniably, Bioverativ's competitors have deep pockets and well-established relationships with doctors that could help them derail Eloctate and Alprolix's momentum. New Article VIDEO: Nasdaq 100 Movers: BIIB, TSCO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Thursday, shares of Tractor Supply topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.3%. And the worst performing Nasdaq 100 component thus far on the day is Biogen, trading down 6.3%. New Article Below is a twelve month price history chart comparing the stock performance of PRGO, BIIB, and MCK: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of RYH's underlying holdings with notable upside to their analyst target prices are Perrigo Company plc (Symbol: PRGO), Biogen Inc (Symbol: BIIB), and McKesson Corp (Symbol: MCK). Similarly, BIIB has 18.27% upside from the recent share price of $281.69 if the average analyst target price of $333.14/share is reached, and analysts on average are expecting MCK to reach a target price of $164.00/share, which is 17.12% above the recent price of $140.03. New Article Although Biogen Inc. (NASDAQ: BIIB) is one of the globe's biggest biotechs -- and it has the balance sheet to prove it -- it could face a big threat soon from an unexpected competitor: Celgene Corp. (NASDAQ: CELG) . First, some background Biogen is the market share-leading manufacturer of medicine used to treat multiple sclerosis, a common autoimmune disease that can be debilitating when it progresses. As the sheath gets damaged, nerve signaling can deteriorate, causing muscle weakness, numbness, blurred vision, and other symptoms. New Article Among the largest underlying components of QUAL, in trading today Kimberly-Clark Corp. (Symbol: KMB) is up about 0.3%, Public Service Enterprise Group Inc (Symbol: PEG) is down about 0.2%, and Biogen Inc (Symbol: BIIB) is lower by about 6.7%. For a complete list of holdings, visit the QUAL Holdings page  The chart below shows the one year price performance of QUAL, versus its 200 day moving average: Looking at the chart above, QUAL's low point in its 52 week range is $58.33 per share, with $70.66 as the 52 week high point - that compares with a last trade of $69.77. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",259.072509765625
2017-02-03 00:00:00+00:00,264.9800109863281,266.0,261.760009765625,264.6700134277344,264.6700134277344,1537500.0,3.5,1.0,0.6250249999999999,"The better news is today's scratch could potentially unlock much larger gains for patient shareholders owning BIIB stock and BIVV as longer-term investments. Click to Enlarge Following a lengthy and large -53% correction in BIIB, the past several months have been spent above its prior downtrend line and confirming support for a bullish trend change with multiple successful testing of last July's breakout. InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Did Biogen Inc (NASDAQ: BIIB ) give you a surprise headache Thursday? New Article The Danish biopharmaceutical company is developing a proprietary formulation of the active ingredient in Biogen 's(NASDAQ: BIIB) oral multiple sclerosis therapy, Tecfidera. FWP data by YCharts So what Forward Pharma doesn't have any drugs to sell yet, but we can safely assume its lead candidate has potential in multiple sclerosis therapy. Now what The announced $1.25 billion cash settlement works out to about $26.67 per share of stock Forward Pharma reported outstanding last April, or about 87.5% of the company's recent market value.",257.6238098144531
2017-02-06 00:00:00+00:00,264.4599914550781,265.7300109863281,263.17999267578125,264.9100036621094,264.9100036621094,1619100.0,3.0,1.0,0.5000249999999999,"Trades for Profits in 3 Months: Biogen (BIIB) Biogen Inc (NASDAQ: BIIB ) stock price was not immune to the sector-wide woes. But on the positive side, BIIB stock has defended current levels well. Assuming that no fundamental bombshells are due soon, I am willing to bet that BIIB will revert higher to the mean and retest $280 per share.",259.60791015625
2017-02-07 00:00:00+00:00,269.4700012207031,269.6700134277344,264.5599975585937,266.1099853515625,266.1099853515625,1546900.0,2.0,1.0,0.250025,"Also, the duo weigh in on Biogen Inc. 's(NASDAQ: BIIB) fourth-quarter earnings and discuss the company's decision to spin off its hemophilia drugs as Bioverativ (NASDAQ: BIVV) . In the beginning of January, Teva's management sat down with investors and outlined a particular scenario -- what would happen to our forecast for Copaxone sales if a generic version hit and was launched in February? But they do have a lot of opportunities to roll out biosimilars, which we talked about on the show before, which are basically, we'll call them generic alternatives to some of the top-selling biologic drugs that are available today for conditions like cancer, etc.",266.7483825683594
2017-02-08 00:00:00+00:00,265.42999267578125,269.010009765625,265.42999267578125,268.739990234375,268.739990234375,1922600.0,2.6666666666666665,1.0,0.4166916666666666,"Biogen Inc. (NASDAQ: BIIB) recently completed spinning off its fast-growing hemophilia drugs into a new company, Bioverativ (NASDAQ: BIVV) . Analysts Kristine Harjes and Todd Campbell walk you through Bioverativ's market potential in this clip from The Motley Fool's Industry Focus: Healthcare podcast. Again, similar to the conversation we just had on the last part the show, reducing the patient burden by lowering the number of doses of the medicine that they need to take every week. New Article In that regard, BIIB - despite some of its attractive fundamental qualities, including a solid balance sheet and high free cash flow - has a lot to answer to. All told, investors have a tough task of separating these issues, much of which are PR-related, to make a bull case for BIIB stock. InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech specialist Biogen Inc (NASDAQ: BIIB ) didn't excite Wall Street with breathtaking fourth-quarter earnings results recently, but analysts remain bullish about BIIB stock, which has a consensus Buy rating and an average price target of $331, suggesting 25% returns from current levels. New Article Among major biotech stocks, Amgen was up 6.5% on Q4 results while Biogen BIIB declined 4%. Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Stemline Therapeutics, Inc. (STML): Free Stock Analysis Report ARIAD Pharmaceuticals, Inc. (ARIA): Free Stock Analysis Report To read this article on Zacks.com click here. Major biotech stocks like Amgen AMGN and Gilead GILD reported fourth quarter results -- while both topped estimates, revenue outlook fell short of expectations.",264.73699951171875
2017-02-10 00:00:00+00:00,270.67999267578125,276.4100036621094,269.9800109863281,274.760009765625,274.760009765625,1648900.0,3.0,1.0,0.5000249999999999,"Following the spinoff of two of its fastest-growing drugs, Biogen Inc. (NASDAQ: BIIB) is more focused on neurological disease than it's been in years. In this clip from The Motley Fool's Industry Focus: Healthcare podcast, Kristine Harjes and Todd Campbell discuss what might be next for the large-cap biotech giant. Celgene (NASDAQ: CELG) has been working on a drug that is taken orally for multiple sclerosis, and data is expected in the first half of this year. New Article AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports AMGN's forecasted earnings growth in 2017 as 5.36%, compared to an industry average of 3.8%. For more information on the declaration, record and payment dates, visit the AMGN Dividend History page.",270.5858154296875
2017-02-13 00:00:00+00:00,276.2799987792969,279.760009765625,275.1600036621094,278.9100036621094,278.9100036621094,1795500.0,2.5,1.0,0.375025,"Shares added by 1.86% Biogen Inc ( BIIB ) - 15,584,387 shares, 4.01% of the total portfolio. PRIMECAP Management New Purchases: LGF.B , LGF.A , GD , CBS, SIG, MXL, TPX, DHX.A, SKX, SPLK, Added Positions:AZN, ALKS, WHR, LLY, BMRN, NVS, KLAC, IMAX, AAL, DAL, Reduced Positions:AMGN, SCHW, NVDA, MSFT, MDT, UNP, TXN, MMC, POT, XOM, Sold Out:CPHD, FFIV, PBR.A, ATEN, CAB, CBI, ESV, PBR, TWLO, For the details of PRIMECAP Management's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=PRIMECAP+Management These are the top 5 holdings of PRIMECAP Management Eli Lilly and Co ( LLY ) - 57,501,098 shares, 4.16% of the total portfolio. Shares reduced by 3.04% New Purchase: Lions Gate Entertainment Corp (LGF.A) PRIMECAP Management initiated holdings in Lions Gate Entertainment Corp. New Article Among the largest underlying components of BIB, in trading today Biogen Inc (Symbol: BIIB) is up about 0.9%, Regeneron Pharmaceuticals, Inc. (Symbol: REGN) is up about 2.4%, and Illumina Inc (Symbol: ILMN) is higher by about 0.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra Nasdaq Biotechnology (Symbol: BIB) where we have detected an approximate $16.0 million dollar outflow -- that's a 3.8% decrease week over week (from 9,250,000 to 8,900,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",276.6827392578125
2017-02-15 00:00:00+00:00,284.57000732421875,292.8900146484375,284.239990234375,292.6400146484375,292.6400146484375,2601200.0,2.0,1.0,0.250025,"Biogen (NASDAQ: BIIB) claims one of the most promising Alzheimer's disease candidates right now. Patients with Alzheimer's disease taking a 60 mg dose of the experimental drug experienced sustained reduction in the levels of beta-amyloid peptides. But while verubecestat reduced amyloid beta, Merck's external data-monitoring committee stated that the experimental drug had ""virtually no chance of finding a positive clinical effect"" in improving cognition.",280.1450500488281
2017-02-16 00:00:00+00:00,292.5,293.9800109863281,287.760009765625,290.1300048828125,290.1300048828125,1834900.0,4.0,1.0,0.7500249999999999,"They have one such deal with Biogen (BIIB) for a drug that will go by the name of Spinraza, designed to treat children with spinal muscular atrophy, for which the marketing plan is already under review in both the U.S. and Europe. Obviously that reduces, or rather diversifies, the inherent risk of achieving good trial results and makes it likely that Ionis will have multiple commercial drugs on their books before too long. Those estimates, however, quite possibly dont give enough credit to IONSs management for something else that they have shown that they are good at: negotiating advantageous partnership deals with big players in the industry.",285.77880859375
2017-02-21 00:00:00+00:00,289.1600036621094,289.9100036621094,286.2200012207031,286.8999938964844,286.8999938964844,1471200.0,2.0,1.0,0.250025,"Factors to Consider Ionis earns revenues in the form of upfront, milestone and other payments under its partnerships with leading health care companies like Biogen Inc. BIIB and Glaxo. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Exact Sciences Corporation (EXAS): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Ionis and Akcea plan to report pivotal data from the phase III APPROACH study evaluating volanesorsen in patients with familial chylomicronemia syndrome in the first quarter of 2017.",273.3148498535156
2017-02-22 00:00:00+00:00,287.75,289.42999267578125,285.2200012207031,287.6300048828125,287.6300048828125,1046000.0,3.0,1.0,0.5000249999999999,"Andreas HalvorsenTradesPortfolioCALAINCYKITETSROBIIBAndreas HalvorsenPremium Members This article first appeared on GuruFocus . The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",268.38372802734375
2017-02-23 00:00:00+00:00,287.75,288.1099853515625,283.3599853515625,284.75,284.75,1418900.0,5.0,1.0,1.000025,"Biogen (NASDAQ: BIIB) is the overall market share leader, with a variety of drugs combining to control one-third of total MS market share. A new, better alternative Celgene's ozanimod is a selective S1P targeting drug that reduces MS relapses by sequestering lymphocytes so that they don't respond to inflammation. Personally, I think ozanimod sales could be even bigger than that, depending on the final safety data and the FDA prescribing label.",263.22021484375
2017-02-27 00:00:00+00:00,285.3900146484375,291.25,284.2699890136719,291.1300048828125,291.1300048828125,1295100.0,3.0,1.0,0.5000249999999999,"Biogen (NASDAQ: BIIB) and Gilead Sciences (NASDAQ: GILD) don't compete against each other -- at least not yet. The company's best hope for a new winner in its MS franchise is opicinumab, which blocks the LINGO-1 protein that inhibits growth of the protective sheath covering nerve fibers. Filgotinib could be the company's first foray into the autoimmune disease market if the JAK1 inhibitor proves successful in any of the three late-stage clinical studies underway for the drug. New Article Among the largest underlying components of QUAL, in trading today Kimberly-Clark Corp. (Symbol: KMB) is off about 0.3%, Public Service Enterprise Group Inc (Symbol: PEG) is trading flat, and Biogen Inc (Symbol: BIIB) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares Edge MSCI USA Quality Factor ETF (Symbol: QUAL) where we have detected an approximate $117.3 million dollar inflow -- that's a 3.4% increase week over week in outstanding units (from 47,650,000 to 49,250,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",266.0965270996094
2017-02-28 00:00:00+00:00,290.1300048828125,291.4200134277344,287.19000244140625,288.6000061035156,288.6000061035156,1251300.0,2.5,1.0,0.375025,"Selling Tysabri Royalty Stream The company announced that it has signed an agreement to sell the royalty stream that it receives on net sales of Biogen Inc.'s BIIB multiple sclerosis drug, Tysabri, to Royalty Pharma for up to $2.85 billion. Click to get this free report Perrigo Company (PRGO): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Sunesis Pharmaceuticals, Inc. (SNSS): Free Stock Analysis Report To read this article on Zacks.com click here. The company also announced that it has signed an agreement to divest the royalties it receives in multiple sclerosis drug, Tysabri, in order to monetize the asset. New Article That aside, the income model is solid and BIIB stock should survive these temporary price pressures. 8 of the Most Overrated Stocks on Wall Street Right Now The Alternate: Sell the BIIB July $220 naked put. Remember, you are not required to hold these BIIB stock options trades open through their expiration and you may close any of them for partial gains or losses at any time.",264.8963928222656
2017-03-01 00:00:00+00:00,290.07000732421875,294.1700134277344,289.1400146484375,293.260009765625,293.260009765625,1319700.0,4.0,1.0,0.7500249999999999,"The biggest event of the quarter happened just days before the books closed, when Spinraza was approved by the Food and Drug Administration in late December, triggering a milestone payment from partner Biogen (NASDAQ: BIIB) . Ionis had good news on the pipeline front in December, as well, when it reported positive data from the COMPASS phase 3 trial testing volanesorsen in patients with severe hypertriglyceridemia. In January, after the books closed, Ionis signed a deal with Novartis (NYSE: NVS) to develop and commercialize two early stage cardiovascular disease drugs, AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx.",270.9472961425781
2017-03-02 00:00:00+00:00,293.6400146484375,296.92999267578125,291.0,293.5899963378906,293.5899963378906,1282400.0,5.0,1.0,1.000025,"What happened After reporting fourth-quarter financials in late January and announcing positive phase 3 trial results for its promising multiple sclerosis drug in February, shares in Celgene Corp. (NASDAQ: CELG) climbed more than 5% last month, according to S&P Global Market Intelligence . Last year's performance was supported by ongoing sales growth for its best-selling Revlimid, a multiple myeloma medicine that's become the leading drug prescribed in the first- and second-line setting. Celgene invested $4.5 billion back into R&D last year, and in mid-February, management reported that ozanimod, one of its most promising drugs in development, aced its phase 3 study for use in MS.",266.39862060546875
2017-03-03 00:00:00+00:00,293.1199951171875,298.0,293.1199951171875,297.8500061035156,297.8500061035156,1170700.0,3.0,1.0,0.5000249999999999,"Figure 1 shows a sample screen shot of the ""Individual Portfolio Tracker,"" which contains some of my strong stocks I discussed in an article on seven stocks for 2017 : Allegiant Travel Co. ( ALGT ), Biogen Inc. ( BIIB ) and Novo Nordisk A/S ( NVO ). As discussed in a previous article , GuruFocus launched a new, user-friendly home page in February. For example, Figure 3 shows that companies like Infosys Ltd. ( INFY ) and Qualcomm Inc. ( QCOM ) have been removed from the Historical Low Price-Sales Screener.",263.0290222167969
2017-03-06 00:00:00+00:00,297.0899963378906,297.8999938964844,294.3999938964844,295.6600036621094,295.6600036621094,1395600.0,3.333333333333333,1.0,0.5833583333333334,"In reporting results for the final quarter of 2016, the management of mid-cap biotech Alkermes plc (NASDAQ: ALKS) made its case that 2017 will bring plenty of good news to investors. Compliance with a treatment regimen can be a big challenge for the drug's target patients, so the Aristada dosing options of once every month or six weeks provide a solid clinical benefit. With important data on a pipeline of at least three potential blockbusters reading out in the next few quarters and a stock that is 30% below its peak in late 2015, investors looking for opportunities in the biotech space should take a look at Alkermes. New Article Biogen Inc. BIIB has an Earnings ESP of +0.60% and a Zacks Rank #3. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report BioDelivery Sciences International, Inc. (BDSI): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Apart from restructuring Bunavail's sales territories, the company is working on securing new or improved positioning on other managed care contracts either on an exclusive or preferred status. New Article Biogen Inc. BIIB has an Earnings ESP of +0.60% and a Zacks Rank #3. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Inovio Pharmaceuticals, Inc. (INO): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. The FDA has asked the company to provide additional data to support the shelf-life of the newly designed and manufactured disposable parts of the Cellectra 5PSP immunotherapy delivery device.",253.56666564941406
2017-03-07 00:00:00+00:00,293.8900146484375,293.8900146484375,290.6700134277344,291.1000061035156,291.1000061035156,1298400.0,2.333333333333333,1.0,0.3333583333333332,"Among the largest underlying components of IYH, in trading today Gilead Sciences, Inc. (Symbol: GILD) is down about 1.6%, Allergan PLC (Symbol: AGN) is down about 1.9%, and Biogen Inc (Symbol: BIIB) is lower by about 1%. For a complete list of holdings, visit the IYH Holdings page  The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $135.32 per share, with $159.15 as the 52 week high point - that compares with a last trade of $157.04. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Despite headwinds for its multiple sclerosis (MS) franchise, Biogen (NASDAQ: BIIB) has been on a roll lately. He said that good progress is being made to secure reimbursement for Spinraza, adding that Biogen won't allow any patient to forgo treatment in the meantime because of lack of insurance coverage. Biogen turned a lot of heads in December with results from an early-stage clinical study of experimental Alzheimer's disease drug aducanumab. New Article As a result, 2016 ended up being a dismal year for biotech stocks with big companies like Biogen Inc. BIIB , Gilead Sciences, Inc. GILD , and Alexion Pharmaceuticals, Inc. ALXN feeling the impact of the drug pricing controversy. Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. However, all that changed post Nov 8, 2016 when biotech stocks got a shot in the arm with the surprise win of Donald Trump on hopes that the drug pricing issue would not be a key priority for a non-Clinton administration.",254.53009033203125
2017-03-08 00:00:00+00:00,290.17999267578125,294.82000732421875,288.7200012207031,294.0899963378906,294.0899963378906,1243600.0,2.0,1.0,0.250025,"Among major biotech stocks, Biogen BIIB was up 0.9% while Gilead GILD declined 2.1%. Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Juno Therapeutics, Inc. (JUNO): Free Stock Analysis Report Concert Pharmaceuticals, Inc. (CNCE): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Volanesorsen cut down triglyceride levels in patients with familial chylomicronemia syndrome (FCS) by 77% after 3 months compared to an 18% increase in the placebo arm.",260.17584228515625
2017-03-09 00:00:00+00:00,291.2699890136719,294.9200134277344,290.44000244140625,293.0599975585937,293.0599975585937,1281200.0,5.0,1.0,1.000025,"What happened After reporting better-than-expected results in the fourth quarter and providing investors with an update on its R&D progress, shares in Ionis Pharmaceuticals (NASDAQ: IONS) increased more than 12% last month, according to S&P Global Market Intelligence . Sales should grow throughout this year, and given a lack of treatment alternatives, and a six-figure price tag, royalties in the teen percentages could be meaningful to Ionis Pharmaceuticals relatively quickly. Overall, Ionis Pharmaceuticals' target is to become profitable on a pro-forma basis in 2017, and if it does, it will mark an important milestone for this mid-cap biotech stock, and for that reason, investors are right to be optimistic.",253.74517822265625
2017-03-10 00:00:00+00:00,293.3099975585937,293.8999938964844,289.45001220703125,292.239990234375,292.239990234375,1303700.0,2.5,1.0,0.375025,"Waltham, Mass.-based Bioverativ, spun off from pharmaceutical giant Biogen ( BIIB ) on Feb. 1, has $325 million in cash and no debt. ""We have a vision to build a great rare disease company that is focused on blood disorders and has the potential to create significant value for shareholders,"" Bioverativ Chief Executive John Cox said recently . ""We believe Bioverativ shares offer a unique mix of newly launching assets, a diverse development pipeline, and a strong balance sheet, all of which leaves it well positioned in this competitive area."" New Article In Europe, Biogen (NASDAQ: BIIB) is already marketing drugs ""biosimilar"" to Humira. Today, we're taking one high-profile Wall Street pick and putting it under the microscope... AbbVie (NYSE: ABBV) shareholders are in a funk. Over the past five years, S&P Global Market Intelligence data show how AbbVie's cash flow has had endured substantial bumps, and some amazing rises as well.",244.79673767089844
2017-03-13 00:00:00+00:00,291.54998779296875,293.8500061035156,290.1499938964844,292.95001220703125,292.95001220703125,1291500.0,1.5,1.0,0.125025,"GILD is a part of the Health Care sector, which includes companies such as Amgen Inc. ( AMGN ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports GILD's forecasted earnings growth in 2017 as -29.64%, compared to an industry average of 7.3%. For more information on the declaration, record and payment dates, visit the GILD Dividend History page. New Article Acorda has a licensing agreement with Biogen BIIB for Fampyra in markets outside the U.S. (AGN): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. In 2015 and 2016, Acorda reached settlement agreements with six of the generic companies including Allergan plc AGN .",245.66989135742188
2017-03-16 00:00:00+00:00,285.010009765625,285.42999267578125,275.70001220703125,278.9599914550781,278.9599914550781,3870900.0,2.25,1.0,0.312525,"And the worst performing Nasdaq 100 component thus far on the day is Biogen ( BIIB ), trading down 3.7%. VIDEO: Nasdaq 100 Movers: BIIB, QVCA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Thursday, shares of Liberty Interactive Corp ( QVCA ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.6%. New Article Physical Therapy, Inc. (NYSE: USPH ), down 7 percent, and Biogen Inc (NASDAQ: BIIB ), down 6 percent. Leading and Lagging Sectors Telecommunications services shares climbed 0.58 percent in trading on Thursday. Meanwhile, top gainers in the sector included China Unicom (Hong Kong) Limited (ADR) (NYSE: CHU ), and 8x8, Inc. (NASDAQ: EGHT ). New Article And the worst performing S&P 500 component thus far on the day is Biogen ( BIIB ), trading down 3.6%. VIDEO: S&P 500 Movers: BIIB, ORCL The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Thursday, shares of Oracle ( ORCL ) topped the list of the day's best performing components of the S&P 500 index, trading up 8.4%. New Article For instance, the price-earnings ratios of Celgene Corporation (NASDAQ: CELG ) and Pfizer Inc. (NYSE: PFE ) are three and two times that of BIIB, respectively. In the current choppy environment, it is difficult to find perfect entry points into pricey volatile stocks like BIIB using traditional investing. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen Inc (NASDAQ: BIIB ) stock, much like the rest of the biotech and healthcare industry, has had a tumultuous few months. New Article Biogen Inc. ( BIIB ) had the largest percent change down (-4.67%) while Baidu, Inc. ( BIDU ) had the largest percent change gain rising 2.63%. Thursday's session closes with the NASDAQ Composite Index at 5,900.76. The Dow Jones index closed down -.07% for the day; a total of -15.55 points. New Article Particularly high volume was seen for the $270 strike put option expiring March 17, 2017 , with 783 contracts trading so far today, representing approximately 78,300 underlying shares of BIIB. Below is a chart showing MPC's trailing twelve month trading history, with the $50 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 10,399 contracts thus far today. That number of contracts represents approximately 1.0 million underlying shares, working out to a sizeable 73.1% of BIIB's average daily trading volume over the past month, of 1.4 million shares. New Article Combined, BIIB and ILMN make up approximately 3.0% of the underlying holdings of XLV. Within that group, Biogen Inc (Symbol: BIIB) and Illumina Inc (Symbol: ILMN) are two of the day's laggards, showing a loss of 4.8% and 4.0%, respectively. Combined, CNP and FE make up approximately 4.0% of the underlying holdings of XLU. New Article Among the largest underlying components of IBB, in trading today Biogen Inc (Symbol: BIIB) is off about 4.5%, Regeneron Pharmaceuticals, Inc. (Symbol: REGN) is off about 0.9%, and Incyte Corporation (Symbol: INCY) is lower by about 2.3%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $240.30 per share, with $303.74 as the 52 week high point - that compares with a last trade of $299.90. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",259.5876770019531
2017-03-17 00:00:00+00:00,276.07000732421875,280.6099853515625,274.6099853515625,276.0899963378906,276.0899963378906,3140200.0,3.6666666666666665,1.0,0.6666916666666666,"Yesterday afternoon, the company included phase 1 trial data that could make this a nervous weekend for Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) investors. What happened Shares of AveXis Inc (NASDAQ: AVXS) , a clinical-stage biotech company developing gene therapies, are adding to a tremendous run-up this year with a 16.8% gain as of 11:30 a.m. EDT during Friday's session. Results from a phase 1 trial released along with its fourth-quarter earnings report yesterday showed that 15 of 15 SMA patients treated with its lead candidate, AVXS-101, remained event-free at 13.6 months. New Article The trial is a randomized five week, head-to-head phase III study which will evaluate the gastrointestinal tolerability (GI) of ALKS 8700 462 mg twice daily compared to Biogen Inc.'s BIIB Tecfidera 240 mg twice daily in approximately 420 patients with relapsing-remitting MS (RRMS). Click to get this free report Alkermes PLC (ALKS): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Heska Corporation (HSKA): Free Stock Analysis Report To read this article on Zacks.com click here. Alkermes' key areas of focus include central nervous system (CNS) disorders like schizophrenia, depression, addiction and multiple sclerosis. New Article Some of its key holdings including Amgen Inc. ( AMGN ) and Biogen Inc. ( BIIB ) declined 1.4% and 4.7%, respectively. Click to get this free report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Chevron Corporation (CVX): Free Stock Analysis Report Tiffany & Co. (TIF): Free Stock Analysis Report Alphabet Inc. (GOOGL): Free Stock Analysis Report To read this article on Zacks.com click here. Financial stocks rallied northward following optimism that Fed's decision to hike interest rates will boost the sector, which in turn helped curb some of the day's losses.",265.3367614746094
2017-03-21 00:00:00+00:00,276.3999938964844,284.7099914550781,274.5400085449219,275.7900085449219,275.7900085449219,3841600.0,4.0,1.0,0.7500249999999999,"Biogen (NASDAQ: BIIB) won approval for its SMA drug, Spinraza, in December. However, the other factor involves activist investor group venBio Select Advisor, LLC, which filed a lawsuit to block the Seattle Genetics deal and has made a play to get four slots on the company's board of directors. The continuing drama has Immunomedics investors contemplating an even more lucrative agreement with Seattle Genetics or perhaps a sale of the company. New Article In company news, Biogen ( BIIB ) shares were holding on to a narrow gain on Tuesday after the biotech company won an intellectual property rights courts ruling against hedge fund manager Kyle Bass over its Tecfidera multiple sclerosis medication. BIIB shares closed 0.6% higher at $276.38 each. In a new research note obtained by Reuters, Mizuho analyst Salim Syed said the decision should keep Tecfidera away from generic competition for at least four or five more years. New Article Biotech stocks, which have been showing signs of recovery this year, slipped last week following the release of the Budget Blueprint for 2018, Amgen's AMGN data on its PCSK9 inhibitor, Repatha, and a couple of analyst downgrades for Biogen BIIB . Click to get this free report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Cellectis S.A. (CLLS): Free Stock Analysis Report Blueprint Medicines Corporation (BPMC): Free Stock Analysis Report Mateon Therapeutics, Inc. (MATN): Free Stock Analysis Report To read this article on Zacks.com click here. A faster drug approval process and the proposed removal of outdated regulations that drive up costs and slow down innovation should also work in favor of this sector.",275.5113525390625
2017-03-28 00:00:00+00:00,275.5899963378906,276.7099914550781,272.5,274.1099853515625,274.1099853515625,1149400.0,4.0,1.0,0.7500249999999999,"Rally After Blows The latest rally comes despite major setbacks this month, including Trump tweets on drug prices and serious blows to big-name biotechsAmgen ( AMGN ) and Biogen ( BIIB ), which cast a pall on the entire industry. On Tuesday, SPDR S&P Biotech ( XBI ) and iShares Nasdaq Biotechnology ( IBB ) were modestly lower but holding above the 10-week moving average - a bullish sign after a recent test of that critical marker of support. Biotechnology ETFs rallied sharply in January and February as higher beta names swung into favor after President Trump's shock election win.",271.3945007324219
2017-03-29 00:00:00+00:00,273.9100036621094,273.9100036621094,268.20001220703125,268.5299987792969,268.5299987792969,2632200.0,3.0,1.0,0.5000249999999999,"And the worst performing Nasdaq 100 component thus far on the day is Biogen ( BIIB ), trading down 1.3%. VIDEO: Nasdaq 100 Movers: BIIB, VRTX The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Wednesday, shares of Vertex Pharmaceuticals ( VRTX ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 24.6%. New Article We remind investors that Biogen Inc. BIIB has a strong position in the MS market backed by a wide range of products including Avonex, Tysabri, Tecfidera & Plegridy. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Retrophin, Inc. (RTRX): Free Stock Analysis Report Heska Corporation (HSKA): Free Stock Analysis Report To read this article on Zacks.com click here. Roche Holdings AGRHHBY announced that the FDA has approved Ocrevus (ocrelizumab) as the first and only drug for both relapsing and primary progressive forms of multiple sclerosis.",268.9273986816406
2017-03-31 00:00:00+00:00,269.29998779296875,275.0,268.0199890136719,273.4200134277344,273.4200134277344,2747400.0,2.6666666666666665,1.0,0.4166916666666666,"Especially high volume was seen for the $280 strike call option expiring April 21, 2017 , with 3,945 contracts trading so far today, representing approximately 394,500 underlying shares of BIIB. Below is a chart showing PX's trailing twelve month trading history, with the $125 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 10,647 contracts, representing approximately 1.1 million underlying shares or approximately 62% of BIIB's average daily trading volume over the past month, of 1.7 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $280 strike highlighted in orange: And Expedia Inc (Symbol: EXPE) saw options trading volume of 7,636 contracts, representing approximately 763,600 underlying shares or approximately 45.4% of EXPE's average daily trading volume over the past month, of 1.7 million shares. New Article So what A U.S. patent board ruled against Forward Pharma's claim that Biogen 's(NASDAQ: BIIB) multiple sclerosis drug Tecfidera infringed on patents held by Forward Pharma. Biogen agreed to pay Forward Pharma $1.25 billion upfront and to pay a royalty of 10% from January 1, 2021 to December 31, 2028, and a royalty of 20% from January 1, 2029 until the patent expired, assuming it had an exclusive right to Forward Pharma's patent. Separately, Acorda Therapeutics announced that the U.S. District Court invalidated four of its patents covering its multiple sclerosis drug Ampyra. New Article Forward Pharma A/S (NASDAQ: FWP ) was down, falling around 20 percent to $21.51 on news of Biogen Inc (NASDAQ: BIIB )'s patent victory over the active ingredient in their competing multiple sclerosis treatments. Leading the sector was strength from American Midstream Partners LP (NYSE: AMID ) and Cia Energetica de Minas Gerais CEMIG-ADR. Equities Trading UP Akari Therapeutics PLC (ADR) (NASDAQ: AKTX ) shares shot up 45 percent to $10.16 after the company disclosed that the FDA has granted Fast Track designation for Coversin.",268.1977844238281
2017-04-03 00:00:00+00:00,274.0799865722656,274.7900085449219,271.2900085449219,272.69000244140625,272.69000244140625,1589000.0,2.0,1.0,0.250025,"Acorda has a licensing agreement with Biogen BIIB for marketing Fampyra outside the U.S. (AGN): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. The court upheld one patent for the extended-release (tablets, 10 mg) formulation of the drug, which is set to expire in Jul 2018.",266.434814453125
2017-04-05 00:00:00+00:00,274.4800109863281,274.6499938964844,270.07000732421875,270.44000244140625,270.44000244140625,1340200.0,2.5,1.0,0.375025,"Combined, BIIB and BMY make up approximately 5.3% of the underlying holdings of XLV. Among large Healthcare stocks, Biogen Inc (Symbol: BIIB) and Bristol-Myers Squibb Co. (Symbol: BMY) are the most notable, showing a loss of 0.7% and 0.6%, respectively. Combined, SRE and AES make up approximately 5.4% of the underlying holdings of XLU. New Article Below is a twelve month price history chart comparing the stock performance of CELG, BIIB, and TSRO: Combined, CELG, BIIB, and TSRO represent 19.34% of the Biotech ETF. Three of BBH's underlying holdings with notable upside to their analyst target prices are Celgene Corp. (Symbol: CELG), Biogen Inc (Symbol: BIIB), and Tesaro Inc (Symbol: TSRO). Similarly, BIIB has 15.28% upside from the recent share price of $274.24 if the average analyst target price of $316.13/share is reached, and analysts on average are expecting TSRO to reach a target price of $170.42/share, which is 14.23% above the recent price of $149.19.",262.9763488769531
2017-04-06 00:00:00+00:00,270.1400146484375,272.6000061035156,269.3399963378906,270.94000244140625,270.94000244140625,1622600.0,3.0,1.0,0.5000249999999999,"Acorda has a licensing agreement with Biogen BIIB for marketing Fampyra outside the U.S. Acorda Therapeutics, Inc. Price Acorda Therapeutics, Inc. Price | Acorda Therapeutics, Inc. Quote Zacks Rank Acorda currently carries a Zacks Rank #3 (Hold). (AGN): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Teva Pharmaceutical Industries Limited (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. The workforce reduction, which is expected to be completed in Apr 2017, is part of the company's strategy to significantly lower its operating expenses.",261.571044921875
2017-04-07 00:00:00+00:00,270.6000061035156,270.8399963378906,267.32000732421875,268.7300109863281,268.7300109863281,1677600.0,2.0,1.0,0.250025,"Biogen Inc (BIIB) The biotech sector is fracturing along with the market as this range-bound group of stocks is seeing an increase in volatility again. BIIB shares have been struggling to rebound from an oversold condition that developed a few weeks ago, to no avail. Looking at a longer-term chart, $270 has also played an important role as support and resistance, a level that BIIB shares are trying to maintain prices above right now.",262.5069274902344
2017-04-10 00:00:00+00:00,268.67999267578125,270.3999938964844,268.1400146484375,269.29998779296875,269.29998779296875,861000.0,4.5,1.0,0.8750249999999999,"Apart from elagolix, AbbVie has several candidates in different stages of development across a wide range of therapeutic areas and has partnerships with companies like Roche, Bristol-Myers Squibb Company BMY and Biogen Inc. BIIB . Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc.ABBV along with Neurocrine Biosciences, Inc. NBIX announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids. New Article Rebif did $1.86 billion in sales in 2016, and Biogen 's(NASDAQ: BIIB) MS drugs based on interferon beta-1a, Avonex and Plegridy, sold $2.8 billion. Swiss drugmaker Roche Holdings (NASDAQOTH: RHHBY) got a nod from the FDA for its multiple sclerosis drug Ocrevus at the end of March, triggering hope from MS sufferers and dread from competitors. A major new advance Ocrevus is a new approach to treating MS, a disease in which the body's immune system attacks the sheath around nerve fibers.",259.9610290527344
2017-04-17 00:00:00+00:00,271.5,274.6400146484375,271.0,274.04998779296875,274.04998779296875,1025800.0,3.0,1.0,0.5000249999999999,"Biogen Inc.BIIB recently announced that it has inked a deal to buy worldwide rights for Bristol-Myers Squibb's BMY anti-tau antibody, BMS-986168, for an upfront payment of $300 million. Promising pipeline candidates include aducanumab (BIIB037, Alzheimer's disease). Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Galena Biopharma, Inc. (GALE): Free Stock Analysis Report Heska Corporation (HSKA): Free Stock Analysis Report To read this article on Zacks.com click here.",249.9702911376953
2017-04-18 00:00:00+00:00,273.92999267578125,275.17999267578125,269.7200012207031,271.1600036621094,271.1600036621094,1379500.0,3.5,1.0,0.6250249999999999,"Biogen (NASDAQ: BIIB) received FDA approval for the drug, which was initially developed by Ionis Pharmaceuticals in December 2016. The highest-priced drugs have two things in common: They all treat rare and dangerous diseases, and they all cost hundreds of thousands of dollars per year. Interferon gamma helps lower the risk and severity of infections in individuals with CGD and can slow the worsening of SMO in patients. New Article Earlier last week, Bristol-Myers entered into an agreement with Biogen BIIB for an upfront payment of $300 million to license its anti-eTau compound, BMS-986168, for progressive supranuclear palsy (PSP). Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Galena Biopharma, Inc. (GALE): Free Stock Analysis Report Heska Corporation (HSKA): Free Stock Analysis Report To read this article on Zacks.com click here. The partnership will focus on developing translational biomarkers and diagnostics for the evaluation of non-alcoholic steatohepatitis (NASH) in pre-clinical models of fibrotic diseases and in clinical settings.",248.7114715576172
2017-04-19 00:00:00+00:00,272.7200012207031,274.0,271.0799865722656,271.94000244140625,271.94000244140625,1190300.0,1.0,1.0,2.4999999999997247e-05,"Biogen in Licensing Agreement with Bristol-Myers: Biogen BIIB , which is looking to strengthen its Alzheimer's disease (AD) pipeline, announced a licensing agreement with Bristol-Myers Squibb for exclusive rights to BMS-986168, an anti-tau candidate. Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report The Medicines Company (MDCO): Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report OncoMed Pharmaceuticals, Inc. (OMED): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. The FDA's complete response letter (CRL) for Incyte INCY and Lilly's experimental rheumatoid arthritis (RA) treatment was the big news in the biotech sector while OncoMed OMED continued to be hit by more pipeline setbacks.",252.54835510253906
2017-04-20 00:00:00+00:00,272.20001220703125,273.6300048828125,270.7799987792969,272.4599914550781,272.4599914550781,981200.0,4.0,1.0,0.7500249999999999,"Biogen (BIIB), for example, has, alongside a couple of partnerships and biosimilars (biotech generics), only seven proprietary therapies in the market but has EBITDA of over $6 billion. Now, for those readers of a certain age or who have led a somewhat sheltered existence, this means nothing, but many will understand that today, 4/20, is a logical day to talk about one of the fastest growing businesses in the U.S.: Marijuana. GWPH trades and is ultimately priced in the same way as other pharma companies in that it moves based on the perception of the efficacy and prospects for approval of its drugs rather than the trend towards the broad legalization of cannabis. New Article Biogen Inc.BIIB , a well-known name in the multiple sclerosis (MS) market, will report first-quarter 2017 results on Apr 25, before the market opens. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Celldex Therapeutics, Inc. (CLDX): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen expects relatively stable demand for both Tecfidera and Tysabri in 2017 as patient growth in ex-U.S. markets offsets the modest decline in the U.S.",258.7645263671875
2017-04-24 00:00:00+00:00,274.92999267578125,278.69000244140625,274.6099853515625,276.8599853515625,276.8599853515625,2007300.0,2.4,1.0,0.350025,"Particularly high volume was seen for the $270 strike put option expiring April 28, 2017 , with 484 contracts trading so far today, representing approximately 48,400 underlying shares of BIIB. Below is a chart showing ISRG's trailing twelve month trading history, with the $817.50 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 7,906 contracts, representing approximately 790,600 underlying shares or approximately 56.8% of BIIB's average daily trading volume over the past month, of 1.4 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $270 strike highlighted in orange: For the various different available expirations for AAPL options , ISRG options , or BIIB options , visit StockOptionsChannel.com. New Article 3 Stocks to Watch on Monday: Hasbro, Inc. (HAS), Halliburton Company (HAL) and C R Bard Inc (BCR) The hedge (optional): Sell BIIB Oct $340/$345 credit call spread where I have an 85% theoretical chance of yielding 10% on risk. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen Inc (NASDAQ: BIIB ) has been awfully kind to us in 2017. Oh sure, the stock price is awful, down 3% amid an up market, but we've been successfully able to squeeze profits out of BIIB stock despite its tepid movement. New Article More From InvestorPlace 8 Retail Stocks That Can Win Despite Amazon The 10 Best Stocks to Buy for the Next Decade Make Biogen Inc (BIIB) Stock Pay You, Even With No Dividend The post Monday's Vital Data: Apple Inc. (AAPL), Visa Inc (V) and Micron Technology, Inc (MU) appeared first on InvestorPlace . Turning to Friday's most active options, Apple Inc. (NASDAQ: AAPL ) saw call volume slip despite data that there could be nearly 70 million potential customers waiting for an iPhone 8. Investors appear unsure ahead of next month's quarterly earnings report, though analysts remain broadly positive on potential sales for the coming iPhone 8. New Article Biogen Inc.BIIB Biogen, a well-known name in the multiple sclerosis (MS) market, is also scheduled to announce results before the opening bell. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Lilly's performance has been rather poor with earnings missing expectations in three of the last four quarters, while beating in only one, bringing the average negative surprise to 3.39%. New Article Biotech major, Biogen, Inc.BIIB , is one of the companies that will be reporting results tomorrow. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. This week, earnings season for the pharma and biotech sector will start in earnest with several major companies scheduled to report results.",251.76107788085938
2017-04-25 00:00:00+00:00,290.0,291.8999938964844,285.8999938964844,286.8900146484375,286.8900146484375,3126300.0,3.25,1.0,0.5625249999999999,"Ionis Pharmaceuticals '(NASDAQ: IONS) collaboration partner Biogen (NASDAQ: BIIB) reported first-quarter financial results earlier today, and in that report, it disclosed that sales of Ionis and Biogen's Spinraza totaled $47 million during its first quarter on the market. Ionis hasn't had tremendous success (yet) in getting its drugs across the finish line, but there's evidence that the company's about to take the next step and have its first billion-dollar blockbuster on the market. And, because Spinraza's addressable patient population in the U.S. is 9,000, and it costs six figures annually, industry watchers think its sales will eventually exceed $1 billion. New Article Cambridge, MA-based Biogen Inc.BIIB one of the world's leading biotechnology companies, focuses on therapeutic areas including neurology and immunology. BIIB has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 5.86%. Biogen Inc. Price and EPS Surprise Biogen Inc. Price and EPS Surprise | Biogen Inc. Quote Currently, BIIB has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. New Article Back in 2015, biotech juggernaut Biogen (NASDAQ: BIIB) made headlines on the news that its investigational Alzheimer's disease (AD) treatment aducanumab showed strong efficacy in an early-stage clinical trial. Late last year, Biogen released data from this long-term study indicating that aducanumab slowed cognitive decline for these early-stage patients. Similarly, Eli Lilly 's solanezumab, which also showed promising ability to destroy amyloid, failed in 2016 to demonstrate disease-slowing effects for AD in late-stage clinical trials. New Article InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen Inc (NASDAQ: BIIB ) stock was up on Tuesday following the release of its earnings report for the first quarter of 2017. BIIB stock was up 4% as of noon Tuesday. More From InvestorPlace 10 Dividend Stocks That Will Deliver Double-Digit Returns Every Year 10 Stocks That Won't Exist in a Decade 5 Tech Stocks to Buy for Growth AND Dividends The post Biogen Inc (BIIB) Stock Pops on Strong Q1 Earnings appeared first on InvestorPlace . New Article VIDEO: Nasdaq 100 Movers: ESRX, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Tuesday, shares of Biogen ( BIIB ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 5.0%. And the worst performing Nasdaq 100 component thus far on the day is Express Scripts Holding ( ESRX ), trading down 10.6%. New Article Biogen Inc.BIIB reported better-than-expected results in the first-quarter of 2017. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Quarter in Detail Sales of oral multiple sclerosis (MS) drug Tecfidera rose 1% from the year-ago period to $958 million. New Article Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 60% Average next regular session additional gain: 1.6% Over the prior three fiscal years (12 quarters), when shares of BIIB rose in the extended-hours session in reaction to its earnings announcement, history shows that 60.0% of the time (6 events) the stock posted additional gains in the following regular session by an average of 1.6%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 3.4% Over that same historical period, when shares of BIIB dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 3.4% by the following regular session close. Extended-Hours Dollar Volume: $78,767,991 Biogen Idec ( BIIB ) is due to issue its quarterly earnings report in the upcoming extended-hours session. New Article Eli Lilly and Company Price, Consensus and EPS Surprise Eli Lilly and Company Price, Consensus and EPS Surprise | Eli Lilly and Company Quote Biogen Inc. BIIB , which also reported today, beat estimates for both earnings and sales in the first quarter. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Basaglar - Lilly and partner Boehringer Ingelheim's follow-on insulin to Sanofi's SNY blockbuster drug, Lantus - was launched in the U.S. in mid-Dec 2016 where it generated revenues of $22.0 million in the quarter.",250.14285278320312
2017-04-26 00:00:00+00:00,285.2799987792969,286.6199951171875,279.57000732421875,279.9800109863281,279.9800109863281,2146700.0,3.5,1.0,0.6250249999999999,"With this in mind, Amgen (NASDAQ: AMGN) and Biogen (NASDAQ: BIIB) have both proven to be particularly outstanding vehicles to gain exposure to this high-flying industry. Last year, for example, Amgen rolled out 94 country/product approvals, generated a record $23 billion in annual revenue, and worked diligently toward developing the market for its ground-breaking cardiovascular disease drug, Repatha. Moreover, Biogen and its partner Ionis Pharmaceuticals (NASDAQ: IONS) priced their newly approved spinal muscular atrophy medicine, Spinraza, at a stunning $125,000 per treatment -- causing a number of payers to immediately limit access to the drug to only the absolute sickest patients (Type 1 or infantile onset). New Article Biogen (NASDAQ: BIIB) reported first-quarter earnings on Tuesday, resulting in investors excited about the potential for Spinraza, its new spinal muscular atrophy drug developed with Ionis Pharmaceuticals (NASDAQ: IONS) , but tolerating ho-hum sales growth of its multiple sclerosis drugs. What management had to say Biogen CEO Michel Vounatsos gave some interesting stats that show the potential to grow Spinraza sales substantially from here. Looking forward Management plans to update its 2017 guidance after the second quarter is complete, but it's likely the earnings estimate will be adjusted downward given the $300 million Biogen recently agreed to pay Bristol-Myers Squibb (NYSE: BMY) to license its anti-tau Alzheimer's disease drug.",255.13795471191406
2017-04-27 00:00:00+00:00,279.57000732421875,281.2200012207031,275.6000061035156,276.57000732421875,276.57000732421875,2268500.0,4.0,1.0,0.7500249999999999,"It won approval for Spinraza, a drug that is partnered with Biogen (NASDAQ: BIIB) for a rare disease called spinal muscle atrophy, and it is preparing to file for a second rare disease therapy partnered with a company it is spinning off to market drugs for blood lipid conditions. What makes the technology significant, and the company interesting to investors, is that it can potentially be applied to a wide variety of diseases, including some that have been considered ""un-druggable"" in the past. Rare diseases are only part of the opportunity ahead for bluebird; cancer is a big target as well, and the company is partnered with Celgene (NASDAQ: CELG) for a CAR-T treatment.",258.43304443359375
2017-04-28 00:00:00+00:00,277.0899963378906,277.2799987792969,271.0599975585937,271.2099914550781,271.2099914550781,1803400.0,4.0,1.0,0.7500249999999999,"Ampyra is marketed in ex-U.S. markets by Biogen Inc. BIIB under the trade name Fampyra. Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Galena Biopharma, Inc. (GALE): Free Stock Analysis Report Heska Corporation (HSKA): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline Updates On Feb 2017, the company announced positive phase III clinical data on CVT-301 (INBRIJA), which is being evaluated for the treatment of Parkinson's disease.",257.101318359375
2017-05-02 00:00:00+00:00,271.510009765625,273.25,269.7200012207031,271.3399963378906,271.3399963378906,1384300.0,2.5,1.0,0.375025,"Among the largest underlying components of BIB, in trading today Biogen Inc (Symbol: BIIB) is up about 0.2%, Regeneron Pharmaceuticals, Inc. (Symbol: REGN) is off about 0.1%, and Illumina Inc (Symbol: ILMN) is relatively unchanged. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra Nasdaq Biotechnology (Symbol: BIB) where we have detected an approximate $12.6 million dollar outflow -- that's a 3.1% decrease week over week (from 8,100,000 to 7,850,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article At Biogen ( BIIB ), a filing with the SEC revealed that on Thursday, Director Alexander J. Denner bought 73,858 shares of BIIB, at a cost of $278.50 each, for a total investment of $20.57M. Investors can grab BIIB even cheaper than Denner did, with shares trading as low as $270.86 at last check today which is 2.7% below Denner's purchase price. VIDEO: Tuesday 5/2 Insider Buying Report: BIIB, WWD The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",249.42713928222656
2017-05-03 00:00:00+00:00,271.44000244140625,272.5,270.0899963378906,271.3599853515625,271.3599853515625,929000.0,3.0,1.0,0.5000249999999999,"The table below details the recent insider buying activity observed at TDG: TDG - last trade: $250.84 - Recent Insider Buys: And Biogen Inc (Symbol: BIIB), the #30 largest holding among components of the Morningstar Wide Moat ETF (Symbol: MOAT), shows 2 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $24,288,061 worth of BIIB, which represents approximately 2.25% of the ETF's total assets at last check. The recent insider buying activity observed at BIIB is detailed in the table below: BIIB - last trade: $271.34 - Recent Insider Buys: 10 ETFs With Stocks That Insiders Are Buying  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",249.27928161621094
2017-05-04 00:00:00+00:00,271.1300048828125,272.5299987792969,267.6099853515625,268.6000061035156,268.6000061035156,1143400.0,4.0,1.0,0.7500249999999999,"If you want an email notification each time Sheraz publishes a new article, please click here >>> Today's Must Read Exxon Mobil (XOM) Beats on Q1 Earnings, Misses Revenues JPMorgan (JPM) Q1 Results Indicates Revenue Growth to Persist Union Pacific (UNP) Beats on Q1 Earnings and Revenues Featured Reports Biogen (BIIB) Q1 Results Top, Spinraza Sales Strong The Zacks analyst is encouraged by the stronger-than-expected sales of newly launched drug Spinraza for spinal muscular atrophy ADP (ADP) Beats Q3 Earnings Estimates, New Bookings Decline The Zacks analyst thinks ADP holds a dominant position in the payroll processing and human capital management market, primarily due to its robust product portfolio. Other noteworthy reports we are featuring today include Biogen (BIIB), ADP (ADP) and Becton Dickinson (BDX). Click to get this free report Exxon Mobil Corporation (XOM): Free Stock Analysis Report Union Pacific Corporation (UNP): Free Stock Analysis Report J P Morgan Chase & Co (JPM): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Becton, Dickinson and Company (BDX): Free Stock Analysis Report Automatic Data Processing, Inc. (ADP): Free Stock Analysis Report To read this article on Zacks.com click here. New Article So what Ionis Pharmaceuticals' collaboration partner, Biogen Inc. (NASDAQ: BIIB) , won FDA approval for Spinraza in December, and on April 25, Biogen reported first-quarter financial results showing strong demand for Spinraza during its first full quarter on the market. What happened Shares of Ionis Pharmaceuticals (NASDAQ: IONS) rallied 20% in April, according to S&P Global Market Intelligence , following news that sales of Spinraza are off to a solid start and that it had inked a collaboration deal to develop therapeutics for use in China. In exchange for a license to its IP, Ionis Pharmaceuticals got an undisclosed up-front payment and equity in Suzhou Ribo.",255.18020629882812
2017-05-05 00:00:00+00:00,268.32000732421875,269.5,261.0,262.1499938964844,262.1499938964844,1914100.0,2.6666666666666665,1.0,0.4166916666666666,"Especially high volume was seen for the $275 strike call option expiring June 16, 2017 , with 526 contracts trading so far today, representing approximately 52,600 underlying shares of BIIB. Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Biogen Inc (Symbol: BIIB), where a total volume of 7,448 contracts has been traded thus far today, a contract volume which is representative of approximately 744,800 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 50.8% of BIIB's average daily trading volume over the past month, of 1.5 million shares. New Article Combined, BIIB and INCY make up approximately 2.8% of the underlying holdings of XLV. Within that group, Biogen Inc (Symbol: BIIB) and Incyte Corporation (Symbol: INCY) are two large stocks that are lagging, showing a loss of 2.8% and 2.2%, respectively. Combined, USB and NAVI make up approximately 2.9% of the underlying holdings of XLF. New Article Stocks recently featured in the blog include Exxon Mobil (NYSE: XOM- Free Report ), JPMorgan (NYSE: JPM- Free Report ), Union Pacific (NYSE: UNP- Free Report ), Biogen (NASDAQ: BIIB- Free Report ) and Becton Dickinson (NYSE: BDX- Free Report ). Other noteworthy reports we are featuring today include Biogen (NASDAQ: BIIB- Free Report ) and Becton Dickinson (NYSE: BDX- Free Report ). Get the full Report on XOM - FREE Get the full Report on JPM - FREE Get the full Report on UNP - FREE Get the full Report on BIIB - FREE Get the full Report on BDX - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.",260.3199768066406
2017-05-09 00:00:00+00:00,260.989990234375,263.6600036621094,260.2799987792969,261.2799987792969,261.2799987792969,1159200.0,3.0,1.0,0.5000249999999999,"Below is a twelve month price history chart comparing the stock performance of RDUS, JUNO, and BIIB: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYH's underlying holdings with notable upside to their analyst target prices are Radius Health Inc (Symbol: RDUS), Juno Therapeutics Inc (Symbol: JUNO), and Biogen Inc (Symbol: BIIB). Similarly, JUNO has 40.89% upside from the recent share price of $22.16 if the average analyst target price of $31.22/share is reached, and analysts on average are expecting BIIB to reach a target price of $320.15/share, which is 22.94% above the recent price of $260.42.",264.1266174316406
2017-05-10 00:00:00+00:00,260.6300048828125,262.29998779296875,257.0199890136719,257.9200134277344,257.9200134277344,1503600.0,2.0,1.0,0.250025,"Among the largest underlying components of IWF, in trading today Nike (Symbol: NKE) is down about 0.1%, Biogen Inc (Symbol: BIIB) is off about 1%, and Salesforce.com Inc (Symbol: CRM) is relatively unchanged. For a complete list of holdings, visit the IWF Holdings page  The chart below shows the one year price performance of IWF, versus its 200 day moving average: Looking at the chart above, IWF's low point in its 52 week range is $95.45 per share, with $117.70 as the 52 week high point - that compares with a last trade of $117.24. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",260.3909912109375
2017-05-11 00:00:00+00:00,257.2699890136719,258.19000244140625,252.69000244140625,254.1499938964844,254.1499938964844,1850600.0,2.0,1.0,0.250025,"Ionis Pharmaceuticals (NASDAQ: IONS) released first-quarter earnings on May 9, but the most interesting number -- sales of Spinraza -- was already known since Ionis' partner, Biogen (NASDAQ: BIIB) , disclosed sales of $47 million a few weeks ago. Also in April, Biogen presented new interim data at the American Academy of Neurology meeting from the Nurture study testing Spinraza in infants with the mutation that causes spinal muscular atrophy but who haven't exhibited symptoms yet. Ionis and Akcea, which it's in the process of spinning out , announced positive results from the phase 3 Approach trial of volanesorsen in patients with familial chylomicronemia syndrome (FCS).",255.8393096923828
2017-05-12 00:00:00+00:00,255.4100036621093,256.29998779296875,253.3000030517578,254.83999633789065,254.83999633789065,1119800.0,3.0,1.0,0.5000249999999999,"AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports AMGN's forecasted earnings growth in 2017 as 6.14%, compared to an industry average of 8.6%. The following ETF(s) have AMGN as a top-10 holding: iShares Nasdaq Biotechnology Index Fund ( IBB ) PowerShares Dynamic Pharmaceuticals ( PJP ) PowerShares Dynamic Biotech &Genome ( PBE ) SPDR Select Sector Fund - Health Care ( XLV ) VanEck Vectors Biotech ETF ( BBH ).",251.0902099609375
2017-05-15 00:00:00+00:00,253.97000122070312,259.95001220703125,253.97000122070312,258.5299987792969,258.5299987792969,1653600.0,3.0,1.0,0.5000249999999999,"Especially high volume was seen for the $262.50 strike call option expiring May 19, 2017 , with 521 contracts trading so far today, representing approximately 52,100 underlying shares of BIIB. Below is a chart showing RTN's trailing twelve month trading history, with the $160 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 6,838 contracts, representing approximately 683,800 underlying shares or approximately 43.8% of BIIB's average daily trading volume over the past month, of 1.6 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $262.50 strike highlighted in orange: And Monsanto Co (Symbol: MON) options are showing a volume of 6,960 contracts thus far today.",246.80328369140625
2017-05-16 00:00:00+00:00,259.44000244140625,260.6199951171875,256.6000061035156,257.6400146484375,257.6400146484375,1049700.0,3.5,1.0,0.6250249999999999,"Biotechnology has been one of the hottest areas for investors over the last five years due to the advent of multiple game-changing new medicines, and the ever-expanding human population that's putting a tremendous amount of pressure on healthcare systems worldwide. Put simply, I believe it's frankly hard to justify holding most individual biotech stocks for especially long periods of time because of the rather limited lifespan of their products, and the political blowback over drug prices in the United States. While the iShares Nasdaq Biotechnology Index does come with a somewhat rich expense ratio of 0.47%, it also offers a super easy route toward a highly diversified -- and therefore far less risky -- approach to investing in biotech. New Article Biogen Inc. BIIB announced the acquisition of New York-based private pharma company Remedy Pharmaceuticals' phase III candidate, Cirara for an upfront payment of $120 million. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report Akari Therapeutics PLC (AKTX): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen has another drug in development, called natalizumab which is being evaluated in a phase IIb study to improve its functional outcomes by limiting brain inflammation after strokes.",249.81385803222656
2017-05-17 00:00:00+00:00,255.3800048828125,256.1400146484375,251.1699981689453,251.33999633789065,251.33999633789065,1413500.0,1.0,1.0,2.4999999999997247e-05,"Biogen BIIB was in the news this week not only for an agreement that will boost its pipeline but also for a favorable decision in a securities litigation. Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Sangamo BioSciences, Inc. (SGMO): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report To read this article on Zacks.com click here. Tecfidera, which was off to a strong start following its launch and a major contributor to the top line, saw sales stumbling once the company announced a progressive multifocal leukoencephalopathy (PML)-related patient death.",254.4325714111328
2017-05-18 00:00:00+00:00,252.22999572753903,254.1499938964844,251.58999633789065,252.8099975585937,252.8099975585937,1242600.0,2.0,1.0,0.250025,"Among the largest underlying components of VV, in trading today Biogen Inc (Symbol: BIIB) is up about 0.6%, PayPal Holdings Inc (Symbol: PYPL) is up about 0.5%, and Danaher Corp (Symbol: DHR) is up by about 0.2%. For a complete list of holdings, visit the VV Holdings page  The chart below shows the one year price performance of VV, versus its 200 day moving average: Looking at the chart above, VV's low point in its 52 week range is $90.89 per share, with $110.34 as the 52 week high point - that compares with a last trade of $108.59. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",248.07911682128906
2017-05-24 00:00:00+00:00,249.3000030517578,254.3699951171875,246.1199951171875,253.3300018310547,253.3300018310547,2225100.0,3.0,1.0,0.5000249999999999,"The biotechnology company, which was spun off from Biogen Inc. ( BIIB ) in February, has a market cap of $5.7 billion; its shares were trading around $52.5 on Wednesday with a price-earnings (P/E) ratio of 82.03, a price-book (P/B) ratio of 9.7 and a price-sales (P/S) ratio of 6. The firm seeks value in a limited number of companies that are out of favor or undergoing a transition. Earlier this month, Blue Bird Corp. ( BLBD ) announced it will be incorporating Allison's FuelSense 2.0 into its buses.",243.71597290039062
2017-05-25 00:00:00+00:00,252.6499938964844,254.4499969482422,252.0,252.97000122070312,252.97000122070312,1552300.0,2.0,1.0,0.250025,"Biogen Inc.BIIB announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. The standard approval was based on positive results of the phase III ENHANCE study, which was conducted to evaluate the long-term safety and efficacy of Fampyra in patients with both relapsing and progressive forms of MS.",246.62278747558594
2017-05-26 00:00:00+00:00,252.58999633789065,253.6199951171875,250.509994506836,250.8000030517578,250.8000030517578,833100.0,2.6666666666666665,1.0,0.4166916666666666,"It has been about a month since the last earnings report for Biogen Inc.BIIB . Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen expects relatively stable demand for both Tecfidera and Tysabri in 2017 as patient growth in ex-U.S. markets offsets the modest decline in the U.S. due to rising competition including from Ocrevus. New Article Holmes: I always like a bargain, and Biogen ( BIIB ) is no exception. By Jeff Miller : Each week the Stock Exchange highlights the results from different technical trading methods. And here is a nice summary ( Timothy Gornall at Seeking Alpha ) of what the company does - bringing orthodontics to regular dentists. New Article Notably in Apr 2017, Biogen Inc. BIIB announced that it has inked a deal to buy worldwide rights for Bristol-Myers Squibb's BMY anti-tau antibody, BMS-986168, for an upfront payment of $300 million. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report To read this article on Zacks.com click here. This includes MK-6240, a tau ligand which is currently being assessed as a potential Positron Emission Tomography (PET) imaging agent for quantifying the brain burden of neurofibrillary tangle pathology in people with AD.",254.21119689941406
2017-05-30 00:00:00+00:00,250.3999938964844,251.5500030517578,246.33999633789065,246.5399932861328,246.5399932861328,1366800.0,3.5,1.0,0.6250249999999999,"Full Marketing Approval for Biogen's Fampyra in the EU: Biogen BIIB got full marketing approval from the European Commission (EC) for Fampyra, which is indicated for walking improvement in people with multiple sclerosis (MS). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Inovio Pharmaceuticals, Inc. (INO): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report Puma Biotechnology Inc (PBYI): Free Stock Analysis Report BioCryst Pharmaceuticals, Inc. (BCRX): Free Stock Analysis Report To read this article on Zacks.com click here. The European marketing application for axicabtagene ciloleucel is slated for submission in the third quarter (Read more: Kite Pharma Cancer Drug BLA Gets Priority Review Status ). New Article If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read UnitedHealth (UNH) Grows Via Optum, Axes Exchange Losses Better Coal Scenario Bodes Well for Union Pacific (UNP) Biogen (BIIB) Diversifies Beyond Multiple Sclerosis Featured Reports Lower Cash Costs Boost Suncor (SU), Syncrude Outage Hurts While Suncor's lower cash costs and strong production platform bode well, unplanned outages at Syncrude oil sands project have kept the Zacks analyst on the sidelines. Tuesday May 30, 2017 Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc (UNH), Union Pacific Corporation (UNP) and Biogen Inc (BIIB). Click to get this free report United Technologies Corporation (UTX): Free Stock Analysis Report Union Pacific Corporation (UNP): Free Stock Analysis Report UnitedHealth Group Incorporated (UNH): Free Stock Analysis Report PNC Financial Services Group, Inc. (The) (PNC): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Accenture PLC (ACN): Free Stock Analysis Report To read this article on Zacks.com click here.",254.0797882080078
2017-05-31 00:00:00+00:00,247.3099975585937,247.97999572753903,244.27999877929688,247.7700042724609,247.7700042724609,1893500.0,3.5,1.0,0.6250249999999999,"But the pooled dataset across the drug's clinical program failed to provide evidence of a significant improvement on disability compared to Biogen 's (NASDAQ: BIIB) injected drug Avonex. Turning to specifics, Celgene sports a dominant multiple myeloma franchise headlined by its megablockbuster Revlimid, and it has rapidly transformed the inflammatory disease drug , Otezla, into a blockbuster product as well. Because of the size of this deal, along with Celgene agreeing to certain lock-up provisions on its share ownership in Juno, most onlookers assumed this research partnership was simply a prelude to a full-on buyout later down the road. New Article Stocks recently featured in the blog include UnitedHealth Group Inc (NYSE: UNH- Free Report ), Union Pacific Corp. (NYSE: UNP- Free Report ), Biogen Inc (NASDAQ: BIIB- Free Report ), United Technologies Corp. (NYSE: UTX- Free Report ) and Accenture Plc (NYSE: ACN- Free Report ). Here are highlights from Tuesday's Analyst Blog: Top Research Reports for UnitedHealth, Union Pacific & Biogen Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Inc (NYSE: UNH- Free Report ), Union Pacific Corp. (NYSE: UNP- Free Report ) and Biogen Inc (NASDAQ: BIIB- Free Report ). Get the full Report on UNH - FREE Get the full Report on UNP - FREE Get the full Report on BIIB - FREE Get the full Report on UTX - FREE Get the full Report on ACN - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. New Article Biogen Inc. BIIB : Cambridge, MA-based Biogen is, perhaps, the most well-known name in the MS space. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Teva Pharmaceutical Industries Limited (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. About 2.3 million people across the world suffer from MS, one of the most common neurological disorders and causes of disability in young adults, while hundreds of thousands remain undiagnosed. New Article Shares of Biogen (NASDAQ: BIIB) and Gilead Sciences (NASDAQ: GILD) are both down year to date, with Gilead's shareholders experiencing the worse pain. Sales for Gilead's HIV franchise, on the other hand, could kick into higher gear if the company's bictegravir/F/TAF combo gains regulatory approval. Gilead has high hopes for winning in the potentially lucrative NASH market, with two other mid-stage candidates targeting the indication.",242.32330322265625
2017-06-02 00:00:00+00:00,252.97999572753903,258.260009765625,252.13999938964844,256.6499938964844,256.6499938964844,1731800.0,3.0,1.0,0.5000249999999999,"Biogen Inc.BIIB announced granting of marketing authorization to its marketed drug Spinraza (nusinersen) by European Commission under the accelerated assessment program for treating patients with 5q spinal muscular atrophy (SMA). Click to get this free report Bayer AG (BAYRY): Free Stock Analysis Report VIVUS, Inc. (VVUS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, Biogen licensed the global rights to develop, manufacture and commercialize Spinraza from Ionis Pharmaceuticals IONS , a leader in antisense therapeutics. New Article Among the largest underlying components of BBH, in trading today Biogen Inc (Symbol: BIIB) is up about 0.5%, Quintiles IMS Holdings Inc (Symbol: Q) is up about 0.7%, and Illumina Inc (Symbol: ILMN) is up by about 0.4%. For a complete list of holdings, visit the BBH Holdings page  The chart below shows the one year price performance of BBH, versus its 200 day moving average: Looking at the chart above, BBH's low point in its 52 week range is $95.77 per share, with $123.15 as the 52 week high point - that compares with a last trade of $119.97. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Especially high volume was seen for the $260 strike call option expiring June 09, 2017 , with 582 contracts trading so far today, representing approximately 58,200 underlying shares of BIIB. Below is a chart showing LEN's trailing twelve month trading history, with the $55 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 7,899 contracts, representing approximately 789,900 underlying shares or approximately 53.1% of BIIB's average daily trading volume over the past month, of 1.5 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $260 strike highlighted in orange: And Range Resources Corp (Symbol: RRC) saw options trading volume of 24,020 contracts, representing approximately 2.4 million underlying shares or approximately 43.8% of RRC's average daily trading volume over the past month, of 5.5 million shares.",240.0348358154297
2017-06-06 00:00:00+00:00,257.0599975585937,258.29998779296875,254.9600067138672,257.1600036621094,257.1600036621094,1080700.0,3.0,1.0,0.5000249999999999,"NVIDIA (NASDAQ: NVDA) , Biogen (NASDAQ: BIIB) , and JPMorgan Chase (NYSE: JPM) all have that potential. Patients with spinal muscular atrophy (SMA) are just now beginning to experience the effects of Spinraza, a new product marketed by Biogen and originally developed by Ionis Pharmaceuticals . The company reported very encouraging results last year from an early stage clinical study of the drug, with some evidence that aducanumab could improve cognition in patients with Alzheimer's disease by targeting amyloid plaques in the brain. New Article That represents an 11% royalty rate, since its partner, Biogen (NASDAQ: BIIB) , already reported that first-quarter sales of the drug were $47 million . What happened Shares of Ionis Pharmaceuticals (NASDAQ: IONS) , a commercial-stage biotech focused on RNA-targeted therapeutics, dropped 6% in May according to data from S&P Global Market Intelligence . The bummer inotersen news overshadowed the good-looking earnings results and Approach data, leading shares to take a step back in May.",244.1790771484375
2017-06-09 00:00:00+00:00,256.3099975585937,262.3699951171875,254.8699951171875,259.8900146484375,259.8900146484375,1575900.0,2.0,1.0,0.250025,"What happened Biotech titan Biogen (NASDAQ: BIIB) had a rough time last month as a pair of unrelated issues helped send its shares down by 8.58%, according to data from S&P Global Market Intelligence . So, Biogen could reasonably fund one or more acquisitions via debt financing if the competitive threats to its MS franchise do materialize as expected and its pipeline isn't able to deliver a major drug capable of offsetting these losses. That said, Biogen doesn't appear to have the right mix of ingredients in place to allow it to break away from the political malaise that's haunting the broader industry, suggesting that its shares will likely continue to slide in the coming months along with the IBB.",245.65560913085938
2017-06-12 00:00:00+00:00,260.2300109863281,265.4800109863281,259.57000732421875,262.1099853515625,262.1099853515625,1576700.0,4.0,1.0,0.7500249999999999,"Biogen Inc (Symbol: BIIB), which makes up 0.24% of the Vanguard Russell 1000 ETF ( VONE ), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at BIIB: BIIB - last trade: $259.89 - Recent Insider Buys: And Synchrony Financial (Symbol: SYF), the #201 largest holding among components of the Vanguard Russell 1000 ETF ( VONE ), shows 2 directors and officers as recently filing Form 4's indicating purchases. The ETF holds a total of $1,599,925 worth of BIIB, making it the #90 largest holding.",242.35826110839844
2017-06-13 00:00:00+00:00,261.9700012207031,262.1199951171875,259.54998779296875,261.4200134277344,261.4200134277344,1312400.0,3.0,1.0,0.5000249999999999,"GILD is a part of the Health Care sector, which includes companies such as Amgen Inc. ( AMGN ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports GILD's forecasted earnings growth in 2017 as -30.9%, compared to an industry average of 7.1%. For more information on the declaration, record and payment dates, visit the GILD Dividend History page.",233.81881713867188
2017-06-14 00:00:00+00:00,255.5599975585937,257.3800048828125,250.8800048828125,253.3699951171875,253.3699951171875,3067600.0,2.5,1.0,0.375025,"VIDEO: Nasdaq 100 Movers: BIIB, ALXN The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Wednesday, shares of Alexion Pharmaceuticals topped the list of the day's best performing components of the Nasdaq 100 index, trading up 7.2%. And the worst performing Nasdaq 100 component thus far on the day is Biogen, trading down 3.2%. New Article Especially high volume was seen for the $270 strike call option expiring June 30, 2017 , with 1,159 contracts trading so far today, representing approximately 115,900 underlying shares of BIIB. Below is a chart showing AAPL's trailing twelve month trading history, with the $160 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 9,109 contracts thus far today. That number of contracts represents approximately 910,900 underlying shares, working out to a sizeable 63.7% of BIIB's average daily trading volume over the past month, of 1.4 million shares. New Article Biogen Inc. ( BIIB ) had the largest percent change down (-3.08%) while Alexion Pharmaceuticals, Inc. ( ALXN ) had the largest percent change gain rising 9.26%. The Dow Jones index closed up .22% for the day; a total of 46.09 points. Chevron Corporation ( CVX ) had the largest percent change down (-1.41%) while Home Depot, Inc. (The) ( HD ) had the largest percent change gain rising 1.8%. New Article Biogen Inc. 's BIIB chief financial officer (CFO) for the last 10 years, Paul Clancy, is joining Alexion Pharmaceuticals, Inc. ALXN next month. Click to get this free report Bayer AG (BAYRY): Free Stock Analysis Report Pepsico, Inc. (PEP): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Clancy will replace Dave Anderson, who will become a senior adviser to chief executive officer (CEO) Ludwig Hantson.",225.80345153808594
2017-06-15 00:00:00+00:00,253.6000061035156,255.759994506836,253.1499938964844,255.0200042724609,255.0200042724609,1443700.0,2.5,1.0,0.375025,"BIIB Stock Options Play The Trade: Sell the Oct $195 put and collect $1.75 to open. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen Inc (NASDAQ: BIIB ) stock has had a choppy few months. That aside, The fundamentals of BIIB remain stable. New Article Early industry innovators like Amgen ( AMGN ), Biogen ( BIIB ) and Gilead Sciences ( GILD ) currently find themselves in ""big trouble,"" according to Loncar Investments Chief Executive Brad Loncar, largely as victims of their own success. ""Two or three years ago, when you (were) in a bull market, I think generalists started to pay attention,"" RBC's Eckler told Investor's Business Daily. Eckler sees gene therapy and rare diseases as strong sectors, noting Bluebird and AveXis (AVXS) are developing drugs in those arenas.",232.3141326904297
2017-06-16 00:00:00+00:00,255.4900054931641,256.7699890136719,250.88999938964844,251.7400054931641,251.7400054931641,2427200.0,4.5,1.0,0.8750249999999999,"Players in PEGylation and polymer conjugate chemistry technology space include Biogen BIIB , Savient Pharmaceuticals, Dr. Reddy's and Novo Nordisk among others. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Nektar Therapeutics (NKTR): Free Stock Analysis Report To read this article on Zacks.com click here. Nektar's PEGylation technology has facilitated the development of 10 approved products in the U.S. and the EU, through partnerships with healthcare companies, namely, AstraZeneca's AZN Movantik, UCB's Cimzia and Amgen's AMGN Neulasta among others. New Article The company was spun off from Biogen (BIIB) in February of this year and reported its first full quarter as a stand-alone company in early May. Click to get this free report BIOVERATIV INC (BIVV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Bioverativ (BIVV) is a biotechnology company focused on the discovery and commercialization of innovative therapies for the treatment of hemophilia and other rare blood disorders.",243.71766662597656
2017-06-19 00:00:00+00:00,253.22999572753903,262.2799987792969,252.94000244140625,260.5400085449219,260.5400085449219,1956200.0,4.0,1.0,0.7500249999999999,"Combined, PKI and BIIB make up approximately 2.1% of the underlying holdings of XLV. Within the sector, PerkinElmer, Inc. (Symbol: PKI) and Biogen Inc (Symbol: BIIB) are two large stocks leading the way, showing a gain of 5.9% and 4.0%, respectively. Combined, AMD and MU make up approximately 0.8% of the underlying holdings of XLK.",252.06427001953125
2017-06-21 00:00:00+00:00,266.1099853515625,279.8099975585937,266.1099853515625,278.6000061035156,278.6000061035156,3158500.0,3.333333333333333,1.0,0.5833583333333334,"Particularly high volume was seen for the $282.50 strike call option expiring June 23, 2017 , with 2,405 contracts trading so far today, representing approximately 240,500 underlying shares of BIIB. Below is a chart showing CMG's trailing twelve month trading history, with the $425 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 18,083 contracts, representing approximately 1.8 million underlying shares or approximately 110.7% of BIIB's average daily trading volume over the past month, of 1.6 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $282.50 strike highlighted in orange: And Apple Inc (Symbol: AAPL) options are showing a volume of 180,864 contracts thus far today. New Article Biogen ( BIIB ), Incyte ( INCY ) and BioMarin (BMRN) were among the pharma names that helped the Nasdaq outperform its peers. Another day of selling in oil pushed the S&P 500 and the Dow Jones Industrial Average into the red for a second straight session, while gains in health stocks helped the Nasdaq Composite buck the weaker trend. While the US stockpiles data initially gave futures a bounce, the selling story came back as some traders looked at the chances of West Texas Intermediate hitting below the $40 a barrel level in the next few days. New Article Surging Biotech Stocks: Biogen (BIIB) Biogen Inc (NASDAQ: BIIB ) shares are up 4% in mid-day trading, crossing above the 200-day moving average to make another run at three-year overhead resistance near $310. BIIB will next report results on July 25 before the bell. Reports that the White House's executive order on drug pricing - something President Trump has frequently touched on - may not be released for weeks.",252.0761260986328
2017-06-26 00:00:00+00:00,281.739990234375,282.8900146484375,277.6400146484375,279.8099975585937,279.8099975585937,1279500.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of JKD, in trading today Altria Group Inc (Symbol: MO) is up about 0.3%, Biogen Inc (Symbol: BIIB) is down about 0.4%, and Anthem Inc (Symbol: ANTM) is lower by about 0.8%. For a complete list of holdings, visit the JKD Holdings page  The chart below shows the one year price performance of JKD, versus its 200 day moving average: Looking at the chart above, JKD's low point in its 52 week range is $116.19 per share, with $148.7078 as the 52 week high point - that compares with a last trade of $148.70. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",254.96478271484375
2017-06-29 00:00:00+00:00,275.0,275.20001220703125,268.9100036621094,271.8800048828125,271.8800048828125,1035300.0,2.0,1.0,0.250025,"Biogen's Humira Biosimilar Gets CHMP Backing: Another company that got a positive CHMP opinion is Biogen BIIB -- the company's biosimilar version of AbbVie's top-selling blockbuster drug, Humira, got a positive opinion. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report AVEO Pharmaceuticals, Inc. (AVEO): Free Stock Analysis Report Portola Pharmaceuticals, Inc. (PTLA): Free Stock Analysis Report To read this article on Zacks.com click here. FDA approval makes Bevyxxa the first and only anticoagulant for hospital and extended duration prophylaxis (35 to 42 days) of venous thromboembolism (VTE) in acutely ill medical patients.",251.67098999023438
2017-07-05 00:00:00+00:00,272.9700012207031,278.3699951171875,272.6099853515625,277.7099914550781,277.7099914550781,1326300.0,3.5,1.0,0.6250249999999999,"So far, Biogen 's (NASDAQ: BIIB) spinoff of Bioverativ (NASDAQ: BIVV) at the beginning of the year definitely seems to be working well. Shire 's (NASDAQ: SHPG) hemophilia franchise, which includes one of the top drugs on the market, Advate, made more than $650 million in sales in the first quarter of this year. True North's lead candidate, monoclonal antibody TNT009, is being evaluated in a phase 1 clinical study in treating cold agglutinin disease (CAgD). New Article Over the last six months, Vertex was up 71.2% while Biogen BIIB was down 6.6% (See the last biotech stock roundup here: EU Nod for Regeneron RA Drug, Portola Soars on FDA Nod ). Click to get this free report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Alkermes PLC (ALKS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Opexa Therapeutics, Inc. (OPXA): Free Stock Analysis Report Cara Therapeutics, Inc. (CARA): Free Stock Analysis Report To read this article on Zacks.com click here. Amgen's Vectibix Label Expanded: Amgen's AMGN Vectibix gained FDA approval for the first-line treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC) in combination with FOLFOX and as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.",256.4283752441406
2017-07-06 00:00:00+00:00,275.57000732421875,276.8900146484375,271.0,271.9599914550781,271.9599914550781,1309700.0,4.0,1.0,0.7500249999999999,"Biogen Inc. (NASDAQ: BIIB ) is a leader in the $20 billion global market for multiple sclerosis treatments. 7 ETFs That Can Make You Love Retirement Biotech investors got a rude awakening when President Trump used his first news conference on January 11th to call out drug makers, saying they were, ""getting away with murder."" The recent launch of Tecfidera establishes the company's dominance in the space for the next few years, and pipeline drugs for Alzheimer's and other neurology diseases support a strong sales outlook.",265.41595458984375
2017-07-10 00:00:00+00:00,273.5,274.0799865722656,270.3099975585937,273.5799865722656,273.5799865722656,942200.0,2.5,1.0,0.375025,"Among the largest underlying components of BIB, in trading today Biogen Inc (Symbol: BIIB) is off about 0.8%, Regeneron Pharmaceuticals, Inc. (Symbol: REGN) is off about 0.9%, and Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is lower by about 1.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares Ultra Nasdaq Biotechnology (Symbol: BIB) where we have detected an approximate $70.4 million dollar outflow -- that's a 14.8% decrease week over week (from 8,800,000 to 7,500,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Fundamentally, Amgen stock is cheap from a price-earnings perspective and it does so with great net profit margins. It's twice as cheap as Merck & Co., Inc. (NYSE: MRK ), three times cheaper than Celgene Corporation (NASDAQ: CELG ) and runs much better net margins than both. The Alternate Bet: Sell AMGN stock Oct $150/$145 bull put spread where I have about the same chance of success but with limited risk.",258.13055419921875
2017-07-12 00:00:00+00:00,274.1499938964844,276.45001220703125,272.3299865722656,275.0799865722656,275.0799865722656,1406500.0,3.0,1.0,0.5000249999999999,"Below is a twelve month price history chart comparing the stock performance of ACAD, BMRN, and BIIB: Combined, ACAD, BMRN, and BIIB represent 11.23% of the Biotech ETF. Three of BBH's underlying holdings with notable upside to their analyst target prices are Acadia Pharmaceuticals Inc (Symbol: ACAD), BioMarin Pharmaceutical Inc. (Symbol: BMRN), and Biogen Inc (Symbol: BIIB). Similarly, BMRN has 28.90% upside from the recent share price of $90.92 if the average analyst target price of $117.20/share is reached, and analysts on average are expecting BIIB to reach a target price of $322.31/share, which is 18.60% above the recent price of $271.76.",246.7296905517578
2017-07-13 00:00:00+00:00,276.0400085449219,280.75,272.6099853515625,278.3599853515625,278.3599853515625,1422500.0,2.0,1.0,0.250025,"Biogen (NASDAQ: BIIB) recorded $2.38 billion in product revenue in the first quarter -- a nice haul for a large biotech -- but 40% of its sales came from its top-selling multiple-sclerosis drug Tecfidera. Close, but only half a cigar It should be noted that Biogen's anti-CD20 drugs, Rituxan and Gazyva, combined for $1.04 billion of sales, besting Tecfidera. Waiting to exhale Between now and 2020 when the Alzheimer's drug's phase 3 trials read out, Biogen's stock will be tied to how well the company can compete in the crowded multiple-sclerosis market, and how quickly it can diversify away from it.",241.19557189941406
2017-07-17 00:00:00+00:00,280.1000061035156,284.3099975585937,279.510009765625,282.6499938964844,282.6499938964844,1531200.0,3.0,1.0,0.5000249999999999,"Particularly high volume was seen for the $285 strike call option expiring July 21, 2017 , with 680 contracts trading so far today, representing approximately 68,000 underlying shares of BIIB. Below is a chart showing AGN's trailing twelve month trading history, with the $250 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 6,711 contracts, representing approximately 671,100 underlying shares or approximately 42.7% of BIIB's average daily trading volume over the past month, of 1.6 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $285 strike highlighted in orange: For the various different available expirations for VHC options , AGN options , or BIIB options , visit StockOptionsChannel.com. New Article In trading on Monday, shares of Biogen Inc (Symbol: BIIB) crossed above their 200 day moving average of $281.35, changing hands as high as $284.20 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $230.29 per share, with $307.33 as the 52 week high point - that compares with a last trade of $284.04. According to the ETF Finder at ETF Channel, BIIB makes up 9.03% of the iShares Nasdaq Biotechnology ETF (Symbol: IBB) which is trading up by about 0.6% on the day Monday.",242.07249450683594
2017-07-18 00:00:00+00:00,283.010009765625,283.67999267578125,280.3099975585937,282.6000061035156,282.6000061035156,1126700.0,3.333333333333333,1.0,0.5833583333333334,"Late last year, the FDA approved the first one -- Spinraza -- a drug discovered by Ionis Pharmaceuticals (NASDAQ: IONS) and marketed by Biogen (NASDAQ: BIIB) . Let's take a closer look at AveXis Inc.'s surprising success, and the arena its lead candidate for the treatment of spinal muscular atrophy (SMA) could eventually compete in, to see if the stock is still a buy at recent prices. Historical data shows 75% of infants that display SMA symptoms don't reach 13.6 months of age without requiring constant breathing support from a ventilator. New Article Investors eyeing a purchase of Biogen Inc (Symbol: BIIB) stock, but cautious about paying the going market price of $281.89/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to BIIB's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. For other put options contract ideas at the various different available expirations, visit the BIIB Stock Options page of StockOptionsChannel.com. New Article Biogen Inc (Symbol: BIIB), which makes up 5.86% of the Biotech ETF ( BBH ), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at BIIB: BIIB - last trade: $282.65 - Recent Insider Buys: 10 ETFs With Stocks That Insiders Are Buying  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The ETF holds a total of $40,341,890 worth of BIIB, making it the #5 largest holding.",244.0
2017-07-19 00:00:00+00:00,283.5199890136719,285.8399963378906,280.510009765625,281.95001220703125,281.95001220703125,1103500.0,2.0,1.0,0.250025,"Among major biotech stocks, Biogen BIIB was up almost 4%. Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report Puma Biotechnology Inc (PBYI): Free Stock Analysis Report To read this article on Zacks.com click here. Key highlights this week include impressive data from Vertex's VRTX cystic fibrosis (CF) pipeline while companies like Gilead GILD and Puma PBYI got FDA approval for their hepatitis C virus (HCV) and breast cancer treatments, respectively.",260.290771484375
2017-07-20 00:00:00+00:00,282.17999267578125,284.32000732421875,280.75,281.44000244140625,281.44000244140625,1049200.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of ITOT, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.8%, Costco Wholesale Corp (Symbol: COST) is up about 0.2%, and Biogen Inc (Symbol: BIIB) is lower by about 0.1%. For a complete list of holdings, visit the ITOT Holdings page  The chart below shows the one year price performance of ITOT, versus its 200 day moving average: Looking at the chart above, ITOT's low point in its 52 week range is $47.42 per share, with $56.71 as the 52 week high point - that compares with a last trade of $56.60. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",262.0981140136719
2017-07-24 00:00:00+00:00,283.0,285.3500061035156,280.010009765625,284.70001220703125,284.70001220703125,1476200.0,4.5,1.0,0.8750249999999999,"Biogen Inc.BIIB Biogen, a well-known name in the multiple sclerosis (MS) market,is also scheduled to announce results before the opening bell. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The second-quarter reporting cycle seems to have gotten off to a good start, with an abundance of positive surprises, particularly on the revenue front. New Article Biogen Inc. ( BIIB ) is reporting for the quarter ending June 30, 2017. In the past year BIIB has beat the expectations every quarter. Zacks Investment Research reports that the 2017 Price to Earnings ratio for BIIB is 13.87 vs. an industry ratio of 4.50, implying that they will have a higher earnings growth than their competitors in the same industry.",252.35716247558594
2017-07-25 00:00:00+00:00,290.010009765625,291.9100036621094,280.239990234375,282.9599914550781,282.9599914550781,3110000.0,2.857142857142857,1.0,0.4643107142857143,"Lgt Capital Partners Ltd. New Purchases: DPS , C , Added Positions: UNH , SBUX, AKAM, BIIB, CL, MS, CELG, AMG, VZ, NDAQ, Reduced Positions:AWK, MRK, CERN, AQN, MCD, ISRG, DVMT, AAPL, MAS, Sold Out:INDA, TGNA, WFM, CARS, For the details of LGT CAPITAL PARTNERS LTD.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=LGT+CAPITAL+PARTNERS+LTD. Shares added by 5.35% Biogen Inc ( BIIB ) - 152,155 shares, 4.15% of the total portfolio. Added: Biogen Inc ( BIIB ) Lgt Capital Partners Ltd. added to the holdings in Biogen Inc by 29.35%. New Article Biogen Inc.BIIB , a well-known name in the multiple sclerosis (MS) market, surpassed expectations both for earnings and sales in the second quarter of 2017. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The drugmaker also raised its revenue guidance for 2017 as sales of its newest drug Spinraza (spinal muscular atrophy) witnessed faster-than-expected adoption in the U.S. Shares of Biogen rose almost 5% in pre-market trading in response to the strong results. New Article Making moves this morning on their latest quarterly results are Alphabet Inc (NASDAQ: GOOGL ) and Biogen Inc (NASDAQ: BIIB ), though Michael Kors Holdings Ltd (NYSE: KORS ) is also making waves via a big-name buyout in the fashion space. Biogen Inc (BIIB) Lastly, BIIB is making large strides forward following beats on both the top and bottom lines reported this morning. BIIB stock is up roughly 5% this morning, bringing shares back up from roughly breakeven. New Article Cambridge, MA-based Biogen Inc.BIIB one of the world's leading biotechnology companies, focuses on therapeutic areas including neurology and immunology. BIIB has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 5.29%. Biogen Inc. Price and EPS Surprise Biogen Inc. Price and EPS Surprise | Biogen Inc. Quote Currently, BIIB has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. New Article Particularly high volume was seen for the $295 strike call option expiring July 28, 2017 , with 1,992 contracts trading so far today, representing approximately 199,200 underlying shares of BIIB. Below is a chart showing PCRX's trailing twelve month trading history, with the $55 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 13,693 contracts, representing approximately 1.4 million underlying shares or approximately 116% of BIIB's average daily trading volume over the past month, of 1.2 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $295 strike highlighted in orange: For the various different available expirations for CTRN options , PCRX options , or BIIB options , visit StockOptionsChannel.com. New Article Eli Lilly and Company Price, Consensus and EPS Surprise Eli Lilly and Company Price, Consensus and EPS Surprise | Eli Lilly and Company Quote Biogen Inc. BIIB , which also reported second-quarter results today, beat estimates for both earnings and sales. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Basaglar - Lilly and partner Boehringer Ingelheim's follow-on insulin to Sanofi's SNY blockbuster drug, Lantus - was launched in the U.S. in mid-Dec 2016 where it generated revenues of $59.5 million in the quarter. New Article Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 54.5% Average next regular session additional gain: 1.6% Over the prior three fiscal years (12 quarters), when shares of BIIB rose in the extended-hours session in reaction to its earnings announcement, history shows that 54.5% of the time (6 events) the stock posted additional gains in the following regular session by an average of 1.6%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 6.8% Over that same historical period, when shares of BIIB dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 6.8% by the following regular session close. Extended-Hours Dollar Volume: $74,988,907 Biogen Idec ( BIIB ) is due to issue its quarterly earnings report in the upcoming extended-hours session.",260.2779235839844
2017-07-26 00:00:00+00:00,288.54998779296875,296.95001220703125,285.0199890136719,295.6099853515625,295.6099853515625,3014600.0,3.333333333333333,1.0,0.5833583333333334,"Biogen (NASDAQ: BIIB) started the biotech earnings season off with a bang, generating enough revenue for the company to have confidence to increase its revenue guidance for the year. The lower income from operations and earnings was due to research-and-development expenses that included $360 million related to the licensing deal with Bristol-Myers Squibb (NYSE: BMY) for its anti-tau Alzheimer's disease drug candidate, now called BIIB092, and a $120 million charge related to the acquisition of a phase-3-ready stroke treatment, BIIB093, from Remedy Pharmaceuticals. Earnings weren't nearly as hot, but Biogen has a good excuse: one-time investments in the company's future that lowered the bottom-line results. New Article BIOGEN INC BIIB is a large-cap growth stock in the Biotechnology & Drugs industry. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068. The following are today's upgrades for Validea's Patient Investor model based on the published strategy of Warren Buffett. New Article Akamai Technologies, Inc. ( AKAM ) had the largest percent change down (-14.62%) while Biogen Inc. ( BIIB ) had the largest percent change gain rising 4.47%. NASDAQ Market Wrap As of 7/26/2017 4:44:01 PM NASDAQ COMPOSITE INDEX 6,422.75 milestone closes at 115 STOCKS REACHED A 52 WEEK HIGH 13 THOSE REACHING LOWS TOTALEDBiogen Inc. [BIIB]TOPS ADVANCERS LISTOF NASDAQ 100 INDEX % 4.47 ROSE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Wednesday's session closes with the NASDAQ Composite Index reaching a historical high.",263.3699645996094
2017-07-28 00:00:00+00:00,287.4800109863281,289.29998779296875,284.0,287.44000244140625,287.44000244140625,869200.0,3.0,1.0,0.5000249999999999,"Ampyra is marketed in the ex-U.S. markets by Biogen Inc. BIIB under the trade name, Fampyra. Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline Updates In Jun 2017, the company has submitted a new drug application (NDA) to the FDA for Inbrija for treatment of patients suffering from Parkinson's disease (PD). New Article Among the largest underlying components of VHT, in trading today Lilly (Eli) & Co (Symbol: LLY) is down about 0.5%, Thermo Fisher Scientific Inc (Symbol: TMO) is off about 0.7%, and Biogen Inc (Symbol: BIIB) is lower by about 1.3%. For a complete list of holdings, visit the VHT Holdings page  The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $120.38 per share, with $151.29 as the 52 week high point - that compares with a last trade of $147.30. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",261.6249084472656
2017-07-31 00:00:00+00:00,287.6000061035156,290.9599914550781,287.5899963378906,289.5899963378906,289.5899963378906,1272200.0,4.0,1.0,0.7500249999999999,Explosive Healthcare Stocks to Buy: Biogen Inc (BIIB) Click to Enlarge Shares of Biogen Inc (NASDAQ: BIIB ) just transitioned into an intermediate-term bullish pattern as the stock is now attracting more investor cash. 7 Blue-Chip Stocks You Shouldn't Hold Anymore The resulting cash that is flowing back into the sector brings with it many opportunities to buy some names that have strong double-digit growth potential for the second half of 2017. 7 Small-Cap Stocks With Big-League Potential The break through $300 will strengthen the bull market trend for Biogen shares and target another 15%-20% move in the second half of the year.,257.08612060546875
2017-08-01 00:00:00+00:00,290.79998779296875,291.8599853515625,289.54998779296875,291.1499938964844,291.1499938964844,1195400.0,3.0,1.0,0.5000249999999999,"Factors to Consider Ionis earns revenues in the form of upfront, milestone and other payments under its partnerships with leading health care companies like Biogen Inc. BIIB and Glaxo. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report TESARO, Inc. (TSRO): Free Stock Analysis Report Esperion Therapeutics, Inc. (ESPR): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Last month, Ionis and Akcea submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for volanesorsen for the treatment of patients with familial chylomicronemia syndrome (FCS).",252.41221618652344
2017-08-04 00:00:00+00:00,286.8900146484375,288.6300048828125,284.45001220703125,288.2699890136719,288.2699890136719,746000.0,4.0,1.0,0.7500249999999999,"At Holdings Channel , we have reviewed the latest batch of the 24 most recent 13F filings for the 06/30/2017 reporting period, and noticed that Biogen Inc (Symbol: BIIB) was held by 10 of these funds. Worth noting is that MARSHALL WACE ASIA Ltd , included in this recent batch of 13F filers, exited BIIB common stock as of 06/30/2017. While looking at individual 13F filings can sometimes be misleading due to the long-only nature of the information, the sum total across groups of funds from one reporting period to another can be a lot more revealing and relevant, providing interesting stock ideas that merit further research, like Biogen Inc (Symbol: BIIB).",251.78042602539062
2017-08-07 00:00:00+00:00,289.17999267578125,291.1700134277344,288.1700134277344,291.010009765625,291.010009765625,1035600.0,3.5,1.0,0.6250249999999999,"Biotech juggernautBiogen (NASDAQ: BIIB) netted second-quarter revenue of $3.08 billion, or $4.07 a share, a 6% increase over last year and crushing analyst estimates of $2.81 billion. Sarepta recently settled a patent dispute with BioMarin Pharmaceutical , agreeing to pay a one-time $35 million upfront fee plus royalty and milestone payments on its exon-skipping platform. By settling the suit, Sarepta is now able to expand the global reach of Exondys 51 under a new managed access program, through which the addressable market is much larger than in the United States. New Article Revenues of $16.2 million from the Queen et al. licenses were higher than the year-ago figure of $14.2 million, courtesy higher royalties on Tysabri from Biogen Inc. BIIB . Click to get this free report PDL BioPharma, Inc. (PDLI): Free Stock Analysis Report Enzo Biochem, Inc. (ENZ): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Valeant Pharmaceuticals International, Inc. (VRX): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, the company received cash payments of $34.6 million from the royalty rights acquired from Depomed, primarily related to Glumetza, a product marketed by Valeant Pharmaceuticals International, Inc. VRX .",256.85638427734375
2017-08-08 00:00:00+00:00,291.17999267578125,291.70001220703125,288.5,289.260009765625,289.260009765625,931200.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of VHT, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is down about 0.7%, Biogen Inc (Symbol: BIIB) is off about 0.8%, and Aetna Inc. (Symbol: AET) is lower by about 0.1%. For a complete list of holdings, visit the VHT Holdings page  The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $120.38 per share, with $151.29 as the 52 week high point - that compares with a last trade of $147.35. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",261.5101318359375
2017-08-09 00:00:00+00:00,285.7900085449219,289.4700012207031,285.7300109863281,288.739990234375,288.739990234375,777500.0,2.0,1.0,0.250025,"Stocks recently featured in the blog includeBiogen (NASDAQ: BIIB - Free Report ), Activision (NASDAQ: ATVI - Free Report ), Cigna (NYSE: CI - Free Report )Kraft Heinz (NASDAQ: KHC - Free Report ) and Equinix (NASDAQ: EQIX - Free Report ). Today's Research Daily features new research reports on 16 major stocks, including Biogen (NASDAQ: BIIB - Free Report ), Activision (NASDAQ: ATVI - Free Report ) and Cigna (NYSE: CI - Free Report ). Get the full Report on BIIB - FREE Get the full Report on ATVI - FREE Get the full Report on CI - FREE Get the full Report on KHC - FREE Get the full Report on EQIX - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.",257.0648498535156
2017-08-11 00:00:00+00:00,282.3999938964844,285.8999938964844,281.2900085449219,283.67999267578125,283.67999267578125,727200.0,4.0,1.0,0.7500249999999999,"Biogen (NASDAQ: BIIB) reported $203 million in sales of their spinal muscular atrophy drug, Spinraza, during its second full year on the market, netting Ionis $22.4 million in royalties on sales of the drug. Ionis Pharmaceuticals (NASDAQ: IONS) reported second-quarter earnings earlier this week and then followed up on Friday with a disclosure that it's getting full rights back to two of its drugs, inotersen and IONIS-FB-LRx, after GlaxoSmithKline (NYSE: GSK) decided not to license them. In May, the company reported positive results for its NEURO-TTR phase 3 trial testing inotersen in patients with hereditary TTR amyloidosis.",244.63690185546875
2017-08-14 00:00:00+00:00,285.0799865722656,286.5799865722656,284.0,286.04998779296875,286.04998779296875,786800.0,3.0,1.0,0.5000249999999999,"AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports AMGN's forecasted earnings growth in 2017 as 7.32%, compared to an industry average of 6.8%. The following ETF(s) have AMGN as a top-10 holding: iShares Nasdaq Biotechnology Index Fund ( IBB ) PowerShares Dynamic Pharmaceuticals ( PJP ) PowerShares Dynamic Biotech &Genome ( PBE ) SPDR Select Sector Fund - Health Care ( XLV ) VanEck Vectors Biotech ETF ( BBH ).",245.1319122314453
2017-08-15 00:00:00+00:00,287.1000061035156,289.7099914550781,285.510009765625,287.9200134277344,287.9200134277344,861700.0,3.0,1.0,0.5000249999999999,"Alfred Sandrock, the Chief Medical Officer of Biogen (BIIB) has said that ""neurology is the new oncology."" Click to get this free report Alkermes PLC (ALKS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. First, the reason short-term trading is so hard is because our brains evolved for very different challenges than those of watching our money fluctuate up and down wildly on a screen full of red and green arrows.",240.8235626220703
2017-08-16 00:00:00+00:00,291.1600036621094,296.9100036621094,290.2900085449219,294.0799865722656,294.0799865722656,1684300.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of TQQQ, in trading today Alphabet Inc (Symbol: GOOG) is up about 0.6%, Amgen Inc (Symbol: AMGN) is up about 0.7%, and Biogen Inc (Symbol: BIIB) is up by about 2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the ProShares UltraPro QQQ (Symbol: TQQQ) where we have detected an approximate $55.6 million dollar inflow -- that's a 2.9% increase week over week in outstanding units (from 16,950,000 to 17,450,000). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",240.2471160888672
2017-08-17 00:00:00+00:00,293.07000732421875,294.0,284.2900085449219,284.4200134277344,284.4200134277344,1590600.0,2.0,1.0,0.250025,"Especially high volume was seen for the $290 strike put option expiring August 18, 2017 , with 691 contracts trading so far today, representing approximately 69,100 underlying shares of BIIB. Below is a chart showing NVDA's trailing twelve month trading history, with the $165 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 7,087 contracts, representing approximately 708,700 underlying shares or approximately 55% of BIIB's average daily trading volume over the past month, of 1.3 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $290 strike highlighted in orange: For the various different available expirations for DE options , NVDA options , or BIIB options , visit StockOptionsChannel.com.",233.43580627441406
2017-08-18 00:00:00+00:00,283.3099975585937,285.6700134277344,281.6499938964844,281.7699890136719,281.7699890136719,814100.0,3.0,1.0,0.5000249999999999,"Below is a twelve month price history chart comparing the stock performance of PCLN, BIIB, and FB: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of OEF's underlying holdings with notable upside to their analyst target prices are Priceline Group Inc (Symbol: PCLN), Biogen Inc (Symbol: BIIB), and Facebook Inc (Symbol: FB). Similarly, BIIB has 14.13% upside from the recent share price of $284.42 if the average analyst target price of $324.61/share is reached, and analysts on average are expecting FB to reach a target price of $189.96/share, which is 13.81% above the recent price of $166.91.",243.722900390625
2017-08-21 00:00:00+00:00,280.95001220703125,284.04998779296875,280.6000061035156,283.1499938964844,283.1499938964844,850300.0,2.0,1.0,0.250025,"Biogen BIIB , a key player in the MS market, has been asked to submit information on five MS drugs - Avonex, Tysabri, Tecfidera, Plegridy and Zinbryta (co-promoted with AbbVie). Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Bayer AG (BAYRY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Teva Pharmaceutical Industries Limited (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, information provided by the National Multiple Sclerosis Society shows that the average wholesale price of MS disease modifying therapies shot up from $16,000 in 2004 to $61,000 in 2013 and $83,688 in 2017.",237.47483825683594
2017-08-22 00:00:00+00:00,284.1300048828125,288.1499938964844,283.1099853515625,286.7200012207031,286.7200012207031,945000.0,3.0,1.0,0.5000249999999999,"Orbimed Advisors Llc New Purchases: CI , CLVS , EVHC , JUNO, IOVA, IART, CTIC, NVUS, ARGX, VRNA, Added Positions:GILD, MYL, BIIB, ALNY, REGN, CELG, IMMU, JNJ, GBT, NVRO, Reduced Positions:HCA, PFE, SHPG, BMY, AET, INCY, IRWD, BMRN, AGN, BSX, Sold Out:CNC, THC, EGRX, ACAD, COO, SRPT, BCR, EXAS, CLSD, For the details of ORBIMED ADVISORS LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=ORBIMED+ADVISORS+LLC These are the top 5 holdings of ORBIMED ADVISORS LLC Alexion Pharmaceuticals Inc ( ALXN ) - 3,871,786 shares, 5% of the total portfolio. Shares added by 9.37% Biogen Inc ( BIIB ) - 1,630,000 shares, 4.69% of the total portfolio. Sold Out: Tenet Healthcare Corp (THC) Orbimed Advisors Llc sold out the holdings in Tenet Healthcare Corp.",233.6870880126953
2017-08-23 00:00:00+00:00,286.0,286.0,282.260009765625,282.6400146484375,282.6400146484375,1047400.0,3.5,1.0,0.6250249999999999,"and Rep. Peter Welch (D-Vt.) have sent letters to seven drugmakers, including Biogen (NASDAQ: BIIB) and Teva Pharmaceutical Industries (NYSE: TEVA) , asking for information about factors related to pricing for their MS products. Two members of the U.S. House of Representatives Committee on Oversight and Government Reform want to know why the prices of multiple sclerosis (MS) drugs are so high. It's also important to note that these drugmakers don't charge a penny more than what insurance companies and pharmacy benefits managers (PBMs) are willing to pay. New Article Meanwhile, Biogen BIIB was in the news with an investigation being launched into the rising prices of multiple sclerosis (""MS"") drugs. Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Alkermes PLC (ALKS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Ironwood Pharmaceuticals, Inc. (IRWD): Free Stock Analysis Report To read this article on Zacks.com click here. Aceneuramic acid extended release (Ace-ER) failed to meet the primary as well as key secondary endpoints in a phase III study in patients with GNE myopathy (""GNEM"").",232.93240356445312
2017-08-24 00:00:00+00:00,283.6600036621094,285.79998779296875,281.79998779296875,285.45001220703125,285.45001220703125,801500.0,4.0,1.0,0.7500249999999999,"His top positions in the sector hail from a variety of industries: Biogen ( BIIB ), Eli Lilly and Co. ( LLY ) and McKesson Corp. ( MCK ). Steven Cohen ( Trades , Portfolio ), founder of Point72 Asset Management, made a 1098% increase to his holding of Pacira Pharmaceuticals ( PCRX ), he revealed this week. In a second-quarter earnings release, Pacira Pharmaceuticals CEO Dave Stack said the company has made progress in its goal to make Exparel the ""only single-dose long-acting local analgesic for postsurgical pain.""",230.32968139648438
2017-08-25 00:00:00+00:00,287.3099975585937,289.8500061035156,284.8900146484375,285.0599975585937,285.0599975585937,900500.0,5.0,1.0,1.000025,"Biogen Inc.BIIB announced that its biosimilar version of AbbVie, Inc.'s ABBV top-selling blockbuster drug, Humira has been approved by the European Commission. Click to get this free report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that the biosimilar was granted a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) in June this year.",232.4645538330078
2017-08-28 00:00:00+00:00,288.1199951171875,295.5,287.0,292.29998779296875,292.29998779296875,1447800.0,4.0,1.0,0.7500249999999999,"Combined, BIIB and ILMN make up approximately 3.0% of the underlying holdings of XLV. Within that group, Biogen Inc (Symbol: BIIB) and Illumina Inc (Symbol: ILMN) are two of the day's stand-outs, showing a gain of 2.9% and 2.5%, respectively. Combined, MU and CTL make up approximately 0.8% of the underlying holdings of XLK. New Article Biogen Inc (Symbol: BIIB), which makes up 0.26% of the Vanguard Russell 1000 ETF (Symbol: VONE), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at BIIB: BIIB - last trade: $285.06 - Recent Insider Buys: And KeyCorp (Symbol: KEY), the #275 largest holding among components of the Vanguard Russell 1000 ETF (Symbol: VONE), shows 4 directors and officers as recently filing Form 4's indicating purchases. The ETF holds a total of $1,713,340 worth of BIIB, making it the #87 largest holding.",238.36228942871094
2017-08-29 00:00:00+00:00,289.3599853515625,293.79998779296875,289.3599853515625,293.5799865722656,293.5799865722656,903300.0,4.333333333333333,1.0,0.8333583333333333,"While the recent bounce in biotech land has largely taken place in sync, shares of Biogen Inc (NASDAQ: BIIB ) through the lens of technical analysis and in my eye are showing a tight chart pattern and thus a great way to define risk for a breakout trade setup. Here, note that from April through now BIIB stock has traced out a clearly visible inverse head-and-shoulders pattern as I marked with the series of black lines. BIIB Stock Charts Click to Enlarge Moving averages legend: red - 200 week, blue - 100 week, yellow - 50 week Looking at the multiyear weekly chart of BIIB stock we see that after an initial sharp rally in July 2016 the stock settled in to a wide but well-defined sideways trading range that has since frustrated many a trader. New Article  Shares of Expedia Inc. EXPE declined 4.5% after the company's Chief Executive Officer Dara Khosrowshahi announced that he would be joining Uber as CEO  Biogen Inc.'s BIIB shares surged 2.5% following positive results from an Alzhiemer's drug study  Shares of Gilead Sciences Inc. GILD increased 1.2% after it entered into an agreement with Kite Pharma Inc. KITE to acquire the company for a whopping $11 billion in cash  Johnson & Johnson's JNJ shares increased almost 0.1% after it announced favorable results in a phase 3 study of its blood-thinning drug Xarelto Want the latest recommendations from Zacks Investment Research? Click to get this free report Expedia, Inc. (EXPE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Kite Pharma, Inc. (KITE): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen Inc.BIIB announced data from a long-term study on its Alzheimer's disease (AD) candidate, aducanumab. Biogen's AD pipeline comprises candidates with different mechanisms of action including anti-tau candidate (BIIB092/BMS-986168 - with potential in AD as well as progressive supranuclear palsy (PSP)), anti-amyloid (aducanumab) candidates as well as a BACE inhibitor (elenbecestat) program. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here.",236.3668670654297
2017-08-30 00:00:00+00:00,291.4599914550781,305.489990234375,291.4599914550781,303.75,303.75,1916800.0,4.0,1.0,0.7500249999999999,"Biotech Stocks to Buy: Biogen (BIIB) Click to Enlarge Biogen Inc (NASDAQ: BIIB ) shares are breaking up and over a three-year resistance zone with a move up and over the $300-a-share level. InvestorPlace - Stock Market News, Stock Advice & Trading Tips U.S. equities are continuing to melt higher on Wednesday as fears over the North Korean missile strike earlier in the week are fading amid a fresh focus on possible tax reform legislation. 7 Best Fidelity Funds for Long-Term Diversification Here are five biotech stocks surging in response: Biotech Stocks to Buy: Gilead (GILD) Click to Enlarge Gilead Sciences shares are blasting to a gain of nearly 6% as investors continue to digest news of the acquisition of KITE on Monday.",243.03366088867188
2017-08-31 00:00:00+00:00,304.5899963378906,316.8500061035156,304.19000244140625,316.5599975585937,316.5599975585937,2503600.0,3.0,1.0,0.5000249999999999,"Combined, BIIB and CELG make up approximately 5.7% of the underlying holdings of XLV. Within that group, Biogen Inc (Symbol: BIIB) and Celgene Corp. (Symbol: CELG) are two large stocks leading the way, showing a gain of 3.8% and 3.1%, respectively. Combined, MRO and NFX make up approximately 1.5% of the underlying holdings of XLE.",242.31143188476562
2017-09-07 00:00:00+00:00,317.3599853515625,325.7699890136719,315.0,323.8999938964844,323.8999938964844,1571600.0,4.0,1.0,0.7500249999999999,"Apart from elagolix, AbbVie has several candidates in different stages of development across a wide range of therapeutic areas and has partnerships with companies like Roche RHHBY , Bristol-Myers BMY and Biogen BIIB . Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The NDA filing is supported by positive results from two replicate pivotal phase III trials evaluating elagolix, a gonadotropin-releasing hormone (GnRH) antagonist, in this indication.",231.155029296875
2017-09-11 00:00:00+00:00,329.6000061035156,329.95001220703125,322.82000732421875,326.5400085449219,326.5400085449219,1301300.0,3.0,1.0,0.5000249999999999,"In recent trading, shares of Biogen Inc (Symbol: BIIB) have crossed above the average analyst 12-month target price of $324.61, changing hands for $326.33/share. But the whole reason to look at the average BIIB price target in the first place is to tap into a ""wisdom of crowds"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with BIIB crossing above that average target price of $324.61/share, investors in BIIB have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $324.61 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? New Article Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $350.00 strike highlighted in red: Considering the fact that the $350.00 strike represents an approximate 8% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the January 2020 expiration. New Article What happened Biotech titan Biogen (NASDAQ: BIIB) saw its shares rise by 8.73% last month, according to data from S&P Global Market Intelligence . This healthy march northward was sparked by an encouraging clinical update for the biotech's early-stage Alzheimer's disease drug candidate, aducanumab, toward the end of the month. So what While the amyloid hypothesis appears to be based on sound logic, the late-stage clinical data across a variety of experimental candidates has so far provided little empirical support that lowering plaque levels within the CNS is, in fact, the key to battling this deadly disease.",226.1552734375
2017-09-13 00:00:00+00:00,329.57000732421875,330.0,323.3999938964844,324.04998779296875,324.04998779296875,1160900.0,3.5,1.0,0.6250249999999999,"Biogen (BIIB) Biogen Inc. (NASDAQ: BIIB ) focuses on developing therapies for neurological, autoimmune and hematologic disorders. Biotech is set up for another run of equal size thanks to innovations in cancer treatments, genomic mapping and digital medicine. The 10 Best Tech Stocks from Top-Ranked Analysts That demand was unleashed Monday as Amgen led the biotech sector higher with a 3.2% gain, which can be partially attributed to announced results from the Phase 3 ARCH study showing that its Evinity drug successfully aided other therapies in reducing new vertebral and hip fracture risk in postmenopausal women with osteoporosis at high risk for fracture. New Article GILD is a part of the Health Care sector, which includes companies such as Amgen Inc. ( AMGN ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports GILD's forecasted earnings growth in 2017 as -24.51%, compared to an industry average of 5.6%. For more information on the declaration, record and payment dates, visit the GILD Dividend History page.",222.82164001464844
2017-09-15 00:00:00+00:00,324.9100036621094,325.989990234375,320.3699951171875,321.260009765625,321.260009765625,2235400.0,4.0,1.0,0.7500249999999999,"Among the largest underlying components of IBB, in trading today Biogen Inc (Symbol: BIIB) is trading flat, Regeneron Pharmaceuticals, Inc. (Symbol: REGN) is down about 1.4%, and Alexion Pharmaceuticals Inc. (Symbol: ALXN) is up by about 1%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $246.71 per share, with $336.72 as the 52 week high point - that compares with a last trade of $332.32. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",243.7814178466797
2017-09-19 00:00:00+00:00,318.42999267578125,319.44000244140625,316.4599914550781,317.92999267578125,317.92999267578125,779300.0,2.5,1.0,0.375025,"InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen Inc (NASDAQ: BIIB ) stock had a fantastic start to September with a 15% rally. Instead, I will use BIIB options to bet on the fact that the proven support levels will hold through 2017. BIIB is not cheap, however, so I can't justify betting long on it expecting future appreciation in value. New Article More From InvestorPlace 5 of the Toughest Stocks to Withstand a Downturn The 7 Best Dow Jones Stocks to Buy Today Profit From the Biogen Inc (BIIB) Stock Dip! Play the Support Test in VanEck Vectors Gold Miners ETF (GDX) I personally like the long call position, as premiums are fair relative to stock volatility and implieds are priced near 52-week lows. With risk contained to a fairly modest 2% of QCOM stock through November expiration and shares positioned nicely for a reaction rally given the pattern completion and bearish relative weakness in 2017, waiting for an expected better opportunity to hedge the long call and eventually adjust into a spread appears very approachable at this time. New Article More From InvestorPlace 3 Retail Stocks Perking Back Up Profit From the Biogen Inc (BIIB) Stock Dip! The 7 Best Dow Jones Stocks to Buy Today Undoubtedly, spectators who missed the initial breakout trade will be eyeing this dip with interest. Click to Enlarge Source: OptionsAnalytix With an implied volatility rank at a lowly 4%, GDX options are relatively cheap which suggests a long call play is worth a shot. New Article More From InvestorPlace The 7 Best Dow Jones Stocks to Buy Today 7 Dependable Mutual Funds for Retirement Profit From the Biogen Inc (BIIB) Stock Dip! Nvidia is also a higher risk/higher beta stock than average, so risk adjustments (similar to Sharpe ratios) need to be made. Click to Enlarge So rather than chase momentum here, let's use the options market to get paid to wait and position to be a buyer at lower levels.",238.3605194091797
2017-09-25 00:00:00+00:00,318.2799987792969,321.5,316.9599914550781,317.510009765625,317.510009765625,1284600.0,3.0,1.0,0.5000249999999999,"Let's put Biogen Inc.BIIB stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks: PE Ratio A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. Clearly, BIIB is a solid choice on the value front from multiple angles. This gives BIIB a Zacks VGM score-or its overarching fundamental grade-of B.",239.4967041015625
2017-09-26 00:00:00+00:00,318.2099914550781,320.5,314.0,317.0599975585937,317.0599975585937,944300.0,2.0,1.0,0.250025,"Among the largest underlying components of MOAT, in morning trading today Polaris Industries is down about 0.2%, and Biogen is lower by about 0.8%. And on a percentage change basis, the ETF with the biggest outflow was the ProShares UltraPro 3x Crude Oil ETF, which lost 200,000 of its units, representing a 30.8% decline in outstanding units compared to the week prior. VIDEO: MOAT, OILU: Big ETF Outflows The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",231.80165100097656
2017-09-28 00:00:00+00:00,312.75,314.57000732421875,308.8800048828125,310.0,310.0,957200.0,3.0,1.0,0.5000249999999999,"Ten other drug firms are working on Humira biosimilars, including Biogen ( BIIB ), Novartis ( NVS ), Dow's Pfizer ( PFE ) and Mylan (MYL), Evercore analyst Umer Raffat said in a note to clients. AbbVie ( ABBV ) launched to a record high Thursday after it settled a patent dispute with Amgen ( AMGN ) that will require the No. [ibd-display-video id=2322998 width=50 float=left autostart=true]By the closing bell on the stock market today , AbbVie popped 5%, near 88.96, though in earlier trades shares were up as much as 7.3% to a record high of 90.95.",233.96554565429688
2017-09-29 00:00:00+00:00,309.0899963378906,313.6000061035156,303.0,313.1199951171875,313.1199951171875,1647600.0,3.0,1.0,0.5000249999999999,"Especially high volume was seen for the $302.5 strike put option expiring September 29, 2017 , with 1,190 contracts trading so far today, representing approximately 119,000 underlying shares of BIIB. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 7,266 contracts have traded so far, representing approximately 726,600 underlying shares. That amounts to about 54.9% of BIIB's average daily trading volume over the past month of 1.3 million shares.",235.29824829101562
2017-10-02 00:00:00+00:00,315.19000244140625,317.1300048828125,313.1199951171875,316.1700134277344,316.1700134277344,1674000.0,2.6,1.0,0.400025,"Some better-ranked stocks in health care sector include Regeneron Pharmaceuticals, Inc. REGN , Biogen Inc. BIIB and Aduro BioTech, Inc. ADRO . Click to get this free report Novo Nordisk A/S (NVO): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report To read this article on Zacks.com click here. Novo NordiskNVO announced that the FDA has approved its fast-acting mealtime insulin aspart, Fiasp, for the treatment of adults with diabetes. New Article Biotech Stocks to Buy: Biogen (BIIB) Biogen Inc (NASDAQ: BIIB ) shares look ready to exit a month-long pullback after losing about 10% from the highs set in early September. BIIB will next report results on Oct. 24 before the bell. Biotech stocks are playing along as well now, with the group breaking up and out of a two-month consolidation range after a flurry of buying interest in late August. New Article Some better-ranked stocks in health care sector include Regeneron Pharmaceuticals, Inc. REGN , Biogen Inc. BIIB and Aduro BioTech, Inc. ADRO . Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report To read this article on Zacks.com click here. Eli Lilly and CompanyLLY announced a number of leadership changes in order to focus on bringing newer drugs to the market. New Article Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), PetroChina (PTR) and Biogen (BIIB). Click to get this free report PetroChina Company Limited (PTR): Free Stock Analysis Report Procter & Gamble Company (The) (PG): Free Stock Analysis Report Norfolk Souther Corporation (NSC): Free Stock Analysis Report Halliburton Company (HAL): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Accenture PLC (ACN): Free Stock Analysis Report To read this article on Zacks.com click here. You can see all of today's research reports here >>> Buy-rated Procter & Gamble 's estimates are trending upward over the last 60 days, hinting analysts' optimism about the company. New Article If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Procter & Gamble (PG) Rides on $10 Billion Cost Saving Plan Upstream Unit Boosts PetroChina (PTR), Gas Price Cut a Woe Biogen's (BIIB) Diversifies Beyond MS, Spinraza Starts Solid Featured Reports Express Scripts' (ESRX) Generic Utilization to Drive Growth The Zacks analyst thinks Express Scripts' increased generic utilization, and focus on mail orders to drive growth. Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), PetroChina (PTR) and Biogen (BIIB). Click to get this free report PetroChina Company Limited (PTR): Free Stock Analysis Report Procter & Gamble Company (The) (PG): Free Stock Analysis Report Norfolk Souther Corporation (NSC): Free Stock Analysis Report Halliburton Company (HAL): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Accenture PLC (ACN): Free Stock Analysis Report To read this article on Zacks.com click here.",248.08816528320312
2017-10-03 00:00:00+00:00,317.1099853515625,317.79998779296875,313.9100036621094,317.3900146484375,317.3900146484375,850900.0,3.25,1.0,0.5625249999999999,"If approved, AVXS-101 would rival Spinraza from Biogen ( BIIB ) and Ionis Pharmaceuticals ' ( IONS ). AveXis ( AVXS ) touched a record high Tuesday, but PTC Therapeutics ( PTCT ) plunged by double digits as each biotech presented updates on their spinal muscular atrophy programs during the World Muscle Society annual meeting. ""Overall, the patients continue to appear to progress substantially better than what would be expected in the natural history course of the disease,"" RBC analyst Brian Abrahams said in a note to clients. New Article Biogen (NASDAQ: BIIB) and Ionis Pharmaceuticals (NASDAQ: IONS) got their SMA drug, Spinraza, approved last year. So what It's been a roller coaster for PTC Therapeutics, falling last week after FDA briefing documents didn't paint its Duchenne muscular dystrophy drug, Translarna, in the best light. The data comes from the first part of the two-part Sunfish clinical trial that measures the level of SMN protein, which is mutated in patients with SMA, at increasing doses of RG7916. New Article Stocks recently featured in the blog include Procter & Gamble (NYSE: PG- Free Report ), PetroChina (NYSE: PTR- Free Report ), Biogen (Nasdaq: BIIB- Free Report ), Accenture (NYSE: ACN- Free Report ) and Norfolk Southern (NYSE: NSC- Free Report ). Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (NYSE: PG- Free Report ), PetroChina (NYSE: PTR- Free Report ) and Biogen (Nasdaq: BIIB- Free Report ). Get the full Report on PG - FREE Get the full Report on PTR - FREE Get the full Report on BIIB - FREE Get the full Report on ACN - FREE Get the full Report on NSC - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. New Article Biogen Inc.BIIB : Based in Cambridge, MA, Biogen is one of the world's leading biotechnology companies. Click to get this free report Pepsico, Inc. (PEP): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report CBRE Group, Inc. (CBG): Free Stock Analysis Report Texas Instruments Incorporated (TXN): Free Stock Analysis Report Applied Materials, Inc. (AMAT): Free Stock Analysis Report To read this article on Zacks.com click here. The U.S. equity market maintained a steady momentum, rebuffing geopolitical threats related to North Korean missile tests and deadly terrorist attacks in the home soil in Las Vegas. New Article Biogen, Inc. BIIB Biogen has a strong position in the multiple sclerosis market backed by a wide range of products. Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Another factor that has contributed to the sector's surge is that President Trump's expected action on drug prices may not be as onerous as previously feared. New Article Some better-ranked stocks in the health care sector include Regeneron Pharmaceuticals, Inc. REGN and Biogen Inc. BIIB . (AGN): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The drug also showed in vitro (study in controlled environment outside human body) activity against certain gram negative bacteria, which causes HABP/VABP. New Article I'll say, for me personally, I was invested in Biogen (NASDAQ: BIIB) in part because of their Alzheimer's treatment that they were putting in the clinic, which is still ongoing through clinical trials. Hope was running high at Axovant Sciences (NASDAQ: AXON) that that teaming up their drug intepirdine with the top-selling Alzheimer's disease treatment, Aricept, could improve patients' lives. I think the reason for that enthusiasm or optimism was because, again, you're targeting this massive, large population that's growing, and currently has totally inadequate treatment options associated with it. New Article Some better-ranked stocks in health care sector are Regeneron Pharmaceuticals, Inc. REGN , Biogen Inc. BIIB and Aduro BioTech, Inc. ADRO . Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report Mallinckrodt PLC (MNK): Free Stock Analysis Report To read this article on Zacks.com click here. A tentative approval of xenon for inhalation will expand Mallinckrodt's portfolio of hospital drug-device combination products providing therapies for patients.",260.0728759765625
2017-10-04 00:00:00+00:00,313.57000732421875,316.54998779296875,306.0,314.9200134277344,314.9200134277344,1067600.0,2.6666666666666665,1.0,0.4166916666666666,"Some other bullish-ranked stocks in the health care sector are ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB and Aduro BioTech, Inc. ADRO . Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report Celsion Corporation (CLSN): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Celsion CorporationCLSN announced results from phase Ib study - OVATION - evidently showing biological activity of its immunotherapy candidate, GEN1, in advanced ovarian cancer patients. New Article Among the largest underlying components of VHT, in trading today Allergan PLC (Symbol: AGN) is down about 0.3%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.8%, and Biogen Inc (Symbol: BIIB) is lower by about 1.2%. For a complete list of holdings, visit the VHT Holdings page  The chart below shows the one year price performance of VHT, versus its 200 day moving average: Looking at the chart above, VHT's low point in its 52 week range is $120.38 per share, with $154.66 as the 52 week high point - that compares with a last trade of $154.43. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Stocks to Consider A better-ranked biotech/drug stock is Biogen, Inc. BIIB with a Zacks Rank #2 (Buy). (AGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Teva Pharmaceutical Industries Limited (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Allergan plcAGN announced that the FDA has approved its Botox Cosmetic product for a third indication - temporary improvement of moderate to severe forehead lines in appearance, associated with frontalis muscle activity in adults. New Article Key Picks Some other top-ranked biotech stocks sporting the same bullish rank as Amgen include Biogen, Inc. BIIB and Celgene Corporation CELG . Click to get this free report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report CytomX Therapeutics, Inc. (CTMX): Free Stock Analysis Report To read this article on Zacks.com click here. Markedly, the companies will develop CytomX Probody T-cell engaging bispecific program that targets the EGFR protein, thereby offering significant potential in treating various types of cancers. New Article Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD and Biogen Inc. BIIB . Click to get this free report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Emergent Biosolutions, Inc. (EBS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Emergent BioSolutions Inc.EBS announced that it has closed the acquisition of anthrax monoclonal antibody, raxibacumab, from GlaxoSmithkline plc GSK . New Article Two other components making moves today are Biogen ( BIIB ), trading down 2.2%, and Netflix ( NFLX ), trading up 3.9% on the day. In early trading on Wednesday, shares of Mylan ( MYL ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 17.6%. And the worst performing Nasdaq 100 component thus far on the day is JD.com ( JD ), trading down 2.3%.",269.20892333984375
2017-10-05 00:00:00+00:00,320.7200012207031,330.9800109863281,320.2799987792969,326.739990234375,326.739990234375,2159800.0,3.7142857142857135,1.0,0.6785964285714287,"Biogen Inc (Symbol: BIIB), which makes up 1.26% of the Guggenheim U.S. Large Cap Optimized Volatility ETF ( OVLC ), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at BIIB: BIIB - last trade: $314.92 - Recent Insider Buys: 10 ETFs With Stocks That Insiders Are Buying  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The ETF holds a total of $18,396 worth of BIIB, making it the #21 largest holding. New Article Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB and Aduro BioTech, Inc. ADRO , each holding a Zacks Rank #2 (Buy). Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, OmniAb is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies. New Article Biogen Inc. BIIB is another stock worth considering in the health care sector, also carrying a Zacks Rank #2. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report Catabasis Pharmaceuticals, Inc. (CATB): Free Stock Analysis Report PTC Therapeutics, Inc. (PTCT): Free Stock Analysis Report To read this article on Zacks.com click here. Catabasis Pharmaceuticals, Inc.CATB announced data from a phase II study, which showed that its pipeline candidate, edasalonexent substantially slowed disease progression, in male children with Duchenne muscular dystrophy (""DMD""). New Article Biogen (BIIB) has risen 2.1% to $321.60 after getting upgraded to Overweight from Equal Weight at Morgan Stanley, while Celgene (CELG) has fallen 2.5% to $142.90 after Morgan Stanley cut it to Underweight from Equal Weight. Stocks look set for a higher open today ahead of U.S. jobless claims data this morning. Acadia Pharmaceuticals (ACAD) has jumped 6.5% to $41.70 after its drug for treating dementia was granted breakthrough status by the FDA. New Article Biogen ( BIIB ) rose sharply to its highest level since July 2015 after Morgan Stanley upgraded the biotech to overweight from equal weight and raised the price target to 375 from 311. The stock market's morning advance stalled at midday, but the main indexes were holding most of the day's gains in afternoon trading Thursday. ""While the (Office 365) upgrade cycle is obvious and well-known, investors are missing the explosive potential of eSports ... as well as an emerging marketing effort that we believe will increasingly look like, and compete with, Salesforce.com ( CRM ),"" the analysts said. New Article In early trading on Thursday, shares of Norwegian Cruise Line Holdings topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.8%. Year to date, Norwegian Cruise Line Holdings registers a 36.6% gain. And the worst performing Nasdaq 100 component thus far on the day is Celgene, trading down 4.5%. New Article Other stocks worth considering in the health care sector include Adaptimmune Therapeutics PLC ADAP , Biogen Inc. BIIB and Aduro BioTech, Inc. ADRO . Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Adaptimmune Therapeutics PLC (ADAP): Free Stock Analysis Report Aduro Biotech, Inc. (ADRO): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. ACADIA Pharmaceuticals Inc.ACAD announced the initiation of a phase III study - HARMONY - for evaluating its antipsychotic drug, Nuplazid, for the treatment of hallucinations and delusions associated with dementia-related psychosis.",274.61334228515625
2017-10-06 00:00:00+00:00,325.2099914550781,328.5,324.6000061035156,327.4800109863281,327.4800109863281,1039000.0,2.5,1.0,0.375025,"In the same week, prescriptions of Gilead Sciences ' ( GILD ) hepatitis C drug Harvoni and Biogen 's ( BIIB ) multiple sclerosis drug Tecfidera declined 8%-10%, he said. Intercept Pharmaceuticals ( ICPT ) toppled Friday on a report outlining a 25% dip in prescriptions of liver disease-drug Ocaliva the week the Food and Drug Administration warned doctors of overdose-related deaths. ""The downtick suggests re-education of physicians on proper dosing will continue to be important for Intercept,"" RBC analyst Brian Abrahams wrote in a note to clients. New Article Particularly high volume was seen for the $325 strike call option expiring October 06, 2017 , with 675 contracts trading so far today, representing approximately 67,500 underlying shares of BIIB. Below is a chart showing GDOT's trailing twelve month trading history, with the $45 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 5,778 contracts, representing approximately 577,800 underlying shares or approximately 47.1% of BIIB's average daily trading volume over the past month, of 1.2 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $325 strike highlighted in orange: And Salesforce.com Inc (Symbol: CRM) saw options trading volume of 18,918 contracts, representing approximately 1.9 million underlying shares or approximately 45.5% of CRM's average daily trading volume over the past month, of 4.2 million shares.",254.96185302734375
2017-10-09 00:00:00+00:00,327.4599914550781,332.239990234375,326.3299865722656,329.010009765625,329.010009765625,902400.0,3.0,1.0,0.5000249999999999,"Some better-ranked stocks in health care sector include ACADIA Pharmaceuticals Inc. ACAD , Biogen Inc. BIIB , each carrying a Zacks Rank #2 (Buy). Click to get this free report Sanofi (SNY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Emergent Biosolutions, Inc. (EBS): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report To read this article on Zacks.com click here. Emergent BioSolutions will also assume responsibility for Sanofi's existing 10-year Centers for Disease Control and Prevention or CDC contract with a remaining value of up to approximately $160 million for deliveries of ACAM2000 to the Strategic National Stockpile.",249.88412475585938
2017-10-10 00:00:00+00:00,328.54998779296875,332.8699951171875,328.25,332.8299865722656,332.8299865722656,1004000.0,3.0,1.0,0.5000249999999999,"Biogen Inc. (NASDAQ: BIIB) shareholders have seen their investment rise fivefold over the same time frame, before accounting for the Bioverativspinoff earlier this year. BIIB PE Ratio (TTM) data by YCharts. The case for Biogen Inc. Exploding sales for a string of expensive multiple sclerosis (MS) treatments made this one of the best performing biotech stocks of all time, but its dominance in this arena is fading fast.",251.19566345214844
2017-10-12 00:00:00+00:00,332.92999267578125,334.32000732421875,330.0400085449219,333.3099975585937,333.3099975585937,1120200.0,3.0,1.0,0.5000249999999999,"When biotech companies like Celgene ( CELG ), Biogen ( BIIB ) and Gilead Sciences ( GILD ) put their drugs through extensive trials to gain FDA approval, they turn to clinical research firms like PRA Health Sciences ( PRAH ). 1 ranking within the medical research equipment and services industry group, ahead of QuintilesIMS ( Q ), Catalent (CTLT) and ICON (ICLR). In August, the company announced it was acquiring Symphony Health Solutions , a provider of cloud-based analytics for the biopharmaceutical industry.",251.8720703125
2017-10-13 00:00:00+00:00,333.260009765625,338.94000244140625,332.07000732421875,337.6400146484375,337.6400146484375,1360300.0,4.0,1.0,0.7500249999999999,"Biogen ( BIIB ), Gilead Sciences ( GILD ) and Sarepta Therapeutics ( SRPT ) will build on momentum in the biotech sphere to beat Wall Street expectations for the third quarter, an analyst predicted Friday. [ibd-display-video id=2359800 width=50 float=left autostart=true]""Large-cap biotech stocks have been strong as we head into the third-quarter reporting period,"" Credit Suisse analyst Alethia Young wrote in a note to clients. Young calls for Spinraza, a spinal muscular atrophy drug developed with Ionis Pharmaceuticals (IONS), to beat the consensus view for $250 million.",248.35076904296875
2017-10-16 00:00:00+00:00,337.7300109863281,344.3699951171875,333.1700134277344,335.67999267578125,335.67999267578125,1176600.0,3.6,1.0,0.6500250000000001,"Particularly high volume was seen for the $335 strike call option expiring October 20, 2017 , with 708 contracts trading so far today, representing approximately 70,800 underlying shares of BIIB. Below is a chart showing BMY's trailing twelve month trading history, with the $65 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 4,788 contracts thus far today. That number of contracts represents approximately 478,800 underlying shares, working out to a sizeable 42.6% of BIIB's average daily trading volume over the past month, of 1.1 million shares. New Article Top biotechs Biogen ( BIIB ) and Gilead Sciences ( GILD ) fell 1% and 1.6%, respectively. Biotech stocks collectively inched down Monday after President Donald Trump reiterated his concerns that U.S. drug prices are ""out of control"" during a Cabinet meeting, according to a number of reports. Trump's comments come amid the rising likelihood he will enact an executive order to tug down drug prices in the U.S., Needham analysts Kevin Caliendo and Alan Carr wrote in a report Monday. New Article The six companies are Celgene ( CELG ), Biogen ( BIIB ), Regeneron Pharmaceuticals ( REGN ), Kite Pharma, Incyte ( INCY ) and Loxo Oncology ( LOXO ). IBD's biotech industry stock group has climbed 33% this year, shucking off the pains of the politically charged election season in 2016 and concerns that President Trump will work to lower drug prices. His comments to IBD came amid a series of regulatory approvals and acquisitions in cancer treatment, including Gilead Sciences ' (GILD) foray into cellular therapy with its August agreement to acquire Kite for nearly $12 billion. New Article Recipients of the inaugural awards are Celgene ( CELG ), Biogen ( BIIB ), Regeneron Pharmaceuticals ( REGN ), Kite Pharma, which was recently acquired by Gilead Sciences ( GILD ), Incyte ( INCY ) and Loxo Oncology (LOXO). Investor's Business Daily has created the IBD Biotech Innovator Awards to recognize leading companies with groundbreaking treatments already on the market or close to final approvals. The men and women researching, creating, testing and marketing biotech drugs represent often the medical fields' best hope for conquering cancer, Alzheimer's and other hard-to-cure ailments. New Article In recent trading, shares of Biogen Inc (Symbol: BIIB) have crossed above the average analyst 12-month target price of $334.39, changing hands for $337.64/share. But the whole reason to look at the average BIIB price target in the first place is to tap into a ""wisdom of crowds"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with BIIB crossing above that average target price of $334.39/share, investors in BIIB have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $334.39 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table?",244.3898162841797
2017-10-17 00:00:00+00:00,343.1199951171875,348.6499938964844,339.69000244140625,344.4700012207031,344.4700012207031,1616300.0,3.2,1.0,0.550025,"Biogen (BIIB) has risen 1.9% to $342 after getting upgraded to Buy from Neutral at Mizuho, and to Buy from Hold at Stifel. Boeing (BA) has fallen 1.5% to $255.80 after competitor Bombardier (BDRBF) formed a joint venture withAirbus (EADSY). UnitedHealth Group (UNH) has risen 1.7% to $196.49 after beating earnings forecasts and offering above-consensus guidance. New Article Biogen (BIIB) is another big biotech that is cheap. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Teva Pharmaceutical Industries Limited (TEVA): Free Stock Analysis Report Aetna Inc. (AET): Free Stock Analysis Report To read this article on Zacks.com click here. Aetna (AET) is in the managed care group, which, is one of the most difficult areas to be in right now due to Obamacare uncertainty. New Article Combined, JNJ and BIIB make up approximately 14.0% of the underlying holdings of XLV. Within the sector, Johnson & Johnson (Symbol: JNJ) and Biogen Inc (Symbol: BIIB) are two of the day's stand-outs, showing a gain of 3.5% and 3.2%, respectively. Combined, PCG and ETR make up approximately 6.4% of the underlying holdings of XLU. New Article In the Nasdaq 100, biotech stock Biogen ( BIIB ) advanced 3% despite noise from President Trump on drug prices. U.S. stock indexes were mixed in midday action Tuesday, as health insurance provider UnitedHealth ( UNH ) kept the blue chip Dow at the front of the pack. [ibd-display-video id=2372040 width=50 float=left autostart=true]Volume in the stock market today was down on the NYSE but up on the Nasdaq compared with the same time Monday. New Article Biogen (NASDAQ: BIIB) , Halozyme Therapeutics (NASDAQ: HALO) , and Ionis Pharmaceuticals (NASDAQ: IONS) stocks have all recently hit 52-week highs. CEO Michel Vounatsos said in his comments on Biogen's second-quarter results that Spinraza could help shift ""the center of gravity"" for the company beyond multiple sclerosis (MS). Shares spiked early this year after Halozyme announced positive results from a phase 2 study of PEGPH20 in combination with Abraxane and gemcitabine in treating late-stage pancreatic cancer.",262.4031677246094
2017-10-18 00:00:00+00:00,346.5599975585937,348.8399963378906,343.5400085449219,344.5799865722656,344.5799865722656,1246700.0,3.0,1.0,0.5000249999999999,"Ionis to get $10M Milestone Payment from Biogen on Study Initiation: Ionis Pharmaceuticals IONS is set to receive a $10 million milestone payment from partner Biogen BIIB related to the initiation of a phase I/IIa study on IONIS-MAPTRx in patients with mild Alzheimer's disease (""AD""). Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Spark Therapeutics, Inc. (ONCE): Free Stock Analysis Report Immune Design Corp. (IMDZ): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Important news this week include priority review for Exelixis's EXEL label expansion plans for Cabometyx and a positive FDA panel outcome for Spark Therapeutics's ONCE Luxturna. New Article We expect Biogen Inc.BIIB , a well-known name in the multiple sclerosis (MS) market, to beat expectations when it reports third-quarter 2017 results on Oct 24, before the market opens. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer, Inc. (PFE): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. However, rising competition from Roche's RHHBY newly launched MS drug Ocrevus may hurt sales of Tysabri modestly as in the second quarter.",271.4588317871094
2017-10-19 00:00:00+00:00,343.3999938964844,346.1099853515625,338.1099853515625,342.4200134277344,342.4200134277344,1291800.0,3.0,1.0,0.5000249999999999,"Biogen (Nasdaq: BIIB- Free Report ) is another big biotech that is cheap. Get the full Report on GILD - FREE Get the full Report on BIIB - FREE Get the full Report on TEVA - FREE Get the full Report on ABBV - FREE Get the full Report on AET - FREE Follow us on Twitter: https://twitter.com/zacksresearch Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Teva Pharmaceutical Industries Limited (TEVA): Free Stock Analysis Report Aetna Inc. (AET): Free Stock Analysis Report To read this article on Zacks.com click here.",270.31646728515625
2017-10-20 00:00:00+00:00,343.0,343.3099975585937,333.92999267578125,338.1000061035156,338.1000061035156,1909300.0,2.0,1.0,0.250025,"Among the largest underlying components of IYH, in trading today Lilly (Eli) & Co (Symbol: LLY) is up about 0.5%, Thermo Fisher Scientific Inc (Symbol: TMO) is up about 0.8%, and Biogen Inc (Symbol: BIIB) is lower by about 1.8%. For a complete list of holdings, visit the IYH Holdings page  The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $137.30 per share, with $176.36 as the 52 week high point - that compares with a last trade of $175.82. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",267.62896728515625
2017-10-23 00:00:00+00:00,335.25,335.510009765625,327.8299865722656,328.54998779296875,328.54998779296875,1885200.0,3.75,1.0,0.6875249999999999,"Biogen Inc.BIIB Biogen, a well-known name in the multiple sclerosis (MS) market, is also scheduled to announce results before the opening bell. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. However, rising competition from Roche's RHHBY newly launched MS drug Ocrevus may hurt sales of Tysabri modestly. New Article Particularly high volume was seen for the $345 strike call option expiring October 27, 2017 , with 434 contracts trading so far today, representing approximately 43,400 underlying shares of BIIB. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 7,185 contracts have traded so far, representing approximately 718,500 underlying shares. That amounts to about 57.8% of BIIB's average daily trading volume over the past month of 1.2 million shares. New Article Biogen Inc. ( BIIB ) is reporting for the quarter ending September 30, 2017. In the past year BIIB has beat the expectations every quarter. Zacks Investment Research reports that the 2017 Price to Earnings ratio for BIIB is 15.70 vs. an industry ratio of -11.20, implying that they will have a higher earnings growth than their competitors in the same industry. New Article With results this impressive, Biogen (NASDAQ: BIIB) has plenty to worry about. New cancer therapies often cost more than $100,000 for a year of treatment, and once you factor in hospitalization expenses for patients who don't respond, Gilead's $373,000 list price for a single Yescarta infusion could save end payers a bundle in the long run. While Celgene will put up the cash for expensive mid- to late-stage development, Bluebird remains eligible for hefty milestone and royalty payments if one of these partnered CAR-T therapies continues to succeed.",269.04071044921875
2017-10-24 00:00:00+00:00,319.0,321.1099853515625,301.8099975585937,315.7300109863281,315.7300109863281,5849300.0,2.636363636363636,1.0,0.409115909090909,"Biogen (BIIB) has fallen 2.3% to $321 despite beating earrings forecasts. Stocks look set for a higher open as Caterpillar (CAT) and 3M (MMM) report better-than-expected earnings. TD Ameritrade Holding (AMTD) has gained 2.9% to $49.50 after beating earnings forecast and offering above-consensus guidance. New Article Biogen Inc.BIIB , a well-known name in the multiple sclerosis (MS) market, surpassed expectations both for earnings and sales in the third quarter of 2017. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The company's revenue was driven by continued a strong performance of its newest drug Spinraza, for spinal muscular atrophy. New Article Although Biogen (NASDAQ: BIIB) recorded a quarter-to-quarter gain in global Spinraza sales, stagnant U.S. sales of the partnered drug suggest it could hit a saturation point earlier than expected. What happened Shares of Ionis Pharmaceuticals Inc. (NASDAQ: IONS) dipped 13% lower in early morning trading on Tuesday after its most important collaboration partner reported some disturbing third-quarter sales figures. Investors are beating down Ionis stock today because third-quarter Spinraza sales came in just $3 million higher than the previous quarter, while inventory levels stayed flat. New Article Meanwhile, top losers in the sector included Biogen Inc (NASDAQ: BIIB ), down 7 percent, and Omeros Corporation (NASDAQ: OMER ) down 8 percent. Shares of Knoll Inc (NYSE: KNL ) got a boost, shooting up 13 percent to $22.55 as the company posted upbeat results for its third quarter on Monday. Pain Therapeutics, Inc. (NASDAQ: PTIE ) shares were also up, gaining 67 percent to $6.27 after the company reported successful Phase I study for PTI-125. New Article Ionis Pharmaceuticals (NASDAQ: IONS) lost 11% of its market value after commercialization partner Biogen (NASDAQ: BIIB) reported third-quarter sales of its drug, Spinraza, that failed to match industry watchers' forecasts. In Biogen's third-quarter conference call, it walked investors through the disconnect, citing lumpiness associated with the dosing schedule as the key reason for the slower-than-hoped quarter-over-quarter growth. All eyes ahead Ionis Pharmaceuticals is heading into its third-quarter financial report, having already boosted its operating income guidance for the year based on receiving $27.6 million in Spinraza royalties in the first six months of 2017. New Article And the worst performing Nasdaq 100 component thus far on the day is Biogen ( BIIB ), trading down 6.9%. VIDEO: Nasdaq 100 Movers: BIIB, HAS The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Biogen is showing a gain of 7.9% looking at the year to date performance. New Article Biogen ( BIIB ), Eli Lilly ( LLY ) and Novartis ( NVS ) toppled early Tuesday, despite beating analyst expectations in third quarter, as Biogen faced pressure in its multiple sclerosis unit and Novartis delayed a strategic decision regarding its Alcon eye unit. ""Biogen disclosed that there was a 75% increase of the number of Spinraza patients in Q3 as compared to Q2, and the ex-U.S. launch is surpassing the initial U.S. trajectory,"" Leerink analyst Geoffrey Porges said in a note to clients. Further complicating Biogen's results were that sales its core multiple sclerosis unit trailed views by 1%, led by drug Tysabri, Porges said. New Article BIOGEN INC ( BIIB ) is a large-cap growth stock in the Biotechnology & Drugs industry. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068. The following are today's upgrades for Validea's Patient Investor model based on the published strategy of Warren Buffett. New Article Cambridge, MA-based Biogen Inc.BIIB one of the world's leading biotechnology companies, focuses on therapeutic areas including neurology and immunology. BIIB has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 6.41%. Check back later for our full write up on this BIIB earnings report later! New Article Two other components making moves today are Biogen ( BIIB ), trading down 6.7%, and Caterpillar ( CAT ), trading up 5.5% on the day. In early trading on Tuesday, shares of Corning ( GLW ) topped the list of the day's best performing components of the S&P 500 index, trading up 5.5%. And the worst performing S&P 500 component thus far on the day is Whirlpool ( WHR ), trading down 10.2%. New Article Today's three big stock charts analyze the price patterns of Biogen Inc (NASDAQ: BIIB ), Lockheed Martin Corporation (NYSE: LMT ) and McDonald's Corporation (NYSE: MCD ) as two out of three of these companies are trading lower in the wake of their earnings results creating potential buying opportunities. Biogen Inc (BIIB) Biogen shares traded strongly right into their earnings report, suggesting that the company needed to nail their earnings report to avoid a ""sell the news"" situation that would take BIIB stock back into its trading range. Today's selling is taking BIIB stock below its 50-day moving average, currently at $315.",276.35809326171875
2017-10-25 00:00:00+00:00,317.9599914550781,320.25,313.0,314.6400146484375,314.6400146484375,1879900.0,2.0,1.0,0.250025,"Biogen (NASDAQ: BIIB) , one of the world's leading biopharma companies, generates billions of dollars in sales every quarter. FDA approval of Plegridy, a longer-lasting formulation of Avonex, and Tecfidera's status as the most commonly used oral drug have insulated Biogen's MS market share so far, but competition is stiffening, and that's creating risk. What could offset MS revenue risk Biogen's spending a lot of its R&D budget on non-MS indications, including Alzheimer's disease. New Article Read the highlights section below for more on all of these moves Today's Portfolio Highlights: Healthcare Innovators: Shares of Biogen (BIIB) slipped 7% this morning despite better-than-expected earnings and revenues in its third quarter report. Income Investor: In his first move as the new editor of the portfolio, Brian Hamilton sold Enterprise Products Partners (EPD) for an approximately 14% profit. The short-covered stocks included:  Continental Resources (CLR, +10.1%)  ConocoPhillips (COP)  DigitalGlobe (DGI)  EOG Resources (EOG) The new buys replacing these names are:  Charter Communications (CHTR)  Blackhawk Network (HAWK)  Molina Healthcare (MOH)  Teradata Corp. (TDC) Learn more about this emotion-free portfolio that takes advantage of falling and volatile markets by reading the Short List Trader Guide.",273.9942626953125
2017-10-26 00:00:00+00:00,310.0,313.57000732421875,305.1199951171875,307.6400146484375,307.6400146484375,1905300.0,2.5,1.0,0.375025,"Among the biotech/pharma bigwigs, Eli Lilly and Company LLY , Biogen Inc. BIIB and Amgen Inc. AMGN have reported their third-quarter results this week. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Merck's new products like Keytruda (cancer), Zepatier (HCV) and Bridion (sugammadex) Injection are likely to drive the top line this quarter. New Article Biotech Stocks Getting Battered: Biogen (BIIB) Biogen Inc (NASDAQ: BIIB ) shares, which have already gapped down 13% from their recent highs, look set to decline below their late September lows in a possible prelude to a drop to its August lows, which would be worth another 8% decline from here. BIIB will next report results on Jan. 25 before the bell. The catalyst for the rebound was a ""dovish taper"" decision by the European Central Bank, which promised to extend their bond buying program into 2018, albeit at a diminished rate.",272.8428039550781
2017-10-27 00:00:00+00:00,307.45001220703125,309.6000061035156,305.0,307.739990234375,307.739990234375,1679800.0,3.0,1.0,0.5000249999999999,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here BIOGEN INC ( BIIB ) is a large-cap growth stock in the Biotechnology & Drugs industry. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068. The Company's brands include Marie Callender's, Healthy Choice, Slim Jim, Hebrew National, Orville Redenbacher's, Peter Pan, Reddi-wip, PAM, Snack Pack, Banquet, Chef Boyardee, Egg Beaters, Rosarita, Fleischmann's and Hunt's.",261.23602294921875
2017-10-30 00:00:00+00:00,307.739990234375,317.6700134277344,307.20001220703125,315.79998779296875,315.79998779296875,1469600.0,2.5,1.0,0.375025,"U.S. stock indexes all were in the red early Monday afternoon amid a report that corporate tax cuts could be delayed, even as Broadcom ( AVGO ), Apple ( AAPL ), Skyworks Solutions ( SWKS ) and Biogen ( BIIB ) pushed higher. The Nasdaq turned negative and the other major averages extended losses on a Bloomberg report that House Republicans are considering a plan to phase in corporate tax cuts over five years, though there's no final decision. Apple rose nearly 2% midday Monday, padding Friday's breakout past a 160.97 buy point. New Article Among the largest underlying components of BBH, in trading today Biogen Inc (Symbol: BIIB) is up about 2.1%, Quintiles IMS Holdings Inc (Symbol: Q) is off about 0.2%, and Shire plc (Symbol: SHPG) is higher by about 2.2%. For a complete list of holdings, visit the BBH Holdings page  The chart below shows the one year price performance of BBH, versus its 200 day moving average: Looking at the chart above, BBH's low point in its 52 week range is $99.60 per share, with $136.83 as the 52 week high point - that compares with a last trade of $127.77. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",254.92698669433594
2017-10-31 00:00:00+00:00,315.17999267578125,316.8599853515625,310.5,311.6600036621094,311.6600036621094,1201600.0,2.0,1.0,0.250025,"This week, Biogen (NASDAQ: BIIB) reported earnings, and Ionis Pharmaceuticals ' (NASDAQ: IONS) stock sold off significantly on the news that its drug Spinraza, which Biogen helps commercialize, really missed the mark on its U.S. sales. In this week's episode of Industry Focus: Healthcare , analysts Kristine Harjes and Todd Campbell break down what really happened with Spinraza this quarter, and why this dip in Ionis' market cap could be a buying opportunity for long-term investors. [laughs] But just to make sure that we've got you covered on the news, really quickly, Gilead's drug Yescarta was approved on October 18th for advanced diffuse large b-cell lymphoma, which is the most common type of NHL in adults.",254.73963928222656
2017-11-01 00:00:00+00:00,312.75,319.95001220703125,311.57000732421875,315.7300109863281,315.7300109863281,1386200.0,4.0,1.0,0.7500249999999999,"Ampyra is marketed in the ex-U.S. markets by Biogen Inc. BIIB under the trade name, Fampyra. Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Pipeline Updates The company, along with the third-quarter earning release, announced that it expects to resubmit the new drug application (""NDA"") for its Parkinson's disease (""PD"") candidate, Inbrija in the fourth quarter of 2017. New Article Factors to Consider Ionis earns revenues in the form of upfront, milestone and other payments under its partnerships with leading health care companies like Biogen Inc. BIIB and Glaxo. Click to get this free report Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Agenus Inc. (AGEN): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. During the quarter, Ionis and Akcea submitted regulatory applications to the European Medicines Agency (""EMA""), the FDA and Health Canada for volanesorsen for the treatment of patients with familial chylomicronemia syndrome (""FCS"").",249.06004333496094
2017-11-02 00:00:00+00:00,316.0,319.2200012207031,308.5899963378906,309.3999938964844,309.3999938964844,1570900.0,3.5,1.0,0.6250249999999999,"In a welcome move, Biogen ( BIIB ) saw its Relative Strength Rating rise from 70 to 73 on Thursday. Decades of market research shows that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 in the early stages of their moves. See How IBD Helps You Make More Money In Stocks Biogen is not currently showing a potential buy point. New Article Shares added by 16.16% Biogen Inc ( BIIB ) - 52,608 shares, 2.59% of the total portfolio. Stoneridge Investment Partners Llc New Purchases: MO , MDLZ , MRK , NWL, WY, HPE, AET, RRC, ARNC, JEC, Added Positions:AAPL, FLS, JNJ, JPM, WHR, XOM, AMZN, HOLX, COTY, UTX, Reduced Positions:TSN, MYL, HRL, NCLH, SIG, CMCSA, ZTS, CTSH, MU, TXT, Sold Out:GILD, CHTR, PM, SYY, HBI, WFM, FLR, COG, GS, DRE, For the details of STONERIDGE INVESTMENT PARTNERS LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=STONERIDGE+INVESTMENT+PARTNERS+LLC These are the top 5 holdings of STONERIDGE INVESTMENT PARTNERS LLC Apple Inc ( AAPL ) - 172,693 shares, 4.19% of the total portfolio. Sold Out: Philip Morris International Inc (PM) Stoneridge Investment Partners Llc sold out the holdings in Philip Morris International Inc.",252.0294189453125
2017-11-03 00:00:00+00:00,309.7900085449219,314.2099914550781,308.2099914550781,314.1400146484375,314.1400146484375,828000.0,2.6666666666666665,1.0,0.4166916666666666,"Shares reduced by 4.99% Biogen Inc ( BIIB ) - 179,058 shares, 4.94% of the total portfolio. WestEnd Advisors, LLC New Purchases: BAC , SPSB , FLOT , IWB, Added Positions:KR, IYG, XLV, STIP, VEU, TJX, XLY, KHC, XLP, DIS, Reduced Positions:ADBE, PYPL, UNH, MA, GOOGL, MSFT, MDT, CELG, JPM, AAPL, For the details of WestEnd Advisors, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=WestEnd+Advisors%2C+LLC These are the top 5 holdings of WestEnd Advisors, LLC PayPal Holdings Inc ( PYPL ) - 888,247 shares, 5.01% of the total portfolio. Added: SPDR Select Sector Fund - Health Care (XLV) WestEnd Advisors, LLC added to the holdings in SPDR Select Sector Fund - Health Care by 21.23%. New Article Revenues of $1.4 million from the Queen et al. licenses were lower than the year-ago figure of $15 million due to recognition of a refund liability of $13.5 million for the potential overpayment amount received from Biogen BIIB . Click to get this free report PDL BioPharma, Inc. (PDLI): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report Valeant Pharmaceuticals International, Inc. (VRX): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, the company received cash payments of $26.3 million from the royalty rights acquired from Depomed, primarily related to Glumetza, a product marketed by Valeant Pharmaceuticals International, Inc. VRX . New Article Shares reduced by 7.03% Biogen Inc ( BIIB ) - 16,517 shares, 3.64% of the total portfolio. Lipe & Dalton New Purchases: C , SYF , MCK , ESRX, HD, CFG, BRK.B, JPM, BA, ADP, Added Positions:QCOM, CVS, LYB, BCE, T, TRP, BMY, MCD, AMZN, Reduced Positions:BAX, MS, MDLZ, CI, TUP, DE, TEL, GE, KORS, INTC, Sold Out:AIG, IWM, RYN, BP, EFA, AGNPRA, SRCLP, NVO, EEM, IWF, For the details of Lipe & Dalton's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Lipe+%26+Dalton These are the top 5 holdings of Lipe & Dalton NXP Semiconductors NV ( NXPI ) - 54,945 shares, 4.37% of the total portfolio. GuruFocus has detected 6 Warning Signs with T. Click here to check it out.",249.55966186523438
2017-11-07 00:00:00+00:00,315.94000244140625,315.9800109863281,310.4599914550781,313.57000732421875,313.57000732421875,887500.0,2.0,1.0,0.250025,"Revenue included $32.89 million in royalties from Spinraza, a spinal muscular atrophy drug initially developed by Ionis and now commercialized by Biogen ( BIIB ). Ionis Pharmaceuticals ( IONS ) shares fell early Tuesday after third-quarter sales lagged expectations and the biotech reported no adjusted earnings. ""With sales of over $520 million so far this year, Spinraza is on track to be one of the most successful rare-disease drug launches in history,"" Chief Operating Officer B. Lynne Parshall said.",245.45018005371094
2017-11-09 00:00:00+00:00,312.0,313.9700012207031,308.8999938964844,309.9599914550781,309.9599914550781,895400.0,3.0,1.0,0.5000249999999999,"Sphera Funds Management Ltd. New Purchases: CEL , AGN , TEVA , RETA, ZGNX, INSM, GLD, KDMN, VRTX, PANW, Added Positions:MRK, PTLA, CLVS, BIIB, CLLS, CELG, TSRO, SHPG, SPNS, MGNX, Reduced Positions:CSTE, ARRY, ITRN, AVEO, UNP, NOMD, SEDG, ADMS, TJX, SNA, Sold Out:NVS, BMY, ALXN, ALNY, ICPT, GLYC, DBVT, BLCM, ENDP, LRCX, For the details of SPHERA FUNDS MANAGEMENT LTD.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=SPHERA+FUNDS+MANAGEMENT+LTD. Shares added by 10.00% Biogen Inc ( BIIB ) - 105,000 shares, 4.72% of the total portfolio. These are the top 5 holdings of SPHERA FUNDS MANAGEMENT LTD. SPDR Series Trust S&P Biotech ( XBI ) - 1,400,000 shares, 17.39% of the total portfolio.",257.10528564453125
2017-11-10 00:00:00+00:00,310.1000061035156,311.70001220703125,306.3900146484375,310.44000244140625,310.44000244140625,820700.0,4.0,1.0,0.7500249999999999,"Ionis Pharmaceuticals (NASDAQ: IONS) reported third-quarter financials that were better than hoped on Tuesday, but the worry of slowing U.S. sales of Spinraza, a rare disease drug that's licensed to Biogen (NASDAQ: BIIB) , caused a short-term tumble in its share price. The gap is staggering at first glance, but a closer look suggests it's Spinraza's complicated dosing schedule that's to blame for the anemic quarter-over-quarter performance, not a drop-off in patient demand. If the dosing schedule is to blame for the U.S. sales miss, then it's going to be hard to accurately predict royalty income to Ionis Pharmaceuticals in any given quarter until prescription volume gets big enough to smooth out the impact.",247.41201782226562
2017-11-13 00:00:00+00:00,310.4700012207031,316.07000732421875,308.57000732421875,315.7099914550781,315.7099914550781,1186800.0,2.0,1.0,0.250025,"And that fact doesn't bode well for the slew of other experimental anti-amyloid treatments therapies currently under development for AD right now -- such as Biogen 's (NASDAQ: BIIB) aducanumab, or Amgen (NASDAQ: AMGN) and Novartis ' (NYSE: NVS) BACE1 inhibitor, CNP520 -- just to name a few. Although neither Lilly nor Merck has totally abandoned its aspirations of potentially bringing the first disease-modifying treatment to market for AD, the cold, hard truth is that the current approach of reducing amyloid plaques in the brain has been a complete dead end thus far. The backstory is that medical cannabis has been hypothesized to be a potent AD drug ever since a 2003 study showing that some of the support elements (neuralgia) of the central nervous system negatively impacted by the growth of amyloid plaques tend to overexpress so-called ""endocannabinoid receptors.""",253.68328857421875
2017-11-14 00:00:00+00:00,313.3399963378906,314.44000244140625,307.5,309.69000244140625,309.69000244140625,1214300.0,4.0,1.0,0.7500249999999999,"Ionis Pharmaceuticals ' (NASDAQ: IONS) third-quarter earnings were a bit humdrum considering partner Biogen (NASDAQ: BIIB) spilled the beans on sales of Spinraza a few weeks ago when it reported its earnings. Ionis provided more detail on the phase 3 NEURO-TTR trial for inotersen, showing that 50% of treated patients with hereditary TTR amyloidosis had an improvement in their quality of life from baseline. Akcea Therapeutics (NASDAQ: AKCA) , which Ionis spun off in July, has submitted marketing applications in the EU, U.S., and Canada for volanesorsen for the treatment of patients with familial chylomicronemia syndrome.",255.7335662841797
2017-11-15 00:00:00+00:00,309.69000244140625,313.19000244140625,308.0,310.2799987792969,310.2799987792969,1294000.0,2.0,1.0,0.250025,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here BIOGEN INC ( BIIB ) is a large-cap growth stock in the Biotechnology & Drugs industry. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068. It caters its services to various sectors, such as oil and gas exploration, production and refining; chemicals and polymers; programs for various national governments, including aerospace, defense, and environmental programs; buildings; infrastructure and telecommunications; mining and minerals; pharmaceuticals and biotechnology; power; pulp and paper; technology and manufacturing, and food and consumer products.",254.4500732421875
2017-11-16 00:00:00+00:00,310.7200012207031,314.6199951171875,309.67999267578125,313.9800109863281,313.9800109863281,731700.0,3.0,1.0,0.5000249999999999,"Americafirst Capital Management, Llc New Purchases: EXC , TMO , BIIB , IGT, XEL, PPL, A, SID, BAX, BMRN, Added Positions:SYY, EIX, SRE, MO, PG, UAL, DE, GIS, YUM, TSN, Reduced Positions:AET, CI, UNH, GD, ADM, K, CLX, BG, AGNC, LMT, Sold Out:KMB, ESRX, DEO, WMB, BAYRY, JCOM, TDG, MDU, OTTR, ORA, For the details of AMERICAFIRST CAPITAL MANAGEMENT, LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=AMERICAFIRST+CAPITAL+MANAGEMENT%2C+LLC These are the top 5 holdings of AMERICAFIRST CAPITAL MANAGEMENT, LLC Sysco Corp ( SYY ) - 32,225 shares, 3.21% of the total portfolio. New Position Biogen Inc ( BIIB ) - 2,636 shares, 1.52% of the total portfolio. New Purchase: Biogen Inc ( BIIB ) Americafirst Capital Management, Llc initiated holdings in Biogen Inc.",241.40504455566406
2017-11-17 00:00:00+00:00,313.4700012207031,316.0,310.17999267578125,313.9700012207031,313.9700012207031,907400.0,3.0,1.0,0.5000249999999999,"The aforementioned Bristol-Myers Squibb has been suggested as one possibility, and Biogen Inc (NASDAQ: BIIB ) is another plausible possibility . Though the PFE stock price has almost doubled since generic versions of Lipitor were introduced (bear in mind Pfizer shares suffered plenty before the drug fell off the patent cliff), revenue only began to grow again last year. Early this week, Purkiss made a point of saying sales of Ibrance is being underestimated, suggesting that rather than achieving just a little less than $7 billion in revenue in 2023, it could actually produce nearly $13-billion worth of business that year as its approved uses were expanded and caregivers saw its efficacy.",244.1432342529297
2017-11-20 00:00:00+00:00,313.6000061035156,315.760009765625,309.1700134277344,309.4599914550781,309.4599914550781,667200.0,2.0,1.0,0.250025,"On Monday, Biogen ( BIIB ) received an upgrade to its Relative Strength ( RS ) Rating , from 70 to 73. See if Biogen can continue to show renewed price strength and hit that benchmark. Corcept Therapeutics ( CORT ), Hutchison China MediTech ( HCM ) and Ligand Pharmaceuticals ( LGND ) are among the top 5 highly rated stocks within the group.",254.35699462890625
2017-11-21 00:00:00+00:00,310.8699951171875,311.2200012207031,306.1099853515625,309.0599975585937,309.0599975585937,1281600.0,2.0,1.0,0.250025,"Chesapeake Energy Corporation Could Be Setting up for a Big Breakout The Alternate Bet: Sell the BIIB Jan 2018 $275/$270 credit put spread where my risk is limited. Source: Biogen via YouTube Biogen Inc (NASDAQ: BIIB ) stock managed to still be up almost 10% year-to-date. While BIIB stock has a high face value of $310 per share, it is not expensive.",254.68380737304688
2017-11-22 00:00:00+00:00,308.9100036621094,311.1099853515625,307.1499938964844,309.79998779296875,309.79998779296875,732500.0,2.5,1.0,0.375025,"Biogen BIIB was weak through May and has since rallied. Click to get this free report General Electric Company (GE): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report Chipotle Mexican Grill, Inc. (CMG): Free Stock Analysis Report Macy's Inc (M): Free Stock Analysis Report To read this article on Zacks.com click here. (2: 00 ) - Tracey's Top Stock Picks (11: 40 ) - Ticker Recap and Extra Tips (13: 35 ) - Episode Roundup: Podcast@Zacks.com Welcome to Episode #69 of the Value Investor Podcast Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio service , shares some of her top value investing tips and stock picks. New Article Over the last six months, Biogen BIIB was up 23.6% while Regeneron lost 14.6% (See the last biotech stock roundup here: Dynavax Vaccine Gets FDA Nod, Loxo Inks Deal with Bayer ). Click to get this free report Celgene Corporation (CELG): Free Stock Analysis Report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Cytokinetics, Incorporated (CYTK): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report United Therapeutics Corporation (UTHR): Free Stock Analysis Report TESARO, Inc. (TSRO): Free Stock Analysis Report To read this article on Zacks.com click here. The decision to discontinue development was based on new information obtained from the phase III program related to previously disclosed agranulocytosis (the absence of white blood cells, which fight infection) and associated serious adverse events.",249.6240234375
2017-11-27 00:00:00+00:00,310.07000732421875,312.45001220703125,307.010009765625,311.7300109863281,311.7300109863281,1353300.0,2.75,1.0,0.437525,"Biogen (NASDAQ: BIIB) is following the old saying, ""If you can't beat 'em, join 'em"" for its multibillion drug Tecfidera or, more accurately, ""If you might not be able to beat 'em later, license 'em now."" The inactive structure will hopefully result in fewer gastrointestinal side effects compared to Tecfidera, which caused abdominal pain in 18% of patients in the clinical trials supporting its approval. Some of the concern likely has to do with wording in the Securities and Exchange Commission document for the deal that puts a lot of pressure on the aforementioned EVOLVE-MS-2 head-to-head gastrointestinal tolerability study. New Article Sphera Funds Management Ltd. New Purchases: CEL , AGN , TEVA , RETA, ZGNX, INSM, GLD, KDMN, VRTX, PANW, Added Positions:MRK, PTLA, CLVS, BIIB, CLLS, CELG, TSRO, SHPG, SPNS, MGNX, Reduced Positions:CSTE, ARRY, ITRN, AVEO, UNP, NOMD, SEDG, ADMS, TJX, SNA, Sold Out:NVS, BMY, ALXN, ALNY, ICPT, GLYC, DBVT, BLCM, BCLI, ENDP, For the details of SPHERA FUNDS MANAGEMENT LTD.'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=SPHERA+FUNDS+MANAGEMENT+LTD. Shares added by 10.00% Biogen Inc ( BIIB ) - 105,000 shares, 4.72% of the total portfolio. These are the top 5 holdings of SPHERA FUNDS MANAGEMENT LTD. SPDR Series Trust S&P Biotech ( XBI ) - 1,400,000 shares, 17.39% of the total portfolio. New Article Biogen ( BIIB ) will pay Alkermes ( ALKS ) $28 million upfront and up to $200 million in milestones to gain another multiple sclerosis treatment in its arsenal as key drug Tecfidera faces a patent cliff in the mid-2020s. Investors had been concerned about Alkermes' ability to commercialize ALKS 8700, as well as challenge Biogen's massive multiple sclerosis drug franchise, Leerink analyst Paul Matteis wrote in a note to clients. ""To this point from our perspective, Biogen seems to be the perfect partner for Alkermes and could use ALKS 8700 as a life-cycle extender should the company's dosing (intellectual property) for Tecfidera come under fire,"" he said. New Article BiogenBIIB was weak through May and has since rallied. Click to get this free report General Electric Company (GE): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Exxon Mobil Corporation (XOM): Free Stock Analysis Report Chipotle Mexican Grill, Inc. (CMG): Free Stock Analysis Report Macy's Inc (M): Free Stock Analysis Report To read this article on Zacks.com click here. Every week, Tracey will be joined by guests to discuss the hottest investing topics in stocks, bonds and ETFs and how it impacts your life.",247.59490966796875
2017-11-28 00:00:00+00:00,314.1199951171875,317.3900146484375,312.1000061035156,317.1400146484375,317.1400146484375,1100700.0,2.0,1.0,0.250025,"BiogenBIIB and Alkermes plcALKS announced a global license and collaboration agreement to develop and commercialize Alkermes' phase III multiple sclerosis (""MS"") candidate, ALKS 8700. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Alkermes PLC (ALKS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Per the deal, Biogen was granted worldwide commercialization rights to Alkermes' ALKS 8700 for an upfront payment of $28 million.",251.96409606933594
2017-11-29 00:00:00+00:00,317.5,321.2900085449219,316.2300109863281,319.9599914550781,319.9599914550781,1360800.0,2.0,1.0,0.250025,"BiogenBIIB and Alkermes plcALKS announced a global license and collaboration agreement to develop and commercialize Alkermes' phase III multiple sclerosis (""MS"") candidate, ALKS 8700. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Alkermes PLC (ALKS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Per the deal, Biogen was granted worldwide commercialization rights to Alkermes' ALKS 8700 for an upfront payment of $28 million. New Article Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), AbbVie (ABBV) and Biogen (BIIB). If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Amazon (AMZN) Prime and AWS Impress, Rising Expenses a Worry AbbVie's (ABBV) Humira Blossoms in a Crowded Space Biogen's (BIIB) Multiple Sclerosis Products Face Competition Featured Reports NRG Energy (NRG) Gains From Transformation Plan & Drop-Down The Zacks analyst believes NRG Energy gains from its Transformation Plans, which are helping in cost savings and debt reduction. Click to get this free report McCormick & Company, Incorporated (MKC): Free Stock Analysis Report Helmerich & Payne, Inc. (HP): Free Stock Analysis Report Hyatt Hotels Corporation (H): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Amazon.com, Inc. (AMZN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here.",261.3421936035156
2017-11-30 00:00:00+00:00,320.69000244140625,323.69000244140625,317.760009765625,322.1700134277344,322.1700134277344,1186200.0,3.6,1.0,0.6500250000000001,"When biotech companies like Celgene ( CELG ), Biogen ( BIIB ) and Gilead Sciences ( GILD ) put their drugs through extensive trials to gain FDA approval, they turn to clinical research firms like PRA Health Sciences ( PRAH ). 1 ranking within the medical research equipment and services industry group, ahead of Illumina ( ILMN ), IQVIA (IQV), Catalent (CTLT) and Icon (ICLR). PRA Health also fell, but managed to find support at its 50-day line as it tries to complete a new flat base and keep adding to the big gains it's made since its 2014 IPO. New Article Stocks recently featured in the blog include AmazonAMZN , AbbVieABBV , BiogenBIIB , McCormickMKC and HyattH . Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report McCormick & Company, Incorporated (MKC): Free Stock Analysis Report Hyatt Hotels Corporation (H): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. However, increased operating expenses to support expansion of its business into new markets and territories, localize the availability of products and grow its content will keep margins under pressure. New Article First, it' CEO is Steve Holtzman, who served as executive vice president of corporate development at biotech behemoth Biogen ( BIIB ) until March last year (when he took the job at Decibel). The announcement details a collaboration deal with a privately held entity called Decibel Therapeutics, which is a Massachusetts-based biotech company that - as its name aptly suggests - is trying to develop a range of treatments targeting problems with the ear and hearing. This is pretty much unheard of these days in the health care sector, with the company doing the majority of the funding (as Regeneron is here) generally picking up rights to assets (at least in some global regions) when the collaboration bears fruit. New Article The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Biogen ( BIIB ) is now the #96 analyst pick, moving up by 4 spots. Looking at the stock price movement year to date, Biogen ( BIIB ) is showing a gain of 12.8%. VIDEO: S&P 500 Analyst Moves: BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article At Biogen ( BIIB ), a filing with the SEC revealed that on Wednesday, Director Alexander J. Denner purchased 30,000 shares of BIIB, at a cost of $317.36 each, for a total investment of $9.52M. VIDEO: Thursday 11/30 Insider Buying Report: BIIB, MDCO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Denner was up about 1.7% on the purchase at the high point of today's trading session, with BIIB trading as high as $322.91 at last check today.",248.2952117919922
2017-12-04 00:00:00+00:00,319.20001220703125,321.75,315.5599975585937,317.3999938964844,317.3999938964844,908700.0,2.0,1.0,0.250025,"Among the largest underlying components of IYH, in trading today Thermo Fisher Scientific Inc (Symbol: TMO) is off about 4.1%, Biogen Inc (Symbol: BIIB) is down about 0.2%, and Aetna Inc. (Symbol: AET) is higher by about 1.4%. For a complete list of holdings, visit the IYH Holdings page  The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $140.21 per share, with $177.00 as the 52 week high point - that compares with a last trade of $176.35. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",237.5492401123047
2017-12-05 00:00:00+00:00,317.6600036621094,322.25,317.6600036621094,319.8699951171875,319.8699951171875,915600.0,3.0,1.0,0.5000249999999999,"Biogen ( BIIB ) is a biopharmaceutical company that earns high marks from our Warren Buffett-inspired investment strategy based on its predictable and consistently growing earnings, ability to pay off debt with earnings in under two years, and management's use of retained earnings which reflects a return of 19.9%. At the time of publication, John Reese and/or his private clients were long MU, GIB, BIIB, UTHR, OZRK, BX, UFPI and TX The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. As companies strive to remain competitive (capital spending has been relatively low in recent years), investment in upgrading technology may also serve as a boost to the sector.",231.6520538330078
2017-12-06 00:00:00+00:00,319.0,320.5799865722656,311.75,314.6600036621094,314.6600036621094,938800.0,4.0,1.0,0.7500249999999999,"Over the last six months, Biogen BIIB was up 23.7% while Regeneron REGN lost 22.5% (See the last biotech stock roundup here: Regeneron Down on Eylea Data, Biogen-Alkermes in MS Deal ). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Clovis Oncology, Inc. (CLVS): Free Stock Analysis Report Revance Therapeutics, Inc. (RVNC): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report To read this article on Zacks.com click here. Repatha was also approved for use as an adjunct to diet, alone or in combination with other lipid-lowering therapies like statins, for the treatment of adults with primary hyperlipidemia to reduce low density lipoprotein cholesterol (LDL-C).",225.9508056640625
2017-12-11 00:00:00+00:00,327.0899963378906,330.6099853515625,322.6600036621094,328.0299987792969,328.0299987792969,1142800.0,4.0,1.0,0.7500249999999999,"But all that noise may obscure new potential buy signals from big names like Microsoft ( MSFT ), Intel ( INTC ), Fiat Chrysler ( FCAU ), Biogen ( BIIB ) and AbbVie (ABBV). Intel edged up 0.7% to 43.66, finding support at its 50-day average as it climbs off the low end of its base with a 47.40 entry. IBD'S TAKE:Flat bases, which require a minimum of five weeks, have been especially common in recent months with the market grinding higher.",236.79478454589844
2017-12-12 00:00:00+00:00,325.20001220703125,327.8999938964844,323.8399963378906,327.75,327.75,747400.0,4.0,1.0,0.7500249999999999,"In a welcome move, Biogen ( BIIB ) saw its Relative Strength Rating rise from 68 to 72 on Tuesday. [ibd-display-video id=2102289 width=50 float=left autostart=true] This exclusive rating from Investor's Business Daily identifies price movement with a 1 (worst) to 99 (best) score. See How IBD Helps You Make More Money In Stocks Biogen is building a cup without handle with a 348.94 entry .",238.57875061035156
2017-12-13 00:00:00+00:00,328.2099914550781,332.8500061035156,327.25,330.7099914550781,330.7099914550781,1129200.0,2.5,1.0,0.375025,"GILD is a part of the Health Care sector, which includes companies such as Amgen Inc. ( AMGN ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports GILD's forecasted earnings growth in 2017 as -25%, compared to an industry average of 6.4%. For more information on the declaration, record and payment dates, visit the GILD Dividend History page. New Article With the Republican tax bill and the strong demand for new growth products in mind, I think Biogen (NASDAQ: BIIB) , BioMarin (NASDAQ: BMRN) , bluebird bio (NASDAQ: BLUE) , Geron Corp. (NASDAQ: GERN) , and Sage Therapeutics (NASDAQ: SAGE) are all likely to get taken out in 2018. Amgen is dealing with the loss of exclusivity for its blood-conditioning medicines Neupogen and Epogen, Gilead Sciences is experiencing a rapid decline in its hepatitis C franchise and facing new threats to its dominance in HIV, J&J's blockbuster arthritis drug Remicade is battling generic competition now, and Pfizer's top-selling pain medication, Lyrica, is near the end of its patent life as well. And BioMarin's present market cap of less than $16 billion wouldn't be much of a barrier for any of the aforementioned companies -- that is, if they wanted a top-tier orphan drug product portfolio and clinical pipeline.",239.1549072265625
2017-12-14 00:00:00+00:00,332.0,332.0,321.1099853515625,323.54998779296875,323.54998779296875,1173900.0,2.0,1.0,0.250025,"Biogen ( BIIB ) and Ionis Pharmaceuticals ( IONS ) sank Thursday after AveXis ( AVXS ) announced its plan to start a trial in spinal muscular atrophy that would rival their new drug, Spinraza. AveXis also said Wednesday it met with the Food and Drug Administration on Dec. 5 to discuss its plans for AVXS-101 in patients with type 1 spinal muscular atrophy. Teva Pharma Announces Layoffs, Suspends Dividend To Tackle Debt This Biotech Stock Seen As Cheapest Among Rivals In Cancer Drugs Is Biogen's Multiple Sclerosis Franchise Getting A New Lease On Life? New Article Biogen ( BIIB ) fell 2% after AveXis ( AVXS ) said it will start a trial for a spinal muscular atrophy treatment that would rival a new drug from Biogen and Ionis Pharmaceuticals (IONS). Disney ( DIS ) led the Dow with a nearly 3% gain after it finalized a deal to acquire 21st Century Fox 's ( FOXA ) entertainment assets. Delta Air Lines (DAL), hosting its investor day, forecast solid 2018 and fourth-quarter results, including more bullish expectations for unit revenue.",248.22357177734375
2017-12-20 00:00:00+00:00,330.75,335.79998779296875,329.29998779296875,333.4700012207031,333.4700012207031,1276500.0,3.2,1.0,0.550025,"Companies that are currently working on Alzheimer's disease treatments include players like Biogen BIIB , Novartis, AstraZeneca, Eisai and Amgen. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report bluebird bio, Inc. (BLUE): Free Stock Analysis Report Juno Therapeutics, Inc. (JUNO): Free Stock Analysis Report To read this article on Zacks.com click here. Although there are still a few days left for the year to end, 2017 has turned out to be pretty good for the pharma and biotech sector where FDA approvals are concerned. New Article New SMA Collaboration between Biogen & Ionis: Biogen BIIB has entered into a new collaboration agreement with Ionis Pharmaceuticals, Inc. IONS under which new antisense oligonucleotide drug candidates will be identified for the treatment of spinal muscular atrophy (""SMA""). Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Spark Therapeutics, Inc. (ONCE): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Key highlights this week include the FDA approval of Luxturna, the first gene therapy for a genetic disease, the first and only pharmacologic treatment for an inherited retinal disease (""IRD"") and the first adeno-associated virus (""AAV"") vector gene therapy and the earlier-than-expected label expansion of Exelixis's EXEL Cabometyx. New Article Shares reduced by 5.84% Biogen Inc ( BIIB ) - 1,630,000 shares, 4.9% of the total portfolio. Orbimed Advisors Llc New Purchases: CMTA , UHS , KALA , ALPN, ONCE, SYBX, ZLAB, NVO, DCPH, MCRB, Added Positions:AET, IMMU, ALNY, JUNO, REGN, SEM, IART, JAZZ, GLPG, IOVA, Reduced Positions:ICPT, EW, INSM, GKOS, HCA, SGYP, ALXN, BSX, SHPG, MGLN, Sold Out:HUM, SIEN, TSRO, NERV, CLLS, AMRN, For the details of ORBIMED ADVISORS LLC's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=ORBIMED+ADVISORS+LLC These are the top 5 holdings of ORBIMED ADVISORS LLC Alexion Pharmaceuticals Inc ( ALXN ) - 3,645,486 shares, 4.91% of the total portfolio. Celgene Corp ( CELG ) - 3,351,977 shares, 4.69% of the total portfolio. New Article Among the day's movers, Biogen ( BIIB ) added nearly 2% as it works on the right side of a base. The Nasdaq composite, S&P 500 and Dow Jones industrial average edged lower in afternoon trading Wednesday as earnings reports from Micron Technology ( MU ), FedEx ( FDX ), Stitch Fix ( SFIX ) and Red Hat ( RHT ) got the most attention. Earnings and sales at the new issue topped expectations, but Wall Street is still focused on high selling, general and administrative expenses at the company. New Article BIIB has expanded its collaboration with Ionis Pharmaceuticals, Inc. IONS to enhance its portfolio of medicines to treat spinal muscular atrophy (SMA), a devastating neuromuscular disease. Click to get this free report H Lundbeck A/S (HLUYY): Free Stock Analysis Report XOMA Corporation (XOMA): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. It consolidated Biogen's position in the neurological disease market with the drug being the first and only treatment to be approved in the United States for SMA.",243.41909790039062
2017-12-21 00:00:00+00:00,319.75,328.6000061035156,319.04998779296875,322.5199890136719,322.5199890136719,2212900.0,3.5,1.0,0.6250249999999999,"Biogen ( BIIB ) sank Thursday after its Alzheimer's drug failed at a 12-month analysis - but the trial will continue out to its predetermined 18-month mark, Biogen and partner Eisai said. ""Consensus (and we) were carrying minimal risk-adjusted sales for this asset in the Biogen model, therefore any stock impact today should be fairly muted in our opinion,"" Mizuho analyst Salim Syed said in a note to clients. Although the results from the interim analysis for BAN2401 underscore inherent risk in Biogen's Alzheimer's pipeline, there are several notable differences between the drugs making it too premature to conclude outcomes for either trial, he said. New Article Two other components making moves today are Biogen ( BIIB ), trading down 2.4%, and Baidu ( BIDU ), trading up 2.3% on the day. And the worst performing Nasdaq 100 component thus far on the day is Paychex ( PAYX ), trading down 2.9%. Paychex is showing a gain of 10.3% looking at the year to date performance. New Article Rituximab is sold under the brand name, Rituxan, by Roche 's ( RHHBY ) Genentech and Biogen ( BIIB ). Celgene ( CELG ) toppled late Thursday after its drug regimen failed in a Phase 3 study of patients with a form of non-Hodgkin lymphoma. [ibd-display-video id=3037425 width=50 float=left autostart=true] In after-hours trading on the stock market today , Celgene dove 4.5%, near 103, after closing down 0.4%, at 107.88. New Article Particularly high volume was seen for the $310 strike put option expiring January 19, 2018 , with 333 contracts trading so far today, representing approximately 33,300 underlying shares of BIIB. Below is a chart showing KMX's trailing twelve month trading history, with the $70 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 6,481 contracts thus far today. That number of contracts represents approximately 648,100 underlying shares, working out to a sizeable 59.8% of BIIB's average daily trading volume over the past month, of 1.1 million shares. New Article Other noteworthy reports we are featuring today include Concho Resources (CXO), Biogen (BIIB) and Marathon Petroleum (MPC). Biogen (BIIB) Diversifies Beyond Multiple Sclerosis Though weakening trends in multiple sclerosis (MS) market is a concern, the Zacks analyst likes Biogen's efforts to diversify beyond MS to other areas like Alzheimer's. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Marathon Petroleum Corporation (MPC): Free Stock Analysis Report FedEx Corporation (FDX): Free Stock Analysis Report Concho Resources Inc. (CXO): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report To read this article on Zacks.com click here. New Article In today's episode of The Motley Fool's Industry Focus: Healthcare , analyst Kristine Harjes and healthcare stock-picker Todd Campbell highlight the biggest healthcare stories of 2017, including the launch of game-changing drugs from Biogen (NASDAQ: BIIB) and Gilead Sciences (NASDAQ: GILD) , how we're trying to solve the opioid crisis, why Amazon.com (NASDAQ: AMZN) has Walgreens Boots Alliance (NASDAQ: WBA) and CVS Health (NYSE: CVS) scurrying, and more. Campbell: I tell you, Kristine, I have to admit to you and all the listeners, I struggled with this show a little bit only because when you're knee-deep in the trenches of an industry or a sector, sometimes it's hard to pull yourself up and get into a tree and get the bird's-eye view of the landscape and see, this is where we've been, and maybe this is where we're going. I think, going back to one year ago, if I had looked at the future of Obamacare and said, is this going to survive giving the current political climate, I would not have anticipated that the Republicans in control right now wouldn't have been able to get the job done on repealing and replacing it.",244.69412231445312
2017-12-22 00:00:00+00:00,323.1600036621094,323.5,318.7699890136719,319.5,319.5,887000.0,2.5,1.0,0.375025,"Stocks recently featured in the blog include Pfizer PFE , FedExFDX , AbbottABT , BiogenBIIB and Marathon PetroleumMPC . Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Marathon Petroleum Corporation (MPC): Free Stock Analysis Report FedEx Corporation (FDX): Free Stock Analysis Report To read this article on Zacks.com click here. You can see all of today's research reports here >>> Pfizer 's shares have underperformed the peer group so far this year (the stock is up +12.2% over this period vs. a +16.1% increase for the Zacks Large-Cap Pharmaceuticals industry). New Article Shares of Biogen Inc.BIIB declined by almost 3.3% after the company's Alzheimer's candidate, BAN2401, failed to meet the criteria for success based on a 12-months interim analysis as the primary endpoint in a mid-stage trial. Notably, the company's Alzheimer's disease (AD) pipeline comprises candidates with different mechanisms of action including anti-tau candidate (BIIB092/BMS-986168-with potential in AD as well as progressive supranuclear palsy (PSP)), anti-amyloid (aducanumab) candidates as well as a BACE inhibitor (elenbecestat) program. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here.",258.7174987792969
2017-12-27 00:00:00+00:00,319.92999267578125,322.25,318.8699951171875,320.07000732421875,320.07000732421875,600900.0,3.5,1.0,0.6250249999999999,"Key highlights this week include the announcement of a couple of acquisition agreements as well as pipeline news from Biogen BIIB and Celgene CELG . Click to get this free report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report BioMarin Pharmaceutical Inc. (BMRN): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Sucampo Pharmaceuticals, Inc. (SCMP): Free Stock Analysis Report Ignyta, Inc. (RXDX): Free Stock Analysis Report To read this article on Zacks.com click here. An Independent Data Monitoring Committee said that BAN2401 did not meet the criteria for success based on a Bayesian analysis at 12 months as the primary endpoint in the phase II study. New Article The median tenure of chief executives at large-cap biotech companies was just one year in 2017, plunging from 11 years in 2007, amid key transition periods at Amgen ( AMGN ), Celgene ( CELG ), Biogen ( BIIB ) and Vertex Pharmaceuticals ( VRTX ), an analyst said Wednesday. Investors are also likely to view these executives as having less power to broker mergers and acquisitions , contributing to expectations for relatively modest deal activity in 2018 despite the improved cash positions of most large-caps, Porges said. Through the 2000s, biotech companies were operated by chief executives with long tenures, mostly scientific backgrounds, proven track records, and familiarity to investors, Porges said.",254.63504028320312
2017-12-29 00:00:00+00:00,320.54998779296875,322.75,318.239990234375,318.57000732421875,318.57000732421875,619500.0,2.0,1.0,0.250025,"Biogen 's ( BIIB ) multiple sclerosis drug Tecfidera had $1.07 billion in sales in the third quarter alone. Celgene ( CELG ) crashed 30% in a five-day period in October, first on news that it halted trials of a Crohn's disease drug, then on disappointing sales and a dimmed outlook. Overstock CEO Patrick Byrne is part of a joint venture building a blockchain-based global registry for property rights in the developing world.",245.76890563964844
2018-01-02 00:00:00+00:00,321.1499938964844,335.42999267578125,318.3299865722656,334.1700134277344,334.1700134277344,1422500.0,5.0,1.0,1.000025,"Combined, INCY and BIIB make up approximately 2.7% of the underlying holdings of XLV. Within the sector, Incyte Corporation (Symbol: INCY) and Biogen Inc (Symbol: BIIB) are two large stocks leading the way, showing a gain of 6.9% and 4.4%, respectively. Combined, AAP and DISH make up approximately 0.6% of the underlying holdings of IYC.",240.01376342773438
2018-01-03 00:00:00+00:00,333.4599914550781,340.45001220703125,332.7099914550781,339.8500061035156,339.8500061035156,1121700.0,3.5,1.0,0.6250249999999999,"Biogen ( BIIB ) saw a welcome improvement to its Relative Strength ( RS ) Rating on Wednesday, with an upgrade from 68 to 75. Over 100 years of market history shows that the best-performing stocks often have an 80 or better RS Rating in the early stages of their moves. Earnings growth rose in the company's most recent report from -3% to 22%, but the top line fell from 6% to 4%. New Article Among those, she counts Regeneron Pharmaceuticals ( REGN ), Gilead Sciences ( GILD ), Biogen ( BIIB ), Bioverativ ( BIVV ) and United Therapeutics ( UTHR ). Generalists are still hanging out on the biotech sidelines, an analyst said Wednesday, but specialist investors are willing to look for ""ideas that could work"" amid coming tax reform. ""We think investors have yet to digest the potential positive impacts from tax reform on the biotech space,"" Credit Suisse analyst Alethia Young said in a note to clients.",250.83367919921875
2018-01-04 00:00:00+00:00,339.7300109863281,341.3999938964844,335.4599914550781,339.989990234375,339.989990234375,967100.0,3.0,1.0,0.5000249999999999,"Over the last six months, Biogen was up 24.7% while Celgene lost 16.2% (See the last biotech stock roundup here: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo ). Among major biotech stocks, Biogen BIIB gained 6.2%. Click to get this free report GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report Seattle Genetics, Inc. (SGEN): Free Stock Analysis Report Spark Therapeutics, Inc. (ONCE): Free Stock Analysis Report United Therapeutics Corporation (UTHR): Free Stock Analysis Report To read this article on Zacks.com click here.",245.851806640625
2018-01-05 00:00:00+00:00,342.0,344.1199951171875,339.0599975585937,342.489990234375,342.489990234375,1486400.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of IWF, in trading today NVIDIA Corp (Symbol: NVDA) is off about 0.8%, Lowe's Companies Inc (Symbol: LOW) is up about 1.4%, and Biogen Inc (Symbol: BIIB) is higher by about 0.5%. For a complete list of holdings, visit the IWF Holdings page  The chart below shows the one year price performance of IWF, versus its 200 day moving average: Looking at the chart above, IWF's low point in its 52 week range is $105.82 per share, with $138.3999 as the 52 week high point - that compares with a last trade of $138.33. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",240.1892547607422
2018-01-08 00:00:00+00:00,341.45001220703125,341.94000244140625,327.260009765625,329.6499938964844,329.6499938964844,1438800.0,2.333333333333333,1.0,0.3333583333333332,"Combined, BIIB and REGN make up approximately 3.2% of the underlying holdings of XLV. Within that group, Biogen Inc (Symbol: BIIB) and Regeneron Pharmaceuticals, Inc. (Symbol: REGN) are two large stocks that are lagging, showing a loss of 3.8% and 2.9%, respectively. Combined, LB and ULTA make up approximately 0.8% of the underlying holdings of IYC. New Article Last month, Biogen, Inc. BIIB announced that an Alzheimer's disease study on BAN2401 failed to show early positive which raised investor concern about the candidate's chances of success. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The decision to end the neuroscience-discovery program will mainly affect employees at facilities in Andover and Cambridge, MA, and Groton, CT. Pfizer, however, intends to continue development of pain candidate, tanezumab, which it is developing in late-stage studies in partnership with Eli Lilly LLY , label expansion efforts for pain drug Lyrica and its rare disease program. New Article Two other components making moves today are Biogen ( BIIB ), trading down 2.9%, and NVIDIA ( NVDA ), trading up 3.1% on the day. In early trading on Monday, shares of Seagate Technology ( STX ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 8.2%. And the worst performing Nasdaq 100 component thus far on the day is Shire ( SHPG ), trading down 3.9%.",230.46604919433594
2018-01-09 00:00:00+00:00,329.6499938964844,339.489990234375,329.0599975585937,336.3599853515625,336.3599853515625,1326400.0,2.0,1.0,0.250025,"Especially high volume was seen for the $340 strike call option expiring January 19, 2018 , with 1,614 contracts trading so far today, representing approximately 161,400 underlying shares of BIIB. Below is a chart showing ABBV's trailing twelve month trading history, with the $105 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 8,443 contracts, representing approximately 844,300 underlying shares or approximately 75% of BIIB's average daily trading volume over the past month, of 1.1 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $340 strike highlighted in orange: For the various different available expirations for MCK options , ABBV options , or BIIB options , visit StockOptionsChannel.com.",237.65573120117188
2018-01-11 00:00:00+00:00,338.010009765625,338.5400085449219,329.3399963378906,333.07000732421875,333.07000732421875,1002000.0,2.0,1.0,0.250025,"The Relative Strength ( RS ) Rating for Biogen ( BIIB ) entered a higher percentile Thursday, as it got a lift from 70 to 73. [ibd-display-video id=2385970 width=50 float=left autostart=true] This exclusive rating from Investor's Business Daily measures price performance with a 1 (worst) to 99 (best) score. History reveals that the market's biggest winners tend to have an 80 or higher RS Rating in the early stages of their moves.",248.27755737304688
2018-01-17 00:00:00+00:00,339.7200012207031,347.7799987792969,337.2799987792969,344.8699951171875,344.8699951171875,1429000.0,3.0,1.0,0.5000249999999999,"Especially high volume was seen for the $340 strike call option expiring March 16, 2018 , with 454 contracts trading so far today, representing approximately 45,400 underlying shares of BIIB. Below is a chart showing PSX's trailing twelve month trading history, with the $110 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 4,962 contracts thus far today. That number of contracts represents approximately 496,200 underlying shares, working out to a sizeable 43.8% of BIIB's average daily trading volume over the past month, of 1.1 million shares.",252.61422729492188
2018-01-18 00:00:00+00:00,343.989990234375,345.0,337.5,344.44000244140625,344.44000244140625,1302500.0,4.0,1.0,0.7500249999999999,"The Relative Strength ( RS ) Rating for Biogen ( BIIB ) moved into a new percentile Thursday, as it got a lift from 68 to 71. See if Biogen can continue to show renewed price strength and clear that threshold. Once a stock moves 5% or higher beyond the original entry, it's considered extended and out of buy range.",258.1033935546875
2018-01-19 00:00:00+00:00,347.57000732421875,347.57000732421875,341.82000732421875,342.4100036621094,342.4100036621094,1232200.0,2.5,1.0,0.375025,"What happened Shares of Acorda Therapeutics Inc. (NASDAQ: ACOR) , a biopharmaceutical company focused on neurological disorders, popped 15.4% during early morning trading after Bloomberg reported that Biogen Inc. (NASDAQ: BIIB) and several smaller suitors appear interested in a potential sale. The shares spiked today largely in response to reports of interest from neuroscience heavyweight Biogen. Now what It's important to point out Biogen hasn't officially expressed interest in buying anything from Acorda. New Article (+) FORD (+158.06%) Announced acquisition of Intelligent Product Solutions (+) ACOR (+8.80%) Possible takeover target by Biogen ( BIIB ) or others (+) CRBP (+4.01%) Initiated at Raymond James with outperform rating, $24 price target Stocks are mixed at midday on Friday as focus shifts to Washington as lawmakers scramble to avert a government shutdown on Saturday. The S&P 500 and Nasdaq returned some of their earlier gains but remain propped up by strength in Amazon ( AMZN ) and Nike ( NKE ), while the Dow was weighed down by losses in component stocks International Business Machines ( IBM ) and American Express ( AXP ), both of which lost ground after reporting recent quarterly results. New Article (+) FORD (+08%) Announced acquisition of Intelligent Product Solutions (+) ACOR (+13.40%) Possible takeover target by Biogen ( BIIB ) or others (+) OCUL (+5.23%) Upgraded to buy from neutral at BTIG Research Stock futures returned their earlier gains and have drifted into negative territory with Wall Street struggling to stay positive despite pressure on the energy complex from lower oil prices , and the looming risk from a government shutdown on Saturday. Early bargain-hunting following Thursday's pull-back has evaporated into the NYSE open with the Dow and S&P 500 trading lower, but the Nasdaq clinging to a slight gain. New Article (+) FORD (+110%) Announced acquisition of Intelligent Product Solutions (+) ACOR (+13.40%) Possible takeover target by Biogen ( BIIB ) or others (+) OCUL (+5.23%) Upgraded to buy from neutral at BTIG Research Early bargain-hunting following Thursday's pull-back has evaporated into the NYSE open with the Dow and S&P 500 trading lower, but the Nasdaq clinging to a slight gain. At 1:30pm ET, San Francisco Fed president John Williams will give a speech at the Bay Area Council Economic Institute conference, with Q&A to follow.",251.97531127929688
2018-01-22 00:00:00+00:00,343.5899963378906,347.82000732421875,342.0299987792969,347.6400146484375,347.6400146484375,1195200.0,3.142857142857143,1.0,0.5357392857142856,"We remind investors that Bioverativ was part of Biogen Inc. BIIB before the latter spun it off in February 2017.Bioverativ began trading on Nasdaq from Feb 2. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report BIOVERATIV INC (BIVV): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, the deal is line with Sanofi's long-term outlook to strengthen its presence in specialty care and leadership in rare diseases. New Article BIVV stock has been trading for less than a year since the company was formed as a spin-off from Biogen Inc (NASDAQ: BIIB ). Last week, InvestorPlace contributor, Swarup Gupta of Zacks Investment Research, highlighted BIVV as one of four great healthcare stocks to buy ahead of earnings. The deal could be a sign of more mergers and acquisitions activity in the biotech sector, with predictions by some experts of renewed interest by big pharma companies om smaller firms. New Article Biogen Inc.BIIB , a well-known name in the multiple sclerosis (MS) market, will report fourth-quarter 2017 results on Jan 25, before the market opens. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Emergent Biosolutions, Inc. (EBS): Free Stock Analysis Report To read this article on Zacks.com click here. Spinraza, approved for spinal muscular atrophy in December 2016, witnessed faster-than-anticipated adoption in the United States in the first half of 2017 backed by robust underlying demand. New Article France's Sanofi ( SNY ) agreed to buy recent Biogen ( BIIB ) spinoff Bioverativ ( BIVV ) for $11.6 billion, the companies announced early Monday. [ibd-display-video id=3098352 width=50 float=left autostart=true] Sanofi's deal values Bioverativ for $105 a share cash, a 64% premium to Friday's close. FANG Stocks Make News As Investors Mull Shutdown Impact Check Out These 4 Stocks Near Buys In First-Stage Bases The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Just a few months later, the company submitted volanesorsen for regulatory review in the U.S., Europe, and Canada as a treatment for familial chylomicronemia syndrome, a genetic disorder in which the body can't break down fats correctly. A potential blockbuster comes back home Investors learned in August that pharma giant GlaxoSmithKline (NYSE: GSK) had declined to exercise its option to move forward with inotersen, a possible treatment for hereditary TTR amyloidosis, a disorder that can cause serious heart or nerve damage. This move was a bit of a head-scratcher because the clinical data on inotersen looked quite good and the drug could be a cash cow should it win approval. New Article InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bioverativ Inc (NASDAQ: BIVV ), spun out of Biogen Inc. (NASDAQ: BIIB ) less than a year ago, drew an $11.6 billion bid from Sanofi SA (ADR) (NYSE: SNY ) on Jan. 22, a 64% premium over its closing price on Jan. 19. CAR-T Before the Horse Most of the candidates for acquisition are working on immunotherapies against cancer, replacing T-cells that no longer function with new cells customized to the genetics of the patient. He is the author of the historical mystery romance The Reluctant Detective Travels in Time , available now at the Amazon Kindle store. New Article What happened Shares of Bioverativ Inc. (NASDAQ: BIVV) , a hemophilia drugmaker that was spun off from Biogen (NASDAQ: BIIB) last year, are up by 62.6% in pre-market trading this morning. The biotech's stock is rising in response to the news that the French biopharma giant Sanofi (NYSE: SNY) has bought the company in all-cash deal valued at approximately $11.6 billion. Perhaps because of its recent failures on the mergers and acquisitions scene, Sanofi was apparently willing to pay 8.5 times Bioverativ's projected 2018 sales to get this deal done.",251.49456787109375
2018-01-23 00:00:00+00:00,348.0,354.2799987792969,345.739990234375,346.75,346.75,1186200.0,3.6666666666666665,1.0,0.6666916666666666,"Alkermes has a global license and collaboration agreement with Biogen Inc (NASDAQ: BIIB ) for ALKS 8700 for the treatment of multiple sclerosis. Meanwhile, Alkermes expects to complete filing a rolling submission for ALKS 5461 (major depressive disorder) in January with a potential advisory committee meeting and FDA decision in the second half of the year. XOMA's shares have been on an upward trajectory from August following the signing of licensing agreements with Novartis AG (NYSE: NVS ) for gevokizumab and intellectual property covering the use of IL-1 beta targeting antibodies in the treatment of cardiovascular disease. New Article Biogen Inc (Symbol: BIIB), which makes up 1.36% of the First Trust Mega Cap AlphaDEX Fund (Symbol: FMK), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at BIIB: BIIB - last trade: $347.64 - Recent Insider Buys: 10 ETFs With Stocks That Insiders Are Buying  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The ETF holds a total of $217,936 worth of BIIB, making it the #34 largest holding. New Article In fact, last week Acorda Therapeutics's shares were up on rumors that Biogen BIIB is interested in acquiring the company. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Juno Therapeutics, Inc. (JUNO): Free Stock Analysis Report To read this article on Zacks.com click here. Another acquisition announcement was made yesterday - French pharma giant Sanofi SNY said that it will be buying biopharma company Bioverativ for $11.6 billion.",248.5664520263672
2018-01-24 00:00:00+00:00,348.8900146484375,350.1199951171875,342.29998779296875,346.5,346.5,1512600.0,2.25,1.0,0.312525,"Particularly high volume was seen for the $340 strike put option expiring January 26, 2018 , with 932 contracts trading so far today, representing approximately 93,200 underlying shares of BIIB. Below is a chart showing HLF's trailing twelve month trading history, with the $110 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 10,919 contracts thus far today. That number of contracts represents approximately 1.1 million underlying shares, working out to a sizeable 101.2% of BIIB's average daily trading volume over the past month, of 1.1 million shares. New Article Only about a year after Bioverativ (NASDAQ: BIVV) was spun off from Biogen (NASDAQ: BIIB) , Sanofi (NYSE: SNY) has swooped in and acquired it for $11.6 billion. Although Bioverativ's drugs have been a commercial success, they face stiff competition from deeply embedded competitors , including Shire (NASDAQ: SHPG) , which bought Baxalta for $32 billion in 2016, and Bayer (NASDAQOTH: BAYRY) . Bioverativ's ability to deliver that kind of market-beating growth in the face of stiff competition is likely a big reason why Sanofi was willing to pay top dollar to acquire it. New Article Biogen Inc. ( BIIB ) is reporting for the quarter ending December 31, 2017. In the past year BIIB has beat the expectations every quarter. Zacks Investment Research reports that the 2017 Price to Earnings ratio for BIIB is 15.78 vs. an industry ratio of -5.30, implying that they will have a higher earnings growth than their competitors in the same industry. New Article [ibd-display-video id=3100459 width=50 float=left autostart=true] The earnings fire hose will be on full blast tomorrow with reports from Intel ( INTC ), Caterpillar ( CAT ), Biogen ( BIIB ), Celgene ( CELG ) and Starbucks ( SBUX ) among the big names coming out with quarterly results. Caterpillar management may comment on whether its U.S. business already is getting a boost from the investment incentives packed into recent tax cuts, which allow companies to immediately write off new and used equipment purchases. They will follow United Airlines (UAL), which reported strong quarterly results late Tuesday but also vowed to continue matching fares from low-cost rivals , setting off fears of a prolonged price war in the industry.",249.20416259765625
2018-01-25 00:00:00+00:00,358.0,358.0,341.2099914550781,353.739990234375,353.739990234375,1863000.0,3.142857142857143,1.0,0.5357392857142856,"In other sector news: + Karyopharm Therapeutics ( KPTI ) raced to an 8% gain and a session high of $11.30 a share at one point Thursday after announcing a $217 mln deal selling its KPT-350 prospective treatment for various neurological, autoimmune and inflammatory conditions to biotech conglomerate Biogen ( BIIB ). Among health care stocks moving on news: - Ocular Therapeutix ( OCUL ) plunged over 17% on Thursday, dropping to a session low of $5.13 a share, after today announcing plans for a $32.5 million public offering of 6.5 mln common shares at $5 each, a 19.2% discount to Wednesday's closing price. + Smith & Nephew ( SNN ) rose over 4% on Thursday after analysts at JPMorgan raised their investment recommendation for the medical equipment manufacturer to Overweight from Neutral. New Article Expected movers: - Varian Medical Systems ( VAR ): rose nearly 6% after reporting late Wednesday better-than-expected results for fiscal Q1 and raising its 2018 guidance - Xilinx ( XLNX ): rose 4% after reporting better-than-expected fiscal Q3 revenue but EPS falls short after tax reform expense - Karyopharm Therapeutics ( KPTI ): agrees to sell its KPT-350 product to Biogen ( BIIB ) in a transaction valued at $217 million Other news: - Ocular Therapeutix ( OCUL ): fell almost 13% after it said late Wednesday it has commenced an underwritten public offering of its common stock - Summit Therapeutics (SMMT): says a phase 2 proof of concept study of ezutromid in patients with Duchenne muscular dystrophy showed a statistically significant and meaningful reduction in muscle damage News from overseas: Smith & Nephew (SN, SN.L) was up 4.6% after JPMorgan raised the medical equipment maker to Overweight from Neutral, while Next was up 2.2% after RBC raised the clothing and homewares retailer to Outperform from Sector Perform. Top Health Care stocks: MRK: -flat AMGN: flat Health care shares were mostly higher in Thursday's pre-market trading . New Article Biogen Inc.BIIB reported fourth-quarter 2017 earnings per share of $5.26, which missed the Zacks Consensus Estimate of $5.44 by 3.3%. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report BIOVERATIV INC (BIVV): Free Stock Analysis Report To read this article on Zacks.com click here. We remind investors that last year Biogen spun off its hemophilia business into a new company called Bioverativ BIVV . New Article Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 45.5% Average next regular session additional gain: 1.9% Over the prior three fiscal years (12 quarters), when shares of BIIB rose in the extended-hours session in reaction to its earnings announcement, history shows that 45.5% of the time (5 events) the stock posted additional gains in the following regular session by an average of 1.9%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 6.8% Over that same historical period, when shares of BIIB dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 6.8% by the following regular session close. Extended-Hours Dollar Volume: $66,591,489 Biogen Idec ( BIIB ) is due to issue its quarterly earnings report in the upcoming extended-hours session. New Article BIIB holds a strong position in the multiple sclerosis (MS) market with a wide range of products including Avonex, Tysabri, Tecfidera and Plegridy. BIIB has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 8.09%. Check back later for our full write up on this BIIB earnings report later! New Article Biogen ( BIIB ) is a ""safe"" large-cap biotech to own in 2018, an analyst said Thursday after the firm issued bullish full-year guidance and topped fourth-quarter sales forecasts, though adjusted profit lagged expectations and shares were up only slightly. [ibd-display-video id=3104805 width=50 float=left autostart=true] Still, investors have yet to fully grasp future competitive dynamics surrounding Biogen's multiple sclerosis franchise and Ionis Pharmaceuticals ( IONS )-partnered spinal muscular atrophy drug, Spinraza, RBC analyst Brian Abrahams said in a note to clients. Piper Jaffray analyst Christopher Raymond blamed the earnings miss on a 29-cent impact related to an impairment charge Biogen had to take on multiple sclerosis drug Zinbryta. New Article The Nasdaq Composite slimmed its opening gain to 0.3% higher, as Lam Research ( LRCX ), Xilinx ( XLNX ) and Biogen ( BIIB ) all backtracked their early advances. [ibd-display-video id=3104805 width=50 float=left autostart=true] The Dow Jones industrial average jumped 0.4% at the start of trade, the S&P 500 rolled 0.3% higher, as Caterpillar ( CAT ) and 3M ( MMM ) gave up the early gains that followed their quarterly reports. The maker of radiation therapy and imaging systems reported late Wednesday its fiscal first-quarter earnings spiked 113%, with revenue and full-year guidance also topping forecasts.",236.78488159179688
2018-01-26 00:00:00+00:00,356.1700134277344,370.5700073242188,356.04998779296875,367.9100036621094,367.9100036621094,2232700.0,3.2,1.0,0.550025,"Biotech and Pharmaceutical Stocks to Buy:Biogen (BIIB) Biogen Inc (NASDAQ: BIIB ) shares are up nearly 4% on Friday to push up and over its October highs as investors greeted the company's latest quarterly results with glee. The catalyst was headlines that European regulators approved PFE's diabetes drug Steglatro developed in collaboration with Merck & Co., Inc. (NYSE: MRK ). Investors have been spurred by solid quarterly results, raised forward guidance and the impact of the GOP's tax cut legislation. New Article Biogen ( BIIB ) had its Relative Strength ( RS ) Rating upgraded from 76 to 81 Friday. [ibd-display-video id=2385970 width=50 float=left autostart=true] This exclusive rating from Investor's Business Daily tracks price movement with a 1 (worst) to 99 (best) score. History reveals that the best stocks tend to have an RS Rating of at least 80 in the early stages of their moves. New Article Biogen ( BIIB ) saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 94 the day before. The market's biggest winners often have a 95 or higher grade in the early stages of a new price run. Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks. New Article That's good news technically, as prior extreme bullishness was reset to a more neutral and bearish state and should allow BIIB to move higher with greater ease. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Following a volatile earnings reaction, there's more reasons than not both off and on the price chart to see the path of least resistance as up at biotech Biogen Inc (NASDAQ: BIIB ). But for bullish-minded traders, a well-placed long-call vertical spread in BIIB stock is what seals the deal. New Article [ibd-display-video id=3098352 width=50 float=left autostart=true] That was two years before Biogen ( BIIB ) and Ionis Pharmaceuticals ' ( IONS ) Spinraza became the first-ever drug approved to treat spinal muscular atrophy. Leerink analyst Seamus Fernandez found in a Jan. 16 report that payers are balking at prices of insulins, respiratory drugs for asthma and chronic obstructive pulmonary disease, and hepatitis C therapies. As a result, large pharma companies like Roche (RHHBY), Novartis (NVS) and Bristol-Myers Squibb (BMY) - with portfolios in the more insulated areas - are facing less pushback.",236.94313049316406
2018-01-29 00:00:00+00:00,365.1499938964844,367.8999938964844,357.4700012207031,358.4800109863281,358.4800109863281,1317200.0,3.6666666666666665,1.0,0.6666916666666666,"Biogen (NASDAQ: BIIB) completed the year with a solid performance, as its new drug for spinal muscular atrophy, Spinraza, boosted revenue. Looking further ahead, 2019 could see the approval of BIIB098, a multiple sclerosis drug Biogen licensed from Alkermes . In short, Biogen is managing its multiple sclerosis franchise as best it can, while waiting for results from Alzheimer's disease drug aducanumab, which could accelerate revenue growth again in a few years. New Article The takeover will complement Sanofi's $11.6 billion purchase of Bioverativ , a spinoff from Biogen ( BIIB ), announced a week ago. Sanofi's arrival as a white knight is a setback for Novo's effort to bolster its stable of treatments for rare blood disorders as its main diabetes business grapples with price pressures. Ablynx's most advanced treatment, called caplacizumab, is poised for approval this year for an unusual disorder in which blood clots form in small vessels throughout the body. New Article [ibd-display-video id=3112610 width=50 float=left autostart=true] The deal comes a week after Sanofi said it would spend $11.6 billion to acquire Biogen ( BIIB ) spinoff Bioverativ ( BIVV ), a hemophilia drug specialist. Sanofi 's ( SNY ) second deal in a week could spur a ""robust"" buying period in biopharma, an analyst said Monday after the French drugmaker outbid Novo Nordisk ( NVO ) for Belgium's Ablynx ( ABLX ). ""In our view, Sanofi's aggressiveness in mergers and acquisitions may precede a more robust period of deals within biopharma as the effects of U.S. tax reform are felt and valuations for late-stage assets continue to drive higher,"" he said in a note to clients.",243.98768615722656
2018-02-08 00:00:00+00:00,326.6700134277344,328.70001220703125,311.5,311.7900085449219,311.7900085449219,1414600.0,2.5,1.0,0.375025,"Biogen Inc.BIIB announced that its multiple sclerosis (MS) product, Tysabri (natalizumab) failed to meet the primary and secondary endpoints in a phase IIb study, evaluating the medicine for another indication - acute ischemic stroke (AIS). Biogen is developing BIIB093 for the treatment of large hemispheric stroke (LHI), a severe form of stroke with no available therapy. It had acquired BIIB093 from Remedy Pharmaceuticals in May last year. New Article Below is a twelve month price history chart comparing the stock performance of SWK, TXN, and BIIB: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of MGK's underlying holdings with notable upside to their analyst target prices are Stanley Black & Decker Inc (Symbol: SWK), Texas Instruments Inc. (Symbol: TXN), and Biogen Inc (Symbol: BIIB). Similarly, TXN has 14.85% upside from the recent share price of $101.92 if the average analyst target price of $117.05/share is reached, and analysts on average are expecting BIIB to reach a target price of $375.17/share, which is 14.77% above the recent price of $326.89.",232.54867553710938
2018-02-09 00:00:00+00:00,313.2699890136719,319.92999267578125,302.2799987792969,316.7799987792969,316.7799987792969,2180400.0,2.5,1.0,0.375025,"Stocks recently featured in the blog include NovartisNVS , BPBP and BiogenBIIB . Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report BP p.l.c. Meanwhile, the strategic decision on Alcon to retain the business or separation via capital market transactions such as a spin-off or an initial public offering has been postponed for 2019. New Article Especially high volume was seen for the $335 strike put option expiring March 16, 2018 , with 751 contracts trading so far today, representing approximately 75,100 underlying shares of BIIB. Below is a chart showing PWR's trailing twelve month trading history, with the $33 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 6,602 contracts, representing approximately 660,200 underlying shares or approximately 48.3% of BIIB's average daily trading volume over the past month, of 1.4 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $335 strike highlighted in orange: And Illinois Tool Works, Inc. (Symbol: ITW) saw options trading volume of 7,055 contracts, representing approximately 705,500 underlying shares or approximately 46.8% of ITW's average daily trading volume over the past month, of 1.5 million shares.",229.05177307128906
2018-02-13 00:00:00+00:00,315.010009765625,319.0,312.3500061035156,316.989990234375,316.989990234375,732900.0,3.0,1.0,0.5000249999999999,"AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports AMGN's forecasted earnings growth in 2018 as 5.07%, compared to an industry average of 6.7%. For more information on the declaration, record and payment dates, visit the AMGN Dividend History page.",227.69500732421875
2018-02-14 00:00:00+00:00,315.3599853515625,316.45001220703125,288.0,296.0799865722656,296.0799865722656,5426400.0,2.4,1.0,0.350025,"So what Here's a review of the headline numbers from the quarter: Revenue jumped 29% to $275 million thanks to broad strength in product sales and the company's recently announced deal with Biogen (NASDAQ: BIIB) . Meanwhile, Biogen looks poised to submit BIIB098 for regulatory review -- which should trigger a $50 million milestone payment -- and investors should also get a look at phase 2 results for a schizophrenia product candidate called ALKS 3831. Aripiprazole Lauroxil NanoCrystal Dispersion, which is a compound that helps patients get started with Alkermes' schizophrenia drug Aristada, has been submitted for regulatory review. New Article In trading on Wednesday, shares of Biogen Inc (Symbol: BIIB) crossed below their 200 day moving average of $302.48, changing hands as low as $288.00 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $244.28 per share, with $370.57 as the 52 week high point - that compares with a last trade of $296.08. According to the ETF Finder at ETF Channel, BIIB makes up 7.58% of the iShares Nasdaq Biotechnology ETF (Symbol: IBB) which is trading higher by about 2.1% on the day Wednesday. New Article Biogen (NASDAQ: BIIB) , Groupon (NASDAQ: GRPN) , and Omeros (NASDAQ: OMER) were among the worst performers on the day. Investors had initially feared the return of inflationary pressure after this morning's CPI report from the Labor Department, but despite higher bond yields, market participants ended up paying little attention to the implications and instead bid up stock indexes. The e-commerce company best known for its once-groundbreaking daily deals business said that gross billings fell 2%, fueling a 4% drop in revenue and resulting in adjusted earnings that didn't live up to expectations . New Article Biogen Inc. ( BIIB ) had the largest percent change down (-6.6%) while Alexion Pharmaceuticals, Inc. ( ALXN ) had the largest percent change gain rising 8.1%. The NASDAQ 100 index closed up 1.85% for the day; a total of 121.17 points. The Dow Jones index closed up 1.03% for the day; a total of 253.04 points. New Article In December 2017, Biogen BIIB announced that an Alzheimer's disease study on BAN2401 failed to show early positive results, which raised investor concern about the candidate's chances of success. Click to get this free report Pfizer, Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. APECS was a phase III study evaluating the efficacy and safety of verubecestat, an oral -amyloid precursor protein site-cleaving enzyme (BACE) inhibitor, versus placebo.",227.93173217773438
2018-02-15 00:00:00+00:00,298.8500061035156,300.75,289.2699890136719,299.3800048828125,299.3800048828125,3040900.0,2.5,1.0,0.375025,"The results were driven by strong growth of the company's proprietary products, Vivitrol and Aristada, higher manufacturing and royalty revenues, and upfront payment from Biogen BIIB related to the collaboration for BIIB098. In November 2017, Alkermes and Biogen announced a global license and collaboration agreement to develop and commercialize Alkermes' phase III multiple sclerosis (""MS"") candidate, BIIB098 (ALKS8700). Click to get this free report Alkermes PLC (ALKS): Free Stock Analysis Report XOMA Corporation (XOMA): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. New Article For a full detailed analysis using NASDAQ's Guru Analysis tool, click here BIOGEN INC ( BIIB ) is a large-cap growth stock in the Biotechnology & Drugs industry. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068. This strategy seeks out firms with long-term, predictable profitability and low debt that trade at reasonable valuations.",230.56912231445312
2018-02-16 00:00:00+00:00,297.75,298.5,290.8800048828125,291.8699951171875,291.8699951171875,2943100.0,1.75,1.0,0.187525,"In trading on Friday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $290.8813 per share. A bullish investor could look at BIIB's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of BIIB shares: Looking at the chart above, BIIB's low point in its 52 week range is $244.28 per share, with $370.57 as the 52 week high point - that compares with a last trade of $291.87. New Article Especially high volume was seen for the $325 strike call option expiring March 16, 2018 , with 509 contracts trading so far today, representing approximately 50,900 underlying shares of BIIB. Below is a chart showing COHU's trailing twelve month trading history, with the $17.50 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 11,836 contracts thus far today. That number of contracts represents approximately 1.2 million underlying shares, working out to a sizeable 69.2% of BIIB's average daily trading volume over the past month, of 1.7 million shares. New Article Biogen BIIB also announced that it has decided to increase the number of patients (enrolment) in studies being conducted on its crucial Alzheimer's disease candidate, aducanumab, which raised concerns regarding the chances of success of the treatment. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. This strategy, part of FDA's ongoing efforts to expand access to safe and effective treatment options for many serious conditions, suggests that the agency may be open to an accelerated approval process for such drugs. New Article Ampyra is marketed in the ex-U.S. markets by Biogen Inc. BIIB under the trade name, Fampyra. Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report XOMA Corporation (XOMA): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc.ACOR reported adjusted earnings of 61 cents per share in the fourth quarter of 2017, which missed the Zacks Consensus Estimate of $1.09.",238.86936950683594
2018-02-20 00:00:00+00:00,292.0,294.8800048828125,286.510009765625,287.45001220703125,287.45001220703125,2004500.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of IBB, in trading today Biogen Inc (Symbol: BIIB) is down about 0.1%, Celgene Corp (Symbol: CELG) is down about 0.5%, and Regeneron Pharmaceuticals, Inc. (Symbol: REGN) is lower by about 1.7%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $94.20 per share, with $119.30 as the 52 week high point - that compares with a last trade of $110.26. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Investors considering a purchase of Biogen Inc (Symbol: BIIB) stock, but tentative about paying the going market price of $293.12/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to BIIB's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. For other put options contract ideas at the various different available expirations, visit the BIIB Stock Options page of StockOptionsChannel.com.",227.67987060546875
2018-02-21 00:00:00+00:00,287.5599975585937,290.6600036621094,285.1099853515625,286.1000061035156,286.1000061035156,1922400.0,4.0,1.0,0.7500249999999999,"Ionis earns the majority of its revenues in the form of royalty from Biogen BIIB on sales of spinal muscular atrophy drug, Spinraza. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report GlaxoSmithKline PLC (GSK): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Ionis entered a strategic collaboration with AstraZeneca in 2012 to develop treatment for cardiovascular, metabolic and renal diseases.",229.62200927734375
2018-02-22 00:00:00+00:00,287.70001220703125,291.9100036621094,283.9700012207031,284.8099975585937,284.8099975585937,2484700.0,2.0,1.0,0.250025,"Factors to Consider Ionis earns revenues in the form of upfront, milestone and other payments under its partnerships with leading health care companies like Biogen BIIB . Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Atara Biotherapeutics, Inc. (ATRA): Free Stock Analysis Report Gemphire Therapeutics Inc. (GEMP): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. The company has a disappointing track record and missed estimates twice in the four trailing quarters while beating the same on two occasions, delivering an average negative earnings surprise of 6.67%.",247.5004119873047
2018-02-23 00:00:00+00:00,287.5899963378906,294.239990234375,285.6000061035156,292.7799987792969,292.7799987792969,2541500.0,3.0,1.0,0.5000249999999999,"If you only made an investing decision based on recent stock performance, Biogen Inc. (NASDAQ: BIIB) would be a hands-down winner over Celgene Corporation (NASDAQ: CELG) . However, Biogen has another promising late-stage candidate -- multiple sclerosis drug BIIB098. Biogen expects to file for approval of BIIB098 later this year.",240.84962463378906
2018-02-26 00:00:00+00:00,294.0,296.1000061035156,288.79998779296875,290.010009765625,290.010009765625,1448300.0,2.5,1.0,0.375025,"Particularly high volume was seen for the $305 strike call option expiring April 20, 2018 , with 511 contracts trading so far today, representing approximately 51,100 underlying shares of BIIB. Below is a chart showing LGIH's trailing twelve month trading history, with the $55 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 8,687 contracts, representing approximately 868,700 underlying shares or approximately 44.4% of BIIB's average daily trading volume over the past month, of 2.0 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $305 strike highlighted in orange: And Kraft Heinz Co (Symbol: KHC) options are showing a volume of 27,084 contracts thus far today. New Article It has been about a month since the last earnings report for Biogen Inc.BIIB . Will the recent negative trend continue leading up to its next earnings release, or is BIIB due for a breakout? Biogen Inc. Price and Consensus Biogen Inc. Price and Consensus | Biogen Inc. Quote VGM Scores At this time, BIIB has a nice Growth Score of B, a grade with the same score on the momentum front.",254.3699493408203
2018-03-06 00:00:00+00:00,286.8599853515625,288.67999267578125,283.760009765625,285.9800109863281,285.9800109863281,881700.0,3.0,1.0,0.5000249999999999,"Based in Cambridge, MA, Biogen Inc.BIIB has been paying particular attention on stepping up research work on Alzheimer's. Click to get this free report Astrazeneca PLC (AZN): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Merck & Company, Inc. (MRK): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Coming to other life-threatening conditions, CNBC reports that deaths related to Alzheimer's have skyrocketed 89% while those following heart diseases have dropped 14% since the turn of the century.",253.62684631347656
2018-03-09 00:00:00+00:00,285.8699951171875,286.760009765625,281.70001220703125,286.1000061035156,286.1000061035156,1715000.0,4.0,1.0,0.7500249999999999,"The Queen et al. licenses royalty including royalties from the sale of Biogen's BIIB multiple sclerosis drug, Tysabri, also declined in the quarter under review on lower sales of the product. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report PDL BioPharma, Inc. (PDLI): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Valeant Pharmaceuticals International, Inc. (VRX): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, the company received cash payments of $32.8 million from the royalty rights acquired from Depomed, primarily related to Glumetza, a product marketed by Valeant Pharmaceuticals International, Inc. VRX .",268.03399658203125
2018-03-12 00:00:00+00:00,286.0,286.67999267578125,279.2900085449219,279.8999938964844,279.8999938964844,2349000.0,1.5,1.0,0.125025,"- Biogen ( BIIB ) declined Monday after the biotech company acquired a prospective schizophrenia drug, PF-04958242, from Pfizer ( PFE ) for an upfront payment of $75 million plus up to $515 million more in additional development and commercialization milestone payments, as well as tiered royalties in the low to mid-teen percentages. Among health care stocks moving on news: + Sarepta Therapeutics ( SRPT ) streaked to an 18-year high on Monday, climbing more than 6% to its best price since March 2000 at $74.36 a share, after saying it plans to complete a rolling submission of its golodirsen prospective treatment for Duchenne muscular dystrophy after receiving input from an FDA advisory panel. Based on minutes from the company's meeting last month with the U.S. Food and Drug Administration's Division of Neurology Products, together with results from a Phase I/II trial of the phosphordiamidate morpholino oligimer, the company expects it will submit the new drug application for golodirsen by the end of the year and seeking an accelerated review based on an increase in dystrophin protein as a surrogate endpoint. New Article In trading on Monday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $279.29 per share. A bullish investor could look at BIIB's 29.7 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of BIIB shares: Looking at the chart above, BIIB's low point in its 52 week range is $244.28 per share, with $370.57 as the 52 week high point - that compares with a last trade of $279.90.",268.515380859375
2018-03-13 00:00:00+00:00,282.2099914550781,286.5400085449219,280.5199890136719,283.239990234375,283.239990234375,2258600.0,3.0,1.0,0.5000249999999999,"Biogen Inc.BIIB has agreed to acquire a phase IIb ready candidate, PF-04958242, which is being developed for cognitive impairment associated with schizophrenia (CIAS) from pharma giant Pfizer, Inc. PFE . Biogen's Alzheimer's disease (AD) pipeline comprises candidates with different mechanisms of action including anti-tau candidate (BIIB092 - with potential in AD as well as progressive supranuclear palsy (PSP)), anti-amyloid (aducanumab) candidates as well as a BACE inhibitor (elenbecestat) program. In Maylast year, Biogen purchased a phase III candidate, BIIB093/Cirara from Remedy Pharmaceuticals, which is being studied for the treatment of large hemispheric stroke (LHI), a severe form of stroke with no available therapy. New Article Among the largest underlying components of BBH, in trading today Celgene Corp (Symbol: CELG) is up about 0.8%, Biogen Inc (Symbol: BIIB) is up about 2.1%, and Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is higher by about 0.4%. For a complete list of holdings, visit the BBH Holdings page  The chart below shows the one year price performance of BBH, versus its 200 day moving average: Looking at the chart above, BBH's low point in its 52 week range is $115.69 per share, with $136.83 as the 52 week high point - that compares with a last trade of $128.20. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article QUALCOMM Incorporated ( QCOM ) had the largest percent change down (-4.95%) while Biogen Inc. ( BIIB ) had the largest percent change gain rising 1.19%. NASDAQ Market Wrap As of 3/13/2018 4:44:02 PM BILLIONS OF 2.51 NASDAQ SHARES TRADED TODAY 46 STOCKS REACHED A 52 WEEK HIGH 11 THOSE REACHING LOWS TOTALEDBiogen Inc. [BIIB]TOPS ADVANCERS LISTOF NASDAQ 100 INDEX % 1.19 ROSE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The NASDAQ 100 index closed down -1.19% for the day; a total of -84.61 points.",252.72903442382812
2018-03-14 00:00:00+00:00,285.0299987792969,289.1700134277344,282.7099914550781,285.7200012207031,285.7200012207031,2039500.0,3.0,1.0,0.5000249999999999,"Wall Street thinks pretty highly of Biogen Inc. (NASDAQ: BIIB) . Several seemingly promising Alzheimer's disease drugs from other drugmakers have made it to late-stage clinical studies, only to ultimately fail. While treating Alzheimer's disease could be the most important key to Biogen's future success, the company currently relies largely on its multiple sclerosis (MS) franchise. New Article (Read more: Orexigen Plummets on Filing of Chapter 11 of Bankruptcy Code ) Biogen to Buy Cognitive Impairment Asset From Pfizer : Biogen BIIB announced that it will acquire a phase IIb ready AMPA receptor potentiator for cognitive impairment associated with schizophrenia from Pfizer PFE for an upfront payment of $75 million along with milestone payments of up to $515 million as well as tiered royalties in the low to mid-teen percentages. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Orexigen Therapeutics, Inc. (OREX): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report To read this article on Zacks.com click here. Key highlights of the week include Regeneron announcing positive data on Praluent, Sarepta seeking rapid approval of second DMD drug, while Orexigen filing for bankruptcy. New Article GILD is a part of the Health Care sector, which includes companies such as Amgen Inc. ( AMGN ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports GILD's forecasted earnings growth in 2018 as -27.39%, compared to an industry average of 7.7%. For more information on the declaration, record and payment dates, visit the GILD Dividend History page. New Article Here were some other ratings and price target updates after last month's quarterly report... Jefferies: Hold rating and $380 PT Morgan Stanley: Equal Weight rating and bumps PT from $401 to $415 SunTrust: Hold rating and $430 PT Credit Suisse: Buy rating and $440 PT BMO Capital: Market Perform rating PT boosts from $398 to $444 Cowen & Co.: Hold rating and $450 PT Leerink Swann: Buy rating and lowers PT from $568 to $502 Guggenheim: Buy rating and $530 PT In my experience with old guard Biotech's like Gilead (GILD) and Biogen (BIIB), it looks like the worst has been discounted in REGN shares under $325. Disclosure: I own shares of REGN, BIIB, and GILD for the Zacks Healthcare Innovators portfolio. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here.",258.0657653808594
2018-03-16 00:00:00+00:00,289.3999938964844,292.29998779296875,287.4700012207031,287.6199951171875,287.6199951171875,2294200.0,3.0,1.0,0.5000249999999999,"The Multiple Sclerosis (MS) space hit the headlines once again following biotech bigwig, Biogen BIIB and partner AbbVie's ABBV decision to withdraw their jointly owned MS drug, Zinbryta voluntarily on a worldwide basis due to risk of liver injury. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. An autoimmune inflammatory disease of the centrol nervous system, MS disrupts the normal functioning of the brain, optic nerves and spinal cord through inflammation and tissue loss.",251.52813720703125
2018-03-19 00:00:00+00:00,285.8299865722656,286.489990234375,276.42999267578125,278.3699951171875,278.3699951171875,1530400.0,2.0,1.0,0.250025,"Stocks recently featured in the blog include BiogenBIIB , AbbVieABBV , NovartisNVS , Teva PharmceuticalsTEVA and CelgeneCELG . Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. An autoimmune inflammatory disease of the centrol nervous system, MS disrupts the normal functioning of the brain, optic nerves and spinal cord through inflammation and tissue loss.",234.2108154296875
2018-03-20 00:00:00+00:00,278.6600036621094,281.3999938964844,276.510009765625,279.67999267578125,279.67999267578125,1313400.0,4.0,1.0,0.7500249999999999,"Breakeven lies at $286.60, while a maximum profit of $3.40, or $340 per pair of contracts - a potential return of 112% - is possible if BIIB stock closes at or above $290 when April options expire. The upside to this put sell strategy is that you keep the premium as long as BIIB stock closes above $255 when April options expire next month. InvestorPlace - Stock Market News, Stock Advice & Trading Tips The bad news is that Biogen Inc (NASDAQ: BIIB ) stock is down 32% since the end of January.",219.00018310546875
2018-03-21 00:00:00+00:00,279.6099853515625,280.9800109863281,275.8599853515625,277.2900085449219,277.2900085449219,1340000.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of OEF, in trading today Charter Communications Inc (Symbol: CHTR) is trading flat, Danaher Corp (Symbol: DHR) is off about 0.3%, and Biogen Inc (Symbol: BIIB) is lower by about 0.1%. For a complete list of holdings, visit the OEF Holdings page  The chart below shows the one year price performance of OEF, versus its 200 day moving average: Looking at the chart above, OEF's low point in its 52 week range is $103.02 per share, with $127.67 as the 52 week high point - that compares with a last trade of $119.77. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",219.6723175048828
2018-03-22 00:00:00+00:00,275.4599914550781,278.3699951171875,271.6300048828125,271.8900146484375,271.8900146484375,1748600.0,4.0,1.0,0.7500249999999999,"It's been a great decade to own stocks in general, but those of you who bought Celgene Corporation (NASDAQ: CELG) or Biogen, Inc. (NASDAQ: BIIB) back in 2008 fared even better than most. According to Evaluate Pharma, the overall size of the oncology market will swell at a 13% annual growth rate and hit $192 billion in 2022, and Celgene is well positioned to command a leading share. Ocrevus is the first therapy strong enough to significantly slow down disease progression for patients with the most aggressive form of MS. That efficacy combined with a stellar safety profile made it the most impressive new drug launch of 2017.",222.73822021484375
2018-04-05 00:00:00+00:00,271.8299865722656,272.989990234375,263.8399963378906,264.9800109863281,264.9800109863281,1804300.0,2.0,1.0,0.250025,"And the worst performing Nasdaq 100 component thus far on the day is Micron Technology, trading down 3.1%. Micron Technology is showing a gain of 25.8% looking at the year to date performance. VIDEO: Nasdaq 100 Movers: MU, FB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",229.68869018554688
2018-04-06 00:00:00+00:00,263.510009765625,266.1600036621094,256.7699890136719,257.6499938964844,257.6499938964844,1954000.0,2.0,1.0,0.250025,"Healthcare stocks were the weakest performers, with Biogen Inc (NASDAQ: BIIB ) down 2.7% after being downgraded by analysts at Barclays. Facebook, Inc. (NASDAQ: FB ) outperformed yesterday, however, rising 2.7% after CEO Mark Zuckerberg said he didn't think the #deletefacebook movement has had much of an impact. 7 Best Platform Stocks to Buy Now Chipmakers lagged after Nvidia Corporation (NASDAQ: NVDA ) fell 2.2% following cautious commentary from noted short-side research outfit Citron. New Article Biogen Inc.BIIB and partner Samsung Bioepis have announced resolution of an ongoing patent dispute with AbbVie ABBV regarding Biogen's biosimilar version (Imraldi) of AbbVie's blockbuster arthritis drug, Humira, in the EU. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Also in the United States, Samsung Bioepis entered into a settlement agreement with AbbVie, which would allow the former to bring Humira biosimilar into the U.S. market by Jan 31, 2023.",221.6932373046875
2018-04-09 00:00:00+00:00,258.2900085449219,264.4599914550781,254.3300018310547,257.5199890136719,257.5199890136719,2235500.0,4.0,1.0,0.7500249999999999,"Significantly, an approved product for the cure of SMA in the United States is Biogen's BIIB , Spinraza (nusinersen), the first and the only treatment to get an FDA nod in the country for the indication. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report AveXis, Inc. (AVXS): Free Stock Analysis Report To read this article on Zacks.com click here. Initially, though the acquisition is anticipated to negatively impact Novartis' operating income due to increased research & development expenses, it is later on expected to substantially contribute to the company's bottom line from 2020 onward. New Article Novartis' newly acquired SMA franchise is expected to compete directly against Biogen (NASDAQ: BIIB) and Ionis Pharmaceuticals ' (NASDAQ: IONS) FDA-approved Spinraza. Now what Novartis' willingness to pay a sky-high premium for AveXis appears to be more about the company's growing interest in gene therapies for neurological disorders in general, and not just about SMA as a stand-alone indication. Novartis struck a licensing deal with Spark Therapeutics earlier this year for the biotech's gene therapy, Luxturna , that treats an inherited form of vision loss.",225.2833251953125
2018-04-10 00:00:00+00:00,261.510009765625,267.5799865722656,259.44000244140625,265.0899963378906,265.0899963378906,1983200.0,4.0,1.0,0.7500249999999999,"Also, of late, Biogen BIIB has announced resolution of the ongoing patent dispute with AbbVie regarding Biogen's biosimilar version of Humira, in the EU. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The phase III SELECT-COMPARE study is designed to evaluate the efficacy and safety of upadacitinib (15 mg) compared with placebo and AbbVie's marketed drug, Humira (adalimumab), over 12 weeks on patients with moderate-to-severe RA, who are on a stable background of methotrexate and had an inadequate response. New Article But is the deal bad news for Biogen (NASDAQ: BIIB) ? Novartis (NYSE: NVS) announced early Monday morning that it plans to buy clinical-stage gene therapy company Avexis (NASDAQ: AVXS) for $8.7 billion, gaining promising spinal muscular atrophy (SMA) candidate AVXS-101. AVXS-101 is well ahead of Novartis' internal candidate, which is in a phase 1/2 clinical study that isn't scheduled to wrap up until late next year. New Article Biogen 's (NASDAQ: BIIB) Spinraza has been one of the fastest drugs to reach billion-dollar blockbuster territory in recent memory, but its sales could slow as soon as next year because of new competition from Novartis (NYSE: NVS) . On Monday, Novartis announced it's spending $8.7 billion to get its hands on a gene therapy developed by AveXis (NASDAQ: AVXS) that targets Spinraza's addressable market. The backstory Spinraza, which is licensed to Biogen by Ionis Pharmaceuticals (NASDAQ: IONS) , is used to treat spinal muscular atrophy (SMA), a rare and life-threatening genetic disease.",233.1970977783203
2018-04-11 00:00:00+00:00,263.3599853515625,269.95001220703125,262.0,265.989990234375,265.989990234375,1771500.0,2.5,1.0,0.375025,"(Read more: Conatus' Emricasan Fails in Phase II Study, Shares Sink ) Biogen Settles Litigation With AbbVie For Humira Biosimilar : Biogen Inc. BIIB and partner Samsung Bioepis announced an agreement with AbbVie ABBV for the commercialization of Imraldi, a biosimilar of Humira. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Conatus Pharmaceuticals Inc. (CNAT): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report AveXis, Inc. (AVXS): Free Stock Analysis Report Spectrum Pharmaceuticals, Inc. (SPPI): Free Stock Analysis Report To read this article on Zacks.com click here. AveXis lead product candidate, AVXS-101, is being evaluated as one-time gene replacement therapy for spinal muscular atrophy, a disease which results in early death or life-long disability with considerable healthcare costs. New Article If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Renewable Assets, Rise in Customers to Drive NextEra (NEE) Rising Healthcare Spending, Buyouts to Drive Danaher (DHR) Biogen's (BIIB) Spinraza Shines, Core Competition Heats Up Featured Reports Growing Short-Cycle Investments to Benefit Flowserve (FLS) Per the Zacks analyst, Flowserve is set to benefit from rising short-cycle investments as client spending improves due to stable oil price, improving regulatory conditions and recent tax reforms. Today's Research Daily features new research reports on 16 major stocks, including NextEra (NEE), Danaher (DHR) and Biogen (BIIB). Click to get this free report Royal Caribbean Cruises Ltd. (RCL): Free Stock Analysis Report NextEra Energy, Inc. (NEE): Free Stock Analysis Report Facebook, Inc. (FB): Free Stock Analysis Report Danaher Corporation (DHR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report To read this article on Zacks.com click here.",236.8228302001953
2018-04-12 00:00:00+00:00,268.6700134277344,270.17999267578125,266.2699890136719,267.44000244140625,267.44000244140625,1238300.0,3.25,1.0,0.5625249999999999,"Find out what this means for Novartis, why Biogen (NASDAQ: BIIB) might be getting the stink eye from their investors right about now, whether or not Novartis overpaid to tuck this company under their belt, and more. In this week's episode of Industry Focus: Healthcare , host Michael Douglass and Motley Fool contributor Shannon Jones look at what went wrong with Incyte's Epacadostat, where the company can go from here, and what this unfortunately means for the immuno-oncology sector on the whole. In particular, and coming up in just a couple of weeks, Olumiant, which is an Eli Lilly -partnered rheumatoid arthritis drug that is currently already approved in Europe, is set to have its day with the FDA here. New Article Stocks recently featured in the blog include NextEraNEE , DanaherDHR , BiogenBIIB , FacebookFB and AppleAAPL . Click to get this free report NextEra Energy, Inc. (NEE): Free Stock Analysis Report Facebook, Inc. (FB): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report Danaher Corporation (DHR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. NextEra Energy's investment to strengthen its infrastructure and ongoing capital projects, when completed, will help it serve its expanding customer base more efficiently. New Article Among the largest underlying components of IBB, in trading today Gilead Sciences Inc (Symbol: GILD) is up about 2.4%, Biogen Inc (Symbol: BIIB) is up about 1.2%, and Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is up by about 2.7%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $94.20 per share, with $119.30 as the 52 week high point - that compares with a last trade of $107.16. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article We note that few days ago, Biogen Inc.BIIB and partner Samsung Bioepis announced resolution of an ongoing patent dispute with AbbVie regarding Biogen's biosimilar version (Imraldi) of AbbVie's Humira, in the EU. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Mylan N.V.MYL is partnering with Fujifilm Kyowa Kirin Biologics Co., Ltd. to commercialize a biosimilar to AbbVie's ABBV blockbuster arthritis drug Humira (adalimumab).",224.2805633544922
2018-04-16 00:00:00+00:00,267.44000244140625,269.260009765625,262.2099914550781,263.1099853515625,263.1099853515625,1323300.0,4.0,1.0,0.7500249999999999,"In November, Alkermes and Biogen announced a partnership to commercialize ALKS-8700, now called BIIB098, for multiple sclerosis. On March 2, the company reported that it had received a Refusal to File (RTF) letter from the FDA, saying it was unable to review the data in the submittal package ""based on insufficient evidence of overall effectiveness for the proposed indication, and that additional well-controlled clinical trials are needed prior to the resubmission of the NDA."" Today, in yet another stunning turn of events, Alkermes announced in a terse press release that the FDA had reversed its decision of two weeks ago and will review the application after all, with a target action date of January 31, 2019.",225.88990783691406
2018-04-18 00:00:00+00:00,265.5,270.739990234375,265.5,268.0299987792969,268.0299987792969,1382200.0,2.0,1.0,0.250025,"Biogen Inc. ( BIIB ), Amgen Inc, ( AMGN ), Gilead Sciences Corp. ( GILD ) [...] Read more on ETFtrends.com. The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech exchange traded fund by assets, and other biotechnology assets have recently been slumping, but some analysts believe big biotechnology stocks can rebound. IBB tracks the Nasdaq Biotechnology Index and holds nearly 160 stocks.",224.18275451660156
2018-04-20 00:00:00+00:00,266.0299987792969,267.6600036621094,261.20001220703125,263.0199890136719,263.0199890136719,1584500.0,3.75,1.0,0.6875249999999999,"In other sector news: + Ionis Pharmaceuticals ( IONS ) was higher Friday after signing a new, 10-year collaboration pact with Biogen ( BIIB ) to develop antisense drugs to treat a wide range of neurological diseases. Among health care stocks moving on news: + Vaxart ( VXRT ) soared to a nearly 20% gain soon after Friday's opening bell following the drug discovery firm saying sales for its Inavir single-dose influenza vaccine generated more than JPY20 billion, or about $185.9 million, in sales for Japanese drug-maker Daiichi Sankyo Co. during the first three months of 2018, triggering a $5 million milestone payment for Vaxart. - Clementia Pharmaceuticals ( CMTA ) dropped over 15% on Friday despite the special drugmaker beginning Phase II testing to evaluate its palovarotene drug candidate to treat multiple osteochondromas, a hereditary form of benign bone tumors, in pediatric patients between 2 to 14 years old. New Article Biogen BIIB is a dominant player in the MS market with drugs like Avonex, Tysabri, Tecfidera, Plegridy and Zinbryta. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis AGNVS announced encouraging data from the phase III study, EXPAND, on oral, once-daily siponimod (BAF312) in patients with secondary progressive multiple sclerosis (""SPMS""). New Article In other sector news: + Ionis Pharmaceuticals ( IONS ) was higher Friday after signing a 10-year collaboration pact with Biogen ( BIIB ) to develop antisense drugs to treat a wide range of neurological diseases. Shares of health care companies in the S&P 500 were down about 0.5% as a group while the Nasdaq Biotechnology index fell 0.5%. Among health care stocks moving on news: - Clementia Pharmaceuticals ( CMTA ) dropped over 15% on Friday despite the drugmaker saying it had begun Phase II testing of its palovarotene drug to treat multiple osteochondromas, a hereditary form of benign bone tumors, in pediatric patients. New Article Biogen Inc.BIIB , a well-known name in the multiple sclerosis (MS) market, will report first-quarter 2018 results on Apr 24, before the market opens. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. On the fourth-quarter conference call, Biogen said that since Ocrevus launch, it has witnessed a decrease in the number of patient starts and an increase in discontinuation of Tysabri in the United States.",219.35031127929688
2018-04-23 00:00:00+00:00,263.1400146484375,264.4800109863281,258.0,259.29998779296875,259.29998779296875,1922300.0,3.0,1.0,0.5000249999999999,"Biogen Inc. ( BIIB ) is reporting for the quarter ending March 31, 2018. BIIB missed the consensus earnings per share in the 4th calendar quarter of 2017 by -3.31%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for BIIB is 10.62 vs. an industry ratio of -7.10, implying that they will have a higher earnings growth than their competitors in the same industry. New Article The first commercialized product to emerge from Biogen Inc. 's (NASDAQ: BIIB) collaboration deal with Ionis Pharmaceuticals Inc. (NASDAQ: IONS) is an out-of-the-park home run. BIIB098 may have a differentiated profile, but that hardly makes its late-stage pipeline a fountain of innovation that can drive overall revenue growth. Biogen's going to foot the bill for development and commercialization expenses, leaving Ionis eligible to receive royalty and milestone payments should one of the partnered programs ever generate sales. New Article Biogen Inc. BIIB Biogen Inc. Price and EPS Surprise Biogen Inc. Price and EPS Surprise | Biogen Inc. Quote Biogen is also slated to release first-quarterearnings before the market opens. (Read More: What's in Store for Biogen (BIIB) This Earnings Season? Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Biogen BIIB is a dominant player in the MS market with drugs like Avonex, Tysabri, Tecfidera, Plegridy and Zinbryta. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Roche Holding AGRHHBY announced encouraging data on multiple sclerosis (""MS"") drug Ocrevus at the 70th American Academy of Neurology (""AAN"") Annual Meeting, held from Apr 21-27 in Los Angeles, CA.",231.35678100585938
2018-04-24 00:00:00+00:00,253.7100067138672,266.7300109863281,249.1699981689453,262.1499938964844,262.1499938964844,3619800.0,2.714285714285715,1.0,0.4285964285714286,"In other sector news: + Biogen ( BIIB ) was more than 1% higher Tuesday after reporting non-GAAP Q1 net income of $6.05 per share, beat the Capital IQ consensus looking for $5.94 per share. Shares of health care companies in the S&P 500 were down about 0.1% as a group while the Nasdaq Biotechnology index was dropping almost 0.8%. Among health care stocks moving on news: - Incyte ( INCY ) retreated Tuesday, recently sinking almost 8%, after an FDA advisory panel recommended the agency only approve the 2-milligram formation of its Baricitinib drug candidate rather than the 4-milligram version of the rheumatoid arthritis medication, citing safety concerns and their risk-benefit profiles. New Article Biogen Inc. 's BIIB reported first-quarter 2018 earnings per share of $6.05, which beat the Zacks Consensus Estimate of $5.93 by 2%. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Notably, in March 2018, Biogen announced the decision to withdraw Zinbryta from the markets, within less than two years of its FDA approval, due to growing safety concerns and limited commercial adoption of the drug because of its restrictive label. New Article What Shares of Ionis Pharmaceuticals (NASDAQ: IONS) ended the day down 10.6% after an earnings report from partner Biogen (NASDAQ: BIIB) started the day on a sour note. On the IONIS-HTTRx front, Ionis reported data from a phase 1/2 study at the American Academy of Neurology meeting. We already knew the drug was able to knock down mutant huntingtin protein levels, but the new data from a post-hoc analysis shows that reductions in the protein level improves the total motor score and symbol digit modalities score, two measures doctors use to rate the severity of Huntington's disease. New Article BIIB holds a strong position in the multiple sclerosis (MS) market with a wide range of products including Avonex, Tysabri, Tecfidera and Plegridy. BIIB has a pretty good earnings track record with the company delivering positive earnings surprises in three of the last four quarters with an average surprise of 6.91%. Check back later for our full write up on this BIIB earnings report later! New Article Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 44.4% Average next regular session additional gain: 1.5% Over the prior three fiscal years (12 quarters), when shares of BIIB rose in the extended-hours session in reaction to its earnings announcement, history shows that 44.4% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.5%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 100% Average next regular session additional loss: 4.4% Over that same historical period, when shares of BIIB dropped in the extended-hours in reaction to its earnings announcement, history shows that 100.0% of the time (2 events) the stock dropped further, adding to the extended-hours losses by an average of 4.4% by the following regular session close. Extended-Hours Dollar Volume: $63,891,586 Biogen Idec ( BIIB ) is due to issue its quarterly earnings report in the upcoming extended-hours session. New Article In other sector news: + Biogen ( BIIB ) rose over 1% on Tuesday after reporting non-GAAP Q1 net income of $6.05 per share, beating the IQ consensus looking for $5.94 per share. Among health care stocks moving on news: + Enzo Biochem ( ENZ ) was edging higher in late Tuesday after saying the U.S. Patent Trial and Appeal Board has rejected a petition filed by Hologic ( HOLX ) seeking an for inter partes review challenging Enzo's patented process for detecting polynucleotides and determining genetic mutations. - Incyte ( INCY ) retreated as much as 8% on Tuesday after an FDA advisory panel recommended the agency only approve the 2-milligram formation of its Baricitinib drug candidate rather than the 4-milligram version of the rheumatoid arthritis medication, citing safety concerns and their risk-benefit profiles. New Article Expected movers: - Eli Lilly and Company ( LLY ): posts Q1 beat, lifts FY guidance above Street - Incyte ( INCY ): FDA advisory committee only recommends approval of 2mg dose of baricitinib, not 4mg - Biogen ( BIIB ): beats on adjusted EPS, misses on revenue in Q1 - Centene ( CNC ): Q1 adjusted EPS beats analyst forecasts; revenue falls short; pulls back full-year estimate The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Top Health care stocks: Health care shares were higher ahead of the bell on Tuesday.",224.3915557861328
2018-04-25 00:00:00+00:00,262.70001220703125,274.3999938964844,262.2699890136719,269.45001220703125,269.45001220703125,2765700.0,2.333333333333333,1.0,0.3333583333333332,"VIDEO: Nasdaq 100 Movers: CHKP, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing Nasdaq 100 component thus far on the day is Check Point Software Technologies, trading down 6.8%. Check Point Software Technologies is lower by about 7.4% looking at the year to date performance. New Article Drug-developer Biogen (NASDAQ: BIIB) reported a pretty strong earnings increase in the first quarter. The company also added to its pipeline through a deal with Pfizer for its schizophrenia drug PF-04958242, which now goes by the equally nonspecific name BIIB104. The only reason for the decently sized year-over-year increase in revenue came from sales of Spinraza, Biogen's spinal muscular atrophy drug. New Article Biogen Misses on Sales : Biogen BIIB missed revenue estimates in the first quarter as Spinraza sales were drab. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Prothena Corporation plc (PRTA): Free Stock Analysis Report Calithera Biosciences, Inc. (CALA): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Over the past week while Amgen revised its annual guidance, Biogen reported quarterly numbers wherein sales missed estimates.",233.9873046875
2018-04-26 00:00:00+00:00,271.1000061035156,277.42999267578125,270.5199890136719,273.8599853515625,273.8599853515625,2084800.0,3.0,1.0,0.5000249999999999,"Research and development revenue earned as part of its collaboration with Biogen (NASDAQ: BIIB) for BIIB098 -- which used to be called ALKS 8700 -- was $17.5 million. The commercial-stage biopharma shook investors' confidence in early April when it announced that it received a refuse to file letter from the Food and Drug Administration for ALKS 5461, an important pipeline candidate designed to treat depression. What management had to say CFO James Frates was pleased with the company's first-quarter results, noting that they were ""in line with our expectations and reflect the solid growth of our proprietary commercial products and the continued strength of our royalty and manufacturing business."" New Article Also, they take a look at Biogen 's (NASDAQ: BIIB) recent deal with Ionis (NASDAQ: IONS) . In this week's episode of Industry Focus: Healthcare , analyst Kristine Harjes and Motley Fool contributor Shannon Jones explain why the results were so promising, what this could mean for the future of medical marijuana, and a few important things investors need to know about GW before diving in. Typically, the advisory committee meeting will happen before a PDUFA, particularly if the FDA is looking at something that's a novel type of drug or if there are any other sorts of questions surrounding its approval, where they want a little bit more guidance from a full panel of people who are experts on the topic.",239.6022186279297
2018-04-27 00:00:00+00:00,275.6000061035156,279.44000244140625,274.010009765625,276.79998779296875,276.79998779296875,1955600.0,3.0,1.0,0.5000249999999999,"In the face of the media-driven alarm sirens driven by ""weak"" sales of Biogen's Spinraza and its leading multiple sclerosis franchise seeing declining revenues, BIIB stock is up about 10% from Tuesday's tainted and pooh-poohed low and nearly 6% above Monday night's close. 9 Highest-Yielding Dividend Aristocrats to Buy Today Bottom line, BIIB stock's report was an overall strong effort offering a profit beat, overall solid sales growth and very modest revenue drug misses versus forecasts. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Following another volatile earnings reaction, there are plenty of reasons both off and on the price chart to appreciate the upside in biotech giant Biogen Inc (NASDAQ: BIIB ). New Article In November 2017, Alkermes and Biogen BIIB announced a global license and collaboration agreement to develop and commercialize Alkermes' phase III multiple sclerosis candidate, BIIB098 (ALKS8700). For BIIB098, preparation of the regulatory submission has begun and the company remains on track to submit the NDA toward year-end 2018. Click to get this free report Alkermes plc (ALKS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report Protagonist Therapeutics, Inc. (PTGX): Free Stock Analysis Report To read this article on Zacks.com click here.",234.4062957763672
2018-04-30 00:00:00+00:00,277.5799865722656,280.3099975585937,273.45001220703125,273.6000061035156,273.6000061035156,2083300.0,2.0,1.0,0.250025,"Biogen (NASDAQ: BIIB) investors have been anxiously awaiting a transformative deal to jump-start growth. On Friday, April 20, Biogen announced it would be paying nearly $1 billion to access more of Ionis ' (NASDAQ: IONS) pipeline of antisense drug candidates. In this clip of Industry Focus: Healthcare , Kristine Harjes and Shannon Jones discuss who got the better end of this deal and what it means for Biogen moving forward.",216.2999725341797
2018-05-01 00:00:00+00:00,274.8900146484375,279.7200012207031,271.69000244140625,274.6099853515625,274.6099853515625,1910300.0,2.5,1.0,0.375025,"Factors to Consider Ionis earns revenues in the form of upfront, milestone and other payments under its partnerships with leading health care companies like Biogen BIIB . Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Emergent Biosolutions Inc. (EBS): Free Stock Analysis Report Vanda Pharmaceuticals Inc. (VNDA): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Ionis also granted an exclusive, worldwide license for inotersen to Akcea Therapeutics to leverage the latter's commercial infrastructure and capabilities for a successful launch of the drug. New Article Biogen Inc. (NASDAQ: BIIB) and Gilead Sciences Inc. (NASDAQ: GILD) have a lot in common. BIIB098 is a prodrug that metabolizes in the body to produce a drug, monomethyl fumirate (MMF). The good news is that the company's top-selling product, multiple sclerosis (MS) drug Tecfidera, continues to enjoy sales growth.",220.2672882080078
2018-05-02 00:00:00+00:00,273.0,277.57000732421875,264.0299987792969,274.1300048828125,274.1300048828125,3616700.0,2.0,1.0,0.250025,"Among the largest underlying components of IBB, in trading today Celgene Corp (Symbol: CELG) is down about 1%, Biogen Inc (Symbol: BIIB) is off about 3.6%, and Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is lower by about 0.2%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $94.20 per share, with $119.30 as the 52 week high point - that compares with a last trade of $103.09. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",240.40158081054688
2018-05-09 00:00:00+00:00,269.75,275.7200012207031,269.07000732421875,274.0299987792969,274.0299987792969,1377300.0,3.0,1.0,0.5000249999999999,"Case in point: Spreading $10,000 evenly among shares of Biogen Inc. (NASDAQ: BIIB) , Celgene Corporation (NASDAQ: CELG) , and Gilead Sciences Inc. (NASDAQ: GILD) around this time in 1998 would have made you a millionaire already. In 2017, Biogen spun off its rare bleeding disorder segment into a separate company that Sanofi (NYSE: SNY) acquired for a whopping $11.6 billion in cash earlier this year. Biogen also reported a rare disease drug that launched at the beginning of 2017, called Spinraza, that achieved a $1.5 billion annualized run rate during its fifth quarter since earning an FDA approval. New Article Revenue increased thanks to $41 million in royalties from Biogen 's (NASDAQ: BIIB) sales of Spinraza, up from just $5 million in the year-ago quarter. Ionis Pharmaceuticals (NASDAQ: IONS) reported first-quarter earnings with revenue up substantially, but expenses rising even faster, as it prepares to launch two drugs this year. Despite the higher revenue, earnings turned negative on a GAAP (generally accepted accounting principles) basis: Ionis and Akcea Therapeutics (NASDAQ: AKCA) increased spending in preparation for the launch of Tegsedi for hereditary transthyretin amyloidosis (hATTR), and Waylivra for familial chylomicronemia syndrome, a rare disease that causes the buildup of lipids.",242.71420288085938
2018-05-10 00:00:00+00:00,272.6499938964844,276.260009765625,272.1000061035156,274.0,274.0,1416600.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of IBB, in trading today Celgene Corp (Symbol: CELG) is off about 1.2%, Biogen Inc (Symbol: BIIB) is up about 0.2%, and Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is up by about 1.2%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $94.20 per share, with $119.30 as the 52 week high point - that compares with a last trade of $104.30. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",256.266357421875
2018-05-11 00:00:00+00:00,274.3599853515625,283.5899963378906,274.3599853515625,282.3900146484375,282.3900146484375,1908700.0,2.0,1.0,0.250025,"Two other components making moves today are NVIDIA Corp ( NVDA ), trading down 1.9%, and Biogen ( BIIB ), trading up 2.4% on the day. In early trading on Friday, shares of Regeneron Pharmaceuticals ( REGN ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.5%. And the worst performing Nasdaq 100 component thus far on the day is Symantec Corp ( SYMC ), trading down 31.8%.",248.54922485351562
2018-05-14 00:00:00+00:00,282.3399963378906,285.5199890136719,281.0199890136719,282.3399963378906,282.3399963378906,2027100.0,3.5,1.0,0.6250249999999999,"Although BIIB has traded at a recent price of $282.39/share, the average analyst target is 24.91% higher at $352.74/share. Below is a twelve month price history chart comparing the stock performance of BIIB, MCK, and WFC: Combined, BIIB, MCK, and WFC represent 7.31% of the Morningstar Wide Moat ETF. Three of MOAT's underlying holdings with notable upside to their analyst target prices are Biogen Inc (Symbol: BIIB), McKesson Corp (Symbol: MCK), and Wells Fargo & Co. (Symbol: WFC). New Article We note that Biogen, Inc. BIIB holds a strong position in the MS market with a wide range of products including Avonex, Tysabri, Tecfidera and Plegridy. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis AGNVS announced that the FDA has approved the label expansion for its multiple sclerosis (""MS"") drug Gilenya (fingolimod).",247.54994201660156
2018-05-15 00:00:00+00:00,280.1600036621094,281.7300109863281,275.0,276.0599975585937,276.0599975585937,1729000.0,3.5,1.0,0.6250249999999999,"There's a lot for investors to like about Amgen Inc. (NASDAQ: AMGN) and Biogen Inc. (NASDAQ: BIIB) . One of America's largest pharmacy benefits managers recently dropped Repatha in favor of a rival therapy from Regeneron (NASDAQ: REGN) and Sanofi (NYSE: SNY) . Although Spinraza's trajectory could quickly reverse, Biogen made a smart move by expanding its investment into the company that discovered it, Ionis Pharmaceuticals (NASDAQ: IONS) . New Article AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports AMGN's forecasted earnings growth in 2018 as 9%, compared to an industry average of 9%. For more information on the declaration, record and payment dates, visit the AMGN Dividend History page.",247.86593627929688
2018-05-17 00:00:00+00:00,280.260009765625,281.6199951171875,277.260009765625,280.57000732421875,280.57000732421875,1830700.0,2.5,1.0,0.375025,"VIDEO: S&P 500 Analyst Moves: BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The latest tally of analyst opinions from the major brokerage houses shows that among the components of the S&P 500 index, Biogen is now the #107 analyst pick, moving up by 1 spot. This rank is formed by averaging the analyst opinions for each component from each broker, and then ranking the 500 components by those average opinion values. New Article Unfortunately for investors, June's discovery wasn't exciting enough for Sangamo partners Biogen (NASDAQ: BIIB) and Shire (NASDAQ: SHPG) . The potential for ZFN to offer patients immunity to HIV has yet to be realized, but the excitement surrounding June's study caused Sangamo's stock to soar to nearly $25 per share, its highest point since going public nearly 15 years earlier. Also in January, Sangamo reported that the Food and Drug Administration cleared it to begin a study in hemophilia A, and granted an orphan designation to its treatment for mucopolysaccharidosis I (MPS I), a rare pediatric disorder.",243.97830200195312
2018-05-21 00:00:00+00:00,281.3599853515625,282.1000061035156,276.4200134277344,277.6700134277344,277.6700134277344,1628100.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of IBB, in trading today Biogen Inc (Symbol: BIIB) is up about 0.2%, Celgene Corp (Symbol: CELG) is off about 1.9%, and Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is higher by about 0.5%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $94.20 per share, with $119.30 as the 52 week high point - that compares with a last trade of $108.06. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",245.58224487304688
2018-05-24 00:00:00+00:00,283.44000244140625,285.4700012207031,281.79998779296875,284.4100036621094,284.4100036621094,1148200.0,2.75,1.0,0.437525,"SEE ALSO: 7 ""Strong Buy"" Dividend Stocks That Should Rip Higher Market value: $59.6 billion Dividend yield: N/A Yes, a biotech stock has earned a spot on a list of workhorse health-care names, though Biogen ( BIIB , $283.75) isn't as ""biotech-y"" as the word normally implies. As Lowry also notes, ""the company's experimental drug, called BIIB-037, could become the first disease-modifying treatment for Alzheimer's."" Alzheimer's is yet another elusive and poorly treated disease, but BIIB-037 - also called Aducanumab - is a promising monoclonal antibody that abates the amyloid beta plaque that's believed to clump within the brain of individuals that eventually develop the disease. New Article Rituxan Rituxan is another product from Roche's Genentech, although Biogen Inc (NASDAQ: BIIB ) also has a hand in its success as a therapy for some types of non-Hodgkin's lymphoma. Those are pretty competitive arenas already, but if Pfizer wanted to push its biosimilar to its limits, there's way of extracting a little more revenue outside of Avastin's biggest target market. Though Humira has been something of a punching bag due to expectations of its demise (stemming from a loss of patent protection in the EU) those doubts haven't been quite as merited as voiced. New Article With BIIB, there will be a tension with its own origination business, as resources need to be allocated to both the branded drugs and biosimilars, but there's enough expertise at Biogen to make this happen. Biogen Is a Pharma Stock with a Next-Level Development Plan Source: Biogen via YouTube My other choice is perhaps more of a biotechnology stock than big pharma, but call it what you will, Biogen Inc. (NASDAQ: BIIB ) not only has established a beachhead with numerous drugs, it's going to be a leader in biosimilar technology. I'm moving on to focus more on my investment advisory newsletter, raising and placing capital for businesses and high net worth individuals, and non-finance related activities. New Article It has been about a month since the last earnings report for Biogen Inc.BIIB . Will the recent positive trend continue leading up to its next earnings release, or is BIIB due for a pullback? Biogen Inc. Price and Consensus Biogen Inc. Price and Consensus | Biogen Inc. Quote VGM Scores At this time, BIIB has a nice Growth Score of B, though it is lagging a lot on the momentum front with an F. However, the stock was allocated a grade of B on the value side, putting it in the second quintile for this investment strategy.",244.80661010742188
2018-05-30 00:00:00+00:00,288.489990234375,297.5,287.9599914550781,294.3999938964844,294.3999938964844,1987500.0,3.0,1.0,0.5000249999999999,"For a full detailed analysis using NASDAQ's Guru Analysis tool, click here BIOGEN INC ( BIIB ) is a large-cap value stock in the Biotechnology & Drugs industry. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068. The Company's subsidiaries include Philip Morris USA Inc. (PM USA), which is engaged in the manufacture and sale of cigarettes in the United States; John Middleton Co. (Middleton), which is engaged in the manufacture and sale of machine-made cigars and pipe tobacco, and UST LLC ( UST ), which, through its subsidiaries, including U.S. Smokeless Tobacco Company LLC (USSTC) and Ste.",246.60064697265625
2018-06-04 00:00:00+00:00,297.0400085449219,301.510009765625,296.1199951171875,298.9100036621094,298.9100036621094,1028000.0,2.0,1.0,0.250025,"Spinal muscular atrophy drug Spinraza, which was licensed to Biogen (NASDAQ: BIIB) , is one such drug that's put Ionis and its antisense technology on the map. This deal with Biogen is expected to push Ionis' cash balance to north of $2 billion, giving the company the flexibility to go shopping or perhaps to hang on to more of its experimental assets, as opposed to licensing them out. Long story short, Ionis has demonstrated that its technology works, is sporting a huge pile of cash, has perhaps the most impressive pipeline of any mid-cap biotech, and is expected to be profitable on a recurring basis moving forward.",242.29551696777344
2018-06-06 00:00:00+00:00,299.1499938964844,303.94000244140625,298.8900146484375,303.75,303.75,1371200.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of IBB, in trading today Biogen Inc (Symbol: BIIB) is up about 0.7%, Celgene Corp (Symbol: CELG) is trading flat, and Gilead Sciences Inc (Symbol: GILD) is higher by about 0.1%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $96.835 per share, with $119.30 as the 52 week high point - that compares with a last trade of $109.88. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article + Alkermes ( ALKS ) climbed as much as 5% on Wednesday after the specialty drugmaker said it received a $50 million milestone payment from Biogen ( BIIB ) following a review of preliminary gastrointestinal tolerability data from ongoing Phase III testing of their BIIB098 drug candidate to treat relapsing forms of mucular sclerosis. The companies are expecting to file a new drug application for BIIB098 with U.S. regulators by the end of the year. Among health care stocks moving on news: + Enanta Pharmaceuticals ( ENTA ) pushed out to a new record high on Wednesday, rising more than 12% to reach a best-ever $109.93 a share, after analysts at Roth Capital began coverage of the biotech company developing small-molecule drugs to treat viral infections and liver diseases with a Buy stock rating and a $133 price target. New Article + Alkermes ( ALKS ) climbed as much as 5% on Wednesday after the specialty drugmaker said it received a $50 million milestone payment from Biogen ( BIIB ) following a review of preliminary gastrointestinal tolerability data from ongoing phase III testing of their BIIB098 drug candidate to treat relapsing forms of mucular sclerosis. The companies are expecting to file a new drug application for BIIB098 with US regulators by the end of the year. In other sector news: + Cellectar Biosciences ( CLRB ) soared almost 32% on Wednesday, topping out at $1.27 a share, after receiving a rare pediatric disease designation for its CLR131 drug candidate to treat rhabdomyosarcoma, a rare form of juvenile cancer, from the U.S. Food and Drug Administration.",251.94900512695312
2018-06-07 00:00:00+00:00,304.3299865722656,307.9100036621094,303.0599975585937,305.3699951171875,305.3699951171875,1392900.0,4.0,1.0,0.7500249999999999,"Other investors in DDF include Biogen BIIB , Eli Lilly LLY and Glaxo GSK , among others. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. In 2015, Pfizer became part of the Dementia Discovery Fund (DDF), which was formed to speed up the development of new treatments for neurological diseases by bringing together major pharma companies, the U.K. government and Alzheimer's Research UK.",262.06903076171875
2018-06-08 00:00:00+00:00,304.67999267578125,304.989990234375,300.3599853515625,303.2900085449219,303.2900085449219,1519800.0,4.0,1.0,0.7500249999999999,"Biogen IncBIIB announced that it has signed an option agreement with private biotech, TMS Co., Ltd. to acquire the latter's phase II acute stroke candidate TMS-007 and backup compounds. To pursue innovative approaches in therapeutic area, Biogen already has a phase III ready pipeline candidate, BIIB093, under development for the prevention and treatment of edema in large hemispheric infarction, a severe type of stroke. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Genomic Health, Inc. (GHDX): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report CRISPR THERAPTC (CRSP): Free Stock Analysis Report To read this article on Zacks.com click here. New Article We note that Roche's subsidiary, Genentech and Biogen BIIB , have a collaboration agreement for Rituxan in the United States while Roche markets MabThera (brand name of Rituxan outside the United States) in the rest of the world, except Japan, where Rituxan is co-marketed by Chugai and Zenyaku Kogyo Co. Ltd. Approval of new drugs and a potential label expansion of existing drugs bode well for Roche, as its legacy drugs like Herceptin and MabThera are facing competition from biosimilars. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Roche HoldingsRHHBY announced that the FDA has approved Rituxan (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV).",253.73667907714844
2018-06-13 00:00:00+00:00,306.4700012207031,310.9100036621094,305.5799865722656,306.9100036621094,306.9100036621094,1180300.0,2.6666666666666665,1.0,0.4166916666666666,"Biogen BIIB is trading with a forward P/E of 12.9. Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Valeant Pharmaceuticals International, Inc. (VRX): Free Stock Analysis Report Lannett Co Inc (LCI): Free Stock Analysis Report To read this article on Zacks.com click here. (1: 30 ) - Tracey's Top Stock Picks (11: 45 ) - Health Service Industry (14: 20 ) - Episode Roundup: Podcast@Zacks.com Welcome to Episode #96 of the Value Investor Podcast Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio service , shares some of her top value investing tips and stock picks. New Article GILD is a part of the Health Care sector, which includes companies such as Amgen Inc. ( AMGN ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports GILD's forecasted earnings growth in 2018 as -32.83%, compared to an industry average of 9.4%. For more information on the declaration, record and payment dates, visit the GILD Dividend History page. New Article Biogen Acquires Asset for Thrombosis : Biogen BIIB entered into an exclusive option agreement with TMS Co., Ltd. to acquire TMS-007 and backup compounds for an upfront payment of $4 million. Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Axovant Sciences Ltd. (AXON): Free Stock Analysis Report To read this article on Zacks.com click here. In addition, the European Commission (EC) approved a label expansion for Prolia (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.",251.17921447753906
2018-06-14 00:00:00+00:00,307.4700012207031,309.6000061035156,304.6700134277344,305.67999267578125,305.67999267578125,1344600.0,3.0,1.0,0.5000249999999999,"Below is a twelve month price history chart comparing the stock performance of JNJ, BIIB, and WFC: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of OEW's underlying holdings with notable upside to their analyst target prices are Johnson & Johnson (Symbol: JNJ), Biogen Inc (Symbol: BIIB), and Wells Fargo & Co. (Symbol: WFC). Similarly, BIIB has 14.17% upside from the recent share price of $306.91 if the average analyst target price of $350.39/share is reached, and analysts on average are expecting WFC to reach a target price of $62.65/share, which is 13.58% above the recent price of $55.16.",251.12721252441406
2018-06-15 00:00:00+00:00,306.04998779296875,309.5,303.4200134277344,305.0299987792969,305.0299987792969,1882400.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of IBB, in trading today Biogen Inc (Symbol: BIIB) is trading flat, Gilead Sciences Inc (Symbol: GILD) is down about 1.4%, and Celgene Corp (Symbol: CELG) is lower by about 0.3%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $96.835 per share, with $119.30 as the 52 week high point - that compares with a last trade of $111.16. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article While the MS market holds immense potential, competition is stiff with the likes of Biogen, Inc. BIIB . Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Roche RHHBY announced encouraging data from the final analysis of the CLL11 study, evaluating Gazyva-based treatment in previously untreated chronic lymphocytic leukaemia (CLL). New Article BiogenBIIB is trading with a forward P/E of 12.9. Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Valeant Pharmaceuticals International, Inc. (VRX): Free Stock Analysis Report Lannett Co Inc (LCI): Free Stock Analysis Report To read this article on Zacks.com click here. Every week, Tracey Ryniec, the editor of Zacks Value Investor portfolio service , shares some of her top value investing tips and stock picks.",247.4236602783203
2018-06-18 00:00:00+00:00,294.04998779296875,294.9700012207031,283.239990234375,289.1199951171875,289.1199951171875,3409000.0,2.1666666666666665,1.0,0.2916916666666666,"Likewise, Biogen (NASDAQ: BIIB) and Ionis Pharmaceuticals (NASDAQ: IONS) , which have the only SMA drug on the market, are feeling the heat from the promising data with shares down 5.6% and 7.3%, respectively. By comparison, Biogen and Ionis Pharmaceuticals' Spinraza produced at least a four-point improvement in CHOP-INTEND in 63% of the 52 babies tested at day 183. As bad as an injection into the spine sounds, Spinraza only has to be administered four times a year, while giving medication to a baby daily could be challenging. New Article Particularly high volume was seen for the $285 strike put option expiring June 22, 2018 , with 971 contracts trading so far today, representing approximately 97,100 underlying shares of BIIB. Below is a chart showing FB's trailing twelve month trading history, with the $200 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 10,629 contracts thus far today. That number of contracts represents approximately 1.1 million underlying shares, working out to a sizeable 74.3% of BIIB's average daily trading volume over the past month, of 1.4 million shares. New Article Align Technology ( ALGN ) is the component faring the best Monday, up by about 1.9% on the day, while Biogen ( BIIB ) is lagging other components of the iShares Global Healthcare ETF, trading lower by about 5.6%. The iShares Global Healthcare ETF ( IXJ ) is seeing unusually high volume in afternoon trading Monday, with over 290,000 shares traded versus three month average volume of about 31,000. Components of that ETF with the highest volume on Monday were Pfizer ( PFE ), trading off about 1% with over 12.1 million shares changing hands so far this session, and Merck ( MRK ), off about 1.5% on volume of over 4.7 million shares. New Article Combined, BIIB and ABC make up approximately 2.3% of the underlying holdings of XLV. Among large Healthcare stocks, Biogen Inc (Symbol: BIIB) and AmerisourceBergen Corp. (Symbol: ABC) are the most notable, showing a loss of 5.6% and 3.6%, respectively. Combined, KMB and HSY make up approximately 2.2% of the underlying holdings of IYK. New Article Biogen (NASDAQ: BIIB) , Baytex Energy (NYSE: BTE) , and Catalyst Biosciences (NASDAQ: CBIO) were among the worst performers on the day. Currently, Spinraza, which Biogen licenses from Ionis Pharmaceuticals , has been the go-to treatment for spinal muscular atrophy, posting very close to $1 billion in sales during 2017. Although proponents of the deal point to the average annual production exceeding 100,000 barrels of oil equivalent per day, shareholders appear to be unhappy about the level of dilution involved in Baytex's having made the purchase. New Article VIDEO: Nasdaq 100 Movers: BIIB, JD The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing Nasdaq 100 component thus far on the day is Biogen, trading down 5.9%. Biogen is lower by about 9.9% looking at the year to date performance.",242.19224548339844
2018-06-19 00:00:00+00:00,286.1400146484375,296.010009765625,286.0400085449219,292.0400085449219,292.0400085449219,1706200.0,3.0,1.0,0.5000249999999999,"Investors eyeing a purchase of Biogen Inc (Symbol: BIIB) shares, but cautious about paying the going market price of $294.31/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to BIIB's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. For other put options contract ideas at the various different available expirations, visit the BIIB Stock Options page of StockOptionsChannel.com. New Article Following this presentation, shares of rival company, Biogen Inc. BIIB fell more than 5% on Monday. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Aeglea BioTherapeutics, Inc. (AGLE): Free Stock Analysis Report PTC Therapeutics, Inc. (PTCT): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of PTC Therapeutics, Inc.PTCT gained 27.5% on Jun 18, following the presentation of encouraging preliminary data from part I of the pivotal FIREFISH study.",249.7589569091797
2018-06-20 00:00:00+00:00,293.1000061035156,298.44000244140625,292.3699951171875,296.8599853515625,296.8599853515625,1273600.0,3.5,1.0,0.6250249999999999,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $300.00 strike highlighted in red: Considering the fact that the $300.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading this week, for the August 17th expiration. New Article PTC Therapeutics (NASDAQ: PTCT) shares took off after updated data from a trial evaluating risdiplam suggested it could mount a stiff challenge to Biogen 's (NASDAQ: BIIB) and Ionis Pharmaceuticals ' (NASDAQ: IONS) Spinraza for the treatment of spinal muscular atrophy (SMA), a rare and life-threatening genetic disease. Diagnosed in childhood or early adulthood, SMA type 3 patients have the best prognosis, but they still endure significant challenges to quality of life, including eventually losing the ability to walk. Although Spinraza is revolutionary, it doesn't help everyone, and that leaves the door open to competitors, including PTC Therapeutics, which is developing risdiplam with Roche Holdings (NASDAQOTH: RHHBY) under a licensing pact the two companies inked in 2011.",253.1646728515625
2018-06-25 00:00:00+00:00,295.9200134277344,297.1499938964844,289.20001220703125,292.19000244140625,292.19000244140625,1685500.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of IBB, in trading today Gilead Sciences Inc (Symbol: GILD) is down about 0.3%, Biogen Inc (Symbol: BIIB) is off about 0.8%, and Celgene Corp (Symbol: CELG) is higher by about 0.3%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $100.221 per share, with $119.30 as the 52 week high point - that compares with a last trade of $111.35. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",248.1822509765625
2018-06-28 00:00:00+00:00,289.32000732421875,290.3299865722656,285.32000732421875,288.75,288.75,1405900.0,2.0,1.0,0.250025,"If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read New, Cancer Drugs to Support J&J's (JNJ) Top Line Biogen's (BIIB) Spinraza Shines, Core Competition Heats Up Strong Crossover & Truck Sales Drive General Motors (GM) Featured Reports Valero (VLO) Banks on Throughput, Blending Cost a Concern The Zacks analyst believes that improving throughput volume on higher refinery utilization will help Valero to generate more cash flow. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Biogen (BIIB) and General Motors (GM). Click to get this free report Valero Energy Corporation (VLO): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report General Motors Company (GM): Free Stock Analysis Report General Growth Properties, Inc. (GGP): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ameriprise Financial, Inc. (AMP): Free Stock Analysis Report To read this article on Zacks.com click here.",252.3984832763672
2018-07-02 00:00:00+00:00,290.29998779296875,296.1199951171875,288.1300048828125,295.7699890136719,295.7699890136719,1116400.0,4.0,1.0,0.7500249999999999,"We note that Genentech, a subsidiary of Roche RHHBY and Biogen, Inc. BIIB are developing Rituxan in partnership which is currently being evaluated in a phase II study for the treatment of aTTP. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. A marketing authorization application (""MAA"") is seeking approval of the candidate for the treatment of patients experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), a rare blood-clotting disorder.",257.9203796386719
2018-07-03 00:00:00+00:00,296.0599975585937,296.9200134277344,292.6400146484375,293.510009765625,293.510009765625,452900.0,2.0,1.0,0.250025,"Among the largest underlying components of IBB, in trading today Gilead Sciences Inc (Symbol: GILD) is up about 0.7%, Amgen Inc (Symbol: AMGN) is up about 0.8%, and Biogen Inc (Symbol: BIIB) is relatively unchanged. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $100.221 per share, with $119.30 as the 52 week high point - that compares with a last trade of $111.20. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",243.86489868164062
2018-07-06 00:00:00+00:00,347.04998779296875,367.8900146484375,340.54998779296875,357.4800109863281,357.4800109863281,12857000.0,3.736842105263159,1.0,0.6842355263157897,"Shares of Biogen Inc. (NASDAQ: BIIB ) got a boost, shooting up 15 percent to $344.95 in reaction to encouraging results from a clinical study. Economists were expecting an addition of 200,000 nonfarm jobs Equities Trading UP Black Box Corporation (NASDAQ: BBOX ) shares shot up 92 percent to $1.82 after the nano-cap company said it will partner with an un-named but ""renowned and prominent"" social media organization for its global data center expansion program. The company and its Japan-based partner Eisai Co said its Alzheimer's drug BAN2401 was able to slow down the progression of the disease among patients who were given the highest dose after an 18 month treatment. New Article Tech rose 1.2% on Friday and healthcare gained 1.4% in the S&P's best increases, with biotechnology surging as Biogen ( BIIB ) jumped 20% on a positive Alzheimer's treatment trial result. (+) BIIB (+19.63%) Alzheimer's drug succeeds in mid-stage trial (+) TUSK (+7.09%) Barclays raises PT (+) LULU (+3.23%) BofA lifts price target to $140 from $121 (+) DB (+3.01%) Shares rise amid reports of buying interest (+) SATS (+1.87%) Says won't make another offer for Inmarsat (+) KMI (+1.93%) RBC edges up price target by $1 to $20 Wall Street capped a choppy, holiday-shortened week on an upswing, as investors cheered better-than-expected jobs data that helped allay worries about the ramping up of the US-China trade war. New Article Particularly high volume was seen for the $350 strike call option expiring July 06, 2018 , with 1,731 contracts trading so far today, representing approximately 173,100 underlying shares of BIIB. Below is a chart showing AMZN's trailing twelve month trading history, with the $1700 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 33,665 contracts thus far today. That number of contracts represents approximately 3.4 million underlying shares, working out to a sizeable 246.1% of BIIB's average daily trading volume over the past month, of 1.4 million shares. New Article (+) DB (+3.1%) Shares rise amid reports of buying interest (+) BIIB (+17.1%) Alzheimer's drug succeeds in mid-stage trial (+) SATS (+2%) Says won't make another offer for Inmarsat (+) TUSK (7.4%) Barclays raises PT Positive results from Biogen's ( BIIB ) study of its lead Alzheimer's treatment boosted the US health care sector. US stocks advanced for a second straight day, boosted Friday by stronger-than-expected jobs gains that overshadowed trade tensions. New Article In other sector news: + Biogen ( BIIB ) soared as much as 23% on Friday after the biotech conglomerate and Japanese drug maker reported positive topline results from phase II testing of their BAN2401 drug candidate, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's disease. Among health care stocks moving on news: + TG Therapeutics ( TGTX ) was almost 4% higher Friday afternoon, extending a day-long advance after a new regulatory filing showing Sean Power, chief financial officers at the biopharmaceuticals company, earlier this week sold a total of 47,191 shares of the company's stock, cutting his TG Therapeutics stake to 438,267 shares. - Regulus Therapeutics ( RGLS ) plunged to a new, all-time low on Friday, falling over 50% to a worst-ever price of 36 a share after disclosing plans to suspend clinical testing of its RG-102 drug candidate to treat Alport syndrome and laying off 60% of its workforce in a bid to stretch its remaining funds to the middle of 2019. New Article Components of that ETF showing particular strength include shares of Biogen ( BIIB ), up about 18.3% and shares of Corbus Pharmaceuticals Holdings ( CRBP ), up about 8.2% on the day. Among components of that ETF with the weakest showing on Friday were shares of Centerra Gold (CG.CA), lower by about 5.8%, and shares of Royal Gold ( RGLD ), lower by about 2.5% on the day. VIDEO: Friday's ETF Movers: IBB, GDX The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Tesla, Inc. ( TSLA ) had the largest percent change down (-.08%) while Biogen Inc. ( BIIB ) had the largest percent change gain rising 19.63%. NASDAQ Market Wrap As of 7/6/2018 4:45:01 PM BILLIONS OF 1.88 NASDAQ SHARES TRADED TODAY 81 STOCKS REACHED A 52 WEEK HIGH 13 THOSE REACHING LOWS TOTALEDBiogen Inc. [BIIB]TOPS ADVANCERS LISTOF NASDAQ 100 INDEX % 19.63 ROSE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Friday's session closes with the NASDAQ Composite Index at 7,688.39. New Article As for individual stocks, Biogen (NASDAQ: BIIB) made headlines with positive results from a trial of an Alzheimer's drug, and PriceSmart (NASDAQ: PSMT) fell after reporting earnings. A positive jobs report overcame investor concerns about trade on Friday, and the Dow Jones Industrial Average (DJINDICES: ^DJI) and the S&P 500 (SNPINDEX: ^GSPC) closed the day and the week in the green. The phase 2 trial of BAN2401, an anti-amyloid beta protofibril antibody that Biogen is developing along with its Japanese partner Eisai , tested the various doses of the drug against a placebo in 856 patients with early Alzheimer's disease. New Article Among health care stocks moving on news: + Biogen ( BIIB ) soared almost 13% after the biotech company and Japanese drug maker Eisai late Thursday reported positive topline results from phase II testing of their BAN2401 drug candidate, an anti-amyloid beta protofibril antibody, in 856 patients with early Alzheimer's disease. - Regulus Therapeutics ( RGLS ) dropped more than 40% pre-market Friday after disclosing plans late Thursday to suspend clinical testing of its RG-102 drug candidate to treat Alport syndrome and to lay off 60% of its workforce in a bid to stretch its remaining funds to the middle of 2019. It also said talks with Sanofi ( SNY ) to restructure their partnership on RG-102 were ongoing and that it planned to focus its preclinical research activities on its Hepatitis B virus programs. New Article Then payrolls were released, In today's Morning Movers, we... Getty Images ...explain why the market is ignoring the tariffs that went into effect today; ...highlight the news that has Biogen (BIIB) trading up more than 10%; ...and catalog the day's ratings changes, including a downgrade for Costco Wholesale (COST). Biogen (BIIB) has jumped 13% to $336.49 following positive data from a clinical trial of its Alzheimer's drug. The Dow Jones Industrial Average looked set for a lower open this morning after U.S. tariffs on China went into effect overnight. New Article Several major biotech stocks rallied on Friday after Biogen BIIB reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease. BIIB is currently sporting a Zacks Rank #3 (Hold). Click to get this free report ISHARES NDQ BIO (IBB): ETF Research Reports Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Eisai Co. (ESALY): Free Stock Analysis Report To read this article on Zacks.com click here. New Article InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen (NASDAQ: BIIB ) stock was soaring today on positive results from a recent Alzheimer's drug trial conducted with Eisai . BIIB stock was up 14% as of Friday morning. Source: Biogen via YouTube The trail was to determine the effectiveness of BAN2401 in slowing the progression of patients' Alzheimer's Disease Composite Score. New Article In trading on Friday, shares of Biogen Inc (Symbol: BIIB) crossed above their 200 day moving average of $304.34, changing hands as high as $367.89 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $249.17 per share, with $370.57 as the 52 week high point - that compares with a last trade of $344.14. Click here to find out which 9 other stocks recently crossed above their 200 day moving average  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Shares of Biogen Inc. (NASDAQ: BIIB ) got a boost, shooting up 15 percent to $344.95 in reaction to encouraging results from a clinical study. Economists were expecting an addition of 200,000 nonfarm jobs Equities Trading UP Black Box Corporation (NASDAQ: BBOX ) shares shot up 92 percent to $1.82 after the nano-cap company said it will partner with an un-named but ""renowned and prominent"" social media organization for its global data center expansion program. The company and its Japan-based partner Eisai Co said its Alzheimer's drug BAN2401 was able to slow down the progression of the disease among patients who were given the highest dose after an 18 month treatment. New Article VIDEO: Nasdaq 100 Movers: LRCX, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Friday, shares of Biogen ( BIIB ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 17.8%. And the worst performing Nasdaq 100 component thus far on the day is Lam Research ( LRCX ), trading down 1.2%. New Article Biogen Inc. 's BIIB shares were up around 7% in after-market trading on Thursday on positive top-line data from a mid-stage study evaluating its pipeline candidate, BAN2401 for the treatment of early Alzheimer's disease (AD). Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. In late 2017, data announced from the same study failed to show early positive results, which raised investors' concerns about the candidate's chances of success. New Article VIDEO: S&P 500 Movers: QRVO, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Friday, shares of Biogen ( BIIB ) topped the list of the day's best performing components of the S&P 500 index, trading up 18.4%. And the worst performing S&P 500 component thus far on the day is Qorvo ( QRVO ), trading down 2.0%. New Article Shares of Biogen Inc. (NASDAQ: BIIB ) got a boost, shooting up 17 percent to $350.39 in reaction to encouraging results from a clinical study. Economists were expecting an addition of 200,000 nonfarm jobs Equities Trading UP Black Box Corporation (NASDAQ: BBOX ) shares shot up 64 percent to $1.56 after the nano-cap company said it will partner with an un-named but ""renowned and prominent"" social media organization for its global data center expansion program. The company and its Japan-based partner Eisai Co said its Alzheimer's drug BAN2401 was able to slow down the progression of the disease among patients who were given the highest dose after an 18 month treatment. New Article Biogen Inc. ( BIIB ) is +40.16 at $338.97, with 265,978 shares traded. As reported by Zacks, the current mean recommendation for BIIB is in the ""buy range"". The following are the most active stocks for the pre-market session : Aegean Marine Petroleum Network Inc. ( ANW ) is +0.32 at $2.35, with 1,048,145 shares traded.",240.38682556152344
2018-07-09 00:00:00+00:00,357.92999267578125,360.3500061035156,347.510009765625,354.0,354.0,3872800.0,3.75,1.0,0.6875249999999999,"In recent trading, shares of Biogen Inc (Symbol: BIIB) have crossed above the average analyst 12-month target price of $350.39, changing hands for $357.48/share. But the whole reason to look at the average BIIB price target in the first place is to tap into a ""wisdom of crowds"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with BIIB crossing above that average target price of $350.39/share, investors in BIIB have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $350.39 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? New Article Two other components making moves today are Biogen ( BIIB ), trading down 1.8%, and Wynn Resorts ( WYNN ), trading up 2.9% on the day. And the worst performing Nasdaq 100 component thus far on the day is Take-Two Interactive Software ( TTWO ), trading down 2.2%. Take-Two Interactive Software is showing a gain of 9.9% looking at the year to date performance. New Article Here's what CTI BioPharma's CEO Adam Craig had to say about the results: Given the disappointing news, it isn't hard to figure out why shares are tumbling today. Now what While downbeat clinical news is never good, CTI BioPharma's shares are not being mauled too badly today, because this company's primary pipeline asset is called Pacritinib. The company has high hopes for the experimental myelofibrosis drug and expects to report top-line clinical data from a phase 2 trial in the first quarter of 2019. New Article Within the healthcare sector, the share price of Biogen Inc. BIIB increased 19.6% - its biggest gain since February 2004 - following announcement of positive results from a phase 2 trial of its Alzheimer's drug BAN2401. Click to get this free report Facebook, Inc. (FB): Free Stock Analysis Report Apple Inc. (AAPL): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Wall Street continues its winning streak for the second straight session with all three major stock indexes closing in positive territory on Friday.",239.33969116210938
2018-07-10 00:00:00+00:00,347.5400085449219,347.8999938964844,339.1499938964844,344.82000732421875,344.82000732421875,3425600.0,2.0,1.0,0.250025,"CTI BioPharma Corp.CTIC and its privately-held partner Servier announced the failure of their pivotal phase III study evaluating cancer drug, Pixuvri, in combination with Roche RHHBY and Biogen's BIIB Rituxan (rituximab) for the treatment of B-cell non-Hodgkin lymphoma (""NHL""). Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report CTI BioPharma Corp. (CTIC): Free Stock Analysis Report To read this article on Zacks.com click here. Pixuvri has conditional approval in Europe as monotherapy for the treatment of multiply relapsed or refractory aggressive B-cell NHL. New Article Two other components making moves today are Biogen ( BIIB ), trading down 3.5%, and Wynn Resorts ( WYNN ), trading up 2.0% on the day. In early trading on Tuesday, shares of Idexx Laboratories ( IDXX ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 2.5%. And the worst performing Nasdaq 100 component thus far on the day is Cerner Corp. ( CERN ), trading down 4.3%. New Article Read on to see why Cerner (NASDAQ: CERN) , Biogen (NASDAQ: BIIB) , and Alphabet (NASDAQ: GOOG) (NASDAQ: GOOGL) slumped today. Finally, Class A shares of Google parent Alphabet edged just into negative territory at the end of the day, giving up earlier gains following a Wall Street Journalreport (subscription required) that the internet search giant will likely face a multibillion-euro antitrust fine from the European Commission (EC) for abusing the market leadership of its Android mobile operating system. According to ""people familiar with the matter,"" the EC is expected to find that Alphabet ""thwarted potential competitors to safeguard its mobile-advertising business,"" the strength of which Google has singled out in recent quarters as a primary driver of its top-line growth. New Article - Teresa Rivas Upgrades & Downgrades Biogen (BIIB) is down 1.1% to $350 after Robert W. Baird downgraded it to Neutral. In today's Morning Movers, we... Getty Images ...explain why earnings season will be less about profits and more about what companies say about trade; ...review PepsiCo's (PEP) results; ...and highlight a downgrade for Chipotle Mexican Grill (CMG). ""That will leave markets sensitive to earnings discussions and any developments on the trade front, especially as the S&P is approaching key resistance in the upper 2700's where the last rally failed, and stocks pulled back,"" says The Sevens' Reports Tom Essaye. New Article Specifically, BIIB stock jumped nearly 20% after an update on BAN-2401, a phase 2 drug that showed a statistically significant slowdown in the memory loss associated with Alzheimer's. InvestorPlace - Stock Market News, Stock Advice & Trading Tips On Friday, Biogen (NASDAQ: BIIB ) shares soared on news that one of its Alzheimer's drug trials was showing tremendous promise. Aducanumab Validated In and of itself, the encouraging news regarding BAN-2401 may not have moved BIIB stock the way it did on Friday.",231.17393493652344
2018-07-11 00:00:00+00:00,341.8399963378906,346.20001220703125,340.0,344.1000061035156,344.1000061035156,1786600.0,3.0,1.0,0.5000249999999999,"Of course, my ""bet against all Alzheimer's drugs"" thesis took a bit of a hit last week when biotech blue-chip Biogen (NASDAQ: BIIB) , which is working alongside partner Eisai (NASDAQOTH: ESALY) , reported positive mid-stage data on blockbuster hopeful BAN2401. In other words, with the exception of visibly noticing cognitive decline in the patient, it's very difficult for researchers to predict the risk factors and biomarkers responsible for Alzheimer's early enough to make a difference. The phase 3 Mindset trial, which enrolled more than 1,300 patients, demonstrated no statistically significant improvement in the primary endpoint, which was a drug-placebo difference on the Alzheimer's Disease Assessment Scale-Cognitive Subscale. New Article Positive data released by bigwig Biogen, Inc. BIIB from a mid-stage study for the treatment of Alzheimer's disease created a stir in the biotech sector last week. Click to get this free report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Idera Pharmaceuticals, Inc. (IDRA): Free Stock Analysis Report Axovant Sciences Ltd. (AXON): Free Stock Analysis Report Acceleron Pharma Inc. (XLRN): Free Stock Analysis Report To read this article on Zacks.com click here. Among other news, Celgene Corporation CELG reported positive data on a key pipeline candidate from a late-stage study while Axovant AXON gained on yet another licensing deal. New Article Among the largest underlying components of IBB, in trading today Gilead Sciences Inc (Symbol: GILD) is off about 1%, Amgen Inc (Symbol: AMGN) is off about 0.8%, and Biogen Inc (Symbol: BIIB) is lower by about 0.2%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $100.221 per share, with $119.30 as the 52 week high point - that compares with a last trade of $116.52. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",239.3256378173828
2018-07-12 00:00:00+00:00,347.0299987792969,348.07000732421875,343.54998779296875,347.6600036621094,347.6600036621094,1304400.0,3.0,1.0,0.5000249999999999,"I have also been an investor in BiogenBIIB , maker of two different drugs in clinical trials to treat Alzheimer's. When Biogen had to expand the study size (number of patients) in trials of both drugs, that's when sentiment turned so sour on BIIB shares. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report bluebird bio, Inc. (BLUE): Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report CRISPR THERAPTC (CRSP): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Venclexta's label was expanded last month as monotherapy or in combination with Roche/Biogen's BIIB Rituxan for the treatment of relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma in second or later line settings. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVieABBV announced that a combination regimen of its blockbuster cancer drug, Imbruvica (ibrutinib), failed in a phase III study - DBL3001 - evaluating it as first-line treatment for diffuse large B-cell lymphoma (""DLBCL"").",237.7736053466797
2018-07-13 00:00:00+00:00,347.010009765625,351.6700134277344,344.04998779296875,348.4800109863281,348.4800109863281,1168600.0,2.75,1.0,0.437525,"If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Emerging Markets Growth to Propel PepsiCo's (PEP) Revenues Lilly's (LLY) New Drugs Drive Sales amid Rising Competition Broadcom (AVGO) Drives on Wireless Products & Acquisitions Featured Reports Biogen (BIIB) Diversifies Portfolio, Competition Heats Up The Zacks analyst likes Biogen's efforts to diversify beyond its core area of multiple sclerosis (MS) to others like Alzheimer's. Other noteworthy reports we are featuring today include Biogen (BIIB), 3M (MMM) and Marathon Petroleum (MPC). Click to get this free report Pepsico, Inc. (PEP): Free Stock Analysis Report Marathon Petroleum Corporation (MPC): Free Stock Analysis Report 3M Company (MMM): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Broadcom Limited (AVGO): Free Stock Analysis Report To read this article on Zacks.com click here. New Article For perspective, Biogen 's (NASDAQ: BIIB) Spinraza became the only FDA-approved treatment for SMA in late 2016, and its sales are already tracking at an annualized pace of over $1.2 billion, even though only 40% of patients see an improvement on it. Today, wet-AMD treatment usually involves the use of Novartis ' (NYSE: NVS) or Regeneron Pharmaceuticals ' (NASDAQ: REGN) anti-vascular endothelial growth factor (VEGF) therapies -- Lucentis and Eylea, respectively. RGX-501 uses Regenxbio's AAV8 vector to deliver a functioning LDL-receptor gene into a patients' liver cells, restoring their ability to break down LDL and thus reducing the risk of plaque buildup. New Article Particularly high volume was seen for the $350 strike call option expiring July 20, 2018 , with 867 contracts trading so far today, representing approximately 86,700 underlying shares of BIIB. Below is a chart showing FDX's trailing twelve month trading history, with the $237.50 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 10,620 contracts, representing approximately 1.1 million underlying shares or approximately 48% of BIIB's average daily trading volume over the past month, of 2.2 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $350 strike highlighted in orange: For the various different available expirations for WYNN options , FDX options , or BIIB options , visit StockOptionsChannel.com. New Article Drugmakers' dustbins are filled with failed attempts to slow the progression of Alzheimer's disease, yet drug developers, including Biogen (NASDAQ: BIIB) , remain undaunted in their pursuit of new treatments. Biogen, ticker BIIB, reported encouraging data from an Alzheimer's drug last week. In this episode of Industry Focus: Healthcare , host Kristine Harjes is joined by Fool.com contributor Todd Campbell to discuss the data, the challenges associated with developing Alzheimer's disease drugs, and the impact on Biogen investors.",243.54103088378906
2018-07-16 00:00:00+00:00,348.79998779296875,353.20001220703125,346.1000061035156,353.0299987792969,353.0299987792969,1460100.0,3.0,1.0,0.5000249999999999,"Stocks recently featured in the blog include PepsiCoPEP , Eli Lilly (LLY), BroadcomAVGO , BiogenBIIB and Marathon PetroleumMPC . Click to get this free report Pepsico, Inc. (PEP): Free Stock Analysis Report Broadcom Limited (AVGO): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Marathon Petroleum Corporation (MPC): Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks analyst thinks Lilly's new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo have been driving revenues and the trend is expected to continue in 2018.",240.110595703125
2018-07-18 00:00:00+00:00,353.8099975585937,358.75,350.2799987792969,358.510009765625,358.510009765625,1399800.0,2.5,1.0,0.375025,"In most countries of Europe, Samsung Bioepis' partner Biogen BIIB and Amgen have license to launch their biosimilar versions from Oct 16 this year. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Per the agreement, Mylan will have a license to launch its biosimilar Humira in the United States and in various other countries, excluding Europe, on Jul 31, 2023. New Article While I agree, examples he cites such as Biogen (NASDAQ: BIIB ), Teva (NYSE: TEVA ) and McKesson (NYSE: MCK ) will see much slower profit growth over the next five years. Now, as it moves forward with a new management team, pushes new drugs through testing, and integrates two new companies into the Celgene ecosystem, CELG stock looks well-positioned to recover. The purchase of Impact Biomedicines and Juno Therapeutics, both meant to compensate for the losses associated with Revlimid's patent expiration, has placed a financial strain on CELG stock.",242.80499267578125
2018-07-19 00:00:00+00:00,356.20001220703125,360.2699890136719,356.0400085449219,358.1099853515625,358.1099853515625,1650600.0,2.5,1.0,0.375025,"Biogen Inc.BIIB will report second-quarter 2018results on Jul 24, before market open. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. On the first-quarter call, management had highlighted that overall patient numbers for Spinraza grew in the quarter - a trend we expect to continue. New Article Among the largest underlying components of IBB, in trading today Biogen Inc (Symbol: BIIB) is down about 0.3%, Gilead Sciences Inc (Symbol: GILD) is off about 0.9%, and Amgen Inc (Symbol: AMGN) is lower by about 0.9%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $100.221 per share, with $119.30 as the 52 week high point - that compares with a last trade of $117.55. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",241.2952880859375
2018-07-23 00:00:00+00:00,358.7099914550781,362.2200012207031,355.8800048828125,358.1300048828125,358.1300048828125,1884600.0,3.5,1.0,0.6250249999999999,"Biogen Inc. ( BIIB ) is reporting for the quarter ending June 30, 2018. BIIB missed the consensus earnings per share in the 4th calendar quarter of 2017 by -3.31%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for BIIB is 14.98 vs. an industry ratio of -8.60, implying that they will have a higher earnings growth than their competitors in the same industry. New Article What's in Store for LLY & BIIB? Eli Lilly and Company Price and EPS Surprise Eli Lilly and Company Price and EPS Surprise | Eli Lilly and Company Quote Biogen Inc.BIIB , from the Biomedical and Genetics sub-industry, recorded better-than-expected results in three of the trailing four quarters, with an average positive earnings surprise of 6.25%. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. New Article One of these late-stage candidates has especially attracted attention: Biogen 's (NASDAQ: BIIB) aducanumab. Dave Morgan, a lead representative of the organization and a professor at Michigan State University, said: ""Preparing the healthcare system to accommodate the efficient treatment of millions of Americans when a cure comes online is far from trivial. AC Immune's share price also jumped on the news , because investors saw the small biotech's lead candidate crenezumab as having a similar mechanism of action as BAN2401. New Article Top Stock Trades for Tomorrow #5: Biogen (BIIB) Some people have been wondering about Biogen (NASDAQ: BIIB ). In any regard, BIIB promptly pulled back to about $340. If $340 holds as support, BIIB could be rangebound for a bit.",236.74713134765625
2018-07-24 00:00:00+00:00,380.0,383.0,366.010009765625,372.8399963378906,372.8399963378906,4191700.0,4.0,1.0,0.7500249999999999,"US stocks moved broadly higher going into the midday on Tuesday, with tech and health care stocks leading the gains after strong quarterly earnings from Google-parent Alphabet (GOOG, GOOGL), Biogen ( BIIB ) and other companies. The flash composite Purchasing Managers' Index dropped 0.3% to 55.9 in July after sliding 0.4% points to 56.2 in June. The Richmond Fed manufacturing index dipped to 20 in July after rising five points to 21 in June. New Article Biogen Inc.BIIB reported second-quarter 2018 earnings per share of $5.80, which beat the Zacks Consensus Estimate of $5.22 by 11.1%. Earnings excluded certain one-time payments related to some agreements, which include a new collaboration agreement with Ionis Pharmaceuticals, Inc. IONS , acquisition of schizophrenia candidate, BIIB104, from Pfizer and a license agreement with Bristol-Myers BMY for Alzheimer's disease (""AD"") candidate, BIIB092. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. New Article In today's Morning Movers, we... Getty Images/iStockphoto ...marvel at the strength of earnings so far this quarter; ...wonder if the market finally got to the point where it can't ignore the strong profits any longer; ...highlight strong earnings from Alphabet (GOOGL), Biogen (BIIB), and Lockheed Martin (LMT). Biogen (BIIB) is up 5.6% to $378 after reporting second-quarter earnings. Have we reached the point where the market finally decides it can no longer ignore the strong incoming data despite tariff fears? New Article VIDEO: Nasdaq 100 Movers: HAS, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Tuesday, shares of Biogen ( BIIB ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.5%. And the worst performing Nasdaq 100 component thus far on the day is Hasbro ( HAS ), trading down 3.1%. New Article Cambridge, MA-based Biogen Inc.BIIB holds a strong position in the multiple sclerosis (""MS"") market with a wide range of products including Avonex, Tysabri, Tecfidera and Plegridy. Check back later for our full write up on this BIIB earnings report later! Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. New Article It initially expects to study a combination of its BIIB110 investigational therapy and ALG-802 in multiple neuromuscular indications including patients with spinal muscular atrophy or amyotrophic lateral sclerosis. Among health care stocks moving on news: + Biogen ( BIIB ) jumped to a three-year high on Tuesday, rising to its best share price since July 2015 at $283.00 a share after reporting adjusted Q2 earnings and sales exceeding analyst projections. Also, shares of health care companies in the S&P 500 also were up over 0.7% as a group although the Nasdaq Biotechnology index was slipping nearly 0.3% in recent trading, giving back a nearly 1.3% advance earlier. New Article Hasbro, Inc. ( HAS ) had the largest percent change down (-4.65%) while Biogen Inc. ( BIIB ) had the largest percent change gain rising 4.11%. NASDAQ Market Wrap As of 7/24/2018 4:45:01 PM BILLIONS OF 2.06 NASDAQ SHARES TRADED TODAY 44 STOCKS REACHED A 52 WEEK HIGH 36 THOSE REACHING LOWS TOTALEDBiogen Inc. [BIIB]TOPS ADVANCERS LISTOF NASDAQ 100 INDEX % 4.11 ROSE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The NASDAQ 100 index closed up .47% for the day; a total of 34.47 points. New Article US stocks held on to gains around midday on Tuesday, with tech and health care stocks leading the rally after strong quarterly earnings from Google-parent Alphabet (GOOG, GOOGL), Biogen ( BIIB ) and other companies. The flash composite Purchasing Managers' Index dropped 0.3% to 55.9 in July after sliding 0.4% points to 56.2 in June. (+) FB (+1.7%) Sets up Chinese subsidiary, report says (+) EYEG (+14.7%) FDA OKs 2 pilot studies for co.'s ocular bandage gel (+) BLIN (+29.3%) Launches UK B2C e-commerce website New Article It initially expects to study a combination of its BIIB110 investigational therapy and ALG-802 in multiple neuromuscular indications including patients with spinal muscular atrophy or amyotrophic lateral sclerosis. In other sector news: + Biogen ( BIIB ) jumped to a three-year high on Tuesday, reaching its best share price since July 2015 at $283.00 a share, after reporting adjusted Q2 earnings and sales exceeding analyst projections. Also, shares of health care companies in the S&P 500 also were up almost 0.9% as a group although the Nasdaq Biotechnology index was slipping over 0.1% lower in recent trade, giving back a nearly 1.3% advance earlier today.",237.5959930419922
2018-07-25 00:00:00+00:00,374.1000061035156,388.6700134277344,372.9400024414063,383.8299865722656,383.8299865722656,4686600.0,3.8,1.0,0.7000249999999999,"While the last week was pretty low key for the biotech sector, with a few regulatory updates, the sector is back in focus as bigwig Biogen, Inc. BIIB reported better-than-expected second-quarter results and also upped its guidance. Click to get this free report Agios Pharmaceuticals, Inc. (AGIO): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Reata Pharmaceuticals, Inc. (RETA): Free Stock Analysis Report To read this article on Zacks.com click here. The study achieved statistical significance on key secondary endpoints evaluating Alzheimer's Disease Composite Score and on reduction of amyloid accumulated in the brain as measured using amyloid-PET (positron emission tomography). New Article Biogen (NASDAQ: BIIB) reported solid second-quarter earnings on Tuesday, buoyed by a doubling in sales of its spinal muscular atrophy drug Spinraza, which was developed with Ionis Pharmaceuticals (NASDAQ: IONS) . On the Alzheimer's front, the company disclosed that BAN2401, which is being developed in partnership with Eisai , helped patients taking the drug for 18 months in a phase 2 study. These include an option to acquire a phase 2 compound for acute ischemic stroke called TMS-007, a pair of drugs from AliveGen that may help multiple neuromuscular indications including spinal muscular atrophy, another deal with longtime partner Ionis Pharmaceuticals to develop antisense drugs for neurological diseases, and increasing the ownership in its biosimilar joint venture Samsung Bioepis, to 49.9%. New Article It paid out a total of $589 million in association with a new collaboration agreement with Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ), an option payment to partner Neurimmune and the acquisition of BIIB104 from Pfizer Inc. (NYSE: PFE ). InvestorPlace - Stock Market News, Stock Advice & Trading Tips When shares of Biogen Inc. (NASDAQ: BIIB ) broke out on July 5 following positive trial results for its Alzheimer's drug study, the company needed a strong quarterly report to prevent a post-earnings sell-off. It looks as though the worst is over for BIIB stock. New Article The sectors recently received impetus from encouraging trial results announced by Biogen BIIB . Click to get this free report Illumina, Inc. (ILMN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Xenon Pharmaceuticals Inc. (XENE): Free Stock Analysis Report Vanda Pharmaceuticals Inc. (VNDA): Free Stock Analysis Report Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Pharming Group NV (PHGUF): Free Stock Analysis Report To read this article on Zacks.com click here. Meanwhile, Trump is slated to meet European Commission President Jean-Claude Juncker on Jul 25 to discuss trade issues. New Article Harley-Davidson Inc.'s HOG shares jumped 7.7% after the company reported second-quarter 2018 adjusted earnings per share of $1.45 surpassing the Zacks Consensus Estimate of $1.35 Biogen Inc. BIIB surged 4.1% after the company posted second-quarter 2018 adjusted earnings per share of $5.80 beating the Zacks Consensus Estimate of $5.22 Eli Lilly and Co.'s LLY shares soared 5% after the company reported second-quarter 2018 adjusted earnings per share of $1.50 outpacing the Zacks Consensus Estimate of $1.31 Shares of Whirlpool Corp. WHR plunged 14.5% after the company posted second-quarter 2018 adjusted earnings per share of $3.20 lagging the Zacks Consensus Estimate of $3.63 Want the latest recommendations from Zacks Investment Research? Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Whirlpool Corporation (WHR): Free Stock Analysis Report Harley-Davidson, Inc. (HOG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",243.3106689453125
2018-07-26 00:00:00+00:00,340.5,353.4100036621094,337.0,344.739990234375,344.739990234375,4924000.0,2.333333333333333,1.0,0.3333583333333332,"What happened Shares of the top biotech company Biogen (NASDAQ: BIIB) fell by as much as 12% today on higher than normal volume for the stock. The nuts and bolts version of the story is that the drug's potential clinical benefit in terms of cognitive decline may be due to nothing less than an imbalance in the study's design. So what Specifically, Biogen and Eisai reported that patients in the high dose arm of the study exhibited a slower cognitive decline than those who received a placebo. New Article Intrexon ( XON ) is the component faring the best Thursday, higher by about 4.7% on the day, while Biogen ( BIIB ) is lagging other components of the First Trust NYSE Arca Biotechnology Index Fund ETF, trading lower by about 11.9%. The First Trust NYSE Arca Biotechnology Index Fund ETF ( FBT ) is seeing unusually high volume in afternoon trading Thursday, with over 808,000 shares traded versus three month average volume of about 61,000. Components of that ETF with the highest volume on Thursday were Gilead Sciences ( GILD ), trading down about 1.6% with over 10.0 million shares changing hands so far this session, and Celgene ( CELG ), up about 0.5% on volume of over 6.1 million shares. New Article Combined, BIIB and ABMD make up approximately 2.6% of the underlying holdings of XLV. Within the sector, Biogen Inc (Symbol: BIIB) and ABIOMED, Inc. (Symbol: ABMD) are two of the day's laggards, showing a loss of 11.3% and 9.7%, respectively. One ETF closely tracking Materials stocks is the Materials Select Sector SPDR ETF ( XLB ), which is up 0.6% in midday trading, and down 0.83% on a year-to-date basis.",249.10360717773438
2018-07-27 00:00:00+00:00,346.20001220703125,346.4700012207031,339.1099853515625,340.3999938964844,340.3999938964844,2426100.0,3.5,1.0,0.6250249999999999,"What management had to say CFO James Frates called the second quarter ""strong"" and credited the revenue boost to the combination of ""solid growth of our proprietary commercial products, the continued strength of our royalty and manufacturing business, as well as the receipt of a $50 million payment related to our collaboration with Biogen for BIIB098."" A large collaboration payment from its partnership with Biogen (NASDAQ: BIIB) helped drive total revenue growth of 39%. License revenue from its collaboration with Biogen related to BIIB098 (which was previously called ALKS 8700) was $48.3 million. New Article Among the largest underlying components of IBB, in trading today Biogen Inc (Symbol: BIIB) is off about 1%, Gilead Sciences Inc (Symbol: GILD) is up about 0.2%, and Amgen Inc (Symbol: AMGN) is lower by about 0.1%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $100.221 per share, with $120.06 as the 52 week high point - that compares with a last trade of $116.32. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",256.7933654785156
2018-07-31 00:00:00+00:00,332.1700134277344,338.739990234375,330.8999938964844,334.3699951171875,334.3699951171875,2052700.0,5.0,1.0,1.000025,"Biogen Inc. (NASDAQ: BIIB) has expanded beyond multiple sclerosis (MS) into other key neurological indications. However, Biogen could have a promising prodrug for treating MS on the way in BIIB098, which is in phase 3 clinical testing. Biogen and Eisai announced encouraging results a few weeks ago from a phase 2 study of BAN2401 that showed slowing progression of the disease and a significant reduction of amyloid accumulations in the brain.",256.1087646484375
2018-08-01 00:00:00+00:00,335.8399963378906,344.739990234375,334.3800048828125,344.0599975585937,344.0599975585937,1688400.0,3.0,1.0,0.5000249999999999,"Biogen Announces Results on AD Candidate: Biogen Inc. BIIB and partner Eisai Co., Ltd. announced detailed results from the phase III study (Study 201) on Alzheimer's disease (AD) candidate, BAN2401 an anti-amyloid beta (A) protofibril antibody, at the Alzheimer's Association International Conference (AAIC) 2018. Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Earnings took center stage for the biotech sector this week, with quite a few bigwigs like Gilead Sciences GILD , Amgen AMGN , Vertex Pharmaceuticals VRTX and Celgene CELG coming up with second-quarter results. New Article Factors at Play Ionis earns revenues in the form of upfront, milestone and other payments under its partnerships with leading health care companies like Biogen BIIB . Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Aimmune Therapeutics, Inc. (AIMT): Free Stock Analysis Report Editas Medicine, Inc. (EDIT): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis Report To read this article on Zacks.com click here. Beginning second quarter, the company's R&D revenues will include a certain amortized portion of $500 million technology access fee and equity premium related to its strategic collaboration with Biogen. New Article Combined, ABMD and BIIB make up approximately 2.5% of the underlying holdings of XLV. Within that group, ABIOMED, Inc. (Symbol: ABMD) and Biogen Inc (Symbol: BIIB) are two large stocks leading the way, showing a gain of 2.8% and 2.4%, respectively. One ETF closely tracking Financial stocks is the Financial Select Sector SPDR ETF ( XLF ), which is flat on the day in midday trading, and up 0.91% on a year-to-date basis. New Article Stocks recently featured in the blog include: ComcastCMCSA , United TechnologiesUTX , BiogenBIIB , MondelezMDLZ and ValeroVLO . Click to get this free report Comcast Corporation (CMCSA): Free Stock Analysis Report United Technologies Corporation (UTX): Free Stock Analysis Report Mondelez International, Inc. (MDLZ): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Valero Energy Corporation (VLO): Free Stock Analysis Report To read this article on Zacks.com click here. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.",255.967041015625
2018-08-03 00:00:00+00:00,350.1000061035156,350.57000732421875,342.2699890136719,344.2099914550781,344.2099914550781,1164400.0,3.0,1.0,0.5000249999999999,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $385.00 strike highlighted in red: Considering the fact that the $385.00 strike represents an approximate 11% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the June 2020 expiration. New Article Given the price-earnings ratio in the low teens and the projected high single-digit growth rates of its net income, I believe that BIIB stock is as close to a hold as an equity can get. Moreover, a low price-earnings ratio and an improved but average profit growth level give investors little reason to buy or sell BIIB stock. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen (NASDAQ: BIIB ) stock has come down from its recent high. New Article For Immediate Release Chicago, IL - August 2, 2018 - Stocks in this week's article are Biogen Inc.BIIB , Thermo Fisher Scientific Inc. TMO , HCA Healthcare, Inc.HCA , Gilead Sciences Inc.GILD and QUALCOMM Inc.QCOM . Click to get this free report QUALCOMM Incorporated (QCOM): Free Stock Analysis Report Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report HCA Healthcare, Inc. (HCA): Free Stock Analysis Report To read this article on Zacks.com click here. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.",250.08973693847656
2018-08-06 00:00:00+00:00,343.0400085449219,344.2200012207031,340.3299865722656,341.1700134277344,341.1700134277344,1034200.0,3.333333333333333,1.0,0.5833583333333334,"Among the largest underlying components of IBB, in trading today Gilead Sciences Inc (Symbol: GILD) is down about 0.5%, Biogen Inc (Symbol: BIIB) is off about 0.8%, and Amgen Inc (Symbol: AMGN) is lower by about 0.5%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $100.221 per share, with $120.06 as the 52 week high point - that compares with a last trade of $116.74. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Biogen Inc.BIIB is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. Click to get this free report Fastenal Company (FAST): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report HCA Healthcare, Inc. (HCA): Free Stock Analysis Report KLA-Tencor Corporation (KLAC): Free Stock Analysis Report Robert Half International Inc. (RHI): Free Stock Analysis Report To read this article on Zacks.com click here. Wall Street's bullish wave, which commenced in July, continues in the first week of August despite the presence of trade war concerns and geopolitical conflicts. New Article SEE ALSO: The 10 Best Dividend Stocks of All Time Market value: $69.0 billion Analysts' opinion: 17 strong buy, 1 buy, 7 hold, 0 sell, 0 strong sell It might be time for Biogen ( BIIB , $344.21) to start paying a dividend. A dividend also could help smooth out some of the volatility that BIIB investors have had to deal with. Annual long-term earnings growth is promising, though, at nearly 8% for BIIB, according to Thomson Reuters.",256.5932922363281
2018-08-09 00:00:00+00:00,350.8800048828125,352.25,345.7799987792969,346.8999938964844,346.8999938964844,1322300.0,2.0,1.0,0.250025,"Royalty revenues from the Queen et al. licenses were lower than the year-ago period's yield, mainly due to the extinguishment of Biogen's BIIB U.S. product supply of its multiple sclerosis drug Tysabri. Click to get this free report Illumina, Inc. (ILMN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report PDL BioPharma, Inc. (PDLI): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. This decrease is mainly attributable to the change in PDL's strategy to a pharmaceutical business model and a sharp decline in royalties.",248.68589782714844
2018-08-13 00:00:00+00:00,343.7900085449219,344.3699951171875,339.2200012207031,340.7900085449219,340.7900085449219,1077700.0,3.0,1.0,0.5000249999999999,"Royalties from Biogen (NASDAQ: BIIB) for sales of Spinraza came in at $57 million, more than double the year-ago quarter. In the second quarter, Ionis Pharmaceuticals (NASDAQ: IONS) continued bringing in royalties from its spinal muscular atrophy drug Spinraza. In July, Ionis' marketing partner Akcea Therapeutics (NASDAQ: AKCA) received EU approval for Tegsedi, the brand name for inotersen that treats hereditary transthyretin amyloidosis (ATTR).",247.83836364746094
2018-08-15 00:00:00+00:00,341.0,343.9200134277344,337.3099975585937,340.7200012207031,340.7200012207031,953200.0,3.0,1.0,0.5000249999999999,"AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports AMGN's forecasted earnings growth in 2018 as 10.89%, compared to an industry average of 10.4%. For more information on the declaration, record and payment dates, visit the AMGN Dividend History page.",249.03712463378906
2018-08-16 00:00:00+00:00,342.0799865722656,345.3299865722656,340.4599914550781,342.92999267578125,342.92999267578125,882500.0,4.0,1.0,0.7500249999999999,"Some other top-ranked stocks in the biotech sector are Gilead Sciences GILD , Ligand Pharmaceuticals LGND and Biogen BIIB . Click to get this free report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report To read this article on Zacks.com click here. Vertex Pharmaceuticals IncorporatedVRTX announced FDA approval for its cystic fibrosis drug, Kalydeco (ivacaftor), for expanded use in children aged 12 months to two years. New Article In July, Biogen BIIB announced that treatment of Alzheimer's disease patients with its pipeline candidate, BAN2401, has slowed the progression of the disease. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Pain Therapeutics, Inc.PTIE announced that the National Institutes of Health (NIH) has awarded a clinical research grant of $3.2 million to support a mid-stage study on its lead pipeline candidate, PTI-125, a small molecule being investigated for treating Alzheimer's disease.",245.82321166992188
2018-08-17 00:00:00+00:00,341.0,346.8299865722656,339.1300048828125,345.2200012207031,345.2200012207031,917300.0,3.333333333333333,1.0,0.5833583333333334,"Investors focused on the Medical space have likely heard of Biogen (BIIB), but is the stock performing well in comparison to the rest of its sector peers? Over the past 90 days, the Zacks Consensus Estimate for BIIB's full-year earnings has moved 6.34% higher. BIIB is currently sporting a Zacks Rank of #2 (Buy). New Article Investors focused on the Medical space have likely heard of Biogen (BIIB), but is the stock performing well in comparison to the rest of its sector peers? The Zacks Consensus Estimate for BIIB's full-year earnings has moved 6.34% higher within the past quarter. BIIB is currently sporting a Zacks Rank of #2 (Buy). New Article Some of its industry peers are also solid potential picks, including Bristol-Myers Squibb (BMY), Vertex Pharmaceuticals (VRTX), and Biogen (BIIB), all of which currently have a Zacks Rank of at least #2 and a VGM Score of at least B, making them well-rounded choices. Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. For the current fiscal year, Eli Lilly and is expected to post earnings of $5.43 per share on $24.42 billion in revenues.",246.63153076171875
2018-08-23 00:00:00+00:00,344.9700012207031,344.9700012207031,339.239990234375,341.8900146484375,341.8900146484375,750000.0,2.0,1.0,0.250025,A month has gone by since the last earnings report for Biogen (BIIB). Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Zinbryta generated no revenues in the quarter as the drug was withdrawn from the market in March 2018 due to growing safety concerns and limited commercial adoption.,249.3141326904297
2018-08-24 00:00:00+00:00,343.0299987792969,343.0299987792969,339.7699890136719,342.3299865722656,342.3299865722656,620000.0,2.0,1.0,0.250025,"Especially high volume was seen for the $340 strike put option expiring September 21, 2018 , with 984 contracts trading so far today, representing approximately 98,400 underlying shares of BIIB. Below is a chart showing PYPL's trailing twelve month trading history, with the $90 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 5,704 contracts, representing approximately 570,400 underlying shares or approximately 45.9% of BIIB's average daily trading volume over the past month, of 1.2 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $340 strike highlighted in orange: For the various different available expirations for PVH options , PYPL options , or BIIB options , visit StockOptionsChannel.com.",240.69180297851562
2018-08-27 00:00:00+00:00,343.29998779296875,343.32000732421875,340.4200134277344,342.70001220703125,342.70001220703125,704600.0,2.5,1.0,0.375025,"Biogen (NASDAQ: BIIB ), one of the largest biotech companies in the world, trades at a price-to-sales ratio of about 6, so let's give these earlier-stage companies a conservative price-to-sales ratio of 4. The Time to Buy CRISPR Stocks Is Now Outside of the fact that gene editing is on track to save lives, there is also an exciting investment angle to the technology. Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of FUTR Stocks and the ETF Bulletin. New Article Among the largest underlying components of IBB, in trading today Biogen Inc (Symbol: BIIB) is off about 0.2%, Gilead Sciences Inc (Symbol: GILD) is up about 1.5%, and Celgene Corp (Symbol: CELG) is up by about 1.2%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $100.221 per share, with $120.06 as the 52 week high point - that compares with a last trade of $118.93. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",238.3748779296875
2018-08-29 00:00:00+00:00,347.1600036621094,352.0199890136719,346.1600036621094,349.989990234375,349.989990234375,1291300.0,1.0,1.0,2.4999999999997247e-05,"Spinraza, an Ionis drug that Biogen (NASDAQ: BIIB) launched at the end of 2016, hit an annualized $1.7 billion run rate in the second quarter. Despite the risk of uncontrolled bleeding, an independent advisory committee voted 12-to-8 in favor of approval because the drug effectively lowers triglycerides, which should lead to less organ damage over time. Unfortunately, an experimental gene therapy under development by Novartismight derail the Spinraza gravy train, which would leave Ionis far more reliant on success from some big discovery deals the biotech signed recently.",241.7179718017578
2018-08-30 00:00:00+00:00,350.1499938964844,355.94000244140625,348.3699951171875,352.739990234375,352.739990234375,875900.0,2.0,1.0,0.250025,"VIDEO: Nasdaq 100 Movers: DLTR, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing Nasdaq 100 component thus far on the day is Dollar Tree, trading down 11.0%. Dollar Tree is lower by about 21.6% looking at the year to date performance.",248.104736328125
2018-08-31 00:00:00+00:00,351.260009765625,354.1300048828125,350.0199890136719,353.489990234375,353.489990234375,867200.0,2.0,1.0,0.250025,"Especially high volume was seen for the $327.50 strike put option expiring September 21, 2018 , with 503 contracts trading so far today, representing approximately 50,300 underlying shares of BIIB. Below is a chart showing COOL's trailing twelve month trading history, with the $35 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 5,709 contracts, representing approximately 570,900 underlying shares or approximately 58.6% of BIIB's average daily trading volume over the past month, of 974,360 shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $327.50 strike highlighted in orange: For the various different available expirations for GRUB options , COOL options , or BIIB options , visit StockOptionsChannel.com.",240.7566375732422
2018-09-05 00:00:00+00:00,344.3699951171875,349.42999267578125,342.75,346.6000061035156,346.6000061035156,1039000.0,3.0,1.0,0.5000249999999999,"Biogen Inc.BIIB announced the initiation of phase III study - CHARM - to evaluate its pipeline candidate, BIIB093, for the prevention and treatment of severe cerebral edema in large hemispheric infarction (""LHI""). BIIB093 is an intravenous (""IV"") formulation of glibenclamide. The company believes that BIIB093 has the potential to improve patient outcomes and reduce mortality risk.",239.16014099121094
2018-09-06 00:00:00+00:00,345.44000244140625,346.989990234375,339.6099853515625,341.3399963378906,341.3399963378906,833800.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of PBE, in trading today Illumina Inc (Symbol: ILMN) is up about 1%, Biogen Inc (Symbol: BIIB) is down about 1.1%, and Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is lower by about 1.5%. For a complete list of holdings, visit the PBE Holdings page  The chart below shows the one year price performance of PBE, versus its 200 day moving average: Looking at the chart above, PBE's low point in its 52 week range is $43.08 per share, with $60.49 as the 52 week high point - that compares with a last trade of $59.06. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",238.23780822753906
2018-09-10 00:00:00+00:00,342.69000244140625,342.8500061035156,337.5299987792969,340.25,340.25,1105500.0,3.0,1.0,0.5000249999999999,"Especially high volume was seen for the $350 strike call option expiring September 14, 2018 , with 539 contracts trading so far today, representing approximately 53,900 underlying shares of BIIB. Below is a chart showing JBHT's trailing twelve month trading history, with the $135 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 3,880 contracts, representing approximately 388,000 underlying shares or approximately 42% of BIIB's average daily trading volume over the past month, of 923,745 shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $350 strike highlighted in orange: For the various different available expirations for AKAM options , JBHT options , or BIIB options , visit StockOptionsChannel.com.",237.63809204101562
2018-09-11 00:00:00+00:00,340.6600036621094,341.4800109863281,337.0899963378906,337.70001220703125,337.70001220703125,906700.0,2.5,1.0,0.375025,"Meanwhile, Alkermes is developing a treatment for relapsing forms of multiple sclerosis in collaboration with Biogen BIIB . Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Alkermes plc (ALKS): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The company a study arm to evaluate ALKS 4230 in combination with FDA-approved PD-1 inhibitor, Merck's MRK Keytruda (pembrolizumab) in patients with advanced solid tumors. New Article Acorda has a licensing agreement with Biogen Inc. BIIB for Fampyra in outside U.S markets. Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. In July, the Federal Circuit denied Acorda's plea for a preliminary injunction to avoid at-risk launches prior to the Appeals Court decision.",256.1592712402344
2018-09-12 00:00:00+00:00,337.9599914550781,340.42999267578125,333.0299987792969,340.0299987792969,340.0299987792969,869400.0,2.5,1.0,0.375025,"Below is a twelve month price history chart comparing the stock performance of MNST, TSLA, and BIIB: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of EQWL's underlying holdings with notable upside to their analyst target prices are Monster Beverage Corp (Symbol: MNST), Tesla Inc (Symbol: TSLA), and Biogen Inc (Symbol: BIIB). Similarly, TSLA has 13.04% upside from the recent share price of $279.44 if the average analyst target price of $315.87/share is reached, and analysts on average are expecting BIIB to reach a target price of $375.83/share, which is 11.29% above the recent price of $337.70. New Article GILD is a part of the Health Care sector, which includes companies such as Amgen Inc. ( AMGN ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports GILD's forecasted earnings growth in 2018 as -23.36%, compared to an industry average of 9.3%. For more information on the declaration, record and payment dates, visit the GILD Dividend History page.",258.7406311035156
2018-09-13 00:00:00+00:00,341.04998779296875,342.4100036621094,337.8299865722656,340.5799865722656,340.5799865722656,862300.0,4.0,1.0,0.7500249999999999,"Lets dive right in: Biogen Massachusetts-based Biogen (BIIB) has turned $68.4 billion biotech giant in the last four decades. How much room do BIIB shares have to fly? Notably, Matteis set a 12-month price target on BIIB stock of $394, marking almost 16% upside potential.",260.09503173828125
2018-09-14 00:00:00+00:00,341.32000732421875,342.0599975585937,337.3699951171875,338.67999267578125,338.67999267578125,882000.0,3.0,1.0,0.5000249999999999,"Acorda has a licensing agreement with Biogen Inc. BIIB for Fampyra in the ex U.S. markets. Click to get this free report Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report Mylan N.V. (MYL): Free Stock Analysis Report To read this article on Zacks.com click here. Acorda Therapeutics, Inc.ACOR announced that the FDA has extended time to review its new drug application (NDA), which seeks an approval for its Parkinson's disease candidate Inbrija. New Article Among the largest underlying components of IBB, in trading today Biogen Inc (Symbol: BIIB) is trading flat, Gilead Sciences Inc (Symbol: GILD) is down about 0.1%, and Celgene Corp (Symbol: CELG) is lower by about 0.4%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $100.221 per share, with $122.53 as the 52 week high point - that compares with a last trade of $118.53. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",264.5450744628906
2018-09-17 00:00:00+00:00,338.5599975585937,338.5599975585937,333.5,334.3999938964844,334.3999938964844,944100.0,2.5,1.0,0.375025,"Especially high volume was seen for the $355 strike call option expiring September 21, 2018 , with 1,115 contracts trading so far today, representing approximately 111,500 underlying shares of BIIB. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 4,970 contracts have traded so far, representing approximately 497,000 underlying shares. That amounts to about 55.3% of BIIB's average daily trading volume over the past month of 899,135 shares. New Article Not surprisingly, biotech titans Celgene (NASDAQ: CELG) and Biogen (NASDAQ: BIIB) are among the leaders in this ongoing biopharma revolution. For instance, its flagship cancer franchise -- consisting of the triple threat of Abraxane, Pomalyst and Revlimid -- is on track to rake in a staggering $13.5 billion in revenue this year. Moreover, its emerging anti-inflammatory segment -- headlined by the plaque psoriasis treatment Otezla -- is expected to contribute a healthy $1.5 billion to its total annual revenues in 2018.",265.54339599609375
2018-09-21 00:00:00+00:00,343.1000061035156,345.4100036621094,338.5199890136719,345.4100036621094,345.4100036621094,3874500.0,3.0,1.0,0.5000249999999999,"Stocks recently featured in the blog include Wells Fargo WFC , Schlumberger SLB , Biogen BIIB , American Express AXP and Illinois Tool Works ITW . Click to get this free report Wells Fargo & Company (WFC): Free Stock Analysis Report American Express Company (AXP): Free Stock Analysis Report Illinois Tool Works Inc. (ITW): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Schlumberger Limited (SLB): Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks analyst thinks the crisis related to the revelation of illegally opening millions of accounts in 2016, auto-lending issues and impact of other malpractices will take some time to alleviate. New Article Biotech bigwig Biogen, Inc. BIIB and partner Eisai are evaluating a number of candidates for AD. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Allergan plc (AGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Crenezumab is currently being studied in two phase III, two-year, randomized, double-blind, placebo-controlled, multicenter clinical trials (CREAD 1 and 2) for addressing patients in early AD stage. New Article Top ETF holdings Biogen (NASDAQ: BIIB) , Amgen (NASDAQ: AMGN) , and Gilead Sciences (NASDAQ: GILD) make up a total of roughly 25% of the fund's assets. Political pressures stemming from high-profile price-gouging allegations from certain players in the pharmaceutical industry led to fears that greater regulation would make biotechs much less profitable. Although a typical number of drug approvals and mergers and acquisitions in the industry took place in that time frame, uncertainty still made investors nervous.",270.1253356933594
2018-09-26 00:00:00+00:00,342.20001220703125,353.2099914550781,341.739990234375,349.3699951171875,349.3699951171875,1595600.0,5.0,1.0,1.000025,"Among the largest underlying components of IBB, in trading today Biogen Inc (Symbol: BIIB) is up about 1.4%, Gilead Sciences Inc (Symbol: GILD) is up about 1.2%, and Celgene Corp (Symbol: CELG) is up by about 1.5%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $100.221 per share, with $122.53 as the 52 week high point - that compares with a last trade of $121.37. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",265.0441589355469
2018-09-28 00:00:00+00:00,355.0,357.0,352.42999267578125,353.3099975585937,353.3099975585937,1542900.0,4.0,1.0,0.7500249999999999,"Among the biotech bigwigs, Gilead GILD , Celgene CELG , Vertex VRTX , Biogen BIIB and Amgen beat earnings and revenue estimates. Click to get this free report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report Mesoblast Limited (MESO): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Trevena, Inc. (TRVN): Free Stock Analysis Report To read this article on Zacks.com click here. Outlook We expect the favorable trend in the sector to continue in the rest of the year as the companies carry on their investments in developing pipeline, building global business and driving new product growth.",270.9919128417969
2018-10-02 00:00:00+00:00,353.1400146484375,353.989990234375,344.3999938964844,345.4100036621094,345.4100036621094,1340100.0,2.0,1.0,0.250025,"Particularly high volume was seen for the $345 strike put option expiring October 05, 2018 , with 1,216 contracts trading so far today, representing approximately 121,600 underlying shares of BIIB. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Biogen Inc (Symbol: BIIB), where a total volume of 10,295 contracts has been traded thus far today, a contract volume which is representative of approximately 1.0 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 84.5% of BIIB's average daily trading volume over the past month, of 1.2 million shares.",271.37774658203125
2018-10-04 00:00:00+00:00,350.7799987792969,351.9800109863281,340.6499938964844,343.1000061035156,343.1000061035156,1079200.0,3.0,1.0,0.5000249999999999,"Notably, Biogen's BIIB Spinraza is already approved to treat children and adults with SMA, which reflects the prevailing competition in the market. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. RocheRHHBY announced interim encouraging clinical data from two pivotal studies - FIREFISH and SUNFISH - on pipeline candidate, risdiplam at the 23rd International Annual Congress of the World Muscle Society in Mendoza, Argentina.",263.0810241699219
2018-10-08 00:00:00+00:00,340.6700134277344,345.57000732421875,338.2200012207031,343.0299987792969,343.0299987792969,852400.0,3.0,1.0,0.5000249999999999,"We note that Biogen, Inc. BIIB holds a strong position in the MS market with a wide range of products, including Avonex, Tysabri, Tecfidera and Plegridy. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Siponimod, an experimental oral once-daily selective modulator of specific subtypes of the sphingosine-1-phosphate (S1P) receptor, is being evaluated for the treatment of secondary progressive multiple sclerosis (SPMS) in adults. New Article Investors considering a purchase of Biogen Inc (Symbol: BIIB) stock, but cautious about paying the going market price of $343.46/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to BIIB's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. For other put options contract ideas at the various different available expirations, visit the BIIB Stock Options page of StockOptionsChannel.com.",264.82635498046875
2018-10-10 00:00:00+00:00,342.6400146484375,346.7200012207031,337.5299987792969,337.5299987792969,337.5299987792969,1420200.0,4.0,1.0,0.7500249999999999,"Biogen Presents Data on Spinraza : Biogen BIIB presented encouraging interim results from an ongoing open-label, single-arm efficacy and safety study, NURTURE, on Spinraza in 25 presymptomatic infants with Spinal Muscular Atrophy (SMA). Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report VistaGen Therapeutics, Inc. (VTGN): Free Stock Analysis Report To read this article on Zacks.com click here. Results of the study showed that Otezla 30 mg twice daily achieved a highly statistically significant improvement in the primary endpoint of the Scalp Physician's Global Assessment (ScPGA) response at week 16 compared with placebo. New Article While the MS market holds immense potential, competition is stiff with the likes of Biogen, Inc. BIIB . Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The new data will be presented at the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS), scheduled to be held in Berlin, Germany from Oct 10 to 12.",274.32574462890625
2018-10-11 00:00:00+00:00,338.2300109863281,340.8500061035156,324.4599914550781,327.2699890136719,327.2699890136719,1395700.0,3.0,1.0,0.5000249999999999,"Stocks recently featured in the blog include: AltriaMO , U.S. BancorpUSB , BiogenBIIB , EcolabECL and HSBC HoldingsHSBC . Click to get this free report U.S. Bancorp (USB): Free Stock Analysis Report HSBC Holdings plc (HSBC): Free Stock Analysis Report Ecolab Inc. (ECL): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Altria Group, Inc. (MO): Free Stock Analysis Report To read this article on Zacks.com click here. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. New Article We note that Biogen, Inc. BIIB holds a strong position in the MS market with a wide range of products, including Avonex, Tysabri, Tecfidera and Plegridy. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Novartis AGNVS announced encouraging top-line results from the phase IIIb ASSESS study on multiple sclerosis drug, Gilenya. New Article Rituxan is marketed by Biogen BIIB and Genentech USA, a subsidiary of Roche. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Teva Pharmaceutical Industries LimitedTEVA along with South Korean partner Celltrion Inc. announced that the FDA's Oncologic Drugs Advisory Committee has voted unanimously (16-0) recommending approval of CT-P10, their proposed monoclonal antibody (mAb) biosimilar to Roche's RHHBY Rituxan.",280.318115234375
2018-10-15 00:00:00+00:00,329.9700012207031,332.07000732421875,327.3800048828125,328.4100036621094,328.4100036621094,921000.0,3.5,1.0,0.6250249999999999,"Below is a twelve month price history chart comparing the stock performance of IDXX, BIIB, and VAR: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of RYH's underlying holdings with notable upside to their analyst target prices are Idexx Laboratories, Inc. (Symbol: IDXX), Biogen Inc (Symbol: BIIB), and Varian Medical Systems Inc (Symbol: VAR). Similarly, BIIB has 18.09% upside from the recent share price of $330.94 if the average analyst target price of $390.80/share is reached, and analysts on average are expecting VAR to reach a target price of $124.33/share, which is 18.09% above the recent price of $105.29. New Article Roche RHHBY and Biogen BIIB have multiple pipeline candidates is several stages of development for the treatment of the disease. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Allergan plc (AGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Corium International, Inc. (CORI): Free Stock Analysis Report To read this article on Zacks.com click here. Corium International, Inc. CORI announced that it has entered a definitive merger agreement with a private investment firm, Gurnet Point Capital.",280.3951416015625
2018-10-19 00:00:00+00:00,323.0599975585937,327.1199951171875,318.5199890136719,320.4100036621094,320.4100036621094,1885000.0,3.0,1.0,0.5000249999999999,"Biogen Inc.BIIB will report third-quarter 2018 results on Oct 23, before market open. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Menlo Therapeutics Inc. (MNLO): Free Stock Analysis Report To read this article on Zacks.com click here. Factors to Consider In the second quarter of 2018, performance of Biogen's multiple sclerosis (""MS"") drugs improved compared to the first quarter of the year as patient growth in international markets offset decline in the United States due to competitive pressure from Roche's RHHBY newly launched MS drug, Ocrevus. New Article Two other components making moves today are Biogen ( BIIB ), trading down 1.5%, and DENTSPLY SIRONA ( XRAY ), trading up 6.7% on the day. In early trading on Friday, shares of PayPal Holdings ( PYPL ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 9.3%. Year to date, PayPal Holdings registers a 15.1% gain. New Article BIIB098 (initially known as ALKS 8700) is being developed in collaboration with Biogen Inc. BIIB to treat relapsing forms of multiple sclerosis (MS). Alkermes expects to submit a new drug application (NDA) for BIIB098 to the FDA later in 2018. Alkermes may also receive a $150-million milestone payment from Biogen upon the FDA approval of the NDA for BIIB098, on or before Dec 31, 2021.",267.880615234375
2018-10-22 00:00:00+00:00,322.29998779296875,323.8500061035156,314.1600036621094,315.5400085449219,315.5400085449219,1736300.0,2.5,1.0,0.375025,"Among the largest underlying components of IBB, in trading today Gilead Sciences Inc (Symbol: GILD) is down about 1.2%, Biogen Inc (Symbol: BIIB) is down about 1.3%, and Celgene Corp (Symbol: CELG) is lower by about 2.8%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $100.221 per share, with $122.97 as the 52 week high point - that compares with a last trade of $108.88. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Biogen Inc. ( BIIB ) is reporting for the quarter ending September 30, 2018. BIIB missed the consensus earnings per share in the 4th calendar quarter of 2017 by -3.31%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for BIIB is 12.66 vs. an industry ratio of -10.30, implying that they will have a higher earnings growth than their competitors in the same industry.",255.99224853515625
2018-10-23 00:00:00+00:00,315.0,326.5,311.0,316.1499938964844,316.1499938964844,2414500.0,3.428571428571428,1.0,0.6071678571428573,"Among health care stocks moving on news: (+) Biogen ( BIIB ) was more than 1% higher this afternoon, reversing a more than 1% mid-day decline that followed the genetics drugmaker releasing sharply improved Q3 financial results, including a 17% increase in non-GAAP net income compared with year-ago levels to $7.40 per share and easily beating the $6.76 per share analysts mean. In other sector news: (+) Proteostasis Therapeutics ( PTI ) still was more than 3% higher in late Tuesday trading, easing from a nearly 18% gain that followed the biotechnology company disclosing plans to sell 9 million shares of its common stock. (-) Tetraphase ( TTPH ) was little changed this afternoon, largely recovering from a more than 10% decline that followed the specialty drugmaker publishing positive data from Phase III testing of its Xerava drug candidate in patients suffering from obesity and renal problems and treating complicated intra-abdominal infection. New Article Biogen Inc (NASDAQ: BIIB) Q3 2018 Earnings Conference Call Oct. 23, 2018 , 8:00 a.m. We are building for the depths in neuromuscular diseases, with initiation of a Phase 1 trial of BIIB078, an ASO targeting C9orf72, the most common genetic cause of ALS. And we continue to be optimistic about the potential for BIIB067, targeting SOD1 for ALS. New Article In other sector news: (=) Biogen ( BIIB ) was unchanged after it released Q3 results, with non-GAAP earnings per diluted share rising by 17% year-on-year to $7.40, beating the $6.76 mean from analysts polled by Capital IQ. Early movers include: (-) Proteostasis Therapeutics ( PTI ), which was more than 5% lower after it disclosed plans for a public offering of 9 million shares of its common stock. (+) Tetraphase ( TTPH ) was rising by 4% after reporting data from its phase 3 study supporting the efficacy of Xerava in treating complicated intra-abdominal infection in patients suffering from obesity and renal problems. New Article In trading on Tuesday, shares of Biogen Inc (Symbol: BIIB) crossed below their 200 day moving average of $313.27, changing hands as low as $311.00 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $249.17 per share, with $388.67 as the 52 week high point - that compares with a last trade of $316.49. Click here to find out which 9 other stocks recently crossed below their 200 day moving average  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Cambridge, MA-based Biogen Inc.BIIB holds a strong position in the multiple sclerosis (""MS"") market with a wide range of products including Avonex, Tysabri, Tecfidera and Plegridy. Check back later for our full write up on this BIIB earnings report later! Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Despite the positive Biogen earnings report for the third quarter of 2018, BIIB stock wasn't taking off today. Compare Brokers The post Biogen Earnings: 10 Highlights From BIIB's Q3 appeared first on InvestorPlace . Source: Biogen via YouTube Here are some highlights from the most recent earnings report from Biogen (NASDAQ: BIIB ). New Article Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 44.4% Average next regular session additional gain: 1.5% Over the prior three fiscal years (12 quarters), when shares of BIIB rose in the extended-hours session in reaction to its earnings announcement, history shows that 44.4% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.5%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 50% Average next regular session additional loss: 2% Over that same historical period, when shares of BIIB dropped in the extended-hours in reaction to its earnings announcement, history shows that 50.0% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 2.0% by the following regular session close. Extended-Hours Dollar Volume: $25,411,140 Biogen Idec ( BIIB ) is due to issue its quarterly earnings report in the upcoming extended-hours session.",242.50184631347656
2018-10-24 00:00:00+00:00,315.94000244140625,319.69000244140625,301.0899963378906,302.04998779296875,302.04998779296875,2766800.0,3.25,1.0,0.5625249999999999,"Research and development revenue -- the bulk of which is attributable to its partnership deal with Biogen (NASDAQ: BIIB) -- was $16.3 million. Double-digit sales growth of the company's propriety products helped drive an outsized gain on the bottom line. What management had to say CFO James Frates commented on what drove the company's growth: CEO Richard Pops also updated investors on the company's pipelines and upcoming milestones: Looking forward The continued progress allowed management to favorably increase its guidance for the full-year 2018: Revenue is expected to land between $1.015 billion to $1.045 billion. New Article It was a busy week for the biotech sector as quite a few companies came out with data on key drugs while bigwig Biogen BIIB announced third-quarter results. (See the last biotech stock roundup here: Biotech Stock Roundup: GILD, BIIB Present Data, VTGN Gains on Fast Track Status ). Click to get this free report Sanofi (SNY): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Merrimack Pharmaceuticals, Inc. (MACK): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Biogen (NASDAQ: BIIB) put up solid double-digit revenue growth in the second quarter, with earnings growing even faster. But investors rightfully continue to worry about the future when year-over-year comparisons for its current growth driver, recently launched Spinraza, start to get tougher. Yesterday, Biogen and partner UCB said their drug dapirolizumab pegol failed to show a statistically significant improvement in patients with lupus in a phase 2b study. New Article In trading on Wednesday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 27.8, after changing hands as low as $301.09 per share. A bullish investor could look at BIIB's 27.8 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of BIIB shares: Looking at the chart above, BIIB's low point in its 52 week range is $249.17 per share, with $388.67 as the 52 week high point - that compares with a last trade of $302.05.",246.57565307617188
2018-10-26 00:00:00+00:00,292.8500061035156,304.8999938964844,291.0,300.1700134277344,300.1700134277344,2174300.0,2.0,1.0,0.250025,"Particularly high volume was seen for the $340 strike put option expiring January 18, 2019 , with 1,503 contracts trading so far today, representing approximately 150,300 underlying shares of BIIB. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Biogen Inc (Symbol: BIIB), where a total volume of 11,954 contracts has been traded thus far today, a contract volume which is representative of approximately 1.2 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 83.7% of BIIB's average daily trading volume over the past month, of 1.4 million shares.",245.80178833007812
2018-10-30 00:00:00+00:00,301.9200134277344,306.69000244140625,298.3399963378906,306.2799987792969,306.2799987792969,1482700.0,3.0,1.0,0.5000249999999999,"In August, a label expansion of Imbruvica in combination with Roche/Biogen's BIIB Rituxan for treating Waldenstrm's macroglobulinemia was approved by the FDA. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie's flagship product, Humira, which is approved for several inflammatory indications, continues to witness strong demand trends despite launch of drugs with new mechanisms of action and competition from indirect biosimilars.",236.8686981201172
2018-11-05 00:00:00+00:00,314.17999267578125,318.79998779296875,313.5799865722656,317.1499938964844,317.1499938964844,1020000.0,3.0,1.0,0.5000249999999999,"BIIB stock does not pay a dividend, so the company is choosing to buy back shares and spend in R&D to create long-term value. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen Inc. (NASDAQ: BIIB ) fell alongside the broad market selloff in October, but Biogen stock rallied rebounded when it reported third-quarter results. With BIIB stock price still in value territory at 15 times earnings and 11 times forward earnings, investors should take a closer look at the latest results.",246.01654052734375
2018-11-07 00:00:00+00:00,323.1300048828125,331.8800048828125,322.3999938964844,331.510009765625,331.510009765625,1371500.0,2.0,1.0,0.250025,"Notably, Amgen Inc. AMGN , Biogen Inc. BIIB and Johnson & Johnson JNJ to name a few should breathe a sigh of relief as many of their drugs derive sales growth from price increases. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report Lockheed Martin Corporation (LMT): Free Stock Analysis Report The Boeing Company (BA): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Molina Healthcare, Inc (MOH): Free Stock Analysis Report HCA Healthcare, Inc. (HCA): Free Stock Analysis Report To read this article on Zacks.com click here. This achievement, however, means that the Republicans will no longer control both wings of the Congress, handing Trump's political opponents a stronghold in Washington and that in turn could change the outlook for the 2020 presidential election.",234.96434020996094
2018-11-08 00:00:00+00:00,330.5199890136719,331.4100036621094,325.0,326.0400085449219,326.0400085449219,1088300.0,2.0,1.0,0.250025,"Royalty revenues from the Queen et al. licenses were lower than the year-ago period, mainly due to lower product supplies of Biogen's BIIB multiple sclerosis drug, Tysabri. Click to get this free report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report PDL BioPharma, Inc. (PDLI): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. In September 2018, PDL BioPharma announced that its board of directors approved a new $100 million worth share buyback program of the company's common stock.",235.18788146972656
2018-11-09 00:00:00+00:00,325.7699890136719,326.6300048828125,322.0899963378906,325.20001220703125,325.20001220703125,783000.0,3.0,1.0,0.5000249999999999,"Biogen (BIIB) Source: Biogen via YouTube Biogen Inc. (NASDAQ: BIIB ) reported third-quarter earnings on Oct. 23. And with both pharmaceutical stocks and healthcare plan providers both trading higher the day after the elections, markets may correctly anticipate healthy profits ahead in this sector. Teva also put extra care in providing customers with the best experience, from the moment they are in the physician's office through to the accessing and administrating process for the product.",231.9924774169922
2018-11-12 00:00:00+00:00,324.8999938964844,325.0,317.5599975585937,318.8999938964844,318.8999938964844,954900.0,4.0,1.0,0.7500249999999999,"Royalties from Biogen (NASDAQ: BIIB) for sales of Spinraza more than doubled year over year to $70 million. Lipid-lowering drug Waylivra, which is also to be sold by Akcea Therapeutics, was rejected by the FDA in August, but the companies are discussing with the agency what they need to do to gain approval. It'll also have initial sales of Tegsedi, although investors should be prepared for a slow launch, as some time will be needed to get patients set up on the drug with insurance reimbursement. New Article Among the largest underlying components of IYH, in trading today Biogen Inc (Symbol: BIIB) is off about 0.6%, Danaher Corp (Symbol: DHR) is off about 0.6%, and Express Scripts Holding Co (Symbol: ESRX) is up by about 0.5%. For a complete list of holdings, visit the IYH Holdings page  The chart below shows the one year price performance of IYH, versus its 200 day moving average: Looking at the chart above, IYH's low point in its 52 week range is $166.89 per share, with $204.83 as the 52 week high point - that compares with a last trade of $196.02. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",233.5006866455078
2018-11-14 00:00:00+00:00,321.5599975585937,322.7799987792969,312.989990234375,313.54998779296875,313.54998779296875,1390900.0,3.0,1.0,0.5000249999999999,"AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports AMGN's forecasted earnings growth in 2018 as 13.18%, compared to an industry average of 9.8%. For more information on the declaration, record and payment dates, visit the AMGN Dividend History page.",231.02432250976562
2018-11-21 00:00:00+00:00,319.8900146484375,321.04998779296875,315.2799987792969,315.5599975585937,315.5599975585937,746900.0,2.5,1.0,0.375025,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $320.00 strike highlighted in red: Considering the fact that the $320.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the January 2019 expiration. New Article Looking at individual holdings, Amgen Inc (AMGN) accounts for about 5.71% of total assets, followed by Vertex Pharmaceuticals Inc (VRTX) and Biogen Inc (BIIB). Click to get this free report PWRSH-DYN BIO (PBE): ETF Research Reports ISHARES NDQ BIO (IBB): ETF Research Reports SPDR-SP BIOTECH (XBI): ETF Research Reports Biogen Inc. (BIIB): Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the Invesco Dynamic Biotechnology & Genome ETF (PBE), a passively managed exchange traded fund launched on 06/23/2005.",228.28273010253906
2018-11-29 00:00:00+00:00,329.0599975585937,330.989990234375,324.6000061035156,326.6099853515625,326.6099853515625,821300.0,3.0,1.0,0.5000249999999999,"Rituxan is marketed by Biogen BIIB and Genentech USA, a subsidiary of Roche. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Teva Pharmaceutical Industries Ltd.TEVA and its South-Korean partner Celltrion announced that the FDA has approved their monoclonal antibody (mAb) biosimilar to Roche's RHHBY blockbuster cancer drug, Rituxan (rituximab).",222.39471435546875
2018-12-04 00:00:00+00:00,332.9200134277344,336.29998779296875,321.8299865722656,322.7300109863281,322.7300109863281,1345500.0,3.0,1.0,0.5000249999999999,"Significantly, an approved product for the cure of SMA in the United States is Biogen's BIIB , Spinraza (nusinersen), the first and the only treatment to get an FDA nod in the country for this indication. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Axovant Sciences Ltd. (AXON): Free Stock Analysis Report uniQure N.V. (QURE): Free Stock Analysis Report To read this article on Zacks.com click here. Zolgensma, an investigational gene replacement therapy, is being developed for the treatment of spinal muscular atrophy (SMA), a neurodegenerative disease accounting for the highest genetic cause of death in infants.",226.85084533691406
2018-12-07 00:00:00+00:00,324.6000061035156,326.54998779296875,316.1499938964844,316.7300109863281,316.7300109863281,1172100.0,4.0,1.0,0.7500249999999999,"It showed treatment with the highest dose of BIIB067 over a three-month period led to a statistically significant lowering of SOD1 protein levels in the cerebrospinal fluid and slowing of clinical decline as measured by the ALS Functional Rating Scale-Revised compared with placebo. Biogen Inc.BIIB announced that it has obtained a worldwide license to develop and commercialize Ionis Pharmaceuticals' IONS pipeline candidate, BIIB067 (IONIS-SOD1RX). BIIB067 is an investigational candidate, currently evaluated for the treatment of amyotrophic lateral sclerosis (ALS) patients with superoxide dismutase 1 (SOD1) mutations.",230.84970092773438
2018-12-10 00:00:00+00:00,317.94000244140625,321.1099853515625,310.989990234375,319.44000244140625,319.44000244140625,968100.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of IBB, in trading today Amgen Inc (Symbol: AMGN) is down about 0.4%, Biogen Inc (Symbol: BIIB) is up about 0.1%, and Celgene Corp (Symbol: CELG) is lower by about 2.3%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $100.221 per share, with $122.97 as the 52 week high point - that compares with a last trade of $102.83. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",222.49383544921875
2018-12-11 00:00:00+00:00,323.6400146484375,326.6300048828125,318.3599853515625,319.7900085449219,319.7900085449219,1050100.0,5.0,1.0,1.000025,"BIIB is one of the world's leading biotechnology companies focusing on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders and neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS). Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report To read this article on Zacks.com click here. In addition, in-licensing deals are on the rise with the bigwigs collaborating with smaller and mid-sized players that boast promising mid-to-late stage pipeline candidates or interesting technology.",205.09584045410156
2018-12-12 00:00:00+00:00,324.3399963378906,330.75,319.5400085449219,322.6099853515625,322.6099853515625,1401500.0,3.333333333333333,1.0,0.5833583333333334,"GILD is a part of the Health Care sector, which includes companies such as Amgen Inc. ( AMGN ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports GILD's forecasted earnings growth in 2018 as -24.72%, compared to an industry average of 8.8%. For more information on the declaration, record and payment dates, visit the GILD Dividend History page. New Article It showed that treatment with the highest dose of BIIB067 over a three-month period led to a statistically significant lowering of SOD1 protein levels in cerebrospinal fluid and slowing of clinical decline as measured by the ALS Functional Rating Scale-Revised compared with placebo. Biogen In-Licenses Candidate From Ionis : Biogen Inc. BIIBannounced that it exercised its option to obtain a worldwide license to develop and commercialize Ionis Pharmaceuticals' IONS pipeline candidate, BIIB067 (IONIS-SOD1RX). BIIB067 is an investigational candidate, currently evaluated for the treatment of amyotrophic lateral sclerosis (ALS) patients with superoxide dismutase 1 (SOD1) mutations. New Article Stocks recently featured in the blog include: Gilead Sciences GILD , Alexion Pharmaceuticals ALXN , Regeneron Pharmaceuticals, Inc. REGN and Biogen Inc. BIIB . Click to get this free report ISHARES NDQ BIO (IBB): ETF Research Reports Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. While the once leading portfolio of blockbuster HCV drugs is facing competitive pressure, Gilead's HIV franchise maintains momentum, driven by the continued uptake of Genvoya and Odefsey, and the rapid adoption of Biktarvy.",203.54266357421875
2018-12-13 00:00:00+00:00,323.9700012207031,325.69000244140625,319.0,320.1400146484375,320.1400146484375,1220700.0,3.0,1.0,0.5000249999999999,"It showed that treatment with the highest dose of BIIB067 over a three-month period led to a statistically significant lowering of SOD1 protein levels in cerebrospinal fluid and slowing of clinical decline as measured by the ALS Functional Rating Scale-Revised compared with placebo. Stocks recently featured in the blog include: Gilead Sciences, Inc. GILD , Conatus Pharmaceuticals CNAT , Biogen Inc. BIIB , Ionis Pharmaceuticals IONS and Exelixis, Inc. EXEL . Here are highlights from Wednesday's Analyst Blog: Biotech Stock Roundup: GILD, BIIB & More It was a pretty ho-hum week for the biotech sector with regular pipeline and regulatory updates.",205.6239471435547
2018-12-17 00:00:00+00:00,315.4599914550781,323.92999267578125,310.9700012207031,313.1000061035156,313.1000061035156,1397600.0,4.0,1.0,0.7500249999999999,"Notably, Biogen's BIIB Spinraza is already approved to treat children and adults with SMA, which reflects the prevailing competition in the market. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report PTC Therapeutics, Inc. (PTCT): Free Stock Analysis Report To read this article on Zacks.com click here. The designation is primarily based on results from Part 1 of the pivotal studies FIREFISH and SUNFISH (in children and adults with Type II and III SMA).",219.37149047851562
2018-12-18 00:00:00+00:00,313.8099975585937,313.94000244140625,289.7200012207031,294.75,294.75,2990800.0,3.0,1.0,0.5000249999999999,"ALKS and partner Biogen BIIB announced that they have submitted a new drug application (NDA) to the FDA for diroximel fumarate (BIIB098), a novel oral fumarate being developed for the treatment of relapsing forms of multiple sclerosis (MS). Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Alkermes plc (ALKS): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. The NDA submission was supported by data from EVOLVE-1, a phase III study that evaluated long-term safety in relapsing-remitting MS (RRMS) in about 700 patients dosed with diroximel fumarate. New Article And the worst performing Nasdaq 100 component thus far on the day is Biogen ( BIIB ), trading down 3.4%. VIDEO: Nasdaq 100 Movers: BIIB, NXPI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Tuesday, shares of NXP Semiconductors ( NXPI ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.9%. New Article Particularly high volume was seen for the $325 strike call option expiring December 21, 2018 , with 855 contracts trading so far today, representing approximately 85,500 underlying shares of BIIB. Below is a chart showing BA's trailing twelve month trading history, with the $360 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 7,488 contracts, representing approximately 748,800 underlying shares or approximately 63.5% of BIIB's average daily trading volume over the past month, of 1.2 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $325 strike highlighted in orange: And Brighthouse Financial Inc (Symbol: BHF) options are showing a volume of 10,365 contracts thus far today. New Article Below is a twelve month price history chart comparing the stock performance of AXTA, ST, and BIIB: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of QUS's underlying holdings with notable upside to their analyst target prices are Axalta Coating Systems Ltd (Symbol: AXTA), Sensata Technologies Holding PLC (Symbol: ST), and Biogen Inc (Symbol: BIIB). Similarly, ST has 33.40% upside from the recent share price of $41.98 if the average analyst target price of $56.00/share is reached, and analysts on average are expecting BIIB to reach a target price of $386.16/share, which is 23.33% above the recent price of $313.10. New Article And the worst performing S&P 500 component thus far on the day is Biogen ( BIIB ), trading down 3.2%. VIDEO: S&P 500 Movers: BIIB, BA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Two other components making moves today are Philip Morris International ( PM ), trading down 2.9%, and Darden Restaurants ( DRI ), trading up 4.2% on the day.",216.4508056640625
2018-12-20 00:00:00+00:00,292.489990234375,296.5899963378906,289.6099853515625,292.3299865722656,292.3299865722656,1648100.0,2.0,1.0,0.250025,"By Caroline Humer and John Miller NEW YORK/ZURICH, Dec 20 () - Biogen Inc's Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG's experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its U.S. price and long-term success rates, a preliminary report from an independent U.S. nonprofit organization said on Thursday. Novartis aims to provide a cure with its gene therapy, which is to be called Zolgensma and is expected to receive U.S. approval in the first half of 2019. On that basis, when used in patients with symptomatic Type I SMA, it said the Novartis therapy represents a cost of $240,000 per quality- adjusted life year.",217.91384887695312
2018-12-21 00:00:00+00:00,291.32000732421875,296.239990234375,280.3999938964844,280.6000061035156,280.6000061035156,3070800.0,1.6,1.0,0.150025,"Among the largest underlying components of IBB, in trading today Gilead Sciences Inc (Symbol: GILD) is up about 2.1%, Biogen Inc (Symbol: BIIB) is up about 0.3%, and Celgene Corp (Symbol: CELG) is lower by about 0.5%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $92.95 per share, with $122.97 as the 52 week high point - that compares with a last trade of $94.11. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Ireland is making this claim because Elan Pharma -- which was acquired by Perrigo in 2013 -- only paid a 12.5% tax rate when it sold its multiple sclerosis drug Tysabri to Biogen (NASDAQ: BIIB) . What happened After the company revealed that it might owe a sizable amount in back taxes, shares of Perrigo (NYSE: PRGO) , a maker of consumer goods and over-the-counter pharmaceutical products , dropped 21% as of 10:25 a.m. EST on Friday. That number is awfully close to the company's potential tax liability, which suggests that Wall Street doesn't have a lot of faith in management's ability to sidestep the payment. New Article However, in the EU, Amgen AMGN , Biogen BIIB and Sandoz's biosimilars were launched in October this year, while others like Momenta, Pfizer PFE and Fresenius Kabi will launch their versions as soon as they get EMA's approval. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. The company is seeking approval of upadacitinib for the treatment of adult patients with moderate to severe rheumatoid arthritis (""RA""). New Article (-) Perrigo Company ( PRGO ) shares fell 27% after Irish regulators levied a EUR1.64 billion ($1.9 billion) tax liability on the pharmaceuticals company following its sale of the intellectual property and related assets underlying its Tysabri multiple sclerosis drug to Biogen ( BIIB ) in 2013. Among health care stocks moving on news: (-) Jazz Pharmaceuticals ( JAZZ ) dropped to a nearly two-year low on Friday, sinking almost 10% to its lowest share price since January 2017 at $118.16 a share after the US Food and Drug Administration extended the review period for the company's solriamfetol drug candidate by an extra three months so it can better examine proposed labeling for the experimental nacrolepsy treatment. The gene therapy company was selected to join the Nasdaq Biotechnology Index, effective with the start of trading on Dec. 24. New Article Early movers include: (-) Perrigo Company ( PRGO ), which was down more than 12% after it said it will file an appeal with the Irish Tax Appeals Commission after the Irish Revenue Commissioners sought a EUR1.64 billion ($1.9 billion) tax payment from the company resulting from the sale of a stake in multiple sclerosis drug Tysabri intellectual property and related assets to Biogen ( BIIB ) in 2013. (-) Proteostasis Therapeutics Inc ( PTI ) was sinking by more than 24% after the biotechnology company said that it now expects to report complete efficacy and safety data on cystic fibrosis in the first quarter of 2019. In other sector news: (=) Rocket Pharmaceuticals ( RCKT ), a gene therapy company, has been selected for addition to the Nasdaq Biotechnology Index, effective prior to market open on Dec. 24.",226.3456268310547
2018-12-24 00:00:00+00:00,281.17999267578125,286.75,278.4599914550781,278.5,278.5,997500.0,3.0,1.0,0.5000249999999999,"The notice from the Irish government stated that Elan Pharma is liable to pay the said tax amount related to the sale of Tysabri intellectual property and related assets to Biogen BIIB in 2013. Click to get this free report AtriCure, Inc. (ATRC): Free Stock Analysis Report Perrigo Company plc (PRGO): Free Stock Analysis Report Haemonetics Corporation (HAE): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. However, the Irish revenue department stated in the notice that the sale related to Tysabri should be considered as chargeable gains subject to ahigher tax rate of 33%.",231.485107421875
2018-12-27 00:00:00+00:00,290.19000244140625,294.42999267578125,283.5,294.4100036621094,294.4100036621094,1477600.0,4.0,1.0,0.7500249999999999,"Last week, Perrigo received a notice from the Irish government which held Elan Pharma, a subsidiary of Perrigo, liable to pay the said tax amount related to its sale of Tysabri intellectual property and related assets to Biogen BIIB in 2013. Click to get this free report AtriCure, Inc. (ATRC): Free Stock Analysis Report Perrigo Company plc (PRGO): Free Stock Analysis Report Haemonetics Corporation (HAE): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Perrigo Company plcPRGO rallied 11.5% on Dec 26 as the deadline to appeal against the tax bill of $1.9 billion from Ireland government approaches.",237.57276916503906
2019-01-04 00:00:00+00:00,311.79998779296875,323.6300048828125,309.8999938964844,318.3299865722656,318.3299865722656,1532600.0,4.5,1.0,0.8750249999999999,"(RTTNews.com) - Biogen Inc ( BIIB ) and Skyhawk Therapeutics, Inc. announced a strategic collaboration in which the companies will leverage Skyhawk's SkySTAR technology platform with the goal of discovering small molecule treatments for patients with neurological diseases. The agreement grants Biogen an exclusive license to worldwide intellectual property rights on research-stage therapeutic candidates for the treatment of multiple sclerosis, spinal muscular atrophy and additional neurological disorders. Separately, Biogen and C4 Therapeutics announced a strategic collaboration to investigate the use of C4T's protein degradation platform to discover and develop potential new treatments for neurological conditions, such as Alzheimer's disease and Parkinson's disease. New Article In November 2017, Biogen in-licensed the worldwide commercialization rights to Alkermes' ALKS BIIB098, a novel oral fumarate, which the company claims has a potentially differentiated profile to Tecfidera. Last month, Biogen along with Alkermes submitted a new drug application (NDA) to the FDA for diroximel fumarate (BIIB098), currently being developed for the treatment of relapsing forms of MS. Biogen Inc.BIIB announced that it has enrolled the first patient in a phase IIIb study to evaluate an extended interval dosing (EID) of Tysabri (natalizumab) for treating patients with relapsing multiple sclerosis (MS).",231.26730346679688
2019-01-07 00:00:00+00:00,319.2799987792969,327.260009765625,317.4100036621094,322.3999938964844,322.3999938964844,1316500.0,3.0,1.0,0.5000249999999999,"Biogen Inc.BIIB announced two strategic collaborations to develop potential therapies for Alzheimer's disease, Parkinson's disease and other devastating neurological diseases. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report AC Immune SA (ACIU): Free Stock Analysis Report To read this article on Zacks.com click here. For its research services and the exclusive license to the SkySTAR's platform, Biogen made an upfront payment of $74 million to Skyhawk while the latter will also be entitled to potential future milestones and royalties.",228.1064453125
2019-01-08 00:00:00+00:00,324.5299987792969,325.8999938964844,320.4700012207031,324.44000244140625,324.44000244140625,1008100.0,2.0,1.0,0.250025,"Smaller biotechs that are growing will continue to be acquired by companies such as Biogen ( BIIB , $322.40), the third-largest S&P 500 biotech company by market cap. In the third quarter ended Sept. 30, 2018, BIIB generated $1.7 billion in operating cash flow from $3.4 billion in revenue (65% from MS) and $1.5 billion in non-GAAP net income. BIIB generated $3.7 billion in free cash flow through the first nine months of 2018, giving it the financial chops to withstand any economic downturn.",226.04522705078125
2019-01-09 00:00:00+00:00,325.760009765625,330.70001220703125,324.4599914550781,326.6300048828125,326.6300048828125,1223600.0,3.0,1.0,0.5000249999999999,"SEE ALSO: 20 Expert Market Outlooks for 2019 52-week low/high: $249.17/$388.67 Market value: $65.4 billion P/E ratio: 12 Dividend yield: N/A Biogen ( BIIB , $324.44) has several blockbuster medications on the market for multiple sclerosis and cancer, as well as as a robust pipeline of drugs in clinical trials for neurological and neurodegenerative diseases, including Alzheimer's. The global economy is slowing, a trade war with China still lingers despite negotiations, and the Federal Reserve remains likely to raise short-term interest rates, albeit slowly. Consider Nvidia ( NVDA , $139.83), a leading designer of cutting-edge graphics processing units, which are used in a variety of high-end computer applications, especially for complex gaming software. New Article Biogen Enrols First Patient in MS Study : Biogen BIIB announced that it has enrolled the first patient in a phase IIIb study evaluating the efficacy and safety of extended interval dosing for Tyasbri compared to standard interval dosing (SID) in patients with relapsing multiple sclerosis (MS). Click to get this free report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Loxo Oncology, Inc. (LOXO): Free Stock Analysis Report Sage Therapeutics, Inc. (SAGE): Free Stock Analysis Report To read this article on Zacks.com click here. Moreover, the revised agreement gives Sanofi the right to opt-in to the BCMAxCD3 and MUC16xCD3 bispecific programs, when proof of concept is achieved or when the allocated funding is expended.",234.63185119628906
2019-01-11 00:00:00+00:00,329.3999938964844,333.57000732421875,327.8299865722656,333.2099914550781,333.2099914550781,1317800.0,4.0,1.0,0.7500249999999999,"Biogen (BIIB) Biogen (NASDAQ: BIIB ) was also on the list of price increases for 2019. Now near $330, BIIB bulls are near a make-or-break point. Investors who believe BIIB is attractive - trading at about 12 times forward earnings with expectations to grow sales and earnings 2.5% and 8.5% in 2019, respectively - will want to see it hold above these two marks.",226.88986206054688
2019-01-14 00:00:00+00:00,331.2799987792969,331.5199890136719,327.7200012207031,330.4200134277344,330.4200134277344,952500.0,3.0,1.0,0.5000249999999999,"Let's take a closer look at these top long-term stocks to buy now: Biogen (BIIB) Source: Biogen via YouTube Biogen (NASDAQ: BIIB ) has a dominant position in neuroscience. ""2019 will likely be a big year for BIIB as investors prepare for Aducanumab's Phase 3 data in Alzheimer's, slated to be released at the end of 2019/early 2020. If the trial works, it could send BIIB stock up $100-plus (about $33%) from current levels.",234.53546142578125
2019-01-17 00:00:00+00:00,331.239990234375,339.9599914550781,330.32000732421875,338.3399963378906,338.3399963378906,1004700.0,4.0,1.0,0.7500249999999999,"Biogen (BIIB), which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its nex t quarterly report ?",224.99464416503906
2019-01-24 00:00:00+00:00,336.9100036621094,337.2099914550781,331.9700012207031,332.8699951171875,332.8699951171875,1090900.0,2.0,1.0,0.250025,"Among the largest underlying components of IBB, in trading today Biogen Inc (Symbol: BIIB) is off about 0.6%, Celgene Corp (Symbol: CELG) is trading flat, and Illumina Inc (Symbol: ILMN) is up by about 0.1%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $89.01 per share, with $122.97 as the 52 week high point - that compares with a last trade of $108.05. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",226.59727478027344
2019-01-28 00:00:00+00:00,335.19000244140625,335.8800048828125,326.8399963378906,330.010009765625,330.010009765625,1230500.0,3.5,1.0,0.6250249999999999,"Particularly high volume was seen for the $400 strike call option expiring April 18, 2019 , with 2,387 contracts trading so far today, representing approximately 238,700 underlying shares of BIIB. Below is a chart showing ALGN's trailing twelve month trading history, with the $210 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 6,549 contracts thus far today. That number of contracts represents approximately 654,900 underlying shares, working out to a sizeable 53.8% of BIIB's average daily trading volume over the past month, of 1.2 million shares. New Article Biogen Inc. ( BIIB ) is reporting for the quarter ending December 31, 2018. BIIB missed the consensus earnings per share in the 4th calendar quarter of 2017 by -3.31%. Zacks Investment Research reports that the 2018 Price to Earnings ratio for BIIB is 13.03 vs. an industry ratio of -4.40, implying that they will have a higher earnings growth than their competitors in the same industry.",210.92469787597656
2019-01-29 00:00:00+00:00,327.1400146484375,335.0799865722656,326.010009765625,334.4800109863281,334.4800109863281,1645700.0,3.7000000000000006,1.0,0.675025,"In other sector news: (+) Biogen ( BIIB ) was fractionally higher Tuesday after reporting non-GAAP Q4 net income of $6.99 per share on $3.53 billion in revenue, beating the Capital IQ consensus expecting $6.72 per share on $3.39 billion in revenue for the three months ended Dec. 31. Among health care stocks moving on news: (-) Canopy Growth ( CGC ) slipped Tuesday, falling 6.5%, following a BNN Bloomberg television report in Canada said Alan Gertner, the head of retail sales for the medical marijuana purveyor, has left the company. (-) Allergan ( AGN ) retreated Tuesday, sinking 6%, after issuing financial guidance for the current quarter ending in March trailing analyst expectations. New Article Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $355.00 strike highlighted in red: Considering the fact that the $355.00 strike represents an approximate 6% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the March 2020 expiration. New Article (RTTNews.com) - Biogen Inc. ( BIIB ) reported that its net income attributable to the company for the fourth-quarter was $946.8 million or $4.73 per share, compared to a loss of $297.4 million or $1.40 per share in the prior year. Analysts polled by Thomson Reuters expected the company to report earnings of $6.73 per share. Wall Street currently is looking for fiscal year 2019 earnings of $28.02 per share on annual revenues of $13.65 billion. New Article Jan 29 () - Biogen Inc beat analysts' estimates for fourth-quarter profit and revenue on Tuesday, driven by demand for its muscle disease treatment Spinraza and top-selling multiple sclerosis drug Tecfidera. The company expects full-year adjusted earnings in the range of $28.00 to $29.00 per share. Excluding items, it earned $6.99 per share, above the average analyst estimate of $6.73. New Article Biogen Inc.BIIB reported fourth-quarter 2018 earnings per share of $6.99, which beat the Zacks Consensus Estimate of $6.72. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Johnson & Johnson (JNJ): Get Free Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Zinbryta generated no revenues in the quarter as the drug was withdrawn from the market in March 2018, due to growing safety concerns and limited commercial adoption. New Article Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 50% Average next regular session additional gain: 1.5% Over the prior three fiscal years (12 quarters), when shares of BIIB rose in the extended-hours session in reaction to its earnings announcement, history shows that 50.0% of the time (4 events) the stock posted additional gains in the following regular session by an average of 1.5%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 33.3% Average next regular session additional loss: 2% Over that same historical period, when shares of BIIB dropped in the extended-hours in reaction to its earnings announcement, history shows that 33.3% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 2.0% by the following regular session close. Extended-Hours Dollar Volume: $22,557,701 Biogen Idec ( BIIB ) is due to issue its quarterly earnings report in the upcoming extended-hours session. New Article Jan 29 () - Biogen Inc reported a 6.6 percent rise in fourth-quarter revenue on Tuesday, driven by higher sales of its blockbuster muscle disease treatment Spinraza. Net income attributable to Biogen was $946.8 million, or $4.73 per share, for the three months ended Dec. 31, compared with a net loss of $297.4 million, or $1.40 per share, a year earlier, which included a charge of $1.2 billion related to the U.S. tax overhaul. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Looking at individual holdings, Nike Inc Cl B (NKE) accounts for about 1.10% of total assets, followed by Union Pacific Corp (UNP) and Biogen Inc (BIIB). Click to get this free report Union Pacific Corporation (UNP): Get Free Report iShares Core S&P 500 ETF (IVV): ETF Research Reports SPDR S&P 500 ETF (SPY): ETF Research Reports Biogen Inc. (BIIB): Get Free Report NIKE, Inc. (NKE): Get Free Report To read this article on Zacks.com click here. It has amassed assets over $458.48 M, making it one of the average sized ETFs attempting to match the Large Cap Blend segment of the US equity market. New Article In other sector news: (+) Biogen ( BIIB ) was 1% higher Tuesday after reporting non-GAAP Q4 net income of $6.99 per share on $3.53 billion in revenue, beating the Capital IQ consensus expecting $6.72 per share on $3.39 billion in revenue for the three months ended Dec. 31. US Sen. Patty Murray (D-Wash) Tuesday wrote the medical conglomerate seeking information about allegations the company knew about the presence of asbetos in its talc-based baby powder. (-) Canopy Growth ( CGC ) slipped Tuesday, falling 6.5%, following a BNN Bloomberg television report in Canada that said Alan Gertner, the head of retail sales for the medical marijuana purveyor, has left the company. New Article Jan 29 () - Biogen Inc beat analysts' estimates for fourth-quarter profit and revenue on Tuesday, buoyed by higher sales of its top-selling multiple sclerosis drugs, and forecast full-year profit ahead of Wall Street expectations. ""While the dosing schedule of Spinraza (once every four months) creates potential for irregular quarterly sales, we had estimated continued new patient accrual in international markets,"" William Blair analyst Matt Phipps said in a note. The company said on Tuesday it expects global Spinraza revenue to be relatively stable in the current quarter and sees mid- to high-teen growth in sales for the drug this year.",212.2059783935547
2019-01-30 00:00:00+00:00,326.20001220703125,331.0,321.4200134277344,327.8599853515625,327.8599853515625,2387900.0,3.0,1.0,0.5000249999999999,"Biogen (NASDAQ: BIIB) posted solid fourth-quarter earnings on Tuesday, but lackluster 2019 revenue guidance leaves investors twiddling their thumbs waiting for growth from the next big hit from the biotech's drug pipeline. On the pipeline front, Biogen released promising clinical trial data for Alzheimer's drug BAN2401 with partner Eisai, and for BIIB067 (for a form of familial amyotrophic lateral sclerosis) with Ionis Pharmaceuticals. Nevertheless, the guidance should be enough to hold investors' interest as they wait for the pipeline to develop, with the biggest data release coming from Biogen's lead Alzheimer's drug aducanumab.",211.3065948486328
2019-02-01 00:00:00+00:00,333.75,333.75,326.07000732421875,330.9100036621094,330.9100036621094,1180900.0,3.0,1.0,0.5000249999999999,"In this episode of The Motley Fool's Industry Focus Healthcare , host Shannon Jones is joined by Motley Fool contributor Todd Campbell to discuss: The imminent results for Biogen 's (NASDAQ: BIIB) Alzheimer's disease moonshot; Why European regulators could make this a big year for bluebird bio (NASDAQ: BLUE) ; How targeting the cause of sickle-cell disease could pan out for Global Blood Therapeutics (NASDAQ: GBT) ; A new treatment for peanut allergy is around the corner thanks to Aimmune Therapeutics (NASDAQ: AIMT) ; Vertex Pharmaceuticals ' (NASDAQ: VRTX) big opportunity to significantly boost its addressable market; and The news that could transform Duchenne's muscular dystrophy treatment and send Sarepta Therapeutics ' (NASDAQ: SRPT) revenue soaring. That's ticker symbol BIIB. Anyone who's listened to our show knows from past discussions on Alzheimer's just how hard that is, and what a moonshot it would be if they were able to develop a drug that does, indeed, either slow the progressions of this disease or maybe even, who knows, someday reverse it.",208.51248168945312
2019-02-04 00:00:00+00:00,331.3699951171875,334.1099853515625,326.6099853515625,334.07000732421875,334.07000732421875,990700.0,1.5,1.0,0.125025,"Alkermes is developing ALKS 3831 for schizophrenia and BIIB098 in collaboration with Biogen BIIB for treating multiple sclerosis. In December, an NDA was filed with the FDA for BIIB098. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Alkermes plc (ALKS): Get Free Report Galectin Therapeutics Inc. (GALT): Free Stock Analysis Report To read this article on Zacks.com click here. New Article At Biogen ( BIIB ), a filing with the SEC revealed that on Friday, Director Alexander J. Denner bought 62,800 shares of BIIB, for a cost of $327.59 each, for a total investment of $20.57M. VIDEO: Monday 2/4 Insider Buying Report: BIIB, NRGX The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And at PIMCO Energy and Tactical Credit Opportunities Fund ( NRGX ), there was insider buying on Wednesday, by Mark R. Kiesel who bought 280,000 shares at a cost of $20.00 each, for a total investment of $5.6M.",211.27798461914062
2019-02-07 00:00:00+00:00,323.8999938964844,325.2099914550781,307.0,308.7300109863281,308.7300109863281,2786600.0,2.5,1.0,0.375025,"In trading on Thursday, shares of Biogen Inc (Symbol: BIIB) crossed below their 200 day moving average of $320.33, changing hands as low as $315.66 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $249.17 per share, with $388.67 as the 52 week high point - that compares with a last trade of $315.70. Click here to find out which 9 other stocks recently crossed below their 200 day moving average  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen Inc. ( BIIB ) had the largest percent change down (-7.36%) while Electronic Arts Inc. ( EA ) had the largest percent change gain rising 4.85%. The Dow Jones index closed down -.87% for the day; a total of -220.77 points. The current value is 25,169.53. International Business Machines Corporation ( IBM ) had the largest percent change down (-2.3%) while Walmart Inc. ( WMT ) had the largest percent change gain rising 1.14%.",208.39715576171875
2019-02-08 00:00:00+00:00,307.1099853515625,316.7099914550781,305.45001220703125,315.1199951171875,315.1199951171875,1633700.0,3.0,1.0,0.5000249999999999,"If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Increasing Revenues, Solid Balance Sheet Aid Visa (V) Subscriber Gains, Wireless Initiatives Benefit Charter (CHTR) Biogen (BIIB) Rides on Spinraza and In-Licensing Agreements Featured Reports Growth from New Drugs Helps Roche (RHHBY) Combat Biosimilars Per the Zacks analyst, strong growth of Ocrevus, Perjeta, Tecentriq, Alecensa and Hemlibra has helped Roche offset lower sales due to biosimilar competition in Europe. Today's Research Daily features new research reports on 16 major stocks, including Visa (V), Charter Communications (CHTR) and Biogen (BIIB). (BP): Get Free Report Biogen Inc. (BIIB): Get Free Report BB&T Corporation (BBT): Get Free Report To read this article on Zacks.com click here.",219.86557006835938
2019-02-11 00:00:00+00:00,316.1199951171875,317.8999938964844,314.5400085449219,316.8699951171875,316.8699951171875,1360900.0,4.0,1.0,0.7500249999999999,"Stocks recently featured in the blog include: VisaV , Charter CommunicationsCHTR , BiogenBIIB , BP plcBP and BB&TBBT . Click to get this free report BB&T Corporation (BBT): Get Free Report Charter Communications, Inc. (CHTR): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report BP p.l.c. The Zacks analyst thinks Visa's strategic acquisitions and alliances, technology upgrades and effective marketing have paved the way for long-term growth and consistent increase in revenues.",218.42657470703125
2019-02-13 00:00:00+00:00,321.0,323.6600036621094,319.239990234375,321.5400085449219,321.5400085449219,1136800.0,3.0,1.0,0.5000249999999999,"AMGN is a part of the Health Care sector, which includes companies such as Gilead Sciences, Inc. ( GILD ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports AMGN's forecasted earnings growth in 2019 as -3.27%, compared to an industry average of 9.1%. For more information on the declaration, record and payment dates, visit the AMGN Dividend History page.",224.09405517578125
2019-02-14 00:00:00+00:00,321.0,325.7799987792969,318.57000732421875,324.7099914550781,324.7099914550781,1245900.0,2.5,1.0,0.375025,"In the past few days, biotech giants such as Amgen Inc.AMGN , Gilead SciencesGILD , Biogen Inc.BIIB and Alexion PharmaceuticalsALXN have come up with earnings results, of which some offered downbeat guidance while some failed to top estimates on both lines. Click to get this free report First Trust NYSE Arca Biotechnology Index Fund (FBT): ETF Research Reports iShares Nasdaq Biotechnology ETF (IBB): ETF Research Reports VanEck Vectors Biotech ETF (BBH): ETF Research Reports Biogen Inc. (BIIB): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report To read this article on Zacks.com click here. However, the momentum slackened of late on mixed earnings for the fourth quarter (read: What's Behind the Biotech ETF Rally to Start 2019? New Article It's not a Bristol-Myers Squibb (NYSE: BMY ), Celgene (NASDAQ: CELG ), Biogen (NASDAQ: BIIB ) or another large cap biotech company. Breaking Down VKTX Stock Viking Therapeutics is a self-described ""clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders."" Gilead's Selonsertib liver treatment failed its Phase 3 clinical trial earlier this week , thus giving some hope to VKTX stock.",232.72531127929688
2019-02-15 00:00:00+00:00,328.0899963378906,333.2799987792969,324.7099914550781,332.8699951171875,332.8699951171875,1435700.0,4.0,1.0,0.7500249999999999,"Research and development revenues were $15.6 million, of which $14.4 million was related to the collaboration with Biogen Inc. BIIB for BIIB098. 2019 Outlook The company expects total revenues of $1.14-$1.19 billion, driven by anticipated growth of the company's proprietary products and an expected $150-million milestone payment from Biogen in the fourth quarter, related to the potential FDA approval of diroximel fumarate (BIIB098). Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Alkermes plc (ALKS): Free Stock Analysis Report To read this article on Zacks.com click here.",234.4464111328125
2019-02-19 00:00:00+00:00,330.8299865722656,335.94000244140625,330.8299865722656,333.0,333.0,946800.0,3.0,1.0,0.5000249999999999,"In December, Alkermes and its partner Biogen (NASDAQ: BIIB) filed for Food and Drug Administration (FDA) approval of diroximel fumarate, which Biogen plans to market under the name Vumerity. Sales of opioid and alcohol-dependence drug Vivitrol increased 11% year over year as states including Michigan, Pennsylvania, California, Florida, and Kentucky increase coverage of the drug as a treatment option for patients suffering from substance-use disorder. In January, Alkermes got bad news from the FDA when the agency turned down the marketing application for its depression drug ALKS 5461.",246.1526641845703
2019-02-20 00:00:00+00:00,332.3699951171875,335.29998779296875,331.57000732421875,335.1600036621094,335.1600036621094,859900.0,1.0,1.0,2.4999999999997247e-05,"In the EU, Amgen AMGN , Biogen BIIB and Novartis' NVS generic subsidiary - Sandoz's - biosimilars were unveiled last October. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV announced that the FDA has accepted its new drug application (NDA) for its oral investigational JAK inhibitor, upadacitinib, and also granted a priority review to the same.",251.4696044921875
2019-02-21 00:00:00+00:00,329.9700012207031,331.489990234375,320.3900146484375,321.1700134277344,321.1700134277344,1441200.0,2.0,1.0,0.250025,"Two other components making moves today are Biogen ( BIIB ), trading down 3.4%, and Advanced Micro Devices ( AMD ), trading up 1.2% on the day. In early trading on Thursday, shares of Henry Schein ( HSIC ) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 1.7%. And the worst performing Nasdaq 100 component thus far on the day is NetEase ( NTES ), trading down 5.4%. New Article In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Biogen Inc (Symbol: BIIB) has taken over the #114 spot from Vulcan Materials Co (Symbol: VMC), according to ETF Channel . Below is a chart of Biogen Inc versus Vulcan Materials Co plotting their respective rank within the S&P 500 over time (BIIB plotted in blue; VMC plotted in green): Below is a three month price history chart comparing the stock performance of BIIB vs. VMC: BIIB is currently trading off about 3.7%, while VMC is off about 0.2% midday Thursday. Favorites  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",247.12234497070312
2019-02-22 00:00:00+00:00,321.19000244140625,325.3900146484375,320.42999267578125,325.3299865722656,325.3299865722656,1030000.0,2.0,1.0,0.250025,"By Deena Beasley Feb 22 () - An experimental gene therapy for spinal muscular atrophy (SMA) developed by Novartis AG would be worth up to $900,000, according to an independent U.S. nonprofit organization that reviews the value of drugs and medical treatments. The Boston-based Institute for Clinical and Economic Review (ICER) made the determination using a commonly cited cost-effectiveness threshold that values each ""quality-adjusted life year"" (QALY) gained at $100,000 to $150,000. The company said in an emailed statement on Friday that ""both the rare disease community and various governmental bodies"" suggest that $500,000 per QALY ""is the appropriate standard to protect vulnerable populations and allow access to innovative, transformational therapies.""",258.937744140625
2019-02-25 00:00:00+00:00,327.95001220703125,331.989990234375,326.25,327.4800109863281,327.4800109863281,839000.0,3.5,1.0,0.6250249999999999,"We would like to remind investors that last December, Biogen Inc. BIIB obtained a worldwide license to develop and commercialize Ionis' pipeline candidate, BIIB067 (IONIS-SOD1RX). BIIB067 is an investigational candidate, currently being evaluated for the treatment of amyotrophic lateral sclerosis (ALS) patients with superoxide dismutase 1 (SOD1) mutations. Henceforth, Biogen will bear the entire future costs and expenses incurred for the development and commercialization of BIIB067. New Article Below is a twelve month price history chart comparing the stock performance of AMZN, BIIB, and CAT: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of OEW's underlying holdings with notable upside to their analyst target prices are Amazon.com Inc (Symbol: AMZN), Biogen Inc (Symbol: BIIB), and Caterpillar Inc. (Symbol: CAT). Similarly, BIIB has 17.71% upside from the recent share price of $325.33 if the average analyst target price of $382.96/share is reached, and analysts on average are expecting CAT to reach a target price of $159.07/share, which is 14.70% above the recent price of $138.68.",262.0506896972656
2019-02-26 00:00:00+00:00,327.2300109863281,329.1499938964844,325.1300048828125,327.6199951171875,327.6199951171875,742900.0,3.0,1.0,0.5000249999999999,"Alkermes PlcALKS and partner Biogen Inc.BIIB announced that the FDA has accepted for review the new drug application (NDA) for diroximel fumarate (BIIB098), the novel oral fumarate, which has been developed for the treatment of relapsing forms of multiple sclerosis (MS). Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Alkermes plc (ALKS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. The FDA has set an action date in the fourth quarter of 2019.If approved, Biogen and Alkermes plan to market diroximel fumarate under the brand name Vumerity. New Article Roche (NASDAQOTH: RHHBY) recently agreed to buy Spark Therapeutics (NASDAQ: ONCE) for a whopping 150% premium over its previous day's closing price, and investors want to know which gene therapy stocks could be next to receive a buyout offer from a big pharma with plenty of cash. Takeda might be stretched a bit too far after a record-setting $62 billion merger with Shire last year to make another purchase in the near term, but investors should know that hemophilia treatments were a key attraction that brought the Japanese pharmaceutical giant to the deal table. After showing the FDA some breathtaking early results for an experimental gene therapy called valrox (valoctocogene roxaparvovec) last year, BioMarin began enrolling more patients into a special cohort designed to support an application for accelerated approval.",260.0762939453125
2019-02-27 00:00:00+00:00,326.5299987792969,330.0299987792969,325.510009765625,328.8900146484375,328.8900146484375,598500.0,5.0,1.0,1.000025,"So what Ionis booked $70 million in royalties from Biogen (NASDAQ: BIIB) for sales of the latter's spinal muscular atrophy drug Spinraza. What happened Shares of Ionis Pharmaceuticals (NASDAQ: IONS) are up 14% at 2:03 p.m. EST after the company released fourth-quarter earnings that beat management's expectations. Tegsedi, which Ionis' spinoff, Akcea Therapeutics (NASDAQ: AKCA) , sells for the treatment of polyneuropathy of hereditary transthyretin amyloidosis, added an additional $2 million in revenue.",259.91461181640625
2019-03-04 00:00:00+00:00,335.6000061035156,336.57000732421875,324.44000244140625,327.260009765625,327.260009765625,1046900.0,3.583333333333334,1.0,0.6458583333333333,"Compare Brokers The post NITE, BIIB: Nightstar Therapeutics Stock Soars on Biogen Buy appeared first on InvestorPlace . InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nightstar Therapeutics stock was soaring on Monday following news that Biogen (NASDAQ: BIIB ) is acquiring it. This is a newly-incorporated company and wholly-owned subsidiary of BIIB. New Article Shares of Nightstar Therapeutics plc (NASDAQ: NITE ) shot up 66 percent to $25.18 after the company agreed to be acquired by Biogen Inc (NASDAQ: BIIB ) for $25.50 per share in cash. Top Headline Childrens Place Inc (NASDAQ: PLCE ) reported downbeat results for its fourth quarter and issued weak guidance. Equities Trading UP Ascendis Pharma A/S (NASDAQ: ASND ) shares got a boost, shooting up 60 percent to $111.20 after the company disclosed that its TransCon Growth Hormone trial met its primary endpoint. New Article Shares of Nightstar Therapeutics plc (NASDAQ: NITE ) shot up 66 percent to $25.17 after the company agreed to be acquired by Biogen Inc (NASDAQ: BIIB ) for $25.50 per share in cash. Top Headline Childrens Place Inc (NASDAQ: PLCE ) reported downbeat results for its fourth quarter and issued weak guidance. Equities Trading UP Ascendis Pharma A/S (NASDAQ: ASND ) shares got a boost, shooting up 63 percent to $113.10 after the company disclosed that its TransCon Growth Hormone trial met its primary endpoint. New Article As for individual stocks, Biogen (NASDAQ: BIIB) announced it's buying Nightstar Therapeutics (NASDAQ: NITE) , and Village Farms International (NASDAQ: VFF) is launching an effort to enter the U.S. hemp market. The Dow Jones Industrial Average (DJINDICES: ^DJI) and the S&P 500 (SNPINDEX: ^GSPC) posted modest losses in a low-volume session. The company also has earlier clinical testing underway for a treatment for X-linked retinitis pigmentosa, another rare disease that causes blindness. New Article Per settlements with seven manufacturers including Amgen AMGN , Biogen BIIB , Pfizer PFE and Momenta, Humira biosimilars are expected to be launched in the United States in 2023. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Data from these studies showed that more than half of the patients receiving risankizumab achieved complete skin clearance at one year.AbbVie's application will now be reviewed by the European Commission, which will announce its decision in two months' time. New Article Ionis booked $70 million in royalties from Biogen 's (NASDAQ: BIIB) sales of their spinal muscular atrophy drug Spinraza, up from $52 million in the year-ago quarter. Ionis Pharmaceuticals (NASDAQ: IONS) beat management's expectations in the fourth quarter, as it closed out its third consecutive year of adjusted operating profitability helping the company fund the development of its pipeline. In its first quarter on the market, Tegsedi, which treats the polyneuropathy form of hereditary transthyretin amyloidosis, added another $2 million in revenue. New Article (+) WRE (+5.96%) To be added to S&P SmallCap 600 Index (+) CSII (+9.14%) Named to S&P SmallCap 600 index (+) ( NITE ) (+66.10%) Agreed to be bought by Biogen ( BIIB ) Major market indexes opened the week on a sour note led lower by the Dow Jones Industrial Average as health care and financial stocks tumbled. However, the early positive mood dwindled as economic news in part prompted investors to start selling. New Article Stocks moving on news include: (+) Nightstar Therapeutics ( NITE ), which was surging more than 66% as it agreed to be acquired by a subsidiary of Biogen ( BIIB ) in a transaction valued at $877 million. AMGN: Flat Top health care stocks were advancing pre-market Monday. (+) Ascendis Pharma ( ASND ) was gaining more than 57% in value after the company said results from a late-stage trial demonstrated that its once-weekly TransCon Growth Hormone (hGH) was superior to a daily growth hormone on the primary endpoint of annualized height velocity (AHV) at 52 weeks. New Article March 4 () - Biogen Inc said on Monday it will buy Nightstar Therapeutics Plc for about $800 million in cash as the company looks to tap into a potentially lucrative gene therapy market. Gene therapy, an emerging field of biotechnology, uses specially engineered viruses, or viral vectors, to deliver genetic material into defective cells, in hopes of improving or potentially even curing an inherited condition. ""Nightstar would accelerate our entry into ophthalmology by contributing two mid- to late-stage gene therapy assets."" New Article In other sector news: (+) Nightstar Therapeutics ( NITE ) jumped over 66% on Monday after the clinical-stage biotech company agreed to an $877 million buyout transaction from Biogen ( BIIB ), which will pay $25.50 in cash for each Nightstar share, representing a 68.2% premium over Friday's closing price. (+) Cardiovascular Systems Inc. ( CSII ) was climbing 10.5% after the medical device company was picked to join the S&P SmallCap 600 index next Monday, March 11, replacing Nutrisystem Inc. ( NTRI ), which is being acquired by Tivity Health (TVTY) in a deal expected to close in coming days. (-) Inovio Pharmaceuticals (INO) dropped almost 4% after beginning enrollment for the second round of phase III testing of its VGX-3100 DNA-based immunotherapy to treat cervical dysplasia caused by the human papillomavirus. New Article In other sector news: (+) Nightstar Therapeutics ( NITE ) jumped over 66% higher on Monday after the clinical-stage biotech company agreed to an $877 million buyout transaction from Biogen ( BIIB ), which will pay $25.50 in cash for each Nightstar share, representing a 68.2% premium over Friday's closing price. Among health care stocks moving on news: (+) Cardiovascular Systems Inc. ( CSII ) was climbing 9% after the medical device company was picked to join the S&P SmallCap 600 index next Monday, March 11, replacing Nutrisystem Inc. ( NTRI ), which is being acquired by Tivity Health ( TVTY ) in a deal expected to close in coming days. (-) Inovio Pharmaceuticals (INO) dropped almost 5% after beginning enrollment for the second round of phase III testing of its VGX-3100 DNA-based immunotherapy to treat cervical dysplasia caused by the human papillomavirus. New Article Shares of Nightstar Therapeutics plc (NASDAQ: NITE ) shot up 66 percent to $25.19 after the company agreed to be acquired by Biogen Inc (NASDAQ: BIIB ) for $25.50 per share in cash. Top Headline Childrens Place Inc (NASDAQ: PLCE ) reported downbeat results for its fourth quarter and issued weak guidance. Equities Trading UP Ascendis Pharma A/S (NASDAQ: ASND ) shares got a boost, shooting up 66 percent to $114.88 after the company disclosed that its TransCon Growth Hormone trial met its primary endpoint.",254.6925048828125
2019-03-05 00:00:00+00:00,327.75,330.1199951171875,325.0400085449219,326.8699951171875,326.8699951171875,1020400.0,3.0,1.0,0.5000249999999999,"The Children's Place, Inc.'s PLCE shares tanked 10.3% after the company reported fourth quarter 2018 earnings per share of $1.10, lower than the Zacks Consensus Estimate of $2.11 a share Biogen Inc.'s BIIB shares declined 2.1% after the company announced that it had agreed to purchase Nightstar Therapeutics plc NITE for $25.50 a share Shares of Ascendis Pharma A/S ASND rallied 74% after the company announced that its TransCon Growth Hormone trial had achieved the desired primary end result Shares of Takeda Pharmaceutical Company Limited TAK , rose 5.2% after the company announced that it had entered into a partnership with Lupus Therapeutic Partners to start Phase 1 trial for lupus treatment Want the latest recommendations from Zacks Investment Research? Click to get this free report Ascendis Pharma A/S (ASND): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Children's Place, Inc. (The) (PLCE): Free Stock Analysis Report Nightstar Therapeutics PLC Sponsored ADR (NITE): Free Stock Analysis Report Takeda Pharmaceutical Co. (TAK): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article BiogenBIIB announced that it has entered into an agreement to acquire London based clinical-stage gene-therapy company, Nightstar Therapeutics NITE . Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Spark Therapeutics, Inc. (ONCE): Free Stock Analysis Report Nightstar Therapeutics PLC Sponsored ADR (NITE): Free Stock Analysis Report To read this article on Zacks.com click here. Our Take Biogen holds a strong position in the multiple sclerosis (MS) market, with a wide range of products like Avonex, Tysabri, Tecfidera and Plegridy.",262.6660461425781
2019-03-06 00:00:00+00:00,327.489990234375,328.4100036621094,317.8399963378906,317.9700012207031,317.9700012207031,1007800.0,4.0,1.0,0.7500249999999999,"Shares of Nightstar Therapeutics NITE soared after Biogen BIIB announced an agreement to acquire the former. Click to get this free report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report ImmunoGen, Inc. (IMGN): Free Stock Analysis Report Nightstar Therapeutics PLC Sponsored ADR (NITE): Free Stock Analysis Report To read this article on Zacks.com click here. Celgene Corporation CELG obtained a priority review for its drugs from the FDA while CHMP gave a positive opinion on the label expansion of Regeneron's Dupixent.",272.5723571777344
2019-03-12 00:00:00+00:00,313.0799865722656,315.2799987792969,311.260009765625,312.7200012207031,312.7200012207031,1332200.0,2.0,1.0,0.250025,"A tentative approval will boost Celgene's portfolio but competition is stiff in the MS market with the likes of Biogen BIIB . Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report bluebird bio, Inc. (BLUE): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Celgene CorporationCELG announced that it has submitted a Marketing Authorization Application to the European Medicines Agency (EMA) for pipeline candidate, ozanimod.",265.47930908203125
2019-03-13 00:00:00+00:00,313.1199951171875,321.2200012207031,312.1099853515625,320.5599975585937,320.5599975585937,1107200.0,3.0,1.0,0.5000249999999999,"GILD is a part of the Health Care sector, which includes companies such as Amgen Inc. ( AMGN ) and Biogen Inc. ( BIIB ). Zacks Investment Research reports GILD's forecasted earnings growth in 2019 as 1.3%, compared to an industry average of 6.8%. For more information on the declaration, record and payment dates, visit the GILD Dividend History page. New Article Stocks recently featured in the blog include: Visa V , Honeywell HON , Biogen BIIB , Humana HUM and EOG Resources EOG . Click to get this free report Honeywell International Inc. (HON): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Humana Inc. (HUM): Free Stock Analysis Report EOG Resources, Inc. (EOG): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report To read this article on Zacks.com click here. The Zacks analyst thinks numerous strategic acquisitions and alliances, technology upgrades and effective marketing have paved the way for long-term growth and consistent increase in revenues.",268.54327392578125
2019-03-14 00:00:00+00:00,321.5299987792969,323.54998779296875,318.70001220703125,321.5199890136719,321.5199890136719,1157500.0,5.0,1.0,1.000025,"Among the largest underlying components of IBB, in trading today Celgene Corp (Symbol: CELG) is trading flat, Biogen Inc (Symbol: BIIB) is off about 0.3%, and Gilead Sciences Inc (Symbol: GILD) is lower by about 1%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $89.01 per share, with $122.97 as the 52 week high point - that compares with a last trade of $112.83. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",270.6138916015625
2019-03-15 00:00:00+00:00,321.9599914550781,330.1000061035156,321.9599914550781,329.8699951171875,329.8699951171875,2368100.0,1.0,1.0,2.4999999999997247e-05,"Royalty revenues from the Queen et al. licenses were significantly lower than the year-ago period, mainly due to lower product supplies of Biogen's BIIB multiple sclerosis drug, Tysabri. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report PDL BioPharma, Inc. (PDLI): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Trevena, Inc. (TRVN): Free Stock Analysis Report To read this article on Zacks.com click here. Earlier this month, the authorized generic version of Tekturna (150 mg/300 mg tablets) was launched in the United States.",262.1075439453125
2019-03-21 00:00:00+00:00,230.07000732421875,235.7700042724609,224.6000061035156,226.8800048828125,226.8800048828125,21621700.0,1.8846153846153848,1.0,0.221178846153846,"Biogen Inc (NASDAQ: BIIB) was down, falling around 30 percent to $225.65 after the company said it will discontinue an ongoing Alzheimer's drug study. Shares of Sorrento Therapeutics Inc (NASDAQ: SRNE) shot up 39 percent to $4.84 after the company presented at Oppenheimer's healthcare conference in New York on Wednesday. Micron Technology, Inc. (NASDAQ: MU) shares were also up, gaining 10 percent to $43.96 after the company reported upbeat earnings for its second quarter on Wednesday. New Article One company that's not looking better this morning is biopharma major Biogen BIIB , which is down more than 26% at this hour in early trading. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The Philly Fed survey for March has also come out this morning, with a surprise read to the upside: 13.7, more than double what analysts had been expecting. New Article The biggest loser was Biogen ( BIIB ), which plunged 29% after it and Eisai of Japan said they were discontinuing trials of an Alzheimer's treatment. Shares of semiconductor companies surged after Micron Technology ( MU ) posted earnings that beat expectations after the close Wednesday. (+) SPI (+60.92%) Acquires 1.998 MW of solar projects in Greece (+) PHUN (+54.64%) Narrows 2018 loss after revenue jumps year-on-year New Article In equities, shares of Biogen ( BIIB ) were 27.1% lower pre-bell after the company and its partner Eisai Co. Ltd., said they will discontinue their global phase 3 trials, Engage and Emerge, evaluating aducanumab in Alzheimer's patients. US stock futures dropped Thursday after the Federal Reserve adopted a more dovish tone late Wednesday, saying it will likely keep rates steady for the rest of the year, while comments from the White House surrounding the trade dispute with China also damped sentiment. At 10 am, forecasters see a marginal increase of 0.1% in the index of leading economic indicators for February against January's 0.1% decline. New Article Biogen Inc. ( BIIB ) had the largest percent change down (-29.23%) while Western Digital Corporation ( WDC ) had the largest percent change gain rising 9.77%. The Dow Jones index closed up .84% for the day; a total of 216.84 points. NASDAQ Market Wrap As of 3/21/2019 4:43:59 PM NASDAQ COMPOSITE INDEX th 5 ADVANCES FOR THE CONSECUTIVE DAY 78 STOCKS REACHED A 52 WEEK HIGH 19 THOSE REACHING LOWS TOTALEDWestern Digital Corporation [WDC]TOPS ADVANCERS LISTOF NASDAQ 100 INDEX % 9.77 ROSE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen Inc (NASDAQ: BIIB ) was down, falling around 27 percent to $233.62 after the company said it will discontinue an ongoing Alzheimer's drug study. Superconductor Technologies Inc. (NASDAQ: SCON ) shares were also up, gaining 23 percent to $2.0262 after the company reported better-than-expected Q4 EPS and sales. Equities Trading DOWN Guess?, Inc. (NYSE: GES ) shares dropped 14 percent to $18.89 after the company reported worse-than-expected Q4 EPS results. New Article Biogen Inc (NASDAQ: BIIB ) was down, falling around 30 percent to $225.65 after the company said it will discontinue an ongoing Alzheimer's drug study. Shares of Sorrento Therapeutics Inc (NASDAQ: SRNE ) shot up 39 percent to $4.84 after the company presented at Oppenheimer's healthcare conference in New York on Wednesday. Micron Technology, Inc. (NASDAQ: MU ) shares were also up, gaining 10 percent to $43.96 after the company reported upbea t earnings for its second quarter on Wednesday. New Article In equities, shares of Biogen ( BIIB ) were 27.4% lower pre-bell after the company and its partner Eisai Co. Ltd., said they will discontinue their global phase 3 trials, Engage and Emerge, evaluating aducanumab in Alzheimer's patients. US stocks were set for a downbeat session Thursday after the Federal Reserve adopted a more dovish tone late Wednesday, saying it will likely keep rates steady for the rest of the year, while comments from the White House surrounding the trade dispute with China also damped sentiment. (+) MU (+3%) Q2 earnings, revenue top forecasts (+) SPI (+133%) Acquires 1.998 megawatts of solar projects in Greece (+) NVCN (+17.3%) Secures favorable court ruling in patent dispute with CardiAQ in Germany (+) CAG (+7%) Q3 profit tops Street mark, misses on revenues New Article One company that's not looking better this morning is biopharma major Biogen BIIB , which is down more than 26% at this hour in early trading. Click to get this free report SPDR Dow Jones Industrial Average ETF (DIA): ETF Research Reports SPDR S&P 500 ETF (SPY): ETF Research Reports Invesco QQQ (QQQ): ETF Research Reports Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The Philly Fed survey for March has also come out this morning, with a surprise read to the upside: 13.7, more than double what analysts had been expecting. New Article And the worst performing Nasdaq 100 component thus far on the day is Biogen ( BIIB ), trading down 27.6%. VIDEO: Nasdaq 100 Movers: BIIB, MU The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Two other components making moves today are Twenty-first Century Fox ( TFCFA ), trading down 3.2%, and Western Digital Corp ( WDC ), trading up 5.0% on the day. New Article (-) Biogen ( BIIB ) fell over 29% after saying it was discontinuing phase III testing of its aducanumab drug candidate after an independent study concluded the prospective Alzheimer's treatment was unlikely to meet its primary endpoint. Among health care stocks moving on news: (+) aTyr Pharma ( LIFE ) rallied Thursday, rising nearly 13%, after the bio-therapeutics company announced plans to present data from a successful pilot study of its ATYR-1923 drug candidate as a potential treatment for patients with interstitial lung diseases at an industry conference beginning March 29 in Atlanta. In other sector news: (+) Neovasc ( NVCN ) climbed 1% after saying a German court has dismissed a case filed by Edwards Lifesciences CardiAQ LLC against the Canadian medical device company. New Article In corporate news, shares of Biogen, Inc. ( BIIB ) plunged more than 28%, earlier touching their lowest level since June 2016, as the company, which was the biggest decliner on both S&P and Nasdaq markets, said it decided along with Eisai Co. of Japan to discontinue trials of an Alzheimer's treatment after data showed the studies weren't likely to meet their primary endpoint. In the UK, the British pound slipped toward the $1.300 mark after Prime Minister Theresa May blamed the House of Commons for Brexit chaos in a televised address late Wednesday. (+) SPI (+72.01%) Acquires 1.998 MW of solar projects in Greece (+) PHUN (+33.97%) Narrows 2018 loss after revenue jumps year-on-year (+) AXSM (+14.00%) CFO Nick Pizzie purchases 5,400 shares in two tranches to total ownership to 36,340 New Article As for individual stocks, Biogen (NASDAQ: BIIB) announced the failure of its lead Alzheimer's drug, and Levi Strauss & Co. (NYSE: LEVI) soared after going public today. An independent data monitoring committee conducted a futility analysis and concluded that the trials were unlikely to meet their primary endpoint. Aducanumab was designed to reduce abnormal protein deposits called amyloid plaques in the brains of Alzheimer's patients. New Article Diroximel fumarate/BIIB098 (initially known as ALKS 8700) is being developed in collaboration with Biogen BIIB to treat relapsing forms of multiple sclerosis (MS). Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Alkermes plc (ALKS): Free Stock Analysis Report To read this article on Zacks.com click here. The company has a diversified product portfolio and a promising pipeline of candidates targeting major central nervous system (CNS) disorders, including schizophrenia, depression, addiction and multiple sclerosis. New Article On Thursday, Biogen (NASDAQ: BIIB) announced it is shuttering its high-profile, late-stage aducanumab study. The study's primary endpoint was the demonstration of improvement in cognitive and functional impairment based on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score compared to a placebo. Historically, 99% of the Alzheimer's disease drugs that have entered human clinical studies have ended up in laboratory dustbins rather than on pharmacy shelves. New Article Early movers include: (-) Biogen ( BIIB ), which was down more than 27% after the company and Eisai said they were ending two phase 3 trials of the Alzheimer's treatment aducanumab as an independent study said the drug was unlikely to meet its primary endpoint. AMGN: Flat Top health care stocks were retreating pre-market Thursday. (-) Oragenics ( OGEN ) was dropping more than 30% in value after it priced its previously announced underwritten public offering of 16.7 million shares of common stock, short-term warrants to purchase 8.3 million shares of common stock, and long-term warrants to purchase 8.3 million shares of common stock, at $0.75 per share and accompanying warrants for gross proceeds of $12.5 million. New Article What happened Shares of biotech heavyweight Biogen (NASDAQ: BIIB) are in a tailspin this morning after the company and its partner Eisai (NASDAQOTH: ESALF) reported that they would discontinue two late-stage trials for Alzheimer's disease drug candidate aducanumab. Biogen and Eisai noted in the press release that their decision is based on the recommendation of an independent data-monitoring committee following a futility analysis. The biotech's core multiple sclerosis franchise is in decline , and its top growth driver -- Spinraza -- could face some stiff competition from a rival gene therapy soon. New Article Two questions spring to mind: How can that happen, and, more importantly for traders and investors, is it a reason for existing shareholders to bail and/or does it make BIIB a buy at these levels? That is just what happened this morning with Biogen (BIIB). When the news hit, BIIB lost over twenty five percent in a heartbeat. New Article Wise drug developers say only fools rush in, but Biogen (NASDAQ: BIIB) couldn't help falling in love with early data for experimental Alzheimer's drug aducanumab about four years ago. Even though Biogen raised the drug's list price, sales in the region fell 1%, to $3.3 billion, as pharmacy benefit managers demanded larger rebates to keep it in accessible formulary tiers. Novartis spent $8.7 billion last year to acquire a single-administration gene therapy, Zolgensma, and the Food and Drug Administration (FDA) will probably announce an approval decision in April. New Article Biogen Inc (NASDAQ: BIIB) was down, falling around 29 percent to $227.27 after the company said it will discontinue an ongoing Alzheimer's drug study. Shares of Sorrento Therapeutics Inc (NASDAQ: SRNE) shot up 23 percent to $4.30 after the company presented at Oppenheimer's healthcare conference in New York on Wednesday. Superconductor Technologies Inc. (NASDAQ: SCON) shares were also up, gaining 35 percent to $2.25 after the company reported better-than-expected Q4 EPS and sales. New Article Biogen Inc (NASDAQ: BIIB) was down, falling around 27 percent to $233.62 after the company said it will discontinue an ongoing Alzheimer's drug study. Superconductor Technologies Inc. (NASDAQ: SCON) shares were also up, gaining 23 percent to $2.0262 after the company reported better-than-expected Q4 EPS and sales. Equities Trading DOWN Guess?, Inc. (NYSE: GES) shares dropped 14 percent to $18.89 after the company reported worse-than-expected Q4 EPS results. New Article Biogen (NASDAQ: BIIB) and its partner, Japanese drugmaker Eisai , announced that they would halt two late-stage clinical studies evaluating aducanumab in treating Alzheimer's disease. Another MS treatment, BIIB098, could win FDA approval by late 2019, but it could also cannibalize sales of Tecfidera. The stunning setback for the biotech's most promising pipeline candidate left investors with a key question: What's next for Biogen after its Alzheimer's disease drug flop? New Article In trading on Thursday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 17.7, after changing hands as low as $226.61 per share. A bullish investor could look at BIIB's 17.7 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of BIIB shares: Looking at the chart above, BIIB's low point in its 52 week range is $226.61 per share, with $388.67 as the 52 week high point - that compares with a last trade of $228.63. New Article Biogen Inc (NASDAQ: BIIB ) was down, falling around 29 percent to $227.27 after the company said it will discontinue an ongoing Alzheimer's drug study. Shares of Sorrento Therapeutics Inc (NASDAQ: SRNE ) shot up 23 percent to $4.30 after the company presented at Oppenheimer's healthcare conference in New York on Wednesday. Superconductor Technologies Inc. (NASDAQ: SCON ) shares were also up, gaining 35 percent to $2.25 after the company reported better-than-expected Q4 EPS and sales. New Article One company that's not looking better this morning is biopharma major Biogen BIIB , which is down more than 26% at this hour in early trading. Click to get this free report SPDR Dow Jones Industrial Average ETF (DIA): ETF Research Reports SPDR S&P 500 ETF (SPY): ETF Research Reports Invesco QQQ (QQQ): ETF Research Reports Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The Philly Fed survey for March has also come out this morning, with a surprise read to the upside: 13.7, more than double what analysts had been expecting. New Article Biogen (NASDAQ: BIIB) was sharply lower on bad news regarding what had been a promising candidate treatment, but Micron Technology (NASDAQ: MU) moved higher following the release of its most recent financial results. The stock market moved higher Thursday morning, spurred by optimism that the U.S. economy will continue to expand even amid global pressures and ongoing worries about trade. At first glance, the results weren't pretty, with revenue plunging more than 20% and adjusted net income dropping an even steeper 44% compared to the same period a year ago.",254.91297912597656
2019-03-22 00:00:00+00:00,225.1000061035156,226.8000030517578,216.4900054931641,216.7100067138672,216.7100067138672,8490900.0,1.8,1.0,0.200025,"In terms of the other Nasdaq-listed companies that were recognized on the list this year, Biogen Inc. (Nasdaq: BIIB) has committed to a 35% reduction in emissions across its entire supply chain. CSR would not adequately cover supply chain oversight (SCO), which is the process whereby a large multinational drives better, more responsible and transparent practices at all of the companies in their supplier universe and is essential, for instance, to Microsoft's sustainability leadership. But we are probably best known for our advocacy on a global stage, within the exchange and financial markets community: researching ESG performance measures, representing corporate interests with the largest sustainability reporting frameworks, and advocating for more voluntary disclosure. New Article Biogen BIIB and its Japan-based partner Eisai announced the discontinuation of two late-stage studies evaluating their Alzheimer's disease candidate, aducanumab. Biogen is also evaluating BIIB092 in a phase II study for Alzheimer's disease. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. New Article Source: Shutterstock The massive drop was truly an unsettling surprise for BIIB shareholders as the drug was seen as a multi-billion blockbuster and game-changing medication for treating the disease. Disclosure: At the time of writing, Aaron Levittheld a long positionin the iShares NASDAQ Biotechnology Index ( IBB ) -which holds GILD, BIIB and AMGN. For investors in Biogen (NASDAQ: BIIB ) - and more importantly millions of Alzheimer's patients around the world - yesterday was a down day. New Article Biogen Inc.'s BIIB shares dipped 29.2% after the company announced that it had decided to discontinue the late-stage trials for an Alzheimer's treatment Conagra Brands, Inc.'s CAG shares rallied 12.8% after the company reported fiscal third quarter 2019 earnings per share of $0.51, surpassing the Zacks Consensus Estimate o f earnings of $0.48 Shares of Darden Restaurants, Inc. DRI surged 6.9% after the company reported fiscal third quarter 2019 earnings per share of $1.80, higher the Zacks Consensus Estimate of earnings of $1.75 a share Shares of Williams-Sonoma, Inc. WSM rallied 4.2% after the company announced fourth quarter 2018 earnings per share of $2.10, surpassing the Zacks Consensus Estimate of $1.97 a share Want the latest recommendations from Zacks Investment Research? Click to get this free report Conagra Brands Inc. (CAG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Darden Restaurants, Inc. (DRI): Free Stock Analysis Report Williams-Sonoma, Inc. (WSM): Free Stock Analysis Report To read this article on Zacks.com click here. Today, you can download 7 Best Stocks for the Next 30 Days. New Article The Company offers denims from brands, such as Miss Me, Rock Revival, Big Star Vintage, Buffalo Jeans, KanCan, Flying Monkey and Levi's. Its other brands include Hurley, Billabong, Affliction, American Fighter, Fast & Furious, Oakley, Fox, Puma, Obey, RVCA, Salvage, 7 Diamonds, Nixon, Amuse Society, Free People, White Crow, Corral, Reef, Kustom, Timberland, UGG, TOMS, SAXX, Stance, Lokai, Ray-Ban, and Fossil. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig.",246.66668701171875
2019-03-25 00:00:00+00:00,220.0200042724609,221.8800048828125,216.1199951171875,220.259994506836,220.259994506836,5968600.0,2.0,1.0,0.250025,"They selected Biogen (NASDAQ: BIIB) , CVS Health (NYSE: CVS) , and Intuitive Surgical (NASDAQ: ISRG) . The company's core multiple sclerosis franchise is headed in the wrong direction, and its closely watched Alzheimer's disease drug, aducanumab, just flamed out in a pair of late-stage studies . Keeping with this theme, Biogen's recent acquisition of the gene therapy company Nightstar Therapeutics for its late-stage choroideremia candidate, NSR-REP1, also isn't expected to move the needle from a top-line perspective anytime soon. New Article Particularly high volume was seen for the $225 strike call option expiring March 29, 2019 , with 560 contracts trading so far today, representing approximately 56,000 underlying shares of BIIB. Below is a chart showing NWSA's trailing twelve month trading history, with the $13 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 15,185 contracts thus far today. That number of contracts represents approximately 1.5 million underlying shares, working out to a sizeable 60.4% of BIIB's average daily trading volume over the past month, of 2.5 million shares. New Article Year to date, O'Reilly Automotive registers a 11.3% gain. And the worst performing Nasdaq 100 component thus far on the day is Tesla, trading down 3.2%. VIDEO: Nasdaq 100 Movers: TSLA, ORLY The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article When Biogen (NASDAQ: BIIB) and Eisai announced their decision to pull the plug on a late-stage trial for aducanumab in treating Alzheimer's disease , it was just the latest in a long string of failures for experimental treatments targeting the neurodegenerative disease. A lesser-known hypothesis about the pathology of Alzheimer's disease hasn't received much attention from investors or biopharmaceutical companies, but it may emerge as the next logical step on the path to developing successful therapies. Koninklijke Philips N.V. (NYSE: PHG) , commonly called Phillips in the U.S. might be the biggest catch for biopharmaceutical companies eager to develop a successful Alzheimer's treatment that includes improving sleep quality.",237.4228973388672
2019-03-26 00:00:00+00:00,221.88999938964844,233.759994506836,221.57000732421875,232.9100036621093,232.9100036621093,6808300.0,3.0,1.0,0.5000249999999999,"A tentative approval will boost Celgene's portfolio, but competition is stiff in the MS market from the likes of Biogen BIIB . Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report bluebird bio, Inc. (BLUE): Free Stock Analysis Report To read this article on Zacks.com click here. Celgene CorporationCELG announced that it has submitted a New Drug Application (NDA) to the FDA for multiple sclerosis (MS) candidate, ozanimod. New Article Viacom (NASDAQ: VIA) (NASDAQ: VIAB) , Ferroglobe (NASDAQ: GSM) , and Biogen (NASDAQ: BIIB) were among the top performers. The two companies have been no strangers to past merger speculation , but even without guarantees that any deal will eventually get done, Viacom shareholders seem pleased at the idea. Ferroglobe apparently wasn't actively looking to sell the hydroelectric assets, but it has gotten expressions of interest from other parties even after regional regulators failed to approve a past offer for their sale. New Article Per settlements with a set of seven manufacturers including Amgen AMGN , Biogen BIIB , Pfizer PFE , Momenta among others, Humira biosimilars are expected to be launched across the United States in 2023. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. Following this nod, Japan became the first country to approve Skyrizi for patients suffering psoriatic disease and failing to show an adequate response to the conventional therapies. New Article The current value is 7,351.15. lululemon athletica inc. ( LULU ) had the largest percent change down (-2.06%) while Biogen Inc. ( BIIB ) had the largest percent change gain rising 5.74%. NASDAQ Market Wrap As of 3/26/2019 4:44:00 PM BILLIONS OF 2.57 NASDAQ SHARES TRADED TODAY 34 STOCKS REACHED A 52 WEEK HIGH 18 THOSE REACHING LOWS TOTALEDBiogen Inc. [BIIB]TOPS ADVANCERS LISTOF NASDAQ 100 INDEX % 5.74 ROSE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The Dow Jones index closed up .55% for the day; a total of 140.9 points. New Article Biogen 's (NASDAQ: BIIB) biggest trial bombs, and the stock tanks along with it. In this episode of Motley Fool Money , host Chris Hill and analysts Emily Flippen, Jim Mueller, and Jason Moser hit on some of the biggest recent news in the market. Hill: Shares of Papa John's had fallen 40% in the past two years, but the stock moved higher on Friday when the company announced its newest member of the board of directors: Shaquille O'Neal!",247.5906524658203
2019-03-27 00:00:00+00:00,232.94000244140625,237.7700042724609,227.0800018310547,229.9499969482422,229.9499969482422,4041500.0,5.0,1.0,1.000025,"We note that Biogen, Inc. BIIB holds a strong position in the MS market, with a wide range of products, including Avonex, Tysabri, Tecfidera and Plegridy. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report To read this article on Zacks.com click here. Swiss pharma giant Novartis AGNVS announced that the FDA has approved pipeline candidate Mayzent (siponimod), a next generation, selective sphingosine 1-phosphate receptor modulator, for the treatment of adults with relapsing forms of multiple sclerosis (MS).",233.05282592773438
2019-03-28 00:00:00+00:00,230.97999572753903,236.27999877929688,230.1100006103516,232.82000732421875,232.82000732421875,2856400.0,2.0,1.0,0.250025,"Although BIIB has traded at a recent price of $229.95/share, the average analyst target is 27.92% higher at $294.16/share. Below is a twelve month price history chart comparing the stock performance of BIIB, UNH, and ALLY: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of DIVB's underlying holdings with notable upside to their analyst target prices are Biogen Inc (Symbol: BIIB), UnitedHealth Group Inc (Symbol: UNH), and Ally Financial Inc (Symbol: ALLY). New Article In this segment from Motley Fool Money, host Chris Hill and senior analyst Jim Mueller talk about the disappointing news that Biogen (NASDAQ: BIIB) has pulled the plug on its trials for aducanumab, which targets amyloid plaque, as well as where drug developers might look next, and whether the company's shares are a buy after their steep pullback. Chris Hill: Shares of Biogen fell more than 30% this week after the company ended the trial for an Alzheimer's drug that it was developing. Jim, this is still a $43 billion company, but this was a gut-punch, not just for shareholders but for the patients and families who are dealing with Alzheimer's and were hoping for some type of treatment. New Article Biogen's (NASDAQ: BIIB) bid to reshape Alzheimer's disease treatment was delivered a big blow last week when it decided to bail on its once-promising Alzheimer's drug aducanumab. Todd, let's kick things off with the story that everybody's talking about, and that is none other than Biogen, BIIB. Aducanumab's failure raises big questions about Biogen's future, particularly since sales for its multiple sclerosis drugs are slipping and its treatment for spinal muscular atrophy (SMA), Spinraza, could face stiff competition soon.",231.59478759765625
2019-04-01 00:00:00+00:00,239.07000732421875,239.4600067138672,232.22000122070312,232.4900054931641,232.4900054931641,3504200.0,4.0,1.0,0.7500249999999999,"Another leading biotech, Biogen BIIB announced that it will acquire Nightstar Therapeutics. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Roche Holding AG (RHHBY): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. The CHMP recommended approval of the triplet regimen of Revlimid as combination therapy with Velcade and dexamethasone (RVd) for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.",233.7304229736328
2019-04-02 00:00:00+00:00,232.3500061035156,237.5500030517578,232.3500061035156,233.2700042724609,233.2700042724609,3337100.0,2.0,1.0,0.250025,"At this stage, the Health Care Select Sector SPDR Fund (NYSEARCA:) best represents the opportunity at hand. Mistakes happen and sometimes they have tragic consequences but the real problems are when the companies do evil things and this is not the case. Meanwhile, it is imperative that the bulls maintain footing below, so they need to hold $79 per share, or else they risk losing the momentum that they so desperately need to breach the band of resistance.",243.25001525878906
2019-04-03 00:00:00+00:00,235.0,235.0,228.5,231.3999938964844,231.3999938964844,3937400.0,5.0,1.0,1.000025,"So what We can attribute Nightstar Therapeutics stock's stellar performance last month to a buyout offer from biotech giant Biogen (NASDAQ: BIIB). What happened Shares of Nightstar Therapeutics (NASDAQ: NITE), a U.K-based clinical-stage gene therapy company, soared 71.2% in March, according to data from S&P Global Market Intelligence. This big premium makes sense when one considers that ""Nightstar's late-stage gene therapy NSR-REP1 for choroideremia (a rare, retinal disorder that has no available treatments) is expected to generate over $700 million in annual peak sales, if approved,"" according to my colleague George Budwell.",235.8839569091797
2019-04-04 00:00:00+00:00,231.3999938964844,236.8000030517578,231.0399932861328,235.0399932861328,235.0399932861328,2629700.0,2.5,1.0,0.375025,"Biogen 's (NASDAQ: BIIB) disclosure that aducanumab doesn't appear to help patients with Alzheimer's disease is a major blow to the big biotech's future growth, especially since its pipeline is fairly limited . IONIS-SOD1Rx, which Biogen calls BIIB067, is arguably the most promising of the group; its interim phase 1 data shows that the drug can lower the level of SOD1 protein, which potentiates an inherited form of amyotrophic lateral sclerosis (ALS). The companies also have an Alzheimer's disease drug IONIS-MAPTRx (BIIB080) in development. New Article What happened Shares of Biogen (NASDAQ: BIIB) shed 29.2% of their value last month, according to data from S&P Global Market Intelligence. Biogen stock cratered in response to the news that its closely watched Alzheimer's disease drug candidate, aducanumab, was destined to miss its primary endpoints in two ongoing late-stage trials, according to a futility analysis performed by an independent data-monitoring committee. Even though Alzheimer's disease has been a graveyard for experimental medications for the better part of the past two decades, the biotech's management decided against a bolt-on acquisition in the buildup to this readout. New Article Among the largest underlying components of MGK, in trading today Biogen Inc (Symbol: BIIB) is up about 1.1%, Colgate-Palmolive Co. (Symbol: CL) is off about 0.3%, and The Charles Schwab Corporation (Symbol: SCHW) is higher by about 0.2%. For a complete list of holdings, visit the MGK Holdings page  The chart below shows the one year price performance of MGK, versus its 200 day moving average: Looking at the chart above, MGK's low point in its 52 week range is $99.508 per share, with $129.38 as the 52 week high point  that compares with a last trade of $126.32. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Biogen's (NASDAQ: BIIB) disclosure that aducanumab doesn't appear to help patients with Alzheimer's disease is a major blow to the big biotech's future growth, especially since its pipeline is fairly limited. IONIS-SOD1Rx, which Biogen calls BIIB067, is arguably the most promising of the group; its interim phase 1 data shows that the drug can lower the level of SOD1 protein, which potentiates an inherited form of amyotrophic lateral sclerosis (ALS). The companies also have an Alzheimer's disease drug IONIS-MAPTRx (BIIB080) in development.",238.448974609375
2019-04-11 00:00:00+00:00,240.5200042724609,240.75,231.0500030517578,233.8300018310547,233.8300018310547,2875600.0,3.0,1.0,0.5000249999999999,"Especially high volume was seen for the $340 strike put option expiring January 17, 2020 , with 2,000 contracts trading so far today, representing approximately 200,000 underlying shares of BIIB. Below is a chart showing UNM's trailing twelve month trading history, with the $40 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 20,294 contracts thus far today. That number of contracts represents approximately 2.0 million underlying shares, working out to a sizeable 49.7% of BIIB's average daily trading volume over the past month, of 4.1 million shares. New Article The group as a whole has a backdrop of unstable financials, FDA approvals, the next drug trial finally being the big one or keeping larger competitors such as a Biogen (NASDAQ:) or Merck (NYSE:) at bay. But for now, this $7.2 billion market cap stock with its attractive forward P/E of 17.6, 0.5 PEG ratio and priced at 8.5x sales with the success of Cabometyx and sports a solid development pipeline which may just yet, make Exelixis a household name. After a successful corrective challenge of prior lateral resistance and 62% retracement level from EXEL stocks 2015 low to 2018 cycle high last October, shares have been trending higher in the right side of a cup-shaped weekly base. New Article Especially high volume was seen for the $340 strike put option expiring January 17, 2020, with 2,000 contracts trading so far today, representing approximately 200,000 underlying shares of BIIB. Below is a chart showing UNM's trailing twelve month trading history, with the $40 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 20,294 contracts thus far today. That number of contracts represents approximately 2.0 million underlying shares, working out to a sizeable 49.7% of BIIB's average daily trading volume over the past month, of 4.1 million shares.",247.11354064941406
2019-04-12 00:00:00+00:00,235.0,236.7899932861328,233.6100006103516,234.5,234.5,2001800.0,3.0,1.0,0.5000249999999999,"The company has already hired an investment banker to assist with the process, according to a Bloomberg report, while a Jefferies analyst last month identified Biogen ( BIIB ) as a likely suitor for Biohaven after pulling the plug on its aducanumab drug candidate after the prospective Alzheimer's medication failed to outperform a placebo in breaking down beta amyloid plaques during phase III testing. Among health care stocks moving on news: (+) Biohaven Pharmaceutical ( BHVN ) was almost 20% higher late in Friday trading amid market speculation the biotechnology company is exploring a potential sale after recently attracting takeover interest. (-) TRACON Pharmaceuticals ( TCON ) tumbled nearly 50% after scrapping phase III testing of a combination of its TRC105 drug candidate and a previously approved chemotherapy, Votrient, in patients with advanced or metastatic cancer of the inner lining of their blood vessels due to futility as determined by its Independent Data Monitoring Committee.",264.67626953125
2019-04-16 00:00:00+00:00,232.1699981689453,233.44000244140625,227.4199981689453,228.72000122070312,228.72000122070312,2425000.0,2.0,1.0,0.250025,"In trading on Tuesday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $229.60 per share. A bullish investor could look at BIIB's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of BIIB shares: Looking at the chart above, BIIB's low point in its 52 week range is $216.12 per share, with $388.67 as the 52 week high point  that compares with a last trade of $230.32. New Article In trading on Tuesday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 29.9, after changing hands as low as $229.60 per share. A bullish investor could look at BIIB's 29.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of BIIB shares: Looking at the chart above, BIIB's low point in its 52 week range is $216.12 per share, with $388.67 as the 52 week high point - that compares with a last trade of $230.32.",262.54296875
2019-04-17 00:00:00+00:00,229.7700042724609,231.8800048828125,225.27999877929688,227.17999267578125,227.17999267578125,2507500.0,2.3333333333333326,1.0,0.3333583333333333,"Apple (NASDAQ: AAPL) and Biogen (NASDAQ: BIIB) are facing down troubles that could create value if resolved. In this case, Apple is turning in a score twice that of its benchmark, highlighting the company's exceptional ability to deploy capital to generate profits for shareholders. As a result, the company has to look for other ways to spur growth, either through a new pipeline drug or an acquisition in order to deliver good returns to investors. New Article So what First, Novartis (NYSE: NVS) announced interim phase 3 data for its gene therapy Zolgensma, which treats spinal muscular atrophy (SMA), the same disease treated by Ionis' and Biogen 's (NASDAQ: BIIB) Spinraza. However, there were a couple of indirect news items from competitors and collaborators that seem to have investors taking profits on Ionis' shares that were up 87% over the last year through yesterday. There wasn't a control arm of untreated patients, but typically, 50% of babies do not survive or will require permanent ventilation by the time they reach 10.5 months of age. New Article Apple (NASDAQ: AAPL) and Biogen (NASDAQ: BIIB) are facing down troubles that could create value if resolved. In this case, Apple is turning in a score twice that of its benchmark, highlighting the company's exceptional ability to deploy capital to generate profits for shareholders. As a result, the company has to look for other ways to spur growth, either through a new pipeline drug or an acquisition in order to deliver good returns to investors. New Article Among the largest underlying components of IBB, in trading today Celgene Corp (Symbol: CELG) is off about 0.3%, Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is off about 2.7%, and Biogen Inc (Symbol: BIIB) is lower by about 0.1%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $89.01 per share, with $122.97 as the 52 week high point  that compares with a last trade of $106.92. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article So what First, Novartis (NYSE: NVS) announced interim phase 3 data for its gene therapy Zolgensma, which treats spinal muscular atrophy (SMA), the same disease treated by Ionis' and Biogen's (NASDAQ: BIIB) Spinraza. However, there were a couple of indirect news items from competitors and collaborators that seem to have investors taking profits on Ionis' shares that were up 87% over the last year through yesterday. There wasn't a control arm of untreated patients, but typically, 50% of babies do not survive or will require permanent ventilation by the time they reach 10.5 months of age. New Article Apple (NASDAQ: AAPL) and Biogen (NASDAQ: BIIB) are facing down troubles that could create value if resolved. In this case, Apple is turning in a score twice that of its benchmark, highlighting the company's exceptional ability to deploy capital to generate profits for shareholders. As a result, the company has to look for other ways to spur growth, either through a new pipeline drug or an acquisition in order to deliver good returns to investors.",266.7415466308594
2019-04-22 00:00:00+00:00,226.9900054931641,232.17999267578125,226.57000732421875,228.8099975585937,228.8099975585937,1802900.0,2.0,1.0,0.250025,"Among large drug manufacturers -- those with market capitalization over $10 billion -- the two stocks that have fallen the most in 2019 are Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV). The other two drugs in phase 3 trials are BIIB093 for stroke, which the company expects could generate $1 billion in revenue in 2022, and Vumerity (also known as BIIB098 and ALKS 8700), a next-generation MS drug licensed from Alkermes that could help compensate for losses by Tecfidera. The company's hepatitis C treatment Mavyret was a surprisingly big winner last year, bringing in $819 million in revenue and grabbing 50% market share from entrenched competitor Gilead Sciences.",267.4018859863281
2019-04-24 00:00:00+00:00,232.0200042724609,232.8000030517578,223.4600067138672,224.3999938964844,224.3999938964844,4123900.0,3.5,1.0,0.6250249999999999,"Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 42.9% Average next regular session additional gain: 0.7% Over the prior three fiscal years (12 quarters), when shares of BIIB rose in the extended-hours session in reaction to its earnings announcement, history shows that 42.9% of the time (3 events) the stock posted additional gains in the following regular session by an average of 0.7%. Last 12 Qtrs Negative Only Price Reactions Percent of time added to extended-hours losses: 25% Average next regular session additional loss: 2% Over that same historical period, when shares of BIIB dropped in the extended-hours in reaction to its earnings announcement, history shows that 25.0% of the time (1 event) the stock dropped further, adding to the extended-hours losses by an average of 2.0% by the following regular session close. Extended-Hours Dollar Volume: $22,407,747 Biogen Idec (BIIB) is due to issue its quarterly earnings report in the upcoming extended-hours session. New Article We plan to present data from the single and multiple ascending dose portions of the Phase 1/2 study of BIIB067 in the emerging science session at the American Academy of Neurology, Annual Meeting next month, and you will hear more specifically about our ALS pipeline at an R&D investor webcast on June 5th. Biogen Inc  (NASDAQ: BIIB) Q1 2019 Earnings Call April 24, 2019, 8:00 a.m. Today, we have 23 programs in clinical development, including BIIB098, which has been filed with the FDA, and we expect ten mid to late-stage clinical readouts by the end of the 2020. New Article It also comes in above Wall Streets earnings per share estimate of $6.84 for the period, but couldnt keep BIIB stock from dropping today. It also beats out analysts revenue estimate of $3.39 billion for the quarter, but BIIB stock is still down today. Biogen earnings for the first quarter of 2019 have BIIB stock down on Wednesday despite it beating it estimates. New Article (RTTNews) - Biogen Inc. (BIIB) revealed a profit for its first quarter that rose from the same period last year. Excluding items, Biogen Inc. reported adjusted earnings of $1.37 billion or $6.98 per share for the period. Analysts had expected the company to earn $6.84 per share, according to figures compiled by Thomson Reuters.",284.890380859375
2019-04-25 00:00:00+00:00,224.02999877929688,232.1999969482422,223.08999633789065,229.88999938964844,229.88999938964844,2547800.0,2.5,1.0,0.375025,"Biogen (NASDAQ: BIIB) continues to lean on sales growth of its spinal muscular atrophy drug, Spinraza, to drive revenue. On the pipeline front, in addition to the aforementioned disappointing news on aducanumab, Biogen started the phase 3 Valor study of tofersen (BIIB067), which is also partnered with Ionis Pharmaceuticals. We took aggressive steps to diversify our portfolio in the past, but in the context of our current cash flow generation and the profile of our balance sheet, we can do both, buying back and also conduct some BD M&A activities. New Article Among the largest underlying components of IBB, in trading today Celgene Corp (Symbol: CELG) is up about 0.2%, Gilead Sciences Inc (Symbol: GILD) is up about 0.6%, and Biogen Inc (Symbol: BIIB) is higher by about 2.4%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $89.01 per share, with $122.97 as the 52 week high point  that compares with a last trade of $105.55. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",284.2539367675781
2019-04-26 00:00:00+00:00,230.25,231.44000244140625,226.69000244140625,230.52999877929688,230.52999877929688,1660800.0,4.0,1.0,0.7500249999999999,"In February, Alkermes and partner Biogen's (NASDAQ: BIIB) marketing application for multiple sclerosis drug Vumerity was accepted by the FDA. Investors were a little disappointed with Alkermes' (NASDAQ: ALKS) first-quarter results, but assuming the issues are transient like management claims, the drugmaker appears to be setting itself up for future growth. The earnings number includes a noncash charge related to the fair value of a milestone payment on a drug candidate that Alkermes sold to Recro Pharma in 2015.",288.30126953125
2019-05-02 00:00:00+00:00,229.8300018310547,234.4900054931641,229.22000122070312,230.5200042724609,230.5200042724609,1965600.0,2.5,1.0,0.375025,"Especially high volume was seen for the $340 strike put option expiring January 17, 2020, with 1,400 contracts trading so far today, representing approximately 140,000 underlying shares of BIIB. Below is a chart showing ABMD's trailing twelve month trading history, with the $250 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 15,894 contracts, representing approximately 1.6 million underlying shares or approximately 66.5% of BIIB's average daily trading volume over the past month, of 2.4 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $340 strike highlighted in orange: And Occidental Petroleum Corp (Symbol: OXY) saw options trading volume of 57,830 contracts, representing approximately 5.8 million underlying shares or approximately 62.3% of OXY's average daily trading volume over the past month, of 9.3 million shares. New Article Below is a twelve month price history chart comparing the stock performance of JBHT, BIIB, and ISRG: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of QQXT's underlying holdings with notable upside to their analyst target prices are J.B. Hunt Transport Services, Inc. (Symbol: JBHT), Biogen Inc (Symbol: BIIB), and Intuitive Surgical Inc (Symbol: ISRG). Similarly, BIIB has 18.17% upside from the recent share price of $229.50 if the average analyst target price of $271.21/share is reached, and analysts on average are expecting ISRG to reach a target price of $581.07/share, which is 16.90% above the recent price of $497.05.",282.9267578125
2019-05-06 00:00:00+00:00,228.9499969482422,236.67999267578125,227.5,236.07000732421875,236.07000732421875,2368700.0,3.0,1.0,0.5000249999999999,"VIDEO: Monday 5/6 Insider Buying Report: BIIB, UNH The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. At Biogen (BIIB), a filing with the SEC revealed that on Thursday, Director Alexander J. Denner purchased 118,342 shares of BIIB, at a cost of $229.94 each, for a total investment of $27.21M. Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money.",295.075439453125
2019-05-07 00:00:00+00:00,233.7899932861328,238.1699981689453,227.69000244140625,229.0200042724609,229.0200042724609,3150300.0,2.0,1.0,0.250025,"Among the largest underlying components of IBB, in trading today Biogen Inc (Symbol: BIIB) is down about 2.2%, Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is off about 1.2%, and Illumina Inc (Symbol: ILMN) is lower by about 1%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $89.01 per share, with $122.97 as the 52 week high point  that compares with a last trade of $107.04. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",306.2008361816406
2019-05-09 00:00:00+00:00,229.1699981689453,229.5200042724609,224.33999633789065,228.47000122070312,228.47000122070312,2108500.0,3.0,1.0,0.5000249999999999,"Particularly high volume was seen for the $335 strike put option expiring June 21, 2019, with 2,200 contracts trading so far today, representing approximately 220,000 underlying shares of BIIB. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 16,557 contracts have traded so far, representing approximately 1.7 million underlying shares. That amounts to about 72.5% of BIIB's average daily trading volume over the past month of 2.3 million shares. New Article Biotech firm Biogen (BIIB, $226) is a good example. Earlier this year, Senators Chuck Schumer and Bernie Sanders announced plans to introduce legislation that would require companies to meet conditions--such as paying a $15 minimum wage and providing certain health care benefits, including paid sick leave--before they could repurchase shares. Shares have rebounded a bit since the buyback announcement but still sit more than 40% below their 2018 high and well below their fair value, according to Morningstar analyst Karen Andersen, given that Biogen is developing promising treatments for other neurological disorders.",300.01531982421875
2019-05-14 00:00:00+00:00,225.8800048828125,230.4499969482422,225.4100036621093,229.17999267578125,229.17999267578125,1905700.0,3.0,1.0,0.5000249999999999,"Royalties from Biogen (NASDAQ: BIIB) on spinal muscular atrophy (SMA) drug Spinraza added $60 million, while Tegsedi added $7 million. Ionis Pharmaceuticals (NASDAQ: IONS) started the year off on a positive note, doubling revenue in the first quarter thanks to a large licensing payment from one of its partners. What management had to say Elizabeth Hougen, Ionis Pharmaceuticals' chief financial officer, noted the strong sales of Spinraza have come from Biogen's move into adults with less severe forms of the disease: ""Biogen believes the global SMA patient population is significantly larger than initial estimates, which supports their expectation of continued growth from patient uptake in new markets.",291.318359375
2019-05-23 00:00:00+00:00,232.94000244140625,233.22000122070312,227.3800048828125,229.1100006103516,229.1100006103516,2120700.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of FXH, in trading today Bruker Corp (Symbol: BRKR) is off about 0.7%, Mednax, Inc. (Symbol: MD) is down about 1.9%, and Biogen Inc (Symbol: BIIB) is lower by about 1.7%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the First Trust Health Care AlphaDEX Fund (Symbol: FXH) where we have detected an approximate $40.2 million dollar outflow -- that's a 3.3% decrease week over week (from 16,650,002 to 16,100,002). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",296.6763610839844
2019-05-24 00:00:00+00:00,229.72999572753903,230.5200042724609,225.82000732421875,227.0599975585937,227.0599975585937,1792500.0,3.0,1.0,0.5000249999999999,"What Zolgensma does Historically, SMA treatment involved supportive care, but Biogen (NASDAQ: BIIB) and Ionis Pharmaceuticals (NASDAQ: IONS) won FDA approval for Spinraza in 2016, after trials demonstrated it can help patients. On Friday, the Food and Drug Administration (FDA) gave a green light to Novartis' (NYSE: NVS) Zolgensma, a revolutionary gene therapy for spinal muscular atrophy (SMA). Rather than fixing the splicing error in SMN2, Zolgensma uses a viral vector -- AAV9 -- specifically engineered by Regenxbio to deliver a functioning copy of the missing or mutated SMN gene.",283.9540100097656
2019-06-03 00:00:00+00:00,220.3099975585937,226.5800018310547,219.509994506836,223.3699951171875,223.3699951171875,1714600.0,3.5,1.0,0.6250249999999999,"Although BIIB has traded at a recent price of $219.29/share, the average analyst target is 21.14% higher at $265.64/share. Below is a twelve month price history chart comparing the stock performance of BIIB, SCCO, and CCL: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of JKD's underlying holdings with notable upside to their analyst target prices are Biogen Inc (Symbol: BIIB), Southern Copper Corp (Symbol: SCCO), and Carnival Corp (Symbol: CCL). New Article Biotech titans Biogen (NASDAQ: BIIB) and Amgen (NASDAQ: AMGN) have both been outstanding growth vehicles for investors over the prior two decades. Amgen, on the other hand, has yet to convince investors that its strategy of aggressively buying back shares and plowing cash into an already-rich dividend program is wise in light of the biotech's falling sales for a host of older medications. And the biotech's main growth driver in the past year -- spinal muscular atrophy medicine Spinraza, which was co-developed with Ionis Pharmaceuticals -- is facing a serious competitive threat from Novartis' newly approved gene therapy Zolgensma.",263.2158203125
2019-06-06 00:00:00+00:00,225.17999267578125,228.1699981689453,223.8500061035156,224.3500061035156,224.3500061035156,1641700.0,4.0,1.0,0.7500249999999999,"An estimated 150,000 people are diagnosed with trigeminal neuralgia every year, and this chronic pain condition is more common in women than in men. Painkillers, Botox, and surgical procedures like stereotactic radiosurgery, rhizotomy, microvascular decompression, and transcutaneous electrical nerve stimulation are some of the other treatment options for trigeminal neuralgia. The current drugs prescribed for trigeminal neuralgia are said to have only suboptimal efficacy and tolerability, according to experts, and patients face a significant burden of illness.",255.43392944335938
2019-06-10 00:00:00+00:00,227.5200042724609,230.58999633789065,226.5,228.3999938964844,228.3999938964844,1312800.0,3.0,1.0,0.5000249999999999,"Investors considering a purchase of Biogen Inc (Symbol: BIIB) stock, but cautious about paying the going market price of $229.16/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to BIIB's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. For other put options contract ideas at the various different available expirations, visit the BIIB Stock Options page of StockOptionsChannel.com.",256.1268615722656
2019-06-13 00:00:00+00:00,231.0500030517578,233.8300018310547,229.6999969482422,231.259994506836,231.259994506836,1166100.0,1.0,1.0,2.4999999999997247e-05,"Particularly high volume was seen for the $340 strike put option expiring January 17, 2020, with 900 contracts trading so far today, representing approximately 90,000 underlying shares of BIIB. Below is a chart showing REGN's trailing twelve month trading history, with the $370 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 8,090 contracts, representing approximately 809,000 underlying shares or approximately 54% of BIIB's average daily trading volume over the past month, of 1.5 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $340 strike highlighted in orange: And Garmin Ltd (Symbol: GRMN) options are showing a volume of 5,010 contracts thus far today.",255.525146484375
2019-06-17 00:00:00+00:00,228.759994506836,232.9600067138672,227.5500030517578,231.77999877929688,231.77999877929688,1669000.0,3.0,1.0,0.5000249999999999,"Biogen Inc (Symbol: BIIB), which makes up 0.67% of the iShares Morningstar Large-Cap ETF (JKD), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at BIIB: BIIB  last trade: $227.67  Recent Insider Buys: 10 ETFs With Stocks That Insiders Are Buying  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The ETF holds a total of $5,577,249 worth of BIIB, making it the #48 largest holding. New Article Among the largest underlying components of IBB, in trading today Gilead Sciences Inc (Symbol: GILD) is up about 1.2%, Biogen Inc (Symbol: BIIB) is up about 1.5%, and Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is higher by about 1.4%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $89.01 per share, with $122.97 as the 52 week high point  that compares with a last trade of $105.47. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",249.74087524414062
2019-06-18 00:00:00+00:00,233.9499969482422,237.75,232.5399932861328,233.009994506836,233.009994506836,1646000.0,2.0,1.0,0.250025,"Amgen (NASDAQ: AMGN), Biogen (NASDAQ: BIIB), and Gilead Sciences (NASDAQ: GILD) are three big drugmakers that I think are most likely to make acquisitions in the not-too-distant future. This week got off to a rousing start for the biopharmaceutical world with Pfizer's (NYSE: PFE) announcement that it's acquiring Array BioPharma (NASDAQ: ARRY) for $11.4 billion. The bad news for Biogen is that Spinraza now has competition with the recent FDA approval of Novartis' (NYSE: NVS) SMA gene therapy Zolgensma.",249.4796142578125
2019-06-19 00:00:00+00:00,232.6100006103516,234.4199981689453,231.8600006103516,233.88999938964844,233.88999938964844,1802500.0,3.0,1.0,0.5000249999999999,"Biogen (BIIB) Much like GILD stock, shares of sector heavyweight Biogen (NASDAQ:) have been under extreme technical duress the past few years. Most recently, the pain in BIIB stock came after the companys announcement that it was The suffering came despite the fact that BIIB posted stronger-than-forecast results in late April. The Trade Buy BIIB stock above Mays candle high of $238.17 to confirm the pattern bottom.",240.45263671875
2019-06-25 00:00:00+00:00,236.3999938964844,245.3500061035156,235.9900054931641,240.2899932861328,240.2899932861328,2108700.0,2.0,1.0,0.250025,"Source: Shutterstock Sorting Out the Macro We said it the other day, but it bears repeating: Investors are not navigating a normal period of time. That said, recent housing data was disappointing, consumer confidence slipped to a multi-year low and while it seems forgotten, the jobs report earlier this month was a major miss. After ripping higher last week on solid earnings, shares were under pressure Tuesday, likely for the same reason that MSFT stock fell so much: profit-taking. New Article VIDEO: Nasdaq 100 Movers: NTES, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Tuesday, shares of Biogen (BIIB) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.4%. And the worst performing Nasdaq 100 component thus far on the day is NetEase (NTES), trading down 3.0%. New Article But with the company's top-selling diabetes, cancer, and immunology therapies, well over half of Lilly's total revenue comes from biologic drugs, making it a biotech stock according to the criteria used for this ranking. The company's hepatitis C virus (HCV) franchise continues to generate billions of dollars in revenue annually, although sales have dropped as Gilead and its main rival AbbVie battle each other for fewer new patients. It's also hoping to add new approved indications for Descovy as a pre-exposure prophylaxis (PrEP) therapy for HIV and for Yescarta as a treatment for previously treated diffuse large B-cell lymphoma (DLBCL).",239.83828735351562
2019-07-08 00:00:00+00:00,234.25,234.25,228.02999877929688,230.83999633789065,230.83999633789065,1539900.0,2.5,1.0,0.375025,"What happened Biogen (NASDAQ: BIIB), a blue chip biotech stock, has shed an unsightly 22.3% of its value over the course of the first six months of 2019, according to data from S&P Global Market Intelligence. The biotech's multiple sclerosis franchise has stalled from a revenue generation standpoint and it's unclear whether newer drug candidates in the pipeline can pick up the slack. Biogen doesn't have a particularly robust late-stage pipeline to fall back on and its management team appears content to rely on earlier-stage assets to create shareholder value. New Article Particularly high volume was seen for the $255 strike call option expiring July 19, 2019, with 1,006 contracts trading so far today, representing approximately 100,600 underlying shares of BIIB. Below is a chart showing EPAM's trailing twelve month trading history, with the $180 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 7,297 contracts, representing approximately 729,700 underlying shares or approximately 44% of BIIB's average daily trading volume over the past month, of 1.7 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $255 strike highlighted in orange: For the various different available expirations for MED options, EPAM options, or BIIB options, visit StockOptionsChannel.com.",245.90530395507812
2019-07-16 00:00:00+00:00,234.3000030517578,235.0399932861328,231.0599975585937,231.5500030517578,231.5500030517578,1207200.0,2.0,1.0,0.250025,"Especially high volume was seen for the $235 strike call option expiring August 16, 2019, with 3,566 contracts trading so far today, representing approximately 356,600 underlying shares of BIIB. Below is a chart showing COST's trailing twelve month trading history, with the $285 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 15,732 contracts, representing approximately 1.6 million underlying shares or approximately 91.8% of BIIB's average daily trading volume over the past month, of 1.7 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $235 strike highlighted in orange: And Ulta Beauty Inc (Symbol: ULTA) saw options trading volume of 4,327 contracts, representing approximately 432,700 underlying shares or approximately 63.5% of ULTA's average daily trading volume over the past month, of 681,265 shares.",249.9316864013672
2019-07-22 00:00:00+00:00,232.5200042724609,235.2400054931641,231.2899932861328,232.47999572753903,232.47999572753903,1274700.0,3.5,1.0,0.6250249999999999,"* AutoNation Inc. (AN) * JetBlue Airways Corp. (JBLU) * Biogen Inc. (BIIB) * Chipotle Mexican Grill Inc. (CMG) * Coca-Cola Co. (KO) * Harley-Davidson Inc. (HOG) * Hasbro Inc. (HAS) * Texas Instruments Inc. (TXN) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - As investors brace for a busy earnings week, here's a list of few companies that will be among the most closely watched big names reporting on Tuesday, July 23. New Article Biogens Positive Developments Source: Shutterstock Biogen is trying to pick itself up months after Biogen stock got hammered back in March, sinking from $320 to as low as $220 after BIIB and Eisai terminated two trials of their Alzheimers drug. Still, BIIBs MS franchise remains a key player in its long-term strategy. Biogens consistent performance is keeping BIIB stock in a tight trading range between $225 and $240.",264.048583984375
2019-07-23 00:00:00+00:00,239.0,246.9900054931641,238.2100067138672,243.8800048828125,243.8800048828125,3295000.0,3.75,1.0,0.6875249999999999,"The table below details the recent insider buying activity observed at CMP: CMP  last trade: $54.71  Recent Insider Buys: And Biogen Inc (Symbol: BIIB), the #28 largest holding among components of the Morningstar Wide Moat ETF (MOAT), shows 2 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $48,146,732 worth of BIIB, which represents approximately 2.08% of the ETF's total assets at last check. The recent insider buying activity observed at BIIB is detailed in the table below: BIIB  last trade: $232.48  Recent Insider Buys: 10 ETFs With Stocks That Insiders Are Buying  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article (RTTNews) - Biogen Inc. (BIIB) reported that its second quarter GAAP net income attributable to the company rose to $1.5 billion or $7.85 per share from $867 million or $4.18 per share in the second quarter of 2018. The prior net income was impacted by $589 million or $2.84 per share related to the 10-year exclusive agreement with Ionis Pharmaceuticals, Inc., the acquisition of BIIB104 from Pfizer Inc., the option payment to Neurimmune SubOne AG, and the option agreement with TMS Co., Ltd. Non-GAAP net income was $1.7 billion or $9.15 per share, compared to $1.2 billion or $5.80 per share in the previous year. Analysts polled by Thomson Reuters expected the company to report earnings of $7.53 per share and revenues of $3.47 billion for the second-quarter. New Article Biogen Inc (NASDAQ: BIIB) Q2 2019 Earnings Call Jul 23, 2019, 8:00 a.m. I'm also pleased to announce that we have dosed the first subject in the Phase 1 study of BIIB091, a highly potent and selective small molecule inhibitor of Bruton's Tyrosine Kinase or BTK. Notably, BIIB091 is a non-covalent inhibitor of BTK, which we believe, together with its high potency and selectivity, has a potentially best-in-class profile. New Article Biogen earnings for the second quarter of the year have BIIB stock heading higher on Tuesday. It was also a blessing for BIIB stock by coming in well above Wall Streets earnings per share estimate of $7.53 for the period. It was also good news for BIIB stock by beating out analysts revenue estimate of $3.47 billion for the quarter.",263.76727294921875
2019-07-24 00:00:00+00:00,244.6999969482422,245.92999267578125,239.1499938964844,241.2400054931641,241.2400054931641,1565000.0,4.0,1.0,0.7500249999999999,"Biogen (NASDAQ: BIIB) put up relatively impressive sales numbers in the second quarter, with earnings per share growing like gangbusters as the drugmaker cut expenses and repurchased shares to boost the bottom line. In the second half of this year, investors will also get data for BIIB092 in progressive supranuclear palsy, a brain disorder that causes problems with waking. In June, Biogen closed its acquisition of genetic eye disease specialist Nightstar Therapeutics, adding two mid- to late-stage gene therapy programs.",269.2199401855469
2019-07-26 00:00:00+00:00,233.9100036621093,238.4499969482422,232.32000732421875,238.2100067138672,238.2100067138672,1544500.0,3.0,1.0,0.5000249999999999,"The year-over-year revenue decline came from a one-time $48.3 million revenue bump in the year-ago quarter from Biogen (NASDAQ: BIIB) licensing multiple sclerosis treatment Vumerity, while the most recent quarter had just $1 million in licensing revenue. Alkermes (NASDAQ: ALKS) turned in a solid-enough quarter, but a pullback in guidance for its growth-driver antipsychotic drug Aristada led investors to fret over the biotech's near-term future. Manufacturing and royalties from Acorda Therapeutics and Biogen's Ampyra/Fampyra were cut in half, although that was expected as Ampyra faces generic competition in the U.S.",274.5710144042969
2019-07-30 00:00:00+00:00,237.3300018310547,242.63999938964844,236.0599975585937,241.509994506836,241.509994506836,1215900.0,3.0,1.0,0.5000249999999999,"Sales of Biogen's (NASDAQ: BIIB) top-selling multiple sclerosis drug Tecfidera brought in almost $4.3 billion last year, and sales are on pace to be even higher this year. Great call At the time of the licensing deal, Biogen didn't know whether the slightly different chemical structure would actually reduce the gastrointestinal issues, but $200 million was a small price to pay to find out the answer. The companies plan to present the data at a future medical meeting, which is why they want to hold back the actual primary endpoint results, but we can get an idea of the magnitude of the difference from the side effect profile. New Article (RTTNews) - Alkermes plc (ALKS) and Biogen Inc. (BIIB) announced positive results from EVOLVE-MS-2, a large, randomized, double-blind, five-week, Phase 3 study of diroximel fumarate, an investigational, novel oral fumarate with a distinct chemical structure, for relapsing-remitting multiple sclerosis or RRMS, compared to TECFIDERA or dimethyl fumarate. Alkermes noted that Diroximel fumarate demonstrated statistically superior GI tolerability compared to dimethyl fumarate on the EVOLVE-MS-2 study's primary endpoint, as well as a low discontinuation rate of less than 1% due to GI adverse events. Biogen plans to market diroximel fumarate under the conditionally approved brand name VUMERITY.",269.2952575683594
2019-08-01 00:00:00+00:00,238.759994506836,245.3000030517578,236.4199981689453,243.0599975585937,243.0599975585937,1871000.0,2.5,1.0,0.375025,"Especially high volume was seen for the $225 strike put option expiring August 16, 2019, with 1,179 contracts trading so far today, representing approximately 117,900 underlying shares of BIIB. Below is a chart showing NDAQ's trailing twelve month trading history, with the $97.50 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 9,771 contracts thus far today. That number of contracts represents approximately 977,100 underlying shares, working out to a sizeable 75% of BIIB's average daily trading volume over the past month, of 1.3 million shares. New Article The orphan-drug maker Catalyst Pharmaceuticals (NASDAQ: CPRX) and the premium marijuana dispensary company MedMen Enterprises (OTC: MMNFF) are two promising prospects. Catalyst's core value proposition nevertheless rests squarely on Firdapse's continued uptake in LEMS, highlighting the serious threat this alternative therapy poses to the company's near- and long-term prospects. This proposed deal would cement MedMen's position as one of the country's largest marijuana dispensaries, giving it a whopping 86 retail licenses on a pro forma basis.",275.4784240722656
2019-08-20 00:00:00+00:00,235.08999633789065,235.5500030517578,230.75,231.27999877929688,231.27999877929688,843600.0,2.0,1.0,0.250025,"CEO Doug Ingram noted in the company's Q2 conference call that there would be no Food and Drug Administration advisory-committee review of golodirsen (as there was for Exondys 51). On Monday, Sarepta announced that it had received a complete response letter (CRL) from the FDA rejecting its application for golodirsen. The more worrisome concern cited by the FDA related to potential renal toxicity -- damage to kidneys caused by a drug or toxin.",278.5306091308594
2019-08-21 00:00:00+00:00,232.8000030517578,233.77999877929688,231.5,233.17999267578125,233.17999267578125,807500.0,3.0,1.0,0.5000249999999999,"Among health care stocks moving on news: (+) Invitae Corp (NVTA) rose over 3% after the genetic information company and Biogen (BIIB) late Tuesday said they would be making their rapid-result SMA STAT diagnostic test for spinal muscular atrophy available for free in the US as part of the companies' SMA Identified program. The new test cuts the time needed to confirm a definitive diagnosis from around three weeks currently to just four days and allowing physicians and patients to begin treatment sooner. In other sector news: (+) Pfizer (PFE) rose more the 1% after disclosing plans to spend $500 million on a new gene therapy manufacturing facility in Sanford, N.C., where it also produces vaccine components and bolstering the drugmaker's ability to develop medicines for patients with rare diseases.",285.11663818359375
2019-08-30 00:00:00+00:00,220.72999572753903,221.67999267578125,217.8999938964844,219.75,219.75,1226300.0,2.0,1.0,0.250025,"Especially high volume was seen for the $220 strike put option expiring August 30, 2019, with 433 contracts trading so far today, representing approximately 43,300 underlying shares of BIIB. Below is a chart showing ITW's trailing twelve month trading history, with the $148 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 4,644 contracts, representing approximately 464,400 underlying shares or approximately 40.1% of BIIB's average daily trading volume over the past month, of 1.2 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $220 strike highlighted in orange: For the various different available expirations for CI options, ITW options, or BIIB options, visit StockOptionsChannel.com.",283.9850769042969
2019-09-03 00:00:00+00:00,218.1499938964844,219.88999938964844,216.08999633789065,217.44000244140625,217.44000244140625,1385000.0,3.0,1.0,0.5000249999999999,"Biogen Inc (Symbol: BIIB), which makes up 1.96% of the Morningstar Wide Moat ETF (MOAT), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at BIIB: BIIB  last trade: $219.75  Recent Insider Buys: 10 ETFs With Stocks That Insiders Are Buying  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. The ETF holds a total of $45,966,426 worth of BIIB, making it the #28 largest holding.",292.4513244628906
2019-09-09 00:00:00+00:00,225.5800018310547,231.0599975585937,224.38999938964844,230.0,230.0,1651800.0,3.0,1.0,0.5000249999999999,"Especially high volume was seen for the $270 strike call option expiring November 15, 2019, with 1,620 contracts trading so far today, representing approximately 162,000 underlying shares of BIIB. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 8,259 contracts have traded so far, representing approximately 825,900 underlying shares. That amounts to about 71.8% of BIIB's average daily trading volume over the past month of 1.2 million shares.",285.7990417480469
2019-09-13 00:00:00+00:00,232.0,237.97999572753903,232.0,236.6300048828125,236.6300048828125,1689000.0,3.0,1.0,0.5000249999999999,"(RTTNews) - Eisai Co. Ltd., a global research and development-based pharmaceutical company headquartered in Japan, and Biogen Inc. (BIIB) have decided to discontinue the Phase III clinical studies of BACE inhibitor elenbecestat in patients with early Alzheimer's disease. The Data Safety Monitoring Board recommended to discontinue these trials due to unfavorable risk-benefit ratio. The Phase III program for elenbecestat consisted of two global clinical studies with identical protocols.",291.7736511230469
2019-09-16 00:00:00+00:00,236.1699981689453,240.5,234.82000732421875,236.1199951171875,236.1199951171875,1598400.0,2.0,1.0,0.250025,"Particularly high volume was seen for the $230 strike put option expiring October 18, 2019, with 516 contracts trading so far today, representing approximately 51,600 underlying shares of BIIB. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Biogen Inc (Symbol: BIIB), where a total volume of 6,489 contracts has been traded thus far today, a contract volume which is representative of approximately 648,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 49.8% of BIIB's average daily trading volume over the past month, of 1.3 million shares.",285.747314453125
2019-09-24 00:00:00+00:00,240.0,241.47000122070312,235.1499938964844,236.1999969482422,236.1999969482422,1545300.0,2.0,1.0,0.250025,"Particularly high volume was seen for the $220 strike put option expiring October 18, 2019, with 3,270 contracts trading so far today, representing approximately 327,000 underlying shares of BIIB. Below is a chart showing ISRG's trailing twelve month trading history, with the $485 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 10,915 contracts, representing approximately 1.1 million underlying shares or approximately 70.6% of BIIB's average daily trading volume over the past month, of 1.5 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $220 strike highlighted in orange: And Capital One Financial Corp (Symbol: COF) options are showing a volume of 11,878 contracts thus far today.",282.5176086425781
2019-09-27 00:00:00+00:00,231.27999877929688,233.2400054931641,228.1300048828125,230.22000122070312,230.22000122070312,1340200.0,3.0,1.0,0.5000249999999999,"Both companies have five programs in late-stage development, with Biogen and its partner Alkermes also anticipating FDA approval for MS drug BIIB098 later this year. If there were a hall of fame for biotech stocks, Biogen (NASDAQ: BIIB) and Amgen (NASDAQ: AMGN) would be in it. If approved, though, BIIB098 is likely to cannibalize sales of Tecfidera to some extent.",289.8993835449219
2019-09-30 00:00:00+00:00,230.27999877929688,235.25,229.4199981689453,232.82000732421875,232.82000732421875,1182400.0,4.0,1.0,0.7500249999999999,"That may allow DNL747, a drug that combats neuroinflammation, from Denali Therapuetics (NASDAQ: DNLI); arimoclomol, an amplifier of the cellular housekeeping machinery, by Orphazyme; tofersen, a gene-silencing drug for a genetic form of ALS, in development by Biogen (NASDAQ: BIIB); or any of the other drugs that were submitted for inclusion to get their chance to shine. Originally developed by AstraZeneca (NYSE: AZN) for another rare, neurodegenerative disease called multiple system atrophy, Biohaven licensed the rights to verdiperstat in September 2018. Based on the drug's unique mechanism, oral tablet formulation, and that it had previously been tested in approximately 250 patients, ALS experts selected verdiperstat for the Platform Trial.",286.84552001953125
2019-10-01 00:00:00+00:00,232.759994506836,234.0399932861328,224.6699981689453,227.1999969482422,227.1999969482422,1805800.0,3.0,1.0,0.5000249999999999,"(RTTNews) - Biogen (BIIB) said that it has appointed Alfred Sandrock as Executive Vice President, Research and Development, in addition to his responsibilities as Chief Medical Officer, and Alphonse Galdes as Executive Vice President, Pharmaceutical Operations and Technology, Effective immediately. Michael Ehlers has decided to step down as Executive Vice President, Research and Development, and will leave Biogen effective October 11, 2019, to pursue a new career opportunity. He was named Chief Medical Officer in 2012 and since joining the company in 1998, has held several senior executive positions, including Senior Vice President of Development Sciences, Senior Vice President of Neurology Research and Development and Vice President of Clinical Development, Neurology.",280.8807678222656
2019-10-02 00:00:00+00:00,226.5599975585937,228.3500061035156,220.6100006103516,221.259994506836,221.259994506836,1990800.0,2.0,1.0,0.250025,"Particularly high volume was seen for the $210 strike put option expiring October 25, 2019, with 420 contracts trading so far today, representing approximately 42,000 underlying shares of BIIB. Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Biogen Inc (Symbol: BIIB), where a total volume of 6,828 contracts has been traded thus far today, a contract volume which is representative of approximately 682,800 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 42.9% of BIIB's average daily trading volume over the past month, of 1.6 million shares.",275.50714111328125
2019-10-03 00:00:00+00:00,221.6999969482422,223.47999572753903,219.6999969482422,222.5,222.5,1827500.0,4.0,1.0,0.7500249999999999,"(RTTNews) - Biogen Canada announced results from the NURTURE study, demonstrating that infants who initiated treatment with SPINRAZA or nusinersen injection prior to the onset of clinical symptoms of spinal muscular atrophy or SMA attained positive results compared to the natural history of the disease. NURTURE is the first study investigating a treatment targeting the underlying cause of spinal muscular atrophy in infants treated pre-symptomatically. Spinal Muscular Atrophy is a rare, debilitating neurodegenerative condition that is characterized by loss of motor neurons in the spinal cord and lower brain stem, resulting in severe and progressive muscular atrophy and weakness.",275.8807678222656
2019-10-07 00:00:00+00:00,225.63999938964844,229.759994506836,224.0,226.9900054931641,226.9900054931641,1572000.0,3.0,1.0,0.5000249999999999,"Although BIIB has traded at a recent price of $224.00/share, the average analyst target is 19.23% higher at $267.08/share. Below is a twelve month price history chart comparing the stock performance of BIIB, VEEV, and BMY: Combined, BIIB, VEEV, and BMY represent 6.32% of the Morningstar Wide Moat ETF. Three of MOAT's underlying holdings with notable upside to their analyst target prices are Biogen Inc (Symbol: BIIB), Veeva Systems Inc (Symbol: VEEV), and Bristol-Myers Squibb Co. (Symbol: BMY).",274.8106994628906
2019-10-09 00:00:00+00:00,223.1499938964844,224.1499938964844,221.8999938964844,222.1300048828125,222.1300048828125,1429300.0,3.0,1.0,0.5000249999999999,"Biogen Inc (Symbol: BIIB), which makes up 1.12% of the Vanguard Health Care ETF (VHT), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The table below details the recent insider buying activity observed at BIIB: BIIB  last trade: $221.94  Recent Insider Buys: And Biohaven Pharmaceutical Holding Co Ltd (Symbol: BHVN), the #154 largest holding among components of the Vanguard Health Care ETF (VHT), shows 5 directors and officers as recently filing Form 4's indicating purchases. The ETF holds a total of $111,806,650 worth of BIIB, making it the #25 largest holding. New Article Especially high volume was seen for the $240 strike put option expiring January 17, 2020, with 652 contracts trading so far today, representing approximately 65,200 underlying shares of BIIB. Below is a chart showing LNN's trailing twelve month trading history, with the $60 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 9,573 contracts, representing approximately 957,300 underlying shares or approximately 57.6% of BIIB's average daily trading volume over the past month, of 1.7 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $240 strike highlighted in orange: And Under Armour Inc (Symbol: UAA) saw options trading volume of 18,904 contracts, representing approximately 1.9 million underlying shares or approximately 53.4% of UAA's average daily trading volume over the past month, of 3.5 million shares.",275.6769714355469
2019-10-10 00:00:00+00:00,222.13999938964844,224.2100067138672,221.9600067138672,223.0,223.0,1471200.0,2.0,1.0,0.250025,"Biogen (NASDAQ: BIIB) and Gilead Sciences (NASDAQ: GILD) are both biotech royalty. The biotech's core multiple sclerosis franchise has clearly plateaued, the spinal muscular atrophy medicine Spinraza is facing a serious competitive threat from Novartis' gene therapy Zolgensma, and its bet on biosimilars could take the better part of the next decade to truly pay dividends. New CEO Daniel O'Day has carved the cell cancer immunotherapy unit Kite Pharma out into a separate business with its own leadership team, deepened its ties with the checkpoint inhibitor specialist Agenus, and drastically upped the biotech's stake in the anti-inflammatory space through a broader partnership with Galapagos NV.",279.2300720214844
2019-10-14 00:00:00+00:00,222.5,226.3800048828125,221.83999633789065,225.759994506836,225.759994506836,2553900.0,2.0,1.0,0.250025,"Vir was co-founded three years ago by Robert Nelsen, who is probably the most successful biotech venture capitalist in the world. Because of fear, panic, and short-selling, individual investors can now buy shares of an attractive biotech for a much lower price than the billionaires were paying. The Motley Fool owns shares of and recommends Alnylam Pharmaceuticals, Biogen, Bluebird Bio, Editas Medicine, Illumina, and Slack Technologies.",279.269287109375
2019-10-22 00:00:00+00:00,310.0,318.0,279.1600036621094,281.8699951171875,281.8699951171875,21843100.0,3.833333333333334,1.0,0.7083583333333333,"VIDEO: Nasdaq 100 Movers: HAS, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Tuesday, shares of Biogen (BIIB) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 36.7%. And the worst performing Nasdaq 100 component thus far on the day is Hasbro (HAS), trading down 13.7%. New Article Well, guess what happened to Biogen (NASDAQ: BIIB) on Tuesday. But as always, caution is warranted in the biotech sector, where even the most promising drug candidates are not guaranteed to succeed in testing and ultimately win regulatory approval. In a tech industry event in California, Lyft CEO Logan Green and President John Zimmer said that the company will flip to a profit by the close of 2021... at least on an adjusted, pre-tax operating basis. New Article As for individual stocks, good news for Alzheimer's sufferers was also good news for shareholders of Biogen (NASDAQ: BIIB), and McDonald's (NYSE: MCD) reported a disappointing profit. The company said in a conference call that examination of a larger set of data in consultation with the FDA showed that the futility analysis didn't accurately predict the outcome, and in fact patients with longer exposure to a higher dose of the drug showed a significant reduction in clinical decline of cognition and function. Besides being a positive development for aducanumab, the findings renew hope for Biogen's other amyloid-fighting drug candidate, BAN2401, which the company plans to submit to the FDA in early 2020. New Article (RTTNews) - Biogen Inc. (BIIB) and Eisai, Co. Ltd. said, after consulting with the U.S. FDA, Biogen plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer's disease. The decision is based on a new analysis, conducted by Biogen in consultation with the FDA, of a larger dataset from the Phase 3 clinical studies that were discontinued in March 2019. The company said it will continue dialogue with regulatory authorities including those in Europe and Japan. New Article (RTTNews) - Biogen Inc. (BIIB) said it delivered solid performance in the third quarter driven by continued resilience from its MS core business and growth from SPINRAZA and biosimilars. Non-GAAP earnings per share increased 24 percent from previous year. On average, 27 analysts polled by Thomson Reuters expected the company to report profit per share of $8.27, for the quarter. New Article Stocks moving on news include: (+) Biogen (BIIB), which was gaining more than 38% in value after it reported Q3 non-GAAP earnings of $9.17 per share, up from $7.40 per share in the year-ago period and exceeding the consensus forecast of $8.27 per share provided by Capital IQ-polled analysts. Most health care giants were advancing pre-market Tuesday. Separately, the company said it plans to seek approval for an investigational treatment for early Alzheimer's disease from the US Food and Drug Administration. New Article Biogen Inc (NASDAQ: BIIB) Q3 2019 Earnings Call Oct 22, 2019, 8:00 a.m. In movement disorders, we continue to advance to Phase 2 study of BIIB092 or gosuranemab, an antibody targeting extracellular tau in PSP with data expected by the end of the year. In Parkinson's disease, we continue to progress the Phase 2 study of BIIB054, an antibody targeting extracellular alpha-synuclein. New Article In other sector news: (+) Biogen (BIIB) was more than 30% higher after saying it plans to seek approval for an investigational treatment for early Alzheimer's disease from the US Food and Drug Administration. Among health care stocks moving on news: (+) NewLink Genetics (NLNK) climbed more than 5% after an European Medicines Agency advisory committee recommended giving conditional marketing authorization to the company's V920 Ebola Zaire vaccine. (+) Arrowhead Pharmaceuticals (ARWR) advanced Tuesday, posting a 6% gain at midday after Chardan raised its price target for the genetic therapies company by $13 to $45 a share and reiterated its buy investment rating for the stock. New Article What happened Biotech heavyweight Biogen (NASDAQ: BIIB) saw its shares rise by as much as 43.7% in premarket trading Tuesday morning. Biogen shocked the industry this morning by announcing that it plans on pursuing a regulatory application for the Alzheimer's disease candidate aducanumab in the United States. The company said that this analysis showed that early Alzheimer's disease patients receiving the high-dose treatment of aducanumab exhibited a statistically significant reduction in clinical decline at week 78. New Article In other sector news: (+) Biogen (BIIB) was more than 26% higher in late trade after saying it plans to seek approval for an investigational treatment for early Alzheimer's disease from the US Food and Drug Administration. (+) NewLink Genetics (NLNK) climbed nearly 5% after a European Medicines Agency advisory committee recommended giving conditional marketing authorization to the company's V920 Ebola Zaire vaccine. (+) Arrowhead Pharmaceuticals (ARWR) advanced Tuesday, posting a 6.6% gain this afternoon after Chardan raised its price target for the genetic therapies company by $13 to $45 a share and reiterated its buy investment rating for the stock. New Article Combined, BIIB and CNC make up approximately 1.8% of the underlying holdings of XLV. Among large Healthcare stocks, Biogen Inc (Symbol: BIIB) and Centene Corp (Symbol: CNC) are the most notable, showing a gain of 29.0% and 7.9%, respectively. Combined, PXD and FANG make up approximately 3.5% of the underlying holdings of XLE. New Article In early trading on Tuesday, shares of Biogen (BIIB) topped the list of the day's best performing components of the S&P 500 index, trading up 35.8%. VIDEO: S&P 500 Movers: HAS, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing S&P 500 component thus far on the day is Hasbro (HAS), trading down 14.4%.",287.9031982421875
2019-10-23 00:00:00+00:00,285.239990234375,286.6700134277344,275.6600036621094,278.82000732421875,278.82000732421875,5522400.0,2.75,1.0,0.437525,"(RTTNews) - Biogen Inc. (BIIB) reportedly are ""reasonably confident"" that the U.S. Food and Drug Administration will approve its experimental Alzheimer's drug. According to CNBC, Biogen CEO Michel Vounatsos told that he is ""reasonably confident"" of receiving approval from FDA for aducanumab, its experimental Alzheimer's drug. Shares of Biogen surged about 26% on Tuesday after the drugmaker announced plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer's disease. New Article Millions of Alzheimer's disease patients, their families, and their friends felt their hearts sink when Biogen (NASDAQ: BIIB) broke the bad news that an experimental Alzheimer's therapy, aducanumab, had failed a pivotal study. Biogen told us that aducanumab failed an interim futility analysis seven months ago, but now the company's arguing that it was wrong and the Alzheimer's candidate actually succeeded. The data monitors that performed the interim analysis had only 18-month results from 1,748 patients, but efficacy measurements were poor enough to assume the big study had no chance to succeed. New Article Biogen (NASDAQ: BIIB) has been a bust for much of 2019. One of them, BIIB098, awaits FDA approval. The biotech said that its decision to submit aducanumab for Food and Drug Administration approval in early 2020 was based on a new analysis of a larger data set from its two late-stage studies that were discontinued earlier this year. New Article In recent trading, shares of Biogen Inc (Symbol: BIIB) have crossed above the average analyst 12-month target price of $253.95, changing hands for $281.87/share. But the whole reason to look at the average BIIB price target in the first place is to tap into a ""wisdom of crowds"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with BIIB crossing above that average target price of $253.95/share, investors in BIIB have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $253.95 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table?",290.6722106933594
2019-10-24 00:00:00+00:00,278.2099914550781,287.0400085449219,278.010009765625,285.67999267578125,285.67999267578125,2803200.0,2.5,1.0,0.375025,"BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068. The following are today's upgrades for Validea's Patient Investor model based on the published strategy of Warren Buffett. New Article Among the largest underlying components of FBT, in trading today Biogen Inc (Symbol: BIIB) is up about 2.2%, Seattle Genetics Inc (Symbol: SGEN) is up about 1.2%, and Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is higher by about 1.3%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the First Trust NYSE Arca Biotechnology Index Fund (Symbol: FBT) where we have detected an approximate $25.6 million dollar outflow -- that's a 1.5% decrease week over week (from 13,000,002 to 12,800,002). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",287.8232116699219
2019-10-28 00:00:00+00:00,283.760009765625,295.9700012207031,283.3900146484375,295.5400085449219,295.5400085449219,2395100.0,3.0,1.0,0.5000249999999999,"Last week was an exciting one for anyone with shares of Arvinas (NASDAQ: ARVN) or Biogen (NASDAQ: BIIB) in their portfolio. Removing troublesome proteins that drive tumor growth seems like an elegant solution for overpowering treatment-resistance mechanisms, but it could prove disastrous if ARV-110's protein-degrading activity isn't limited to AR. Biogen: An interesting discovery This former top-performing biotech stock jumped 31% higher last week, after the company revived aducanumab, an Alzheimer's disease (AD) candidate that had been left for dead earlier this year.",283.4654846191406
2019-10-31 00:00:00+00:00,300.0199890136719,301.5799865722656,295.57000732421875,298.7099914550781,298.7099914550781,1959900.0,4.0,1.0,0.7500249999999999,"Biotechnology major Biogen (NASDAQ: BIIB) saw its stock soar by over 25% in Tuesdays trading, after the company indicated that it intends to seek regulatory approval for its investigational treatment for early-stage Alzheimers disease. The company said that the decision to now pursue approvals is based on the availability of new data from a larger patient group and interactions with the FDA. For more information on Biogens Net Income and EPS, view our interactive dashboard analysis.",278.1664733886719
2019-11-01 00:00:00+00:00,299.7900085449219,303.7900085449219,298.57000732421875,299.20001220703125,299.20001220703125,1463300.0,2.333333333333333,1.0,0.3333583333333332,"So it seemed to be this spring for Biogen's (NASDAQ: BIIB) aducanumab. For decades, every tale in the world of Alzheimer's drug development has followed the same story arc: first a period of hope, expensive effort, and no small amount of brilliance. In this segment of the Oct. 25 Motley Fool Money podcast, host Chris Hill and senior analyst Ron Gross consider just how extraordinary this turn of events is, and offer up an opinion on the obvious question for investors: Is it too late to buy in to Biogen? New Article Biogen (NASDAQ: BIIB) has big news for the company and, hopefully, humanity in general. Jason Moser owns shares of Amazon, Apple, Etsy, Hasbro, Mastercard, PayPal Holdings, Twitter, Visa, and Walt Disney. Steve Broido owns shares of Amazon, Apple, Facebook, Mastercard, Microsoft, Netflix, PayPal Holdings, Shopify, Twitter, Visa, and Walt Disney. New Article Biogen (NASDAQ: BIIB) shook up the medical world by announcing its plans to file with the FDA for a new Alzheimer's drug -- one that the company seemed to have abandoned just earlier this year. In this episode of MarketFoolery, host Mac Greer chats with analysts Ron Gross and Andy Cross about some recent business news. I think this is a chance for shareholders to benefit from a new leadership at the CEO level that hopefully will continue to bring operational discipline into Under Armour and help to boost those North American sales numbers that they desperately need.",268.9156494140625
2019-11-07 00:00:00+00:00,289.5199890136719,290.5599975585937,285.6000061035156,286.8699951171875,286.8699951171875,1430700.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of MOAT, in trading today State Street Corp. (Symbol: STT) is up about 2.3%, Biogen Inc (Symbol: BIIB) is off about 0.6%, and Bristol-Myers Squibb Co. (Symbol: BMY) is up by about 0.3%. For a complete list of holdings, visit the MOAT Holdings page  The chart below shows the one year price performance of MOAT, versus its 200 day moving average: Looking at the chart above, MOAT's low point in its 52 week range is $38.64 per share, with $53.465 as the 52 week high point  that compares with a last trade of $53.35. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",270.0167541503906
2019-11-08 00:00:00+00:00,286.5299987792969,293.3900146484375,285.25,293.25,293.25,1477100.0,3.0,1.0,0.5000249999999999,"Biogen's (NASDAQ: BIIB) drug pipeline took a massive hit earlier this year when the company stopped development of its Alzheimer's disease drug, aducanumab, for a lack of efficacy. Just like a zombie, biotech behemoth Biogen, ticker BIIB, is now resurrecting a program back from the grave. In this episode of Industry Focus: Healthcare, host Shannon Jones and Fool.com contributor Todd Campbell explain why aducanumab was shelved in the first place and whether Biogen's data is good enough to secure an FDA approval.",267.0758972167969
2019-11-12 00:00:00+00:00,295.0,296.25,289.1199951171875,291.3999938964844,291.3999938964844,1860900.0,3.0,1.0,0.5000249999999999,"Especially high volume was seen for the $285 strike put option expiring November 15, 2019, with 2,760 contracts trading so far today, representing approximately 276,000 underlying shares of BIIB. Below is a chart showing CPB's trailing twelve month trading history, with the $45.50 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 17,662 contracts thus far today. That number of contracts represents approximately 1.8 million underlying shares, working out to a sizeable 57.8% of BIIB's average daily trading volume over the past month, of 3.1 million shares. New Article Biotech Stocks to Buy: Biogen (BIIB) Source: Shutterstock Biogen (NASDAQ:) shares languished through much of 2019 when the company abruptly canceled its Alzheimers drug. Adding BIIB094 to its pipeline will advance its antisense oligonucleotide (or ASO) for targeting the most common genetic cause of Parkinsons disease. The company managed its mature product line and will have more than enough cash flow to grow its dividend and service the debt incurred through the Allergan buyout.",263.8143310546875
2019-11-14 00:00:00+00:00,282.8399963378906,282.8399963378906,271.4800109863281,275.1499938964844,275.1499938964844,2354800.0,2.0,1.0,0.250025,"Combined, REGN and BIIB make up approximately 1.9% of the underlying holdings of XLV. Among large Healthcare stocks, Regeneron Pharmaceuticals, Inc. (Symbol: REGN) and Biogen Inc (Symbol: BIIB) are the most notable, showing a loss of 2.3% and 2.0%, respectively. Combined, KHC and PM make up approximately 6.7% of the underlying holdings of IYK.",256.1897888183594
2019-11-15 00:00:00+00:00,278.25,283.95001220703125,277.1099853515625,282.2699890136719,282.2699890136719,1922200.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of MOAT, in trading today State Street Corp. (Symbol: STT) is off about 0.2%, Biogen Inc (Symbol: BIIB) is up about 1.6%, and Bristol-Myers Squibb Co. (Symbol: BMY) is higher by about 0.2%. For a complete list of holdings, visit the MOAT Holdings page  The chart below shows the one year price performance of MOAT, versus its 200 day moving average: Looking at the chart above, MOAT's low point in its 52 week range is $38.64 per share, with $53.78 as the 52 week high point  that compares with a last trade of $53.71. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",257.49285888671875
2019-11-22 00:00:00+00:00,288.3999938964844,301.8599853515625,288.32000732421875,299.0799865722656,299.0799865722656,3288200.0,4.0,1.0,0.7500249999999999,"(RTTNews) - Biogen Inc. (BIIB) said that the Phase 3 EVOLVE-MS-2 study demonstrated improved patient-assessed gastrointestinal or GI tolerability of Vumerity, a new FDA-approved treatment for relapsing forms of multiple sclerosis or MS, compared to Tecfidera. Results for the primary endpoint show patients treated with Vumerity self-reported 46 percent fewer days with intensity scores of =2 on the Individual Gastrointestinal Symptom and Impact Scale (IGISIS), compared to Tecfidera. The EVOLVE-MS-2 results also indicate that compared to TECFIDERA, VUMERITY-treated patients had lower discontinuations due to GI adverse events (AEs) (0.8 percent vs. 4.8 percent).",261.6612548828125
2019-11-27 00:00:00+00:00,303.6099853515625,304.0,298.67999267578125,303.3500061035156,303.3500061035156,1369900.0,4.0,1.0,0.7500249999999999,"Indeed, the company's most recent results reflect the success of these efforts -- Q3 worldwide net revenues rose 3% to $8.5 billion despite the decline in Humira's sales and AbbVie raised its 2019 full-year adjusted earnings per share (EPS) guidance. In June, the company announced that it would acquire Allergan (NYSE: AGN), a specialty-drug manufacturer known for blockbuster drugs such as Botox and Restasis, for $63 billion. With $16 billion in annual revenue in mostly unrelated therapeutic markets, Allergan's addition will further wean AbbVie off of dependence on Humira's franchise. New Article Multinational biotech Biogen (NASDAQ: BIIB) is facing two important decisions -- one that could open the door to a vast new market (Alzheimer's disease treatment) and another that could challenge the dominance of its top-selling multiple sclerosis (MS) drug. It's the perfect moment to keep an eye on the share price, but with those two unknowns hovering, it may be too early for biotech investors to expect steady gains or a lasting rebound. Any positive details from the Clinical Trials on Alzheimer's Disease meeting next month could be a short-term catalyst for further gains, but the slowing growth in MS drugs and the uncertainty surrounding the FDA and Tecfidera patent decisions may lead to volatility.",251.90286254882812
2019-12-06 00:00:00+00:00,299.67999267578125,304.5599975585937,299.67999267578125,300.260009765625,300.260009765625,2261100.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of PJP, in trading today Medicines Co (Symbol: MDCO) is up about 0.3%, Lilly (Eli) & Co (Symbol: LLY) is up about 0.2%, and Biogen Inc (Symbol: BIIB) is higher by about 0.9%. For a complete list of holdings, visit the PJP Holdings page  The chart below shows the one year price performance of PJP, versus its 200 day moving average: Looking at the chart above, PJP's low point in its 52 week range is $54.86 per share, with $69.3792 as the 52 week high point  that compares with a last trade of $63.83. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",244.83973693847656
2019-12-09 00:00:00+00:00,300.2699890136719,304.32000732421875,295.4599914550781,295.54998779296875,295.54998779296875,2077000.0,3.0,1.0,0.5000249999999999,"Investors eyeing a purchase of Biogen Inc (Symbol: BIIB) shares, but tentative about paying the going market price of $300.10/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to BIIB's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. For other put options contract ideas at the various different available expirations, visit the BIIB Stock Options page of StockOptionsChannel.com. New Article PDL said that it planned to ""halt the execution of its growth strategy, cease additional strategic investments, and pursue a formal process to unlock value by monetizing the Company's assets and returning net proceeds to shareholders."" The company's cash and other assets, including its stakes in cataract and astigmatism laser surgery provider LENSAR and Evofem Biosciences, arguably make PDL worth significantly more than its recent market cap. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and PDL BioPharma wasn't one of them!",248.3645782470703
2019-12-12 00:00:00+00:00,291.94000244140625,296.1700134277344,290.92999267578125,293.8500061035156,293.8500061035156,1951100.0,2.0,1.0,0.250025,"On Dec. 5, Biogen (NASDAQ: BIIB) announced its initial phase 3 trial results for its late-stage Alzheimer's drug candidate, aducanumab. However, while patients taking higher doses had indeed shown some signs of improvement, the information proved much more confusing than first anticipated and it was far from the home run Biogen bulls were hoping for. Analyst Steven Seedhouse from Raymond James said, ""We assign 0% probability to aducanumab being approved,"" while Wedbush's Laura Chico said that this data was as ""clear as mud.""",254.25477600097656
2019-12-13 00:00:00+00:00,298.0,304.0,294.8900146484375,296.8299865722656,296.8299865722656,1946100.0,1.0,1.0,2.4999999999997247e-05,"(RTTNews) - Biogen Inc. (BIIB) said that it will discontinue development of gosuranemab for progressive supranuclear palsy and other primary tauopathies. The primary endpoint of the Phase 2 PASSPORT of gosuranemab for progressive supranuclear palsy was not statistically significant. The company noted that it will continue its ongoing Phase 2 TANGO study of gosuranemab for mild cognitive impairment due to Alzheimer's disease (AD) or mild AD, given differences in disease pathology.",244.66123962402344
2019-12-17 00:00:00+00:00,301.8599853515625,301.92999267578125,296.29998779296875,297.1099853515625,297.1099853515625,1360300.0,4.0,1.0,0.7500249999999999,"Biotech Stocks to Buy: Biogen (BIIB) Source: Pavel Kapysh / Shutterstock.com Biogen (NASDAQ:) rose from $220 to $300 in October when the company said it would resume filing for approval to bring its Alzheimers therapy drug to market. And so, if the drug passes regulatory review, BIIB stock will live up to its hype. Analysts who offer a price target on BIIB stock have an average of a .",242.88519287109375
2019-12-19 00:00:00+00:00,297.2699890136719,298.7699890136719,295.010009765625,297.5799865722656,297.5799865722656,1472400.0,4.0,1.0,0.7500249999999999,"Biogen Inc. (BIIB) Source: Pavel Kapysh / Shutterstock.com Forward Price-to-Earnings Ratio: 9 Some value stocks trade for peanuts thanks to pessimism. For starters, BIIB has been hit hard on the general pessimism surrounding healthcare stocks and the current political environment. As a maker of expensive neuroscience drugs, BIIB is in the crosshairs of potential pricing regulation. New Article The FDA approved Vascepa for the treatment of patients with high triglyceride (blood sugar) levels who are taking statins (cholesterol-lowering drugs) and have heart disease. Litigation and Valuation Some of those who are bearish on Amarin stock have raised the issue of lawsuits that have been filed by generic drug makers seeking to market versions of Vascepa. But what some investors (and short sellers) may not have known is that Teva (NYSE:), the largest generic drug maker in the world with a pretty big market cap of $11 billion, settled its lawsuit against Amarin in 2018.",250.80555725097656
2019-12-24 00:00:00+00:00,301.6400146484375,304.6499938964844,301.07000732421875,304.07000732421875,304.07000732421875,433700.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of IBB, in trading today Illumina Inc (Symbol: ILMN) is trading flat, Biogen Inc (Symbol: BIIB) is up about 0.6%, and Regeneron Pharmaceuticals, Inc. (Symbol: REGN) is higher by about 0.1%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $90.13 per share, with $123.11 as the 52 week high point  that compares with a last trade of $122.81. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",243.54641723632812
2020-01-03 00:00:00+00:00,290.7699890136719,292.67999267578125,290.2200012207031,290.8500061035156,290.8500061035156,700100.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of IBB, in trading today Gilead Sciences Inc (Symbol: GILD) is off about 0.5%, Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is down about 0.5%, and Biogen Inc (Symbol: BIIB) is lower by about 0.7%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $96.03 per share, with $123.68 as the 52 week high point  that compares with a last trade of $118.74. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",233.41993713378906
2020-01-08 00:00:00+00:00,288.8800048828125,294.19000244140625,287.8099975585937,292.6600036621094,292.6600036621094,1059000.0,2.0,1.0,0.250025,"AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two pharma stocks that haven't performed well lately. Beyond Humira, the company can count on such products as cancer drugs Venclexta and Imbruvica, as well as Skyrizi, a medicine for moderate-to-severe plaque psoriasis. The company's lineup also includes MS drug Tysabri, a treatment for spinal muscular atrophy, and Flixabi, a biosimilar for rheumatoid arthritis.",228.2897186279297
2020-01-09 00:00:00+00:00,293.989990234375,296.57000732421875,292.3599853515625,294.29998779296875,294.29998779296875,966500.0,2.0,1.0,0.250025,"Especially high volume was seen for the $295 strike call option expiring January 10, 2020, with 394 contracts trading so far today, representing approximately 39,400 underlying shares of BIIB. Below is a chart showing WHR's trailing twelve month trading history, with the $140 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 6,410 contracts, representing approximately 641,000 underlying shares or approximately 48% of BIIB's average daily trading volume over the past month, of 1.3 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $295 strike highlighted in orange: For the various different available expirations for BLK options, WHR options, or BIIB options, visit StockOptionsChannel.com.",237.13815307617188
2020-01-10 00:00:00+00:00,294.6400146484375,298.739990234375,294.3599853515625,296.510009765625,296.510009765625,1164500.0,3.0,1.0,0.5000249999999999,"In recent trading, shares of Biogen Inc (Symbol: BIIB) have crossed above the average analyst 12-month target price of $293.96, changing hands for $294.30/share. But the whole reason to look at the average BIIB price target in the first place is to tap into a ""wisdom of crowds"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with BIIB crossing above that average target price of $293.96/share, investors in BIIB have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $293.96 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table?",244.29258728027344
2020-01-13 00:00:00+00:00,294.8099975585937,295.5,290.8299865722656,293.8999938964844,293.8999938964844,1401100.0,2.5,1.0,0.375025,"Among the largest underlying components of IBB, in trading today Gilead Sciences Inc (Symbol: GILD) is off about 0.5%, Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is trading flat, and Biogen Inc (Symbol: BIIB) is lower by about 0.9%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $96.03 per share, with $123.68 as the 52 week high point  that compares with a last trade of $119.34. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Biogen (NASDAQ: BIIB) announced it has reached an agreement with Pfizer (NYSE: PFE) to buy a drug in early development that is designed to treat debilitating symptoms related to the disruption of daily rhythms in patients with Alzheimer's and Parkinson's disease. Pfizer spun off its drug candidates for central nervous system (CNS) disorders in 2018 to create Cerevel Therapeutics, jointly owned with Bain Capital, but PF-05251749 apparently didn't make the cut and was put up for sale at a low price. Biogen intends to initiate a phase 2B study of PF-05251749 in the fourth quarter of 2020 as part of its effort to grow its assets in CNS drugs.",243.3655242919922
2020-01-14 00:00:00+00:00,294.1000061035156,306.3500061035156,291.2699890136719,298.9700012207031,298.9700012207031,2112600.0,4.0,1.0,0.7500249999999999,"Newly released research from the Universities of Edinburgh and Dundee have found that certain probiotics can reduce the buildup of a specific protein linked to the onset of Parkinson's. Researchers used worms that were specifically designed to produce the human version of the alpha-synuclein protein, which is associated with the deterioration of dopamine-producing nerve cells in the brain. In June 2019, Johns Hopkins University School of Medicine found that in mice, alpha-synuclein protein can travel from the intestines to the brain, where it eventually starts destroying dopamine-producing nerve cells.",235.48126220703125
2020-01-15 00:00:00+00:00,298.94000244140625,300.3699951171875,292.4100036621094,293.0899963378906,293.0899963378906,1975600.0,3.0,1.0,0.5000249999999999,"Biogen (BIIB) Source: Provided by Finviz For Biogen (NASDAQ:), it does seem like more gains are on the way. BIIB stock has been trading sideways for years, and still sits well below early 2015 levels. On Tuesday, two of the three indices closed in the red; the Dow Jones Industrial Average eked out a 0.15% gain thanks to an earnings beat from JPMorgan Chase (NYSE:).",231.0320587158203
2020-01-16 00:00:00+00:00,294.489990234375,294.79998779296875,284.239990234375,286.1400146484375,286.1400146484375,2800000.0,2.6666666666666665,1.0,0.4166916666666666,"Within that group, Biogen Inc (Symbol: BIIB) and Regeneron Pharmaceuticals, Inc. (Symbol: REGN) are two of the day's laggards, showing a loss of 2.4% and 1.5%, respectively. Combined, BIIB and REGN make up approximately 2.2% of the underlying holdings of XLV. Combined, HP and APA make up approximately 1.6% of the underlying holdings of XLE. New Article What happened Biotech heavyweight Biogen (NASDAQ: BIIB) failed to follow the broader industry higher last year. So what Biogen's stock lost ground for three key reasons in 2019: The company's core multiple sclerosis franchise essentially flatlined from a revenue generation standpoint. Although Biogen did reel off a handful of important business development deals in 2019, the company didn't pursue a bolt-on acquisition that would immediately change its near-term outlook. New Article Much of the company's money is coming from sales of blockbuster rare disease drug Spinraza, a partnership with Biogen (NASDAQ: BIIB). Fortunately, there are some mid-cap biotechs actually making a profit and that have development pipelines stocked with drug candidates that could produce big winners, giving patient investors the opportunity for gains while riding out the occasional disappointment. In October, the company's subsidiary Akcea (NASDAQ: AKCA) announced it inked a deal with Pfizer (NYSE: PFE) to advance AKCEA-ANGPTL3-LRx, a drug that has the potential to treat large populations of patients with type 2 diabetes, high levels of blood triglycerides, and non-alcoholic fatty liver disease (NASH).",229.89675903320312
2020-01-21 00:00:00+00:00,286.5400085449219,287.8399963378906,282.760009765625,287.19000244140625,287.19000244140625,2253100.0,2.5,1.0,0.375025,"Biogen (NASDAQ: BIIB) shocked investors last year when it said it would submit its investigational Alzheimer's drug to the Food and Drug Administration for approval -- months after halting studies that showed the drug didn't work. Often, the FDA bases a decision on ""surrogate"" endpoints, which measure quicker-to-establish elements like tumor shrinkage in the case of cancer drugs, rather than clinical outcomes like survival or disease-free status. ""The FDA has increasingly accepted less data and more surrogate measures, and has shortened its review times,"" according to a recent paper in The Journal of the American Medical Association. New Article Among the largest underlying components of IBB, in trading today Gilead Sciences Inc (Symbol: GILD) is off about 0.9%, Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is down about 0.3%, and Biogen Inc (Symbol: BIIB) is relatively unchanged. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $96.03 per share, with $123.68 as the 52 week high point  that compares with a last trade of $121.12. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",230.2584991455078
2020-01-23 00:00:00+00:00,287.2300109863281,288.0799865722656,281.2099914550781,284.2099914550781,284.2099914550781,1936100.0,4.0,1.0,0.7500249999999999,"""This large, global trial confirms the efficacy of risdiplam in an advanced and difficult-to-treat population, including many infants whose disease had already progressed significantly before starting treatment,"" Roche's Chief Medical officer, Levi Garraway said. However, pharmaceutical giants have had some success in this area, with both Biogen's Spinraza and Novartis' Zolgensma making injectable drugs available for infants with SPA. Wall Street analysts, such as Canto Fitzgerald's Alethia Young, think that the drug could reach blockbuster status with peak annual revenues of over $1 billion in the future.",223.08226013183594
2020-01-27 00:00:00+00:00,278.1400146484375,282.3299865722656,276.239990234375,281.1400146484375,281.1400146484375,1405500.0,2.0,1.0,0.250025,"In early trading on Monday, shares of Biogen (BIIB) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 0.3%. VIDEO: Nasdaq 100 Movers: AAL, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing Nasdaq 100 component thus far on the day is American Airlines Group (AAL), trading down 6.9%.",210.8592529296875
2020-01-29 00:00:00+00:00,282.04998779296875,283.3800048828125,279.6600036621094,282.5199890136719,282.5199890136719,1166200.0,2.5,1.0,0.375025,"Among the largest underlying components of IBB, in trading today Gilead Sciences Inc (Symbol: GILD) is up about 0.1%, Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is down about 0.2%, and Biogen Inc (Symbol: BIIB) is lower by about 0.3%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $96.03 per share, with $123.68 as the 52 week high point  that compares with a last trade of $117.67. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Biogen Biogen's (NASDAQ: BIIB) top line reflected more than $14.2 billion in sales over the past 12 months as it looks to be on track for another improved year. With a forward price-to-earnings multiple of less than nine and a PEG ratio of one, the stock is a very good buy when factoring in the future growth of the company. And while that will certainly diversify the company's sales and inject more growth, its execution will be heavily scrutinized by investors given its hefty $63 billion price tag.",199.44473266601562
2020-01-30 00:00:00+00:00,288.1199951171875,288.1199951171875,276.1400146484375,277.5299987792969,277.5299987792969,1601000.0,3.1666666666666665,1.0,0.5416916666666668,"The drugmaker also has a biosimilar to Biogen's (NASDAQ: BIIB) and Roche's (OTC: RHHBY) Rituxan that was submitted to the FDA in December. Psoriasis and psoriatic arthritis treatment Otezla, which Amgen acquired to facilitate Bristol-Myers Squibb's (NYSE: BMY) closing of its deal with Celgene, added $178 million in revenue during the five weeks or so that Amgen owned the drug during the quarter. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Amgen wasn't one of them! New Article (RTTNews) - Biogen Inc. (BIIB) released a profit for its fourth quarter that increased from last year. Excluding items, Biogen Inc. reported adjusted earnings of $1.49 billion or $8.34 per share for the period. Analysts had expected the company to earn $8.02 per share, according to figures compiled by Thomson Reuters. New Article (RTTNews) - While reporting financial results for the fourth quarter on Thursday, Biogen Inc. (BIIB) initiated its earnings, adjusted earnings and revenue guidance for the full-year 2020. On average, analysts polled by Thomson Reuters expect the company to report earnings of $33.03 per share on revenues of $14.06 billion for the year. Analysts' estimates typically exclude special items. New Article Biogen Inc (NASDAQ: BIIB) Q4 2019 Earnings Call Jan 30, 2020, 8:00 a.m. Fifth, beyond aducanumab, we continue to expand and progress our pipeline with approval for VUMERITY in the US, a positive data readout for BIIB059 in lupus, and adding seven new clinical program in MS, ALS, Parkinson's disease, ophthalmology and brain contusion. In addition to aducanumab, we continue to advance a broad Alzheimer's disease portfolio, including the Phase III study of BAN2401; BIIB080, a tau-targeted antisense oligonucleotide in Phase I; BIIB076, an anti-tau antibody in Phase I; and gosuranemab, a distinct anti-tau antibody in Phase II for which we expect data next year. New Article Biogen (NASDAQ: BIIB) delivered its fourth-quarter earnings report on Thursday, showing revenue up 4% year-over-year to $3.67 billion. Sales of its older interferon drugs for multiple sclerosis continued their decline of the last few years, falling 14%. But its growth rate is decelerating -- for the year, Spinraza sales were up 22% -- now that the drug must compete with Novartis' gene therapy Zolgensma. New Article Specifically, the drugmaker topped Factset's consensus revenue estimate for the three-month period by a healthy 3.38% and Wall Street's non-GAAP earnings-per-share forecast by a striking 13.8%. Even AstraZeneca (NYSE: AZN) and its supercharged portfolio of red-hot diabetes, oncology, and respiratory medicines isn't expected to hit such lofty heights when the drugmaker reports its latest financial results next month. The most potent value creators in biopharma tend to come from internally discovered candidates or products in-licensed during early stages of development (preclinical or immediately after a successful proof-of-concept trial).",199.23326110839844
2020-01-31 00:00:00+00:00,276.0799865722656,276.2799987792969,267.5899963378906,268.8500061035156,268.8500061035156,1701700.0,2.6666666666666665,1.0,0.4166916666666666,"The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday recommended that the European Commission approve Pfizer's (NYSE: PFE) drug Ruxience, a biosimilar to MabThera, which to Roche (OTC: RHHBY) and Biogen (NASDAQ: BIIB) sell in the U.S. as Rituxan. CHMP's positive opinion was based on a clinical trial, dubbed Reflections B3281006, which compared Ruxience to the branded biologic drug MabThera in patients with a specific type of follicular lymphoma. This difference in how they're manufactured means that while another company may be able to develop a biologic that does essentially the same thing as a previously approved drug, that new version -- the biosimilar -- will not be not quite the same as the original -- thus the ""similar"" in the name. New Article The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday recommended that the European Commission approve Pfizer's (NYSE: PFE) drug Ruxience, a biosimilar to MabThera, which to Roche (OTC: RHHBY) and Biogen (NASDAQ: BIIB) sell in the U.S. as Rituxan. CHMP's positive opinion was based on a clinical trial, dubbed Reflections B3281006, which compared Ruxience to the branded biologic drug MabThera in patients with a specific type of follicular lymphoma. This difference in how they're manufactured means that while another company may be able to develop a biologic that does essentially the same thing as a previously approved drug, that new version -- the biosimilar -- will not be not quite the same as the original -- thus the ""similar"" in the name. New Article In trading on Friday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 27.1, after changing hands as low as $267.59 per share. A bullish investor could look at BIIB's 27.1 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of BIIB shares: Looking at the chart above, BIIB's low point in its 52 week range is $215.775 per share, with $338.87 as the 52 week high point  that compares with a last trade of $268.53.",206.42605590820312
2020-02-04 00:00:00+00:00,276.3999938964844,285.6000061035156,275.94000244140625,283.2900085449219,283.2900085449219,1684400.0,2.0,1.0,0.250025,"iShares Russell Top 200 Value ETF IWX $57.37 $63.41 10.53% Humana Inc. HUM $333.09 $378.53 13.64% Honeywell International Inc HON $171.32 $193.90 13.18% Biogen Inc BIIB $272.73 $308.05 12.95% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IWX's underlying holdings with notable upside to their analyst target prices are Humana Inc. (Symbol: HUM), Honeywell International Inc (Symbol: HON), and Biogen Inc (Symbol: BIIB). Similarly, HON has 13.18% upside from the recent share price of $171.32 if the average analyst target price of $193.90/share is reached, and analysts on average are expecting BIIB to reach a target price of $308.05/share, which is 12.95% above the recent price of $272.73.",210.8826141357422
2020-02-05 00:00:00+00:00,285.6300048828125,374.989990234375,279.17999267578125,332.8699951171875,332.8699951171875,10159200.0,3.0,1.0,0.5000249999999999,"What happened Shares of Alkermes (NASDAQ: ALKS) closed almost 11% higher in Wednesday trading on news that Biogen (NASDAQ: BIIB) had successfully defended its patent on its multiple sclerosis drug Tecfidera. So what If the Patent Trial and Appeal Board (PATB) had ruled in favor of challenger Mylan (NASDAQ: MYL), that company could have launched a generic version of Tecfidera that would have competed with Vumerity. This patent win will give Biogen until 2028 to get patients to switch over to Vumerity, maximizing Alkermes' royalties on the drug. New Article Biogen (NASDAQ: BIIB) is up 18% today as news regarding a crucial patent ruling came out in the company's favor. A U.S. appeals panels denied a patient challenge (otherwise known as an inter partes review, or IPR) for Biogen's multiple sclerosis drug Tecfidera, which was contested by a generic version developed by Mylan. The loss of the patent would have meant that Mylan's cheaper generic drug could enter the market, siphoning off a major part of Tecfidera's revenue. New Article Amgen recently submitted a biologics license application to the FDA for a biosimilar version of Rituxan, Biogen's (NASDAQ: BIIB) and Genentech's cancer drug. What happened Shares of Amgen (NASDAQ: AMGN) fell 10.4% in January, according to data provided by S&P Global Market Intelligence, after the stock rose 24% last year and reached an all-time high in December. While brighter news such as a 10% increase in the 2020 first-quarter dividend and a Food and Drug Administration approval for Amgen's fourth biosimilar buoyed the shares late last year, as fourth-quarter and full-year earnings approached, some investors decided to lock in profits in anticipation of a further slowdown in the company's older products.",212.54458618164062
2020-02-07 00:00:00+00:00,335.3900146484375,340.32000732421875,331.6600036621094,338.70001220703125,338.70001220703125,2209400.0,3.6666666666666665,1.0,0.6666916666666666,"Learn about Vertex (NASDAQ: VRTX), Biogen (NASDAQ: BIIB), and Novartis (NYSE: NVS) -- what these companies do, how they've performed for investors, where they can grow from here, what kinds of treatments they offer consumers. Moser: [laughs] Well, I must admit, when we came up with this Wild Card Wednesday idea and found that you were moving on to other jobs here, I thought, you know what, I need to make sure I get this in my head to get Shannon back in here quickly. If the FDA -- which has leaned more lenient recently, especially with high unmet need areas like Alzheimer's -- if this happens, this could be a true game changer, not just for Biogen but biotech in general. New Article On Thursday, Roche (OTC: RHHBY) announced the much-anticipated results from a study of the company's experimental spinal muscular atrophy (SMA) drug, resdiplam. The data showed a significant improvement in the motor functions of patients taking risdiplam in comparison to the placebo group. Further details SMA is a genetic disorder that causes patients to lose muscle control due to the deterioration of nerve cells in the spine and brain. New Article However, Biogen (NASDAQ: BIIB) shocked the biotech world with its bombshell announcement last October that it's seeking Food and Drug Administration approval for an Alzheimer's therapy that initially failed its pivotal trial. The scientific thesis for Cortexyme's approach focuses on the discovery that the P. gingivalis bacteria can enter the bloodstream and make its way to the brain, particularly in older individuals and those with a genetic predisposition. Case in point: European specialty pharma Lundbeck paid $100 million to secure the rights to an Alzheimer's disease drug from Myriad Genetics in 2008.",211.6056365966797
2020-02-10 00:00:00+00:00,332.0,339.5599975585937,330.239990234375,338.92999267578125,338.92999267578125,1867000.0,2.0,1.0,0.250025,"Among the largest underlying components of IBB, in trading today Gilead Sciences Inc (Symbol: GILD) is trading flat, Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is up about 0.5%, and Biogen Inc (Symbol: BIIB) is lower by about 0.8%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $96.03 per share, with $123.68 as the 52 week high point  that compares with a last trade of $121.86. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",207.6079864501953
2020-02-11 00:00:00+00:00,338.0599975585937,340.04998779296875,329.7200012207031,332.2900085449219,332.2900085449219,1806200.0,2.0,1.0,0.250025,"Biogen (NASDAQ: BIIB) shares surged as much as 32% on Wednesday after the company won a patent challenge to its billion-dollar multiple sclerosis (MS) drug, Tecfidera. The U.S. Food and Drug Administration (FDA) approved Vumerity in October, and the product's first quarter on the market generated $5 million; it will take time to see if this new treatment can indeed reach the sales levels of the current blockbuster. Writing ahead of the decision, SVB Leerink analyst Geoffrey Porges, who expected Biogen to prevail, had predicted a 5% share gain on a victory and a 12% decline on a loss of the review and appeal. New Article Among large Healthcare stocks, Wellcare Health Plans Inc (Symbol: WCG) and Biogen Inc (Symbol: BIIB) are the most notable, showing a loss of 42.8% and 2.0%, respectively. Combined, WCG and BIIB make up approximately 1.8% of the underlying holdings of XLV. Combined, UAA and UA make up approximately 0.2% of the underlying holdings of IYK.",223.56869506835938
2020-02-13 00:00:00+00:00,329.20001220703125,338.8800048828125,329.0,334.25,334.25,1307300.0,3.0,1.0,0.5000249999999999,"Not surprisingly, the big biotechs Amgen (NASDAQ: AMGN), Biogen (NASDAQ: BIIB), and Gilead Sciences (NASDAQ: GILD) have each delivered million-dollar paydays for their original shareholders. In fact, the brave souls who got in on the ground floor in some of the industry's biggest names typically only had to shell out fairly modest amounts of capital (less than $10,000) to realize a million-dollar gain. What's more, Gilead's stock would have delivered a staggering $1.47 million in total returns if you sold it at the top back in 2015, when the company's all-star hepatitis C franchise was generating money hand over fist.",220.27281188964844
2020-02-18 00:00:00+00:00,343.6600036621094,344.0,334.0899963378906,337.1000061035156,337.1000061035156,1515100.0,2.6666666666666665,1.0,0.4166916666666666,"Among the largest underlying components of IBB, in trading today Gilead Sciences Inc (Symbol: GILD) is off about 0.6%, Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is down about 0.8%, and Biogen Inc (Symbol: BIIB) is up by about 1%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $96.03 per share, with $123.68 as the 52 week high point  that compares with a last trade of $121.86. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article (RTTNews) - Warren Buffett's business conglomerate Berkshire Hathaway Inc. (BRK.A, BRK.B), on February 14, disclosed its equity portfolio for the fourth quarter of 2019, listing new stakes in The Kroger (KR) and Biogen (BIIB). Berkshire Hathaway bought a 2.4% stake in one of the largest grocery retailers in the country, Kroger for $549 million. Analysts polled by Thomson Reuters expect earnings to be $0.55 per share on revenue of $28.83 billion in the quarter. New Article SEE ALSO: 30 Massive Dividend Increases From the Past Year Biogen Action: New position Shares held: 648,447 Value of stake: $192,414,000 Berkshire Hathaway boosted its holdings in the health-care sector after buying a new stake in biotechnology giant Biogen (BIIB, $333.00). The BIIB holdings account for just 0.08% of BRK.B's total equity portfolio. BIIB is having success with Spinraza, a medication for spinal muscular atrophy.",215.9525146484375
2020-02-19 00:00:00+00:00,338.0,341.7699890136719,335.4200134277344,341.0400085449219,341.0400085449219,1488400.0,2.0,1.0,0.250025,"And a big biotech, Biogen (NASDAQ: BIIB), was one of the new additions. Risky business Biogen achieved tremendous success with its multiple sclerosis franchise; MS drugs such as Avonex, Plegridy, Tysabri, and Tecfidera racked up huge sales. That growth, which is unspectacular for a biotech, stemmed largely from the company's spinal muscular atrophy (SMA) drug Spinraza.",215.07150268554688
2020-02-21 00:00:00+00:00,336.9700012207031,337.82000732421875,334.6000061035156,336.7099914550781,336.7099914550781,923200.0,3.0,1.0,0.5000249999999999,"The latest report discloses Berkshire Hathaway's established new positions in Kroger (NYSE: KR) and Biogen (NASDAQ: BIIB). BIIB Price to Free Cash Flow data by YCharts. A patent win, plus a long-shot bet that could pay off Warren Buffett typically avoids tough-to-understand industries like biotech, but that didn't stop Biogen from showing up in the Oracle of Omaha's portfolio last quarter.",220.4909210205078
2020-02-25 00:00:00+00:00,327.20001220703125,330.6099853515625,322.70001220703125,324.1099853515625,324.1099853515625,1831100.0,3.0,1.0,0.5000249999999999,"Biogen (BIIB) Source: Pavel Kapysh / Shutterstock.com Since the start of February 2020, shares of Biogen (NASDAQ:) exploded from a low of $269.76 to a recent high of $336. Its better to have a than to own all of a rhinestone. If youre not looking to buy up companies across the United States, stick with the basics and make stock market purchases in Warren Buffetts signature style. While we have great respect for Berkshire, its track record in consumables is mixed (Kraft (NASDAQ:) recently and Walmart (NYSE:) a few years ago). New Article Biogen: 648,447 shares purchased Now, if there was a purchase that had all the hallmarks of not being Buffett's doing, the 648,447-share purchase of biotech company Biogen (NASDAQ: BIIB) is it. Although 13Fs do have limitations (e.g., the holdings listed are 45 days old when made public), they can still offer incredible insight as to what sectors, industries, stocks, and trends have money managers' attention. The reason Buffett acquired more than 11.4 million additional shares of Occidental is simple: He views it as more attractive than integrated oil and gas giant Phillips 66, which he continues to pare down.",209.2667694091797
2020-02-26 00:00:00+00:00,326.9800109863281,330.92999267578125,323.6099853515625,327.45001220703125,327.45001220703125,1411300.0,3.6666666666666665,1.0,0.6666916666666666,"Notable purchases included about $450 million worth of Occidental Petroleum (NYSE: OXY) and new stakes in Kroger (NYSE: KR) and Biogen (NASDAQ: BIIB) worth about $575 million and $200 million, respectively, as of this writing. Now, only two conditions need to be met: Buffett and Vice Chairman Charlie Munger must both agree that the stock price is below its intrinsic value, as determined by conservative calculation methods. The repurchases leave Berkshire with sufficient cash reserves, which the company has typically defined as $20 billion. New Article It's marketed by Biogen (NASDAQ: BIIB), which pays royalties to Ionis. Ionis Pharmaceuticals (NASDAQ: IONS) reported its fourth-quarter and full-year results on Wednesday, and surpassed its revenue and earnings estimates for the year. Ionis has multiple deals in place with big pharma players, including  collaborations with Roche, Pfizer, Novartis, Bayer, AstraZeneca, and GlaxoSmithKline. New Article Among the largest underlying components of IBB, in trading today Gilead Sciences Inc (Symbol: GILD) is up about 1.5%, Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is up about 1.7%, and Biogen Inc (Symbol: BIIB) is higher by about 0.8%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $96.03 per share, with $123.92 as the 52 week high point  that compares with a last trade of $118.49. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",222.7069854736328
2020-02-27 00:00:00+00:00,324.7200012207031,325.54998779296875,309.6300048828125,310.0799865722656,310.0799865722656,2221100.0,3.0,1.0,0.5000249999999999,"(RTTNews) - Biogen Inc. (BIIB) and Sangamo Therapeutics Inc. (SGMO), Thursday announced that they have reached a global collaboration deal to develop gene regulation therapies for Alzheimer's, Parkinson's, neuromuscular, and other neurological diseases. The companies will leverage Sangamo's proprietary zinc finger protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases. ""As a pioneer in neuroscience, Biogen will collaborate with Sangamo on a new gene regulation therapy approach, working at the DNA level, with the potential to treat challenging neurological diseases of global significance. New Article Sangamo Therapeutics (NASDAQ: SGMO) announced after the bell on Thursday that it signed a partnership with Biogen (NASDAQ: BIIB) to develop a number of gene-editing treatments. Another candidate Sangamo is working on, ST-502, treats another class of neurodegenerative disorders known as synucleinopathies, which includes Alzheimer's disease. The announcement also mentioned a third undisclosed neuromuscular disease that the two biotech companies are targeting, although it's anyone's guess at this point as to which condition it could be.",225.15960693359375
2020-02-28 00:00:00+00:00,300.2300109863281,310.5400085449219,299.0,308.3900146484375,308.3900146484375,2396200.0,4.0,1.0,0.7500249999999999,"What happened Shares of Sangamo Therapeutics (NASDAQ: SGMO) closed up 28% on Friday after the biotech announced a deal with Biogen (NASDAQ: BIIB) to develop up to 12 drugs using Sangamo's proprietary zinc finger protein technology. Now what This is clearly a great deal for Sangamo, with plenty of up-front cash to help pay for its pipeline of other drugs. * David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Sangamo Therapeutics wasn't one of them!",232.4593963623047
2020-03-03 00:00:00+00:00,320.2799987792969,333.0,311.8699951171875,315.7799987792969,315.7799987792969,2036100.0,4.0,1.0,0.7500249999999999,"What happened Shares of Biogen (NASDAQ: BIIB) rose 14.7% in February, according to data provided by S&P Global Market Intelligence, after the company won a patent ruling concerning its blockbuster multiple sclerosis drug. An even bigger catalyst for Biogen in the coming months will likely be news linked to aducanumab, the investigational Alzheimer's treatment the company revived in the fall after ending the program earlier in the year. But any further good news on the Tecfidera patent, progress in Vumerity sales, and optimism about the company's Alzheimer's treatment may send the biotech stock higher.",231.77642822265625
2020-03-05 00:00:00+00:00,319.7300109863281,326.45001220703125,315.0,317.70001220703125,317.70001220703125,1470400.0,3.0,1.0,0.5000249999999999,"It invests in 214 stocks of pharmaceutical and biotech firms that trade on the Nasdaq, with Gilead Sciences (NASDAQ: GILD), Vertex Pharmaceuticals (NASDAQ: VRTX), Amgen (NASDAQ: AMGN), Biogen (NASDAQ: BIIB), and Regeneron (NASDAQ: REGN) as the five largest holdings as of Feb. 28. That growth is ""driven by a continued move to passive and increased awareness of the attractive tax efficiency, cost, liquidity and transparency characteristics of ETFs,"" wrote Bank of America analyst Mary Ann Bartels in December. The iShares Nasdaq Biotechnology Fund has lagged the competition over the last few years, so if you're looking for higher growth potential, you may want to consider some of its rivals.",214.34426879882812
2020-03-09 00:00:00+00:00,301.0,306.9700012207031,293.760009765625,297.19000244140625,297.19000244140625,2149500.0,2.0,1.0,0.250025,"Over the past few days, health officials in Cambridge, Massachusetts, reported on a cluster of 26 cases of COVID-19 that were traced to a Biogen (NASDAQ: BIIB) internal strategy meeting held in late February. Two people from Indiana who attended the same meeting have tested positive, prompting Indianapolis-based Eli Lilly (NYSE: LLY) to take precautionary measures to prevent the coronavirus from spreading further. Opportunity to shine While the COVID-19 outbreak will be a net negative for the pharmaceutical industry, the months ahead will give internal messaging services from companies like Slack Technologies (NYSE: WORK) and Microsoft (NASDAQ: MSFT) a chance to show their worth.",213.79315185546875
2020-03-10 00:00:00+00:00,304.489990234375,308.7699890136719,289.5799865722656,305.6300048828125,305.6300048828125,2378600.0,4.0,1.0,0.7500249999999999,"Among the largest underlying components of IBB, in trading today Gilead Sciences Inc (Symbol: GILD) is down about 4.4%, Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is up about 1.5%, and Biogen Inc (Symbol: BIIB) is up by about 1.1%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $96.03 per share, with $123.92 as the 52 week high point  that compares with a last trade of $110.43. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",214.52236938476562
2020-03-12 00:00:00+00:00,280.0,285.4200134277344,266.010009765625,268.8800048828125,268.8800048828125,2901000.0,3.5,1.0,0.6250249999999999,"Recently, Vir announced it was partnering up with Biogen (NASDAQ: BIIB) to develop and manufacture antibodies that could treat COVID-19. The latest situation report from the World Health Organization (WHO) shows that there are now more than 125,000 confirmed cases of the disease and more than 4,600 deaths. Several biotech companies are racing to find a vaccine or a treatment for the rapidly spreading disease. New Article In other sector news: (+) Vir Biotechnology (VIR) surged Thursday, rising more than 11% in recent trade after saying it was collaborating with Biogen (BIIB) to develop antibodies that could potentially treat COVID-19. Among health care stocks moving on news: (+) Predictive Oncology (POAI) climbed 5% after the medical-device distributor announced its purchase of privately held Soluble Therapeutics and its health science center technology to aid in the development of drugs and vaccines targeting coronaviruses, including COVID-19, and acute respiratory syndromes. The companies said they already were working to produce human monoclonal antibodies even while they are finalizing a clinical development and manufacturing agreement.",209.5325927734375
2020-03-13 00:00:00+00:00,279.1400146484375,306.0,276.239990234375,305.2099914550781,305.2099914550781,3641100.0,3.0,1.0,0.5000249999999999,"Biogen (NASDAQ: BIIB) and Mylan (NASDAQ: MYL) stocks each closed the day up 13.5%. Several also spiked near the end of the day today as President Trump held a news conference where he declared a national emergency that he said would ""open up access"" to up to $50 billion to fight the COVID-19 coronavirus. Trump's press conference also seemed to inspire a degree of confidence that the federal government would take decisive action to mitigate the coronavirus outbreak. New Article Biogen (NASDAQ: BIIB) and Eli Lilly instructed all employees to work from home whenever possible, after employees from both companies tested positive for COVID-19. The trade group intends to spend the rest of the week cleaning all its facilities, and it asked employees who met with the visitor who tested positive to self-quarantine until March 20. For example, Arcus Biosciences (NYSE: RCUS) is a clinical-stage biotech that had hoped to impress investors with clinical trial data for AB928, a potential new treatment for colon cancer.",205.62669372558594
2020-03-16 00:00:00+00:00,281.8599853515625,309.3500061035156,273.5899963378906,281.7200012207031,281.7200012207031,3862600.0,3.0,1.0,0.5000249999999999,"Biotech Stocks to Buy: Biogen (BIIB) Source: Pavel Kapysh / Shutterstock.com Biogen (NASDAQ:BIIB) rose from $220 to $300 in October when the company said it would resume filing for approval to bring its Alzheimers therapy drug to market. And so, if the drug passes regulatory review, BIIB stock will live up to its hype. Analysts who offer a price target on BIIB stock have an average of a $306.75 price target.",193.18588256835938
2020-03-17 00:00:00+00:00,285.3299865722656,314.6499938964844,284.1400146484375,305.32000732421875,305.32000732421875,2625900.0,4.0,1.0,0.7500249999999999,Biogen (NASDAQ: BIIB) stock was up 9.3% as of 3:13 p.m. EDT. What happened Shares of several biotechs jumped on Tuesday as the overall stock market rebounded from a major downturn yesterday on reports that a huge federal stimulus package could be in the works. So what A federal stimulus package could help individuals and businesses ride out the rough patch the coronavirus outbreak is causing.,199.085205078125
2020-03-20 00:00:00+00:00,288.0199890136719,301.8800048828125,277.8099975585937,278.7699890136719,278.7699890136719,2730000.0,3.0,1.0,0.5000249999999999,"Meanwhile, Berkshire's newest picks -- Kroger (NYSE: KR) and Biogen (NASDAQ: BIIB) -- have dramatically outperformed the market during these troubled times, proving that in times of turmoil, Berkshire's ""risk-off"" philosophy is the more resilient play. In fact, that's one of the reasons Buffett himself was ambivalent about the Kroger buy, which we now know was made by one of his top lieutenants, Ted Weschler or Todd Combs. The original Aducanumab study had been canceled, but in October, Biogen reinstated its trials due to new data that indicated the drug reduced the decline in Alzheimer's patients at higher doses.",203.76779174804688
2020-03-23 00:00:00+00:00,283.3500061035156,288.0599975585937,262.25,269.19000244140625,269.19000244140625,2695400.0,3.5,1.0,0.6250249999999999,"Within Warren Buffett's own portfolio, for instance, the healthcare giants Biogen (NASDAQ: BIIB), Johnson & Johnson (NYSE: JNJ), and Teva Pharmaceutical Industries (NYSE: TEVA) all appear to be trading at bargain basement prices after their steep declines over the past few weeks. Investors appear to be worried that J&J's consumer healthcare segment, which sells baby powder, Band-Aids, and skin and hair care products, among many others, may take a major hit from the COVID-19 economic downturn. For instance, Teva was recently involved in a multistate opioid lawsuit, its balance sheet sports a large amount of debt, and it has yet to bring a new flagship medication to market in the years since Copaxone went generic. New Article Among the largest underlying components of IBB, in trading today Biogen Inc (Symbol: BIIB) is off about 0.5%, Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is up about 5.4%, and Illumina Inc (Symbol: ILMN) is up by about 2.4%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $92.15 per share, with $123.92 as the 52 week high point  that compares with a last trade of $99.07. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",174.00926208496094
2020-03-24 00:00:00+00:00,278.8900146484375,283.260009765625,269.9800109863281,276.19000244140625,276.19000244140625,3464100.0,2.0,1.0,0.250025,"Drug manufacturers AbbVie (NYSE: ABBV) and Biogen (NASDAQ: BIIB) are two of the bigger names in the industry, and their stocks offer investors two enticing approaches: one that's focused on growth, and another that's centered around stability and recurring income. About a year ago, the company's stock went over a cliff, falling from $320 down to a low of about $215 after Biogen said it was going to scrap drug trials related to aducanumab, which treats Alzheimer's. The deal, which the companies expect will close in May of this year, will give AbbVie access to Botox, which was Allergan's top-selling drug in 2019, generating $3.8 billion in revenue.",176.06947326660156
2020-03-25 00:00:00+00:00,274.7300109863281,300.8399963378906,268.1300048828125,284.9800109863281,284.9800109863281,2678900.0,2.0,1.0,0.250025,"Last week, Biogen (NASDAQ: BIIB) said in a statement that it doesn't expect interruptions in manufacturing, but couldn't exclude the possibility depending on how the crisis develops. With the temporary shutdown of stores, retailers can expect a drop in sales during the current quarter -- and maybe even beyond as the crisis weighs on the economy and shoppers' wallets. According to Barron's, Bank of America analyst Geoff Meacham, in a note earlier this month predicted the effects on biopharmaceutical companies would be ""limited.""",181.73330688476562
2020-03-26 00:00:00+00:00,284.739990234375,306.7699890136719,284.510009765625,304.94000244140625,304.94000244140625,2270100.0,4.0,1.0,0.7500249999999999,"Bristol Myers Squibb (NYSE: BMY) announced on Thursday that the Food and Drug Administration has approved Zeposia (ozanimod) for treating adults with relapsed multiple sclerosis (MS), an autoimmune disease where the body's immune system attacks the protective myelin sheathes that cover its nerves. The FDA approval was based on two large late-stage clinical studies in which Zeposia demonstrated higher efficacy than Biogen's MS drug Avonex. Celgene resubmitted its application in March 2019, less than three months after Bristol Myers Squibb announced its plans to acquire the biotech.",188.55014038085938
2020-03-27 00:00:00+00:00,297.0,307.1400146484375,294.25,296.75,296.75,1653100.0,3.0,1.0,0.5000249999999999,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $305.00 strike highlighted in red: Considering the fact that the $305.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options become available this week, for the May 15th expiration.",177.85142517089844
2020-03-30 00:00:00+00:00,300.0,321.4100036621094,298.0799865722656,316.1300048828125,316.1300048828125,1747300.0,2.0,1.0,0.250025,"In fact, its top ten holdings, including Gilead Sciences (NASDAQ: GILD), Vertex Pharmaceuticals (NASDAQ: VRTX), Amgen (NASDAQ: AMGN), and Biogen (NASDAQ: BIIB), make up 53% of the portfolio. The emerging coronavirus pandemic highlights the world's dependence on pharmaceutical and biotech companies to produce drugs and vaccines to help overcome all types of illness. In disease areas with multiple treatment options, patients may transition to oral medicines (traditional pills and capsules) that can be taken at home rather than going to a clinic to receive an infusion or shot.",167.94235229492188
2020-03-31 00:00:00+00:00,313.4800109863281,319.94000244140625,309.20001220703125,316.3800048828125,316.3800048828125,2869100.0,2.0,1.0,0.250025,"Among the largest underlying components of IBB, in trading today Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is up about 1.4%, Biogen Inc (Symbol: BIIB) is trading flat, and Illumina Inc (Symbol: ILMN) is lower by about 1%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $92.15 per share, with $123.92 as the 52 week high point  that compares with a last trade of $108.81. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",171.9541473388672
2020-04-01 00:00:00+00:00,308.8099975585937,313.4599914550781,290.3500061035156,293.2699890136719,293.2699890136719,2177500.0,3.0,1.0,0.5000249999999999,"Biogen (NASDAQ: BIIB) surprised everyone by announcing in late 2019 it would seek marketing approval for aducanumab as a treatment in Alzheimer's disease. Neratinib was originally owned by Pfizer, which abandoned development after the drug candidate delivered a statistically significant yet underwhelming survival benefit, while also giving 40% of individuals in clinical trials severe diarrhea. It made sense on paper, but there were real-world reasons for the fragmentation that seem obvious in hindsight, such as insurance coverage decisions, doctor preferences, and a deluge of treatment options.",182.37872314453125
2020-04-02 00:00:00+00:00,290.1000061035156,307.1499938964844,290.0,304.4700012207031,304.4700012207031,3286600.0,4.0,1.0,0.7500249999999999,"What happened Stocks entered a bear market in March, but shares of Biogen (NASDAQ: BIIB) moved higher, rising 2.59% during the month, according to data provided by S&P Global Market Intelligence. Biogen gained as investors sought out shares of companies perceived as safe havens during the coronavirus outbreak. And some pharmaceutical and biotech companies have announced temporary suspensions in clinical trial enrollment as hospitals devote resources to COVID-19 patients.",180.60580444335938
2020-04-03 00:00:00+00:00,303.70001220703125,311.5199890136719,296.8099975585937,300.510009765625,300.510009765625,1422800.0,2.0,1.0,0.250025,"7 Restaurant Stocks to Buy for a Big Rebound Berkshires 13F for the last quarter of 2019 shows it buying shares in Kroger (NYSE:KR) and Biogen (NASDAQ:BIIB). He is doing good works, like helping Goldman Sachs (NYSE:GS) get needed masks to Mt. As its recent annual report shows Berkshire owns GEICO, as well as some of the biggest insurance and re-insurance operations in the world.",179.94935607910156
2020-04-06 00:00:00+00:00,308.489990234375,314.1400146484375,300.6000061035156,311.3900146484375,311.3900146484375,3181100.0,4.0,1.0,0.7500249999999999,"This is California-based Vir's second partnership with a major drugmaker for the development of a potential coronavirus treatment, having last month signed a letter of intent with Biogen Inc BIIB.O. Adds share price, background April 6 (Reuters) - British drugmaker GlaxoSmithKline GSK.L will invest $250 million in Vir Biotechnology Inc VIR.O and collaborate to develop potential treatments for COVID-19, the disease caused by the new coronavirus, the companies said on Monday. The companies said initial focus will be to accelerate development of Vir's investigational treatments, VIR-7831 and VIR-7832, and plan to directly start with a mid-stage trial within the next three to five months. New Article This is California-based Vir's second partnership with a major drugmaker for the development of a potential coronavirus treatment, having last month signed a letter of intent with Biogen Inc BIIB.O. By Trisha Roy and Manas Mishra April 6 (Reuters) - British drugmaker GlaxoSmithKline GSK.L will invest $250 million in Vir Biotechnology Inc VIR.O and collaborate to develop potential antibody treatments for COVID-19, the disease caused by the new coronavirus, the companies said on Monday. Initial focus will be on accelerating development of Vir's investigational treatments, VIR-7831 and VIR-7832, and then directly starting with a mid-stage trial within the next three to five months, the companies said. New Article This is California-based Vir's second partnership with a major drugmaker for the development of a potential coronavirus treatment, having last month signed a letter of intent with Biogen Inc BIIB.O. April 6 (Reuters) - British drugmaker GlaxoSmithKline Plc GSK.L will invest $250 million in Vir Biotechnology Inc VIR.O and collaborate to develop potential treatments for COVID-19, the disease caused by the new coronavirus, the companies said on Monday. Drugmakers across the globe are rushing to develop a treatment or vaccine for the fast-spreading coronavirus that has killed over 68,400 people globally.",188.1331329345703
2020-04-07 00:00:00+00:00,314.94000244140625,319.6000061035156,299.6099853515625,301.2099914550781,301.2099914550781,2457700.0,2.0,1.0,0.250025,"AbbVie (NYSE: ABBV) $113.7 billion Adaptive Biotechnologies (NASDAQ: ADPT)  $3.4 billion Alnylam Pharmaceuticals (NASDAQ: ALNY) $12.6 billion Amgen (NASDAQ: AMGN) $122.9 billion Bayer (OTC: BAYRY) $60.2 billion Biogen (NASDAQ: BIIB) $54.1 billion CSL Behring  $89.8 billion CytoDyn (NASDAQOTH:CYDY) $1.3 billion Gilead Sciences (NASDAQ: GILD) $96.6 billion Grifols (NASDAQ: GRFS) $19.5 billion Incyte (NASDAQ: INCY) $18 billion Eli Lilly (NYSE: LLY) $135.8 billion Novartis (NYSE: NVS) $193.1 billion Regeneron Pharmaceuticals (NASDAQ: REGN) $55.5 billion Roche Holding (OTC: RHHBY) $286.7 billion Sanofi $112.9 billion Takeda Pharmaceutical (NYSE: TAK) $47.6 billion Vanda Pharmaceuticals (NASDAQ: VNDA) $568.7 million Vir Biotechnology (NASDAQ: VIR) $3.9 billion Data sources: Biotechnology Innovation Organization, company press releases, Yahoo! The biotech's messenger RNA (mRNA) vaccine was developed in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). Gilead's remdesivir, which was originally developed to treat the Ebola virus, is in late-stage clinical studies and could be the most promising treatment, according to World Health Organization Assistant Director-General Bruce Aylward.",212.6988067626953
2020-04-09 00:00:00+00:00,315.1000061035156,322.45001220703125,314.010009765625,321.04998779296875,321.04998779296875,1479600.0,3.5,1.0,0.6250249999999999,"Biogen (BIIB) Source: Provided by Finviz Traders love to talk about Biogen (NASDAQ:BIIB) stock as its one of the best-known names in biotechnology. On Wednesday the investing community apparently started to feel that the curve may be flattening on the spread of the novel coronavirus. These standouts are worth examining, so lets see what tale the charts are telling for Thursdays three big stock selections. New Article Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $322.50 strike highlighted in red: Considering the fact that the $322.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the May 29th expiration.",196.3148193359375
2020-04-16 00:00:00+00:00,331.1499938964844,340.3800048828125,328.1700134277344,338.3399963378906,338.3399963378906,1602600.0,3.5,1.0,0.6250249999999999,"April 16 (Reuters) - Biogen Inc BIIB.O said on Thursday it had joined a consortium to build a collection of biological and medical data, where its employees who had tested and recovered from the coronavirus would be able to participate. Several employees of the U.S. drugmaker had tested positive for the coronavirus after an internal company meeting in Boston earlier this year. Biogen said the consortium included Broad Institute of MIT and Harvard, and Partners HealthCare. New Article Adds details on collaboration April 16 (Reuters) - Biogen Inc BIIB.O said on Thursday it had joined a consortium to build a collection of biological and medical data, where its employees who had tested for and recovered from the coronavirus would be able to participate. The potential volunteers are Biogen employees who were among the first people in Massachusetts to be diagnosed with and recover from COVID-19, as well as close contacts, including those who were not tested or who may not have had symptoms, it said. The collaboration will help collect data to advance knowledge and search for potential vaccines and treatments, Biogen added.",198.44805908203125
2020-04-17 00:00:00+00:00,345.9700012207031,346.04998779296875,335.2900085449219,342.54998779296875,342.54998779296875,1701800.0,2.0,1.0,0.250025,"In partnership with the Broad Institute of MIT and Harvard, Biogen (NASDAQ: BIIB) has formed a consortium that will build and share a COVID-19 biobank. In early March, an executive from Biogen didn't realize they were COVID-19 positive while shaking hands with colleagues at the company's annual leadership meeting. If the biobank can develop a large enough universe of data from those volunteers, researchers will have better odds of figuring out why some people who become infected recover without exhibiting serious symptoms, while others have much more severe cases.",204.6472930908203
2020-04-20 00:00:00+00:00,338.6400146484375,350.239990234375,337.2799987792969,339.4100036621094,339.4100036621094,1620700.0,1.6666666666666667,1.0,0.1666916666666666,"The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.7% ** Carrier Global Corp , up 6.6% ** Howmet Aerospace Inc , up 6.4% The top three S&P 500 .PL.INX percentage losers: ** L Brands Inc , down 7.5% ** Vornado Realty Trust , down 6.3% ** Occidental Petroleum Corp , down 6% The top three NYSE .PG.N percentage gainers: ** Regional Health Properties Inc , up 36.5% ** Pacer Developed Markets International Cash CWS , up 23.2% ** Montage Resources Corp , up 23% The top three NYSE .PL.N percentage losers: ** Invesco Mortgage Capital Inc , down 22.5% ** Direxion Daily S&P Biotech Bear 3X Shares , down 16.5% ** Independence Contract Drilling Inc , down 11.9% The top three Nasdaq .PG.O percentage gainers: ** Benitec Biopharma Limited , up 107.4% ** Cyclacel Pharmaceuticals Inc , up 103.8% ** Novavax Inc , up 32.9% The top three Nasdaq .PL.O percentage losers: ** Vericity Inc , down 19.5% ** Akazoo SA , down 19% ** Liberty TripAdvisor Holdings Inc , down 17.9% ** Aytu BioScience Inc AYTU.O: up 3.6% BUZZ-Aytu: Rises on gaining exclusive license to potential COVID-19 treatment ** Redhill Biopharma RDHL.O: up 12.5% BUZZ-Redhill Biopharma: Rises on agreement with NIAID to test cancer drug for COVID-19 ** Atossa Therapeutics Inc ATOS.O: up 5.6% BUZZ-Atossa Therapeutics up as co seeks FDA nod to begin COVID-19 study ** Gilead Sciences Inc GILD.O: down 1.3% BUZZ-Gilead: Brokerages downgrade on uncertainty over commercial value of COVID-19 drug ** Seattle Genetics Inc SGEN.O: up 5.1% BUZZ-Street View: Seattle Genetics' breast cancer therapy approval brings some cheer ** Campbell Soup Co CPB.N: up 3.4% BUZZ-Campbell Soup: Rises on strong retail demand ** Incyte Corp INCY.O: up 1.4% BUZZ-Incyte: Touches fresh 2-yr high after FDA approval of cancer therapy ** ViaSat Inc VSAT.O: up 2.5% BUZZ-ViaSat Inc: Rises as brokerage upgrades on higher residential internet demand ** 2U Inc TWOU.O: down 7.4% BUZZ-2U drops ahead of $300 mln convertible debt deal ** Masimo Corp MASI.O: down 0.4% BUZZ-Masimo Corp: Needham downgrades on likely slow 2H20 growth ** Avalon GloboCare Corp AVCO.O: up 7.9% BUZZ-Avalon GloboCare: Rises as therapy shows promise in combating cytokine storm - Reuters News ** Shake Shack Inc SHAK.N: up 5.9% BUZZ-Shake Shack beefs up capital, gives back government loan; shares dip ** Exelixis Inc EXEL.O: up 23.5% BUZZ-Exelixis jumps as cancer drug combo shows promise in study ** AGNC Investment Corp AGNC.O: down 0.5% ** Annaly Capital Management Inc NLY.N: down 1.8% ** Apollo CRE Finance ARI.N: down 4.9% ** Blackstone Mortgage Trust Inc BXMT.N: down 3.1% ** Ladder Capital Corp LADR.N: down 3.4% ** Starwood Property Trust Inc STWD.N: down 3.9% ** TPG RE Finance Trust Inc TRTX.N: down 3.8% BUZZ-U.S. mortgage REITs: DB cuts PT citing ""stressed scenarios"" ** INmune Bio Inc INMB.O: up 9.3% BUZZ-INmune Bio Inc: Rises on plans to begin COVID-19 trial ** Mustang Bio Inc MBIO.O: up 1.4% BUZZ-Mustang Bio: Rises after EMA's favorable classification of ""bubble boy"" therapy ** Meredith Corp MDP.N: down 6.5% BUZZ-Meredith Corp: Falls on withdrawing 2020 outlook as ad sales get hit ** Lennox International LII.N: up 2.0% BUZZ-Lennox International: Falls on weak Q1, warns of 20% hit from coronavirus ** Ducommun Inc DCO.N: up 3.6% BUZZ-Ducommun: Jumps as Q1 revenue forecast higher than Wall Street estimates ** Alexion Pharmaceuticals Inc ALXN.O: up 4.9% BUZZ-Alexion rises on study to test blood disorder drug for COVID-19 ** Clorox Co CLX.N: up 1.8% BUZZ-Clorox: Up as Deutsche Bank expects strong Q3 helped by coronavirus ** Peloton Interative Inc PTON.O: down 3.2% BUZZ-Peloton skids as BMO slaps with first ""sell"" rating since IPO ** Terex Corp TEX.N: down 4.2% ** Manitowoc Company Inc MTW.N: down 3.4% BUZZ-GS removes Terex and Manitowoc from ""buy list"", downgrades to ""neutral"" ** Anixa Biosciences Inc ANIX.O: up 10.6% BUZZ-Anixa Biosciences: Rises on partnership for potential treatment of COVID-19 ** Cyclacel Pharmaceutical Inc CYCC.O: up 103.8% BUZZ-Cyclacel: Jumps on deal to study drugs to treat COVID-19 patients ** Boeing Co BA.N: down 4.9% BUZZ-Benchmark sees Boeing cut 787 production by 30%; lowers PT ** Eros International EROS.N: down 0.2% BUZZ-Eros International: Soars after deal to merge with STX Entertainment ** Medpace Holdings Inc MEDP.O: down 0.8% ** ICON Plc ICLR.O: down 0.4% BUZZ-Baird downgrades two contract research organizations on COVID-19 impact ** Xeris Pharmaceutical Inc XERS.O: up 15.1% BUZZ-Xeris Pharma: Rises on positive results from seizure medication study ** United Airlines Holdings Inc UAL.O: down 3.4% BUZZ-United Airlines drops on estimated quarterly loss, dour outlook ** Walt Disney Co DIS.N: down 2.3% BUZZ-Disney: Falls as brokerages move to sidelines citing hit to theme parks ** Cheesecake Factory Inc CAKE.O: up 5.9% BUZZ-Cheesecake Factory: Rises on $200 mln investment from Roark Capital ** Exxon Mobil Corp XOM.N: down 3.0% ** Chevron Corp CVX.N: down 1.8% ** Devon Energy Corp DVN.N: down 0.4% ** Callon Petroleum Co CPE.N: down 3.4% ** Chesapeake Energy Corp CHK.N: down 1.5% ** Occidental Petroleum Corp OXY.N: down 6.1% ** Schlumberger NV SLB.N: flat ** Halliburton Co HAL.N: up 0.1% ** TechnipFMC Plc FTI.N: down 1.4% BUZZ-Oil stocks drop as concerns over rising crude storage weigh on prices BUZZ-Street View: Schlumberger's dividend cut the first step on road to recovery BUZZ-Halliburton: Falls on $1.1 bln impairment charges ** Safe-T Group SFET.O: up 18.2% BUZZ-Safe-T Group: Jumps on upbeat Q1 revenue forecast ** AbbVie Inc ABBV.N: up 1.8% BUZZ-AbbVie Inc: RBC expects rebound in 2021, upgrades to ""outperform"" ** Facebook Inc FB.O: flat BUZZ-Facebook: Credit Suisse cuts PT as coronavirus impacts ad revenue ** Biogen Inc BIIB.O: up 1.3% BUZZ-Biogen Inc: Alzheimer's drug in focus ahead of Q1, not earnings ** Abbott Laboratories ABT.N: up 3.9% BUZZ-Abbott, Roche to benefit from surging demand for COVID-19 antibody tests - analyst ** DuPont de Nemours Inc DD.N: up 5.5% BUZZ-DuPont: Rises on expectations of stronger Q1 from coronavirus-driven demand ** Co-Diagnostics Inc CODX.O: up 17.4% BUZZ-Co-Diagnostics: Rises on increased U.S. sales of COVID-19 testing kits ** Acadia Healthcare Co Inc ACHC.O: down 0.1% ** Brookdale Senior Living Inc BKD.N: down 3.2% ** Ensign Group Inc ENSG.O: down 0.4% ** Select Medical Holdings Corp SEM.N: down 4.1% BUZZ-Strong headwinds imminent for facility-based health care providers - Analyst ** General Motors Co GM.N: flat ** Ford Motor Co F.N: down 1.7% BUZZ-CS cuts PT on Ford, GM on heavy cash burn in H1 2020 ** Royal Caribbean Cruises Ltd RCL.N: down 3.4% ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 4.9% ** Carnival Corp CCL.N: down 1.4% BUZZ-J.P. Morgan slashes cruise operators' PT on virus impact The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and the Dow Jones headed lower on Monday following a strong two-week rally as oil prices crashed and investors grew cautious at the start of a week that is likely to bring more dismal quarterly earnings reports and economic data..N At 17:55 ET, the Dow Jones Industrial Average .DJI was down 0.92% at 24,020.4. down 1.79% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article The top three NYSE percentage gainers premarket .PRPG.NQ: ** Eros International Plc , up 42.0% ** Renren Inc , up 21.2% ** FGL Holdings Inc , up 17.6% The top three NYSE percentage losers premarket .PRPL.NQ: ** Invesco Mortgage Capital Inc , down 31.2% ** Par Pacific Holdings Inc , down 30.7% ** Cedar Realty Trust Inc , down 26.7% The top three Nasdaq percentage gainers premarket .PRPG.O: ** American Virtual Cloud Technologies Inc , up 75.2% ** Safe-T Group Ltd , up 44.6% ** Cyclacel Pharmaceuticals Inc , up 32.4% The top three Nasdaq percentage losers premarket .PRPL.O: ** Allegro Merger Corp , down 40.3% ** HL Acquisitions Corp , down 30.1% ** Allegro Merger Equity Warrants , down 30% ** Exxon Mobil Corp XOM.N: down 5.5% premarket ** Chevron Corp CVX.N: down 4.5% premarket ** Devon Energy Corp DVN.N: down 8.8% premarket ** Callon Petroleum Co CPE.N: down 9.6% premarket ** Chesapeake Energy Corp CHK.N: down 13.5% premarket ** Occidental Petroleum Corp OXY.N: down 9.4% premarket ** Schlumberger NV SLB.N: down 6.7% premarket ** Halliburton Co HAL.N: down 8.3% premarket ** TechnipFMC Plc FTI.N: down 6.4% premarket BUZZ-Oil stocks drop as concerns over rising crude storage weigh on prices BUZZ-Street View: Schlumberger's dividend cut the first step on road to recovery BUZZ-Halliburton: Falls on $1.1 bln impairment charges ** Safe-T Group SFET.O: up 44.6% premarket BUZZ-Safe-T Group: Jumps on upbeat Q1 revenue forecast ** Facebook Inc FB.O: down 1.0% premarket BUZZ-Facebook: Credit Suisse cuts PT as coronavirus impacts ad revenue ** Biogen Inc BIIB.O: down 1.3% premarket BUZZ-Biogen Inc: Alzheimer's drug in focus ahead of Q1, not earnings ** DuPont de Nemours Inc DD.N: up 4.0% premarket BUZZ-DuPont: Rises on expectations of stronger Q1 from coronavirus-driven demand ** Co-Diagnostics Inc CODX.O: up 11.4% premarket BUZZ-Co-Diagnostics: Rises on increased U.S. sales of COVID-19 testing kits ** General Motors Co GM.N: down 2.7% premarket ** Ford Motor Co F.N: down 3.3% premarket BUZZ-CS cuts PT on Ford, GM on heavy cash burn in H1 2020 ** Royal Caribbean Cruises Ltd RCL.N: down 4.6% premarket ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 5.0% premarket ** Carnival Corp CCL.N: down 4.6% premarket BUZZ-J.P. Morgan slashes cruise operators' PT on virus impact (Reporting by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures fell on Monday as a slump in oil prices pounded energy stocks, with investors also bracing for another batch of dour first-quarter earnings reports and economic data..N At 13:08 ET, Dow e-minis 1YMc1 were down 2.21% at 23,626. S&P 500 e-minis ESc1 were down 1.90% at 2,815.5, while Nasdaq 100 e-minis NQc1 were down 0.90% at 8,729.75. New Article The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc , up 14.1% ** Carrier Global Corp , up 6.6% ** DuPont de Nemours Inc, up 5% The top three S&P 500 .PL.INX percentage losers: ** Vornado Realty Trust , down 4.9% ** Lennar Corporation , down 4.7% ** Occidental Petroleum Corp , down 4.7% The top three NYSE .PG.N percentage gainers: ** Regional Health Properties Inc , up 41.6% ** Montage Resources Corp , up 26.8% ** Build-A-Bear Workshop Inc , up 26.2% The top three NYSE .PL.N percentage losers: ** Invesco Mortgage Capital Inc , down 19.5% ** Direxion Daily S&P Biotech Bear 3X Shares , down 13% ** Manning & Napier Inc , down 12.7% The top three Nasdaq .PG.O percentage gainers: ** Cyclacel Pharmaceuticals Inc , up 89.5% ** American Virtual Cloud Technologies Inc , up 43.8% ** Benitec Biopharma Limited , up 42.9% The top three Nasdaq .PL.O percentage losers: ** Liberty TripAdvisor Holdings Inc , down 18.4% ** BiondVax Pharmaceuticals Equity Warrants , down 15% ** Green Plains Partners LP , down 14% ** Avalon GloboCare Corp AVCO.O: up 12.9% BUZZ-Avalon GloboCare: Rises as therapy shows promise in combating cytokine storm ** Shake Shack Inc SHAK.N: up 6.3% BUZZ-Shake Shack beefs up capital, gives back government loan ** Exelixis Inc EXEL.O: up 25.5% BUZZ-Exelixis jumps as cancer drug combo shows promise in study ** AGNC Investment Corp AGNC.O: up 0.1% ** Annaly Capital Management Inc NLY.N: up 0.2% ** Apollo CRE Finance ARI.N: down 3.7% ** Blackstone Mortgage Trust Inc BXMT.N: down 3.0% ** Ladder Capital Corp LADR.N: flat ** Starwood Property Trust Inc STWD.N: down 2.1% ** TPG RE Finance Trust Inc TRTX.N: down 3.0% BUZZ-U.S. mortgage REITs: DB cuts PT citing ""stressed scenarios"" ** INmune Bio Inc INMB.O: up 7.1% BUZZ-INmune Bio Inc: Rises on plans to begin COVID-19 trial ** Mustang Bio Inc MBIO.O: up 2.4% BUZZ-Mustang Bio: Rises after EMA's favorable classification of ""bubble boy"" therapy ** Meredith Corp MDP.N: down 9.7% BUZZ-Meredith Corp: Falls on withdrawing 2020 outlook as ad sales get hit ** Ducommun Inc DCO.N: up 4.6% BUZZ-Ducommun: Jumps as Q1 revenue forecast higher than Wall Street estimates ** Alexion Pharmaceuticals Inc ALXN.O: up 4.4% BUZZ-Alexion rises on study to test blood disorder drug for COVID-19 ** Clorox Co CLX.N: up 1.9% BUZZ-Clorox: Up as Deutsche Bank expects strong Q3 helped by coronavirus ** Peloton Interative Inc PTON.O: down 4.5% BUZZ-Peloton skids as BMO slaps first ""sell"" rating since IPO ** Terex Corp TEX.N: down 4.7% ** Manitowoc Company Inc MTW.N: down 2.5% BUZZ-GS removes Terex and Manitowoc from ""buy list"", downgrades to ""neutral"" ** Anixa Biosciences Inc ANIX.O: up 11.6% BUZZ-Anixa Biosciences: Rises on partnership for potential treatment of COVID-19 ** Cyclacel Pharmaceutical Inc CYCC.O: up 89.5% BUZZ-Cyclacel: Jumps on deal to study drugs to treat COVID-19 patients ** Boeing Co BA.N: down 3.1% BUZZ-Benchmark sees Boeing cut 787 production by 30%; lowers PT ** Eros International EROS.N: up 9.0% BUZZ-Eros International: Soars after deal to merge with STX Entertainment ** Medpace Holdings Inc MEDP.O: down 1.9% ** ICON Plc ICLR.O: up 0.1% BUZZ-Baird downgrades two contract research organizations on COVID-19 impact ** Xeris Pharmaceutical Inc XERS.O: up 10.2% BUZZ-Xeris Pharma: Rises on positive results from seizure medication study ** United Airlines Holdings Inc UAL.O: down 3.2% BUZZ-United Airlines drops on estimated quarterly loss, dour outlook ** Walt Disney Co DIS.N: down 2.8% BUZZ-Disney: Falls as brokerages move to sidelines citing hit to theme parks ** Cheesecake Factory Inc CAKE.O: up 7.6% BUZZ-Cheesecake Factory: Rises on $200 mln investment from Roark Capital ** Exxon Mobil Corp XOM.N: down 2.2% ** Chevron Corp CVX.N: down 1.0% ** Devon Energy Corp DVN.N: up 1.1% ** Callon Petroleum Co CPE.N: down 2.5% ** Chesapeake Energy Corp CHK.N: down 1.0% ** Occidental Petroleum Corp OXY.N: down 4.8% ** Schlumberger NV SLB.N: up 0.4% ** Halliburton Co HAL.N: up 3.5% ** TechnipFMC Plc FTI.N: down 0.5% BUZZ-Oil stocks drop as concerns over rising crude storage weigh on prices BUZZ-Street View: Schlumberger's dividend cut the first step on road to recovery BUZZ-Halliburton: Falls on $1.1 bln impairment charges ** Safe-T Group SFET.O: up 17.6% BUZZ-Safe-T Group: Jumps on upbeat Q1 revenue forecast ** AbbVie Inc ABBV.N: up 0.3% BUZZ-AbbVie Inc: RBC expects rebound in 2021, upgrades to ""outperform"" ** Facebook Inc FB.O: up 0.3% BUZZ-Facebook: Credit Suisse cuts PT as coronavirus impacts ad revenue ** Biogen Inc BIIB.O: up 1.5% BUZZ-Biogen Inc: Alzheimer's drug in focus ahead of Q1, not earnings ** Abbott Laboratories ABT.N: up 1.0% BUZZ-Abbott, Roche to benefit from surging demand for COVID-19 antibody tests - analyst ** DuPont de Nemours Inc DD.N: up 5.0% BUZZ-DuPont: Rises on expectations of stronger Q1 from coronavirus-driven demand ** Co-Diagnostics Inc CODX.O: up 13.8% BUZZ-Co-Diagnostics: Rises on increased U.S. sales of COVID-19 testing kits ** Acadia Healthcare Co Inc ACHC.O: up 0.4% ** Brookdale Senior Living Inc BKD.N: down 1.8% ** Ensign Group Inc ENSG.O: down 1.2% ** Select Medical Holdings Corp SEM.N: down 3.6% BUZZ-Strong headwinds imminent for facility-based health care providers - Analyst ** General Motors Co GM.N: down 0.3% ** Ford Motor Co F.N: down 1.2% BUZZ-CS cuts PT on Ford, GM on heavy cash burn in H1 2020 ** Royal Caribbean Cruises Ltd RCL.N: down 1.6% ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 2.7% ** Carnival Corp CCL.N: down 1.4% BUZZ-J.P. Morgan slashes cruise operators' PT on virus impact The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh A slide in energy stocks weighed on Wall Street on Monday as crude prices crashed at the start of a week packed with quarterly earnings reports and economic data likely to underline the damage from the coronavirus outbreak..N At 16:05 ET, the Dow Jones Industrial Average .DJI was down 0.94% at 24,014.95. down 1.98% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",197.85877990722656
2020-04-22 00:00:00+00:00,302.75,306.989990234375,289.0199890136719,298.010009765625,298.010009765625,6650100.0,2.571428571428572,1.0,0.3928821428571429,"Among the largest underlying components of IBB, in trading today Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is up about 1.4%, Biogen Inc (Symbol: BIIB) is down about 11.7%, and Regeneron Pharmaceuticals, Inc. (Symbol: REGN) is lower by about 0.6%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $92.15 per share, with $128.46 as the 52 week high point  that compares with a last trade of $121.90. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Particularly high volume was seen for the $300 strike call option expiring April 24, 2020, with 1,064 contracts trading so far today, representing approximately 106,400 underlying shares of BIIB. Below is a chart showing CNNE's trailing twelve month trading history, with the $35 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 21,524 contracts thus far today. That number of contracts represents approximately 2.2 million underlying shares, working out to a sizeable 101.9% of BIIB's average daily trading volume over the past month, of 2.1 million shares. New Article In company news, Biogen (BIIB) fell 8.9% after Wednesday saying it does not expect to file the biological license application for its experimental aducanumab treatment for Alzheimer's disease until the quarter ending Sept. 30, upstaging better-than-expected Q1 results. The company has been preparing for a pre-filing meeting with the US Food and Drug Administration scheduled for later this summer and said it has been submitting portions of the BLA filing for the anti-amyloid beta candidate in collaboration with Eisai Co. Immunomedics (IMMU) rose about 1.2% after the US Food and Drug Administration Wednesday approved its trodelvy product candidate for the treatment of adults with metastatic triple-negative breast cancer who have been treated at least twice for the disease in the past. Prothena (PRTA) was 2.4% lower, bouncing back from a nearly 21% decline earlier Wednesday, after the neuroscience company said its prasinezumab drug candidate failed to meet the primary endpoint of the first half of a phase II study in patients with early Parkinson's disease. New Article VIDEO: S&P 500 Movers: BIIB, EXPE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing S&P 500 component thus far on the day is Biogen, trading down 9.4%. Biogen is showing a gain of 0.4% looking at the year to date performance. New Article (RTTNews) - Biogen Inc. (BIIB) on Wednesday reported net income attributable to the company for the first quarter of $1.40 billion or $8.08 per share, up from $1.41 billion or $7.15 per share in the prior-year quarter. On average, analysts polled by Thomson Reuters expected the company to report earnings of $7.73 per share for the quarter on revenues of $3.41 billion. Multiple sclerosis (MS) revenues, including $162 million in royalties on the sales of Ocrevus, increased 9 percent from the prior year to $2.28 billion. New Article Biogen Inc (NASDAQ: BIIB) Q1 2020 Earnings Call Apr 22, 2020, 8:00 a.m. However, we do anticipate that a portion of these ten readouts will be delayed, including the Phase III study of BIIB093 or IV glibenclamide for large hemispheric infarction, as this study involves administration of BIIB093 in an acute hospital setting. Beyond aducanumab, we continue to advance a broad Alzheimer's disease portfolio, including the Phase III study of BAN2401; BIIB080, a tau-targeted antisense oligonucleotide in Phase I; and BIIB076, an anti-tau antibody in Phase I; and gosuranemab, a distinct anti-tau antibody in Phase II Turning to neuromuscular disorders. New Article Biogen (NASDAQ: BIIB) released its first-quarter earnings report before the market opened on Wednesday, reporting $3.5 billion in revenue, a 1% year-over-year increase. However, arguably the most crucial part of Biogen's report was an update regarding its potential treatment for Alzheimer's disease, aducanumab, which the company is developing in collaboration with Esai (OTC: ESALY). In March 2019, Biogen discontinued the development of aducanumab because it had not demonstrated  effectiveness against the symptoms of Alzheimer's in a phase 3 clinical trial. New Article Adds details on aducanumab filing, compares with estimates, adds shares April 22 (Reuters) - Biogen Inc BIIB.O said on Wednesday it would delay filing for marketing approval of its much-awaited experimental Alzheimer's disease drug to the third quarter, sending its shares down 7%. Biogen had scrapped two clinical studies of the drug, aducanumab, in March 2019 after initial analysis showed the trials would not succeed. It later reversed course, saying analysis of the discontinued clinical studies showed some patients benefited from taking higher doses over an extended period of time. New Article The top three NYSE percentage gainers premarket .PRPG.NQ: ** Global Ship Lease Inc GSL.N, up 43.9% ** Delek Logistics Partners , up 28.3% ** NVR Inc , up 27.8% The top three NYSE percentage losers premarket .PRPL.NQ: ** SEACOR Marine Holdings Inc , down 25.6% ** Unit Corp , down 23% ** Borr Drilling Ltd , down 16.4% The top three Nasdaq percentage gainers premarket .PRPG.O: ** SAExploration Holdings Inc , up 151.9%- ** Kaixin Auto Holdings , up 64.8% ** Immunic Inc , up 58.9% The top three Nasdaq percentage losers premarket .PRPL.O: ** VBI Vaccines Inc , down 29.5% ** Company name not found , down 26.6% ** TORM Plc , down 23.6% ** Coca-Cola Co KO.N: up 1.1% premarket BUZZ-Street View: Coca-Cola unlikely to lose fizz in the long run ** Netflix Inc NFLX.O: down 2.0% premarket BUZZ-Netflix: Drops as co warns quarantine boost may prove to be short-lived ** Emerson Electric Co EMR.N: up 1.2% premarket BUZZ-Street View: Emerson Electric not pulling forecast is a good sign ** Lockheed Martin Corp LMT.N: up 1.5% premarket BUZZ-Street View: Lockheed Martin results affirm defense sector as safe haven ** Intel Corp INTC.O: up 2.0% premarket BUZZ-Intel Corp: Jefferies raises PT on data center growth ** Texas Instruments Inc TXN.O: up 2.8% premarket BUZZ-Street View: Texas Instruments' long-term growth trends intact ** Expedia Group Inc EXPE.O: up 6.6% premarket BUZZ- Expedia Group: Rises on report of stake sale to private equity firms ** United Airlines Holdings Inc UAL.O: down 3.0% premarket BUZZ-United Airlines down after $1 bln-plus equity haul ** Chipotle Mexican Grill Inc CMG.N: up 6.3% premarket BUZZ-Chipotle Mexican Grill: Red hot as online sales help during pandemic ** Delta Air Lines Inc DAL.N: up 2.9% premarket BUZZ-Delta Air jumps as cheap fuel, cost cuts likely to reduce Q2 expenses by half ** Biogen Inc BIIB.O: down 6.4% premarket BUZZ-Biogen: Down as co pushes Alzheimer's drug filing to Q3 ** Unit Corp UNT.N: down 23.0% premarket BUZZ-Unit Corp shares hover near record lows ** SAExploration Holdings SAEX.O: up 151.9% premarket BUZZ-SAExploration Holdings: Surges three-fold on new project announcement ** Kimberly-Clark Corp KMB.N: up 1.8% premarket BUZZ-Kimberly-Clark: Rises as strong tissue sales drive quarterly beat (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures rebounded on Wednesday as upbeat quarterly earnings reports lifted investor sentiment following a two-day selloff due to a record crash in oil prices, although companies warned of more pain in the coming months..N At 08:07 ET, Dow e-minis 1YMc1 were up 1.20% at 23,205. S&P 500 e-minis ESc1 were up 1.30% at 2,767.5, while Nasdaq 100 e-minis NQc1 were up 1.25% at 8,536.75. New Article (RTTNews) - Biogen Inc. (BIIB) will host a conference call at 8:00 AM ET on April 22, 2020, to discuss Q1 20 earnings results. To access the live webcast, log on to https://www.investornetwork.com/event/presentation/61397 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article On Tuesday, the Food and Drug Administration approved the combination of Imbruvica and Rituximab as a treatment for patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL); Rituximab is a cancer drug marketed by Biogen (NASDAQ: BIIB). With sales of Humira -- by far AbbVie's biggest moneymaker -- losing steam in Europe due to competition from biosimilars, the pharma giant has high hopes for Imbruvica. With the largest body of clinical evidence, a robust survival benefit, and the highest category rating in treatment guidelines today, we remain confident that Imbruvica will be a significant growth contributor for many years to come."" New Article VIDEO: Nasdaq 100 Movers: BIIB, LRCX The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing Nasdaq 100 component thus far on the day is Biogen, trading down 9.7%. Biogen is showing a gain of 0.1% looking at the year to date performance. New Article The top three S&P 500 .PG.INX percentage gainers: ** Halliburton Company , up 10.5% ** Expedia Group Inc , up 9.2%- ** Chipotle Mexican Grill Inc , up 8.8%- The top three S&P 500 .PL.INX percentage losers: ** L Brands Inc , down 15.1% ** Biogen Inc , down 10.5%- ** United Airlines Holdings Inc , down 6.5%- The top three NYSE .PG.N percentage gainers: ** UBS ETRACS S&P GSCI Crude Oil Total Return Index ETN , up 48.5% ** Delek Logistics Partners , up 45.7% ** SilverBow Resources Inc , up 36.1% The top three NYSE .PL.N percentage losers: ** DB Crude Oil Double Short ETN , down 19% ** American Eagle Outfitters Inc , down 15.9% ** L Brands Inc , down 15.1% The top three Nasdaq .PG.O percentage gainers: ** SAExploration Holdings Inc , up 115.9% ** Peck Company Holdings Inc , up 101.4% ** Kewaunee Scientific Corp , up 29.9 % The top three Nasdaq .PL.O percentage losers: ** TORM Plc , down 28.1% ** Energous Corp , down 17.8% ** Euroseas Ltd , down 15.8% ** Exxon Mobil Corp XOM.N: up 3.0% ** Chevron Corp CVX.N: up 2.7% ** Occidental Petroleum Corp OXY.N: up 6.8% ** Apache Corp APA.N: up 6.5% ** Devon Energy Corp DVN.N: up 5.6% ** SM Energy Co SM.N: up 0.7% BUZZ-Oil and gas stocks rise as crude steadies after hitting lowest this century ** American Eagle Outfitters Inc AEO.N: down 15.9% BUZZ-American Eagle falls as co pulls guidance, announces $400 mln capital raise ** Snap Inc SNAP.N: up 26.9% BUZZ-Snap: Jumps on Q1 revenue beat, higher daily users ** Thermo Fisher Scientific Inc TMO.N: up 2.9% BUZZ-Thermo Fisher: Up on Q1 beat; Cowen says co well-positioned to bear virus hit ** Peck Company Holdings Inc PECK.O: up 101.4% BUZZ-Peck Company Holdings: Gains on green bond partnership ** VBI Vaccines Inc VBIV.O: down 27.6% BUZZ-VBI Vaccines drops on deep-discounted, upsized stock deal ** Zoom Video Communications Inc ZM.O: up 3.2% BUZZ-Zoom rises as co tightens security features on app ** Rogers Communications Inc RCI.N: down 2.6% BUZZ-Rogers: Falls after co pulls 2020 guidance amid coronavirus uncertainty ** Netflix Inc NFLX.O: down 1.6% BUZZ-Netflix: Drops as co warns quarantine boost may prove to be short-lived ** Emerson Electric Co EMR.N: up 1.9% BUZZ-Street View: Emerson Electric not pulling forecast is a good sign ** Lockheed Martin Corp LMT.N: up 1.2% BUZZ-Street View: Lockheed Martin results affirm defense sector as safe haven ** Intel Corp INTC.O: up 4.7% BUZZ-Intel Corp: Jefferies raises PT on data center growth ** Texas Instruments Inc TXN.O: up 3.5% BUZZ-Street View: Texas Instruments' long-term growth trends intact ** Expedia Group Inc EXPE.O: up 9.2% BUZZ- Expedia Group: Rises on report of stake sale to private equity firms ** United Airlines Holdings Inc UAL.O: down 6.5% BUZZ-United Airlines down after $1 bln-plus equity haul ** Chipotle Mexican Grill Inc CMG.N: up 8.9% BUZZ-Chipotle Mexican Grill: Red hot as online sales help during pandemic ** Delta Air Lines Inc DAL.N: down 1.6% BUZZ-Delta Air jumps as cheap fuel, cost cuts likely to reduce Q2 expenses by half ** Biogen Inc BIIB.O: down 10.6% BUZZ-Biogen: Down as co pushes Alzheimer's drug filing to Q3 ** Unit Corp UNT.N: down 9.5% BUZZ-Unit Corp shares hover near record lows ** SAExploration Holdings SAEX.O: up 115.9% BUZZ-SAExploration Holdings: Surges three-fold on new project announcement ** Quest Diagnostics DGX.N: up 3.6% BUZZ-Quest Diagnostics: Up as Q1 results beat lowered expectations ** Mallinckrodt Plc MNK.N: up 7.4% BUZZ-Mallinckrodt: Gains after U.S. FDA sets action date for kidney treatment ** Johnson & Johnson JNJ.N: up 2.8% BUZZ-J&J: BOFA global research sees stock outperforming, upgrades to ""buy"" ** Goldman Sachs Group Inc GS.N: up 1.0% ** JPMorgan Chase & Co JPM.N: up 2.3% ** Citigroup Inc C.N: up 1.2% ** Wells Fargo & Co WFC.N: up 0.8% ** Bank of America Corp BAC.N: up 1.9% ** Morgan Stanley MS.N: up 1.7% BUZZ-U.S. big banks gain as Treasury yields rise ** Teradyne Inc TER.O: up 3.0% BUZZ-Teradyne: Jumps on better-than-expected Q1 profit, upbeat Q2 outlook The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes rose on Wednesday on signs of more stimulus to aid small businesses ride out the coronavirus-induced economic slump and a recovery in oil prices. up 1.94% (Compiled by Amal S in Bengaluru) ((Amal.S@thomsonreuters.com; within U.S.+1 646 223 8780; outside U.S. +91 80 6749 3677;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen (BIIB) was declining by more than 6% even after it reported a Q1 non-GAAP EPS of $9.14, up from $6.98 in the 2019 quarter and significantly higher than the consensus estimate of $7.69 from analysts surveyed by Capital IQ. The Health Care SPDR (XLV) and iShares NASDAQ Biotechnology Index (IBB) were advancing by more than 1%, while the Vanguard Health Care ETF (VHT) and iShares Dow Jones US Healthcare (IYH) were unchanged. BioNTech (BNTX) was surging above 32% after the company and its partner Pfizer (PFE) said the German regulatory authority, the Paul-Ehrlich-Institut, has approved the phase 1/2 clinical trial for BioNTech's BNT162 vaccine program to combat the COVID-19 disease.",196.321533203125
2020-04-23 00:00:00+00:00,293.6099853515625,297.44000244140625,291.57000732421875,292.25,292.25,2911100.0,2.0,1.0,0.250025,"On the other hand, drugmaker Eisai lost 8.9% after Biogen Inc BIIB.O on Wednesday delayed the filing for marketing approval of its experimental Alzheimer's disease drug developed jointly with Eisai. Analysts are sanguine about Japanese corporate earnings this year in the expectation of swift economic recovery from the coronavirus outbreak, though some strategists and investors caution such optimism could be misplaced. Shares of some companies related to the semi-conductor industry also jumped after their U.S. peers gained sharply, with the Philadelphia Semiconductor index .SOX surging 5.9% in its biggest one-day leap since April 6.",208.72836303710938
2020-04-24 00:00:00+00:00,293.0599975585937,297.94000244140625,290.1000061035156,297.79998779296875,297.79998779296875,1778800.0,3.0,1.0,0.5000249999999999,"iShares MSCI Kokusai ETF TOK $61.57 $69.42 12.75% Coca-Cola European Partners plc CCEP $39.28 $48.33 23.05% Teva Pharmaceutical Industries Ltd TEVA $10.18 $11.72 15.15% Biogen Inc BIIB $292.25 $336.09 15.00% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of TOK's underlying holdings with notable upside to their analyst target prices are Coca-Cola European Partners plc (Symbol: CCEP), Teva Pharmaceutical Industries Ltd (Symbol: TEVA), and Biogen Inc (Symbol: BIIB). Similarly, TEVA has 15.15% upside from the recent share price of $10.18 if the average analyst target price of $11.72/share is reached, and analysts on average are expecting BIIB to reach a target price of $336.09/share, which is 15.00% above the recent price of $292.25.",214.41409301757812
2020-04-27 00:00:00+00:00,300.5799865722656,305.0,299.739990234375,303.239990234375,303.239990234375,1611400.0,2.0,1.0,0.250025,"By William Hoffman NEW YORK, April 27 (IFR) - At least 14 corporate borrowers are in the US high-grade primary on Monday with new deals. Nationwide Mutual is back in the market after postponing its deal last week because of a failure to build adequate investor demand. Other issuers include Biogen, Air Products and Chemicals, Emerson Electric, Idex Corp, Diageo Capital, Georgia Pacific, Snap-on Inc and an overnight trade from Korea East-West Power.",218.0146484375
2020-04-29 00:00:00+00:00,308.8399963378906,313.3399963378906,304.6300048828125,304.7099914550781,304.7099914550781,2100100.0,5.0,1.0,1.000025,"Last week, Cara and its partner, Vifor Fresenius Medical Care Renal Pharma, announced positive results from a global late-stage study of Korsuva injection in treating CKD-aP in patients on hemodialysis. Cara anticipates completing an interim statistical analysis within the next couple of months for a phase 2 study evaluating an oral version of Korsuva in treating pruritis in patients with atopic dermatitis. With Cara Therapeutics' market cap currently below $750 million, the stock should have plenty of room to run if Korsuva wins regulatory approvals and reaches its commercial potential.",223.4209442138672
2020-04-30 00:00:00+00:00,299.0,305.04998779296875,296.1400146484375,296.8299865722656,296.8299865722656,2291100.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of IBB, in trading today Gilead Sciences Inc (Symbol: GILD) is up about 1.6%, Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is down about 0.5%, and Biogen Inc (Symbol: BIIB) is lower by about 0.8%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $92.15 per share, with $128.95 as the 52 week high point  that compares with a last trade of $125.37. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",228.8037567138672
2020-05-01 00:00:00+00:00,295.07000732421875,297.9200134277344,291.8800048828125,293.0899963378906,293.0899963378906,1538700.0,2.0,1.0,0.250025,"Biogen's (NASDAQ: BIIB) aducanumab may become the newest addition to the list. In short, an original interim analysis in April 2019 of aducanumab's phase 3 trials concluded there was a high possibility the experimental studies were futile and should be closed. Instead, a variety of variables within the eligibility criteria of the trials themselves, such as age, progression of disease, weight, diet, drug use, etc., might have played a significant part in these results.",232.09793090820312
2020-05-04 00:00:00+00:00,294.0599975585937,297.8999938964844,293.0199890136719,296.5199890136719,296.5199890136719,1253100.0,2.6666666666666665,1.0,0.4166916666666666,"In the past week, drugmaker Biogen Inc BIIB.O and U.S. health insurer Anthem Inc ANTM.N have also sold new bonds at low rates, which the companies said were partly to fund share buybacks. By Kate Duguid and Joshua Franklin NEW YORK, May 4 (Reuters) - Apple Inc AAPL.O on Monday capitalized on the Federal Reserve's emergency measures in response to the coronavirus outbreak to issue its cheapest bonds in years, making it the latest blue-chip company to do so to fund stock buybacks and dividends. While the Federal Reserve has yet to buy a single corporate bond, the intervention has fueled record issuance by companies in need of funding, such as Boeing Co BA.N, Marriott International Inc MAR.O and Ford Motor Co F.N. New Article Truxima is the only biosimilar to Genentech's and Biogen's (BIIB) Rituxan medication and can also be used to treat granulomatosis with polyangiitis, an autoimmune disease characterized by inflammation of the blood vessels. The companies plan on soon meeting with the US Food and Drug Administration and other regulatory authorities to discuss an accelerated filing process, with human clinical expected to begin by the end of 2020. GTX-102 currently being evaluated in a phase I/II study expected to eventually enroll 20 pediatric patients with the rare, neurogenetic disorder causing developmental disabilities and other nerve-related symptoms. New Article What happened Biogen (NASDAQ: BIIB) shares fell 6.18% in April, according to data provided by S&P Global Market Intelligence, as the biotech company said it would submit a key drug to the U.S. Food and Drug Administration later than expected. As part of an update in its earnings report, Biogen said it would complete the regulatory filing of its investigational Alzheimer's drug, aducanumab, in the third quarter after meetings with the FDA. In October the shares rebounded 26% in one trading session after Biogen said a broader study showed just the opposite and decided to submit the drug for regulatory approval.",238.2411651611328
2020-05-05 00:00:00+00:00,297.1400146484375,306.5,297.0799865722656,304.44000244140625,304.44000244140625,1348400.0,3.0,1.0,0.5000249999999999,"Biogen (NASDAQ: BIIB), the biotech company, issued $3 billion in bonds this week with proceeds partially going to repurchase shares. Those rates are the cheapest Apple has paid to issue debt in seven years, notes Reuters, citing data from Refinitiv IFR. Despite that dip, Apple's board authorized an increase of $50 billion for its stock buyback program and raised its dividend 6% to $0.82 a share.",235.31214904785156
2020-05-06 00:00:00+00:00,305.04998779296875,312.6600036621094,304.9800109863281,306.7799987792969,306.7799987792969,1255500.0,3.0,1.0,0.5000249999999999,"The top three S&P 500 .PG.INX percentage gainers: ** FLIR Systems Inc FLIR.O, up 9.9% ** Davita Inc DVA.N, up 7.1% ** Kla Corp KLAC.O, up 5.9% The top three S&P 500 .PL.INX percentage losers: ** Occidental Petroleum Corp OXY.N, down 9.2% ** Simon Property Group Inc SPG.N, down 7.7% ** Cincinnati Financial Corp CINF.O, down 7.7% The top NYSE .PG.N percentage gainer: ** Cars.Com Inc CARS.N, up 43.6% The top two NYSE .PL.N percentage losers: ** Nautilus Inc NLS.N, down 18.5% ** Bluegreen Vacations Corp BXG.N, down 16.7% The top three Nasdaq .PG.O percentage gainers: ** Macrogenics MGNX.O, up 259.7% ** Liveperson Inc LPSN.O, up 41.5% ** Axcla Health Inc AXLA.O, up 26.8% The top three Nasdaq .PL.O percentage losers: ** Wealthbridge Acquisition Ltd HHHH.O, down 25.4% ** Clensprk Inc CLSK.O, down 24.6% ** Inogen Inc INGN.O, down 20.2% ** Mesoblast Ltd MESO.O: up 7.3% BUZZ-Up after dosing first COVID-19 patients in U.S. study ** Office Depot Inc ODP.O: up 16.5% BUZZ-Jumps on strong results, withdraws 2020 guidance ** Mercadolibre Inc MELI.O: up 20.8% BUZZ-Jumps as online shoppers boost Q1 revenue ** General Motors Co GM.N: up 4.3% BUZZ-Jumps on Q1 beat; to resume U.S. production on May 18 ** Cars.com Inc CARS.N: up 43.6% BUZZ-Surges on strong Q1 results ** Bunge Ltd BG.N: down 13.4% BUZZ-Slips after swinging to Q1 loss, 2020 forecast cut ** Wendy's Co WEN.O: up 6.8% BUZZ-Jumps as co sees improving sales, breakfast success amid lockdown ** Clearwater Paper CLW.N: up 16.0% BUZZ-Rises after surprise profit on higher demand for tissues ** Venator Materials Plc VNTR.N: up 11.0% BUZZ-Rises on surprise Q1 profit, revenue beat ** Silk Road Medical Inc SILK.O: down 12.7% BUZZ-Falls on upsized secondary stock offering ** OneSpan Inc OSPN.O: up 13.0% BUZZ-Rises on profit beat, upbeat forecast ** LivePerson Inc LPSN.O: up 41.5% BUZZ-Gains on Q1 revenue beat, full-year outlook ** Activision Blizzard Inc ATVI.O: up 5.9% BUZZ-Jumps on strong outlook, Electronic Arts falls ** Beyond Meat Inc BYND.O: up 24.3% BUZZ-Street View: Virus takes bite out of Beyond Meat's growth ** CPS Technologies Corp CPSH.O: up 32.8% BUZZ-Set for best day in more than 10 years on higher earnings ** CVS Health Corp CVS.N: up 1.1% BUZZ-Gains as coronavirus-led stockpiling drives Q1 beat ** Wayfair Inc W.N: up 8.4% BUZZ-Brokerages hike PT on Q1 revenue beat ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 0.4% BUZZ-Drifts higher after upsized $2.2 bln recap ** Delphi Technologies Plc DLPH.N: up 16.1% BUZZ-Gains after BorgWarner reaffirms commitment to buy co ** Prudential Financial Inc PRU.N: down 6.9% BUZZ-Falls on dismal Q1 results ** DarioHealth Corp DRIO.O: up 9.5% BUZZ-Up after FDA approves use of glucose meters in hospitals ** Axcella Health Inc AXLA.O: up 26.8% BUZZ-Surges on positive results for liver disease drugs ** SmileDirectClub Inc SDC.O: up 10.8% BUZZ-Jumps on partnership with health insurer Anthem ** Beyond Meat Inc BYND.O: up 24.3% BUZZ-Reheats as results beat ** Nautilus Inc NLS.N: down 18.5% BUZZ-Sheds weight - stock plummets after Q1 results ** Everbridge Inc EVBG.O: up 21.1% BUZZ-Jumps on smaller-than-expected loss, upbeat forecast ** GrafTech International Ltd EAF.N: down 14.7% BUZZ-Slides on drop in sales, COVID-19 impact ** Merck & Co Inc MRK.N: up 0.2% ** Amgen Inc AMGN.O: up 1.0% ** Biogen Inc BIIB.O: up 2.2% ** AbbVie Inc ABBV.N: up 1.9% BUZZ-Pharma sector's pipeline quality improves, mixed impact of COVID-19 - Moody's ** Virgin Galactic Holdings Inc SPCE.N: up 8.9% BUZZ-Virgin Galactic gains altitude after co unveils new NASA partnership ** Intercept Pharmaceuticals Inc ICPT.O: up 12.2% ** NGM Biopharmaceuticals Inc NGM.O: up 8.4% BUZZ-Intercept, NGM rise on rival Novo's mixed NASH drug data The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and Nasdaq rose on Wednesday on hopes of a pickup in business activity as U.S. states eased coronavirus-induced curbs, with investors also looking past a stunning 20 million plunge in U.S. private payrolls last month. down 2.16% (Compiled by Mrinalika Roy and Trisha Roy in Bengaluru) ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",233.51791381835938
2020-05-11 00:00:00+00:00,313.4100036621094,330.1300048828125,313.0,328.010009765625,328.010009765625,1513500.0,3.0,1.0,0.5000249999999999,"My educated guess is that Buffett was busy adding to JPMorgan Chase (NYSE: JPM), with his team building up its stakes in Biogen (NASDAQ: BIIB) and Kroger (NYSE: KR). On Saturday, May 2, Buffett held his company's annual shareholder meeting (albeit virtually) and provided the usual dose of long-term wisdom that investors look for. For instance, Buffett introduced a slide during his shareholder meeting showing that he and his team purchased $426 million worth of equities in April, but sold almost $6.51 billion in stock.",219.09503173828125
2020-05-12 00:00:00+00:00,329.9100036621094,335.0,318.8900146484375,319.7699890136719,319.7699890136719,1882100.0,4.0,1.0,0.7500249999999999,"Biogen Another probable addition during the first quarter is biotech blue-chip Biogen (NASDAQ: BIIB). With a steady focus on digital and mobile banking apps, and a CEO (Jamie Dimon) whom Buffett greatly admires, JPMorgan Chase is a very likely add during the first quarter. In this instance, we're assuredly talking about the decisions being made by Buffett's investment team, as the Oracle of Omaha is generally no fan of drugmakers and keeping up on clinical study results.",219.01260375976562
2020-05-13 00:00:00+00:00,320.8999938964844,327.20001220703125,312.6600036621094,314.9599914550781,314.9599914550781,1795900.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of MTUM, in trading today Advanced Micro Devices Inc (Symbol: AMD) is up about 2%, Biogen Inc (Symbol: BIIB) is up about 1.5%, and Humana Inc. (Symbol: HUM) is lower by about 1.5%. For a complete list of holdings, visit the MTUM Holdings page  The chart below shows the one year price performance of MTUM, versus its 200 day moving average: Looking at the chart above, MTUM's low point in its 52 week range is $88.83 per share, with $137.69 as the 52 week high point  that compares with a last trade of $121.65. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",221.75807189941406
2020-05-19 00:00:00+00:00,314.6700134277344,316.8500061035156,308.6600036621094,310.0799865722656,310.0799865722656,862100.0,3.0,1.0,0.5000249999999999,"One biotechnology investment thats not strictly a coronavirus play, however, is Biogen (NASDAQ:BIIB) stock. 7 Financial Stocks with Dependable Dividends Perhaps the most encouraging statistic, however, relates to Biogens non-GAAP diluted earnings per share. The company remains in an excellent financial position and Biogens path to an Alzheimers treatment, while delayed, isnt necessarily closed off.",229.14198303222656
2020-05-22 00:00:00+00:00,304.1099853515625,305.0299987792969,300.79998779296875,304.5299987792969,304.5299987792969,690100.0,3.5,1.0,0.6250249999999999,"Among the largest underlying components of IVE, in trading today International Business Machines Corp (Symbol: IBM) is down about 0.7%, Fidelity National Information Services Inc (Symbol: FIS) is off about 0.4%, and Biogen Inc (Symbol: BIIB) is lower by about 0.4%. For a complete list of holdings, visit the IVE Holdings page  The chart below shows the one year price performance of IVE, versus its 200 day moving average: Looking at the chart above, IVE's low point in its 52 week range is $81.70 per share, with $132.10 as the 52 week high point  that compares with a last trade of $104.84. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article BIIB stock tanked in March 2019, falling 29% in its worst day of trading ever, after news broke that it was ending trials for a blockbuster Alzheimers drug called Aducanumab. Co-Diagnostics (NASDAQ:CODX) iBioPharma (NYSE:IBIO) Moderna (NASDAQ:MRNA) Biogen (NASDAQ:BIIB) Gilead Sciences (NASDAQ:GLID) Vertex Pharmaceuticals (NASDAQ:VRTX) Inovio (NASDAQ:INO) Some have seen their share price explode this year based on their Covid-19 involvement. BioGen (BIIB) BIIB)"" width=""300"" height=""169""> Source: Pavel Kapysh / Shutterstock.com BioGen is a biotech company based in Cambridge, Massachusetts.",231.2896270751953
2020-05-29 00:00:00+00:00,300.9800109863281,307.82000732421875,297.9100036621094,307.0899963378906,307.0899963378906,1917300.0,3.0,1.0,0.5000249999999999,"However, Spinraza faces the prospect of stiff competition from Roche's risdiplam, assuming the new SMA drug wins regulatory approvals. The biotech's antisense technology, which focuses on destroying messenger RNA to prevent disease-causing proteins from being produced, holds the potential to address a wide range of diseases, giving Ionis a tremendous growth runway over the long term. In addition, the company plans to meet with the FDA in the second half of 2020 about the next steps for AXS-14 after the drug met the primary endpoints in a late-stage study targeting fibromyalgia.",232.67381286621094
2020-06-01 00:00:00+00:00,305.7200012207031,306.95001220703125,300.70001220703125,301.45001220703125,301.45001220703125,863000.0,3.0,1.0,0.5000249999999999,"The company's approach is uncontroversial from a scientific perspective, given that neutralizing antibodies from COVID-19 survivors have already been shown to combat the disease in vitro by numerous independent research teams and similar therapies were successfully used to treat human patients with SARS. Similarly, Vir's approach is front-run by ongoing clinical trials testing the efficacy of antibodies from recovered COVID-19 patients on improving disease outcomes in people who are currently ill. By bucking the traditional wisdom regarding exclusivity and drug development, Vir has a real chance of entering the market sooner than competitors at a time when demand for its product would be enormously high.",235.50877380371094
2020-06-04 00:00:00+00:00,302.989990234375,303.9599914550781,297.54998779296875,299.6499938964844,299.6499938964844,1019000.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of IBB, in trading today Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is up about 0.3%, Biogen Inc (Symbol: BIIB) is down about 0.3%, and Illumina Inc (Symbol: ILMN) is up by about 0.4%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $92.15 per share, with $136.20 as the 52 week high point  that compares with a last trade of $133.05. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",246.92672729492188
2020-06-08 00:00:00+00:00,304.4800109863281,306.0599975585937,299.1300048828125,301.260009765625,301.260009765625,1491000.0,4.0,1.0,0.7500249999999999,"Here are three technology companies, two drug stocks, and two entertainment giants to consider buying: Microsoft (NASDAQ:MSFT) Intel (NASDAQ:INTC) Apple (NASDAQ:AAPL) AbbVie (NYSE:ABBV) Biogen (NASDAQ:BIIB) Walt Disney Company (NYSE:DIS) Biogen (BIIB) Source: Pavel Kapysh / Shutterstock.com Biogen is trading in a narrow range in the last six months because the company is busy shoring up its cash balance. Biogens aducanumab regulatory filing is a positive catalyst for BIIB stock.",243.00906372070312
2020-06-09 00:00:00+00:00,297.0,297.3399963378906,291.0,293.739990234375,293.739990234375,2045800.0,5.0,1.0,1.000025,"It bought the facility in Hillerod, Denmark, in August from Biogen Inc BIIB.O for about $890 million. TOKYO, June 10 (Reuters) - Fujifilm Holdings Corp 4901.T will spend $928 million to double capacity at a drug manufacturing facility in Denmark, which it has pledged to use in producing COVID-19 treatments, as the Japanese company steps up its pivot towards healthcare. Fujifilm previously announced that the Denmark site would offer future manufacturing capacity to the COVID-19 Therapeutics Accelerator to speed-up the response to the global pandemic.",240.3768310546875
2020-06-10 00:00:00+00:00,296.0799865722656,296.8099975585937,291.8999938964844,295.25,295.25,1430800.0,3.0,1.0,0.5000249999999999,"Biogen (NASDAQ: BIIB) has taken its shareholders on a roller-coaster ride over the past year or so, and more potential trouble is on the horizon for the biotech. Biogen discontinued the development of the drug candidate in March 2019, revealing that it had failed to prove effective against the symptoms of Alzheimer's in a phase 3 clinical trial. However, the biotech changed its tune on aducanumab in October after analysis of a larger data set revealed that Alzheimer's patients treated with the drug experienced ""significant benefits on measures of cognition and function."" New Article (RTTNews) - Biogen Inc. (BIIB) said the NURTURE study in pre-symptomatic patients with spinal muscular atrophy showed that early and sustained treatment with SPINRAZA for up to 4.8 years enabled unprecedented survival in infants genetically diagnosed with SMA. After up to 4.8 years of continuous treatment with SPINRAZA, all treated pre-symptomatically were alive, and none require permanent ventilation. Patients continued to maintain and make progressive gains in motor function.",234.5349578857422
2020-06-11 00:00:00+00:00,293.6600036621094,294.3900146484375,281.20001220703125,283.2200012207031,283.2200012207031,1669500.0,1.0,1.0,2.4999999999997247e-05,"In trading on Thursday, shares of Biogen Inc (Symbol: BIIB) crossed below their 200 day moving average of $287.39, changing hands as low as $281.20 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $215.775 per share, with $374.99 as the 52 week high point  that compares with a last trade of $283.22. The BIIB DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other stocks recently crossed below their 200 day moving average  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",242.68499755859375
2020-06-12 00:00:00+00:00,286.0599975585937,286.9599914550781,273.5899963378906,279.2699890136719,279.2699890136719,2041100.0,2.0,1.0,0.250025,"Among the largest underlying components of IBB, in trading today Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is up about 2.2%, Biogen Inc (Symbol: BIIB) is trading flat, and Illumina Inc (Symbol: ILMN) is up by about 1.9%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $92.15 per share, with $136.20 as the 52 week high point  that compares with a last trade of $128.98. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",246.76988220214844
2020-06-15 00:00:00+00:00,276.3599853515625,278.989990234375,272.0199890136719,278.489990234375,278.489990234375,2187800.0,3.0,1.0,0.5000249999999999,"Below is a twelve month price history chart comparing the stock performance of CMP, BIIB, and MCHP: Combined, CMP, BIIB, and MCHP represent 7.92% of the Morningstar Wide Moat ETF. Morningstar Wide Moat ETF MOAT $52.29 $57.56 10.09% Compass Minerals International Inc CMP $50.48 $60.50 19.85% Biogen Inc BIIB $279.27 $323.17 15.72% Microchip Technology Inc MCHP $99.63 $115.20 15.63% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of MOAT's underlying holdings with notable upside to their analyst target prices are Compass Minerals International Inc (Symbol: CMP), Biogen Inc (Symbol: BIIB), and Microchip Technology Inc (Symbol: MCHP).",253.00157165527344
2020-06-17 00:00:00+00:00,283.6000061035156,285.2799987792969,279.67999267578125,281.4599914550781,281.4599914550781,2070600.0,4.0,1.0,0.7500249999999999,"InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen (NASDAQ:BIIB) stock has looked so good at various times over the past nine months. BIIB stock couldnt dodge the massacre, suffering a peak-to-trough decline of 30%, bottoming near $262 in March. In 2019, BIIB generated free cash flow of $6.4 billion.",255.77540588378906
2020-06-18 00:00:00+00:00,261.0799865722656,270.19000244140625,258.95001220703125,260.29998779296875,260.29998779296875,6575000.0,2.428571428571428,1.0,0.357167857142857,"Biogen Inc BIIB.O dropped 5.2% after a U.S. district court ruled in favor of generic drugmaker Mylan NV MYL.O in a patent dispute over drugmaker's blockbuster multiple sclerosis drug Tecfidera. By Medha Singh and Devik Jain June 18 (Reuters) - The S&P 500 and the Dow were largely unchanged on Thursday as investors stayed on the sidelines amid an uptick in coronavirus infections in parts of the United States and an elevated level of weekly jobless claims. The Labor Department's report showed weekly jobless claims declining for the eleventh straight week, but the pace of declines has slowed as tepid demand and fractured supply chains have sparked a second wave of layoffs. New Article The top three S&P 500 .PG.INX percentage gainers: ** Dish Network Corp DISH.OQ, up 6.9% ** Waters Corp WAT.N, up 5.4% ** Occidental Petroleum OXY.N, up 4.4% The top three S&P 500 .PL.INX percentage losers: ** Kroger Co KR.N, down 5.7% ** Biogen Inc BIIB.OQ, down 5.4% ** Alliance Data Systems Corp ADS.N, down 4% The top three NYSE .PG.N percentage gainers: ** Nuvrra Environmental Solutions NES.N, up 52.4% ** Ntn Buzztime NTN.N, up 30.3% ** Bbx Capital Corp BBX.N, up 21.2% The top three NYSE .PL.N percentage losers: ** American Shared Hospital Services AMS.N, down 24.5% ** China Rapid Finance XRF.N, down 15.2% ** Team Inc TISI.N, down 14.8% The top three Nasdaq .PG.O percentage gainers: ** Verifyme Inc VRME.O, up 3,104% ** Urban One Inc UONE.O, up 119.3% ** Aethlon Medical Inc AEMD.O, up 104.3% The top three Nasdaq .PL.O percentage losers: ** Arts Way Manufacturing ARTW.O, down 32.5 % ** Highway Holding HIHO.O, down 24.9 % ** Atlantic American Corp AAME.O, down 23.1 % ** ABM Industries ABM.N: up 16.1% BUZZ-Gains as Q2 profit beats ** Orion Group Holdings ORN.N: up 14.6% BUZZ-Jumps on $17 mln dredging contracts ** Carnival Corp CCL.N: down 1.4% BUZZ-Drops on downbeat forecast, dismal Q2 results ** Rexahn Pharmaceuticals REXN.O: up 11.1% BUZZ-Surges on merger agreement with Ocuphire ** Farmmi Inc FAMI.O: up 80.7% BUZZ-Surges as subsidiary gets repeat order for mushroom supply ** U.S. Steel X.N: down 10.8% BUZZ-Slides on $429 mln equity raise ** Chevron Corp CVX.N: up 0.8% BUZZ-Chevron, Total most likely to enter deals during this downturn- Cowen ** Tonix Pharmaceuticals TNXP.O: up 6.0% BUZZ-Jumps on expanding COVID-19 vaccine collaboration ** Adamas Pharmaceuticals ADMS.O: down 3.5% BUZZ-Down on stopping development of multiple sclerosis drug ** Quicklogic Corp QUIK.O: down 18.6% BUZZ-Slumps on lowered Q2 revenue forecast ** IDEAYA Biosciences Inc IDYA.O: down 20.3% BUZZ-Falls on $100 mln stock offer ** Fox Factory FOXF.O: down 1.2% BUZZ-Falls after co prices upsized stock offering ** Francesca's Holdings FRAN.O: down 6.8% BUZZ-Drops as Q1 sales halve on pandemic-driven closures ** Globus Maritime GLBS.O: down 40.6% BUZZ-Drops on pricing upsized offering at discount ** Leap Therapeutics LPTX.O: down 15.9% BUZZ-Drops on $45 mln stock deal ** Tesla TSLA.O: up 1.3% BUZZ-Jefferies hikes PT to second highest on Street ** Spotify SPOT.N: up 10.5% BUZZ-Hits record high on DC Comics podcast deal ** Catalyst Biosciences CBIO.O: down 12.7% BUZZ-Falls on $30 mln equity raise ** Biogen BIIB.O: down 5.4% BUZZ-Slides after losing patent ruling for multiple sclerosis drug ** Athene Holding ATH.N: up 7.0% BUZZ-Gains on $500 mln minority stake buy in insurer Jackson ** Hertz Global Holdings HTZ.N: down 5.5% BUZZ-Falls a day after it suspends share sale ** Designer Brands DBI.N: down 3.4% BUZZ-Drops on wider-than-expected loss due to store closures ** Amedisys AMED.O: up 3.8% BUZZ-Benchmark upgrades on likely higher 2021 EBITDA ** First Solar FSLR.O: up 1.8% BUZZ-Gains on 15-yr power purchase deal with Dow ** Iveric bio ISEE.O: up 23.9% BUZZ-Jumps after big equity offering upsize ** 1-800-Flowers.Com FLWS.O: up 4.1% BUZZ-Up on full-year outlook raise ** Paylocity Holding PCTY.O: up 7.3% BUZZ-RBC raises rating, hikes PT to Street high The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and the Dow were largely unchanged on Thursday as investors stayed on the sidelines amid an uptick in coronavirus infections in parts of the United States and an elevated level of weekly jobless claims. down 0.63% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article And biotech firm Biogen (BIIB, -7.5%) sank amid a federal court ruling invalidating a patent for its multiple sclerosis drug Tecfidera. And on the COVID-19 front, investors have more to worry about than case spikes in the U.S., including in Florida, where scientists at Children's Hospital of Philadelphia and the University of Pennsylvania said the state is showing ""all the markings of the next large epicenter of coronavirus transmission."" That hardly means we're in for another 30% decline like we saw in February and March, but the market could lose some of its froth if outbreaks continue to worsen in the Sun Belt, which could put a damper on the pace of the economic recovery. New Article Meanwhile, shares of Biogen (NASDAQ: BIIB) have declined by about 6% in 2020, but may rebound sharply due to solid business performance. Its flagship products include Tecfidera and Vumerity, which are derived from fumeric acid -- a common food additive that's generally used to add tartness -- and are used to treat multiple sclerosis. With more than 2.1 million Americans already infected, over 116,000 dead, and rising case counts in a large percentage of U.S. states, I believe Gilead can still profit by supplying remdesivir -- thus far one of the two only proven effective COVID-19 treatments. New Article June 18 (Reuters) - A U.S. district court on Thursday ruled in favor of generic drugmaker Mylan NV MYL.O in a patent dispute over Biogen Inc's BIIB.O blockbuster multiple sclerosis drug Tecfidera, sending the drugmaker's shares down 7%. The ruling comes months after the U.S. Court of Appeals for the Federal Circuit ruled that a bioequivalent version of Tecfidera made by Banner Life Sciences LLC does not infringe a Biogen patent that was set to expire in June. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Arun Koyyur) ((saumya.joseph@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 2676; Twitter: @SaumyaSibi;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks fell at the open on Thursday as an uptick in COVID-19 infections in the United States threatened to upend bets of a swift economic recovery, with data showing weekly jobless claims remained elevated amid a second wave of layoffs. The top three S&P 500 .PG.INX percentage gainers: ** Mylan NV , up 4.3% ** Waters Corp , up 2.4% ** Church & Dwight Co , up 2.3% The top three S&P 500 .PL.INX percentage losers: ** Biogen Inc , down 6% ** Carnival Corp , down 4.5% ** H & R Block Inc , down 3.7% The top three NYSE .PG.N percentage gainers: ** Bbx Capital Corp , up 26.3% ** Turkcell , up 9.9% ** Abm Industries Inc , up 9.3% The top three NYSE .PL.N percentage losers: ** Cohen & Compny Inc , down 21.4% ** Team Inc , down 15.7% ** Us Steel Corp , down 12.6% The top three Nasdaq .PG.O percentage gainers: ** Verifyme Inc , up 2,900% ** Alpine Immune Sciences Inc , up 179.6% ** Aethlon Medical Inc , up 95.1% The top three Nasdaq .PL.O percentage losers: ** Arts Way Manufacturing , down 25.1% ** Quicklogic Corp , down 19.7% ** Highway Holdings , down 19.5% ** ABM Industries ABM.N: up 10.3% BUZZ-Gains as Q2 profit beats ** Orion Group Holdings ORN.N: up 21.3% BUZZ-Jumps on $17 mln dredging contracts ** Carnival Corp CCL.N: down 4.6% BUZZ-Drops on downbeat forecast, dismal Q2 results ** Rexahn Pharmaceuticals REXN.O: up 17.0% BUZZ-Surges on merger agreement with Ocuphire ** Farmmi Inc FAMI.O: up 90.8% BUZZ-Surges as subsidiary gets repeat order for mushshroom supply ** U.S. Steel X.N: down 12.6% BUZZ-Slides on $429 mln equity raise ** Tonix Pharmaceuticals TNXP.O: up 10.4% BUZZ-Jumps on expanding COVID-19 vaccine collaboration ** Adamas Pharmaceuticals ADMS.O: down 1.4% BUZZ-Down on stopping development of multiple sclerosis drug ** Quicklogic Corp QUIK.O: down 19.7% BUZZ-Slumps on lowered Q2 revenue forecast ** IDEAYA Biosciences Inc IDYA.O: down 16.5% BUZZ-Falls on $100 mln stock offer ** Fox Factory FOXF.O: down 5.8% BUZZ-Falls after co prices upsized stock offering ** Francesca's Holdings FRAN.O: down 10.9% BUZZ-Drops as Q1 sales halve on pandemic-driven closures ** Globus Maritime GLBS.O: down 45.1% BUZZ-Drops on pricing upsized offering at discount ** Leap Therapeutics LPTX.O: down 18.7% BUZZ-Drops on $45 mln stock deal The 11 major S&P 500 sectors: Communication Services down 0.64% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen Inc BIIB.O dropped 6.4% after a U.S. district court ruled in favor of generic drugmaker Mylan NV MYL.O in a patent dispute over drugmaker's blockbuster multiple sclerosis drug Tecfidera. By Medha Singh and Devik Jain June 18 (Reuters) - The S&P 500 was little changed on Thursday as coronavirus infections picked up again in parts of the United States and data showed an elevated level of weekly jobless claims, lending weight to predictions of a prolonged economic recovery. ""The market has fully priced in a majority of the gains coming out of this recovery phase and it's not really going to go much higher until we get better data down the road,"" said Andrew Smith, chief investment strategist at Delos Capital Advisors, in Dallas, Texas. New Article In company news, Biogen (BIIB) slid 7% lower after Thursday saying the US District Court in northern West Virginia invalidated the company's patent for its Tecfidera drug treatment for multiple sclerosis. Rexahn Pharmaceuticals (REXN) rose 6.6% after agreeing to an all-stock merger offer from privately held ophthalmic drugmaker Ocuphire Pharma. Under terms of the proposed transaction, Rexahn investors will own about 14% of the combined company, which will change its name to Ocuphire Pharma and trade under the OCUP ticker symbol after the deal's expected close later this year. New Article Biogen Inc BIIB.O dropped 7.6% after a U.S. district court ruled in favor of generic drugmaker Mylan NV MYL.O in a patent dispute. By Stephen Culp NEW YORK, June 18 (Reuters) - Wall Street struggled for direction on Thursday as investors weighed a resurgence in coronavirus infections and the possibility of a new round of shutdowns against data that suggested the U.S. economy might not bounce back with quick, V-shaped recovery. ""It's not unusual after huge moves to trade sidewise,"" said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana. New Article Biogen Inc BIIB.O dropped after a U.S. district court ruled in favor of generic drugmaker Mylan NV MYL.O in a patent dispute. By Stephen Culp NEW YORK, June 18 (Reuters) - The S&P 500 closed nominally higher on Thursday as investors weighed a resurgence in coronavirus infections and the possibility of a new round of shutdowns as well as data that suggested the U.S. economy might not bounce back with quick, V-shaped recovery. ""The market's looking for its next big impulse,"" said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana. New Article Biogen (BIIB) slid 7.4% lower after a federal judge in West Virginia Thursday ruled for rival Mylan (MYL) and invalidated the patent for the drugmaker's Tecfidera medication, citing Biogen's ""lack of a written description"" for the lucrative multiple sclerosis treatment. Net proceeds will fund research and development and clinical testing of prospective medications, working capital and other general corporate purposes. Rexahn Pharmaceuticals (REXN) rose over 20% after agreeing to an all-stock merger offer from privately held ophthalmic drugmaker Ocuphire Pharma. New Article Biogen's (NASDAQ: BIIB) Tecfidera is one of the world's best-selling multiple sclerosis drugs, and on Thursday, a judge in the Northern District of West Virginia ruled that a key patent on it is invalid. 503 Server Error: Service Unavailable: Back-end server is at capacity for url: https://www.fool.com/a/disclosure?uids=180995070&usernames=&tickers=NASDAQ%3ABIIB%2CNASDAQ%3AMYL&serviceId=0&profile=usmf-free The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. According to Reuters, Judge Irene Keeley agreed, finding that the biotech company didn't ""adequately describe the claimed invention."" New Article In trading on Thursday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 28.1, after changing hands as low as $258.95 per share. A bullish investor could look at BIIB's 28.1 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of BIIB shares: Looking at the chart above, BIIB's low point in its 52 week range is $215.775 per share, with $374.99 as the 52 week high point  that compares with a last trade of $260.30. New Article By Saumya Joseph June 18 (Reuters) - A U.S. district court on Thursday ruled in favor of generic drugmaker Mylan NV MYL.O in a patent dispute over Biogen Inc's BIIB.O blockbuster multiple sclerosis drug, Tecfidera, sending Biogen's shares down nearly 6%. Tecfidera has been Biogen's main growth driver since it was launched in 2013, generating sales of $4.43 billion in 2019, accounting for nearly a third of total revenue. A court in the Northern District of West Virginia ruled Mylan had established that the asserted claims of Biogen's patent were invalid.",253.34642028808594
2020-06-19 00:00:00+00:00,261.75,271.989990234375,259.79998779296875,271.0,271.0,7723100.0,2.333333333333333,1.0,0.3333583333333332,"VIDEO: S&P 500 Movers: BIIB, VIAC The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing S&P 500 component thus far on the day is Biogen, trading down 7.5%. Biogen is lower by about 12.3% looking at the year to date performance. New Article VIDEO: Nasdaq 100 Movers: BIIB, LBTYA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing Nasdaq 100 component thus far on the day is Biogen, trading down 7.5%. One other component making moves today is Ross Stores, trading down 4.6% on the day. New Article Court Rules In Favor Of Mylan In Tecfidera Patent Suit The U.S. District Court for the Northern District of West Virginia has invalidated Biogen Inc.'s (BIIB) patent covering its multiple sclerosis Tecfidera, clearing the way for Mylan's launch of a generic version of the drug. BIIB closed the day's trading at $260.30, down 7.52%. The accelerated approval granted to TAZVERIK on Thursday is for two indications: -- Adult patients with relapsed or refractory FL whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies.",255.45278930664062
2020-06-23 00:00:00+00:00,266.3699951171875,273.010009765625,265.489990234375,268.19000244140625,268.19000244140625,1820100.0,3.0,1.0,0.5000249999999999,"Moderna (NASDAQ: MRNA) set the record for the biggest initial public offering (IPO) in biotech history on Dec. 6, 2018. However, the company's earnings have soared by a CAGR of 41.8% during the same period -- thanks in large part to provisions related to increased cash flow from Vertex's Trikafta. I'd like to see how some of the drugs linked to some of the company's newer royalty deals, such as Amgen's heart failure therapy omecamtiv mecarbil, fare. New Article Combined, BIIB and ALGN make up approximately 1.8% of the underlying holdings of XLV. Within that group, Biogen Inc (Symbol: BIIB) and Align Technology Inc (Symbol: ALGN) are two large stocks leading the way, showing a gain of 2.8% and 2.7%, respectively. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Tuesday.",265.7848205566406
2020-06-29 00:00:00+00:00,260.8399963378906,263.67999267578125,258.3999938964844,260.3500061035156,260.3500061035156,899300.0,3.0,1.0,0.5000249999999999,"Eli Lilly (NYSE: LLY), Axsome Therapeutics (NASDAQ: AXSM), and Biogen (NASDAQ: BIIB) all have promising drugs for the treatment or detection of Alzheimer's. In 2016, the Indianapolis-based company's stock dropped more than 10% in one day when Alzheimer's candidate solanezumab failed its phase 3 trial because it did not slow cognitive decline in subjects. Lilly had $22.3 billion in net sales last year (and boasts 35,000 employees), so it has plenty to fall back on if Tauvid isn't a huge moneymaker.",275.1833190917969
2020-07-01 00:00:00+00:00,266.8900146484375,269.32000732421875,261.8699951171875,264.7699890136719,264.7699890136719,1093800.0,2.0,1.0,0.250025,"But the stock's popularity may have driven its price up to the point where it is no longer a good bargain compared with the slightly smaller and less rapidly growing Biogen (NASDAQ: BIIB). As it turns out, Biogen's true value lies in its larger drug-development pipeline as well as its operational efficiency, both of which have laid a strong foundation for the company to be more successful than Vertex in the long term. The most important thing to realize before investing in Biogen, however, is that it will likely take about a year before its underlying value translates into stock growth as a result of the timing of the drug-development cycle.",277.449951171875
2020-07-02 00:00:00+00:00,265.489990234375,267.9800109863281,264.1199951171875,265.1199951171875,265.1199951171875,942900.0,2.0,1.0,0.250025,"What happened Biogen (NASDAQ: BIIB) shares slid 12.9% in June, according to data provided by S&P Global Market Intelligence, as the company lost a patent ruling on its blockbuster multiple sclerosis (MS) drug. In a challenge involving rival Mylan, a federal court in West Virginia invalidated Biogen's Tecfidera patent. As for Vumerity, launched late last year, sales haven't yet picked up, even though the drug offers the same efficacy as Tecfidera but with fewer side effects.",270.1524963378906
2020-07-06 00:00:00+00:00,268.0400085449219,270.7099914550781,267.1300048828125,269.79998779296875,269.79998779296875,859400.0,3.0,1.0,0.5000249999999999,"Some of the companies it partners with are AbbVie (NASDAQ:ABBV), Biogen (NASDAQ:BIIB), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), and Vertex Pharmaceuticals (NASDAQ:VRTX). According to a 2013 study by Andrew Lo and Sourya V. Naraharisetti of MIT: new alternative investment companies have emerged to bridge the biopharma funding gap by purchasing economic interests in drug royalty streams. Such purchases allow universities and biopharma companies to monetize their intellectual property, creating greater financial flexibility for them while giving investors an opportunity to participate in the life sciences industry at lower risk.",266.3454895019531
2020-07-08 00:00:00+00:00,294.32000732421875,294.989990234375,278.1700134277344,280.19000244140625,280.19000244140625,3257800.0,3.3125,1.0,0.5781499999999999,"(RTTNews) - Shares of biotechnology company Biogen Inc. (BIIB) are rising more than 5 percent or $14.51 in Wednesday's morning trade at $282.86. If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer's disease. Aducanumab would also be the first therapy to demonstrate that removing amyloid beta resulted in better clinical outcomes. New Article VIDEO: Nasdaq 100 Movers: ALXN, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing Nasdaq 100 component thus far on the day is Alexion Pharmaceuticals, trading down 1.0%. Alexion Pharmaceuticals is showing a gain of 2.9% looking at the year to date performance. New Article Adds details on submission, background July 8 (Reuters) - Biogen Inc BIIB.O said on Wednesday that it submitted a marketing application for its experimental Alzheimer's disease therapy, aducanumab, to the U.S. Food and Drug Administration (FDA), sending its shares up more than 8% in premarket trading. The U.S. FDA now has 60 days to decide whether to accept the application for review, Biogen and partner Eisai Co Ltd 4523.T said in a joint statement. The companies reversed course in October, reviving plans to seek U.S. approval for aducanumab, saying detailed analysis of discontinued trials showed the drug to be effective when administered in high quantities to patients over an extended period. New Article Biogen Inc BIIB.O jumped 6.9% in premarket trading after the company said it submitted the marketing application for its experimental Alzheimer's disease therapy, aducanumab, to the U.S. Food and Drug Administration. By C Nivedita and Medha Singh July 8 (Reuters) - Wall Street's main indexes were set to open slightly higher in choppy trade on Wednesday as investors' faith in an economic recovery wobbled on the back of the surge in coronavirus caseloads across the country. The Nasdaq notched an intraday record high on Tuesday but all the three main stock indexes finished lower as investors booked profits following a strong run after a batch of upbeat data strengthened the case for a bounce back in economy. New Article Biogen (BIIB) was over 7% higher after the biotechnology company said it has completed the submission of a biologics license application (BLA) to the Food and Drug Administration for aducanumab, an investigational treatment for Alzheimer's disease. Health care firms were flat to higher premarket Wednesday as the Health Care SPDR (XLV) was inactive, while the iShares NASDAQ Biotechnology Index (IBB) was recently up 0.7%. Intersect ENT (XENT) was surging past 35% after Ireland-based Medtronic (MDT) offered to acquire the company, Bloomberg News reported, citing people with knowledge of the matter. New Article Click to Enlarge Source: Chart courtesy of StockCharts.com Biogen (NASDAQ:BIIB) shares got off to a fast start on the day, climbing about 9% at its highs. 3: Biogen (BIIB) If BIIB stock was healthy, shares would have held $290 and these key moving averages, as it made its way up toward $310. New Article Biogen Inc BIIB.O jumped 5.8% after the company said it submitted the marketing application for its experimental Alzheimer's disease therapy, aducanumab. By C Nivedita and Medha Singh July 8 (Reuters) - Technology shares boosted Wall Street's main indexes on Wednesday as early signs of an economic rebound dominated over fears of another lockdown due to a jump in coronavirus cases across the country. GOL/ ""We expect the tug of war between better economic data and concerns over rising COVID-19 cases to continue through the month unless we get better daily virus numbers, and/or news on a vaccine,"" said Art Hogan, chief market strategist at National Securities in New York. New Article The top three S&P 500 .PG.INX percentage gainers: ** Twitter Inc , up 6.1% ** Lennar Corp , up 5.1% ** Biogen Inc , up 4.9% The top three S&P 500 .PL.INX percentage losers: ** Mosaic Company , down 6.4% ** Mohawk Industries Inc , down 6.1% ** Corteva Inc , down 4.9% The top NYSE .PG.N percentage gainer: ** Container Store Group , up 33.8% The top three NYSE .PL.N percentage losers: ** Mogu Inc , down 29.7% ** Unique Fabricating Inc , down 13.1% ** MV Oil Trust , down 12.5% The top two Nasdaq .PG.O percentage gainers: ** Bluecity Holdings , up 71.9% ** National General , up 64.6% The top three Nasdaq .PL.O percentage losers: ** Centogene NV , down 16.7% ** Gilat Satellite Networks , down 14.6% ** Hepion Pharmaceuticals Inc , down 11.9% ** Synaptics Inc SYNA.O: up 10.3% BUZZ-Rises on deal to buy rights to Broadcom's wireless IoT unit ** Allstate Corp ALL.N: down 4.0% Insurer Allstate to buy National General for about $4 bln ** Levi Strauss LEVI.N: down 7.8% BUZZ-Down on margin warning despite revenue beat Levi Strauss Warns of weak second half on pandemic woes, to cut 700 jobs ** AMC Entertainment AMC.N: up 1.9% BUZZ-AMC: Rises on report co nearing financing deal to avoid near-term bankruptcy ** Clean Energy Fuels Corp CLNE.O: up 50.7% BUZZ-Jumps on partnership with Chevron ** Party City Holdco PRTY.N: up 10.5% BUZZ-Jumps after regaining compliance with NYSE listing standards ** Simply Good Foods SMPL.O: up 3.1% BUZZ-Rises as Q3 results beat expectations ** Kohl's Corp KSS.N: up 3.0% BUZZ-Kohl's better positioned to recover from reopenings - BofA ** Cambium Networks Corp CMBM.O: up 14.0% BUZZ-Jumps on upbeat Q2 prelim revenue ** Vivus Inc VVUS.O: down 24.5% BUZZ-Slumps after filing for bankruptcy protection ** Biogen BIIB.O: up 4.8% BUZZ-Jumps on U.S. marketing application submission for Alzheimer's drug ** National General Holdings Corp NGHC.O: up 64.6% BUZZ-Soars on Allstate's $4 bln takeover offer ** ForeScout Technologies FSCT.O: up 4.5% BUZZ-Rises on upbeat Q2 revenue forecast ** Concert Pharmaceuticals Inc CNCE.O: up 5.1% BUZZ-Jumps after FDA Breakthrough Therapy Designation ** Intersect ENT XENT.O: up 29.7% BUZZ-Intersect ENT surges on report of Medtronic's takeover offer ** KKR & Co KKR.N: up 7.7% BUZZ-Rises on over $4 bln deal to buy Global Atlantic Financial ** DAVIDsTEA DTEA.O: down 18.2% BUZZ-Drops after filing for creditor protection ** Rekor Systems REKR.O: up 1.4% BUZZ-Rises on revenue growth forecast ** Nikola Corp NKLA.O: up 16.9% BUZZ-Nikola rises as JP Morgan upgrades EV truck maker to ""overweight"" The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Technology shares boosted Wall Street's main indexes on Wednesday as early signs of an economic rebound offset fears of another lockdown due to a jump in coronavirus cases across the country. down 0.19% (Compiled by Bharath Manjesh in Bengaluru) ((Bharath.ManjeshR@thomsonreuters.com; outside U.S. +91 80 6749 2703;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen Inc BIIB.O jumped 4.4% after the company said it submitted the marketing application for its experimental Alzheimer's disease therapy, aducanumab. By Caroline Valetkevitch July 8 (Reuters) - U.S stocks rose on Wednesday and the Nasdaq hit a record closing high, supported by technology shares as early signs of an economic rebound offset concern about further lockdowns due to a jump in coronavirus cases across the country. Investors have been weighing a string of upbeat economic data including record job additions and a rebound in the service sector in June, against the surge in U.S. coronavirus cases recently, but the S&P 500 is still up more than 40% from its March closing low. New Article Biogen Inc BIIB.O jumped 5.2% after the company said it submitted the marketing application for its experimental Alzheimer's disease therapy, aducanumab. By C Nivedita and Medha Singh July 8 (Reuters) - Wall Street's major indexes edged higher in choppy trading on Wednesday, supported by technology shares as early signs of an economic rebound overrode fears of another lockdown due to a jump in coronavirus cases across the country. ""People are debating whether or not the low in the economy has actually been reached so they're sticking with growth stocks and that's technology,"" said Robert Pavlik, senior portfolio manager at SlateStone Wealth LLC in New York. New Article Especially high volume was seen for the $260 strike put option expiring August 21, 2020, with 4,288 contracts trading so far today, representing approximately 428,800 underlying shares of BIIB. Below is a chart showing AAP's trailing twelve month trading history, with the $140 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 34,567 contracts thus far today. That number of contracts represents approximately 3.5 million underlying shares, working out to a sizeable 158.1% of BIIB's average daily trading volume over the past month, of 2.2 million shares. New Article Biogen Inc BIIB.O jumped 4.2% after the company said it submitted the marketing application for its experimental Alzheimer's disease therapy, aducanumab. By C Nivedita and Medha Singh July 8 (Reuters) - U.S stocks were slightly higher in choppy trading on Wednesday, supported by technology shares as early signs of an economic rebound offset concern about further lockdowns due to a jump in coronavirus cases across the country. Investors have been weighing a string of upbeat economic data including record job additions and a rebound in the service sector in June, against the surge in U.S. coronavirus cases recently, but the S&P 500 is still up about 40% from its March closing low. New Article However, Biogen (NASDAQ: BIIB) posted gains today based on hopes for treating a different disease. Even as other major market benchmarks struggled to stay in positive territory, the Nasdaq flirted with its record levels, climbing 1% as of 3 p.m. EDT. Biogen has asked the FDA to give the application priority review status in the hopes of becoming the first company to produce a therapy that can slow the health decline caused by Alzheimer's. New Article Biogen (NASDAQ: BIIB) has finally submitted a biologics license application (BLA) for aducanumab, a monthly infusion that prevents amyloid plaques from forming in the brain. The first new drug application for an experimental therapy meant to prevent Alzheimer's disease from worsening finally reached regulators on Wednesday. Biogen ran a pair of pivotal studies with aducanumab, only one of which measured a significant benefit with regard to patients' dementia ratings after treatment with the highest dose tested. New Article What happened Shares of Biogen (NASDAQ: BIIB) were jumping 4.3% higher as of 3:42 p.m. EDT on Wednesday after rising as much as 9.9% earlier in the day. The gain came after the biotech announced that it had completed the submission of a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for aducanumab as a treatment for Alzheimer's disease. However, hopes were dashed last year after Biogen halted two late-stage studies of aducanumab after an independent data-monitoring committee determined that the experimental drug was unlikely to be effective. New Article And the worst performing S&P 500 component thus far on the day is Mosaic, trading down 3.3%. Mosaic is lower by about 42.5% looking at the year to date performance. VIDEO: S&P 500 Movers: MOS, FTI The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",258.5943298339844
2020-07-10 00:00:00+00:00,277.17999267578125,279.489990234375,275.3500061035156,278.8800048828125,278.8800048828125,955300.0,2.5,1.0,0.375025,"With safety not being a major sticking point for most of these respondents, we suspect the regulatory debate is likely to come down to whether perceived tolerability + the unmet need win out over a questionable efficacy data + trial conduct/analysis. All in all, Kasimov reiterated a Hold rating on BIIB shares along with a $293 price target, which implies a modest 5% upside. Take for instance biotech Biogen (BIIB). On Wednesday, Biogen disclosed it had submitted a BLA (biologics license application) to the U.S. Food and Drug Administration (FDA) for its potential Alzheimer treatment, aducanumab. New Article InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen (NASDAQ:BIIB) looked like it was finally ready to run. BIIB stock opened north of $294, but quickly moved lower. Above puts $310-plus in play for BIIB stock.",259.3926696777344
2020-07-16 00:00:00+00:00,282.2200012207031,282.32000732421875,276.8099975585937,279.5400085449219,279.5400085449219,944300.0,2.0,1.0,0.250025,"Investors considering a purchase of Biogen Inc (Symbol: BIIB) shares, but cautious about paying the going market price of $280.46/share, might benefit from considering selling puts among the alternative strategies at their disposal. Selling a put does not give an investor access to BIIB's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. For other put options contract ideas at the various different available expirations, visit the BIIB Stock Options page of StockOptionsChannel.com.",263.31121826171875
2020-07-21 00:00:00+00:00,285.0,285.0,280.0299987792969,280.19000244140625,280.19000244140625,888500.0,3.4,1.0,0.600025,"July 21 (Reuters) - Biogen Inc BIIB.O said on Tuesday it plans to start a global clinical study to assess the safety and benefits of its spinal muscular atrophy drug Spinraza in children who were previously treated with Novartis AG's NOVN.S rival therapy Zolgensma. The study aims at evaluating Spinraza to potentially improve clinical outcomes in some patients who do not respond sufficiently to the gene therapy Zolgensma, the company said. (https://reut.rs/3jsVIis) (Reporting by Manojna Maddipatla in Bengaluru; Editing by Aditya Soni) ((manojna.kalyani@thomsonreuters.com; +91 8061822700;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article (RTTNews) - Biogen Inc. (BIIB) said that it has appointed Michael McDonnell as Executive Vice President and Chief Financial Officer, effective August 15, 2020. McDonnell succeeds Jeffrey Capello, who has served as Biogen's Executive Vice President and Chief Financial Officer since December 2017. Capello will step down from his current role as Chief Financial Officer effective with McDonnell's appointment on August 15, 2020, and will remain with the company until September 15, 2020, to assist with the transition. New Article iogen (BIIB) is set to report second quarter fiscal 2020 earnings results before the opening bell Wednesday. But while Biogen has faced some operational hurdles due to the pandemic, the company recently filed an application with the FDA, seeking approval for its Alzheimer's disease drug aducanumab. Biopharma analyst Carter Gould of Barclays thinks the ruling, if upheld, could impact Biogens free cash flow by one-third. New Article July 21 (Reuters) - Biogen Inc BIIB.O on Tuesday named IQVIA Holding Inc's IQV.N Michael McDonnell as chief financial officer, effective Aug. 15. McDonnell succeeds Jeffrey Capello, who will remain with the company until Sept. 15 to assist with the transition, the drugmaker said in a statement. Separately, healthcare services company IQVIA said Ron Bruehlman will succeed McDonnell as chief financial officer on an interim basis. New Article Biogen Inc. (BIIB) is reporting for the quarter ending June 30, 2020. In the past year BIIB has beat the expectations every quarter. Zacks Investment Research reports that the 2020 Price to Earnings ratio for BIIB is 8.54 vs. an industry ratio of -12.90, implying that they will have a higher earnings growth than their competitors in the same industry.",262.5980224609375
2020-07-22 00:00:00+00:00,285.3599853515625,286.4800109863281,279.1000061035156,280.8099975585937,280.8099975585937,1392100.0,3.0,1.0,0.5000249999999999,"(RTTNews) - While reporting financial results for the second quarter on Wednesday, Biogen Inc. (BIIB) raised its earnings and adjusted earnings guidance for the full-year 2020, while trimming annual revenue outlook. On average, analysts polled by Thomson Reuters expect the company to report earnings of $32.96 per share on revenues of $13.94 billion for the year. The Street expected the company to report earnings of $8.04 per share on revenues of $3.44 billion for the quarter. New Article stores growing less relevant ** FirstEnergy Corp FE.N: down 14.4% BUZZ-Scotiabank cuts rating over nuclear bailout bribery inquiry ** Lockheed Martin LMT.N: up 0.5% BUZZ-Street View: Lockheed Martin ready to battle COVID-19 disruptions ** Pfizer Inc PFE.N: up 4.2% ** BioNtech SE BNTX.O: up 5.5% BUZZ-Pfizer, BioNtech jump on $1.95 bln deal with U.S. for COVID-19 vaccine ** Biogen Inc BIIB.O: up 1.8% BUZZ-Biogen jumps on Q2 profit beat, higher 2020 profit outlook BUZZ-CFO change could be indicative of M&A to come - Mizuho ** Science Applications International Corp SAIC.N: up 3.1% BUZZ-Up on winning $89 mln U.S. Army contract ** IQVIA Holdings Inc IQV.N: up 2% BUZZ-IQVIA: Rises on 2020 profit forecast raise and Q2 profit beat ** Spotify Technology SA SPOT.N: up 4.3% BUZZ-Rises on new licensing deal with Universal Music Group ** Nasdaq Inc NDAQ.O: up 1.1% BUZZ-Nasdaq rises on profit beat fueled by record trading volumes ** Check Point Software CHKP.O: up 4.4% BUZZ-Nears record high after strong Q2 results ** HCA Healthcare Inc HCA.N: up 5.9% BUZZ-Rises on revenue beat as patient volumes rebound ** Global Eagle Entertainment ENT.O: down 37.1% BUZZ-Slips on filing for Chapter 11 bankruptcy protection ** Option Care Health Inc OPCH.O: down 13.5% BUZZ-Continues slide after pricing downsized stock offering The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and Dow opened lower on Wednesday as an escalation in tensions between United States and China offset optimism about another round of fiscal stimulus for the virus-stricken economy. The top three S&P 500 .PG.INX percentage gainers: ** Best Buy Co Inc , up 6.3% ** HCA Healthcare Inc , up 5.7% ** Pfizer Inc , up 4.2% The top three S&P 500 .PL.INX percentage losers: ** Kohl's Corp , down 5.5% ** Oneok Inc , down 3.5% ** HollyFrontier Corp , down 3.5% The top three NYSE .PG.N percentage gainers: ** Mexco Energy Corp , up 183% ** ION Geophysical Corp , up 9.4% ** Fortress Value Acquisition Corp , up 8.8% The top three NYSE .PL.N percentage losers: ** Ibio Inc , down 16.7% ** Leju Holdings Ltd , down 13.5% ** Itau Corpbanca , down 5.5% The top three Nasdaq .PG.O percentage gainers: ** Sundance Energy Inc , up 55.5% ** U.S. Energy Corp , up 31.5% ** Mid-Con Energy Partners LP , up 23.3% The top three Nasdaq .PL.O percentage losers: ** Global Eagle Entertainment , down 37.1% ** Molecular Data Inc , down 18.2% ** Midatech Pharma PLC , down 18.6% ** Boeing Co BA.N: down 1.5% BUZZ-Falls as Cathay Pacific to defer orders, MAX return likely delayed ** Macy's Inc M.N: down 3.7% ** Kohls Corp KSS.N: down 5.5% BUZZ-Macy's, Kohl's fall as UBS sees dept. New Article stores growing less relevant ** FirstEnergy Corp FE.N: down 19.4% BUZZ-Scotiabank cuts rating over nuclear bailout bribery inquiry ** Lockheed Martin LMT.N: up 2.6% BUZZ-Street View: Lockheed Martin ready to battle COVID-19 disruptions ** Pfizer Inc PFE.N: up 3.4% ** BioNtech SE BNTX.O: up 8.1% BUZZ-Pfizer, BioNtech jump on $1.95 bln deal with U.S. for COVID-19 vaccine ** Capital One Financial Corp COF.N: up 2.7% BUZZ-Street View: Capital One Financial in good capital position to weather downturn ** Biogen Inc BIIB.O: up 0.9% BUZZ-Biogen jumps on Q2 profit beat, higher 2020 profit outlook BUZZ-CFO change could be indicative of M&A to come - Mizuho ** Science Applications International Corp SAIC.N: up 5.2% BUZZ-Up on winning $89 mln U.S. Army contract ** General Motors Co GM.N: up 0.2% ** Ford Motor Co F.N: up 1.6% BUZZ-Credit Suisse raises PT on GM, Ford; points to North America recovery ** IQVIA Holdings Inc IQV.N: up 4.6% BUZZ-IQVIA: Rises on 2020 profit forecast raise and Q2 profit beat ** Spotify Technology SA SPOT.N: up 5.6% BUZZ-Rises on new licensing deal with Universal Music Group ** Nasdaq Inc NDAQ.O: up 2.1% BUZZ-Nasdaq rises on profit beat fueled by record trading volumes ** Lithia Motors LAD.N: up 16.7% BUZZ-Set to open at record high after profit beat ** HCA Healthcare Inc HCA.N: up 9.3% BUZZ-Rises on revenue beat as patient volumes rebound ** Global Eagle Entertainment ENT.O: down 27.6% BUZZ-Slips on filing for Chapter 11 bankruptcy protection ** Option Care Health Inc OPCH.O: down 11.3% BUZZ-Continues slide after pricing downsized stock offering ** Tellurian Inc TELL.O: down 27.2% BUZZ-Down as co flags impairment hit, mulls changes to Driftwood project ** CytoSorbents Corp CTSO.O: up 8.5% BUZZ-CytoSorbents bounces after medical device co prices upsized stock deal ** Best Buy Co Inc BBY.N: up 7.7% BUZZ-Hits record high as online sales surge ** United Airlines Holdings Inc UAL.O: down 2.2% BUZZ-Warns only COVID-19 vaccine can rescue travel demand, shares fall ** Amphenol Corp APH.N: up 1.8% BUZZ-Rises on Q2 results beat The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 ticked higher in a choppy session on Wednesday as a boost from Microsoft and optimism about another round of stimulus for the virus-stricken economy countered worries over worsening ties between the United States and China. The top three S&P 500 .PG.INX percentage gainers: ** NVR Inc , up 9.7% ** HCA Healthcare Inc , up 9.2% ** Best Buy Co Inc , up 7.7% The top three S&P 500 .PL.INX percentage losers: ** FirstEnergy Corp , down 19.5% ** Kohl's Corp , down 6.7% ** Northern Trust Corp , down 5.6% The top three NYSE .PG.N percentage gainers: ** Mexco Energy Corp , up 255.6% ** Oblong Inc , up 51.8% ** Indonesia Energy Corp , up 38.1% The top three NYSE .PL.N percentage losers: ** Independence Contract Drilling Inc , down 19.7% ** FirstEnergy Corp , down 19.5% ** Ibio Inc , down 15.0% The top three Nasdaq .PG.O percentage gainers: ** Sundance Energy Inc , up 61.6% ** U.S. Energy Corp , up 37.7% ** Houghton Mifflin Harcourt Co , up 20.3% The top three Nasdaq .PL.O percentage losers: ** Global Eagle Entertainment Inc ENT.O, down 27.6% ** Midatech Pharma MTP.O, down 25.3% ** Molecular Data Inc , down 20.3% ** Thermo Fisher Scientific Inc TMO.N: up 1.7% BUZZ-Rises on Q2 profit, revenue beat ** Macy's Inc M.N: down 6.3% ** Kohls Corp KSS.N: down 6.7% BUZZ-Macy's, Kohl's fall as UBS sees dept. New Article July 22 (Reuters) - Biogen Inc BIIB.O reported a 3.2% rise in second-quarter profit on Wednesday, getting a lift from demand for its top-selling multiple sclerosis drug Tecfidera. Net income attributable to the company rose to $1.54 billion, or $9.59 per share, in the three months ended June 30 from $1.49 billion, or $7.85 per share, a year earlier. (Reporting by Trisha Roy and Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila) ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Adds details on sales of multiple sclerosis treatments, share movement July 22 (Reuters) - Biogen Inc BIIB.O raised its 2020 earnings forecast after better-than-expected sales of its multiple sclerosis treatment Tecfidera helped the drugmaker beat second-quarter profit estimates. The drug faces increasing competition from newer treatments, including Roche Holding AG's ROG.S Ocrevus, and Biogen in June lost a patent dispute with Mylan NV MYL.O over Tecfidera. The company, which named a new chief financial officer on Tuesday, now expects 2020 full-year adjusted profit to be between $34 and $36 per share, up from its prior forecast of between $31.50 and $33.50. New Article Shares of Biogen (NASDAQ: BIIB) hardly moved following the release of second-quarter earnings results that beat Wall Street's expectations on the top and bottom lines. Despite that outperformance, the stock was close to flat in mid-afternoon trading Wednesday, down 0.3% as of 2:15 p.m. EDT, because investors aren't expecting double-digit-percentage earnings growth to continue much longer. As potentially the first disease-modifying therapy for Alzheimer's disease, sales of aducanumab could solve all of Biogen's problems, but its approval is far from guaranteed. New Article The top three NYSE percentage gainers premarket .PRPG.NQ: ** Ion Geophysical Corp , up 11.2% ** Fortress Value Acquisition Corp , up 11.1% ** Everi Holdings Inc , up 8.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Snap Inc , down 7.9% ** Switch Inc , down 7% ** FinVolution Group , down 6.3% The top three Nasdaq percentage gainers premarket .PRPG.O: ** US Energy Corp , up 39.5% ** Mid-Con Energy Partners LP , up 25.1% ** Atossa Therapeutics Inc , up 23.2% The top three Nasdaq percentage losers premarket .PRPL.O: ** Verb Technology Company Inc , down 27.8% ** Midatech Pharma PLC , down 18.6% ** Open Lending Corp , down 9% ** Boeing Co BA.N: down 0.9% premarket BUZZ-Falls as Cathay Pacific to defer orders, MAX return likely delayed ** Texas Instruments Inc TXN.O: up 1.2% premarket BUZZ-Street View: Texas Instruments well-positioned to tap opportunities ** Biogen Inc BIIB.O: up 2.6% premarket BUZZ-CFO change could be indicative of M&A to come - Mizuho ** Macy's Inc M.N: down 4.0% premarket ** Kohls Corp KSS.N: down 4.2% premarket BUZZ-Macy's, Kohl's fall as UBS sees dept. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures fell on Wednesday as investors shunned risky assets after Washington ordered a shutdown of the Chinese consulate in Houston, escalating tensions between the world's two largest economies. stores growing less relevant (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article stores growing less relevant ** FirstEnergy Corp FE.N: down 6.1% premarket BUZZ-Scotiabank cuts rating over nuclear bailout bribery inquiry ** Lockheed Martin LMT.N: up 0.2% premarket BUZZ-Street View: Lockheed Martin ready to battle COVID-19 disruptions ** Pfizer Inc PFE.N: up 4.6% premarket ** BioNtech SE BNTX.O: up 7.5% premarket BUZZ-Pfizer, BioNtech jump on $1.95 bln deal with U.S. for COVID-19 vaccine ** Biogen Inc BIIB.O: up 2.2% premarket BUZZ-Biogen jumps on Q2 profit beat, higher 2020 profit outlook BUZZ-CFO change could be indicative of M&A to come - Mizuho ** Science Applications International Corp SAIC.N: up 3.0% premarket BUZZ-Up on winning $89 mln U.S. Army contract ** IQVIA Holdings IQV.N: up 2.9% premarket BUZZ-IQVIA: Rises on 2020 profit forecast raise and Q2 profit beat ** Spotify Technology SA SPOT.N: up 4.8% premarket BUZZ-Rises on new licensing deal with Universal Music Group ** Nasdaq Inc NDAQ.O: up 1.0% premarket BUZZ-Nasdaq rises on profit beat fueled by record trading volumes (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and Dow were set to open lower on Wednesday as an escalation in tensions between the United States and China offset optimism about another round of fiscal stimulus for the virus-stricken economy. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Endeavour Silver Corp EXK.N, up 13.0% ** Castlight Health Inc CSLT.K, up 12.8% ** Fortress Value Acquisition Corp FVAC.K, up 10.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Amersco Inc AMRC.K, down 9.4% ** Independence Contract Drilling Inc ICD.N, down 9.3% ** Medley Management Inc MDLY.K, down 8% The top three Nasdaq percentage gainers premarket .PRPG.O: ** US Energy Corp USEG.O, up 39.7% ** Bionano Genomics Inc BNGO.O, up 30.9% ** Mid-Con Energy Partners LP MCEP.O, up 27.9% The top three Nasdaq percentage losers premarket .PRPL.O: ** Verb Technology Company Inc VERB.O, down 28.5% ** Tonix Pharmaceuticals Holding Corp TNXP.O, down 16.1% ** Microvision Inc MVIS.O, down 12.6% ** Teradyne Inc TER.O: up 4.9% premarket BUZZ-Rises on Q2 revenue beat, upbeat outlook ** Boeing Co BA.N: down 1.0% premarket BUZZ-Falls as Cathay Pacific to defer orders, MAX return likely delayed ** Texas Instruments Inc TXN.O: up 1.3% premarket BUZZ-Street View: Texas Instruments well-positioned to tap opportunities ** Coca-Cola Co KO.N: up 0.7% premarket BUZZ-Street View: Coca-Cola on a bumpy road to recovery ** Macy's Inc M.N: down 3.8% premarket ** Kohls Corp KSS.N: down 3.6% premarket BUZZ-Macy's, Kohl's fall as UBS sees dept.",271.895751953125
2020-07-23 00:00:00+00:00,282.260009765625,282.260009765625,277.5299987792969,278.510009765625,278.510009765625,948000.0,3.0,1.0,0.5000249999999999,"Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh S&P 500 and Dow futures hovered near five-month highs on Thursday, as signs that a new coronavirus relief package was at hand lifted sentiment ahead of weekly unemployment data. ET, Dow e-minis 1YMc1 were up 0.37% at 26,984. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Bluegreen Vacations Corp , up 12.8% ** Helix Enery Solutions Group , up 12.6% ** Meritage Homes Corp MTH.N, up 9.5% The top three NYSE percentage losers premarket .PRPL.NQ: ** Jumia Technologies AG , down 8.3% ** Pacific Coast Oil Trust , down 6.4% ** Relx PLC , down 5.4% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Entera Bio Ltd , up 83.2% ** Liquid Media Group Ltd , up 49.4% ** US Energy Corp , up 47.6% The top three Nasdaq percentage losers premarket .PRPL.O: ** Ascena Retail Group Inc , down 31.6% ** Kingold Jewelry Inc , down 13% ** Lonestar Resources US Inc , down 10.6% ** Tesla Inc TSLA.O: up 5.1% premarket BUZZ-Street View: Tesla's underwhelming Q2 a far cry from its stock performance ** Microsoft Corp MSFT.O: down 2.1% premarket BUZZ-Street View: Azure woes cloud Microsoft's Q4; better positioned than rivals ** Kinder Morgan Inc KMI.N: down 1.4% premarket BUZZ-Street View: Kinder Morgan Q2 lacks clarity in uncertain macro environment (Compiled by Shivani Kumaresan in Bengaluru; Editing by Rashmi Aich) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",264.7167663574219
2020-07-27 00:00:00+00:00,282.67999267578125,287.25,279.54998779296875,286.19000244140625,286.19000244140625,1968100.0,3.0,1.0,0.5000249999999999,"Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and Nasdaq rose at the open on Monday as investors shrugged off surging COVID-19 cases and U.S.-China tensions, betting instead on more stimulus and a dovish signal from the Federal Reserve to revive a battered domestic economy. The top three S&P 500 .PG.INX percentage gainers: ** Tapestry Inc , up 4.9% ** Biogen Inc , up 3.2% ** Newmont Corp , up 3.2% The top three S&P 500 .PL.INX percentage losers: ** Hasbro Inc , down 3.4% ** Ulta Beauty Inc , down 2.4% ** Centene Corp , down 2.1% The top three NYSE .PG.N percentage gainers: ** CNX Midstream Partners LP , up 24.8% ** Endeavour Silver Corp , up 13.3% ** Platinum Group Metals Ltd , up 13.1% The top three NYSE .PL.N percentage losers: ** VolitionRX Ltd VNRX.N, down 8.4% ** Peabody Energy Corp , down 8.4% ** CNX Resources Corp , down 8% The top three Nasdaq .PG.O percentage gainers: ** Wilhelmina International Inc , up 154.9% ** Socket Moble Inc , up 153.4% ** TCR2 Therapeutics Inc , up 45.1% The top three Nasdaq .PL.O percentage losers: ** WiMi Hologram Cloud Inc , down 26.8% ** Wisekey International Holding AG , down 18.9% ** Vaxart Inc , down 18.5% ** Schlumberger NV SLB.N: up 1.1% BUZZ-Street View: Schlumberger well positioned for coming cycle ** Moderna Inc MRNA.O: up 6.2% BUZZ-Jumps on more U.S. funding for its COVID-19 vaccine ** Qualcomm Inc QCOM.O: up 0.8% BUZZ-JP Morgan raises PT on upside from 5G phone shipments ** Hasbro Inc HAS.O: down 3.6% BUZZ-Q2 results miss due to store closures, product shortages ** MediciNova Inc MNOV.O: up 13.7% BUZZ-Rises on deal to develop COVID-19 vaccine ** Barrick Gold GOLD.N: up 4.7% ** Newmont Corp NEM.N: up 3.3% BUZZ-U.S.-listed gold miners rise as bullion skyrockets ** dMY Technology Inc DMYT.N: up 10.2% BUZZ-Jumps on SPAC deal to take Rush Street Interactive public - ** CNX Midstream Partners LP CNXM.N: up 24.2% BUZZ-Surges on buyout deal with CNX Resources ** Can-Fite BioPharma CANF.N: up 8.7% BUZZ-Rises as co seeks FDA nod to test COVID-19 drug candidate ** ON Semiconductor Corp ON.O: up 1.5% BUZZ-Needham raises PT on automotive market recovery ** Ocugen Inc OCGN.O: up 13.0% BUZZ-Rises on orphan drug status for eye disorder drug ** ServiceNow Inc NOW.N: up 0.3% BUZZ-Brokerage Needham raises PT on potential from rapid digital shift ** Lincoln Electric Holdings Inc LECO.O: up 2.7% BUZZ-Rises as cost-cutting powers Q2 beat ** Under Armour Inc UAA.N: down 1.0% BUZZ-Falls after founder, CFO get Wells notice ** PDS Biotechnology Corp PDSB.O: up 19.5% BUZZ-Rises as preclinical COVID-19 vaccine trial shows promise ** American Airlines group Inc AAL.O: up 1.8% BUZZ-Rises as brokerage says bankruptcy not on cards in 2020 The 11 major S&P 500 sectors: Communication Services down 0.37% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Fifth Third Bancorp FITB $19.54 $22.62 15.75% Biogen Inc BIIB $272.33 $307.04 12.75% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of MGV's underlying holdings with notable upside to their analyst target prices are (Symbol: BRK.B), Fifth Third Bancorp (Symbol: FITB), and Biogen Inc (Symbol: BIIB). Similarly, FITB has 15.75% upside from the recent share price of $19.54 if the average analyst target price of $22.62/share is reached, and analysts on average are expecting BIIB to reach a target price of $307.04/share, which is 12.75% above the recent price of $272.33. New Article Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks rebounded on Monday as investors shrugged off surging COVID-19 cases and U.S.-China tensions, betting instead on more stimulus to revive a battered domestic economy ahead of a week packed with quarterly earnings reports. The top three S&P 500 .PG.INX percentage gainers: ** Newmont Corp , up 3.7% ** Biogen Inc , up 3.6% ** Alexion Pharmaceuticals Inc , up 3.6% The top three S&P 500 .PL.INX percentage losers: ** Hasbro Inc , down 7.8% ** American Electric Power Company Inc , down 6.8% ** Carnival Corp , down 6.5% The top three NYSE .PG.N percentage gainers: ** Sogou Inc , up 47.1% ** Amira Nature Foods Ltd , up 30.4% ** CNX Midstream Partners LP , up 21.2% The top three NYSE .PL.N percentage losers: ** Ibio Inc , down 12.6% ** Range Resources RRC.N, down 11.5% ** Medley Capital Corp , down 9.8% The top three Nasdaq .PG.O percentage gainers: ** Wilhelmina International Inc , up 163.7% ** Socket Moble Inc , up 102% ** MediciNova Inc , up 63.8% The top three Nasdaq .PL.O percentage losers: ** WiMi Hologram Cloud Inc , down 33.9% ** Trident Acquisitions Corp , down 28.3% ** Vaxart Inc , down 23.4% ** Verizon Communications Inc VZ.N: up 0.3% BUZZ-Street View: Verizon's long-term strategy intact despite 5G competition ** Qualcomm Inc QCOM.O: up 1.7% BUZZ-JP Morgan raises PT on upside from 5G phone shipments ** Hasbro Inc HAS.O: down 7.9% BUZZ-Q2 results miss due to store closures, product shortages ** MediciNova Inc MNOV.O: up 63.8% BUZZ-Rises on deal to develop COVID-19 vaccine ** Barrick Gold GOLD.N: up 4.3% ** Newmont Corp NEM.N: up 3.7% BUZZ-U.S.-listed gold miners rise as bullion skyrockets ** dMY Technology Inc DMYT.N: up 4.1% BUZZ-Jumps on SPAC deal to take Rush Street Interactive public - ** CNX Midstream Partners LP CNXM.N: up 21.5% BUZZ-Surges on buyout deal with CNX Resources ** Can-Fite BioPharma CANF.N: up 7.9% BUZZ-Rises as co seeks FDA nod to test COVID-19 drug candidate ** ON Semiconductor Corp ON.O: up 2.0% BUZZ-Needham raises PT on automotive market recovery ** Ocugen Inc OCGN.O: up 42.2% BUZZ-Rises on orphan drug status for eye disorder drug ** ServiceNow Inc NOW.N: up 1.0% BUZZ-Brokerage Needham raises PT on potential from rapid digital shift ** Lincoln Electric Holdings Inc LECO.O: up 1.0% BUZZ-Rises as cost-cutting powers Q2 beat ** PDS Biotechnology Corp PDSB.O: up 2.8% BUZZ-Rises as preclinical COVID-19 vaccine trial shows promise ** Lemonade Inc LMND.O: down 7.6% BUZZ-Leaks as Goldman initiates with ""sell"" on risk profile ** Onconova Therapeutics Inc ONTX.O: up 9.0% BUZZ-Rises on seeking NIH funding to study cancer drug in COVID-19 patients ** Archer Daniels Midland Co ADM.N: down 0.7% BUZZ-Credit Suisse cuts PT of ADM, Bunge on weak industry fundamentals ** Emergent Biosolutions Inc EBS.N: up 2.5% BUZZ-Up on COVID-19 vaccine manufacture deal with AstraZeneca ** Sogou Inc SOGO.N: up 47.1% BUZZ-Jumps on take-private offer from Tencent ** EQT Corp EQT.N: down 4.8% BUZZ-Drops on second-quarter loss, lower revenue ** Koppers Holdings KOP.N: up 18.1% BUZZ-Rises on upbeat prelim Q2 results ** Moderna MRNA.O: up 6.4% BUZZ-Jumps on start of late-stage trial of potential COVID-19 vaccine ** Walgreens Boots Alliance Inc WBA.O: down 2.5% BUZZ-Slides after CEO decides to step down ** Professional Diversity Network Inc IPDN.O: down 29.5% BUZZ-Slumps on pricing stock offering at discount ** Datadog Inc DDOG.O: up 1.6% BUZZ-Needham hikes PT on growth prospects ** Spotify Technology SA SPOT.N: up 0.2% BUZZ-Stifel raises PT on strong podcast outlook ** Dun & Bradstreet Inc DNB.N: down 2.1% BUZZ-Most analysts bullish on turnaround story as IPO quiet period ends The 11 major S&P 500 sectors: Communication Services down 1.30% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article VIDEO: S&P 500 Movers: HAS, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing S&P 500 component thus far on the day is Hasbro, trading down 7.4%. Hasbro is lower by about 32.0% looking at the year to date performance. New Article Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes gained on Monday as investors looked past surging U.S. COVID-19 cases, betting instead on more stimulus to revive a battered domestic economy ahead of a week packed with quarterly earnings reports. The top three S&P 500 .PG.INX percentage gainers: ** Alexion Pharmaceuticals Inc , up 5.6% ** KLA Corp , up 4.9% ** Biogen Inc , up 4.3% The top three S&P 500 .PL.INX percentage losers: ** Hasbro Inc , down 7.8% ** Carnival Corp , down 6.8% ** Norwegian Cruise Line Holdings Ltd , down 6.7% The top three NYSE .PG.N percentage gainers: ** Sogou Inc , up 47.7% ** Amira Nature Foods Ltd , up 30.1% ** CNX Midstream Partners LP , up 25.3% The top three NYSE .PL.N percentage losers: ** Ambow Education Holding Ltd , down 21.8% ** Indonesa Energy Corporation Ltd , down 15.7% ** Ibio Inc , down 13.4% The top three Nasdaq .PG.O percentage gainers: ** Wilhelmina International Inc , up 216.6% ** Socket Moble Inc , up 103.4% ** MediciNova Inc , up 98.6% The top three Nasdaq .PL.O percentage losers: ** WiMi Hologram Cloud Inc , down 34.6% ** Tridnt Acquisitions Corp , down 28.3% ** Sequential Brands Group Inc , down 22.2% ** Verizon Communications Inc VZ.N: up 0.1% BUZZ-Street View: Verizon's long-term strategy intact despite 5G competition ** American Express Co AXP.N: up 0.1% BUZZ-Street View: AmEx comeback hinges on travel, entertainment recovery ** Qualcomm Inc QCOM.O: up 3.0% BUZZ-JP Morgan raises PT on upside from 5G phone shipments ** Hasbro Inc HAS.O: down 7.8% BUZZ-Q2 results miss due to store closures, product shortages ** MediciNova Inc MNOV.O: up 98.6% BUZZ-Rises on deal to develop COVID-19 vaccine ** Barrick Gold GOLD.N: up 4.5% ** Newmont Corp NEM.N: up 2.3% BUZZ-U.S.-listed gold miners rise as bullion skyrockets ** dMY Technology Inc DMYT.N: up 4.4% BUZZ-Jumps on SPAC deal to take Rush Street Interactive public - ** CNX Midstream Partners LP CNXM.N: up 25.3% BUZZ-Surges on buyout deal with CNX Resources ** Can-Fite BioPharma CANF.N: up 6.7% BUZZ-Rises as co seeks FDA nod to test COVID-19 drug candidate ** ON Semiconductor Corp ON.O: up 2.9% BUZZ-Needham raises PT on automotive market recovery ** Ocugen Inc OCGN.O: up 48.3% BUZZ-Rises on orphan drug status for eye disorder drug ** ServiceNow Inc NOW.N: up 2.4% BUZZ-Brokerage Needham raises PT on potential from rapid digital shift ** Lincoln Electric Holdings Inc LECO.O: up 1.1% BUZZ-Rises as cost-cutting powers Q2 beat ** PDS Biotechnology Corp PDSB.O: up 6.1% BUZZ-Rises as preclinical COVID-19 vaccine trial shows promise ** Lemonade Inc LMND.O: down 7.1% BUZZ-Leaks as Goldman initiates with ""sell"" on risk profile ** Onconova Therapeutics Inc ONTX.O: up 7.2% BUZZ-Rises on seeking NIH funding to study cancer drug in COVID-19 patients ** Archer Daniels Midland Co ADM.N: down 0.4% BUZZ-Credit Suisse cuts PT of ADM, Bunge on weak industry fundamentals ** Emergent Biosolutions Inc EBS.N: up 3.5% BUZZ-Up on COVID-19 vaccine manufacture deal with AstraZeneca ** Sogou Inc SOGO.N: up 47.5% BUZZ-Jumps on take-private offer from Tencent ** EQT Corp EQT.N: down 3.9% BUZZ-Drops on second-quarter loss, lower revenue ** Koppers Holdings KOP.N: up 18.4% BUZZ-Rises on upbeat prelim Q2 results ** Moderna MRNA.O: up 8.3% BUZZ-Jumps on start of late-stage trial of potential COVID-19 vaccine ** Walgreens Boots Alliance Inc WBA.O: down 1.3% BUZZ-Slides after CEO decides to step down ** Professional Diversity Network Inc IPDN.O: down 29.0% BUZZ-Slumps on pricing stock offering at discount ** Datadog Inc DDOG.O: up 3.3% BUZZ-Needham hikes PT on growth prospects ** Spotify Technology SA SPOT.N: up 0.7% BUZZ-Stifel raises PT on strong podcast outlook ** Dun & Bradstreet Inc DNB.N: down 2.5% BUZZ-Most analysts bullish on turnaround story as IPO quiet period ends ** Diffusion Pharma DFFN.O: down 12.9% BUZZ-Falls on COVID-19 drug trial delay ** Black Knight Inc BKI.N: up 1.9% BUZZ-Rises as co set to acquire Optimal Blue ** Diana Shipping DSX.N: down 2.1% BUZZ-Drops on wider quarterly loss The 11 major S&P 500 sectors: Communication Services down 1.34% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",273.4276123046875
2020-07-28 00:00:00+00:00,286.2699890136719,287.0,280.1600036621094,280.3500061035156,280.3500061035156,1158900.0,2.0,1.0,0.250025,"If you own shares of Biogen (NASDAQ: BIIB) or are thinking about purchasing this stock, you might be curious about what your investment would look like now if you'd bought in during the 2008 recession. BIIB data by YCharts Biogen's balance sheet has been less affected by the pandemic than its stock price. The company is also awaiting a decision from the U.S. Food and Drug Administration (FDA) regarding the pending approval of aducanumab, its investigational human monoclonal antibody treatment for Alzheimer's disease. New Article Particularly high volume was seen for the $270 strike put option expiring June 18, 2021, with 450 contracts trading so far today, representing approximately 45,000 underlying shares of BIIB. Below is a chart showing AKAM's trailing twelve month trading history, with the $107 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 7,682 contracts, representing approximately 768,200 underlying shares or approximately 63.1% of BIIB's average daily trading volume over the past month, of 1.2 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $270 strike highlighted in orange: And Alphabet Inc (Symbol: GOOG) options are showing a volume of 9,810 contracts thus far today.",279.78118896484375
2020-08-06 00:00:00+00:00,275.760009765625,279.0,274.95001220703125,277.6600036621094,277.6600036621094,756500.0,3.0,1.0,0.5000249999999999,"To the upside, Denali Therapeutics (DNLI) raced 37.5% higher after announcing a binding agreement with Biogen (BIIB) to jointly develop and commercialize Denali's small molecule LRRK2 inhibitor program to treat Parkinson's disease. Denali also is eligible for up to $1.13 billion in payments as the LRRK2 program meets certain development and commercial milestones. Bausch Health (BHC) also climbed about 6% after Thursday disclosing plans to spin off its eye health business into a separate publicly traded company and continuing as a pharmaceutical company focused on gastroenterology, neurology and aesthetics and dermatological applications. New Article To the upside, Denali Therapeutics (DNLI) raced more than 35% higher after announcing a binding agreement with Biogen (BIIB) to jointly develop and commercialize Denali's small molecule LRRK2 inhibitor program to treat Parkinson's disease. Denali also is eligible for up to $1.13 billion in payments as the LRRK2 program meets certain development and commercial milestones. Bausch Health (BHC) also climbed almost 4% after Thursday disclosing plans to spin off its eye health business into a separate publicly traded company and continuing as a pharmaceutical company focused on gastroenterology, neurology and aesthetics and dermatological applications. New Article (RTTNews) - Shares of Denali Therapeutics Inc. (DNLI) were gaining 48 percent in Thursday regular trading, after Biogen Inc. (BIIB) announced a $465 million equity investment as part of a collaboration on Denali's treatment for Parkinson's disease. Biogen will also receive rights to opt into two programs and a right of first negotiation for two additional programs, in each case for neurodegenerative diseases leveraging Denali's Transport Vehicle (TV) technology platform to cross the blood-brain barrier (BBB). Biogen will receive exclusive option rights to two programs for neurodegenerative diseases utilizing Denali's blood-brain barrier crossing TV technology platform, including for amyloid beta, plus right of first negotiation for two additional unnamed TV platform programs.",287.25238037109375
2020-08-07 00:00:00+00:00,311.1400146484375,312.0,299.2900085449219,305.7099914550781,305.7099914550781,4454600.0,3.8461538461538463,1.0,0.7115634615384615,"(RTTNews) - Shares of drugmaker Biogen Inc. (BIIB) are rising more than 9% Friday morning after the company said that the FDA has accepted the Biologics License Application (BLA) for aducanumab, the company's drug candidate for Alzheimer's disease. The application has been granted Priority Review, with the decision due on March 7, 2021. It has traded in the range of $215.78- $374.99 in the past 52 weeks. New Article VIDEO: S&P 500 Movers: ILMN, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing S&P 500 component thus far on the day is Illumina, trading down 12.4%. Illumina is showing a gain of 5.4% looking at the year to date performance. New Article Aug 7 (Reuters) - Biogen Inc BIIB.O and Japan's Eisai Co Ltd 4523.T said on Friday the U.S. Food and Drug Administration has accepted their marketing application for experimental Alzheimer's disease treatment aducanumab. If approved, aducanumab would become the first therapy to reduce the clinical decline associated with Alzheimer's disease. The FDA has set a date of March 7 for taking a decision on the treatment. New Article Adds shares, background Aug 7 (Reuters) - Biogen Inc BIIB.O and Japan's Eisai Co Ltd 4523.T said on Friday the U.S. Food and Drug Administration had accepted their marketing application for experimental Alzheimer's disease treatment aducanumab, with a decision due by March 7. If approved, aducanumab would become the first therapy to reduce the clinical decline associated with Alzheimer's disease and has the potential to become a multi-billion dollar seller, according to analysts. Biogen in October last year revived plans to seek approval for the treatment, months after scrapping the development of the drug. New Article The top three NYSE percentage gainers premarket .PRPG.NQ: ** Natural Gas Services Group Inc , up 28.4% ** Genesis Healthcare Inc , up 22.7% ** Seritage Growth Properties , up 17.8% The top three NYSE percentage losers premarket .PRPL.NQ: ** Alteryx Inc , down 20.7% ** Greenbrier Companies Inc , down 15.6% ** Pacific Drilling SA , down 14.2% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Anpac Bio-Medical Science Co Ltd , up 100.2% ** Conduent Inc , up 78.8% ** Kazia Therapeutics Limited , up 75.2% The top three Nasdaq percentage losers premarket .PRPL.O: ** Research Frontiers Inc , down 25% ** Transact Technologies Inc , down 23% ** KBL Merger Corp. IV , down 21.1% ** Booking Holdings Inc BKNG.O: up 4.3% premarket BUZZ-Street View: Booking Holdings' trends improving despite headwinds ** Pacific Drilling SA PACD.N: down 14.2% premarket BUZZ-Slips after Q2 loss widens; seeks restructuring options ** Novavax Inc NVAX.O: up 0.4% premarket BUZZ-Rises on COVID-19 vaccine deals in Japan, India ** Dish Network Corp DISH.O: up 4.1% premarket BUZZ-Gains after revenue beat, smaller loss in TV subscribers ** Uber Technologies Inc UBER.N: down 3.0% premarket BUZZ-Street View: Uber Eats will deliver strength while ride-hailing suffers ** Clean Energy Fuels Corp CLNE.O: down 10.2% premarket BUZZ-Drops as COVID-19 pandemic hurts Q2 fuel sales ** Twilio Inc TWLO.N: down 3.8% premarket BUZZ-Slides after pricing $1.25 bln equity offering ** Illumina Inc ILMN.O: down 13.6% premarket BUZZ-Down on Q2 profit, revenue miss ** Biogen Inc BIIB.O: up 12.2% premarket BUZZ-Jumps as FDA accepts Alzheimer's drug marketing application ** Tencent Music Entertainment Group TME.N: down 4.6% premarket ** Bilibili Inc BILI.O: down 3.2% premarket BUZZ-Tech shares fall after Trump orders ban on Chinese apps ** Co-Diagnostics Inc CODX.O: up 3.3% premarket BUZZ-Up after COVID-19 test gets Australia nod ** Canadian Solar Inc CSIQ.O: up 4.6% premarket BUZZ-Climbs on surprise Q2 profit (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures pared early declines on Friday as data showed the economy added more jobs than expected last month, easing fears that a nascent recovery in the labor market was stalling. ET, Dow e-minis 1YMc1 were down 0.36% at 27,188. New Article Biogen (BIIB) was also up by more than 12%. The company said it has signed an agreement with Eversana to commercialize and distribute Qtrypta if the migraine treatment is approved by the US Food and Drug Administration. The US FDA has accepted and has granted a priority review of its biologics license application for aducanumab, a drug candidate being co-developed with Eisai Co. Ltd. for the treatment of Alzheimer's disease. New Article The drug, risdiplam, will be sold under the brand name Evrysdi and compete with Biogen's BIIB.O Spinraza, the first medicine approved for the leading genetic cause of death in infants, and Novartis' NOVN.S gene therapy Zolgensma. Aug 7 (Reuters) - U.S. health regulators on Friday approved an oral treatment from Roche ROG.S and PTC Therapeutics PTCT.O for spinal muscular atrophy, in adults and children two months of age and older. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber) ((manojna.kalyani@thomsonreuters.com; +91 8061822700;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article The top three S&P 500 .PG.INX percentage gainers: ** Biogen Inc , up 11.4% ** T Mobile Us In , up 7.8% ** Nortonlifelock Inc , up 6.4% The top three S&P 500 .PL.INX percentage losers: ** Illumina Inc , down 12.1% ** EOG Resources Inc , down 9.2% ** Fortinet Inc , down 7.6% The top three NYSE .PG.N percentage gainers: ** Sailpoint Technologies Holdings Inc , up 20.8% ** Rocket Companies Inc , up 16.5% ** Elevate Credit Inc , up 16.3% The top three NYSE .PL.N percentage losers: ** Alteryx Inc , down 27.4% ** Universal Technical Institue Inc , down 12.4% ** Bluegreen Vacations Corp , down 11.9% The top three Nasdaq .PG.O percentage gainers: ** Anpac Bio-Medical Science Co Ltd , up 88.3% ** Kazia Therapeutics Ltd , up 70.7% ** Sirius International Insurance Group Ltd , up 65.4% The top three Nasdaq .PL.O percentage losers: ** Olb Grop Inc , down 42.4% ** Everspin Technologies Inc , down 28.3% ** Capricor Therapeutics Inc , down 18% ** Booking Holdings Inc BKNG.O: up 1.3% BUZZ-Street View: Booking Holdings' trends improving despite headwinds ** Pacific Drilling SA PACD.N: down 8.1% BUZZ-Slips after Q2 loss widens; seeks restructuring options ** Novavax Inc NVAX.O: up 0.5% BUZZ-Novavax: Rises on COVID-19 vaccine deals in Japan, India ** Dish Network Corp DISH.O: up 3.8% BUZZ-Gains after revenue beat, smaller loss in TV subscribers ** Uber Technologies Inc UBER.N: down 4.1% BUZZ-Street View: Uber Eats will deliver strength while ride-hailing suffers ** Twilio Inc TWLO.N: down 4.1% BUZZ-Slides after pricing $1.25 bln equity offering ** Illumina Inc ILMN.O: down 12.0% BUZZ-Down on Q2 profit, revenue miss ** Biogen Inc BIIB.O: up 11.5% BUZZ-Jumps as FDA accepts Alzheimer's drug marketing application ** Tencent Music Entertainment Group TME.N: down 4.9% ** Bilibili Inc BILI.O: down 3.9% Headline of story OR Buzz OR Brief USN ** Co-Diagnostics Inc CODX.O: up 3.1% BUZZ-Up after COVID-19 test gets Australia nod ** Canadian Solar Inc CSIQ.O: up 11.8% BUZZ-Climbs on surprise Q2 profit ** AnPac Bio-Medical Science Co Ltd ANPC.O: up 88.3% BUZZ-More than doubles on nearing COVID-19 test validation ** GoPro Inc GPRO.O: down 5.7% BUZZ-Falls on Q2 loss, revenue miss ** NortonLifeLock Inc NLOK.O: up 6.4% BUZZ-Set for record high on upbeat earnings, outlook ** Dropbox Inc DBX.O: down 7.7% BUZZ-Falls as CFO Ajay Vashee prepares to step down ** Intercontinental Exchange Inc ICE.N: down 1.0% BUZZ-Down on $11 bln deal to buy mortgage tech firm Ellie Mae The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks opened lower on Friday as data showed a sharp slowdown in U.S. employment growth and as President Donald Trump cranked up friction with Beijing with moves to ban WeChat and TikTok. up 0.12% (Compiled by Shivani Kumaresan in Bengaluru) ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article What happened Shares of Biogen (NASDAQ: BIIB) rose sharply on Friday after the biotech company said its experimental Alzheimer's disease drug had been granted priority review status by the U.S. Food and Drug Administration (FDA). If approved, aducanumab, as the drug is called, would be the first therapy to meaningfully alter the course of Alzheimer's disease. In October 2017, Biogen partnered with Japanese pharmaceutical company Eisai to develop and commercialize the drug. New Article Roche and PTC Therapeutics set the list price of their new rare disease drug at a relatively modest $340,000 per year to compete with already approved treatments from Biogen (NASDAQ: BIIB) and Novartis (NYSE: NVS). Evrysdi priced to compete Evrysidi, formerly known as risdiplam, is an easy-to-swallow treatment that allows SMA patients to produce functional copies of the survival motor neuron protein they lack. At $2.125 million per dose, Zolgensma's the most expensive drug Americans have ever seen -- but this gene therapy only requires a single administration. New Article In trading on Friday, shares of Biogen Inc (Symbol: BIIB) crossed above their 200 day moving average of $296.77, changing hands as high as $312.00 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $215.775 per share, with $374.99 as the 52 week high point  that compares with a last trade of $301.46. The BIIB DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other stocks recently crossed above their 200 day moving average  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article The drug, risdiplam, will be sold under the brand name Evrysdi and will compete with Biogen's BIIB.O Spinraza, the first medicine approved for the disease, and Novartis' NOVN.S gene therapy, Zolgensma. Adds details on spinal muscular atrophy, drug's availability Aug 7 (Reuters) - The U.S. Food and Drug Administration on Friday approved an oral treatment from Roche Holding AG ROG.S and PTC Therapeutics Inc PTCT.O for spinal muscular atrophy in adults and children two months and above. Spinal muscular atrophy is the leading genetic cause of infant deaths that prevents the body from producing a protein necessary for neuromuscular development. New Article VIDEO: Nasdaq 100 Movers: ILMN, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing Nasdaq 100 component thus far on the day is Illumina, trading down 12.5%. Illumina is showing a gain of 5.3% looking at the year to date performance.",282.5546569824219
2020-08-10 00:00:00+00:00,308.0,308.5,298.4200134277344,300.260009765625,300.260009765625,1525000.0,4.0,1.0,0.7500249999999999,"In recent trading, shares of Biogen Inc (Symbol: BIIB) have crossed above the average analyst 12-month target price of $304.08, changing hands for $305.71/share. But the whole reason to look at the average BIIB price target in the first place is to tap into a ""wisdom of crowds"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with BIIB crossing above that average target price of $304.08/share, investors in BIIB have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $304.08 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table?",295.03839111328125
2020-08-19 00:00:00+00:00,284.79998779296875,286.95001220703125,279.4599914550781,279.9800109863281,279.9800109863281,1542400.0,2.5,1.0,0.375025,"Especially high volume was seen for the $265 strike put option expiring September 18, 2020, with 378 contracts trading so far today, representing approximately 37,800 underlying shares of BIIB. Below is a chart showing MCD's trailing twelve month trading history, with the $195 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 5,663 contracts thus far today. That number of contracts represents approximately 566,300 underlying shares, working out to a sizeable 45.4% of BIIB's average daily trading volume over the past month, of 1.2 million shares. New Article Combined, GILD and BIIB make up approximately 3.2% of the underlying holdings of XLV. Among large Healthcare stocks, Gilead Sciences Inc (Symbol: GILD) and Biogen Inc (Symbol: BIIB) are the most notable, showing a loss of 4.7% and 2.3%, respectively. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday.",298.23455810546875
2020-08-24 00:00:00+00:00,277.4800109863281,279.7200012207031,274.8900146484375,276.5599975585937,276.5599975585937,1006400.0,3.0,1.0,0.5000249999999999,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $280.00 strike highlighted in red: Considering the fact that the $280.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options become available this week, for the April 2021 expiration.",302.8454284667969
2020-08-27 00:00:00+00:00,280.1499938964844,282.3900146484375,278.3699951171875,279.260009765625,279.260009765625,1503200.0,3.0,1.0,0.5000249999999999,"Particularly high volume was seen for the $255 strike put option expiring September 18, 2020, with 817 contracts trading so far today, representing approximately 81,700 underlying shares of BIIB. Below is a chart showing LYV's trailing twelve month trading history, with the $60 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 5,594 contracts, representing approximately 559,400 underlying shares or approximately 45.8% of BIIB's average daily trading volume over the past month, of 1.2 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $255 strike highlighted in orange: And International Business Machines Corp (Symbol: IBM) saw options trading volume of 16,427 contracts, representing approximately 1.6 million underlying shares or approximately 45.6% of IBM's average daily trading volume over the past month, of 3.6 million shares.",299.79541015625
2020-09-14 00:00:00+00:00,271.2799987792969,279.3999938964844,271.2699890136719,278.2900085449219,278.2900085449219,1102400.0,3.2,1.0,0.550025,"ZURICH, Sept 14 (Reuters) - Swiss drugmaker Roche ROG.S on Monday said two-thirds of spinal muscular atrophy (SMA) patients who have begun taking its new medicine Evrysdi have previously got rival treatments Zolgensma from Novartis NOVN.S or Biogen's BIIB.O Spinraza. ""We see patients with all types of SMA,"" said Teresa Graham, head of pharma global product strategy, on a call with investors. (Writing by John Miller, reporting by Paul Arnold; Editing by Michael Shields) ((J.Miller@thomsonreuters.com; +41 58 306 7734; Reuters Messaging: j.miller.thomsonreuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Adds details, background ZURICH, Sept 14 (Reuters) - Swiss drugmaker Roche ROG.S on Monday said two-thirds of spinal muscular atrophy (SMA) patients now taking its newly approveddrug Evrysdi have previously received rival treatments Zolgensma from Novartis NOVN.S or Biogen's BIIB.O Spinraza. Spinraza, Biogen's $2 billion per year seller that must be administered via spinal infusion about once every four months, may face more direct competition from Roche's drug, which as a once-daily oral may have more convenient administration, analysts have said. ""We see patients with all types of SMA,"" Teresa Graham, Roche's head of pharma global product strategy, said on a call with investors about initial Evrysdi sales. New Article For investors who want to add companies that enjoy stability and reliable growth to their portfolios, Amgen (NASDAQ: AMGN) and Biogen (NASDAQ: BIIB) are easy quick picks. As early as 2021, expected approvals of new drugs may also lift the year-over-year quarterly sales revenues of both companies from their single-digit percentage points, driving growth in the process. Given that heart failure is one of the leading causes of death worldwide, success with omecamtiv would allow the company to establish a foothold in a massive market with the potential to drive long-term growth. New Article For investors who want the stability and reliable growth of an established business, Amgen (NASDAQ: AMGN) and Biogen (NASDAQ: BIIB) are trusty quick picks. Given that cardiovascular disease and heart failure specifically is one of the leading causes of death worldwide, success with omecamtiv mecarbil would mean that the company could enter a massive market with the potential to drive long-term growth. Amgen's other program to watch is its Otezla, an oral non-biologic treatment that it purchased from Celgene for $13.4 billion in cash as part of the latter's 2019 merger with Bristol Meyers Squibb (NYSE: BMY). New Article (RTTNews) - Biotechnology company Biogen Inc. (BIIB) announced Monday 'Healthy Climate, Healthy Lives,' a groundbreaking $250 million, 20-year initiative to eliminate fossil fuels across its operations. Biogen's goal is to eliminate its fossil fuel emissions by 2040, as well as be a catalyst for positive change by advancing the science around how fossil fuels impact human health and taking action to promote climate and health equity. Fossil fuel emissions drive the climate crisis and emit harmful air pollutants that are a leading cause of death around the globe, claiming nearly 9 million lives annually with the greatest toll on the most vulnerable.",306.8829040527344
2020-09-15 00:00:00+00:00,280.0400085449219,283.2900085449219,276.45001220703125,278.45001220703125,278.45001220703125,1105400.0,3.0,1.0,0.5000249999999999,"The stock fell 21% from its pre-crisis peak of $90 to a low of $71 in late March when a rapid increase in the number Covid-19 cases outside China resulted in heightened fears of an imminent global economic downturn. The rally across industries over recent months can primarily be attributed to the Fed stimulus which largely put investor concerns about the near-term survival of companies to rest. The flattening of Covid cases in badly hit U.S. and European cities is also giving investors confidence that developed countries have put the worst of the pandemic behind them. New Article Biogen (NASDAQ: BIIB) hasn't had the best year -- and not necessarily because of the COVID-19 pandemic. BIIB data by YCharts Mixed second-quarter results Biogen benefited from a couple of positive bumps during its second quarter, which ended June 30. One of these experimental drugs is called BIIB059, and it is being developed as a treatment for lupus, an inflammatory disease in which the body's immune system attacks its own tissue.",305.7942199707031
2020-09-23 00:00:00+00:00,273.1099853515625,278.3800048828125,271.2099914550781,272.20001220703125,272.20001220703125,982900.0,2.0,1.0,0.250025,"So far, Alzheimer's drugs have nearly always stumbled in trials, though the U.S. Food and Drug Administration is now reviewing experimental treatment aducanumab from Biogen BIIB.O and Japan's Eisai 4523.T, marking the first Alzheimer's drug application in 17 years to be reviewed by the agency. The drug targets ""tau"" proteins believed to play a role in Alzheimer's and offers an alternative to treatments aiming to fight amyloid beta peptides in the brain. The outcome of the Phase 2 trial - in patients with an early stage of Alzheimer's - means the failure rate for drugs aiming to fight the brain-wasting illness, which afflicts tens of millions of people worldwide, remains at nearly 100%.",303.4608154296875
2020-09-30 00:00:00+00:00,283.8699951171875,284.8500061035156,280.7900085449219,283.67999267578125,283.67999267578125,1200000.0,3.0,1.0,0.5000249999999999,"ZURICH, Sept 29 (Reuters) - Switzerland's Relief Therapeutics RLFB.S and U.S. partner NeuroRx said on Wednesday they struck deals with Bachem BANB.S and Nephron Pharmaceuticals to supply and make a 50-year-old drug, aviptadil, that is in clinical trials against COVID-19. Relief and NeuroRx said the pact with Switzerland's Bachem, to supply peptides, and U.S. generics maker Nephron, to manufacture aviptadil, also being called RLF-100 by the companies, is aimed at having supplies sufficient to treat 1 million patients, should the drug prove effective in the studies. (Reporting by John Miller; Editing by Michael Shields) ((J.Miller@thomsonreuters.com; +41 58 306 7734; Reuters Messaging: j.miller.thomsonreuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",311.0540771484375
2020-10-02 00:00:00+00:00,281.6499938964844,285.4700012207031,276.0599975585937,277.6400146484375,277.6400146484375,976000.0,2.0,1.0,0.250025,"These options include some large, highly successful companies such as Biogen (NASDAQ: BIIB) and Gilead Sciences (NASDAQ: GILD). XBI attempts to track the total return of the S&P Biotechnology Select Industry Index, adjusted for fees and expenses. Even Gilead's September announcement of its planned acquisition of Immunomedics, XBI's top holding, wasn't enough to spark a comeback.",300.8721008300781
2020-10-05 00:00:00+00:00,278.6700134277344,285.9200134277344,277.3599853515625,284.17999267578125,284.17999267578125,888000.0,3.0,1.0,0.5000249999999999,"Among top Nasdaq stocks, Amgen (NASDAQ: AMGN) was higher by more than 4%, while Seattle Genetics (NASDAQ: SGEN) climbed almost 5% and Biogen (NASDAQ: BIIB) picked up 3%. Last week, Congressional hearings brought Amgen officials before the House of Representatives, where they faced scrutiny over drug pricing practices. Components like semiconductors are unsung heroes of the tech sector, while biotech is also a high-growth area with tons of potential for advances over the long run.",301.0214538574219
2020-10-07 00:00:00+00:00,282.239990234375,287.0799865722656,280.8999938964844,285.75,285.75,646500.0,4.0,1.0,0.7500249999999999,"Biotech heavyweight Biogen is attempting to become the first company to breach this untapped drug market with its amyloid plaque-busting monoclonal antibody aducanumab. The heart of the matter is that Cassava is staring down a massive commercial opportunity with sumifilam -- especially if Biogen's closely watched AD drug candidate is ultimately rejected. Viewed in this light, it's easy to understand why investors bid up this small-cap biotech stock last month. Now what The bad news is that Cassava doesn't appear to have the financial capacity to advance sumifilam into a costly phase 3 trial. New Article The long list includes AstraZeneca (NYSE:AZN), Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Biontech (NASDAQ:BNTX), CureVac (NASDAQ:CVAC), Gilead (NASDAQ:GILD), GlaxoSmithKline (NYSE:GSK), Ibio (NYSE:IBIO), Inovio Pharmaceuticals (NASDAQ:INO), Johnson & Johnson (NYSE:JNJ), Merck (NYSE:MRK), Moderna (NASDAQ:MRNA), Novavax (NASDAQ:NVAX), Pfizer (NYSE:PFE), Regeneron Pharmaceuticals (NASDAQ:REGN), Sanofi (NASDAQ:SNY), and Sorrento Therapeutics (NASDAQ:SRNE). According to recent research led by Ruklanthi de Alwis of the Duke-NUS Medical School: There are no licensed vaccines or proven antiviral therapy to protect or treat against Covid-19. Analysts estimate global human vaccine market will grow at a CAGR of 7.73% during the period 2018-2022. North America is expected to show robust growth due to factors such as large presence of manufacturers, robust government policy regarding the healthcare, and high awareness among the population for several vaccines. GERM, which has 63 holdings, started trading in June 2020 and hopes to capture part of this growth in the treatment of infectious diseases, especially in vaccines.",304.1285095214844
2020-10-13 00:00:00+00:00,288.5299987792969,292.7699890136719,287.1300048828125,291.4599914550781,291.4599914550781,683000.0,2.0,1.0,0.250025,"Biogen Biogen's (NASDAQ: BIIB) financial outlook appears rather negative, as the company's multiple sclerosis drug Tecfidera is already facing generic competition amid an ongoing legal battle over the validity of its patent protection. The ongoing coronavirus pandemic has caused a select few blue-chip pharma companies to fall way below their intrinsic values, even with all the bad news priced in. Fortunately, the healthcare conglomerate is taking dramatic measures to restructure, with a plan to save 1.5 billion euros per year in operating expenses until 2024.",302.3189697265625
2020-10-15 00:00:00+00:00,284.8500061035156,286.3800048828125,280.1000061035156,280.6300048828125,280.6300048828125,852900.0,2.0,1.0,0.250025,"Bayer Aktiengesellschaft (OTC: BAYRY) and Biogen (NASDAQ: BIIB) are both massive and multinational healthcare companies, but the case in favor of investing in each company is dramatically different. The company's portfolio of products includes common consumer health staples like aspirin and Alka-Seltzer, as well as prescription drugs and controversial agrochemicals, like the weed controller Roundup. And while its crop-sciences segment continues to grow at a slower pace, in June, the company agreed to settle a massive class action lawsuit resulting from the negative health impacts of its Roundup herbicide for a sum of around $9.6 billion.",296.6570739746094
2020-10-16 00:00:00+00:00,282.42999267578125,284.489990234375,279.510009765625,280.010009765625,280.010009765625,843100.0,3.0,1.0,0.5000249999999999,"The company holds a monopoly in the market for drugs that treat cystic fibrosis (CF), a rare condition that affects internal organs such as the lungs. Vertex Pharma's crown jewel is Trikafta, a medicine that can treat 90% of patients with CF, whereas its previous drugs only addressed a smaller proportion of this market. It is worth noting that Vertex's stock recently plunged after the company announced it would discontinue the development of VX-814, a potential treatment for alpha-1 antitrypsin deficiency (AATD).",295.6953125
2020-10-19 00:00:00+00:00,279.2699890136719,280.04998779296875,268.2099914550781,268.7699890136719,268.7699890136719,1207900.0,3.0,1.0,0.5000249999999999,"The top three S&P 500 .PG.INX percentage gainers: ** L Brands Inc , up 4.7 % ** United Airlines Holdings Inc , up 3.8 % ** Freeport-McMoRan Inc , up 3.4 % The top three S&P 500 .PL.INX percentage losers: ** EOG Resources Inc , down 2.5 % ** Vornado Realty Trust , down 2.3 % ** Diamondback Energy Inc , down 2 % The top three NYSE .PG.N percentage gainers: ** Front Yard Residential Corp , up 35.6 % ** AMC Entertainment Holdings Inc , up 23 % ** Natuzzi S.p.A. , up 21.1 % The top three NYSE .PL.N percentage losers: ** American Equity Investment Life Holding Co , down 15 % ** Ihuman Inc , down 10.4 % ** Hyliion Holdings Corp , down 6.5 % The top three Nasdaq .PG.O percentage gainers: ** Kaixin Auto Holdings , up 183.6 % ** Code Chain New Continent Ltd , up 122.7 % ** BOQI International Medical Inc , up 60.8 % The top three Nasdaq .PL.O percentage losers: ** Abraxas Petroleum Corp , down 25.5 % ** CHF Solutions, Inc , down 18.2 % ** The9 Ltd , down 15.2 % ** Tesla TSLA.O: up 0.8% BUZZ-Tesla: Wedbush bets on strong Q3 performance, hikes PT to $500 ** Abbott ABT.N: up 1.0% BUZZ-Abbott's heart device could receive national coverage under Medicare- Cowen ** American Airlines AAL.O: up 1.3% BUZZ-American Airlines: Gains after co hints 737 MAX could return by 2020-end ** Concho Resources CXO.N: up 0.2% BUZZ-Concho Resources rises on ConocoPhillips' $9.7 bln buyout deal ** Biogen Inc BIIB.O: down 1.0% BUZZ-FDA panel meet on Alzheimer's drug remains focus - analysts ** Centogene CNTG.O: up 14.3% BUZZ-Centogene: Up as U.S. FDA grants emergency use for COVID-19 test ** L Brands LB.N: up 4.7% BUZZ-L Brands: J.P.Morgan raises PT on strong Bath & Body Works margins expectations ** Fluidigm FLDM.O: up 4.7% BUZZ-Fluidigm leaps after Trump administration provides COVID-19 test in Texas ** Cisco CSCO.O: down 0.9% BUZZ-Cisco: Credit Suisse cuts PT ahead of Q1 results ** AMC AMC.N: up 23.0% BUZZ-AMC shares rise as New York state prepares to reopen theaters ** D.R. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes inched higher at the open on Monday on hopes of a coronavirus vaccine by the year-end, while investors were also encouraged by signs an agreement in Washington on a fiscal package could be reached soon. Horton: Rises on buying smaller rival in Texas for $23 mln ** Front Yard Residential RESI.N: up 35.6% BUZZ-Front Yard Residential: Jumps on $767 mln go-private deal ** GoodRx Holdings GDRX.O: down 3.7% BUZZ-Street View: Wall Street expects GoodRx to benefit from strong consumer brand ** JinkoSolar JKS.N: up 6.1% BUZZ-JinkoSolar: Up on supply deal for Kozani project ** BioSpecifics BSTC.O: up 44.4% BUZZ-BioSpecifics: Hits record high on takeover deal from Endo ** Kamada KMDA.O: up 8.8% BUZZ-Kamada: Rises on supply deal with Israel for experimental COVID-19 treatment ** ARC Document Solutions ARC.N: up 18.4% BUZZ-ARC Document Solutions: Up on stronger Q3 result expectations ** Aerie Pharma AERI.O: down 13.9% BUZZ-Aerie Pharma: BOFA says post COVID-19 pathway looks challenging, downgrades ** Warner Music WMG.O: up 2.4% BUZZ-Warner Music rises on upbeat FY20 revenue forecast ** Microchip Technology MCHP.O: up 2.4% BUZZ-Microchip Technology: MS sees upside in second half, upgrades ** Tivity Health Inc TVTY.O: up 3.6% BUZZ-Tivity Health Inc: Rises after divesting nutrition business ** OraSure Tech OSUR.O: up 18.0% BUZZ-OraSure Tech: Surges as COVID-19 saliva testing device gets emergency use tag ** Bentley Systems BSY.O: down 8.1% BUZZ-Bentley Systems: IPO banks' initiations skew 'neutral' after research quiet period ends ** MEDNAX Inc MD.N: down 6.0% BUZZ-MEDNAX Inc: At 5-month low after Deutsche Bank downgrade ** BOQI International Medical Inc BIMI.N: up 57.0% BUZZ-BOQI International Medical surges as Guanzan acquisition powers Q2 revenue jump The 11 major S&P 500 sectors: Communication Services New Article The top three NYSE percentage gainers premarket .PRPG.NQ: ** Front Yard Residential Corp , up 34.8% ** ARC Document Solutions Inc , up 22.3% ** SEACOR Marine Holdings Inc , up 18.0% The top three NYSE percentage losers premarket .PRPL.NQ: ** American Equity Investment Life Holding , down 8.7% ** Hudbay Minerals Inc , down 8.1% ** Navios Maritime Partners , down 7.5% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Code Chain New Continent Ltd , up 164.5% ** Kaixin Auto Holdings , up 71.0% ** Boqi International Medical Inc , up 58.8% The top three Nasdaq percentage losers premarket .PRPL.O: ** Paya Holdings Equity Warrants , down 35.1% ** Ameri Holdings Equity Warrants , down 32.3% ** CHF Solutions Inc , down 18.9% ** Tesla TSLA.O: up 1.5% premarket BUZZ-Tesla: Wedbush bets on strong Q3 performance, hikes PT to $500 ** Abbott ABT.N: up 0.8% premarket BUZZ-Abbott's heart device could receive national coverage under Medicare- Cowen ** Microsoft Corp MSFT.O: up 0.5% premarket BUZZ-Microsoft: Jefferies raises PT on hopes of strong Q1 results ** American Airlines AAL.O: up 1.0% premarket BUZZ-American Airlines: Gains after co hints 737 MAX could return by 2020-end ** OraSure Tech OSUR.O: up 19.5% premarket BUZZ-OraSure Tech: Surges as COVID-19 saliva testing device gets emergency use tag ** Biogen Inc BIIB.O: down 0.2% premarket BUZZ-FDA panel meet on Alzheimer's drug remains focus - analysts ** Centogene CNTG.O: up 7.7% premarket BUZZ-Centogene: Up as U.S. FDA grants emergency use for COVID-19 test ** Schlumberger NV SLB.N: up 0.9% premarket BUZZ-Street View: Schlumberger's 2021 margins likely to grow above 2019 levels ** L Brands LB.N: up 3.2% premarket BUZZ-L Brands: J.P.Morgan raises PT on strong Bath & Body Works margins expectations ** Concho Resources CXO.N: up 2.9% premarket BUZZ-Concho Resources rises on ConocoPhillips' $9.7 bln buyout deal ** Beyond Air Inc XAIR.O: up 3.6% premarket BUZZ-Beyond Air Inc: Jumps on upcoming data presentation on Nitric Oxide on coronavirus ** AMC AMC.N: up 8.2% premarket BUZZ-AMC shares rise as New York state prepares to reopen theaters ** D.R. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes were set to inch higher at the open on Monday on hopes of a coronavirus vaccine by the year-end, while investors were also encouraged by signs an agreement in Washington on a fiscal package could be reached soon. Horton: Rises on buying smaller rival in Texas for $23 mln ** Front Yard Residential RESI.N: up 34.8% premarket BUZZ-Front Yard Residential: Jumps on $767 mln go-private deal ** JinkoSolar JKS.N: up 1.8% premarket BUZZ-JinkoSolar: Up on supply deal for Kozani project (Compiled by Tiyashi Datta) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",296.1514892578125
2020-10-20 00:00:00+00:00,270.45001220703125,271.9800109863281,266.0899963378906,267.1199951171875,267.1199951171875,1155400.0,3.0,1.0,0.5000249999999999,"Biogen Inc. (BIIB) is reporting for the quarter ending September 30, 2020. In the past year BIIB has beat the expectations every quarter. Zacks Investment Research reports that the 2020 Price to Earnings ratio for BIIB is 7.76 vs. an industry ratio of -16.10, implying that they will have a higher earnings growth than their competitors in the same industry.",290.5160217285156
2020-10-21 00:00:00+00:00,264.989990234375,271.0400085449219,260.29998779296875,268.9100036621094,268.9100036621094,1848600.0,3.0,1.0,0.5000249999999999,"Adds detail on forecast, Tecfidera Oct 21 (Reuters) - Drugmaker Biogen Inc BIIB.O on Wednesday cut its full-year profit forecast for 2020 after the launch of a generic rival to its blockbuster multiple sclerosis (MS) drug, Tecfidera. (https://bit.ly/35hIq2d) The company now sees demand of Tecfidera, its top-selling drug which generated $4.43 billion in sales in 2019, falling significantly in the fourth quarter. Mylan NV MYL.O launched a generic version of Tecfidera in August with U.S. Food and Drug Administration's approval. New Article The top three S&P 500 .PG.INX percentage gainers: ** Twitter Inc , up 7.7 % ** Chubb Ltd , up 5.6 % ** Teradyne Inc , up 4.7 % The top three S&P 500 .PL.INX percentage losers: ** Netflix Inc , down 6.2 % ** Etsy Inc , down 6.1 % ** KeyCorp , down 5.4 % The top three NYSE .PG.N percentage gainers: ** Snap Inc , up 35.1 % ** Calix Inc , up 26.6 % ** China Unicom (Hong Kong) Ltd , up 11.8 % The top three NYSE .PL.N percentage losers: ** Weidai Ltd , down 54.6 % ** Armstrong Flooring Inc , down 28.5 % ** GSX Techedu Inc , down 27.5 % The top three Nasdaq .PG.O percentage gainers: ** Marin Software Inc , up 127.5 % ** Astrotech Corp , up 102.4 % ** Puhui Wealth Investment Management Co Ltd , up 27.8 % The top three Nasdaq .PL.O percentage losers: ** KBL Merger Corp IV , down 17.4 % ** Kaixin Auto Holdings , down 16.6 % ** Hexindai Inc , down 16.6 % ** Snap Inc SNAP.N: up 35.1% BUZZ-Snap Inc: Surges on strong quarterly revenue, user growth ** Astrotech Corp ASTC.O: up 102.4% BUZZ-Astrotech: Surges on deal to develop rapid COVID-19 breath test ** Pioneer Natural Resources Co PXD.N: down 1.7% BUZZ-Pioneer Natural, Parsley Energy drop after $4.5 bln deal ** Lockheed Martin Corp LMT.N: down 1.0% BUZZ-Street View: Lockheed Martin's future looks bright; F-16 skyline robust ** Facebook Inc FB.O: up 4.7% ** Twitter Inc TWTR.N: up 7.7% ** Snap Inc SNAP.N: up 35.1% ** Pinterest Inc PINS.N: up 10.4% BUZZ-Social media cos up on Snap's strong Q3 revenue, user growth ** Mosaic Co MOS.N: up 1.1% BUZZ-Mosaic: Slips as Citi cuts PT on limited upside to phosphate import duties ** Procter & Gamble Co PG.N: up 1.0% BUZZ-Street View: Procter & Gamble products likely to be in demand even in 2021 ** Sunrun Inc RUN.O: down 6.1% BUZZ-Sunrun down after Morgan Stanley prices big block of shares ** CRISPR Therapeutics CRSP.O: down 13.8% BUZZ-CRISPR Therapeutics: Falls as co reports patient death in CAR-T cancer therapy trial ** Armstrong Flooring Inc AFI.N: down 28.5% BUZZ-Armstrong Flooring: Slides on fall in Q3 net sales ** ManpowerGroup Inc MAN.N: up 2.4% BUZZ-ManpowerGroup: JPM sees COVID-19 vaccine-led recovery in 2021, upgrades ** Lithia Motors Inc LAD.N: up 1.7% BUZZ-Lithia Motors: Gains after robust used-car sales drive profit beat ** Dave & Buster's Entertainment Inc PLAY.O: up 1.2% BUZZ-Dave & Buster's: Rises as Raymond James upgrades to 'strong buy' ** AutoNation Inc AN.N: up 4.8% BUZZ-AutoNation surges on profit jump, share buyback plan ** PayPal Holdings Inc PYPL.O: up 3.6% BUZZ-PayPal rises on joining crypto market, Barclays PT raise ** PNM Resources Inc PNM.N: up 8.3% BUZZ-PNM Resources: Jumps; Iberdrola offers $4.3 bln to create renewables giant ** NetSol Technologies Inc NTWK.O: up 6.3% BUZZ-NetSol Technologies: Up on launch of NFS Ascent Retail Platform ** Aptinyx Inc APTX.O: down 6.8% BUZZ-Aptinyx falls on planned equity raise ** Titan Machinery Inc TITN.O: up 5.2% BUZZ-Titan Machinery: Rises as William Blair upgrades to 'outperform' on strong balance sheet ** Baker Hughes BKR.N: up 3.4% BUZZ-Baker Hughes: Climbs on Q3 revenue beat, cost cuts ** Casella Waste Systems Inc CWST.O: down 6.8% BUZZ-Casella Waste Systems drops after pricing stock offering ** Selecta Biosciences Inc SELB.O: up 23.4% BUZZ-Selecta Biosciences jumps on FDA rare pediatric disease designation for drug ** Biogen Inc BIIB.O: down 1.0% BUZZ-Biogen cuts full-year profit forecast, shares fall ** Slack Technologies Inc WORK.N: down 5.8% BUZZ-Slack staggers after Morgan Stanley turns bearish on rising competition ** Zosano Pharma Corp ZSAN.O: down 30.4% BUZZ-Zosano Pharma: Plunges after FDA declines to approve migraine treatment ** Nikola Corp NKLA.O: up 10.1% BUZZ-Nikola Corp: Up after GM exec raises hopes of keeping deal alive The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 climbed on Wednesday helped by gains in internet companies Facebook and Alphabet, while investors waited for signs that Washington could be close to agreeing on the next coronavirus aid package to support a fragile economic recovery. down 0.05% (Compiled by Tiyashi Datta) ((tiyashi.datta@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article The FDA had previously placed a clinical hold on BIIB089 due to dorsal root ganglion toxicity, a pathology commonly observed in preclinical studies and which may also occur following use of the currently available AAV mediated SMA gene therapy. Biogen Inc (NASDAQ: BIIB) Q3 2020 Earnings Call Oct 21, 2020, 8:00 a.m. We are continuing to analyze a significant data set from this study to further inform our MS research in this area, including for BIIB061.",299.3513488769531
2020-10-23 00:00:00+00:00,267.2300109863281,267.2300109863281,262.1700134277344,265.0,265.0,1016200.0,4.0,1.0,0.7500249999999999,"Also, MYL stock has declined 2% from the low of $16 seen in March 2020, significantly underperforming the broader markets, with the S&P500 seeing a 53% rise over the same period, as the Fed stimulus largely put investor concerns about the near-term survival of companies to rest. Phases of Covid-19 crisis: Early- to mid-March 2020: Fear of the coronavirus outbreak spreading rapidly translates into reality, with the number of cases accelerating globally Late-March 2020 onward: Social distancing measures + lockdowns April 2020: Fed stimulus suppresses near-term survival anxiety May-June 2020: Recovery of demand, with the gradual lifting of lockdowns  no panic anymore despite a steady increase in the number of cases. July-October 2020: Poor Q2 results and lukewarm Q3 expectations, but continued improvement in demand, a decline in the number of new cases, and progress with vaccine development buoy market sentiment.",302.2166748046875
2020-10-26 00:00:00+00:00,263.510009765625,264.17999267578125,255.8300018310547,256.760009765625,256.760009765625,1241000.0,2.5,1.0,0.375025,"Among the largest underlying components of IBB, in trading today Gilead Sciences Inc (Symbol: GILD) is off about 1.7%, Illumina Inc (Symbol: ILMN) is off about 1.7%, and Biogen Inc (Symbol: BIIB) is lower by about 1.4%. For a complete list of holdings, visit the IBB Holdings page  The chart below shows the one year price performance of IBB, versus its 200 day moving average: Looking at the chart above, IBB's low point in its 52 week range is $92.15 per share, with $146.529 as the 52 week high point  that compares with a last trade of $135.47. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article On October 22, the FDA approved Gilead's (GILD) Veklury (remdesivir), the first drug for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization. Another notable first to be achieved on the regulatory front is the approval of Regeneron Pharmaceuticals' (REGN) Inmazeb, the first FDA-approved treatment for Ebola virus infection in adult and pediatric patients, on October 14. The month also saw the first drug regimen approved for mesothelioma in 16 years when the drug combination of Opdivo and Yervoy was greenlighted by the FDA on October 2 for the first-line treatment of adults with malignant pleural mesothelioma that cannot be removed by surgery.",294.7340393066406
2020-10-27 00:00:00+00:00,256.3299865722656,258.70001220703125,254.92999267578125,255.3000030517578,255.3000030517578,1105400.0,1.0,1.0,2.4999999999997247e-05,"Ever since Biogen (NASDAQ: BIIB) revived a phase 3 Alzheimer's program a year ago, investors have been waiting with bated breath for the next steps. The biotech cut its 2020 earnings forecast due to generic competition weighing on its multiple sclerosis (MS) blockbuster drug, Tecfidera. Early last year, Biogen halted the program after an independent committee said trials were unlikely to meet their primary endpoint, which was to slow patients' cognitive and functional decline.",283.7002868652344
2020-10-28 00:00:00+00:00,251.02999877929688,253.2100067138672,244.17999267578125,244.259994506836,244.259994506836,1647700.0,2.0,1.0,0.250025,"The neurology drug developer Biogen (NASDAQ: BIIB) reported its quarterly earnings on Oct. 21 , stating that its total revenue fell by 6% compared to 2019, reaching $3.37 billion for FY 2020. This collapse has its genesis in the diminishing sales of drugs like Tecfidera for multiple sclerosis (MS), which sold 15% less in the third quarter than in the year prior due to its patent exclusivity expiring. The latest phase 2 trial to study opicinumab didn't demonstrate statistically significant beneficial effects for either of its two endpoints pertaining to slowing disease progression, leading Biogen to stop development. New Article Robinson Worldwide , down 10.1 % ** Akamai Technologies Inc , down 9 % The top three NYSE .PG.N percentage gainers: ** Tupperware Brands Corp , up 33.6 % ** MediaAlpha Inc , up 33.4 % ** Community Health Systems , up 32.8 % The top three NYSE .PL.N percentage losers: ** Callaway Golf , down 22.4 % ** Universal Insurance Holdings Inc , down 17.9 % ** Renren Inc , down 15.5 % The top three Nasdaq .PG.O percentage gainers: ** Astrotech Corp , up 28.4 % ** Scholar Rock Holding Corp , up 25.2 % ** Applied UV Inc , up 24 % The top three Nasdaq .PL.O percentage losers: ** Biodesix Inc , down 20.6 % ** Akerna Corp , down 20.5 % ** Chefs' Warehouse Inc , down 19.7 % ** EQT Corp EQT.N: down 2.3% BUZZ-EQT: Down on plans to buy Chevron's Appalachia assets for $735 mln ** Microsoft Corp MSFT.O: down 4.2% BUZZ-Microsoft shares gyrate after Q1 report ** Caesars Entertainment Inc CZR.O: down 4.1% BUZZ-Caesars Entertainment to sell Tropicana Evansville operations for $480 mln ** ExxonMobil Corp XOM.N: down 2.7% ** Chevron Corp CVX.N: down 3.4% ** TechnipFMC Plc FTI.N: down 5.4% ** Halliburton Co HAL.N: down 7.3% ** Diamondback Energy Inc FANG.O: down 4.6% ** Marathon Oil Corp MRO.N: down 5.2% ** Conocophillips COP.N: down 3.0% ** Apache Corp APA.O: down 5.1% ** Devon Energy Corp DVN.N: down 5.4% ** Callon Petroleum Co CPE.N: down 5.3% ** Occidental Petroleum Corp OXY.N: down 2.8% ** Phillips 66 PSX.N: down 3.8% BUZZ-U.S. energy shares dive: WTI crude sinks on COVID-19 case spike ** Fiverr International Ltd FVRR.N: up 6.5% BUZZ-Fiverr International: Jumps on third-quarter revenue beat ** Microsoft Corp MSFT.O: down 4.2% BUZZ-Street View: Microsoft likely on track for solid growth ahead ** Lyft Inc LYFT.O: down 3.6% BUZZ-Lyft: Cowen & Co cuts PT ahead of Q3 earnings ** General Electric Co GE.N: up 9.2% BUZZ-GE: Shares rise on smaller Q3 loss ** First Solar Inc FSLR.O: up 11.1% BUZZ-First Solar jumps after strong Q3, upbeat forecast; JP Morgan hikes PT ** Intel Corp INTC.O: down 2.2% BUZZ-Intel: Falls; brokerage lowers PT after AMD-Xilinx deal ** Goldman Sachs Group Inc GS.N: down 3.0% ** JPMorgan Chase & Co JPM.N: down 2.3% ** Morgan Stanley MS.N: down 1.7% ** Bank of America Corp BAC.N: down 2.0% ** Wells Fargo & Co WFC.N: down 2.3% ** Citigroup Inc C.N: down 1.6% ** U.S Bancorp USB.N: down 2.2% BUZZ-U.S. bank shares slide; Treasury yields dip on virus jitters ** Spirit Airlines Inc SAVE.N: down 5.1% ** Southwest Airlines Co LUV.N: down 4.2% ** Alaska Air Group Inc ALK.N: down 4.7% ** Delta Air Lines Inc DAL.N: down 4.5% ** American Airlines Group Inc AAL.O: down 2.2% ** Royal Caribbean Cruises Ltd RCL.N: down 4.6% ** Norwegian Cruise Line Holdings Ltd NCLH.N: down 7.6% ** Carnival Corp CCL.N: down 8.0% ** Hilton Worldwide Holdings Inc HLT.N: down 2.9% ** Hyatt Hotels Corp H.N: down 1.8% ** Mariott International Inc MAR.O: down 2.8% ** TripAdvisor Inc TRIP.O: down 3.4% ** Booking Holdings Inc BKNG.O: down 3.7% ** Expedia Group Inc EXPE.O: down 2.3% BUZZ-Travel stocks tumble on fears of more COVID-19 lockdowns ** Bunge Ltd BG.N: up 3.3% BUZZ-Bunge Ltd: Surges on Q3 revenue beat ** Tupperware Brands Corp TUP.N: up 33.6% BUZZ-Tupperware Brands: Gains as quarterly sales jump ** Bed Bath & Beyond Inc BBBY.O: down 11.5% Bed Bath & Beyond: Sinks as sales forecast fails to impress Street ** Advanced Micro Devices Inc AMD.O: down 2.7% BUZZ-Street View: AMD unlocks expanded market opportunity with Xilinx deal **Hess Corp HES.N: down 1.3% BUZZ-Hess: Falls on wider-than-expected Q3 loss, cuts FY production outlook ** Six Flags Entertainment Corp SIX.N: down 7.8% BUZZ-Six Flags Entertainment: Drops after revenue misses estimates ** ** MSCI Turkey ETF TUR.O: down 3.7% BUZZ-Turkey-focused ETF drops; lira hits record low as traders' bearishness grows ** Deutsche Bank AG DB.N: down 1.5% BUZZ-Deutsche Bank's U.S. shares rise on surprise Q3 net profit ** Omnicom Group Inc OMC.N: down 5.5% BUZZ-Omnicom: MoffettNathanson upgrades to ""neutral"" on growth prospects for 2021 ** Mastercard Inc MA.N: down 7.1% BUZZ-Mastercard: Set to open at 3-mth low on Q3 profit slump ** Barrick Gold Corp GOLD.N: down 4.8% ** AngloGold Ashanti Ltd AU.N: down 5.9% ** Agnico Eagle Mines Ltd AEM.N: down 5.3% ** Gold Fields Ltd GFI.N: down 8.0% BUZZ-Gold miners slip as stronger dollar hits bullion prices ** Akerna Corp KERN.O: down 20.5% BUZZ-Akerna Corp: Falls on $12 mln discounted offering ** Dine Brands Global Inc DIN.N: up 2.5% BUZZ-Dine Brands: Rises as quarterly earnings beat estimates ** Summit Materials Inc SUM.N: down 13.2% BUZZ-Summit Materials: Drops as low cement sales hit Q3 results ** Chefs' Warehouse Inc CHEF.O: down 19.7% BUZZ-Chefs' Warehouse: Falls on bigger-than-expected Q3 loss ** Chewy Inc CHWY.N: up 5.1% BUZZ-Chewy Inc: Rises on launch of telehealth service for pets ** Tenable Holdings Inc TENB.O: down 3.2% BUZZ-Tenable Holdings: Rises as brokerages hike PTs after strong forecast ** Callaway Golf Co ELY.N: down 22.4% BUZZ-Callaway Golf: Hits 4-month low on deal to buy rest of Topgolf ** Hawaiian Holdings Inc HA.O: down 9.9% BUZZ-Hawaiian Holdings slides as pandemic hits Q3 results, outlook ** Biogen Inc BIIB.O: down 2.7% BUZZ-Biogen's aducanumab unlikely to get FDA green light: Baird ** Enterprise Products Partners LP EPD.N: down 1.4% BUZZ-Enterprise Products Partners: Falls on Q3 rev miss, drop in crude shipment volumes ** Marine Products Corp MPX.N: down 9.5% BUZZ-Marine Products set for worst day in over a month on weak sales ** Anthem Inc ANTM.N: down 3.5% BUZZ-Anthem down after warning of higher costs in Q4 ** Titan Pharmaceuticals Inc TTNP.O: up 58.3% BUZZ-Titan Pharma: Jumps on deal to buy drug to treat chronic itching ** MiRagen Therapeutics Inc MGEN.O: up 117.3% BUZZ-MiRagen Therapeutics: Surges on Viridian acquisition ** Root Inc ROOT.O: up 2.6% BUZZ-Root Inc: Falls nearly 4% in Nasdaq debut ** MediaAlpha Inc MAX.N: up 33.4% BUZZ-MediaAlpha Inc: Rises 21% in NYSE debut ** Enphase Energy Inc ENPH.O: up 4.1% BUZZ-Enphase Energy: Gains on multiple PT raises, Q3 results beat ** Biodesix Inc BDSX.O: down 20.6% BUZZ-Biodesix Inc: Slumps 24.5% in Nasdaq debut ** Community Health Systems Inc CYH.N: up 32.8% BUZZ-Community Health Systems jumps after strong results, CEO change The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 and the Dow hit their lowest levels since late-September on Wednesday as coronavirus cases surged globally and fears of a contested U.S. presidential election next week added to worries..N At 13:10 ET, the Dow Jones Industrial Average .DJI was down 3.16% at 26,595.47. The top three S&P 500 .PG.INX percentage gainers: ** General Electric Co , up 9.2 % ** Automatic Data Processing Inc , up 6 % ** Trane Technologues PLC Ord , up 4.6 % The top three S&P 500 .PL.INX percentage losers: ** DexCom Inc , down 11.8 % ** C.H.",281.8918762207031
2020-10-30 00:00:00+00:00,247.259994506836,252.2100067138672,243.72999572753903,252.07000732421875,252.07000732421875,1413500.0,1.6666666666666667,1.0,0.1666916666666666,"The top three NYSE percentage gainers premarket .PRPG.NQ: ** Mohawk Industries Inc MHK.N, up 15.5% ** Plantronics Inc PLT.N, up 14.3% ** Essex Property Trust Inc ESS.N, up 11.3% The top three NYSE percentage losers premarket .PRPL.NQ: ** Ryerson Holding Corp RYI.N, down 22.9% ** Hexo Corp HEXO.N, down 18% ** Twitter Inc TWTR.N, down 14.4% The top Nasdaq percentage gainers premarket .PRPG.O: ** BioLine RX Ltd BLRX.O, up 53.4% ** Phio Pharmaceuticals Corp PHIOW.O, up 48.8% The top Nasdaq percentage losers premarket .PRPL.O: ** Bellicum Pharmaceuticals Inc BLCM.O, down 33.9% ** Axovant Gene Therapies Ltd AXGT.O, down 32.6% ** Alphabet Inc GOOGL.O: up 8.1% premarket BUZZ-Street View: Alphabet's ad boost points to sharp recovery ** Facebook Inc FB.O: down 0.1% premarket ** Amazon.com Inc AMZN.O: down 1.4% premarket ** Apple Inc AAPL.O: down 3.6% premarket ** Microsoft Corp MSFT.O: down 0.8% premarket BUZZ-Big Tech cos slide on mixed quarterly reports ** Twitter Inc TWTR.N: down 14.4% premarket BUZZ-Street View: Not much to like on Twitter ** Bloom Energy Corp BE.N: down 6.6% premarket BUZZ-Bloom Energy down after Q3 rev miss ** Chevron Corp CVX.N: up 0.4% premarket BUZZ-PREVIEW: Chevron shares climb ahead of results Friday ** Zendesk Inc ZEN.N: up 10.3% premarket BUZZ-Zendesk: Jumps as brokerages hike PTs after strong Q3 result, outlook raise ** Vertex Pharmaceuticals Inc VRTX.O: down 1.0% premarket BUZZ-Street View: Vertex's pipeline troubles overshadow profit beat ** Equillium Inc EQ.O: up 18.5% premarket BUZZ-Equillium: Soars on U.S. FDA nod to start COVID-19 drug late-stage trials ** Bellicum Pharmaceuticals Inc BLCM.O: down 33.9% premarket BUZZ-Bellicum tumbles on weak data from pancreatic cancer drug trial ** Gaming and Leisure Properties Inc GLPI.O: down 0.8% premarket BUZZ-Gaming and Leisure Prop's slips after raising equity to fund acquisitions ** Lear Corp LEA.N: down 3.9% premarket BUZZ-Lear Corp: Rises on Q3 earnings beat, upbeat FY rev outlook ** BioLine RX Ltd BLRX.O: up 53.4% premarket BUZZ-BioLine RX: Surges on positive review of cancer treatment study ** Carvana Co CVNA.N: up 3.5% premarket BUZZ-Carvana up on Q3 revenue beat ** Axovant Gene Therapies Ltd AXGT.O: down 32.6% premarket BUZZ- Axovant: Slumps on delay in study of gene therapy for Parkinson's ** Biogen Inc BIIB.O: up 1.9% premarket BUZZ-Biogen gains after EMA accepts application for Alzheimer's treatment aducanumab ** SM Energy Co SM.N: up 7.5% premarket BUZZ-SM Energy: Rises after smaller-than-expected Q3 loss ** Colgate-Palmolive Co CL.N: up 0.8% premarket BUZZ-Colgate-Palmolive: Up after brushing past estimates on demand, pricing ** AbbVie Inc ABBV.N: up 2.4% premarket BUZZ-AbbVie: Gains on Q3 profit beat, FY outlook hike ** Honeywell International Inc HON.N: down 2.1% premarket BUZZ-Honeywell slips despite Q3 profit beat as aerospace unit sales drag ** ResMed Inc RMD.N: up 9.1% premarket BUZZ-ResMed: Profit beats on ventilator demand, shares up (Compiled by Amruta Khandekar) ((Amruta.Khandekar@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street was set to tumble again on Friday, triggered by a selloff in tech heavyweights following their underwhelming business updates, with a record rise in coronavirus cases and nerves over the presidential election adding to a downbeat mood. .N At 8:57 am ET, Dow e-minis 1YMc1 were down 0.68% at 26,377. New Article Adds details on treatment Oct 30 (Reuters) - Biogen Inc BIIB.O and Eisai Co Ltd 4523.T said on Friday the European health regulator has accepted for review the marketing application for their closely watched experimental Alzheimer's treatment aducanumab. If approved, aducanumab will become the first therapy to reduce the clinical decline in patients with Alzheimer's disease, which is the most common cause of dementia. The European Medicines Agency's acceptance of the application comes ahead of a Nov. 6 panel meeting of outside experts to the FDA to assess the benefits and risks associated with the drug. New Article Oct 30 (Reuters) - Biogen Inc BIIB.O and partner Eisai Co Ltd 4523.T said on Friday the European health regulator has accepted for review the marketing application for its closely-watched experimental Alzheimer's treatment aducanumab. Aducanumab is also under review with the U.S. Food and Drug Administration. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber) ((manojna.kalyani@thomsonreuters.com; +91 8061822700;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",286.74200439453125
2020-11-02 00:00:00+00:00,253.63999938964844,255.8000030517578,248.259994506836,248.9900054931641,248.9900054931641,1469500.0,4.0,1.0,0.7500249999999999,"By Deena Beasley Nov 2 (Reuters) - The U.S. Food and Drug Administration, citing conflict of interest, has recused a member of an 11-person advisory committee set to review Biogen Inc's BIIB.O experimental Alzheimer's drug aducanumab on Friday. Knopman, who said he was recused because of his involvement in conducting clinical trials of aducanumab, has been a vocal critic of the drug, including in a paper published on Sunday in the journal Alzheimer's & Dementia. ""Aducanumab's efficacy as a treatment for the cognitive dysfunction in Alzheimer's disease cannot be proven by clinical trials with divergent outcomes,"" he wrote.",293.7792663574219
2020-11-03 00:00:00+00:00,250.5200042724609,251.8000030517578,243.57000732421875,247.009994506836,247.009994506836,1449800.0,3.0,1.0,0.5000249999999999,"KBLM.O, down 22.3 % ** Biomarin Pharma BMRN.O: down 2.0% BUZZ-Falls on concerns over FDA review of growth disorder treatment ** Humana HUM.N: up 2.6% BUZZ-Rises on strong 2021 profit outlook, Q3 earnings ** Emerson Electric EMR.N: up 2.3% BUZZ-Emerson Electric: Gains after cost cuts drive quarterly profit beat ** Aptevo Therapeutics APVO.O: up 19.5% BUZZ-Surges after cancer symptoms disappear in study patient ** Eaton Corp ETN.N: up 2.4% BUZZ-Up on Q3 results beat ** Fabrinet FN.N: up 7.2% BUZZ-Hits 2-month high after Q1 results beat estimates ** Spirit AeroSystems SPR.N: up 4.0% BUZZ-Up after forecasting lower 2021 cash burn ** Alibaba BABA.N: down 8.0% BUZZ-Drops after Shanghai stock exchange suspends Ant's A-share IPO ** Fox Corp FOXA.O: down 2.8% BUZZ-Rises after Q1 profit beat ** Designer Brands DBI.N: up 12.1% BUZZ-Rises as Susquehanna upgrades to 'neutral' ** GW Pharma GWPH.O : up 22.5% BUZZ-Up as co starts study on cannabis-based drug for MS, Q3 results ** Telenav TNAV.O: up 20.2% BUZZ-Jumps on go-private deal with CEO-led firm ** Ferrari NV RACE.N: up 7.7% BUZZ-Zooms after raising profit forecast as shipments recover ** CDW Corp CDW.O: up 3.2% BUZZ-Brokerages turn bullish after upbeat Q3 ** 3D Systems Corp DDD.N: up 6.6% BUZZ-Rises on $65 mln sale of software businesses ** UnitedHealth UNH.N: up 2.8% ** Anthem ANTM.N: up 4.9% ** Humana HUM.N: up 2.6% BUZZ-Health insurers trade higher ahead of U.S. presidential elections ** Thomson Reuters TRI.N: up 3.6% BUZZ-Profit beat lifts stock ** Sysco Corp SYY.N: up 6.3% BUZZ-Rises on better-than-expected quarterly results ** Aurinia Pharma AUPH.O: down 12.7% BUZZ-Falls on failure of dry-eye syndrome drug study ** Gilead Sciences Inc GILD.O: up 0.4% BUZZ-Value investors should keep Gilead Sciences on the radar: Mizuho ** Tilray TLRY.O: down 1.4% ** Cronos CRON.O: down 0.2% ** Sundial Growers SNDL.O: !RIC {RIC.NB} is invalid ** Aurora Cannabis ACB.N: up 1.1% BUZZ-Pot stocks gain as investors bet on Biden-Harris victory ** Esperion Therapeutic ESPR.O: down 15.7% BUZZ-Analysts ring alarm bells over cash balance ** Jakks Pacific Inc JAKK.O: up 25.1% BUZZ-Surges as Q3 results beat ** Paypal PYPL.O: down 2.5% BUZZ-Falls on disappointing Q4 outlook; some analysts remain bullish ** Mondelez International Inc MDLZ.O: up 0.4% BUZZ-Mondelez forecast suggests strong momentum in 2021 ** Trivago NV TRVG.O: up 3.5% BUZZ-Jumps on smaller-than-expected loss in Q3 ** TechnipFMC FTI.N: up 1.2% BUZZ-Rises on stake disclosure by shareholder ** Biogen BIIB.O: down 2.0% BUZZ-Cantor slashes PT on concerns over Spinraza competition, growth ** Plug Power PLUG.O: up 9.5% BUZZ-Gains after D.E. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes jumped on Tuesday as investors bet that one of the country's most divisive presidential races could end with a clear victory for Democratic nominee Joe Biden and a swift deal on more fiscal stimulus. Shaw discloses passive stake ** Alaska Communications ALSK.O: up 57.9% BUZZ-Soars on go-private deal ** Baxter BAX.N: down 0.2% BUZZ-Fall in Baxter shares potential ""buying opportunity"" - JPM ** Goldman Sachs GS.N: up 4.1% ** JPMorgan Chase & Co JPM.N: up 3.2% ** Morgan Stanley MS.N: up 2.9% BUZZ-U.S. banks track Treasury yields higher as investors bet on Biden win ** Bristol Myers BMY.N: up 3.7% BUZZ-Up after psoriasis drug meets main goals in late-stage study ** STRATA Skin Science SSKN.O: up 8.9% BUZZ-STRATA Skin Sciences rises after brokerage upgrades to 'buy' ** Exelon EXC.O: up 3.7% BUZZ-Up as co weighs separating generation business from utilities ** Arista Networks ANET.N: up 15.7% BUZZ-Surges after beating profit est for third quarter ** Uber Technologies Inc UBER.N: up 3.0% ** Lyft Inc LYFT.O: up 6.6% BUZZ-Bernstein says focus on California's gig-worker ballot measure ** Wayfair W.N: up 7.5% BUZZ-Jumps as Q3 revenue beats estimates ** Pacific Biosciences PACB.O: down 3.4% BUZZ-Drops on missing Q3 revenue estimates ** McKesson Corp MCK.N: up 5.4% BUZZ-Up after raising profit forecast ** Zebra Technologies ZBRA.O: up 7.5% BUZZ-Rises on better-than-expected results, forecast ** Beasley Broadcast Group BBGI.O: up 33.8% BUZZ-Soars; co expects to reduce op-ex by $32 mln The 11 major S&P 500 sectors: Communication Services New Article By Deena Beasley Nov 3 (Reuters) - U.S. health experts this week will decide whether to recommend approval for Biogen Inc's BIIB.O Alzheimer's drug, which could become the first new treatment for the mind-wasting disease in decades even as serious questions persist over whether data show if it works. Last October, the company shocked many Alzheimers experts by reversing course, saying that a new analysis showed aducanumab could help patients with early-stage disease preserve their ability to function independently for longer. They have been trying to lower the bar and help any company to get a drug approved, said Dr. Marwan Sabbagh, from the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. New Article When Bristol Myers Squibb subsequently decided to bail on the deal in favor of its own cancer drug, the CEO of Exelixis left the company to run Biogen. The climb back, and a hopeful future In the years since that trial failure, the company has been resilient, signing agreements with multiple marketing partners, continuing to leverage cabozantinib, and working to develop new drugs. EXEL Revenue (Annual) data by YCharts Just this month, the FDA granted a priority review for the combination of Cabometyx with Bristol Myers Squibb's Opdivo as a treatment for patients with advanced kidney cancer. New Article KBLMU.O, down 20.4% ** Alibaba BABA.N: down 6.8% BUZZ-Slumps after China suspends Ant's $37 bln listing ** Fox Corp FOXA.O: down 2.9% BUZZ-Rises after Q1 profit beat ** Designer Brands DBI.N: up 13.8% BUZZ-Rises as Susquehanna upgrades to 'neutral' ** GW Pharma GWPH.O : up 18.6% BUZZ-Up as co starts study on cannabis-based drug for MS, Q3 results ** Telenav TNAV.O: up 20.0% BUZZ-Jumps on go-private deal with CEO-led firm ** Ferrari NV RACE.N: up 7.9% BUZZ-Zooms after raising profit forecast as shipments recover ** CDW Corp CDW.O: up 2.6% BUZZ-Brokerages turn bullish after upbeat Q3 ** 3D Systems Corp DDD.N: up 8.2% BUZZ-Rises on $65 mln sale of software businesses ** UnitedHealth UNH.N: up 3.0% ** Anthem ANTM.N: up 5.3% ** Humana HUM.N: up 4.3% BUZZ-Health insurers trade higher ahead of U.S. presidential elections ** Thomson Reuters TRI.N: up 3.5% BUZZ-Profit beat lifts stock ** Sysco Corp SYY.N: up 4.7% BUZZ-Rises on better-than-expected quarterly results ** Aurinia Pharma AUPH.O: down 12.8% BUZZ-Falls on failure of dry-eye syndrome drug study ** Esperion Therapeutic ESPR.O: down 16.3% BUZZ-Analysts ring alarm bells over cash balance ** Jakks Pacific Inc JAKK.O: up 23.8% BUZZ-Surges as Q3 results beat ** Paypal PYPL.O: down 1.8% BUZZ-Falls on disappointing Q4 outlook; some analysts remain bullish ** Mondelez International Inc MDLZ.O: up 1.2% BUZZ-Mondelez forecast suggests strong momentum in 2021 ** Trivago NV TRVG.O: up 2.8% BUZZ-Jumps on smaller-than-expected loss in Q3 ** TechnipFMC FTI.N: up 2.3% BUZZ-Rises on stake disclosure by shareholder ** Biogen BIIB.O: down 1.3% BUZZ-Cantor slashes PT on concerns over Spinraza competition, growth ** Plug Power PLUG.O: up 8.6% BUZZ-Gains after D.E. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes jumped on Tuesday as investors bet that one of the country's most divisive presidential races could end with a clear victory for Democratic nominee Joe Biden and a swift deal on more fiscal stimulus. Shaw discloses passive stake ** Alaska Communications ALSK.O: up 57.6% BUZZ-Soars on go-private deal ** Baxter BAX.N: up 0.1% BUZZ-Fall in Baxter shares potential ""buying opportunity"" - JPM ** Goldman Sachs GS.N: up 3.9% ** JPMorgan Chase & Co JPM.N: up 3.7% ** Morgan Stanley MS.N: up 3.0% BUZZ-U.S. banks track Treasury yields higher as investors bet on Biden win ** OraSure Tech OSUR.O: up 0.3% BUZZ-Rises as second COVID-19 saliva kit gets emergency use nod ** Bristol Myers BMY.N: up 3.3% BUZZ-Up after psoriasis drug meets main goals in late-stage study ** STRATA Skin Science SSKN.O: up 8.1% BUZZ-STRATA Skin Sciences rises after brokerage upgrades to 'buy' ** Exelon EXC.O: up 4.1% BUZZ-Up as co weighs separating generation business from utilities ** Arista Networks ANET.N: up 15.7% BUZZ-Surges after beating profit est for third quarter ** Uber Technologies Inc UBER.N: up 2.2% ** Lyft Inc LYFT.O: up 5.9% BUZZ-Bernstein says focus on California's gig-worker ballot measure ** Wayfair W.N: up 5.5% BUZZ-Jumps as Q3 revenue beats estimates ** Pacific Biosciences PACB.O: down 3.6% BUZZ-Drops on missing Q3 revenue estimates ** McKesson Corp MCK.N: up 6.4% BUZZ-Up after raising profit forecast ** Zebra Technologies ZBRA.O: up 7.4% BUZZ-Rises on better-than-expected results, forecast ** Beasley Broadcast Group BBGI.O: up 40.3% BUZZ-Soars premarket; co expects to reduce op-ex by $32 mln ** Cardlytics CDLX.O: down 2.2% BUZZ-Rises as brokerages hike PTs after Q3 results The 11 major S&P 500 sectors: Communication Services",301.2015686035156
2020-11-04 00:00:00+00:00,253.1999969482422,363.9200134277344,251.75,355.6300048828125,355.6300048828125,14591500.0,4.363636363636362,1.0,0.8409340909090908,"Pfizer PFE.N, Merck & Co MRK.N, Biogen BIIB.O, Regeneron Pharmaceuticals REGN.O, Bristol Myers BMY.N and Johnson & Johnson JNJ.N all rose between 1.6% and 3.7%. Gains for Joe Biden in vote tallies in the swing states of Wisconsin and Michigan cooled initial selling of renewable energy, marijuana and other companies seen as potential beneficiaries of a sweeping Democrat victory. .N Following are major movers as traders and investors in New York's main stock indexes digested the results and President Donald Trump's chances of beating Biden to win a second term. New Article The top three S&P 500 .PG.INX percentage gainers: ** Biogen Inc BIIB.O, up 27.4% ** Cigna Corp CI.N, up 13.5% ** Anthem Inc ANTM.N, up 9.5% The top three S&P 500 .PL.INX percentage losers: ** Comerica Inc CMA.N, down 10% ** Zions Bancorp ZION.O, down 8.1% ** United Rental URI.N, down 7.8% The top NYSE .PG.N percentage gainers: ** Uber Technologies UBER.N, up 13.9% ** Cigna Corp CI.N, up 13.5% The top NYSE .PL.N percentage losers: ** Corecivic CXW.N, down 16% ** Clearwater Paper CLW.N, down 15.4% The top Nasdaq .PG.O percentage gainers: ** Biogen Inc BIIB.O, up 27.4% ** Digirad DRAD.O, up 22.7% The top three Nasdaq .PL.O percentage losers: ** Repro Med Systems KRMD.O, down 27.6% ** Aptevo Therapeutics APVO.O, down 20.2% ** Andersons ANDE.O, down 19.2% ** Wendy's WEN.O: down 3.8% BUZZ-Wendy's: Drops on quarterly revenue miss ** Prudential Financial PRU.N: down 0.6% BUZZ-Prudential Financial: MS hikes PT on upbeat Q3 results ** Kura Oncology KURA.O : down 3.0% BUZZ-Slips on safety concerns in leukemia treatment trial ** Alibaba BABA.N: up 1.9% BUZZ-Remains top internet mega-cap pick ** Digirad Corp DRAD.O: up 22.7% BUZZ-Digirad gains on sale of mobile healthcare unit ** Coca-Cola Consolidated COKE.O: up 5.2% BUZZ-Jumps on strong Q3 results ** Supernus Pharma SUPN.O: up 19.9% BUZZ-Jumps as seizure medication drives strong Q3 results ** Tabula Rasa HealthCare TRHC.O: down 15.3% BUZZ-Tabula Rasa HealthCare down on revenue fall ** Mercury Systems MRCY.O: down 4.0% BUZZ-Slips on lower Q1 profit as expenses rise ** Park Ohio Holdings Corp PKOH.O: up 4.1% BUZZ-Jumps on Q3 beat ** Nabors Industries Ltd NBR.N: down 2.2% BUZZ-Slips after Q3 revenue misses estimates ** Barrick Gold GOLD.N: up 1.0% ** AngloGold AU.N: up 0.7% ** Agnico Eagle Mines AEM.N: down 0.5% BUZZ-Gold miners fall as dollar gains on tight White House race ** Enphase ENPH.O: down 4.3% ** Sunpower SPWR.O: down 6.9% ** First Solar FSLR.O: down 8.1% ** Solaredge SEDG.O: down 2.0% BUZZ-U.S. solar energy stocks slide with presidential election too close to call ** Uber Technologies Inc UBER.N: up 13.9% ** Lyft Inc LYFT.O: up 11.8% BUZZ-Jumps after winning bid to keep California drivers as contractors ** UnitedHealth UNH.N: up 9.5% ** CVS Health Corp CVS.N: up 3.2% ** Anthem ANTM.N: up 9.5% BUZZ-Health insurers rise amid ongoing tight U.S. election race ** Apple Inc AAPL.O: up 3.9% ** Amazon.com Inc AMZN.O: up 5.7% ** Alphabet Inc GOOGL.O: up 6.9% ** Netflix Inc NFLX.O: up 3.7% BUZZ-Big Tech jumps amid tightening White House race ** Roku ROKU.O: up 4.8% BUZZ-Rises as brokerage raises PT ahead of Q3 results ** Super Micro Computer SMCI.O: up 17.0% BUZZ-Up on earnings beat for Q1 ** Fox Corp FOXA.O: down 3.7% BUZZ-Fox Corp rises after brokerages turn bullish after upbeat Q1 ** Vertiv Holdings VRT.N: up 3.1% BUZZ-Vertiv Holdings rises on Q3 revenue beat The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Technology stocks pushed Wall Street's major averages higher on Wednesday as the race for the White House went down to the wire, although investors remained worried about the prospect of a contested result. up 0.03% (Compiled by Arundhati Sarkar in Bengaluru) ((Arundhati.Sarkar@thomsonreuters.com; twitter.com/Arundhati_05; +1 646 223 8780 Ext: 2776)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Behind the numbers Biogen paid Ionis $74 million in royalties for spinal muscular atrophy (SMA) drug Spinraza in the third quarter. Tegsedi is now available in 15 countries as a treatment for hereditary transthyretin amyloidosis (hATTR) with polyneuropathy, a rare genetic disease. Although the SMA drug isn't the fantastic growth driver it once was, Biogen CEO Michel Vounatsos stated in his company's Q3 conference call last week, ""Despite increased competition, we believe Spinraza can continue to grow and serve as a foundation of care."" New Article The top three S&P 500 .PG.INX percentage gainers: ** Biogen Inc BIIB.O, up 40.3% ** Cigna Corp CI.N, up 13.9% ** Eli Lilly LLY.N, up 13.8% The top three S&P 500 .PL.INX percentage losers: ** Comerica Inc CMA.N, down 10.2% ** Zions Bancorporation ZION.O, down 9.2% ** Vulcan Materials VMC.N, down 7.4% The top NYSE .PG.N percentage gainers: ** Xpeng Inc XPEV.N, up 18.3% ** American Well Corp AMWL.N, up 14.1% The top NYSE .PL.N percentage losers: ** Corecivic Inc CXW.N, down 16.8% ** Clearwater Paper CLW.N down 14.5% The top three Nasdaq .PG.O percentage gainers: ** Biogen BIIB.O, up 40.3% ** Cassava Sciences SAVA.O, up 26.9% ** Digirad DRAD.O, up 26.7% The top three Nasdaq .PL.O percentage losers: ** Repro Med Systems KRMD.O, down 28.5% ** KBL Merger Corp. IV. KBLM.O, down 18% ** Andersons ANDE.O, down 17.3% ** Advanced Micro Devices AMD.O: up 5.3% BUZZ-Goldman upgrades to 'Conviction List', cites ""compelling"" opportunity ** Biogen BIIB.O: up 40.3% BUZZ-Soars as Alzheimer's drug approval chances improve ** LogicBio LOGC.O: up 4.3% BUZZ-Rises as rare metabolism disorder therapy gets FDA fast track tag ** Lockheed Martin LMT.N: up 4.5% ** Raytheon Technologies RTX.N: up 1.5% ** Northrop Grumman NOC.N: up 5.7% ** Boeing Co BA.N: up 0.2% ** General Dynamics GD.N: up 3.0% BUZZ-U.S. defense stocks gain as Republicans seen retaining control of the Senate ** KKR & Co Inc KKR.N: up 6.7% ** Blackstone Group Inc BX.N: up 6.8% ** BlackRock Inc BLK.N: up 3.3% ** Apollo Global Management Inc APO.N: up 5.0% BUZZ-U.S. PE firms gain on prospect of Republicans retaining Senate control ** Wendy's WEN.O: down 4.5% BUZZ-Wendy's: Drops on quarterly revenue miss ** Kura Oncology KURA.O : down 1.2% BUZZ-Slips on safety concerns in leukemia treatment trial ** Alibaba BABA.N: up 4.1% BUZZ-Remains top internet mega-cap pick ** Digirad Corp DRAD.O: up 26.7% BUZZ-Digirad gains on sale of mobile healthcare unit ** Coca-Cola Consolidated COKE.O: up 2.6% BUZZ-Jumps on strong Q3 results ** Supernus Pharma SUPN.O: up 18.1% BUZZ-Jumps as seizure medication drives strong Q3 results ** Tabula Rasa HealthCare TRHC.O: down 15.9% BUZZ-Tabula Rasa HealthCare down on revenue fall ** Mercury Systems MRCY.O: down 6.9% BUZZ-Slips on lower Q1 profit as expenses rise ** Park Ohio Holdings Corp PKOH.O: up 2.8% BUZZ-Jumps on Q3 beat ** Barrick Gold GOLD.N: down 0.8% ** AngloGold AU.N: down 1.4% ** Agnico Eagle Mines AEM.N: down 1.8% BUZZ-Gold miners fall as dollar gains on tight White House race ** Enphase ENPH.O: down 3.3% ** Sunpower SPWR.O: down 6.1% ** First Solar FSLR.O: down 7.1% ** Solaredge SEDG.O: down 0.2% BUZZ-U.S. solar energy stocks slide with presidential election too close to call ** Uber Technologies Inc UBER.N: up 13.1% ** Lyft Inc LYFT.O: up 11.9% BUZZ-Jumps after winning bid to keep California drivers as contractors ** Chevron Corp CVX.N: up 1.7% ** Exxon Mobil Corp XOM.N: up 1.3% ** Occidental Petroleum OXY.N: up 2.9% BUZZ-Oil stocks up as crude rises after Trump falsely claims victory in U.S. election ** UnitedHealth UNH.N: up 10.5% ** CVS Health Corp CVS.N: up 2.7% ** Anthem ANTM.N: up 11.2% BUZZ-Health insurers rise amid ongoing tight U.S. election race ** Apple Inc AAPL.O: up 4.1% ** Amazon.com Inc AMZN.O: up 6.1% ** Alphabet Inc GOOGL.O: up 7.3% ** Netflix Inc NFLX.O: up 2.9% BUZZ-Big Tech jumps amid tightening White House race ** Roku ROKU.O: up 5.0% BUZZ-Rises as brokerage raises PT ahead of Q3 results ** Pfizer PFE.N: up 4.7% ** Merck & Co MRK.N: up 7.0% ** Biogen BIIB.O: up 40.3% BUZZ-Big pharma rises as U.S. presidential race tightens ** Super Micro Computer SMCI.O: up 21.6% BUZZ-Up on earnings beat for Q1 ** Fox Corp FOXA.O: down 6.3% BUZZ-Fox Corp rises after brokerages turn bullish after upbeat Q1 ** Vertiv Holdings VRT.N: up 2.9% BUZZ-Vertiv Holdings rises on Q3 revenue beat The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Technology stocks pushed Wall Street indexes sharply higher on Wednesday as an early vote count pointed to a close race for the White House, although investors remained worried about the prospect of a contested result. New Article Adds shares, FDA staff comment Nov 4 (Reuters) - Biogen Inc's BIIB.O experimental Alzheimer's disease drug was found effective enough in a large trial to support approval, U.S. Food and Drug Administration staff said on Wednesday, potentially making it the first drug to be approved in decades to slow down the progress of the memory robbing disease. The FDA staff's comments that come ahead of a meeting of a panel of independent advisers to the health regulator on Friday sent shares of the company soaring 30%. Biogen said it changed plans after a new analysis of the two studies showed a high dose of the drug could slow the disease's progression. New Article In trading on Wednesday, the First Trust NYSE Arca Biotechnology Index Fund ETF is outperforming other ETFs, up about 6.4% on the day. Among components of that ETF with the weakest showing on Wednesday were shares of M&T Bank, lower by about 8.7%, and shares of ZION, lower by about 8.5% on the day. VIDEO: Wednesday's ETF Movers: FBT, KRE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article When one political party controls both the White House and both chambers of the U.S. Congress, the prospects of major changes that could negatively impact drugmakers tend to be greater. Whether Biden or Donald Trump ultimately prevail in the presidential contest, it could be challenging for either person to move forward with their agenda without winning some level of bipartisan support. Now what What really matters going forward for AstraZeneca, Bristol Myers Squibb, and Lilly is how well their existing products perform and whether or not their key pipeline candidates succeed in clinical testing. New Article Combined, BIIB and LLY make up approximately 4.0% of the underlying holdings of XLV. Within that group, Biogen Inc (Symbol: BIIB) and Lilly (Eli) & Co (Symbol: LLY) are two large stocks leading the way, showing a gain of 44.6% and 15.1%, respectively. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. New Article Click to EnlargeSource: Chart courtesy of StockCharts.com Biogen (NASDAQ:BIIB) shares ripped higher on Wednesday, climbing more than 40% at one point in the session. 1: Biogen (BIIB) More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next 1,000% Winner Radical New Battery Could Dismantle Oil Markets Revolutionary Tech Behind 5G Rollout Is Being Pioneered By This 1 Company Daily Picks: Stocks to Buy Ahead of the Election The post 4 Top Stock Trades for Thursday: BIIB, PTON, GM, WEN appeared first on InvestorPlace. New Article The five best-performing S&P stocks today were all in the healthcare industry, with Biogen (NASDAQ: BIIB) leading the way, up 44% on news about a potentially breakthrough drug. While Democrats could gain some seats in the Senate, and the odds at this writing favor former Vice President Joe Biden to win the White House, it's looking very unlikely the party will come out of elections with a commanding majority that it would need to accomplish its full legislative agenda, including healthcare regulations that could be bad for insurer's profits. For tech stocks, the basic idea is this: Further economic stimulus may not happen quickly, and it may not be as generous as a Democrat-controlled federal government would have delivered. New Article KBLM.O, down 16.6% ** Advanced Micro Devices AMD.O: up 5.8% BUZZ-Goldman upgrades to 'Conviction List', cites ""compelling"" opportunity ** Biogen BIIB.O: up 40.3% BUZZ-Soars as Alzheimer's drug approval chances improve ** Lockheed Martin LMT.N: up 4.7% ** Raytheon Technologies RTX.N: up 1.3% ** Northrop Grumman NOC.N: up 5.3% ** Boeing Co BA.N: flat ** General Dynamics GD.N: up 2.4% BUZZ-U.S. defense stocks gain as Republicans seen retaining control of the Senate ** KKR & Co Inc KKR.N: up 6.6% ** Blackstone Group Inc BX.N: up 6.8% ** BlackRock Inc BLK.N: up 4.2% ** Apollo Global Management Inc APO.N: up 5.3% BUZZ-U.S. PE firms gain on prospect of Republicans retaining Senate control ** Kandi Tech KNDI.O: up 16.0% BUZZ-Jumps on regulatory clearance for two electric-vehicle models ** Trade Desk TTD.O: up 9.1% BUZZ-Rises as brokerages hike PTs ahead of result ** Zebra Tech ZBRA.O: up 2.8% BUZZ-Needham turns bullish on upbeat quarterly earnings, outlook ** Geo Group GEO.N: down 12.0% ** CoreCivic Inc CXW.N: down 16.7% BUZZ-U.S. prison operators reverse course to slump as Biden leads key states ** Allogene Therapeutics ALLO.O: down 12.6% BUZZ-Drops on bigger Q3 loss ** Vulcan Materials VMC.N: down 5.9% ** Martin Marietta Materials MLM.N: down 6.0% ** Jacobs Engineering J.N: down 4.0% BUZZ-Construction stocks hammered as U.S. election still undecided ** Clearwater Paper CLW.N: down 12.9% BUZZ-Set for worst day in over 7 months on softer Q4 outlook ** PulteGroup Inc PHM.N: up 7.2% ** Tri Pointe TPH.N: up 5.2% ** D.R. Horton Inc DHI.N: up 7.0% ** Toll Brothers Inc TOL.N: up 5.3% BUZZ-U.S. homebuilders gain as Treasury yields drop after early vote count ** Corsair Gaming CRSR.O: up 6.5% BUZZ-Rises as brokerage hikes PT before Q3 results ** LogicBio LOGC.O: up 2.1% BUZZ-Rises as rare metabolism disorder therapy gets FDA fast track tag ** Wendy's WEN.O: down 4.0% BUZZ-Wendy's: Drops on quarterly revenue miss ** Prudential Financial PRU.N: down 2.8% BUZZ-Prudential Financial: MS hikes PT on upbeat Q3 results ** Kura Oncology KURA.O : down 0.5% BUZZ-Slips on safety concerns in leukemia treatment trial ** Alibaba BABA.N: up 4.0% BUZZ-Remains top internet mega-cap pick ** Digirad Corp DRAD.O: up 18.7% BUZZ-Digirad gains on sale of mobile healthcare unit ** Coca-Cola Consolidated COKE.O: up 2.4% BUZZ-Jumps on strong Q3 results ** Supernus Pharma SUPN.O: up 18.0% BUZZ-Jumps as seizure medication drives strong Q3 results ** Tabula Rasa HealthCare TRHC.O: down 17.1% BUZZ-Tabula Rasa HealthCare down on revenue fall ** Mercury Systems MRCY.O: down 5.2% BUZZ-Slips on lower Q1 profit as expenses rise ** Park Ohio Holdings Corp PKOH.O: up 2.0% BUZZ-Jumps on Q3 beat ** Nabors Industries Ltd NBR.N: up 2.1% BUZZ-Slips after Q3 revenue misses estimates ** Barrick Gold GOLD.N: down 1.3% ** AngloGold AU.N: down 2.1% ** Agnico Eagle Mines AEM.N: down 3.1% BUZZ-Gold miners fall as dollar gains on tight White House race ** Enphase ENPH.O: down 0.1% ** Sunpower SPWR.O: down 4.8% ** First Solar FSLR.O: down 6.6% ** Solaredge SEDG.O: down 0.5% BUZZ-U.S. solar energy stocks slide with presidential election too close to call ** Uber Technologies Inc UBER.N: up 11.8% ** Lyft Inc LYFT.O: up 8.6% BUZZ-Jumps after winning bid to keep California drivers as contractors ** Chevron Corp CVX.N: up 2.0% ** Exxon Mobil Corp XOM.N: up 1.7% ** Occidental Petroleum OXY.N: up 2.3% BUZZ-Oil stocks up as crude rises after Trump falsely claims victory in U.S. election ** UnitedHealth UNH.N: up 11.6% ** CVS Health Corp CVS.N: up 3.2% ** Anthem ANTM.N: up 12.3% BUZZ-Health insurers rise amid ongoing tight U.S. election race ** Apple Inc AAPL.O: up 4.2% ** Amazon.com Inc AMZN.O: up 5.8% ** Alphabet Inc GOOGL.O: up 6.2% ** Netflix Inc NFLX.O: up 2.7% BUZZ-Big Tech jumps amid tightening White House race ** Roku ROKU.O: up 4.5% BUZZ-Rises as brokerage raises PT ahead of Q3 results ** Pfizer PFE.N: up 4.6% ** Merck & Co MRK.N: up 7.0% ** Biogen BIIB.O: up 40.3% BUZZ-Big pharma rises as U.S. presidential race tightens ** Super Micro Computer SMCI.O: up 20.9% BUZZ-Up on earnings beat for Q1 ** Vertiv Holdings VRT.N: up 2.4% BUZZ-Vertiv Holdings rises on Q3 revenue beat The 11 major S&P 500 sectors: Communication Services The top three S&P 500 .PG.INX percentage gainers: ** Biogen Inc BIIB.O, up 40.3% ** Eli Lilly LLY.N, up 15.4% ** Cigna Corp CI.N, up 13.8% The top three S&P 500 .PL.INX percentage losers: ** Comerica CMA.N, down 9.1% ** Zions Bancorp ZION.O, down 8.9% ** M&T Bank MTB.N, down 8.2% The top NYSE .PG.N percentage gainers: ** Xpeng Inc XPEV.N, up 19.4% ** Eli Lilly LLY.N, up 15.4% ** Cigna Corp CI.N, up 13.8% The top NYSE .PL.N percentage losers: ** Corecivic Inc CXW.N, down 16.7% ** Clearwater CLW.N, down 13% ** Contura Energy, down 12.1% The top three Nasdaq .PG.O percentage gainers: ** Biogen BIIB.O, up 40.3% ** Athira Pharma ATHA.O, up 36.8% ** Cassava Sciences SAVA.O, up 33.1% The top three Nasdaq .PL.O percentage losers: ** Repro Med Systems KRMD.O, down 26.9% ** Tabula Rasa HealthCare TRHC.O, down 17.1% ** KBL Merger Corp. IV.",297.8302917480469
2020-11-05 00:00:00+00:00,348.0,348.0,321.5,328.8999938964844,328.8999938964844,5070300.0,2.857142857142857,1.0,0.4643107142857143,"Pharmaceutical firm Eisai 4523.T jumped 17.91% to hit its daily limit after the company and its partner Biogen Inc BIIB.O moved closer to receiving the U.S. FDA's nod for their Alzheimer drug. TOKYO, Nov 5 (Reuters) - Japanese shares ended at a more than two-year high on Thursday, buoyed by overnight Wall Street gains, while focus remained on final tally for the U.S. presidential election after several state results gave a narrow lead to Democrat Joe Biden and a likelihood of divided Congress. Analysts said stocks were supported by overnight Wall Street gains as the likelihood of gridlock in Congress made investors optimistic that major policy changes would be difficult to enact. New Article BIIB data by YCharts The company stopped a pair of phase III clinical trials in early 2019 when it appeared the drug wasn't helping patients. It's finally time for the Food and Drug Administration's committee of outside experts to decide on aducanumab, Biogen's (NASDAQ: BIIB) controversial drug for Alzheimer's disease. The opinion is split The FDA's summary concludes that Study 302 -- the positive one at the high dose -- is ""robust and exceptionally persuasive on several of the instruments used to evaluate efficacy."" New Article In recent trading, shares of Biogen Inc (Symbol: BIIB) have crossed above the average analyst 12-month target price of $291.21, changing hands for $355.63/share. But the whole reason to look at the average BIIB price target in the first place is to tap into a ""wisdom of crowds"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with BIIB crossing above that average target price of $291.21/share, investors in BIIB have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $291.21 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? New Article VIDEO: Nasdaq 100 Movers: BIIB, QCOM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing Nasdaq 100 component thus far on the day is Biogen, trading down 6.4%. Biogen is showing a gain of 12.1% looking at the year to date performance. New Article And underperforming other ETFs today is the First Trust NYSE Arca Biotechnology Index Fund ETF, down about 0.1% in Thursday afternoon trading. Among components of that ETF with the weakest showing on Thursday were shares of Bluebird Bio, lower by about 13.4%, and shares of Biogen, lower by about 8.2% on the day. VIDEO: Thursday's ETF Movers: TAN, FBT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks jumped on Thursday as bets on Republicans retaining control of the Senate eased worries of major policy changes that could hurt corporate America under a Joe Biden White House, even as the presidential election hung in balance. The top three S&P 500 .PG.INX percentage gainers: ** Qualcomm Inc , up 13.1% ** Albemarle Corp , up 11.6% ** Parker-Hannifin Corp , up 10.1% The top three S&P 500 .PL.INX percentage losers: ** Hanesbrands , down 20.3% ** Biogen Inc , down 8.3% ** Incyte Corp , down 5.8% The top three NYSE .PG.N percentage gainers: ** Resideo Technologies , up 35.3% ** Aurora Cannabis , up 32.8% ** Sandridge Energy , up 29.4% The top three NYSE .PL.N percentage losers: ** Hanesbrands , down 20.3% ** Ping Idenity Holding , down 17% ** Direxion Daily Junior Gold Miners , down 15.1% The top three Nasdaq .PG.O percentage gainers: ** Altus Midstream , up 140.2 % ** Hall of Fame Resort & Entertainment Co , up 123.6 % ** Oncternal Therapeutics Inc , up 81.5 % The top three Nasdaq .PL.O percentage losers: ** Clovis Oncology , down 21.3 % ** Amyris Inc , down 17.9 % ** Lendingtree Inc , down 17.1 % ** Mastercard Inc MA.N : up 2.2% ** Visa Inc V.N : up 1.8% BUZZ-U.S. card firms: Rise as investors turn to defensive stocks ** Tilray Inc TLRY.O : up 26.7% ** Aurora Cannabis ACB.N : up 32.8% ** Canopy Growth CGC.N : up 11.5% ** Cronos CRON.O : up 14.5% ** Sundial Growers SNDL.O: up 13.4% BUZZ-Pot stocks fly high as Biden inches closer to White House ** Aphria Inc APHA.O : up 11.0% BUZZ-Cannabis producer Aphria gains on deal to buy beer maker SweetWater ** Barrick ABX.TO : up 6.8% BUZZ-Rises on upbeat Q3, dividend hike ** Canopy Growth CGC.N : up 11.5% BUZZ-Rises on launch of CBD beverage line ** General Motors GM.N : up 1.9% BUZZ-Jumps as rebound in truck, SUV sales drives Q3 beat ** Qualcomm Inc QCOM.O : up 13.1% BUZZ-Jumps as brokerages raise PTs on strong Q1 forecast ** Match Group Inc MTCH.O : up 4.9% BUZZ-Set to open at record high as Tinder drives Q3 beat ** Expedia EXPE.O : up 3.8% BUZZ-Gains on smaller-than-expected Q3 loss ** Qualcomm Inc QCOM.O : up 13.1% ** Apple Inc AAPL.O : up 2.3% BUZZ-Street View: 5G to provide blazing fast growth for Qualcomm ** Intercontinental Exchange ICE.N : up 2.4% BUZZ-Rises as Thoma Bravo cashes out ** Bluebird Bio BLUE.O : down 14.8% BUZZ-Analysts concerned over delay in sickle cell disease therapy application ** Expedia Group Inc EXPE.O: up 3.8% BUZZ-up as brokerages turn bullish after smaller-than-expected Q3 loss ** Inogen Inc INGN.O : down 14.8% ** JPMorgan Chase JPM.N : up 3.9% BUZZ-COVID-19 will continue to affect Inogen in the near term-JPM ** Ping Identity Holding PING.N : down 17.0% BUZZ-slumps on weak Q4 subscription guide ** Electronic Arts EA.O : up 1.9% BUZZ-Rises as co extends deals with UFC, NHL ** Cardinal Health CAH.N : up 5.9% BUZZ-Rises on Q1 rev beat; Baird sees COVID-19 headwinds falling ** Nikola NKLA.O : up 4.1% BUZZ-Set for best day in nearly a month ** Hall of Fame Resort HOFV.O : up 123.6% BUZZ-Spikes on Sports Illustrated Studios media deal ** Resideo Tech REZI.N : up 35.3% BUZZ-Jumps most on record on strong Q4 forecast ** Hanesbrands Inc HBI.N : down 20.3% BUZZ-Down as pandemic hits Q3 sales ** Dominion Energy D.N : up 0.5% BUZZ-Up on profit beat, outlook ** Qorvo Inc QRVO.O : up 7.6% BUZZ-Surges as brokerages hike PTs after strong Q2 result ** New York Times NYT.N : down 3.9% BUZZ-Down after warning of easing growth ** LendingTree Inc TREE.O : down 17.1% BUZZ-Falls on lower Q3 revenue and profit ** Huntington Ingalls HII.N : up 3.5% BUZZ-Military shipbuilder Huntington Ingalls rises after results beat The 11 major S&P 500 sectors: Communication Services up 0.98% (Reporting by Lasya Priya M in Bengaluru) ((LasyaPriya.M@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Doctor surveys have indicated a third of the 2.2 million Americans with mild dementia could be on a new drug within three years, Cowen analysts note. Assume annual sales at just a third of that level and put them on a multiple of five, a rule of thumb valuation metric for the industry, and Biogen's drug may be worth $60 billion or more. The agencys calculus may be simple: Alzheimers is awful, patients lack therapies and the side effects appear mild, so setting a lower bar might make sense.",289.4447937011719
2020-11-06 00:00:00+00:00,328.8999938964844,328.8999938964844,328.8999938964844,328.8999938964844,328.8999938964844,600.0,3.0,1.0,0.5000249999999999,"Nov 6 (Reuters) - A meeting of outside advisers to the U.S. Food and Drug Administration convened on Friday to discuss whether to recommend approval of Biogen Inc's BIIB.O experimental Alzheimer's disease drug aducanumab. The agency is expected to make its decision by March, with aducanumab poised to become the first new treatment for the disease in decades and the first that appears to be able to slow progression of the fatal, mind-wasting condition, should it win U.S. approval. Alzheimer's disease is the sixth leading cause of death in the United States and there is ""a profound and enormous unmet medical need"" for new treatments, Billy Dunn, director of neurology products for the FDA's Center for Drug Evaluation and Research, said during the meeting. New Article After a long day of the Food and Drug Administration and Biogen (NASDAQ: BIIB) arguing that Biogen's Alzheimer's disease drug, aducanumab, should be approved, the FDA's committee of outside experts pushed back and voted strongly against the drug. After a closer look at the data, Biogen concluded that the higher dose of the drug was helping patients, and the leadership at the FDA seemed convinced as well. The third question asked about the drug's pharmacodynamics, which basically means whether aducanumab was doing what it was supposed to do: remove amyloid beta plaques from patient's brains. New Article By Deena Beasley and Manojna Maddipatla Nov 6 (Reuters) - Most outside advisers to the U.S. Food and Drug Administration voted ""no"" to whether a successful trial of Biogen Inc's BIIB.O experimental Alzheimer's drug can be viewed as evidence that it is effective without regard for a second, failed study. The data from the successful trial - detailed by Biogen and the FDA at the meeting - ""doesn't add up to strong evidence,"" said committee member Dr. Aaron Kesselheim, associate professor at Harvard Medical School. Alzheimer's disease is the sixth leading cause of death in the United States and there is ""a profound and enormous unmet medical need"" for new treatments, Billy Dunn, director of neurology products for the FDA's Center for Drug Evaluation and Research, said during the meeting. New Article By Deena Beasley and Manojna Maddipatla Nov 6 (Reuters) - A panel of outside advisers to the U.S. Food and Drug Administration on Friday voted that one of two large studies on Biogen Inc's BIIB.O experimental Alzheimer's disease drug cannot be viewed alone without regard for the other failed trial. Alzheimer's disease is the sixth leading cause of death in the United States and there is ""a profound and enormous unmet medical need"" for new treatments, Billy Dunn, director of neurology products for the FDA's Center for Drug Evaluation and Research, said during the meeting. Biogen in October last year revived its plans to seek approval for aducanumab, months after it had said that an independent futility analysis of its two pivotal trials showed they were unlikely to succeed. New Article Eisai 4523.T was up 3.7% on expectations that the company and its partner Biogen Inc BIIB.O moved closer to receiving the U.S. FDA's nod for their Alzheimer drug. TOKYO, Nov 6 (Reuters) - Japan's Nikkei index on Friday ended at its highest level in 29 years, tracking strong moves in global equities, as investors hoped a gridlock in U.S. Congress during a possible Joe Biden presidency would be able to stall major policy changes. Investors are anticipating a Joe Biden victory and the Republicans retaining control of the Senate, allowing the latter to block the Democrats' agenda such as corporate tax hikes and massive borrowing for large spending.",299.3198547363281
2020-11-09 00:00:00+00:00,230.82000732421875,239.5,223.25,236.259994506836,236.259994506836,9252600.0,3.5,1.0,0.625025,"What happened Biotech heavyweight Biogen (NASDAQ: BIIB) saw its shares sink by as much as 32% in pre-market trading Monday. The biotech's stock is under serious pressure today following a negative advisory committee vote for its experimental Alzheimer's disease drug aducanumab last Friday. So what Biogen's braintrust, for reasons that aren't altogether clear, apparently had high hopes for aducanumab ahead of this advisory committee meeting. New Article But another drugmaker Biogen Inc BIIB.O slumped 28.2% as a panel of experts to the U.S. health regulator voted against the drugmaker's experimental Alzheimer's treatment. By Sinad Carew NEW YORK, Nov 9 (Reuters) - The S&P 500 and the Dow rallied sharply but closed shy of their records on Monday as investors bet that a full economic reopening was finally in sight following the first positive data from a late-stage COVID-19 vaccine trial. With a 14% advance the S&P energy index .SPNY led gainers among the S&P 500's 11 major sectors and registered its biggest daily percentage gain since March as investors bet demand would climb again when people become more comfortable with the idea of traveling as the health crisis subsides. New Article Eisai 4523.T dived 23.6% after a panel to the U.S. health regulator voted that a potential Alzheimer's treatment from the firm and Biogen Inc BIIB.O has not been proven to slow progression of the disease. By Hideyuki Sano TOKYO, Nov 9 (Reuters) - Japan's Nikkei share average on Monday reached a high last seen almost three decades ago, after Joe Biden clinched the U.S. presidency, with Honda Motors 7267.T leading gains among carmakers on strong earnings figures. Investors, who had held off purchases last week due to U.S. political uncertainty, rushed to buy as they focused on Biden's ability to expand fiscal stimulus and measures to reduce the spread of COVID-19. New Article Biogen Inc BIIB.O slumped about 30% as a panel of experts to the U.S. health regulator voted against the drugmaker experiment Alzheimer's treatment. By Medha Singh and Shivani Kumaresan Nov 9 (Reuters) - The S&P 500 and the Dow hit record highs on Monday as the first successful data from a late-stage COVID-19 vaccine trial spurred hopes of the economy recovering quickly from a year of pandemic-driven crisis. ""This (news) is extremely important and should give the market confidence that Pfizer's candidate offers a breakthrough in terms of reaching herd immunity at some point next year,"" said Robin Winkler, strategist at Deutsche Bank Research. New Article Combined, BIIB and BIO make up approximately 1.2% of the underlying holdings of XLV. Among large Healthcare stocks, Biogen Inc (Symbol: BIIB) and Bio-Rad Laboratories Inc (Symbol: BIO) are the most notable, showing a loss of 28.2% and 7.9%, respectively. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Monday. New Article While Pfizer shares were higher on the news, the overall healthcare sector .SPXHC was underperforming the broader S&P 500, in large part due to a sharp decline in Biogen BIIB.O after a U.S. Food and Drug Administration panel voted against its Alzheimers treatment. By Chuck Mikolajczak NEW YORK, Nov 9 (Reuters) - Shares of stocks that have been demolished as the coronavirus and related lockdowns have crippled the global economy surged on Monday following positive news from Pfizer PFE.N and its German partner BioNTech 22UAy.DE about is experimental COVID-19 vaccine. If Pfizer's vaccine is as good as people are saying it is that's a game changer for consumer behavior and a lot of the trends we've seen of the cyclical sectors being depressed are going to reverse on that hope that this is the beginning of the end of our dealing with COVID-19,"" said Chris Zaccarelli, Chief Investment Officer, Independent Advisor Alliance, Charlotte, North Carolina. New Article The top three NYSE percentage gainers premarket .PRPG.NQ: ** Amc Entertat Hld , up 59.0% ** Penn Real Est , up 41.4% ** Carnival Plc Adr , up 35.4% The top three NYSE percentage losers premarket .PRPL.NQ: ** Highpoint Resrcs , down 29.3% ** Fiverr Intrntltd , down 11% ** Wayfair Inc , down 10.2% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Sundial Growers Inc , up 136.0% ** Aptevo Therapeutics Inc , up 95.1% ** Company name not found , up 50.7% The top three Nasdaq percentage losers premarket .PRPL.O: ** Monocle Acquisition , down 40% ** Biogen Inc , down 28.9% ** Company name not found , down 23.5% ** McDonald's MCD.N: up 5.1% premarket BUZZ-PREVIEW: Seen posting 10% earnings drop ** New York Times NYT.N: up 4.3% premarket BUZZ-Evercore ISI upgrades on subscriber growth expectations ** Sundial Growers Inc SNDL.O: up 136.0% premarket ** Canopy Growth Corp CGC.N: up 8.2% premarket ** Aphria Inc APHA.O: up 11.8% premarket ** Cronos Group CRON.O: up 13.4% premarket ** Aurora Cannabis Inc ACB.N: up 22.0% premarket ** Tilray Inc TLRY.O: up 16.4% premarket BUZZ-Pot stocks high on Biden election win ** Array Technologies ARRY.O: down 0.7% premarket BUZZ-JPM, CS start coverage eyeing solar market growth ** MSCI Turkey ETF TUR.O: up 8.3% premarket BUZZ-Jumps as country's finance minister resigns ** Biogen BIIB.O: down 28.9% premarket BUZZ-Street View: Approval of Biogen's Alzheimer's drug no longer a slam dunk ** F5 Networks FFIV.O: up 9.8% premarket BUZZ-Up on report of Elliott's stake ** Pfizer PFE.N: up 11.9% premarket BUZZ-Jumps after company says its COVID-19 vaccine is more than 90% effective ** JPMorgan Chase & Co JPM.N: up 8.0% premarket ** Morgan Stanley MS.N: up 6.6% premarket ** Wells Fargo WFC.N: up 7.9% premarket ** Citigroup C.N: up 8.2% premarket BUZZ-U.S. banks track market gains as Pfizer says vaccine effective (Compiled by Shreyasee Raj in Bangalore) ((Shreyasee.Raj@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Futures tracking the S&P 500 hit a record high on Monday after U.S. drugmaker Pfizer said its experimental vaccine was more than 90% effective in preventing COVID-19 based on initial data from a large study. .N At 7:55 ET, Dow e-minis 1YMc1 were up 5.21% at 29,674. New Article But another drugmaker Biogen Inc BIIB.O slumped 28.2% as a panel of experts to the U.S. health regulator voted against the drugmaker's experimental Alzheimer's treatment. By Sinad Carew NEW YORK, Nov 9 (Reuters) - The S&P 500 and the Dow rallied sharply but closed shy of their records on Monday as investors bet that a full economic reopening was finally in sight following the first positive data from a late-stage COVID-19 vaccine trial. With a 14% advance the S&P energy index .SPNY led gainers among the S&P 500's 11 major sectors and registered its biggest daily percentage gain since March as investors bet demand would climb again when people become more comfortable with the idea of traveling as the health crisis subsides. New Article Biogen Inc BIIB.O slumped about 30% as a panel of experts to the U.S. health regulator voted against the drugmaker experiment Alzheimer's treatment. By Medha Singh and Shivani Kumaresan Nov 9 (Reuters) - Wall Street's main indexes hit record highs on Monday as the first successful data from a late-stage COVID-19 vaccine trial spurred hopes of the economy recovering quickly from a year of pandemic-driven crisis. World stocks scaled a record high earlier in the day and the dollar remained weak as expectations of better global trade ties and more monetary stimulus under President-elect Biden lifted demand for risky assets. New Article MKTS/GLOB Biogen Inc BIIB.O slumped about 27.7% as a panel of experts to the U.S. health regulator voted against the drugmaker experiment Alzheimer's treatment. By Sinad Carew NEW YORK, Nov 9 (Reuters) - Wall Street's three major indexes hit record highs on Monday as the first positive data from a late-stage COVID-19 vaccine trial prompted hopes that an economic recovery from the pandemic-driven crisis was finally in sight. Oil prices surged more than 8% and pushed up energy stocks while U.S. Treasuries sold off after U.S. drugmaker Pfizer PFE.N and its German partner BioNTech BNTX.O said a large-scale trial of their vaccine showed it was more than 90% effective in preventing COVID-19. New Article But another drugmaker Biogen Inc BIIB.O slumped as a panel of experts to the U.S. health regulator voted against the drugmaker's experimental Alzheimer's treatment. By Sinad Carew NEW YORK, Nov 9 (Reuters) - The S&P 500 ended higher but closed just shy of a record on Monday as investors bet that a full economic reopening was finally in sight following the first positive data from a late-stage COVID-19 vaccine trial. The S&P energy index .SPNY led gainers among the S&P 500's 11 major sectors and registered its biggest daily percentage gain in months as investors bet demand would climb again when people become more comfortable with the idea of traveling as the health crisis subsides. New Article VIDEO: S&P 500 Movers: BIIB, KIM The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Monday, shares of Kimco Realty topped the list of the day's best performing components of the S&P 500 index, trading up 33.4%. And the worst performing S&P 500 component thus far on the day is Biogen, trading down 30.9%. New Article The top three NYSE percentage gainers premarket .PRPG.NQ: ** Amc Entertat Hld , up 83.1% ** Ashford Hosptlty , up 41.0% ** Cinemark Hldgs , up 40.4% The top three NYSE percentage losers premarket .PRPL.NQ: ** Highpoint Resrcs , down 23.4% ** Duff & Plp Mdstm , down 17.1% ** Nautilus Inc , down 13.6% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Sundial Growers Inc , up 128.0% ** Aptevo Therapeutics Inc , up 112.0% ** Company name not found , up 54.5% The top three Nasdaq percentage losers premarket .PRPL.O: ** Monocle Acquisition , down 43.6% ** Quidel Corp , down 32.3% ** Biogen Inc , down 28.2% ** New York Times NYT.N: up 1.4% premarket BUZZ-Evercore ISI upgrades on subscriber growth expectations ** Sundial Growers Inc SNDL.O: up 128.0% premarket ** Canopy Growth Corp CGC.N: up 12.0% premarket ** Aphria Inc APHA.O: up 15.3% premarket ** Cronos Group CRON.O: up 14.0% premarket ** Aurora Cannabis Inc ACB.N: up 30.6% premarket ** Tilray Inc TLRY.O: up 20.5% premarket BUZZ-Pot stocks high on Biden election win ** Array Technologies ARRY.O: down 4.0% premarket BUZZ-JPM, CS start coverage eyeing solar market growth ** MSCI Turkey ETF TUR.O: up 8.8% premarket BUZZ-Jumps as country's finance minister resigns ** Biogen BIIB.O: down 28.2% premarket BUZZ-Street View: Approval of Biogen's Alzheimer's drug no longer a slam dunk ** F5 Networks FFIV.O: up 14.3% premarket BUZZ-Up on report of Elliott's stake ** Pfizer PFE.N: up 16.1% premarket BUZZ-Jumps after company says its COVID-19 vaccine is more than 90% effective ** JPMorgan Chase & Co JPM.N: up 9.1% premarket ** Morgan Stanley MS.N: up 7.2% premarket ** Wells Fargo WFC.N: up 8.4% premarket ** Citigroup C.N: up 8.8% premarket BUZZ-U.S. banks track market gains as Pfizer says vaccine effective ** TrueCar TRUE.O: up 8.4% premarket BUZZ-Rises after brokerage upgrades to 'market outperform' ** Pfizer PFE.N: up 16.1% premarket ** BioNTech BNTX.O: up 27.2% premarket BUZZ-Rise as COVID-19 vaccine shown effective in large study ** Mastercard Inc MA.N: up 8.5% premarket ** Visa Inc V.N: up 6.9% premarket ** American Express Co AXP.N: up 19.0% premarket BUZZ-U.S. card firms jump on vaccine cheer ** Fisker Inc FSR.N: up 7.3% premarket BUZZ-Rises as Cowen initiates with 'outperform' ** CVS Health Corp CVS.N: up 2.1% premarket BUZZ-Street View: CVS Health's long-term story seems intact ** KKR & Co Inc KKR.N: up 4.9% premarket ** Blackstone Group Inc BX.N: up 2.8% premarket ** BlackRock Inc BLK.N: up 4.3% premarket ** Apollo Global Management Inc APO.N: up 4.4% premarket BuZZ-U.S. private equity firms rise as Pfizer says vaccine effective ** Calliditas Therapeutics CALT.O: up 50.0% premarket BUZZ-Soars on positive data for its kidney disease treatment ** American Airlines AAL.O: up 23.8% premarket ** Hilton Worldwide HLT.N: up 15.3% premarket ** Carnival Corp CCL.N: up 31.0% premarket ** MGM Resorts International MGM.N: up 15.3% premarket BUZZ-U.S. airlines, travel stocks soar after Pfizer's COVID-19 vaccine more than 90% effective (Reporting by Shreyasee Raj in Bangalore) ((Shreyasee.Raj@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock prices surged on Monday as news of the first successful late stage COVID-19 vaccine trials stirred hopes of the economy emerging from a year of pandemic-driven crisis. .N At 8:29 ET, Dow e-minis 1YMc1 were up 5.57% at 29,776. New Article Nov 9 (Reuters) - Biogen Inc's BIIB.O shares slumped about 30% on Monday as the drugmaker's chances of getting a regulatory approval for its experiment Alzheimer's treatment suffered a blow after a panel of experts to the U.S. Food and Drug Administration voted against the medicine. ""Approving aducanumab, in the face of such an overwhelmingly negative vote and commentary, is virtually impossible and would destroy the agency's reputation at a very tenuous time for the regulator, ahead of potential actions on COVID vaccines,"" Baird analyst Brian Skorney said. If approved, aducanumab would become the first new treatment for Alzheimer's in decades and the first that appears to be able to slow progression of the fatal, mind-wasting condition, potentially bringing in billions of dollars in sales for Biogen.",310.4812927246094
2020-11-11 00:00:00+00:00,239.8000030517578,249.44000244140625,238.0800018310547,244.02999877929688,244.02999877929688,2332100.0,2.6666666666666665,1.0,0.4166916666666666,"Particularly high volume was seen for the $240 strike put option expiring November 20, 2020, with 7,056 contracts trading so far today, representing approximately 705,600 underlying shares of BIIB. Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Biogen Inc (Symbol: BIIB), where a total volume of 27,499 contracts has been traded thus far today, a contract volume which is representative of approximately 2.7 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 108.1% of BIIB's average daily trading volume over the past month, of 2.5 million shares. New Article A regulatory filing with the Securities and Exchange Commission in February revealed that Berkshire had bought more than 648,000 shares of Biogen (NASDAQ: BIIB). However, Biogen announced in October of last year that it planned to file for FDA approval based on a new analysis of late-stage clinical studies evaluating aducanumab. Baird analyst Brian Skorney wrote to investors, ""Approving aducanumab, in the face of such an overwhelmingly negative vote and commentary, is virtually impossible and would destroy the agency's reputation at a very tenuous time for the regulator, ahead of potential actions on COVID-19 vaccines."" New Article The Nightstar deal did bring in the late-stage asset BIIB111 (timrepigene emparvovec) as a possible treatment for a rare, degenerative, X-linked inherited retinal disorder known as choroideremia. Biogen (NASDAQ: BIIB) might be in deep trouble. The biotech's core multiple sclerosis franchise has been hit hard by generic competition this year, and its plan to recoup these lost sales with newer medicines like Vumerity simply isn't working.",308.4412841796875
2020-11-12 00:00:00+00:00,244.7100067138672,246.7400054931641,240.7100067138672,241.5500030517578,241.5500030517578,1586800.0,3.5,1.0,0.6250249999999999,"Shares in Biogen (NASDAQ: BIIB) were up 44% on Wednesday, Nov. 4, to a high of $359.95 after a U.S. Food and Drug Administration (FDA) clinical review signaled that the biotech's phase 3 study on aducanumab showed the drug's effectiveness in slowing the progression of Alzheimer's disease. The companies ended two studies early in March 2019 when the drug didn't seem to work, then reversed that decision in October 2019, saying that later results showed aducanumab was effective in high doses. Biogen says aducanumab is a monoclonal antibody that binds to aggregates of amyloid plaques in the brain; by reducing the size and number of these ""tangles,"" it could slow the progression of Alzheimer's disease. New Article Core earnings before special items in 2020 will likely be between 5.05 billion euro ($5.94 billion) and 5.25 billion euros, The German group said in a statement on Thursday, also citing the release of provisions worth 365 million after winning a legal dispute with Biogen BIIB.O. By Ludwig Burger FRANKFURT, Nov 12 (Reuters) - Healthcare and chemicals group Merck KGaA MRCG.DE lifted its guidance for full year earnings after the scramble to ready treatments and vaccines against the coronavirus bolstered demand for its supplies for biotech labs. In the third quarter, adjusted core profit for the group, or earnings before interest, taxes, depreciation and amortisation (EBITDA), jumped more than 50% to 1.7 billion euros, beating the average estimate of 1.6 billion in an analyst poll posted on its website.",316.5697937011719
2020-11-18 00:00:00+00:00,248.8099975585937,251.509994506836,240.7700042724609,240.97999572753903,240.97999572753903,1829100.0,3.0,1.0,0.5000249999999999,"Particularly high volume was seen for the $330 strike call option expiring December 18, 2020, with 1,417 contracts trading so far today, representing approximately 141,700 underlying shares of BIIB. Below is a chart showing AAN's trailing twelve month trading history, with the $70 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 12,917 contracts, representing approximately 1.3 million underlying shares or approximately 47.5% of BIIB's average daily trading volume over the past month, of 2.7 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $330 strike highlighted in orange: And Verint Systems, Inc (Symbol: VRNT) options are showing a volume of 1,662 contracts thus far today. New Article For two of them, it is working in partnership with Takeda (NYSE: TAK); for the other, it teamed up with Biogen (NASDAQ: BIIB), the beleaguered company that has garnered headlines for its on-again, off-again Alzheimer's candidate aducanumab. This month, Cassava released data from a phase 2b trial of sumifilam; the study tested two dose levels, and participants taking both showed significant improvements on both metrics. For investors, Denali shares could prove the best of both worlds, offering the potential upside of an Alzheimer's breakthrough with the safety of a big pharma partner shouldering much of the financial burden of its development.",311.6526184082031
2020-11-19 00:00:00+00:00,241.4199981689453,245.5500030517578,240.5,244.009994506836,244.009994506836,1222000.0,3.0,1.0,0.5000249999999999,"However, there are a couple of attractive stocks that are trading at relatively cheap prices right now, including Biogen (NASDAQ: BIIB) and Facebook (NASDAQ: FB). Biogen claimed that there was sufficient positive data from its earlier studies to warrant seeking official approval from the U.S. Food and Drug Administration (FDA). Since the optimism surrounding aducanumab appears to be more muted, there's not a lot of hype built into the stock price, which trades at 8.2 times earnings. New Article The top three NYSE percentage gainers premarket .PRPG.NQ: ** Phoenix New Media Limited FENG.K, up 56.5% ** StarTek Inc , up 21.8% ** L Brands Inc , up 16.2% The top three NYSE percentage losers premarket .PRPL.NQ: ** Tidewater Inc , down 40.3% ** X Financial , down 33.6% ** Snap-On Inc , down 8.3% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Trident Acquisitions Corp TDACW.O, up 114.7% ** Forum Merger III Corp FIIIW.O, up 100.0% ** Big Rock Partners Acquisition Corp BRPAR.O, up 37.4% The top three Nasdaq percentage losers premarket .PRPL.O: ** Ebang International Holdings Inc EBON.O, down 18.4% ** BIO-key International, Inc BKYI.O, down 17.3% ** Monocle Acquisition Corp , down 14.4% ** L Brands Inc LB.N: up 16.2% premarket BUZZ-L Brands: Blowout Q3 pushes shares to near three-year high ** NVIDIA Corp NVDA.O: down 1.5% premarket BUZZ-Nvidia falls as it expects decline in Q4 data center sales ** Aptevo Therapeutics Inc APVO.O: up 32.7% premarket BUZZ-Aptevo Therapeutics: Surges on buyout bid from Tang Capital Partners LP ** ReneSola Ltd SOL.N: up 5.9% premarket BUZZ-ReneSola: Rises on deal to co-develop solar projects in the UK ** Biogen Inc BIIB.O: up 1.2% premarket BUZZ-Biogen's pipeline could drive growth if Alzheimer's drug not approved ** RedHill Biopharma Ltd RDHL.O: up 10.1% premarket BUZZ-RedHill Biopharma: Up on safety panel nod to continue COVID-19 treatment study ** Macy's Inc M.N: down 4.5% premarket BUZZ-Macy's: Falls as weak sales outlook overshadows Q3 beat ** CIIG Merger Corp CIIC.O: up 15.2% premarket BUZZ-CIIG Merger Corp leaps after big jump on EV SPAC deal ** Nasdaq Inc NDAQ.O: down 1.8% premarket BUZZ-Nasdaq: Set for near 2-month low on Verafin acquisition plans ** GoPro Inc GPRO.O: down 5.6% premarket BUZZ-GoPro drops after co launches $100 mln convertible debt deal ** Corcept Therapeutics CORT.O: up 20.6% premarket BUZZ-Corcept: Rises on patent lawsuit win for hormone disorder drug, PT raise ** Forum Merger III Corp FIII.O: up 7.6% premarket BUZZ-Forum Merger III: Jumps on report of EV deal ** Bilibili Inc BILI.O: up 4.6% premarket BUZZ-Bilibili Inc rises on strong Q4 revenue forecast ** Transocean Ltd RIG.N: up 4.1% premarket BUZZ-Transocean: Rises on deepwater contract extensions in Brazil ** Sonos Inc SONO.O: up 17.6% premarket BUZZ-Sonos Inc: Rises after strong Q4 results; brokerages raise PTs (Compiled by Chavi Mehta) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes were set to slip on Thursday as soaring COVID-19 cases and an unexpected rise in weekly jobless claims raised fears of stalling growth in the world's largest economy. .N At 9:06 ET, Dow e-minis 1YMc1 were down 0.18% at 29,337.",311.3091735839844
2020-11-20 00:00:00+00:00,243.8699951171875,246.47999572753903,243.0,244.1499938964844,244.1499938964844,1334800.0,3.0,1.0,0.5000249999999999,"SPDR MFS Systematic Value Equity ETF SYV $65.78 $72.23 9.80% QTS Realty Trust Inc QTS $62.49 $76.08 21.75% Citigroup Inc C $52.14 $62.73 20.31% Biogen Inc BIIB $244.01 $293.15 20.14% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of SYV's underlying holdings with notable upside to their analyst target prices are QTS Realty Trust Inc (Symbol: QTS), Citigroup Inc (Symbol: C), and Biogen Inc (Symbol: BIIB). Similarly, C has 20.31% upside from the recent share price of $52.14 if the average analyst target price of $62.73/share is reached, and analysts on average are expecting BIIB to reach a target price of $293.15/share, which is 20.14% above the recent price of $244.01.",312.5994873046875
2020-11-27 00:00:00+00:00,242.0,244.3300018310547,241.0,243.77999877929688,243.77999877929688,699200.0,4.0,1.0,0.7500249999999999,"Adds details on agreement, background Nov 27 (Reuters) - Biogen Inc BIIB.O will take a $650 million stake in Sage Therapeutics SAGE.O and pay $875 million in upfront payment as they jointly develop and sell treatments for neurological disorder, the two companies said on Friday. The companies will collaborate on two drugs for neurological disorders - zuranolone and SAGE-324 - in the United States. (Reporting by Mrinalika Roy in Bengaluru; Editing by Arun Koyyur) ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article (RTTNews) - Biogen Inc. (BIIB) and Sage Therapeutics, Inc. (SAGE) said Friday they have entered into a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders, and SAGE-324 for essential tremor and other neurological disorders. Biogen and Sage will share responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside the U.S., Biogen will be responsible for development and commercialization, excluding Japan, Taiwan and South Korea with respect to zuranolone, and will pay Sage tiered royalties in the high teens to low twenties. Biogen noted that if approved, zuranolone would also be highly complementary to several of its own therapeutic areas of focus, including multiple sclerosis (MS), Alzheimer's disease (AD), spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD).",312.9853820800781
2020-11-30 00:00:00+00:00,243.4600067138672,244.19000244140625,239.5599975585937,240.1699981689453,240.1699981689453,2193500.0,3.0,1.0,0.5000249999999999,"The top three S&P 500 .PG.INX percentage gainers: ** IHS Markit Ltd , up 9.2% ** S&P Global Inc , up 3.1% ** Pfizer Inc , up 2.7% The top three S&P 500 .PL.INX percentage losers: ** HollyFrontier Corp , down 5.6% ** American Airlines , down 5% ** Carnival Corp , down 4.8% The top two NYSE .PG.N percentage gainers: ** Navios Maritime , up 37.3% ** FlexShares STOXX , up 24.1% The top three NYSE .PL.N percentage losers: ** Hyliion Holdings Corp , down 17.9% ** Mogu Inc , down 17.2% ** Jumia Technologies AG , down 15.7% The top three Nasdaq .PG.O percentage gainers: ** China Automotive , up 60.3% ** AquaBounty Technologies , up 39.9% ** Trident Acquisitions Corp , up 33.3% The top three Nasdaq .PL.O percentage losers: ** Francesca's Holdings , down 26.1% ** Nikola Corp , down 25.6% ** Yunji Inc , down 17.3% ** Moderna MRNA.O: up 14.7% BUZZ-Jumps on emergency authorization plans for COVID-19 vaccine ** Canaan Inc CAN.O: down 9.4% BUZZ-Falls on lower Q3 revenue, net loss ** SuperCom SPCB.O: up 51.2% BUZZ-Nearly doubles on new contract ** China Customer Relations Centers CCRC.O: up 3.0% BUZZ-Rises on go-private offer ** China Automotive Systems Inc CAAS.O: up 60.3% BUZZ-Up on strong forecast for power steering products ** CNOOC CEO.N: down 15.4% BUZZ-Drops after Reuters reports Trump to add co to defense blacklist ** Sage Therapeutics SAGE.O: down 9.5% ** Biogen Inc BIIB.O: down 1.1% BUZZ-Timing of Sage-Biogen deal raises questions ** Nikola NKLA.O: down 25.6% BUZZ-Nikola slumps as General Motors ditches proposed equity stake ** Sunesis Pharma SNSS.O: up 22.0% BUZZ-Rises on merger agreement with Viracta Therapeutics ** GrubHub GRUB.N: up 0.7% BUZZ-DoorDash launches up to $2.8 bln IPO; Airbnb in the wings ** Francesca's Holdings FRAN.O: down 26.1% BUZZ-Slides as media report says bankruptcy filing likely ** Fang Holdings Ltd SFUN.N: up 9.9% BUZZ-Rises on takeover offer from General Atlantic ** Northern Genesis Acquisition NGA.N: up 4.6% BUZZ- Up on deal to take Lion Electric public ** Sundial Growers SNDL.O: up 36.0% BUZZ-Gains as co cuts some debt ** Equillium EQ.O: down 1.0% BUZZ-H.C.Wainwright says co's decision on COVID-19 trial ""premature"" ** Exxon Mobil Corp XOM.N: down 3.2% ** Chevron Corp CVX.N: down 2.0% ** Halliburton HAL.N: down 1.3% ** Baker Hughes BKR.N: down 0.9% ** SM Energy SM.N: down 3.9% ** Murphy Oil MUR.N: down 5.7% ** Marathon Petroleum MPC.N: down 2.9% BUZZ-Oil stocks fall as OPEC+ members debate 2021 output policy ** Kadmon KDMN.N: up 4.1% BUZZ-Up after FDA accepts application for drug to treat immune condition ** CDK Global CDK.O: up 6.2% BUZZ-Up on $1.45 bln deal to sell international unit ** Synchrony Financial SYF.N: up 0.3% BUZZ-MS sees U.S. big banks firing on all cylinders in 2021 ** Slack Technologies WORK.N: up 4.1% BUZZ-Slack jumps as nears Salesforce deal - report ** Collectors Universe CLCT.O: up 3.3% BUZZ-Up on buyout offer from Nat Turner-led investor group ** Hookipa Pharma HOOK.O: up 6.8% BUZZ-Surges as vaccine for organ transplant patients shows promise in study ** Zscaler ZS.O: up 1.2% BUZZ-Zscaler gains as brokerages hike PT ahead of Q1 results ** Newmont Corp NEM.N: down 1.4% ** Barrick Gold Corp GOLD.N: down 0.7% ** Kinross Gold Corp KGC.N: down 1.8% ** AngloGold Ashanti AU.N: down 0.9% ** Harmony Gold HMY.N: down 2.2% ** Gold Fields GFI.N: down 2.2% BUZZ-Gold stocks inch lower as bullion drops on vaccine-led economic recovery bets ** Mogu Inc MOGU.N: down 17.2% BUZZ-Slumps after lower revenue The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes dipped on Monday as investors paused to take stock of a stellar month ahead of crucial economic reports this week. down 0.54% (Compiled by Shreyasee Raj) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stock index futures dipped on Monday as investors paused ahead of crucial economic indicators later this week to take stock of what was set to be a record-setting month for the benchmark S&P 500. .N At 7:45 ET, Dow e-minis 1YMc1 were down 0.35% at 29,768. The top three NYSE percentage gainers premarket .PRPG.NQ: ** Northern Genesis Acquisition Corp NGA.N, up 21.0% ** Navios Maritime NM.N, up 20.7% ** Genworth Financial GNW.N, up 16.1% The top three NYSE percentage losers premarket .PRPL.NQ: ** CNOOC Ltd CEO.N, down 12.7% ** Arlington Asset Investment Corp AAIC.N, down 10.2% ** Borr Drilling Ltd BORR.N, down 9.6% The top three Nasdaq percentage gainers premarket .PRPG.O: ** Supercom Ltd SPCB.O, up 104.5% ** AGBA Acquisition Equity Warrants AGBAW.O, up 57.9% ** US Well Services Equity Warrants USWSW.O, up 52.9% The top three Nasdaq percentage losers premarket .PRPL.O: ** Francesca's Holdings Corp FRAN.O, down 33.3% ** Scworx Corp WORX.O, down 11.3% ** SGOCO Group Ltd SGOC.O, down 11.1% ** Tesla TSLA.O: up 3.0% premarket BUZZ-Tesla eyes fifth straight session of gains ** IHS Markit INFO.N: up 4.5% premarket BUZZ-IHS Markit rises on $44 bln deal with S&P Global [nL4N2IG2YC ** Costco COST.O: up 0.5% premarket BUZZ-Telsey sees strong November sales, raises PT ** Sage Therapeutics SAGE.O: up 2.4% premarket BUZZ-Timing of Sage-Biogen deal raises questions ** Novavax NVAX.O: down 7.9% premarket BUZZ-Falls on second delay to U.S. COVID-19 vaccine trial ** Moderna MRNA.O: up 11.3% premarket BUZZ-Jumps on emergency authorization plans for COVID-19 vaccine ** CrowdStrike CRWD.O: up 2.2% premarket BUZZ-Up as Needham raises PT, expects strong Q3 results ** Canaan Inc CAN.O: down 7.3% premarket BUZZ-Falls on lower Q3 revenue, net loss (Compiled by Shreyasee Raj) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article The top three NYSE percentage gainers premarket .PRPG.NQ: ** Ternium SA TX.N, up 38.7% ** Navios Maritime NM.N, up 29.0% ** Northern Genesis Acquisition Corp NGA.N, up 23.1% The top three NYSE percentage losers premarket .PRPL.NQ: ** Rev Group Inc REVG.N, down 29.4% ** California Resources Corp CRC.N, down 20% ** CNOOC Ltd CEO.n, down 11.2% The top three Nasdaq percentage gainers premarket .PRPG.O: ** China Automotive Systems Inc CAAS.O, up 88.8% ** Supercom Ltd SPCB.O, up 78.8% ** US Well Services Equity Warrants USWSW.O, up 52.9% The top three Nasdaq percentage losers premarket .PRPL.O: ** Francesca's Holdings Corp FRAN.O, down 34.5% ** Intersect Ent Inc XENT.O, down 28% ** Nikola Corporation NKLA.O, down 17.7% ** Tesla TSLA.O: up 2.7% premarket BUZZ-Tesla eyes fifth straight session of gains ** IHS Markit INFO.N: up 6.5% premarket BUZZ-IHS Markit rises on $44 bln deal with S&P Global [nL4N2IG2YC ** Costco COST.O: up 0.8% premarket BUZZ-Telsey sees strong November sales, raises PT ** Sage Therapeutics SAGE.O: up 0.4% premarket ** Biogen Inc BIIB.O: down 0.2% premarket BUZZ-Timing of Sage-Biogen deal raises questions ** Novavax NVAX.O: down 6.5% premarket BUZZ-Falls on second delay to U.S. COVID-19 vaccine trial ** Moderna MRNA.O: up 13.2% premarket BUZZ-Jumps on emergency authorization plans for COVID-19 vaccine ** CrowdStrike CRWD.O: up 2.8% premarket BUZZ-Up as Needham raises PT, expects strong Q3 results ** SuperCom SPCB.O: up 78.8% premarket BUZZ-Nearly doubles on new contract ** Applied DNA APDN.O: up 1.5% premarket BUZZ-Applied DNA up on nod to test COVID-19 vaccine candidate in cats ** Moderna Inc MRNA.O: up 13.2% premarket BUZZ-Moderna jumps on plans to seek emergency use of COVID-19 vaccine ** Methanex Corp MEOH.O: down 1.1% premarket BUZZ-Bernstein downgrades on dim methanol price outlook ** NetApp NTAP.O: up 0.5% premarket BUZZ-Evercore hikes PT ahead of Q1 results ** China Automotive Systems Inc CAAS.O: up 88.8% premarket BUZZ-Up on strong forecast for power steering products ** CNOOC CEO.N: down 11.2% premarket BUZZ-Drops after Reuters reports Trump to add co to defense blacklist ** Plug Power PLUG.o: up 3.0% premarket BUZZ-Gains on partnership with Gaussin ** Nikola NKLA.O: down 17.7% premarket BUZZ-Falls as General Motors ditches proposed equity stake ** Sunesis Pharma SNSS.O: up 35.3% premarket BUZZ-Rises on merger agreement with Viracta Therapeutics ** GrubHub GRUB.N: up 1.8% premarket BUZZ-DoorDash launches up to $2.8 bln IPO; Airbnb in the wings (Compiled by Shreyasee Raj) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 was set to open lower on Monday as investors paused to take stock of what was set to be the benchmark index's best November ever. .N At 8:56 ET, Dow e-minis 1YMc1 were down 0.47% at 29,735.",309.5858459472656
2020-12-03 00:00:00+00:00,248.3800048828125,249.2100067138672,243.1999969482422,244.08999633789065,244.08999633789065,897100.0,3.0,1.0,0.5000249999999999,"If the markets correct then the bottom is not yet in for these three either: Boston Scientific (NYSE:BSX) Amgen (NASDAQ:AMGN) Biogen (NASDAQ:BIIB) Biotech Stocks to Buy: Boston Scientific (BSX) Source: Charts by TradingView BSX stock lost almost half of its value when the pandemic hit. Biogen (BIIB) Source: Charts by TradingView BIIB stock is the cheapest of the three today by far. For the last seven years, BIIB stock has been ping-ponging inside a horizontal range between $220 and the highs. New Article Biogen (NASDAQ: BIIB), Fastly (NYSE: FSLY), and Gamestop (NYSE: GME) are three stocks that have been largely shunned by the investment world due to significant woes in their operations. Adding insult to injury, the company also lost a litigation battle that resulted in the invalidation of its U.S. patents protecting Tecfidera, a multiple sclerosis drug. Even assuming Biogen loses half of its earnings in the future due to the loss of Tecfidera's exclusivity in the U.S., the stock still trades for about 14 times free cash flow.",310.4136047363281
2020-12-04 00:00:00+00:00,244.8600006103516,248.9600067138672,244.1000061035156,245.8699951171875,245.8699951171875,961300.0,3.0,1.0,0.5000249999999999,"The top three S&P 500 .PG.INX percentage gainers: ** Diamondback Energy Inc , up 10.2% ** Occidental Petroleum Corp , up 9.3% ** Phillips 66 , up 6.5% The top three S&P 500 .PL.INX percentage losers: ** Royal Carribean Cruises Ltd , down 4.1% ** Ulta Beauty Inc , down 3.4% ** L Brands Inc , down 2.5% The top three NYSE .PG.N percentage gainers: ** Star Peak Energy Transition Corp , up 35.7% ** Callon Petroleum Co , up 23% ** PagerDuty Inc , up 20.8% The top three NYSE .PL.N percentage losers: ** MicroSectors US Big Oil Index , down 17.1% ** Yext Inc , down 16% ** Direxion Daily , down 13.1% The top three Nasdaq .PG.O percentage gainers: ** China HGS Real Estate Inc , up 158.5% ** Collective Growth Equity Warrants , up 134.3% ** Pioneer Power Solutions Inc , up 51% The top three Nasdaq .PL.O percentage losers: ** Ondas Holdings Inc , down 50.2% ** Lizhi Inc , down 18% ** Precision BioSciences Inc , down 17.3% ** DocuSign DOCU.O: up 7.7% BUZZ-Rises on upbeat Q3 results, outlook ** PagerDuty PD.N: up 20.8% BUZZ-Surges on upbeat annual forecast ** Sutro Biopharma STRO.O: up 33.8% BUZZ-Up on positive data from early-stage cancer trial ** BioCryst BCRX.O: up 16.2% BUZZ-Jumps after FDA approves swelling disorder treatment ** Cloudera Inc CLDR.N: up 8.9% BUZZ-Rises on upbeat results, $500 mln share buyback plan ** EQT EQT.N: up 5.7% ** Cabot Oil & Gas COG.N: up 1.1% BUZZ-Evercore recommends shifting to EQT Corp vs Cabot Oil among natgas equities ** Sage Therapeutics SAGE.O: up 3.8% ** Biogen Inc BIIB.O: up 1.0% BUZZ-Rises as Mizuho upgrades to 'buy' on Biogen deal ** GameStop GME.N: up 4.8% BUZZ-Rises as Wedbush hikes PT on new console launches ** Alibaba BABA.N: up 0.2% ** Sea SE.N: up 8.9% BUZZ-Up on winning digital banking license from Singapore ** Cambium Networks CMBM.O: down 14.4% BUZZ-Dips as top holder trims stake ** Yext Inc YEXT.N: down 16.0% BUZZ-Slumps as Q4 sales outlook disappoints ** Cooper COO.N: down 0.3% BUZZ-Slightly better Q4 but COVID-19 uncertainties remain ** American Airlines AAL.O: up 1.1% ** Spirit Airlines SAVE.N: up 1.7% BUZZ-U.S. airlines rise as stimulus hopes build ** Ulta Beauty ULTA.O: down 3.4% BUZZ-Down as holiday-quarter same-store sales view disappoints ** Domo Inc DOMO.O: up 14.9% BUZZ-Jumps on strong Q3 results ** Ollie's Bargain Outlet OLLI.O: down 9.8% BUZZ-Falls as brokerages cut PTs ** Luminar LAZR.O: up 34.1% BUZZ-Gleams after impressive debut ** Carvana CVNA.N: up 3.1% BUZZ-Rises as Jefferies starts with 'buy' on market share potential ** Tilly's TLYS.N: down 12.8% BUZZ-Down as retailer sees lower holiday-quarter sales, profit ** Dish Network DISH.O: down 0.6% BUZZ-Down as Guggenheim downgrades to 'neutral' ** Mind Technology Inc MIND.O: up 7.1% BUZZ-Surges on Q3 revenue beat ** Sundial Growers SNDL.O: down 7.9% BUZZ-Falls on filing new shelf registration for up to $200 mln ** Huazhu Group Ltd HTHT.O: down 1.4% BUZZ-Falls on surprise Q3 loss ** Magenta Therapeutics MGTA.O: up 2.2% BUZZ-Rises on collaboration for sickle cell disease therapy ** Cimarex Energy XEC.N: up 3.7% BUZZ-Gains on announcement of quarterly dividend ** Eli Lilly LLY.N: up 2.7% BUZZ-Rises on partnering with UnitedHealth for COVID-19 antibody trial ** Meten EdtechX Education METX.O: down 10.7% BUZZ-Falls on lower Q3 revenue, loss ** Oshkosh OSK.N: up 3.6% ** Federal Signal FSS.N: up 5.9% ** Terex Corp TEX.N: up 2.1% BUZZ-KeyBanc upgrades, shares gain ** Pioneer Power Solutions PPSI.O: up 51.0% BUZZ-Surges after settlement with Myers Power ** Stitch Fix SFIX.O: down 3.0% BUZZ-Stock move ""too far too fast"" - MKM Partners ** Boeing BA.N: down 1.3% BUZZ-Down after cutting widebody production rate again ** Burning Rock Biotech BNR.O: down 4.0% BUZZ-Falls on $58 mln discounted secondary offering The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh The S&P 500 jumped to an all-time high on Friday as data showing the slowest jobs growth in six months reinforced expectations for a new fiscal stimulus bill to help revive the economy from its worst downturn in decades. up 0.03% (Compiled by Shreyasee Raj) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article The top three S&P 500 .PG.INX percentage gainers: ** Diamondback Energy Inc , up 10.3% ** Occidental Petroleum Corp , up 7.7% ** TechnipFMC PLC , up 7.4% The top three S&P 500 .PL.INX percentage losers: ** Sempra Energy , down 3% ** Ulta Beauty Inc , down 2.7% ** Boeing Co , down 2.5% The top three NYSE .PG.N percentage gainers: ** Star Peak Energy Transition Corp , up 44.2% ** Pagerduty Inc , up 24.7% ** Concord Medical Services , up 24.6% The top three NYSE .PL.N percentage losers: ** MicroSectors US Big Oil Index , down 17.6% ** Yext Inc , down 15.6% ** Tillys Inc , down 13% The top three Nasdaq .PG.O percentage gainers: ** Collective Growth Equity Warrants , up 147.6% ** China HGS Real Estate Inc , up 126.1% ** Luminar Technologies Equity Warrant , up 58.6% The top three Nasdaq .PL.O percentage losers: ** Ondas Holdings Inc , down 50.8% ** Ever-Glory International Group Inc , down 21.1% ** Kaixin Auto Holdings , down 19.1% ** DocuSign DOCU.O: up 6.3% BUZZ-Rises on upbeat Q3 results, outlook ** PagerDuty PD.N: up 24.7% BUZZ-Surges on upbeat annual forecast ** Sutro Biopharma STRO.O: up 35.4% BUZZ-Up on positive data from early-stage cancer trial ** BioCryst BCRX.O: up 14.3% BUZZ-Jumps after FDA approves swelling disorder treatment ** Cloudera Inc CLDR.N: up 9% BUZZ-Rises on upbeat results, $500 mln share buyback plan ** EQT EQT.N: up 4.4% BUZZ-Evercore recommends shifting to EQT Corp vs Cabot Oil among natgas equities ** Sage Therapeutics SAGE.O: up 1.1% ** Biogen Inc BIIB.O: up 0.9% BUZZ-Rises as Mizuho upgrades to 'buy' on Biogen deal ** GameStop GME.N: up 6.7% BUZZ-Rises as Wedbush hikes PT on new console launches ** Alibaba BABA.N: up 0.1% ** Sea SE.N: up 9.1% BUZZ-Up on winning digital banking license from Singapore ** Genesco Inc GCO.N: up 3.4% BUZZ-Rises on Q3 revenue, profit beat ** Cambium Networks CMBM.O: down 13.3% BUZZ-Dips as top holder trims stake ** Yext Inc YEXT.N: down 15.6% BUZZ-Slumps as Q4 sales outlook disappoints ** Cooper COO.N: up 0.6% BUZZ-Slightly better Q4 but COVID-19 uncertainties remain ** American Airlines AAL.O: up 1.7% ** Spirit Airlines SAVE.N: up 3.8% BUZZ-U.S. airlines rise as stimulus hopes build ** Ulta Beauty ULTA.O: down 2.8% BUZZ-Down as holiday-quarter same-store sales view disappoints ** Domo Inc DOMO.O: up 19.0% BUZZ-Jumps on strong Q3 results ** Ollie's Bargain Outlet OLLI.O: down 9.4% BUZZ-Falls as brokerages cut PTs ** Luminar LAZR.O: up 37.6% BUZZ-Gleams after impressive debut ** Carvana CVNA.N: up 4.5% BUZZ-Rises as Jefferies starts with 'buy' on market share potential ** Tilly's TLYS.N: down 13.0% BUZZ-Down as retailer sees lower holiday-quarter sales, profit ** Dish Network DISH.O: down 1.6% BUZZ-Down as Guggenheim downgrades to 'neutral' ** Mind Technology Inc MIND.O: up 2.0% BUZZ-Surges on Q3 revenue beat ** Sundial Growers SNDL.O: down 1.6% BUZZ-Falls on filing new shelf registration for up to $200 mln ** Huazhu Group Ltd HTHT.O: down 0.8% BUZZ-Falls on surprise Q3 loss ** Magenta Therapeutics MGTA.O: up 3.1% BUZZ-Rises on collaboration for sickle cell disease therapy ** Cimarex Energy XEC.N: up 3.7% BUZZ-Gains on announcement of quarterly dividend ** Eli Lilly LLY.N: up 2.8% BUZZ-Rises on partnering with UnitedHealth for COVID-19 antibody trial ** Meten EdtechX Education METX.O: down 10.1% BUZZ-Falls on lower Q3 revenue, loss ** Oshkosh OSK.N: up 3.2% ** Federal Signal FSS.N: up 6.3% ** Terex Corp TEX.N: up 3.3% BUZZ-KeyBanc upgrades, shares gain ** Pioneer Power Solutions PPSI.O: up 49.8% BUZZ-Surges after settlement with Myers Power ** Stitch Fix SFIX.O: down 3.5% BUZZ-Stock move ""too far too fast"" - MKM Partners ** Boeing BA.N: down 2.5% BUZZ-Down after cutting widebody production rate again ** Burning Rock Biotech BNR.O: down 4.0% BUZZ-Falls on $58 mln discounted secondary offering ** Activision Blizzard ATVI.O: up 2.1% BUZZ-Rises as ""Call of Duty"" tops $3 bln in net bookings ** Nutrien NTR.N: up 2.7% BUZZ-Climbs as CFRA upgrades on bullish U.S. agriculture outlook ** Sigilon Therapeutics SGTX.O: up 32.8% BUZZ-Jumps more than 22% in Nasdaq debut ** JPMorgan Chase & Co JPM.N: up 0.7% ** Bank of America BAC.N: up 0.8% ** Wells Fargo WFC.N: up 1.1% ** Goldman Sachs GS.N: up 1.4% ** Morgan Stanley MS.N: up 1.3% BUZZ-U.S. big banks rise on stimulus hopes ** Exxon Mobil Corp XOM.N: up 2.4% ** Chevron Corp CVX.N: up 2.6% ** Diamondback Energy FANG.O: up 10.3% ** Halliburton Co HAL.N: up 6.0% ** Baker Hughes BKR.N: up 4.4% ** Phillips 66 PSX.N: up 5.6% BUZZ-Oil stocks gain on OPEC+ supply compromise ** QCR Holdings QCRH.O: up 1.7% BUZZ-Gains as brokerage raises PT on growth outlook The 11 major S&P 500 sectors: Communication Services Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh Wall Street's main indexes jumped to all-time highs on Friday as data showing the slowest jobs growth in six months reinforced investors expectations for a new fiscal stimulus bill to help revive the economy from its worst downturn in decades. down 0.92% (Compiled by Shreyasee Raj) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Especially high volume was seen for the $400 strike call option expiring March 19, 2021, with 802 contracts trading so far today, representing approximately 80,200 underlying shares of BIIB. Below is a chart showing HAL's trailing twelve month trading history, with the $20 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 8,996 contracts, representing approximately 899,600 underlying shares or approximately 44.1% of BIIB's average daily trading volume over the past month, of 2.0 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $400 strike highlighted in orange: And MicroStrategy Inc. (Symbol: MSTR) saw options trading volume of 1,774 contracts, representing approximately 177,400 underlying shares or approximately 43.2% of MSTR's average daily trading volume over the past month, of 410,660 shares.",308.27777099609375
2020-12-08 00:00:00+00:00,244.6300048828125,246.8800048828125,243.52999877929688,246.42999267578125,246.42999267578125,1228400.0,3.0,1.0,0.5000249999999999,"GLP-1s, or Glucagon-like peptide-1s, are drugs used for type 2 diabetes patients that both control blood sugar and have been shown to improve heart health, kidney function, and even aid weight loss. NVO data by YCharts One of the most important metrics Since the turn of the century, management has steadily increased its return on invested capital (ROIC) -- net income minus the dividend, divided by the total debt plus equity. The ability to shift from insulin to GPT-1 drugs as competition heated up also shows the company is not a one-drug wonder, desperately clinging to the profits of a single franchise. New Article We must also consider the practicalities of delivering the vaccine during a pandemic, with distancing and other restrictions, as well as the vaccines storage and delivery requirements. 7 Cheap Stocks to Buy Before the Market Realizes their Worth With that information, here are 7 coronavirus vaccine stocks still in the race: AstraZeneca (NYSE:AZN) Biogen (NASDAQ:BIIB) BioNTech (NASDAQ:BNTX) GlaxoSmithKline (NYSE:GSK) Moderna (NASDAQ:MRNA) Pfizer (NYSE:PFE) Sanofi (NASDAQ:SNY) The World Health Organization (WHO) releases regular updates on COVID-19 candidate vaccines. Market participants should expect volatility in the days ahead as vaccine news headlines ebb and flow. Biogen (BIIB) 52-Week range: $223.25  $374.99 YTD change: Down 18.22% Dividend yield: N/A Cambridge, Massachusetts-based Biogen develops therapies for a range of diseases. BIIBs forward P/E and P/S ratios are 9.50 and 2.84, respectively.",308.3153076171875
2020-12-09 00:00:00+00:00,248.0,249.4499969482422,242.83999633789065,244.75,244.75,1364600.0,4.0,1.0,0.7500249999999999,"Two drug companies that have made brain science their mission -- Biogen (NASDAQ: BIIB) and Sage Therapeutics (NASDAQ: SAGE) -- announced on Nov. 27 that they've teamed up to advance a potential treatment for depression. BIIB data by YCharts What's Biogen getting out of it? Zuranolone is being developed to help people with MDD and postpartum depression and SAGE-324 is under investigation to treat essential tremor -- rhythmic shaking caused by a disorder of the nervous system. New Article TOKYO, Dec 10 (Reuters) - Biogen BIIB.O said on Thursday it filed for regulatory approval in Japan for an Alzheimer's disease drug it developed with local partner Eisai Co. Eisai's shares surged in Tokyo trading. U.S.-based Biogen and Eisai have jointly developed three experimental drugs for Alzheimer's, which affects millions around the world and has not seen a new treatment in decades. Biogen in October 2019 revived approval plans for aducanumab months after an analysis of its two pivotal trials showed the drug was unlikely to succeed.",306.3927307128906
2020-12-10 00:00:00+00:00,247.4499969482422,247.4499969482422,242.0,242.97999572753903,242.97999572753903,1276400.0,4.0,1.0,0.7500249999999999,"Biogen (BIIB) said that the New Drug Application (J-NDA) for aducanumab was submitted to the countrys Ministry of Health, Labor and Welfare (MHLW), and is now under regulatory review in Japan, Europe and the US. This does beg the question as to the read-through to aducanumab. (See BIIB stock analysis on TipRanks) Thats difficult to say given the wildcard that asset has been to date, but were still skeptical, the analyst added. Japan is the third market where we have applied for regulatory approval for aducanumab, and the filing represents continued progress on our commitment to bring this therapy to patients around the world, said Biogen CEO Michel Vounatsos.",305.0694885253906
2020-12-15 00:00:00+00:00,246.4900054931641,249.77999877929688,244.0399932861328,248.72999572753903,248.72999572753903,1231500.0,3.0,1.0,0.5000249999999999,"Biogen The third Buffett stock to avoid like the plague is blue chip biotech Biogen (NASDAQ: BIIB). Part of Kraft Heinz's transformation strategy involves netting $2 billion in gross productivity efficiencies by 2024 to offset inflation and cash needed for other important investments. Biogen is valued at less than 10 times Wall Street's earnings per share consensus for 2021, and it's on track to generate at least $5.3 billion in free cash flow for a third consecutive year in 2020.",291.2500305175781
2020-12-17 00:00:00+00:00,247.1600036621093,251.6100006103516,245.6699981689453,250.2400054931641,250.2400054931641,1279000.0,2.333333333333333,1.0,0.3333583333333332,"Biogen (NASDAQ: BIIB) had a wild 2020. After two court rulings this summer, generics are hitting the market and eroding the $3.3 billion in annual sales of the company's flagship drug Tecfidera. The competition caused Biogen management to cut full-year 2020 sales and earnings forecasts in October, but they've been making deals to fill the hole. New Article BOSTON, Dec 17 (Reuters) - Biogen Inc BIIB.O has agreed to pay $22 million to resolve U.S. allegations that it illegally used two charities that help cover Medicare patients' out-of-pocket drug costs as a means to pay them kickbacks to use its multiple sclerosis drugs. The deal, announced by the U.S. Justice Department on Thursday, was the latest to result from an industry-wide probe of drugmakers' financial support of patient assistance charities that has resulted in more than $1 billion in settlements. (Reporting by Nate Raymond in Boston) ((Nate.Raymond@thomsonreuters.com and Twitter @nateraymond; 347-243-6917; Reuters Messaging: nate.raymond.thomsonreuters.com@reuters.net)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article By Nate Raymond BOSTON, Dec 17 (Reuters) - Biogen Inc BIIB.O has agreed to pay $22 million to resolve U.S. allegations that it illegally used two charities that help cover Medicare patients' out-of-pocket drug costs as a means to pay them kickbacks to use its multiple sclerosis drugs. A specialty pharmacy that performed services for the Cambridge, Massachusetts-based company, Advanced Care Scripts, has also agreed to pay $1.4 million to resolve allegations it conspired to help Biogen use the charities as conduits. But the government has alleged that various pharmaceutical companies including Biogen used such charities as means to improperly pay the co-pay obligations of Medicare patients using their drugs, in violation of the Anti-Kickback Statute.",304.53021240234375
2020-12-18 00:00:00+00:00,251.77999877929688,254.0,248.5,249.6199951171875,249.6199951171875,3455400.0,2.0,1.0,0.250025,"Biogen (NASDAQ: BIIB) is a large-cap biotech that has witnessed significant volatility this year, with over 40% price swings in both directions. There is a lot at stake for Biogen, as the company is facing a substantial revenue decline of its already-marketed therapies and is having trouble finding ways to make up those lost sales. A declining business Biogen encountered a major setback when last month, after a panel of experts at the U.S. Food and Drug Administration voted unanimously that aducanumab failed to demonstrate efficacy in a key late-stage study.",294.2691345214844
2020-12-21 00:00:00+00:00,246.75,249.0,242.58999633789065,248.32000732421875,248.32000732421875,1279800.0,3.5,1.0,0.6250249999999999,"(RTTNews) - Biogen Inc. (BIIB) said that the European Commission has approved a new intramuscular or IM injection route of administration for Plegridy or peginterferon beta-1a for the treatment of relapsing-remitting multiple sclerosis or MS. Bioequivalence between the two dosing regimens was confirmed and data show that participants receiving PLEGRIDY through IM administration experienced fewer injection site reactions in comparison to participants receiving SC administration. The company said that the approval adds to its broad MS portfolio which includes the subcutaneous injection of PLEGRIDY. New Article We believe that Biogen stock (NASDAQ: BIIB), a biotechnology company focused on treatments for neurological diseases, is a good buying opportunity at the present time. BIIB stock trades near $250 currently and it is, in fact, down 27% from its pre-Covid high of around $340 in February 2020  just before the coronavirus pandemic hit the world. BIIB stock has had a volatile ride the past few months.",300.64117431640625
2020-12-24 00:00:00+00:00,250.2700042724609,251.1999969482422,247.509994506836,248.88999938964844,248.88999938964844,459500.0,2.5,1.0,0.375025,"Biogen (NASDAQ: BIIB) aducanumab Alzheimer's disease 3/7/2021 bluebird bio (NASDAQ: BLUE) ide-cel Multiple myeloma 3/27/2021 Targeted Therapeutics (NASDAQ: TGTX) umbralisib Marginal zone lymphoma 2/15/2021 PDUFA: Prescription drug user fee act. If a well-heeled pharmaceutical company like Bristol Myers Squibb stumbles over an unforeseen manufacturing issue, investors could get nervous about smaller biotechs trying to develop their own complex treatments. Earlier this month, TG Therapeutics began a rolling submission for its next new drug candidate, ublituximab plus umbralisib (U2), as a combination treatment for the most common form of leukemia. New Article Below is a twelve month price history chart comparing the stock performance of BMRN, ALNY, and BIIB: Combined, BMRN, ALNY, and BIIB represent 11.32% of the Biotech ETF. Three of BBH's underlying holdings with notable upside to their analyst target prices are BioMarin Pharmaceutical Inc (Symbol: BMRN), Alnylam Pharmaceuticals Inc (Symbol: ALNY), and Biogen Inc (Symbol: BIIB). Similarly, ALNY has 18.78% upside from the recent share price of $138.62 if the average analyst target price of $164.65/share is reached, and analysts on average are expecting BIIB to reach a target price of $293.52/share, which is 16.85% above the recent price of $251.20.",312.7922058105469
2020-12-28 00:00:00+00:00,248.47999572753903,249.1100006103516,243.02999877929688,244.1499938964844,244.1499938964844,1234200.0,3.0,1.0,0.5000249999999999,"That number works out to 46.5% of BIIB's average daily trading volume over the past month, of 1.3 million shares. Particularly high volume was seen for the $400 strike call option expiring January 15, 2021, with 1,802 contracts trading so far today, representing approximately 180,200 underlying shares of BIIB. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Biogen Inc (Symbol: BIIB), where a total volume of 5,966 contracts has been traded thus far today, a contract volume which is representative of approximately 596,600 underlying shares (given that every 1 contract represents 100 underlying shares).",311.94464111328125
2021-01-04 00:00:00+00:00,245.7400054931641,246.3999938964844,238.3999938964844,242.9499969482422,242.9499969482422,1563400.0,2.0,1.0,0.250025,"Biogen It'd also be a smart move for investors to avoid biotech blue chip Biogen (NASDAQ: BIIB) in 2021. Even though software-as-a-service (SaaS) stocks have been given a pass on their bottom lines by Wall Street, Snowflake simply isn't growing fast enough to support an $80 billion market cap. The coronavirus disease 2019 (COVID-19) pandemic forced people to eat at home more often, leading to an uptick in spending on the company's easy-to-make meals and condiments.",319.07501220703125
2021-01-08 00:00:00+00:00,249.8800048828125,252.63999938964844,248.8000030517578,252.5399932861328,252.5399932861328,988700.0,3.0,1.0,0.5000249999999999,"(RTTNews) - Biogen Inc. (BIIB) said the first patient has been treated in the global clinical study, RESPOND. The phase 4 study will examine SPINRAZA in infants and children with spinal muscular atrophy who still have unmet clinical needs following treatment with gene therapy Zolgensma. The two-year RESPOND study will be conducted at approximately 20 sites worldwide and aims to enroll up to 60 children with spinal muscular atrophy. New Article Particularly high volume was seen for the $325 strike call option expiring February 19, 2021, with 460 contracts trading so far today, representing approximately 46,000 underlying shares of BIIB. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 6,284 contracts have traded so far, representing approximately 628,400 underlying shares. That amounts to about 49.9% of BIIB's average daily trading volume over the past month of 1.3 million shares.",323.7357177734375
2021-01-11 00:00:00+00:00,255.8600006103516,275.489990234375,253.3099975585937,267.5199890136719,267.5199890136719,2999200.0,3.5,1.0,0.6250249999999999,"Lilly, along with companies like Biogen Inc BIIB.O and Eisai Co Ltd 4523.T, is one of the last large drugmakers pursuing treatments for Alzheimer's - a disease that afflicts nearly 6 million Americans and millions more worldwide. By Deena Beasley Jan 11 (Reuters) - Eli Lilly and Co LLY.N said on Monday a trial of its experimental Alzheimer's drug donanemab showed it slowed by about a third the rate of decline in a combined measure of cognition and function in early-stage victims of the disease. ""This study shows that the presence of amyloid is an important accelerant of Alzheimer's disease,"" Daniel Skovronsky, Lillys chief scientific officer, told Reuters. New Article Shares of Biogen Inc BIIB.O, which is developing a similar drug, rose 7%. By Deena Beasley Jan 11 (Reuters) - Eli Lilly and Co LLY.N said on Monday a small trial of its experimental Alzheimer's drug found that it slowed by about a third the rate of decline in a combined measure of cognition and function in patients at an early stage of the mind-wasting disease. ""This study shows that the presence of amyloid is an important accelerant of Alzheimer's disease,"" Daniel Skovronsky, Lillys chief scientific officer, told Reuters.",320.6339416503906
2021-01-14 00:00:00+00:00,269.489990234375,280.489990234375,268.0,280.2900085449219,280.2900085449219,1520400.0,4.5,1.0,0.8750249999999999,"In a sign of the pharmaceutical industry's growing demand for this data, Biogen Inc BIIB.O said on Monday it was launching a virtual study in partnership with Apple AAPL.O to study cognitive decline using Apple Watch and iPhone devices. Amgen, a U.S. drugmaker, made a new investment in the combined company, joining Target RWE owners Norwest Venture Partners and 22C Capital. The data that firms such as Target RWE gather is valuable for pharmaceutical companies seeking to expand or refine the types of patients for whom a drug would be beneficial, and also negotiate reimbursement with health insurers. New Article In trading on Thursday, shares of Biogen Inc (Symbol: BIIB) crossed above their 200 day moving average of $278.64, changing hands as high as $280.43 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $223.25 per share, with $374.99 as the 52 week high point  that compares with a last trade of $280.29. The BIIB DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other stocks recently crossed above their 200 day moving average  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",329.0040283203125
2021-01-19 00:00:00+00:00,276.75,282.42999267578125,272.57000732421875,273.8399963378906,273.8399963378906,1213900.0,2.0,1.0,0.250025,"I think Biogen (NASDAQ: BIIB) is probably a really good example here. In this video from Motley Fool Live, recorded on Jan. 4, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss the pros and cons of investing before binary events. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.",318.2012939453125
2021-01-21 00:00:00+00:00,270.25,270.67999267578125,267.7699890136719,270.1199951171875,270.1199951171875,806500.0,2.0,1.0,0.250025,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $272.50 strike highlighted in red: Considering the fact that the $272.50 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the March 5th expiration.",324.6179504394531
2021-01-22 00:00:00+00:00,270.3399963378906,272.7099914550781,268.4800109863281,269.44000244140625,269.44000244140625,691100.0,3.0,1.0,0.5000249999999999,"Biogen Biotech blue chip Biogen (NASDAQ: BIIB) (say that three time fast) might also be given the heave-ho by midyear. Furthermore, the prospect of higher corporate tax rates under the Biden administration could reduce operating cash flow and slow Charter's ability to buy back its stock. My suspicion is Combs and Weschler saw value in Biogen's existing assets as well as the potential of experimental Alzheimer's disease drug aducanumab.",307.2821350097656
2021-01-27 00:00:00+00:00,267.70001220703125,268.6600036621094,262.989990234375,265.1499938964844,265.1499938964844,1116300.0,3.5,1.0,0.6250249999999999,"With that in mind, let's look at two companies that find themselves in this exact situation: Provention Bio (NASDAQ: PRVB) and Biogen (NASDAQ: BIIB). The company's leading candidate is PRV-031 (teplizumab), a medicine that could delay the onset of type-1 diabetes (T1D) in at-risk patients; no such approved drug exists at the moment. First, note that in March 2019, Biogen actually discontinued the development of aducanumab because an analysis performed by an independent committee indicated that the drug was unlikely to meet its primary endpoints in two phase 3 clinical trials. New Article Particularly high volume was seen for the $375 strike call option expiring March 19, 2021, with 1,536 contracts trading so far today, representing approximately 153,600 underlying shares of BIIB. Below is a chart showing MIK's trailing twelve month trading history, with the $22.50 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 10,138 contracts thus far today. That number of contracts represents approximately 1.0 million underlying shares, working out to a sizeable 84.5% of BIIB's average daily trading volume over the past month, of 1.2 million shares.",318.72137451171875
2021-01-29 00:00:00+00:00,294.42999267578125,296.3800048828125,281.510009765625,282.6099853515625,282.6099853515625,4789400.0,3.1666666666666665,1.0,0.5416916666666668,"Combined, BIIB and HOLX make up approximately 1.5% of the underlying holdings of XLV. Among large Healthcare stocks, Biogen Inc (Symbol: BIIB) and Hologic Inc (Symbol: HOLX) are the most notable, showing a gain of 5.8% and 4.2%, respectively. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Friday. New Article On Friday morning, Biogen (NASDAQ: BIIB) released an update regarding its Biologics License Application (BLA) for aducanumab as a potential treatment for Alzheimer's disease (AD). As a reminder, Biogen originally discontinued this drug's development back in March 2019, as it didn't look likely to meet its primary endpoint in a pair of late-stage clinical trials. Biogen submitted a BLA to the U.S. Food and Drug Administration in July 2020, and the health industry regulator granted the experimental medicine priority review with a PDUFA date of March 7, 2021. New Article Biogen (BIIB) rose 6% after saying the US Food and Drug Administration extended the review period for its aducanumab investigational treatment for Alzheimer's disease by three months until June 7. To the upside, Novavax (NVAX) raced 65% higher to its best share price since July 2015 at $235.50 after late Thursday saying its NVX-CoV2373 vaccine candidate for COVID-19 showed efficacy of 89.3% during a late-stage trial in the UK. Biogen had submitted additional analyses and clinical data for the drug candidate in a response to an FDA request, with the agency then needing more time for review. New Article (RTTNews) - Biogen Inc. (BIIB) and Japan-based Eisai Co., Ltd. said Friday that the U.S. Food and Drug Administration or FDA has extended the review period for the Biologics License Application (BLA) for aducanumab by three months. The updated Prescription Drug User Fee Act or PDUFA action date is June 7, 2021, the companies noted. Biogen said that as part of the ongoing review, it submitted a response to an information request by the FDA, including additional analyses and clinical data. New Article Jan 29 (Reuters) - Biogen Inc BIIB.O and partner Eisai Co Ltd 4523.T said on Friday the U.S. Food and Drug Administration has extended the review period by three months for aducanumab, its experimental treatment for Alzheimer's disease. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shounak Dasgupta) ((manojna.kalyani@thomsonreuters.com; +91 8061822700)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen (BIIB) rose 6.5% after saying the US Food and Drug Administration extended the review period for its aducanumab investigational treatment for Alzheimer's disease by three months until June 7. To the upside, Novavax (NVAX) raced almost 76% higher to its best share price since July 2015 at $235.50 after late Thursday said its NVX-CoV2373 vaccine candidate for COVID-19 showed efficacy of 89.3% during a late-stage trial in the UK. Biogen had submitted additional analyses and clinical data for the drug candidate in a response to an FDA request, with the agency then needing more time for review.",337.3042907714844
2021-02-01 00:00:00+00:00,283.20001220703125,284.75,274.7200012207031,278.4599914550781,278.4599914550781,1445700.0,4.0,1.0,0.7500249999999999,"(RTTNews) - Biogen Inc. (BIIB) said Monday that the U.S. Food and Drug Administration has approved a new intramuscular (IM) injection route of administration for PLEGRIDY (peginterferon beta-1a) for the treatment of relapsing forms of multiple sclerosis or MS. Biogen noted that the FDA approval expands the company's portfolio of MS treatments, which also includes the subcutaneous (SC) administration of PLEGRIDY, and follows the European Commission's marketing authorization for the IM administration in December 2020. The new IM administration offers people living with relapsing MS the efficacy and safety of PLEGRIDY with the potential for significantly reduced injection site reactions. According to Biogen, bioequivalence between the two dosing regimens was confirmed and data show that participants receiving PLEGRIDY through IM administration experienced fewer injection site reactions in comparison to participants receiving SC administration (14.4 percent versus 32.1 percent).",333.800048828125
2021-02-02 00:00:00+00:00,281.29998779296875,282.5,276.8299865722656,277.7200012207031,277.7200012207031,1194000.0,3.0,1.0,0.5000249999999999,"Biogen Inc. (BIIB) is reporting for the quarter ending December 31, 2020. In the past year BIIB has beat the expectations every quarter. Zacks Investment Research reports that the 2020 Price to Earnings ratio for BIIB is 8.24 vs. an industry ratio of 15.40.",332.1767578125
2021-02-03 00:00:00+00:00,269.989990234375,278.54998779296875,262.0799865722656,263.25,263.25,2521700.0,1.8333333333333333,1.0,0.2083583333333333,"(RTTNews) - Biogen Inc. (BIIB) reported earnings for fourth quarter that fell from last year. Excluding items, Biogen Inc. reported adjusted earnings of $706 million or $4.58 per share for the period. Analysts had expected the company to earn $4.87 per share, according to figures compiled by Thomson Reuters. New Article Biogen's (NASDAQ: BIIB) shares sank more than 17% last year while the overall market soared, reflecting significant investor pessimism. The biotech announced fourth-quarter net income of $358 million, or $2.32 per share, based on generally accepted accounting principles (GAAP). In particular, he noted the anticipated U.S. Food and Drug Administration (FDA) decision on Alzheimer's disease candidate aducanumab in June. New Article Detailed Analysis of NETEASE INC (ADR) Full Guru Analysis for NTES Full Factor Report for NTES BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068. Detailed Analysis of BIOGEN INC Full Guru Analysis for BIIB Full Factor Report for BIIB CHEMED CORPORATION (CHE) is a mid-cap growth stock in the Healthcare Facilities industry. New Article Feb 3 (Reuters) - Drugmaker Biogen Inc BIIB.O reported a 75.1% fall in fourth-quarter profit on Wednesday, hit by increased competition for its multiple sclerosis drug Tecfidera and higher costs. Net income attributable to the company fell to $357.9 million, or $2.32 per share, in the three months ended Dec. 31, from $1.44 billion, or $8.08 per share, a year earlier. (Reporting by Dania Nadeem and Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila) ((Dania.Nadeem@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article (RTTNews) - While reporting financial results for the fourth quarter on Wednesday, Biogen Inc. (BIIB) initiated its adjusted earnings and revenue guidance for the full-year 2021, below analysts' expectations. On average, analysts polled by Thomson Reuters expect the company to report earnings of $24.67 per share on revenues of $11.22 billion for the year. Multiple sclerosis (MS) revenues, including royalties on the sales of OCREVUS, decreased 24 percent from the prior year to $1.81 billion. New Article Adds details on forecast, background Feb 3 (Reuters) - Drugmaker Biogen Inc BIIB.O on Wednesday provided a full-year adjusted profit forecast that included sales from its Alzheimer's drug being reviewed by the U.S. drug agency. The road to getting a regulatory approval for the drug has been rocky, with Biogen and partner Eisai Co Ltd 4523.T scrapping two studies in March 2019 and reversing that decision a few months later. (Reporting by Dania Nadeem and Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila) ((Dania.Nadeem@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",331.3420104980469
2021-02-04 00:00:00+00:00,262.1600036621094,270.3900146484375,260.9700012207031,267.3900146484375,267.3900146484375,1663200.0,2.0,1.0,0.250025,"Especially high volume was seen for the $380 strike call option expiring July 16, 2021, with 2,000 contracts trading so far today, representing approximately 200,000 underlying shares of BIIB. Below is a chart showing LMT's trailing twelve month trading history, with the $340 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 8,562 contracts, representing approximately 856,200 underlying shares or approximately 58.4% of BIIB's average daily trading volume over the past month, of 1.5 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $380 strike highlighted in orange: For the various different available expirations for CHTR options, LMT options, or BIIB options, visit StockOptionsChannel.com. New Article Biogen Inc. (NASDAQ:BIIB) came out with its annual results last week, and we wanted to see how the business is performing and what industry forecasters think of the company following this report. NasdaqGS:BIIB Earnings and Revenue Growth February 5th 2021 Taking into account the latest results, the 28 analysts covering Biogen provided consensus estimates of US$11.1b revenue in 2021, which would reflect a not inconsiderable 18% decline on its sales over the past 12 months. These estimates imply that sales are expected to slow, with a forecast revenue decline of 18%, a significant reduction from annual growth of 6.2% over the last five years. New Article Biogens (BIIB) CEO, Michel Vounatsos said, In 2020 Biogen executed well and maintained leadership across our core businesses in multiple sclerosis (MS), spinal muscular atrophy (SMA), and biosimilars, while simultaneously making significant progress towards building a multi-franchise portfolio through both internal pipeline developments and multiple new strategic collaborations. The company also provided financial guidance for FY21. It also foreshadows just how dismal things could get if key upcoming regulatory and pipeline events dont go their way. Furthermore, Kasimov said, That said, there is a lot of optionality in this story with the aducanumab Alzheimers PDUFA [prescription drug user fee act] obviously at the forefront 1H21 is clearly setting up to be a make-or-break period for BIIB. The rest of the Street is in line with Kasimovs outlook with a Hold consensus rating. (See Biogen stock analysis on TipRanks ) Although we expect a financial reset in 2021 primarily due to the entry of TECFIDERA generics, we believe that 2021 has the potential to be a transformative year for our pipeline with an anticipated regulatory decision in the U.S. on aducanumab for Alzheimers disease in June as well as pivotal trial readouts in postpartum depression, major depressive disorder, ALS [Lou Gehrigs disease], and choroideremia, Vounatsos added. New Article Recently, Biogen (NASDAQ: BIIB) became another casualty in the beta-amyloid battle, after a panel of experts at the U.S. Food and Drug Administration (FDA) overwhelmingly voted that its experimental drug, aducanumab, did not establish efficacy in a pivotal phase 3 clinical study. If you had invested $10,000 in shares of mid-cap biotech Cassava Sciences (NASDAQ: SAVA) at the beginning of the year, your position would have grown to a stunning $99,650 as of Feb. 3. An interim data release of an open-label investigation revealed 50 patients with Alzheimer's disease saw a 10% improvement in their cognitive functions six months after treatment with simufilam. New Article Biogen throws in the towel on potential Parkinson's Drug Biogen Inc. (BIIB) has discontinued the development of BIIB054 (Cinpanemab), a potential Parkinson's drug, following the failure of that compound in a phase II study. The phase II study of BIIB054, dubbed SPARK, has not met its primary or secondary endpoints. The company has recognized an impairment charge of approximately $75.4 million during the fourth quarter of 2020, as a result of terminating BIIB054.",329.85986328125
2021-02-09 00:00:00+00:00,268.2300109863281,269.3900146484375,265.8999938964844,269.3099975585937,269.3099975585937,749600.0,3.0,1.0,0.5000249999999999,"Cassava Sciences didn't include a placebo group for comparisons, but the company is confident it will succeed in a larger phase 3 study based partly on prior clinical research conducted by another sponsor: Biogen (NASDAQ: BIIB). Cassava Sciences soared last week after the company reported positive results from a clinical trial with mild to moderately affected Alzheimer's disease patients. That's because the company spent decades funneling investors' money into an ill-fated attempt to develop an abuse-deterrent pain reliever called Remoxy before finally switching gears to focus on Alzheimer's disease in 2019.",329.29949951171875
2021-02-10 00:00:00+00:00,271.45001220703125,277.25,268.4599914550781,275.0,275.0,1353800.0,4.0,1.0,0.7500249999999999,"In trading on Wednesday, shares of Biogen Inc (Symbol: BIIB) crossed above their 200 day moving average of $274.67, changing hands as high as $277.25 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $223.25 per share, with $363.92 as the 52 week high point  that compares with a last trade of $275.00. The BIIB DMA information above was sourced from TechnicalAnalysisChannel.com Free Report: Top 7%+ Dividends (paid monthly) Click here to find out which 9 other stocks recently crossed above their 200 day moving average  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",316.93682861328125
2021-02-11 00:00:00+00:00,278.510009765625,282.75,276.69000244140625,278.8099975585937,278.8099975585937,1214200.0,3.0,1.0,0.5000249999999999,"Alkermes (NASDAQ: ALKS) proved to be a disappointment for investors last year, with its stock slipping while the overall market soared. The biotech announced a fourth-quarter net loss of $42.6 million, or $0.27 per share, based on generally accepted accounting principles (GAAP). In the fourth quarter of 2019, the company received a $150 million milestone payment from Biogen related to U.S. Food and Drug Administration (FDA) approval of Vumerity in treating multiple sclerosis (MS).",305.068359375
2021-02-12 00:00:00+00:00,278.1199951171875,280.2200012207031,274.8299865722656,278.0299987792969,278.0299987792969,1033900.0,2.6666666666666665,1.0,0.4166916666666666,"The Food and Drug Administration (FDA) recently extended its timeframe to approve or reject Biogen (NASDAQ: BIIB) and Eisai's (OTC: ESALY) Alzheimer's disease drug aducanumab by three months to June 7, 2021. In this video from Motley Fool Live, recorded on Feb. 1, Fool.com contributors Brian Orelli and Keith Speights discuss how the delay could actually be good news for the companies. It's kind of a catch-22, or maybe not catch-22 is the best phrase, but if there's a candidate that everyone thinks has a good shot at getting approved and the FDA delays, the stock goes down. New Article Biogen (NASDAQ: BIIB) is facing its biggest moment ever. Investors speculated that, if the FDA was sure about following the panel's advice, it wouldn't have lengthened the review period. The former met the primary endpoint of showing a reduction in clinical decline (measured by cognition and daily function). New Article Best Biotech Stocks To Buy [Or Avoid] Now Cancer Genetics Inc. (NASDAQ: CGIX) Bio-Path Holdings Inc. (NASDAQ: BPTH) Biogen Inc. (NASDAQ: BIIB) Pacific Biosciences of California Inc. (NASDAQ: PACB) Cancer Genetics Inc. Cancer Genetics or CGI is a leader in drug discovery and preclinical oncology and immuno-oncology services. All things said, is BIIB stock a top biotech stock to buy? With the merger, both companies will be able to collaborate on drug discovery and development for two major areas; advanced animal models and relevant human high-throughput organoid platforms.",292.3340148925781
2021-02-17 00:00:00+00:00,276.07000732421875,280.0599975585937,273.70001220703125,276.6700134277344,276.6700134277344,960300.0,3.5,1.0,0.6250249999999999,"Shares of San Francisco-based Vir, which is run by former Biogen Inc BIIB.O Chief Executive Officer George Scangos, rose 12.4% before the opening bell. By Rebecca Spalding Feb 17 (Reuters) - GlaxoSmithKline GSK.L and Vir Biotechnology Inc VIR.O will expand an existing partnership developing antibody therapies for COVID-19 to other diseases, the companies said on Wednesday. GSK and Vir said people 65 and older with underlying conditions have a higher risk of dying of the virus and historically, vaccines have had lower efficacy in this group. New Article The company generated net income in the fourth quarter of $171 million based on generally accepted accounting principles (GAAP). Biogen's multiple sclerosis drug Tysabri made Royalty Pharma $93 million in the fourth quarter, a 10% year-over-year increase. Over the longer period through 2025, the company expects adjusted cash receipts will increase by a compound annual growth rate (CAGR) of 7% to 10%.",305.6479797363281
2021-02-23 00:00:00+00:00,281.989990234375,284.8699951171875,275.6700134277344,279.0799865722656,279.0799865722656,1306200.0,3.333333333333333,1.0,0.5833583333333334,"In this Motley Fool Live video, recorded on Feb. 17, Fool.com contributors Keith Speights and Brian Orelli discuss whether or not investors should worry about the potential impact of these delays. Moderna announced yesterday that its contract manufacturer, Catalent (NYSE: CTLT), experienced some what they call short-term delays in releasing some doses of the COVID vaccine, mRNA-1273. Moderna has a nice pipeline, but I think it's been richly valued based on that fact that they're going to maybe do 10, 20 billion in sales of the COVID-19 vaccine, and then the question is just how long will it last. New Article There are two ways to imagine where Biogen (NASDAQ: BIIB) will be in five years. BIIB Revenue (Annual) data by YCharts The half-empty argument If aducanumab isn't approved, the financials don't look good for the biotech company's future. In that worst case scenario, Biogen will be a company with declining revenue and a relatively small pipeline whose biggest sellers are facing increasing pricing pressure. New Article This has already been seen in Europe, where Humira has already lost patent protection and is facing competition from biosimilars such as Amgen's (NASDAQ: AMGN) Amgevita, Novartis' (NYSE: NVS) Hyrimoz, Biogen (NASDAQ: BIIB) and Samsung Bioepis' Imraldi, and Mylan's (NASDAQ: MYL) Hulio. However, investors seem to be ignoring these well-established pharmaceutical players with diversified product portfolios, deep research pipelines, broad geographic presence, robust cash flows, and healthy balance sheets. Already approved by the U.S. Food and Drug Administration (FDA) for treating atopic dermatitis, sinus infections, and asthma, Dupixent is also being studied in late-stage clinical trials for eight additional diseases.",303.1402587890625
2021-02-26 00:00:00+00:00,278.2799987792969,278.9200134277344,269.3099975585937,272.8800048828125,272.8800048828125,1535100.0,3.0,1.0,0.5000249999999999,"Stocks to Sell for March: Biogen (BIIB) Source: Pavel Kapysh / Shutterstock.com A couple weeks ago, a slew of drug companies announced earnings. 8 Stocks to Buy for March These seven stocks to sell for March are a very good start: Biogen (NASDAQ:BIIB) Boston Scientific (NYSE:BSX) Duke Energy (NYSE:DUK) GlaxoSmithKline (NYSE:GSK) Las Vegas Sands (NYSE:LVS) Raytheon (NYSE:RTX) But BIIB came in mixed, with weak earnings but good revenue.",292.6055908203125
2021-03-03 00:00:00+00:00,267.79998779296875,269.2799987792969,263.79998779296875,266.6000061035156,266.6000061035156,1037100.0,2.0,1.0,0.250025,"Especially high volume was seen for the $200 strike put option expiring June 18, 2021, with 1,107 contracts trading so far today, representing approximately 110,700 underlying shares of BIIB. Below is a chart showing DRI's trailing twelve month trading history, with the $145 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 6,150 contracts thus far today. That number of contracts represents approximately 615,000 underlying shares, working out to a sizeable 49.7% of BIIB's average daily trading volume over the past month, of 1.2 million shares.",284.09710693359375
2021-03-10 00:00:00+00:00,269.5199890136719,269.5199890136719,262.6000061035156,262.6099853515625,262.6099853515625,1736400.0,3.0,1.0,0.5000249999999999,"ProShares ProShares S&P 500 Ex-Financials ETF SPXN $80.53 $88.76 10.22% International Flavors & Fragrances Inc. IFF $131.31 $145.40 10.73% Biogen Inc BIIB $266.49 $294.41 10.48% Broadridge Financial Solutions Inc BR $141.98 $156.62 10.31% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of SPXN's underlying holdings with notable upside to their analyst target prices are International Flavors & Fragrances Inc. (Symbol: IFF), Biogen Inc (Symbol: BIIB), and Broadridge Financial Solutions Inc (Symbol: BR). Similarly, BIIB has 10.48% upside from the recent share price of $266.49 if the average analyst target price of $294.41/share is reached, and analysts on average are expecting BR to reach a target price of $156.62/share, which is 10.31% above the recent price of $141.98.",291.8128967285156
2021-03-11 00:00:00+00:00,263.0599975585937,268.0,260.54998779296875,267.44000244140625,267.44000244140625,1596300.0,2.0,1.0,0.250025,"The FDA established the Fast Track program to expedite the review of drugs that target serious conditions and that fill an unmet medical need. Hunter syndrome is a rare genetic disease that can lead to neurodegeneration and damage to organs including the heart and lungs. In addition, the company anticipates kicking off a phase 1b study of DNL343 in treating neurodegenerative disease amyotrophic lateral sclerosis (ALS) in the second half of 2021.",285.14111328125
2021-03-15 00:00:00+00:00,268.0199890136719,271.42999267578125,250.4199981689453,260.1300048828125,260.1300048828125,2829400.0,2.5,1.0,0.375025,"Unfortunately, the results strongly suggest that Eli Lilly and Biogen (NASDAQ: BIIB) have a lot more work to do. That could be a big problem for Eli Lilly because the Trailblazer study assaulted trial participants with a battery of different tests and the iADRS was the only measurement in which donanemab provided a statistically significant benefit. The FDA is eager to approve an amyloid-clearing AD drug from Biogen called aducanumab even though independent experts unanimously agree that pivotal trial results didn't show evidence of a benefit. New Article By Manas Mishra March 15 (Reuters) - ElevateBio said on Monday it has raised $525 million in new funding led by Matrix Capital Management, to help increase manufacturing capacity and also advance development of its cell and gene therapies. The funding comes as larger drugmakers work to build their own manufacturing plants for gene therapies, in a drive to better control production of the world's priciest medicines. Biogen Inc said earlier this month that it planned to spend $200 million to build a new gene therapy manufacturing facility.",284.01507568359375
2021-03-17 00:00:00+00:00,258.5,267.2900085449219,257.2200012207031,264.1499938964844,264.1499938964844,1092900.0,4.0,1.0,0.7500249999999999,"When you think of the word ""biotech,"" Biogen (NASDAQ: BIIB) may be one of the first companies to come to mind. A transformative decision on the horizon Biogen's immediate future -- when it comes to revenue and stock price -- is in the hands of the U.S. Food and Drug Administration (FDA). It's clear an FDA approval would result in a major stock price gain -- and a brilliant future for Biogen.",279.8120422363281
2021-03-22 00:00:00+00:00,267.3399963378906,273.8599853515625,266.0,272.3399963378906,272.3399963378906,1169000.0,3.0,1.0,0.5000249999999999,"Especially high volume was seen for the $280 strike call option expiring April 16, 2021, with 4,152 contracts trading so far today, representing approximately 415,200 underlying shares of BIIB. Below is a chart showing JBHT's trailing twelve month trading history, with the $160 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 13,546 contracts, representing approximately 1.4 million underlying shares or approximately 98.5% of BIIB's average daily trading volume over the past month, of 1.4 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $280 strike highlighted in orange: And Kansas City Southern (Symbol: KSU) options are showing a volume of 5,137 contracts thus far today.",278.9754638671875
2021-03-24 00:00:00+00:00,267.0400085449219,270.75,265.6600036621094,265.69000244140625,265.69000244140625,951800.0,2.0,1.0,0.250025,"We have some big news on the way with Biogen -- ticker is BIIB -- hoping to win FDA approval for an Alzheimer's disease drug. Lilly announced results from a phase 2 study of an experimental Alzheimer's disease drug called, I hope I pronounce this right, donanemab. It reminds me of the Peanuts cartoon where Charlie Brown -- he wants to kick the football, Lucy holds it, and every single time she yanks it away.",287.8233642578125
2021-03-25 00:00:00+00:00,267.4700012207031,280.0,264.3599853515625,273.9700012207031,273.9700012207031,1685100.0,2.0,1.0,0.250025,"After those stocks' recent struggles, management teams and shareholders are hoping the news will get their share prices moving back toward previous highs. The biotech laid off half of its workforce last year, changed CEOs, and inked a deal with Biogen that provided a much-needed cash infusion, but split its share of future proceeds from its tent-pole depression treatment. The latest data released at the American Hematological Society (ASH) in late November showed that both candidates were able to achieve a response rate in patients as a monotherapy -- without being administered in combination with other treatments.",290.24395751953125
2021-03-26 00:00:00+00:00,272.2099914550781,277.1099853515625,271.0299987792969,276.6300048828125,276.6300048828125,665300.0,4.0,1.0,0.7500249999999999,"Top Health Care Stocks To Buy [Or Sell] Now Aptose Biosciences Inc. (NASDAQ: APTO) Neurocrine Biosciences Inc. (NASDAQ: NBIX) Koninklijke Philips (NYSE: PHG) Biogen Inc. (NASDAQ: BIIB) Aptose Biosciences Inc. First up is clinical-stage biotech company, Aptose Biosciences. While investors could be watching BIIB stock because of that, a recent analyst note could have just made a better case for the stock. Specifically, Mizuho analyst Salim Syed wrote that two other key updates could boost BIIB stock soon.",283.8388977050781
2021-03-30 00:00:00+00:00,273.7900085449219,279.45001220703125,273.07000732421875,276.010009765625,276.010009765625,882100.0,4.5,1.0,0.8750249999999999,"Rival treatments include Zolgensma from Novartis NOVN.S and Biogen's BIIB.O Spinraza. ZURICH, March 30 (Reuters) - Roche's ROG.S Evrysdi has won approval from the European Commission as the first and only at-home treatment for spinal muscular atrophy (SMA), the Swiss drugmaker said on Tuesday. The drugmaker said it was working with reimbursement and assessment bodies in European countries to enable broad and rapid access. New Article Evrysdi and Novartis's Zolgensma are already taking away sales from Biogen's rival treatment BIIB.O Spinraza, whose U.S. sales in the final quarter of 2020 fell by more than a third. Adds details ZURICH, March 30 (Reuters) - Swiss drugmakers Roche ROG.S and Novartis NOVN.S each won European approval for drugs on Tuesday in a sign that the rival Basel-based companies are increasingly competing for the same patients. Roche's Evrysdi, already approved in the United States, gained backing from the European Commission for spinal muscular atrophy (SMA), where Novartis's $2.1 million per patient gene therapy Zolgensma has become the treatment of choice for infants diagnosed with the genetic, muscle-wasting disease.",277.683349609375
2021-04-06 00:00:00+00:00,276.1700134277344,276.5,271.29998779296875,271.760009765625,271.760009765625,1006500.0,1.0,1.0,2.4999999999997247e-05,"A crucial moment for biotech giant Biogen (NASDAQ: BIIB) is only two months away. Then, just last week, three members of the FDA advisory panel wrote a piece in The Journal of the American Medical Association (JAMA) reiterating their negative views on aducanumab. They said post hoc analyses are useful in designing future trials -- but they shouldn't be the sole element supporting regulatory approval.",282.0737609863281
2021-04-07 00:00:00+00:00,272.0,272.0,267.17999267578125,268.0199890136719,268.0199890136719,851400.0,3.0,1.0,0.5000249999999999,"In trading on Wednesday, shares of Biogen Inc (Symbol: BIIB) crossed below their 200 day moving average of $269.13, changing hands as low as $267.18 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $223.25 per share, with $363.92 as the 52 week high point  that compares with a last trade of $268.02. The BIIB DMA information above was sourced from TechnicalAnalysisChannel.com Free Report: Top 7%+ Dividends (paid monthly) Click here to find out which 9 other stocks recently crossed below their 200 day moving average  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article (RTTNews) - Biogen Inc. (BIIB) said the European Commission has granted marketing authorization for a subcutaneous injection of TYSABRI to treat relapsing-remitting multiple sclerosis. The company noted that the subcutaneous option provides a shorter administration time and expands access to treatment for patients and physicians beyond the infusion setting. The approval is based on data from the DELIVER and REFINE studies, which showed comparability to the Q4W IV administration of 300mg TYSABRI in efficacy, pharmacokinetic and pharmacodynamic profiles.",292.2531433105469
2021-04-08 00:00:00+00:00,272.20001220703125,272.20001220703125,265.3699951171875,265.7300109863281,265.7300109863281,800900.0,3.5,1.0,0.6250249999999999,"(RTTNews) - Biogen Inc. (BIIB) and Bio-Thera Solutions have reached an agreement to develop, manufacture and commercialize BAT1806, a phase 3 clinical stage anti-interleukin-6 receptor monoclonal antibody that is a proposed biosimilar referencing ACTEMRA (tocilizumab). Biogen will gain exclusive regulatory, manufacturing and commercial rights to BAT1806 in all countries excluding China. Biogen will also pay Bio-Thera Solutions tiered royalties. New Article That downside risk was realized by Biogen Inc. (NASDAQ:BIIB) shareholders over the last year, as the share price declined 15%. NasdaqGS:BIIB Earnings Per Share Growth April 8th 2021 It's good to see that there was some significant insider buying in the last three months. On the bright side, long term shareholders have made money, with a gain of 1.4% per year over half a decade.",281.39990234375
2021-04-09 00:00:00+00:00,265.7300109863281,268.5899963378906,263.5,268.1700134277344,268.1700134277344,874100.0,2.0,1.0,0.250025,"Especially high volume was seen for the $350 strike call option expiring June 18, 2021, with 794 contracts trading so far today, representing approximately 79,400 underlying shares of BIIB. Below is a chart showing JNJ's trailing twelve month trading history, with the $160 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 5,699 contracts, representing approximately 569,900 underlying shares or approximately 48.4% of BIIB's average daily trading volume over the past month, of 1.2 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $350 strike highlighted in orange: And Best Buy Inc (Symbol: BBY) saw options trading volume of 13,193 contracts, representing approximately 1.3 million underlying shares or approximately 46.6% of BBY's average daily trading volume over the past month, of 2.8 million shares.",284.7655029296875
2021-04-13 00:00:00+00:00,264.9100036621094,266.9700012207031,262.4200134277344,266.19000244140625,266.19000244140625,823300.0,3.0,1.0,0.5000249999999999,"Biogen (NASDAQ: BIIB) also has a drug designed to prevent motor neuron damage, called Spinraza. This means the company's modest market cap could swell to many times its current size, if Frequency Therapeutics can show strong evidence that a single injection of its lead drug works as intended. Progressive nerve damage leads to the wasting away of muscle mass, but six-month data from the phase 2 Topaz trial suggested apitegromab could help SMA patients make meaningful improvements in motor function.",282.5484619140625
2021-04-16 00:00:00+00:00,270.6099853515625,273.8299865722656,269.7900085449219,270.3099975585937,270.3099975585937,1014800.0,3.6666666666666665,1.0,0.6666916666666666,"For instance, in the rare eye disease market, Editas may be facing threats from Roche's (OTC: RHHBY) Spark Therapeutics, Sanofi (NASDAQ: SNY), and Biogen's (NASDAQ: BIIB) Nightstar -- all of which have a considerable head start or products already on the market. FibroGen It usually is not a reassuring sign to see that, right before going in front of the U.S. Food and Drug Administration (FDA) for review, a company wants to clarify prior data in regards to cardiovascular safety. Unsurprisingly, FibroGen barely eked out positive data in its post-hoc analysis for its lead compound, roxadustat, which is being studied for the treatment of anemia associated with chronic kidney disease. New Article This approval expands Biogens (BIIB) footprint in China. Biogen Incs TECFIDERA has received approval from the National Medical Products Administration (NMPA) in China for treating relapsing multiple sclerosis (MS). We are committed to expanding our presence in China and working with the MS community to address unmet medical needs through innovative therapies and solutions. (See Biogen stock analysis on TipRanks) The approval is based on two Phase 3 studies, DEFINE and CONFIRM. New Article Especially high volume was seen for the $340 strike call option expiring April 16, 2021, with 1,560 contracts trading so far today, representing approximately 156,000 underlying shares of BIIB. Below is a chart showing STAY's trailing twelve month trading history, with the $19.65 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 7,681 contracts thus far today. That number of contracts represents approximately 768,100 underlying shares, working out to a sizeable 77.9% of BIIB's average daily trading volume over the past month, of 985,480 shares.",285.4815979003906
2021-04-21 00:00:00+00:00,272.6300048828125,273.3900146484375,266.5,269.8500061035156,269.8500061035156,1053000.0,4.0,1.0,0.7500249999999999,"Biogen Inc. (BIIB) is reporting for the quarter ending March 31, 2021. BIIB missed the consensus earnings per share in the 4th calendar quarter of 2020 by -7.1%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for BIIB is 14.81 vs. an industry ratio of -7.00, implying that they will have a higher earnings growth than their competitors in the same industry.",274.42486572265625
2021-04-22 00:00:00+00:00,260.0,264.5199890136719,257.0299987792969,259.0,259.0,2411300.0,2.6666666666666665,1.0,0.4166916666666666,"(RTTNews) - While reporting financial results for the first quarter on Thursday, Biogen Inc. (BIIB) raised its adjusted earnings guidance for the full-year 2021, but maintained revenue outlook. On average, 30 analysts polled by Thomson Reuters expect the company to report earnings of $18.41 per share on revenues of $10.57 billion for the year. The Street expected the company to report earnings of $5.04 per share on revenues of $2.65 billion for the quarter. New Article It's fair to say that Biogen (NASDAQ: BIIB) is at a pivotal point. It hopes to achieve success in treating Alzheimer's disease but must first jump a major hurdle by winning U.S. Food and Drug Administration (FDA) approval. Those results apparently didn't give investors a warm and fuzzy feeling, though: The biotech stock slipped 4% in early trading. New Article April 22 (Reuters) - Biogen Inc BIIB.O reported a 70.7% fall in first-quarter profit on Thursday, as its top-selling multiple sclerosis drug Tecfidera faced increased competition from cheaper generic drugs. Net income attributable to the company fell to $410.2 million, or $2.69 per share, in the three months ended March, from $1.40 billion, or $8.08 per share, a year earlier. (Reporting by Mrinalika Roy in Bengaluru; Editing by Sriraj Kalluvila) ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen (BIIB) was lower after it reported Q1 adjusted earnings of $5.34 per share, down from $9.14 per share a year earlier. The Health Care SPDR (XLV) was little changed and the iShares NASDAQ Biotechnology Index (IBB) was 0.11% lower in recent trading. Analysts polled by Capital IQ had projected normalized EPS of $1.86. New Article And the worst performing Nasdaq 100 component thus far on the day is Micron Technology, trading down 4.2%. Micron Technology is showing a gain of 14.0% looking at the year to date performance. VIDEO: Nasdaq 100 Movers: MU, OKTA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen Inc BIIB.O beat quarterly profit estimates on stronger-than-expected sales for its muscle wasting disorder drug, though concerns over its reliance on its yet-to-be approved Alzheimer's therapy, aducanumab, weighed on shares. By Herbert Lash NEW YORK, April 22 (Reuters) - U.S. stocks dived on Thursday on reports President Joe Biden planned to almost double the capital gains tax, news analysts said provided an excuse to take profits in a directionless market ahead of big tech's earnings next week. Markets have been listless after the Dow .DJI and S&P 500 .SPX recently scaled all-time peaks as investors await guidance from Microsoft Corp MSFT.O, Google parent Alphabet Inc GOOGL.O and Facebook Inc FB.O when they report earnings next week. New Article Biogen Inc BIIB.O beat estimates for quarterly profit on stronger-than-expected sales for its muscle wasting disorder drug, though concerns over its reliance on its yet-to-be approved Alzheimer's therapy, aducanumab, weighed on shares. By Herbert Lash NEW YORK, April 22 (Reuters) - U.S. stocks dived on Thursday on reports President Joe Biden planned to almost double the capital gains tax, news analysts said provided an excuse to take profits in a directionless market ahead of big tech's earnings next week. The speedy U.S. vaccination rollout has improved the economic outlook as people plan summer vacations and spending on leisure activities, but a surge in COVID-19 cases in India and elsewhere in Asia has kept investors anxious, Hayes said. New Article (RTTNews) - Biogen Inc. (BIIB) will host a conference call at 8:00 AM ET on April 22, 2021, to discuss Q1 21 earnings results. To access the live webcast, log on to https://investors.biogen.com/investor-relations The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen Inc (NASDAQ: BIIB) Q1 2021 Earnings Call Apr 22, 2021, 8:00 a.m. Additionally, we plan to present detailed results from the Phase 1b study of BIIB080 in mild Alzheimer's disease at the upcoming AAIC meeting later this year. BIIB080 is a tau targeted antisense oligonucleotide that aims to reduce the production of all forms of tau, both intracellular and extracellular.",266.4561767578125
2021-04-23 00:00:00+00:00,260.3299865722656,263.94000244140625,258.2900085449219,262.6300048828125,262.6300048828125,911400.0,2.0,1.0,0.250025,"Biogen (BIIB) reported $410 million in net income, or $2.69 a share. BIIB scores an 8 out of 10 on the TipRanks Smart Score rating system, implying that the stock is expected to outperform market averages. Biogens share price fell 4% on Thursday after the company reported first-quarter financial results and increased its full-year earnings guidance.",262.666748046875
2021-04-26 00:00:00+00:00,264.45001220703125,270.489990234375,261.2200012207031,269.4599914550781,269.4599914550781,1115700.0,2.0,1.0,0.250025,"Particularly high volume was seen for the $350 strike call option expiring June 18, 2021, with 853 contracts trading so far today, representing approximately 85,300 underlying shares of BIIB. Below is a chart showing ALKS's trailing twelve month trading history, with the $25 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 6,617 contracts thus far today. That number of contracts represents approximately 661,700 underlying shares, working out to a sizeable 69.2% of BIIB's average daily trading volume over the past month, of 956,445 shares.",270.2078552246094
2021-05-03 00:00:00+00:00,267.8699951171875,275.54998779296875,267.7300109863281,275.3099975585937,275.3099975585937,981800.0,3.0,1.0,0.5000249999999999,"Biogen Inc (Symbol: BIIB), which makes up 0.55% of the iShares MSCI USA Value Factor ETF (VLUE), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $84,933,371 worth of BIIB, making it the #54 largest holding. The table below details the recent insider buying activity observed at BIIB: BIIB  last trade: $267.33  Recent Insider Buys:",261.640625
2021-05-06 00:00:00+00:00,268.6700134277344,273.0299987792969,268.5,272.1099853515625,272.1099853515625,929600.0,2.0,1.0,0.250025,"Berkshire's biotech bet In late 2019, Berkshire scooped up more than 192,000 shares of Biogen (NASDAQ: BIIB). His longtime business partner, Charlie Munger, didn't mince any words, though, stating, ""The whole damn development is disgusting and contrary to the interest of civilization."" Biogen's revenue is declining, and sales for its previous top-selling drug Tecfidera continue to plunge as generic rivals gain market share.",257.7501220703125
2021-05-07 00:00:00+00:00,270.6600036621094,279.20001220703125,270.6600036621094,274.0400085449219,274.0400085449219,936100.0,2.0,1.0,0.250025,"Particularly high volume was seen for the $240 strike put option expiring May 21, 2021, with 514 contracts trading so far today, representing approximately 51,400 underlying shares of BIIB. Below is a chart showing LOW's trailing twelve month trading history, with the $207.50 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 5,839 contracts thus far today. That number of contracts represents approximately 583,900 underlying shares, working out to a sizeable 61.8% of BIIB's average daily trading volume over the past month, of 944,350 shares.",257.46575927734375
2021-05-11 00:00:00+00:00,274.260009765625,281.5299987792969,273.5,278.3900146484375,278.3900146484375,950900.0,4.0,1.0,0.7500249999999999,"On April 23, Robert W. Baird analyst Brian Skorney reiterated a Sell rating on BIIB stock with a $216 price target (21.6% potential downside). Biogen (BIIB) has entered into a research collaboration with Capsigen Inc. to develop novel adeno-associated virus (AAV) capsids. Biogen Head of R&D Alfred Sandrock, Jr., M.D., Ph.D., said, Through this collaboration, we aim to solve key technological challenges in the delivery of gene therapies to target tissues.",260.3121337890625
2021-05-14 00:00:00+00:00,281.4700012207031,282.0799865722656,276.0299987792969,280.2099914550781,280.2099914550781,991000.0,2.0,1.0,0.250025,"(RTTNews) - Biogen Inc. (BIIB) Friday said its XIRIUS study of cotoretigene toliparvovec failed to meet its primary endpoint in Phase 2/3 in patients with X-linked retinitis pigmentosa or XLRP. Cotoretigene toliparvovec or BIIB112 is an investigational AAV8 vector-based gene therapy administered by subretinal injection. The company further noted that the study obtained positive trends in other pre-specified clinically relevant endpoints, such as a measure of visual acuity under low light conditions. New Article Particularly high volume was seen for the $320 strike call option expiring June 18, 2021, with 1,157 contracts trading so far today, representing approximately 115,700 underlying shares of BIIB. Below is a chart showing PLT's trailing twelve month trading history, with the $45 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 8,930 contracts thus far today. That number of contracts represents approximately 893,000 underlying shares, working out to a sizeable 91.6% of BIIB's average daily trading volume over the past month, of 975,175 shares. New Article Biogen (BIIB) was down almost 1% after saying topline results from a phase 2/3 study of cotoretigene toliparvovec to treat patients with X-linked retinitis pigmentosa failed to meet its primary endpoint. The Health Care SPDR (XLV) was 0.53% higher and the iShares NASDAQ Biotechnology Index (IBB) was up more than 1% recently. Dr. Reddy's Laboratories (RDY) was slightly lower as it posted fiscal Q4 earnings of 33.29 Indian rupees ($0.46) per share, down from 46.01 rupees per share a year earlier. New Article Adds study details, background May 14 (Reuters) - Biogen Inc's BIIB.O experimental gene therapy for a genetic retinal disease that leads to progressive vision loss did not meet the main goal of a mid-to-late stage study, the drugmaker said on Friday. The treatment, BIIB112, did not show significant improvement in retinal sensitivity in patients with X-linked retinitis pigmentosa, a rare eye condition that has no approved treatments. The drug, however, showed positive trends in improving visual acuity under low light conditions and Biogen is analyzing the complete data from the study to figure out next steps.",258.86492919921875
2021-05-19 00:00:00+00:00,278.3699951171875,281.8999938964844,276.07000732421875,281.75,281.75,723100.0,2.0,1.0,0.250025,"SEE MORE 13 Stocks Activist Investors Are Buying Getty Images Biogen Market value: $42.3 billion Timeline to watch: June 2021 Truth be told, monster biotech Biogen (BIIB, $281.01) has had a long fight with Alzheimer's medications. BIIB hopes to change that, but the road has been bumpy. BIIB did a U-turn on the treatment later that year, saying it would submit it to the FDA after more trials.",267.2845458984375
2021-05-20 00:00:00+00:00,281.0,290.3599853515625,280.010009765625,286.57000732421875,286.57000732421875,1094300.0,3.0,1.0,0.5000249999999999,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $290.00 strike highlighted in red: Considering the fact that the $290.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading this week, for the October 15th expiration.",263.4682312011719
2021-05-21 00:00:00+00:00,288.239990234375,289.9100036621094,282.7799987792969,283.19000244140625,283.19000244140625,940200.0,3.0,1.0,0.5000249999999999,Biogen (BIIB) and Ginkgo Bioworks said they initiated a gene therapy collaboration with the goal of developing recombinant adeno-associated virus-based vectors used to develop gene therapies to treat certain neurological and neuromuscular diseases. BIIB shares were up 0.5% premarket. Health care stocks were gaining in pre-bell trading Friday with the Health Care SPDR (XLV) gaining 0.27% and the iShares NASDAQ Biotechnology Index (IBB) recently climbing by 0.54%.,256.1744689941406
2021-05-26 00:00:00+00:00,273.29998779296875,274.3500061035156,266.2300109863281,267.8399963378906,267.8399963378906,1777500.0,2.5,1.0,0.375025,"In the past three years, shareholders of Biogen Inc. (NASDAQ:BIIB) have seen a loss on their investment. NasdaqGS:BIIB CEO Compensation May 26th 2021 A Look at Biogen Inc.'s Growth Numbers Over the past three years, Biogen Inc. has seen its earnings per share (EPS) grow by 11% per year. According to our data, Biogen Inc. has a market capitalization of US$41b, and paid its CEO total annual compensation worth US$19m over the year to December 2020. New Article In this note we focus on a comparative analysis of BioMarin Pharmaceutical stock performance during the current financial crisis with that during the 2008 recession in our interactive dashboard. Conclusion Phases of Covid-19 Crisis: Early- to mid-March 2020: Fear of the coronavirus outbreak spreading rapidly translates into reality, with the number of cases accelerating globally Late-March 2020 onward: Social distancing measures + lockdowns April 2020: Fed stimulus suppresses near-term survival anxiety May-June 2020: Recovery of demand, with gradual lifting of lockdowns  no panic anymore despite a steady increase in the number of cases Since late 2020: Weak quarterly results, but continued improvement in demand and progress with vaccine development buoy market sentiment. As the global economy opens up and restrictions are lifted in phases, overall volume of new patient starts will rise, boding well for BMRN stock in the near term.",255.05023193359375
2021-05-27 00:00:00+00:00,269.1000061035156,269.1000061035156,266.0,267.3699951171875,267.3699951171875,1792800.0,4.0,1.0,0.7500249999999999,"Over the past three years, Biogen (NASDAQ: BIIB) stock has taken investors on the ride of a lifetime. Back in November, a panelist of experts from the regulatory agency overwhelmingly voted that the ENGAGE and EMERGE clinical trials did not provide sufficient evidence for aducanumab's approval. In February, the Alzheimer's Association, a non-profit, retaliated against a group of researchers for tweeting a deeply skeptical article about aducanumab scheduled for publication in the organization's scientific journal.",252.94676208496094
2021-05-28 00:00:00+00:00,269.0,271.989990234375,266.0,267.4800109863281,267.4800109863281,957000.0,3.0,1.0,0.5000249999999999,"Below is a twelve month price history chart comparing the stock performance of BIIB, JNJ, and HUM: Combined, BIIB, JNJ, and HUM represent 11.77% of the The Health Care Select Sector SPDR Fund ETF. The Health Care Select Sector SPDR Fund ETF XLV $123.12 $134.93 9.59% Biogen Inc BIIB $267.37 $294.96 10.32% Johnson & Johnson JNJ $168.81 $185.50 9.89% Humana Inc. HUM $439.36 $481.50 9.59% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of XLV's underlying holdings with notable upside to their analyst target prices are Biogen Inc (Symbol: BIIB), Johnson & Johnson (Symbol: JNJ), and Humana Inc. (Symbol: HUM).",250.74325561523438
2021-06-01 00:00:00+00:00,272.3500061035156,272.3500061035156,264.1199951171875,267.1499938964844,267.1499938964844,1340800.0,3.0,1.0,0.5000249999999999,"Especially high volume was seen for the $300 strike call option expiring June 04, 2021, with 472 contracts trading so far today, representing approximately 47,200 underlying shares of BIIB. Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Biogen Inc (Symbol: BIIB), where a total volume of 8,152 contracts has been traded thus far today, a contract volume which is representative of approximately 815,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 81% of BIIB's average daily trading volume over the past month, of 1.0 million shares. New Article (RTTNews) - Biogen Inc. (BIIB) and China's Bio-Thera Solutions, Ltd. announced Tuesday results from the Phase 3 study of BAT1806, a proposed biosimilar referencing ACTEMRA/RoACTEMRA (tocilizumab). The study met its primary endpoints, demonstrating equivalence to the reference medicine in patients with moderate to severe rheumatoid arthritis (RA) inadequately controlled by methotrexate therapy. The BAT1806 clinical trial was a global, randomized, multicenter, double-blind, parallel-group, Phase 3 active-control study designed to evaluate the safety, efficacy, immunogenicity and PK of BAT1806 compared to ACTEMRA/RoACTEMRA in 621 patients with moderate to severe rheumatoid arthritis with inadequate response to methotrexate.",251.44537353515625
2021-06-02 00:00:00+00:00,269.2699890136719,271.8599853515625,267.7799987792969,269.3500061035156,269.3500061035156,1187500.0,2.6666666666666665,1.0,0.4166916666666666,"A crucial decision is days -- or maybe even hours -- away for Biogen (NASDAQ: BIIB). A positive decision seems crucial for Biogen because the company predicts declining sales of its big multiple sclerosis blockbuster and is in need of a new growth driver. But in the post-study analysis, Biogen looked at a group of some Engage participants who received higher doses of the drug candidate. New Article Biogen (NASDAQ: BIIB) hopes that changes this week as the Food and Drug Administration (FDA) is set to rule on its application for aducanumab. BIIB data by YCharts It turned out, one of the studies showed participants who received a high dose of the drug had better results than those who got the placebo. Won't back down Aducanumab is a monoclonal antibody that binds to the sticky plaque compound that many researchers believe kills brain cells in those with the Alzheimer's. New Article Here's why shares of Biogen (NASDAQ: BIIB), Vertex Pharmaceuticals (NASDAQ: VRTX), and Sage Therapeutics (NASDAQ: SAGE) will be extra jumpy this month. Some of the industry's biggest players are waiting for clinical trial results and decisions from the FDA that could send their stock prices rocketing higher overnight or stomp them into the dirt. Sage Therapeutics This company develops drugs for depression, but its first treatment to earn FDA approval, Zulresson hasn't made the splash investors had hoped for.",255.70950317382812
2021-06-04 00:00:00+00:00,274.1700134277344,291.7099914550781,273.3699951171875,286.1400146484375,286.1400146484375,2956200.0,2.5,1.0,0.375025,"By Deena Beasley June 4 (Reuters) - U.S. regulators are slated to decided by Monday whether to approve Biogen Inc's BIIB.O controversial Alzheimer's disease drug, and Wall Street analysts and industry observers are deeply divided on its chances of making it over the finish line. A panel of outside advisers to the FDA voted in November that aducanumab had not been proven to slow Alzheimer's progression, despite a report from agency staff that said results from the successful trial were persuasive. Analysts have also speculated that the FDA could proffer a narrow approval - limiting aducanumab's use to certain patients, for instance, or requiring more data to prove that the drug is effective. New Article Among large Healthcare stocks, Biogen Inc (Symbol: BIIB) and Illumina Inc (Symbol: ILMN) are the most notable, showing a gain of 5.7% and 3.9%, respectively. Combined, BIIB and ILMN make up approximately 2.2% of the underlying holdings of XLV. Combined, IPGP and NVDA make up approximately 4.7% of the underlying holdings of XLK.",250.4532470703125
2021-06-07 00:00:00+00:00,295.3500061035156,468.5499877929688,286.0,395.8500061035156,395.8500061035156,17954100.0,3.4782608695652173,1.0,0.6195902173913042,"That could all change today, when Biogens (BIIB) controversial Alzheimers drug aducanumabs fate is decided by the regulators. (To watch Yees track record, click here) The Jefferies analyst sits squarely in the BIIB bull camp, while the Street, as a whole, has a more measured view. In fact, the stock hasn't recovered much since the negative vote in Q4 as a reflection it was a pretty ominous sign. Recall, last year an FDA advisory panel voted against approving the drug, and while the FDA does not have to follow the panels lead, the decision was a blow to investors confidence. New Article In company news, Biogen (BIIB) jumped out to a a nearly 39% gain after the US Food and Drug Administration Monday granted accelerated approval for the Aduhelm Alzheimer's treatment developed in a partnership with Eisai, the first therapy approved for the brain disease in nearly two decades. Bionano Genomics (BNGO) rose 22% after the life sciences instrumentation company said it has hired former PerkinElmer (PKI) and Sema4 sales executive Jason Priar as its new chief commercial officer. Cerecor (CERC) climbed almost 12% after saying it secured up to $35 million in term loan funding from Horizon Technology Finance (HRZN), including an initial $20 million tranche and the remaining $15 million contingent on the biopharmaceuticals company achieving certain milestones. New Article The decision by the FDA to approve Biogen's (NASDAQ: BIIB) Alzheimer's disease treatment aducanumab, to be marketed as Aduhelm, has given new hope to more than 5 million Americans with the disease, and their loved ones. When the Food and Drug Administration initially signaled in November that it was likely to approve the monoclonal antibody treatment, Biogen stock jumped by 43%, adding $16 billion in market capitalization to the company. Shares of Cassava Sciences may offer a better opportunity for investors than Biogen, but even its management doesn't believe that any single drug will be able to fully treat Alzheimer's disease. New Article Drugmaker Biogen Inc BIIB.O rose 3.1% ahead of the U.S. FDA's decision on whether to approve its Alzheimer's drug aducanumab. By Shashank Nayar June 7 (Reuters) - Wall Street's main indexes were set for a tepid open on Monday as investors remained on the fence ahead of key inflation data later this week, while heavyweight technology shares largely shrugged off a deal by the world's richest nations on a global minimum corporate tax. The Group of Seven (G7) advanced economies agreed on Saturday to back a minimum global corporate tax rate of at least 15%, but analysts said immediate market implications would be minimal since the details remained to be negotiated over the coming months. New Article The Nasdaq Biotechnology index was soaring 2.7% after the US Food and Drug Administration Monday issued an accelerated approval for Biogen's (BIIB) and Eisai's Aduhelm Alzheimer's medication. In company news, Bionano Genomics (BNGO) rose 22% after the life sciences instrumentation company said it has hired former PerkinElmer (PKI) and Sema4 sales executive Jason Priar as its new chief commercial officer. Cerecor (CERC) climbed almost 14% after saying it secured up to $35 million in term loan funding from Horizon Technology Finance Corp (HRZN), including an initial $20 million tranche and the remaining $15 million contingent on the biopharmaceuticals company achieving certain milestones. New Article Drugmaker Biogen Inc BIIB.O rose 2.8% ahead of the U.S. FDA's decision on whether to approve its Alzheimer's drug aducanumab. By Shashank Nayar June 7 (Reuters) - U.S. stocks were little changed on Monday as investors remained on the fence ahead of key inflation data later this week, while heavyweight technology shares largely shrugged off a deal by the world's richest nations on a global minimum corporate tax. U.S. stocks ended higher on Friday after a tepid U.S. monthly jobs report relieved investors concerned about the Federal Reserve scaling back its massive stimulus program sooner than expected. New Article U.S. regulators approved Biogen Inc's BIIB.O aducanumab as the first treatment to address an underlying cause of Alzheimer's disease. QTS Realty surges on reports of deal with Blackstone Biogen halted as FDA approves Alzheimer's drug ""Meme stocks"" extend rally led by retail participation Small-cap stocks outperform broader market Indexes: Dow down 0.38%, S&P off o.31%, Nasdaq flat Adds comment, details; updates prices By Shashank Nayar June 7 (Reuters) - The S&P 500 eased on Monday, although it remained 0.5% away from its all-time high, as a deal by the world's richest nations on a global minimum corporate tax overshadowed bets on a full economic reopening. U.S. stocks ended higher on Friday after a tepid U.S. monthly jobs report relieved investors concerned about the Federal Reserve scaling back its massive stimulus program sooner than expected. New Article The FDA on Monday approved aducanumab from Biogen (NASDAQ: BIIB) and its longtime collaboration partner Eisai (OTC: ESALY). Aduhelm acts in the brain to remove amyloid protein fragments before they can form sticky plaques associated with Alzheimer's disease. Patients who receive monthly infusions of the drug will need regular MRIs to monitor for signs of dangerous brain swelling that occurred in some clinical trial participants, but the label contains no black box warnings to hinder its uptake. New Article Drugmaker Biogen Inc BIIB.O rose 3.1% ahead of the U.S. FDA's decision on whether to approve its Alzheimer's drug aducanumab. By Shashank Nayar June 7 (Reuters) - Futures tracking the S&P 500 and the Nasdaq fell on Monday as investors remained on the fence ahead of key inflation data later this week, while heavyweight technology shares largely shrugged off a deal by the world's richest nations on a global minimum corporate tax. The Group of Seven (G7) advanced economies agreed on Saturday to back a minimum global corporate tax rate of at least 15%, but analysts said immediate market implications would be minimal since the details remained to be negotiated over the coming months. New Article NEW YORK (Reuters Breakingviews) - A problem with Americas way of delivering healthcare is that it asks patients to put a price on hope. The FDA also has the option to pull the drug from the market if a subsequent study Biogen will perform doesnt show patient benefit. In November 2020, a panel of experts convened by the FDA concluded there was insufficient evidence to prove the drug was effective in treating Alzheimers. New Article By Deena Beasley June 7 (Reuters) - The U.S. FDA on Monday is expected to give its thumbs up or down on Biogen Inc's BIIB.O aducanumab, a decision that will affect the future of Alzheimer's disease research and treatment and show the agency's willingness to approve badly needed medicines based on less than definitive data. It is ""likely to reverberate throughout the biopharma sector, influencing overall sentiment on the space, perceptions on regulatory flexibility, and business development dynamics,"" RBC Capital Markets analyst Brian Abrahams said in a recent research note. The waters were further muddied when FDA staff concluded that the successful trial offered enough persuasive evidence, only to have a panel of outside advisers to the agency vote in November that data did not prove aducanumab could slow Alzheimer's progression. New Article Aduhelm, developed by Biogen Inc.(BIIB)/Eisai Co., Ltd., has been granted accelerated approval by the U.S. regulatory agency. BIIB is currently trading at $454.90, up 58.11%; LLY is at $228.95, up 13.33%. The primary objective of the study was to evaluate the efficacy of monthly doses of aducanumab as compared with placebo in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score. New Article Adobe (NASDAQ:ADBE) AstraZeneca (NASDAQ:AZN) Biogen (NASDAQ:BIIB) Dominos Pizza (NYSE:DPZ) Illumina (NASDAQ:ILMN) OReilly Automotive (NASDAQ:ORLY) Verizon (NYSE:VZ) Stocks to Buy Right Now: Adobe (ADBE) ADBE) logo on wall of corporate building."" Stocks to Buy Right Now: Biogen (BIIB) Source: Pavel Kapysh / Shutterstock.com 52-week range: $223.25  $363.92 This next stock to buy also comes from the biopharma industry. For the past year, BIIB stock is down about 7% but its up about 17% YTD. New Article U.S. regulators on Monday approved a drug jointly developed by Eisai and Biogen Inc's BIIB.O as the first treatment to attack a likely cause of Alzheimer's disease. TOKYO, June 8 (Reuters) - Japan's stock index Nikkei changed course and inched down on Tuesday, as losses in market heavyweights offset gains in drugmakers after Eisai Co's 4523.T Alzheimer drug received U.S. nod. ""Investors are also scooping up Japanese shares which lagged behind their global peers as prospects of an economic recovery has brightened amid a rollout of COVID-19 vaccines."" New Article Although all eyes will be on Biogen (NASDAQ: BIIB) after the FDA's historic approval of its Alzheimer's drug, aducanumab, the NIH funding keeps the momentum going for Cassava. What happened Shares of Cassava Sciences (NASDAQ: SAVA) rose 15% in May, according to data provided by S&P Global Market Intelligence. After a positive meeting with the Food and Drug Administration (FDA) in February, its treatment for Alzheimer's Disease (AD) got more good news in May: It received a $2.7 million grant from the National Institutes of Health (NIH). New Article Click to Enlarge Source: Chart courtesy of TrendSpider Biogen (NASDAQ:BIIB) received FDA approval for its Alzheimers drug, allowing the stock to erupt higher on Monday. 2: Biogen (BIIB) On the downside, Id like to see BIIB stock hold the $350 to $375 area. New Article Biogen (NASDAQ: BIIB) surged higher by more than 38% on Monday, and the gains came on hopes that the company might finally be able to solve the problem of Alzheimer's disease once and for all. But that's what happened today, and although the decision involves some controversy, the latest approval from the U.S. Food and Drug Administration paves the way for a potential breakthrough for the more than 6 million Americans who suffer from a terrible and debilitating illness. Using the marketing name Aduhelm for the drug, Biogen claimed the status as having the first and only Alzheimer's treatment addressing what it called ""a defining pathology of the disease"" by reducing amyloid beta plaque levels in patients' brains. New Article What happened Biotech heavyweight Biogen (NASDAQ: BIIB) is poised for a sizable jump in its share price later today once the trading halt on its stock is lifted following the surprise Food and Drug Administration approval of its controversial Alzheimer's disease drug aducanumab. The biotech's partner on this project, Eisai (OTC: ESALY), is enjoying a banner day in the market in the wake of this news, with the Japanese biopharma's shares rising by an astounding 45% as of 11:24 a.m. EDT Monday morning. The fact is that Biogen might ultimately generate upward of $10 billion per year from aducanumab, making it one of the best-selling drugs of all time. New Article * Biogen surges after FDA approves Alzheimer's drug * AMC leads extended ""meme stocks"" rally * Small-cap stocks outperform broader market * Indexes: Dow down 0.36%, S&P off 0.08%, Nasdaq up 0.49% (Updates with prices) By Stephen Culp NEW YORK, June 7 (Reuters) - The S&P 500 ended a languid session slightly in the red on Monday, with investors standing by on news of a global minimum corporate tax rate, lingering inflation fears, and a lack of market-moving economic news. Lawmakers in Washington are doubling down on efforts to craft a bipartisan infrastructure spending package, with House Democrats expected to bring a bill to vote as early as Wednesday. Data center operator QTS Realty Trust jumped 21.2% on reports of a takeover deal by investment firm Blackstone Group worth $6.7 billion. New Article Within that group, Biogen Inc (Symbol: BIIB) and Eli Lilly (Symbol: LLY) are two large stocks leading the way, showing a gain of 43.1% and 13.8%, respectively. Combined, BIIB and LLY make up approximately 4.5% of the underlying holdings of XLV. Combined, HFC and FANG make up approximately 2.2% of the underlying holdings of XLE. New Article Shares of Biogen Inc BIIB.O surged 42.741.7% on news that the Food and Drug Administration approved its Alzheimer's disease drug aducanumab. By Stephen Culp NEW YORK, June 7 (Reuters) - Wall Street started the week mixed on Monday as buyers stood on the sidelines on news of a global minimum corporate tax rate and lingering inflation fears, and a lack of market-moving catalysts. Lawmakers in Washington are doubling down on efforts to craft a bipartisan infrastructure spending package, with House Democrats expected to bring a bill to vote as early as Wednesday. New Article The tech-heavy index was helped by a massive 38.3% surge in Biogen (BIIB) shares, which came alive after the Food and Drug Administration approved the company's Alzheimer's treatment. ""We had upgraded BIIB on the potential for the regulatory saga around adu to create significant upside,"" says Canaccord Genuity analyst Sumant Kulkarni (Buy). ""Some might take profits here, but we continue to like the stock as today's approval allows BIIB to play much more strategic offense vs. what was a largely defensive posture earlier forced by competition to core products such as Tecfidera, Spinraza, etc."" New Article (Updates to market close) By Stephen Culp NEW YORK, June 7 (Reuters) - The S&P 500 ended a languid session nominally lower on Monday, with investors standing by on news of a global minimum corporate tax rate, lingering inflation fears, and a lack of market-moving catalysts. Lawmakers in Washington are doubling down on efforts to craft a bipartisan infrastructure spending package, with House Democrats expected to bring a bill to vote as early as Wednesday. Data center operator QTS Realty Trust jumped on reports of a takeover deal by investment firm Blackstone Group worth $6.7 billion.",247.18434143066406
2021-06-08 00:00:00+00:00,389.1000061035156,399.0700073242188,373.0,395.3699951171875,395.3699951171875,12209300.0,3.666666666666666,1.0,0.6666916666666668,"On June 7, the U.S. Food and Drug Administration (FDA) approved Biogen's (NASDAQ: BIIB) Aduhelm (aducanumab) for the treatment of Alzheimer's disease. Aduhelm previously failed two phase 3 clinical studies evaluating its efficacy and only demonstrated a therapeutic signal through a post-hoc analysis. The verdict There is a lot of panic buying at the moment, as most investors expected Aduhelm to outright fail to receive regulatory clearance. New Article Adds comments on demand, background June 8 (Reuters) - Biogen Inc BIIB.O said on Tuesday it expects to begin shipping its newly approved Alzheimer's drug Aduhelm in about two weeks and has prepared more than 900 healthcare centers for the intravenous infusion treatment. The U.S. Food and Drug Administration on Monday approved Aduhelm as the first treatment to target a likely underlying cause of Alzheimer's disease, sticky deposits of a protein called amyloid-beta. Revenue from Aduhelm could start ramping up in 2022 and beyond, but could be low in 2021 due to the need for sites to prepare to diagnose and treat patients, and the time that it will take to secure insurance coverage for the drug, McDonnell said. New Article NasdaqGS:BIIB Price Based on Past Earnings June 8th 2021 If you'd like to see what analysts are forecasting going forward, you should check out our free report on Biogen. Biogen Inc. (NASDAQ:BIIB) shareholders have had their patience rewarded with a 44% share price jump in the last month. Taking a look back first, the company's earnings per share growth last year wasn't something to get excited about as it posted a disappointing decline of 40%. New Article Biogen's (NASDAQ: BIIB) months of waiting on pins and needles are over. The FDA stated in briefing documents provided to the advisory committee that reviewed the drug that Biogen's clinical results were ""highly persuasive"" and showed ""an acceptable safety profile."" The bigger picture You might think that scooping up shares of a biotech with a freshly approved drug that could realistically generate peak annual sales of $10 billion is a no-brainer. New Article The global biotechnology company Biogen, Inc. (BIIB) and Eisai, Co. Ltd, a pharmaceutical company based in Japan, received accelerated approval from the FDA for ADUHELM, a pathbreaking treatment for Alzheimers disease. As part of the accelerated approval, Biogen will conduct a controlled trial to verify the clinical benefit of ADUHELM in patients with Alzheimers disease. (See Biogen stock analysis on TipRanks) The drug is said to have certain adverse symptoms in patients including ARIA (Amyloid Related Imaging Abnormalities), confusion, dizziness, visual disturbances, and nausea. New Article Like the move in Biogen (NASDAQ:BIIB) the other day, the stock rallied to the 161.8% extension before backing off. Click to Enlarge Source: Chart courtesy of TrendSpider Fastly (NYSE:FSLY) reported an outage overnight, taking a number of prominent websites down. Click to Enlarge Source: Chart courtesy of TrendSpider The iShares Russell 2000 ETF (NYSEARCA:IWM) is back in a leadership role, with the index near its highs. New Article By Julie Steenhuysen CHICAGO, June 8 (Reuters) - For Bill McKay, 69, of Haslett, Michigan, the U.S. approval of Biogen Inc's BIIB.O controversial Alzheimer's drug on Monday offers hope that the veteran of 29 marathons can keep on running. Bill McKay, a former coordinator in a lab that has been working on COVID-19 vaccines, was diagnosed with Alzheimer's last year and has what he describes as ""entry level"" disease, including memory problems and trouble navigating. Although the FDA approved the drug broadly for treatment of Alzheimer's dementia, Leahy said she plans to offer it to patients in the earliest stages of the disease - the group tested in clinical trials. New Article One day after flying sky high, Biogen (NASDAQ: BIIB) stock quickly obeyed gravity by falling marginally on Tuesday. Among the Biogen raisers was Stifel's Paul Matteis, who dramatically lifted his price target on the stock by $100 to $446 per share while maintaining his buy rating. Other prognosticators becoming notably more bullish on Biogen Tuesday included William Blair's Matt Phipps; he cranked his recommendation one notch higher, to outperform (read: buy) from the previous market perform (neutral). New Article By Julie Steenhuysen CHICAGO, June 8 (Reuters) - For Bill McKay, 69, of Haslett, Michigan, the U.S. approval of Biogen Inc's BIIB.O new Alzheimer's drug on Monday offers hope that the veteran of 29 marathons can keep on running. Bill McKay, a former coordinator in a lab that has been working on COVID-19 vaccines, was diagnosed with Alzheimer's last year and has what he describes as ""entry level"" disease, including memory problems and trouble navigating. The FDA has required a confirmatory trial to demonstrate that the Biogen treatment works as intended to slow cognitive and functional decline by removing amyloid plaques from the brain, but that could take years. New Article Especially high volume was seen for the $395 strike call option expiring June 11, 2021, with 5,103 contracts trading so far today, representing approximately 510,300 underlying shares of BIIB. Below is a chart showing WEN's trailing twelve month trading history, with the $30 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 84,479 contracts thus far today. That number of contracts represents approximately 8.4 million underlying shares, working out to a sizeable 419.6% of BIIB's average daily trading volume over the past month, of 2.0 million shares. New Article A tweet from Sen. Ron Wyden today blasted Biogen's (NASDAQ: BIIB) decision to price its newly approved Alzheimer's drug, Aduhelm, at $56,000 per year. Nevertheless, Biogen believes reducing amyloid beta plaques offers newfound hope to over 6 million Americans diagnosed with the disease, making Aduhelm worth its $56,000 per year price. On Twitter, Sen. Wyden reacted to Biogen's decision by tweeting: ""It's unconscionable to ask seniors and taxpayers to pay $56,000 a year for a drug that has yet to be proven effective. New Article June 8 (Reuters) - Biogen Inc BIIB.O said on Tuesday it expects to begin shipping its newly approved Alzheimer's drug Aduhelm in about two weeks and that over 900 infusion centers are ready to implement the treatment to patients. The U.S. Food and Drug Administration on Monday approved Aduhelm as the first treatment to target a likely underlying cause of Alzheimer's disease - sticky deposits of a protein called amyloid beta. Biogen Chief Executive Michel Vounatsos said the sites include clinical trials centers with currently confirmed amyloid beta positive patients, as well as other sites with the necessary infrastructure to diagnose and treat patients.",236.29104614257812
2021-06-09 00:00:00+00:00,395.0,414.7999877929688,390.8399963378906,406.9400024414063,406.9400024414063,6196900.0,2.333333333333333,1.0,0.3333583333333332,"Top Health Care Stocks To Buy [Or Sell] Today Biogen Inc (NASDAQ: BIIB) Novo Nordisk A/S (NYSE: NVO) Eli Lilly And Co (NYSE: LLY) Medtronic PLC (NYSE: MDT) Biogen Inc Biogen is making the headlines right now and with good reasons. On Monday, BIIB stock soared by a staggering 38.34% to close at $395.85. Hence, would you consider BIIB stock a top health care stock to buy now? New Article By Deena Beasley June 9 (Reuters) - Two members of a panel of outside advisors to the U.S. Food and Drug Administration have resigned in protest at the agency's decision to approve Biogen Inc's BIIB.O Aduhelm for treatment of Alzheimer's disease despite the committees recommendation against doing so. ""I was very disappointed at how the advisory committee input was treated by the FDA,"" Dr. Knopman told Reuters. The FDA on Monday gave the drug ""accelerated approval, based on evidence that it can reduce a likely contributor to Alzheimers, rather than proof of a clear benefit against the disease. New Article Eisai 4523.T dropped as much as 8.5% after two days of gains by daily limit after U.S. regulators approved the drug, developed by the firm and Biogen BIIB.O, for Alzheimer's disease. TOKYO, June 10 (Reuters) - Japanese shares inched higher on Thursday, as the service sector gained on prospects of economic reopenings and drugmakers rose on reports of government support, though Eisai eased after a big jump following U.S. approval of its Alzheimer's disease drug. Japan plans to finish vaccinating all citizens who have applied for shots by October-November, Prime Minister Yoshihide Suga said during a debate between party leaders on Wednesday.",251.59010314941406
2021-06-10 00:00:00+00:00,406.9400024414063,426.8200073242188,404.25,414.7099914550781,414.7099914550781,4753800.0,2.857142857142857,1.0,0.4643107142857143,"The sharp jump in BIIB stock can be attributed to the U.S. FDAs approval of Aduhelm, Biogens treatment for Alzheimers disease. BIIB stock has partly been weighed down due to Roches Evrysdi (risdiplam) approval by the U.S. FDA for the treatment of spinal muscular atrophy (SMA). Despite a large 45% move over the last five trading sessions, we believe BIIB stock can see much higher levels in the near term, primarily due to a sharp pickup in sales and earnings as Aduhelm hits the market. New Article By Mark Marex, Product Development Senior Specialist The Nasdaq Biotechnology Index (NBI) was launched on November 1, 1993, when the industry was still in the midst of the original biotech revolution ushered in by the discovery of recombinant DNA technology and Genentechs IPO in 1980. McKinsey Global Institute estimates that up to 60% of the worlds physical inputs could be made using biological means, while up to 45% of the worlds disease burden could be addressed, leading to $2-4T of annual direct economic potential globally by 2030-40.2 In practical terms, this means for example, shifting some meat and plant production from traditional, resource-intensive agricultural methods to lab-grown, while increasing yields in the former thanks to precision mapping of a plant or soils microbiome and subsequent genetic engineering; repurposing fermentation (and other existing, natural processes) to create sustainable, biodegradable (and in some cases, even self-repairing) fabrics; truly personalized medicine and nutrition plans stemming from increasingly cost-effective human genomics and direct-to-consumer testing; leveraging biofuels to more efficiently store energy while initiating biosequestration processes to capture carbon emissions; even using DNA to store near-limitless quantities of data. Summary While the Coronavirus pandemic continues to pose significant risks to both the macroeconomic and physical health of the entire planet, the Nasdaq Biotechnology Index offers a unique lens through which to view human societys scientific and technological advancements in fighting the virus. New Article What happened The U.S. Food and Drug Administration (FDA) granted accelerated approval to Biogen's (NASDAQ: BIIB) Alzheimer's disease drug Aduhelm (aducanumab) on Monday. The stocks of other companies developing experimental Alzheimer's disease therapies also jumped on news of the FDA approval of Aduhelm. Shares of Eli Lilly (NYSE: LLY), which is evaluating two candidates in late-stage clinical studies targeting the neurodegenerative disorder, rose 15.6%. New Article U.S. regulators earlier this week approved a drug developed by the firm and Biogen BIIB.O for Alzheimer's disease. TOKYO, June 10 (Reuters) - Japan's Nikkei index closed higher on Thursday, as shipping firms rose on prospects of more economic reopenings and drugmakers were boosted by reports of government support. Signs that more economies are reopening amid a steady vaccine rollout underpinned shipping firms .ISHIP.T, with Nippon Yusen 9101.T jumping 3.65% to be the biggest gainer on the Nikkei. New Article Drugmaker Eisai 4523.T jumped 7% after a sharp fall in the previous session amid a volatile trade this week after U.S. regulators approved of a drug developed by the firm and Biogen BIIB.O for Alzheimer's disease. TOKYO, June 11 (Reuters) - Japanese shares inched down in seesaw trading on Friday as technology stocks pulled back from early gains, with investors remaining cautious about the pace of domestic economic recovery. Toshiba 6502.T fell 1.48% after a report from independent investigators said the conglomerate asked the trade ministry to help counter activist investors at its annual general meeting last July. New Article (RTTNews) - Two members of an advisory committee of US Food and Drug Administration have resigned over the regulator's decision to approve Biogen Inc.'s (BIIB) new Alzheimer's drug. Mayo Clinic neurologist Dr. David Knopman, a panel member who recused from the advisors' meeting to review the drug due to conflict of interest, resigned on Wednesday. According to health-care magazine STAT News, a second member of the committee, Dr. Joel Perlmutter, has also resigned. New Article Going into Mondays PDUFA date for aducanumab, Biogens (BIIB) Alzheimers disease drug, the general view on Wall Street was that the treatments chances of making it pass the regulators were pretty slim. (See BIIB stock analysis on TipRanks) To find good ideas for biotech stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. While the FDA acknowledged the advisory committees negative opinion and controversies surrounding the drugs filing, in the end, the regulatory body decided that the treatments benefits outweighed the risks.",252.1936798095703
2021-06-11 00:00:00+00:00,423.3299865722656,427.5,395.3299865722656,396.6400146484375,396.6400146484375,4221600.0,2.75,1.0,0.437525,"The post BIIB Stock: 9 Things to Know About Biogens Alzheimer Drug Approval Controversy appeared first on InvestorPlace. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen (NASDAQ:BIIB) stock is dipping lower today on the additional controversy surrounding the approval of its Alzheimers drug, Aduhelm. Source: PictureDesignSwiss / Shutterstock.com Heres everything investors need to know about the drug approval controversy and why its affecting BIIB stock. New Article That includes the latest news concerning Chewy (NYSE:CHWY), Senseonics Holdings (NYSEMKT:SENS), and Biogen (NASDAQ:BIIB) shares. SENS Stock: Why Reddit Is Betting Big on a Short Squeeze for Senseonics Today BIIB Stock: 9 Things to Know About Biogens Alzheimer Drug Approval Controversy On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The post CCXI Stock: 12 Things to Know About ChemoCentryx as Shares Surge Today appeared first on InvestorPlace. New Article When the Food and Drug Administration (FDA) approved Biogen's (NASDAQ: BIIB) aducanumab -- now marketed as Aduhelm -- for treating Alzheimer's Disease, it marked the end of a long drought. Biogen initially scrapped its two aducanumab phase 3 studies in early 2019, then decided to file for regulatory approval later that year after analyzing a larger data set. The floodgates are open Whether Biogen is able to prove the efficacy of Aduhelm in its continuing study or another Alzheimer's drug becomes the darling of Wall Street, one thing is clear. New Article Drugmaker Eisai 4523.T jumped 7.0% after a sharp fall in the previous session amid a volatile trade this week following U.S. regulators' approval of a drug developed by the firm and Biogen BIIB.O for Alzheimer's disease. Toshiba Corp 6502.T shed 1.59% after an explosive investigation released on Thursday found the company and the government colluded to lean on foreign investors to fall in line with management's wishes. Some market participants doubt Japan's economy will recover as quickly as that of the United States and other advanced nations, as the country grapples with a fourth wave of the pandemic. New Article That includes the latest news that has Senseonics Holdings (NYSEMKT:SENS) and Biogen (NASDAQ:BIIB) shares on the move, as well as the winners and losers in pre-market trading today. More Friday Stock Market News SENS Stock: Why Reddit Is Betting Big on a Short Squeeze for Senseonics Today BIIB Stock: 9 Things to Know About Biogens Alzheimer Drug Approval Controversy Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. Source: rafapress / Shutterstock.com The bad news from Chewys earnings report doesnt have to do with its most recent results. New Article The Biogen Inc BIIB.O drug, Aduhelm, was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer's, rather than proof that it slows progression of the lethal mind-wasting disease. He said the FDA made its decision ""by fiat,"" and had not asked its advisors to consider whether the drug's ability to remove a type of brain plaques known as beta amyloid would improve outcomes for patients. Biogen has said that some 1.5 million Americans with early-stage Alzheimer's will be eligible for the drug, priced at an average of $56,000 per year, with the federal Medicare insurance program for seniors likely on the hook for most of the cost. New Article That includes the most recent news concerning Novan (NASDAQ:NOVN), ChemoCentryx (NASDAQ:CCXI), and Biogen (NASDAQ:BIIB). More Medical Stock News for Friday NOVN Stock: The Positive Trial Results Sending Novan Skyrocketing Today CCXI Stock: 12 Things to Know About ChemoCentryx as Shares Surge Today BIIB Stock: 9 Things to Know About Biogens Alzheimer Drug Approval Controversy On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. It also points out that the study confirmed its proof of concept for an oral small molecule corrector to promote the proper folding of the mutant Z-AAT protein. New Article Healthcare stocks <.SPXHC> sank 1.1% and were among the worst-performing S&P sectors amid growing criticism of the U.S. Food and Drug Administration's controversial approval of an Alzheimer's drug developed by Biogen Inc BIIB.O. By Ambar Warrick and Devik Jain June 11 (Reuters) - U.S. stock indexeswere flat on Friday as focus turned to next week's Federal Reserve meeting, while technology and growth- exposed sectors gained after inflation data calmed fears over a long-term spike in consumer prices. With recent data also indicating weakness in the labor market, the Fed is widely expected to maintain accommodative policy at its meeting next week, which is positive for stocks and other risk-driven assets. New Article The Food and Drug Administration is facing mounting criticism over its ""accelerated approval"" of Biogen Inc's BIIB.O Alzheimer's drug Aduhelm without strong evidence of its ability to combat the disease. By Stephen Culp NEW YORK, June 11 (Reuters) - The S&P 500 closed nominally higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected. Investors now turn their attention to the Fed's statement at the conclusion of next week's two-day monetary policy meeting, which will be parsed for clues regarding the central bank's timetable for raising key interest rates. New Article The Food and Drug Administration is facing mounting criticism over its ""accelerated approval"" of Biogen Inc's BIIB.O Alzheimer's drug Aduhelm without strong evidence of its ability to combat the disease. By Stephen Culp NEW YORK, June 11 (Reuters) - Wall Street stocks were mixed at the close of a languid week marked with few market-moving catalysts and lingering concerns over whether longer-term inflation could prompt the U.S. Federal Reserve to tighten its dovish policy sooner than expected. The Nasdaq .IXIC was modestly higher, and the S&P 500 .SPX was essentially flat, with the latter hovering just below its record closing high, while the Dow .DJI, weighed by healthcare stocks .SPXHC edged into negative territory. New Article The Food and Drug Administration is facing mounting criticism over its ""accelerated approval"" of Biogen Inc's BIIB.O Alzheimer's drug Aduhelm without strong evidence of its ability to combat the disease. By Stephen Culp NEW YORK, June 11 (Reuters) - U.S. stocks closed modestly higher at the end of a torpid week marked with few market-moving catalysts and persistent concerns over whether current inflation spikes could linger and cause the U.S. Federal Reserve to tighten its dovish policy sooner than expected. Investors now turn their attention to the Fed's statement at the conclusion of next week's two-day monetary policy meeting, which will be parsed for clues regarding the central bank's timetable for raising key interest rates. New Article On the heels of a controversial U.S. Food and Drug Administration (FDA) decision, J.P. Morgan Securities chimed in on Biogen (BIIB) with a hefty price-target hike. Though May's CPI reading saw its fastest growth since summer of 2008 -- up 6% year-over-year, and 0.6% for the month -- Wall Street largely shrugged it off, sending the S&P 500 to finally snag a fresh record high on Thursday. Tilray (TLRY) also entered the fold, and the cannabis producer's CEO welcomed the attention with open arms, lauding retail traders' high level of knowledge on the company and its products.",264.4445495605469
2021-06-14 00:00:00+00:00,396.239990234375,409.8800048828125,395.1400146484375,406.1400146484375,406.1400146484375,2102600.0,4.0,1.0,0.7500249999999999,"And the worst performing Nasdaq 100 component thus far on the day is Moderna, trading down 8.6%. Moderna is showing a gain of 91.6% looking at the year to date performance. VIDEO: Nasdaq 100 Movers: MRNA, ADBE The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",257.3531188964844
2021-06-15 00:00:00+00:00,403.5,410.4100036621094,393.9100036621094,396.0799865722656,396.0799865722656,1905100.0,3.0,1.0,0.5000249999999999,"Eisai shares have been volatile since the company's Alzheimer's drug, developed in partnership with Biogen Inc BIIB.O, got a nod from U.S. regulators last week. TOKYO, June 15 (Reuters) - Japanese shares closed higher on Tuesday, buoyed by technology and growth-oriented stocks following a strong finish on the Nasdaq overnight, while drug makers extended their gains. The Nikkei .N225 jumped 0.96% to 29,441.30, posting its biggest gain since late May, while the broader Topix .TOPX rose 0.8% to 1,975.48, closing at its highest since early April. New Article The Cambridge, Massachusetts-based company has been developing zuranolone with partner Biogen Inc BIIB.O. The 543-participant study assessed Sage's once-daily oral drug, zuranolone, as a two-week course for depression episodes, after which patients can return to work or their normal life. Biogen tied up with Sage in a deal worth over $1.5 billion plus milestone payments in November to co-develop drugs for depression and other neurological disorders. New Article Biogen (NASDAQ: BIIB) investors got some great news last week when the U.S. Food and Drug Administration (FDA) approved the company's Alzheimer's drug, Aduhelm. Back in November, shares of Biogen skyrocketed when the FDA called the company's drug trials ""highly persuasive"" and hinted that approval may be inevitable given its effectiveness. While analysts have been cheering, setting price targets as high as $500 for Biogen, those rosy outlooks could change quickly if another trial doesn't put critics' fears to rest. New Article In corporate news, Biogen Inc BIIB.O fell 0.9% in premarket trading after the drugmaker's potential therapy for choroideremia, an inherited disease that leads to vision loss, did not meet the main goal in a late-stage study. By Shashank Nayar June 15 (Reuters) - Futures tied to the S&P 500 and the Nasdaq held near record highs on Tuesday as investors looked for comments from the Federal Reserve about whether a recent jump in inflation would prompt a sooner-than-expected tapering in monetary policy. The Fed is likely to announce in August or September a strategy for reducing its massive bond buying program, but won't start cutting monthly purchases until early next year, a Reuters poll of economists found. New Article Sage Therapeutics (SAGE) and Biogen (BIIB) said their phase 3 study of zuranolone in patients with major depressive disorder has met its primary endpoint. The Health Care SPDR (XLV) was advancing by 0.13% and the iShares NASDAQ Biotechnology Index (IBB) was declining 0.07%. Cerevel Therapeutics Holdings (CERE) was climbing 6.9% after saying its CVL-871 therapy received a fast-track designation from the US Food and Drug Administration for treating dementia-related apathy. New Article BIIB data by YCharts Biogen's results for its first quarter ending March 31 weren't impressive, though, and the company owes this performance almost entirely to Aduhelm. Biotech giant Biogen (NASDAQ: BIIB) can certainly testify to the truth of this piece of wisdom. The controversial decision will likely continue generating tons of headlines, but with this major win under its belt, how much upside can Biogen's shareholders expect? New Article In corporate news, Biogen Inc BIIB.O dipped 0.1% after the drugmaker's potential therapy for choroideremia, an inherited disease that leads to vision loss, did not meet the main goal in a late-stage study. By Shashank Nayar and Medha Singh June 15 (Reuters) - U.S. stocks eased on Tuesday after the S&P 500 hit a record high earlier in the session, as investors awaited cues from the Federal Reserve about whether a recent jump in inflation would prompt a sooner-than-expected tapering in monetary policy. Assurance from the Fed that rising prices, coupled with falling U.S. Treasury yields, are transitory have helped ease some concerns over inflation with all eyes turning to the central bank's statement at the end of its two-day policy meeting on Wednesday. New Article Sage Therapeutics (SAGE, -19.3%) was a notable decliner after the biotech reported Phase 3 data for the depression drug it's producing with Biogen (BIIB, -2.5%). ""May's decline in headline sales was mostly concentrated in durable goods categories, which had shown especially outsized gains in March,"" say Barclays economists Jonathan Millar and Michael Gapen. ""Markets have been discounting recent economic data with the belief that some of the base effects, supply chain constraints and bottlenecks (expect to hear that word a lot tomorrow) will begin to unwind as we approach Q3."" New Article In corporate news, Biogen Inc BIIB.O dipped 0.7% after the drugmaker's potential therapy for choroideremia, an inherited disease that leads to vision loss, did not meet the main goal in a late-stage study. By Shashank Nayar and Medha Singh June 15 (Reuters) - U.S. stocks eased on Tuesday after the S&P 500 hit a record high earlier in the session, as a strong inflation reading for May raised caution that the Federal Reserve could taper monetary stimulus sooner than expected. Assurance from the Fed that rising prices are transitory and falling U.S. Treasury yields have helped ease some concerns over inflation and supported U.S. stocks in recent weeks, with all eyes now on the central bank's statement at the end of its two-day policy meeting on Wednesday. New Article So what Today, Sage Therapeutics announced top-line results from the Waterfall study with zuranolone, a potential new drug for major depressive disorder that the company is developing in partnership with Biogen (NASDAQ: BIIB). Finally, results from the Waterfall study suggest zuranolone isn't capable of reliably providing long-term benefits. Today's results for zuranolone suggest its chances of earning accelerated approval from the Food and Drug Administration are slim. New Article Biogen (NASDAQ: BIIB) stock has been on fire for the past month with a stunning gain of 46%, adding over $20 billion to its market cap. The major plot twist Aduhelm demonstrated a small, variable, nonreplicable benefit in improving cognition among patients with mild or moderate Alzheimer's disease in clinical studies. From an investment standpoint, however, everything is working out -- Biogen plans to roll out Aduhelm within two weeks, and analysts from UBS are already predicting a whopping $13 billion in peak sales.",264.671142578125
2021-06-16 00:00:00+00:00,394.2999877929688,403.010009765625,388.5199890136719,391.30999755859375,391.30999755859375,1572800.0,3.2,1.0,0.550025,"Biopharmaceutical company Sage Therapeutics, Inc. (SAGE) and Biogen Inc. (BIIB), a pioneer in neuroscience, together announced positive results for the Zuranolone drug, which is being evaluated for the treatment of Major Depressive Disorder (MDD). Following the announcement, Oppenheimer analyst Jay Olson reiterated a Buy rating on the stock with a price target of $100, implying 70.1% upside potential to current levels. Olson said, We believe these results support the rapid-acting profile of Zuranolone as a differentiated approach to episodic MDD, which remains a large unmet need We suspect market reaction reflects misconceptions about relative importance of rapid onset vs. durability, providing an attractive entry point for SAGE. The rest of the Street is cautiously optimistic about the stock with a Moderate Buy consensus rating based on 8 Buys versus 9 Holds. New Article Now that the Food and Drug Administration has approved Biogen's (NASDAQ: BIIB) Aduhelm despite its mixed results, it theoretically made it much easier for new treatments to get the green light. Despite its phase 2 study only being set up to detect biomarkers (secondary indicators of possible improvement), preliminary data is showing gains in primary function. In four previous animal models studied for memory and learning, the drug led to a full recovery in mice with AD, stroke, Down syndrome, and traumatic brain injury. New Article It would be no exaggeration to say last weeks FDA decision to approve Aduhelm - Biogens (BIIB) treatment for Alzheimers - is a landmark result in the fight against the memory-obliterating disease. The leading neurologist oversees 1,000+ Alzheimer's patients at his South U.S. center and has taken part in 30-40 trials including BIIB's EMERGE study and Roches trials. 30-40% of patients will 'drop out' due to PET radiopharmacy ordering failures (10-15%), ARIA safety, dosing inconvenience, and noncompliance (skipping dose). All in all, Yee rates BIIB shares a Buy and his $500 price target implies ~28% upside from current levels. New Article By Deena Beasley June 16 (Reuters) - A U.S. hospital on Wednesday will give the first infusion of an expensive, controversial new Alzheimer's drug from Biogen Inc BIIB.O before Medicare had even said what it will pay for - and with some doctors upset by its approval last week. Dr. David Knopman, a neurologist at the Mayo Clinic in Rochester, Minnesota was one of three experts who resigned from a panel of advisors to the FDA which had recommended that the agency not approve Biogen's drug. Biogen, which is partnered on the drug with Japanese drugmaker Eisai Co Ltd 4523.T, has set an average price of $56,000 a year, which the Alzheimer's Association - a longtime outspoken supporter of the company - called ""simply unacceptable."" New Article By Deena Beasley June 16 (Reuters) - A U.S. hospital on Wednesday gave the first infusion of an expensive, controversial new Alzheimer's drug from Biogen Inc BIIB.O before Medicare had even said what it will pay for - and with some doctors upset by its approval last week. Dr. David Knopman, a neurologist at the Mayo Clinic in Rochester, Minnesota was one of three experts who resigned from the panel of advisors which had recommended that the FDA not approve Biogen's drug. Biogen said it hoped the ""value-based contract"" it agreed to with Cigna last week that will track the drug's effectiveness was a step toward ""efficient and affordable patient access.""",267.5072326660156
2021-06-17 00:00:00+00:00,391.30999755859375,396.8900146484375,380.1700134277344,383.5199890136719,383.5199890136719,1832800.0,4.0,1.0,0.7500249999999999,"7 A-Rated Biotech Stocks to Buy Now With that in mind here are 4 undervalued biotech stocks that belong on your buy list: Sage Therapeutics (NASDAQ:SAGE) Innoviva (NASDAQ:INVA) Biogen (NASDAQ:BIIB) SIGA Technologies (NASDAQ:SIGA) These biotech stocks combine above-average long-term growth prospects with below-average valuation multiples. Biogen (BIIB) Source: PictureDesignSwiss / Shutterstock.com Biogen stock recently had a nice rally as the Food and Drug Administration green lit the companys drug Aduhelm for treatment of Alzheimers disease. And despite the bad year of 2020, BIIB stock shows consistency when it comes to the bottom line, profitability; Biogen has turned a profit every year since 2011.",278.8642272949219
2021-06-18 00:00:00+00:00,387.1900024414063,391.0,381.6499938964844,388.4400024414063,388.4400024414063,2873600.0,2.0,1.0,0.250025,"When the U.S. Food and Drug Administration (FDA) approved Biogen's (NASDAQ: BIIB) drug Aduhelm for Alzheimer's disease on June 7, its stock immediately popped nearly 64%, rewarding shareholders who had stayed the course through the long and difficult approval process. Why there still might be upside for investors who buy the stock right now Peak revenue from Aduhelm could be as much as $10 billion per year if Biogen can deeply penetrate the market of 6 million patients with Alzheimer's in the U.S. Poor efficacy could pull margins lower, but the real risk is that doctors will hesitate to prescribe an expensive and dubiously effective drug, thereby driving down sales. New Article By Deena Beasley and Julie Steenhuysen June 18 (Reuters) - Data from clinical trials of three experimental Alzheimer's disease drugs expected to start emerging next year could help shed light on whether U.S. regulators were justified in their controversial approval of a Biogen Inc BIIB.O treatment without clear evidence that it works. But data expected much sooner on three drugs that work in a similar manner - Eli Lilly and Co's LLY.N donanemab, Roche Holding AG's ROG.S gantenerumab, and partners Eisai Co 4523.T and Biogen's lecanemab - could give the medical community a better sense of whether Aduhelm is up to the job of slowing the ravages of Alzheimer's. All four drugs are antibodies aimed at reducing the accumulation of the sticky plaques composed of a protein called beta amyloid found in the brains of people with Alzheimer's, a disease that currently afflicts some six million Americans.",275.3020324707031
2021-06-21 00:00:00+00:00,388.8599853515625,390.989990234375,379.1099853515625,380.9100036621094,380.9100036621094,1897900.0,2.0,1.0,0.250025,"Among the largest underlying components of XBI, in trading today Biogen Inc (Symbol: BIIB) is down about 0.1%, Intellia Therapeutics Inc (Symbol: NTLA) is up about 3.7%, and CareDx Inc (Symbol: CDNA) is higher by about 1%. For a complete list of holdings, visit the XBI Holdings page  The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $100.64 per share, with $174.79 as the 52 week high point  that compares with a last trade of $133.87. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Among large Healthcare stocks, Biogen Inc (Symbol: BIIB) and Organon & Co (Symbol: OGN) are the most notable, showing a loss of 1.7% and 0.6%, respectively. Combined, BIIB and OGN make up approximately 1.4% of the underlying holdings of XLV. In afternoon trading on Monday, Technology & Communications stocks are the worst performing sector, higher by 1.1%. New Article Along with Biogen (NASDAQ: BIIB) and Japanese pharma Shionogi, Sage secured $1.59 billion in cash and investments to develop zuranolone. The trial design also excluded patients who had active psychosis or pregnancy-related depressive symptoms, were at risk of suicide, had failed previous courses of antidepressive therapy, or had a history of bipolar disorder or schizophrenia. That's not all: Patients receiving zuranolone experienced far higher rates of somnolence, dizziness, headaches, and sedation compared to placebo.",271.77191162109375
2021-06-22 00:00:00+00:00,379.9500122070313,381.0,369.489990234375,374.3999938964844,374.3999938964844,1770000.0,2.0,1.0,0.250025,"By Julie Steenhuysen June 22 (Reuters) - The U.S. Food and Drug Administration on Tuesday released a sweeping series of memos revealing a clear struggle within the agency ahead of its controversial decision to approve Biogen's BIIB.O Alzheimer's drug Aduhelm. The June 7 approval has been met with fierce opposition by some scientists criticizing the FDA's decision making, culminating in the public resignations of three of the 11 members of its independent advisory panel. ""What we heard really shaped our thinking in our discussions over these almost seven months between the advisory committee and the approval,"" Dr. Patrizia Cavazzoni, director of the Center for Drug Evaluation and Research, said in a telephone interview with Reuters. New Article By Julie Steenhuysen June 22 (Reuters) - The U.S. Food and Drug Administration on Tuesday released a sweeping series of memos revealing a clear struggle within the agency ahead of its controversial decision to approve Biogen's BIIB.O Alzheimer's drug Aduhelm. The June 7 approval has been met with fierce opposition by some scientists criticizing the FDA's decision making, culminating in the public resignations of three of the 11 members of its independent advisory panel. ""What we heard really shaped our thinking in our discussions over these almost seven months between the advisory committee and the approval,"" said Dr. Patrizia Cavazzoni, director of the FDA's Center for Drug Evaluation and Research.",270.6070861816406
2021-06-23 00:00:00+00:00,376.010009765625,376.010009765625,364.2999877929688,371.8999938964844,371.8999938964844,1778500.0,3.5,1.0,0.6250249999999999,"June 23 (Reuters) - Biogen Inc BIIB.O and Japanese partner Eisai Co 4523.T said on Wednesday the U.S. Food and Drug Administration had granted breakthrough therapy designation to their experimental therapy, lecanemab, for patients with early Alzheimer's. The drug works in a similar manner to Biogen's Aduhelm, which was approved earlier this month. It removes sticky deposits of a protein called amyloid beta from the brains of patients in the earlier stages of Alzheimer's in order to stave off its impact, including memory loss and the inability to take care of oneself. New Article June 23 (Reuters) - Biogen Inc BIIB.O and partner Eisai Co Ltd 4523.T said on Wednesday they were working to speed up completion of a confirmatory trial of their controversial Alzheimer's drug that was recently given an accelerated approval by the U.S. drug regulator. On Tuesday, the FDA defended its decision to approve the drug and told Reuters it was working with the drugmakers to accelerate the completion of the study. Biogen and its partner said they were engaging with U.S. Centers for Medicare & Medicaid Services (CMS) to help provide patients across a spectrum of financial situations access to the drug.",267.39520263671875
2021-06-24 00:00:00+00:00,349.9599914550781,358.3699951171875,346.3500061035156,349.1600036621094,349.1600036621094,4647600.0,2.714285714285715,1.0,0.4285964285714286,"The news comes weeks after Biogen Inc BIIB.O Alzheimer's drug, Aduhelm, was approved under the U.S. Food and Drug Administration's accelerated approval pathway, for which the agency came under intense criticism as questions were raised on the strength of the clinical data. The drugmaker said it intends to file the marketing application based on data from the mid-stage trial. The FDA granted donanemab a breakthrough therapy designation, meant to expedite the development and review of medicines for serious or life-threatening conditions. New Article Large-cap biotech Biogen (NASDAQ: BIIB) recently advanced its own Alzheimer's drug, Aduhelm, past regulatory hurdles despite questionable efficacy data. That company's recent anti-tau antibody, BIIB092, also showed no statistically significant benefit in improving cognition in phase 2. In the clinical trial, patients with mild to moderate Alzheimer's disease who took simufilam showed statistically significant improvements in biomarkers present in their cerebrospinal fluids. New Article Below, we'll look at why Eli Lilly (NYSE: LLY) and Luminar Technologies (NASDAQ: LAZR) stood out from the crowd on Thursday as stocks with great prospects for a bright future. That took the market cap of the drugmaker above the $225 billion mark, and Lilly continued a string of record highs from throughout the past year as it offered good news in the fight against Alzheimer's disease. That motivated a change in Lilly's strategy, as it now hopes to take advantage of the expedited process for reviewing study results to seek full FDA approval for donanemab as soon as later this year. New Article In response, Biogen Inc BIIB.O, which received a controversial approval for its Alzheimer's drug aducanumab earlier this month, tumbled 6.1%. By Noel Randewich and Devik Jain June 24 (Reuters) - The Nasdaq and the S&P 500 indexes closed at record highs on Thursday, with the Dow also jumping almost 1% after U.S. President Joe Biden embraced a bipartisan Senate infrastructure deal. Construction and mining equipment maker Caterpillar CAT.N and aerospace firm Boeing BA.N both jumped more than 2%, helping lift the Dow Jones Industrial Average. New Article In response, Biogen Inc BIIB.O, which received a controversial approval for its Alzheimer's drug aducanumab earlier this month, dropped 7.5%. By Devik Jain and Medha Singh June 24 (Reuters) - The Nasdaq was set to open at a record high on Thursday, boosted by shares of Tesla and other top-shelf technology firmsas data showing fewer weekly jobless claims pointed to a steady recovery in the labor market. Initial claims for state unemployment benefits fell 7,000 to 411,000 for the week ended June 19, the Labor Department said on Thursday, but were still higher than the 380,000 that economists had forecast. New Article In response, Biogen Inc BIIB.O, which received a controversial approval for its Alzheimer's drug aducanumab earlier this month, dropped 5%. By Devik Jain and Medha Singh June 24 (Reuters) - The Nasdaq and the S&P 500 indexes hit all-time highs on Thursday, boosted by shares of Tesla and other top-shelf technology firmsas data showing fewer weekly jobless claims bolstered views of a steady recovery in the labor market. So far this month, the value index .IVX, which includes economy-linked energy, financial and industrial stocks, is lagging its tech-heavy growth counterpart .IGX despite maintaining a strong lead year-to-date. New Article VIDEO: S&P 500 Movers: BIIB, LLY The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Year to date, Eli Lilly registers a 39.3% gain. And the worst performing S&P 500 component thus far on the day is Biogen, trading down 5.5%. New Article Biogen (NASDAQ:BIIB) had a major breakthrough with the approval of its Alzheimers vaccine aducanumab, which is sold under the brand name Aduhelm. Though there are differing opinions about the vaccines effectiveness, BIIB stock returned a healthy 30% so far in June. Late last month, the FDAs advisory board granted it breakthrough therapy designation and a Biologics License Application (BLA) review on priority. New Article * Weekly jobless claims fall, Q1 GDP unrevised at 6.4% * Tesla shares boost Nasdaq, S&P 500 * Lilly jumps on plan to seek approval for Alzheimer's drug (Updates with end of session) By Noel Randewich and Devik Jain June 24 (Reuters) - The Nasdaq and the S&P 500 indexes closed at record highs on Thursday, with the Dow also jumping after U.S. President Joe Biden embraced a bipartisan Senate infrastructure deal. Construction and mining equipment maker Caterpillar and aerospace firm Boeing jumped, helping lift the Dow Jones Industrial Average. ""In the short term, I think there will be some 'buy the rumor and sell the news' in materials and industrials, but as we start to see more details come out about how the money will be spent, I think we will get a continued benefit,"" said Sal Bruno, chief investment officer at IndexIQ in New York. New Article NEW YORK (Reuters Breakingviews) - Eli Lillys announcement on Thursday that it would seek approval https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-receives-us-fdas-breakthrough-therapy for its Alzheimers drug years ahead of schedule proves the power of incentives. It comes just two weeks after the U.S. Food and Drug Administration approved a Biogen therapy that is shown to reduce protein plaques in patients brains. (By Robert Cyran) On Twitter http://twitter.com/breakingviews Capital Calls - More concise insights on global finance: NFL tries opportunistic stake-sale play Bank of England loses a bulwark against groupthink UK housebuilder may have hit haggling limit Visa $2 bln EU fintech deal has ominous precedent Siemens digital hype lacks ambition (Editing by Richard Beales and Oliver Taslic) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Among large Healthcare stocks, Biogen Inc (Symbol: BIIB) and ABIOMED, Inc. (Symbol: ABMD) are the most notable, showing a loss of 5.5% and 3.0%, respectively. Combined, BIIB and ABMD make up approximately 1.5% of the underlying holdings of XLV. In afternoon trading on Thursday, Utilities stocks are the worst performing sector, not showing much of a gain. New Article In response, Biogen Inc BIIB.O, which received a controversial approval for its Alzheimer's drug aducanumab earlier this month, dropped almost 6%. By Noel Randewich and Devik Jain June 24 (Reuters) - The Nasdaq and the S&P 500 indexes hit all-time highs on Thursday, with the Dow also jumping, as U.S. President Joe Biden embraced a bipartisan Senate infrastructure deal. ""In the short term, I think there will be some 'buy the rumor and sell the news' in materials and industrials, but as we start to see more details come out about how the money will be spent, I think we will get a continued benefit,"" said Sal Bruno, chief investment officer at IndexIQ in New York. New Article In response, Biogen Inc BIIB.O, which received a controversial approval for its Alzheimer's drug aducanumab earlier this month, dropped 6%. By Devik Jain and Medha Singh June 24 (Reuters) - The Nasdaq and the S&P 500 indexes hit all-time highs on Thursday, boosted by shares of Tesla and other top-shelf technology firmsas data showing fewer weekly jobless claims bolstered views of a steady recovery in the labor market. Initial claims for state unemployment benefits fell 7,000 to 411,000 for the week ended June 19, the Labor Department said on Thursday, but were still higher than the 380,000 that economists had forecast. New Article VIDEO: Nasdaq 100 Movers: BIIB, TSLA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing Nasdaq 100 component thus far on the day is Biogen, trading down 5.0%. Biogen is showing a gain of 44.3% looking at the year to date performance.",259.5339050292969
2021-06-25 00:00:00+00:00,348.6700134277344,353.57000732421875,345.1300048828125,347.92999267578125,347.92999267578125,2251600.0,1.0,1.0,2.4999999999997247e-05,"Adds details from House panel statement, background June 25 (Reuters) - U.S. lawmakers on Friday announced an investigation into the approval and pricing of Biogen Inc's BIIB.O Alzheimer's drug, Aduhelm, amid concerns over its steep price and doubts if the clinical evidence proves the drug works. The drug, which has a list price of $56,000 per year, was approved by the U.S. regulators as the first treatment to attack a likely cause of Alzheimer's on June 7. ""We have serious concerns about the steep price of Biogen's new Alzheimer's drug Aduhelm and the process that led to its approval despite questions about the drug's clinical benefit,"" House Committee on Oversight and Reform said in a statement. New Article June 25 (Reuters) - A U.S. House panel said on Friday it would examine the approval and pricing of Biogen Inc's BIIB.O Alzheimer's drug, Aduhelm. Biogen had announced a list price of $56,000 per year for the drug. (Reporting by Dania Nadeem in Bengaluru; Editing by Arun Koyyur) ((Dania.Nadeem@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",264.902099609375
2021-06-28 00:00:00+00:00,343.0,343.4599914550781,333.2799987792969,340.2699890136719,340.2699890136719,1942700.0,3.6666666666666665,1.0,0.6666916666666666,"Plus, Motley Fool contributor Keith Speights discusses the latest on COVID-19 vaccines, Johnson & Johnson (NYSE: JNJ), and the controversy surrounding the FDA's approval of Biogen's (NASDAQ: BIIB) treatment for Alzheimer's. Homebuilder Lennar (NYSE: LEN) posts strong profits, and electric-truck maker Lordstown Motors (NASDAQ: RIDE) needs new management. The consumer goods business founded by actress Jessica Alba posted revenue that was higher than expected, but shares of Honest Company falling this week and down 30% from its IPO just last month, Jason? New Article What happened Alzamend Neuro (NASDAQ:ALZN) stock popped on Monday, with shares jumping 11.8% as of 3:42 p.m. EDT after rising as much as 41.2% at one point. However, Biogen's recent U.S. approval win for Aduhelm has generated significantly more interest among investors in companies such as Alzamend that are developing experimental therapies to target the indication. Now what The main thing to watch with Alzamend is the company's progress in filing an Investigational New Drug (IND) application for AL001 to advance the candidate into early-stage clinical testing. New Article VIDEO: Nasdaq 100 Movers: BIIB, NTES The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing Nasdaq 100 component thus far on the day is Biogen, trading down 3.5%. Biogen is showing a gain of 37.1% looking at the year to date performance.",264.2912902832031
2021-06-29 00:00:00+00:00,338.8699951171875,346.7099914550781,336.7200012207031,345.7200012207031,345.7200012207031,1427500.0,2.6666666666666665,1.0,0.4166916666666666,"Biogen (NASDAQ: BIIB) received fantastic news in early June with the U.S. Food and Drug Administration (FDA) approved Aduhelm in treating Alzheimer's disease. Biogen announced that its experimental gene therapy targeting a rare genetic retinal disease didn't meet the primary or key secondary endpoints at a phase 3 study. Speights: Yeah, Brian, I can't help but think how this news would have impacted Biogen, how the company not received FDA approval for Aduhelm. New Article Biogen's (NASDAQ: BIIB) stock roared on June 7 after the unexpected approval of its Alzheimer's disease drug, Aduhelm. The latest problem appears to be that the FDA gave Biogen special treatment with Aduhelm by interpreting the drug's proven ability to clear amyloid beta proteins as evidence of its efficacy in treating Alzheimer's symptoms. Notably, while plaques of amyloid beta proteins are associated with Alzheimer's disease, researchers have long struggled to understand exactly how they relate to its progression or a patient's symptoms. New Article InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen (NASDAQ:BIIB) stock has been one of the few drug stocks that have lit up the investment world recently. Upon the announcement in early June, BIIB stock leaped more than 60% to $407 per share. Since then, BIIB pulled back to less than $345, but the stock is still up 40% in 2021.",266.0860595703125
2021-06-30 00:00:00+00:00,345.0,349.5,342.75,346.2699890136719,346.2699890136719,1067000.0,2.5,1.0,0.375025,"Despite a large 45% move over the last five trading sessions, we believe BIIB stock can see much higher levels in the near term, primarily due to a sharp pickup in sales and earnings as Aduhelm hits the market. [Updated: 6/28/2021] BIIB Stock Decline The stock price of Biogen (NASDAQ:BIIB) has seen a 10% drop over the last five trading days. BIIB stock has seen a massive rally from levels of $267 in early June to around $380 last week, before dropping to $348 currently. New Article Many in the scientific community weren't thrilled that the U.S. Food and Drug Administration (FDA) approved Biogen's (NASDAQ: BIIB) Aduhelm in treating Alzheimer's disease. Brian was in a bad mood last week after Biogen won FDA approval of its Alzheimer's disease drug. Speights: Do you think that the Alzheimer's Association is maybe most concerned about the potential out-of-pocket cost, the co-pays that Medicare patients, in particular, might have to pay for this drug?",270.2908935546875
2021-07-01 00:00:00+00:00,346.0,350.3800048828125,345.4599914550781,348.9200134277344,348.9200134277344,998000.0,3.0,1.0,0.5000249999999999,"Let me throw out one wild card here, and we'll call this reckless prediction: How about a merger of equals with Biogen (NASDAQ: BIIB)? Many investors expect that Vertex Pharmaceuticals (NASDAQ: VRTX) could make additional acquisitions in the not-too-distant future with its growing cash stockpile. I think the two like Vertex's better just because while its revenue gains or growth is slowing, it's definitely they're not declining yet, and I don't think they will over the years I think they're just starting to launch in Europe.",281.1279602050781
2021-07-02 00:00:00+00:00,349.5400085449219,350.07000732421875,343.8500061035156,348.7200012207031,348.7200012207031,811800.0,4.0,1.0,0.7500249999999999,"The tie-up comes weeks after U.S. authorities approved the first new Alzheimer's drug in almost two decades, Biogen Inc's BIIB.O Aduhelm, reinvigorating the industry's efforts to develop more treatments in a challenging therapy category. July 2 (Reuters) - GlaxoSmithKline Plc GSK.L and U.S. firm Alector Inc ALEC.O will together develop antibody-based treatments for Parkinson's, Alzheimer's and other similar diseases in a deal worth up to $2.2 billion, the drugmakers said on Friday. GSK and Alector will develop two of the U.S. company's experimental treatments that target a protein called progranulin, to fight off neurodegenerative diseases such as Alzheimer's and Parkinson's, which affect the nervous system and can cause problems with regular mental and physical functioning.",272.373779296875
2021-07-07 00:00:00+00:00,344.95001220703125,355.82000732421875,344.3900146484375,355.3299865722656,355.3299865722656,1377600.0,2.0,1.0,0.250025,"The controversial approval of Aduhelm, an Alzheimer's disease drug from Biogen (NASDAQ: BIIB) pushed shares of the biotech stock through the roof in June. When the FDA granted accelerated approval to Aduhelm, it opened a door that Eli Lilly (NYSE: LLY) has already started stepping through with its Alzheimer's disease treatment candidate, donanemab. Instead, the FDA granted Aduhelm accelerated approval based on biomarker data which in this case, involves measuring the clearance of amyloid plaques thought to be responsible for Alzheimer's disease.",274.8911437988281
2021-07-08 00:00:00+00:00,350.07000732421875,370.05999755859375,350.07000732421875,369.0499877929688,369.0499877929688,2344900.0,2.5,1.0,0.375025,"Eisai 4523.T edged up 0.57% as its partner Biogen BIIB.O said the U.S. Food and Drug Administration has narrowed use of its Alzheimer's drug, after the agency drew sharp criticism for its initial approval of the drug. TOKYO, July 9 (Reuters) - Japanese shares fell on Friday, and are on track to post their worst weekly drop in nearly a year, on worries about a slowing economic recovery after Japan declared a fourth state of emergency to counter the resurgence of COVID-19 infections. Restaurant operator Global-Dining 7625.T lost 3.29% as the government is planning to take stricter measures against eateries that do not comply with the order to shorten business hours. New Article Amazon.com (NASDAQ:AMZN) Biogen (NASDAQ:BIIB) Intel (NASDAQ:INTC) So, Whats an investor to do? Biogen (BIIB) And with BIIBs monthly stochastics bullishly expanding in neutral territory, this pullback looks like a more certain blue-chip stock to buy. New Article July 8 (Reuters) - Biogen Inc BIIB.O said on Thursday the U.S. Food and Drug Administration has approved changes to the product information for its Alzheimer's disease drug to specify that it has not been studied in treating later stages of the disease. Treatment with the drug, Aduhelm, should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, according to the updated product information on the drug. (Reporting by Manas Mishra in Bengaluru; Editing by Saumyadeb Chakrabarty) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manasmishra24; within U.S. +1 646 223 8780, outside U.S. +91 806749 2709;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article And the worst performing Nasdaq 100 component thus far on the day is CSX, trading down 5.3%. CSX is showing a gain of 3.2% looking at the year to date performance. VIDEO: Nasdaq 100 Movers: CSX, MRNA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen (NASDAQ: BIIB) has been in the spotlight recently thanks to a promising drug candidate for treating a terrible disease, while Golden Nugget Online Gaming (NASDAQ: GNOG) has largely remained under the radar in the gambling industry. The approval came as a shock to many industry watchers, who have been skeptical of Aduhelm's ability to go beyond its demonstrated reduction in amyloid plaque buildup and actually provide favorable cognitive outcomes for Alzheimer's patients. Nevertheless, many see alternative candidate treatments from Eli Lilly (NYSE: LLY) and others as potentially having better prospects for lasting improvement for Alzheimer's patients in the long run. New Article Adds details from statement, background July 8 (Reuters) - Biogen Inc BIIB.O said on Thursday the U.S. Food and Drug Administration has approved changes to product information on its Alzheimer's disease drug, effectively narrowing the target population, sending its shares down 3% before the bell. Aduhelm, also known as aducanumab, was studied in patients with early disease who tested positive for a component of amyloid brain plaques, but the FDA approval last month did not restrict its use to a specific group of patients. The updated label, which was approved by the FDA after the company submitted it, also said there was no safety or effectiveness data on initiating treatment at earlier or later stages of the disease.",274.9731140136719
2021-07-09 00:00:00+00:00,371.8599853515625,372.1199951171875,351.010009765625,358.1600036621094,358.1600036621094,2720100.0,2.5,1.0,0.375025,"July 9 (Reuters) - The acting commissioner of the Food and Drug Administration on Friday called for a federal investigation into the agency's approval of Biogen's BIIB.O treatment for Alzheimer's disease. (Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manasmishra24; within U.S. +1 646 223 8780, outside U.S. +91 806749 2709;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Eisai 4523.T gained 2.05% as its partner Biogen BIIB.O said the U.S. Food and Drug Administration has narrowed use of its Alzheimer's drug, after the agency drew sharp criticism for its initial approval of the drug. TOKYO, July 9 (Reuters) - Japanese shares fell to a near eight-week low on Friday, on worries over a slowing economic recovery after the country declared a COVID-19 emergency, but losses were trimmed on hopes that the Bank of Japan might have stepped in to support the market. Restaurant operator Global-Dining 7625.T edged up 0.62% after losing as much as 5.5% as its president said he was ""shocked"" by comments from a government minister that he would ask banks to pressure eateries that don't comply with stricter coronavirus measures. New Article (RTTNews) - The U.S. Food and Drug Administration has called for an investigation on the recent approval of Biogen Inc.'s (BIIB) Alzheimer's drug, Aduhelm. Acting FDA Commissioner Dr. Janet Woodcock has asked the Office of the Inspector General to investigate interactions between the U.S. agency and Biogen representatives prior to the drug's approval on June 7. ""Given the ongoing interest and questions, today I requested that @OIGatHHS conduct an independent review and assessment of interactions between representatives of Biogen and FDA during the process that led to the approval of Aduhelm,"" Woodcock tweeted. New Article In company news, the US Food and Drug Administration on Friday requested the Department of Health & Human Services to start a probe into the approval of Biogen (BIIB) and Eisai's Aduhelm injection for the treatment of Alzheimer's disease. Johnson & Johnson's (JNJ) Janssen Pharmaceutical Companies reported positive data from a late-stage study to evaluate Stelara as a treatment for ulcerative colitis. TransCode Therapeutics (RNAZ) rose about 23% to $4.92 in its trading debut Friday on Nasdaq after the developer of RNA-based cancer treatments priced its initial public offering of 6.25 million shares at $4 per share. New Article Among large Healthcare stocks, Biogen Inc (Symbol: BIIB) and DexCom Inc (Symbol: DXCM) are the most notable, showing a loss of 2.8% and 1.9%, respectively. Combined, BIIB and DXCM make up approximately 2.0% of the underlying holdings of XLV. In afternoon trading on Friday, Utilities stocks are the worst performing sector, not showing much of a gain. New Article The repercussions of the stunning approval by the Food and Drug Administration (FDA) of Biogen's (NASDAQ: BIIB) Alzheimer's disease drug Aduhelm continue. See the 10 stocks *Stock Advisor returns as of June 7, 2021 Keith Speights: The United States House of Representatives Committee on Energy and Commerce has launched an inquiry into the FDA's approval of Biogen's Alzheimer's disease drug Aduhelm. On the FDA side, I'm on the record saying I don't understand how the FDA could have come to the conclusion of giving an accelerated approval for lowering amyloid plaques when we don't have a good handle on whether that actually improves cognition or at least slows the decline of cognition.",277.9195556640625
2021-07-12 00:00:00+00:00,357.0299987792969,357.989990234375,348.6000061035156,349.0400085449219,349.0400085449219,1188600.0,2.6666666666666665,1.0,0.4166916666666666,"According to a report published by Reuters, the U.S. Food and Drug Administration is seeking a federal investigation into the interactions between its representatives and Biogen (BIIB) that led to the approval of the company's Alzheimer's disease treatment Aduhelm last month. Biogens shares closed 3% lower on Friday after Janet Woodcock, the FDAs Acting Commissioner, asked the Office of the Inspector General at the Department of Health and Human Services (HHS) to check whether the talks were consistent with the agencys policies. The spokesperson of HHS's Office of the Inspector General, Tesia Williams, said, We received the letter and are reviewing it for appropriate action. (See Biogen stock chart on TipRanks) The FDA approved Aduhelm on June 7 despite strong objections from its experts. New Article Biogen Inc's BIIB.O drug Aduhelm could create hope for millions of older Americans afflicted with Alzheimers - if it is effective in combating the disease. Most Advantage enrollees are in plans that charge 20% coinsurance for Part B drugs provided in-network, mirroring the traditional program, according to Kaiser - the co-insurance rates can be much higher out of network. This gives credence to the argument that the pharmaceutical industry cannot be relied on to deliver value to patients, said Rachel Sachs, a professor of law at Washington University in St. Louis who wrote about the Aduhelm controversy recently for the journal Health Affairs. New Article Adds background July 12 (Reuters) - The U.S. government on Monday started a review process for national Medicare coverage of Biogen Inc's BIIB.O Alzheimer's drug, Aduhelm, that was recently approved by the country's health regulator. (https://go.cms.gov/3hzMa6H) Aduhelm is priced at $56,000 per year, which could represent significant spending for the government's Medicare program for people aged 65 and older. Currently, coverage for the drug is determined at the local level by Medicare administrative contractors, who represent 12 jurisdictions across the country.",288.1654357910156
2021-07-13 00:00:00+00:00,349.0899963378906,357.239990234375,347.5,351.9200134277344,351.9200134277344,974200.0,3.0,1.0,0.5000249999999999,"Biogen (BIIB) recently inked a license and partnership agreement with InnoCare Pharma Limited. Biogen will gain exclusive rights to Orelabrutinib for the worldwide treatment of multiple sclerosis (MS) and few other autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan). Orelabrutinib is a small molecule Brutons tyrosine kinase inhibitor (BTKi) that is administered orally to patients of MS, cancer, and certain other autoimmune diseases as a potential treatment. New Article Within that group, Biogen Inc (Symbol: BIIB) and Zoetis Inc (Symbol: ZTS) are two large stocks leading the way, showing a gain of 1.1% and 0.9%, respectively. Combined, BIIB and ZTS make up approximately 3.1% of the underlying holdings of XLV. In afternoon trading on Tuesday, Healthcare stocks are the best performing sector, losing just 0.2%. New Article Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) have enjoyed good working relationships with both the Centers for Disease Control & Prevention (CDC) and the U.S. Food and Drug Administration (FDA). A quick and forceful response On July 8, Pfizer chief scientific officer Mikael Dolsten told Reuters in an interview that his company and its partner, BioNTech (NASDAQ: BNTX), plan to soon file for U.S. and European emergency use authorizations (EUA) for a third booster dose. FDA Commissioner Dr. Janet Woodcock even requested an independent investigation into interactions between the agency's staff and Biogen during the review process for the drug.",292.4562683105469
2021-07-14 00:00:00+00:00,351.3299865722656,358.7699890136719,349.67999267578125,352.0599975585937,352.0599975585937,1237100.0,2.0,1.0,0.250025,"July 14 (Reuters) - The U.S. Food and Drug Administration could potentially have done more to avoid the current controversies around its accelerated approval of Biogen Inc's BIIB.O Alzheimer's drug, Aduhelm, FDA acting Commissioner Janet Woodcock said during a Wednesday summit hosted by Stat. The FDA last week called for an independent federal probe into its representatives' interactions with Biogen ahead of the regulator's approval of Aduhelm last month. ""The accelerated approval was based on very solid grounds,"" Woodcock said during Stat's Breakthrough Science Summit. New Article By Carl O'Donnell and Trisha Roy July 14 (Reuters) - The U.S. Food and Drug Administration could potentially have done more to avoid the current controversies around its accelerated approval of Biogen Inc's BIIB.O Alzheimer's drug, Aduhelm, FDA acting Commissioner Janet Woodcock said during a Wednesday summit hosted by Stat. The FDA last week called for an independent federal probe into its representatives' interactions with Biogen ahead of the regulator's approval of Aduhelm last month. Aduhelm was approved by the FDA on June 7 despite strong objection from its expert advisory panel, resulting in the resignation of three of its 11 members.",287.9412841796875
2021-07-15 00:00:00+00:00,341.8500061035156,343.0400085449219,323.7099914550781,328.1600036621094,328.1600036621094,3031700.0,3.0,1.0,0.5000249999999999,"By Deena Beasley July 15 (Reuters) - Biogen Inc's BIIB.O Alzheimer's drug, the first new treatment for the memory-robbing disease in nearly 20 years, hit new barriers on Thursday with some large hospitals declining to use it and health insurers delaying a decision while awaiting coverage terms from Medicare. ""The tide turned on Friday when the inspector general investigation was announced, and the potential allegation of irregularity in the FDA/Biogen relationship,"" Dr. Sam Gandy, director of the Mount Sinai Center for Cognitive Health, told Reuters. U.S. starts national Medicare coverage policy review for Biogen's Aduhelm FDA seeks probe into its talks with Biogen before Alzheimer's drug approval (Reporting by Deena Beasley; Additional reporting by Manas Mishra in Bangalaru and Julie Steenhuysen in Chicago; Editing by Howard Goller) ((deena.beasley@thomsonreuters.com)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article VIDEO: Nasdaq 100 Movers: BIIB, JD The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing Nasdaq 100 component thus far on the day is Biogen, trading down 4.3%. Biogen is showing a gain of 37.6% looking at the year to date performance.",293.6338806152344
2021-07-16 00:00:00+00:00,323.9700012207031,331.1099853515625,323.0,324.6199951171875,324.6199951171875,1534800.0,2.5,1.0,0.375025,"That includes what to know about Moderna (NASDAQ:MRNA) as it prepares to join the S&P 500, why Biogen (NASDAQ:BIIB) was falling yesterday, and more. More Recent Medical Stock News MRNA Stock: 10 Things to Know About Moderna as It Gets Ready to Join the S&P 500 BIIB Stock: The Drug Ban News That Has Biogen Stumbling Today AHPI Stock: 5 Things to Know About Red-Hot Allied Healthcare as It Rockets Higher On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. Roxadustat is FibroGens oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of anemia due to chronic kidney disease (CKD) in adult patients. New Article The Nikkei's biggest decliner was Eisai 4523.T, which fell 13% after some large hospitals declined to use an Alzheimer's drug similar to the one it developed with Biogen BIIB.O. By Kevin Buckland TOKYO, July 16 (Reuters) - Japan's benchmark Nikkei share average dipped below the psychologically key 28,000 mark on Friday as tech shares tracked declines on Wall Street overnight, while a continued surge in coronavirus infections dented investor sentiment. The tech-heavy Nikkei .N225 fell as low as 27,847.35 before closing the session 1% down at 28,003.08, tracking Nasdaq Composite .IXIC-led declines in U.S. shares. New Article In one corner, there's the reigning champion, Biogen (NASDAQ: BIIB), the maker of Aduhelm, an Alzheimer's drug which regulators recently approved for sale, a move that was met with great controversy including a Congressional investigation. The company estimates that up to 2 million patients will be eligible for treatment with Adulhelm in the U.S., eventually making several billions of dollars per year in revenue -- a massive contribution to its already-profitable portfolio. That means it'll easily outcompete Aduhelm for market share if it gets approved, provided that early results remain true throughout the rest of the clinical trials process. New Article That includes a drug ban hitting Biogen (NASDAQ:BIIB), Allied Healthcare Products (NASDAQ:AHPI) gaining interest from retail traders, as well as whats happening with Reddit favorite Clover Health (NASDAQ:CLOV). More Recent Healthcare Stocks News BIIB Stock: The Drug Ban News That Has Biogen Stumbling Today AHPI Stock: 5 Things to Know About Red-Hot Allied Healthcare as It Rockets Higher CLOV Stock: Why One Analyst Is Now Souring on Clover Health On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. Source: Shutterstock MRNA stock is set to join the S&P 500 before trading starts on Wednesday.",294.80999755859375
2021-07-19 00:00:00+00:00,323.0799865722656,326.9700012207031,320.1099853515625,324.1600036621094,324.1600036621094,1036300.0,1.0,1.0,2.4999999999997247e-05,"Biogen (NASDAQ: BIIB) hasn't been all that successful in wooing investors lately. A series of unfortunate events On July 12, Medicare officials began a review of Adulhelm to decide who can receive it based on whether the drug is a reasonable and necessary treatment. Despite its questionable effectiveness, the drug could cost the Medicare program as much as $57 billion a year (at a price tag of $56,000 per patient annually) if made available to all U.S. Alzheimer's sufferers.",298.4407043457031
2021-07-20 00:00:00+00:00,324.70001220703125,327.5199890136719,317.260009765625,322.489990234375,322.489990234375,1384600.0,2.0,1.0,0.250025,"For instance, Biogen (NASDAQ: BIIB) has a new drug on the market for Alzheimer's; the U.S. Food and Drug Administration (FDA) approved it in a highly controversial decision. While Cassava hasn't started its phase 3 trial yet, the possibility of a drug that might actually help Alzheimer's patients has made this small-cap stock one of the best performers of 2021 so far. ""Today's top-line results disappoint and are not consistent with previous clinical experience for reasons that are unclear at the moment,"" CEO Remi Barbier said in a news release at the time.",292.63763427734375
2021-07-21 00:00:00+00:00,321.4100036621094,324.5199890136719,318.2900085449219,322.9599914550781,322.9599914550781,1126300.0,3.75,1.0,0.6875249999999999,"By Deena Beasley July 21 (Reuters) - U.S. hospitals that were expected to be early adopters of Biogens BIIB.O Alzheimers drug have treated only a handful of patients since its early June approval as they wait for the first payments from the governments Medicare program for people aged 65 and older. Other leading institutions, including in Michigan, Florida and Rhode Island, were eager to make the therapy available to patients in the hope it will provide a benefit, but told Reuters this week they are proceeding slowly while Medicare determines how it will cover Aduhelm, initially priced at about $56,000 per year. Sonda Rossman, head of disease state initiatives, therapeutics, and clinical research at MIND, said the institute is testing more patients for Aduhelm eligibility, but is ""being very cautious"" about financial, as well as medical, risks. New Article Biogen Inc. (BIIB)is reporting for the quarter ending June 30, 2021. BIIB missed the consensus earnings per share in the 4th calendar quarter of 2020 by -7.1%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for BIIB is 17.33 vs. an industry ratio of -2.60, implying that they will have a higher earnings growth than their competitors in the same industry. New Article So what The FDA's controversial approval of Aduhelm from Biogen (NASDAQ: BIIB) this June has many retail investors excited about the next potential Alzheimer's disease treatment. Investors are anticipating a new set of clinical-trial data from the company's lead candidate, simufilam, to be presented at the Alzheimer's Association International Conference (AAIC) later this month. Last September, Cassava Sciences showed how 28 days of treatment with simufilam significantly reduced signs of worsening dementia as measured from samples of cerebrospinal fluid (CSF). New Article Two biotechs whose lead products offer great potential are Vertex Pharmaceuticals (NASDAQ: VRTX) and Biogen (NASDAQ: BIIB). The company is best known for its suite of medicines that treat cystic fibrosis (CF), a potentially deadly genetic condition that affects a patient's internal organs, including the lungs and the digestive system. The company boasts several exciting pipeline programs, including CTX001, a gene-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia that it's developing in collaboration with CRISPR Therapeutics.",290.32110595703125
2021-07-22 00:00:00+00:00,320.0400085449219,330.6400146484375,319.2300109863281,326.3599853515625,326.3599853515625,1485600.0,2.9166666666666665,1.0,0.4791916666666667,"[nL4N2OY1QT] Healthcare companies including, drugmaker Biogen Inc BIIB.O rose 0.9% on raising its full-year revenue expectations, while medical device maker Abbott Laboratories ABT.N added 0.2% after its quarterly profit more than doubled. By Devik Jain and Shreyashi Sanyal July 22 (Reuters) - U.S. stock indexes were set for a subdued open on Thursday after data showed an unexpected rise in weekly jobless claims, while a steady flow of positive earnings reports offered markets some support. A shift in attention to corporate earnings and the so-called value stocks have helped Wall Street recoup most of its declines from earlier in the week that were triggered by concerns about the fast-spreading Delta variant of the coronavirus. New Article Abbott Laboratories ABT.N, Domino's Pizza Inc DPZ.N, Biogen Inc BIIB.O, Snap Inc SNAP.N and Intel Corp INTC.O are among the major companies reporting results later in the day. ET, is expected to show the number of Americans filing new claims for unemployment benefits fell for the week ended July 17, amid rampant worker shortages. A shift in attention to corporate earnings and the so-called value stocks have helped Wall Street recoup most of its declines from earlier in the week that were triggered by concerns about the fast-spreading Delta variant of the coronavirus. New Article The U.S. Food and Drug Administration (FDA) pushed back its approval decision for Olumiant in treating severe atopic dermatitis to review additional data. Probably the most important of the company's positive developments was its decision to pursue accelerated approval for Alzheimer's disease candidate donanemab, based on phase 2 data. The FDA's decision on accelerated approval for donanemab will no doubt be pivotal in whether or not Lilly's share price will continue to climb significantly. New Article If you belong to the latter group, here are two stocks that are a bit on the risky side, but could deliver huge gains if their respective prospects pan out: Planet 13 Holdings (OTC: PLNH.F) and Cassava Sciences (NASDAQ: SAVA). Planet 13 Holdings Wall Street analyst Owen Bennett recently called the U.S. marijuana industry a ""generational wealth opportunity."" Before the approval of Biogen's Aduhelm, there have been a long list of failed attempts at developing successful treatments for AD -- and some of these potential medicines had also produced great results in phase 2 studies. New Article Adds details on earnings, Aduhelm July 22 (Reuters) - Biogen Inc BIIB.O on Thursday raised its full-year revenue expectations, and defended the approval of its Alzheimer's disease drug by the U.S. Food and Drug Administration last month. The decision by the FDA to approve the drug, Aduhelm, despite its panel of outside experts recommending against it has drawn criticism from doctors and hospitals, with some saying they will not prescribe the drug or have prescribed it very slowly. (Reporting by Manas Mishra in Bengaluru; Editing by Sriraj Kalluvila) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manasmishra24; within U.S. +1 646 223 8780, outside U.S. +91 806749 2709;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Drugmaker Biogen Inc BIIB.Ogained 0.8% on raising its full-year revenue expectations. By Devik Jain and Shreyashi Sanyal July 22 (Reuters) - The S&P 500 and the Dow indexes fell on Thursday after data showed weekly jobless claims hit a two-month high, while a rise in megacap growth stocks offered some support to the technology-heavy Nasdaq. A shift in attention to corporate earnings and the so-called value stocks have helped Wall Street recoup most of its declines from earlier in the week that were triggered by concerns about the fast-spreading Delta variant of the coronavirus. New Article Biogen (BIIB) climbed 2% after raising its FY21 revenue outlook to $10.65 billion to $10.85 billion compared with its prior forecast range expecting between $10.45 billion to $10.75 billion and Thursday also defended its Aduhelm medication in a open letter to the Alzheimer's community against accusations US regulators approved the drug despite mixed trial data for its efficacy. In company news, NRx Pharmaceuticals (NRXP) was surging more than 43% higher, giving back a portion of an earlier 80% advance that followed the company saying it has validated a commercial intravenous formulation and container closure method for its Zyesami drug candidate, making the COVID-19 treatment suitable for high-volume manufacturing. NRx earlier this week reported phase II/III trial data showing Zyesami can help prevent cytokine storms in patients with COVID-19. New Article Drugmaker Biogen Inc BIIB.O gained 1.3% on raising its full-year revenue expectations, while Domino's Pizza Inc DPZ.N jumped 13.0% to a record high on upbeat quarterly results. By Devik Jain and Shreyashi Sanyal July 22 (Reuters) - Wall Street's main indexes edged lower on Thursday after an unexpected rise in weekly jobless claims cooled a rally in economy-linked cyclical stocks, while gains in megacap growth firms kept declines at bay. Data showed the number of Americans filing new claims for unemployment benefits increased by 51,000 to a seasonally adjusted 419,000 in the week ended July 17, hitting a two-month high. New Article Drugmaker Biogen Inc BIIB.O gained 1.2% after hiking its full-year revenue guidance, while Domino's Pizza Inc DPZ.N surged 14.2% to an all-time high on the heels of its quarterly report. By Stephen Culp NEW YORK, July 22 (Reuters) - Wall Street edged higher on Thursday, as lackluster economic data and mixed corporate earnings sent investors back to growth stocks. But megacap market leaders such as Apple Inc AAPL.O, Amazon.com AMZN.O, Facebook Inc FB.O, Google-owner Alphabet Inc GOOGL.O and Microsoft Corp MSFT.O rose ahead of their quarterly results next week, putting the tech-laden Nasdaq out front. New Article Biogen inc (NASDAQ: BIIB) Q2 2021 Earnings Call Jul 22, 2021, 8:00 a.m. Although we were disappointed to learn that the Phase 2 study of gosuranemab in early Alzheimer's disease did not meet the primary or secondary endpoints, we do not believe these results diminish the relevance of tau as a potential therapeutic target in Alzheimer's disease, whereas we have discontinued the BIIB092 program, we are continuing the development of BIIB080, our antisense oligonucleotide, which aims to reduce the production of all forms of tau both intra and extracellular. During the Phase 2a study of TMS-007, now referred to as BIIB131, the patients were dosed 4.5 to 12 hours after the onset of stroke symptoms with an average of 9.5 hours. New Article Biogen (BIIB) climbed 1.2% after raising its FY21 revenue outlook to $10.65 billion to $10.85 billion compared with its prior forecast range of $10.45 billion to $10.75 billion. NRx Pharmaceuticals (NRXP) surged nearly 64%, giving back some of its earlier 80% advance after saying it has validated a commercial intravenous formulation and container closure method for its Zyesami drug candidate, making the COVID-19 treatment suitable for high-volume manufacturing. NRx earlier this week reported phase II/III trial data showing Zyesami can help prevent cytokine storms in patients with COVID-19. New Article Drugmaker Biogen Inc BIIB.O gained 1.1% after hiking its full-year revenue guidance, while Domino's Pizza Inc DPZ.N surged 14.6% to an all-time high on the heels of its quarterly report. By Stephen Culp NEW YORK, July 22 (Reuters) - Big tech helped Wall Street inch up to a higher close on Thursday, modestly building on a two-day rally as lackluster economic data and mixed corporate earnings prompted a pivot back to growth stocks. But megacap tech and tech-adjacent stocks, such as Microsoft Corp MSFT.O, Amazon.com AMZN.O, Apple Inc AAPL.O, Facebook Inc FB.O and Alphabet Inc GOOGL.O, rose ahead of their quarterly results next week, putting the Nasdaq out front.",286.4139709472656
2021-07-23 00:00:00+00:00,322.1000061035156,328.1499938964844,319.8500061035156,325.3999938964844,325.3999938964844,1015900.0,2.0,1.0,0.250025,"Especially high volume was seen for the $327.50 strike call option expiring July 23, 2021, with 424 contracts trading so far today, representing approximately 42,400 underlying shares of BIIB. Below is a chart showing CWH's trailing twelve month trading history, with the $31.09 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 7,868 contracts, representing approximately 786,800 underlying shares or approximately 46.8% of BIIB's average daily trading volume over the past month, of 1.7 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $327.50 strike highlighted in orange: For the various different available expirations for SPLK options, CWH options, or BIIB options, visit StockOptionsChannel.com.",282.2910461425781
2021-07-26 00:00:00+00:00,324.4100036621094,335.0,322.510009765625,331.92999267578125,331.92999267578125,1269500.0,4.0,1.0,0.7500249999999999,"(RTTNews) - A Phase 1b placebo-controlled, multiple ascending dose clinical study data showed that BIIB080/IONIS-MAPTRx met its primary objective of safety and tolerability in patients with mild Alzheimer's disease, Biogen Inc. (BIIB) and Ionis Pharmaceuticals Inc. (IONS) said in a statement. BIIB080 is an investigational antisense therapy designed to target microtubule-associated protein tau mRNA and prevent production of tau protein. According to the companies, the study demonstrated robust time and dose dependent lowering of tau protein in cerebrospinal fluid over the three-month treatment period and sustained reductions during the six-month post-treatment period.",283.7850036621094
2021-07-27 00:00:00+00:00,332.07000732421875,334.5,326.5,333.9599914550781,333.9599914550781,929300.0,2.0,1.0,0.250025,"July 27 (Reuters) - Biogen Inc BIIB.O withdrew its paper that analyzed results from the clinical trials of its controversial Alzheimer's drug, Aduhelm, that was submitted to medical journal JAMA, Axios reported on Tuesday, citing two sources familiar with the matter. Biogen withdrew the paper as JAMA considered rejecting it unless edits were made, according to the report. (https://bit.ly/3f2zsvf) The U.S. Food and Drug Administration last month approved Aduhelm despite strong objection from its own expert advisory panel, citing convincing evidence that Aduhelm can clear amyloid brain plaques and benefit Alzheimer's patients.",268.91455078125
2021-07-28 00:00:00+00:00,333.75,336.95001220703125,329.82000732421875,334.17999267578125,334.17999267578125,713600.0,3.0,1.0,0.5000249999999999,"In addition, by adding positions in Biogen (BIIB), Illumina (ILMN), and Moderna (MRNA), the fund now holds a 25% allocation in healthcare  ideal timing as it happens, as fears of Delta and other Covid variants have investors once again looking for opportunities in the sector. As of its most recent quarterly rebalance, QQQAs contains only part of the FANMAG companies: tts positions in Facebook (FB) and Alphabet (GOOGL) together total 9.6% of the assets within the fund. Whereas MTUM rebalanced in May and reduced its allocation to information technology stocks, QQQA maintained its focus on growth companies.",263.391845703125
2021-07-29 00:00:00+00:00,334.989990234375,336.9200134277344,329.0,329.1700134277344,329.1700134277344,660200.0,2.75,1.0,0.437525,"What happened Shares of Annovis Bio (NYSEMKT: ANVS) are getting hammered in response to disappointing data for the company's Alzheimer's disease candidate. Today's flop was a harsh reminder that Anavex Life Sciences has been testing its lead candidate, blarcamesine, in different forms of dementia for over a decade, and the company still hasn't shown evidence that it significantly reduces cognitive decline for Alzheimer's disease patients, compared to a placebo. Blarcamesine from Anavex Life Sciences produced arguably successful clinical-trial data in an open-label phase 2 Alzheimer's disease trial five years ago. New Article Investors who are banking on the success of Cassava's silmufilam are generally basing this perception on how the U.S. Food and Drug Administration (FDA) handled Biogen's (NASDAQ: BIIB) Adulhelm. While Adulhelm failed two clinical studies, the agency nonetheless granted the drug conditional approval based on its ability to reduce beta-amyloid markers in patients' brains, which are theorized to cause Alzheimer's disease (the correlation is pretty low). In a phase 2b data release, the drug did not demonstrate efficacy in lowering patients' beta-amyloid markers (and in fact raised them), so the company likely can't convince the FDA to approve it that way. New Article July 29 (Reuters) - Biogen Inc BIIB.O and partner Eisai Co Ltd 4523.T on Thursday revealed the design of an upcoming study of their controversial Alzheimer's treatment, Aduhelm. The study, designed to collect real-world, long-term effectiveness and safety data on Aduhelm, will enroll 6,000 patients over fours years in the United States, according to details released during the Alzheimer's Association International Conference. Biogen said the main goal of the current study will be to evaluate how well Aduhelm slows the progress of Alzheimer's in dosed patients. New Article And while Biogen's (NASDAQ: BIIB) drug, Aduhelm, has made headlines for slowing the progression of Alzheimer's Disease-related dementia, it does not necessarily reduce the number of agitation events experienced. BTAI data by YCharts April's bad news shouldn't have been a surprise BioXcel's lead compound is a dissolving oral film of dexmedetomidine, a drug that has been around for a while. Biogen investors looking for exposure to the Alzheimers Disease market may be in for a tumultuous ride after a 50% gain on the back of Aduhelm approval, followed by reports of slower-than-expected sales in its first few weeks, narrower labeling from the FDA, and major hospital systems taking a stance against administering the expensive intravenous therapy.",254.2626495361328
2021-07-30 00:00:00+00:00,326.3699951171875,331.45001220703125,325.3999938964844,326.7300109863281,326.7300109863281,942800.0,2.0,1.0,0.250025,"In this article we are going to estimate the intrinsic value of Biogen Inc. (NASDAQ:BIIB) by projecting its future cash flows and then discounting them to today's value. NasdaqGS:BIIB Discounted Cash Flow July 30th 2021 The assumptions The calculation above is very dependent on two assumptions. For Biogen, we've put together three additional elements you should further research: Risks: Be aware that Biogen is showing 3 warning signs in our investment analysis , you should know about... Future Earnings: How does BIIB's growth rate compare to its peers and the wider market? New Article Shares of Biogen (NASDAQ: BIIB) soared in June after the U.S. Food and Drug Administration (FDA) granted accelerated approval for the company's Alzheimer's drug, Aduhelm. Biogen is in a tough spot; it has reported soft sales numbers in its most recent quarters, and the many question marks surrounding Aduhelm -- and how many doctors may end up prescribing it -- only make it a riskier investment. On Biogen's earnings call in July, management stated that ""a few centers have indicated that they will not provide access to Aduhelm for now,"" and while the pace is ""a bit slower than what we assumed, ... we are making tremendous progress with some positives and some headwinds."" New Article Biogen (NASDAQ: BIIB) faces continued challenges for several of its current products. In this Motley Fool Live video, recorded on July 19, 2021, healthcare and cannabis bureau chief Corinne Cardina and Motley Fool contributor Keith Speights answer a viewer's question about whether now is a good time to buy Biogen stock. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.",257.26409912109375
2021-08-02 00:00:00+00:00,327.0400085449219,336.0799865722656,326.260009765625,331.70001220703125,331.70001220703125,962600.0,3.0,1.0,0.5000249999999999,"Below is a twelve month price history chart comparing the stock performance of BIIB, JAZZ, and BHC: Combined, BIIB, JAZZ, and BHC represent 10.09% of the Invesco Dynamic Pharmaceuticals ETF. Invesco Dynamic Pharmaceuticals ETF PJP $81.16 $94.04 15.87% Biogen Inc BIIB $326.73 $408.86 25.14% Jazz Pharmaceuticals plc JAZZ $169.52 $208.13 22.78% Bausch Health Companies Inc BHC $29.25 $35.73 22.14% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of PJP's underlying holdings with notable upside to their analyst target prices are Biogen Inc (Symbol: BIIB), Jazz Pharmaceuticals plc (Symbol: JAZZ), and Bausch Health Companies Inc (Symbol: BHC). New Article (RTTNews) - Biogen Inc. (BIIB) said results from phase 3b NOVA Study showed that every six-week natalizumab IV administration provides a high level of efficacy in controlling Multiple Sclerosis disease activity in patients who switched from the approved every four-week dosing regimen. The primary endpoint showed a numerical difference between the mean number of new or newly enlarging T2 hyperintense lesions at week 72 of 0.05 (Q4W) and 0.20 (Q6W) \, which based on the full trial results is not clinically meaningful. The company noted that a complete analysis of the study data is ongoing and detailed results will be shared in a future scientific forum.",245.29476928710938
2021-08-03 00:00:00+00:00,331.8099975585937,338.3599853515625,325.0899963378906,338.0,338.0,1326700.0,3.0,1.0,0.5000249999999999,"Shares of the biotechnology company Biogen (BIIB) have caught the eye of investors ever since the U.S. FDA (Food and Drug Administration) granted accelerated approval to Aduhelm, its Alzheimers disease drug, on June 7. Syed mentioned that the EMA (European Medicines Agency) had not approved Aduhelm, and also cited P&T (Pharmacy and Therapeutics) approval risks, among other risks that could potentially push consensus peak sales lower. The analyst further added that the Street may not be accounting for the non-controlling interest (NCI) line in the DCF (discounted cash flow). Syed said, We asked Biogen if the Street is properly capturing NCI in models (and namely in the DCF), and Biogen responded that it was not willing to opine. Nevertheless, Biogen raised its full-year revenue guidance following Aduhelms FDA approval. The average Biogen price target of $433.38 implies 30.7% upside potential to current levels.",240.16224670410156
2021-08-04 00:00:00+00:00,336.9200134277344,342.8599853515625,335.0299987792969,338.1000061035156,338.1000061035156,1216600.0,2.0,1.0,0.250025,"Aug 4 (Reuters) - An independent federal review has been launched into the U.S. Food & drug Administration's accelerated approval pathway using which the agency approved Biogen Inc's BIIB.O Alzheimer's treatment Aduhelm. The FDA has faced heavy criticism for approving the Biogen drug without definitive evidence of patient benefit and over objections of its own panel of outside experts. ""We will determine if the application of FDA's pertinent policies and procedures allow for inappropriate relationships with pharmaceutical officials and other external entities,"" HHS OIG spokeswoman Tesia Williams said in a statement.",255.04869079589844
2021-08-05 00:00:00+00:00,336.8299865722656,340.5,334.4200134277344,336.5899963378906,336.5899963378906,714900.0,3.0,1.0,0.5000249999999999,"Since getting clearance from the U.S. Food and Drug Administration (FDA) for its Alzheimer's drug, Aduhelm, on June 7, Biogen (NASDAQ: BIIB) has continued to face an ever-intensifying whirlwind of controversy. Biogen's clinical trials of Aduhelm demonstrated that the drug convincingly cleared patients' brains of beta amyloid, one of the proteins associated with Alzheimer's disease. Management is defending its decision to move ahead with Aduhelm by painting public criticism as being rooted in misinformation about everything from clinical trial design to regulatory matters and efficacy data analysis. New Article The stock is starting to appeal to a different group of investors On July 29, Cassava reported a packet of data showing that simufilam improved cognition, slowed the progression of Alzheimer's disease, and elicited positive changes in a smattering of biomarkers. Frequently, one company's breakthroughs or setbacks seem to ripple through the stock prices of other Alzheimer's drug producers as the market swells with confidence or pessimism in light of new information. Notably, Biogen was able to get its drug, Aduhelm, approved on the basis of its favorable biomarker data even though it didn't have much evidence to support improvement in cognitive benchmarks or in the rate of Alzheimer's progression.",256.5811767578125
2021-08-06 00:00:00+00:00,335.75,342.1600036621094,333.0,340.0,340.0,822200.0,4.0,1.0,0.7500249999999999,"The stock price of Eli Lilly (NYSE: LLY) has seen a rise of nearly 10% over the last twenty-one trading days, and it is also up a solid 55% year-to-date. Some of Eli Lillys drugs, including Trulicty, Verzenio, and Taltz are expected to do well in the near term, led by market share gains. Calculation of Event Probability and Chance of Rise using last ten years data After moving 5.1% or more over a five-day period, the stock rose in the next five days on 55% of the occasions.",251.57876586914062
2021-08-09 00:00:00+00:00,339.989990234375,347.3399963378906,338.0,340.20001220703125,340.20001220703125,1046800.0,3.0,1.0,0.5000249999999999,"Shares of Cassava Sciences (NASDAQ: SAVA) lost 18.6% of their value in July, according to S&P Global Market Intelligence data, but that's a bit misleading. After nine months, 66% of the 50 patients in the trial saw an average improvement of 3 points on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog). Simufilam, a twice-daily oral tablet, would likely be much less expensive than Aduhelm, which is given via a monthly intravenous injection and is expected to cost $56,000 a year per patient.",254.20382690429688
2021-08-11 00:00:00+00:00,337.3900146484375,342.0,336.3900146484375,339.04998779296875,339.04998779296875,784100.0,2.333333333333333,1.0,0.3333583333333332,"Aug 11 (Reuters) - The U.S. Veterans Health Administration (VHA) will not include Aduhelm, the $56,000-a-year Alzheimer's drug made by Biogen Inc BIIB.O and Eisai Co Ltd 4523.T, on its list of approved drugs due to a lack of evidence that it is effective as well as safety concerns, the agency said on Wednesday. ""It is not being added to the VA National Formulary due to the risk of significant adverse drug events and to the lack of evidence of a positive impact on cognition,"" the agency said in an emailed statement. The FDA itself called last month for an independent federal probe into its representatives' interactions with Biogen ahead of the drug's approval. New Article Right now, the company's financial leverage, as defined by net debt divided by operating income less noncash items, stands at only 1.38 -- far short of the multiple of four or five most rating agencies would consider risky. Excluding revenue from its antibody products, Eli Lilly's top line for the first half of the year jumped by 11% compared to the six months period ending June 30, 2020. Shares of the pharma giant could certainly lose altitude if donanemab hits a clinical or regulatory roadblock, but in the long run, the company has more than enough fuel left in its growth engine to continue beating the market. New Article Over the last two decades, Big Pharma has tried to introduce numerous drugs to combat Alzheimer's disease. What the company thinks will happen is if you fix that broken mutating protein, that patients will stop getting worse. I just had Tim Sparks drop an article from Stat news, I think it was just published yesterday about the release, and it just has a couple of interesting takes from independent researchers who expressed doubts about the benefits of simufilam and called the study results overblown, and again, like Biogen, inappropriate and tough to interpret.",258.7254943847656
2021-08-12 00:00:00+00:00,335.8699951171875,341.0,334.6099853515625,340.67999267578125,340.67999267578125,806400.0,2.333333333333333,1.0,0.3333583333333332,"Indeed, the fact that not many people balked at the $56,000 price tag for Biogen's (NASDAQ: BIIB) recently approved Alzheimer's drug Aduhelm tacitly says drugmakers remain completely in control of their pricing policies... even prices charged to Medicare. Vaccine race: You may recall a bunch of biotech stocks logged stellar performance around the middle of last year, shortly after the COVID-19 contagion turned into a global pandemic. Much of the entire sector's recent weakness also coincides with the Federal Trade Commission's (FTC) creation of a global task force assembled in March to ""build a new approach to pharmaceutical mergers."" New Article Mighty Biogen (NASDAQ: BIIB) is a massive biotech, weighing in at $50 billion (market cap). Biogen recently got its Alzheimer's drug aducanumab approved, even though it failed to beat a placebo and might cause brain bleeds. Next video: Here's What Investors Should Know About Cassava's Alzheimer's Drug Candidate Olivia Zitkus has no position in any of the stocks mentioned. New Article Speights: I'm going to step out on a limb here, Brian, I know we're out of time, but I think that Axsome would be a pretty good candidate for a company like Biogen (NASDAQ: BIIB) to buy. (Note: This video was recorded before Axsome announced that the U.S. Food and Drug Administration identified issues that delay an approval decision on AXS-05 in treating depression.) But in the case of Axsome, the company's already produced clinical trial data that looks pretty successful.",259.5246887207031
2021-08-13 00:00:00+00:00,340.3399963378906,345.0799865722656,339.0199890136719,342.25,342.25,744500.0,2.0,1.0,0.250025,"Moderna Inc. (MRNA) is currently the top holding in QQQA at 7.58%: other healthcare sector securities include Illumina (ILMN), a company that creates innovative technology for DNA sequencing, at 4.83%, and Biogen (BIIB), a biotech company, at 4.28%. The companies have been anticipating the need for boosters for months that would combat new variants as well as protect those who are immunocompromised in which the initial double doses are not as effective. The FDA authorized the use of a Moderna or Pfizer booster on Thursday for immunocompromised individuals, including organ transplant recipients, cancer patients, and those with HIV, reported CNBC. New Article In a highly controversial decision, the Food and Drug Administration recently approved an Alzheimer's drug from Biogen (NASDAQ: BIIB), even though the drug had basically the same efficacy as placebo: In other words, no efficacy at all. For instance, some researchers have suggested that amyloid plaques are a kind of ""scab on the brain,"" an attempt by the body to heal something that has gone wrong. Motley Fool editor and analyst Olivia Zitkus and Fool.com writer Taylor Carmichael met virtually to discuss Biogen's new research. New Article In a surprise move, the Food and Drug Administration approved the new Alzheimer's drug from Biogen (NASDAQ: BIIB), even though the drug failed to beat placebo in its clinical trials. Already the Department of Veterans Affairs has declined to pay for Biogen's drug, citing both its lack of efficacy and safety concerns. But what the FDA did, they approved it because it is reducing the plaques in the brain, even though they are seeing no improvement or significant efficacy in the drug in terms of patients welfare or getting better.",270.98260498046875
2021-08-16 00:00:00+00:00,341.9200134277344,344.0,337.20001220703125,343.5,343.5,836700.0,3.1666666666666665,1.0,0.5416916666666668,"In the second quarter, Berkshire said it exited a $180 million stake in Biogen Inc BIIB.O and reduced investments in Abbvie Inc ABBV.N, Bristol-Myers Squibb Co BMY.N and Merck. That suggests Buffett and his investment managers Todd Combs and Ted Weschler remain wary of valuations as stock prices regularly set new highs. Berkshire has instead bought back about $14.3 billion of its own stock between January and late July though its share price also set records, and now sits just 2% below its May 7 peak. New Article SEE MORE 11 Best Monthly Dividend Stocks and Funds to Buy Getty Images Biogen Action: Exited stake Shares held: 0 Value of stake: $0 It looks like Berkshire Hathaway took advantage of an up market to rid itself of Biogen (BIIB, $343.37). Even at current share prices, the stake would be worth only about $220 million, and that's after BIIB gained 40% for the year-to-date. BRK.B paid an average estimated price of $296.73 per share for BIIB. New Article Berkshire 13F Shows Buffett Dropped Axalta, Biogen, Liberty Global Buffett and his lieutenants sold off the entirety of BRK.B's holdings in Philadelphia-based chemicals company Axalta Coating Systems (AXTA), Massachusetts drugmaker Biogen (BIIB) and U.K. broadband specialist Liberty Global (LBTYA). Berkshire Hathaway's (BRK.B) Form 13F hit Monday afternoon, revealing the stocks Warren Buffett and his team bought and sold during the second quarter of 2021. Let's dig into the some of the biggest Buffett stock adjustments made during the second quarter of 2021, based on Berkshire Hathaway's 13F filed on Aug. 16, 2021, for the period ending June 30, 2021. New Article Especially high volume was seen for the $410 strike call option expiring September 17, 2021, with 1,008 contracts trading so far today, representing approximately 100,800 underlying shares of BIIB. Below is a chart showing WIX's trailing twelve month trading history, with the $250 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 5,032 contracts thus far today. That number of contracts represents approximately 503,200 underlying shares, working out to a sizeable 50.9% of BIIB's average daily trading volume over the past month, of 989,505 shares. New Article However, Cassava might not have to undergo such intense scrutiny given how Biogen (NASDAQ:BIIB) got its drug Aduhelm approved. 7 A-Rated, Large-Cap Stocks You Want in Your Portfolio Cassavas Alzheimers drug simufilam recently completed its phase 2 trials, and its results are remarkable. SAVA Stock and the Path To Approval Cassava plans to conduct two phase 3 clinical trials before the conclusion of this year in testing simufilams efficacy. New Article That drug Biogens (NASDAQ:BIIB) aducanumab  has been mired in controversy. Source: Shutterstock Despite critics negativity, the recently-released interim results of the drugs Phase 2 trial provide overwhelming evidence that simufilam will be the worlds first safe, highly effective treatment for Alzheimers. 7 A-Rated, Large-Cap Stocks You Want in Your Portfolio Remdesivir, which appeared to have some efficacy against the coronavirus in the first six months of last year, was eventually shown to be significantly effective and generated billions of dollars of revenue for its developer, Gilead, despite the doubts of many naysayers.",276.1650695800781
2021-08-20 00:00:00+00:00,339.7200012207031,345.739990234375,337.0799865722656,341.739990234375,341.739990234375,794100.0,2.0,1.0,0.250025,"It's been a great year for Biogen (NASDAQ: BIIB). The U.S. Food and Drug Administration (FDA) recently identified issues with the company's filing for approval of AXS-05 in treating major depressive disorder. The company had hoped to win FDA approval for AXS-05 in treating major depressive disorder this month, although that's unlikely now with the agency's review of deficiencies in Axsome's regulatory filing.",276.5922546386719
2021-08-23 00:00:00+00:00,342.3299865722656,349.6300048828125,341.1600036621094,346.42999267578125,346.42999267578125,810000.0,3.0,1.0,0.5000249999999999,Axsome Therapeutics (NASDAQ:AXSM) shares are soaring over 35% on talk that it would be a good acquisition target for Biogen (NASDAQ:BIIB). Huaneng Power International (NYSE:HNP) stock is heading more than 18% higher as it continues its positive momentum from the last few days. MicroSectors U.S. Big Oil Index -3X Inverse Leveraged ETN (NYSEARCA:NRGD) shares are down 8% in pre-market trading today.,296.9828796386719
2021-08-25 00:00:00+00:00,347.239990234375,347.69000244140625,341.5,342.75,342.75,791000.0,2.6666666666666665,1.0,0.4166916666666666,"Combined, BIIB and CNC make up approximately 1.7% of the underlying holdings of XLV. Within that group, Biogen Inc (Symbol: BIIB) and Centene Corp (Symbol: CNC) are two large stocks that are lagging, showing a loss of 2.0% and 1.8%, respectively. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. New Article Berkshire Hathaway's latest 13-F filing (a quarterly report some institutional investment managers are required to file) revealed that the conglomerate closed its stake in biotech Biogen (NASDAQ: BIIB). During the company's second-quarterearnings conference call CEO Michel Vounatsos said, ""We have seen strong indications of very high initial patient interest in Aduhelm as well as increased referrals from PCPs [primary care physicians] to specialists."" Biogen is exploring options to make the medicine more accessible to those who may not be able to afford it, and it plans to publish the data from its phase 3 studies for Aduhelm in peer-reviewed journals. New Article Biogen (NASDAQ:BIIB) has had a great run on the share market with its stock up by a significant 30% over the last three months. NasdaqGS:BIIB Past Earnings Growth August 25th 2021 Earnings growth is a huge factor in stock valuation. Has the market priced in the future outlook for BIIB?",294.3009033203125
2021-08-26 00:00:00+00:00,343.2799987792969,347.1300048828125,342.0199890136719,342.239990234375,342.239990234375,717200.0,2.0,1.0,0.250025,"That's exactly what I'll be doing today with Cassava Sciences (NASDAQ: SAVA) and Annovis Bio, (NYSEMKT: ANVS) which are both developing drugs for Alzheimer's disease. The next big step for Cassava will be in September, when the company will announce interim results documenting simufilam's efficacy after 12 months of treatment. There's a clear winner, but investors should hedge their bets At the moment, Cassava Sciences looks like a better biotech stock than Annovis Bio because its lead program appears to be more successful at treating Alzheimer's disease.",288.05633544921875
2021-08-27 00:00:00+00:00,341.8099975585937,347.739990234375,338.5199890136719,343.19000244140625,343.19000244140625,614800.0,1.0,1.0,2.4999999999997247e-05,"Contrast this pristine safety record with that of Biogen (NASDAQ: BIIB), whose recently approved Alzheimer's drug has been linked to brain bleeds in some patients. The point of a clinical trial is to assess whether a drug works The pharmaceutical industry is heavily regulated by the federal government, specifically by one agency: the FDA. As the company reported a few weeks ago: The safety profile of simufilam in the interim analysis is consistent with prior human studies.",291.50042724609375
2021-08-30 00:00:00+00:00,342.9200134277344,345.7799987792969,340.75,344.4200134277344,344.4200134277344,555100.0,2.5,1.0,0.375025,"By Deena Beasley Aug 30 (Reuters) - Biogen Inc BIIB.O is providing its controversial and expensive new Alzheimer's drug free of charge for some patients amid slow claim reviews by Medicare, according to sources familiar with the situation, including a doctor treating patients with the drug. The development underscores the division among doctors about whether the $56,000-a-year drug helps patients and how uncertainty about reimbursement from Medicare, the U.S. government health plan for people over age 65, has held back prescriptions and sales. Aduhelm, which is given as a monthly infusion, was approved by the U.S. Food and Drug Administration in June even though one of Biogen's two large clinical trials failed to show a benefit for patients diagnosed with the incurable mind-wasting disease. New Article (RTTNews) - As August draws to a close, let us take a look back at some of the regulatory headlines from that eventful month and look forward to what September has in store. This drug is already approved for the treatment of cataplexy or excessive daytime sleepiness in patients seven years or older with narcolepsy. On Aug.23, Pfizer-BioNTech COVID-19 Vaccine became the first to receive full FDA approval for the prevention of COVID-19 disease in individuals 16 years of age and older.",293.81414794921875
2021-08-31 00:00:00+00:00,344.6199951171875,345.6099853515625,337.8999938964844,338.9100036621094,338.9100036621094,984400.0,1.0,1.0,2.4999999999997247e-05,"Biogen (NASDAQ:BIIB) recently had its Alzheimers drug, Aduhelm, be given accelerated approval by the FDA. While it might be tempting to buy on the dip, its important to remember that the claims made by a former Securities and Exchange Commission enforcement lawyer are serious in nature. The 7 Best Stocks to Buy for September As a science company, we champion facts that can be evaluated and verified, Remi Barbier, Cassavas chief executive officer and founder, said in a statement.",294.1351013183594
2021-09-02 00:00:00+00:00,338.6700134277344,338.69000244140625,327.79998779296875,335.57000732421875,335.57000732421875,1221600.0,2.0,1.0,0.250025,"Changes sourcing, adds details and background on the approval Sept 2 (Reuters) - Two U.S. House committees have requested data and documents from the Food and Drug Administration related to the agency's accelerated approval of Biogen Inc's BIIB.O recently approved Alzheimer's drug, Aduhelm. In a letter dated Sept. 1, lawmakers from the two committees asked FDA to provide the data the agency relied on when it made its decision and to offer more details about who was involved in the decision for accelerated approval. ""We are concerned by apparent anomalies in FDA's processes surrounding its review of Aduhelm,"" chairs of the two committee wrote.",300.8598937988281
2021-09-09 00:00:00+00:00,322.0,322.489990234375,295.2200012207031,300.1499938964844,300.1499938964844,3549600.0,3.0,1.0,0.5000249999999999,"(RTTNews) - Biotech giant Biogen Inc. (BIIB) on Thursday admitted that the launch of its controversial Alzheimer's drug Aduhelm ""was slower than we initially anticipated."" Only about 50 centers around the country have administered at least one dose of Aduhelm, Biogen said at an investor conference sponsored by the investment bank Morgan Stanley. The panel voted 0 yes, 10 no and 1 uncertain that it is ""reasonable"" to consider the single phase III positive study, as primary evidence of effectiveness of Aducanumab for the treatment of Alzheimer's disease. New Article Within that group, Biogen Inc (Symbol: BIIB) and Eli Lilly (Symbol: LLY) are two large stocks that are lagging, showing a loss of 6.8% and 5.3%, respectively. Combined, BIIB and LLY make up approximately 4.7% of the underlying holdings of XLV. Combined, ES and FE make up approximately 5.3% of the underlying holdings of XLU. New Article Especially high volume was seen for the $350 strike call option expiring September 17, 2021, with 1,106 contracts trading so far today, representing approximately 110,600 underlying shares of BIIB. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 17,455 contracts have traded so far, representing approximately 1.7 million underlying shares. That amounts to about 211.6% of BIIB's average daily trading volume over the past month of 825,090 shares. New Article VIDEO: S&P 500 Movers: BIIB, MRNA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing S&P 500 component thus far on the day is Biogen, trading down 5.7%. Biogen is showing a gain of 23.8% looking at the year to date performance. New Article VIDEO: Nasdaq 100 Movers: BIIB, LULU The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Year to date, lululemon athletica registers a 23.0% gain. And the worst performing Nasdaq 100 component thus far on the day is Biogen, trading down 6.0%. New Article A bullish investor could look at BIIB's 21.2 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of BIIB shares: Looking at the chart above, BIIB's low point in its 52 week range is $223.25 per share, with $468.55 as the 52 week high point  that compares with a last trade of $298.84. In trading on Thursday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 21.2, after changing hands as low as $297.55 per share. New Article That is, following the controversy surrounding the approval of Biogens (NASDAQ:BIIB) Aduhelm Alzheimers treatment, the FDA may already be looking with a more critical eye at new candidates to treat this disease. Before then, it seemed that the biotech companys key candidate, Alzheimers treatment Simufilam, was on its way to obtaining U.S. Food and Drug Administration (FDA) approval. You may not want to buy the dip. Beyond Allegations, Other Issues Pose Risks Ill concede that Barbiers claim of short-sellers being behind this incident could prove true. New Article But if you're looking for a great stock to add to your portfolio this month that lends catalysts from both of these profitable industries, Veeva Systems should be a strong contender for your watch list. Three paths to profits with gene editing Steve Ditto (Editas Medicine): In 2020, American biochemist Jennifer Doudna was awarded the Nobel Prize in Chemistry for the discovery of CRISPR gene-editing technology. Based on this tremendous advancement, industry observers like Cathie Wood of ARK Investment Management believe we are entering a genomic revolution where gene-editing has the potential to generate hundreds of billions of dollars in new revenue and trillions in new market capitalizations.",293.91943359375
2021-09-10 00:00:00+00:00,299.9700012207031,302.4700012207031,295.25,299.8099975585937,299.8099975585937,1380200.0,2.5,1.0,0.375025,"On the other hand, Eisai 4523.T lost 8.7% after Biogen Inc BIIB.O shares tumbled after it said the launch of its Alzheimer's drug, which the two firms have developed, was slower than what was initially anticipated. TOKYO, Sept 10 (Reuters) - Japan's Nikkei hit a six-month high on Friday and the broader Topix index touched its best level since 1990, extending their bull run since the end of August on hopes for a new government and further improvement in earnings. Hopes that a new leader at Japan's dominant ruling party would compile an economic stimulus and secure a decisive election victory have boosted shares prices after unpopular Prime Minister Yoshihide Suga offered to resign last week. New Article What happened Shares of Biogen (NASDAQ: BIIB) were sinking 10% this week as of the market close on Thursday. The slide came after the company's CEO stated on Thursday that the launch of Alzheimer's disease drug Aduhelm has been slower than expected. So what Biogen CEO Michel Vounatsos spoke at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday.",294.055908203125
2021-09-13 00:00:00+00:00,301.8699951171875,306.4599914550781,300.0,301.94000244140625,301.94000244140625,797500.0,2.0,1.0,0.250025,"The three stocks to buy we picked for us today are: DocuSign (NASDAQ:DOCU) Marathon Digital Holdings (NASDAQ:MARA) Biogen (NASDAQ:BIIB) Stocks to Buy: DocuSign (DOCU) Source: Charts by TradingView DOCU stock just had a technical correction as Wall Street defines it. Stocks to Buy: Biogen (BIIB) Source: Charts by TradingView BIIB stock did not have a good summer. BIIB has been around long enough to earn some benefit of the doubt. New Article It does not work the same way as Biogens (NASDAQ:BIIB). Source: Shutterstock SAVA stock backed off suddenly when a law firm betting against it questioned its clinical data quality. A government website posted a lawyers letter that urged Billy Dun, Food and Drug Administration director, to pause Simufilam clinical trial.",296.3650207519531
2021-09-16 00:00:00+00:00,300.7900085449219,302.92999267578125,296.7699890136719,299.69000244140625,299.69000244140625,752200.0,3.0,1.0,0.5000249999999999,"(RTTNews) - Biogen Inc. (BIIB) announced positive results from its Phase 2 CONVEY study of vixotrigine or BIIB074, a non-opioid investigational oral pain drug being evaluated for the treatment of small fiber neuropathy. Symptoms tend to be worse at night and during periods of rest and can lead to a significant impact on overall quality of life. The 200 mg dose also resulted in statistically significant improvement versus placebo on the mean worst daily pain score at week 12.",276.7955017089844
2021-09-17 00:00:00+00:00,300.8500061035156,300.8500061035156,296.5599975585937,300.19000244140625,300.19000244140625,1680000.0,4.0,1.0,0.7500249999999999,"(RTTNews) - Biogen Inc. (BIIB) announced the Committee for Medicinal Products for Human Use has recommended granting marketing authorization for VUMERITY in the European Union. The company said the positive CHMP opinion was based on data from pharmacokinetic bridging studies comparing VUMERITY and TECFIDERA. VUMERITY is an oral fumarate with a distinct chemical structure from TECFIDERA, approved in the U.S. for the treatment of relapsing forms of multiple sclerosis in adults.",269.800048828125
2021-09-20 00:00:00+00:00,297.94000244140625,301.5799865722656,296.3099975585937,298.489990234375,298.489990234375,932000.0,4.0,1.0,0.7500249999999999,"(RTTNews) - Samsung Bioepis Co., Ltd. and Biogen Inc. (BIIB) announced Monday that the U.S. Food and Drug Administration (FDA) has approved Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab) for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV). Ranibizumab is an anti-vascular endothelial growth factor (VEGF) therapy that prevents vision loss in patients with retinal vascular disorders which can cause irreversible blindness or visual impairments in adults in the U.S. Byooviz is the first ophthalmology biosimilar approved in the U.S. Biosimilars are products that have been demonstrated to be similar in efficacy and safety to the originator's reference product, with the advantage that they offer cost savings and promote sustainable access to therapies. Byooviz is Samsung Bioepis' fifth biosimilar approved in the U.S. New Article Sept 20 (Reuters) - The U.S. Food and Drug Administration on Monday approved South Korean drugmaker Samsung Bioepis Co Ltd and Biogen Inc's BIIB.O biosimilar rival to Roche Holding AG's ROG.S blockbuster eye drug, Lucentis. Biosimilars are cheaper versions of biologic drugs made from living organisms. Lucentis, which already faces competition from Novartis AG's NOVN.S Beovu, is approved to treat eye diseases such as wet age-related macular degeneration and brought in sales of CHF 1.4 billion ($1.50 billion) in 2020. New Article As with many other companies Biogen Inc. (NASDAQ:BIIB) makes use of debt. NasdaqGS:BIIB Debt to Equity History September 20th 2021 A Look At Biogen's Liabilities We can see from the most recent balance sheet that Biogen had liabilities of US$3.35b falling due within a year, and liabilities of US$9.91b due beyond that. Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' New Article Despite a large 45% move over the last five trading sessions, we believe BIIB stock can see much higher levels in the near term, primarily due to a sharp pickup in sales and earnings as Aduhelm hits the market. [Updated: 9/16/2021] Biogen Stock Update A few months back we discussed that the stock price of Biogen (NASDAQ:BIIB) can see a rebound after falling 10% in a week, based on its historical performance. However, BIIB stock has seen a decline of over 12% since then, and it is down 7% in the last five trading days.",257.28997802734375
2021-09-21 00:00:00+00:00,300.9700012207031,304.2099914550781,292.7300109863281,295.5400085449219,295.5400085449219,738000.0,2.0,1.0,0.250025,"In trading on Tuesday, shares of Biogen Inc (Symbol: BIIB) crossed below their 200 day moving average of $295.63, changing hands as low as $292.73 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $223.25 per share, with $468.55 as the 52 week high point  that compares with a last trade of $295.54. The BIIB DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other stocks recently crossed below their 200 day moving average  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",247.22647094726562
2021-09-22 00:00:00+00:00,289.44000244140625,292.1700134277344,285.3999938964844,289.32000732421875,289.32000732421875,1420100.0,2.0,1.0,0.250025,"Among large Healthcare stocks, Incyte Corporation (Symbol: INCY) and Biogen Inc (Symbol: BIIB) are the most notable, showing a loss of 6.8% and 1.8%, respectively. Combined, INCY and BIIB make up approximately 1.1% of the underlying holdings of XLV. In afternoon trading on Wednesday, Utilities stocks are the worst performing sector, higher by 0.3%. New Article (RTTNews) - Biotechnology company Biogen Inc. (BIIB) is considering drastic cost-cutting measures like layoffs, following the poor response to its Alzheimer drug Aduhelm, which was approved by the U.S Food and Drug Administration in June this year, reports said. According to sources, the financial situation is so bad that the company would be trimming its employees and also looking at different cost-cutting measures. The recent drop in sales is the latest development in the company's effort to sell the first approved Alzheimer's therapy since 2003, as there is yet to be sufficient demand for the drug.",240.28607177734375
2021-09-23 00:00:00+00:00,293.69000244140625,299.8299865722656,292.1000061035156,293.20001220703125,293.20001220703125,919300.0,2.0,1.0,0.250025,"In early trading on Thursday, shares of Biogen (BIIB) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.1%. VIDEO: Nasdaq 100 Movers: PDD, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing Nasdaq 100 component thus far on the day is Pinduoduo (PDD), trading down 1.2%.",239.8399658203125
2021-09-24 00:00:00+00:00,289.8599853515625,293.4700012207031,289.0,291.7099914550781,291.7099914550781,817500.0,3.0,1.0,0.5000249999999999,"Particularly high volume was seen for the $300 strike put option expiring January 20, 2023, with 1,250 contracts trading so far today, representing approximately 125,000 underlying shares of BIIB. Below is a chart showing KMPH's trailing twelve month trading history, with the $20 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 5,531 contracts thus far today. That number of contracts represents approximately 553,100 underlying shares, working out to a sizeable 50.6% of BIIB's average daily trading volume over the past month, of 1.1 million shares.",238.32772827148438
2021-09-27 00:00:00+00:00,290.54998779296875,291.0,286.1600036621094,286.6199951171875,286.6199951171875,704300.0,2.0,1.0,0.250025,"By Julie Steenhuysen CHICAGO, Sept 27 (Reuters) - Japanese drugmaker Eisai Co 4523.T on Monday began its application process for its experimental drug for early Alzheimer's disease using an accelerated approval pathway, the same path that helped Eisai's development partner Biogen Inc BIIB.O win U.S. approval of its medication in June. Biogen and Eisai won authorization for Aduhelm based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer's, rather than convincing proof that it slows progression of the lethal disease. The company plans to submit data from its midstage trial of 856 volunteers, which showed that 80% of patients had no amyloid left in their brains after 18 months of treatment.",244.28317260742188
2021-09-28 00:00:00+00:00,290.82000732421875,291.5400085449219,284.25,284.7099914550781,284.7099914550781,785100.0,2.0,1.0,0.250025,"Let's look at recent news in the Alzheimer's space to compare Cassava's situation to Biogen's (NASDAQ: BIIB). Last week, biotech Cassava Sciences (NASDAQ: SAVA) published topline interim-analysis data for simufilam, a potential treatment for Alzheimer's disease. Second, if you pay close attention to the trial protocol, patients are included in the study even if they take Alzheimer's medications approved by the Food and Drug Administration (FDA), such as donepezil.",250.3768310546875
2021-10-01 00:00:00+00:00,281.3500061035156,285.4100036621094,279.239990234375,283.94000244140625,283.94000244140625,925800.0,2.0,1.0,0.250025,"The best way for investors to estimate the addressable market of Cassavas potential Alzheimers disease treatment is by looking at Biogens (NASDAQ:BIIB) Aduhelm drug. Positive Data Lifts SAVA Stock On Sept. 22, Cassava announced the top-line results of a 12-month, open-label study of its simufilam drug candidate for Alzheimers Disease. Data Defended In August, a lawyer who was reportedly representing short sellers of SAVA stock urged Billy Dunn, the director of the FDAs Center for Drug Evaluation and Research, to pause simufilams Phase 3 clinical trial.",242.38226318359375
2021-10-04 00:00:00+00:00,281.44000244140625,284.5599975585937,277.4100036621094,278.32000732421875,278.32000732421875,924900.0,2.5,1.0,0.375025,"Particularly high volume was seen for the $690 strike call option expiring January 20, 2023, with 531 contracts trading so far today, representing approximately 53,100 underlying shares of BIIB. Below is a chart showing ORA's trailing twelve month trading history, with the $60 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 5,133 contracts, representing approximately 513,300 underlying shares or approximately 47.3% of BIIB's average daily trading volume over the past month, of 1.1 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $690 strike highlighted in orange: And Antero Resources Corp (Symbol: AR) options are showing a volume of 33,360 contracts thus far today. New Article Although BIIB has traded at a recent price of $283.94/share, the average analyst target is 43.04% higher at $406.14/share. iShares U.S. Dividend and Buyback ETF DIVB $39.70 $44.38 11.79% Biogen Inc BIIB $283.94 $406.14 43.04% VF Corp. VFC $68.14 $96.33 41.36% OneMain Holdings Inc OMF $57.05 $71.30 24.98% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of DIVB's underlying holdings with notable upside to their analyst target prices are Biogen Inc (Symbol: BIIB), VF Corp. (Symbol: VFC), and OneMain Holdings Inc (Symbol: OMF).",235.406005859375
2021-10-05 00:00:00+00:00,278.3399963378906,282.260009765625,278.3399963378906,280.44000244140625,280.44000244140625,1010500.0,3.0,1.0,0.5000249999999999,"The stock price of Eli Lilly (NYSE: LLY) has seen a decline of 11% over the last twenty-one trading days. There are multiple positives for Eli Lilly to look forward to, including the rise in demand for its Covid-19 antibody cocktail, as well as its promising Alzheimers treatment, something which has kept its stock price buzzing this year, with 40% year-to-date gains. Calculation of Event Probability and Chance of Rise using last ten years data After moving -0.5% or more over a five-day period, the stock rose in the next five days on 56% of the occasions. New Article The pharma company Biogen (NASDAQ: BIIB) has been the locus of persistent and intense controversy surrounding its Alzheimer's disease drug, Aduhelm, which was approved by regulators in June. It's unclear exactly what they did, but people are mad about it, and the stock is threatening to crater -- and you're feeling the initial pang of panic give way to the urge to sell your shares, pronto. If a company's CEO draws oblique criticism in the industry press for their unorthodox managerial practices or eccentric workplace decorum, it could affect the stock price.",248.39764404296875
2021-10-07 00:00:00+00:00,285.5199890136719,290.760009765625,284.5799865722656,287.7699890136719,287.7699890136719,879900.0,3.0,1.0,0.5000249999999999,"Here's why they picked Biogen (NASDAQ: BIIB), Moderna (NASDAQ: MRNA), and Novavax (NASDAQ: NVAX). Back when it was first approved, I warned investors that the drug's efficacy data were questionable, and one shouldn't put all their eggs in one basket to bet on its performance. The most promising drug in its pipeline is tofersen, which is under phase 3 investigation to treat amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease.",263.7192077636719
2021-10-08 00:00:00+00:00,287.44000244140625,288.989990234375,284.0,285.8299865722656,285.8299865722656,629600.0,1.0,1.0,2.4999999999997247e-05,"Biogen's (NASDAQ: BIIB) Alzheimer's disease drug Aduhelm has been embroiled in controversy for a while. That makes it difficult to know the likelihood that how frequent ARIA actually is in patients that are taking the drug. I think that probably getting cumulative doctors that the drug works, it's probably more important than allaying their fears of potentially getting ARIA.",267.76654052734375
2021-10-13 00:00:00+00:00,284.8999938964844,285.29998779296875,280.5,283.6499938964844,283.6499938964844,521400.0,3.0,1.0,0.5000249999999999,Biogen Competition has eroded sales in Biogen's (NASDAQ: BIIB) main business of multiple sclerosis (MS). Wall Street's average analyst estimate predicts Teladoc shares will rise to $193.80 in the coming 12 months. Long-term investors won't mind waiting for Teladoc's booming business to translate into share-price performance.,270.2198486328125
2021-10-15 00:00:00+00:00,285.3399963378906,286.0,278.57000732421875,281.19000244140625,281.19000244140625,1299600.0,3.333333333333333,1.0,0.5833583333333334,"Biogen Earlier this year, Biogen (NASDAQ: BIIB) was handily beating the market, with shares soaring nearly 70%. Newer products, including cancer cell therapies Abecma and Breyanzi, should also emerge as big winners for the company in the near future. If the Alzheimer's disease drug comes anywhere close to achieving analysts' peak sales estimates, Biogen's share price could rebound significantly. New Article VIDEO: Nasdaq 100 Movers: BIIB, MAR The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Year to date, Marriott International, registers a 20.3% gain. And the worst performing Nasdaq 100 component thus far on the day is Biogen, trading down 1.6%. New Article But recent industry setbacks could be souring sentiment: Biogen's BIIB.O new and controversial Alzheimer's treatment has had an uncertain launch, Apellis Pharma APLS.O shares tumbled following disappointing data for its experimental eye drug, and U.S. regulators placed a hold on studies of Allogene Therapeutics' ALLO.O cancer medicine. By Lewis Krauskopf NEW YORK, Oct 15 (Reuters) - Sluggish U.S. biotech shares could require a wave of deal-making or exciting clinical trial results if the sector wants to join the stock market's party after lagging Wall Street's broad advance this year. SVB Leerink analyst Geoffrey Porges said in a note this week that it was ""difficult to see"" a broad rally in the biopharma group in part because of ""the enduring overhang of drug pricing regulation risks, which in our view is likely to last until the end of the year.""",276.8276672363281
2021-10-18 00:00:00+00:00,279.4200134277344,279.5,269.19000244140625,269.7300109863281,269.7300109863281,1496100.0,3.0,1.0,0.5000249999999999,"Combined, MDT and BIIB make up approximately 4.2% of the underlying holdings of XLV. Among large Healthcare stocks, Medtronic PLC (Symbol: MDT) and Biogen Inc (Symbol: BIIB) are the most notable, showing a loss of 5.5% and 3.7%, respectively. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Monday.",287.829345703125
2021-10-19 00:00:00+00:00,270.0,271.6600036621094,266.29998779296875,268.1300048828125,268.1300048828125,1801700.0,2.333333333333333,1.0,0.3333583333333332,"By Dania Nadeem and Amruta Khandekar Oct 19 (Reuters) - Biogen Inc's BIIB.O Alzheimer's drug will be of little help to its third-quarter sales, Wall Street analysts said, as the drugmaker faces an uphill task of convincing hospitals and clinics to use the $56,000-a-year treatment and insurers to reimburse it. ""We expect focus will remain Aduhelm's launch, where signals around initial sales, reimbursement and prescriber sentiment have been negative, and shares have reflected this, taking a round trip nearly all the way back from pre-approval levels,"" said Baird analyst Brian Skorney. Wall Street estimates for Aduhelm sales https://tmsnrt.rs/3DVTOAD Biogen total quarterly saleshttps://tmsnrt.rs/3AWrCvo Biogen total quarterly saleshttps://tmsnrt.rs/3pja0I9 Wall Street estimates for Aduhelm sales https://tmsnrt.rs/3lRBO4f (Reporting by Dania Nadeem and Amruta Khandekar in Bengaluru; Editing by Arun Koyyur) ((Dania.Nadeem@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen Inc. (BIIB)is reporting for the quarter ending September 30, 2021. BIIB missed the consensus earnings per share in the 4th calendar quarter of 2020 by -7.1%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for BIIB is 14.45 vs. an industry ratio of -5.30, implying that they will have a higher earnings growth than their competitors in the same industry. New Article Biogen Inc. (BIIB)is reporting for the quarter ending September 30, 2021. BIIB missed the consensus earnings per share in the 4th calendar quarter of 2020 by -7.1%. Zacks Investment Research reports that the 2021 Price to Earnings ratio for BIIB is 14.45 vs. an industry ratio of -5.30, implying that they will have a higher earnings growth than their competitors in the same industry.",290.9768981933594
2021-10-20 00:00:00+00:00,270.1099853515625,277.8699951171875,264.7799987792969,266.57000732421875,266.57000732421875,2153000.0,2.9166666666666665,1.0,0.4791916666666667,"(RTTNews) - Biogen Inc. (BIIB) released earnings for third quarter that decreased from last year. Excluding items, Biogen Inc. reported adjusted earnings of $709.6 million or $4.77 per share for the period. -Guidance: Full year EPS guidance: $18.85 to $19.35 Full year revenue guidance: $10.8 to $10.9 Bln The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article (RTTNews) - While reporting third-quarter results on Wednesday, Biogen Inc. (BIIB) increased its full year 2021 financial guidance. Analysts polled by Thomson Reuters expect the company to report profit per share of $18.61 on revenue of $10.76 billion. On average, 25 analysts polled by Thomson Reuters expected the company to report profit per share of $4.11, for the quarter. New Article (RTTNews) - Biogen Inc. (BIIB) will host a conference call at 8:00 AM ET on October 20, 2021, to discuss Q3 21 earnings results. To access the live webcast, log on to https://investors.biogen.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Adds details from release, background Oct 20 (Reuters) - Biogen Inc BIIB.O fell well short of Wall Street estimates for third-quarter sales of its Alzheimer's drug Aduhelm on Wednesday, as the drugmaker struggles to sell the treatment to hospitals and get insurers to cover it. Biogen has pinned its hopes on Aduhelm, the first new treatment for the memory-robbing disease in nearly 20 years, as it wrestles with increased competition for its main revenue drivers. Several commercial insurers are waiting for further direction from the U.S. Centers for Medicare & Medicaid Services (CMS) before covering the drug, while some large hospitals have declined to use it. New Article With that in mind, let's look at two quality companies that will help your portfolio shine over the next decade: Intuitive Surgical (NASDAQ: ISRG) and Eli Lilly (NYSE: LLY). That's not to mention the time it takes to train medical staff on the machine, and the instruments and accessories healthcare facilities have to purchase to perform various procedures with it. That's not to mention Eli Lilly's non-diabetes drugs, including cancer medicine Verzenio and Alimta, and immunosuppressant Taltz, all of which are performing splendidly. New Article Then there is the citizen petition that New York-based law firm Labaton Sucharow filed with the FDA requesting that the agency halt clinical trials featuring Simufilam. Add these to the other headwinds that Cassava Sciences could run into, including the very real possibility that Simufilam will fail miserably in its phase 3 clinical trials or that it will encounter regulatory setbacks, and this biotech stock looks far too risky to invest in, even at current levels. But even though that good news out of India will have no notable impact on Ocugen's business, its stock price jumped anyway, topping the $10 mark for the first time in months. New Article However, Biogen Inc BIIB.Oshares closed down 0.6% as it reported a much smaller-than-expected quarterly sales of its Alzheimer's drug while it raised its full year earnings forecast. The S&P had fallen almost 6% below its record by Oct. 4 as investors worried about supply chain problems, profit margin pressures, higher wages and increasing input costs ahead of the earnings season, which kicked off last week. However, shares in IBM IBM.N were down around 5% in after the bell trading on Wednesday after it missed market estimates for third-quarter revenue due to a decline in orders at its managed infrastructure unit ahead of a spinoff. New Article Anthem Inc ANTM.N gained 5.7% and Biogen Inc BIIB.O added 2% after both healthcare companies raised their full-year profit forecasts. By Devik Jain and Shreyashi Sanyal Oct 20 (Reuters) - U.S. stock indexes edged higher on Wednesday, helped by strong quarterly updates from healthcare companies including Anthem and Abbott, while worries remained about the impact of supply chain constraints and inflation on corporate earnings. ""Investors are digesting earnings and the impact of supply chain disruptions on Corporate America,"" said Fiona Cincotta, senior financial markets analyst at City Index. New Article However, Biogen Inc BIIB.O was down slightly as it reported a much smaller-than-expected quarterly sales of its Alzheimer's drug while it raised its full year earnings forecast. By Devik Jain, Shreyashi Sanyal and Sinad Carew Oct 20 (Reuters) - The Dow briefly touched a record high and the S&P 500 traded close to its peak on Wednesday as investors eyed better than expected third-quarter earnings from U.S. companies. The S&P had fallen almost 6% below its record by Oct. 4 as investors worried about supply chain problems, profit margin pressures, higher wages and increasing input costs ahead of the earnings season, which kicked off last week. New Article Anthem Inc ANTM.N jumped 7.2% and Biogen Inc BIIB.O added 0.3% after both healthcare companies raised their full-year earnings forecasts. By Devik Jain and Shreyashi Sanyal Oct 20 (Reuters) - The S&P 500 and the Dow inched closer to record highs on Wednesday after strong forecasts from healthcare companies Anthem and Abbott, while the Nasdaq lagged as technology stocks took a breather. Netflix's NFLX.O global sensation ""Squid Game"" helped lure more customers than expected, the world's largest streaming service said as it predicted a packed lineup would further boost signups through the end of the year. New Article However, Biogen Inc BIIB.Oshares had a choppier session as it reported a much smaller-than-expected quarterly sales of its Alzheimer's drug while it raised its full year earnings forecast. By Devik Jain, Shreyashi Sanyal and Sinad Carew Oct 20 (Reuters) - The S&P 500 and the Dow closed higher on Wednesday as investors eyed better than expected third-quarter earnings from U.S. companies. The S&P had fallen almost 6% below its record by Oct. 4 as investors worried about supply chain problems, profit margin pressures, higher wages and increasing input costs ahead of the earnings season, which kicked off last week. New Article Anthem Inc ANTM.N rose 1.6% and Biogen Inc BIIB.O gained 1.3% after both healthcare companies raised their full-year profit forecasts. By Devik Jain Oct 20 (Reuters) - U.S. stock index futures struggled for direction on Wednesday as investors weighed the impact of supply chain constraints and inflation on corporate earnings, while Netflix shares remained sluggish after its quarterly report. Netflix's NFLX.O global sensation ""Squid Game"" helped lure more customers than expected, the world's largest streaming service said as it predicted a packed lineup would further boost signups through the end of the year.",287.5807189941406
2021-10-21 00:00:00+00:00,266.29998779296875,271.94000244140625,266.2900085449219,270.2099914550781,270.2099914550781,1374200.0,3.0,1.0,0.5000249999999999,"NasdaqGS:BIIB Earnings and Revenue Growth October 21st 2021 Investors should note that institutions actually own more than half the company, so they can collectively wield significant power. If you want to know who really controls Biogen Inc. (NASDAQ:BIIB), then you'll have to look at the makeup of its share registry. NasdaqGS:BIIB Ownership Breakdown October 21st 2021 What Does The Institutional Ownership Tell Us About Biogen? New Article Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $275.00 strike highlighted in red: Considering the fact that the $275.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the December 3rd expiration.",286.73211669921875
2021-10-22 00:00:00+00:00,269.3800048828125,270.3699951171875,264.3500061035156,264.79998779296875,264.79998779296875,873200.0,2.5,1.0,0.375025,"Despite a large 45% move over the last five trading sessions, we believe BIIB stock can see much higher levels in the near term, primarily due to a sharp pickup in sales and earnings as Aduhelm hits the market. [Updated: 10/20/2021] BIIB Stock Decline The stock price of Biogen (NASDAQ: BIIB) reached a 52-week high of $468 this June before a sell-off drove the stock price down over 40% to its current level of around $266. However, now that BIIB stock has seen a fall of 10% in a month, will it continue its downward trajectory, or is a rise imminent? New Article The losses would have been much worse for Ionis Pharmaceuticals, but tofersen is being developed in a partnership with Biogen (NASDAQ: BIIB). So what Treatment with tofersen was supposed to help reduce physical symptoms of ALS, a progressive neurodegenerative disorder that affects around 20,000 new U.S. patients annually. Treatment with tofersen lowered SOD1 protein levels, but this didn't lead to improved scores on the revised amyotrophic lateral sclerosis functional rating scale.",285.3451843261719
2021-10-26 00:00:00+00:00,269.8800048828125,273.6400146484375,267.0199890136719,271.1199951171875,271.1199951171875,1453800.0,3.0,1.0,0.5000249999999999,"Let's look at a different company that has come under fire for its therapy and clinical trials: Biogen (NASDAQ: BIIB) and its Alzheimer's disease treatment, Aduhelm. This month, as Merck (NYSE: MRK) moves forward with an Emergency Use Authorization in the U.S. for its oral antiviral for COVID-19, Atea Pharmaceuticals (NASDAQ: AVIR) stock saw a significant drop. With that much cash on hand and a sizable potential market, this beaten-down biotech might be able to thrive in a few years despite the AT-527 saga, if the dengue fever therapy can get off the ground.",288.2882080078125
2021-10-27 00:00:00+00:00,270.1700134277344,270.6000061035156,259.6300048828125,259.95001220703125,259.95001220703125,1276200.0,4.0,1.0,0.7500249999999999,"A phase 2a study of BIIB131 for acute ischemic stroke demonstrated positive impacts on blood vessel reopening and patient functional recovery when given up to 12 hours from onset of symptoms. The current clot-buster utilized in acute ischemic stroke, Roche's Activase, generated $1.27 billion in revenue in 2020, paving the way for BIIB131 to step in and become a blockbuster if these trial results are replicable. Just when the Aduhelm controversy started to settle down, Biogen (NASDAQ: BIIB) disappointed again for what it was hoping was its next big hit.",271.97314453125
2021-10-28 00:00:00+00:00,260.45001220703125,266.5,260.45001220703125,264.8699951171875,264.8699951171875,1273500.0,1.5,1.0,0.125025,"So far, Aduhelm from Biogen (NASDAQ: BIIB) is the only drug approved to treat Alzheimer's disease patients. Cortexyme (NASDAQ: CRTX) stock has been hammered in response to a failed clinical trial for its experimental Alzheimer's disease treatment. Expect misrepresentation of Alzheimer's trial data Cortexyme's lead candidate atuzaginstat inhibits enzymes secreted by mouth bacteria called Porphyromonas gingivalis. New Article Management thinks shareholders should keep the faith Unlike the various plaque-busting Alzheimer's disease drugs from the likes of Biogen and Eli Lilly, among several others, Cortexyme's experimental therapy was attempting to tackle this devastating neurodegenerative disorder in a completely unique manner. The drug, in effect, failed to improve cognitive function, or a person's ability to perform everyday tasks such as eating without assistance, in patients with mild to moderate forms of the disease. Specifically, the drugmaker's management called attention to the drug's ability to seemingly reduce cognitive decline by a healthy 57% in patients who both tested positive for P. gingivali and who had received a higher dose of atuzaginstat.",257.6722717285156
2021-10-29 00:00:00+00:00,264.4100036621094,268.32000732421875,262.0199890136719,266.67999267578125,266.67999267578125,947600.0,3.0,1.0,0.5000249999999999,"Drugmaker Biogen (NASDAQ: BIIB) is coming off a strong quarter, where it beat expectations and raised its guidance for the full year. And although the company stated on its recentearnings callthat it plans to complete the phase 4 trials ahead of schedule, it did not specify a date as to when the results might become available. Even if you're optimistic about Biogen's future, you may be better off waiting until next year -- or at least until its phase 4 trial results come out and after a positive NCD from Medicare.",259.1025695800781
2021-11-01 00:00:00+00:00,266.1499938964844,274.75,265.5,272.1000061035156,272.1000061035156,1222600.0,3.0,1.0,0.5000249999999999,"Thats slightly over one-third the $56,000 annual price of Biogens (NASDAQ:BIIB) highly problematic Alzheimers treatment, aducanumab. Echoing the assessment of multiple other sources this Redditor says that simufilam has achieved superior cognitive and behavioral results to any other drug tested as an Alzheimers treatment. SAVA Stock Is Tremendously Undervalued Using figures that the Redditor calls ridiculously conservative, the poster suggests that Cassava could charge $20,000 for a year of treatment of simufilam.",250.0223846435547
2021-11-04 00:00:00+00:00,279.5899963378906,280.6199951171875,275.32000732421875,280.4100036621094,280.4100036621094,949100.0,5.0,1.0,1.000025,"Then it's also running head-to-head study of that same Alzheimer's disease drug against Biogen's (NASDAQ: BIIB) Aduhelm. Brian Orelli: On the financial side, revenue increased 18% and some of that was due to its COVID antibody therapies. Speights: Brian, did they happen to mention when they expect to complete the rolling submission for the Alzheimer's disease drug?",241.44813537597656
2021-11-08 00:00:00+00:00,279.510009765625,279.7099914550781,268.2699890136719,272.70001220703125,272.70001220703125,1151900.0,3.5,1.0,0.6250249999999999,"Secondly, Eli Lilly earlier this week announced that it will supply another 614,000 doses of its Covid-19 cocktail (a combination of bamlanivimab and etesevimab) to the U.S. government for a total of $1.3 billion. The company further raised its full-year 2021 outlook for revenues to see incremental growth of $840 million and $0.25 in additional earnings per share, following this development. Calculation of Event Probability and Chance of Rise using last ten years data After moving 6.4% or more over a five-day period, the stock rose in the next five days on 53% of the occasions. New Article Getty Images Biogen Market value: $40.9 billion POWR ratings overall rating: B (Buy) POWR Ratings average broker rating: 1.65 Biogen (BIIB, $278.68) is one of the world's leading biotechnology companies, focusing on developing innovative therapies for serious neurological and neurodegenerative diseases. BIIB has a firm position in the multiple sclerosis market, with several products, including Avonex, Plegridy, Tecfidera and Tysabri. BIIB has an overall grade of B (Buy) in the POWR Ratings system.",239.28109741210938
2021-11-09 00:00:00+00:00,272.0,274.69000244140625,267.0,270.0299987792969,270.0299987792969,894700.0,2.0,1.0,0.250025,"Nov 9 (Reuters) - Biogen Inc BIIB.O said on Tuesday it was investigating the death of a 75-year-old patient who had taken the company's newly approved Alzheimer's drug, Aduhelm, adding that it was not yet known whether it was related to the treatment. Aduhelm, the first new treatment for the memory-robbing disease in nearly 20 years, has been battling slow uptake since its approval in early June despite mixed clinical trial results. Only 0.3% of patients treated with the FDA recommended dose reported serious symptoms associated with ARIA in Aduhelm's clinical trials, Biogen said on Tuesday, adding that those did not result in death.",245.2082977294922
2021-11-10 00:00:00+00:00,270.0299987792969,273.9200134277344,266.04998779296875,266.92999267578125,266.92999267578125,708800.0,2.0,1.0,0.250025,"By Deena Beasley Nov 10 (Reuters) - Roche Holding AG ROG.S, still months away from seeking regulatory approval of its experimental Alzheimer's drug, is already taking aim at rival Biogen Inc's BIIB.O Aduhelm, saying that its medication would be priced competitively. The FDA approved Biogen's drug based on evidence that it reduces amyloid brain plaques, a likely contributor to Alzheimer's, rather than proof that it slows the disease's progression. Biogen banks on government coverage to restart stalled Alzheimer's drug sales FOCUS-Biogen provides free Aduhelm as U.S. clinics await Medicare payment (Reporting by Deena Beasley in Los Angeles; Editing by Will Dunham and Caroline Humer) ((deena.beasley@thomsonreuters.com; 213 955 6746)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",246.22642517089844
2021-11-11 00:00:00+00:00,266.6199951171875,267.6099853515625,264.0,266.57000732421875,266.57000732421875,637700.0,3.0,1.0,0.5000249999999999,"George Scangos, formerly the CEO of Biogen (NASDAQ: BIIB) for many years, now heads up Vir. Novavax wrapped up the final analysis for its seasonal flu vaccine's pivotal trial in September, and the study's results were subsequently published in The Lancet Infectious Diseases. Each year, about 25,000 babies in the U.S. are born infected with it, and about 20% of those have birth defects including learning disabilities, hearing loss, vision impairment, and decreased muscle strength and coordination. New Article Compass, in turn, will face an uphill battle from a regulatory standpoint to get its products on the market in key commercial territories like the U.S., and then to get them covered by the most important third-party payers such as Medicare and Medicaid. Compass' lead product candidate is COMP360, a highly purified dose of psilocybin indicated for patients with treatment-resistant depression (TRD) and administered in a controlled-setting under the guidance of a trained therapist. Compass: Competition is perhaps the biggest risk for shareholders Because of the high unmet need in the TRD space and the potential to rake in billions in annual sales as a result, this indication has attracted numerous would-be competitors. New Article By Deena Beasley Nov 11 (Reuters) - Biogen Inc's BIIB.O Alzheimer's drug Aduhelm, approved by U.S. regulators last year for its ability to reduce amyloid brain plaques, also lowers levels of a second protein that accumulates in the brains of people with the disease, according to new data released by the company on Thursday. We now have robust and concordant data that Aduhelm has effect on two core defining pathologies of Alzheimers disease,"" Biogen research chief Alfred Sandrock said in a statement. The FDA has defended its decision by saying there is clear evidence that Aduhelm removes amyloid from the brains of people with Alzheimers, arguing that the effect is reasonably likely to predict a clinical benefit to patients.",258.11181640625
2021-11-12 00:00:00+00:00,270.6700134277344,272.54998779296875,267.5199890136719,270.42999267578125,270.42999267578125,845000.0,2.6,1.0,0.400025,"Biogen Inc BIIB.O rose 2.0% after late-stage studies found its Alzheimer's drug Aduhelm significantly lowered blood levels of an abnormal form of the protein tau that accumulates in the brains of people with the disease. Wall Street's main indexes tracked weekly declines of more than 1%, their first since the turn of October, as hot U.S. inflation readings sapped investor sentiment and halted an earnings-driven streak of record closing highs. Meanwhile, Reuters reported President Joe Biden and Chinese leader Xi Jinping are expected to hold a virtual summit on Monday amid tensions over trade, human rights and military activities. New Article Biogen Inc BIIB.O rose 2.1% after late-stage studies found that its Alzheimer's drug Aduhelm significantly lowered blood levels of an abnormal form of the protein tau. Tesla's top boss Elon Musk sold more shares of the electric car maker, regulatory filings showed, after offloading about $5 billion worth of stock following a poll he posted on Twitter. U.S.-listed shares of Alibaba Group Holding BABA.K slipped 0.4% after the e-commerce giant said its sales - or gross merchandise value - during the Singles Day event grew at the slowest rate ever, underscoring the headwinds for China's tech firms. New Article Biogen Inc BIIB.O rose 0.5% after late-stage studies found its Alzheimer's drug Aduhelm significantly lowered blood levels of an abnormal form of the protein tau that accumulates in the brains of people with the disease. The S&P 500 .SPX and Dow .DJI indexes tracked weekly declines of about 1%, their first since the turn of October, as hot U.S. inflation readings sapped investor sentiment and halted an earnings-driven streak of record closing highs. Reuters reported earlier in the day that President Joe Biden and Chinese leader Xi Jinping are expected to hold a virtual summit on Monday amid tensions over trade, human rights and military activities. New Article Biogen Inc BIIB.O rose 1.3% after late-stage studies found its Alzheimer's drug Aduhelm significantly lowered blood levels of an abnormal form of the protein tau that accumulates in the brains of people with the disease. Wall Street's main indexes were set for weekly declines, their first since the turn of October, as hot U.S. inflation readings sapped investor sentiment and halted an earnings-driven streak of record closing highs. Reuters reported earlier in the day that President Joe Biden and Chinese leader Xi Jinping are expected to hold a virtual summit on Monday amid tensions over trade, human rights and military activities. New Article Biogen (BIIB) was climbing past 2% after saying Aduhelm, the trade name of aducanumab-avwa, ""significantly lowered"" blood levels of an abnormal type of p-tau, a protein that is a defining feature of Alzheimer's disease, when compared with placebo. Health care stocks were gaining in Friday's premarket trading. Analysts polled by Capital IQ projected adjusted EPS of $1.25.",275.8750915527344
2021-11-15 00:00:00+00:00,273.82000732421875,276.5,270.70001220703125,271.82000732421875,271.82000732421875,756300.0,3.0,1.0,0.5000249999999999,"Its larger revenue streams come from Vertex Pharmaceuticals Inc VRTX.O treatments for cystic fibrosis, Biogen Inc's BIIB.O Tysabri for multiple sclerosis, and AbbVie's Imbruvica for various cancers. Berkshire also eliminated its small stakes in Organon & Co OGN.N, a Merck spinoff specializing in contraception and other women's health products, and telecommunications company Liberty Global Plc LBTYA.O. It also owns dozens of businesses including the BNSF railroad, Geico auto insurance and Dairy Queen ice cream. New Article Nov 15 (Reuters) - Biogen Inc BIIB.O said on Monday its research chief Alfred Sandrock, who led development of its Alzheimer's disease drug Aduhelm, is leaving the company after a 23-year run. The company said Sandrock will retire by the end of this year, and Priya Singhal will lead the research & development unit on an interim basis until a permanent successor is identified. He had served as the chief medical officer for Biogen for about eight years before joining its executive committee in 2015.",286.9187927246094
2021-11-17 00:00:00+00:00,254.5599975585937,261.4100036621094,252.0200042724609,258.3800048828125,258.3800048828125,1497000.0,2.0,1.0,0.250025,"The European Commission (EC) has given its green light to Biogen, Inc. (BIIB) to market its multiple sclerosis (MS) treatment Vumerity (diroximel fumarate) in the European Union (EU). Headquartered in Massachusetts, Biogen is a biopharmaceutical company that engages in the discovery, development, and sale of drugs for the treatment of neurological and neurodegenerative diseases. Comments The Assistant Professor at the Department of Neurology, Ruhr-University Bochum, Simon Faissner, said, This medication allows for MS patients in the EU to be treated without having to think about dietary restrictions or when to take a dose in relation to mealtimes which, when treating a chronic disease, may provide patients with additional flexibility in their daily lives. R&D Head Retires Meanwhile, Biogen has announced the retirement of Alfred W. Sandrock, Jr., the Head of its Research & Development department, effective December 31. New Article Biotech giant Biogen (NASDAQ: BIIB) shocked the investing world earlier this year when it earned regulatory approval for its Alzheimer's disease (AD) drug, Aduhelm. In its latest quarterly update, Eli Lilly announced that it had initiated a rolling submission with the FDA for a Biologics License Application (BLA) for accelerated approval of donanemab in treating AD. The best-case scenario for Eli Lilly would be for donanemab to earn approval next year and prove better than Aduhelm at clearing the built-up beta-amyloid plaques in the planned late-stage study. New Article Nov 17 (Reuters) - Biogen Inc BIIB.O said on Wednesday the European Medicines Agency's panel had given a negative trend vote against the marketing application for its Alzheimer's disease drug. (Reporting by Manas Mishra in Bengaluru; Editing by Krishna Chandra Eluri) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manasmishra24)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Adds details Nov 17 (Reuters) - Biogen Inc BIIB.O said on Wednesday a European Medicines Agency panel has voted against the marketing application for its Alzheimer's disease drug, sending shares of the drugmaker down 3%. The panel, Committee for Medicinal Products for Human Use, will adopt a final opinion at a December meeting, the company said. The U.S. approval for the drug, aducanumab, has drawn criticism from scientists, who are doubting whether the clinical evidence proves that the treatment works. New Article Biogen (BIIB) was down more than 3% after the company and said aducanumab, which is intended for the treatment of Alzheimer's disease, has received a negative trend vote by the European Medicines Agency's Committee for Medicinal Products for Human Use. The iShares NASDAQ Biotechnology Index (IBB) was recently inactive while the Health Care SPDR (XLV) was down 0.07%. Vir Biotechnology (VIR) was rallying past 7% after the company and GlaxoSmithKline (GSK) unveiled US government contracts totaling $1 billion to purchase sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19. New Article Especially high volume was seen for the $235 strike put option expiring December 17, 2021, with 851 contracts trading so far today, representing approximately 85,100 underlying shares of BIIB. Below is a chart showing SNA's trailing twelve month trading history, with the $230 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 6,811 contracts thus far today. That number of contracts represents approximately 681,100 underlying shares, working out to a sizeable 60.6% of BIIB's average daily trading volume over the past month, of 1.1 million shares. New Article (RTTNews) - Shares of Biogen Inc. (BIIB) are down on Wednesday after the advisory committee of the European Medicines Agency recommended a ""negative trend vote"" for the company's Alzheimer's therapy drug Aducanumab. The ""negative trend vote"" by the EU's Committee for Medicinal Products for Human Use comes after an oral explanation was provided last month. Commenting on the development, Priya Singhal, head of global safety and regulatory sciences and interim head of research and development at Biogen, said, ""While we are disappointed with the trend vote, we strongly believe in the strength of our data and that aducanumab has the potential to make a positive and meaningful difference for people and families affected by Alzheimer's disease.""",284.1701354980469
2021-11-18 00:00:00+00:00,259.9800109863281,260.7300109863281,253.17999267578125,256.7900085449219,256.7900085449219,975800.0,1.5,1.0,0.125025,"Positive data from an open-label study for the company's leading candidate, coupled with the unexpected approval of Biogen's AD drug Aduhelm, helped propel Cassava Sciences stock this year. The trial will enroll 750 AD patients with mild and moderate cases of the disease, and test the safety and efficacy of Simufilam over 52 weeks. The good news is that with the FDA recently announcing that mixing and matching booster shots is acceptable, Covaxin will have an opportunity to penetrate the market in the U.S. even if vaccination rates climb higher (currently, they're at around 60%). New Article Eisai 4523.T dropped 9% after a European Medicines Agency panel voted against approval of Alzheimer's drug the Japanese drugmaker developed with Biogen Inc BIIB.O. TOKYO, Nov 18 (Reuters) - Japanese shares eased on Thursday, with cyclicals and oil companies leading the decline, but they pared losses after a media report that Prime Minister Fumio Kishida's stimulus package will be larger than initially expected. Before the Nikkei report came out, the market had a soft tone after U.S. stocks ended lower overnight, capped by worries the U.S. Federal Reserve may have to raise interest rates more aggressively in the future to tame inflation.",282.1226501464844
2021-11-19 00:00:00+00:00,257.7099914550781,260.1600036621094,254.57000732421875,257.19000244140625,257.19000244140625,898800.0,3.0,1.0,0.5000249999999999,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $260.00 strike highlighted in red: Considering the fact that the $260.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading this week, for the July 2022 expiration.",284.8127136230469
2021-11-24 00:00:00+00:00,253.17999267578125,253.17999267578125,247.6600036621093,250.1300048828125,250.1300048828125,1579800.0,2.0,1.0,0.250025,"Particularly high volume was seen for the $205 strike put option expiring January 21, 2022, with 237 contracts trading so far today, representing approximately 23,700 underlying shares of BIIB. Below is a chart showing RUN's trailing twelve month trading history, with the $45 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 4,889 contracts, representing approximately 488,900 underlying shares or approximately 46.6% of BIIB's average daily trading volume over the past month, of 1.0 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $205 strike highlighted in orange: And Intellia Therapeutics Inc (Symbol: NTLA) saw options trading volume of 3,038 contracts, representing approximately 303,800 underlying shares or approximately 46.5% of NTLA's average daily trading volume over the past month, of 653,205 shares.",277.5064392089844
2021-11-30 00:00:00+00:00,236.5,239.7700042724609,228.67999267578125,235.7400054931641,235.7400054931641,3294300.0,2.5,1.0,0.375025,"Biogen Inc (BIIB) shares closed today at 0.4% above its 52 week low of $235.18, giving the company a market cap of $34B. Beta, a measure of the stocks volatility relative to the overall market stands at 0.3. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -140.2% The company's stock price performance over the past 12 months lags the peer average by -123.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 14.8% higher than the average peer. New Article Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $242.50 strike highlighted in red: Considering the fact that the $242.50 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading this week, for the December 17th expiration.",296.2255554199219
2021-12-01 00:00:00+00:00,236.97999572753903,239.5800018310547,228.8800048828125,229.5,229.5,1672700.0,3.5,1.0,0.6250249999999999,"(RTTNews) - Healthcare company Viatris Inc. (VTRS) announced Wednesday that the United States Court of Appeals for the Federal Circuit affirmed the June 2020 decision by the U.S. District Court for the Northern District of West Virginia invalidating Biogen's Tecfidera patent, U.S. Patent No. Viatris launched the first therapeutically equivalent substitutable generic to Tecfidera in August 2020. ""Bringing a product like generic Tecfidera to market highlights our unwavering commitment to removing barriers to patient access, including challenging unsupportable legal barriers,"" said Michael Goettler, Chief Executive Officer of Viatris. New Article (RTTNews) - Sage Therapeutics, Inc. (SAGE) and Biogen Inc. (BIIB) announced a positive, one-year Zuranolone 50 mg data in the ongoing open-label SHORELINE study in Patients with major depressive disorder or MDD. Zuranolone 50 mg was generally well-tolerated with an overall adverse event profile consistent with data reported earlier and 6.5% of patients discontinuing study drug due to adverse events. Across the LANDSCAPE clinical program to date, zuranolone has consistently demonstrated rapid and sustained improvements in depressive symptoms and a well-tolerated safety profile.",298.8901062011719
2021-12-02 00:00:00+00:00,228.5500030517578,229.47000122070312,224.4600067138672,228.5200042724609,228.5200042724609,1276200.0,3.0,1.0,0.5000249999999999,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $230.00 strike highlighted in red: Considering the fact that the $230.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the January 2022 expiration.",291.9495849609375
2021-12-03 00:00:00+00:00,227.69000244140625,229.0399932861328,221.72000122070312,223.9199981689453,223.9199981689453,1427700.0,2.0,1.0,0.250025,"In negotiations with Biogen Inc BIIB.O for its rare neuromuscular disease drug Nusinersen, the government negotiator told a company official that the firm should ""work harder"" in giving price cuts, stressing that the government's price cap was non-negotiable, before the sides reached an agreement, video clips from state broadcaster CCTV showed. BEIJING, Dec 3 (Reuters) - Pharmaceutical firms have agreed to cut prices by 61.7% on average for 67 medicines to be included in China's national medical insurance coverage in a new round of negotiations, Chinese authorities said on Friday. Last year, drugmakers agreed to an average price cut of around 50% for more than 100 medicines, underscoring China's strong bargaining power, as it seeks to make more drugs affordable for its 1.4 billion people.",284.7746276855469
2021-12-06 00:00:00+00:00,223.1999969482422,226.22000122070312,222.1499938964844,224.1100006103516,224.1100006103516,1101800.0,3.0,1.0,0.5000249999999999,"Although BIIB has traded at a recent price of $223.92/share, the average analyst target is 61.94% higher at $362.61/share. First Trust Large Cap Value AlphaDEX Fund ETF FTA $66.57 $76.63 15.12% Biogen Inc BIIB $223.92 $362.61 61.94% Johnson & Johnson JNJ $159.38 $190.00 19.21% VF Corp. VFC $74.51 $88.36 18.58% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of FTA's underlying holdings with notable upside to their analyst target prices are Biogen Inc (Symbol: BIIB), Johnson & Johnson (Symbol: JNJ), and VF Corp. (Symbol: VFC).",287.5865783691406
2021-12-08 00:00:00+00:00,227.17999267578125,235.22000122070312,225.8999938964844,234.72000122070312,234.72000122070312,1419100.0,3.5,1.0,0.6250249999999999,"Combined, CTLT and BIIB make up approximately 1.1% of the underlying holdings of XLV. Within that group, Catalent Inc (Symbol: CTLT) and Biogen Inc (Symbol: BIIB) are two of the day's stand-outs, showing a gain of 3.1% and 2.9%, respectively. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. New Article (RTTNews) - Sage Therapeutics Inc. (SAGE) and Biogen Inc. (BIIB) said that new analyses from the landscape clinical development program of zuranolone in major depressive disorder or MDD were presented at the American College Of Neuropsychopharmacology Congress. Data from the SHORELINE and WATERFALL Studies in the LANDSCAPE clinical program provided further the understanding of the potential efficacy and safety profile of zuranolone for the treatment of major depressive disorder. The company stated that Zuranolone was generally well-tolerated in a subgroup of patients aged 65 years and older in the SHORELINE Study, showing similar efficacy and safety results in the datasets analyzed to that observed in the general study population. New Article Especially high volume was seen for the $230 strike call option expiring January 21, 2022, with 532 contracts trading so far today, representing approximately 53,200 underlying shares of BIIB. Below is a chart showing MMSI's trailing twelve month trading history, with the $70 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 5,432 contracts thus far today. That number of contracts represents approximately 543,200 underlying shares, working out to a sizeable 43% of BIIB's average daily trading volume over the past month, of 1.3 million shares. New Article Top Biotech Stocks For Your December 2021 Watchlist Prometheus Biosciences Inc. (NASDAQ: RXDX) Longeveron Inc. (NASDAQ: LGVN) Biogen Inc. (NASDAQ: BIIB) Prometheus Biosciences Firstly, Prometheus Biosciences is a clinical-stage biotechnology company that focuses on a precision medicine approach for the discovery, development, and commercialization of novel therapeutics and companion diagnostic products. BIIB stock currently trades at $231.52 as of 12:51 p.m. This life-changing treatment could positively affect the estimated 2.8 million people living with MS. With this piece of information, is BIIB stock worth adding to your watchlist?",281.7932434082031
2021-12-15 00:00:00+00:00,230.1999969482422,236.3699951171875,228.9499969482422,235.8800048828125,235.8800048828125,1262400.0,4.0,1.0,0.7500249999999999,"Multinational biotechnology company Biogen, Inc. (NASDAQ: BIIB) has announced a collaboration agreement with TheraPanacea to focus on multiple therapeutic areas in neuroscience. Through this partnership, the companies aim to leverage machine learning (ML) and AI analysis to develop innovative digital health solutions for personalized and earlier treatment in neurology. Based on the outcome of our prior work with TheraPanacea and their success with AI in oncology, we are excited to further this collaboration. We believe digital health solutions will enable us to pioneer a new era of personalized medicine built upon a foundation of accessibility and precision, Dubuc added.",285.5897216796875
2021-12-16 00:00:00+00:00,237.2899932861328,243.42999267578125,234.8600006103516,235.5200042724609,235.5200042724609,1252200.0,4.0,1.0,0.7500249999999999,"Dec 16 (Reuters) - Biogen Inc BIIB.O said on Thursday it was expecting to submit a final design for a post-marketing confirmatory study of its newly approved Alzheimer's drug, Aduhelm, to the U.S. Food and Drug Administration in March, and begin screening of patients in May. Aduhelm, the first new treatment for the memory-robbing disease in nearly 20 years, is battling slow uptake as experts have questioned the FDA's rationale for clearing the drug without more definitive proof of benefit. Biogen said it anticipates primary completion date to be about four years after the study begins, ahead of the FDA's nine-year requirement.",285.8275451660156
2021-12-17 00:00:00+00:00,233.0,239.8999938964844,232.5800018310547,237.42999267578125,237.42999267578125,2262900.0,3.0,1.0,0.5000249999999999,"(RTTNews) - Biogen Inc. (BIIB), an American company focused on the therapies for the treatment of neurological diseases said it intends to seek re-examination of negative opinion adopted by European Medicines Agency or EMA for the company's Alzheimer's drug aducanumab. EMA's Committee for Medicinal Products for Human Use (CHMP) opted for a negative opinion on Biogen's Marketing Authorization Application (MAA) for aducanumab, for the treatment of the early stages of Alzheimer's disease in the European Union. Priya Singhal, Head of Global Safety & Regulatory Sciences at Biogen, commented: ""As part of the re-examination process, we will seek to address the CHMP's grounds for refusal, with the goal of making this medicine available in the EU.",281.4176940917969
2021-12-20 00:00:00+00:00,239.75,240.0,234.25,236.9600067138672,236.9600067138672,1127700.0,3.0,1.0,0.5000249999999999,"From what we can see, insiders were net buyers in Biogen Inc.'s (NASDAQ:BIIB ) during the past 12 months. NasdaqGS:BIIB Insider Trading Volume December 20th 2021 There are plenty of other companies that have insiders buying up shares. While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, logic dictates you should pay some attention to whether insiders are buying or selling shares. New Article Biogen Inc. (BIIB) said it had received a negative opinion on the Marketing Authorization Application for aducanumab, which was designed to treat early stages of Alzheimers disease, from the Committee for Medicinal Products for Human Use of the European Medicines Agency. According to the TipRanks Risk Factors tool, BIIB is at risk mainly from two factors: Tech and Innovation, and Finance and Corporate, which contribute 20% and 23%, respectively, to the total 30 risks identified for the stock. The opinion was based on data from a global, multi-study clinical development program that included about 3,600 patients. New Article Adds details, background Dec 20 (Reuters) - Biogen Inc BIIB.O said on Monday it would reduce the price of its Alzheimer's disease drug by about 50% to help create a bigger market for the newly approved drug. Biogen believes with insurance coverage, and access to diagnostics and specialized centers, roughly 50,000 patients may initiate treatment with the drug, Aduhelm, in 2022. Biogen has been banking on Aduhelm to buffer a hit from its main revenue drivers facing rising competition, but the drug is facing slow uptake as several commercial insurers wait for further direction from Medicare before covering the drug. New Article (RTTNews) - Biogen Inc. (BIIB) said it will reduce the wholesale acquisition cost of ADUHELM 100 mg/mL injection for intravenous use in the U.S. by approximately 50%, effective January 1, 2022. Michel Vounatsos, CEO at Biogen, said: ""Too many patients are not being offered the choice of ADUHELM due to financial considerations and are thus progressing beyond the point of benefitting from the first treatment to address an underlying pathology of Alzheimer's disease."" The cost-reduction measures are estimated to yield approximately $500 million in annualized savings. New Article Biogen Inc BIIB.O rose 2.3% after the drugmaker said it would slash the price of its Alzheimer's disease drug by about 50%. By Shreyashi Sanyal and Anisha Sircar Dec 20 (Reuters) - U.S. stock indexes were set for a weak opening on Monday, dragged by concerns about the impact of tighter COVID-19 curbs on the global economy, and a potentially devastating setback to President Joe Biden's investment bill. Surging global infections of the Omicron coronavirus variant has sparked worries in financial markets, as many European nations and Britain weigh the possibility of restrictions during Christmas. New Article The Institute for Clinical and Economic Review, whose estimates are followed closely by insurers, said it was cost effective at no more than $8,400 https://icer.org/news-insights/press-releases/icer-publishes-final-evidence-report-and-policy-recommendations-on-aducanumab-for-alzheimers-disease per year. A lower price might persuade some insurers and government programs like Medicare to cover the cost of the drug based on the hope it does something. (By Robert Cyran) Follow @Breakingviews https://twitter.com/Breakingviews on Twitter Capital Calls - More concise insights on global finance: Europes new monetary bad cop has right bark [Europes new monetary bad cop has right bark] Novo lead in obesity race starts to sag Standard Chartered fine is warning for bank bosses Aussie fund manager sails way off course Chinas rate cut augurs worse to come (Editing by Richard Beales and Sharon Lam) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",279.7900695800781
2021-12-22 00:00:00+00:00,236.259994506836,236.479995727539,231.2899932861328,234.479995727539,234.479995727539,783300.0,2.2,1.0,0.300025,"(RTTNews) - Biogen Inc. (BIIB) and Eisai Co. Ltd. said the First Committee on New Drugs of the Pharmaceutical Affairs and Food Sanitation Council in Japan has decided to continue deliberations on the application for the manufacturing and marketing approval of aducanumab for the treatment of Alzheimer's disease. As of October 2017, Biogen and Eisai are collaborating on the global co-development and co-promotion of aducanumab. The companies said they will continue to actively engage with the Pharmaceuticals and Medical Devices Agency in Japan to agree on additional data requirements. New Article TOKYO, Dec 22 (Reuters) - A Japanese health ministry panel said on Wednesday that inconsistent trial results made it difficult to determine the efficacy of an Alzheimer's treatment developed by Eisai Co 4523.T and Biogen Inc BIIB.O. In a statement the panel cited inconsistent results from global Phase III trials and a lack of clinical significance in the drug's ability to reduce plaques in the brain. More than 8 million people in Japan are believed to have dementia or cognitive impairment, while treatment of Alzheimer's patients costs an estimated 7.4 trillion yen ($65 billion) per year. New Article The company recently won a key legal victory for its generic version of Biogen's multiple sclerosis drug Tecfidera. Although Rinvoq's sales will be lower than hoped due to the U.S. Food and Drug Administration's warnings for JAK inhibitors, it should still be a big winner. Arguably the biggest knock against Enterprise Products Partners is that there's a transition in progress away from fossil fuels to renewable energy sources. New Article Eisai Co 4523.T and its United States partner Biogen Inc BIIB.O filed for Japanese regulatory approval just over a year ago for the drug Adulhelm, which was approved in the United States in June. TOKYO, Dec 22 (Reuters) - A Japanese health ministry panel said on Wednesday it was difficult to determine the efficacy of an Alzheimer's treatment based on current data. (Reporting by Rocky Swift; editing by Jason Neely) ((rocky.swift@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Particularly high volume was seen for the $320 strike call option expiring January 28, 2022, with 1,597 contracts trading so far today, representing approximately 159,700 underlying shares of BIIB. Below is a chart showing SNOW's trailing twelve month trading history, with the $370 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 5,983 contracts, representing approximately 598,300 underlying shares or approximately 41.5% of BIIB's average daily trading volume over the past month, of 1.4 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $320 strike highlighted in orange: And Rocket Companies Inc Class A (Symbol: RKT) options are showing a volume of 16,901 contracts thus far today.",285.4260559082031
2021-12-23 00:00:00+00:00,232.9499969482422,236.2100067138672,232.0399932861328,235.4100036621093,235.4100036621093,1003300.0,3.5,1.0,0.6250249999999999,"Last week, the company delivered its latest quarterly report and while its numbers were fine, investors weren't impressed with its guidance for the upcoming year. Adobe anticipates more growth in the years ahead as it takes advantage of companies moving onto the cloud and employees working remotely. Plus, with operating cash flow of more than $2 billion in just the latest quarter, the company could acquire a business if it needed to expand its product base or find new opportunities to pursue. New Article Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $240.00 strike highlighted in red: Considering the fact that the $240.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the February 2022 expiration.",275.8270263671875
2021-12-27 00:00:00+00:00,235.22999572753903,236.6999969482422,232.3600006103516,234.19000244140625,234.19000244140625,1744600.0,5.0,1.0,1.000025,"Biogen Inc. (NASDAQ: BIIB), one of the leading global Biotech stocks, and Japan-based global pharmaceutical company Eisai Co., Ltd. have revealed that lecanemab has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). Lecanemab, an investigational anti-amyloid beta (A) protofibril antibody, is designed to treat early Alzheimers disease (AD). Notably, another Phase 3 clinical study, AHEAD 3-45, to evaluate the efficacy of treatment with lecanemab in patients suffering from preclinical AD and higher amyloid, is ongoing.",270.0675964355469
2021-12-29 00:00:00+00:00,235.0,265.5400085449219,234.1300048828125,258.3099975585937,258.3099975585937,6869700.0,1.6,1.0,0.150025,"SEOUL, Dec 30 (Reuters) - Samsung BioLogics 207940.KS said in a regulatory filing on Thursday that a report saying Samsung Group is in talks to acquire U.S. drugmaker Biogen Inc BIIB.O is not true. South Korean newspaper Korea Economic Daily reported earlier that Samsung is in talks to buy Biogen, citing investment banking sources. (Reporting by Joyce Lee; editing by Richard Pullin) ((joyce.lee@tr.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article SEE MORE The 22 Best ETFs to Buy for a Prosperous 2022 Biogen (BIIB, +9.5%) shares popped after the Korean Economic Daily, citing investment banking sources, reported that Samsung is in talks to buy the biotechnology firm for $42 billion  which would be its largest-ever transaction. Another tame day for the broader indexes shifted the spotlight to individual equities, and interestingly, two very different companies' price moves were tethered to South Korean tech giant Samsung. Also Wednesday, computer-memory maker Micron (MU, +3.5%) enjoyed a decent stock pop after reports that a COVID outbreak in a Chinese factory had forced Samsung  a major rival  to throttle back some production. New Article What happened Is Biogen (NASDAQ: BIIB) about to be acquired? So what According to that report, published in The Korea Economic Daily and citing an unspecified number of ""investment banking sources,"" Samsung Group is in discussions to purchase Biogen. ""Samsung is at the negotiating table with the sell side to acquire Biogen,"" confirmed an unnamed person described as ""a senior official at a global investment bank"" to the Daily. New Article Dec 29 (Reuters) - South Korea's Samsung Group is in talks to buy drugmaker Biogen Inc BIIB.O, the Korea Economic Daily reported on Wednesday, citing investment banking sources. The report said Biogen approached Samsung to sell its shares, which could be valued at more than $42 billion. Biogen and Samsung did not immediately respond to Reuters request for comment. New Article Adds details on the companies Dec 29 (Reuters) - South Korea's Samsung Group is in talks to buy U.S. drugmaker Biogen Inc BIIB.O, Korea Economic Daily reported on Wednesday, citing investment banking sources. The report said Biogen approached Samsung to buy its shares, which could be valued at more than $42 billion. Samsung Group in August said it will invest 240 trillion won ($206 billion) in the next three years to expand its footprint in biopharmaceuticals, artificial intelligence, semiconductors and robotics in the post-pandemic era.",278.72198486328125
2021-12-30 00:00:00+00:00,245.19000244140625,247.0,237.0500030517578,240.0,240.0,4423100.0,2.714285714285715,1.0,0.4285964285714286,"A couple of stocks stood out with big price moves in the early morning session, with Vector Group (NYSE: VGR) and Biogen (NASDAQ: BIIB) both heading lower. Vector Group's primary business is tobacco, but it has also been involved in real estate through its Douglas Elliman (NYSE:DOUG) subsidiary for a long time. On Wednesday, Biogen's stock jumped more than 9% on reports that the biologics business of South Korea's Samsung Group might be interested in buying the biotech company. New Article VIDEO: S&P 500 Movers: BIIB, VIAC The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing S&P 500 component thus far on the day is Biogen, trading down 6.5%. Two other components making moves today are Micron Technology, trading down 2.6%, and Norwegian Cruise Line Holdings, trading up 2.7% on the day. New Article (RTTNews) - Samsung Group is in talks to acquire U.S-based Biogen Inc. (BIIB) in a deal which could be valued at over 50 trillion won (US$42 billion), reported the Korea Economic Daily on Wednesday. BIIB has traded in a range of $221.72 to $468.55 in the last 1 year. The company's multiple sclerosis drug Tecfidera, once a cash cow, lost patent protection in June 2020, and its sales have been on the decline due to generic competition. New Article Among individual stocks, Biogen Inc BIIB.O slipped 6.6%, giving back some gains from the prior session as Samsung BioLogics 207940.KS denied a media report that said the South Korean firm was in talks to buy the U.S. drugmaker. By Medha Singh Dec 30 (Reuters) - The S&P 500 and the Dow were set to open near all-time highs on Thursday, extending a record-setting run as a surprise dip in weekly jobless claims reinforced confidence in the U.S. economy amid a surge in COVID-19 infections. ""The lesser severity of Omicron infection, and shortened quarantine guidance from the CDC, is consistent with our view toward incremental alleviation to supply chain disruption in early-2022,"" wrote Scott Chronert, a U.S. equity strategist at Citigroup. New Article Biogen (BIIB) was over 5% lower after Samsung Group's Samsung Biologics said media reports that it is in negotiations to acquire the company were ""not true."" The iShares NASDAQ Biotechnology Index (IBB) was recently unchanged, and the Health Care SPDR (XLV) was up by 0.16%. Korea Economic Daily reported that Biogen had approached the South Korean drugmaker to sell itself, while website newsdirectory3.com said the transaction amount was expected to exceed 50 trillion won ($42.05 billion). New Article Among individual stocks, Biogen Inc BIIB.O slipped 6.1%, giving back some gains from the prior session as Samsung BioLogics 207940.KS denied a media report that said the South Korean firm was in talks to buy the U.S. drugmaker. By Medha Singh and Bansari Mayur Kamdar Dec 30 (Reuters) - The blue-chip Dow hit an all-time high on Thursday, extending a record-setting run as a dip in weekly jobless claims allayed fears over the economic damage from a rampant surge in COVID-19 infections in the United States. As Wall Street's main indexes look to exit the year with their sharpest three-year surge since 1999, the attention will shift towards the pace of U.S. interest rate hikes in the face of soaring prices and supply chain logjams. New Article (Bitcoin trades 24 hours a day; prices reported here are as of 4 p.m.) So about that Biogen (BIIB) gain yesterday ... However, BIIB shares dropped 7.1% on Thursday after Samsung denied that it was in any discussions with Biogen. The path of least resistance for American equities appeared to be higher for most of a slow-news, low-volume Thursday trading session, but an afternoon swoon resulted in modest losses for the major indexes. New Article VIDEO: Nasdaq 100 Movers: BIIB, PTON The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Thursday, shares of Peloton Interactive topped the list of the day's best performing components of the Nasdaq 100 index, trading up 6.0%. And the worst performing Nasdaq 100 component thus far on the day is Biogen, trading down 6.5%. New Article Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $250.00 strike highlighted in red: Considering the fact that the $250.00 strike represents an approximate 5% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the February 2022 expiration. New Article Click to Enlarge Source: Chart courtesy of TrendSpider On Wednesday, Biogen (NASDAQ:BIIB) rallied 12.5% at the highs and closed higher by 9.5%. 3: Biogen (BIIB) If its the latter, lets see if BIIB stock can clear $250 and the 10-week moving average. New Article Particularly high volume was seen for the $235 strike put option expiring December 31, 2021, with 1,908 contracts trading so far today, representing approximately 190,800 underlying shares of BIIB. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 29,370 contracts have traded so far, representing approximately 2.9 million underlying shares. That amounts to about 191% of BIIB's average daily trading volume over the past month of 1.5 million shares. New Article Among individual stocks, Biogen Inc BIIB.O slipped 7.09%, giving back gains from the prior session as Samsung BioLogics 207940.KS denied a media report that said the South Korean firm was in talks to buy the U.S. drugmaker. Dow, S&P retreat late from record highs Wall St indexes poised for biggest 3-yr gain since 1999 Thin volume could exaggerate price moves -analyst Dow down 0.25%, S&P 500 down 0.30%, Nasdaq down 0.16% Biogen drops as Samsung BioLogics denies deal talk report Disney on track to be the worst performing stock of the year New throughout, updates prices, market activity and comments to official close By Echo Wang Dec 30 (Reuters) - Wall Street closed lower on Thursday, retreating late in thin holiday volume from record highs set early in the session on strong U.S. data including a drop in weekly claims for U.S. unemployment benefits. In 2022, investors will shift their attention to expected U.S. interest rate hikes and midterm elections for U.S. Congress, where President Joe Biden's Democrats now hold a slim majority. New Article Among individual stocks, Biogen Inc BIIB.O slipped 8%, giving back gains from the prior session as Samsung BioLogics 207940.KS denied a media report that said the South Korean firm was in talks to buy the U.S. drugmaker. By Echo Wang Dec 30 (Reuters) - The S&P 500 and the Dow touched all-time highs on Thursday, extending a record-setting run as new claims for U.S. unemployment benefits fell in the week, showing that the Omicron variant of the virus that causes COVID-19 has yet to slow the U.S. economy. As Wall Street's main indexes on track to end the year with their sharpest three-year surge since 1999, the attention will shift towards the pace of U.S. interest rate hikes in the face of soaring prices and supply chain logjams. New Article Among individual stocks, Biogen Inc BIIB.O slipped 6.0%, giving back some gains from the prior session as Samsung BioLogics 207940.KS denied a media report that said the South Korean firm was in talks to buy the U.S. drugmaker. By Medha Singh Dec 30 (Reuters) - U.S. stock index futures rose marginally on Thursday, as easing worries around the Omicron variant put the S&P 500 and the Dow on track to extend record-setting runs, with focus turning to a weekly jobless report to gauge the country's economic health. ""The lesser severity of Omicron infection, and shortened quarantine guidance from the CDC, is consistent with our view toward incremental alleviation to supply chain disruption in early-2022,"" wrote Scott Chronert, a U.S. equity strategist at Citigroup.",278.3845520019531
2021-12-31 00:00:00+00:00,239.759994506836,243.7100067138672,239.5,239.9199981689453,239.9199981689453,1532700.0,2.0,1.0,0.250025,"And the worst performing Nasdaq 100 component thus far on the day is Cadence Design Systems, trading down 1.6%. Cadence Design Systems is showing a gain of 35.8% looking at the year to date performance. VIDEO: Nasdaq 100 Movers: CDNS, LCID The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",286.24383544921875
2022-01-04 00:00:00+00:00,245.1300048828125,245.4499969482422,239.0,241.72999572753903,241.72999572753903,1283400.0,4.0,1.0,0.7500249999999999,"(RTTNews) - Biogen Inc. (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) said Biogen exercised its option to obtain from Ionis a worldwide, royalty-bearing license to develop and commercialize BIIB115/ION306, a preclinical investigational antisense oligonucleotide in development for spinal muscular atrophy. Biogen will be solely responsible for the costs and expenses related to the development, and potential future commercialization of BIIB115 following the option exercise. Biogen plans to advance BIIB115 to clinical trials to investigate safety, tolerability, pharmacokinetics, and efficacy.",287.79327392578125
2022-01-06 00:00:00+00:00,240.3000030517578,242.4499969482422,236.8500061035156,237.3000030517578,237.3000030517578,1036900.0,3.0,1.0,0.5000249999999999,"Although BIIB has traded at a recent price of $239.27/share, the average analyst target is 42.15% higher at $340.13/share. The Health Care Select Sector SPDR Fund ETF XLV $136.62 $149.82 9.66% Biogen Inc BIIB $239.27 $340.13 42.15% Moderna Inc MRNA $215.23 $257.23 19.51% Bio-Techne Corp TECH $434.73 $511.88 17.75% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of XLV's underlying holdings with notable upside to their analyst target prices are Biogen Inc (Symbol: BIIB), Moderna Inc (Symbol: MRNA), and Bio-Techne Corp (Symbol: TECH).",282.19525146484375
2022-01-07 00:00:00+00:00,235.5500030517578,236.8999938964844,231.6199951171875,232.6000061035156,232.6000061035156,1394900.0,2.5,1.0,0.375025,"Here's a pair of biotech giants that had a year to forget: Vertex Pharmaceuticals (NASDAQ: VRTX) and Biogen (NASDAQ: BIIB). The regulatory nod came with plenty of controversy as many experts -- including some affiliated with the U.S. Food and Drug Administration (FDA) -- worried that the data was not convincing enough to support Aduhelm's approval. And with an average price tag of $56,000 per patient -- and a potential target market comprising more than a million people -- Biogen could generate strong sales thanks to Aduhelm. New Article However, the approval of Biogen's therapy, called Aduhelm, came as a surprise since a panel of experts had recommended against it, but it helped raise Cassava Sciences' profile in the eyes of investors. But as it turns out, Labaton Sucharow's claims were rejected due to lack of evidence, and the FDA allowed Cassava Sciences to move forward with its phase 3 studies. With a market cap of $1.93 billion, Cassava Sciences could certainly soar significantly higher if Simufilam proves safe and effective in phase 3 clinical trials, but if that doesn't happen, investors would be left with worthless shares of a company.",276.7035827636719
2022-01-10 00:00:00+00:00,232.75,235.5500030517578,230.5399932861328,235.3099975585937,235.3099975585937,1754000.0,4.0,1.0,0.7500249999999999,"Jan 10 (Reuters) - U.S. Secretary of Health and Human Services Xavier Becerra on Monday asked the country's Medicare program to reassess its 2022 premium hikes, weeks after Biogen Inc BIIB.O cut the price of its Alzheimer's drug by about half. Medicare in November raised the Part B premium, which covers physician and outpatient hospital services, by 15% to $170.10 in 2022, with uncertainty around the coverage decision for the treatment, Aduhelm, one of the drivers behind the increase. Last month, the drugmaker cut the price of Aduhelm to $28,200 for an average weight person after facing slower-than-expected U.S. sales on complaints from hospitals that its high cost was not worth its benefits.",276.15325927734375
2022-01-11 00:00:00+00:00,235.3999938964844,243.7100067138672,235.0,241.5200042724609,241.5200042724609,1557700.0,2.0,1.0,0.250025,By Deena Beasley Jan 11 (Reuters) - The U.S. government's Medicare program on Tuesday said it plans to cover Alzheimer's treatments including Biogen Inc's BIIB.O Aduhelm. Only one of Biogen's two pivotal trials showed Aduhelm can slow the rate of cognitive decline for Alzheimer's patients. Many experts questioned the FDA's rationale for Aduhelm's approval without more definitive proof of benefit and doctors have held back on prescribing it.,268.8150329589844
2022-01-12 00:00:00+00:00,223.1000061035156,227.58999633789065,217.1000061035156,225.33999633789065,225.33999633789065,7511100.0,2.3529411764705883,1.0,0.3382602941176471,"Shares of Biogen Inc BIIB.O fell 9% to $220.44 before the bell, while shares of other drugmakers developing similar treatments such as Eli Lilly and Co LLY.N, Roche Holdings ROG.S and Eisai Co Ltd 4523.T fell between 2% and 4%. Biogen had been banking on the government's coverage decision to help drive up sales of Aduhelm, which was approved in June, against the U.S. FDA's outside advisors' opinion that the treatment's clinical benefits had not been proven. Last month, Biogen cut Aduhelm price to $28,200 for an average weight person after facing slower-than-expected U.S. sales on complaints from hospitals about its high cost. New Article Recap of the Weeks Most Important Stories: Biogen Down on Medicare Update: Shares of Biogen BIIB were down after its controversial Alzheimers disease (AD) drug Aduhelm faced another setback. Biogen Inc. (BIIB): Free Stock Analysis Report Both the companies announced that Part A of the EMPATHY clinical study, which compared single intravenous doses of ensovibep versus placebo to treat COVID-19, met the primary endpoint of viral load reduction over eight days. New Article Medicare plans to cover Biogen's (BIIB) Alzheimer's drug, Aduhelm, for patients enrolled in approved clinical trials, Centers for Medicare & Medicaid Services said. The Health Care SPDR (XLV) was slipping by 0.15% and the iShares Biotechnology ETF (IBB) was climbing by 0.02%. Immuron (IMRN) was gaining more than 56% after saying it was awarded $3.4 million in funding by the US Department of Defense, which the company will use to study a military-dose regimen for Travelan in treating infectious diarrhea. New Article Drugmakers Eli Lilly LLY.N and Biogen BIIB.O dropped 7.8% and 4.0% respectively. Growth and technology stocks, hit by rising Treasury yields and hawkish commentary from the Federal Reserve, have staged a comeback this week, with investors watching a variety of metrics to decide whether to buy the rally or brace for more declines. Big Tech was buoyed by comments from Fed Chair Jerome Powell on Tuesday which sounded less hawkish, easing concerns sparked by minutes from the central bank's December meeting. New Article Biogen (NASDAQ: BIIB) was particularly noteworthy, because news about its treatment for Alzheimer's disease is setting up a potential financial battle between the biotech stock and the U.S. government's Medicare program. Biogen responded with a stern statement saying it is ""imperative to change this draft decision"" to give patients access to treatments that have received approval from the U.S. Food and Drug Administration. That's 350 million euros lower than the company's previous guidance, with Philips blaming the shortfall on global supply chain shortages and postponements in customers choosing to install equipment. New Article Jan 12 (Reuters) - Shares of Biogen Inc BIIB.O fell nearly 10% on Wednesday after the U.S. government announced limited coverage of Alzheimer's treatments including the drugmaker's Aduhelm, dealing a blow to the controversial treatment that was approved last year. Biogen had been banking on the government's coverage decision to help drive up sales of Aduhelm, which it hoped would help counter the hit to revenue from some of its main drugs from rising competition. Last month, the drugmaker cut the price of Aduhelm to $28,200 for an average weight person after facing slower-than-expected U.S. sales on complaints from hospitals that its high cost was not worth its benefits. New Article I (MCMJ) is up over 19% at $10.02 Mainz Biomed B.V. (MYNZ) is up over 11% at $15.71 Femasys Inc. (FEMY) is up over 9% at $3.50 FREYR Battery (FREY) is up over 8% at $10.64 In the Red Nam Tai Property Inc. (NTP) is down over 25% at $8.56 Flux Power Holdings, Inc. (FLUX) is down over 25% at $3.06 Koninklijke Philips N.V. (PHG) is down over 15% at $32.90 Huadi International Group Co., Ltd. (HUDI) is down over 11% at $18.39 Biogen Inc. (BIIB) is down over 9% at $217.51 Aviat Networks, Inc. (AVNW) is down over 9% at $28.54 Save Foods, Inc. (SVFD) is down over 9% at $4.06 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.10 A.M. In the Green Immuron Limited (IMRN) is up over 50% at $3.94 Kidpik Corp. (PIK) is up over 27% at $7.67 Merida Merger Corp. New Article Biogen BIIB.Odropped 9.4%, dragging down the S&P 500 healthcare index .SPXHC, which fell 0.4%. Growth and technology stocks, hit by rising Treasury yields and hawkish commentary from the Federal Reserve, have staged a comeback this week, with investors watching a variety of metrics to decide whether to buy the rally or brace for more declines. Big Tech was buoyed by comments from Fed Chair Jerome Powell on Tuesday which sounded less hawkish, easing concerns sparked by minutes from the central bank's December meeting. New Article The central bank's plan for easing accommodation to fight inflation includes raising interest rates, which analysts expect to start as soon as March, as well as tapering its bond buying program and reducing its asset holdings. ""The fact that bond market yields are standing down is probably a signal for equity investors to take on a little more risk today,"" said Jack Ablin, chief investment officer at Cresset Capital Management in Chicago. Also on the watchlist for this week is the unofficial kick-off of the fourth quarter earnings season with JPMorgan Chase & Co , Citigroup Inc and Morgan Stanley due to report their results on Friday. New Article VIDEO: Nasdaq 100 Movers: BIIB, OKTA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Wednesday, shares of Okta topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.9%. And the worst performing Nasdaq 100 component thus far on the day is Biogen, trading down 9.9%. New Article What happened Shares of Biogen (NASDAQ: BIIB) were sinking 9.5% as of 10:48 a.m. The decline came after the Centers for Medicare and Medicaid Services (CMS) on Tuesday released its proposed National Coverage Determination (NCD) for Biogen's Alzheimer's disease drug Aduhelm. In the company's third-quarter conference call, chief financial officer Michael McDonnell said that Biogen expected revenue for the drug to especially pick up with a positive NCD decision this year. New Article The healthcare index .SPXHC, was weighed down by shares of drugmaker Eli Lilly LLY.N and Biogen BIIB.O throughout the day. The central bank's plan for easing accommodation to fight inflation includes raising interest rates, which analysts expect to start as soon as March, as well as tapering its bond buying program and reducing its asset holdings. ""The fact that bond market yields are standing down is probably a signal for equity investors to take on a little more risk today,"" said Jack Ablin, chief investment officer at Cresset Capital Management in Chicago. New Article Within that group, Biogen Inc (Symbol: BIIB) and Quest Diagnostics, Inc. (Symbol: DGX) are two of the day's laggards, showing a loss of 7.4% and 6.6%, respectively. Combined, BIIB and DGX make up approximately 1.0% of the underlying holdings of XLV. In afternoon trading on Wednesday, Healthcare stocks are the worst performing sector, showing a 0.8% loss. New Article VIDEO: S&P 500 Movers: BIIB, TTWO The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Wednesday, shares of Take-Two Interactive Software, topped the list of the day's best performing components of the S&P 500 index, trading up 5.1%. Year to date, Take-Two Interactive Software, has lost about 12.2% of its value. New Article Biogen BIIB.O declined 9.4% after the U.S. government Medicare program said on Tuesday it plans to cover Alzheimer's treatments but will require patients to be enrolled in a clinical trial, limiting access to the treatment more than many expected. Growth and technology stocks, hit by rising Treasury yields and hawkish commentary from the Federal Reserve, have attempted to climb back this week, with investors watching a variety of metrics to decide whether to buy the rally or brace for more declines. Big Tech recovered early losses and led gains on Tuesday after Fed Chair Jerome Powell sounded less hawkish in his testimony to Congress, easing concerns sparked by minutes from the central bank's December meeting. New Article NEW YORK (Reuters Breakingviews) - Drug investors are worried the preliminary U.S. government decision to restrict https://www.cms.gov/newsroom/press-releases/cms-proposes-medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment payment for Biogens new Alzheimers treatment is a Trojan horse that presages more sweeping limits on medical spending. Meanwhile insurers have been reluctant to pay, and doctors to prescribe it, so Biogen cut the price of the drug by about half. (By Rob Cyran) Follow @Breakingviews https://twitter.com/Breakingviews on Twitter Capital Calls - More concise insights on global finance: Crocs knows how to pandemic Delivery Heros profit motive relieves investors Chinas tech crackdown stresses college kids Tilray gives investors a whiff of good news SECs unicorn hunt is a luxury (Editing by Swaha Pattanaik and Sharon Lam) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Especially high volume was seen for the $250 strike call option expiring January 21, 2022, with 4,305 contracts trading so far today, representing approximately 430,500 underlying shares of BIIB. Looking at options trading activity among components of the S&P 500 index, there is noteworthy activity today in Biogen Inc (Symbol: BIIB), where a total volume of 37,354 contracts has been traded thus far today, a contract volume which is representative of approximately 3.7 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 212.9% of BIIB's average daily trading volume over the past month, of 1.8 million shares.",259.308837890625
2022-01-13 00:00:00+00:00,225.3000030517578,239.63999938964844,225.3000030517578,236.6699981689453,236.6699981689453,3781400.0,1.5,1.0,0.125025,"Adds details from Eisai statement, background on the drug Jan 13 (Reuters) - Biogen Inc BIIB.O has not yet discussed with the Centers for Medicaid and Medicare Services about its decision on the coverage of the drugmaker's Alzheimer's drug, the company's chief executive officer said in a call with analysts. In a draft decision on Tuesday, CMS, which runs the government health plan for people over age 65, said it would cover Aduhelm and similar treatments only for patients enrolled in approved clinical trials. Biogen's Japanese partner Eisai Co Ltd4523.T strongly opposed the draft decision, saying the proposal would severely restrict Medicare beneficiary access for the foreseeable future to all drugs in this class. New Article They are: SPDR S&P Biotech ETF (NYSEARCA:XBI) Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA:LABU) Biogen (NASDAQ:BIIB) Stocks to Buy: SPDR S&P Biotech ETF (XBI) Source: Charts by TradingView The biotech sector is as tricky to trade as they get. Stocks to Buy: Biogen (BIIB) Source: Charts by TradingView The third of our three stocks to buy is Biogen. It recovered some, but BIIB stock still closed down 7%. New Article Jan 13 (Reuters) - Biogen Inc BIIB.O has not discussed with the Centers for Medicaid and Medicare Services about its decision on the coverage of the drugmaker's Alzheimer's drug, the company's chief executive officer said in a call with analyst. In a draft decision on Tuesday, CMS, which runs the government health plan for people over age 65, said it would cover Aduhelm, and similar treatments, only for patients enrolled in approved clinical trials. (Reporting by Manojna Maddipatla and Ankur Banerjee in Bengaluru; Editing by Shinjini Ganguli) ((ankur.banerjee@thomsonreuters.com;; Mobile - +919008417318; Twitter: @AnkurBanerjee17;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen (BIIB) fell more than 1%, extending yesterday's 6.7% slump when Medicare announced that it was restricting patient access to its Alzheimer's drug. The Health Care Select Sector SPDR (XLV) was up 0.4% and the iShares Biotechnology ETF (IBB) was down 0.3% recently. Adagio Therapeutics (ADGI) climbed nearly 15% as its lead monoclonal antibody ADG20 demonstrated neutralization activity against the omicron variant of SARS-CoV-2, the virus that causes COVID-19.",258.04425048828125
2022-01-14 00:00:00+00:00,235.0800018310547,239.47000122070312,233.8000030517578,239.3000030517578,239.3000030517578,1768000.0,2.0,1.0,0.250025,"Just briefly, very quickly, I think Biogen (NASDAQ: BIIB) needs to make an acquisition -- ticker for Biogen is BIIB. But there are some deals that Motley Fool contributors Brian Orelli and Keith Speights hope will happen. But TIGIT's an immune checkpoint inhibitor, so I think that would pair potentially quite nicely with Bristol-Myers Squibb's Opdivo.",272.9844665527344
2022-01-18 00:00:00+00:00,238.8999938964844,238.8999938964844,231.3699951171875,233.8099975585937,233.8099975585937,1631500.0,3.0,1.0,0.5000249999999999,"Other the Roche, Ionis has collaboration deals with leading drugmakers/biotech companies like Biogen BIIB and Novartis NVS, to name a couple, for developing and marketing its medicines. Biogen Inc. (BIIB): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. IONS announced that its partner, Roche Holding AG RHHBY, is designing a new phase II study to evaluate its pipeline candidate, tominersen, in Huntington's disease (HD), a rare neurodegenerative disorder.",274.58203125
2022-01-21 00:00:00+00:00,225.3699951171875,226.3699951171875,220.2899932861328,220.5200042724609,220.5200042724609,2205600.0,1.0,1.0,2.4999999999997247e-05,"In a preliminary decision last week, the U.S. Centers for Medicaid and Medicare Services (CMS), which runs the government health plan for people age 65 and older, said it would cover Biogen Inc's BIIB.O already approved Aduhelm, and similar Alzheimer's disease treatments in development, only for patients enrolled in approved clinical trials. Alzheimer's Association Chief Executive Harry Johns said Medicare's plan ""usurps FDA's role in drug approvals,"" calling it ""an unprecedented and terrible draft decision."" His group, as well as UsAgainstAlzheimer's and GAP - three of the biggest Alzheimer patient organizations - said they plan to fight the decision by appealing to lawmakers, the Biden administration and the U.S. Health Secretary.",263.42962646484375
2022-01-24 00:00:00+00:00,220.22000122070312,224.8699951171875,214.8800048828125,224.69000244140625,224.69000244140625,1995700.0,3.0,1.0,0.5000249999999999,"Biogen Inc. (BIIB) closed at $224.69 in the latest trading session, marking a +1.89% move from the prior day. It is also worth noting that BIIB currently has a PEG ratio of 1.11. Biogen Inc. (BIIB): Free Stock Analysis Report",252.51612854003906
2022-01-25 00:00:00+00:00,221.1600036621093,224.9100036621093,218.3699951171875,222.3099975585937,222.3099975585937,1507200.0,3.0,1.0,0.5000249999999999,"In the latest trading session, Biogen Inc. (BIIB) closed at $222.31, marking a -1.06% move from the previous day. Also, we should mention that BIIB has a PEG ratio of 1.13. BIIB's industry had an average PEG ratio of 1.08 as of yesterday's close.",261.0218505859375
2022-01-27 00:00:00+00:00,221.259994506836,223.7400054931641,218.1999969482422,218.94000244140625,218.94000244140625,1098000.0,3.333333333333333,1.0,0.5833583333333334,"(RTTNews) - Samsung Biologics agreed to buy Biogen Inc.'s (BIIB) equity stake in the Samsung Bioepis joint venture for an aggregate consideration of up to $2.3 billion, the companies said in a statement. As per the terms of the deal, Biogen will receive $1 billion in cash at closing and $1.25 billion to be deferred over two payments of $812.5 million due at the first anniversary and $437.5 million due at the second anniversary of the closing of the transaction. Biogen is eligible to receive up to $50 million contingent upon achievement of certain commercial milestones. New Article Adds statement from Biogen, details SEOUL, Jan 28 (Reuters) - Samsung Biologics Co Ltd 207940.KS said on Friday it plans to acquire Biogen Inc's BIIB.O entire stake in Samsung Bioepis worth 2.8 trillion won ($2.33 billion). Samsung said it expects the deal to be accretive to its earnings in 2022 and will fund the acquisition by issuing new shares. ($1 = 1,203.7700 won) (Reporting by Heekyong Yang and Ann Maria Shibu; Editing by Leslie Adler and Christopher Cushing) ((Heekyong.Yang@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Wall Street expects a year-over-year decline in earnings on lower revenues when Biogen Inc. (BIIB) reports results for the quarter ended December 2021. Biogen Inc. (BIIB): Free Stock Analysis Report While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.",261.406982421875
2022-01-28 00:00:00+00:00,218.1600036621093,225.22999572753903,217.9199981689453,225.2100067138672,225.2100067138672,1325600.0,3.0,1.0,0.5000249999999999,"Biogen BIIB announced an agreement with its South Korean partner, Samsung Biologics to sell its equity stake in their joint venture, Samsung Bioepis for a payment of up to $2.3 billion. Biogen Inc. (BIIB): Free Stock Analysis Report Image Source: Zacks Investment Research In November 2019, Biogen secured exclusive rights to commercialize two new ophthalmology biosimilars from Samsung Bioepis across major markets worldwide, including the United States, Canada, Europe, Japan and Australia. New Article With Eli Lilly, investors are not only getting a top dividend stock, but also an investment that possesses significant growth potential, which can translate into some impressive gains. Stanley Black & Decker has been benefiting from an increase in people doing more repairs around the home during the pandemic as the company's sales during the past three quarters have risen by 26% to $12.8 billion. Its incredibly profitable business, efficient operations, and relatively high dividend yield are three great reasons to buy and hold TD for the long haul.",257.6648864746094
2022-02-01 00:00:00+00:00,227.1699981689453,231.22000122070312,226.9499969482422,229.3699951171875,229.3699951171875,1049600.0,2.0,1.0,0.250025,"VIDEO: Nasdaq 100 Movers: AMAT, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Tuesday, shares of Biogen (BIIB) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 1.3%. And the worst performing Nasdaq 100 component thus far on the day is Applied Materials (AMAT), trading down 3.1%. New Article It is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock has declined 17% over the past three months. NasdaqGS:BIIB Past Earnings Growth February 1st 2022 Earnings growth is an important metric to consider when valuing a stock. However, the company's fundamentals look pretty decent, and long-term financials are usually aligned with future market price movements.",254.91395568847656
2022-02-02 00:00:00+00:00,228.6699981689453,228.7700042724609,222.2700042724609,224.9600067138672,224.9600067138672,1083300.0,3.333333333333333,1.0,0.5833583333333334,"Biogen Sells Equity Stake:  Biogen Inc. BIIB announced that it has entered into an agreement with partner Samsung Biologics to sell its equity stake in their biosimilar joint venture. Biogen Inc. (BIIB): Free Stock Analysis Report The CHMP recommended expanding Dupixent (dupilumab) label in the European Union to include add-on maintenance treatment for children aged six to 11 years with severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO) who are inadequately controlled on two maintenance therapies. New Article International sales were affected by the launch of several direct biosimilar drugs in Europe by other pharma companies, including Amgen AMGN, Sandoz and Biogen BIIB. Biogen Inc. (BIIB): Free Stock Analysis Report Image Source: Zacks Investment Research Quarter in Detail In immunology, key drug Humira recorded a year-over-year sales increase of 3.5% on an operational basis to $5.33 billion. New Article The earnings layout looks favorable for the three drug/biotech companies  Biogen Inc. BIIB, Eli Lilly and Company LLY and Merck & Co., Inc. MRK  set to release quarterly results tomorrow. Biogen Inc. (BIIB): Free Stock Analysis Report Higher demand and volume growth for Eli Lillys key drugs, including Trulicity, Taltz, Verzenio, Jardiance, Olumiant and Emgality, are likely to have driven the top line in the fourth quarter.",252.07192993164062
2022-02-03 00:00:00+00:00,215.0,223.13999938964844,212.5599975585937,220.1699981689453,220.1699981689453,2005000.0,2.5714285714285725,1.0,0.3928821428571428,"(RTTNews) - Biogen Inc. (BIIB) reported that its fourth quarter non-GAAP earnings per share was $3.39 compared to a loss of $1.05, prior year. On average, 28 analysts polled by Thomson Reuters expected the company to report profit per share of $3.38, for the quarter. Analysts expect the company to report profit per share of $18.85 on revenue of $10.34 billion. New Article U.S. Medicare plans to sharply limit coverage of Biogen's BIIB.O already-approved Aduhelm drug for the brain-wasting disease, deepening a debate over the evidence of its usefulness. ""Our strategy is to deliver unequivocal efficacy,"" the head of Roche's pharmaceuticals division, William Anderson, told journalists in a call covering 2021 results. ""Our goal is ... to deliver a knock-out blow on the disease in a way that is really compelling and clear,"" he said, citing the large size and long duration of two ongoing late-stage trials. New Article (RTTNews) - Biogen Inc. (BIIB) will host a conference call at 8:00 AM ET on February 3, 2022, to discuss Q4 21 earnings results. To access the live webcast, log on to https://investors.biogen.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen Inc. (BIIB) came out with quarterly earnings of $3.39 per share, beating the Zacks Consensus Estimate of $3.32 per share. Biogen Inc. (BIIB): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. New Article Biogen (BIIB) reported Q4 adjusted earnings of $3.39 per diluted share, compared with a per-share loss of $1.05 a year earlier. The Health Care SPDR (XLV) was down 0.27% and the iShares NASDAQ Biotechnology Index (IBB) was recently declining by over 1%. Cardinal Health (CAH) was over 2% lower after it reported fiscal Q2 non-GAAP earnings of $1.27 per diluted share, down from $1.74 a year earlier. New Article New additions include the exercise of the option with Ionis on BIIB115, an investigational ASO with the potential for extended dosing intervals in SME, as well as the recent initiation of a Phase 1 study in Angelman syndrome, a rare genetic neurodevelopmental disorder that affects the nervous system and causes severe physical and learning disabilities with symptoms beginning in infancy. Biogen (NASDAQ: BIIB) Q4 2021 Earnings Call Feb 03, 2022, 8:00 a.m. First, we have BIIB080, which is an ASO that we believe facilitates tau mRNA degradation and has demonstrated both a time and dose-dependent reduction of CSF phospho and total tau in Phase 1. New Article Biogen BIIB reported fourth-quarter 2021 earnings per share of $3.39, which beat the Zacks Consensus Estimate of $3.32. Biogen Inc. (BIIB): Free Stock Analysis Report In January 2022, the Centers for Medicare & Medicaid Services (CMS) released a proposed National Coverage Determination (NCD) decision for the class of anti-amyloid antibodies like Aduhelm.",260.6537780761719
2022-02-04 00:00:00+00:00,215.3000030517578,223.1000061035156,215.2700042724609,221.52999877929688,221.52999877929688,1265800.0,2.0,1.0,0.250025,"Feb 4 (Reuters) - The U.S. antitrust regulator has asked Biogen Inc BIIB.O to present documents related to the approval and marketing of its Alzheimer's disease treatment, the drugmaker disclosed in a filing. Biogen in its annual report on Thursday said the U.S. Federal Trade Commission had sent it a civil investigative demand, similar to a subpoena. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15; within U.S. +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",260.5359802246094
2022-02-07 00:00:00+00:00,220.7400054931641,223.42999267578125,219.38999938964844,221.3000030517578,221.3000030517578,832600.0,3.0,1.0,0.5000249999999999,"(RTTNews) - Biogen Inc. (BIIB) said that it has reached agreement with Xbrane Biopharma to develop, manufacture, and commercialize Xcimzane, a preclinical monoclonal antibody that is a proposed biosimilar referencing Cimzia or certolizumab pegol. Cimzia's primary indication is for rheumatoid arthritis in adults as well as axial spondylarthrosis, psoriasis and Crohn's disease. Under the terms of the agreement, Biogen will gain exclusive global regulatory, manufacturing, and commercial rights to Xcimzane and will be the Marketing Authorization Holder.",258.0888977050781
2022-02-09 00:00:00+00:00,224.3300018310547,228.52999877929688,222.2100067138672,226.8099975585937,226.8099975585937,989700.0,3.0,1.0,0.5000249999999999,"Below is a twelve month price history chart comparing the stock performance of VEEV, BIIB, and CMCSA: Combined, VEEV, BIIB, and CMCSA represent 5.40% of the Morningstar Wide Moat ETF. Morningstar Wide Moat ETF MOAT $73.87 $87.43 18.35% Veeva Systems Inc VEEV $231.98 $316.59 36.47% Biogen Inc BIIB $222.39 $287.10 29.10% Comcast Corp CMCSA $49.21 $61.89 25.76% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of MOAT's underlying holdings with notable upside to their analyst target prices are Veeva Systems Inc (Symbol: VEEV), Biogen Inc (Symbol: BIIB), and Comcast Corp (Symbol: CMCSA). New Article Over the past week, earnings took center stage in the biotech sector as most bigwigs like Bristol-Myers BMY, Amgen AMGN, Regeneron REGN and Biogen BIIB reported fourth-quarter results. While Xbrane will be responsible for the pre-clinical development of Xcimzane, BIIB will undertake all remaining development activities. Biogen Inc. (BIIB): Free Stock Analysis Report",270.5552978515625
2022-02-10 00:00:00+00:00,224.47000122070312,226.97000122070312,219.02999877929688,220.0399932861328,220.0399932861328,1316000.0,4.25,1.0,0.8125249999999999,"By Carl O'Donnell Feb 10 (Reuters) - Biogen Inc BIIB.O is urging Medicare to broadly reimburse its recently authorized Alzheimer's drug, in response to a proposal by the U.S. government to sharply limit coverage of new drugs for the brain-wasting disease. In a preliminary proposal last month, the U.S. Centers for Medicaid and Medicare Services (CMS), which runs the government health plan for people age 65 and older, said it would cover Biogen's Aduhelm, and similar Alzheimer's treatments in development, only for patients enrolled in approved clinical trials. Biogen said in an open letter published on Thursday that questions around the efficacy of new Alzheimer's treatments will be best answered with real-world data collected from broad use of drugs like Aduhelm. New Article On Feb 3, Biogen BIIB reported fourth-quarter 2021 earnings per share of $3.39, which outpaced the Zacks Consensus Estimate of $3.32. Biogen Inc. (BIIB): Free Stock Analysis Report Biotech sector has witnessed new investment opportunities amid the pandemic as a race was triggered to introduce vaccines and treatment options. New Article Biogen (NASDAQ: BIIB) offered investors a huge win last year when regulators approved Aduhelm -- its controversial Alzheimer's treatment. BIIB PE Ratio (Forward) data by YCharts The stock has traded at around today's level from time to time over the past few years. BIIB data by YCharts I don't expect Biogen to immediately climb. New Article A couple of already high-yielding stocks that are paying more than the S&P 500 average of 1.3% and have fallen near their 52-week lows are Gilead Sciences (NASDAQ: GILD) and 3M (NYSE: MMM). At the low point of its EPS estimate, Gilead's payout ratio would still be fairly modest at 62%; that would leave plenty of room for the company not only to support but also to grow its already high dividend, which currently yields 4.6%. The lone exception and growth catalyst in Q4 was its consumer business (e.g. bandages, cleaning, and stationery products) which rose by 4% and helped keep the quarter's sales just slightly above the prior-year numbers.",273.4041442871094
2022-02-16 00:00:00+00:00,216.729995727539,216.729995727539,213.38999938964844,214.5500030517578,214.5500030517578,763800.0,3.2,1.0,0.550025,"(RTTNews) - Sage Therapeutics Inc. (SAGE) and Biogen Inc. (BIIB) said that the phase 3 CORAL study in people with major depressive disorder met its primary and key secondary endpoints. At the Day 3 primary endpoint, zuranolone 50 mg co-initiated with a standard of care antidepressant showed a statistically significant reduction in depressive symptoms. Zuranolone 50 mg co-initiated with a standard of care antidepressant was generally well-tolerated with most treatment emergent adverse events reported as mild or moderate and no new safety signals identified. New Article They've done a deal with Biogen (NASDAQ: BIIB) for five targets in the neurological space, and then they have one with Calico for aging, which includes cancer. They're expecting phase I data in peripheral T-cell lymphoma, a couple of different blood cancers as well as solid tumors. But I think their lead target is a little unproven at this point, so there's no guarantees that even knocking down the drug is going to translate into actually treating disease, but we should know that fairly soon. New Article And from the five-year view, things are no better: BIIB Revenue (Quarterly) data by YCharts Though there are still a few reasons to buy the stock, pressure on the top and bottom lines is bound to continue. If you're a former Biogen (NASDAQ: BIIB) investor like me, you might feel compelled to warn other people away from the stock. Then, after the approval and the surrounding controversy, rather than admitting that the medicine's efficacy required further elaboration in post-market trials, senior officers at the company accused detractors as purveyors of misinformation. New Article Sage Therapeutics (SAGE) and Biogen (BIIB) said a phase 3 study of zuranolone to treat patients with major depressive disorder met its primary and key secondary endpoints. The iShares NASDAQ Biotechnology Index (IBB) was declining by 0.2%, and the Health Care SPDR (XLV) was 0.28% lower recently. Avenue Therapeutics (ATXI) was shedding more than 45% in value after saying two advisory panels of the US Food and Drug Administration voted ""no"" when asked whether data showed that benefits of IV tramadol outweighed risks for acute pain management in an inpatient setting. New Article Adds details on study results, timeline for application Feb 16 (Reuters) - Sage Therapeutics SAGE.O and Biogen Inc BIIB.O said their drug in combination with a standard of care antidepressant met the main goal of showing rapid and significant reduction in depressive symptoms in a late-stage study. The drug, zuranolone, also met the study's secondary goal of showing an improvement in symptoms when administered with a standard of care antidepressant, compared to a combination of placebo and antidepressants over a two-week period, the drugmakers said on Wednesday. Sage plans to start submitting data for U.S. approval of the drug for major depressive disorder on a rolling basis early this year and is aiming to complete the application by the second half of the year.",269.28936767578125
2022-02-17 00:00:00+00:00,212.6000061035156,214.13999938964844,209.07000732421875,210.6000061035156,210.6000061035156,1083600.0,4.5,1.0,0.8750249999999999,"Biogen Inc (BIIB) shares closed today at 1.5% above its 52 week low of $211.29, giving the company a market cap of $31B. Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70. New Article Sage Therapeutics SAGE along with partner Biogen BIIB announced that a phase III study on their experimental drug zuranolone in adult patients with major depressive disorder (MDD) met its primary and key secondary endpoints. Biogen Inc. (BIIB): Free Stock Analysis Report The data from the CORAL study shows that adding zuranolone to conventional antidepressant medicines may offer more rapid relief from depressive symptoms than the current standard of care.",276.9515075683594
2022-02-23 00:00:00+00:00,210.07000732421875,211.5500030517578,208.94000244140625,209.0800018310547,209.0800018310547,964600.0,3.5,1.0,0.6250249999999999,"Sage, Biogen Report Data: Sage Therapeutics, Inc. SAGE, and Biogen Inc. BIIB announced that the CORAL study on zuranolone in patients with major depressive disorder (MDD) met the trial endpoints. Biogen Inc. (BIIB): Free Stock Analysis Report Dupixent did not reach statistical significance in interim analysis despite numeric improvements observed across key endpoints in this phase III study in patients refractory to omalizumab. New Article In 2021, Biogen (NASDAQ: BIIB) received approval from the U.S. Food and Drug Administration (FDA) for its Alzheimer's drug candidate, Aduhelm. In this video clip from ""The Pharma & Biotech Show,"" recorded on Feb. 9, Motley Fool contributor Taylor Carmichael asks Dr. Frank David, author of The Pharmagellan Guide to Analyzing Biotech Clinical Trials, about what Biogen's drug approval means for investors and other biopharma companies. Should other drug companies, as they figure out how their scheduling and how they're doing their protocol, should they focus more on this objective criteria or is that approval just the desperation that we're seeing for people with Alzheimer's?",276.4172058105469
2022-02-24 00:00:00+00:00,204.8600006103516,207.0500030517578,200.3600006103516,203.1199951171875,203.1199951171875,1883300.0,4.0,1.0,0.7500249999999999,"Stocks recently featured in the blog include: Regeneron Pharmaceuticals, Inc. REGN, Sage Therapeutics, Inc. SAGE, Biogen BIIB, Agios Pharmaceuticals, Inc. AGIO and Atara Biotherapeutics, Inc. ATRA. Biogen Inc. (BIIB): Free Stock Analysis Report Dupixent did not reach statistical significance in interim analysis despite numeric improvements observed across key endpoints in this phase III study in patients refractory to omalizumab.",267.97076416015625
2022-02-25 00:00:00+00:00,204.4900054931641,209.92999267578125,203.8800048828125,207.3800048828125,207.3800048828125,1035200.0,3.0,1.0,0.5000249999999999,"Image Source: Zacks Investment Research Quarter in Detail Ionis has licensed Spinraza to Biogen BIIB. Biogen Inc. (BIIB): Free Stock Analysis Report Pipeline Update Ionis has phase III studies ongoing for six medicines (internal as well as partnered) across eight indications, which include tofersen for SOD1-ALS (amyotrophic lateral sclerosis); pelacarsen for cardiovascular disease due to elevated Lp(a) levels; olezarsen for familial chylomicronemia syndrome, or FCS and severe hypertriglyceridemia, eplontersen for TTR amyloidosis, ION363 for amyotrophic lateral sclerosis, or ALS, with mutations in the fused in sarcoma gene, or FUS (FUS-ALS) and donidalorsen for hereditary angioedema or HAE.",266.17047119140625
2022-03-01 00:00:00+00:00,210.5800018310547,213.8000030517578,209.4100036621093,210.33999633789065,210.33999633789065,804400.0,3.5,1.0,0.6250249999999999,"The year-over-year decline was primarily owing to a decrease in revenues from the companys collaboration with Biogen BIIB. Biogen Inc. (BIIB): Free Stock Analysis Report Denali remains on track to begin dosing patients in the phase II/III study evaluating DNL310, an investigational brain-penetrant enzyme replacement therapy, to treat Hunter syndrome in first-half 2022. New Article AstraZeneca's rare diseases unit Alexion and Neurimmune - the firm behind the discovery of Biogen's BIIB.O Alzheimer's drug aducanumab - will work on evaluating a monoclonal antibody for the treatment of transthyretin amyloid cardiomyopathy. The potentially fatal condition is characterised by deposits of proteins called amyloid fibrils in the walls of the heart which causes them to become stiff and result in the organ being unable to pump and circulate blood effectively. Anglo-Swedish drugmaker AstraZeneca, which made a $39 billion bet on Alexion's rare diseases portfolio in 2020, has had major success with monoclonal antibodies in recent times with its Evusheld treatment for COVID-19.",269.4542541503906
2022-03-04 00:00:00+00:00,208.94000244140625,211.3600006103516,208.94000244140625,209.4499969482422,209.4499969482422,708800.0,2.2,1.0,0.300025,"(RTTNews) - S&P 500 constituent The Charles Schwab Corp. (SCHW) will replace Biogen Inc. (BIIB) in the S&P 100 effective prior to the opening of trading on March 21, Standard & Poor's said in a statement. BellRing Brands Inc. (BRBR) will replace Cerence Inc. (CRNC) in the S&P MidCap 400, and Cerence will replace Cooper-Standard Holdings Inc. (CPS) in the S&P SmallCap 600 effective prior to the opening of trading on March 14. S&P MidCap 400 constituent Post Holdings Inc. (POST) is converting its interest in BellRing Brands into new BellRing Brands stock and then distributing 80.1% of that interest to shareholders on March 11. New Article In the latest trading session, Biogen Inc. (BIIB) closed at $209.45, marking a -0.84% move from the previous day. It is also worth noting that BIIB currently has a PEG ratio of 1.26. Biogen Inc. (BIIB): Free Stock Analysis Report New Article Biogen (BIIB) was slipping 0.4% this afternoon in choppy trade after the drug maker overnight said partner company Eisai has begun the application process with Japanese regulators for their lecanemab prospective treatment for Alzheimer's disease. Ocugen (OCGN) dropped nearly 18% after the genetic therapies company Friday said the US Food and Drug Administration declined to issue an emergency use authorization for its Covaxin vaccine candidate for COVID-19 in youth between 2 to 18 years old. The company will continue working with the agency to determine a regulatory pathway for pediatric use of Covaxin. New Article Biogen (BIIB) was slipping 0.9% this afternoon in choppy trade after the drugmaker overnight said partner company Eisai has begun the application process with Japanese regulators for their lecanemab prospective treatment for Alzheimer's disease. Health care stocks have reversed course once again this afternoon and were trading narrowly mixed shortly ahead of Friday's closing bell. Ocugen (OCGN) dropped 22.5% after the genetic therapies company Friday said the US Food and Drug Administration declined to issue an emergency use authorization for its Covaxin vaccine candidate for COVID-19 in youth between 2 to 18 years old. New Article Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $215.00 strike highlighted in red: Considering the fact that the $215.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options become available this week, for the October 21st expiration.",267.2991027832031
2022-03-10 00:00:00+00:00,201.0,203.3600006103516,194.94000244140625,198.63999938964844,198.63999938964844,1166200.0,3.0,1.0,0.5000249999999999,"DNLI also has a collaboration agreement with Biogen BIIB for its Parkinsons disease (PD) candidate. In August 2020, DNLI and BIIB announced the selection of BIIB122/DNL151, a small molecule inhibitor of LRRK2, to advance into two late-stage studies. Biogen Inc. (BIIB): Free Stock Analysis Report New Article Biogen Inc. (BIIB) closed at $198.64 in the latest trading session, marking a -1.79% move from the prior day. We can also see that BIIB currently has a PEG ratio of 1.21. BIIB's industry had an average PEG ratio of 1.06 as of yesterday's close.",255.09054565429688
2022-03-14 00:00:00+00:00,198.58999633789065,201.5200042724609,192.6699981689453,193.7700042724609,193.7700042724609,1475800.0,2.6666666666666665,1.0,0.4166916666666666,"March 14 (Reuters) - Japan's Eisai Co Ltd 4523.T will surrender its rights to share profit from Aduhelm, the Alzheimer's treatment drug jointly developed with U.S. partner Biogen Inc BIIB.O, and instead receive sales royalties, the companies said on Monday. Beginning January next year, Eisai will receive royalties from Aduhelm, which starts at 2% and reaches 8% when annual sales exceed $1 billion, the companies said in a joint statement, adding that Biogen now had ""sole decision making"" and commercialization rights for the drug. Lecanemab works in a similar manner to Aduhelm and gets rid of sticky deposits of a protein called amyloid beta from brains of patients in the initial stages of the disease to mitigate its impact. New Article In the latest trading session, Biogen Inc. (BIIB) closed at $193.77, marking a -1.97% move from the previous day. BIIB's full-year Zacks Consensus Estimates are calling for earnings of $16 per share and revenue of $9.91 billion. Investors should also note that BIIB has a PEG ratio of 1.19 right now. New Article In trading on Monday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 28.9, after changing hands as low as $192.67 per share. A bullish investor could look at BIIB's 28.9 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of BIIB shares: Looking at the chart above, BIIB's low point in its 52 week range is $192.67 per share, with $468.55 as the 52 week high point  that compares with a last trade of $193.77.",256.6523742675781
2022-03-15 00:00:00+00:00,193.2100067138672,197.4199981689453,193.08999633789065,197.3600006103516,197.3600006103516,1306300.0,2.5,1.0,0.375025,"WisdomTree U.S. ESG Fund ETF RESP $44.96 $56.21 25.00% FedEx Corp FDX $211.13 $319.20 51.19% Scientific Games Corp SGMS $56.51 $84.50 49.53% Biogen Inc BIIB $193.77 $284.07 46.60% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of RESP's underlying holdings with notable upside to their analyst target prices are FedEx Corp (Symbol: FDX), Scientific Games Corp (Symbol: SGMS), and Biogen Inc (Symbol: BIIB). Similarly, SGMS has 49.53% upside from the recent share price of $56.51 if the average analyst target price of $84.50/share is reached, and analysts on average are expecting BIIB to reach a target price of $284.07/share, which is 46.60% above the recent price of $193.77. New Article (RTTNews) - Biogen Inc. (BIIB) and Eisai Co., Ltd. (ESALY.PK) have amended their existing collaboration agreement on Alzheimer's disease treatments. Effective as of January 1, 2023, Eisai will receive a tiered royalty based on net sales of ADUHELM rather than sharing global profits and losses. Overall, economic arrangements for both companies in 2022 are expected to remain materially unchanged with Eisai's share of expenses capped at an agreed amount for the costs related to development, commercialization, and manufacturing of ADUHELM for the period from January 1, 2022 to December 31, 2022.",243.9013671875
2022-03-16 00:00:00+00:00,201.22999572753903,204.25,198.0599975585937,203.8000030517578,203.8000030517578,1075000.0,3.333333333333333,1.0,0.5833583333333334,"By Julie Steenhuysen March 16 (Reuters) - Biogen Inc BIIB.O on Wednesday published long-awaited results of studies supporting approval of its Alzheimer's drug in a lesser-known medical journal whose editor was a leader on the research, adding controversy to the already troubled treatment. ""It has always been our intention for our Phase 3 data to be peer-reviewed to provide physicians with a greater understanding of the appropriate use of Aduhelm, and we have worked urgently to that end,"" Biogen spokeswoman Ashleigh Koss said in an emailed statement. Biogen's Aduhelm has been embroiled in controversy since the U.S. Food and Drug Administration granted it accelerated approval even after its expert panel of outside advisers recommended against it, saying there was not enough evidence of patient benefit. New Article Adds data details, background March 16 (Reuters) - Biogen Inc BIIB.O said on Wednesday patients in a long-term trial of its Alzheimer's drug Aduhelm experienced reductions in two key disease indicators after nearly two and a half years of treatment. Leading experts questioned that move and the U.S. government Medicare program has proposed that the drug's use only be allowed by patients enrolled in a new trial. Biogen presented the data at the International Conference on Alzheimer's and Parkinson's Diseases currently underway in Barcelona. New Article March 16 (Reuters) - Biogen Inc BIIB.O said on Wednesday patients in a long-term trial of its Alzheimer's drug Aduhelm experienced significant reductions in two key disease indicators, after nearly two and a half years of treatment. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Maju Samuel) ((manojna.kalyani@thomsonreuters.com; +91 8061822700;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",246.59214782714844
2022-03-17 00:00:00+00:00,203.0399932861328,206.6000061035156,202.009994506836,205.32000732421875,205.32000732421875,1057100.0,1.0,1.0,2.4999999999997247e-05,"(RTTNews) - Viatris Inc. (VTRS) said that the United States Court of Appeals for the Federal Circuit denied Biogen's request that the Court reconsider its prior decision affirming the invalidity of Biogen's U.S. Patent No. Following the Court's denial of Biogen's rehearing petition, the '514 patent remains invalid. Viatris' subsidiary Mylan Pharmaceuticals Inc. launched the first therapeutically equivalent substitutable generic to Tecfidera in August 2020.",238.1245574951172
2022-03-21 00:00:00+00:00,207.6999969482422,209.02999877929688,203.9900054931641,206.8099975585937,206.8099975585937,1284400.0,4.0,1.0,0.7500249999999999,"Biogen Inc. (BIIB) closed the most recent trading day at $206.81, moving -0.84% from the previous trading session. Also, we should mention that BIIB has a PEG ratio of 1.29. BIIB's industry had an average PEG ratio of 1.14 as of yesterday's close.",238.30007934570312
2022-03-22 00:00:00+00:00,206.6600036621093,212.1100006103516,206.0,210.9199981689453,210.9199981689453,849600.0,2.0,1.0,0.250025,"Biotech giant Biogen (NASDAQ: BIIB) has generated many headlines in the past couple of years, largely due to its Alzheimer's disease (AD) therapy, Aduhelm, and that drug's controversial path to approval in the U.S. BIIB data by YCharts 1. Declining revenue Drugmakers typically benefit from patents that allow them to sell their products on the market without worrying about cheaper generic competition, at least for a set period.",239.45223999023438
2022-03-28 00:00:00+00:00,210.0800018310547,212.259994506836,208.22999572753903,211.67999267578125,211.67999267578125,807500.0,2.5,1.0,0.375025,"Ionis Pharmaceuticals (IONS) shares were down about 4% after the company and Biogen (BIIB) said they are discontinuing the clinical program for their investigational drug for the treatment of C9orf72-associated amyotrophic lateral sclerosis. Health care stocks were edging higher pre-bell Monday. Under the terms of the agreement, Axsome will pay Jazz Pharmaceuticals $53 million upfront, a high single-digit royalty on net sales in the US in current indication and a mid single-digit royalty on US sales in future indications. New Article (RTTNews) - Ionis Pharmaceuticals, Inc. (IONS) and Biogen Inc's (BIIB) BIIB078, an investigational antisense oligonucleotide for C9orf72-associated amyotrophic lateral sclerosis, did not meet any secondary efficacy endpoints and it did not demonstrate clinical benefit, as per phase 1 study results. Participants in the BIIB078 90 mg dose cohort trended toward a greater decline than those in the placebo group across secondary endpoints. In the dose cohorts up to 60 mg there were no consistent differences between the BIIB078 group and the placebo group.",239.85989379882812
2022-03-29 00:00:00+00:00,212.9600067138672,215.92999267578125,212.6600036621093,214.9499969482422,214.9499969482422,699600.0,2.0,1.0,0.250025,"Image Source: Zacks Investment Research The FDA approval of Biogens BIIB AD drug, Aduhelm, in June 2021 has put the spotlight on companies with promising AD candidates in their pipeline. Biogen Inc. (BIIB): Free Stock Analysis Report Prothena Corporation plc PRTA announced that the FDA has cleared the investigational new drug (IND) application for pipeline candidate PRX012 for the treatment of Alzheimers disease (AD). New Article Biogen BIIB and partner Ionis Pharmaceuticals IONS announced disappointing top-line results from a phase I study evaluating their investigational antisense drug, BIIB078, in C9orf72-associated amyotrophic lateral sclerosis (ALS). Image Source: Zacks Investment Research Apart from BIIB078, Biogen has multiple other drugs undergoing clinical development targeting ALS indication, which include tofersen, BIIB105 and BIIB100. The phase I study evaluated multiple-dose cohorts of BIIB078 against placebo in adults with C9orf72-associated ALS. New Article Nerve cells that carry signals from brains to muscles degrade at different rates for different ALS patients but most lose the use of their limbs and their ability to breathe independently three to five years after they begin noticing symptoms. You may recall several members of the neurology committee resigned in protest last year after the agency ignored its negative recommendations and approved Aduhelm, a highly controversial treatment for Alzheimer's disease from Biogen. The agency noted multiple problems with the design of Amylyx's phase 2 trial, including a measured benefit that just barely reached statistical significance.",239.34225463867188
2022-03-30 00:00:00+00:00,214.9499969482422,216.3600006103516,210.32000732421875,211.02999877929688,211.02999877929688,585400.0,3.333333333333333,1.0,0.5833583333333334,"Biogen, Ionis Discontinue Candidate:  Biogen BIIB and partner Ionis Pharmaceuticals announced disappointing top-line results from an early-stage study evaluating pipeline candidate BIIB078.The candidate is an investigational antisense oligonucleotide being evaluated for C9orf72-associated amyotrophic lateral sclerosis (ALS). The phase I study was a randomized, placebo-controlled, dose-escalating trial to evaluate BIIB078 administered intrathecally to adults (n=106) with C9orf72-associated ALS. BIIB078 did not meet any secondary efficacy endpoints and did not demonstrate clinical benefit. New Article One other stock from the broader Zacks Medical sector, Biogen Inc. (BIIB), is yet to report results for the quarter ended March 2022. Biogen Inc. (BIIB): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. New Article (RTTNews) - Biogen Inc. (BIIB) said that it has submitted the final study protocol for the confirmatory envision trial of Alzheimer's disease drug, Aduhelm, to the U.S. Food and Drug Administration for review and approval. The company expects the first patient to enter screening in May 2022 and the trial's primary completion approximately four years after the study begins. The confirmatory trial is a requirement based on FDA's accelerated approval of Aduhelm (aducanumab-avwa) 100 mg/mL injection for intravenous use in early Alzheimer's disease.",242.87144470214844
2022-03-31 00:00:00+00:00,212.1300048828125,213.2400054931641,210.1000061035156,210.6000061035156,210.6000061035156,951400.0,3.0,1.0,0.5000249999999999,"Biogen BIIB announced that it has submitted the final study protocol for the phase IV post-marketing confirmatory study, ENVISION, for its new Alzheimers disease (AD) drug Aduhelm (aducanumab) for review to the FDA. Biogen Inc. (BIIB): Free Stock Analysis Report The accelerated approval granted to Aduhelm was based on data from phase III studies  EMERGE and ENGAGE   in patients with early-stage AD.",245.35963439941406
2022-04-04 00:00:00+00:00,212.0599975585937,213.5,211.07000732421875,211.63999938964844,211.63999938964844,800500.0,3.0,1.0,0.5000249999999999,"For Immediate Release Chicago, IL  April 4, 2022  Zacks Equity Research shares Advanced Micro Devices AMD as the Bull of the Day and Biogen BIIB asthe Bear of the Day. Bottom line on BIIB: This key innovator is a must-own for large-cap Biotech portfolios. Biogen Inc. (BIIB): Free Stock Analysis Report New Article Biogen Inc. (BIIB) closed at $211.64 in the latest trading session, marking a +0.47% move from the prior day. BIIB's full-year Zacks Consensus Estimates are calling for earnings of $15.52 per share and revenue of $9.92 billion. Also, we should mention that BIIB has a PEG ratio of 1.3.",245.92532348632812
2022-04-05 00:00:00+00:00,210.3800048828125,214.13999938964844,207.3500061035156,207.6100006103516,207.6100006103516,1404900.0,3.0,1.0,0.5000249999999999,"Particularly high volume was seen for the $170 strike put option expiring January 20, 2023, with 1,700 contracts trading so far today, representing approximately 170,000 underlying shares of BIIB. Below is a chart showing NCLH's trailing twelve month trading history, with the $23.50 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 5,983 contracts, representing approximately 598,300 underlying shares or approximately 58% of BIIB's average daily trading volume over the past month, of 1.0 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $170 strike highlighted in orange: And Generac Holdings Inc (Symbol: GNRC) saw options trading volume of 3,226 contracts, representing approximately 322,600 underlying shares or approximately 55% of GNRC's average daily trading volume over the past month, of 586,310 shares.",248.5762939453125
2022-04-07 00:00:00+00:00,210.22000122070312,212.9600067138672,208.3699951171875,211.63999938964844,211.63999938964844,779100.0,2.5,1.0,0.375025,"Adds details of decision, background April 7 (Reuters) - The U.S. government health plan for people age 65 and over on Thursday issued its final coverage policy for Biogen Inc's BIIB.O Alzheimer's drug, Aduhelm, saying that it would limit it to patients in clinical trials. In January, Medicare said it had significant doubts about the potential benefits of Aduhelm and proposed restricting use to clinical trials for it and similar experimental treatments designed to remove amyloid plaques from the brains of people with early Alzheimer's. For drugs approved by the traditional FDA process that showed clear patient benefit, the agency said there would not be any subsequent clinical trial requirements. New Article April 7 (Reuters) - The U.S. government health plan for people over age 65 on Thursday issued its final coverage policy for Biogen Inc's Alzheimer's drug, Aduhelm, saying that it would limit it to patients in clinical trials. For drugs similar to Aduhelm, the Centers for Medicare and Medicaid Services said it would allow coverage if the medication is approved after a standard review by the Food and Drug Administration. (Reporting By Deena Beasley; Editing by Leslie Adler) ((deena.beasley@thomsonreuters.com; 213 955 6746; Reuters Messaging: deena.beasley.thomsonreuters.com@reuters.net)) Keywords: BIOGEN ALZHEIMERS/ (URGENT) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $210.00 strike highlighted in red: Considering the fact that the $210.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the May 27th expiration. New Article That, coupled with consistent top-line growth, can ensure that the company's bottom line gets bigger over time, which makes the stock a better buy and leads to better returns for investors. Globus is an impressive growth stock, and the only reason I could see why investors might be cautious about it is that it trades at 36 times its future profits (Eli Lilly is slightly lower at 34). The FDA granted the cervical cancer drug accelerated approval in September 2021, and analysts believe it has the potential to be a blockbuster, with annual revenue topping more than $1 billion at its peak.",250.6166229248047
2022-04-08 00:00:00+00:00,211.17999267578125,218.0200042724609,210.3600006103516,214.75,214.75,1410700.0,2.5714285714285725,1.0,0.3928821428571428,"InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biogen (NASDAQ:BIIB) stock is trending lower today on news that Medicare will limit coverage of its Aduhelm drug for Alzheimers. What Happened With BIIB Stock In its decision, Medicare said it will also limit access to Aduhelm to people who have mild dementia, and who have amyloid plaques, the proteins Aduhelm is designed to target in the human brain. Whats Next for Biogen BIIB stock takes a hit today on news that Medicare will not cover the cost of its pricey Alzheimer medication for many Americans. New Article Biogen Inc. (BIIB) closed at $214.75 in the latest trading session, marking a +1.47% move from the prior day. Also, we should mention that BIIB has a PEG ratio of 1.31. Biogen Inc. (BIIB): Free Stock Analysis Report New Article Drugmaker Biogen (BIIB) was briefly on top of the world. Hedge Funds Coming Back, Dividends Uncertain The news for Biogen isn't all bad, however. That's going to make finding investors willing to buy in on Biogen's big-ticket price tag a tough sell. New Article On Thursday, after a months-long review and a pressure campaign from patient advocacy groups, the Centers for Medicare and Medicaid Services (CMS) said it would only pay for Biogen Inc's BIIB.O Aduhelm, and other drugs that work in a similar fashion, for patients enrolled in valid clinical studies, unless the treatments demonstrate clear evidence of patient benefit. Eisai's lecanemab and Lilly's donanemab, like Aduhelm, are monoclonal antibodies designed to remove beta-amyloid, a type of protein fragment that accumulates in the brains of Alzheimer's patients. Medicare, however, has decided to allow standard reimbursement only for Alzheimer's drugs approved under the traditional FDA process based on ""a direct measure of clinical benefit."" New Article On Thursday, after a months-long review and a pressure campaign from patient advocacy groups, the Centers for Medicare and Medicaid Services (CMS) said it would only pay for Biogen Inc's BIIB.O Aduhelm, and other drugs that work in a similar fashion, for patients enrolled in valid clinical studies, unless they have demonstrated clear evidence of patient benefit. Eisai's lecanemab, like Aduhelm, is a monoclonal antibody designed to remove beta-amyloid, a type of protein fragment that accumulates in the brains of Alzheimer's patients. Alzheimer's drugs approved under the traditional FDA process based on ""a direct measure of clinical benefit"" would be covered as standard treatments without the limitations, CMS said. New Article Biogens (NASDAQ:BIIB) Alzheimers drug Aduhelm failed several clinical trials but went ahead with FDA approval anyway. Cancer, diabetes, dementia, heart diseases and other chronic illnesses are unfortunately not only commonplace but far more expensive to treat, making them better targets than those companies pursuing rarer conditions. Within a month, Longeverons management revealed that the FDA had granted Lomecel-B Orphan Drug Designation (ODD) for the treatment of rare heart defects in infants. New Article Biogen (BIIB) shares were slightly higher despite the US Centers for Medicare & Medicaid Services limiting the coverage policy for Aduhelm, the company's drug treatment for Alzheimer's disease. VYNE Therapeutics (VYNE) was marginally higher after the company late Thursday reported positive efficacy results from a phase 1b segment of a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis, a skin disorder. MediciNova (MNOV) said late Thursday data from a mid-stage trial showed that its MN-166 neuroimmune modulator reduced rates of heavy drinking and measures of alcohol craving in patients with alcohol-use disorder.",254.59718322753906
2022-04-13 00:00:00+00:00,208.5599975585937,214.3999938964844,208.07000732421875,213.97999572753903,213.97999572753903,671600.0,2.0,1.0,0.250025,"Particularly high volume was seen for the $210 strike put option expiring May 20, 2022, with 913 contracts trading so far today, representing approximately 91,300 underlying shares of BIIB. Below is a chart showing DGX's trailing twelve month trading history, with the $140 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 4,574 contracts, representing approximately 457,400 underlying shares or approximately 46.4% of BIIB's average daily trading volume over the past month, of 986,025 shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $210 strike highlighted in orange: For the various different available expirations for TXG options, DGX options, or BIIB options, visit StockOptionsChannel.com.",255.84104919433594
2022-04-14 00:00:00+00:00,214.3999938964844,216.0,212.1999969482422,212.5500030517578,212.5500030517578,917900.0,4.0,1.0,0.7500249999999999,"Biogen Inc. (BIIB) closed the most recent trading day at $212.55, moving -0.67% from the previous trading session. BIIB's full-year Zacks Consensus Estimates are calling for earnings of $15.51 per share and revenue of $9.9 billion. Investors should also note that BIIB has a PEG ratio of 1.32 right now. New Article We can look at the performance of big players like Amgen or Biogen that, respectively, have delivered triple-digit and double-digit share-price growth over the past decade. Vertex aims to file for regulatory approval of its one-time curative treatment for blood disorders by the end of the year. Vertex's shares already have gained 28% so far this year and ongoing CF revenue and progress in these clinical programs could keep them moving higher. New Article The FDAs nod to Biogens BIIB Aduhelm in June 2021 has put the spotlight on AD since its controversial approval. Biogen Inc. (BIIB): Free Stock Analysis Report INmune Bios INMB stock price rose 12.2% on Wednesday after management announced that it has dosed the first patient in a phase II study with XPro1595 (XPro), its investigational candidate for Alzheimers disease (AD).",248.96263122558594
2022-04-19 00:00:00+00:00,212.97999572753903,224.32000732421875,212.5500030517578,223.0200042724609,223.0200042724609,1448600.0,5.0,1.0,1.000025,"Biogen Inc. (BIIB), which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider. Biogen Inc. (BIIB): Free Stock Analysis Report The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.",245.21380615234375
2022-04-20 00:00:00+00:00,224.2700042724609,225.5,220.2700042724609,220.42999267578125,220.42999267578125,1028600.0,3.0,1.0,0.5000249999999999,"The top ten constituents currently add to around 46.67% and include: Amgen (AMGN) Gilead Sciences (GILD) Moderna (MRNA) Regeneron Pharmaceuticals (REGN) Illumina (ILMN) Vertex Pharmaceuticals (VRTX) Biogen (BIIB) AstraZeneca (AZN) Seagen (SGEN) BioNTech (BNTX) How has the Nasdaq Biotechnology Index performed? Its advantages in terms of lower cost to produce, ease of transport, and longer shelf life, have made it one of the most important vaccinations in the quest to ensure global coverage. Offers investors a transparent, effective benchmark for tracking new entrants into the public markets Again, it is important to maintain appropriate weightings among the more volatile, younger small-cap segment of the industry and its more stable, older large-cap members.",242.7456817626953
2022-04-21 00:00:00+00:00,222.3699951171875,224.77999877929688,218.3000030517578,218.3999938964844,218.3999938964844,932200.0,2.5,1.0,0.375025,"Image Source: Zacks Investment Research The FDAs approval of Biogens BIIB Alzheimer's disease (AD) drug, Aduhelm, in 2021 put the spotlight on other companies that are developing AD drugs as investors are now optimistic about the prospects of these pipeline candidates. Biogen Inc. (BIIB): Free Stock Analysis Report The FDA recently cleared the investigational new drug (IND) application for Prothenas PRX012, a potential best-in-class anti-amyloid beta (A) antibody in development to treat AD. New Article Biogen (NASDAQ: BIIB) has been a volatile investment over the past year. Aduhelm is the company's Alzheimer's treatment that the Food and Drug Administration granted accelerated approval for last year, even though the agency's panel was not convinced of its effectiveness. Despite what seems to be horrible news for the company and its blockbuster drug that analysts previously projected could hit $10 billion in annual sales, the healthcare stock hasn't fallen off a cliff. New Article Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $225.00 strike highlighted in red: Considering the fact that the $225.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the June 3rd expiration. New Article In the latest trading session, Biogen Inc. (BIIB) closed at $218.40, marking a -0.92% move from the previous day. Also, we should mention that BIIB has a PEG ratio of 1.36. Biogen Inc. (BIIB): Free Stock Analysis Report",239.46624755859375
2022-04-22 00:00:00+00:00,217.47999572753903,220.47999572753903,209.7100067138672,209.9900054931641,209.9900054931641,1342900.0,1.5,1.0,0.125025,"Adds background on European review, U.S. sales April 22 (Reuters) - Biogen Inc BIIB.O said on Friday it has decided to withdraw the marketing authorization application for its troubled Alzheimer's drug, aducanumab, in Europe and has notified the decision to the regulator. The European Medicines Agency had in December rejected the drug and Biogen had sought a re-examination of its decision. Sales of the drug, once expected to be a multi-billion dollar product, have been marginal in the United States following a backlash over the U.S. health regulator's controversial approval decision last June. New Article April 22 (Reuters) - Biogen Inc BIIB.O said on Friday it has notified the European Medicines Agency of its decision to withdraw the marketing authorization application for its troubled Alzheimer's drug, aducanumab. (Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15; within U.S. +1 646 223 8780;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",240.30264282226562
2022-04-26 00:00:00+00:00,213.0,214.509994506836,206.5200042724609,206.9900054931641,206.9900054931641,1110300.0,2.75,1.0,0.437525,"Wall Street expects a year-over-year decline in earnings on lower revenues when Biogen Inc. (BIIB) reports results for the quarter ended March 2022. Biogen Inc. (BIIB): Free Stock Analysis Report While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. New Article It's been a forgettable year for Biogen (NASDAQ: BIIB). BIIB093, Biogen's leading acute stroke therapy currently in phase 3 trials, has not statistically improved clinical outcomes at 90 days. In light of this ongoing approval saga, it's hard to imagine that the CMS (and other insurance companies) would pay up for a treatment proven on only a single-arm study, as these are generally considered lower-quality evidence. New Article SEE MORE Hedge Funds' 25 Top Blue-Chip Stocks to Buy Now Biogen Market value: $31.5 billion Dividend yield: N/A POWR Ratings overall rating: B (Buy) POWR Ratings average broker rating: 2.19 Biogen (BIIB, $214.54) focuses on developing therapies and treatments for neurological and neurodegenerative diseases such as multiple sclerosis (MS), Alzheimer's, dementia, Parkinson's and spinal muscular atrophy. Over the past year, BIIB stock is down 20%. Over the last five years, BIIB has made over 20 acquisitions, licensing or development deals. New Article Wall Street expects a year-over-year decline in earnings on lower revenues when Biogen Inc. (BIIB) reports results for the quarter ended March 2022. Biogen Inc. (BIIB): Free Stock Analysis Report While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.",236.07569885253906
2022-04-27 00:00:00+00:00,207.6199951171875,209.92999267578125,206.2400054931641,206.94000244140625,206.94000244140625,728800.0,3.333333333333333,1.0,0.5833583333333334,"We expect Biogen BIIB to beat expectations when it reports first-quarter 2022 results on May 3, before market open. Biogen Inc. (BIIB): Free Stock Analysis Report Among Biogens MS drugs, sales of Tecfidera are likely to have declined steeply, hurt by the launch of multiple generics products in the United States. New Article Biogen Inc. BIIB has an Earnings ESP of +1.32% and a Zacks Rank #3. BIIB delivered a four-quarter earnings surprise of 11.72%, on average. Biogen Inc. (BIIB): Free Stock Analysis Report New Article Biogens AD Drug Update:  Biogen BIIB has decided to withdraw its Marketing Authorization Application (MAA) for Alzheimers disease drug aducanumab. Biogen Inc. (BIIB): Free Stock Analysis Report Biogens MAA had been under review by the CHMP in response to the companys request to re-examine the negative opinion the regulatory body issued in December 2021.",233.44210815429688
2022-04-28 00:00:00+00:00,207.7899932861328,211.2899932861328,204.8600006103516,210.4100036621093,210.4100036621093,876700.0,3.333333333333333,1.0,0.5833583333333334,"Biogen Inc. (BIIB) closed the most recent trading day at $210.41, moving +1.68% from the previous trading session. Also, we should mention that BIIB has a PEG ratio of 1.29. To follow BIIB in the coming trading sessions, be sure to utilize Zacks.com. New Article Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $210.00 strike highlighted in red: Considering the fact that the $210.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the June 10th expiration. New Article Biogen Inc. BIIB has an Earnings ESP of +0.74% and a Zacks Rank #3. BIIB delivered a four-quarter earnings surprise of 11.72%, on average. Biogen Inc. (BIIB): Free Stock Analysis Report",232.83956909179688
2022-04-29 00:00:00+00:00,210.6699981689453,214.6199951171875,206.97000122070312,207.44000244140625,207.44000244140625,1049400.0,2.6666666666666665,1.0,0.4166916666666666,"These include Novo Nordisk NVO, Vertex Pharmaceuticals VRTX,Regeneron Pharmaceuticals, Inc. REGN, Moderna MRNA and Biogen BIIB. Biogen Inc. (BIIB): Free Stock Analysis Report Among the big pharma companies that have reported so far, Bristol-Myers, Gilead, Eli Lilly, Sanofi, Merck and Glaxo beat on both earnings and sales. New Article International sales were affected by the launch of several direct biosimilar drugs in Europe by other pharma companies, including Amgen AMGN, Sandoz and Biogen BIIB. Biogen Inc. (BIIB): Free Stock Analysis Report Image Source: Zacks Investment Research Quarter in Detail In immunology, key drug Humira recorded a year-over-year sales decrease of 1.8% on an operational basis to $4.74 billion. New Article Stocks to Consider Here are some large drug/biotech stocks that have the right combination of elements to beat on earnings this time around: Biogen BIIB has an Earnings ESP of +0.74% and a Zacks Rank #3. BIIBis scheduled to release its first-quarter 2022 results on May 3. Biogen Inc. (BIIB): Free Stock Analysis Report",225.12158203125
2022-05-02 00:00:00+00:00,206.3000030517578,209.1199951171875,202.5200042724609,207.32000732421875,207.32000732421875,1526200.0,2.6666666666666665,1.0,0.4166916666666666,"Pfizer PFE, Biogen BIIB, Incyte Corporation INCY, Esperion Therapeutics ESPR and Teva Pharmaceutical TEVA are scheduled to release first-quarter earnings on May 3. BIIBs earnings beat estimates in each of the last four quarters, the average being 11.7%. Biogen Inc. (BIIB): Free Stock Analysis Report New Article Particularly high volume was seen for the $290 strike call option expiring October 21, 2022, with 629 contracts trading so far today, representing approximately 62,900 underlying shares of BIIB. Below is a chart showing CLX's trailing twelve month trading history, with the $200 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 4,628 contracts thus far today. That number of contracts represents approximately 462,800 underlying shares, working out to a sizeable 46% of BIIB's average daily trading volume over the past month, of 1.0 million shares. New Article Stocks recently featured in the blog include: Novo Nordisk NVO, Vertex Pharmaceuticals VRTX, Regeneron Pharmaceuticals, Inc. REGN, Moderna MRNA and Biogen BIIB. Biogen Inc. (BIIB): Free Stock Analysis Report Among the big pharma companies that have reported so far, Bristol-Myers, Gilead, Eli Lilly, Sanofi, Merck and Glaxo beat on both earnings and sales.",211.43875122070312
2022-05-03 00:00:00+00:00,209.1199951171875,214.77999877929688,205.0,205.6999969482422,205.6999969482422,1545700.0,2.142857142857143,1.0,0.2857392857142857,"Biogen Inc BIIB.O dipped 3.0% after it reported a 26% fall in quarterly profit and said its Chief Executive Officer Michel Vounatsos will step down. Estee Lauder Cos Inc EL.N slumped 9.5% after the cosmetics maker cut its full-year sales forecast on fresh coronavirus restrictions in China and the crisis in Ukraine. Focus is squarely on Fed Chair Jerome Powell's press conference on Wednesday for comments on the future path of interest rates and balance sheet reduction. New Article Biogen BIIB reported first-quarter 2022 earnings per share (EPS) of $3.62, which missed the Zacks Consensus Estimate of $4.41. Biogen Inc. (BIIB): Free Stock Analysis Report Restructuring Initiatives Following the failure of Aduhelm commercialization, Biogen announced a set of near-term operational priorities to drive renewed growth and value creation over time. New Article Adds details on cost cuts, background May 3 (Reuters) - Biogen Inc's BIIB.O Chief Executive Officer Michel Vounatsos is stepping down, at a time the drugmaker is grappling with insurance coverage issues related to its Alzheimer's drug Aduhelm. Biogen was betting on Aduhelm, the first new treatment for the memory-robbing disease in nearly 20 years, to act as a buffer as its main revenue drivers face rising competition. Biogen said on Tuesday it was looking at substantially eliminating commercial infrastructure related to Aduhelm and plans for more cost cuts, in addition to the current program to save $500 million annually. New Article Biogen (NASDAQ: BIIB) Q1 2022 Earnings Call May 03, 2022, 8:00 a.m. This includes actively planning for the phase 2 study of BIIB080, our tau ASO, and initiation of dosing in the phase 1 study of BIIB113. BIIB113 is a small molecule inhibitor of O-GlcNAcase or OGA, an enzyme believed to catalyze the removal of post-translational modification of the tau protein. New Article (RTTNews) - While reporting financial results for the first quarter on Tuesday, Biogen Inc. (BIIB) reaffirmed its adjusted earnings and revenue guidance for the full-year 2022. On average, analysts polled by Thomson Reuters expect the company to report earnings of $15.44 per share on revenues of $9.87 billion for the year. The Street expected the company to report earnings of $4.38 per share on revenues of $2.50 billion for the quarter. New Article (RTTNews) - Biogen Inc. (BIIB) will host a conference call at 8:00 AM ET on May 3, 2022, to discuss Q1 22 earnings results. To access the live webcast, log on to https://investors.biogen.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen Inc. (BIIB) came out with quarterly earnings of $3.62 per share, missing the Zacks Consensus Estimate of $4.41 per share. Biogen Inc. (BIIB): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions.",220.169677734375
2022-05-04 00:00:00+00:00,208.47000122070312,211.6199951171875,203.4100036621093,210.1000061035156,210.1000061035156,1093300.0,2.5,1.0,0.375025,"Shares of biotech company Biogen (NASDAQ:BIIB) got a significant boost last year after the U.S. FDA granted accelerated approval to its Alzheimers disease drug Aduhelm. BIIB stock has a neutral Smart Score of 4 out of 10. Meanwhile, Robert W. Baird analyst Brian Skorne views that Aduhelm is effectively dead following the CMS decision to restrict its coverage. New Article Biogen BIIB performance was, however, disappointing. Biogen Inc. (BIIB): Free Stock Analysis Report The candidate is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy manufactured using proprietary technology.",222.21910095214844
2022-05-05 00:00:00+00:00,207.6300048828125,209.38999938964844,199.58999633789065,201.17999267578125,201.17999267578125,1384800.0,3.333333333333333,1.0,0.5833583333333334,"Image Source: Zacks Investment Research Quarter in Detail Ionis has licensed Spinraza to Biogen BIIB. Biogen Inc. (BIIB): Free Stock Analysis Report The SG&A expenses decreased in the quarter due to cost efficiencies realized from integrating Akcea and restructuring commercial operations. New Article (You can read the full research report on Ford Motor here >>>) Other noteworthy reports we are featuring today include Biogen Inc. (BIIB), PPG Industries, Inc. (PPG), and Expedia Group, Inc. (EXPE). Today's Must Read Oracle (ORCL) Rides on Cloud Suite Adoption & Partnerships Free Cashflow Lifts Union Pacific (UNP), Cost Woes Linger Ford (F) Banks on EV Lineup for Growth Amid Cost Woes Featured Reports Biogen's (BIIB) Upcoming Product Launches May Revive Growth The Zacks analyst says that potential new product launches like lecanemab, zuranolone and additional biosimilars can help revive growth at Biogen, which is facing multiple challenges at present. Biogen Inc. (BIIB): Free Stock Analysis Report New Article Biogen's (NASDAQ: BIIB) biggest problem a couple of years ago was similar to that of every other biotech that's been around for a while. He will continue in his role until a replacement is found, but it will be up to the new leader to execute this plan and ensure a return to growth. The company and partner Eisai plan on submitting another Alzheimer's candidate -- lecanemab -- for regulatory approval by the first quarter of next year.",228.7445526123047
2022-05-09 00:00:00+00:00,191.0500030517578,193.9100036621093,187.1600036621093,187.5399932861328,187.5399932861328,1589700.0,4.0,1.0,0.7500249999999999,"Health Care Stocks To Buy [Or Sell] Today Moderna Inc. (NASDAQ: MRNA) Veru Inc. (NASDAQ: VERU) Biogen Inc. (NASDAQ: BIIB) Novavax Inc. (NASDAQ: NVAX) UnitedHealth Group Inc. (NYSE: UNH) Moderna Inc. If approved, MR-004 has the potential to become the first prescription digital therapeutic for gait deficit in MS. With that being said, is BIIB stock a buy? As people attempt to stay healthy amidst these trying times, investors could be considering jumping into this defensive sector in the stock market today.",221.65899658203125
2022-05-10 00:00:00+00:00,191.1999969482422,197.509994506836,190.9199981689453,195.0,195.0,1603400.0,3.0,1.0,0.5000249999999999,"On May 3, Biogen BIIB reported first-quarter 2022 earnings per share of $3.62, which lagged the Zacks Consensus Estimate of $4.41. Biogen Inc. (BIIB): Free Stock Analysis Report However, the space witnessed new investment opportunities to introduce vaccines and treatment options amid the pandemic. New Article Among large Healthcare stocks, Biogen Inc (Symbol: BIIB) and Incyte Corporation (Symbol: INCY) are the most notable, showing a gain of 4.9% and 4.2%, respectively. Combined, BIIB and INCY make up approximately 0.9% of the underlying holdings of XLV. In afternoon trading on Tuesday, Technology & Communications stocks are the best performing sector, up 1.8%.",225.1788330078125
2022-05-11 00:00:00+00:00,192.2899932861328,198.13999938964844,190.509994506836,191.07000732421875,191.07000732421875,1483500.0,2.0,1.0,0.250025,"Biogen Biogen (NASDAQ: BIIB) is another player that's faced struggles in recent times. The company also cut its annual forecast due to weakness in two key businesses: mental health and chronic care. For instance, chronic care signups are taking longer than expected because employers are dealing with the coronavirus situation and bringing employees back to offices.",225.6576690673828
2022-05-12 00:00:00+00:00,190.5599975585937,194.97999572753903,188.509994506836,194.32000732421875,194.32000732421875,1313900.0,3.0,1.0,0.5000249999999999,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $195.00 strike highlighted in red: Considering the fact that the $195.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the July 1st expiration.",224.9866180419922
2022-05-16 00:00:00+00:00,197.88999938964844,200.9199981689453,196.47000122070312,198.3800048828125,198.3800048828125,831500.0,3.0,1.0,0.5000249999999999,"Although BIIB has traded at a recent price of $199.11/share, the average analyst target is 36.20% higher at $271.18/share. Vanguard Mega Cap Value ETF MGV $101.65 $120.45 18.50% Biogen Inc BIIB $199.11 $271.18 36.20% Rocket Companies Inc RKT $8.11 $10.83 33.58% Danaher Corp DHR $249.19 $330.85 32.77% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of MGV's underlying holdings with notable upside to their analyst target prices are Biogen Inc (Symbol: BIIB), Rocket Companies Inc (Symbol: RKT), and Danaher Corp (Symbol: DHR).",218.5437774658203
2022-05-25 00:00:00+00:00,202.5399932861328,203.32000732421875,198.1000061035156,202.3600006103516,202.3600006103516,932500.0,2.0,1.0,0.250025,"We note that the Biogens BIIB Alzheimers drug, Aduhelm, has spotlighted the AD market since its controversial FDA approval in June 2021. Sales of the drug are likely to be minimal as BIIB significantly reduces commercial infrastructure. Biogen Inc. (BIIB): Free Stock Analysis Report",211.8691864013672
2022-05-26 00:00:00+00:00,202.97999572753903,205.72999572753903,202.33999633789065,204.22000122070312,204.22000122070312,532000.0,3.0,1.0,0.5000249999999999,"And that's because the company has all but thrown in the towel on Aduhelm after the Centers for Medicare and Medicaid Services refused to pay for the Alzheimer's disease drug in most cases. For example, Bristol Myers Squibb has won two important U.S. regulatory approvals for heart-failure drug Camzyos (mavacamten) and combination immunotherapy Opdualag this year. CEO Giovanni Caforio stated in Bristol Myers Squibb's Q1 conference call that he's confident the company can deliver $25 billion or more in non-risk-adjusted revenue growth by 2029.",207.47964477539062
2022-05-27 00:00:00+00:00,205.259994506836,207.3600006103516,203.1300048828125,206.1999969482422,206.1999969482422,1013300.0,3.0,1.0,0.5000249999999999,"Particularly high volume was seen for the $275 strike call option expiring July 15, 2022, with 980 contracts trading so far today, representing approximately 98,000 underlying shares of BIIB. Below is a chart showing LVS's trailing twelve month trading history, with the $35 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 7,101 contracts thus far today. That number of contracts represents approximately 710,100 underlying shares, working out to a sizeable 59.2% of BIIB's average daily trading volume over the past month, of 1.2 million shares.",216.81785583496094
2022-05-31 00:00:00+00:00,204.9600067138672,204.9600067138672,199.1499938964844,200.0,200.0,1767400.0,5.0,1.0,1.000025,"Other approved treatments include Biogens BIIB Spinraza (nusinersen) and Novartis NVS gene therapy Zolgensma Biogens Spinraza generated sales of $472.5 million in the first quarter. Biogen Inc. (BIIB): Free Stock Analysis Report The recent regulatory nod was based on the interim RAINBOWFISH data, which showed that the majority of pre-symptomatic babies treated with Evrysdi achieved key milestones, such as sitting and standing with half walking after 12 months of treatment.",211.6642608642578
2022-06-01 00:00:00+00:00,202.0,202.22000122070312,198.47000122070312,200.0,200.0,1055300.0,3.6666666666666665,1.0,0.6666916666666666,"June 1 (Reuters) - Sage Therapeutics Inc SAGE.O and Biogen's BIIB.O experimental drug showed improvement in depressive symptoms among women with postpartum depression at day 15, meeting the main goal of a late-stage study, the companies said on Wednesday. (Reporting by Amruta Khandekar; Editing by Devika Syamnath) ((Amruta.Khandekar@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Adds background, details on study June 1 (Reuters) - Sage Therapeutics Inc SAGE.O and Biogen's BIIB.O experimental drug to treat postpartum depression met the main goal of a late-stage study, the companies said on Wednesday. It also met its secondary goals, leading to improvement in symptoms as early as the third day of treatment compared with placebo. About 1 in 8 women experience symptoms of postpartum depression, according to the U.S. Centers of Disease Control and Prevention (CDC). New Article Pipeline Updates From Biogen:  Biogen BIIB and partner Denali Therapeutics announced that dosing started in the global phase IIb LUMA study to evaluate the efficacy and safety of BIIB122 (DNL151) compared to placebo in approximately 640 participants with early-stage Parkinsons disease. BIIB122 is an inhibitor of LRRK2, a potential novel target intended to impact the underlying biology and slow the progression of Parkinsons disease. The phase IIb multi-center, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of BIIB122 in people with early-stage Parkinsons disease, aged between 30 years and 80 years.",215.2447967529297
2022-06-02 00:00:00+00:00,199.3300018310547,200.22999572753903,193.8600006103516,198.509994506836,198.509994506836,1094300.0,2.5,1.0,0.375025,"It has been about a month since the last earnings report for Biogen Inc. (BIIB). Biogen Inc. (BIIB): Free Stock Analysis Report New Restructuring Initiatives Following its failure with Aduhelm, Biogen announced a set of near-term operational priorities to drive renewed growth and value creation over time. New Article It has been about a month since the last earnings report for Biogen Inc. (BIIB). Biogen Inc. (BIIB): Free Stock Analysis Report New Restructuring Initiatives Following its failure with Aduhelm, Biogen announced a set of near-term operational priorities to drive renewed growth and value creation over time. New Article In Coinbase's most recent quarter (ending March 31), that percentage fell to 25%, just a couple of points higher than Ethereum's share. Coinbase's volatility will likely scare off risk-averse investors, but if you're bullish on crypto, this is another growth stock that could be worth investing in right now. The Motley Fool has positions in and recommends Bitcoin, Coinbase Global, Inc., Ethereum, and Zoom Video Communications. New Article The drug is being developed in collaboration with Biogen Inc. BIIB. Per the terms of the agreement, both SAGE and BIIB will jointly develop and commercialize zuranolone (for MDD and PDD) as well as SAGE-324 (for essential tremor and other neurological disorders). Biogen Inc. (BIIB): Free Stock Analysis Report",199.87994384765625
2022-06-03 00:00:00+00:00,198.1000061035156,204.63999938964844,197.8500061035156,200.6199951171875,200.6199951171875,867300.0,3.0,1.0,0.5000249999999999,"(RTTNews) - Ionis Pharmaceuticals, Inc. (IONS) said its partner Biogen reported results from the phase 3 VALOR study and its open-label extension of tofersen, which is being evaluated for people with superoxide dismutase 1 amyotrophic lateral sclerosis. The data showed that earlier initiation of tofersen, compared to delayed initiation, slowed declines in clinical function, respiratory function, muscle strength and quality of life. Early survival data suggested a lower risk of death or permanent ventilation with earlier initiation of tofersen. New Article LLY Revenue (Annual) data by YCharts New top-performing drugs Trulicity and Humalog, together generating close to $9 billion in sales last year, have taken the place of Zyprexa and Cymbalta for the company. And while it isn't approved as a weight-loss treatment, the drug shows incredible potential there and could be a game-changer for Eli Lilly's future. Although the stock might not replicate the incredibly impressive returns it generated over the past 10 years, it still has the potential to continue beating the market for the foreseeable future. New Article So what The company announced on Wednesday that zuranolone, a drug it is developing with Biogen, had met its primary endpoints in a phase 3 study to treat women with postpartum depression. The drug was also found to be well tolerated and showed the same safety profile that it had in clinical development, with only mild symptoms in some women who took the daily dose of zuranolone for two weeks. According to the Centers for Disease Control and Prevention, one in eight women have symptoms of postpartum depression shortly after giving birth.",199.43881225585938
2022-06-06 00:00:00+00:00,203.5200042724609,203.5399932861328,195.7100067138672,197.1100006103516,197.1100006103516,803900.0,2.0,1.0,0.250025,"ATVI Activision Blizzard Inc. D BEN Franklin Resources, Inc. D BIIB Biogen Inc. D COF Capital One Financial Group D DLR Digital Realty Trust, Inc. D IP International Paper Company D JHX James Hardie Industries PLC D TAK Takeda Pharmaceutical Co. Ltd. D TGT Target Corporation D UI Ubiquiti Inc. D If youre looking for the best stocks to buy, then I encourage you to give my Growth Investor Buy List stocks a look. Target reported that fuel and freight costs exceeded expectations by $1 billion in the first quarter, and the company noted that higher wages and excessive inventories also weighed on results. I recently added eight new energy, fertilizer and commodity-related stocks to the Buy Lists, as they represent the sweet spot in the current environment.",201.85414123535156
2022-06-07 00:00:00+00:00,195.759994506836,201.47000122070312,195.47999572753903,201.0800018310547,201.0800018310547,791000.0,2.0,1.0,0.250025,"Biogen BIIB announced that it has entered into a license and collaboration agreement with privately-held Alectos Therapeutics to develop and commercialize the latters novel Parkinsons disease candidate, AL01811. Biogen and Denali initiated a mid-stage study to evaluate their pipeline candidate, BIIB122, in patients with early-stage Parkinsons disease. Biogen and Denalis BIIB122 targets a novel gene, LRRK2, that has the potential to impact the underlying biology and slow the progression of Parkinsons disease.",208.0294647216797
2022-06-08 00:00:00+00:00,201.0800018310547,208.4900054931641,200.0,206.72999572753903,206.72999572753903,1559000.0,3.0,1.0,0.5000249999999999,"Especially high volume was seen for the $197.50 strike call option expiring June 17, 2022, with 548 contracts trading so far today, representing approximately 54,800 underlying shares of BIIB. Below is a chart showing JBHT's trailing twelve month trading history, with the $160 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 7,044 contracts, representing approximately 704,400 underlying shares or approximately 66.2% of BIIB's average daily trading volume over the past month, of 1.1 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $197.50 strike highlighted in orange: For the various different available expirations for WDC options, JBHT options, or BIIB options, visit StockOptionsChannel.com.",205.01315307617188
2022-06-09 00:00:00+00:00,205.97999572753903,206.52999877929688,202.17999267578125,202.22000122070312,202.22000122070312,894100.0,3.333333333333333,1.0,0.5833583333333334,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $210.00 strike highlighted in red: Considering the fact that the $210.00 strike represents an approximate 3% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the July 29th expiration. New Article A lot has changed for Biogen (NASDAQ: BIIB) in just a year's time. The problem is that both revenue and profits have been trending in the wrong direction over the past few years for Biogen: BIIB Revenue (Quarterly) data by YCharts The bulk of the company's revenue comes from multiple sclerosis (MS) drugs. Biogen does have a large pipeline that features multiple trials in phase three for products that could help add revenue in the not-too-distant future. New Article Ticker Company Current Price BIIB Biogen $206.04 HRMY Harmony Biosciences $46.49 GBT Global Blood Therapeutics $24.48 CRSP CRISPR Therapeutics $74.78 EBS Emergent Biosolutions $31.64 CINC CinCor Pharma $15.21 VIGL Vigil Neuroscience $3.14 Biogen (BIIB) One of the larger biotech stocks to buy featuring a market capitalization of over $29 billion at time of writing, Biogen (NASDAQ:BIIB) specializes in neuroscience. Presumably, then, its underlying marketing machinery is better able to convince investors to acquire BIIB shares. On a year-to-date basis, BIIB has taken a bit of a slide, dipping down nearly 16%.",203.15072631835938
2022-06-15 00:00:00+00:00,196.1699981689453,199.25,193.38999938964844,197.259994506836,197.259994506836,760200.0,2.0,1.0,0.250025,"Three stocks that I'm not convinced are buys yet -- even at their reduced prices -- are Biogen (NASDAQ: BIIB), Twitter (NYSE: TWTR), and Costco Wholesale (NASDAQ: COST). A concerning trend is that both the company's operating margin and revenue have been declining over the past five years: BIIB Operating Margin (Quarterly) data by YCharts. But for a company facing losses in exclusivity, growing competition, and no catalyst to turn its business around -- besides just a pipeline that may or may not pan out -- the stock has all the makings of a value trap.",199.46414184570312
2022-06-16 00:00:00+00:00,193.32000732421875,193.88999938964844,188.5399932861328,191.52999877929688,191.52999877929688,1024900.0,2.25,1.0,0.312525,"Although BIIB has traded at a recent price of $197.26/share, the average analyst target is 30.46% higher at $257.35/share. Vanguard S&P 500 Value ETF VOOV $133.66 $168.95 26.41% Biogen Inc BIIB $197.26 $257.35 30.46% Hewlett Packard Enterprise Co HPE $14.07 $18.14 28.90% FedEx Corp FDX $232.78 $299.00 28.45% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of VOOV's underlying holdings with notable upside to their analyst target prices are Biogen Inc (Symbol: BIIB), Hewlett Packard Enterprise Co (Symbol: HPE), and FedEx Corp (Symbol: FDX). New Article Adoption of the first new Alzheimer's treatment in nearly 20 years, made by rival U.S. drugmaker Biogen Inc BIIB.O, spectacularly underwhelmed after the U.S. health regulator gave the green light to the treatment without clear evidence of patient benefit, driven in part by the lack of options for the most common form of dementia. By Natalie Grover ZURICH/LONDON, June 16 (Reuters) - Roche's experimental Alzheimer's drug crenezumab failed to meaningfully slow or prevent cognitive decline in people at risk of a rare, inherited form of the disease, the Swiss drugmaker said on Thursday. The failure marks another blow to the hypothesis that targeting toxic protein plaque known as beta amyloid in the brain is a viable approach to arresting the progression of Alzheimer's disease. New Article The FDAs approval of Biogens BIIB AD drug, Aduhelm, in 2021 put the spotlight on this field. Biogen Inc. (BIIB): Free Stock Analysis Report Roche RHHBY has announced disappointing results from a study evaluating crenezumab in autosomal dominant Alzheimers disease (AD). New Article Particularly high volume was seen for the $255 strike call option expiring October 21, 2022, with 684 contracts trading so far today, representing approximately 68,400 underlying shares of BIIB. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 4,456 contracts have traded so far, representing approximately 445,600 underlying shares. That amounts to about 44.3% of BIIB's average daily trading volume over the past month of 1.0 million shares.",195.29962158203125
2022-06-17 00:00:00+00:00,192.1100006103516,204.259994506836,192.1100006103516,201.7400054931641,201.7400054931641,1884700.0,3.0,1.0,0.5000249999999999,"Roche/AC Immunes Alzheimer candidates failure hurt the share price of Eli Lilly LLY and Biogen BIIB. Biogen Inc. (BIIB): Free Stock Analysis Report On Thursday, Roche RHHBY and partner AC Immune ACIU announced data from an Alzheimers disease study on pipeline candidate, crenezumab, which showed that the treatment did not demonstrate a statistically significant clinical benefit.",194.7696075439453
2022-06-23 00:00:00+00:00,207.72999572753903,211.9100036621093,207.6999969482422,211.3800048828125,211.3800048828125,864000.0,3.0,1.0,0.5000249999999999,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $210.00 strike highlighted in red: Considering the fact that the $210.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the August 5th expiration.",196.10183715820312
2022-06-27 00:00:00+00:00,210.32000732421875,213.67999267578125,208.1300048828125,213.57000732421875,213.57000732421875,972600.0,3.0,1.0,0.5000249999999999,"With that information, here are seven biotech stocks to buy in July: BIIB Biogen $211.93 BNTX BioNTech $134.04 GILD Gilead Sciences $63.08 HALO Halozyme Therapeutics $46.90 MRNA Moderna $144.27 UTHR United Therapeutics  $238.95 Biogen (BIIB) Source: PictureDesignSwiss / Shutterstock.com 52-week range: $187.16  $396.89 Biogen (NASDAQ:BIIB) specializes in neuroscience, specifically multiple sclerosis (MS), spinal muscular atrophy (SPA), and Alzheimers. BIIB stock has fallen around 13% YTD. New Article Particularly high volume was seen for the $220 strike call option expiring July 01, 2022, with 641 contracts trading so far today, representing approximately 64,100 underlying shares of BIIB. Below is a chart showing UPST's trailing twelve month trading history, with the $40 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 4,834 contracts thus far today. That number of contracts represents approximately 483,400 underlying shares, working out to a sizeable 42% of BIIB's average daily trading volume over the past month, of 1.2 million shares.",187.5616455078125
2022-06-29 00:00:00+00:00,202.07000732421875,205.9199981689453,199.8699951171875,205.22999572753903,205.22999572753903,1260100.0,3.0,1.0,0.5000249999999999,"Biogen (NASDAQ: BIIB) Biogen is a biotech company focused on developing therapies for neurological diseases and related therapeutic adjacencies. Lecanemab's success is key to BIIB's growth. Nadeau reiterated a Buy rating with a price target of $285. Risinger expects Gileads HIV franchise to deliver modest sales growth over the near-term, and looks forward to oncology data readouts ahead to assess the company's diversification initiatives and pipeline prospects.",186.2953643798828
2022-07-05 00:00:00+00:00,208.97999572753903,212.72999572753903,206.77999877929688,212.5800018310547,212.5800018310547,897900.0,3.333333333333333,1.0,0.5833583333333334,"Ticker Company Price ILMN Ilumina $190.75 BIIB Biogen $211.07 IQV Iqvia Holdings $212.57 Biotech Stocks: Ilumina (ILMN) Source: The thinkorswim platform from TD Ameritrade Drawdown Depth: -66% Illumina (NASDAQ:ILMN) provides sequencing and array-based solutions for genetic and genomic analysis. Biogen (BIIB) Source: The thinkorswim platform from TD Ameritrade Drawdown Depth: -56% Cambridge-based Biogen (NASDAQ:BIIB) is a global biopharmaceutical giant that boasts a market cap near $30 billion. That alone makes BIIB stock one of the hardest biotech stocks to buy and thus one of the easier ones to sell. New Article By Deena Beasley July 5 (Reuters) - The U.S. Food and Drug Administration will expedite its review of Eisai Co Ltd's 4523.T and Biogen Inc's BIIB.O experimental Alzheimer's drug lecanemab, with a decision due by Jan 6, 2023, the companies said on Tuesday. Lecanemab, like the partners' previous drug Aduhelm, is an antibody designed to remove sticky deposits of a protein called amyloid beta from the brains of people with early Alzheimers, a disease that leads to memory loss and the inability to care for oneself. But Medicare, the U.S. government health plan for people over age 65, this year said it would only pay for Aduhelm if patients were enrolled in a valid clinical trial, serving to sharply curtail the medication's use. New Article By Deena Beasley July 5 (Reuters) - The U.S. Food and Drug Administration will expedite its review of Eisai Co Ltd's 4523.T and Biogen Inc's BIIB.O experimental Alzheimer's drug lecanemab, with a decision due by Jan 6, 2023, the companies said on Tuesday. Lecanemab, like the partners' previous drug Aduhelm, is an antibody designed to remove sticky deposits of a protein called amyloid beta from the brains of people with early Alzheimers, a disease that leads to memory loss and the inability to care for oneself. But Medicare, the U.S. government health plan for people over age 65, this year said it would only pay for Aduhelm if patients were enrolled in a valid clinical trial, serving to sharply curtail the medication's use.",185.0204315185547
2022-07-06 00:00:00+00:00,213.1100006103516,216.8000030517578,211.1699981689453,215.97999572753903,215.97999572753903,969400.0,4.0,1.0,0.7500249999999999,"Biogen BIIB, along with partner Eisai, announced that the FDA has accepted their biologics license application (BLA) seeking accelerated approval for its anti-amyloid beta protofibril antibody candidate lecanemab (BAN2401) to treat early Alzheimers disease (AD). Biogen Inc. (BIIB): Free Stock Analysis Report LLY's phase II study, TRAILBLAZER-ALZ, investigated the efficacy and safety of donanemab in patients with early, symptomatic AD. New Article Shares of biotech giant Biogen (NASDAQ: BIIB) have dropped by 40% in the past year, easily underperforming the broader market over this period. BIIB data by YCharts Is Aduhelm a flop? According to this plan, the CMS will only cover Aduhelm for AD patients with mild cognitive impairment who are enrolled in CMS-approved clinical trials. New Article Especially high volume was seen for the $170 strike put option expiring January 20, 2023, with 617 contracts trading so far today, representing approximately 61,700 underlying shares of BIIB. Below is a chart showing PYPL's trailing twelve month trading history, with the $250 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 5,967 contracts thus far today. That number of contracts represents approximately 596,700 underlying shares, working out to a sizeable 50.8% of BIIB's average daily trading volume over the past month, of 1.2 million shares.",199.3778076171875
2022-07-08 00:00:00+00:00,216.3800048828125,220.7899932861328,215.8999938964844,218.8000030517578,218.8000030517578,918900.0,4.0,1.0,0.7500249999999999,"The phase III RESILIENT study, which expects to enroll 180 patients, will evaluate the safety and efficacy of taldefgrobep as an adjunctive therapy in patients already on a stable dose of Biogens BIIB Spinraza (nusinersen) or Roches Evrysdi (risdiplam) or with a history of treatment with onasemnogene abeparvovec-xioi in comparison to placebo. Biogen Inc. (BIIB): Free Stock Analysis Report Biohaven Pharma BHVN announced the initiation of enrollment in a phase III study to assess the safety and efficacy of taldefgrobep alfa in patients with spinal muscle atrophy (SMA).",219.59803771972656
2022-07-11 00:00:00+00:00,217.5599975585937,218.0,214.5200042724609,215.259994506836,215.259994506836,609700.0,4.0,1.0,0.7500249999999999,"The company made headlines during the earlier stages of the coronavirus pandemic as it won authorization for a monoclonal antibody treatment. The idea is they issue more stock to current investors in order to lower the price of each individual share. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.",219.92422485351562
2022-07-13 00:00:00+00:00,211.9199981689453,216.3500061035156,211.9199981689453,214.52999877929688,214.52999877929688,635100.0,2.0,1.0,0.250025,"The market expects Biogen Inc. (BIIB) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2022. Biogen Inc. (BIIB): Free Stock Analysis Report This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.",216.04592895507812
2022-07-15 00:00:00+00:00,215.3699951171875,217.3600006103516,213.75,217.009994506836,217.009994506836,732100.0,4.0,1.0,0.7500249999999999,Biogen BIIB has an Earnings ESP of +4.41% and a Zacks Rank #3. BIIB is scheduled to release its second-quarter 2022 results on Jul 20. Biogen Inc. (BIIB): Free Stock Analysis Report,216.0093536376953
2022-07-18 00:00:00+00:00,217.57000732421875,218.7899932861328,213.0500030517578,214.33999633789065,214.33999633789065,1056100.0,3.0,1.0,0.5000249999999999,"Especially high volume was seen for the $220 strike call option expiring August 19, 2022, with 1,380 contracts trading so far today, representing approximately 138,000 underlying shares of BIIB. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Biogen Inc (Symbol: BIIB), where a total volume of 5,567 contracts has been traded thus far today, a contract volume which is representative of approximately 556,700 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 50.2% of BIIB's average daily trading volume over the past month, of 1.1 million shares.",219.0710906982422
2022-07-19 00:00:00+00:00,217.7400054931641,222.1999969482422,216.27999877929688,220.259994506836,220.259994506836,1075200.0,4.0,1.0,0.7500249999999999,"Biogen Inc. (BIIB)is reporting for the quarter ending June 30, 2022. BIIB missed the consensus earnings per share in the 1st calendar quarter of 2022 by -17.91%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for BIIB is 13.78 vs. an industry ratio of -0.70, implying that they will have a higher earnings growth than their competitors in the same industry. New Article Biogen Inc. (BIIB)is reporting for the quarter ending June 30, 2022. BIIB missed the consensus earnings per share in the 1st calendar quarter of 2022 by -17.91%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for BIIB is 13.78 vs. an industry ratio of -0.70, implying that they will have a higher earnings growth than their competitors in the same industry.",240.3059844970703
2022-07-20 00:00:00+00:00,217.0,220.6999969482422,204.6699981689453,207.4900054931641,207.4900054931641,1991500.0,2.727272727272727,1.0,0.4318431818181816,"Adds details on forecast, background July 20 (Reuters) - Biogen Inc BIIB.O on Wednesday posted second-quarter profit that more than doubled, driven by a roughly $1.5-billion gain from the sale of its equity stake in the Samsung Bioepis Joint Venture. The drugmaker also raised its annual profit forecast to $15.25 to $16.75 per share from $14.25 to $16.00 previously. (Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Combined, ELV and BIIB make up approximately 3.0% of the underlying holdings of XLV. Among large Healthcare stocks, Elevance Health Inc (Symbol: ELV) and Biogen Inc (Symbol: BIIB) are the most notable, showing a loss of 8.8% and 6.9%, respectively. Comparing these stocks and ETFs on a trailing twelve month basis, below is a relative stock price performance chart, with each of the symbols shown in a different color as labeled in the legend at the bottom: Here's a snapshot of how the S&P 500 components within the various sectors are faring in afternoon trading on Wednesday. New Article Shares of Biogen (NASDAQ: BIIB) have tanked 9.1% this year following the biotechnology companys failed bet on its Alzheimers disease drug, Aduhelm. Skorney expects BIIB to generate revenues of $2.54 billion versus Street estimates of $2.48 billion in Q2. The company stated that according to the National Coverage Decision (NCD) from the Centers for Medicare and Medicaid Services (CMS), patients with Medicare will be reimbursed only if they are a part of an approved clinical trial. BIIB stated that this decision was likely to reduce future demand for ADUHELM to a minimal level. As a result, in Q1, the company wrote off around $275 million of inventory related to Aduhelm. New Article (RTTNews) - Biogen Inc. (BIIB) will host a conference call at 8:00 AM ET on July 20, 2022, to discuss Q2 22 earnings results. To access the live webcast, log on to https://investors.biogen.com/events-and-presentations/upcoming-events The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article July 20 (Reuters) - Biogen Inc's BIIB.O second-quarter profit more than doubled on Wednesday, driven by a roughly $1.5-billion gain from the sale of its equity stake in the Samsung Bioepis Joint Venture. (Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Given the consistent lack of efficacy observed across the primary and secondary measures of cognition and functioning, while demonstrating expected drug exposure levels during the entire 12-week evaluation period, we have decided to discontinue the BIIB104 program in CIAS. Biogen (NASDAQ: BIIB) Q2 2022 Earnings Call Jul 20, 2022, 8:00 a.m. And we were disappointed to learn that the BIIB104 phase 2 study in schizophrenia was not positive. New Article Biogen Inc. (BIIB) came out with quarterly earnings of $5.25 per share, beating the Zacks Consensus Estimate of $4.09 per share. Biogen Inc. (BIIB): Free Stock Analysis Report Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. New Article Earnings this morning from top companies such as Biogen (NASDAQ: BIIB), Abbott Laboratries (NYSE: ABT) and ASML Holding N.V. (NASDAQ: ASML) reported early morning Wednesday, while investors anxiously await Tesla, Inc. (NASDAQ: TSLA) will report after the market closes today. Shares of BIIB stock moved lower in Wednedays trading session. Stock Market Today Mid-Morning Updates On Wednesday morning, the Dow Jones Industrial Average recovered by 72 points as of 11:12 am EST. New Article Biogen (BIIB) fell 5.8% following its earnings report. In the second quarter, BIIB saw revenue fall 7% year-over-year to $2.6 billion as sales of the company's spinal muscular atrophy (SMA) drug Spinraza declined 14% amid increased competition. Still, total revenue beat analysts' consensus estimate, as did BIIB's earnings of $5.25 per share. New Article Biogen BIIB reported second-quarter 2022 earnings per share (EPS) of $5.25, which significantly beat the Zacks Consensus Estimate of $4.10. Biogen Inc. (BIIB): Free Stock Analysis Report In April 2022, The Centers for Medicare & Medicaid Services (CMS) released its final National Coverage Determination (NCD) decision for the class of anti-amyloid antibodies approved by the FDA like Aduhelm. New Article In early trading on Wednesday, shares of Datadog topped the list of the day's best performing components of the Nasdaq 100 index, trading up 5.8%. And the worst performing Nasdaq 100 component thus far on the day is Pinduoduo, trading down 3.3%. VIDEO: Nasdaq 100 Movers: PDD, DDOG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",246.61282348632812
2022-07-21 00:00:00+00:00,208.2700042724609,214.67999267578125,207.94000244140625,214.0599975585937,214.0599975585937,1136800.0,4.0,1.0,0.7500249999999999,"Other than Novartis, Ionis has partnerships with many drug giants like AstraZeneca AZN and Biogen BIIB. While BIIB is responsible for commercializing Spinraza worldwide, Ionis receives royalties from Biogen on Spinrazas sales. Biogen Inc. (BIIB): Free Stock Analysis Report",251.6687774658203
2022-07-25 00:00:00+00:00,205.9900054931641,207.9600067138672,204.17999267578125,207.57000732421875,207.57000732421875,776900.0,3.5,1.0,0.6250249999999999,"Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Biogen Inc. (BIIB) and Illumina (ILMN). BIIB currently has a forward P/E ratio of 13.07, while ILMN has a forward P/E of 49.31. We also note that BIIB has a PEG ratio of 0.98. New Article Biogen Inc. (BIIB) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). Biogen Inc. (BIIB): Free Stock Analysis Report Therefore, the Zacks rating upgrade for Biogen Inc. basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.",249.2024383544922
2022-07-26 00:00:00+00:00,206.6999969482422,214.02000427246088,206.6999969482422,210.8500061035156,210.8500061035156,916200.0,3.6,1.0,0.6500250000000001,"Adds details on FDA review, background July 26 (Reuters) - The U.S. Food and Drug Administration has agreed to review Biogen Inc's BIIB.O experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS), after the therapy failed a late-stage study but showed promise in some patients. The drug, tofersen, in October failed to produce a statistically significant change in functional status for patients with fast-progressing ALS compared to placebo after 28 weeks of treatment. In June, the company said data from a follow-on study suggested that early administration of tofersen can benefit people living with ALS who have a genetic mutation called SOD1. New Article Especially high volume was seen for the $220 strike call option expiring August 19, 2022, with 361 contracts trading so far today, representing approximately 36,100 underlying shares of BIIB. Below is a chart showing FIVE's trailing twelve month trading history, with the $75 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 5,919 contracts, representing approximately 591,900 underlying shares or approximately 59% of BIIB's average daily trading volume over the past month, of 1.0 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $220 strike highlighted in orange: And Spotify Technology SA (Symbol: SPOT) options are showing a volume of 10,625 contracts thus far today. New Article Biogen BIIB beat on sales and earnings in the second quarter and the company upped its financial guidance. Biogen Inc. (BIIB): Free Stock Analysis Report Novartis reported mixed results as earnings beat estimates but sales missed the mark. New Article Looking at individual holdings, Catalent Inc (CTLT) accounts for about 5.31% of total assets, followed by Vertex Pharmaceuticals Inc (VRTX) and Biogen Inc (BIIB). Biogen Inc. (BIIB): Free Stock Analysis Report However, some investors believe in the possibility of beating the market through exceptional stock selection, and choose a different type of fund that tracks non-cap weighted strategies: smart beta. New Article July 26 (Reuters) - U.S. Food and Drug Administration granted priority review to Biogen Inc's BIIB.O experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS), the drugmaker said on Tuesday. Biogen licensed the treatment, tofersen, from Ionis Pharmaceuticals Inc IONS.O. (Reporting by Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli) ((mrinalika.roy@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",240.0818634033203
2022-07-27 00:00:00+00:00,209.6499938964844,213.6699981689453,209.6499938964844,212.9199981689453,212.9199981689453,848800.0,3.0,1.0,0.5000249999999999,Biogens Q2 Earnings: Biogen BIIB beat on both sales and earnings in the second quarter. Biogen Inc. (BIIB): Free Stock Analysis Report Gileads wholly owned company Kite announced that the CHMP has issued a positive opinion for Chimeric Antigen Receptor (CAR) T-cell therapy Tecartus (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and above with relapsed or refractory (r/r) B-cell precursor acute lymphoblastic leukemia (ALL).,243.02865600585938
2022-07-28 00:00:00+00:00,212.3600006103516,215.22000122070312,208.72999572753903,214.1999969482422,214.1999969482422,852600.0,5.0,1.0,1.000025,"It was found that in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate, BIIB800 had equivalent efficacy and comparable safety and immunogenicity to tocilizumab. I am bullish on Biogen (BIIB) stock. In early June, Biogen and Bio-Thera Solutions presented positive Phase 3 data for investigational biosimilar candidate BIIB800.",234.46157836914062
2022-07-29 00:00:00+00:00,212.509994506836,216.69000244140625,211.58999633789065,215.0599975585937,215.0599975585937,1152000.0,4.0,1.0,0.7500249999999999,"International sales were affected by the launch of several direct biosimilar drugs in Europe by other pharma companies, including Amgen AMGN, Sandoz and Biogen BIIB. Biogen Inc. (BIIB): Free Stock Analysis Report In fact, Amgen, Biogen, Boehringer Ingelheim, Pfizer, Sandoz and many other companies also received FDA approvals for a Humira-biosimilar but commercialization is expected to start after the loss of exclusivity for Humira in the United States in 2023.",238.39718627929688
2022-08-03 00:00:00+00:00,210.0,217.02999877929688,210.0,213.6000061035156,213.6000061035156,1005500.0,3.0,1.0,0.5000249999999999,"Looking at individual holdings, Kellogg Co (K) accounts for about 3.01% of total assets, followed by Gilead Sciences Inc (GILD) and Biogen Inc (BIIB). Biogen Inc. (BIIB): Free Stock Analysis Report It has amassed assets over $6.67 billion, making it one of the largest ETFs attempting to match the Large Cap Blend segment of the US equity market.",242.9019775390625
2022-08-04 00:00:00+00:00,214.7400054931641,218.8600006103516,214.7400054931641,217.3000030517578,217.3000030517578,991200.0,2.0,1.0,0.250025,"Looking at individual holdings, Kellogg Co (K) accounts for about 3.01% of total assets, followed by Gilead Sciences Inc (GILD) and Biogen Inc (BIIB). Biogen Inc. (BIIB): Free Stock Analysis Report On the other hand, some investors who believe that it is possible to beat the market by superior stock selection opt to invest in another class of funds that track non-cap weighted strategies--popularly known as smart beta.",238.3601531982422
2022-08-05 00:00:00+00:00,215.8300018310547,219.07000732421875,215.0599975585937,218.1999969482422,218.1999969482422,670500.0,2.0,1.0,0.250025,"Particularly high volume was seen for the $260 strike call option expiring October 21, 2022, with 620 contracts trading so far today, representing approximately 62,000 underlying shares of BIIB. Below is a chart showing PAYC's trailing twelve month trading history, with the $390 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 5,301 contracts, representing approximately 530,100 underlying shares or approximately 55.9% of BIIB's average daily trading volume over the past month, of 948,745 shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $260 strike highlighted in orange: For the various different available expirations for LLY options, PAYC options, or BIIB options, visit StockOptionsChannel.com.",238.5955352783203
2022-08-08 00:00:00+00:00,216.7899932861328,222.22000122070312,215.3800048828125,217.5599975585937,217.5599975585937,932100.0,3.0,1.0,0.5000249999999999,"In trading on Monday, shares of Biogen Inc (Symbol: BIIB) crossed above their 200 day moving average of $221.49, changing hands as high as $222.22 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $187.16 per share, with $351.86 as the 52 week high point  that compares with a last trade of $220.00. The BIIB DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other stocks recently crossed above their 200 day moving average  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",256.0841369628906
2022-08-09 00:00:00+00:00,216.33999633789065,218.6000061035156,214.2899932861328,217.58999633789065,217.58999633789065,564900.0,3.0,1.0,0.5000249999999999,"In May 2022, Denali and Biogen announced that dosing had commenced in the global phase IIb LUMA study to evaluate the efficacy and safety of BIIB122 compared to placebo in 640 participants with early-stage PD. Denali Therapeutics Inc. Price, Consensus and EPS Surprise Denali Therapeutics Inc. price-consensus-eps-surprise-chart | Denali Therapeutics Inc. Quote Recent Updates Denali has collaborated with Biogen BIIB to advance its LRRK2 inhibitor program to address Parkinsons disease (PD). Biogen Inc. (BIIB): Free Stock Analysis Report",256.0155029296875
2022-08-10 00:00:00+00:00,220.6000061035156,221.6199951171875,216.97999572753903,221.0399932861328,221.0399932861328,925500.0,4.0,1.0,0.7500249999999999,"Image Source: Zacks Investment Research Quarter in Detail Ionis has licensed Spinraza to Biogen BIIB. Biogen Inc. (BIIB): Free Stock Analysis Report Pipeline Update Ionis has phase III studies ongoing for six medicines (internal as well as partnered) across eight indications, which include tofersen for SOD1-ALS (amyotrophic lateral sclerosis); pelacarsen for cardiovascular disease due to elevated Lp(a) levels; olezarsen for familial chylomicronemia syndrome, or FCS and severe hypertriglyceridemia, eplontersen for TTR amyloidosis, ION363 for amyotrophic lateral sclerosis, or ALS, with mutations in the fused in sarcoma gene, or FUS (FUS-ALS) and donidalorsen for hereditary angioedema or HAE.",267.0696716308594
2022-08-15 00:00:00+00:00,220.9900054931641,222.5,217.9600067138672,222.3800048828125,222.3800048828125,669900.0,3.0,1.0,0.5000249999999999,"If the data from this study is positive, it will become easier to meet the high level of evidence criteria set forth by The Centers for Medicare & Medicaid Services (CMS) in the final National Coverage Determination (NCD) decision released in April for the class of anti-amyloid antibodies approved by the FDA like Biogens BIIB Aduhelm. Biogen Inc. (BIIB): Free Stock Analysis Report Other two important candidates for which Lilly has filed regulatory application seeking accelerated approval from the FDA are donanemab and pirtobrutinib, in Alzheimer's disease and mantle cell lymphoma indications, respectively.",266.5419921875
2022-08-18 00:00:00+00:00,216.94000244140625,216.97999572753903,214.3300018310547,216.33999633789065,216.33999633789065,514500.0,4.0,1.0,0.7500249999999999,"In late July, Biogen BIIB reported second-quarter 2022 earnings per share (EPS) of $5.25, which significantly beat the Zacks Consensus Estimate of $4.10. Biogen Inc. (BIIB): Free Stock Analysis Report Biotech stocks were huge beneficiaries of the pandemic as many of these companies were developing new vaccines and treatments for Covid-19, leading to a surge in IPOs and venture capital investments.",274.0936584472656
2022-08-19 00:00:00+00:00,215.7899932861328,216.6100006103516,212.4600067138672,214.08999633789065,214.08999633789065,623400.0,3.333333333333333,1.0,0.5833583333333334,"Biogen announced that the phase II TALLLY study on BIIB104 for cognitive impairment associated with schizophrenia (CIAS) did not meet its primary or secondary efficacy endpoints. Biogen decided to discontinue the development of BIIB104 for CIAS, following consistent lack of efficacy observed across the primary and secondary measures of cognition and functioning. It has been about a month since the last earnings report for Biogen Inc. (BIIB). New Article As with many other companies Biogen Inc. (NASDAQ:BIIB) makes use of debt. NasdaqGS:BIIB Debt to Equity History August 19th 2022 How Healthy Is Biogen's Balance Sheet? Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' New Article What happened Shares of the commercial-stage healthcare company Axsome Therapeutics (NASDAQ: AXSM) were up by a handsome 31.4%, on heavy volume, as of 9:53 a.m. The drug's review took longer than expected due to issues with the analytical methods in the Chemistry, Manufacturing, and Controls section of its regulatory application. That being said, Axsome's brain trust will probably want an astronomical premium, relative to its current valuation, in a buyout scenario.",260.8935241699219
2022-08-22 00:00:00+00:00,212.25,212.82000732421875,207.1999969482422,207.6999969482422,207.6999969482422,760600.0,3.0,1.0,0.5000249999999999,"Particularly high volume was seen for the $225 strike call option expiring August 26, 2022, with 238 contracts trading so far today, representing approximately 23,800 underlying shares of BIIB. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Biogen Inc (Symbol: BIIB), where a total volume of 3,649 contracts has been traded thus far today, a contract volume which is representative of approximately 364,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 46.3% of BIIB's average daily trading volume over the past month, of 788,105 shares.",252.87413024902344
2022-08-25 00:00:00+00:00,202.4900054931641,205.0599975585937,200.69000244140625,204.8300018310547,204.8300018310547,673200.0,3.5,1.0,0.6250249999999999,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $210.00 strike highlighted in red: Considering the fact that the $210.00 strike represents an approximate 4% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the October 7th expiration. New Article Biogen Inc. (BIIB) closed the most recent trading day at $204.83, moving +1.51% from the previous trading session. BIIB's full-year Zacks Consensus Estimates are calling for earnings of $16.36 per share and revenue of $9.99 billion. We can also see that BIIB currently has a PEG ratio of 0.92.",260.8680419921875
2022-08-30 00:00:00+00:00,196.6000061035156,197.77999877929688,195.1699981689453,196.0800018310547,196.0800018310547,623000.0,3.0,1.0,0.5000249999999999,"Particularly high volume was seen for the $185 strike put option expiring September 09, 2022, with 387 contracts trading so far today, representing approximately 38,700 underlying shares of BIIB. Below is a chart showing ISRG's trailing twelve month trading history, with the $235 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 3,486 contracts thus far today. That number of contracts represents approximately 348,600 underlying shares, working out to a sizeable 47.9% of BIIB's average daily trading volume over the past month, of 727,815 shares.",255.1383819580078
2022-08-31 00:00:00+00:00,197.88999938964844,198.4900054931641,193.6499938964844,195.3800048828125,195.3800048828125,871300.0,3.0,1.0,0.5000249999999999,"Biogen Inc. (BIIB) closed the most recent trading day at $195.38, moving -0.36% from the previous trading session. BIIB's full-year Zacks Consensus Estimates are calling for earnings of $16.36 per share and revenue of $9.99 billion. Meanwhile, BIIB's PEG ratio is currently 0.9.",260.6059875488281
2022-09-07 00:00:00+00:00,195.4199981689453,201.25,194.4499969482422,200.6699981689453,200.6699981689453,766200.0,2.0,1.0,0.250025,"Especially high volume was seen for the $170 strike put option expiring October 21, 2022, with 382 contracts trading so far today, representing approximately 38,200 underlying shares of BIIB. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 4,458 contracts have traded so far, representing approximately 445,800 underlying shares. That amounts to about 62.7% of BIIB's average daily trading volume over the past month of 710,500 shares.",269.9764709472656
2022-09-08 00:00:00+00:00,201.1600036621093,208.0500030517578,201.1600036621093,207.97999572753903,207.97999572753903,1039100.0,3.0,1.0,0.5000249999999999,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $210.00 strike highlighted in red: Considering the fact that the $210.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the October 28th expiration.",268.7935791015625
2022-09-09 00:00:00+00:00,208.38999938964844,212.9199981689453,208.08999633789065,211.83999633789065,211.83999633789065,1053000.0,5.0,1.0,1.000025,"One other stock in the same industry, Biogen Inc. (BIIB), finished the last trading session 3.6% higher at $207.98. BIIB has returned -9.2% over the past month. Biogen Inc. (BIIB): Free Stock Analysis Report",268.11224365234375
2022-09-12 00:00:00+00:00,212.1000061035156,216.1699981689453,211.0800018310547,212.8800048828125,212.8800048828125,955400.0,3.0,1.0,0.5000249999999999,"In trading on Monday, shares of Biogen Inc (Symbol: BIIB) crossed above their 200 day moving average of $214.38, changing hands as high as $216.17 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $187.16 per share, with $306.46 as the 52 week high point  that compares with a last trade of $214.32. Click here to find out which 9 other stocks recently crossed above their 200 day moving average  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",278.70489501953125
2022-09-13 00:00:00+00:00,208.8999938964844,209.97000122070312,203.2899932861328,203.9100036621093,203.9100036621093,1064000.0,3.0,1.0,0.5000249999999999,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $260.00 strike highlighted in red: Considering the fact that the $260.00 strike represents an approximate 27% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading this week, for the January 2025 expiration.",264.6138000488281
2022-09-14 00:00:00+00:00,204.8999938964844,205.07000732421875,200.75,204.1100006103516,204.1100006103516,840800.0,3.0,1.0,0.5000249999999999,"Especially high volume was seen for the $285 strike call option expiring October 21, 2022, with 946 contracts trading so far today, representing approximately 94,600 underlying shares of BIIB. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 8,868 contracts have traded so far, representing approximately 886,800 underlying shares. That amounts to about 114.4% of BIIB's average daily trading volume over the past month of 775,280 shares. New Article Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $205.00 strike highlighted in red: Considering the fact that the $205.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the June 2023 expiration.",267.3739929199219
2022-09-21 00:00:00+00:00,205.52999877929688,209.25,199.3000030517578,199.33999633789065,199.33999633789065,1068500.0,4.0,1.0,0.7500249999999999,"By Mrinalika Roy Sept 21 (Reuters) - Longer-term use and early initiation of Biogen Inc's BIIB.O experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) was effective in slowing disease progression, according to a new analysis by the company published on Wednesday. ALS, also known as Lou Gehrig's disease, breaks down nerve cells in the brain and spinal cord that make muscles work, leading to progressive paralysis and death. Biogen last October had said the drug missed the main goal of the late-stage study, failing to show statistically significant improvement in the functional status of patients with fast-progressing ALS at six months.",268.546630859375
2022-09-23 00:00:00+00:00,200.27999877929688,200.6199951171875,194.4499969482422,197.77999877929688,197.77999877929688,1443600.0,4.0,1.0,0.7500249999999999,"Apart from AstraZeneca, Ionis has collaboration deals with other pharma giants including Biogen BIIB and Novartis NVS. BIIB is responsible for commercializing Spinraza which is approved for treating spinal muscular atrophy worldwide. Biogen Inc. (BIIB): Free Stock Analysis Report",269.7096252441406
2022-09-26 00:00:00+00:00,197.44000244140625,199.8099975585937,194.6300048828125,195.75,195.75,1021400.0,2.0,1.0,0.250025,"By Nate Raymond BOSTON, Sept 26 (Reuters) - Biogen Inc BIIB.O has finalized a $900 million settlement resolving a whistleblower lawsuit accusing the biotech company of paying doctors kickbacks to prescribe multiple sclerosis drugs, the U.S. Department of Justice said on Monday. The lawsuit accused Biogen of directing millions of dollars in kickbacks to doctors to prescribe its MS drugs Avonex, Tysabri and Tecfidera from 2009 to 2014. His lawyer, Thomas Greene, has called the settlement the largest recovery in over 150 years of False Claims Act cases to be secured by a whistleblower without the intervention or participation of the government.",263.0820007324219
2022-09-27 00:00:00+00:00,197.0200042724609,200.9499969482422,195.5,197.7899932861328,197.7899932861328,849100.0,3.6,1.0,0.6500250000000001,"Biogen (NASDAQ:BIIB) agreed to pay $900 million to resolve claims that it paid kickbacks to doctors for prescribing its drugs over competitors. With back-to-back setbacks, its prudent to ask whether BIIB is a good investment. TipRanks data shows that Wall Street analysts remain sidelined on BIIB stock. New Article NasdaqGS:BIIB Earnings and Revenue Growth September 27th 2022 Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. If you want to know who really controls Biogen Inc. (NASDAQ:BIIB), then you'll have to look at the makeup of its share registry. NasdaqGS:BIIB Ownership Breakdown September 27th 2022 What Does The Institutional Ownership Tell Us About Biogen? New Article By Deena Beasley and Julie Steenhuysen Sept 27 (Reuters) - An experimental Alzheimer's drug developed by Eisai Co Ltd 4523.T and Biogen Inc BIIB.O significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, the companies said on Tuesday. Eisai said the results from the 1,800-patient trial prove the longstanding theory that removal of sticky deposits of a protein called amyloid beta from the brains of people with early Alzheimer's can delay advance of the debilitating disease. The so-called amyloid hypothesis has been challenged by some scientists, particularly after the U.S. Food and Drug Administration's controversial approval of Aduhelm in 2021 based on its plaque-clearing ability rather than proof that it helped slow cognitive decline. New Article By Deena Beasley and Julie Steenhuysen Sept 27 (Reuters) - An experimental Alzheimer's drug developed by Eisai Co Ltd 4523.T and Biogen Inc BIIB.O significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, the companies said on Tuesday. The injected drug, lecanemab, slowed progress of the brain-wasting disease by 27% compared to a placebo, meeting the study's main goal, and offering an apparent win for the companies and potentially for patients and their families desperate for an effective treatment. Eisai said the results from the 1,800-patient trial prove the longstanding theory that removal of sticky deposits of a protein called amyloid beta from the brains of people with early Alzheimer's can delay advance of the debilitating disease. New Article (RTTNews) - Biogen Inc. (BIIB) and Eisai Co., Ltd.'s investigational Alzheimer's disease drug lecanemab could potentially slow the progression of the disease in a large global Phase 3 clinical trial, the companies said in a statement. Lecanemab treatment met the primary endpoint and reduced clinical decline on the global cognitive and functional scale, CDR-SB, compared with placebo at 18 months by 27%, which represents a treatment difference in the score change of -0.45 in the analysis of Intent-to-treat population. Starting as early as six months, across all time points, the treatment showed highly statistically significant changes in CDR-SB from baseline compared to placebo.",260.48748779296875
2022-09-28 00:00:00+00:00,282.9599914550781,283.44000244140625,265.0199890136719,276.6099853515625,276.6099853515625,16232000.0,4.0,1.0,0.750025,"Biotech stocks have been among those hit hardest by the bear market in 2022, but Biogen (NASDAQ: BIIB) announced good news in a key clinical trial that has huge implications for those suffering from a harsh and debilitating disease. Investors on Wall Street continued to have doubts about when the stock market is likely to recover, as ongoing worries about inflation, interest rates, and the global financial system have everyone on edge. The news validates the strategic shift that Biogen made after its Aduhelm Alzheimer's treatment sparked controversy about its effectiveness in fighting the disease and called into question its entire program. New Article Bucking the overall slide, Biogen BIIB.O surged 50.4% after its Alzheimer's drug, developed with Japanese partner Eisai 4523.T, succeeded in slowing cognitive decline. By Shreyashi Sanyal Sept 28 (Reuters) - The Dow and S&P 500 were set to open higher on Wednesday as easing Treasury yields gently lifted rate-sensitive growth stocks, but the gains were capped by losses in Apple Inc after it dropped plans to boost iPhone production. Meanwhile, shares of the world's most valuable public company AAPL.O fell 2.3% in premarket trading after Bloomberg reported that Apple told suppliers to curtail efforts to increase assembly of its iPhone 14 products by as many as 6 million units in the second half of this year. New Article Biogen (BIIB) was gaining more than 49% in value after the company and Eisai said lecanemab, an investigational Alzheimer's disease treatment, met its primary endpoint and all key secondary endpoints in a phase 3 trial. The Health Care SPDR (XLV) was up more than 1% and the iShares Biotechnology Index (IBB) was recently climbing past 3%. Ocugen (OCGN) was rallying past 13% after saying it has entered into an exclusive license agreement with Washington University in Missouri for the rights to develop, manufacture and commercialize its intranasally delivered COVID-19 vaccine in the US, Europe and Japan. New Article Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said their experimental drug significantly slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, a rare positive outcome in a field littered with failure. By Natalie Grover LONDON, Sept 28 (Reuters) - The results of a key Alzheimer's drug trial on Wednesday have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal brain disease, giving a big boost to similar studies being run by Roche and Eli Lilly. Dr. Kristian Steen Frederiksen, director of a clinical trial unit at the University of Copenhagen said the latest data was solid evidence that amyloid beta is not just an ""innocent bystander"" in the development of dementia drugs. New Article Helping cut some declines on the Nasdaq, Biogen BIIB.O shares surged 35.8% after its Alzheimer's drug, developed with Japanese partner Eisai 4523.T, succeeded in slowing cognitive decline. By Shreyashi Sanyal and Ankika Biswas Sept 28 (Reuters) - The Dow and the S&P 500 indexes gained in volatile trading on Wednesday as easing Treasury yields gently lifted rate-sensitive growth stocks, while losses in Apple Inc after it dropped plans to boost iPhone production weighed on the Nasdaq. Shares of the world's most valuable public company AAPL.O lost 3.94% after Bloomberg reported that Apple told suppliers to curtail efforts to increase assembly of its iPhone 14 products by as many as 6 million units in the second half of this year. New Article VIDEO: S&P 500 Movers: AAPL, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Year to date, Biogen registers a 13.2% gain. And the worst performing S&P 500 component thus far on the day is Apple, trading down 3.9%. New Article In the Green Silo Pharma, Inc. (SILO) is up over 82% at $9.31 Prothena Corporation plc (PRTA) is up over 63% at $50.63 Biogen Inc. (BIIB) is up over 42% at $281.65 NextPlat Corp (NXPL) is up over 42% at $2.87 Acumen Pharmaceuticals, Inc. (ABOS) is up over 37% at $6.45 Annovis Bio, Inc. (ANVS) is up over 16% at $15.10 Longeveron Inc. (LGVN) is up over 15% at $4.64 MOGU Inc. (MOGU) is up over 14% at $2.85 Cassava Sciences, Inc. (SAVA) is up over 12% at $51.96 Eli Lilly and Company (LLY) is up over 7% at $335.30 Azure Power Global Limited (AZRE) is up over 7% at $6.20 In the Red Mind Medicine (MindMed) Inc. (MNMD) is down over 35% at $3.97 Nano Labs Ltd (NA) is down over 18% at $2.60 Avenue Therapeutics, Inc. (ATXI) is down over 13% at $6.27 Getty Images Holdings, Inc. (GETY) is down over 11% at $7.05 IDEXX Laboratories, Inc. (IDXX) is down over 9% at $300.00 QVC, Inc. 6.250% Senior Secured (QVCC) is down over 9% at $16.61 Warby Parker Inc. (WRBY) is down over 9% at $13.20 MFA Financial, Inc. (MFA) is down over 9% at $8.05 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 07.25 A.M. ET). New Article VIDEO: Nasdaq 100 Movers: AAPL, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Wednesday, shares of Biogen topped the list of the day's best performing components of the Nasdaq 100 index, trading up 36.3%. And the worst performing Nasdaq 100 component thus far on the day is Apple, trading down 4.0%. New Article Biogen (BIIB) surged 40% after saying the lecanemab drug candidate it developed with Japanese biopharmaceuticals company Eisai to treat Alzheimer's disease met its primary endpoint during phase 3 testing. In company news, PepGen (PEPG) shares more than doubled in value on Wednesday, at one point climbing nearly 150% to an intra-day high of $12.84, after the company said its PGN-EDO51 drug candidate to treat Duchenne muscular dystrophy met its primary endpoint during phase 1 testing. Nano-X Imaging (NNOX) added over 21% after the medical device company said it filed a premarket notification for its Nanox.ARC digital x-ray system with US regulators. New Article Biogen Inc BIIB.O surged after saying its experimental Alzheimer's drug, developed with Japanese partner Eisai Co Ltd 4523.T, succeeded in slowing cognitive decline. By Noel Randewich and Shreyashi Sanyal Sept 28 (Reuters) - Wall Street ended sharply higher on Wednesday following its recent sell-off, helped by falling Treasury yields, while Apple dropped on concerns about demand for iPhones. US/GVD/EUR Also pushing yields lower on Treasuries with maturities six months and longer, the Bank of England said it would buy long-dated British bonds in a move aimed at restoring financial stability in markets rocked globally by the fiscal policy of the new government in London. New Article In company news, Biogen (BIIB) soared over 37% after saying the lecanemab drug candidate it developed with Japanese biopharmaceuticals company Eisai to treat Alzheimer's disease met its primary endpoint and all key secondary endpoints in a phase 3 trial. Nano-X Imaging (NNOX) climbed nearly 23% after the medical device company said it filed a premarket notification for its Nanox.ARC digital x-ray system with US regulators. Investors also received an equal number of warrants exercisable at $4.25 per share. New Article But the number of Alzheimers patients will rise substantially in future years, and the drugs appearance of efficacy  assuming the underlying data back up what the companies said Tuesday  means it will probably be reimbursed by insurers and governments. Japanese pharmaceutical company Eisai and its U.S. peer Biogen said on Sept. 27 a drug they were developing for the treatment of Alzheimers effectively slowed cognitive decline in a trial of about 1,800 patients in the early stages of the disease. The drug, lecanemab, slowed the progression of the disease at 18 months by 27% compared to the placebo, using a numeric scale that quantifies the severity of symptoms. New Article Biogen Inc BIIB.O surged 37% after saying its experimental Alzheimer's drug, developed with Japanese partner Eisai Co Ltd 4523.T, succeeded in slowing cognitive decline. By Noel Randewich and Shreyashi Sanyal Sept 28 (Reuters) - Wall Street rebounded strongly on Wednesday following its recent sell-off, helped by easing Treasury yields, while Apple dropped on concerns about demand for iPhones. US/GVD/EUR Helping push Treasury yields lower, the Bank of England said it would buy long-dated British bonds in a move aimed at restoring financial stability in markets rocked globally by the fiscal policy of the new government in London. New Article By Natalie Grover LONDON, Sept 28 (Reuters) - Shares in Biogen BIIB.O and Eisai 4523.T soared on Wednesday reflecting the surprise trial success of their experimental Alzheimer's drug, which also lifted the stocks of rival drugmakers Roche ROG.S and Eli Lilly LLY.N. Against the odds, Biogen and Eisai on Tuesday said their experimental drug, lecanemab, slowed progress of the brain-wasting disease by 27% compared with a placebo, in a large trial of patients in the early stages of Alzheimer's. This so-called amyloid hypothesis suffered a particularly heavy blow last year, after U.S. regulators overruled their own panel of outside experts to approve another Biogen drug called Aduhelm, based on its plaque-clearing ability rather than proof that it helped slow cognitive decline. New Article Biogen BIIB along with partner Eisai announced that their large phase III confirmatory study, Clarity AD, on anti-amyloid beta protofibril antibody candidate lecanemab (BAN2401) to treat early Alzheimers disease (early AD), has met the primary endpoint The Clarity AD study is evaluating lecanemab for the treatment of mild cognitive impairment (MCI) due to AD and mild AD (collectively known as early AD) with the confirmed presence of amyloid pathology in the brain. Biogen Inc. (BIIB): Free Stock Analysis Report The study met the primary endpoint by showing that treatment with lecanemab in the early stages of the disease reduced the rate of clinical decline on the CDR-SB scale by 27% compared to placebo. New Article So what Moderna's positive news came from across the Atlantic Ocean, where the European Medicines Agency (EMA) accepted a conditional marketing authorization (CMA) application for the company's bivalent coronavirus booster vaccine. Moderna didn't hesitate to point out that the new booster has already been given the green light by the U.S. Food and Drug Administration (FDA) and a host of other jurisdictions, including Australia, Taiwan, and the U.K. Now what But there were two developments that leeched investor optimism. Biogen and its partner Eisai announced late Tuesday that their lecanemab Alzheimer's drug met the primary endpoint of a late-stage clinical trial, reducing cognitive decline by almost 30%. New Article ** South Korean President promised to appropriately deal with economic shocks in one of the most direct indications about measures to stop the spread of a sense of panic in financial markets. ** Among heavyweights, technology giant Samsung Electronics rose 0.38%, peer SK Hynix gained 1.23%, and battery maker LG Energy Solution jumped 3.11%. ** Foreigners bought shares worth 33.7 billion won ($23.57 million), turning net buyers for the first time in eight sessions. New Article What happened Shares of Biogen (NASDAQ: BIIB) were skyrocketing 36% as of 11:10 a.m. The huge gain came after the company and its partner Eisai (OTC: ESALY) announced positive results on Tuesday from their late-stage Clarity AD study evaluating lecanemab in treating Alzheimer's disease. Biogen and Eisai stated that lecanemab met the primary endpoint of the study with a 27% reduction in cognitive decline compared with placebo at 18 months.",269.66400146484375
2022-09-29 00:00:00+00:00,269.2900085449219,271.3800048828125,260.3599853515625,264.2799987792969,264.2799987792969,6184000.0,3.5,1.0,0.6250249999999999,"Biogen BIIB and partner Eisai recently announced that their big global phase III confirmatory study, Clarity AD, on investigational anti-amyloid beta protofibril antibody candidate lecanemab (BAN2401) for treating early Alzheimers Disease (AD), met the primary endpoint. Shares of BIIB surged 39.85% in response to the news. Biogen Inc. (BIIB): Free Stock Analysis Report New Article Recap of the Weeks Most Important Stories: Biogen, Eisais AD Drug Achieves Goals:  Biogens BIIB shares gained significantly after the company and partner Eisai announced that their big global phase III confirmatory study, Clarity AD, on investigational anti-amyloid beta protofibril antibody candidate lecanemab (BAN2401) for the treatment of early Alzheimers Disease (AD), met the primary endpoint. Biogen Inc. (BIIB): Free Stock Analysis Report Based on these impressive data, Biogens partner Eisai plans to file for traditional approval of lecanemab in the United States and submit regulatory applications in the EU and Japan by the end of the first quarter of 2023. New Article However, major gainer of the tech-heavy index was the biotech bigwig Biogen Inc. BIIB, shares of which soared 39.9%. Biogen Inc. (BIIB): Free Stock Analysis Report Stiff decline in U.S. government bond yields following an unexpected intervention of the Bank of England to stabilize the UKs financial market helped a turnaround for the U.S. stocks. New Article Eisai 4523.T surged 13.56% to a daily limit for a two straight sessions, after the surprise trial success of an experimental Alzheimer's drug developed by the Japanese drug maker and a partner Biogen BIIB.O. TOKYO, Sept 29 (Reuters) - Japan's Nikkei share average ended about 1% higher on Thursday, rebounding from a near three-month low hit in the previous session, led by drugmakers tracking overnight Wall Street gains. ""The main driver for the Nikkei's gain was an advance of Wall Street overnight, which was fuelled by the Bank of England's action,"" said Chihiro Ohta, assistant general manager at theinvestment researchand investor services at SMBC Nikko Securities Wall Street ended sharply higher overnight following its recent sell-off, after Treasuries yields fell, as the Bank of England launched an emergency bond buying programme to stabilise a furious sell-off in gilts. New Article Tens of millions of Alzheimer's disease patients were given a rare dose of good news recently when Biogen (NASDAQ: BIIB) released some encouraging clinical trial results for its new Alzheimer's disease treatment candidate. Citing a lack of evidence that it improves patients' rate of cognitive decline, the Centers for Medicare and Medicaid Services has decided not to pay for treatments like Aduhelm that earn FDA approval under an accelerated pathway. In the pivotal Clarity AD trial, early-stage Alzheimer's disease patients given lecanemab showed 27% less decline on the ""Clinical Dementia Rating -- Sum of Boxes"" (CDR-SB) test after 18 months of treatment. New Article In recent trading, shares of Biogen Inc (Symbol: BIIB) have crossed above the average analyst 12-month target price of $247.28, changing hands for $276.61/share. But the whole reason to look at the average BIIB price target in the first place is to tap into a ""wisdom of crowds"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. And so with BIIB crossing above that average target price of $247.28/share, investors in BIIB have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $247.28 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table?",280.326904296875
2022-09-30 00:00:00+00:00,265.510009765625,271.489990234375,257.0199890136719,267.0,267.0,3749700.0,3.6666666666666665,1.0,0.6666916666666666,"By Julie Steenhuysen CHICAGO, Sept 30 (Reuters) - Clear evidence this week that Eisai 4523.T and Biogen's BIIB.O drug lecanemab slows cognitive decline in early stage dementia has galvanized efforts among Alzheimer's researchers toward a tantalizing goal - preventing dementia even before symptoms start. That amounts to an extra six months or so in which they can cook a meal, use a computer or pay their bills, said Dr. Christopher Van Dyck, director of the Alzheimer's Disease Research Unit at Yale School of Medicine. The findings were especially poignant for Dr. Reisa Sperling, director of the Center for Alzheimer Research and Treatment at Brigham and Women's and Massachusetts General hospitals in Boston, who leads the trial. New Article (RTTNews) - Biogen Inc. (BIIB) announced the European Medicines Agency has accepted the Marketing Authorization Application for BIIB800, a biosimilar candidate referencing RoACTEMRA (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody. Ian Henshaw, Head of Global Biosimilars at Biogen, said: ""If approved, BIIB800 will be a valuable treatment option for people with chronic immune mediated inflammatory diseases."" Biogen has exclusive regulatory, manufacturing and commercial rights to BIIB800 in all countries excluding China. New Article What happened Shares of Biogen (NASDAQ: BIIB) shot up as much as 37.1% this week, according to data from S&P Global Market Intelligence. BIIB data by YCharts Investors immediately got bullish on Biogen stock after the news was announced. The large-cap drugmaker with a market cap of $39 billion announced that its new Alzheimer's drug it developed in a partnership with Eisai showed tremendous promise in a clinical trial.",283.04388427734375
2022-10-03 00:00:00+00:00,269.0,269.5,260.69000244140625,264.29998779296875,264.29998779296875,2498800.0,3.25,1.0,0.5625249999999999,"The move happened after biotech giant Biogen and its partner Esai reported positive top-line results from a phase 3 clinical trial for an Alzheimer's disease (AD) therapy candidate, lecanemab. Top-line data from Biogen and Esai's phase 3 study showed that lecanemab met its primary endpoint by reducing clinical decline on the global cognitive and functional scale by 27%, 18 months after the start of treatment. First, note that Eli Lilly initiated a rolling submission to the U.S. Food and Drug Administration (FDA) for accelerated approval for donanemab in treating early AD in late 2021. New Article Biogen BIIB is facing multiple challenges. Its key phase IIII biosimilar pipeline candidates are SB15, a biosimilar of Regenerons Eylea, and BIIB800, a biosimilar of Roches Actemra. Biogen Inc. (BIIB): Free Stock Analysis Report New Article By Blake Brittain WASHINGTON, Oct 3 (Reuters) - The U.S. Supreme Court on Monday declined to hear Biogen Inc's BIIB.O bid to win reinstatement of a patent on the company's blockbuster multiple sclerosis drug Tecfidera in a dispute with Viatris Inc subsidiary VTRS.O Mylan Pharmaceuticals Inc. The patent-focused U.S. Court of Appeals for the Federal Circuit upheld the judge's ruling in favor of Mylan in a 2-1 decision, finding the patent's written description did not outline its method for treating MS clearly enough. Biogen told the Supreme Court that the Federal Circuit had added ""additional, atextual requirements that distort"" the standard for securing a patent involving a clear written description of the invention and how it is made and used. New Article Components of that ETF showing particular strength include shares of Century Aluminum, up about 17.7% and shares of Coeur Mining, up about 15.3% on the day. Among components of that ETF with the weakest showing on Monday were shares of Tesla, lower by about 8.4%, and shares of Biogen, lower by about 1.5% on the day. VIDEO: Monday's ETF Movers: XME, QVML The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",281.8027648925781
2022-10-04 00:00:00+00:00,266.0,269.8699951171875,264.5,267.45001220703125,267.45001220703125,2162000.0,4.0,1.0,0.7500249999999999,"Regeneron Pharmaceuticals (NASDAQ: REGN), Vertex Pharmaceuticals (NASDAQ: VRTX), and Biogen (NASDAQ: BIIB) are developing remarkable therapies that, instead of merely treating disorders, have the potential to cure them or at least make an impact that no other drug has to date. BIIB data by YCharts. Eylea (aflibercept), an anti-blindness treatment the company is developing with Bayer, showed effectiveness and safety at high dosages in late-stage trials.",279.6556701660156
2022-10-05 00:00:00+00:00,265.2799987792969,266.42999267578125,257.510009765625,261.69000244140625,261.69000244140625,1573600.0,3.0,1.0,0.5000249999999999,"Two drugmakers that feature in the race to find a successful AD treatment are Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB). Several big-name companies are racing to develop effective therapies for Alzheimer's disease (AD), a goal that has proven difficult over the years. The drugmaker's key growth products continue to perform well, including diabetes treatments Trulicity and Jardiance, cancer drugs Verzenio, and immunology medicine Taltz. New Article (29:00) - Have A Plan That Works For Your Investment Timeframe (34:50) - Episode Roundup: XOM, META, NVDA, MSFT, UNH, CNC, BIIB, LLY, ARKK Podcast@Zacks.com Welcome to Episode #331 of the Zacks Market Edge Podcast. Biogen BIIB Biogen shares popped 37% recently after it announced its Alzheimers drug reduced cognitive decline by 27% compared to the placebo. Biogen Inc. (BIIB): Free Stock Analysis Report New Article Biogen stock (NASDAQ: BIIB) has seen a substantial 32% rise in a month, significantly outperforming the broader S&P500 index, down 8%. More importantly, what about BIIB stock in the near term? Now that BIIB stock has seen a rise of 32% in a month, will it continue its upward trajectory, or is a fall imminent?",278.6016845703125
2022-10-06 00:00:00+00:00,261.9700012207031,266.3099975585937,259.1199951171875,262.260009765625,262.260009765625,1246500.0,2.5,1.0,0.375025,"Biotech giant Biogen (NASDAQ: BIIB) was underperforming the market this year -- that is, until the company's shares soared by as much as 37% last week. BIIB data by YCharts. The drugmaker's major win in the stock market came after it reported positive top-line results from a phase 3 clinical trial for lecanemab, a potential therapy for Alzheimer's disease (AD). New Article Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $265.00 strike highlighted in red: Considering the fact that the $265.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the November 25th expiration.",281.3204040527344
2022-10-07 00:00:00+00:00,261.3999938964844,265.9800109863281,256.4800109863281,257.8900146484375,257.8900146484375,1778200.0,3.0,1.0,0.5000249999999999,"Oct 7 (Reuters) - Mathai Mammen, a former executive at drugmaker Johnson & Johnson JNJ.N, has emerged as a top candidate to head Biogen BIIB.O as chief executive officer, news website STAT reported on Friday, citing people familiar with the discussions. In May, Biogen announced that its chief Michel Vounatsos was stepping down amid the company pulling back on selling its controversial Alzheimer's drug Aduhelm. Biogen's Alzheimer drug was seen as the company's next blockbuster treatment, but controversy over its approval without clear evidence of patient benefit and the U.S. government's decision to limit access was a big blow. New Article The AD space is in the spotlight as Biogen BIIB and partner Eisai recently announced that their big global phase III confirmatory study, Clarity AD, on investigational anti-amyloid beta protofibril antibody candidate lecanemab (BAN2401) for treating early AD, met the primary endpoint. Biogen Inc. (BIIB): Free Stock Analysis Report Shares of Annovis Bio, Inc. ANVS gained 2.39% on Oct 6 after the FDA authorized the company to proceed with the phase II/III clinical study of lead candidate buntanetap in moderate Alzheimer's Disease (AD).",284.79254150390625
2022-10-10 00:00:00+00:00,257.5799865722656,258.3900146484375,252.3000030517578,254.77999877929688,254.77999877929688,1191600.0,4.0,1.0,0.7500249999999999,"Among the largest underlying components of XBI, in trading today Biogen Inc (Symbol: BIIB) is down about 1.2%, IVERIC bio Inc (Symbol: ISEE) is off about 1.6%, and BioCryst Pharmaceuticals Inc (Symbol: BCRX) is higher by about 0.3%. For a complete list of holdings, visit the XBI Holdings page  The chart below shows the one year price performance of XBI, versus its 200 day moving average: Looking at the chart above, XBI's low point in its 52 week range is $61.78 per share, with $134.79 as the 52 week high point  that compares with a last trade of $78.28. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand.",268.85791015625
2022-10-11 00:00:00+00:00,251.97000122070312,258.82000732421875,250.3099975585937,254.07000732421875,254.07000732421875,1239000.0,3.0,1.0,0.5000249999999999,"In the latest trading session, Biogen Inc. (BIIB) closed at $254.07, marking a -0.28% move from the previous day. We can also see that BIIB currently has a PEG ratio of 1.55. Biogen Inc. (BIIB): Free Stock Analysis Report",262.893798828125
2022-10-12 00:00:00+00:00,254.509994506836,256.1199951171875,250.94000244140625,253.6699981689453,253.6699981689453,1592300.0,3.25,1.0,0.5625249999999999,"Why this stock might be an interesting purchase Seagen's success is determined by how effectively it can develop and market therapies to treat cancer. It has eight such programs in phase 3 of clinical trials and four ongoing mid-stage investigations that would be wholly new entities if they are eventually approved by regulators and commercialized. Seagen expects Enhertu to cause a drag on the growth of its market share with Tukysa, so it remains to be seen how much its top line will be boosted by the new launches in Europe. New Article Biogen and Eisai On or before Jan. 06, 2023, Biogen (NASDAQ: BIIB) and its collaboration partner, Eisai, could earn accelerated approval for a new Alzheimer's disease drug called lecanemab. The partners shocked the medical community in September with top-line pivotal trial results that show treatment with lecanemab significantly slowed cognitive decline for patients with early-stage Alzheimer's disease. Subsequent label expansions, though, could eventually make it a go-to drug for most members of the HIV-positive community and drive sales past $4 billion annually at its peak. New Article Biogen Inc. (BIIB) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended September 2022. Biogen Inc. (BIIB): Free Stock Analysis Report This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. New Article Pipeline Update From Biogen: Biogen BIIB announced that the first patient has been dosed in the phase II/III AMETHYST study, which will evaluate the efficacy and safety of litifilimab (BIIB059) compared to placebo in cutaneous lupus erythematosus (CLE). Biogen Inc. (BIIB): Free Stock Analysis Report The trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to generate safety and pharmacokinetic (PK) data in healthy volunteers and provide early clinical proof-of-concept in psoriasis patients.",263.0343017578125
2022-10-13 00:00:00+00:00,251.8699951171875,271.989990234375,251.7700042724609,269.94000244140625,269.94000244140625,3279200.0,4.25,1.0,0.8125249999999999,"VIDEO: Nasdaq 100 Movers: TEAM, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Thursday, shares of Biogen (BIIB) topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.3%. And the worst performing Nasdaq 100 component thus far on the day is Atlassian Corp (TEAM), trading down 8.2%. New Article Biogen BIIB has an Earnings ESP of +1.15% and a Zacks Rank #3. BIIB is scheduled to release its third-quarter 2022 results on Oct 25. Biogen Inc. (BIIB): Free Stock Analysis Report New Article Biogen (BIIB) climbed 6.1%, pacing gains for companies in the Nasdaq Composite index following a Stifel upgrade of the specialty drugmaker to buy from hold coupled with a $76 increase in its price target for Biogen shares to $299. Morgan Stanley also raised its price target for Biogen by $36 to $321 and reiterated its overweight stock rating. VectivBio (VECT) climbed more than 19% after reporting positive interim data for its apraglutide drug candidate during phase 2 testing, with adult patients with short bowel syndrome demonstrating a 50% reduction in their need for parenteral support six months after their initial treatments with the synthetic peptide analog. New Article Among gainers, Biogen (BIIB) climbed 6.4%, pacing gains for companies in the Nasdaq Composite index following a Stifel upgrade of the drugmaker to buy from hold coupled with a $76 increase in its price target for Biogen shares to $299. In company news, Relmada Therapeutics (RLMD) plunged almost 80%, earlier dropping to its lowest share price since February 2019, after saying its REL-1017 drug candidate did not produce a statistically significant improvement in symptoms during phase 3 testing in patients with major depressive disorder. InMode (INMD) rose over 14% after the medical device company Thursday projected Q3 results exceeding Wall Street forecasts and also raised its FY22 revenue outlook above the analyst mean.",268.22515869140625
2022-10-17 00:00:00+00:00,266.04998779296875,274.010009765625,264.75,269.54998779296875,269.54998779296875,1658300.0,3.6666666666666665,1.0,0.6666916666666666,"(RTTNews) - Sage Therapeutics, Inc. (SAGE) and Biogen Inc. (BIIB) announced Monday additional data from the Phase 3 SKYLARK Study of zuranolone in adult women with postpartum depression or PPD. Zuranolone (SAGE-217/BIIB125) is a once-daily, 14-day, investigational drug in development for the treatment of major depressive disorder or MDD and PPD. The companies presented the data at the 35th European College of Neuropsychopharmacology (ECNP) Congress, taking place October 15-18, 2022, in Vienna, Austria. New Article Biogen Inc. (BIIB) closed the most recent trading day at $269.55, moving +1.86% from the previous trading session. Also, we should mention that BIIB has a PEG ratio of 1.61. Biogen Inc. (BIIB): Free Stock Analysis Report New Article Updates to add trial failure and background Oct 17 (Reuters) - The U.S. Food and Drug Administration has extended the review of Biogen Inc's BIIB.O experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) by three months, the company said on Monday. Last year, the drug had failed to meet the main goal of a late-stage study and did not show statistically significant improvement in the functional status of patients with fast-progressing ALS. ALS, also known as Lou Gehrig's disease, breaks down nerve cells in the brain and spinal cord that make muscles work, leading to progressive paralysis and death.",285.2893981933594
2022-10-18 00:00:00+00:00,270.0299987792969,273.7099914550781,267.2799987792969,270.2799987792969,270.2799987792969,1348800.0,3.5,1.0,0.6250249999999999,"Biogen BIIB announced that the FDA extended the review period for its new drug application (NDA). Biogen Inc. (BIIB): Free Stock Analysis Report The NDA seeks approval for antisense drug tofersen in patients with amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutation. New Article Especially high volume was seen for the $285 strike call option expiring November 18, 2022, with 1,196 contracts trading so far today, representing approximately 119,600 underlying shares of BIIB. Below is a chart showing MRK's trailing twelve month trading history, with the $100 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 11,283 contracts, representing approximately 1.1 million underlying shares or approximately 43.5% of BIIB's average daily trading volume over the past month, of 2.6 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $285 strike highlighted in orange: And SolarEdge Technologies Inc (Symbol: SEDG) options are showing a volume of 4,850 contracts thus far today.",290.85736083984375
2022-10-19 00:00:00+00:00,269.29998779296875,269.29998779296875,261.9100036621094,264.45001220703125,264.45001220703125,1163600.0,3.0,1.0,0.5000249999999999,"Expected Results of an Industry Player Another stock from the Zacks Medical - Biomedical and Genetics industry, Biogen Inc. (BIIB), is soon expected to post earnings of $4.15 per share for the quarter ended September 2022. Biogen Inc. (BIIB): Free Stock Analysis Report This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.",298.7475280761719
2022-10-20 00:00:00+00:00,263.4200134277344,265.989990234375,260.3299865722656,262.6499938964844,262.6499938964844,1030900.0,2.5,1.0,0.375025,"Regulatory Update From Biogen:  Biogen BIIB announced that the FDA extended the review period for its new drug application (NDA) seeking approval for antisense drug tofersen in patients with amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutation. (See the last biotech stock roundup here: Biotech Stock Roundup: DICE Up on Study Data, GILD, BIIBs Updates & More) Biogen Inc. (BIIB): Free Stock Analysis Report New Article Shares of Biogen (NASDAQ: BIIB) have been volatile in the past few years, largely hinging on success of the company's Alzheimer's treatments. Biogen had high hopes for Alzheimer's treatment Aduhelm but it looks to be a flop, failing to get health officials on board, and even Medicare won't cover it unless patients are using it as part of a clinical trial. The key difference is that Aduhelm obtained accelerated approval from the Food and Drug Administration (FDA) because of its ability to reduce amyloid beta plaque, which is thought to help Alzheimer's patients.",294.1446533203125
2022-10-21 00:00:00+00:00,264.29998779296875,268.5899963378906,261.9200134277344,267.6199951171875,267.6199951171875,1575200.0,2.333333333333333,1.0,0.3333583333333332,"Biogen (NASDAQ: BIIB), for example, currently ranks as the largest of the nearly equal-weighted positions in the ETF. The company and its partner Eisai recently reported successful results for their experimental Alzheimer's disease drug, lecanemab. The big biotech could have more good news on the way soon with anticipated regulatory filings for gene-editing therapy exa-cel, which could provide a functional cure for sickle cell disease and beta-thalassemia. New Article That's when aducanumab, developed by Biogen (NASDAQ: BIIB) and Japanese biopharmaceutical company Eisai, received FDA approval but not without a lot of controversy. Still, Biogen has a lot riding on lecanemab's approval and possibly a decision by CMS to pay for the therapy for Medicaid patients with the disease, as the company's revenue has been declining. Besides donanemab, the company just received Fast Track designation from the FDA for Mounjaro (tirzepatide) to treat obese or overweight adults, an indication that has excited investors. New Article Biogen BIIB will report third-quarter 2022 results on Oct 25, before market open. Biogen Inc. (BIIB): Free Stock Analysis Report Among Biogens MS drugs, sales of Tecfidera are likely to have declined steeply, hurt by the launch of multiple generics products in the United States.",287.9632263183594
2022-10-25 00:00:00+00:00,278.6000061035156,279.6300048828125,265.4599914550781,273.5599975585937,273.5599975585937,2431500.0,3.0,1.0,0.5000249999999999,"Particularly high volume was seen for the $200 strike call option expiring January 20, 2023, with 1,019 contracts trading so far today, representing approximately 101,900 underlying shares of BIIB. Below is a chart showing AVXL's trailing twelve month trading history, with the $9 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 12,851 contracts, representing approximately 1.3 million underlying shares or approximately 47.9% of BIIB's average daily trading volume over the past month, of 2.7 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $200 strike highlighted in orange: For the various different available expirations for LCID options, AVXL options, or BIIB options, visit StockOptionsChannel.com. New Article Biogen BIIB reported third-quarter 2022 adjusted earnings per share (EPS) of $4.77, beating the Zacks Consensus Estimate of $4.13 and our model estimate of $4.30. Biogen Inc. (BIIB): Free Stock Analysis Report This NCD decision has also induced Biogen to substantially wind down commercial operations for Aduhelm and retain only minimal resources to manage patients access programs. New Article Biogen (NASDAQ: BIIB) Q3 2022 Earnings Call Oct 25, 2022, 8:00 a.m. This includes 2 clinical-stage assets targeting tau pathology, BIIB080, our Phase II-ready antisense oligonucleotide; and BIB113, a Phase I small molecule. So we did test our hypothesis with the extracellular tau, and now we are positioned to initiate our Phase II with BIIB080, which is an antisense oligonucleotide that will address all post-translational forms of tau. New Article (RTTNews) - Biogen Inc. (BIIB) said, for full year 2022, the company now projects non-GAAP EPS of $16.50 to $17.15, updated from prior guidance range of $15.25 to $16.75. The company said the increase in full year 2022 revenue and non-GAAP EPS guidance is driven primarily by better than-expected topline performance and continued cost management. On average, 26 analysts polled by Thomson Reuters expected the company to report profit per share of $4.15, for the quarter. New Article Biogen Inc BIIB.O rose 1.3% on hiking its annual profit forecast for the second straight quarter. Coca-Cola jumps on raising annual outlook 3M falls on cutting FY forecast on dollar impact GM shares up as profit beats estimates Earnings from Microsoft, Alphabet awaited Futures down: Dow 0.54%, S&P 0.37%, Nasdaq 0.09% Updates prices, adds comments By Amruta Khandekar and Shreyashi Sanyal Oct 25 (Reuters) - U.S. stock indexeswere set for a subdued open on Tuesday, as investors digested a mixed bag of earnings reports from a flurry of companies ahead of results from megacap firms that could put a recent market rally to test. Earnings reports from companies including Microsoft MSFT.O and Google-owner Alphabet GOOGL.O will offer further clues on the strength of corporate America amid higher Treasury yields and an aggressive Federal Reserve tightening cycle. New Article Adds details on forecast, background Oct 25 (Reuters) - Biogen Inc BIIB.O on Tuesday raised its full-year profit forecast for the second straight quarter, driven by its efforts to cut costs, while investors awaited more data on its new Alzheimer's disease drug next month. The focus of investors as well as Wall Street is squarely on Biogen and Eisai Co Ltd's 4523.T new drug lecanemab that slowed the progress of the disease by 27% in a trial last month. The company raised its full-year adjusted earnings per share forecast to between $16.50 and $17.15 from $15.25 to $16.75 previously. New Article Oct 25 (Reuters) - Biogen Inc BIIB.O reported a 9.7% drop in quarterly sales on Tuesday due to rising competition for its blockbuster multiple sclerosis drug Tecfidera, while investors awaited more data on its new Alzheimer's disease drug next month. The focus of investors as well as Wall Street is squarely on Biogen and Eisai Co Ltd's 4523.T new drug lecanemab that slowed progress of the disease by 27% in a trial last month. (Reporting by Manas Mishra and Bhanvi Satija in Bengaluru; Editing by Arun Koyyur) ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article And the worst performing Nasdaq 100 component thus far on the day is Cadence Design Systems, trading down 2.6%. Cadence Design Systems is lower by about 16.3% looking at the year to date performance. VIDEO: Nasdaq 100 Movers: CDNS, PDD The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",284.8867492675781
2022-10-26 00:00:00+00:00,280.0,284.760009765625,278.44000244140625,280.42999267578125,280.42999267578125,2059900.0,4.0,1.0,0.7500249999999999,"The good news keeps coming in for Biogen (NASDAQ: BIIB). On Sept. 27, Biogen and its partner, Japanese drugmaker Eisai (OTC: ESALY), announced results from a late-stage clinical study evaluating the drug as a treatment for Alzheimer's disease. Zuranolone, an experimental drug being developed by Biogen and Sage Therapeutics for treating depression, stands out as an especially noteworthy candidate. New Article Recap of the Weeks Most Important Stories: Q3 Earnings From BMY, BIIB:  Biogen BIIB reported earnings per share (EPS) of $4.77 in the third quarter of 2022, which beat the Zacks Consensus Estimate of $4.13. Biogen Inc. (BIIB): Free Stock Analysis Report Total revenues of $11.2 billion surpassed the Zacks Consensus Estimate of $11 billion but decreased 2% from the year-ago period due to generic competition for multiple myeloma (MM) drug Revlimid and foreign exchange impacts, partially offset by in-line products (primarily Eliquis and Opdivo) and new product portfolio (primarily Opdualag, Abecma and Reblozyl).",282.14703369140625
2022-11-03 00:00:00+00:00,276.010009765625,282.5899963378906,274.6300048828125,280.25,280.25,869100.0,2.5,1.0,0.375025,"Other noteworthy reports we are featuring today include The Progressive Corporation (PGR), Constellation Brands, Inc. (STZ), and Biogen Inc. (BIIB). Biogen's (BIIB) Upcoming Product Launches May Revive Growth The Zacks analyst says that potential new product launches like lecanemab, zuranolone and additional biosimilars can help revive growth at Biogen, which is facing multiple challenges at present. Biogen Inc. (BIIB): Free Stock Analysis Report New Article Biogen (NASDAQ: BIIB) has been a volatile investment in recent years and its outlook still remains cloudy at best. The two companies could find out as early as January if lecanemab obtains authorization from the Food and Drug Administration (FDA) under an Accelerated Approval Pathway. With Biogen facing growth competition for its key drug, Tecfidera, the company needs a catalyst to make up for that loss and give investors a reason to rally around the business.",270.6159973144531
2022-11-04 00:00:00+00:00,282.5199890136719,283.29998779296875,276.6400146484375,281.82000732421875,281.82000732421875,894500.0,3.0,1.0,0.5000249999999999,"A brief filed in support of Amgen by companies including Biogen Inc BIIB.O, Bristol Myers Squibb Co BMY.N and Merck & Co MRK.N said the Federal Circuit's decision would ""slow the pace of research and development and hinder innovation, to the detriment of patients and the public at large."" By Blake Brittain WASHINGTON, Nov 4 (Reuters) - The U.S. Supreme Court on Friday agreed to hear Amgen Inc's AMGN.O bid to revive patents on its cholesterol drug Repatha that were invalidated due to a legal challenge by rivals Regeneron Pharmaceuticals Inc REGN.O and Sanofi SA SASY.PA. Amgen sued French drugmaker Sanofi and Tarrytown, New York-based partner Regeneron shortly after they sought regulatory approval for Praluent. New Article Stocks recently featured in the blog include: Bank of America Corp. BAC, AT&T Inc. T, Lockheed Martin Corp. LMT, The Progressive Corp. PGR and Biogen Inc. BIIB. Biogen Inc. (BIIB): Free Stock Analysis Report The company remains the largest U.S. defense contractor that has a steady inflow of orders from its leveraged presence in the Army, Air Force, Navy and IT programs. New Article In October 2022, Denali and Biogen initiated the global phase III LIGHTHOUSE study of BIIB122 in up to 400 participants with PD and a confirmed LRRK2 pathogenic variant. Recent Updates Denali has collaborated with Biogen BIIB to advance its LRRK2 inhibitor program to address Parkinsons disease (PD). Biogen Inc. (BIIB): Free Stock Analysis Report",265.7365417480469
2022-11-07 00:00:00+00:00,281.82000732421875,287.9599914550781,281.0899963378906,284.6199951171875,284.6199951171875,1265900.0,3.0,1.0,0.5000249999999999,"Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Repligen (RGEN). This means that BIIB's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. BIIB currently has a forward P/E ratio of 16.60, while RGEN has a forward P/E of 54.96.",256.1096496582031
2022-11-09 00:00:00+00:00,286.3900146484375,289.7799987792969,282.17999267578125,282.3099975585937,282.3099975585937,800700.0,2.5,1.0,0.375025,"Some of the largest companies in the biopharma sector - including GSK GSK.L, AstraZeneca AZN.L, Novartis NOVN.S and Biogen BIIB.O - are implementing year-on-year emissions reductions towards the 2015 Paris goal of limiting global warming to 1.5 degrees Celsius above pre-industrial levels, the report noted. By Natalie Grover LONDON, Nov 9 (Reuters) - Much of the global pharmaceutical and biotech industry has yet to set any targets for reducing carbon emissions in line with the Paris Agreement, a new analysis has found, despite the biggest companies in the sector leading the way. ""But that's not being reflected by a broader cross section of the industry...we still have a big chunk of the sector that doesn't even have targets,"" said James Connelly, one of the authors and CEO of U.S.-based non-profit My Green Lab. New Article Michael Forsythe is an investigative reporter for The New York Times and co-author of the new book When McKinsey Comes to Town: The Hidden Influence of the World's Most Powerful Consulting Firm. Ricky Mulvey: You start that off with the example of US Steel, which I didn't realize this was the largest company in the world at one point, and then McKinsey's advice had disastrous consequences for many of the workers there. Even though in many cases those poor people were actually not required to pay, they were entitled to free care in many instances, but the hospital wanted to boost profit and McKinsey came in and devised this phone system.",252.6889190673828
2022-11-10 00:00:00+00:00,288.75,291.8500061035156,286.7699890136719,290.70001220703125,290.70001220703125,1439000.0,3.0,1.0,0.5000249999999999,"Adds background on Aduhelm, new CEO Nov 10 (Reuters) - Biogen Inc BIIB.O on Thursday tapped pharmaceutical industry veteran Christopher Viehbacher as its new chief executive, after a months-long search for a successor to Michel Vounatsos. Viehbacher served as chief executive of French pharma major Sanofi SASY.PA for six years until he was ousted in 2014 amid declining sales of an important diabetes drug. Biogen said in May Vounatsos, who became the CEO in 2017, would step down after the U.S. government's Medicare program restricted coverage of Aduhelm to patients in clinical trials, severely limiting its use. New Article (RTTNews) - Biotechnology company Biogen Inc. (BIIB) announced Thursday that its Board of Directors has appointed Christopher Viehbacher as President and Chief Executive Officer and a member of the Board of Directors, effective November 14. Under Viehbacher's leadership, Sanofi strengthened and diversified its R&D pipeline and delivered significant value to shareholders. More recently, Viehbacher and Ernesto Bertarelli co-founded Gurnet Point Capital, a Cambridge-based healthcare investment fund, which has led to the creation and continuing development of many innovative companies. New Article Image Source: Zacks Investment Research Quarter in Detail Ionis earns commercial revenues, primarily royalty payments on net sales of Biogens BIIB Spinraza and R&D revenues from partnered medicines. Biogen Inc. (BIIB): Free Stock Analysis Report The medicines include tofersen for SOD1-ALS (amyotrophic lateral sclerosis), pelacarsen for cardiovascular disease due to elevated Lp(a) levels, olezarsen for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG), eplontersen for TTR amyloidosis, ION363 for ALS, with mutations in the fused in sarcoma gene (FUS) or FUS-ALS and donidalorsen for hereditary angioedema (HAE).",246.51536560058594
2022-11-14 00:00:00+00:00,300.1099853515625,305.4800109863281,295.7300109863281,299.0599975585937,299.0599975585937,2686200.0,2.6000000000000005,1.0,0.400025,"By Ludwig Burger ZURICH, Nov 14 (Reuters) - Roche said ROG.S its Alzheimer's drug candidate could not clearly be shown to slow dementia progression in two drug trials, failing to draw level with a recent development success by rivals Biogen BIIB.O and Eisai 4523.T. The Swiss drugmaker said in a statement on Monday that twin studies known as Graduate 1 and 2 did not reach the primary goal of showing that the drug gantenerumab can preserve abilities such as remembering, solving problems, orientation and personal care in patients suffering from early stages of Alzheimer's disease. Roche conducted two equally designed studies with about 1,000 participants each, who were examined and queried by physicians over more than two years. New Article The drug, known as Gantenerumab, was not shown to preserve abilities such as remembering, solving problems, orientation and personal care in patients suffering from early stages of Alzheimers disease. Still, the failure is a setback for chief executive designate Thomas Schinecker and for Roches plans to diversify away from the crowded market for cancer drugs in favour of diseases with fewer cures. (By Aimee Donnellan) Follow @Breakingviews on Twitter Capital Calls - More concise insights on global finance: Alibabas Singles Day enters healthier phase Twitter gives big advertisers the excuse they need Super-voters override self-driving truck controls SoftBank buyout goes from impossible to improbable Tiny crack opens in Chinas zero-Covid wall (Editing by Peter Thal Larsen and Oliver Taslic) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article And the worst performing S&P 500 component thus far on the day is Hasbro, trading down 7.4%. Hasbro is lower by about 42.3% looking at the year to date performance. VIDEO: S&P 500 Movers: HAS, MRNA The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article (RTTNews) - Shares of Biogen Inc. (BIIB) are gaining more than 5 percent on Monday morning trade continuing an uptrend since November 11. There were no corporate announcements on the day to influence the stock movement. Currently, shares are at $302.75, up 4.61 percent from the previous close of $289.45 on a volume of 1,035,959. New Article Shares of Biogen Inc BIIB.O and Eli Lilly LLY.N gained 3.3% and 1.3%, respectively, after the failure of Swiss rival Roche's ROG.S Alzheimer's disease drug candidate. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Losses accelerate into close of choppy session Fed's Brainard signals slower rate hikes ahead Real estate, discretionary biggest S&P sector decliners Biogen, Lilly rise on Roche's Alzheimer's drug failure Indexes down: Dow 0.63%, S&P 500 0.89%, Nasdaq 1.12% Adds further market details By Lewis Krauskopf, Ankika Biswas and Amruta Khandekar Nov 14 (Reuters) - Wall Street's main indexes ended lower on Monday, with real estate and discretionary sectors leading broad declines, as investors digested comments from U.S. Federal Reserve officials about plans for interest rate hikes and looked for next catalysts after last week's big stock market rally. Losses accelerated toward the end of the up-and-down session, with focus turning to Tuesday's producer price index report and markets highly sensitive to inflation data. New Article Among other stocks, Biogen Inc BIIB.O and Eli Lilly LLY.N gained 4.6% and 1.9%, respectively, after the failure of Swiss rival Roche's ROG.S Alzheimer's disease drug candidate. ""That is consistent with what the market's already been telling us,"" said Randy Frederick, vice president of trading and derivatives at Charles Schwab in Texas, referring to traders pricing in a 50-basis-point rate hike by the Fed in December. Tesla Inc TSLA.O fell 1.0% as Chief Executive Elon Musk said ""I have too much work on my plate"" when asked about his recent acquisition of Twitter and his leadership of the electric-vehicle maker. New Article VIDEO: Nasdaq 100 Movers: TEAM, BIIB The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. In early trading on Monday, shares of Biogen topped the list of the day's best performing components of the Nasdaq 100 index, trading up 4.1%. And the worst performing Nasdaq 100 component thus far on the day is Atlassian, trading down 6.0%. New Article Among other stocks, Biogen Inc BIIB.O and Eli Lilly LLY.N gained 3.4% and 1.4%, respectively, after the failure of Swiss rival Roche's ROG.S Alzheimer's disease drug candidate. By Shubham Batra and Ankika Biswas Nov 14 (Reuters) - Wall Street's main indexes slipped on Monday, with the tech-heavy Nasdaq down about 1%, as hawkish comments from a U.S. Federal Reserve official tempered hopes of the central bank toning down its aggressive monetary policy approach. The comments follow a softer-than-expected inflation report last week, which had buoyed hopes that the Fed could scale back its hefty interest rate hikes and helped drive a euphoric market rally. New Article Particularly high volume was seen for the $300 strike call option expiring November 18, 2022, with 1,001 contracts trading so far today, representing approximately 100,100 underlying shares of BIIB. Below is a chart showing PM's trailing twelve month trading history, with the $97.50 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 9,129 contracts, representing approximately 912,900 underlying shares or approximately 65.9% of BIIB's average daily trading volume over the past month, of 1.4 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $300 strike highlighted in orange: For the various different available expirations for IFF options, PM options, or BIIB options, visit StockOptionsChannel.com. New Article In healthcare, shares of Biogen Inc BIIB.O and Eli Lilly LLY.N gained 5% and 2%, respectively, after the failure of Swiss rival Roche's ROG.S Alzheimer's disease drug candidate. By Lewis Krauskopf, Ankika Biswas and Amruta Khandekar Nov 14 (Reuters) - Wall Street's main indexes gained modestly on Monday as investors digested comments from U.S. Federal Reserve officials about the central bank's plans for interest rate hikes and looked for next catalysts following last week's big stock market rally. A massive equity rally late last week was set off by a softer-than-expected inflation report that boosted hopes the Fed could dial back on its monetary tightening that has punished markets this year.",243.80056762695312
2022-11-15 00:00:00+00:00,300.6700134277344,303.7900085449219,297.010009765625,299.7799987792969,299.7799987792969,1282400.0,3.6,1.0,0.6500250000000001,"In recent trading, shares of Biogen Inc (Symbol: BIIB) have crossed above the average analyst 12-month target price of $296.12, changing hands for $299.06/share. And so with BIIB crossing above that average target price of $296.12/share, investors in BIIB have been given a good signal to spend fresh time assessing the company and deciding for themselves: is $296.12 just one stop on the way to an even higher target, or has the valuation gotten stretched to the point where it is time to think about taking some chips off the table? But the whole reason to look at the average BIIB price target in the first place is to tap into a ""wisdom of crowds"" effort, putting together the contributions of all the individual minds who contributed to the ultimate number, as opposed to what just one particular expert believes. New Article Ionis has collaboration deals with pharma giants such as Biogen BIIB, AstraZeneca AZN and Novartis NVS. Ionis receives royalties from BIIB on Spinrazas sales. Biogen Inc. (BIIB): Free Stock Analysis Report New Article Biogen Inc. (NASDAQ:BIIB) Biogen is an American multinational biotechnology company with a focus on the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. In Q3, Cohen increased the stake in BIIB stock to 1.68 million shares (from 455,000 shares), valued at $448 million. Also, the average Biogen price target of $304.08 implies a modest 1.7% upside potential to current levels. New Article Image Source: Zacks Investment Research The news also put the spotlight on other companies developing AD treatments namely Biogen BIIB, Eli Lilly LLY and Prothena. Biogen Inc. (BIIB): Free Stock Analysis Report Nevertheless, despite the complexities associated with developing a treatment for AD and past failures, the space will continue to attract attention from pharma and biotech companies, given the significant unmet need. New Article Among the largest underlying components of RSP, in trading today Biogen Inc (Symbol: BIIB) is up about 0.9%, ABIOMED, Inc. (Symbol: ABMD) is up about 0.2%, and APA Corp (Symbol: APA) is higher by about 0.8%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.",245.47967529296875
2022-11-17 00:00:00+00:00,297.07000732421875,302.92999267578125,296.7900085449219,302.04998779296875,302.04998779296875,959900.0,3.0,1.0,0.5000249999999999,"With that in mind, let's look at three stocks that aren't worth buying right now: Biogen (NASDAQ: BIIB), Inovio Pharmaceuticals (NASDAQ: INO), and Ocugen (NASDAQ: OCGN). BIIB data by YCharts In my view, investors should wait for more news regarding lecanemab before purchasing shares of Biogen. If this new potential AD therapy earns the green light and can avoid the coverage issues Aduhelm has encountered, that will undoubtedly improve the biotech's prospects. New Article A couple of better-ranked stocks in the healthcare space include Merck MRK and Biogen BIIB. Biogen Inc. (BIIB): Free Stock Analysis Report Due to industry-wide price competition among generic pharmaceutical companies and consolidation of buyers, Sandoz experienced significant declines in sales and profits, particularly in the United States.",237.36354064941406
2022-11-21 00:00:00+00:00,304.20001220703125,305.8699951171875,300.3999938964844,301.6300048828125,301.6300048828125,969800.0,2.0,1.0,0.250025,"Particularly high volume was seen for the $285 strike put option expiring June 16, 2023, with 412 contracts trading so far today, representing approximately 41,200 underlying shares of BIIB. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 6,109 contracts have traded so far, representing approximately 610,900 underlying shares. That amounts to about 44.4% of BIIB's average daily trading volume over the past month of 1.4 million shares.",243.2377166748047
2022-11-22 00:00:00+00:00,302.25,307.0,301.6000061035156,306.7200012207031,306.7200012207031,868800.0,4.0,1.0,0.7500249999999999,"The rare disorder is caused by a gene mutation that hampers the body's ability to make factor IX, and current treatments from companies such as Biogen BIIB.O and Pfizer PFE.N focus on regular infusions of the protein. Adds background Nov 22 (Reuters) - The U.S. health regulator on Tuesday approved Australian drugmaker CSL Ltd CSL.AX and partner Uniqure NV's QURE.O gene therapy for hemophilia B, potentially offering a long-term solution for patients with the blood clotting disorder. The approval from the Food and Drug Administration makes the treatment, which will be branded Hemgenix, the first gene therapy for the rare inherited disorder that is usually treated by regular injections of clotting protein factor IX.",239.15118408203125
2022-11-23 00:00:00+00:00,307.0,307.3999938964844,302.1099853515625,303.45001220703125,303.45001220703125,998000.0,3.0,1.0,0.5000249999999999,"A couple of better-ranked stocks in the biotech space include Syndax Pharmaceuticals SNDX and Biogen BIIB. Biogen Inc. (BIIB): Free Stock Analysis Report The drug has been approved as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. New Article Another Medical stock, which has outperformed the sector so far this year, is Biogen Inc. (BIIB). Click to get this free report AMN Healthcare Services Inc (AMN) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. New Article Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Repligen (RGEN). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that BIIB has an improving earnings outlook. BIIB currently has a forward P/E ratio of 18.07, while RGEN has a forward P/E of 54.15. New Article Among the largest underlying components of RSP, in trading today Biogen Inc (Symbol: BIIB) is down about 1.2%, Netflix Inc (Symbol: NFLX) is trading flat, and ABIOMED, Inc. (Symbol: ABMD) is relatively unchanged. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.",234.94378662109375
2022-11-25 00:00:00+00:00,304.3500061035156,307.5299987792969,302.70001220703125,305.1499938964844,305.1499938964844,470800.0,4.0,1.0,0.7500249999999999,"Over the past month, Biogen Inc. (BIIB), a stock from the same industry, has gained 9.2%. Click to get this free report BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.",257.6400146484375
2022-11-28 00:00:00+00:00,296.0299987792969,303.1099853515625,290.3099975585937,291.8999938964844,291.8999938964844,2074400.0,2.2,1.0,0.3000249999999999,"Among other stocks, Biogen Inc BIIB.Ofell 2.3% following a report of death in its experimental Alzheimer's drug trial. Rare protests in major Chinese cities over the weekend against the country's strict zero-COVID curbs have hit growth expectations in the world's second-largest economy. ""If these protests continue, it could disrupt supply chains and the reopenings, a glimpse of which we saw earlier this year,"" said Brian Klimke, director ofinvestment researchat Cetera Financial Group. New Article Among other stocks, Biogen Inc BIIB.Ofell 3.9% following a report of death during a clinical study of its experimental Alzheimer's drug. By Ankika Biswas and Shreyashi Sanyal Nov 28 (Reuters) - Wall Street's main indexes fell on Monday as protests in major Chinese cities against strict COVID-19 policies sparked concerns over economic growth and dragged commodity-linked shares lower, while Apple slid on worries about a hit to iPhone production. Shares of the tech giant AAPL.O fell 2% and weighed the most on the benchmark S&P 500 .SPX index,as growing worker unrest at the world's biggest iPhone factory in China fanned fears of a deeper hit to the already constrained production of higher-end models. New Article Some other top-ranked stocks in the healthcare sector include Biogen BIIB, Gilead GILD and Solid Biosciences SLDB. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Spectrum Pharmaceuticals, Inc. (SPPI) : Free Stock Analysis Report Solid Biosciences Inc. (SLDB) : Free Stock Analysis Report To read this article on Zacks.com click here. Spectrum Pharmaceuticals, Inc. SPPI announced that the company has received a Complete Response Letter (CRL) from the FDA regarding its new drug application (NDA) for pipeline candidate, poziotinib. New Article VIDEO: Nasdaq 100 Movers: BIIB, PDD The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing Nasdaq 100 component thus far on the day is Biogen, trading down 2.1%. Biogen is showing a gain of 24.5% looking at the year to date performance. New Article Biogen Shares of Biogen (NASDAQ: BIIB) have been on a roller coaster over the past couple of years. Unfortunately, Biogen stock fell hard this year because Medicare refuses to pay for Aduhelm citing a lack of clinical evidence that it slows patients' rate of cognitive decline. The stock rebounded this September because a late-stage clinical trial with a similar experimental therapy called lecanemab generated fairly convincing evidence that it actually works for patients with early Alzheimer's disease. New Article Biogen Inc BIIB.Ofell following a report of death during a clinical study of its experimental Alzheimer's drug. By Ankika Biswas and Noel Randewich Nov 28 (Reuters) - U.S. stocks ended sharply lower on Monday after protests in major Chinese cities against strict COVID-19 policies sparked concerns about economic growth, while Apple Inc AAPL.O slid on worries about a hit to iPhone production. Shares of the Cupertino, California tech giant weighed heavily on the benchmark S&P 500 .SPX index as worker unrest at the world's biggest iPhone factory in China fanned fears of a deeper hit to the already constrained production of higher-end phones. New Article Biogen (BIIB) dropped 4.7% after the medical journal Science reported a woman who was treated with the company's lecanemab drug candidate for Alzheimer's disease has died, citing an unpublished case report it obtained. In company news, TC BioPharm (TCBP) tumbled nearly 29% after the immunotherapy company disclosed plans for a $7.4 million private placement of nearly 1.5 million American depositary shares priced at $5 apiece, or 25.5% below Friday's closing price. CinCor Pharma (CINC) plunged almost 48% after the cardio-renal medicines company said its baxdrostat drug candidate failed to meet the primary endpoint of a statistically significant reduction from baseline levels in mean seated systolic blood pressure compared with a placebo during phase 2 testing. New Article Biogen Inc BIIB.Ofell following a report of death during a clinical study of its experimental Alzheimer's drug. By Ankika Biswas and Noel Randewich Nov 28 (Reuters) - U.S. stocks ended sharply lower on Monday after protests in major Chinese cities against strict COVID-19 policies sparked concerns about economic growth, while Apple Inc AAPL.O slid on worries about a hit to iPhone production. Shares of the Cupertino, California tech giant lost 2.6% and weighed heavily on the benchmark S&P 500 .SPX index as worker unrest at the world's biggest iPhone factory in China fanned fears of a deeper hit to the already constrained production of higher-end phones. New Article Biogen Inc BIIB.Ofell3.5% following a report of death during a clinical study of its experimental Alzheimer's drug. By Ankika Biswas and Noel Randewich Nov 28 (Reuters) - Wall Street stocks tumbled on Monday as protests in major Chinese cities against strict COVID-19 policies sparked concerns about economic growth, while Apple Inc AAPL.Oslid on worries about a hit to iPhone production. Shares of the Cupertino, California tech giant fell over 2% and weighed heavily on the benchmark S&P 500 .SPX index as worker unrest at the world's biggest iPhone factory in China fanned fears of a deeper hit to the already constrained production of higher-end phones. New Article A woman receiving lecanemab, an experimental drug developed by Eisai and its U.S. partner Biogen Inc BIIB.O, recently died from a brain haemorrhage, research paper publisher Science.org reported on Sunday. TOKYO, Nov 29 (Reuters) - Shares in Japanese drugmaker Eisai Co 4523.T headed for their biggest plunge in more than a year on Tuesday after a report that a woman in a trial of the company's Alzheimer's disease treatment died. Lecanemab was shown to slow cognitive and functional decline in a large trial of patients in the early stages of Alzheimer's disease, Eisai and Biogen said in September.",267.54632568359375
2022-11-29 00:00:00+00:00,291.1000061035156,293.9700012207031,288.44000244140625,291.4100036621094,291.4100036621094,1104000.0,2.6666666666666665,1.0,0.4166916666666666,"Eisai is developing the drug lecanemab with Biogen Inc. (BIIB). Both cases had significant comorbidities and risk factors including anticoagulation contributing to macrohemorrhage or death. Eisai's Clarity Alzheimer's disease or AD was a global confirmatory Phase 3 placebo-controlled, double-blind, parallel-group, randomized study in 1,795 people with early AD (lecanemab group: 898 placebo group: 897) at 235 sites in North America, Europe, and Asia. New Article Drugmakers Eisai Co Ltd 4523.T and Biogen BIIB.O reported in September that their therapy lecanemab could slow progress of the disease by 27% over 18 months compared with a placebo [. Eisai and Biogen are scheduled to present full data from their lecanemab study on Tuesday at the Clinical Trials on Alzheimer's Disease conference in San Francisco. A growing body of research suggests that rising levels of amyloid in Alzheimers patients act as an accelerant, causing an explosive spread of tau that forms toxic tangles inside brain cells, eventually killing them. New Article Drugmakers Eisai Co Ltd 4523.T and Biogen BIIB.O reported in September that their therapy lecanemab could slow progress of the disease by 27% over 18 months compared with a placebo [. Eisai and Biogen are scheduled to present full data from their lecanemab study on Tuesday at the Clinical Trials on Alzheimer's Disease conference in San Francisco. ""I think lecanemab has reinvigorated the idea that now you could do a combination of amyloid (and) tau, Dr. Reisa Sperling, a neurologist and Alzheimers researcher at Harvard Medical School, said in an interview. New Article A woman receiving lecanemab, an experimental drug developed by Eisai and its U.S. partner Biogen Inc BIIB.O, recently died from a brain haemorrhage, research paper publisher Science.org reported on Sunday. TOKYO, Nov 29 (Reuters) - Shares in Japanese drugmaker Eisai Co 4523.T fell more than 6% on Tuesday after a report that a woman in a trial of the company's Alzheimer's disease treatment died. Lecanemab was shown to slow cognitive and functional decline in a large trial of patients in the early stages of Alzheimer's disease, Eisai and Biogen said in September. New Article (RTTNews) - Concerns are increasing over the safety of Eisai and Biogen's (BIIB) Alzheimer's disease drug lecanemab. In September, Eisai and Biogen told analysts that a phase 3 clinical trial of lecanemab hit its primary endpoint, ending a long string of failures for anti-amyloid antibodies. Rudolph Castellani, a Northwestern University Medical Center neuropathologist who autopsied the body at the request of the patient's husband, is sure about the role lecanemab played in the death. New Article Some better-ranked stocks in the healthcare sector include Biogen BIIB, Gilead GILD and Solid Biosciences SLDB. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Solid Biosciences Inc. (SLDB) : Free Stock Analysis Report CinCor Pharma, Inc. (CINC) : Free Stock Analysis Report To read this article on Zacks.com click here. Shares of CinCor Pharma, Inc. CINC plunged 46.81% on Nov 28, after the company announced disappointing data from the phase II study, HALO, evaluating its lead candidate baxdrostat for hypertension. New Article Particularly high volume was seen for the $430 strike call option expiring July 21, 2023, with 742 contracts trading so far today, representing approximately 74,200 underlying shares of BIIB. Below is a chart showing LVS's trailing twelve month trading history, with the $45.50 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) saw options trading volume of 9,402 contracts, representing approximately 940,200 underlying shares or approximately 79.6% of BIIB's average daily trading volume over the past month, of 1.2 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $430 strike highlighted in orange: For the various different available expirations for RCL options, LVS options, or BIIB options, visit StockOptionsChannel.com. New Article Shares of Biogen BIIB were down 4.3% following reports of the death of a 65-year-old woman who was administered its anti-amyloid beta protofibril antibody candidate lecanemab in clinical studies which increases concerns over the drugs safety. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Prothena Corporation plc (PRTA) : Free Stock Analysis Report To read this article on Zacks.com click here. Prothena is evaluating PRX005, an investigational antibody that targets tau, a protein implicated in diseases including AD, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy and other tauopathies. New Article By Deena Beasley SAN FRANCISCO, Nov 29 (Reuters) - An experimental Alzheimer's disease drug from Eisai 4523.T and Biogen BIIB.O slowed cognitive decline in a closely-watched trial but may carry a risk of dangerous side effects for certain patients, according to new data presented on Tuesday. The companies said in September that the 18-month trial, which enrolled nearly 1,800 participants with early-stage Alzheimer's, found that treatment with lecanemab reduced the rate of decline on a clinical dementia scale (CDR-SB) by 27% compared to a placebo. Eisai believes the trial results prove a longstanding theory that removal of sticky deposits of a protein called amyloid beta from the brains of people with early Alzheimer's can delay advance of the debilitating disease.",268.4778137207031
2022-11-30 00:00:00+00:00,306.2799987792969,311.8800048828125,301.20001220703125,305.1700134277344,305.1700134277344,4068300.0,4.076923076923078,1.0,0.7692557692307691,"In early trading on Wednesday, shares of State Street topped the list of the day's best performing components of the S&P 500 index, trading up 5.9%. And the worst performing S&P 500 component thus far on the day is Bio-Techne, trading down 74.3%. VIDEO: S&P 500 Movers: TECH, STT The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen Inc BIIB.O jumped 4.2% after its experimental Alzheimer's drug slowed cognitive decline in a closely watched trial. By Shreyashi Sanyal Nov 30 (Reuters) - Wall Street was mixed on Wednesday, with the Dow and S&P 500 down and heavyweight growth stocks boosting the Nasdaq as focus shifts to comments from Federal Reserve Chair Jerome Powell later in the day. Powell's speech will be closely watched for signs of a slowdown in the pace of interest rate hikes by the central bank, as well as to assess the general health of the U.S. economy. New Article Biogen Inc BIIB.O jumped 6.0% after its experimental Alzheimer's drug slowed cognitive decline in a closely watched trial. By Shreyashi Sanyal Nov 30 (Reuters) - Wall Street was mixed on Wednesday, with the Dow and S&P 500 down ahead of comments from Federal Reserve Chair Jerome Powell later in the day, while Tesla shares were among top boosts to the Nasdaq after the company's sales in China nearly doubled. Hopes that the Fed will now hike rates in smaller increments and recent data pointing to a mild cooling in prices have positioned the benchmark S&P 500 index .SPX for its second straight month of gains. New Article Biogen Inc BIIB.O rose 4.0% after its experimental Alzheimer's drug made along with Japanese co Eisai Co Ltd 4523.T slowed cognitive decline in a closely watched trial. By Shreyashi Sanyal Nov 30 (Reuters) - U.S. stock index futures edged higher on Wednesday, with those of the Nasdaq rising the most on gains in Tesla shares, while investors treaded cautiously ahead of comments from Federal Reserve Chair Jerome Powell later in day. Hopes that the Fed will now hike rates in smaller increments and recent data pointing to a mild cooling in prices have positioned the benchmark S&P 500 index .SPX for its second straight month of gains. New Article Biogen BIIB said its partner Eisai presented data from their large phase III confirmatory study, Clarity AD, on anti-amyloid beta protofibril antibody candidate lecanemab (BAN2401) to treat early Alzheimers disease (early AD) at the Clinical Trials in Alzheimers Congress held in San Francisco. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report To read this article on Zacks.com click here. The study met the primary endpoint by showing that treatment with lecanemab in the early stages of the disease reduced the rate of clinical decline on the CDR-SB scale by 27% compared to placebo. New Article Biogen Inc BIIB.O jumped 4.3% after its experimental Alzheimer's drug slowed cognitive decline in a closely watched trial. For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Tesla up as sales in China nearly double in November Fed Chair Powell's speech at 1330 ET (1830 GMT) U.S. private payrolls growth slows in November - ADP U.S. preliminary Q3 GDP up more than expected Futures: Dow flat, S&P up 0.10%, Nasdaq up 0.20% Adds comments, updates prices throughout By Shreyashi Sanyal Nov 30 (Reuters) - U.S. stock indexes were set to open flat on Wednesday ahead of comments from Federal Reserve Chair Jerome Powell later in the day, while Tesla shares gained after the electric-vehicle maker's sales in China nearly doubled. Hopes that the Fed will now hike rates in smaller increments and recent data pointing to a mild cooling in prices have positioned the benchmark S&P 500 index .SPX for its second straight month of gains. New Article Unlike Eisai Co Ltd 4523.T and Biogen Inc's BIIB.O lecanemab, which appears to be on track for U.S. regulatory approval after presenting successful trial results on Tuesday, Roche's drug did not show a statistically significant benefit in patients with mild cognitive impairment and early Alzheimer's disease. By Julie Steenhuysen CHICAGO, Nov 30 (Reuters) - Swiss drugmaker Roche ROG.S is closing down most clinical trials of its experimental Alzheimer's drug gantenerumab after it failed to slow advance of the mind-robbing disease in a pair of large, late-stage studies, the company said on Wednesday. ""We remain committed to Alzheimers disease and will direct our focus to new and potentially improved approaches for new treatments,"" Rachelle Doody, Roche's global head of neurodegeneration drug development, said in a statement. New Article Biogen Inc BIIB.Ojumped after its experimental Alzheimer's drug slowed cognitive decline in a closely watched trial. By Noel Randewich and Shreyashi Sanyal Nov 30 (Reuters) - Wall Street ended sharply higher on Wednesday after Federal Reserve Chair Jerome Powell said the central bank might scale back the pace of its interest rate hikes as soon as December. And anything that gives hope to the idea the Fed is becoming less hawkish is viewed as a positive for stocks, at least on a short-term basis,"" said Chuck Carlson, Chief Executive Officer at Horizon Investment Services in Hammond, Indiana. New Article Biogen Inc BIIB.O jumped 4.7% after its experimental Alzheimer's drug slowed cognitive decline in a closely watched trial. By Noel Randewich and Shreyashi Sanyal Nov 30 (Reuters) - Wall Street ended sharply higher on Wednesday after Federal Reserve Chair Jerome Powell said the central bank might scale back the pace of its interest rate hikes as soon as December. And anything that gives hope to the idea the Fed is becoming less hawkish is viewed as a positive for stocks, at least on a short-term basis,"" said Chuck Carlson, Chief Executive Officer at Horizon Investment Services in Hammond, Indiana. New Article Biogen Inc BIIB.O jumped 4.7% after its experimental Alzheimer's drug slowed cognitive decline in a closely watched trial. By Noel Randewich and Shreyashi Sanyal Nov 30 (Reuters) - Wall Street ended sharply higher on Wednesday after Federal Reserve Chair Jerome Powell said the central bank might scale back the pace of its interest rate hikes as soon as December. And anything that gives hope to the idea the Fed is becoming less hawkish is viewed as a positive for stocks, at least on a short-term basis,"" said Chuck Carlson, Chief Executive Officer at Horizon Investment Services in Hammond, Indiana. New Article Some other top-ranked stocks in the healthcare sector include Biogen BIIB and Solid Biosciences SLDB, which carry the same rank as Gilead. Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Solid Biosciences Inc. (SLDB) : Free Stock Analysis Report To read this article on Zacks.com click here. The EC also expanded Biktarvys label for the treatment of HIV infection in virologically suppressed children who are at least two years of age and weigh at least 14 kg. New Article It remains unclear how widely the drug developed with U.S. biotech Biogen Inc BIIB.O will be used due to uncertainty over insurance coverage, including the U.S. government's Medicare plan for people age 65 and over, potential side effects and cost. So there's a massive roadblock in the way of all who could benefit from this treatment,"" said Robert Egge, Alzheimer's Association chief public policy officer Eisai confirmed on Tuesday that lecanemab - an antibody designed to remove sticky deposits of a protein called amyloid beta from the brain - reduced the rate of cognitive decline on a clinical dementia scale by 27% compared to a placebo. Michael Irizarry, Eisai's deputy chief clinical officer, told Reuters ahead of the data release that the company has been in discussions with the agency about reconsidering its policy on Alzheimer's drug coverage. New Article Biogen Inc BIIB.Ojumped 4.6% after its experimental Alzheimer's drug slowed cognitive decline in a closely watched trial. By Noel Randewich and Shreyashi Sanyal Nov 30 (Reuters) - Wall Street jumped on Wednesday after Federal Reserve Chair Jerome Powell said the central bank might scale back the pace of its interest rate hikes as soon as December. And anything that gives hope to the idea the Fed is becoming less hawkish is viewed as a positive for stocks, at least on a short-term basis,"" said Chuck Carlson, Chief Executive Officer at Horizon Investment Services in Hammond, Indiana.",289.2192687988281
2022-12-01 00:00:00+00:00,305.510009765625,306.2799987792969,299.1700134277344,301.8500061035156,301.8500061035156,1927900.0,3.5,1.0,0.6250249999999999,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $305.00 strike highlighted in red: Considering the fact that the $305.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the January 2023 expiration. New Article Over the past month, Biogen Inc. (BIIB), a stock from the same industry, has gained 9.6%. Click to get this free report Repligen Corporation (RGEN) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. New Article Using TipRanks Stock Comparison Tool, we will compare Moderna, Biogen (NASDAQ:BIIB), and IQVIA (NYSE:IQV) to pick the most promising biotech stock as per Wall Street pros. Biogen (BIIB) Stock Biogen is focused on developing therapies for neurological diseases and related therapeutic adjacencies. At $310.58, the average BIIB stock price target of $310.58 suggests a modest upside potential of 1.8% from current levels. New Article Among the largest underlying components of RSP, in trading today Biogen Inc (Symbol: BIIB) is off about 1.4%, ABIOMED, Inc. (Symbol: ABMD) is down about 0.3%, and Gilead Sciences Inc (Symbol: GILD) is up by about 0.5%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.",304.95343017578125
2022-12-02 00:00:00+00:00,299.239990234375,305.0599975585937,297.7799987792969,298.8999938964844,298.8999938964844,1682600.0,4.0,1.0,0.7500249999999999,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $305.00 strike highlighted in red: Considering the fact that the $305.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the February 2023 expiration. New Article Eli Lillys LLY phase III data showed its Alzheimers disease candidate, donanemab leads to a significant reduction of amyloid buildup in the brain compared to Biogens BIIB approved Alzheimers drug, Aduhelm. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Roivant Sciences Ltd. (ROIV) : Free Stock Analysis Report To read this article on Zacks.com click here. AstraZeneca AZN is set to acquire private biotech, Neogene Therapeutics to get access to the latters next-generation T-cell receptor therapies. New Article Another stock from the same industry, Biogen Inc. (BIIB), has gained 7.7% over the past month. Click to get this free report Sarepta Therapeutics, Inc. (SRPT) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.",307.72186279296875
2022-12-05 00:00:00+00:00,299.17999267578125,299.70001220703125,290.2300109863281,292.75,292.75,1498400.0,3.0,1.0,0.5000249999999999,"(RTTNews) - Biogen Inc. (BIIB) announced Monday that the European Medicines Agency or EMA has accepted the Marketing Authorization Application or MAA for review of tofersen to treat rare, genetic form of amyotrophic lateral sclerosis or ALS. Also included are the most current 12-month integrated results from VALOR and the OLE study that were recently published in The New England Journal of Medicine. Regulatory submissions in the U.S. and now EU represent an important step in our efforts to bring the first genetically-targeted treatment for SOD1-ALS to the ALS community as quickly as possible."" New Article Anaexs target market is highly competitive as several other pharma companies like Biogen BIIB and Eli Lilly LLY are also developing their candidates targeting the AD indication. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Anavex Life Sciences Corp. (AVXL) : Free Stock Analysis Report To read this article on Zacks.com click here. The data showed that Biogens candidate did reduce markers of amyloid in early Alzheimers disease and led to moderately less decline in measures of cognition and function than placebo at 18 months. New Article Donanemab may not be as strong of a catalyst for Eli Lilly as a similar candidate, lecanemab, could be for Biogen (NASDAQ:BIIB) and Eisai (OTCMKTS:ESALY). Add secondary potential catalysts, such as Lillys Alzheimers treatment candidate, into the mix, and its clear that theres more than hope and hype at play with this stock. Back in September, based on its strong clinical showing, the UBS analyst team argued that Mounjaro could ultimately achieve peak annual sales of $25 billion.",312.9886779785156
2022-12-06 00:00:00+00:00,292.2200012207031,295.07000732421875,288.5299987792969,291.4700012207031,291.4700012207031,1036100.0,3.0,1.0,0.5000249999999999,"Biogen BIIB announced that the European Medicines Agency (EMA) has accepted the marketing authorization application seeking approval of antisense drug, tofersen in patients with amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutation. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report To read this article on Zacks.com click here. ALS is a rare neurodegenerative disease whose progression leads to a steady decline in the ability to move, speak, eat and eventually breathe. New Article Biogen Inc Contrary to most biotech stocks, Biogen Inc BIIB is highly profitable and has a deep and well-established pipeline of drugs. Image Source: Zacks Investment Research Pictured: BIIB vaulted 40% in September after releasing positive drug data. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Eisai Co. (ESALY) : Free Stock Analysis Report atai Life Sciences N.V. (ATAI) : Free Stock Analysis Report Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report ARK Innovation ETF (ARKK): ETF Research Reports Seelos Therapeutics, Inc. (SEEL) : Free Stock Analysis Report COMPASS Pathways PLC Sponsored ADR (CMPS) : Free Stock Analysis Report Mind Medicine MindMed Inc. (MNMD) : Free Stock Analysis Report Cybin Inc. (CYBN) : Free Stock Analysis Report To read this article on Zacks.com click here.",305.8036193847656
2022-12-07 00:00:00+00:00,292.5599975585937,293.6000061035156,287.1000061035156,292.1499938964844,292.1499938964844,1112700.0,3.0,1.0,0.5000249999999999,"Biogen BIIB and partner Sage Therapeutics SAGE completed the rolling submission of the new drug application (NDA) to the FDA for zuranolone for the potential treatment of major depressive disorder (MDD) and postpartum depression (PPD). Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report To read this article on Zacks.com click here. Clinical data on zuranolone demonstrated that the candidate achieved consistent, rapid, and sustained reductions in depressive symptoms with a good safety profile. New Article Biogen (NASDAQ: BIIB) is a business that generates more than $10 billion in revenue each year, with its multiple sclerosis treatments bringing in the bulk of its sales. With the company's sales declining in recent years, Biogen needs a catalyst to turn things around and help inject some bullishness behind the business, and having an effective treatment for Alzheimer's could play a huge role in that objective. Next year could prove to be a pivotal one for Biogen as investors can finally get some much-needed answers about whether lecanemab, a promising Alzheimer's treatment, could be the game changer the healthcare company is hoping that it will be for the business.",302.9345703125
2022-12-08 00:00:00+00:00,291.8599853515625,292.32000732421875,286.7200012207031,289.1000061035156,289.1000061035156,1695600.0,2.6,1.0,0.400025,"A couple of better-ranked stocks in the healthcare space include Merck MRK and Biogen BIIB. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report To read this article on Zacks.com click here. Novartis NVS announced that the late-stage APPOINT-PNH study (NCT04820530) evaluating investigational oral monotherapy iptacopan in complement-inhibitor-nave (including anti-C5 therapies) adults with paroxysmal nocturnal hemoglobinuria (PNH) met its primary endpoint. New Article Some other top-ranked stocks in the overall healthcare sector are Gilead Sciences, Inc. GILD, Biogen BIIB and Vertex Pharmaceuticals VRTX. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report Esperion Therapeutics, Inc. (ESPR) : Free Stock Analysis Report To read this article on Zacks.com click here. The CLEAR Outcomes is a phase III, event-driven, randomized, multicenter, double-blind, placebo-controlled trial designed to evaluate whether treatment with bempedoic acid reduces the risk of cardiovascular events in patients with or at high risk for cardiovascular disease with documented statin intolerance (inability to tolerate two or more statins, one at a low dose) and elevated LDL-cholesterol levels (fasting blood LDL-C  100 (2.6 mmol/L)). New Article One company to watch right now is Biogen (BIIB). BIIB is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. BIIB is also sporting a PEG ratio of 1.83. New Article On Nov. 30, Lilly said that donanemab, in its phase 3 study of early Alzheimer's patients, reduced amyloid plaque compared to Aduhelm, developed by Biogen. CRISPR doesn't have a marketed product yet, but it expects to complete its New Drug Application for exa-cel to the FDA in the first quarter of 2023 and its submissions in Great Britain and the rest of Europe later this year. The subsidiary paired with professors from European colleges to find computer algorithms to predict how different body cells will react to familiar compounds. New Article Over the past month, Biogen Inc. (BIIB), a stock from the same industry, has gained 3.5%. Click to get this free report Mirati Therapeutics, Inc. (MRTX) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.",294.2851257324219
2022-12-09 00:00:00+00:00,289.1000061035156,292.9700012207031,285.1400146484375,285.3699951171875,285.3699951171875,982600.0,3.6666666666666665,1.0,0.6666916666666666,"Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Techne (TECH). Investors should feel comfortable knowing that BIIB likely has seen a stronger improvement to its earnings outlook than TECH has recently. BIIB currently has a forward P/E ratio of 17.01, while TECH has a forward P/E of 39.26. New Article (RTTNews) - The U.S. Food and Drug Administration has accepted for review the abbreviated Biologics License Application (aBLA) for BIIB800, a biosimilar candidate referencing ACTEMRA (tocilizumab), an anti-interleukin-6 receptor monoclonal antibody, Biogen Inc. (BIIB) said in a statement on Friday. In September 2022, the Marketing Authorization Application for BIIB800 was accepted for review by the European Medicines Agency. ACTEMRA is indicated for several indications, including moderate to severe rheumatoid arthritis in adults as well as juvenile idiopathic polyarthritis and systemic juvenile idiopathic arthritis. New Article Biogen Inc. (BIIB) closed the most recent trading day at $285.37, moving -1.29% from the previous trading session. BIIB's full-year Zacks Consensus Estimates are calling for earnings of $17 per share and revenue of $10.07 billion. Investors should also note that BIIB has a PEG ratio of 1.7 right now.",285.6546630859375
2022-12-12 00:00:00+00:00,285.0,290.8599853515625,282.57000732421875,290.5899963378906,290.5899963378906,1067300.0,2.0,1.0,0.250025,"Among the largest underlying components of XBI, in trading today Horizon Therapeutics plc (Symbol: HZNP) is up about 14.6%, Biogen Inc (Symbol: BIIB) is up about 0.1%, and Veracyte Inc (Symbol: VCYT) is up by about 3%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.",275.2310485839844
2022-12-14 00:00:00+00:00,290.1499938964844,294.17999267578125,287.1499938964844,289.04998779296875,289.04998779296875,905300.0,3.0,1.0,0.5000249999999999,"Donanemab is expected to be a key competitor to Biogens BIIB controversial Alzheimers drug Aduhelm (aducanumab), which was approved by the FDA last year in June. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Kamada Ltd. (KMDA) : Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report To read this article on Zacks.com click here. However, lower revenues from the cancer drug Alimta due to its loss of patent exclusivity and the negative impact of foreign exchange rates are expected to offset some of the top-line gains.",272.15576171875
2022-12-15 00:00:00+00:00,287.5799865722656,287.8999938964844,282.0400085449219,283.44000244140625,283.44000244140625,1090200.0,2.0,1.0,0.250025,"Biogen Inc. (BIIB) closed the most recent trading day at $283.44, moving -1.94% from the previous trading session. Meanwhile, BIIB's PEG ratio is currently 1.7. BIIB's industry had an average PEG ratio of 1.35 as of yesterday's close.",270.86248779296875
2022-12-21 00:00:00+00:00,288.0899963378906,288.29998779296875,284.8699951171875,286.8599853515625,286.8599853515625,797000.0,3.0,1.0,0.5000249999999999,"Biogen Inc. (BIIB) closed at $286.86 in the latest trading session, marking a -0.23% move from the prior day. BIIB's full-year Zacks Consensus Estimates are calling for earnings of $16.98 per share and revenue of $10.07 billion. We can also see that BIIB currently has a PEG ratio of 1.69.",278.3043518066406
2022-12-22 00:00:00+00:00,283.6099853515625,283.6499938964844,278.3099975585937,280.6099853515625,280.6099853515625,946500.0,3.5,1.0,0.6250249999999999,"Pharmaceutical giant Eli Lilly's (NYSE: LLY) potential Alzheimer's disease treatment is in late-stage clinical trials, and could be the next one to cross the regulatory finish line. If the results from this larger trial are positive, Eli Lilly could earn approval for an Alzheimer's disease medicine that could easily achieve peak annual sales well above $1 billion. Plenty of other reasons to buy Donanemab would be a welcome addition to Eli Lilly's portfolio, which already boasts several blockbuster products whose sales are still growing fast -- among them, the diabetes medicine Trulicity and the cancer treatment Verzenio. New Article Eisai and its U.S. partner Biogen Inc BIIB.O are planning to seek full approval of their experimental Alzheimer's drug lecanemab in the United States, Europe and Japan next year. The company developed the test with Japanese drugmaker Eisai Co 6869.T and gained approval from regulators on Dec. 19, it said in a statement. The test kit uses a small amount of the patient's blood to measure amyloid beta accumulation in the brain, allowing for earlier diagnosis and treatment.",281.1760559082031
2022-12-23 00:00:00+00:00,280.45001220703125,280.45001220703125,276.07000732421875,279.1600036621094,279.1600036621094,624800.0,2.8,1.0,0.4500249999999999,"Shares in Eisai and U.S. partner Biogen Inc BIIB.O have been whipsawed for years on the prospects of their experimental treatments for the brain-wasting disease that affects millions across the globe. Science Insider earlier reported a 79-year-old Florida woman in a trial of the antibody treatment died in mid-September after experiencing swelling and bleeding in the brain and seizures. After a previous death in the lecanemab trial, some analysts said it was not clear if use of the drug was raising the risk of bleeding, and cautioned against concurrent use of blood thinners. New Article Adds Eisai's response Dec 23 (Reuters) - An influential drug pricing research group said Eisai Co Ltd 4523.T and Biogen Inc's BIIB.O new Alzheimer's disease treatment lecanemab should be priced lower than the drug Aduhelm that was developed by the companies. In a draft report released on Thursday, the Institute for Clinical and Economic Review (ICER) said a price range of between $8,500 and $20,600 annually for lecanemab would meet some commonly used thresholds for cost effectiveness. Biogen halved the price of its first Alzheimer's drug Aduhelm last year to $28,200 for a person with average weight, amid tepid sales and reimbursement hurdles. New Article Biogen (NASDAQ: BIIB) is one of the biotech-industry's giants and success stories. But Biogen's portfolio is aging -- and that means generic competition has started to weigh on the revenue of its biggest products. Green flag: The potential of lecanemab Biogen's 2022 share gains don't reflect its first months of the year. New Article Among the hottest buys of late are chipmaker Nvidia (NASDAQ: NVDA), and healthcare companies Biogen (NASDAQ: BIIB) and Gilead Sciences (NASDAQ: GILD). At a whopping 71 times earnings, this isn't a cheap stock, but as noted above, profits have been nosediving due to a combination of rising prices and falling sales. Unless you have a strong risk tolerance and can stomach the inevitable rapid price movements, you might be better off putting Biogen on a watch list and waiting to see what happens, rather than placing an order for the healthcare stock. New Article Dec 23 (Reuters) - An influential drug pricing research group said Eisai Co Ltd 4523.T and Biogen Inc's BIIB.O new Alzheimer's disease treatment lecanemab should be priced lower than the drug Aduhelm that was developed by the companies. In a draft report released on Thursday, the Institute for Clinical and Economic Review (ICER) said a price range of between $8,500 and $20,600 annually for lecanemab would meet some commonly used thresholds for cost effectiveness. Biogen halved the price of its first Alzheimer's drug Aduhelm last year to $28,200 for a person with average weight, amid tepid sales and reimbursement hurdles.",282.3067932128906
2022-12-27 00:00:00+00:00,279.8900146484375,279.8900146484375,273.3800048828125,274.7699890136719,274.7699890136719,638600.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of IWS, in trading today AFLAC Inc (Symbol: AFL) is up about 1%, Motorola Solutions Inc (Symbol: MSI) is down about 0.1%, and Biogen Inc (Symbol: BIIB) is lower by about 0.9%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. New Article iShares U.S. Healthcare ETF IYH $283.90 $312.76 10.16% DexCom Inc DXCM $111.44 $125.00 12.17% Biogen Inc BIIB $279.16 $309.54 10.88% Moderna Inc MRNA $199.08 $220.50 10.76% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of IYH's underlying holdings with notable upside to their analyst target prices are DexCom Inc (Symbol: DXCM), Biogen Inc (Symbol: BIIB), and Moderna Inc (Symbol: MRNA). Similarly, BIIB has 10.88% upside from the recent share price of $279.16 if the average analyst target price of $309.54/share is reached, and analysts on average are expecting MRNA to reach a target price of $220.50/share, which is 10.76% above the recent price of $199.08.",288.5226135253906
2022-12-28 00:00:00+00:00,275.6400146484375,276.9200134277344,272.6400146484375,274.0400085449219,274.0400085449219,521000.0,2.5,1.0,0.375025,"Biogen Inc. (BIIB) closed the most recent trading day at $274.04, moving -0.27% from the previous trading session. It is also worth noting that BIIB currently has a PEG ratio of 1.62. BIIB's industry had an average PEG ratio of 1.27 as of yesterday's close. New Article Dec 28 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved TG Therapeutics Inc's TGTX.O drug for patients with relapsing forms of multiple sclerosis, pitting it against rivals from Roche ROG.S and Novartis NOVN.S, according to the health regulator's website. (Reporting by Sriparna Roy, Khushi Mandowara and Raghav Mahobe in Bengaluru; Editing by Anil D'Silva) ((Sriparna.Roy@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article TG Therapeutics did not immediately respond to a Reuters request for details on the pricing and availability of the drug. At least two analysts ahead of the approval had expected Briumvi to cost less than existing drugs in the same class of treatments, which are priced between $65,000 and $83,000 annually. The approval of TG's first commercial product comes at a time when the company announced cost-cut plans following the withdrawal of its lymphatic cancer drug earlier this year. New Article Healthcare company Biogen (NASDAQ: BIIB) has been a volatile one to invest in over the years, to put it mildly. BIIB data by YCharts In the third quarter, Biogen had sales of $2.5 billion, a year-over-year decline of 10%. Why the volatility is likely to continue A positive reading from a study is encouraging news but all investors need to do is look at the roller-coaster ride that Aduhelm (another Alzheimer's treatment) gave Biogen's stock as evidence that the business is by no means in the clear, and that it may still be a long road ahead.",275.1343994140625
2022-12-30 00:00:00+00:00,274.9800109863281,277.1499938964844,272.20001220703125,276.9200134277344,276.9200134277344,640700.0,2.5,1.0,0.375025,"Especially high volume was seen for the $200 strike put option expiring January 20, 2023, with 404 contracts trading so far today, representing approximately 40,400 underlying shares of BIIB. Below is a chart showing PFSI's trailing twelve month trading history, with the $55 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 4,916 contracts, representing approximately 491,600 underlying shares or approximately 43% of BIIB's average daily trading volume over the past month, of 1.1 million shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $200 strike highlighted in orange: And 3M Co (Symbol: MMM) saw options trading volume of 12,185 contracts, representing approximately 1.2 million underlying shares or approximately 42.7% of MMM's average daily trading volume over the past month, of 2.9 million shares. New Article Oversight and Reform Committee Chairwoman Carolyn Maloney and Energy and Commerce Committee Chairman Frank Pallone, Jr. released a staff report following an 18-month investigation into FDA's regulatory review and approval process of Aduhelm as well as Biogen's pricing of the Alzheimer's drug. The report also said that Biogen ""initially set an unjustifiably high price for Aduhelm, at $56,000 per year, to 'make history' for the company, despite the impact on patients and the Medicare program."" Aduhelm was surrounded by controversies since the U.S. FDA approved it for the treatment for Alzheimer's in June last year.",271.3181457519531
2023-01-03 00:00:00+00:00,276.7300109863281,278.0,272.3900146484375,272.6300048828125,272.6300048828125,1090300.0,2.5,1.0,0.375025,"Key approvals will continue to roll in Contrary to the broader market, Eli Lilly has performed exceedingly well over the past 12 months, with the company's shares up by 32% in this period. Eli Lilly recently reported interim results from a phase 3 study in which donanemab proved more effective at clearing brain amyloid plaque than Biogen's approved AD medicine, Aduhelm. Either way, a company like Eli Lilly that offers necessary products and has a strong track record of sustained dividend increases is especially attractive given the current economic conditions. New Article In the latest trading session, Biogen Inc. (BIIB) closed at $272.63, marking a -1.55% move from the previous day. Investors should also note that BIIB has a PEG ratio of 1.63 right now. BIIB's industry had an average PEG ratio of 1.27 as of yesterday's close.",274.79840087890625
2023-01-04 00:00:00+00:00,275.3800048828125,275.44000244140625,269.8800048828125,270.8099975585937,270.8099975585937,1089100.0,3.5,1.0,0.6250249999999999,"(RTTNews) - Biogen Inc. (BIIB) Wednesday announced a license and collaboration agreement with Alcyone Therapeutics to develop ThecaFlex DRx System, an implantable medical device. Biogen said Alcyone's ThecaFlex DRx is intended for subcutaneous delivery of antisense oligonucleotide therapies into the intrathecal space. The ThecaFlex DRx System is expected to help improve the patient treatment experience for spinal muscular atrophy and amyotrophic lateral sclerosis. New Article Lecanemab, developed by Eisai and Biogen Inc BIIB.O, is an antibody designed to remove sticky deposits of a protein called amyloid beta from the brains of early-stage Alzheimer's patients. ""We agree that this case raises important management issues for patients with Alzheimer's disease,"" Eisai researchers said in a response to the Northwestern analysis. They noted that the deceased patient carried two copies of a gene known to increase the risk of developing Alzheimer's and of brain swelling from treatment with an anti-amyloid therapy.",275.7679138183594
2023-01-05 00:00:00+00:00,269.3299865722656,272.79998779296875,265.32000732421875,271.5899963378906,271.5899963378906,1195300.0,3.0,1.0,0.5000249999999999,"Adds details on appointments, background Jan 5 (Reuters) - Biogen Inc BIIB.O said on Thursday it will split its research and development division into two units ahead of a highly anticipated decision by the U.S. health regulator about the company's second Alzheimer's drug. The company named interim R&D chief Priya Singhal as executive vice president, head of development following the separation. Both Singhal and the new research head will report to Chief Executive Officer Christopher Viehbacher, the former Sanofi SA SASY.PA boss who was appointed after a months-long search to replace Michel Vounatsos. New Article Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $270.00 strike highlighted in red: Considering the fact that the $270.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the February 24th expiration. New Article Biogen Inc. BIIB announced that it has entered into a license and collaboration agreement with Massachusetts-based privately held biotech, Alcyone Therapeutics to develop the latters ThecaFlex DRx system, an implantable medical device designed for subcutaneous delivery of antisense oligonucleotide (ASO) therapies into the intrathecal space. Alcyone will also be eligible to receive up to $41 million from BIIB as potential milestone payments upon achieving certain development and commercial milestones. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report To read this article on Zacks.com click here. New Article A bullish investor could look at BIIB's 29.7 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of BIIB shares: Looking at the chart above, BIIB's low point in its 52 week range is $187.16 per share, with $311.88 as the 52 week high point  that compares with a last trade of $269.41. In trading on Thursday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 29.7, after changing hands as low as $265.32 per share.",276.7720947265625
2023-01-06 00:00:00+00:00,276.010009765625,292.5899963378906,272.44000244140625,279.25,279.25,3729300.0,3.4,1.0,0.600025,"BIIB Revenue (Quarterly) data by YCharts Furthermore, investors have put a lot of hope in Biogen's potential AD treatment. Let's look at one company in each category: AstraZeneca (NASDAQ: AZN) and Biogen (NASDAQ: BIIB). It was not performing that well for most of 2022 until it announced positive interim results from an ongoing clinical trial for lecanemab, a potential therapy for Alzheimer's disease (AD). New Article (RTTNews) - Eisai has submitted a supplemental biologics license application to the U.S. Food and Drug Administration for traditional approval of leqembi (lecanemab-irmb) for the treatment of alzheimer's disease, Eisai Co., Ltd. and Biogen Inc. (BIIB) said in a statement on Friday. Eisai said it has initiated submission of data for BLA to the National Medical Products Administration (NMPA) of China in December 2022. Eisai plans to file for marketing authorization applications of lecanemab in Japan and EU by the end of Eisai's fiscal year 2022, which ends March 31, 2023. New Article Looking at individual holdings, Phillips 66 (PSX) accounts for about 1.24% of total assets, followed by Devon Energy Corp (DVN) and Biogen Inc (BIIB). Click to get this free report iShares Morningstar MidCap Value ETF (IMCV): ETF Research Reports Biogen Inc. (BIIB) : Free Stock Analysis Report Devon Energy Corporation (DVN) : Free Stock Analysis Report Phillips 66 (PSX) : Free Stock Analysis Report Vanguard MidCap Value ETF (VOE): ETF Research Reports iShares Russell MidCap Value ETF (IWS): ETF Research Reports To read this article on Zacks.com click here. If you're interested in broad exposure to the Mid Cap Value segment of the US equity market, look no further than the iShares Morningstar MidCap Value ETF (IMCV), a passively managed exchange traded fund launched on 06/28/2004. New Article Adds details Jan 6 (Reuters) - The U.S. Food and Drug Administration approved Eisai Co Ltd's 4523.T and Biogen Inc's BIIB.O Alzheimer's drug lecanemab for patients in the earliest stages of the mind-wasting disease, the agency said on Friday. The drug, to be sold under the brand Leqembi, belongs to a class of treatments that aims to slow the advance of the neurodegenerative disease by removing sticky clumps of the toxic brain protein known as beta amyloid. Initial access to the drug likely will be limited by a number of factors including reimbursement decisions from Medicare, the U.S. government insurance program for Americans aged 65 and older who represent some 90% of individuals likely to be eligible for Leqembi. New Article By Sinad Carew and Ankika Biswas Jan 6 (Reuters) - Wall Street's main indexes all gained more than 2% on Friday after December payrolls expanded more than expected even as wage increases slowed and services activity contracted, easing worries about the Federal Reserve's interest rate hiking path. For the gains, John Augustine, chief investment officer at Huntington National Bank in Columbus, Ohio, pointed to a calming of anxiety that the Fed would raise rates so much that it causes a recession. Fed officials on Friday acknowledged cooling wage growth and other signs of a gradually slowing economy, with Atlanta President Raphael Bostic hinting at the chance of a quarter percentage point hike at the next policy meeting.",273.2493896484375
2023-01-09 00:00:00+00:00,280.5400085449219,281.989990234375,269.0599975585937,274.7200012207031,274.7200012207031,1715700.0,3.5,1.0,0.6250249999999999,"Jan 9 (Reuters) - The $26,500-per-year price tag for Eisai Co Ltd 4523.T and Biogen Inc's BIIB.O newly approved Alzheimer's disease drug is slightly above expectations, but should not dent demand for the promising therapy, Wall Street analysts said. ""As a result of this higher than expected pricing, we think it is reasonable to see peak sales reach $15.2 billion worldwide,"" BMO analyst Evan Seigerman said in a research note. Still, initial patient access will be limited by several factors including reimbursement restrictions by Medicare, the U.S. government insurance program for Americans aged 65 and older who represent some 90% of individuals likely to be eligible for Leqembi. New Article Biogen BIIB announced that the FDA has granted accelerated approval to it and partner Eisais anti-amyloid beta protofibril antibody candidate lecanemab to treat early Alzheimers disease (early AD). Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Anika Therapeutics Inc. (ANIK) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Research Based on data from this study, Eisai also filed a supplemental biologics license application (sBLA) to the FDA to get a traditional approval of Leqembi. New Article Biogen Inc. (BIIB) closed the most recent trading day at $274.72, moving -1.62% from the previous trading session. It is also worth noting that BIIB currently has a PEG ratio of 1.76. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. New Article TOKYO, Jan 10 (Reuters) - Shares of Eisai Co Ltd 4523.T surged in early trade in Tokyo on Tuesday after the U.S. Food and Drug Administration approved the Alzheimer's drug lecanemab developed by it and Biogen Inc BIIB.O for patients in the earliest stages of the disease. The drug, to be sold under the brand Leqembi, belongs to a class of treatments that aim to slow the advance of the neurodegenerative disease by removing sticky clumps of the toxic protein beta amyloid from the brain. (Reporting by David Dolan; Editing by Himani Sarkar) ((david.dolan@thomsonreuters.com; +81 3 4563 2708;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",278.9385681152344
2023-01-10 00:00:00+00:00,276.8299865722656,283.3800048828125,275.32000732421875,281.4599914550781,281.4599914550781,1379200.0,4.0,1.0,0.7500249999999999,"Jan 10 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T said on Tuesday it had submitted a marketing application to the European health regulator for review of its Alzheimer's drug lecanemab, which was recently granted accelerated approval in the United States. (Reporting by Bhanvi Satija in Bengaluru; Editing by Rashmi Aich) ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article (RTTNews) - Eisai has submitted a marketing authorization application or MAA for lecanemab (Brand Name in the U.S.: leqembi), an investigational anti-amyloid beta (A) protofibril antibody, for the treatment of early Alzheimer's disease to the European Medicines Agency, Eisai Co., Ltd. and Biogen Inc. (BIIB) said in a statement on Tuesday. In the U.S., lecanemab was granted accelerated approval as a treatment for Alzheimer's disease by the U.S. Food and Drug Administration on January 6, 2023. Eisai submitted a Supplemental Biologics License Application (sBLA) to the FDA for approval under the traditional pathway on the same day. New Article You can't blame Biogen (NASDAQ: BIIB) investors if they feel a sense of dj vu. CMS was clear in its decision about Aduhelm that it won't pay for the use of monoclonal antibodies that are directed against amyloid for the treatment of Alzheimer's disease. This means that Medicare recipients (who make up the majority of Alzheimer's patients in the U.S.) won't receive any financial assistance in paying for Leqembi.",277.0397644042969
2023-01-11 00:00:00+00:00,281.8500061035156,285.3299865722656,281.239990234375,285.0299987792969,285.0299987792969,1386200.0,3.6666666666666665,1.0,0.6666916666666666,"By Ahmed Aboulenein WASHINGTON, Jan 11 (Reuters) - The U.S. government will announce a list of 10 prescription drugs for which it plans to negotiate the prices for Medicare recipients on Sept. 1, and the prices a year later, a top Biden administration official said on Wednesday. President Joe Biden in August signed into law the Inflation Reduction Act, which among its provisions for the first time allows the federal Medicare health plan for people age 65 and older and the disabled to negotiate prices on some of the most expensive drugs. The U.S. Department of Health and Human Services (HHS) and the Centers of Medicare & Medicaid Services (CMS) - which oversees Medicare and the negotiation process - announced the specific timeline for the first year of negotiations on Wednesday. New Article Biogen Inc. BIIB and partner Eisai announced that the latter has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) seeking approval for their anti-amyloid beta protofibril antibody candidate, lecanemab to treat early Alzheimers disease (mild cognitive impairment due to Alzheimers disease [AD] and mild AD dementia). Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Syndax Pharmaceuticals, Inc. (SNDX) : Free Stock Analysis Report To read this article on Zacks.com click here. Data from the same showed that treatment with lecanemab demonstrated a reduction of clinical decline in early AD and is subject to validation to determine whether the EMA accepts the application for review. New Article 1 to avoid: Biogen Biogen (NASDAQ: BIIB) has many of the trappings of a superstar pharma stock. Discerning between popular growth stocks that have room to run and those that will leave your portfolio in the red isn't an easy task, especially for companies in the biopharma sector. The big catalyst for the business this year is that the Food and Drug Administration just gave its stamp of approval for the company's latest Alzheimer's disease candidate called lecanemab.",271.4525451660156
2023-01-12 00:00:00+00:00,283.95001220703125,288.2099914550781,280.0599975585937,288.0799865722656,288.0799865722656,1218000.0,3.5,1.0,0.6250249999999999,"Looking at individual holdings, Horizon Therapeutics Public Limited Company (HZNP) accounts for about 1.64% of total assets, followed by Biogen Inc. (BIIB) and Halozyme Therapeutics Inc. (HALO). Click to get this free report SPDR S&P Biotech ETF (XBI): ETF Research Reports Biogen Inc. (BIIB) : Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO) : Free Stock Analysis Report iShares Biotechnology ETF (IBB): ETF Research Reports Horizon Therapeutics Public Limited Company (HZNP) : Free Stock Analysis Report First Trust NYSE Arca Biotechnology ETF (FBT): ETF Research Reports To read this article on Zacks.com click here. It has amassed assets over $8.37 billion, making it one of the largest ETFs attempting to match the performance of the Healthcare - Biotech segment of the equity market. New Article Biogen Inc. (BIIB) closed at $288.08 in the latest trading session, marking a +1.07% move from the prior day. Also, we should mention that BIIB has a PEG ratio of 1.8. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here.",279.66839599609375
2023-01-13 00:00:00+00:00,286.989990234375,289.510009765625,285.1499938964844,288.0400085449219,288.0400085449219,1008000.0,4.0,1.0,0.7500249999999999,"Prothena Corporation plc Price and Consensus Prothena Corporation plc price-consensus-chart | Prothena Corporation plc Quote We remind investors that the FDAs approval of Biogens BIIB and Eisais controversial AD drug, Aduhelm, in June 2021 put this space in the spotlight. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Prothena Corporation plc (PRTA) : Free Stock Analysis Report To read this article on Zacks.com click here. The significant increase in the share price can be attributed to the recent spotlight on the Alzheimers Disease (AD) space, as investors are now optimistic about the pipeline candidates of companies developing treatments for the same and Prothena is one of them.",277.0163269042969
2023-01-17 00:00:00+00:00,287.32000732421875,290.1300048828125,286.3299865722656,289.5899963378906,289.5899963378906,1167200.0,2.0,1.0,0.250025,"Companies such as Biogen (NASDAQ: BIIB) and Eisai (OTC: ESALY), which recently secured U.S. regulatory approval for Alzheimer's disease drug Lequembi, could see their profits zapped if major progress is made with ICE. Head-spinning implications The research team is already moving forward with testing this same approach, which they call ICE (inducible changes to the epigenome) in monkeys. Another private company, Rejuvenate Bio, is also pursuing similar research and recently reported results from a study where it modestly increased longevity in elderly mice.",283.7479248046875
2023-01-18 00:00:00+00:00,290.5799865722656,291.9100036621094,282.6499938964844,283.4700012207031,283.4700012207031,1322300.0,3.0,1.0,0.5000249999999999,"Especially high volume was seen for the $345 strike put option expiring January 20, 2023, with 1,119 contracts trading so far today, representing approximately 111,900 underlying shares of BIIB. Below is a chart showing COP's trailing twelve month trading history, with the $130 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 5,725 contracts thus far today. That number of contracts represents approximately 572,500 underlying shares, working out to a sizeable 46.7% of BIIB's average daily trading volume over the past month, of 1.2 million shares.",289.53814697265625
2023-01-19 00:00:00+00:00,281.3999938964844,284.3599853515625,280.1300048828125,280.1300048828125,280.1300048828125,623100.0,3.0,1.0,0.5000249999999999,"Five years ago, pharmaceutical manufacturer Biogen (NASDAQ: BIIB) had a growing business, and Tecfidera was its star multiple sclerosis treatment. BIIB revenue (TTM); data by YCharts. Losses in exclusivity have hammered Tecfidera's sales, and because it has played so much of a role in Biogen's business, total product revenue of $8.8 billion has also been on the decline. New Article In June 2021, shares of Biogen (NASDAQ: BIIB) soared to more than $400 after the Food and Drug Administration (FDA) granted accelerated approval to its Alzheimer's treatment Aduhelm. In the end, there wasn't much support for the treatment in the medical community, and Biogen opted to ""substantially"" scale back on its efforts to commercialize Aduhelm, effectively pivoting to lecanemab. But until the FDA makes a ruling on Leqembi for full, traditional approval, there is going to be considerable uncertainty surrounding the healthcare stock, as that decision could lead to either a surge in price or a significant sell-off.",291.01983642578125
2023-01-20 00:00:00+00:00,282.3599853515625,286.3999938964844,280.2799987792969,285.7699890136719,285.7699890136719,1101500.0,3.0,1.0,0.5000249999999999,"Image Source: Zacks Investment Research The AD target market is highly competitive as several other pharma companies like Anavex Life Sciences AVXL, Biogen BIIB and Roche RHHBY have their drugs targeting the AD indication. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Anavex Life Sciences Corp. (AVXL) : Free Stock Analysis Report To read this article on Zacks.com click here. Eli Lilly LLY announced that the FDA issued a complete response letter (CRL) to its regulatory filing seeking accelerated approval of a new Alzheimers drug, donanemab. New Article The setback for Lilly comes just weeks after the FDA granted Biogen Inc BIIB.O and Japanese drugmaker Eisai Co Ltd's 4523.T accelerated approval for their Alzheimer's drug Leqembi. Jan 20 (Reuters) - The U.S. health regulator's rejection of accelerated approval for Eli Lilly and Co's LLY.N Alzheimer's disease drug extends the market lead for rivals Eisai and Biogen's treatment by months, analysts said. ""This is a modest positive for Biogen"" because it delays donanemab's launch, Jefferies analyst Michael Yee said, adding that Eli Lilly could file for traditional approval by mid-2023. New Article Lilly's shares fell 1.3% to $346.6, while Biogen Inc's BIIB.O shares rose 1.5% to $284.5 in morning trade on Friday. The U.S. Food and Drug Administration (FDA) declined to approve donanemab's application because Lilly had not submitted data from enough patients who were treated for at least a year, the drugmaker said late Thursday. ""This is a modest positive for Biogen"" because it delays donanemab's launch, Jefferies analyst Michael Yee said, adding that Eli Lilly could file for traditional approval by mid-2023.",285.4320983886719
2023-01-23 00:00:00+00:00,285.9700012207031,292.32000732421875,285.5199890136719,291.92999267578125,291.92999267578125,1553000.0,2.0,1.0,0.250025,"Taking into account individual holdings, Horizon Therapeutics Public Limited Company (HZNP) accounts for about 1.64% of the fund's total assets, followed by Biogen Inc. (BIIB) and Halozyme Therapeutics Inc. (HALO). Click to get this free report SPDR S&P Biotech ETF (XBI): ETF Research Reports Biogen Inc. (BIIB) : Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO) : Free Stock Analysis Report iShares Biotechnology ETF (IBB): ETF Research Reports Horizon Therapeutics Public Limited Company (HZNP) : Free Stock Analysis Report First Trust NYSE Arca Biotechnology ETF (FBT): ETF Research Reports To read this article on Zacks.com click here. However, some investors believe in the possibility of beating the market through exceptional stock selection, and choose a different type of fund that tracks non-cap weighted strategies: smart beta.",276.9837341308594
2023-01-24 00:00:00+00:00,291.92999267578125,293.3399963378906,289.3299865722656,291.8800048828125,291.8800048828125,911000.0,3.5,1.0,0.6250249999999999,"Biogen Inc. (BIIB), which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. New Article Biogen Inc. (BIIB) closed at $291.88 in the latest trading session, marking a -0.02% move from the prior day. Meanwhile, BIIB's PEG ratio is currently 1.84. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here.",279.3725280761719
2023-01-25 00:00:00+00:00,291.44000244140625,292.7900085449219,288.3699951171875,292.3399963378906,292.3399963378906,707400.0,2.5,1.0,0.375025,"Jan 25 (Reuters) - Swiss drug contract manufacturer Lonza LONN.S reported full-year core earnings above expectations, as demand from biopharmaceutical companies remained strong throughout the year. That was slightly more than average market expectations of 1.95 billion francs, according to an analyst poll posted on the company's website. (Reporting by Tristan Chabba in Gdansk and Ludwig Burger in Frankfurt Editing by Paul Carrel) ((ludwig.burger@thomsonreuters.com; +49 30 220133634;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Less than two weeks earlier, the agency approved accelerated approval for Eisai's (OTC: ESALY) and Biogen's (NASDAQ: BIIB) Alzheimer's disease drug Leqembi. Last week, the FDA issued a complete response letter for Eli Lilly's (NYSE: LLY) accelerated approval submission of experimental Alzheimer's disease drug donanemab. Last year, the Centers for Medicare and Medicaid Services (CMS) decided against providing reimbursement for Biogen's Alzheimer's disease drug Aduhelm, which was also developed with Eisai.",268.8586120605469
2023-01-26 00:00:00+00:00,292.3399963378906,293.010009765625,289.6700134277344,291.9200134277344,291.9200134277344,557800.0,3.4,1.0,0.600025,"(RTTNews) - The European Medicines Agency has accepted a marketing authorization application for lecanemab (Brand Name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (A) protofibril antibody, for the treatment of early Alzheimer's disease with confirmed amyloid pathology, for review following a standard timeline, Eisai Co., Ltd. and Biogen Inc. (BIIB) said in a statement. On the same day, Eisai submitted a Supplemental Biologics License Application to the FDA for approval under the traditional pathway based on the results from the Phase III Clarity AD confirmatory study. In Japan, Eisai submitted a marketing authorization application to the Pharmaceuticals and Medical Devices Agency on January 16, 2023. New Article Biogen (NASDAQ: BIIB) just scored a major new drug approval for an Alzheimer's disease therapy, so investors are understandably rushing to evaluate whether to buy the stock. Leqembi is a biologic that's intended to reduce the number of amyloid beta plaques in patients' brains, and it's indicated only for people in the early stages of Alzheimer's disease who are afflicted with mild cognitive impairment. Biogen's other attempt at entering the Alzheimer's market, Aduhelm, has been an unmitigated commercial failure since its launch in 2021, and the circumstances of its approval also attracted significant criticism as have the drug's marginal efficacy, severe side effect profile, and high price tag of $56,000 per year. New Article Both large-cap and small-cap biotech stocks such as Biogen Inc BIIB and Madrigal Pharmaceuticals MDGL are participating in the rally. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report NVIDIA Corporation (NVDA) : Free Stock Analysis Report Invesco QQQ (QQQ): ETF Research Reports SPDR S&P 500 ETF (SPY): ETF Research Reports VanEck Semiconductor ETF (SMH): ETF Research Reports SPDR S&P Biotech ETF (XBI): ETF Research Reports Madrigal Pharmaceuticals, Inc. (MDGL) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Research Wednesday, the Vaneck Semiconductor ETF SMH triggered a Golden Cross. New Article Adds background Jan 26 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug. The drug, lecanemab, which was recently granted accelerated approval in the United States, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of patients in the early stages of the mind-wasting disease. The application to the EMA was based on results from a late-stage study that showed the drug slowed down the rate of cognitive decline in patients with early Alzheimer's by 27%, compared with a placebo. New Article Jan 26 (Reuters) - Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug for review. The drug, lecanemab, was recently granted accelerated approval in the United States. (Reporting by Sriparna Roy in Bengaluru; Editing by Subhranshu Sahu) ((Sriparna.Roy@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",277.5019836425781
2023-01-27 00:00:00+00:00,292.3599853515625,295.8999938964844,289.94000244140625,290.0799865722656,290.0799865722656,894200.0,3.0,1.0,0.5000249999999999,"Investors focus has shifted the drug after FDA granted accelerated approval Biogen BIIB and partner Eisais anti-amyloid beta protofibril antibody candidate lecanemab to treat early Alzheimers disease (early AD) last week. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Research Factors to Consider In the fourth quarter, higher demand and volume growth for Lillys key drugs, including Trulicity, Taltz, Verzenio, Jardiance, and Emgality is likely to have provided top-line support.",287.8109436035156
2023-01-30 00:00:00+00:00,287.44000244140625,290.0799865722656,284.3800048828125,285.94000244140625,285.94000244140625,619000.0,3.0,1.0,0.5000249999999999,"Some of the major pharmaceuticals working on AD treatments include Biogen Inc. (NYSE: BIIB), Eli Lilly and Company (NYSE: LLY), and AstraZeneca Plc (NYSE: AZN), which have partnered with smaller biotechnology companies. The amyloid thesis portends that naturally occurring proteins in the brain clump together to form plague between the neurons to disrupt cell functions Simufilam Mechanism Cassava has taken a completely different approach. Cassava believes that misfolded FLNA, a scaffolding protein, disrupts the proper functioning of nerve cells, which can lead to neurodegeneration and AD. New Article Biogen (BIIB) and Eisai said Sunday their drug candidate lecanemab, which is intended for the treatment of Alzheimer's disease, has received priority review status from the Japanese Ministry of Health, Labour and Welfare, shortening its total review period. Health care stocks were in the red pre-bell Monday. The Health Care Select Sector SPDR Fund (XLV) was 0.3% lower and the iShares Biotechnology ETF (IBB) was recently down 0.1% G Medical Innovations (GMVD) was up nearly 110% after saying it received a patent issue notification from the US Patent and Trademark Office for its monitoring products marketed in the US. New Article Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day. It is also worth noting that BIIB currently has a PEG ratio of 1.84. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here.",290.78564453125
2023-02-01 00:00:00+00:00,289.57000732421875,293.2300109863281,286.1300048828125,291.6000061035156,291.6000061035156,755300.0,3.0,1.0,0.5000249999999999,"MRNA Moderna $174.12 INTC Intel $29.02 CTSH Cognizant Technology $69.05 REGN Regeneron $757.14 BIIB Biogen $291.40 CHTR Charter Communications $397.96 MU Micron $62.29 Moderna (MRNA) Source: Carlos l Vives / Shutterstock.com One of the top biotechnology firms of the post-pandemic new normal, Moderna (NASDAQ:MRNA) helped forward the practical applications of the messenger-RNA-based approach. Biogen (BIIB) Source: PictureDesignSwiss / Shutterstock.com Headquartered in Cambridge Massachusetts, Biogen (NASDAQ:BIIB) specializes in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. According to Gurufocus.com, BIIB trades hands at a trailing multiple of 14.6.",280.58807373046875
2023-02-06 00:00:00+00:00,285.0799865722656,292.260009765625,285.0799865722656,288.2799987792969,288.2799987792969,782700.0,3.333333333333333,1.0,0.5833583333333334,"(RTTNews) - Sage Therapeutics, Inc. (SAGE) and Biogen Inc. (BIIB) announced the FDA has accepted the filing of a New Drug Application for zuranolone in the treatment of major depressive disorder and postpartum depression. The application has been granted priority review and the FDA has assigned a PDUFA action date of August 5, 2023. Priya Singhal, Executive Vice President, Head of Development and Interim Head of Research and Global Safety and Regulatory Sciences at Biogen, said: ""The FDA filing acceptance and granting of priority review are important milestones in the mission Biogen and our collaboration partner Sage share to advance the understanding and treatment of depression."" New Article Among large Healthcare stocks, Catalent Inc (Symbol: CTLT) and Biogen Inc (Symbol: BIIB) are the most notable, showing a gain of 20.9% and 2.7%, respectively. Combined, CTLT and BIIB make up approximately 1.1% of the underlying holdings of XLV. In afternoon trading on Monday, Utilities stocks are the best performing sector, losing just 0.2%. New Article Biogen Inc. (BIIB) closed at $288.28 in the latest trading session, marking a +1.64% move from the prior day. Also, we should mention that BIIB has a PEG ratio of 1.8. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here.",273.95330810546875
2023-02-07 00:00:00+00:00,286.5,292.4200134277344,285.1000061035156,291.42999267578125,291.42999267578125,802800.0,4.0,1.0,0.7500249999999999,"Sage Therapeutics, Inc. SAGE and partner, Biogen Inc. BIIB jointly announced that the FDA has accepted their new drug application (NDA) filing for zuranolone, a rapid-acting, once-daily, oral treatment in adults with major depressive disorder (MDD) and postpartum depression (PPD). Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report ADMA Biologics Inc (ADMA) : Free Stock Analysis Report Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report AlloVir, Inc. (ALVR) : Free Stock Analysis Report To read this article on Zacks.com click here. The NDA filing was based on results from the LANDSCAPE and NEST clinical development programs, along with a phase II study of zuranolone completed by Osaka-based Shionogi Pharmaceuticals in adults with MDD.",257.6645812988281
2023-02-08 00:00:00+00:00,288.70001220703125,291.42999267578125,285.2099914550781,285.45001220703125,285.45001220703125,678700.0,3.5,1.0,0.6250249999999999,"What happened Shares of the clinical-stage biopharma Anavex Life Sciences (NASDAQ: AVXL) rose by a stately 17.4% over the course of January, according to data provided by S&P Global Market Intelligence. So what The big deal is that blarcamesine is an orally administered drug, which may confer certain competitive advantages over Eisai and Biogen's twice-monthly intravenous Alzheimer's therapy Leqembi. An Alzheimer's disease drug with a fairly clean safety profile and a disease-modifying capability, after all, could easily generate over $5 billion a year in annual sales. New Article We expect Biogen BIIB to beat expectations when it reports fourth-quarter and full-year 2022 results on Feb 15, before market open. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Alkermes plc (ALKS) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report To read this article on Zacks.com click here. Among Biogens MS drugs, sales of Tecfidera are likely to have declined steeply, hurt by the launch of multiple generics products in the United States. New Article And that's exactly the case of biotech giants Vertex Pharmaceuticals (NASDAQ: VRTX) and Biogen (NASDAQ: BIIB). The bear market crushed many top healthcare stocks -- from young high-growth players to long-established companies generating billions of dollars in earnings. Vertex and partner CRISPR Therapeutics have completed regulatory submissions for exa-cel, a one-time curative treatment for blood disorders, in the U.K. and Europe. New Article Wall Street expects a year-over-year increase in earnings on lower revenues when Biogen Inc. (BIIB) reports results for the quarter ended December 2022. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.",253.01805114746094
2023-02-09 00:00:00+00:00,286.1099853515625,292.1700134277344,286.1099853515625,287.0,287.0,857300.0,3.5,1.0,0.6250249999999999,"Humiras international sales were affected by the launch of several direct biosimilar drugs in Europe by other pharma companies, including Amgen AMGN, Sandoz and Biogen BIIB. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. Amgen, Biogen, Boehringer Ingelheim, Pfizer, Sandoz and many other companies have already received FDA approvals for their own Humira biosimilars, many of which are expected to be launched at various times this year per agreements with AbbVie. New Article Fintel reports that Primecap Management has filed a 13G/A form with the SEC disclosing ownership of 15.70MM shares of Biogen Inc (BIIB). Average portfolio weight of all funds dedicated to BIIB is 0.37%, an increase of 27.42%. The put/call ratio of BIIB is 0.98, indicating a bullish outlook.",256.6253662109375
2023-02-14 00:00:00+00:00,289.82000732421875,292.75,284.760009765625,289.0799865722656,289.0799865722656,1049200.0,4.0,1.0,0.7500249999999999,"Biogen Inc. (BIIB)is reporting for the quarter ending December 31, 2022. BIIB missed the consensus earnings per share in the 1st calendar quarter of 2022 by -17.91%. Zacks Investment Research reports that the 2022 Price to Earnings ratio for BIIB is 16.96 vs. an industry ratio of 4.20, implying that they will have a higher earnings growth than their competitors in the same industry.",253.7195281982422
2023-02-15 00:00:00+00:00,288.0,288.3699951171875,275.5199890136719,278.9800109863281,278.9800109863281,1590300.0,2.9166666666666665,1.0,0.4791916666666667,"Biogen Inc BIIB.O added 1.4% after it beat analysts' estimates for quarterly results on strong demand for its spinal muscular atrophy drug, Spinraza. The benchmark S&P 500 .SPX came under pressure on Tuesday after data showed U.S. consumer prices accelerated in January, boosting expectations that the Fed will raise the policy rate at least twice more this year to the 5%-5.25% range. U.S.-listed shares of Taiwan Semiconductor Manufacturing Co (TSMC) TSM.N fell 5.7% in premarket trading after Warren Buffett's Berkshire Hathaway Inc BRKa.Nslashed its stake in the chipmaker. New Article Feb 15 (Reuters) - Biogen Inc BIIB.O beat Wall Street expectations for quarterly profit and sales on Wednesday, riding on strong demand for its spinal muscular atrophy drug, Spinraza, and forecast modest revenue from its Alzheimer's disease drug this year. Biogen said it was expecting commercialization expenses for Leqembi, the Alzheimer's disease drug developed jointly with Eisai Co Ltd 4523.T, to exceed revenue from the treatment in 2023. The company has been counting on Leqembi to help overcome a series of setbacks from its older Alzheimer's drug Aduhelm, as new Chief Executive Officer Christopher Viehbacher tries to jumpstart growth. New Article By Manas Mishra Feb 15 (Reuters) - Biogen Inc BIIB.O said on Wednesday that Alzheimer's disease drug Leqembi would bring in modest revenue for the year although it might not be enough to offset costs tied to its launch. The company is banking on Leqembi, which was granted accelerated U.S. approval in January, to drive its sales at a time when many of Biogen's top drugs face increasing competition. The company expects full U.S. approval for Leqembi by summer or late this year, and possibly broader insurance coverage by the U.S. Centers for Medicare & Medicaid Services thereafter. New Article And as one of the leading doves on the Fed's policymaking council - Vice Chair Lael Brainard - is set to depart the central bank later this month, her colleagues seem happy for markets to look ever higher for the rates summit. Oil dropped for a second day on Wednesday, as an industry report pointed to ample supplies in the United States and anticipation of further rate hikes sparked concerns over weaker fuel demand and the economic outlook. Key developments that may provide direction to U.S. markets later on Wednesday: * U.S. Feb NAHB housing index, Empire manufacturing index, Jan retail sales, industrial production, Dec business inventories, Dec TIC Treasury holdings data * European Central Bank President Christine Lagarde speaks in European Parliament * U.S. Treasury auctions 20-year bonds * U.S. corp earnings: Cisco, Analog Devices, Marathon, AIG, Equinix, Kraft Heinz, Biogen, Albemarle, ROBLOX, Zillow, Roku, Rollins, EQT, Synopsys Implied Fed Rates to Yearend Surge Above 5%https://tmsnrt.rs/3YwRgmW U.S. Inflationhttps://tmsnrt.rs/3ly0Nf2 UK sees some respite from price risehttps://tmsnrt.rs/3XxyJpi Barclays underperformshttps://tmsnrt.rs/3Ke1dlf (By Mike Dolan, editing by Emelia Sithole-Matarise; mike.dolan@thomsonreuters.com. New Article Looking at individual holdings, Dreyfus Institutional Pre accounts for about 0.76% of total assets, followed by Biogen Inc (BIIB) and Microchip Technology Inc (MCHP). Click to get this free report BNY Mellon US Mid Cap Core Equity ETF (BKMC): ETF Research Reports Biogen Inc. (BIIB) : Free Stock Analysis Report Microchip Technology Incorporated (MCHP) : Free Stock Analysis Report iShares Core S&P Mid-Cap ETF (IJH): ETF Research Reports Vanguard Mid-Cap ETF (VO): ETF Research Reports To read this article on Zacks.com click here. You should consider the BNY Mellon US Mid Cap Core Equity ETF (BKMC), a passively managed exchange traded fund launched on 04/09/2020. New Article (RTTNews) - Biogen Inc. (BIIB) will host a conference call at 8:00 AM ET on February 15, 2023, to discuss Q4 22 earnings results. To access the live webcast, log on to https://investors.biogen.com/events/event-details/q4-and-full-year-2022-earnings-call-webcast The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen BIIB reported fourth-quarter 2022 adjusted earnings per share (EPS) of $4.05, beating the Zacks Consensus Estimate of $3.51. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Arcus Biosciences, Inc. (RCUS) : Free Stock Analysis Report eFFECTOR Therapeutics, Inc. (EFTR) : Free Stock Analysis Report To read this article on Zacks.com click here. Last month, the FDA granted accelerated approval to Biogen and partner Eisais anti-amyloid beta protofibril antibody candidate lecanemab to treat early Alzheimers disease. New Article Biogen Inc. (BIIB) reported $2.54 billion in revenue for the quarter ended December 2022, representing a year-over-year decline of 6.9%. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. New Article Among large Healthcare stocks, Biogen Inc (Symbol: BIIB) and Eli Lilly (Symbol: LLY) are the most notable, showing a loss of 3.7% and 2.7%, respectively. Combined, BIIB and LLY make up approximately 6.2% of the underlying holdings of XLV. Combined, DVN and OXY make up approximately 5.8% of the underlying holdings of XLE. New Article Biogen Inc. (BIIB) came out with quarterly earnings of $4.05 per share, beating the Zacks Consensus Estimate of $3.51 per share. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Seres Therapeutics, Inc. (MCRB) : Free Stock Analysis Report To read this article on Zacks.com click here. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. New Article (RTTNews) - Biotechnology company Biogen Inc. (BIIB) reported Wednesday that profit for the fourth quarter surged 50 percent from last year, reflecting lower expenses despite a 7 percent revenue growth. The company also initiated adjusted earnings and revenue growth guidance for the full-year 2023, in line with estimates. On average, 26 analysts polled by Thomson Reuters expected the company to report earnings of $3.48 per share for the quarter. New Article Particularly high volume was seen for the $292.50 strike call option expiring February 17, 2023, with 295 contracts trading so far today, representing approximately 29,500 underlying shares of BIIB. Below is a chart showing NTAP's trailing twelve month trading history, with the $75 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 4,506 contracts thus far today. That number of contracts represents approximately 450,600 underlying shares, working out to a sizeable 52% of BIIB's average daily trading volume over the past month, of 866,240 shares.",255.90243530273438
2023-02-16 00:00:00+00:00,277.92999267578125,277.92999267578125,270.0,271.5299987792969,271.5299987792969,1511000.0,2.0,1.0,0.250025,Recap of the Weeks Most Important Stories: Biogens Q4 Earnings: Biogen BIIB reported better-than-expected results as it topped both earnings and revenue estimates. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Emergent Biosolutions Inc. (EBS) : Free Stock Analysis Report Blueprint Medicines Corporation (BPMC) : Free Stock Analysis Report To read this article on Zacks.com click here. The FDA Advisory Committees were of the opinion that the benefit-risk profile of NARCAN (naloxone HCl) Nasal Spray is supportive of its use as a nonprescription opioid overdose reversal agent.,256.5146179199219
2023-02-17 00:00:00+00:00,270.9100036621094,278.8599853515625,269.25,278.3800048828125,278.3800048828125,782900.0,3.0,1.0,0.5000249999999999,"BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry. Detailed Analysis of BIOGEN INC BIIB Guru Analysis BIIB Fundamental Analysis Benjamin Graham Portfolio Top Benjamin Graham Stocks About Benjamin Graham: The late Benjamin Graham may be the oldest of the gurus we follow, but his impact on the investing world has lasted for decades after his death in 1976. It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. New Article Below is Validea's daily guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Value Investor model based on the published strategy of Benjamin Graham. BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry.",247.00494384765625
2023-02-21 00:00:00+00:00,277.44000244140625,277.75,271.67999267578125,271.92999267578125,271.92999267578125,1023400.0,3.5,1.0,0.6250249999999999,"In January, the FDA granted accelerated approval for a new Alzheimer's drug from Eisai and Biogen (BIIB). As a result, some researchers have begun to question whether the clinical trials of some of the traditional drugs targeting the -amyloid protein are doing so early enough in the disease process to significantly prevent symptom progression. In fact, one study found that patients taking TNF blockers to treat rheumatoid arthritis had a roughly 50% lower risk of developing Alzheimers. New Article In mid-February, Biogen BIIB reported fourth-quarter 2022 adjusted earnings per share (EPS) of $4.05, beating the Zacks Consensus Estimate of $3.51. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report iShares Biotechnology ETF (IBB): ETF Research Reports Horizon Therapeutics Public Limited Company (HZNP) : Free Stock Analysis Report SPDR S&P Biotech ETF (XBI): ETF Research Reports VanEck Biotech ETF (BBH): ETF Research Reports To read this article on Zacks.com click here. Biotech stocks were huge beneficiaries of the pandemic as many of these companies were developing new vaccines and treatments for Covid-19, leading to a surge in IPOs and venture capital investments.The Fed has been hiking rates since last year.",239.7596893310547
2023-02-22 00:00:00+00:00,272.3699951171875,275.25,271.6300048828125,272.54998779296875,272.54998779296875,760700.0,3.0,1.0,0.5000249999999999,"Two Alzheimer's drugs developed by partners Eisai Co Ltd 4523.T and Biogen Inc BIIB.O, Leqembi and Aduhelm, have so far been approved only under the FDA's accelerated review program, based on evidence of their ability remove sticky deposits of a protein called amyloid. The patient advocacy group estimated that for each day CMS leaves its policy in place, more than 2,000 individuals aged 65 or older may progress from mild dementia due to Alzheimer's to a more advanced stage of the disease at which they are no longer eligible for the new treatments. Trial results published last year showed that, in patients with early Alzheimer's, Leqembi reduced the rate of cognitive decline by 27% compared with a placebo. New Article Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $275.00 strike highlighted in red: Considering the fact that the $275.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the May 19th expiration. New Article Two Alzheimer's drugs developed by partners Eisai Co Ltd 4523.T and Biogen Inc BIIB.O, Leqembi and Aduhelm, have so far only been approved under the FDA's accelerated review program based on evidence of their ability to reduce levels of amyloid brain plaques. The agency said it will also continue to require a registry to collect evidence of patient outcomes to reflect ""real-world"" care. Leqembi is currently also undergoing the FDA's standard review process, which will weigh the drug's impact on cognitive function. New Article One way to limit the risk is to gravitate towards more established biotech companies that have successfully brought a drug to market or are close to doing so. The companys broad scope could be looked at in two ways: 1) the lack of specialization makes it harder to get behind or 2) the diversification improves the odds of commercial success. Positive readouts in pivotal Phase 3 studies of Efgartigimod for immune thrombocytopenia (ITP), TTFields for non-small cell lung cancer (NSCLC) and KarXT for schizophrenia hold big treatment and revenue potential.",247.22108459472656
2023-02-23 00:00:00+00:00,273.0799865722656,275.010009765625,269.0199890136719,271.95001220703125,271.95001220703125,863200.0,2.0,1.0,0.250025,"Quarter in Detail Ionis has licensed Spinraza to Biogen BIIB. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report To read this article on Zacks.com click here. Some of these candidates are tofersen for SOD1-ALS (amyotrophic lateral sclerosis), pelacarsen for cardiovascular disease due to elevated Lp(a) levels, olezarsen for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (SHTG), eplontersen for TTR amyloidosis, and donidalorsen for hereditary angioedema (HAE).",255.26551818847656
2023-02-24 00:00:00+00:00,269.7099914550781,273.2699890136719,267.5299987792969,270.0199890136719,270.0199890136719,904500.0,3.0,1.0,0.5000249999999999,"Below is Validea's daily guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry.",254.98033142089844
2023-02-27 00:00:00+00:00,272.260009765625,274.6499938964844,269.0,269.20001220703125,269.20001220703125,822200.0,5.0,1.0,1.000025,"TOKYO, Feb 28 (Reuters) - Japanese drugmaker Eisai Co Ltd 4523.T and U.S. biotech firm Biogen Inc BIIB.O said on Tuesday that Chinese authorities have given priority review status to Lecanemab, their jointly-developed Alzheimer's disease treatment drug. The drug, recently granted accelerated approval in Japan, is an antibody that has been shown to remove sticky deposits of a protein called amyloid beta from the brains of patients in the early stages of the mind-wasting disease. (Reporting by Mariko Katsumura; Editing by Tom Hogue) ((Mariko.Katsumura@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",251.7620391845703
2023-02-28 00:00:00+00:00,267.760009765625,270.489990234375,266.7699890136719,269.8599853515625,269.8599853515625,1083500.0,3.5,1.0,0.6250249999999999,"(RTTNews) - Eisai Co., Ltd. and Biogen Inc. (BIIB) Tuesday said the Biologics License Application (BLA) for lecanemab, has been designated for Priority Review by the National Medical Products Administration (NMPA) in China. Lecanemab is an investigational anti-amyloid beta (A) protofibril antibody for the treatment of patients with early Alzheimer disease. A marketing authorization application (MAA) to the European Medicines Agency (EMA) was also submitted in January. New Article GlaxoSmithKline's Jesduvroq was approved by the FDA on February 1, becoming the first oral treatment for anemia caused by chronic kidney disease for adults on dialysis. In order to help address the significant increase in plant-based milk alternative products that have become available in the marketplace over the past decade, the U.S. regulatory agency, on Feb.22, issued draft labeling recommendations. This marks the first over-the-counter (OTC) at-home diagnostic test that can differentiate and detect both influenza A and B (commonly referred to as the flu) and SARS-CoV-2, the virus responsible for causing COVID-19. New Article In October 2022, Denali and Biogen initiated the global phase III LIGHTHOUSE study of BIIB122 in up to 400 participants with PD and a confirmed LRRK2 pathogenic variant. Recent Updates Denali has collaborated with Biogen BIIB to advance its LRRK2 inhibitor program to address Parkinsons disease (PD). Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Denali Therapeutics Inc. (DNLI) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report To read this article on Zacks.com click here. New Article By Mariam ESunny and Raghav Mahobe Feb 28 (Reuters) - The U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc's RETA.O drug for the treatment of a rare genetic disorder that causes progressive damage to the nervous system, sending shares up nearly 160% after the bell. Friedreich's ataxia is a neuromuscular disorder that causes muscle weakness, loss of coordination and can lead to patients being bound to a wheelchair in their mid-20s and premature death. Reata's case for approval was based on additional data requested by the FDA and a mid-stage study that the drugmaker said showed patients who took the drug experienced an improvement in neurological functions such as speaking, swallowing and standing, compared with a placebo.",251.03399658203125
2023-03-01 00:00:00+00:00,267.9700012207031,275.3800048828125,267.5299987792969,272.2099914550781,272.2099914550781,1167600.0,4.5,1.0,0.8750249999999999,"The FDA has previously approved drugs for neurological conditions based on limited data such as for Biogen Inc's BIIB.O Alzheimer's drug Aduhelm and Amylyx's AMLX.O ALS drug but those were made under the leadership of Billy Dunn, who resigned from the agency on Monday. Updates with regular hour moves, adds analyst comments March 1 (Reuters) - Shares of Reata Pharmaceuticals Inc RETA.O soared 175% to hit a one-year high in early trading on Wednesday, after the U.S. Food and Drug Administration (FDA) approved its rare disease drug and ended years of uncertainty over its future. Reata's drug Skyclarys is the first approved treatment for Friedreich's Ataxia, a rare genetic disorder that causes progressive damage to the nervous system and can lead to premature death. New Article By Blake Brittain March 1 (Reuters) - Roche's Genentech Inc ROGING.UL sued Biogen MA Inc BIIB.O on Tuesday in San Francisco federal court, claiming Biogen owes additional patent royalties from worldwide sales of its blockbuster multiple-sclerosis and Crohn's disease drug Tysabri. According to Genentech, Biogen has refused to pay royalties on any Tysabri sales since the patents expired more than four years ago. Genentech asked the court for the lost royalties and other money damages for Biogen's alleged breach of contract.",247.82664489746094
2023-03-06 00:00:00+00:00,270.5,272.6400146484375,267.79998779296875,270.25,270.25,1116500.0,3.5,1.0,0.6250249999999999,"What happened Shares of Anavex Life Sciences (NASDAQ: AVXL) rose 12.4% in February, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech's stock closed at $10.87 in January, then rose to a high of $11.93 on Feb. 7, the day the company announced first-quarter earnings. The study looked at 509 patients for more than 48 weeks and found those treated with the therapy were 84% more likely to show improved cognition on the Alzheimer's Disease Assessment Scale-Cognitive subscale. New Article Biogen BIIB announced that the FDA has accepted the supplemental biologics license application (sBLA) filed by partner Eisai. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report eFFECTOR Therapeutics, Inc. (EFTR) : Free Stock Analysis Report To read this article on Zacks.com click here. The FDA issued a complete response letter (CRL) to Eli Lillys BLA seeking accelerated approval of donanemab for the treatment of early symptomatic Alzheimer's disease.",249.29161071777344
2023-03-07 00:00:00+00:00,271.0,271.010009765625,263.989990234375,264.8800048828125,264.8800048828125,640900.0,2.0,1.0,0.250025,"Especially high volume was seen for the $305 strike call option expiring June 16, 2023, with 991 contracts trading so far today, representing approximately 99,100 underlying shares of BIIB. Below is a chart showing CMI's trailing twelve month trading history, with the $250 strike highlighted in orange: Biogen Inc (Symbol: BIIB) saw options trading volume of 4,091 contracts, representing approximately 409,100 underlying shares or approximately 43.4% of BIIB's average daily trading volume over the past month, of 942,875 shares. Below is a chart showing BIIB's trailing twelve month trading history, with the $305 strike highlighted in orange: And Franklin Resources Inc (Symbol: BEN) options are showing a volume of 12,265 contracts thus far today.",242.6304473876953
2023-03-08 00:00:00+00:00,264.8800048828125,265.79998779296875,261.7200012207031,263.0199890136719,263.0199890136719,649600.0,3.0,1.0,0.5000249999999999,"In the latest trading session, Biogen Inc. (BIIB) closed at $263.02, marking a -0.7% move from the previous day. Also, we should mention that BIIB has a PEG ratio of 2.25. To follow BIIB in the coming trading sessions, be sure to utilize Zacks.com.",237.38323974609375
2023-03-09 00:00:00+00:00,264.19000244140625,264.8500061035156,258.2300109863281,258.989990234375,258.989990234375,884000.0,3.0,1.0,0.5000249999999999,"Invesco S&P 500 Revenue ETF RWL $75.65 $88.34 16.77% Edwards Lifesciences Corp EW $77.27 $95.12 23.10% Biogen Inc BIIB $263.02 $322.38 22.57% Illumina Inc ILMN $208.03 $245.07 17.80% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of RWL's underlying holdings with notable upside to their analyst target prices are Edwards Lifesciences Corp (Symbol: EW), Biogen Inc (Symbol: BIIB), and Illumina Inc (Symbol: ILMN). Similarly, BIIB has 22.57% upside from the recent share price of $263.02 if the average analyst target price of $322.38/share is reached, and analysts on average are expecting ILMN to reach a target price of $245.07/share, which is 17.80% above the recent price of $208.03. New Article The AD target market is highly competitive as several other pharma companies like Biogen BIIB and Roche RHHBY have their drugs targeting the AD indication. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report To read this article on Zacks.com click here. Eli Lilly LLY announced that the phase III A4 study evaluating its candidate, solanezumab, in people with preclinical Alzheimer's disease (AD)failed to achieve its primary and secondary endpoints.",245.87088012695312
2023-03-10 00:00:00+00:00,258.989990234375,262.8800048828125,254.8000030517578,256.5599975585937,256.5599975585937,880700.0,3.0,1.0,0.5000249999999999,"Looking at individual holdings, Newmont (NEM) accounts for about 1.06% of total assets, followed by Simon Property Group Reit Inc (SPG) and Biogen Inc (BIIB). Click to get this free report iShares Morningstar Mid-Cap Value ETF (IMCV): ETF Research Reports Biogen Inc. (BIIB) : Free Stock Analysis Report Simon Property Group, Inc. (SPG) : Free Stock Analysis Report Newmont Corporation (NEM) : Free Stock Analysis Report Vanguard Mid-Cap Value ETF (VOE): ETF Research Reports iShares Russell Mid-Cap Value ETF (IWS): ETF Research Reports To read this article on Zacks.com click here. Launched on 06/28/2004, the iShares Morningstar Mid-Cap Value ETF (IMCV) is a passively managed exchange traded fund designed to provide a broad exposure to the Mid Cap Value segment of the US equity market. New Article Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry.",253.42410278320312
2023-03-13 00:00:00+00:00,256.5599975585937,261.29998779296875,255.4100036621093,258.54998779296875,258.54998779296875,1027300.0,3.5,1.0,0.6250249999999999,"Adds background, link to VA document March 13 (Reuters) - Eisai Co Ltd 4523.T and Biogen Inc BIIB.O said on Monday that the U.S. Department of Veteran Affairs (VA) will provide coverage of their Alzheimer's treatment Leqembi to veterans at an early stage of the memory-robbing disease. The VA's coverage comes as initial patient access to the recently approved drug remains limited by a number of factors including reimbursement restrictions by the government's Medicare health program for Americans aged 65 and older, who represent some 90% of individuals likely to be eligible for Leqembi. The drug, known chemically as lecanemab, belongs to a class of antibody treatments designed to slow advance of the neurodegenerative disease by removing sticky clumps of the toxic protein beta amyloid from the brain. New Article March 13 (Reuters) - Eisai Co Ltd 4523.T said on Monday, that the U.S. Veterans' Health Administration (VHA) is providing coverage of its treatment Leqembi to veterans living with early stages of Alzheimer's disease. (Reporting by Pratik Jain) ((Pratik.Jain@thomsonreuters.com;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",255.84803771972656
2023-03-14 00:00:00+00:00,262.1700134277344,265.8099975585937,259.29998779296875,262.3500061035156,262.3500061035156,1110700.0,4.0,1.0,0.7500249999999999,"In the latest trading session, Biogen Inc. (BIIB) closed at $262.35, marking a +1.47% move from the previous day. Also, we should mention that BIIB has a PEG ratio of 2.19. To follow BIIB in the coming trading sessions, be sure to utilize Zacks.com. New Article Biogen (NASDAQ: BIIB) has been one of the more notable names in the biotech industry in the past four years -- and not always for the best of reasons. Like other medicines Biogen has worked on in this therapeutic area, including Aduhelm, Leqembi seeks to clear up amyloid beta plaques in the brains of AD patients, which some researchers believe can help slow the progression of the disease. Reason to sell: Potential regulatory headwinds ahead While the commercialization of Leqembi is a major step forward, it's important to note that it earned the green light in the U.S. under the accelerated approval pathway, which is reserved for therapies that target an unmet need. New Article Major pharmaceutical companies in the biologics segment include Amgen Inc. (NASDAQ: AMGN), Biogen Inc. (NYSE: BIIB), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). The U.S. Food and Drug Administration approved emergency use authorizations for several monoclonal antibody treatments for people infected with COVID-19 to reduce the illness and prevent hospitalization. The company reported an earnings-per-share (EPS) profit of $0.01, excluding non-recurring items, versus a loss of ($0.04) consensus analyst estimates, beating by $0.05.",251.56893920898438
2023-03-16 00:00:00+00:00,259.4599914550781,267.1499938964844,259.3699951171875,265.25,265.25,1010600.0,3.0,1.0,0.5000249999999999,"The first of the new drugs, Japan's Eisai Co 4523.T and Biogen Inc's BIIB.O drug Leqembi, won FDA approval in January under an accelerated review process, after the drug showed some evidence in trials that it could slow the advance of Alzheimer's in early stages of the disease. Leqembi belongs to a new generation of treatments designed to slow advance of the disease by removing sticky clumps of the toxic protein beta amyloid from the brain. Over the past two months, chapters have tweeted, written letters and met congressional staffers and lawmakers, calling on them to apply pressure on the U.S. Department of Health and Human Services (HHS) to expand drug coverage. New Article Biogens BIIB stock has risen 28.8% in the past year against a decrease of 12.3% for the industry. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. Importantly, sales of its key MS drug Tecfidera are declining, hurt by the launch of multiple generic products in the United States. New Article Looking at individual holdings, Horizon Therapeutics Public Limited Company (HZNP) accounts for about 1.64% of total assets, followed by Biogen Inc. (BIIB) and Halozyme Therapeutics Inc. (HALO). Click to get this free report SPDR S&P Biotech ETF (XBI): ETF Research Reports Biogen Inc. (BIIB) : Free Stock Analysis Report Halozyme Therapeutics, Inc. (HALO) : Free Stock Analysis Report iShares Biotechnology ETF (IBB): ETF Research Reports Horizon Therapeutics Public Limited Company (HZNP) : Free Stock Analysis Report First Trust NYSE Arca Biotechnology ETF (FBT): ETF Research Reports To read this article on Zacks.com click here. It has amassed assets over $6.60 billion, making it one of the largest ETFs attempting to match the performance of the Healthcare - Biotech segment of the equity market.",246.9030303955078
2023-03-17 00:00:00+00:00,264.7900085449219,265.2099914550781,260.739990234375,263.1600036621094,263.1600036621094,1602200.0,3.0,1.0,0.5000249999999999,"A month has gone by since the last earnings report for Biogen Inc. (BIIB). Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.",256.24127197265625
2023-03-20 00:00:00+00:00,264.6499938964844,268.7900085449219,262.760009765625,267.9100036621094,267.9100036621094,878400.0,4.0,1.0,0.7500249999999999,"March 20 (Reuters) - The U.S. Food and Drug Administration's staff reviewers on Monday did not raise any new safety concerns about Biogen Inc's BIIB.O experimental drug for treating a rare type of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease. (Reporting by Raghav Mahobe and Bhanvi Satija in Bengaluru; Editing by Krishna Chandra Eluri) ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Adds details from briefing documents March 20 (Reuters) - Staff reviewers of U.S. drug regulator on Monday did not raise any new safety concerns about Biogen Inc's BIIB.O experimental drug for treating a rare type of amyotrophic lateral sclerosis, also known as Lou Gehrig's disease. The risks related to Biogen's drug, tofersen, ""are acceptable to the patient population"" and would not ""preclude approval"", staff reviewers said in briefing documents published on the agency's website. In October 2021, tofersen failed to meet the main goal of a late-stage study, but the company said trends of reduced disease progression were observed.",256.1695251464844
2023-03-21 00:00:00+00:00,268.9700012207031,268.989990234375,264.1400146484375,266.1499938964844,266.1499938964844,621300.0,4.0,1.0,0.7500249999999999,"Biogen Inc. (BIIB) closed the most recent trading day at $266.15, moving -0.66% from the previous trading session. Investors should also note that BIIB has a PEG ratio of 2.27 right now. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here.",254.38330078125
2023-03-22 00:00:00+00:00,266.1099853515625,267.25,260.95001220703125,261.2200012207031,261.2200012207031,530500.0,3.0,1.0,0.5000249999999999,"The effort, unveiled in a statement on Wednesday, comes as Lilly as well as Eisai 4523.T and Biogen BIIB.O are gearing up to sell drugs aimed at slowing the advance of the mind-robbing illness, but their use will require a diagnosis at earlier disease stages than is the norm today. Eisai 4523.T and Biogen's BIIB.O drug Leqembi won FDA approval in January under an accelerated review process, seen as a major breakthrough in therapy development. By Ludwig Burger and Julie Steenhuysen March 22 (Reuters) - Roche ROG.S and Eli Lilly and Co LLY.N are joining forces to develop a blood test for Alzheimer's disease, and plan to kick off a two-year clinical trial involving hundreds of volunteers with the aim of winning U.S. regulatory approval. New Article By Bhanvi Satija March 22 (Reuters) - A panel of advisers to the U.S. health regulator said on Wednesday there was not enough convincing evidence to show the effectiveness of Biogen Inc's BIIB.O experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS). The panel also discussed whether there was sufficient evidence to show that there was a benefit when tofersen reduced levels of the protein neurofilament in patients. The disease results in weakened muscles and causes nerve cells in the brain and spinal cord to break down, affecting physical function and leading to severe disability and death.",258.1065368652344
2023-03-23 00:00:00+00:00,262.8399963378906,267.45001220703125,262.5,265.1700134277344,265.1700134277344,703700.0,3.25,1.0,0.5625249999999999,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $270.00 strike highlighted in red: Considering the fact that the $270.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the May 5th expiration. New Article Results from the 12-week phase Ib study to treat obesity or overweight and type II diabetes showed average weight losses of 4.4%, 6.1% and 7.7% at the 1.2 mg, 1.8 mg and 2.4 mg doses of pemvidutide, respectively, with the placebo group experiencing a mean weight gain of 0.8% Biogens Update on Tofersen NDA: Biogen BIIB announced the outcome of the FDAs Peripheral and Central Nervous System Drugs Advisory Committee meeting on pipeline candidate. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Incyte Corporation (INCY) : Free Stock Analysis Report Altimmune, Inc. (ALT) : Free Stock Analysis Report Karuna Therapeutics, Inc. (KRTX) : Free Stock Analysis Report To read this article on Zacks.com click here. The candidate is being evaluated for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), an ultra-rare, progressive and fatal neurodegenerative disease that results in the loss of motor neurons in the brain and the spinal cord that are responsible for controlling voluntary muscle movement. New Article (RTTNews) - Biotechnology company Biogen Inc. (BIIB) announced the outcome of the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product to treat superoxide dismutase 1 or SOD1 amyotrophic lateral sclerosis or ALS. Tofersen is an antisense oligonucleotide or ASO being evaluated as a treatment for SOD1-ALS, a rare genetic form of the disease affecting around 330 people in the United States. In a statement, the company noted that the Committee voted unanimously yes with 9 votes for consideration of a potential accelerated approval on the question, ""Is the available evidence sufficient to conclude that a reduction in plasma neurofilament light chain or NfL concentration in tofersen-treated patients is reasonably likely to predict clinical benefit of tofersen for treatment of patients with SOD1-ALS?"" New Article Biogen BIIB announced that an FDA advisory committee gave a mostly favorable opinion on its new drug application (NDA) seeking approval for its pipeline candidate, tofersen for treating patients with amyotrophic lateral sclerosis (ALS) with superoxide dismutase 1 (SOD1) mutation. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report To read this article on Zacks.com click here. ALS is a rare neurodegenerative disease whose progression leads to a steady decline in the ability to move, speak, eat and eventually breathe.",261.9767150878906
2023-03-24 00:00:00+00:00,265.44000244140625,271.3599853515625,263.1499938964844,270.0299987792969,270.0299987792969,973400.0,3.333333333333333,1.0,0.5833583333333334,"The Food and Drug Administration's move follows criticism for the accelerated approval pathway, as well as an independent federal review into it after the controversial nod for Biogen Inc's BIIB.O Alzheimer's treatment Aduhelm. Adds details and background March 24 (Reuters) - The U.S. health regulator on Friday proposed cancer drug developers conduct more rigorous trials to seek accelerated approval for their candidates. Drug developers usually depend on such ""single-arm"" studies to gain accelerated approval, and then conduct another trial post-nod to confirm clinical benefits. New Article Biogen (NASDAQ:BIIB)  The biopharmaceutical company discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. BIIB stock has an analyst consensus upside of 24.8%. Further, technological improvements, an aging population, and advancing treatments for chronic diseases and conditions reflect the sectors growth prospects. New Article Humiras international sales are already eroding due to the launch of several direct biosimilar drugs in Europe by other pharma companies, including Amgen AMGN, Novartis NVS Sandoz division and Biogen BIIB. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report To read this article on Zacks.com click here. Management announced topline data from the phase III INSPIRE study, which evaluated Skyrizi (risankizumab) as an induction therapy in adult patients with moderately to severely active ulcerative colitis (UC).",274.006591796875
2023-03-27 00:00:00+00:00,270.8099975585937,272.42999267578125,269.4800109863281,269.9800109863281,269.9800109863281,607800.0,3.333333333333333,1.0,0.5833583333333334,"Other than AstraZeneca, Ionis has partnerships with many pharma giants like Biogen BIIB and Novartis NVS. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report To read this article on Zacks.com click here. Ionis Pharmaceuticals IONS announced positive top-line data from the 66-week analysis of the phase III NEURO-TTRansform study on its investigational anti-sense drug eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). New Article Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry. New Article Biogen Inc. (BIIB) closed at $269.98 in the latest trading session, marking a -0.02% move from the prior day. Meanwhile, BIIB's PEG ratio is currently 2.29. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here.",275.6403503417969
2023-03-28 00:00:00+00:00,270.0599975585937,271.8999938964844,268.7799987792969,270.25,270.25,560300.0,3.0,1.0,0.5000249999999999,"Using TipRanks Stock Comparison Tool, we placed Vertex (NASDAQ:VRTX), Biogen (NASDAQ:BIIB), and IQVIA Holdings (NYSE:IQV) against each other to pick the biotech stock that could deliver the highest returns as per Wall Street analysts. Biogen (NASDAQ:BIIB) Biogen is focused on autoimmune diseases and neurology. The average BIIB stock price target of $330.94 suggests 22.6% upside.",268.6203308105469
2023-03-29 00:00:00+00:00,271.1199951171875,274.6199951171875,270.8900146484375,274.010009765625,274.010009765625,772900.0,3.5,1.0,0.6250249999999999,"(RTTNews) - Biogen Inc. (BIIB) reported Phase 1b clinical data showing that the investigational antisense oligonucleotide therapy, BIIB080, reduced soluble tau protein in cerebrospinal fluid in a dose-dependent and sustained manner in patients with early-stage Alzheimer's disease. BIIB080 also reduced aggregated tau pathology in all brain composites assessed. The Phase 2 CELIA study of BIIB080 is in progress and currently recruiting participants in the U.S. New Article Biogen Inc. (BIIB) closed at $274.01 in the latest trading session, marking a +1.39% move from the prior day. It is also worth noting that BIIB currently has a PEG ratio of 2.29. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here.",254.4557342529297
2023-03-30 00:00:00+00:00,275.7300109863281,276.3800048828125,272.6400146484375,275.1300048828125,275.1300048828125,714000.0,3.0,1.0,0.5000249999999999,"Another stock from the same industry, Biogen Inc. (BIIB), has gained 0.7% over the past month. Click to get this free report Novavax, Inc. (NVAX) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.",255.6803741455078
2023-03-31 00:00:00+00:00,275.44000244140625,279.0,275.44000244140625,278.0299987792969,278.0299987792969,1197000.0,3.0,1.0,0.5000249999999999,"This action was based on the U.S. regulatory agency's scientific review, which found that a complete switch from cigarettes to the smokeless product would lower the risk of developing lung cancer for adult smokers. On March 24, the FDA released a draft guidance, with the goal of enhancing oncology clinical trials to expedite the approval process. On Mar.29, Emergent BioSolutions' Narcan nasal spray secured the FDA nod to be switched from prescription status to over-the-counter use for opioid overdose. New Article (RTTNews) - Drug makers Biogen Inc. (BIIB) and Japan's Eisai Co., Ltd. (ESALY.PK, ESALF.PK) announced Friday new analyses from the Phase 3 Clarity AD study of lecanemab, as well as three additional detailed analyses from the Phase IIb clinical study of lecanemab. Eisai presented the new analyses from the Phase 3 Clarity AD study of lecanemab at the 2023 International Conference on Alzheimer's and Parkinson's Diseases annual meeting AD/PD. Regarding the Phase 3 Clarity AD study of lecanemab, the companies said Eisai presented the new analyses on amyloid-related imaging abnormalities or ARIA with the use of antiplatelet and anticoagulant medications, isolated ARIA-H, and caregiver burden and health-related quality of life or QOL from the trial results. New Article Two IV Alzheimer's drugs developed by partners Eisai Co Ltd 4523.T and Biogen Inc BIIB.O, Leqembi and Aduhelm, have been approved by the U.S. Food and Drug Administration under the agency's accelerated review program, based on evidence of their ability remove amyloid plaques. By Deena Beasley March 31 (Reuters) - Eli Lilly and Co LLY.N on Friday said early data from the first human study of its next-generation Alzheimer's treatment showed that it lowered levels of toxic amyloid plaques in the brains of people in the earliest stages of the mind-wasting disease. The Indianapolis-based drugmaker is launching a Phase III study of the experimental antibody, remternetug, but declined to comment on which doses will be selected for larger, later-stage trials.",250.31210327148438
2023-04-03 00:00:00+00:00,276.3399963378906,279.07000732421875,275.67999267578125,277.3399963378906,277.3399963378906,772800.0,3.0,1.0,0.5000249999999999,"Alzheimer's research has been galvanized by Leqembi, a new treatment from Eisai Co Ltd 4523.T and Biogen Inc BIIB.O that slows advance of the disease in early-stage patients. ""Real-world data is what we need to make a lot of decisions about the effectiveness of medications and looking really at a much broader population than most clinical trials can cover,"" Dr. Nina Silverberg, director of the NIA's Alzheimer's Disease Research Centers program, said in an interview. It also aims to address chronic underrepresentation of people of color and different ethnicities in Alzheimers clinical trials and could help increase enrollment from outside of urban academic medical centers.",241.682861328125
2023-04-06 00:00:00+00:00,285.0599975585937,287.7699890136719,283.79998779296875,286.79998779296875,286.79998779296875,737100.0,4.0,1.0,0.7500249999999999,"We note that FDA granted accelerated approval to Biogen BIIB and patner Eisais Leqembi in January 2023 to treat early AD. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Prothena Corporation plc (PRTA) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Research The company recently announced new preclinical data from its PRX012 program, a potential best-in-class anti-amyloid beta (A) product candidate in development for the treatment of AD, at the 2023 International Conference on Alzheimers and Parkinsons Diseases and related neurological disorders (AD/PD) in Gothenburg, Sweden.",252.2085723876953
2023-04-10 00:00:00+00:00,285.3999938964844,285.6499938964844,280.2900085449219,282.8599853515625,282.8599853515625,475800.0,3.0,1.0,0.5000249999999999,"April 10 (Reuters) - The U.S. Food and Drug Administration (FDA) plans to hold a meeting of its outside experts in June to discuss full approval of the Alzheimer's drug developed by Eisai Co Ltd 4523.T and Biogen Inc BIIB.O, according to a federal filing on Monday. The drug, Leqembi was granted accelerated approval by the FDA in January for patients in the earliest stages of the mind-wasting disease. In the large trial of Leqembi, which is given by infusion, the drug slowed the rate of cognitive decline in patients with early Alzheimer's by 27% compared with a placebo. New Article Detailed Analysis of HCA HEALTHCARE INC HCA Guru Analysis HCA Fundamental Analysis BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry. It is also advancing its mid-to-late stage programs, including zuranolone for major depressive disorder (MDD) and postpartum depression (PPD), BIIB080 for Alzheimer's disease, tofersen for amyotrophic lateral sclerosis (ALS) and both litifilimab and dapirolizumab pegol for certain forms of lupus. Detailed Analysis of BIOGEN INC BIIB Guru Analysis BIIB Fundamental Analysis COMMUNITY HEALTH SYSTEMS INC (CYH) is a small-cap growth stock in the Healthcare Facilities industry.",254.6707305908203
2023-04-11 00:00:00+00:00,283.32000732421875,285.4700012207031,282.489990234375,283.69000244140625,283.69000244140625,556100.0,3.6666666666666665,1.0,0.6666916666666666,"The firm jointly developed the drug with Biogen (NASDAQ:BIIB). The drug works by targeting amyloid and tau proteins that accumulate in the brains of Alzheimers patients, destroying cognitive skills in the process and ultimately leading to death. The good news for investors is that Eisai shares are expected to appreciate massively to the Japanese Yen equivalency of $65 over the coming 12-18 months. New Article ProShares Ultra S&P500 ETF SSO $50.19 $55.41 10.40% Biogen Inc BIIB $282.86 $322.38 13.97% Kinder Morgan Inc. KMI $17.75 $20.07 13.05% Newmont Corp NEM $51.09 $56.74 11.06% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of SSO's underlying holdings with notable upside to their analyst target prices are Biogen Inc (Symbol: BIIB), Kinder Morgan Inc. (Symbol: KMI), and Newmont Corp (Symbol: NEM). Although BIIB has traded at a recent price of $282.86/share, the average analyst target is 13.97% higher at $322.38/share. New Article Fintel reports that on April 11, 2023, Needham reiterated coverage of Biogen (NASDAQ:BIIB) with a Buy recommendation. The firm increased its portfolio allocation in BIIB by 16.89% over the last quarter. The firm decreased its portfolio allocation in BIIB by 23.15% over the last quarter.",266.73797607421875
2023-04-12 00:00:00+00:00,284.57000732421875,287.0899963378906,283.6000061035156,285.7900085449219,285.7900085449219,611200.0,3.0,1.0,0.5000249999999999,"Fintel reports that on April 12, 2023, Morgan Stanley maintained coverage of Biogen (NASDAQ:BIIB) with a Overweight recommendation. The firm decreased its portfolio allocation in BIIB by 99.77% over the last quarter. The firm decreased its portfolio allocation in BIIB by 99.61% over the last quarter. New Article Biogen (BIIB) has exercised an option to license Denali Therapeutics' (DNLI) Antibody Transport Vehicle program targeting amyloid beta. Healthcare stocks were steady late Wednesday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) little changed. Arrowhead Pharmaceuticals (ARWR) shares were rising over 9% after SVB Securities upgraded the company to outperform from market perform and raised its price target to $35 from $21.",266.1003112792969
2023-04-13 00:00:00+00:00,286.260009765625,290.8999938964844,285.45001220703125,289.70001220703125,289.70001220703125,715500.0,2.0,1.0,0.250025,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $290.00 strike highlighted in red: Considering the fact that the $290.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the June 2nd expiration.",256.4894714355469
2023-04-17 00:00:00+00:00,294.0,294.2200012207031,290.04998779296875,292.20001220703125,292.20001220703125,764900.0,3.333333333333333,1.0,0.5833583333333334,"Looking at individual holdings, Dreyfus Institutional Pre accounts for about 0.76% of total assets, followed by Biogen Inc (BIIB) and Microchip Technology Inc (MCHP). Click to get this free report BNY Mellon US Mid Cap Core Equity ETF (BKMC): ETF Research Reports Biogen Inc. (BIIB) : Free Stock Analysis Report Microchip Technology Incorporated (MCHP) : Free Stock Analysis Report iShares Core S&P Mid-Cap ETF (IJH): ETF Research Reports Vanguard Mid-Cap ETF (VO): ETF Research Reports To read this article on Zacks.com click here. It has amassed assets over $432.60 million, making it one of the average sized ETFs attempting to match the Mid Cap Blend segment of the US equity market. New Article Fintel reports that on April 17, 2023, Wedbush maintained coverage of Biogen (NASDAQ:BIIB) with a Neutral recommendation. The firm decreased its portfolio allocation in BIIB by 6.88% over the last quarter. The firm increased its portfolio allocation in BIIB by 159.62% over the last quarter. New Article Fintel reports that on April 17, 2023, Piper Sandler upgraded their outlook for Biogen (NASDAQ:BIIB) from Neutral to Overweight . The firm decreased its portfolio allocation in BIIB by 4.64% over the last quarter. The firm increased its portfolio allocation in BIIB by 158.97% over the last quarter.",249.55392456054688
2023-04-18 00:00:00+00:00,292.3599853515625,294.6199951171875,290.07000732421875,293.8299865722656,293.8299865722656,668900.0,2.333333333333333,1.0,0.3333583333333332,"Biotech giant Biogen (NASDAQ: BIIB) has been trying to develop a successful therapy for Alzheimer's disease (AD) for a long time, and its efforts seem to be about to pay off. BIIB Revenue (Quarterly) data by YCharts. The current policy of the Centers for Medicare and Medicaid Services (CMS) is to cover medicines that go through the accelerated approval pathway for AD, like Leqembi, only for those patients who are enrolled in CMS-approved clinical trials. New Article Particularly high volume was seen for the $275 strike put option expiring May 19, 2023, with 415 contracts trading so far today, representing approximately 41,500 underlying shares of BIIB. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Biogen Inc (Symbol: BIIB), where a total volume of 3,032 contracts has been traded thus far today, a contract volume which is representative of approximately 303,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 42.3% of BIIB's average daily trading volume over the past month, of 717,575 shares. New Article The market expects Biogen Inc. (BIIB) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2023. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.",253.34988403320312
2023-04-19 00:00:00+00:00,292.69000244140625,293.8500061035156,291.9800109863281,292.2699890136719,292.2699890136719,492400.0,4.0,1.0,0.7500249999999999,"Denali Therapeutics and Biogen Denali Therapeutics (DNLI) and Biogen (BIIB) have teamed up to develop DNL151/BIIB122, which aims to counter Parkinson's symptoms by blocking the leucine-rich repeat kinase 2 (LRRK2). As of January 2023, Denali Therapeutics and Biogen had not published any preclinical data on DNL151/BIIB122 yet. In March, BioVie presented the latest results from its Phase 2 trial combining NE3107 with levodopa at the International Conference on Alzheimers and Parkinsons Diseases and Related Neurological Disorders (AD/PD 2023). New Article We expect Biogen BIIB to beat expectations when it reports first-quarter 2023 results on Ap 25, before market open. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Novo Nordisk A/S (NVO) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report To read this article on Zacks.com click here. Sales of another MS drug, Tysabri are also likely to have declined in the first quarter due to increased competitive pressure and price reductions in certain European markets.",265.60430908203125
2023-04-20 00:00:00+00:00,290.239990234375,291.5799865722656,289.260009765625,290.2699890136719,290.2699890136719,653500.0,2.5,1.0,0.375025,"BIIB Revenue (Annual) data by YCharts The big biotech has set its sights on Alzheimer's disease treatment to renew growth. Two great examples are Biogen (NASDAQ: BIIB) and Vertex Pharmaceuticals (NASDAQ: VRTX). BIIB PE Ratio (Forward) data by YCharts That's not surprising, considering Vertex's CF program is still booming. New Article An Industry Player's Expected Results Another stock from the Zacks Medical - Biomedical and Genetics industry, Biogen Inc. (BIIB), is soon expected to post earnings of $3.31 per share for the quarter ended March 2023. Click to get this free report Amgen Inc. (AMGN) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.",267.8722229003906
2023-04-21 00:00:00+00:00,290.6000061035156,294.19000244140625,289.510009765625,293.989990234375,293.989990234375,847800.0,3.5,1.0,0.6250249999999999,"What happened Shares of Keros Therapeutics (NASDAQ: KROS) were up 19.5% for the week in early trading Friday, according to data provided by S&P Global Market Intelligence. On Monday, Piper Sandler analyst Joseph Cantanzaro reiterated his buy rating for Keros, maintaining a price target of $120. And on Wednesday, the company announced it was appointing Alpna Seth, formerly an executive with Nura Bio, Vir Biotechnology, and Biogen, to its board of directors. New Article Fintel reports that on April 21, 2023, B of A Securities maintained coverage of Biogen (NASDAQ:BIIB) with a Neutral recommendation. The firm increased its portfolio allocation in BIIB by 50.16% over the last quarter. The firm decreased its portfolio allocation in BIIB by 99.90% over the last quarter. New Article More study data on Leqembi, a rival drug from partners Eisai Co Ltd 4523.T and Biogen Inc BIIB.O, is also expected in the coming months. ""We believe that they (Medicare) will provide what we would call outright coverage like they do for every other FDA-approved medication,"" Derek Asay, Lilly's senior vice president of government strategy and federal accounts, said in an interview. The severe Medicare restrictions were largely a response to a previous Alzheimer's treatment from Eisai and Biogen, Aduhelm, which won accelerated approval in 2021 with little evidence that it slowed cognitive decline. New Article More study data on Leqembi, a rival drug from partners Eisai Co Ltd 4523.T and Biogen Inc BIIB.O, is also expected in the coming months. ""We believe that they (Medicare) will provide what we would call outright coverage like they do for every other FDA-approved medication,"" Derek Asay, Lilly's senior vice president of government strategy and federal accounts, said in an interview. A spokesperson for CMS said in an emailed comment that the agency is committed to being nimble when reconsidering its coverage in light of new evidence related to clinical benefit, and disputes claims that the policy would leave underserved patient populations without access to the treatments.",266.1994323730469
2023-04-24 00:00:00+00:00,293.989990234375,295.25,292.1700134277344,293.0299987792969,293.0299987792969,1138100.0,3.0,1.0,0.5000249999999999,"Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry.",273.7037658691406
2023-04-25 00:00:00+00:00,291.04998779296875,294.0,280.7099914550781,282.4100036621094,282.4100036621094,1527900.0,3.4444444444444446,1.0,0.6111361111111111,"Biogen (BIIB) fell 3.6% after Chief Executive Christopher Viehbacher said the company has initiated an additional program to cut costs. In company news, Enanta Pharmaceuticals (ENTA) said it sold its 54.5% of future royalty payments from AbbVie (ABBV) on global sales of Mavyret/Maviret to OMERS, a Canadian pension fund, for $200 million. Tracon Pharmaceuticals (TCON) shares dropped 47% after the company said the tribunal in the arbitration against I-Mab (IMAB) conducted under the arbitration of the International Chamber of Commerce awarded Tracon about $23 million. New Article (RTTNews) - Biotechnology company Biogen Inc. (BIIB) reported Tuesday net income attributable to the company for the first quarter of $387.9 million or $2.67 per share, higher than $303.8 million or $2.06 per share in the prior-year quarter. On average, 24 analysts polled by Thomson Reuters expected the company to report earnings of $3.28 per share for the quarter. Looking ahead to fiscal 2023, the company continues to project adjusted earnings in a range of $15.00 to $16.00 per share on a revenue decline in the mid-single digits. New Article Biogen Inc. (BIIB) came out with quarterly earnings of $3.40 per share, beating the Zacks Consensus Estimate of $3.25 per share. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Inovio Pharmaceuticals, Inc. (INO) : Free Stock Analysis Report To read this article on Zacks.com click here. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. New Article Cantor Fitzgerald analyst Prakhar Agrawal said that Briumvi generated $3.3 million in March sales after bringing in $500,000 of revenue in February. The drug works similarly to Eli Lilly's Mounjaro in that it stimulates two insulin-secreting hormones, GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide). However, its revenue is expected to grow considerably thanks to Bruton's tyrosine kinase (BTK) inhibitor Brukinsa, which was first approved in 2019 by the Food and Drug Administration (FDA) to treat mantle cell lymphoma (MCL) and then received approvals in 2021 to treat Waldenstrm macroglobulinemia (WM) and relapsed or refractory marginal zone lymphoma (MZL). New Article For the quarter ended March 2023, Biogen Inc. (BIIB) reported revenue of $2.46 billion, down 2.7% over the same period last year. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. New Article Biogen BIIB reported first-quarter 2023 adjusted earnings per share (EPS) of $3.40, beating the Zacks Consensus Estimate of $3.25 and our model estimate of $3.33. Pipeline Setbacks Biogen announced that it is terminating its involvement in the development of BIIB093 due to operational challenges to help save costs. BIIB093 was being developed in a phase III study for large hemispheric infarction and a phase II study for brain contusion. New Article Biogen (BIIB) were down 3.4% after its Chief Executive Christopher Viehbacher said the company has initiated an additional program to cut costs. In company news, Tracon Pharmaceuticals (TCON) shares dropped over 49% after it said the tribunal in the arbitration against I-Mab (IMAB) conducted under the arbitration of the International Chamber of Commerce awarded Tracon about $23 million. I-Mab in a separate statement called the outcome ""positive."" New Article On April 19th, a data leak revealed that Legend Biotechs Carvykti, a blood cancer therapy, performed extremely well in a recent study. Data showed that just one dose of the multiple myeloma drug lowered the risk of tumor progression and death by 74% compared to standard of care therapies. In addition to establishing the SAB, Legend announced the hiring of Dr. Mythili Koneru as Chief Medical Officer, who served in the same role at cell therapy specialist Marker Therapeutics. New Article April 25 (Reuters) - Biogen Inc BIIB.O on Tuesday beat expectations for quarterly profit on strong sales of spinal muscular atrophy drug Spinraza, but said it would pause or discontinue some studies to cut costs. At least four studies testing stroke and gene therapies and eye disorder treatment will be discontinued or put on hold to reduce research-related expenses, Biogen said in a statement. The drugmaker also reaffirmed its full-year adjusted profit forecast of $15 to $16 per share.",272.81024169921875
2023-04-26 00:00:00+00:00,278.5899963378906,289.239990234375,274.8999938964844,288.0400085449219,288.0400085449219,1817400.0,4.0,1.0,0.7500249999999999,"Fintel reports that on April 26, 2023, Morgan Stanley maintained coverage of Biogen (NASDAQ:BIIB) with a Overweight recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.42%, an increase of 13.77%. The put/call ratio of BIIB is 0.79, indicating a bullish outlook. New Article Fintel reports that on April 26, 2023, Canaccord Genuity maintained coverage of Biogen (NASDAQ:BIIB) with a Buy recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.42%, an increase of 13.50%. The put/call ratio of BIIB is 0.82, indicating a bullish outlook. New Article Among these, Biogen BIIB reports first-quarter results while Incyte INCY gets FDA approval for novel cream formulation of JAK1/JAK2 inhibitor ruxolitinib. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Incyte Corporation (INCY) : Free Stock Analysis Report Arrowhead Pharmaceuticals, Inc. (ARWR): Free Stock Analysis Report bluebird bio, Inc. (BLUE) : Free Stock Analysis Report Morphic Holding, Inc. (MORF) : Free Stock Analysis Report To read this article on Zacks.com click here. Concurrently, Biogen announced that the FDA has approved tofersen100 mg/15mL injection under the brand name Qalsody for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. New Article Fintel reports that on April 26, 2023, Needham maintained coverage of Biogen (NASDAQ:BIIB) with a Buy recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.42%, an increase of 13.77%. The put/call ratio of BIIB is 0.79, indicating a bullish outlook. New Article Especially high volume was seen for the $330 strike call option expiring June 16, 2023, with 559 contracts trading so far today, representing approximately 55,900 underlying shares of BIIB. Below is a chart showing AZO's trailing twelve month trading history, with the $1800 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 4,397 contracts thus far today. That number of contracts represents approximately 439,700 underlying shares, working out to a sizeable 57.2% of BIIB's average daily trading volume over the past month, of 768,250 shares. New Article Fintel reports that on April 26, 2023, Barclays maintained coverage of Biogen (NASDAQ:BIIB) with a Equal-Weight recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.42%, an increase of 13.77%. The put/call ratio of BIIB is 0.79, indicating a bullish outlook. New Article Fintel reports that on April 26, 2023, Atlantic Equities maintained coverage of Biogen (NASDAQ:BIIB) with a Neutral recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.42%, an increase of 13.77%. The put/call ratio of BIIB is 0.79, indicating a bullish outlook.",278.27301025390625
2023-05-03 00:00:00+00:00,315.0,316.69000244140625,309.54998779296875,311.0,311.0,2787500.0,1.6666666666666667,1.0,0.1666916666666666,"Particularly high volume was seen for the $400 strike call option expiring January 19, 2024, with 430 contracts trading so far today, representing approximately 43,000 underlying shares of BIIB. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Biogen Inc (Symbol: BIIB), where a total volume of 5,602 contracts has been traded thus far today, a contract volume which is representative of approximately 560,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 59.1% of BIIB's average daily trading volume over the past month, of 947,605 shares. New Article Using that dementia scale, trial results published last year showed that Eisai Co Ltd 4523.T and Biogen Inc's BIIB.O Leqembi reduced the rate of cognitive decline by 27% compared to a placebo in patients with early Alzheimer's. In the donanemab treatment group, Lilly said brain swelling, a known side effect of drugs of this type, occurred in 24% of participants, with 6.1% experiencing symptoms. Lilly's drug is likely to become the third in its class on the market following U.S. approval of two similar medicines developed by partners Eisai and Biogen - Leqembi and Aduhelm, which failed to gain traction with doctors or insurers after showing little evidence that it slowed cognitive decline. New Article Rival Biogen Inc BIIB.O fell 1.4%. By Ankika Biswas and Sruthi Shankar May 3 (Reuters) - Wall Street's main indexes were set to open higher on Wednesday after a selloff in the previous session, with investors awaiting more economic data ahead of the outcome of a Federal Reserve policy meeting later in the day. ""There's a reasonable belief that some regional banks could be exposed to similar circumstances given rising rates and that we're heading right into a Fed meeting in which they're continuing to raise,"" said Jason Pride, chief of investment strategy and research at Glenmede.",279.8951721191406
2023-05-04 00:00:00+00:00,311.4200134277344,314.3699951171875,309.5799865722656,313.57000732421875,313.57000732421875,1214000.0,3.0,1.0,0.5000249999999999,"Fintel reports that on May 4, 2023, B of A Securities maintained coverage of Biogen (NASDAQ:BIIB) with a Neutral recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.42%, an increase of 10.61%. The put/call ratio of BIIB is 0.79, indicating a bullish outlook. New Article Quarter in Detail Ionis has licensed Spinraza to Biogen BIIB. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report To read this article on Zacks.com click here. Spinraza product sales (recorded by Biogen) were hurt by lower new patients starts in the United States, currency headwinds and unfavorable channel dynamics in the first quarter.",277.5909423828125
2023-05-05 00:00:00+00:00,313.8099975585937,319.739990234375,310.6600036621094,318.0599975585937,318.0599975585937,1734400.0,3.0,1.0,0.5000249999999999,"Today's Must Read ExxonMobil (XOM) Banks on Prolific Permian & Guyana Assets Decent Comparable Sales Run to Fuel Costco's (COST) Top Line Solid Gaming Portfolio Aids Activision's (ATVI) Prospects Featured Reports Biogen's (BIIB) Upcoming Product Launches May Revive Growth The Zacks analyst says that potential new launches, Leqembi in Alzheimer's, tofersen in ALS and zuranolone in depression, can help revive growth at Biogen, which is facing multiple challenges now. (You can read the full research report on Activision Blizzard here >>>) Other noteworthy reports we are featuring today include Biogen Inc. (BIIB), General Dynamics Corporation (GD) and Arista Networks, Inc. (ANET). Click to get this free report General Dynamics Corporation (GD) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Activision Blizzard, Inc (ATVI) : Free Stock Analysis Report Exxon Mobil Corporation (XOM) : Free Stock Analysis Report Costco Wholesale Corporation (COST) : Free Stock Analysis Report Arista Networks, Inc. (ANET) : Free Stock Analysis Report To read this article on Zacks.com click here.",262.1026611328125
2023-05-08 00:00:00+00:00,317.4800109863281,317.4800109863281,310.0,314.3699951171875,314.3699951171875,936100.0,3.0,1.0,0.5000249999999999,"But interest has been buoyed by recent positive data on Alzheimer's drugs developed by Eisai Co Ltd 4523.T with partner Biogen BIIB.O and by Eli Lilly and Co LLY.Ndemonstrating that removing sticky amyloid plaques accumulated in the brain can slow cognition decline caused by the fatal mind-wasting disease. By Natalie Grover LONDON, May 8 (Reuters) - Diabetes drugs that also promote weight loss such as Novo Nordisks NOVOb.CO Ozempic, becoming a darling of celebrities and investors, are being studied to tackle some of the most difficult-to-treat brain disorders, including Alzheimers disease. Ivan Koychev, consultant neuropsychiatrist for Oxford University Hospitals NHS Foundation Trust, is running a trial testing semaglutide with the aim of halting the earliest changes in the brains of people at risk of developing Alzheimer's.",265.7265930175781
2023-05-09 00:00:00+00:00,311.8699951171875,315.69000244140625,311.0899963378906,314.0,314.0,906100.0,2.0,1.0,0.250025,"Recent Updates Last month, Denali announced that Biogen BIIB exercised its option to license Denalis ATV:Abeta. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report Denali Therapeutics Inc. (DNLI) : Free Stock Analysis Report To read this article on Zacks.com click here. In February, Denali reported new interim results from the ongoing open-label, single-arm phase I/II study of DNL310 in children with MPS II (Hunter syndrome), including data from additional participants and up to 104 weeks of treatment.",257.9842529296875
2023-05-10 00:00:00+00:00,315.19000244140625,315.7799987792969,310.7099914550781,313.260009765625,313.260009765625,795100.0,2.0,1.0,0.250025,"Detailed Analysis of WEST PHARMACEUTICAL SERVICES INC. WST Guru Analysis WST Fundamental Analysis BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry. It is also advancing its mid-to-late stage programs, including zuranolone for major depressive disorder (MDD) and postpartum depression (PPD), BIIB080 for Alzheimer's disease, tofersen for amyotrophic lateral sclerosis (ALS) and both litifilimab and dapirolizumab pegol for certain forms of lupus. Detailed Analysis of BIOGEN INC BIIB Guru Analysis BIIB Fundamental Analysis Benjamin Graham Portfolio Top Benjamin Graham Stocks About Benjamin Graham: The late Benjamin Graham may be the oldest of the gurus we follow, but his impact on the investing world has lasted for decades after his death in 1976.",250.53543090820312
2023-05-11 00:00:00+00:00,313.5,313.5899963378906,308.6499938964844,310.5599975585937,310.5599975585937,726300.0,3.4,1.0,0.600025,"Fintel reports that on May 11, 2023, Argus Research maintained coverage of Biogen (NASDAQ:BIIB) with a Buy recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.42%, an increase of 12.91%. The put/call ratio of BIIB is 0.82, indicating a bullish outlook. New Article Among the largest underlying components of QQEW, in trading today lululemon athletica inc (Symbol: LULU) is off about 0.2%, Biogen Inc (Symbol: BIIB) is down about 0.6%, and O'Reilly Automotive, Inc. (Symbol: ORLY) is lower by about 0.2%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the First Trust NASDAQ-100 Equal Weighted Index Fund (Symbol: QQEW) where we have detected an approximate $108.2 million dollar inflow -- that's a 7.4% increase week over week in outstanding units (from 14,800,002 to 15,900,002). These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. New Article Eli Lilly (NYSE: LLY) has a potential Alzheimer's treatment in donanemab that shows a lot of promise. The irony is that earlier in the year, donanemab didn't obtain accelerated approval because of the drug's high success rate. Otherwise, Medicare won't provide coverage for the costly treatments, which can run in the tens of thousands of dollars -- unless patients are involved in clinical trials (a minuscule minority). New Article Leqembi, sold by partners Eisai Co Ltd 4523.T and Biogen Inc BIIB.O at an annual list price of $26,500, was approved this year under the U.S. Food and Drug Administration's accelerated pathway. The Centers for Medicare and Medicaid Services (CMS), the agency that runs the health plan for people age 65 and older, currently covers the medication only for patients enrolled in clinical trials. The agency said it will broaden coverage if Leqembi - and similar drugs that remove a toxic protein called amyloid from the brain - were to receive standard FDA approval. New Article Looking at individual holdings, Newmont (NEM) accounts for about 1.09% of total assets, followed by Biogen Inc (BIIB) and Dow Inc (DOW). Click to get this free report iShares Morningstar Mid-Cap Value ETF (IMCV): ETF Research Reports Biogen Inc. (BIIB) : Free Stock Analysis Report Dow Inc. (DOW) : Free Stock Analysis Report Newmont Corporation (NEM) : Free Stock Analysis Report Vanguard Mid-Cap Value ETF (VOE): ETF Research Reports iShares Russell Mid-Cap Value ETF (IWS): ETF Research Reports To read this article on Zacks.com click here. Launched on 06/28/2004, the iShares Morningstar Mid-Cap Value ETF (IMCV) is a passively managed exchange traded fund designed to provide a broad exposure to the Mid Cap Value segment of the US equity market.",260.2151184082031
2023-05-12 00:00:00+00:00,310.9700012207031,311.4100036621094,307.70001220703125,309.6000061035156,309.6000061035156,442600.0,3.0,1.0,0.5000249999999999,"Biogen (NASDAQ: BIIB) has been a polarizing stock to own over the past few years. Given the narrow scope of the patient base that may benefit from the treatment -- the company says approximately 330 people in the U.S. have this form of the disease -- the peak annual sales could be modest at just $300 million, according to analysts. One big reason it's still a sell Biogen's business has been struggling in recent years as a loss of exclusivity for top-selling multiple sclerosis treatment Tecfidera has weighed on its results.",265.07781982421875
2023-05-15 00:00:00+00:00,310.0,312.4800109863281,309.1499938964844,311.8699951171875,311.8699951171875,495800.0,5.0,1.0,1.000025,"(RTTNews) - Eisai Co., Ltd. and Biogen Inc. (BIIB) said that Health Canada has accepted a New Drug Submission or NDS for lecanemab (brand name in the U.S.: LEQEMBI), an investigational anti-amyloid beta (A) protofibril antibody, for the treatment of early Alzheimer's disease with confirmed amyloid pathology in the brain. On March 3, 2023, the FDA accepted Eisai's sBLA based on the Clarity AD clinical data, and the lecanemab application has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of July 6, 2023. In Japan, Eisai submitted an application for manufacturing and marketing approval to the Pharmaceuticals and Medical Devices Agency (PMDA) on January 16, 2023.",268.0794372558594
2023-05-16 00:00:00+00:00,310.6000061035156,310.6400146484375,306.1099853515625,307.6099853515625,307.6099853515625,638400.0,4.0,1.0,0.7500249999999999,"Biogen BIIB has an interesting pipeline with key assets in Alzheimers. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report Ocuphire Pharma, Inc. (OCUP) : Free Stock Analysis Report To read this article on Zacks.com click here. If Leqembi receives a traditional approval and broader CMS coverage in the United States, the drug has the potential to generate blockbuster sales.",264.3838195800781
2023-05-19 00:00:00+00:00,307.0,310.5,306.5199890136719,308.4800109863281,308.4800109863281,568800.0,2.5,1.0,0.375025,"Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) both have Alzheimer's drugs that are in development and could obtain approval from the Food and Drug Administration (FDA) within the next 12 months. In trials, both Leqembi (Biogen) and donanemb (Eli Lilly) have slowed cognitive decline and therefore could be viable treatments in the fight against the debilitating disease. Analytics firm Grand View Research projects that the global Alzheimer's therapeutics market will expand at a compound annual growth rate of 16.2% through 2030, when it will be worth approximately $15.6 billion. New Article Biogen (BIIB) Source: PictureDesignSwiss / Shutterstock.com Biogen (NASDAQ:BIIB) stock shot higher in October 2022 on the news that one of its Alzheimer drug candidates, Lecanemab received better than expected results in a clinical trial. But BIIB stock didnt hold those gains as some investors were concerned about the accelerated approval process. At that time, BIIB stock could surpass analysts forecast for 7% stock price growth.",259.2213439941406
2023-05-25 00:00:00+00:00,298.510009765625,298.8900146484375,291.6400146484375,297.1300048828125,297.1300048828125,1073000.0,3.0,1.0,0.5000249999999999,A month has gone by since the last earnings report for Biogen Inc. (BIIB). Biogen announced that it is terminating its involvement in the development of BIIB093 due to operational challenges to help save costs. BIIB093 was being developed in a phase III study for large hemispheric infarction and a phase II study for brain contusion.,245.05274963378906
2023-05-26 00:00:00+00:00,298.510009765625,299.1099853515625,294.8299865722656,298.6600036621094,298.6600036621094,945500.0,3.0,1.0,0.5000249999999999,"Among the largest underlying components of IWS, in trading today Phillips 66 (Symbol: PSX) is up about 0.5%, Biogen Inc (Symbol: BIIB) is up about 0.4%, and AFLAC Inc (Symbol: AFL) is higher by about 0.7%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. New Article Another stock from the same industry, Biogen Inc. (BIIB), has gained 1.2% over the past month. Click to get this free report Alkermes plc (ALKS) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.",247.92115783691406
2023-05-30 00:00:00+00:00,297.9200134277344,298.95001220703125,295.0,298.69000244140625,298.69000244140625,802600.0,4.0,1.0,0.7500249999999999,"We note that the FDA granted accelerated approval to Biogen BIIB and partner Eisais Leqembi in January 2023 to treat early Alzheimers Disease. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Prothena Corporation plc (PRTA) : Free Stock Analysis Report Cassava Sciences, Inc. (SAVA) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Research The randomized, double-blind, placebo-controlled CMS study is evaluating the safety and efficacy of simufilam in patients with mild-to-moderate Alzheimers disease dementia. New Article SPDR Portfolio S&P 500 Growth ETF SPYG $57.87 $63.73 10.12% Biogen Inc BIIB $298.66 $331.46 10.98% Atmos Energy Corp. ATO $113.70 $126.14 10.94% AMETEK Inc AME $148.22 $163.56 10.35% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of SPYG's underlying holdings with notable upside to their analyst target prices are Biogen Inc (Symbol: BIIB), Atmos Energy Corp. (Symbol: ATO), and AMETEK Inc (Symbol: AME). Although BIIB has traded at a recent price of $298.66/share, the average analyst target is 10.98% higher at $331.46/share.",248.8846435546875
2023-06-01 00:00:00+00:00,301.0199890136719,308.3800048828125,300.19000244140625,302.4100036621094,302.4100036621094,1033600.0,4.0,1.0,0.7500249999999999,"Fintel reports that on June 1, 2023, Piper Sandler maintained coverage of Biogen (NASDAQ:BIIB) with a Overweight recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.35%, a decrease of 6.18%. The put/call ratio of BIIB is 0.76, indicating a bullish outlook. New Article Adds details on Medicare coverage in paragraph 3, background in paragraphs 4-5 June 1 (Reuters) - The U.S. Medicare health plan will broaden coverage for new Alzheimer's drugs such as Eisai Co Ltd 4523.T and Biogen Inc's BIIB.O Leqembi if they gain full U.S. approval, a federal agency said on Thursday. Eli Lilly LLY.N is also developing an Alzheimer's drug that targets amyloid brain plaques, similar to Eisai and Biogen's Leqembi. (Reporting by Manas Mishra and Leroy D'souza in Bengaluru; Editing by Pooja Desai and Shounak Dasgupta) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",254.9548797607422
2023-06-02 00:00:00+00:00,302.5299987792969,303.1700134277344,297.67999267578125,300.20001220703125,300.20001220703125,816600.0,4.0,1.0,0.7500249999999999,"Fintel reports that on June 2, 2023, RBC Capital reiterated coverage of Biogen (NASDAQ:BIIB) with a Outperform recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.35%, a decrease of 5.86%. The put/call ratio of BIIB is 0.75, indicating a bullish outlook.",250.71485900878906
2023-06-05 00:00:00+00:00,299.6700134277344,304.2900085449219,299.5899963378906,302.1300048828125,302.1300048828125,1085200.0,3.5,1.0,0.6250249999999999,"Among the largest underlying components of IWS, in trading today Motorola Solutions Inc (Symbol: MSI) is up about 1.2%, Phillips 66 (Symbol: PSX) is down about 1.5%, and Biogen Inc (Symbol: BIIB) is up by about 0.6%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. New Article Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry.",262.641845703125
2023-06-06 00:00:00+00:00,303.6499938964844,304.760009765625,298.32000732421875,299.7900085449219,299.7900085449219,911700.0,1.0,1.0,2.4999999999997247e-05,"Biogen BIIB announced that it is discontinuing one of the two studies on its and partner Denali Therapeutics DNLI small molecule LRRK2 inhibitor, BIIB122, for Parkinsons disease. Image Source: Zacks Investment Research Biogen collaborated with Denali Therapeutics in August 2020 to co-develop and co-commercialize BIIB122 for Parkinsons disease. Biogens clinical development program on BIIB122 initially comprised two late-stage studies.",259.85784912109375
2023-06-07 00:00:00+00:00,299.6300048828125,309.29998779296875,294.0400085449219,304.8999938964844,304.8999938964844,2034300.0,3.4,1.0,0.600025,"June 7 (Reuters) - Staff reviewers of the U.S. Food and Drug Administration (FDA) said on Wednesday that Eisai 4523.T and Biogen's BIIB.O Alzheimer's drug, Leqembi, may still be eligible for a full approval despite concerns of brain hemorrhage from using blood thinners along with the drug. The FDA staff's comments about the drug were made in documents released ahead of a meeting of the panel of external advisers on Friday to discuss the Japanese company's application for a traditional approval. (Reporting by Leroy Leo and Khushi Mandowara in Bengaluru; Editing by Krishna Chandra Eluri, Shinjini Ganguli and Anil D'Silva) ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Adds background in paragraphs 3-5, detail on deaths in paragraph 6 June 7 (Reuters) - Staff reviewers of the U.S. Food and Drug Administration (FDA) said on Wednesday that Eisai 4523.T and Biogen's BIIB.O Alzheimer's drug, Leqembi, could still be eligible for a full approval despite concerns of brain hemorrhage from using blood thinners along with the drug. The FDA staff's comments about the drug were made in documents released ahead of a meeting of the panel of external advisers on Friday to discuss the Japanese company's application for a traditional approval. A full approval is expected to boost demand for Leqembi with a wider insurance cover under government's Medicare plans for all American patients over 65 years of age and whose doctors participate in a health agency database. New Article Image Source: Zacks Investment Research Biogen (BIIB) is a Massachusetts-based biotech giant that develops innovative therapies for treating severe neurological and neurodegenerative diseases such as Alzheimers and Parkinsons disease. Unlike most biotech stocks, BIIB is highly profitable. In 2022 alone, BIIB registered $10 billion in sales and earned $17.67 a share in EPS. New Article Fintel reports that on June 7, 2023, Baird reiterated coverage of Biogen (NASDAQ:BIIB) with a Outperform recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.35%, a decrease of 5.81%. The put/call ratio of BIIB is 0.75, indicating a bullish outlook. New Article In addition, Zacks Equity Research provides analysis on Biogen BIIB and Denali Therapeutics' DNLI. Additional content: Biogen (BIIB) to End One of Two Parkinson's Studies Biogen announced that it is discontinuing one of the two studies on its and partner Denali Therapeutics' small molecule LRRK2 inhibitor, BIIB122, for Parkinson's disease. Biogen's clinical development program on BIIB122 initially comprised two late-stage studies.",255.1695098876953
2023-06-08 00:00:00+00:00,310.69000244140625,311.2799987792969,303.69000244140625,308.8800048828125,308.8800048828125,1231600.0,3.333333333333333,1.0,0.5833583333333334,"The FDA issued briefing documents on Biogens BIIB Alzheimers disease (AD) drug Leqembi (lecanemab) for the upcoming Peripheral and Central Nervous System Drugs Advisory Committee (PCNSDAC) Meeting on Jun 9. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Prothena Corporation plc (PRTA) : Free Stock Analysis Report To read this article on Zacks.com click here. Last month, Lilly announced positive data from the phase III TRAILBLAZER-ALZ 2 study that showed that treatment with donanemab significantly slowed cognitive and functional decline in people with early symptomatic AD. New Article Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $310.00 strike highlighted in red: Considering the fact that the $310.00 strike represents an approximate 2% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the July 28th expiration. New Article Pipeline and Regulatory Updates From Biogen:  The company announced that it would discontinue one of the two studies of BIIB122, a small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2), which is being developed in collaboration with Denali Therapeutics Inc. for Parkinsons disease. Meanwhile, key regulatory and pipeline updates from bigwigs like GSK GSK and Biogen BIIB were in the spotlight too during the week. The clinical development program on BIIB122 initially comprised two late-stage studies.",251.9596710205078
2023-06-09 00:00:00+00:00,308.8800048828125,308.8800048828125,308.8800048828125,308.8800048828125,308.8800048828125,0.0,4.666666666666667,1.0,0.9166916666666668,"June 9 (Reuters) - A panel of experts on Friday will discuss whether to recommend traditional U.S. regulatory approval for Eisai 4523.T and Biogen's BIIB.O new Alzheimer's drug Leqembi, a move expected to expand Medicare payment for the treatment. FDA staff reviewers on Wednesday said Eisai's late-stage trial showing Leqembi slowed cognitive decline by 27% in early Alzheimer's patients appeared to confirm the drug's benefit and raised no new safety issues. Regular approval would make Leqembi the first in its class of drugs that work by removing sticky amyloid plaques from the brain to achieve the regulatory milestone. New Article Updates to show meeting underway; adds comment by FDA official in paragraph 4 June 9 (Reuters) - A panel of expert advisers on Friday began their meeting to discuss whether to recommend traditional U.S. regulatory approval for Eisai 4523.T and Biogen's BIIB.O new Alzheimer's drug Leqembi, a move expected to expand Medicare payment for the treatment. FDA staff reviewers on Wednesday said Eisai's late-stage trial showing Leqembi slowed cognitive decline by 27% in early Alzheimer's patients appeared to confirm the drug's benefit and raised no new safety issues. UBS analyst Colin Bristow had said he expects Friday's panel meeting ""to essentially be a formality"" that will lead to approval and broaden access to the medicine. New Article June 9 (Reuters) - A panel of expert advisers on Friday unanimously agreed that a late-stage clinical trial of Eisai 4523.T and Biogen's BIIB.O Leqembi verified the benefit of the treatment for Alzheimer's disease, clearing the way for traditional U.S. regulatory approval. All six advisers on the panel voted in favor of Leqembi for treatment of Alzheimer's disease. (Reporting by Leroy Leo in Bengaluru; editing by Jonathan Oatis) ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",252.4202423095703
2023-06-12 00:00:00+00:00,319.760009765625,319.760009765625,310.0,313.4100036621094,313.4100036621094,1502500.0,3.833333333333334,1.0,0.7083583333333333,"Biogen (BIIB) and partner Eisai said a US Food and Drug Administration advisory committee supported the approval of Leqembi for the treatment of Alzheimer's disease. Chinook Therapeutics (KDNY) was rallying by more than 57% after saying it has agreed to be acquired by Novartis (NVS) in a deal worth up to about $3.5 billion. Intellia Therapeutics (NTLA) was up over 3% after saying interim results from a phase 1/2 trial of its NTLA-2002 candidate, which is intended for the treatment of hereditary angioedema, showed an overall mean decrease of 95% in monthly angioedema attacks for all patients through the latest follow-up. New Article June 12 (Reuters) - Shares of Biogen Inc BIIB.O rose 4% in premarket trade on Monday as an unanimous backing of the company's Alzheimer's drug Leqembi by the U.S. regulator's advisers eased concerns that a traditional approval for the treatment will not come with major new safety warnings. But the advisers said that these could be managed and were balanced against the benefits provided by the drug, which was developed by Biogen and partner Eisai Co 4523.T. ""We believe use will largely be left in the hands of physician-patient discussions,"" said William Blair analyst Myles Minter. New Article FDA advisers supported the approval of BiogenBIIB.O and Eisai's 4523.T Alzheimer's drug, sending the former's shares up 4.6% before the bell. Investors are on the watch for the U.S. Labor Department's consumer price index reading on Tuesday, also the first day of the Fed's meeting, for clues on the U.S. monetary policy path. A rally in megacap stocks, better-than-expected quarterly earnings and hopes that the Fed might be nearing the end of its tightening cycle have caused indexes to rise in recent weeks. New Article BiogenBIIB.O shares rose 1.5% in premarket trading after a U.S. FDA panel of advisers unanimously backed its Alzheimer's drug, Leqembi, raising hopes that a traditional approval for the treatment might not come with major new safety warnings. By Shristi Achar A and Sruthi Shankar June 12 (Reuters) - U.S. stock index futures rose on Monday, setting Wall Street up for a fresh round of gains, while investors awaited inflation data and the Federal Reserve's interest rate decision this week. Since last week, the rally has broadened beyond megacaps to include more economically sensitive sectors such as energy and industrials, and also small-cap stocks as data continues to show a resilient U.S. economy despite higher interest rates. New Article BiogenBIIB.O shares edged up 1.0% after a U.S. FDA panel of advisers unanimously backed its Alzheimer's drug, Leqembi, raising hopes that a traditional approval for the treatment might not come with major new safety warnings. By Shristi Achar A and Sruthi Shankar June 12 (Reuters) - Wall Street's main indexes rose on Monday as investors awaited inflation data and the Federal Reserve's interest rate decision this week, while Oracle Corp hit a record high ahead of its quarterly results later in the day. Since last week, the rally has broadened beyond megacaps to include more economically sensitive sectors such as energy and industrials, and also small-cap stocks as data continues to show a resilient U.S. economy despite higher interest rates. New Article BiogenBIIB.O shares edged up 1.6% after a U.S. FDA panel of advisers unanimously backed its Alzheimer's drug, Leqembi, raising hopes that a traditional approval for the treatment might not come with major new safety warnings. By Shristi Achar A and Sruthi Shankar June 12 (Reuters) - Wall Street's main indexes rose on Monday, extending a recent rally, as investors awaited inflation data and the Federal Reserve's interest rate decision this week, while Oracle hit a record high ahead of quarterly results later in the day. Since last week, the rally has broadened to include more economically sensitive sectors such as energy and industrials, as well as small-cap stocks as data continues to show a resilient U.S. economy despite higher interest rates. New Article BiogenBIIB.Orose 1.3% after a U.S. FDA panel of advisers unanimously backed its Alzheimer's drug, Leqembi, raising expectations that a traditional approval for the treatment might not come with major new safety warnings. By Shristi Achar A and Noel Randewich June 12 (Reuters) - U.S. stocks rallied on Monday, putting the S&P 500 within striking distance of its highest close since April 2022, and Oracle hit a record high ahead of quarterly results as investors awaited inflation data and the Federal Reserve's interest rate decision this week. The rally has recently widened to include more economically sensitive sectors such as energy and industrials, as well as small-cap stocks, as data continues to show a resilient U.S. economy despite higher interest rates. New Article Biogen (BIIB) and partner Eisai said Saturday that a US Food and Drug Administration advisory committee supported the approval of Leqembi to treat Alzheimer's disease. Abbott Laboratories (ABT) said in a regulatory filing on Monday that it has named Philip Boudreau as chief financial officer. A court hearing over a lawsuit against BioNTech (BNTX) in Germany seeking damages for alleged side effects of its COVID-19 vaccine was postponed on Monday after the plaintiff's lawyer requested the case to be heard by different judges, Reuters reported. New Article BiogenBIIB.O shares rose 2.5% in premarket trading after a U.S. FDA panel of advisers unanimously backed its Alzheimer's drug, Leqembi, stoking hopes that a traditional approval for the treatment might not come with major new safety warnings. ET (1136 GMT June 12 (Reuters) - U.S. stock index futures rose on Monday, setting Wall Street up for a fresh round of gains, while investors awaited inflation data and the Federal Reserve's interest rate decision this week. Since last week, the rally has broadened beyond megacaps to include more economically sensitive sectors such as energy, industrial and small-cap stocks as data continues to show a resilient U.S. economy despite higher interest rates. New Article BiogenBIIB.Orose after a U.S. FDA panel of advisers unanimously backed its Alzheimer's drug, Leqembi, raising expectations that a traditional approval for the treatment might not come with major new safety warnings. By Noel Randewich and Shristi Achar A June 12 (Reuters) - The S&P 500 and the Nasdaq rallied on Monday to their highest closing levels since April 2022, while Oracle hit a record high ahead of quarterly results as investors awaited inflation data and the Federal Reserve's interest rate decision this week. The rally has recently widened to include more economically sensitive sectors such as energy and industrials, as well as small-cap stocks, as data continues to show a resilient U.S. economy despite higher interest rates. New Article In company news, Biogen (BIIB) and partner Eisai said Saturday that a US Food and Drug Administration advisory committee supported the approval of Leqembi to treat Alzheimer's disease. Abbott Laboratories (ABT) said in a regulatory filing on Monday that it has named Philip Boudreau as chief financial officer. A court hearing over a lawsuit against BioNTech (BNTX) in Germany seeking damages for alleged side effects of its COVID-19 vaccine was postponed on Monday after the plaintiff's lawyer requested the case to be heard by different judges, Reuters reported. New Article The advisers discussed the risk of using Leqembi in certain patients, like those taking drugs that prevent blood clots and those with a rare condition called cerebral amyloid angiopathy. ""It seems unlikely that the updated FDA label will include additional contraindications,"" said Stifel analyst Paul Matteis, referring to the written information that accompanies an approved drug. The panel considered data from Eisai's confirmatory trial that showed the drug slowed cognitive decline by 27% in early Alzheimer's patients.",255.97262573242188
2023-06-13 00:00:00+00:00,310.8399963378906,312.760009765625,299.5199890136719,304.6000061035156,304.6000061035156,1526900.0,2.8,1.0,0.4500249999999999,"Among the largest underlying components of IWS, in trading today Motorola Solutions Inc (Symbol: MSI) is down about 0.4%, Phillips 66 (Symbol: PSX) is up about 2.3%, and Biogen Inc (Symbol: BIIB) is lower by about 3.4%. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs. New Article The hedge fund's founder, Alex Denner, one of three Sarissa candidates running for seats on Alkermes' 11-member board, said this week that he will give up his board seat at biotech Biogen BIIB.O. The move eliminates ""any claim of conflict whatsoever,"" Sarissa wrote to Alkermes shareholders on Tuesday morning. Alkermes licensed bipolar disorder treatment Lybalvi and the multiple sclerosis drug Vumerity to Biogen for commercialization, and some analysts worried it would be problematic for Denner to potentially sit on both companies' boards. New Article By Natalie Grover LONDON, June 13 (Reuters) - Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai 4523.T and Biogen BIIB.O say its ability to slow cognitive decline may not outweigh its health risks, or be worth the toll on scarce healthcare resources. Lecanemab, branded Leqembi in the U.S., is under regulatory review in Europe and likely poised for traditional U.S. approval next month based on trial data showing it slowed cognitive decline by 27% in patients with early Alzheimer's. A 18-point scale used in the trial to measure functions such as memory and problem solving showed only a small absolute difference in patients who received lecanemab versus those who got a placebo. New Article The hedge fund's founder, Alex Denner, 53, one of three Sarissa candidates running for seats on Alkermes' 11-member board, on Monday said he would give up his board seat at biotech company Biogen BIIB.O. But Denner's move created headlines for Biogen not only because the long-serving director is leaving unexpectedly but also because he nominated his replacement, Susan Langer, 32, who is his live-in romantic partner. Alkermes licensed multiple sclerosis drug Vumerity to Biogen for commercialization, and some analysts worried that it would be problematic for Denner to potentially sit on both companies' boards. New Article VIDEO: Nasdaq 100 Movers: BIIB, JD The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing Nasdaq 100 component thus far on the day is Biogen, trading down 3.1%. Biogen is showing a gain of 9.6% looking at the year to date performance.",250.82313537597656
2023-06-14 00:00:00+00:00,304.6000061035156,306.5199890136719,296.0899963378906,299.989990234375,299.989990234375,1512500.0,5.0,1.0,1.000025,"After a 13% rise in Biogen stock (NASDAQ: BIIB) this year, aligning with the broader S&P500 index returns, we believe it has little room for growth. Looking at a slightly longer term, BIIB stock is up 6% from levels seen in late 2019. Despite lower revenue, BIIB stock has seen a rise this year due to the developments around its pipeline.",256.36004638671875
2023-06-15 00:00:00+00:00,299.7699890136719,300.0,293.2099914550781,297.8299865722656,297.8299865722656,1483000.0,3.25,1.0,0.5625249999999999,"Especially high volume was seen for the $300 strike call option expiring July 28, 2023, with 281 contracts trading so far today, representing approximately 28,100 underlying shares of BIIB. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 4,184 contracts have traded so far, representing approximately 418,400 underlying shares. That amounts to about 41.9% of BIIB's average daily trading volume over the past month of 997,795 shares. New Article ADM Archer Daniels Midland $74.56 CF CF Industries $70.08 BIIB Biogen $297.83 SNA Snap-On $274.27 MPC Marathon Petroleum $113.83 VLO Valero Energy $114.03 GD General Dynamics 4214.96 Archer Daniels Midland (ADM) Source: Zurijeta / Shutterstock.com An American multinational food processing and commodities trading corporation, Archer Daniels Midland (NYSE:ADM) makes an excellent case for undervalued S&P 500 stocks to buy. Biogen (BIIB) Source: Freedom365day / Shutterstock.com Based in Cambridge, Massachusetts, Biogen (NASDAQ:BIIB) is a multinational biotechnology firm specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Thanks to its permanently relevant business, BIIB ranks among the best S&P 500 stocks to buy. New Article In April, the U.S. Food and Drug Administration granted accelerated approval for Biogen's BIIB.O ALS drug based on data that showed it reduced the protein levels. The company said its drug showed a statistically significant reduction in levels of neurofilament protein when compared to a placebo after 24 weeks of treatment. Higher levels of the protein are considered as a predictor of a more rapid decline in clinical function and greater risk of death in patients. New Article Key regulatory and pipeline updates from bigwigs like Biogen BIIB were in the spotlight during the week. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Ironwood Pharmaceuticals, Inc. (IRWD) : Free Stock Analysis Report Journey Medical Corporation (DERM) : Free Stock Analysis Report Chinook Therapeutics, Inc. (KDNY) : Free Stock Analysis Report 2seventy bio, Inc. (TSVT) : Free Stock Analysis Report To read this article on Zacks.com click here. Zigakibart is a targeted biologic therapy with the potential to address the root cause of IgAN, the production of abnormal galactose-deficient IgA and preserve kidney function.",250.95309448242188
2023-06-22 00:00:00+00:00,294.25,296.4599914550781,291.5799865722656,293.95001220703125,293.95001220703125,905600.0,2.0,1.0,0.250025,"By Julie Steenhuysen CHICAGO, June 22 (Reuters) - The U.S. Medicare health plan on Thursday offered details of plans to collect patient data as a condition for reimbursement for Eisai Co Ltd 4523.T and Biogen Inc's BIIB.O new Alzheimer's drug Leqembi, should it win traditional U.S. approval as expected by July 6. CMS will also require doctors to submit results of brain scans, spinal fluid tests or other measures used to assess levels of amyloid - an Alzheimer's protein that is the target of Leqembi and other anti-amyloid drugs. That study, published in November, showed the drug slowed cognitive decline by 27% in early Alzheimer's patients, but was also associated with some serious side effects, including brain swelling and bleeding or microhemorrhages. New Article By Julie Steenhuysen CHICAGO, June 22 (Reuters) - The U.S. Medicare health plan on Thursday offered details of plans to collect patient data as a condition for reimbursement for Eisai Co Ltd 4523.T and Biogen Inc's BIIB.O new Alzheimer's drug Leqembi, should it win traditional U.S. approval as expected by July 6. CMS will also require doctors to submit results of brain scans, spinal fluid tests or other measures used to assess levels of amyloid - an Alzheimer's protein that is the target of Leqembi and other anti-amyloid drugs. The CMS data requirements apply to all Alzheimer's treatments that reduce beta amyloid from the brain, including Eli Lilly and Co's donanemab, which recently reported positive results from its late-stage trial.",250.1011505126953
2023-06-23 00:00:00+00:00,293.3500061035156,293.5199890136719,283.9700012207031,284.5199890136719,284.5199890136719,1427600.0,2.5,1.0,0.375025,"It was two years ago that Biogen's (NASDAQ: BIIB) stock soared to more than $400 on news that its Alzheimer's treatment, Aduhelm (aducanumab), had obtained accelerated approval from the Food and Drug Administration (FDA). With no significant warnings and the drug having obtained the blessing of that key committee, all signs point to a likely approval next month, as Leqembi has a PDFUA date of July 6. When the FDA granted accelerated approval for Aduhelm, there was much more controversy surrounding the question of its effectiveness, with members of the panel of advisors expressing doubts about the drug's usefulness. New Article A bullish investor could look at BIIB's 28.5 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of BIIB shares: Looking at the chart above, BIIB's low point in its 52 week range is $193.65 per share, with $319.76 as the 52 week high point  that compares with a last trade of $286.24. In trading on Friday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 28.5, after changing hands as low as $286.32 per share.",243.0977020263672
2023-06-26 00:00:00+00:00,283.8699951171875,283.95001220703125,279.5599975585937,281.5799865722656,281.5799865722656,833500.0,3.0,1.0,0.5000249999999999,"June 26 (Reuters) - Biogen Inc BIIB.O said on Monday its shareholders had elected Susan Langer, former corporate strategy chief at the biotech company, as a director. (Reporting by Leroy Leo in Bengaluru; Editing by Shilpi Majumdar) ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Adds background throughout June 26 (Reuters) - Biogen BIIB.O shareholders elected former company executive Susan Langer as a director on Monday, weeks after her romantic partner, Alex Denner, vacated the seat and the board nominated her to replace him. Denner was a hedge fund manager, who had been a Biogen director since 2009 and headed the company's nominating and governance committee. (Reporting by Leroy Leo and Khushi Mandowara in Bengaluru, and Svea Herbst-Bayliss in New York; Editing by Shilpi Majumdar) ((Leroy.Dsouza@thomsonreuters.com ; Twitter: https://twitter.com/LeroyLeo7;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",241.48626708984375
2023-06-28 00:00:00+00:00,282.95001220703125,285.67999267578125,281.2900085449219,284.0199890136719,284.0199890136719,618700.0,5.0,1.0,1.000025,"The advisory committee voted 10 for and 4 against that evidence from the Phase III MOVE study show palovarotene is an effective treatment in patients with the ultra-rare bone disease fibrodysplasia ossificans progressiva. The committee further voted 11 for and 3 against on the benefits of palovarotene outweighing the risks, for the treatment of patients with fibrodysplasia ossificans progressiva. Fibrodysplasia ossificans progressiva or FOP is an ultra-rare disease that causes permanent and continuous bone growth in soft and connective tissues like muscles, tendons and ligaments, also known as heterotopic ossification.",244.7430877685547
2023-06-30 00:00:00+00:00,284.9599914550781,286.5,282.9100036621094,284.8500061035156,284.8500061035156,1130800.0,3.0,1.0,0.5000249999999999,"First Trust Large Cap Core AlphaDEX Fund ETF FEX $83.24 $91.72 10.18% Corebridge Financial Inc CRBG $17.68 $24.09 36.26% Biogen Inc BIIB $282.13 $333.29 18.13% Micron Technology Inc. MU $64.33 $73.08 13.61% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of FEX's underlying holdings with notable upside to their analyst target prices are Corebridge Financial Inc (Symbol: CRBG), Biogen Inc (Symbol: BIIB), and Micron Technology Inc. (Symbol: MU). Similarly, BIIB has 18.13% upside from the recent share price of $282.13 if the average analyst target price of $333.29/share is reached, and analysts on average are expecting MU to reach a target price of $73.08/share, which is 13.61% above the recent price of $64.33.",239.83721923828125
2023-07-03 00:00:00+00:00,282.8699951171875,285.6499938964844,281.239990234375,285.44000244140625,285.44000244140625,414700.0,3.0,1.0,0.5000249999999999,"Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry.",236.16558837890625
2023-07-06 00:00:00+00:00,285.95001220703125,286.9200134277344,282.4800109863281,284.989990234375,284.989990234375,1067800.0,3.333333333333333,1.0,0.5833583333333334,"By Deena Beasley and Julie Steenhuysen LOS ANGELES, July 6 (Reuters) - The U.S. Food and Drug Administration on Thursday granted standard approval to Eisai 4523.T and Biogen's BIIB.O Leqembi for patients with Alzheimer's disease, clearing the way for wider insurance coverage of the drug. ""Today we believe is a triumph for the Alzheimer's disease community, after so many years of hard work by so many scientists, physicians and clinical trial participants and their care partners,"" Eisai's U.S. chief executive, Ivan Cheung, said in an interview. Leqembi received ""accelerated"" FDA approval in January based on its amyloid-clearing ability, but the U.S. government's Medicare health plan for people aged 65 and over had questioned the benefits of that class of drugs and restricted coverage only to patients in a clinical trial. New Article Eisai (EASIY) Source: Shutterstock Japanese pharmaceutical juggernaut Eisai (OTCMKTS:EASIY) and biotech giant Biogen (NASDAQ:BIIB) have scored a home run by developing Leqembi, an Alzheimers drug with promising efficacy. Bolstering this achievement, the FDA welcomed Leqembi through its accelerated approval pathway in January and confirmed its clinical benefit last month. Additionally, with roughly 1.5 million individuals grappling with mild cognitive impairment or early-stage Alzheimers in the U.S., a considerable market for Leqembi is unfolding. New Article (RTTNews) - The U.S. Food and Drug Administration granted a traditional approval to Eisai Co., Ltd. (ESALY.PK, ESALF.PK) and Biogen Inc.'s (BIIB) Leqembi (lecanemab-irmb) to treat adult patients with Alzheimer's Disease. Alzheimer's disease is an irreversible, progressive brain disorder affecting more than 6.5 million Americans. The disease slowly destroys memory and thinking skills and eventually, the ability to carry out simple tasks.",241.34718322753906
2023-07-07 00:00:00+00:00,285.5799865722656,286.5400085449219,274.75,275.07000732421875,275.07000732421875,2849400.0,2.375,1.0,0.343775,"In company news, the US Food and Drug Administration on Thursday approved Biogen (BIIB) and Eisai's Leqembi to treat early Alzheimer's, but shares of Biogen were down 3.2% amid production concerns and a ""black box"" warning on the drug for the risk of brain swelling. Novartis' (NVS) patent claims for heart failure drug Entresto were invalidated by a US court in Delaware on Friday. Medigus (MDGS) said that Jeffs' Brands has signed a non-binding letter of intent to acquire a majority stake in B24Chat, an artificial intelligence marketing platform. New Article And underperforming other ETFs today is the The Health Care Select Sector SPDR Fund ETF, down about 0.8% in Friday afternoon trading. Among components of that ETF with the weakest showing on Friday were shares of Fortrea Holdings, lower by about 4.8%, and shares of Biogen, lower by about 2.6% on the day. VIDEO: Friday's ETF Movers: OIH, XLV The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Especially high volume was seen for the $290 strike call option expiring July 14, 2023, with 591 contracts trading so far today, representing approximately 59,100 underlying shares of BIIB. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 8,426 contracts have traded so far, representing approximately 842,600 underlying shares. That amounts to about 77.2% of BIIB's average daily trading volume over the past month of 1.1 million shares. New Article Fintel reports that on July 7, 2023, Needham reiterated coverage of Biogen (NASDAQ:BIIB) with a Buy recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.35%, a decrease of 3.27%. The put/call ratio of BIIB is 0.70, indicating a bullish outlook. New Article Among large Healthcare stocks, Fortrea Holdings Inc (Symbol: FTRE) and Biogen Inc (Symbol: BIIB) are the most notable, showing a loss of 5.1% and 2.1%, respectively. Combined, FTRE and BIIB make up approximately 0.9% of the underlying holdings of XLV. In afternoon trading on Friday, Utilities stocks are the worst performing sector, showing a 0.3% loss. New Article By Bhanvi Satija July 7 (Reuters) - With U.S. approval of Eisai's 4523.T and Biogen's BIIB.O Alzheimer's drug Leqembi secured, Wall Street analysts said they expect other region's health regulators to follow suit even if they share similar concerns about a potentially severe side effect. Shares of both companies fell on Friday, with Biogen down 3.4% or $9.80 at $275.34 in mid-morning U.S. trade, with analysts citing the safety warning as a negative surprise. After the FDA approval and warning, most analysts stuck to their peak global sales estimates for the drug, some of which are above Eisai's own forecast of $7 billion by 2030. New Article Fintel reports that on July 7, 2023, HC Wainwright & Co. reiterated coverage of Biogen (NASDAQ:BIIB) with a Buy recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.35%, a decrease of 3.27%. The put/call ratio of BIIB is 0.70, indicating a bullish outlook. New Article In trading on Friday, shares of Biogen Inc (Symbol: BIIB) crossed below their 200 day moving average of $282.42, changing hands as low as $276.28 per share. The chart below shows the one year performance of BIIB shares, versus its 200 day moving average: Looking at the chart above, BIIB's low point in its 52 week range is $193.65 per share, with $319.76 as the 52 week high point  that compares with a last trade of $276.46. The BIIB DMA information above was sourced from TechnicalAnalysisChannel.com Click here to find out which 9 other stocks recently crossed below their 200 day moving average  Also see:  Cheap Blue Chip Stocks  Funds Holding TD  NDSN YTD Return The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",254.40731811523438
2023-07-10 00:00:00+00:00,275.0,282.739990234375,275.0,281.5799865722656,281.5799865722656,1280500.0,4.0,1.0,0.7500249999999999,"Biogens BIIB stock was down on Friday despite FDAs long-awaited full approval to its and partner Eisais Alzheimers disease (AD) drug, Leqembi. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report To read this article on Zacks.com click here. In January, the FDA issued a complete response letter (CRL) to Eli Lillys LLY BLA seeking accelerated approval for donanemab for the treatment of early symptomatic Alzheimer's disease.",256.5168151855469
2023-07-11 00:00:00+00:00,280.0,280.5199890136719,276.0199890136719,279.8399963378906,279.8399963378906,909300.0,4.0,1.0,0.7500249999999999,"Fintel reports that on July 11, 2023, Morgan Stanley maintained coverage of Biogen (NASDAQ:BIIB) with a Overweight recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.35%, a decrease of 13.33%. The put/call ratio of BIIB is 0.66, indicating a bullish outlook. New Article Leqembi, co-developed with U.S.-based Biogen BIIB.O, won standard approval from the U.S. Food and Drug Administration (FDA) on July 6. Ivan Cheung, aged 46, the global head of the company's Alzheimer's portfolio and chief executive of its U.S. unit, will retire as of July 31, Eisai said in a release. An Eisai spokesperson said that Cheung had met his primary mission in the approval of Leqembi, but will continue to offer some support after his departure. New Article Fintel reports that on July 11, 2023, RBC Capital maintained coverage of Biogen (NASDAQ:BIIB) with a Outperform recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.35%, a decrease of 13.33%. The put/call ratio of BIIB is 0.66, indicating a bullish outlook. New Article Leqembi, co-developed with U.S.-based Biogen BIIB.O, won standard approval from the U.S. Food and Drug Administration (FDA) on July 6. TOKYO, July 11 (Reuters) - The Eisai 4523.T executive who helped garner full U.S. approval for the Japanese drugmaker's Alzheimer's disease treatment Leqembi will retire at the end of this month, the company said on Tuesday. Ivan Cheung, the global head of the company's Alzheimer's portfolio and chief executive of its U.S. subsidiary, will retire as of July 31, Eisai said in a release. New Article We note that the FDA granted accelerated approval to Biogen BIIB and partner Eisais Leqembi in January 2023 to treat early Alzheimers disease. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report Prothena Corporation plc (PRTA) : Free Stock Analysis Report To read this article on Zacks.com click here. The partnership has resulted in Bristol Myers Squibb exercising its option to obtain exclusive worldwide commercial rights for PRX005, Prothena's groundbreaking anti-tau antibody designed for the potential treatment of Alzheimer's disease. New Article Other than AstraZeneca, Ionis has partnerships with many pharma giants like Biogen BIIB and Novartis NVS. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report To read this article on Zacks.com click here. Ionis Pharmaceuticals IONS announced positive top-line data fromthe 85-week analysis of the phase III NEURO-TTRansform study on its investigational anti-sense drug eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN"").",258.14666748046875
2023-07-12 00:00:00+00:00,280.1700134277344,281.67999267578125,277.2900085449219,277.6199951171875,277.6199951171875,1055700.0,3.5,1.0,0.6250249999999999,"If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Biogen Inc. (BIIB). Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. New Article In the latest trading session, Biogen Inc. (BIIB) closed at $277.41, marking a -0.87% move from the previous day. Also, we should mention that BIIB has a PEG ratio of 2.32. BIIB's industry had an average PEG ratio of 1.86 as of yesterday's close.",258.207763671875
2023-07-13 00:00:00+00:00,278.92999267578125,280.8599853515625,276.3999938964844,277.9700012207031,277.9700012207031,985700.0,3.0,1.0,0.5000249999999999,"Biogen currently trades at just 13 times its trailing earnings, which is below its five-year average and nowhere near the highs it hit in 2021: BIIB PE ratio data by YCharts. Investors in Biogen (NASDAQ: BIIB) got some great news last week as the Food and Drug Administration (FDA) approved the company's Alzheimer's drug Leqembi. Now that Leqembi has obtained traditional approval, that's welcome news for Alzheimer's patients as it means they can gain access to the treatment and won't have to pay the full price for it: $26,500. New Article Among these, key news was Biogen BIIB and Eisais drug Leqembis receipt of full FDA approval and Novavaxs NVAX stock price rally on deal amendment with Canadas government. Recap of the Weeks Most Important Stories: BIIBs/ Eisais Drug Approval:  Biogen and partner Eisai announced that the FDA has approved the supplemental biologics license application (sBLA), supporting the traditional approval of their Alzheimers disease (AD) drug Leqembi. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Novavax, Inc. (NVAX) : Free Stock Analysis Report Prothena Corporation plc (PRTA) : Free Stock Analysis Report Caribou Biosciences, Inc. (CRBU) : Free Stock Analysis Report To read this article on Zacks.com click here. New Article Leqembi was developed by Japanese pharmaceutical company Eisai 4523.T, and it is marketed in the U.S. through a partnership with Biogen BIIB.O, the maker of Aduhelm. By Mark Miller July 13 (Reuters) - Federal officials made a splash last week by giving the green light to an expensive new drug that holds promise of slowing the advance of Alzheimers disease. Doubts about the drugs safety and effectiveness ultimately led Medicare officials to sharply limit its use - but not before the program increased the Part B premium for 2022 by a whopping 14.5% to fund expected Aduhelm expenses.",249.1356201171875
2023-07-14 00:00:00+00:00,278.94000244140625,280.0,276.1199951171875,278.92999267578125,278.92999267578125,895300.0,3.5,1.0,0.6250249999999999,"By Blake Brittain July 14 (Reuters) - Roche ROG.S and two of its subsidiaries sued biotech company Biogen BIIB.O in Massachusetts federal court on Thursday, accusing its proposed similar version of Roche's blockbuster rheumatoid arthritis drug Actemra of infringing several of their patents. Roche, Genentech and Chugai Pharmaceutical told the court that Biogen's biosimilar would infringe patents related to making and using their biologic drug. A spokesperson for Roche declined to discuss the case but said the company believes biosimilar competition ""has an important role to play in supporting the financial sustainability of healthcare systems, while making headroom for innovation."" New Article Stocks to Consider Here are some drug stocks that have the right combination of elements to beat on earnings this time around: Biogen BIIB has an Earnings ESP of +1.05% and a Zacks Rank #3. BIIB beat earnings estimates in each of the last four quarters, the average earnings surprise being 15.97%. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report To read this article on Zacks.com click here.",252.02407836914062
2023-07-17 00:00:00+00:00,278.4200134277344,280.489990234375,276.2200012207031,278.3999938964844,278.3999938964844,1189000.0,3.5,1.0,0.6250249999999999,"Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry. New Article With shares of Biogen (NASDAQ: BIIB) falling by 11% in the last 30 days, and by 20% in the last five years, could there be an opportunity for enterprising investors to buy the dip on this struggling biotech stock? Still a sizable chance of recovery The market didn't respond with great positivity to the FDA's full approval of Leqembi, and its shares are flat this year so far. But if you're willing to make a risky bet that's somewhat mitigated by the inexpensiveness of Biogen's stock right now, buying the dip could potentially lead to a decent return over time. New Article Lilly's drug, Donanemab, like Eisai and Biogen's recently approved Leqembi, is an intravenous antibody designed to remove deposits of a protein called beta amyloid from the brains of Alzheimer's patients. The full study results are being presented at the Alzheimer's Association International Conference in Amsterdam and published in JAMA on Monday. The FDA this month granted standard approval to Leqembi, the first Alzheimer's disease modifying treatment to achieve that goal, clearing the way for wider insurance coverage of the drug. New Article The full analysis showed results were less robust for older, later-stage patients as well as those with higher levels of a protein called tau that has been linked to Alzheimer's disease progression. ""These side effects should not be taken lightly,"" but most cases were manageable by monitoring with magnetic resonance imaging (MRI) or stopping the drug, said study investigator Dr. Liana Apostolova, professor in Alzheimer's Disease research at Indiana University School of Medicine. Donanemab, like Eisai and Biogen's recently approved Leqembi, is an intravenous antibody designed to remove deposits of a protein called beta amyloid from the brains of Alzheimer's patients.",259.9150390625
2023-07-18 00:00:00+00:00,278.3999938964844,281.1199951171875,275.7699890136719,276.1700134277344,276.1700134277344,1052200.0,3.6666666666666665,1.0,0.6666916666666666,"Like Lilly, several other pharma companies like Biogen BIIB, Prothena PRTA and Roche RHHBY have been engaged in developing their antibody candidates to treat AD. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Prothena Corporation plc (PRTA) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Research Based on data from the TRAILBLAZER-ALZ 2 study, Lilly completed the resubmission of the biologics license application (BLA) with the FDA seeking approval for donanemab in AD indication during the second quarter. New Article The market expects Biogen Inc. (BIIB) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended June 2023. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. New Article Biogen Inc. (BIIB) closed the most recent trading day at $276.17, moving -0.8% from the previous trading session. It is also worth noting that BIIB currently has a PEG ratio of 2.3. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here.",266.80999755859375
2023-07-19 00:00:00+00:00,276.1700134277344,278.95001220703125,275.8299865722656,276.8900146484375,276.8900146484375,912300.0,3.0,1.0,0.5000249999999999,"Over the past few years, Biogen (NASDAQ: BIIB) has been engaged in a much-talked-about journey to develop an effective Alzheimer's disease (AD) medicine. BIIB data by YCharts Leqembi should succeed where Aduhelm failed Leqembi had previously earned accelerated approval in January. BIIB Revenue (Quarterly) data by YCharts In 2022, Biogen's total revenue came in at $10.2 billion, a decrease of 7% year over year, or a 5% decline in constant currency. New Article The phase 1 INTERCEPT-AD trial of Acumens ACU193 drug candidate showed positive topline results in 65 early-stage Alzheimers disease patients across multiple locations. Acumens return to the $10.00 level comes roughly 10 months after the stock got a boost from Biogens phase 3 data around its controversial Alzheimers drug lecanemab. Mondays ride up the charts is a good example of how quickly biotech stocks can snap back when the market is reminded of a promising drug candidate for widespread disease. New Article Biogen BIIB will report second-quarter 2023 results on Jul 25, before market open. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Moderna, Inc. (MRNA) : Free Stock Analysis Report To read this article on Zacks.com click here. In April, the FDA granted accelerated approval Biogens tofersen 100 mg/15mL injection under the brand name Qalsody for the treatment of amyotrophic lateral sclerosis in adults who have a mutation in the superoxide dismutase 1 gene. New Article Expected Results of an Industry Player Among the stocks in the Zacks Medical - Biomedical and Genetics industry, Biogen Inc. (BIIB) is soon expected to post earnings of $3.77 per share for the quarter ended June 2023. Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.",267.18585205078125
2023-07-24 00:00:00+00:00,276.5400085449219,278.4100036621094,275.70001220703125,277.0,277.0,1173500.0,3.5,1.0,0.6250249999999999,"Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry. New Article Two top examples are Vertex Pharmaceuticals (NASDAQ: VRTX) and Biogen (NASDAQ: BIIB). They're established players bringing in billions of dollars in earnings -- but they still offer the high growth opportunity associated with the word ""biotech."" The company is the world leader in CF treatment -- and thanks to its current products and those on the way, it expects to keep this position through at least the late 2030s.",278.1680908203125
2023-07-25 00:00:00+00:00,279.8599853515625,280.4200134277344,264.3699951171875,270.3099975585937,270.3099975585937,2485300.0,3.0,1.0,0.5000249999999999,"Visa V.N, Verizon Communications VZ.N, Texas Instruments TXN.O, Biogen BIIB.O, General Electric GE.N and General Motors GM.N are also set to report their results later in the day. The U.S. tech giants are expected to signal an end to a nearly year-long slowdown in their cloud businesses as signs of economic resilience encourage clients to boost technology spending, while a pickup in digital ads will also aid their profits. The tech-heavy Nasdaq Composite Index .IXIC has rallied 34.3% this year, helped by outsized gains in rate-sensitive megacap growth companies on optimism over artificial intelligence and hopes of an end to the Fed's tightening cycle. New Article By Khushi Mandowara July 25 (Reuters) - GE HealthCare Technologies Inc GEHC.Osaid on Tuesday that the commercial launch of Alzheimer's treatment and related testing for patients would help drive demand for its imaging equipment at hospitals and medical centers next year. The U.S. Centers for Medicare and Medicaid Services (CMS) has proposed broader coverage for a type of brain scan used in identifying a key Alzheimer's disease protein to determine patients' eligibility for the new treatment. The X-ray and ultrasound machine maker raised its annual profit forecast, after beating quarterly earnings estimates as the availability of electronic components improved, allowing the company to increase production and prices for its equipment. New Article July 25 (Reuters) - Biogen Inc BIIB.O said on Tuesday it expects to slash about 1,000 jobs, or about 11% of its workforce, to save costs as the company ramps up the launch of a new Alzheimer's disease drug in efforts to return to growth. Investors have pinned their hopes on Leqembi, which Biogen sells with Eisai 4523.T, to power growth as money spinner multiple sclerosis and spinal muscular atrophy (SMA) treatments face fierce competition from cheaper versions and rival drugs. The company had said in April it would pause or discontinue at least four studies of experimental drugs to focus on more lucrative options including the Leqembi launch and trim costs. New Article Adds details on drug sales in paragraph 11, background on Leqembi in paragraphs 6 and 7, share movement in paragraph 3 July 25 (Reuters) - Biogen Inc BIIB.O said on Tuesday it expects to slash about 1,000 jobs, or about 11% of its workforce, under a fresh cost-cutting program as the company ramps up the launch of a new Alzheimer's disease drug in efforts to return to growth. Investors have pinned their hopes on Leqembi as the U.S drugmaker's money spinner multiple sclerosis and spinal muscular atrophy (SMA) treatments face fierce competition from cheaper versions and rival drugs. The U.S. Food and Drug Administration in early July granted a standard approval to Leqembi, which Biogen sells with Japan's Eisai 4523.T, clearing the way for wider insurance coverage. New Article (RTTNews) - Biotechnology company Biogen, Inc. (BIIB) reported Tuesday that net income attributable to the company for the second quarter plunged to $591.6 million or $4.07 per share from $1.06 billion or $7.24 per share in the prior-year quarter. On average, 25 analysts polled by Thomson Reuters expected the company to report earnings of $3.77 per share for the quarter. Looking ahead to fiscal 2023, the company continues to project adjusted earnings in a range of $15.00 to $16.00 per share on a revenue decline in the mid-single digits. New Article Biogen Inc. (BIIB) came out with quarterly earnings of $4.02 per share, beating the Zacks Consensus Estimate of $3.77 per share. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Geron Corporation (GERN) : Free Stock Analysis Report To read this article on Zacks.com click here. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. New Article Biogen (BIIB) was more than 1% higher after it reported Q2 non-GAAP earnings of $4.02 per diluted share, down from $5.25 a year earlier but above the $3.76 estimate from analysts polled by Capital IQ. Danaher (DHR) was declining more than 4% after it reported fiscal Q2 adjusted earnings of $2.05 per diluted share, down from $2.76 a year earlier. Medpace Holdings (MEDP) reported Q2 earnings of $1.93 per diluted share, up from $1.46 a year earlier. New Article For the quarter ended June 2023, Biogen Inc. (BIIB) reported revenue of $2.46 billion, down 5.1% over the same period last year. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. New Article Particularly high volume was seen for the $270 strike call option expiring August 18, 2023, with 561 contracts trading so far today, representing approximately 56,100 underlying shares of BIIB. Below is a chart showing MCD's trailing twelve month trading history, with the $300 strike highlighted in orange: Biogen Inc (Symbol: BIIB) options are showing a volume of 6,428 contracts thus far today. That number of contracts represents approximately 642,800 underlying shares, working out to a sizeable 55.3% of BIIB's average daily trading volume over the past month, of 1.2 million shares. New Article Biogen BIIB reported second-quarter 2023 adjusted earnings per share (EPS) of $4.02, beating the Zacks Consensus Estimate of $3.77. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Alkermes plc (ALKS) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. Combined interferon revenues (Avonex and Plegridy) in the quarter were $302.4 million, down 13.6%, hurt by a continued shift from the injectable platform to oral or high-efficacy therapies. New Article Fintel reports that on July 25, 2023, Needham reiterated coverage of Biogen (NASDAQ:BIIB) with a Buy recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.36%, a decrease of 14.99%. The put/call ratio of BIIB is 0.76, indicating a bullish outlook. New Article Fintel reports that on July 25, 2023, Stifel maintained coverage of Biogen (NASDAQ:BIIB) with a Buy recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.36%, a decrease of 14.99%. The put/call ratio of BIIB is 0.76, indicating a bullish outlook. New Article A bullish investor could look at BIIB's 25.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of BIIB shares: Looking at the chart above, BIIB's low point in its 52 week range is $193.65 per share, with $319.76 as the 52 week high point  that compares with a last trade of $266.29. In trading on Tuesday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 25.6, after changing hands as low as $264.37 per share. New Article Biogen (BIIB) was down 2.7% after it said Tuesday it plans to cut 1,000 jobs as part of an ongoing cost-cutting program that will result in $700 million in net operating expense savings by 2025. Humanigen (HGEN) shares plunged 80% after it said Tuesday it expects that it will not be able to continue as a going concern and is exploring all restructuring options. Stoke Therapeutics (STOK) shares tumbled 32% after it said new data showed 32% of subjects in phase 1/2a studies of people treated with STK-001, an investigational drug for severe and progressive genetic epilepsy Dravet syndrome, had a treatment-emergent adverse event. New Article There are always exceptions, though, and on Tuesday it was Biogen's (NASDAQ: BIIB) turn to be atypical. What happened Typically, when a publicly traded company reports an estimates-beating quarter, its stock price rises in reaction. After Biogen published second-quarter figures that featured top- and bottom-line beats, the biotech's stock nevertheless took a hit. New Article Biogen (BIIB) was down 3.6% after it said Tuesday it plans to cut 1,000 jobs as part of an ongoing cost-cutting program that will result in $700 million in net operating expense savings by 2025. In company news, Humanigen (HGEN) shares plunged 77% after it said Tuesday it expects that it will not be able to continue as a going concern and is exploring all restructuring options. Stoke Therapeutics (STOK) shares tumbled 33% after it said new data showed 32% of subjects in phase 1/2a studies of people treated with STK-001, an investigational drug for severe and progressive genetic epilepsy Dravet syndrome, had a treatment-emergent adverse event.",286.6915283203125
2023-07-26 00:00:00+00:00,270.0,270.0,263.0899963378906,265.25,265.25,1517500.0,3.285714285714285,1.0,0.5714535714285712,"Fintel reports that on July 26, 2023, RBC Capital maintained coverage of Biogen (NASDAQ:BIIB) with a Outperform recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.36%, a decrease of 14.99%. The put/call ratio of BIIB is 0.74, indicating a bullish outlook. New Article Among these, Biogens BIIB second-quarter results grabbed the spotlight as the biotech major announced a restructuring program. Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report Kodiak Sciences Inc. (KOD) : Free Stock Analysis Report To read this article on Zacks.com click here. Earlier, the company announced that it is discontinuing the phase III ENHANCE study, a trial investigating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes (MDS). New Article Fintel reports that on July 26, 2023, Wedbush maintained coverage of Biogen (NASDAQ:BIIB) with a Neutral recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.36%, a decrease of 14.99%. The put/call ratio of BIIB is 0.74, indicating a bullish outlook. New Article Fintel reports that on July 26, 2023, HC Wainwright & Co. reiterated coverage of Biogen (NASDAQ:BIIB) with a Buy recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.36%, a decrease of 14.99%. The put/call ratio of BIIB is 0.74, indicating a bullish outlook. New Article Fintel reports that on July 26, 2023, Needham maintained coverage of Biogen (NASDAQ:BIIB) with a Buy recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.36%, a decrease of 14.99%. The put/call ratio of BIIB is 0.74, indicating a bullish outlook. New Article Fintel reports that on July 26, 2023, BMO Capital maintained coverage of Biogen (NASDAQ:BIIB) with a Outperform recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.36%, a decrease of 14.99%. The put/call ratio of BIIB is 0.74, indicating a bullish outlook. New Article Yesterday, Biogen (NASDAQ: BIIB) Chief Executive Officer Christopher Viehbacher barely mentioned the upcoming regulatory decision for zuranolone as a treatment for major depressive disorder (MDD) and postpartum depression (PPD). However, Biogen's leader didn't mention anything on the topic, leading some nervous investors to speculate that a regulatory delay, or an outright rejection, was on the way. Backing this up, Sage's depression medication is forecast to hit nearly $2 billion in annual sales before the decade's end.",283.4789733886719
2023-07-27 00:00:00+00:00,265.7300109863281,267.0199890136719,262.3999938964844,262.7900085449219,262.7900085449219,1283200.0,2.5,1.0,0.375025,"When you think about biotech leaders, the name Biogen (NASDAQ: BIIB) may come to mind. Over the years, this biotechnology giant built a powerful multiple sclerosis (MS) treatment platform that has brought in billions of dollars in earnings. The company and partner Eisai recently scored a win when the U.S. Food and Drug Administration (FDA) granted Leqembi traditional approval. New Article Fintel reports that on July 27, 2023, Scotiabank initiated coverage of Biogen (NASDAQ:BIIB) with a Sector Outperform recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.36%, a decrease of 15.36%. The put/call ratio of BIIB is 0.72, indicating a bullish outlook.",274.2214660644531
2023-07-28 00:00:00+00:00,263.29998779296875,268.260009765625,256.1300048828125,265.2300109863281,265.2300109863281,3168200.0,3.142857142857143,1.0,0.5357392857142856,"Reata Pharmaceuticals RETA.O surged 51.9% after Biogen BIIB.O agreed to buy the rare disease drugmaker for nearly $6.5 billion. By Bansari Mayur Kamdar and Johann M Cherian July 28 (Reuters) - Wall Street opened higher on Friday after data signaling easing inflation pressures added to hopes that the Federal Reserve's policy tightening was ending, while chip stocks rose as Intel posted a surprise quarterly profit. The Bank of Japan made its yield curve control policy more flexible and loosened its defense of a long-term interest rate cap, in moves seen by investors as a prelude to an eventual shift away from massive monetary stimulus. New Article Reata PharmaceuticalsRETA.O surged 52.5% after Biogen BIIB.O agreed to buy the rare disease drugmaker for nearly $6.5 billion. On Thursday, the blue-chips Dow snapped its longest winning streak since 1987 as U.S. Treasury yields pressured stocks after news that the Bank of Japan will allow long-term interest rates to rise. The Bank of Japan made its yield curve control policy more flexible and loosened its defense of a long-term interest rate cap, in moves seen by investors as a prelude to an eventual shift away from massive monetary stimulus. New Article In company news, Reata Pharmaceuticals (RETA) shares soared 53% after the company said it agreed to be bought by Biogen (BIIB) for $172.50 per share in cash. Health care stocks were mixed Friday afternoon, with the NYSE Health Care Index fractionally lower and the Health Care Select Sector SPDR Fund (XLV) rising 0.3%. Centene (CNC) shares were down almost 6% after the managed care company released its Q2 results. New Article Reata PharmaceuticalsRETA.O surged 52.35% after Biogen BIIB.O agreed to buy the rare disease drugmaker for nearly $6.5 billion. On Thursday, the blue-chip Dow snapped its longest winning streak since 1987 as U.S. Treasury yields pressured stocks after news that the Bank of Japan will allow long-term interest rates to rise. The Bank of Japan made its yield curve control policy more flexible and loosened its defense of a long-term interest rate cap, in moves seen by investors as a prelude to an eventual shift away from massive monetary stimulus. New Article Reata PharmaceuticalsRETA.O surged after Biogen BIIB.O agreed to buy the rare disease drugmaker for nearly $6.5 billion. By Carolina Mandl and Bansari Mayur Kamdar July 28 (Reuters) - All three major U.S. indexes ended the week with gains after a slew of earnings from big technology companies, economic data and central bank announcements boosted investor confidence in a soft landing for the U.S. economy. The Bank of Japan made its yield curve control policy more flexible and loosened its defense of a long-term interest rate cap, in moves seen by investors as a prelude to an eventual shift away from massive monetary stimulus. New Article Reata PharmaceuticalsRETA.O surged 54.02% after Biogen BIIB.O agreed to buy the rare disease drugmaker for nearly $6.5 billion. Ford slows EV ramp-up, Q2 commercial vehicle profit booms Chip stocks climb after Intel's surprise quarterly profit P&G tops estimates but signals slowing China demand Core June PCE at 4.1% vs est 4.2% Indexes up: Dow 0.5%, S&P 500 0.99%, Nasdaq 1.90% Updated at 04:00 p.m. ET/2000 GMT By Carolina Mandl and Bansari Mayur Kamdar July 28 (Reuters) - All three major U.S. indexes ended the week with gains, after a slew of Big Tech earnings, economic data and central bank announcements boosted investor confidence in a soft landing for the U.S. economy. The Bank of Japan made its yield curve control policy more flexible and loosened its defense of a long-term interest rate cap, in moves seen by investors as a prelude to an eventual shift away from massive monetary stimulus. New Article Adds details on Reata's treatment in paragraph 2 and 3, background throughout July 28 (Reuters) - Biogen BIIB.O said it would buy biotech firm Reata Pharmaceuticals RETA.O for roughly $6.5 billion to expand its presence in the rare disease drugs market. Through the deal, Biogen will gain Plano, Texas-based Reata's recently approved drug Skyclarys to treat a rare genetic disorder that causes progressive damage to the nervous system. Biogen has said it would look at deals across rare diseases, immunology and neuropsychiatry, as it looks to bulk up its portfolio beyond Alzheimer's drug Leqembi.",279.8355712890625
2023-07-31 00:00:00+00:00,264.260009765625,273.4599914550781,263.5299987792969,270.19000244140625,270.19000244140625,1374500.0,3.285714285714285,1.0,0.5714535714285712,"The announcement follows full U.S. regulatory approval earlier this month of Leqembi, a drug from Eisai 4523.T and partner Biogen BIIB.O that removes amyloid from the brain and has been shown to slow the advance of Alzheimer's in early-stage patients. ""One of the advantages of having an amyloid test is that it lets you know, potentially years in advance of even being symptomatic, that you are at risk for Alzheimer's,"" said Dr. Michael Racke, Quest's medical director of neurology. Quest's consumer test is aimed at adults aged 18 and older who may have mild memory loss or a family history of Alzheimer's and want to understand their own risk for the disease, Racke said. New Article Fintel reports that on July 31, 2023, RBC Capital maintained coverage of Biogen (NASDAQ:BIIB) with a Outperform recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.36%, an increase of 6.53%. The put/call ratio of BIIB is 0.74, indicating a bullish outlook. New Article Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) will soon likely be going head to head in the market for therapies that treat Alzheimer's disease. In this niche, these two rivals are more similar than different Given that Biogen is the business that has Alzheimer's disease therapies on the market today, it's hard to argue that Eli Lilly is even a competitor just yet. Don't decide based on this matchup alone Both Biogen and Eli Lilly are big pharma businesses that have plenty of other products and pipeline candidates outside of Alzheimer's. New Article The announcement follows U.S. regulatory approval earlier this month of Leqembi, a drug from Eisai 4523.T and partner Biogen BIIB.O that removes amyloid from the brain and has been shown to slow the advance of Alzheimer's in early-stage patients. ""One of the advantages of having an amyloid test is that it lets you know, potentially years in advance of even being symptomatic, that you are at risk for Alzheimer's,"" said Dr. Michael Racke, Quest's medical director of neurology. Quest's consumer test is aimed at adults aged 18 and older who may have mild memory loss or a family history of Alzheimer's and want to understand their own risk for the disease, Racke said. New Article Biogen (NASDAQ: BIIB) agreed to buy the drugmaker for $7.3 billion in cash. The U.S. Food and Drug Administration (FDA) approved the once-daily capsule to treat the disease this February, after it improved Freidrich's ataxia rating scale scores for patients in clinical testing. The FDA approved Vyndaqel to treat cardiomyopathy caused by TTR amyloidosis in 2019, and it's already on pace to generate around $2.8 billion in annual sales. New Article Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry. New Article Fintel reports that on July 31, 2023, Needham reiterated coverage of Biogen (NASDAQ:BIIB) with a Buy recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.36%, an increase of 6.53%. The put/call ratio of BIIB is 0.74, indicating a bullish outlook.",286.0767517089844
2023-08-01 00:00:00+00:00,269.3599853515625,269.67999267578125,266.489990234375,269.29998779296875,269.29998779296875,1070600.0,4.0,1.0,0.7500249999999999,"Biogen (BIIB) Source: PictureDesignSwiss / Shutterstock.com Biogen (NASDAQ:BIIB) is a biotech company that specializes in treatments for neurological diseases such as Multiple Sclerosis and Alzheimers. However, BIIB stock barely moved on the news, inching up only 0.9%. The main reason for the pullback in REGN stock, other than declining sales of its Covid-19 antibody treatment, was the U.S. Food and Drug Administrations (FDA) recent rejection  of its application for a higher dose of its eye medication Eylea.",289.2656555175781
2023-08-02 00:00:00+00:00,269.70001220703125,275.8699951171875,269.1499938964844,271.5599975585937,271.5599975585937,1299500.0,4.0,1.0,0.7500249999999999,"Biogen (BIIB) Source: PictureDesignSwiss / Shutterstock.com Biogen (NASDAQ:BIIB) is a hidden gem amid biotech stocks. Research and development within biotech and pharmaceuticals is costly, but Morningstar estimates several products pending approval will likely hit $1 billion in annual sales. The company has a firm grasp of the multiple sclerosis treatment market, with its original therapeutic portfolio continually generating $2 billion in annual sales.",292.696044921875
2023-08-04 00:00:00+00:00,267.0400085449219,269.94000244140625,266.67999267578125,268.9200134277344,268.9200134277344,929600.0,4.0,1.0,0.7500249999999999,"Biogen (NASDAQ:BIIB)  Biogen is a biopharma company that discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. BIIB stocks average price target implies upside potential of 25.3%. The sectors products are perennially in demand, as people always need medical attention and procedures, irrespective of the larger macro environment. New Article Adds context throughout Aug 4 (Reuters) - The U.S. Food and Drug Administration on Friday approved Biogen BIIB.O and Sage Therapeutics' SAGE.O oral pill to treat postpartum depression (PPD) in adults. Analysts were anticipating the stocks of both companies to fall if the drug was approved only for postpartum depression due to the smaller patient population. In 2021, an estimated 21.0 million adults in the United States had at least one episode of major depressive disorder, which is characterized by a persistent feeling of sadness.",298.7505798339844
2023-08-07 00:00:00+00:00,262.9599914550781,271.760009765625,262.9599914550781,271.2300109863281,271.2300109863281,1232300.0,2.25,1.0,0.312525,"Sage TherapeuticsSAGE.O sank 48.4%, while Biogen BIIB.O slipped 0.4% after the U.S. drug regulator declined to approve the companies' joint first-of-its-kind postpartum depression (PPD) pill. Yellow tumbles after filing for bankruptcy protection Berkshire climbs on record operating profit Tyson Foods falls after missing quarterly sales estimates Tesla down after CFO Kirkhorn steps down Indexes up: Dow 0.69%, S&P 0.42%, Nasdaq 0.05% Updated at 09:51 a.m. ET/ 1351 GMT By Bansari Mayur Kamdar and Johann M Cherian Aug 7 (Reuters) - Wall Street climbed higher on Monday following a choppy week, with investors looking ahead to a highly awaited U.S. inflation report due later in the week that could test the market's sharp recovery this year. The main stock indexes ended the week lower on Friday with some investors taking profits after months of gains due to worries over economic data, mixed earnings and rising Treasury yields. New Article By Bhanvi Satija and Mariam Sunny Aug 7 (Reuters) - The U.S. drug regulator's approval of Biogen BIIB.O and Sage Therapeutics' SAGE.O first-of-its-kind postpartum depression (PPD) pill is unlikely to allay the drugmakers' growth concerns, analysts said on Monday. The FDA's decision to decline the drug's approval for a much larger cohort of patients with clinical depression, along with strict safety warnings for its use in PPD, is still a ""strike against (Biogen's) management"", Baird analyst Brian Skorney said. Biogen is unlikely to ""quickly move forward on another late-stage study for MDD"", given its focus on saving costs and its recent announcement of job cuts, Yee said. New Article By Bhanvi Satija and Mariam Sunny Aug 7 (Reuters) - The approval of Biogen BIIB.O and Sage Therapeutics' SAGE.O depression pill for a smaller-than-expected patient cohort has fueled concerns over its growth prospects, analysts said on Monday. Zurzuvae, which was shown to relieve PDD symptoms in just days in clinical studies, is required to be given for two weeks, while the only other existing treatment warrants continuous intravenous infusion for 60 hours. Biogen is unlikely to ""quickly move forward on another late-stage study for MDD"", given its focus on saving costs and job cuts, Jefferies analyst Michael Yee said. New Article Wall Street analysts are expecting payment and diagnostic testing issues to slow the launch of the drug by Eisai and partner Biogen BIIB.O and have publicly pressed the companies for sales information. By Julie Steenhuysen and Deena Beasley CHICAGO, Aug 7 (Reuters) - Five major U.S. health systems said they would offer Eisai and Biogen's promising new Alzheimer's drug Leqembi after working out payment and administrative policies, and how to assess and monitor patients, most likely in the next month or two. Galvin said he had just completed protocols for the treatment at UHealth-the University of Miami Health System, which must be reviewed and adopted by colleagues in departments including radiology, scheduling and billing. New Article Its partner on the drug, Biogen BIIB.O, recovered to trade 0.9% higher. 15 S&P, Nasdaq snap four-session losing streaks Berkshire hits highest close on record operating profit Tyson Foods falls after missing sales estimates Indexes up: Dow 1.16%, S&P 0.90%, Nasdaq 0.61% Adds closing prices By David French Aug 7 (Reuters) - U.S. stocks finished higher on Monday, regaining some of the ground lost last week, as investors added positions ahead of Thursday's highly awaited U.S. inflation report. The main stock indexes ended last week lower as investors took profits after months of gains due to worries over economic data, mixed earnings and rising Treasury yields. New Article Its partner on the drug, Biogen BIIB.O, recovered to trade higher. By David French Aug 7 (Reuters) - U.S. stocks closed higher on Monday, regaining some ground lost last week, as investors added positions ahead of Thursday's highly awaited U.S. inflation report. The main stock indexes ended last week lower as investors took profits after months of gains due to worries over economic data, mixed earnings and rising Treasury yields. New Article Sage TherapeuticsSAGE.O sank 52.5%, while Biogen BIIB.O recovered to trade 0.6% higher, after the U.S. drug regulator declined to approve the companies' joint first-of-its-kind postpartum depression (PPD) pill. Yellow tumbles after filing for bankruptcy protection Berkshire climbs on record operating profit Tyson Foods falls after missing sales estimates Tesla down after CFO steps down Indexes up: Dow 1.13%, S&P 0.74%, Nasdaq 0.3% Updated at 1.57 p.m. ET/ 1957 GMT By Bansari Mayur Kamdar and David French Aug 7 (Reuters) - Wall Street advanced on Monday, shaking off some early choppiness after last week's subdued performance, as investors added positions ahead of Thursday's highly awaited U.S. inflation report. The main stock indexes ended last week lower with investors taking profits after months of gains due to worries over economic data, mixed earnings and rising Treasury yields. New Article Sage TherapeuticsSAGE.Osank 51.1%, while Biogen BIIB.Oslipped 0.5% after the U.S. drug regulator declined to approve the companies' joint first-of-its-kind postpartum depression (PPD) pill. Yellow tumbles after filing for bankruptcy protection Berkshire climbs on record operating profit Tyson Foods falls after missing sales estimates Tesla down after CFO steps down Indexes mixed: Dow up 0.91%, S&P up 0.48%, Nasdaq down 0.13% Updated at 11:38 a.m. ET/ 1538 GMT By Bansari Mayur Kamdar and Johann M Cherian Aug 7 (Reuters) - The benchmark S&P 500 and the Dow climbed higher on Monday following a choppy week, with investors looking ahead to a highly awaited U.S. inflation report due later in the week that could test the market's sharp recovery this year. The main stock indexes ended the week lower on Friday with some investors taking profits after months of gains due to worries over economic data, mixed earnings and rising Treasury yields.",287.99298095703125
2023-08-08 00:00:00+00:00,271.8399963378906,278.95001220703125,271.6499938964844,274.1400146484375,274.1400146484375,1445200.0,2.6,1.0,0.400025,"Fintel reports that on August 7, 2023, Wells Fargo maintained coverage of Biogen (NASDAQ:BIIB) with a Overweight recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.36%, an increase of 6.03%. The put/call ratio of BIIB is 0.71, indicating a bullish outlook. New Article Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry. New Article Fintel reports that on August 7, 2023, Oppenheimer maintained coverage of Biogen (NASDAQ:BIIB) with a Outperform recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.36%, an increase of 6.03%. The put/call ratio of BIIB is 0.71, indicating a bullish outlook. New Article Zuranolone, which Sage Therapeutics developed in collaboration with Biogen (NASDAQ: BIIB), is a novel antidepressant designed to offer fast and durable relief from depressive symptoms, with a short course of treatment and minimal side effects. Sage Therapeutics also has another ongoing collaboration with Biogen to develop and commercialize SAGE-324, which is being evaluated in a midstage trial for essential tremor, a neurological disorder that causes involuntary shaking of the hands and other body parts. The company posted a $160.3 million net loss in the second quarter of 2023, and its PPD franchise isn't expected to ramp up quickly enough to significantly offset its sizable operating expenses. New Article The approval of Leqembi by the Food and Drug Administration (FDA), marked an important advancement in the ongoing fight to effectively treat Alzheimers disease. On the drug side, I suspect doctors and patients will want to try the new treatments, even if their efficacy is not completely established and their administration burdensome, and with the caveat that Aduhelm generated very little revenue. Piot-Deval: Among the emerging and lesser known companies, and bearing in mind that this is not an exhaustive review, I mentioned earlier Alector, Vaxxinity, Acumen, Alnylam and AC Immune.",284.0010986328125
2023-08-09 00:00:00+00:00,273.510009765625,275.6499938964844,270.7099914550781,271.2900085449219,271.2900085449219,613000.0,4.0,1.0,0.7500249999999999,"BIIB Revenue (Quarterly) data by YCharts The acquisition of Reata Pharmaceuticals, whose programs are all in neurology, works well for Biogen since that is also one of the company's main focus areas. Biotech giant Biogen (NASDAQ: BIIB) can't seem to keep its name out of the news. The key asset in the transaction is Reata's Skyclarys, a treatment for Friedreich's ataxia (FA) that earned approval from the U.S. Food and Drug Administration (FDA) in February. New Article Fintel reports that on August 8, 2023, Atlantic Equities maintained coverage of Biogen (NASDAQ:BIIB) with a Neutral recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.36%, a decrease of 13.77%. The put/call ratio of BIIB is 0.72, indicating a bullish outlook. New Article Fintel reports that on August 8, 2023, Truist Securities maintained coverage of Biogen (NASDAQ:BIIB) with a Buy recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.36%, a decrease of 13.77%. The put/call ratio of BIIB is 0.72, indicating a bullish outlook. New Article Fintel reports that on August 8, 2023, Needham maintained coverage of Biogen (NASDAQ:BIIB) with a Buy recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.36%, a decrease of 13.77%. The put/call ratio of BIIB is 0.72, indicating a bullish outlook.",293.4178161621094
2023-08-10 00:00:00+00:00,271.67999267578125,272.57000732421875,268.7699890136719,269.0599975585937,269.0599975585937,934900.0,3.0,1.0,0.5000249999999999,"Quarter in Detail Ionis has licensed Spinraza to Biogen BIIB. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Research Pipeline Update Ionis has phase III studies ongoing for eight medicines (internal as well as partnered) across 10 indications. New Article Biogen (NASDAQ: BIIB) is an intriguing stock right now. BIIB Revenue (Quarterly YoY Growth) data by YCharts At just 15 times earnings, the healthcare stock looks cheap. The acquisition of Reata will help add to the company's rare disease portfolio, which includes Spinraza, a treatment for spinal muscular atrophy. New Article However, in June, Denali and Biogen announced plans to revise the clinical development program for BIIB122/DNL151 based on a review of portfolio timelines and resource prioritization. The massive year-over-year increase of $241.6 million in collaboration revenues was primarily due to an increase of $293.6 million in revenues under the companys collaboration agreement with Biogen BIIB. Collectively, the data from the LUMA study will inform the next steps for developing BIIB122 in PD.",286.1051330566406
2023-08-11 00:00:00+00:00,268.0,276.5199890136719,267.44000244140625,273.67999267578125,273.67999267578125,869700.0,3.0,1.0,0.5000249999999999,"The FDA sent a complete response letter to Sage regarding Zurzuvae's New Drug Application for its use on MDD patients, asking for more studies before approval. The problem for Sage is that roughly 600,000 women every year may have PPD symptoms, while MDD has a much larger patient population. The company is seeing increased sales from PPD therapy Zulresso, and Zurzuvae could ultimately be approved to treat MDD.",272.28192138671875
2023-08-14 00:00:00+00:00,274.04998779296875,274.04998779296875,269.9599914550781,272.739990234375,272.739990234375,715600.0,4.0,1.0,0.7500249999999999,"Fintel reports that on August 14, 2023, Mizuho maintained coverage of Biogen (NASDAQ:BIIB) with a Buy recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.36%, a decrease of 14.24%. The put/call ratio of BIIB is 0.72, indicating a bullish outlook.",266.4864501953125
2023-08-17 00:00:00+00:00,265.260009765625,265.7900085449219,260.94000244140625,261.5,261.5,741800.0,3.0,1.0,0.5000249999999999,"Taking into account individual holdings, United Therapeutics Corp (UTHR) accounts for about 5.28% of the fund's total assets, followed by Biogen Inc (BIIB) and Vertex Pharmaceuticals Inc (VRTX). Click to get this free report Invesco Dynamic Biotechnology & Genome ETF (PBE): ETF Research Reports Biogen Inc. (BIIB) : Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report United Therapeutics Corporation (UTHR) : Free Stock Analysis Report iShares Biotechnology ETF (IBB): ETF Research Reports SPDR S&P Biotech ETF (XBI): ETF Research Reports To read this article on Zacks.com click here. By attempting to pick stocks that have a better chance of risk-return performance, non-cap weighted indexes are based on certain fundamental characteristics, or a combination of such.",253.6464080810547
2023-08-21 00:00:00+00:00,260.9200134277344,266.25,260.4200134277344,265.07000732421875,265.07000732421875,755300.0,4.0,1.0,0.7500249999999999,"The expert panel's decision sets the stage for official approval of the drug, co-developed by Japan's Eisai 4523.T and U.S.-based Biogen BIIB.O. TOKYO, Aug 21 (Reuters) - A Japanese health ministry panel on Monday recommended approval of the Alzheimer's disease treatment Leqembi, following standard approval for the drug granted by U.S. regulators last month. An Eisai executive said this month the company expects to begin marketing Leqembi in Japan within about 60 days of receiving insurance reimbursement approval from the country's national health system.",245.48316955566406
2023-08-22 00:00:00+00:00,264.07000732421875,265.8500061035156,262.6700134277344,262.9800109863281,262.9800109863281,655700.0,3.0,1.0,0.5000249999999999,"Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry.",242.22325134277344
2023-08-24 00:00:00+00:00,263.8299865722656,266.489990234375,262.3500061035156,262.42999267578125,262.42999267578125,515700.0,2.0,1.0,0.250025,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $265.00 strike highlighted in red: Considering the fact that the $265.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the October 6th expiration. New Article Sage isn't likely to get out of the red anytime soon A big problem with many small biotech stocks is that they're fairly risky due to their high costs and lack of significant revenue. Failing to get approval for zuranolone to treat major depressive disorder is a big hit on Sage's growth prospects. Not obtaining regulatory approval for zuranolone to treat a major depressive disorder is a big blow to Sage's business. New Article A month has gone by since the last earnings report for Biogen Inc. (BIIB). Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.",243.1120147705078
2023-08-28 00:00:00+00:00,265.3999938964844,266.4700012207031,263.5400085449219,265.04998779296875,265.04998779296875,359900.0,4.0,1.0,0.7500249999999999,"An explosive move could be close at hand Bank of America securities analyst Jason Gerberry recently upgraded Bluebird's stock to a buy and raised its price target to $10 per share. With a price point likely to top $2 million per patient and a modest 20% penetration rate, lovo-cel would see its annual sales come in at a whopping $8 billion per year. The broader point, though, is that lovo-cel could hit blockbuster sales status -- defined as greater than $1 billion per year -- fairly easily in this rare-disease setting.",249.19540405273438
2023-08-29 00:00:00+00:00,265.3500061035156,268.1499938964844,265.1099853515625,268.0,268.0,525000.0,3.0,1.0,0.5000249999999999,"Fintel reports that on August 29, 2023, RBC Capital maintained coverage of Biogen (NASDAQ:BIIB) with a Outperform recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.35%, a decrease of 0.28%. The put/call ratio of BIIB is 0.79, indicating a bullish outlook. New Article Unlike other marketed treatments like Biogens BIIB Spinraza and Novartis NVS Zolgensma, which take an invasive approach to treating patients, the Roche drug is administered as an oral solution. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report To read this article on Zacks.com click here. Roche RHHBY announced that the European Commission (EC) had approved the label expansion for Evrysdi (risdiplam) to treat spinal muscular atrophy (SMA) in babies aged under two months old. New Article Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) have a lot in common. BIIB data by YCharts. First, the company's revenue has declined as some of its most important products have faced generic competition: BIIB Revenue (Quarterly) data by YCharts. New Article Unlike other marketed treatments like Biogens BIIB Spinraza and Novartis NVS Zolgensma, which take an invasive approach to treating patients, the Roche drug is administered as an oral solution. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report To read this article on Zacks.com click here. Roche RHHBY announced that the European Commission (EC) had approved the label expansion for Evrysdi (risdiplam) to treat spinal muscular atrophy (SMA) in babies aged under two months old.",259.31756591796875
2023-08-30 00:00:00+00:00,268.8399963378906,269.4599914550781,265.25,267.17999267578125,267.17999267578125,552700.0,4.0,1.0,0.7500249999999999,"And here comes an even more exciting surprise, another large company called Biogen (NASDAQ:BIIB) is very interested in Reata. In one of the most important studies, resmetirom was shown to improve liver health by reducing inflammation and fibrosis, two key problems in NASH. More From InvestorPlace ChatGPT IPO Could Shock the World, Make This Move Before the Announcement Musks Project Omega May Be Set to Mint New Millionaires. New Article Several companies including Abcam ABCM.O and Biogen BIIB.O with partner Denali Therapeutics DNLI.O are testing such experimental treatments. By Nancy Lapid Aug 30 (Reuters) - An experimental blood test that detected Parkinsons disease in a preliminary study could become the first specific tool for diagnosing the devastating neurodegenerative condition, researchers said on Wednesday. If its reliability is confirmed in future trials, the test would allow doctors to diagnose the condition earlier and start therapies sooner, before nervous system damage worsens, the researchers said. New Article Biogen Inc. (BIIB) closed the most recent trading day at $267.18, moving -0.31% from the previous trading session. It is also worth noting that BIIB currently has a PEG ratio of 2.9. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here.",261.5558166503906
2023-08-31 00:00:00+00:00,266.8299865722656,269.17999267578125,265.32000732421875,267.3599853515625,267.3599853515625,1012700.0,3.0,1.0,0.5000249999999999,"The U.S. Food and Drug Administration (FDA) in early August approved the company and partner Biogen's BIIB.O pill for postpartum depression (PDD), but rejected it as a treatment for clinical depression, which is a much larger market. Adds details on reorganization plan throughout Aug 31 (Reuters) - Sage Therapeutics SAGE.O said on Thursday it plans to lay off about 188 people, or about 40% of its workforce, weeks after the U.S. health regulator declined to approve its drug to treat major depressive disorder. Sage said the job cuts, which are part of a reorganization plan, will help it launch the drug for women with PDD and also position the company for long-term growth. New Article Biogen Inc. (BIIB) closed the most recent trading day at $267.36, moving +0.07% from the previous trading session. Also, we should mention that BIIB has a PEG ratio of 2.89. BIIB's industry had an average PEG ratio of 2.24 as of yesterday's close.",268.4858703613281
2023-09-01 00:00:00+00:00,269.010009765625,269.7200012207031,266.9100036621094,267.1700134277344,267.1700134277344,522400.0,4.0,1.0,0.7500249999999999,"Sage Therapeutics developed Zurzuvae in collaboration with Biogen BIIB. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report Annovis Bio, Inc. (ANVS) : Free Stock Analysis Report To read this article on Zacks.com click here. In addition, the FDA approval for PPD also comes with a back box warning  advising patients not to drive or operate heavy machinery for at least 12 hours after taking Zurzuvae.",270.1315612792969
2023-09-05 00:00:00+00:00,269.42999267578125,270.5,266.1099853515625,266.2900085449219,266.2900085449219,932500.0,4.0,1.0,0.7500249999999999,"Fintel reports that on September 5, 2023, Morgan Stanley maintained coverage of Biogen (NASDAQ:BIIB) with a Overweight recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.34%, a decrease of 2.38%. The put/call ratio of BIIB is 0.78, indicating a bullish outlook. New Article Biogen BIIB holds a strong position in the MS market with a wide range of products, including Avonex, Tysabri, Tecfidera and Plegridy. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report Exelixis, Inc. (EXEL) : Free Stock Analysis Report Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Research The main reason for the stocks outperformance was the FDAs traditional approval of Leqembi, Biogen and Eisais anti-amyloid beta protofibril antibody drug, for the treatment of Alzheimers disease.",266.182373046875
2023-09-06 00:00:00+00:00,266.4700012207031,266.4700012207031,261.5,263.7200012207031,263.7200012207031,944700.0,2.0,1.0,0.250025,"In the latest trading session, Biogen Inc. (BIIB) closed at $263.72, marking a -0.97% move from the previous day. We can also see that BIIB currently has a PEG ratio of 2.88. To follow BIIB in the coming trading sessions, be sure to utilize Zacks.com.",262.3529357910156
2023-09-07 00:00:00+00:00,263.2099914550781,263.2699890136719,256.9200134277344,261.3399963378906,261.3399963378906,1199200.0,3.0,1.0,0.5000249999999999,"If you want an email notification each time Sheraz publishes a new article, please click here>>> Today's Must Read Humana (HUM) Strong on Brisk Medicaid Business & Buyouts Uniform Rental Unit Aids Cintas (CTAS) Amid Rising Costs Biogen's (BIIB) New Drugs Can Help Revive Growth Featured Reports Investment & Expanding Operation Aid American Water (AWK) Per the Zacks analyst American Water's planned investment to strengthen infrastructure and expanding operation through acquisition and organic means are going to drive its performance. Today's Research Daily features new research reports on 16 major stocks, including Humana Inc. (HUM), Cintas Corp. (CTAS) and Biogen Inc. (BIIB). Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Royal Caribbean Cruises Ltd. (RCL) : Free Stock Analysis Report Humana Inc. (HUM) : Free Stock Analysis Report Cintas Corporation (CTAS) : Free Stock Analysis Report Markel Group Inc. (MKL) : Free Stock Analysis Report American Water Works Company, Inc. (AWK) : Free Stock Analysis Report To read this article on Zacks.com click here. New Article In July, the FDA approved Biogen's BIIB and partner Eisais supplemental biologics license application, supporting the traditional approval of their AD drug Leqembi (lecanemab). Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report Prothena Corporation plc (PRTA) : Free Stock Analysis Report To read this article on Zacks.com click here. The significant surge is mostly attributable to Prothenas robust Alzheimers Disease (AD) pipeline, which spans next-generation antibody immunotherapy, small molecules and vaccines. New Article Looking at individual holdings, Marvell Technology Inc (MRVL) accounts for about 0.66% of total assets, followed by Arthur J Gallagher & Co (AJG) and Biogen Inc (BIIB). Click to get this free report BNY Mellon US Mid Cap Core Equity ETF (BKMC): ETF Research Reports Biogen Inc. (BIIB) : Free Stock Analysis Report Marvell Technology, Inc. (MRVL) : Free Stock Analysis Report Arthur J. Gallagher & Co. (AJG) : Free Stock Analysis Report iShares Core S&P Mid-Cap ETF (IJH): ETF Research Reports Vanguard Mid-Cap ETF (VO): ETF Research Reports To read this article on Zacks.com click here. You should consider the BNY Mellon US Mid Cap Core Equity ETF (BKMC), a passively managed exchange traded fund launched on 04/09/2020. New Article Biogen (BIIB) Source: PictureDesignSwiss / Shutterstock.com Biogen (NASDAQ:BIIB) is another pharma stock that had a great reversal of fortune in the last year. BIIB stock has a B rating in the Portfolio Grader. Biogen also plans to buy Reata Pharmaceuticals (NASDAQ:RETA), which would give it rights to Skyclarys, which is a promising treatment for the neurogenerative condition Friedrichs ataxia.",272.1697998046875
2023-09-08 00:00:00+00:00,262.2200012207031,262.70001220703125,258.6199951171875,258.989990234375,258.989990234375,788100.0,3.5,1.0,0.6250249999999999,"Stocks recently featured in the blog include: Humana Inc. HUM, Cintas Corp. CTAS, Biogen Inc. BIIB, Royal Caribbean Cruises Ltd. RCL and Markel Group Inc. MKL. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Royal Caribbean Cruises Ltd. (RCL) : Free Stock Analysis Report Humana Inc. (HUM) : Free Stock Analysis Report Cintas Corporation (CTAS) : Free Stock Analysis Report Markel Group Inc. (MKL) : Free Stock Analysis Report To read this article on Zacks.com click here. It is also facing multiple challenges at present like the generic erosion of Tecfidera, competitive pressure for Spinraza, declining profit share of Rituxan in the United States and the failure of Aduhelm. New Article The AD target market is highly competitive as several other pharma companies like Biogen BIIB and Eli Lilly LLY have their drugs targeting the AD indication. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report Alector, Inc. (ALEC) : Free Stock Analysis Report To read this article on Zacks.com click here. Shares of Alector ALEC rose 6.8% on Thursday after management announced that it achieved the enrolment target in the phase II INVOKE-2 study on its Alzheimers disease (AD) candidate, AL002.",263.0560302734375
2023-09-12 00:00:00+00:00,258.9200134277344,260.57000732421875,257.8900146484375,258.44000244140625,258.44000244140625,611200.0,4.0,1.0,0.7500249999999999,"In the latest trading session, Biogen Inc. (BIIB) closed at $258.44, marking a -0.19% move from the previous day. Also, we should mention that BIIB has a PEG ratio of 2.8. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here.",269.1595764160156
2023-09-15 00:00:00+00:00,256.6300048828125,257.5799865722656,254.0,254.7899932861328,254.7899932861328,1353000.0,3.0,1.0,0.5000249999999999,"Among the biotech mega-sellers that Sandoz is seeking to copy are Biogen's BIIB.O multiple sclerosis drug Tysabri, AbbVie's ABBV.N rheumatoid arthritis drug Humira, Amgen's AMGN.O bone cancer drug Prolia, also known as Xgeva, and Bayer BAYGn.DE and Regeneron's REGN.O eye drug Eylea with more than $40 billion in annual sales between them. Sandoz, whose first day of trading is scheduled for Oct. 4, has previously said its development pipeline has 25 future biosimilars, cheaper versions of off-patent biologic drugs made from modified living cells, five of which it aims to bring to market over the next two years. Saynor said new biosimilar product launches in Europe and the United States, as blockbuster drugs lose patent protection, were key to reaching the company's growth and margin targets.",259.1596374511719
2023-09-18 00:00:00+00:00,254.94000244140625,256.04998779296875,252.6199951171875,253.3000030517578,253.3000030517578,509800.0,2.5,1.0,0.375025,"Biogen Inc. (BIIB) closed at $253.30 in the latest trading session, marking a -0.58% move from the prior day. Also, we should mention that BIIB has a PEG ratio of 2.76. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. New Article A bullish investor could look at BIIB's 28.6 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of BIIB shares: Looking at the chart above, BIIB's low point in its 52 week range is $194.45 per share, with $319.76 as the 52 week high point  that compares with a last trade of $253.71. In trading on Monday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 28.6, after changing hands as low as $252.62 per share.",251.5303955078125
2023-09-21 00:00:00+00:00,258.79998779296875,260.2699890136719,256.7699890136719,258.92999267578125,258.92999267578125,974600.0,3.0,1.0,0.5000249999999999,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $260.00 strike highlighted in red: Considering the fact that the $260.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the November 3rd expiration. New Article (RTTNews) - Reata Pharmaceuticals Inc. (RETA) said that its stockholders have approved the company's previously announced acquisition by Biogen Inc. (BIIB). Reata said that about 99.65 percent of the votes cast by the Company's Class A common stockholders and Class B common stockholders voted to approve the Merger, which represents approximately 87.99 percent of the total voting power of the shares of the Company's Class A common stock and Class B common stock entitled to vote at the special meeting. In July, Biogen agreed to acquire Reata Pharmaceuticals for $172.50 per share in cash, reflecting an enterprise value of around $7.3 billion.",251.60421752929688
2023-09-22 00:00:00+00:00,259.3299865722656,260.7200012207031,257.0899963378906,257.67999267578125,257.67999267578125,800800.0,3.0,1.0,0.5000249999999999,"Especially high volume was seen for the $275 strike call option expiring January 19, 2024, with 1,046 contracts trading so far today, representing approximately 104,600 underlying shares of BIIB. Below is a chart showing GM's trailing twelve month trading history, with the $45 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 4,193 contracts thus far today. That number of contracts represents approximately 419,300 underlying shares, working out to a sizeable 56% of BIIB's average daily trading volume over the past month, of 749,075 shares.",257.0364685058594
2023-09-25 00:00:00+00:00,257.1000061035156,257.1000061035156,251.8500061035156,255.0200042724609,255.0200042724609,766200.0,3.0,1.0,0.5000249999999999,"Biogen Inc. (NASDAQ: BIIB): Biogen is involved in gene therapy research for various neurological and genetic disorders. That means gene therapy technologies could be the future drivers of big price gains, as weve seen with AI and weight-loss drugs this year. Its treatments specialize in Duchenne muscular dystrophy (DMD), a progressive illness that shortens patients life expectancies. New Article Over the last one year, the FDA has given accelerated approvals to Amylyx Pharmaceuticals' AMLX.O drug Relyvrio and Biogen's BIIB.O Qalsody for treatment of ALS. Adds background throughout Sept 25 (Reuters) - The U.S. Food and Drug Administration's staff reviewers raised concerns on Monday over the safety and efficacy of BrainStorm Cell Therapeutics' BCLI.O therapy for a rare and fatal neurodegenerative disease called amyotrophic lateral sclerosis (ALS). Brainstrom's therapy, NurOwn, is being reviewed for the treatment of ALS, also known as Lou Gehrig's Disease, which affects nerve cells in the brain and spinal cord. New Article Adds details from statement throughout TOKYO, Sept 25 (Reuters) - Japan's Eisai 4523.T said on Monday its Alzheimer's treatment developed with Biogen BIIB.O, Leqembi, was approved by the country's health ministry, making it the second nation after the United States to clear its use. The first FDA-approved disease-modifying Alzheimer's drug, Aduhelm, was also developed by partners Eisai and Biogen, but Medicare coverage restrictions have severely limited its use. An Eisai executive said in August the company expected to begin marketing Leqembi in Japan in about 60 days after receiving insurance reimbursement approval from the national health system. New Article Biogen Inc. (BIIB) closed at $255.02 in the latest trading session, marking a -1.03% move from the prior day. Investors should also note that BIIB has a PEG ratio of 2.79 right now. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here.",250.34371948242188
2023-09-26 00:00:00+00:00,254.97000122070312,258.4599914550781,254.0399932861328,258.04998779296875,258.04998779296875,855900.0,2.5,1.0,0.375025,"Novartis NVS generic arm Sandoz announced that the European Commission (EC) granted marketing authorization to Tyruko (natalizumab), a biosimilar of Biogens BIIB leading multiple sclerosis (MS) drug Tysabri. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Johnson & Johnson (JNJ) : Free Stock Analysis Report To read this article on Zacks.com click here. Per the terms, Polpharma Biologics is responsible for the development of medicine, manufacturing and supply of drug substances and Sandoz has the rights to commercialize and distribute the same in all markets through an exclusive global license. New Article (RTTNews) - Biogen Inc. (BIIB) has completed the acquisition of Reata Pharmaceuticals, Inc. (RETA). Biogen expects significant synergies with its existing rare disease portfolio and plans to update its 2023 financial guidance in conjunction with its third quarter earnings release. The company expects acquisition of Reata to be slightly dilutive to Non-GAAP earnings per share in 2023, roughly neutral in 2024, and significantly accretive beginning in 2025, inclusive of associated transaction costs.",257.7668762207031
2023-09-27 00:00:00+00:00,258.44000244140625,261.3800048828125,255.1600036621093,257.5199890136719,257.5199890136719,806400.0,3.5,1.0,0.6250249999999999,"Currently, IONS earns all its commercial revenues primarily through royalty payments on net sales of Biogen BIIB-marketed drug Spinraza and R&D revenues from partnered medicines. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report To read this article on Zacks.com click here. Ionis Pharmaceuticals IONS announced positive top-line results from the phase III BALANCE study on its investigational LICA drug olezarsen people with familial chylomicronemia syndrome (FCS). New Article Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $275.00 strike highlighted in red: Considering the fact that the $275.00 strike represents an approximate 7% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options become available this week, for the April 2024 expiration.",262.5393371582031
2023-09-28 00:00:00+00:00,258.4800109863281,259.3500061035156,256.25,257.8299865722656,257.8299865722656,641200.0,3.333333333333333,1.0,0.5833583333333334,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $260.00 strike highlighted in red: Considering the fact that the $260.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options become available this week, for the November 17th expiration. New Article Currently, IONS earns all its commercial revenues primarily through royalty payments on net sales of Biogen BIIB-marketed drug Spinraza and R&D revenues from partnered medicines. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report To read this article on Zacks.com click here. Per the terms of the agreement, Ionis will utilize its proprietary technology platforms to discover the two RNA-based therapeutics designed to target AD and HD indications. New Article And that's Biogen (NASDAQ: BIIB). BIIB data by YCharts. Leqembi's additional $1.5 billion in revenue in 2028 will represent roughly 15% of the company's total sales for the current fiscal year.",261.7252502441406
2023-09-29 00:00:00+00:00,258.5299987792969,259.2300109863281,255.25,257.010009765625,257.010009765625,887600.0,5.0,1.0,1.000025,"(RTTNews) - Biogen Inc. (BIIB) announced that the U.S. Food and Drug Administration has approved Tofidence (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing Actemra. Biosimilars are biologic products that have been demonstrated to have equivalent efficacy and comparable safety as the approved reference product, with the advantage that they may offer cost savings and promote expanded and sustainable access to therapies. ""The approval of TOFIDENCE in the U.S. marks another positive step toward helping more people with chronic autoimmune conditions gain access to leading therapies,"" said Ian Henshaw, Global Head of Biosimilars at Biogen.",262.7444763183594
2023-10-02 00:00:00+00:00,255.8500061035156,256.8599853515625,251.0800018310547,252.8600006103516,252.8600006103516,752400.0,3.0,1.0,0.5000249999999999,"First Trust Health Care AlphaDEX Fund ETF FXH $97.16 $123.90 27.52% Bio-Techne Corp TECH $68.07 $101.80 49.54% Qiagen NV QGEN $40.50 $53.33 31.69% Biogen Inc BIIB $257.01 $328.15 27.68% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of FXH's underlying holdings with notable upside to their analyst target prices are Bio-Techne Corp (Symbol: TECH), Qiagen NV (Symbol: QGEN), and Biogen Inc (Symbol: BIIB). Similarly, QGEN has 31.69% upside from the recent share price of $40.50 if the average analyst target price of $53.33/share is reached, and analysts on average are expecting BIIB to reach a target price of $328.15/share, which is 27.68% above the recent price of $257.01. New Article In the latest trading session, Biogen Inc. (BIIB) closed at $252.86, marking a -1.61% move from the previous day. BIIB's full-year Zacks Consensus Estimates are calling for earnings of $15.25 per share and revenue of $9.69 billion. Meanwhile, BIIB's PEG ratio is currently 2.78.",255.4611358642578
2023-10-06 00:00:00+00:00,259.5,265.17999267578125,258.760009765625,263.25,263.25,1080100.0,3.0,1.0,0.5000249999999999,"Particularly high volume was seen for the $230 strike put option expiring January 19, 2024, with 1,052 contracts trading so far today, representing approximately 105,200 underlying shares of BIIB. Below is a chart showing ALK's trailing twelve month trading history, with the $35 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 5,113 contracts thus far today. That number of contracts represents approximately 511,300 underlying shares, working out to a sizeable 63.9% of BIIB's average daily trading volume over the past month, of 799,885 shares.",239.11758422851562
2023-10-09 00:00:00+00:00,262.9800109863281,264.8900146484375,260.0,264.2099914550781,264.2099914550781,612000.0,3.5,1.0,0.6250249999999999,"Biogen BIIB recently acquired Reata Pharmaceuticals, Inc. for $7.3 billion. Click to get this free report Novartis AG (NVS) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Mirati Therapeutics, Inc. (MRTX) : Free Stock Analysis Report To read this article on Zacks.com click here. Bristol Myers Squibb BMY announced that it will acquire commercial-stage oncology company Mirati Therapeutics, Inc. MRTX for $58.00 per share in cash, amounting to a total equity value of $4.8 billion. New Article Biogen Inc. (BIIB) closed at $264.21 in the latest trading session, marking a +0.36% move from the prior day. It is also worth noting that BIIB currently has a PEG ratio of 2.85. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here.",242.6056671142578
2023-10-10 00:00:00+00:00,264.4800109863281,265.19000244140625,262.760009765625,264.1400146484375,264.1400146484375,689900.0,2.0,1.0,0.250025,"That means being able to get them promising new drugs like Eisai 4523.T and Biogen's BIIB.O recently approved Leqembi and Eli Lilly's LLY.N experimental donanemab, as well as inclusion of people with Down syndrome in clinical trials of treatments for Alzheimer's. Reuters has learned that advocacy groups have taken their message directly to the U.S. government Medicare health program, seeking changes to written policies they believe could disqualify people with Down syndrome from reimbursement for the treatments. People with Down syndrome, who were not included in either Eisai or Lillys late-stage trials, have higher-than-average rates of CAA, and neurologists are concerned that removing amyloid with a drug like Leqembi could weaken artery walls, leading to bleeding in the brain.",244.27420043945312
2023-10-11 00:00:00+00:00,265.6000061035156,268.44000244140625,264.8800048828125,266.5199890136719,266.5199890136719,814100.0,3.333333333333333,1.0,0.5833583333333334,"Biogen (BIIB) Source: PictureDesignSwiss / Shutterstock.com Based in Cambridge, Massachusetts, Biogen (NASDAQ:BIIB) is a multinational biotechnology firm. Of course, the other side of this coin is that investors shouldnt look to BIIB to facilitate cryptocurrency-like returns. Over the past 365 days, BIIB returned only about 4%. New Article Biogen Inc. (BIIB), which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. New Article Currently, people who might benefit from Leqembi, the new Alzheimer's drug from Eisai 4523.T and Biogen BIIB.O, need those changes diagnosed through cognitive assessment and a cerebrospinal fluid (CSF) test, which requires an invasive lumbar puncture, or an expensive PET brain scan that may not be reimbursed by health insurers. By Deena Beasley Oct 11 (Reuters) - Blood tests for Alzheimer's are needed to more widely diagnose the brain-wasting disease and understand its prevalence, but it will be another couple of years before they become an everyday tool, medical experts and company executives say. Dr. Sarah Kremen, director of the neurobehavior program at Cedars-Sinai Medical Center in Los Angeles, said amyloid on its own is an unreliable marker for Alzheimer's since many people accumulate brain deposits of the protein as they age, but do not develop dementia.",246.5688018798828
2023-10-12 00:00:00+00:00,266.9200134277344,268.0199890136719,259.3900146484375,260.989990234375,260.989990234375,1553800.0,3.0,1.0,0.5000249999999999,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $265.00 strike highlighted in red: Considering the fact that the $265.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the December 1st expiration.",252.10696411132812
2023-10-13 00:00:00+00:00,261.17999267578125,262.3500061035156,258.8099975585937,262.260009765625,262.260009765625,869800.0,3.75,1.0,0.6875249999999999,"In July, the FDA approved Biogen's BIIB and partner Eisais supplemental biologics license application, supporting the traditional approval of their AD drug Leqembi (lecanemab). Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Prothena Corporation plc (PRTA) : Free Stock Analysis Report Annovis Bio, Inc. (ANVS) : Free Stock Analysis Report To read this article on Zacks.com click here. In the AD/PD study buntanetap showed improvements in cognition and memory in AD and body and brain function in PD patients. New Article Shares of Biogen Inc. (BIIB) have gained 1.8% over the past four weeks to close the last trading session at $260.99, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. But, for BIIB, an impressive average price target is not the only indicator of a potential upside. Here's Why There Could be Plenty of Upside Left in BIIB There has been increasing optimism among analysts lately about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher. New Article The new drugs include Eisai 4523.T and Biogen's BIIB.O Leqembi, and an experimental drug from Eli Lilly LLY.N known as donanemab, which work by removing a protein called beta amyloid from the brain. Adds background on coverage policy, Alzheimer's drugs in paragraphs 3-5 Oct 13 (Reuters) - The U.S. Centers for Medicare and Medicaid Services on Friday removed a national policy that restricted coverage for a type of brain scan called PET needed by doctors to determine if patients are eligible for newly developed Alzheimer's drugs. The change removes the once-per-lifetime limit on beta amyloid PET scans that restricted their use to clinical trials. New Article The new drugs include Eisai 4523.T and Biogen's BIIB.O Leqembi, and an experimental drug from Eli Lilly LLY.N known as donanemab, which work by removing a protein called beta amyloid from the brain. Oct 13 (Reuters) - The U.S. Centers for Medicare and Medicaid Services on Friday removed a national policy that restricted coverage for a type of brain scan called PET needed by doctors to determine if patients are eligible for newly developed Alzheimer's drugs. (Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;)) The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",263.15863037109375
2023-10-16 00:00:00+00:00,262.0400085449219,268.75,261.2200012207031,267.94000244140625,267.94000244140625,1227100.0,3.0,1.0,0.5000249999999999,"BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry. It is also advancing its mid-to-late stage programs, including zuranolone for major depressive disorder (MDD) and postpartum depression (PPD); BIIB080 for Alzheimer's disease; tofersen for amyotrophic lateral sclerosis (ALS), and both litifilimab and dapirolizumab pegol for certain forms of lupus. Detailed Analysis of BIOGEN INC BIIB Guru Analysis BIIB Fundamental Analysis PFIZER INC. (PFE) is a large-cap value stock in the Biotechnology & Drugs industry. New Article Roches Ocrevus faces competition from biotech giant Biogens BIIB strong MS portfolio, which comprises Tysabri, Tecfidera, Vumerity, Avonex, Plegridy and Fampyra. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report To read this article on Zacks.com click here. New data from the FENopta study in RMS show that fenebrutinib crosses the blood-brain barrier with the potential to act directly on the chronic inflammation related to multiple sclerosis (MS).",267.9273681640625
2023-10-18 00:00:00+00:00,266.67999267578125,268.1499938964844,263.3099975585937,263.5,263.5,977000.0,2.0,1.0,0.250025,"Zeroing in on Winners We have highlighted five biotech companies  Amgen AMGN, Biogen BIIB, GSK GSK, Prothena Corporation PRTA and Vertex Pharmaceuticals VRTX  that are expected to deliver a beat in their upcoming quarterly results. BIIB is scheduled to report earnings on Nov 8, before the opening bell. Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report Prothena Corporation plc (PRTA) : Free Stock Analysis Report To read this article on Zacks.com click here. New Article Three stocks that are down big in recent years and that still aren't worth buying today are Biogen (NASDAQ: BIIB), Snap (NYSE: SNAP), and 3M (NYSE: MMM). One thing that has lifted the stock and given investors some hope for the future is the approval of Alzheimer's treatment Leqembi, which Biogen has been developing with Eisai. Aduhelm initially gained accelerated approval for Alzheimer's, but the company ultimately pulled the plug on the drug as health officials weren't convinced of its effectiveness.",268.3118896484375
2023-10-19 00:00:00+00:00,263.45001220703125,263.45001220703125,256.1000061035156,257.29998779296875,257.29998779296875,1225200.0,3.0,1.0,0.5000249999999999,"Sage Therapeutics has developed Zurzuvae in collaboration with Biogen BIIB. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report Deciphera Pharmaceuticals, Inc. (DCPH) : Free Stock Analysis Report To read this article on Zacks.com click here. This FDA designation makes the sponsor eligible for seven years of market exclusivity, following the potential approval and tax credit for qualified clinical studies.",253.52955627441406
2023-10-20 00:00:00+00:00,258.010009765625,260.5,255.4600067138672,257.45001220703125,257.45001220703125,1938400.0,3.0,1.0,0.5000249999999999,"Of course, a lot of upside could potentially be left on the table if BIIB shares really soar, which is why looking at the trailing twelve month trading history for Biogen Inc, as well as studying the business fundamentals becomes important. Below is a chart showing BIIB's trailing twelve month trading history, with the $280.00 strike highlighted in red: Considering the fact that the $280.00 strike represents an approximate 9% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading this week, for the December 15th expiration. New Article Stocks to Consider Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around: Biogen BIIB has an Earnings ESP of +4.58% and a Zacks Rank #2. BIIB beat earnings estimates in each of the last four quarters, the average earnings surprise being 10.53%. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here.",252.19448852539062
2023-10-23 00:00:00+00:00,256.3399963378906,256.3399963378906,251.8800048828125,253.38999938964844,253.38999938964844,963000.0,3.6666666666666665,1.0,0.6666916666666666,"Stocks to Consider Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around: Biogen BIIB has an Earnings ESP of +3.41% and a Zacks Rank #3. BIIB beat earnings estimates in all the last four quarters, the average earnings surprise being 10.53%. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Mirati Therapeutics, Inc. (MRTX) : Free Stock Analysis Report To read this article on Zacks.com click here. New Article Biogen Inc. (BIIB) ended the recent trading session at $253.39, demonstrating a -1.58% swing from the preceding day's closing price. It's also important to note that BIIB currently trades at a PEG ratio of 2.79. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. New Article Biogen BIIB has an Earnings ESP of +3.41% and a Zacks Rank #3. BIIB came up with a four-quarter earnings surprise of 10.53%, on average. BIIB is scheduled to release its third-quarter results on Nov 8.",242.33653259277344
2023-10-24 00:00:00+00:00,253.4199981689453,255.52999877929688,249.4100036621093,252.1100006103516,252.1100006103516,795700.0,2.0,1.0,0.250025,"Biogen BIIB has an Earnings ESP of +3.41% and a Zacks Rank #3. BIIB has a four-quarter positive earnings surprise of 10.53%, on average. BIIB is scheduled to release its third-quarter results on Nov 8.",238.83273315429688
2023-10-25 00:00:00+00:00,249.88999938964844,250.7400054931641,244.6100006103516,246.72000122070312,246.72000122070312,1204000.0,3.0,1.0,0.5000249999999999,"Biogen BIIB has an Earnings ESP of +2.89% and a Zacks Rank #3. BIIB has a four-quarter positive earnings surprise of 10.53%, on average. BIIB is scheduled to release its third-quarter results on Nov 8. New Article By Julie Steenhuysen and Deena Beasley BOSTON, Oct 25 (Reuters) - An injected version of Eisai 4523.T and Biogen's BIIB.O Alzheimer's drug Leqembi works as well as the current intravenous administration at removing toxic brain plaques, but rates of serious side effects were higher, according to an analysis presented by Eisai on Wednesday. The intravenous (IV) form of Leqembi won U.S. approval based on that larger 18-month study showing the drug, which works by removing sticky clumps of beta amyloid from the brain, slowed cognitive decline by 27% for people with early Alzheimer's disease. Separately, Eisai presented an analysis of a small subgroup of patients from its pivotal trial who had early Alzheimer's and low levels of tau, a second protein linked with disease progression and brain cell death. New Article By Julie Steenhuysen and Deena Beasley BOSTON, Oct 25 (Reuters) - An injected version of Eisai 4523.T and Biogen's BIIB.O Alzheimer's drug Leqembi works as well as the current intravenous version at removing toxic brain plaques, according to an analysis presented by Eisai on Wednesday. The intravenous (IV) form of Leqembi won U.S. approval based on that larger 18-month study showing the drug, which works by removing sticky clumps of beta amyloid from the brain, slowed cognitive decline by 27% for people with early Alzheimer's disease. Separately, Eisai presented an analysis of a small subgroup of patients from its pivotal trial who had early Alzheimer's and low levels of tau, a second protein linked with disease progression and brain cell death.",230.41558837890625
2023-10-26 00:00:00+00:00,248.4100036621093,249.97000122070312,241.009994506836,241.0800018310547,241.0800018310547,1364700.0,3.2,1.0,0.550025,"A bullish investor could look at BIIB's 29.4 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of BIIB shares: Looking at the chart above, BIIB's low point in its 52 week range is $241.29 per share, with $319.76 as the 52 week high point  that compares with a last trade of $241.52. In trading on Thursday, shares of Biogen Inc (Symbol: BIIB) entered into oversold territory, hitting an RSI reading of 29.4, after changing hands as low as $241.40 per share. New Article Biogen BIIB has an Earnings ESP of +2.27% and a Zacks Rank #3. Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report To read this article on Zacks.com click here. We expect investors to focus on updates related to CRISPR Therapeutics AGs CRSP pipeline candidates when it reports third-quarter 2023 results. New Article Biogen BIIB has an Earnings ESP of +2.27% and a Zacks Rank #3. BIIB has a four-quarter earnings surprise of 10.53%, on average. BIIB is scheduled to release its third-quarter results on Nov 8. New Article Fintel reports that on October 26, 2023, Wedbush maintained coverage of Biogen (NASDAQ:BIIB) with a Neutral recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.33%, a decrease of 6.78%. The put/call ratio of BIIB is 0.77, indicating a bullish outlook. New Article Fintel reports that on October 26, 2023, Needham reiterated coverage of Biogen (NASDAQ:BIIB) with a Buy recommendation. Average portfolio weight of all funds dedicated to BIIB is 0.33%, a decrease of 6.78%. The put/call ratio of BIIB is 0.77, indicating a bullish outlook.",226.4143524169922
2023-10-30 00:00:00+00:00,235.32000732421875,237.8699951171875,234.38999938964844,237.2100067138672,237.2100067138672,857200.0,4.0,1.0,0.7500249999999999,"Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. BIOGEN INC (BIIB) is a large-cap value stock in the Biotechnology & Drugs industry. New Article Biogen Inc. (BIIB) ended the recent trading session at $237.30, demonstrating a +1.19% swing from the preceding day's closing price. Meanwhile, BIIB's PEG ratio is currently 2.54. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here.",224.6439666748047
2023-10-31 00:00:00+00:00,236.69000244140625,239.0,236.07000732421875,237.5399932861328,237.5399932861328,681400.0,3.0,1.0,0.5000249999999999,"When you look at individual holdings, Amgen Inc (AMGN) accounts for about 5.68% of the fund's total assets, followed by Vertex Pharmaceuticals Inc (VRTX) and Biogen Inc (BIIB). Click to get this free report Invesco Biotechnology & Genome ETF (PBE): ETF Research Reports Biogen Inc. (BIIB) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report iShares Biotechnology ETF (IBB): ETF Research Reports SPDR S&P Biotech ETF (XBI): ETF Research Reports To read this article on Zacks.com click here. However, some investors believe in the possibility of beating the market through exceptional stock selection, and choose a different type of fund that tracks non-cap weighted strategies: smart beta.",230.1864013671875
2023-11-01 00:00:00+00:00,238.5599975585937,241.0599975585937,235.1000061035156,239.6199951171875,239.6199951171875,841700.0,2.0,1.0,0.250025,"Wall Street expects a year-over-year decline in earnings on lower revenues when Biogen Inc. (BIIB) reports results for the quarter ended September 2023. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report MannKind Corporation (MNKD) : Free Stock Analysis Report To read this article on Zacks.com click here. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.",231.87026977539062
2023-11-03 00:00:00+00:00,244.1999969482422,251.509994506836,243.6600036621093,249.5,249.5,992600.0,3.0,1.0,0.5000249999999999,"Quarter in Detail Ionis licensed Spinraza to Biogen BIIB. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Research Pipeline Update Ionis has phase III studies ongoing for nine medicines (internal as well as partnered) across 11 indications.",220.55691528320312
2023-11-06 00:00:00+00:00,249.5,251.5,247.64999389648443,248.6300048828125,248.6300048828125,1061300.0,3.0,1.0,0.5000249999999999,"Walt Disney DIS.N, Instacart CART.O and Biogen BIIB.O are among major companies reporting earnings this week. By Amruta Khandekar and Shristi Achar A Nov 6 (Reuters) - Wall Street's main indexes edged higher in early trade on Monday as investors geared up for commentary by a slew of policymakers later in the week which is likely to provide clarity on whether the Federal Reserve could cut rates next year. Traders' bets that the Fed will hold interest rates steady in December stand at 90%, while pricing in an about 80% chance the first policy easing would come as soon as June, according to the CME Group's FedWatch tool. New Article Walt Disney DIS.N, Instacart CART.O and Biogen BIIB.O are among major companies reporting earnings this week. Traders' bets that the Fed will hold interest rates steady in December stand at 90%, while pricing in an about 80% chance the first policy easing would come as soon as June, according to the CME Group's FedWatch tool. Such expectations will be put to the test this week with a raft of Fed policymakers, including Chair Jerome Powell due to speak in the coming days. New Article We expect Biogen BIIB to beat expectations when it reports third-quarter 2023 results on Nov 8, before market open. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report bluebird bio, Inc. (BLUE) : Free Stock Analysis Report Mirati Therapeutics, Inc. (MRTX) : Free Stock Analysis Report To read this article on Zacks.com click here. However, the FDA issued a complete response letter (CRL) for the new drug application (NDA) seeking approval of zuranolone for the major depressive disorder (MDD) indication. New Article Analysts on Wall Street project that Biogen Inc. (BIIB) will announce quarterly earnings of $3.97 per share in its forthcoming report, representing a decline of 16.8% year over year. With a Zacks Rank #3 (Hold), BIIB is expected closely follow the overall market performance in the near term. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. New Article Eisai (ESAIY) Source: Iryna Imago / Shutterstock.com Eisai (OTCMKTS:ESAIY), a Japanese pharmaceutical firm, is slated to receive 50% of the overall profits from an Alzheimers treatment, Leqembi, which it developed in partnership with American pharmaceutical company Biogen (NASDAQ:BIIB). However, as another InvestorPlace columnist John Blankenhorn recently pointed out, clinical trials take a very long time to conduct and are quite expensive and the Food and Drug Administrations standards for approving treatments are onerous. Hyperplasia refers to multiple genetic conditions that result in an enzyme deficiency that alters the production of adrenal hormones, Fierce Pharma explained. New Article Walt Disney DIS.N, Instacart CART.O and Biogen BIIB.O are among major companies reporting earnings this week. By Chuck Mikolajczak Nov 6 (Reuters) - U.S. stocks closed slightly higher on Monday as investors awaited guidance from a host of Federal Reserve policymakers later in the week on the central bank's policy path, with a large amount of bond supply also due to hit the market. ""Unless something in the economic data prompts it, you won't see them change their tone,"" said Stephen Massocca, senior vice president at Wedbush Securities in San Francisco. New Article Walt Disney DIS.N, Instacart CART.O and Biogen BIIB.O are among major companies reporting earnings this week. By Amruta Khandekar and Shristi Achar A Nov 6 (Reuters) - Wall Street's main indexes were set to edge higher at open on expectations that the Federal Reserve was done with its monetary tightening, while investors geared up for commentary by a slew of policymakers later in the week. Traders' bets that the Fed will hold interest rates steady in December stand at 90%, while pricing in an about 80% chance the first policy easing would come as soon as June, according to the CME Group's FedWatch tool. New Article Walt Disney DIS.N, Instacart CART.O and Biogen BIIB.O are among major companies reporting earnings this week. By Amruta Khandekar and Shristi Achar A Nov 6 (Reuters) - Wall Street's main indexes edged higher on Monday as investors geared up for commentary by a slew of policymakers later in the week which is likely to provide clarity on whether the Federal Reserve could cut rates next year. Traders' bets that the Fed will hold interest rates steady in December stand at 90%, while pricing in an about 80% chance the first policy easing would come as soon as June, according to the CME Group's FedWatch tool. New Article Walt Disney DIS.N, Instacart CART.O and Biogen BIIB.O are among major companies reporting earnings this week. By Chuck Mikolajczak Nov 6 (Reuters) - U.S. stocks closed slightly higher on Monday as investors awaited guidance from a host of Federal Reserve policymakers later in the week on the central bank's policy path, with a large amount of bond supply also due to hit the market. ""Unless something in the economic data prompts it, you won't see them change their tone,"" said Stephen Massocca, senior vice president at Wedbush Securities in San Francisco.",214.82815551757812
2023-11-07 00:00:00+00:00,246.6000061035156,248.38999938964844,241.5200042724609,245.6100006103516,245.6100006103516,1483300.0,3.0,1.0,0.5000249999999999,"After all, analysts raising estimates right before earnings  with the most up-to-date information possible  is a pretty good indicator of some favorable trends underneath the surface for BIIB in this report. Investors are always looking for stocks that are poised to beat at earnings season and Biogen Inc. BIIB may be one such company. In fact, the Most Accurate Estimate for the current quarter is currently at $4.08 per share for BIIB, compared to a broader Zacks Consensus Estimate of $3.97 per share. New Article Eisai, which has a 50:50 profit and loss sharing agreement for Leqembi globally with Biogen BIIB.O, has the final decision-making authority. Nov 7 (Reuters) - Japanese drugmaker Eisai 4523.T said on Tuesday it was targeting revenue of 10 billion yen ($66.5 million) from its recently approved Alzheimer's drug, Leqembi, by March 2024. The company said the launch of Leqembi in the United States was progressing as planned and that 10,000 patients were expected to be on the drug by the end of March 2024. New Article By Khushi Mandowara Nov 7 (Reuters) - Sage Therapeutics SAGE.O has priced the oral postpartum depression (PPD) pill it developed with partner Biogen BIIB.O at $15,900 for a full 14-day course of treatment, the company said on Tuesday, months after the drug was approved by the U.S. health regulator. Piper Sandler analyst Yasmeen Rahimi said the expected price, along with Sage's other efforts for marketing the drug, has helped garner patient enthusiasm and point towards a successful launch. PPD severely alters patients' ability to return to normal functioning and could potentially hurt the mother's relationship with her child. New Article Especially high volume was seen for the $235 strike put option expiring November 10, 2023, with 1,133 contracts trading so far today, representing approximately 113,300 underlying shares of BIIB. Below is a chart showing NXPI's trailing twelve month trading history, with the $170 strike highlighted in orange: And Biogen Inc (Symbol: BIIB) options are showing a volume of 5,187 contracts thus far today. That number of contracts represents approximately 518,700 underlying shares, working out to a sizeable 50.4% of BIIB's average daily trading volume over the past month, of 1.0 million shares.",210.5673370361328
2023-11-08 00:00:00+00:00,245.69000244140625,246.509994506836,229.1000061035156,231.69000244140625,231.69000244140625,2802000.0,2.538461538461539,1.0,0.3846403846153846,"(RTTNews) - (Adds Outlook) Looking ahead, for the full year, Biogen Inc. (BIIB) has cut its guidance to reflect the completed acquisition of Reata and its previously projected dilution to 2023 adjusted income per share, regulatory approval for ZURZUVAE in PPD, and the modification made to the company's presentation of LEQEMBI expenses. Below are the Q3 earnings highlights for Biogen Inc. (BIIB): Earnings: -$68.1 million in Q3 vs. $1.13 billion in the same period last year. On average, 30 analysts polled by Thomson Reuters expect the firm to earn $15.29 per share, for the year. New Article Adds CEO comment in paragraph 5, shares in paragraph 4 Nov 8 (Reuters) - Biogen BIIB.O on Wednesday cut its annual profit forecast, which slipped below Wall Street expectations, due to rising costs from the recent acquisition of Reata Pharmaceuticals and the launch of its Alzheimer's treatment Leqembi. To drive future growth, the drugmaker is leaning on newer products including Leqembi, postpartum depression drug Zurzuvae and the rare disease treatments acquired through its $6.5 billion buyout of Reata. Still, the company beat market expectations for profit in the third quarter, helped by strong sales for its rare muscle-wasting disorder drug Spinraza, sending its shares up about 1.4% in premarket trading. New Article Looking at individual holdings, Amgen Inc (AMGN) accounts for about 5.68% of total assets, followed by Vertex Pharmaceuticals Inc (VRTX) and Biogen Inc (BIIB). Click to get this free report Invesco Biotechnology & Genome ETF (PBE): ETF Research Reports Biogen Inc. (BIIB) : Free Stock Analysis Report Amgen Inc. (AMGN) : Free Stock Analysis Report Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report iShares Biotechnology ETF (IBB): ETF Research Reports SPDR S&P Biotech ETF (XBI): ETF Research Reports To read this article on Zacks.com click here. Launched on 06/23/2005, the Invesco Biotechnology & Genome ETF (PBE) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market. New Article Biotech giant Biogen (BIIB) notched a strong Q3 this morning, putting up $4.36 per share versus $3.99 expected on revenues of $2.53 billion, ahead of the $2.39 billion projected. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report MGM Resorts International (MGM) : Free Stock Analysis Report Ralph Lauren Corporation (RL) : Free Stock Analysis Report The Walt Disney Company (DIS) : Free Stock Analysis Report ARM Holdings PLC Sponsored ADR (ARM) : Free Stock Analysis Report Warner Bros. The Dow rides its longest winning streak since July of this year, while the S&P and Nasdaq are enjoying their strongest moves since 2021. New Article (RTTNews) - Biogen Inc. (BIIB) will host a conference call at 8:00 AM ET on November 8, 2023, to discuss Q3 23 earnings results. To access the live webcast, log on to https://investors.biogen.com/events/event-details/q3-2023-earnings-call-webcast The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Warner Bros Discovery WBD.O and Biogen BIIB.O are among major Wall Street companies set to post quarterly results before the opening bell. Wall Street has kicked off November on a high note, with the the S&P 500 .SPX and the Nasdaq .IXIC notching their longest streak of gains in two years on Tuesday as Treasury yields retreated sharply amid expectations that the Fed has reached the end of its tightening campaign. ""Stocks may well pause for breath as investors balance the hope for rate cuts with building financial stresses in the economy,"" Derren Nathan, head of equity research at Hargreaves Lansdown, said in a note. New Article (RTTNews) - Below are the earnings highlights for Biogen Inc. (BIIB): Earnings: -$68.1 million in Q3 vs. $1.13 billion in the same period last year. Excluding items, Biogen Inc. reported adjusted earnings of $635.5 million or $4.36 per share for the period. -Guidance: Full year EPS guidance: $14.50 to $15.00 The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. New Article Biogen Inc. (BIIB) reported $2.53 billion in revenue for the quarter ended September 2023, representing a year-over-year increase of 0.9%. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report To read this article on Zacks.com click here. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. New Article Biotech giant Biogen BIIB notched a strong Q3 this morning, putting up $4.36 per share versus $3.99 expected on revenues of $2.53 billion, ahead of the $2.39 billion projected. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report MGM Resorts International (MGM) : Free Stock Analysis Report Ralph Lauren Corporation (RL) : Free Stock Analysis Report The Walt Disney Company (DIS) : Free Stock Analysis Report ARM Holdings PLC Sponsored ADR (ARM) : Free Stock Analysis Report Warner Bros. The Dow rides its longest winning streak since July of this year, while the S&P and Nasdaq are enjoying their strongest moves since 2021. New Article Biogen BIIB reported third-quarter 2023 adjusted earnings per share (EPS) of $4.36, beating the Zacks Consensus Estimate of $3.99. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Dynavax Technologies Corporation (DVAX) : Free Stock Analysis Report MEI Pharma, Inc. (MEIP) : Free Stock Analysis Report To read this article on Zacks.com click here. Leqembi gained full approval from the FDA for early Alzheimers disease in the United States and broad reimbursement from the Centers for Medicare & Medicaid Services (CMS) in July. New Article The drug, which Sage has developed in collaboration with Biogen BIIB, is expected to be launched next month under the trade name Zurzuvae. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report ACADIA Pharmaceuticals Inc. (ACAD) : Free Stock Analysis Report Sage Therapeutics, Inc. (SAGE) : Free Stock Analysis Report Apellis Pharmaceuticals, Inc. (APLS) : Free Stock Analysis Report To read this article on Zacks.com click here. The upside was primarily due to expenses related to canceling excess purchase commitments for manufacturing as a result of the complete response letter received from the FDA for zuranolone for the treatment of major depressive disorder (MDD). New Article Nov 8 (Reuters) - Biogen BIIB.O cut its annual profit forecast below Wall Street expectations on Wednesday, on rising costs related to the recent acquisition of rare disease drugmaker Reata Pharmaceuticals and the launch of its Alzheimer's treatment Leqembi. The company had said in July it would cut about 1,000 jobs, or 11% of its workforce, to lower elevated costs compared to rivals and focus on higher-growth products such as Leqembi, which it sells with Japanese partner Eisai 4523.T. Since he was hired a year ago, CEO Christopher Viehbacher has led efforts to cut expenses and help Biogen recover from its missteps around the controversial Alzheimer's drug Aduhelm that never gained traction. New Article With the approval of Zurzuvae in postpartum depression, as well as important new data presented for Leqembi and our tau-targeting ASO, BIIB080, two programs we believe that are critical to expanding Biogen's leadership in Alzheimer's disease. Biogen (NASDAQ: BIIB) Q3 2023 Earnings Call Nov 08, 2023, 8:00 a.m. In the new results, in this small study, for patients treated with the two highest doses of BIIB80, we observed favorable trends on multiple exploratory endpoints of cognition and function as assessed by the CDR sum of boxes, MMSE, and functional activities questionnaire, when compared to the baseline matched external controls at week 100.",211.4451446533203
2023-11-09 00:00:00+00:00,231.97000122070312,232.1100006103516,222.58999633789065,224.6499938964844,224.6499938964844,1578000.0,3.0,1.0,0.5000249999999999,"Biogen (NASDAQ:BIIB)  This biopharma company discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. Yesterday, Craig-Hallum analyst Jeff Van Rhee maintained a Buy rating on the stock. Yesterday, TD Cowen analyst Matt Ramsay reaffirmed a Buy rating on the stock with a price target of $25.",222.1085205078125
2023-11-10 00:00:00+00:00,225.38999938964844,226.9499969482422,221.38999938964844,224.7899932861328,224.7899932861328,1330300.0,2.0,1.0,0.250025,"Meet the big pharma competitors Biogen (NASDAQ: BIIB) is the Alzheimer's market leader, as it has the distinction of having two different medicines on the market. The drug can slow or halt the disease's progression for about seven months on average, though the data suggest it has a difficult side effect profile, similar to Aduhelm's and Leqembi's. More distant questions, like the possibility of restoring function in patients with moderate to advanced disease, will take even longer to broach in clinical trials, never mind to address at scale with a commercialized therapy.",217.98887634277344
2023-11-13 00:00:00+00:00,223.2400054931641,224.72999572753903,220.8600006103516,222.58999633789065,222.58999633789065,856400.0,3.0,1.0,0.5000249999999999,"Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. BIOGEN INC (BIIB) is a large-cap growth stock in the Biotechnology & Drugs industry. New Article Ionis Pharmaceuticals IONS announced positive preliminary data from a clinical study on its pipeline candidate, ION582 (BIIB121), for the treatment of Angelman syndrome, a genetic disorder. Image Source: Zacks Investment Research Ionis is developing ION582 in partnership with Biogen BIIB. Click to get this free report AstraZeneca PLC (AZN) : Free Stock Analysis Report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Biogen Inc. (BIIB) : Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS) : Free Stock Analysis Report To read this article on Zacks.com click here.",223.15403747558594
2023-11-15 00:00:00+00:00,224.42999267578125,231.6699981689453,223.1699981689453,229.6300048828125,229.6300048828125,1346400.0,4.0,1.0,0.7500249999999999,"Lilly has also been a pioneer in developing a treatment for Alzheimer's disease, where it is in a tight race with a partnership between Eisai 4523.T and Biogen BIIB.O, It has said it expects the U.S. Food and Drug Administration to decide by the end of this year whether to approve its new Alzheimer's drug donanemab and submissions to other global regulators are underway. ""It's about an investment in the single-digit billion range,"" said a source familiar with the plans for the proposed new plant, which will be in the state of Rhineland-Palatinate on the French border, adding that it would need large numbers of skilled workers. The announcement looks to be a win for the German government, which is keen to show that Germany remains an attractive manufacturing location despite soaring energy prices caused by the loss of Russian gas following Moscow's invasion of Ukraine.",232.45338439941406
2023-11-16 00:00:00+00:00,231.22000122070312,232.8800048828125,227.8500061035156,229.4600067138672,229.4600067138672,790700.0,4.0,1.0,0.7500249999999999,"Lilly has also been a pioneer in developing a treatment for Alzheimer's disease, where it is in a tight race with a partnership between Eisai 4523.T and Biogen BIIB.O, It has said it expects the U.S. Food and Drug Administration to decide in the first quarter whether to approve its new Alzheimer's drug donanemab, and submissions to other global regulators are underway. The project will be fully funded by the medicines giant, which has seen surging demand for its diabetes drug Mounjaro, people familiar with the matter had told Reuters on Wednesday. Eli Lilly's plans for a plant look to be a win for the German government, keen to show that Europe's biggest economy remains an attractive manufacturing location despite soaring energy prices caused by the loss of Russian gas following Moscow's invasion of Ukraine. New Article Lilly has also been a pioneer in developing a treatment for Alzheimer's disease, where it is in a tight race with a partnership between Eisai 4523.T and Biogen BIIB.O, It has said it expects the U.S. Food and Drug Administration to decide in the first quarter whether to approve its new Alzheimer's drug donanemab, and submissions to other global regulators are underway. The project will be fully funded by the medicines giant, which has seen surging demand for its diabetes drug Mounjaro, now also being used off-label for weight loss, people familiar with the matter had told Reuters on Wednesday. The move looks to be a win for the German government, keen to show that Europe's biggest economy remains an attractive manufacturing location despite soaring energy prices caused by the loss of Russian gas following Moscow's invasion of Ukraine.",232.77310180664062
2023-11-17 00:00:00+00:00,230.94000244140625,230.94000244140625,226.75,228.0,228.0,1447300.0,2.5,1.0,0.375025,"Shares declined last month after Biogen BIIB and partner Eisai presented new data on the investigational subcutaneous (SC) formulation of AD drug Leqembi. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report Prothena Corporation plc (PRTA) : Free Stock Analysis Report To read this article on Zacks.com click here. Prothena Corporation PRTA, a late-stage clinical biotechnology company, has a robust Alzheimers Disease (AD) pipeline, which spans next-generation antibody immunotherapy, small molecules and vaccines. New Article The technology is behind a new class of promising Alzheimer's drugs such as donanemab by Lilly and Leqembi by partners Eisai 4523.T and Biogen BIIB.O. By Ludwig Burger and Paul Arnold BASEL, Nov 17 (Reuters) - Lonza's LONN.S chairman has ruled out plans to use its capacity to fill syringes and provide final production steps for new obesity drugs even as rivals scramble for a share of the booming weight-loss market. Baehny said that because Lonza would have to ""start from scratch"" to produce the peptides that make up the main active ingredient in GLP-1 drugs, it made little sense to enter the market, saying that the company would instead focus on its other high-tech pharmaceuticals technologies.",234.27865600585938
2023-11-20 00:00:00+00:00,228.1300048828125,231.0,228.1300048828125,230.1100006103516,230.1100006103516,819600.0,4.0,1.0,0.7500249999999999,"Eisai 4523.T and Biogen's BIIB.O newly launched Leqembi and Eli Lilly's LLY.N donanemab, now under U.S. regulatory review, are two such treatments that cemented the view that removing amyloid is key to fighting Alzheimers in people with early-stage disease. By Julie Steenhuysen CHICAGO, Nov 20 (Reuters) - Breakthrough Alzheimers treatments that remove toxic proteins from the brain have revived interest in vaccines to treat the memory-robbing disease, potentially offering a cheaper, easy-to-administer option for millions of people, according to interviews with 10 scientists and company executives. Clinical trials are underway or completed for at least seven Alzheimers vaccines designed to harness the immune system to rid the brain of the disease-related proteins beta amyloid or tau, a review of the U.S. governments ClinicalTrials.gov database found.",237.21676635742188
2023-11-22 00:00:00+00:00,230.9499969482422,231.4100036621093,229.4900054931641,231.25,231.25,505500.0,4.0,1.0,0.7500249999999999,"NDX also offers some of the top biotechnology and pharmaceutical companies such as Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB) and AstraZeneca (AZN), all of which are leaders in health care and biotech-related research and development. Be it sipping a coffee at Starbucks (SBUX), working on tasks in Microsoft Office (MSFT), editing an Adobe PDF (ADBE), attending a Zoom meeting (ZM), consulting for Invisalign (ALGN), watching YouTube (GOOG, GOOGL) or Netflix (NFLX), shopping on Amazon (AMZN) or eBay (EBAY), calling someone on your iPhone (AAPL), checking an Airbnb (ABNB) for a vacation or using Booking.com (BKNG) to book tickets, or posting pictures on Instagram (META), Nasdaq-100 companies and their products and services touch us in one way or another every day. The most recent list of companies published includes Apple (AAPL), Tesla (TSLA), Amazon (AMZN), Alphabet (GOOG, GOOGL), Microsoft (MSFT), and Moderna (MRNA).",237.7678985595703
2023-11-27 00:00:00+00:00,231.25,232.25,227.08999633789065,228.7899932861328,228.7899932861328,814900.0,3.0,1.0,0.5000249999999999,"Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. BIOGEN INC (BIIB) is a large-cap growth stock in the Biotechnology & Drugs industry.",224.37704467773438
2023-11-30 00:00:00+00:00,232.67999267578125,235.1100006103516,229.2400054931641,234.0800018310547,234.0800018310547,1492700.0,2.0,1.0,0.250025,"That amounts to about 57.5% of BIIB's average daily trading volume over the past month of 1.1 million shares. Particularly high volume was seen for the $300 strike put option expiring January 19, 2024, with 1,640 contracts trading so far today, representing approximately 164,000 underlying shares of BIIB. Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Biogen Inc (Symbol: BIIB), where a total of 6,279 contracts have traded so far, representing approximately 627,900 underlying shares.",234.04759216308594
2023-12-01 00:00:00+00:00,233.9499969482422,234.759994506836,231.1100006103516,234.63999938964844,234.63999938964844,734900.0,3.0,1.0,0.5000249999999999,"The AD target market is highly competitive as several other pharma companies like Biogen BIIB and Eli Lilly LLY have their drugs targeting the AD indication. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Eli Lilly and Company (LLY) : Free Stock Analysis Report CytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report Annovis Bio, Inc. (ANVS) : Free Stock Analysis Report To read this article on Zacks.com click here. Image Source: Zacks Investment Research This upside came after management reported that it exceeded complete enrolment in the phase II/III study evaluating the efficacy, safety, and tolerability of buntanetap in AD indication over a 12-week treatment period.",232.548583984375
2023-12-04 00:00:00+00:00,234.1100006103516,236.2400054931641,232.32000732421875,232.8500061035156,232.8500061035156,945600.0,3.0,1.0,0.5000249999999999,"Vanguard Large-Cap ETF VV $210.88 $231.90 9.97% Bio-Rad Laboratories Inc BIO $307.00 $503.50 64.01% Albemarle Corp. ALB $126.16 $198.73 57.52% Biogen Inc BIIB $234.64 $319.68 36.24% Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of VV's underlying holdings with notable upside to their analyst target prices are Bio-Rad Laboratories Inc (Symbol: BIO), Albemarle Corp. (Symbol: ALB), and Biogen Inc (Symbol: BIIB). Similarly, ALB has 57.52% upside from the recent share price of $126.16 if the average analyst target price of $198.73/share is reached, and analysts on average are expecting BIIB to reach a target price of $319.68/share, which is 36.24% above the recent price of $234.64.",242.4370574951172
2023-12-08 00:00:00+00:00,237.6499938964844,240.8099975585937,236.8000030517578,239.2899932861328,239.2899932861328,988000.0,3.5,1.0,0.6250249999999999,"Fintel reports that on December 7, 2023, Raymond James upgraded their outlook for Biogen (NASDAQ:BIIB) from Market Perform to Outperform . Average portfolio weight of all funds dedicated to BIIB is 0.32%, a decrease of 7.40%. The put/call ratio of BIIB is 0.74, indicating a bullish outlook. New Article A month has gone by since the last earnings report for Biogen Inc. (BIIB). Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Intra-Cellular Therapies Inc. (ITCI) : Free Stock Analysis Report To read this article on Zacks.com click here. Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.",233.68853759765625
2023-12-11 00:00:00+00:00,248.0,251.19000244140625,242.5,246.1100006103516,246.1100006103516,1428400.0,3.5,1.0,0.6250249999999999,"Below is Validea's guru fundamental report for BIOGEN INC (BIIB). Of the 22 guru strategies we follow, BIIB rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. BIOGEN INC (BIIB) is a large-cap growth stock in the Biotechnology & Drugs industry. New Article The Alzheimer's disease (AD) space continued to be in the spotlight in 2023 with the approval of Biogen BIIB and Eisais drug Leqembi, which was initially granted accelerated approval in January. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Prothena Corporation plc (PRTA) : Free Stock Analysis Report AC Immune (ACIU) : Free Stock Analysis Report Vaxxinity, Inc. (VAXX) : Free Stock Analysis Report To read this article on Zacks.com click here. The interest comes on the heels of data showing an increase of amyloid-related imaging abnormalities (ARIA) observed in the case of the approved therapies, reflected as vasogenic edema or sulcal effusion (ARIA-E) or as hemosiderin deposits such as microhemorrhages and superficial siderosis (ARIA-H).",227.34710693359375
2023-12-12 00:00:00+00:00,247.5500030517578,250.88999938964844,244.1100006103516,249.0399932861328,249.0399932861328,1228800.0,3.333333333333333,1.0,0.5833583333333334,"Biogen (BIIB) Source: Shutterstock Biogen (NASDAQ:BIIB) is a biotechnology company specializing in therapy development for serious and intricate diseases. This intense focus on growth and getting its product approved for the market puts BIIB in our top psychedelic companies to buy. The companies proactive approach to regulatory approval and advancements in treating anxiety disorder has put CYBN on the path to higher potential growth. New Article Stocks recently featured in the blog include: Biogen BIIB, Prothena PRTA, AC Immune's ACIU and Vaxxinity, Inc. VAXX. Click to get this free report Biogen Inc. (BIIB) : Free Stock Analysis Report Prothena Corporation plc (PRTA) : Free Stock Analysis Report AC Immune (ACIU) : Free Stock Analysis Report Vaxxinity, Inc. (VAXX) : Free Stock Analysis Report To read this article on Zacks.com click here. The interest comes on the heels of data showing an increase of amyloid-related imaging abnormalities (ARIA) observed in the case of the approved therapies, reflected as vasogenic edema or sulcal effusion (ARIA-E) or as hemosiderin deposits such as microhemorrhages and superficial siderosis (ARIA-H). New Article (RTTNews) - Sage Therapeutics, Inc. (SAGE) and Biogen Inc. (BIIB) announced Thursday the availability of ZURZUVAE (zuranolone) CIV, a prescription oral treatment for women with postpartum depression or PPD in the United States. The companies are partnering with several specialty pharmacies and ZURZUVAE will be shipped directly to women with PPD who are prescribed the treatment. Kristina Deligiannidis, a principal investigator in the ZURZUVAE clinical development program and Professor, The Feinstein Institutes for Medical Research in Manhasset, New York, said, ""For women with PPD, delayed improvement in depressive symptoms can significantly worsen outcomes.",222.55389404296875
2023-12-13 00:00:00+00:00,249.2700042724609,255.69000244140625,248.759994506836,255.5599975585937,255.5599975585937,1613100.0,3.5,1.0,0.6250249999999999,"(RTTNews) - Biogen Inc. (BIIB) on Friday made an announcement regarding the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending the marketing authorization for SKYCLARYS (omaveloxolone), for treating Friedreich's ataxia in both adults and adolescents aged 16 years and above. The positive opinion of SKYCLARYS by CHMP is based on the placebo-controlled MOXIe Part 2 trial's efficacy and safety data, as patients who received SKYCLARYS showed less physical impairment in comparison to those who were given a placebo, as determined by the modified Friedreich Ataxia Rating Scale (mFARS). The company stated that the EC will review CHMP's recommendation for SKYCLARYS to obtain marketing authorization in the European Union, with a final decision expected in the first quarter of 2024. New Article Intravenous treatment of the drug, co-developed with U.S. partner Biogen BIIB.O, will cost about 2.98 million yen ($20,438) per patient per year, based on a Japanese health ministry panel ruling the same day. TOKYO, Dec 13 (Reuters) - Eisai 4523.T said on Wednesday its Alzheimer's drug Leqembi will launch in Japan on Dec. 20 following its inclusion on the National Health Insurance price list. Leqembi is an antibody designed to remove sticky deposits of a protein called amyloid beta from the brains of Alzheimer's patients.",238.65966796875
